diseaseId	diseaseName	drugId	drugName	type	mechanismOfAction	actionType	symbol	name	phase	status	source
MONDO_0007254	breast cancer	CHEMBL395091	ESKETAMINE	Small molecule	Glutamate [NMDA] receptor negative allosteric modulator	Negative allosteric modulator	GRIN2A	glutamate ionotropic receptor NMDA type subunit 2A	4	Recruiting	https://clinicaltrials.gov/study/NCT05732064
MONDO_0007254	breast cancer	CHEMBL924	ZOLEDRONIC ACID ANHYDROUS	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	4	Completed	https://clinicaltrials.gov/study/NCT00172029,https://clinicaltrials.gov/study/NCT01907880,https://clinicaltrials.gov/study/NCT01129336
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	4	Recruiting	https://clinicaltrials.gov/study/NCT05131841,https://clinicaltrials.gov/study/NCT03355157,https://clinicaltrials.gov/study/NCT03270007
MONDO_0007254	breast cancer	CHEMBL1201568	PEGFILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	4	Completed	https://clinicaltrials.gov/study/NCT03511378,https://clinicaltrials.gov/study/NCT02805205,https://clinicaltrials.gov/study/NCT02805153
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN4A	sodium voltage-gated channel alpha subunit 4	4	Completed	https://clinicaltrials.gov/study/NCT04248179
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	4	Completed	https://clinicaltrials.gov/study/NCT02864030,https://clinicaltrials.gov/study/NCT01961544
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	4	Withdrawn	https://clinicaltrials.gov/study/NCT00774241
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN2A	sodium voltage-gated channel alpha subunit 2	4	Recruiting	https://clinicaltrials.gov/study/NCT05072314
MONDO_0007254	breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	4	Withdrawn	https://clinicaltrials.gov/study/NCT03988114
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dc35c59-f4f3-43b4-8251-0cf5c06cdc80
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN5A	sodium voltage-gated channel alpha subunit 5	4	Recruiting	https://clinicaltrials.gov/study/NCT05072314
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	4	Recruiting	https://clinicaltrials.gov/study/NCT05420454,https://clinicaltrials.gov/study/NCT05420467,https://clinicaltrials.gov/study/NCT04136782,https://clinicaltrials.gov/study/NCT02627248,https://clinicaltrials.gov/study/NCT06217185,https://clinicaltrials.gov/study/NCT04182568
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR1	estrogen receptor 1	4	Completed	https://clinicaltrials.gov/study/NCT02447328
MONDO_0004658	breast carcinoma in situ	CHEMBL1655	TOREMIFENE	Small molecule	Estrogen receptor modulator		ESR2	estrogen receptor 2	4	Withdrawn	https://clinicaltrials.gov/study/NCT03238703
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	4	Recruiting	https://clinicaltrials.gov/study/NCT02627248,https://clinicaltrials.gov/study/NCT06217185,https://clinicaltrials.gov/study/NCT04136782,https://clinicaltrials.gov/study/NCT04182568,https://clinicaltrials.gov/study/NCT05420467,https://clinicaltrials.gov/study/NCT05420454
EFO_0000305	breast carcinoma	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209092s000lbl.pdf
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT04137640
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR1	estrogen receptor 1	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT03591549,https://clinicaltrials.gov/study/NCT05191914
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	4	Unknown status	https://clinicaltrials.gov/study/NCT03123770
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS6	NADH:ubiquinone oxidoreductase subunit S6	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23f3c1f4-0fc8-4804-a9e3-04cf25dd302e
EFO_0000305	breast carcinoma	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86718885-da44-4d3d-b3ca-06cbcedcffd8,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0e6412f-50b4-4fd4-9364-62818d121a07
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB2	NADH:ubiquinone oxidoreductase subunit B2	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
EFO_0000432	breast ductal carcinoma in situ	CHEMBL658	SUFENTANIL	Small molecule	Mu opioid receptor agonist		OPRM1	opioid receptor mu 1	4	Completed	https://clinicaltrials.gov/study/NCT04248179
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05291910
MONDO_0004379	female breast carcinoma	CHEMBL1200694	SEVOFLURANE	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRA6	gamma-aminobutyric acid type A receptor subunit alpha6	4	Completed	https://clinicaltrials.gov/study/NCT02005770
MONDO_0007254	breast cancer	CHEMBL1201179	LAPATINIB DITOSYLATE	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eee37f88-ec6a-4c30-b8aa-e2c71f93088c
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	4	Unknown status	https://clinicaltrials.gov/study/NCT03123770
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT04137640
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA7	NADH:ubiquinone oxidoreductase subunit A7	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03dd3301-e9ce-40af-84e1-7b70fc6557b0
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86718885-da44-4d3d-b3ca-06cbcedcffd8
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND1	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	4	Unknown status	https://clinicaltrials.gov/study/NCT03123770
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e1a3a8d-6a6b-46fd-90ae-c7ad9e9b364b,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ffd3e34-537f-4f65-b00e-57c25bab3b01,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24d10449-2936-4cd3-b7db-a7683db721e4,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6c24189-293f-42ca-b969-75870bb55af0,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea28753a-8631-460a-bfdc-b101eb8ac84a,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=566a00ae-47c0-4cd2-b602-79909bdfd9b1,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4dbbb7c8-a4b5-484d-a2a4-4d925010fc44,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d499be2-fdb5-4b9d-a7ce-3662ec9b2e34,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f10f730f-6479-4f6a-8edc-fa4bd2140c1b,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6cefbdb9-1141-4a53-9d05-f6fcc2746834,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=88d7cdd2-e650-4a16-adec-873927e03e93,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=973efa93-7f9d-440a-a09f-521cf331b5e7
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	4	Recruiting	https://clinicaltrials.gov/study/NCT02627248,https://clinicaltrials.gov/study/NCT04182568,https://clinicaltrials.gov/study/NCT04136782,https://clinicaltrials.gov/study/NCT05420454,https://clinicaltrials.gov/study/NCT06217185,https://clinicaltrials.gov/study/NCT05420467
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	4	Completed	https://clinicaltrials.gov/study/NCT01961544,https://clinicaltrials.gov/study/NCT02864030
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05291910
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	4	Completed	https://clinicaltrials.gov/study/NCT02658734
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND2	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2	4	Completed	https://clinicaltrials.gov/study/NCT05840068
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN3A	sodium voltage-gated channel alpha subunit 3	4	Completed	https://clinicaltrials.gov/study/NCT04248179
MONDO_0007254	breast cancer	CHEMBL1237023	DENOSUMAB	Antibody	Tumor necrosis factor ligand superfamily member 11 inhibitor		TNFSF11	TNF superfamily member 11	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49e5afe9-a0c7-40c4-af9f-f287a80c5c88
MONDO_0007254	breast cancer	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN7A	sodium voltage-gated channel alpha subunit 7	4	Completed	https://clinicaltrials.gov/study/NCT03360214
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN2A	sodium voltage-gated channel alpha subunit 2	4	Completed	https://clinicaltrials.gov/study/NCT04248179
MONDO_0004379	female breast carcinoma	CHEMBL1200694	SEVOFLURANE	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRD	gamma-aminobutyric acid type A receptor subunit delta	4	Completed	https://clinicaltrials.gov/study/NCT02005770
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	4	Unknown status	https://clinicaltrials.gov/study/NCT03123770
MONDO_0007254	breast cancer	CHEMBL4303669	ZOLEDRONIC ACID	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	4	Completed	https://clinicaltrials.gov/study/NCT00172029,https://clinicaltrials.gov/study/NCT01907880,https://clinicaltrials.gov/study/NCT01129336
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23f3c1f4-0fc8-4804-a9e3-04cf25dd302e
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23f3c1f4-0fc8-4804-a9e3-04cf25dd302e
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	4	Unknown status	https://clinicaltrials.gov/study/NCT03123770
MONDO_0007254	breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	4	Withdrawn	https://clinicaltrials.gov/study/NCT03988114
MONDO_0007254	breast cancer	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	4	Suspended	https://clinicaltrials.gov/study/NCT05183828
MONDO_0007254	breast cancer	CHEMBL1654	RISEDRONATE SODIUM	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	4	Completed	https://clinicaltrials.gov/study/NCT00082277
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	4	Completed	https://clinicaltrials.gov/study/NCT01301729,https://clinicaltrials.gov/study/NCT01094184,https://clinicaltrials.gov/study/NCT02419742
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS2	NADH:ubiquinone oxidoreductase core subunit S2	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS2	NADH:ubiquinone oxidoreductase core subunit S2	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA1	NADH:ubiquinone oxidoreductase subunit A1	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dc35c59-f4f3-43b4-8251-0cf5c06cdc80
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN8A	sodium voltage-gated channel alpha subunit 8	4	Recruiting	https://clinicaltrials.gov/study/NCT05072314
MONDO_0007254	breast cancer	CHEMBL596	FENTANYL	Small molecule	Mu opioid receptor agonist		OPRM1	opioid receptor mu 1	4	Unknown status	https://clinicaltrials.gov/study/NCT03051503
EFO_0000305	breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c550dd16-a5e8-44be-87f2-210c15bbb513,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6004fba9-49c0-4781-8134-44bf7cf196fd,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffc0a4be-6091-4157-837e-3637c1e121a6,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49f9e774-52f9-40af-aecf-217c11e243ce
MONDO_0007254	breast cancer	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN1A	sodium voltage-gated channel alpha subunit 1	4	Completed	https://clinicaltrials.gov/study/NCT03360214
MONDO_0007254	breast cancer	CHEMBL1908360	EVEROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45d54974-3fc4-4237-a2fa-3158ca1a8105,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b7c7c9a4-994f-43dc-8cd6-cd6eeed6fa89
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	4	Withdrawn	https://clinicaltrials.gov/study/NCT01156961
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	4	Recruiting	https://clinicaltrials.gov/study/NCT03355157
MONDO_0007254	breast cancer	CHEMBL1908360	EVEROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	4	Completed	https://clinicaltrials.gov/study/NCT01743560
MONDO_0007254	breast cancer	CHEMBL742	KETAMINE	Small molecule	Glutamate [NMDA] receptor negative allosteric modulator	Negative allosteric modulator	GRIN3B	glutamate ionotropic receptor NMDA type subunit 3B	4	Unknown status	https://clinicaltrials.gov/study/NCT03676114
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	4	Recruiting	https://clinicaltrials.gov/study/NCT04136782,https://clinicaltrials.gov/study/NCT02627248,https://clinicaltrials.gov/study/NCT04182568,https://clinicaltrials.gov/study/NCT05420454,https://clinicaltrials.gov/study/NCT06217185,https://clinicaltrials.gov/study/NCT05420467
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT04137640
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636
MONDO_0007254	breast cancer	CHEMBL384467	DEXAMETHASONE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT06300099
MONDO_0007254	breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	4	Recruiting	https://clinicaltrials.gov/study/NCT06169371,https://clinicaltrials.gov/study/NCT05362760
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f59f7811-70b7-4c44-99f7-4f4fdce3ed22,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a630937b-8369-74ad-b68a-f940eb16ff0f,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c806400-5fdc-4398-8475-37f700b3191f,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70aeb960-426c-4805-b956-476bebccd926,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd0ca36d-1f54-4568-8d19-a7152addcd52,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e03d1378-6889-43d5-a34c-f96132cffa88,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c482c813-1eb7-40dd-907a-845a7df112bf,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b35e3633-8893-4b0b-af1e-92e342557199,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2dc690b-4c69-428a-a67e-8ad007c39548,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0ec4bcc-93ea-4c41-a4b6-95ec19491807
MONDO_0007254	breast cancer	CHEMBL1098	BUPIVACAINE	Small molecule	Sodium channel protein type IV alpha subunit blocker		SCN4A	sodium voltage-gated channel alpha subunit 4	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT06252662,https://clinicaltrials.gov/study/NCT02495363
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB11	NADH:ubiquinone oxidoreductase subunit B11	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dc35c59-f4f3-43b4-8251-0cf5c06cdc80
MONDO_0007254	breast cancer	CHEMBL1201179	LAPATINIB DITOSYLATE	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eee37f88-ec6a-4c30-b8aa-e2c71f93088c
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF3	NADH:ubiquinone oxidoreductase complex assembly factor 3	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL1889140	ROPIVACAINE HYDROCHLORIDE	Small molecule	Sodium channel alpha subunit blocker		SCN11A	sodium voltage-gated channel alpha subunit 11	4	Completed	https://clinicaltrials.gov/study/NCT03360214
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	4	Completed	https://clinicaltrials.gov/study/NCT01961544,https://clinicaltrials.gov/study/NCT02864030
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	4	Recruiting	https://clinicaltrials.gov/study/NCT05033769
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA2	NADH:ubiquinone oxidoreductase subunit A2	4	Completed	https://clinicaltrials.gov/study/NCT05840068
EFO_0000305	breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022065lbl.pdf
MONDO_0007254	breast cancer	CHEMBL4297844	TRASTUZUMAB DERUXTECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e67e73e-ddf4-4e4d-8b50-09d7514910b6
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	4	Unknown status	https://clinicaltrials.gov/study/NCT03123770
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	4	Withdrawn	https://clinicaltrials.gov/study/NCT00774241
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS3	NADH:ubiquinone oxidoreductase core subunit S3	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	4	Completed	https://clinicaltrials.gov/study/NCT00372476
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	4	Completed	https://clinicaltrials.gov/study/NCT00372476
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e03d1378-6889-43d5-a34c-f96132cffa88,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70aeb960-426c-4805-b956-476bebccd926,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0ec4bcc-93ea-4c41-a4b6-95ec19491807,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c482c813-1eb7-40dd-907a-845a7df112bf,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c806400-5fdc-4398-8475-37f700b3191f,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b35e3633-8893-4b0b-af1e-92e342557199,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd0ca36d-1f54-4568-8d19-a7152addcd52,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a630937b-8369-74ad-b68a-f940eb16ff0f,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2dc690b-4c69-428a-a67e-8ad007c39548,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f59f7811-70b7-4c44-99f7-4f4fdce3ed22
MONDO_0007254	breast cancer	CHEMBL395091	ESKETAMINE	Small molecule	Glutamate [NMDA] receptor negative allosteric modulator	Negative allosteric modulator	GRIN3A	glutamate ionotropic receptor NMDA type subunit 3A	4	Recruiting	https://clinicaltrials.gov/study/NCT05732064
MONDO_0004379	female breast carcinoma	CHEMBL1200694	SEVOFLURANE	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRE	gamma-aminobutyric acid type A receptor subunit epsilon	4	Completed	https://clinicaltrials.gov/study/NCT02005770
MONDO_0007254	breast cancer	CHEMBL1200778	DEXRAZOXANE HYDROCHLORIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b098c7f5-07a9-49a3-8e8a-f8adda671eca,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f68a34ae-e17e-45b3-8c8e-8d7194b2124a
MONDO_0007254	breast cancer	CHEMBL778	DEXMEDETOMIDINE	Small molecule	Adrenergic receptor alpha-2 agonist		ADRA2B	adrenoceptor alpha 2B	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT06252662,https://clinicaltrials.gov/study/NCT06300099
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dc35c59-f4f3-43b4-8251-0cf5c06cdc80
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ca3c0d4-e629-4d89-a969-3515a62886c6,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24d10449-2936-4cd3-b7db-a7683db721e4
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49f9e774-52f9-40af-aecf-217c11e243ce,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffc0a4be-6091-4157-837e-3637c1e121a6,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6004fba9-49c0-4781-8134-44bf7cf196fd,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c550dd16-a5e8-44be-87f2-210c15bbb513
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dc35c59-f4f3-43b4-8251-0cf5c06cdc80
MONDO_0007254	breast cancer	CHEMBL1201124	KETOROLAC TROMETHAMINE	Small molecule	Cyclooxygenase inhibitor		PTGS2	prostaglandin-endoperoxide synthase 2	4	Withdrawn	https://clinicaltrials.gov/study/NCT03007381
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	4	Withdrawn	https://clinicaltrials.gov/study/NCT00774241
MONDO_0004379	female breast carcinoma	CHEMBL1200694	SEVOFLURANE	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRG2	gamma-aminobutyric acid type A receptor subunit gamma2	4	Completed	https://clinicaltrials.gov/study/NCT02005770
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA11	NADH:ubiquinone oxidoreductase subunit A11	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	4	Unknown status	https://clinicaltrials.gov/study/NCT00912639,https://clinicaltrials.gov/study/NCT02207361,https://clinicaltrials.gov/study/NCT02142790
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA10	NADH:ubiquinone oxidoreductase subunit A10	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0004658	breast carcinoma in situ	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	4	Withdrawn	https://clinicaltrials.gov/study/NCT03238703
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd0ca36d-1f54-4568-8d19-a7152addcd52,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2dc690b-4c69-428a-a67e-8ad007c39548,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70aeb960-426c-4805-b956-476bebccd926,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b35e3633-8893-4b0b-af1e-92e342557199,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0ec4bcc-93ea-4c41-a4b6-95ec19491807,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e03d1378-6889-43d5-a34c-f96132cffa88,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c806400-5fdc-4398-8475-37f700b3191f,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a630937b-8369-74ad-b68a-f940eb16ff0f,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c482c813-1eb7-40dd-907a-845a7df112bf,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f59f7811-70b7-4c44-99f7-4f4fdce3ed22
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT04137640
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	4	Withdrawn	https://clinicaltrials.gov/study/NCT00774241
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	4	Unknown status	https://clinicaltrials.gov/study/NCT03123770
MONDO_0004379	female breast carcinoma	CHEMBL526	PROPOFOL	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRG3	gamma-aminobutyric acid type A receptor subunit gamma3	4	Completed	https://clinicaltrials.gov/study/NCT02005770
EFO_0000305	breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022065lbl.pdf
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
MONDO_0007254	breast cancer	CHEMBL81	RALOXIFENE	Small molecule	Estrogen receptor beta modulator		ESR2	estrogen receptor 2	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcaaa6dc-74e8-4fb8-800c-5574bf0f8de9
MONDO_0007254	breast cancer	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	4	Terminated	https://clinicaltrials.gov/study/NCT00171847
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=241f0b1e-8b95-470d-876f-bf1804daaf18
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	4	Withdrawn	https://clinicaltrials.gov/study/NCT01156961
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT04137640
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV1	NADH:ubiquinone oxidoreductase core subunit V1	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0004658	breast carcinoma in situ	CHEMBL1200675	TOREMIFENE CITRATE	Small molecule	Estrogen receptor modulator		ESR2	estrogen receptor 2	4	Withdrawn	https://clinicaltrials.gov/study/NCT03238703
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c550dd16-a5e8-44be-87f2-210c15bbb513,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffc0a4be-6091-4157-837e-3637c1e121a6,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49f9e774-52f9-40af-aecf-217c11e243ce,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6004fba9-49c0-4781-8134-44bf7cf196fd
EFO_0006861	male breast carcinoma	CHEMBL4297509	ELACESTRANT	Small molecule	Estrogen receptor alpha degrader		ESR1	estrogen receptor 1	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639s000lbl.pdf
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e1a3a8d-6a6b-46fd-90ae-c7ad9e9b364b,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=88d7cdd2-e650-4a16-adec-873927e03e93,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4dbbb7c8-a4b5-484d-a2a4-4d925010fc44,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=566a00ae-47c0-4cd2-b602-79909bdfd9b1,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=973efa93-7f9d-440a-a09f-521cf331b5e7,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6cefbdb9-1141-4a53-9d05-f6fcc2746834,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea28753a-8631-460a-bfdc-b101eb8ac84a,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ffd3e34-537f-4f65-b00e-57c25bab3b01,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6c24189-293f-42ca-b969-75870bb55af0,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24d10449-2936-4cd3-b7db-a7683db721e4,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d499be2-fdb5-4b9d-a7ce-3662ec9b2e34,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f10f730f-6479-4f6a-8edc-fa4bd2140c1b
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	4	Withdrawn	https://clinicaltrials.gov/study/NCT01156961
MONDO_0007254	breast cancer	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e11b0a54-92bd-4790-8b80-f439f7093c01,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa5e4446-19cd-4235-a382-5b48bf6c3b2f
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4L	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	4	Withdrawn	https://clinicaltrials.gov/study/NCT00774241
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB6	NADH:ubiquinone oxidoreductase subunit B6	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	4	Terminated	https://clinicaltrials.gov/study/NCT04031885
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=241f0b1e-8b95-470d-876f-bf1804daaf18
MONDO_0004379	female breast carcinoma	CHEMBL1200694	SEVOFLURANE	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRA2	gamma-aminobutyric acid type A receptor subunit alpha2	4	Completed	https://clinicaltrials.gov/study/NCT02005770
MONDO_0007254	breast cancer	CHEMBL1201568	PEGFILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	4	Active, not recruiting	https://clinicaltrials.gov/study/NCT04781959
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	4	Completed	https://clinicaltrials.gov/study/NCT02502864,https://clinicaltrials.gov/study/NCT02419742,https://clinicaltrials.gov/study/NCT01094184,https://clinicaltrials.gov/study/NCT02445586,https://clinicaltrials.gov/study/NCT01660542,https://clinicaltrials.gov/study/NCT01301729,https://clinicaltrials.gov/study/NCT00127933
MONDO_0007254	breast cancer	CHEMBL1655	TOREMIFENE	Small molecule	Estrogen receptor modulator		ESR1	estrogen receptor 1	4	Completed	https://clinicaltrials.gov/study/NCT02344940
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	4	Completed	https://clinicaltrials.gov/study/NCT01961544,https://clinicaltrials.gov/study/NCT02864030
MONDO_0007254	breast cancer	CHEMBL742	KETAMINE	Small molecule	Glutamate [NMDA] receptor negative allosteric modulator	Negative allosteric modulator	GRIN1	glutamate ionotropic receptor NMDA type subunit 1	4	Unknown status	https://clinicaltrials.gov/study/NCT03676114
MONDO_0007254	breast cancer	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	4	Completed	https://clinicaltrials.gov/study/NCT02816164,https://clinicaltrials.gov/study/NCT02816112,https://clinicaltrials.gov/study/NCT02173262
MONDO_0007254	breast cancer	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	4	Unknown status	https://clinicaltrials.gov/study/NCT00126360,https://clinicaltrials.gov/study/NCT02089854
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	4	Completed	https://clinicaltrials.gov/study/NCT01961544,https://clinicaltrials.gov/study/NCT02864030
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT04137640
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	4	Recruiting	https://clinicaltrials.gov/study/NCT05131841,https://clinicaltrials.gov/study/NCT03270007,https://clinicaltrials.gov/study/NCT03355157
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23f3c1f4-0fc8-4804-a9e3-04cf25dd302e
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	4	Recruiting	https://clinicaltrials.gov/study/NCT04136782,https://clinicaltrials.gov/study/NCT05420454,https://clinicaltrials.gov/study/NCT06217185,https://clinicaltrials.gov/study/NCT05420467,https://clinicaltrials.gov/study/NCT02627248,https://clinicaltrials.gov/study/NCT04182568
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dc35c59-f4f3-43b4-8251-0cf5c06cdc80
MONDO_0007254	breast cancer	CHEMBL34259	METHOTREXATE	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd39255b-81d1-4c08-aecf-acc4f2cdc04a,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e30eaef-5a09-4104-8a11-c32933eadeab,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=68623ad0-a395-4847-88d4-48413c1f4fcf
MONDO_0007254	breast cancer	CHEMBL395091	ESKETAMINE	Small molecule	Glutamate [NMDA] receptor negative allosteric modulator	Negative allosteric modulator	GRIN2D	glutamate ionotropic receptor NMDA type subunit 2D	4	Recruiting	https://clinicaltrials.gov/study/NCT05732064
EFO_0000305	breast carcinoma	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	4	Completed	https://clinicaltrials.gov/study/NCT02248571
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA13	NADH:ubiquinone oxidoreductase subunit A13	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	4	Completed	https://clinicaltrials.gov/study/NCT01660542,https://clinicaltrials.gov/study/NCT00127933,https://clinicaltrials.gov/study/NCT01301729,https://clinicaltrials.gov/study/NCT01094184,https://clinicaltrials.gov/study/NCT02419742,https://clinicaltrials.gov/study/NCT02445586,https://clinicaltrials.gov/study/NCT02502864
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	4	Withdrawn	https://clinicaltrials.gov/study/NCT01156961
MONDO_0007254	breast cancer	CHEMBL2396661	ALPELISIB	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	4	Recruiting	https://clinicaltrials.gov/study/NCT05631795
MONDO_0004379	female breast carcinoma	CHEMBL1200694	SEVOFLURANE	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRA4	gamma-aminobutyric acid type A receptor subunit alpha4	4	Completed	https://clinicaltrials.gov/study/NCT02005770
MONDO_0007254	breast cancer	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	4	Completed	https://clinicaltrials.gov/study/NCT00014638,https://clinicaltrials.gov/study/NCT01553903,https://clinicaltrials.gov/study/NCT00237133,https://clinicaltrials.gov/study/NCT01612871,https://clinicaltrials.gov/study/NCT00237224,https://clinicaltrials.gov/study/NCT01127295,https://clinicaltrials.gov/study/NCT02679755,https://clinicaltrials.gov/study/NCT00688909
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	4	Recruiting	https://clinicaltrials.gov/study/NCT06217185,https://clinicaltrials.gov/study/NCT02627248,https://clinicaltrials.gov/study/NCT04182568,https://clinicaltrials.gov/study/NCT04136782,https://clinicaltrials.gov/study/NCT05420467,https://clinicaltrials.gov/study/NCT05420454
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	4	Completed	https://clinicaltrials.gov/study/NCT01961544,https://clinicaltrials.gov/study/NCT02864030
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR2	estrogen receptor 2	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99cf8b69-4c23-4886-80e9-b23e348b5bd7,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2fc17ba3-83c7-a2b4-8a75-6a0cb1e07682
EFO_0000305	breast carcinoma	CHEMBL2396661	ALPELISIB	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dc35c59-f4f3-43b4-8251-0cf5c06cdc80
MONDO_0007254	breast cancer	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	4	Completed	https://clinicaltrials.gov/study/NCT01301729,https://clinicaltrials.gov/study/NCT02445586,https://clinicaltrials.gov/study/NCT00127933,https://clinicaltrials.gov/study/NCT02419742
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND2	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	4	Completed	https://clinicaltrials.gov/study/NCT01660542,https://clinicaltrials.gov/study/NCT01301729,https://clinicaltrials.gov/study/NCT00127933,https://clinicaltrials.gov/study/NCT02445586,https://clinicaltrials.gov/study/NCT01094184,https://clinicaltrials.gov/study/NCT02502864,https://clinicaltrials.gov/study/NCT02419742
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	4	Completed	https://clinicaltrials.gov/study/NCT02419742,https://clinicaltrials.gov/study/NCT01301729,https://clinicaltrials.gov/study/NCT01094184
MONDO_0007254	breast cancer	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	4	Recruiting	https://clinicaltrials.gov/study/NCT05809024,https://clinicaltrials.gov/study/NCT03355157,https://clinicaltrials.gov/study/NCT05161195
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
MONDO_0007254	breast cancer	CHEMBL1655	TOREMIFENE	Small molecule	Estrogen receptor modulator		ESR1	estrogen receptor 1	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2cab8dd1-3a10-48e6-86ce-0e5275ed49e5,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b3ebaa6-9cbe-405e-8f14-14ce8dcd2a68
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN11A	sodium voltage-gated channel alpha subunit 11	4	Completed	https://clinicaltrials.gov/study/NCT04248179
MONDO_0007254	breast cancer	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	4	Recruiting	https://clinicaltrials.gov/study/NCT05131841,https://clinicaltrials.gov/study/NCT04928261,https://clinicaltrials.gov/study/NCT05036005,https://clinicaltrials.gov/study/NCT05420454,https://clinicaltrials.gov/study/NCT06217185,https://clinicaltrials.gov/study/NCT05420467
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
MONDO_0004379	female breast carcinoma	CHEMBL526	PROPOFOL	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRG2	gamma-aminobutyric acid type A receptor subunit gamma2	4	Completed	https://clinicaltrials.gov/study/NCT02005770
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23f3c1f4-0fc8-4804-a9e3-04cf25dd302e
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN9A	sodium voltage-gated channel alpha subunit 9	4	Completed	https://clinicaltrials.gov/study/NCT04248179
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT04137640
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA1	NADH:ubiquinone oxidoreductase subunit A1	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND6	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	4	Completed	https://clinicaltrials.gov/study/NCT02419742,https://clinicaltrials.gov/study/NCT01301729,https://clinicaltrials.gov/study/NCT01094184
MONDO_0004379	female breast carcinoma	CHEMBL526	PROPOFOL	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRA3	gamma-aminobutyric acid type A receptor subunit alpha3	4	Completed	https://clinicaltrials.gov/study/NCT02005770
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1201464	CHORIOGONADOTROPIN ALFA	Protein	Luteinizing hormone/Choriogonadotropin receptor agonist		LHCGR	luteinizing hormone/choriogonadotropin receptor	4	Completed	https://clinicaltrials.gov/study/NCT03495609
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	4	Completed	https://clinicaltrials.gov/study/NCT00372476
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	4	Recruiting	https://clinicaltrials.gov/study/NCT04136782,https://clinicaltrials.gov/study/NCT06217185,https://clinicaltrials.gov/study/NCT05420467,https://clinicaltrials.gov/study/NCT05420454,https://clinicaltrials.gov/study/NCT02627248,https://clinicaltrials.gov/study/NCT04182568
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23f3c1f4-0fc8-4804-a9e3-04cf25dd302e
MONDO_0007254	breast cancer	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=151ce76c-2d44-4c82-850d-ab213bea4d6b,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bd72fd53-ae0c-4080-9b7f-2d294b14cc86
EFO_0005537	triple-negative breast cancer	CHEMBL4297829	SINTILIMAB	Antibody	Programmed cell death protein 1 antagonist		PDCD1	programmed cell death 1	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05843292
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	4	Completed	https://clinicaltrials.gov/study/NCT01961544,https://clinicaltrials.gov/study/NCT02864030
MONDO_0007254	breast cancer	CHEMBL3545262	SACITUZUMAB GOVITECAN	Antibody drug conjugate	Tumor-associated calcium signal transducer 2 binding agent		TACSTD2	tumor associated calcium signal transducer 2	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57a597d2-03f0-472e-b148-016d7169169d
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	4	Recruiting	https://clinicaltrials.gov/study/NCT03270007,https://clinicaltrials.gov/study/NCT05131841,https://clinicaltrials.gov/study/NCT03355157
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23f3c1f4-0fc8-4804-a9e3-04cf25dd302e
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	4	Completed	https://clinicaltrials.gov/study/NCT01961544,https://clinicaltrials.gov/study/NCT02864030
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN11A	sodium voltage-gated channel alpha subunit 11	4	Recruiting	https://clinicaltrials.gov/study/NCT05072314
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=241f0b1e-8b95-470d-876f-bf1804daaf18
MONDO_0007254	breast cancer	CHEMBL554	LAPATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eee37f88-ec6a-4c30-b8aa-e2c71f93088c
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB8	NADH:ubiquinone oxidoreductase subunit B8	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB1	NADH:ubiquinone oxidoreductase subunit B1	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	4	Completed	https://clinicaltrials.gov/study/NCT02658734
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	4	Recruiting	https://clinicaltrials.gov/study/NCT04182568,https://clinicaltrials.gov/study/NCT04136782,https://clinicaltrials.gov/study/NCT05033769,https://clinicaltrials.gov/study/NCT06217185,https://clinicaltrials.gov/study/NCT05183126,https://clinicaltrials.gov/study/NCT05420454,https://clinicaltrials.gov/study/NCT03355157,https://clinicaltrials.gov/study/NCT05420467
EFO_0000305	breast carcinoma	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=69abd0ff-b200-4d1a-b14a-80e980a8e781,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0b31daa-0792-43d5-af08-8b6a864dc90a,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ecdb646-4d0f-4d1b-ac6a-9cb5deb9ac0d,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61d86c55-9946-273f-4f22-42d3fc33d143,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf066b7a-032a-416c-8d40-15ba581423e3
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	4	Recruiting	https://clinicaltrials.gov/study/NCT05033769,https://clinicaltrials.gov/study/NCT03355157,https://clinicaltrials.gov/study/NCT04136782,https://clinicaltrials.gov/study/NCT05420467,https://clinicaltrials.gov/study/NCT05420454,https://clinicaltrials.gov/study/NCT04182568,https://clinicaltrials.gov/study/NCT05183126,https://clinicaltrials.gov/study/NCT06217185
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	4	Recruiting	https://clinicaltrials.gov/study/NCT05420454,https://clinicaltrials.gov/study/NCT06217185,https://clinicaltrials.gov/study/NCT04136782,https://clinicaltrials.gov/study/NCT02627248,https://clinicaltrials.gov/study/NCT04182568,https://clinicaltrials.gov/study/NCT05420467
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	4	Completed	https://clinicaltrials.gov/study/NCT02679755
MONDO_0007254	breast cancer	CHEMBL1471	APREPITANT	Small molecule	Neurokinin 1 receptor antagonist		TACR1	tachykinin receptor 1	4	Completed	https://clinicaltrials.gov/study/NCT01298193
MONDO_0007254	breast cancer	CHEMBL395091	ESKETAMINE	Small molecule	Glutamate [NMDA] receptor negative allosteric modulator	Negative allosteric modulator	GRIN1	glutamate ionotropic receptor NMDA type subunit 1	4	Recruiting	https://clinicaltrials.gov/study/NCT05732064
MONDO_0007254	breast cancer	CHEMBL1889140	ROPIVACAINE HYDROCHLORIDE	Small molecule	Sodium channel alpha subunit blocker		SCN8A	sodium voltage-gated channel alpha subunit 8	4	Completed	https://clinicaltrials.gov/study/NCT03360214
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN3A	sodium voltage-gated channel alpha subunit 3	4	Recruiting	https://clinicaltrials.gov/study/NCT05072314
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT04137640
MONDO_0007254	breast cancer	CHEMBL778	DEXMEDETOMIDINE	Small molecule	Adrenergic receptor alpha-2 agonist		ADRA2C	adrenoceptor alpha 2C	4	Terminated	https://clinicaltrials.gov/study/NCT03456661
MONDO_0004379	female breast carcinoma	CHEMBL1200694	SEVOFLURANE	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRB1	gamma-aminobutyric acid type A receptor subunit beta1	4	Completed	https://clinicaltrials.gov/study/NCT02005770
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN9A	sodium voltage-gated channel alpha subunit 9	4	Recruiting	https://clinicaltrials.gov/study/NCT05072314
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN8A	sodium voltage-gated channel alpha subunit 8	4	Completed	https://clinicaltrials.gov/study/NCT04248179
MONDO_0007254	breast cancer	CHEMBL1655	TOREMIFENE	Small molecule	Estrogen receptor modulator		ESR2	estrogen receptor 2	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b3ebaa6-9cbe-405e-8f14-14ce8dcd2a68,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2cab8dd1-3a10-48e6-86ce-0e5275ed49e5
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	4	Completed	https://clinicaltrials.gov/study/NCT01301729,https://clinicaltrials.gov/study/NCT02419742,https://clinicaltrials.gov/study/NCT01094184
MONDO_0007254	breast cancer	CHEMBL1487	ATORVASTATIN	Small molecule	HMG-CoA reductase inhibitor		HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN5A	sodium voltage-gated channel alpha subunit 5	4	Completed	https://clinicaltrials.gov/study/NCT04248179
EFO_0000305	breast carcinoma	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=492dbdb2-077e-4064-bff3-372d6af0a7a2
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dc35c59-f4f3-43b4-8251-0cf5c06cdc80
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	4	Recruiting	https://clinicaltrials.gov/study/NCT05131841,https://clinicaltrials.gov/study/NCT03355157,https://clinicaltrials.gov/study/NCT03270007
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA3	NADH:ubiquinone oxidoreductase subunit A3	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffc0a4be-6091-4157-837e-3637c1e121a6,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6004fba9-49c0-4781-8134-44bf7cf196fd,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c550dd16-a5e8-44be-87f2-210c15bbb513,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49f9e774-52f9-40af-aecf-217c11e243ce
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f59f7811-70b7-4c44-99f7-4f4fdce3ed22,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0ec4bcc-93ea-4c41-a4b6-95ec19491807,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70aeb960-426c-4805-b956-476bebccd926,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd0ca36d-1f54-4568-8d19-a7152addcd52,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2dc690b-4c69-428a-a67e-8ad007c39548,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c806400-5fdc-4398-8475-37f700b3191f,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e03d1378-6889-43d5-a34c-f96132cffa88,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a630937b-8369-74ad-b68a-f940eb16ff0f,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c482c813-1eb7-40dd-907a-845a7df112bf,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b35e3633-8893-4b0b-af1e-92e342557199
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dc35c59-f4f3-43b4-8251-0cf5c06cdc80
MONDO_0007254	breast cancer	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	4	Terminated	https://clinicaltrials.gov/study/NCT04657679
MONDO_0007254	breast cancer	CHEMBL1889140	ROPIVACAINE HYDROCHLORIDE	Small molecule	Sodium channel alpha subunit blocker		SCN7A	sodium voltage-gated channel alpha subunit 7	4	Completed	https://clinicaltrials.gov/study/NCT03360214
MONDO_0007254	breast cancer	CHEMBL778	DEXMEDETOMIDINE	Small molecule	Adrenergic receptor alpha-2 agonist		ADRA2A	adrenoceptor alpha 2A	4	Terminated	https://clinicaltrials.gov/study/NCT03456661
MONDO_0007254	breast cancer	CHEMBL1889140	ROPIVACAINE HYDROCHLORIDE	Small molecule	Sodium channel alpha subunit blocker		SCN5A	sodium voltage-gated channel alpha subunit 5	4	Completed	https://clinicaltrials.gov/study/NCT03360214
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND5	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS5	NADH:ubiquinone oxidoreductase subunit S5	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA6	NADH:ubiquinone oxidoreductase subunit A6	4	Completed	https://clinicaltrials.gov/study/NCT05840068
EFO_0000305	breast carcinoma	CHEMBL1655	TOREMIFENE	Small molecule	Estrogen receptor modulator		ESR2	estrogen receptor 2	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2cab8dd1-3a10-48e6-86ce-0e5275ed49e5,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6ff9761-7442-4bff-9e50-858c03e27fd0
MONDO_0007254	breast cancer	CHEMBL1889140	ROPIVACAINE HYDROCHLORIDE	Small molecule	Sodium channel alpha subunit blocker		SCN4A	sodium voltage-gated channel alpha subunit 4	4	Completed	https://clinicaltrials.gov/study/NCT03360214
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS1	NADH:ubiquinone oxidoreductase core subunit S1	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	4	Recruiting	https://clinicaltrials.gov/study/NCT06217185,https://clinicaltrials.gov/study/NCT05033769,https://clinicaltrials.gov/study/NCT04182568,https://clinicaltrials.gov/study/NCT04136782,https://clinicaltrials.gov/study/NCT05420467,https://clinicaltrials.gov/study/NCT05420454,https://clinicaltrials.gov/study/NCT05183126,https://clinicaltrials.gov/study/NCT03355157
MONDO_0007254	breast cancer	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	4	Unknown status	https://clinicaltrials.gov/study/NCT03123770,https://clinicaltrials.gov/study/NCT00531973,https://clinicaltrials.gov/study/NCT02903524
MONDO_0007254	breast cancer	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN2A	sodium voltage-gated channel alpha subunit 2	4	Completed	https://clinicaltrials.gov/study/NCT03360214
MONDO_0007254	breast cancer	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0b31daa-0792-43d5-af08-8b6a864dc90a
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA11	NADH:ubiquinone oxidoreductase subunit A11	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	4	Completed	https://clinicaltrials.gov/study/NCT01094184,https://clinicaltrials.gov/study/NCT02419742,https://clinicaltrials.gov/study/NCT01301729
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB1	NADH:ubiquinone oxidoreductase subunit B1	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23f3c1f4-0fc8-4804-a9e3-04cf25dd302e
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	4	Completed	https://clinicaltrials.gov/study/NCT02864030,https://clinicaltrials.gov/study/NCT01961544
EFO_0000305	breast carcinoma	CHEMBL3707266	RIBOCICLIB SUCCINATE	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209092s000lbl.pdf
EFO_0000305	breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6004fba9-49c0-4781-8134-44bf7cf196fd,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49f9e774-52f9-40af-aecf-217c11e243ce,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c550dd16-a5e8-44be-87f2-210c15bbb513,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffc0a4be-6091-4157-837e-3637c1e121a6
MONDO_0007254	breast cancer	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	4	Completed	https://clinicaltrials.gov/study/NCT00544986,https://clinicaltrials.gov/study/NCT01553903,https://clinicaltrials.gov/study/NCT00323479,https://clinicaltrials.gov/study/NCT00537771,https://clinicaltrials.gov/study/NCT00082277,https://clinicaltrials.gov/study/NCT01127295,https://clinicaltrials.gov/study/NCT01612871
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS5	NADH:ubiquinone oxidoreductase subunit S5	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	4	Completed	https://clinicaltrials.gov/study/NCT00372476
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	4	Completed	https://clinicaltrials.gov/study/NCT02419742,https://clinicaltrials.gov/study/NCT01660542,https://clinicaltrials.gov/study/NCT02502864,https://clinicaltrials.gov/study/NCT00127933,https://clinicaltrials.gov/study/NCT01301729,https://clinicaltrials.gov/study/NCT02445586,https://clinicaltrials.gov/study/NCT01094184
MONDO_0004379	female breast carcinoma	CHEMBL1200694	SEVOFLURANE	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRA1	gamma-aminobutyric acid type A receptor subunit alpha1	4	Completed	https://clinicaltrials.gov/study/NCT02005770
EFO_0000305	breast carcinoma	CHEMBL1201179	LAPATINIB DITOSYLATE	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022059lbl.pdf
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	4	Withdrawn	https://clinicaltrials.gov/study/NCT00774241
MONDO_0004379	female breast carcinoma	CHEMBL1200694	SEVOFLURANE	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRQ	gamma-aminobutyric acid type A receptor subunit theta	4	Completed	https://clinicaltrials.gov/study/NCT02005770
MONDO_0007254	breast cancer	CHEMBL4297840	TISLELIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	4	Recruiting	https://clinicaltrials.gov/study/NCT05861635
EFO_0000305	breast carcinoma	CHEMBL1200675	TOREMIFENE CITRATE	Small molecule	Estrogen receptor modulator		ESR1	estrogen receptor 1	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6ff9761-7442-4bff-9e50-858c03e27fd0,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2cab8dd1-3a10-48e6-86ce-0e5275ed49e5
MONDO_0007254	breast cancer	CHEMBL924	ZOLEDRONIC ACID ANHYDROUS	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	4	Active, not recruiting	https://clinicaltrials.gov/study/NCT03664687
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB10	NADH:ubiquinone oxidoreductase subunit B10	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND3	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3	4	Completed	https://clinicaltrials.gov/study/NCT05840068
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e03d1378-6889-43d5-a34c-f96132cffa88,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a630937b-8369-74ad-b68a-f940eb16ff0f,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c482c813-1eb7-40dd-907a-845a7df112bf,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b35e3633-8893-4b0b-af1e-92e342557199,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f59f7811-70b7-4c44-99f7-4f4fdce3ed22,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70aeb960-426c-4805-b956-476bebccd926,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2dc690b-4c69-428a-a67e-8ad007c39548,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd0ca36d-1f54-4568-8d19-a7152addcd52,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0ec4bcc-93ea-4c41-a4b6-95ec19491807,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c806400-5fdc-4398-8475-37f700b3191f
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	4	Withdrawn	https://clinicaltrials.gov/study/NCT00774241
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	4	Completed	https://clinicaltrials.gov/study/NCT00127933,https://clinicaltrials.gov/study/NCT02502864,https://clinicaltrials.gov/study/NCT01301729,https://clinicaltrials.gov/study/NCT02419742,https://clinicaltrials.gov/study/NCT02445586,https://clinicaltrials.gov/study/NCT01660542,https://clinicaltrials.gov/study/NCT01094184
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	4	Withdrawn	https://clinicaltrials.gov/study/NCT01156961
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	4	Completed	https://clinicaltrials.gov/study/NCT00372476
MONDO_0007254	breast cancer	CHEMBL1889140	ROPIVACAINE HYDROCHLORIDE	Small molecule	Sodium channel alpha subunit blocker		SCN1A	sodium voltage-gated channel alpha subunit 1	4	Completed	https://clinicaltrials.gov/study/NCT03360214
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	4	Completed	https://clinicaltrials.gov/study/NCT02502864,https://clinicaltrials.gov/study/NCT02419742,https://clinicaltrials.gov/study/NCT00127933,https://clinicaltrials.gov/study/NCT01094184,https://clinicaltrials.gov/study/NCT01660542,https://clinicaltrials.gov/study/NCT02445586,https://clinicaltrials.gov/study/NCT01301729
MONDO_0004379	female breast carcinoma	CHEMBL526	PROPOFOL	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRB2	gamma-aminobutyric acid type A receptor subunit beta2	4	Completed	https://clinicaltrials.gov/study/NCT02005770
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	4	Completed	https://clinicaltrials.gov/study/NCT02445586,https://clinicaltrials.gov/study/NCT00127933,https://clinicaltrials.gov/study/NCT02502864,https://clinicaltrials.gov/study/NCT01660542,https://clinicaltrials.gov/study/NCT01094184,https://clinicaltrials.gov/study/NCT01301729,https://clinicaltrials.gov/study/NCT02419742
MONDO_0007254	breast cancer	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	4	Recruiting	https://clinicaltrials.gov/study/NCT03355157
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN10A	sodium voltage-gated channel alpha subunit 10	4	Completed	https://clinicaltrials.gov/study/NCT04248179
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	4	Recruiting	https://clinicaltrials.gov/study/NCT03270007,https://clinicaltrials.gov/study/NCT05131841,https://clinicaltrials.gov/study/NCT03355157
MONDO_0007254	breast cancer	CHEMBL1655	TOREMIFENE	Small molecule	Estrogen receptor modulator		ESR2	estrogen receptor 2	4	Completed	https://clinicaltrials.gov/study/NCT02344940
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	4	Unknown status	https://clinicaltrials.gov/study/NCT03123770
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	4	Withdrawn	https://clinicaltrials.gov/study/NCT00774241
MONDO_0004658	breast carcinoma in situ	CHEMBL1655	TOREMIFENE	Small molecule	Estrogen receptor modulator		ESR1	estrogen receptor 1	4	Withdrawn	https://clinicaltrials.gov/study/NCT03238703
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS1	NADH:ubiquinone oxidoreductase core subunit S1	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR2	estrogen receptor 2	4	Recruiting	https://clinicaltrials.gov/study/NCT05631795,https://clinicaltrials.gov/study/NCT05362760,https://clinicaltrials.gov/study/NCT05161195,https://clinicaltrials.gov/study/NCT03355157
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	4	Unknown status	https://clinicaltrials.gov/study/NCT02207361,https://clinicaltrials.gov/study/NCT02142790,https://clinicaltrials.gov/study/NCT00912639
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR2	estrogen receptor 2	4	Completed	https://clinicaltrials.gov/study/NCT02447328
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	4	Withdrawn	https://clinicaltrials.gov/study/NCT00774241
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAB1	NADH:ubiquinone oxidoreductase subunit AB1	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636
MONDO_0007254	breast cancer	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	4	Recruiting	https://clinicaltrials.gov/study/NCT05753618
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT04137640
MONDO_0007254	breast cancer	CHEMBL3989868	TUCATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f27eb1b9-b7fc-424e-988f-84dd7bb195a3
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05291910
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6004fba9-49c0-4781-8134-44bf7cf196fd,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49f9e774-52f9-40af-aecf-217c11e243ce,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c550dd16-a5e8-44be-87f2-210c15bbb513,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffc0a4be-6091-4157-837e-3637c1e121a6
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ca3c0d4-e629-4d89-a969-3515a62886c6,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24d10449-2936-4cd3-b7db-a7683db721e4
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB10	NADH:ubiquinone oxidoreductase subunit B10	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC1	NADH:ubiquinone oxidoreductase subunit C1	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL1655	TOREMIFENE	Small molecule	Estrogen receptor modulator		ESR2	estrogen receptor 2	4	Unknown status	https://clinicaltrials.gov/study/NCT02089854
MONDO_0007254	breast cancer	CHEMBL1889140	ROPIVACAINE HYDROCHLORIDE	Small molecule	Sodium channel alpha subunit blocker		SCN10A	sodium voltage-gated channel alpha subunit 10	4	Completed	https://clinicaltrials.gov/study/NCT03360214
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23f3c1f4-0fc8-4804-a9e3-04cf25dd302e
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	4	Completed	https://clinicaltrials.gov/study/NCT02658734
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=973efa93-7f9d-440a-a09f-521cf331b5e7,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24d10449-2936-4cd3-b7db-a7683db721e4,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6cefbdb9-1141-4a53-9d05-f6fcc2746834,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4dbbb7c8-a4b5-484d-a2a4-4d925010fc44,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6c24189-293f-42ca-b969-75870bb55af0,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d499be2-fdb5-4b9d-a7ce-3662ec9b2e34,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e1a3a8d-6a6b-46fd-90ae-c7ad9e9b364b,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=88d7cdd2-e650-4a16-adec-873927e03e93,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea28753a-8631-460a-bfdc-b101eb8ac84a,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ffd3e34-537f-4f65-b00e-57c25bab3b01,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=566a00ae-47c0-4cd2-b602-79909bdfd9b1,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f10f730f-6479-4f6a-8edc-fa4bd2140c1b
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
MONDO_0007254	breast cancer	CHEMBL941	IMATINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	4	Completed	https://clinicaltrials.gov/study/NCT00372476
MONDO_0007254	breast cancer	CHEMBL2364649	MARGETUXIMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e97a5872-eabf-463b-8f4c-5b5aed9c7bf0,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB7	NADH:ubiquinone oxidoreductase subunit B7	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0004379	female breast carcinoma	CHEMBL526	PROPOFOL	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRQ	gamma-aminobutyric acid type A receptor subunit theta	4	Completed	https://clinicaltrials.gov/study/NCT02005770
MONDO_0004379	female breast carcinoma	CHEMBL1200694	SEVOFLURANE	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRA5	gamma-aminobutyric acid type A receptor subunit alpha5	4	Completed	https://clinicaltrials.gov/study/NCT02005770
MONDO_0004379	female breast carcinoma	CHEMBL526	PROPOFOL	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRB1	gamma-aminobutyric acid type A receptor subunit beta1	4	Completed	https://clinicaltrials.gov/study/NCT02005770
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c482c813-1eb7-40dd-907a-845a7df112bf,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a630937b-8369-74ad-b68a-f940eb16ff0f,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd0ca36d-1f54-4568-8d19-a7152addcd52,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c806400-5fdc-4398-8475-37f700b3191f,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70aeb960-426c-4805-b956-476bebccd926,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b35e3633-8893-4b0b-af1e-92e342557199,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f59f7811-70b7-4c44-99f7-4f4fdce3ed22,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e03d1378-6889-43d5-a34c-f96132cffa88,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0ec4bcc-93ea-4c41-a4b6-95ec19491807,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2dc690b-4c69-428a-a67e-8ad007c39548
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB7	NADH:ubiquinone oxidoreductase subunit B7	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	4	Completed	https://clinicaltrials.gov/study/NCT02502864,https://clinicaltrials.gov/study/NCT01660542,https://clinicaltrials.gov/study/NCT02445586,https://clinicaltrials.gov/study/NCT02419742,https://clinicaltrials.gov/study/NCT00127933,https://clinicaltrials.gov/study/NCT01301729,https://clinicaltrials.gov/study/NCT01094184
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dc35c59-f4f3-43b4-8251-0cf5c06cdc80
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23f3c1f4-0fc8-4804-a9e3-04cf25dd302e
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24d10449-2936-4cd3-b7db-a7683db721e4,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ca3c0d4-e629-4d89-a969-3515a62886c6
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	4	Completed	https://clinicaltrials.gov/study/NCT02864030,https://clinicaltrials.gov/study/NCT01961544
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA5	NADH:ubiquinone oxidoreductase subunit A5	4	Completed	https://clinicaltrials.gov/study/NCT05840068
EFO_0000305	breast carcinoma	CHEMBL1200675	TOREMIFENE CITRATE	Small molecule	Estrogen receptor modulator		ESR2	estrogen receptor 2	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2cab8dd1-3a10-48e6-86ce-0e5275ed49e5,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6ff9761-7442-4bff-9e50-858c03e27fd0
MONDO_0007254	breast cancer	CHEMBL778	DEXMEDETOMIDINE	Small molecule	Adrenergic receptor alpha-2 agonist		ADRA2A	adrenoceptor alpha 2A	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT06300099,https://clinicaltrials.gov/study/NCT06252662
MONDO_0004379	female breast carcinoma	CHEMBL526	PROPOFOL	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRP	gamma-aminobutyric acid type A receptor subunit pi	4	Completed	https://clinicaltrials.gov/study/NCT02005770
EFO_0000305	breast carcinoma	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208716Orig1s000lbl.pdf
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	4	Completed	https://clinicaltrials.gov/study/NCT00372476
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL3989868	TUCATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf
EFO_0000305	breast carcinoma	CHEMBL1200501	GOSERELIN ACETATE	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6bd94a89-f18a-45e5-d0a4-b343a4f0f03d
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a630937b-8369-74ad-b68a-f940eb16ff0f,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2dc690b-4c69-428a-a67e-8ad007c39548,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e03d1378-6889-43d5-a34c-f96132cffa88,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b35e3633-8893-4b0b-af1e-92e342557199,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70aeb960-426c-4805-b956-476bebccd926,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f59f7811-70b7-4c44-99f7-4f4fdce3ed22,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd0ca36d-1f54-4568-8d19-a7152addcd52,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0ec4bcc-93ea-4c41-a4b6-95ec19491807,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c482c813-1eb7-40dd-907a-845a7df112bf,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c806400-5fdc-4398-8475-37f700b3191f
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	4	Withdrawn	https://clinicaltrials.gov/study/NCT01156961
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB3	NADH:ubiquinone oxidoreductase subunit B3	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	4	Recruiting	https://clinicaltrials.gov/study/NCT06217185,https://clinicaltrials.gov/study/NCT03355157
MONDO_0007254	breast cancer	CHEMBL469	KETOROLAC	Small molecule	Cyclooxygenase inhibitor		PTGS1	prostaglandin-endoperoxide synthase 1	4	Withdrawn	https://clinicaltrials.gov/study/NCT03007381
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	4	Unknown status	https://clinicaltrials.gov/study/NCT02207361,https://clinicaltrials.gov/study/NCT02142790,https://clinicaltrials.gov/study/NCT00912639
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	4	Withdrawn	https://clinicaltrials.gov/study/NCT00774241
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS8	NADH:ubiquinone oxidoreductase core subunit S8	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB11	NADH:ubiquinone oxidoreductase subunit B11	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
EFO_0000305	breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022065lbl.pdf
EFO_0000305	breast carcinoma	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209092s000lbl.pdf
MONDO_0007254	breast cancer	CHEMBL1201124	KETOROLAC TROMETHAMINE	Small molecule	Cyclooxygenase inhibitor		PTGS1	prostaglandin-endoperoxide synthase 1	4	Withdrawn	https://clinicaltrials.gov/study/NCT03007381
MONDO_0007254	breast cancer	CHEMBL1201583	BEVACIZUMAB	Antibody	Vascular endothelial growth factor A inhibitor		VEGFA	vascular endothelial growth factor A	4	Withdrawn	https://clinicaltrials.gov/study/NCT00774241,https://clinicaltrials.gov/study/NCT01156961
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	4	Recruiting	https://clinicaltrials.gov/study/NCT05033769
MONDO_0007254	breast cancer	CHEMBL1201568	PEGFILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	4	Recruiting	https://clinicaltrials.gov/study/NCT05753618
MONDO_0007254	breast cancer	CHEMBL70	MORPHINE	Small molecule	Mu opioid receptor agonist		OPRM1	opioid receptor mu 1	4	Unknown status	https://clinicaltrials.gov/study/NCT03051503
MONDO_0007254	breast cancer	CHEMBL778	DEXMEDETOMIDINE	Small molecule	Adrenergic receptor alpha-2 agonist		ADRA2C	adrenoceptor alpha 2C	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT06252662,https://clinicaltrials.gov/study/NCT06300099
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=241f0b1e-8b95-470d-876f-bf1804daaf18
EFO_0000305	breast carcinoma	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86718885-da44-4d3d-b3ca-06cbcedcffd8,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0e6412f-50b4-4fd4-9364-62818d121a07
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c550dd16-a5e8-44be-87f2-210c15bbb513,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6004fba9-49c0-4781-8134-44bf7cf196fd,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffc0a4be-6091-4157-837e-3637c1e121a6,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49f9e774-52f9-40af-aecf-217c11e243ce
MONDO_0007254	breast cancer	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=492dbdb2-077e-4064-bff3-372d6af0a7a2,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27dd5e6b-72cd-458d-a015-cf4dab5800da,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ebf30894-41cf-480c-8bc3-56f592a13813
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
MONDO_0007254	breast cancer	CHEMBL923	RISEDRONIC ACID	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	4	Completed	https://clinicaltrials.gov/study/NCT00082277
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	4	Completed	https://clinicaltrials.gov/study/NCT00127933,https://clinicaltrials.gov/study/NCT01094184,https://clinicaltrials.gov/study/NCT02419742,https://clinicaltrials.gov/study/NCT01301729,https://clinicaltrials.gov/study/NCT02502864,https://clinicaltrials.gov/study/NCT01660542,https://clinicaltrials.gov/study/NCT02445586
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT04137640
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd0ca36d-1f54-4568-8d19-a7152addcd52,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0ec4bcc-93ea-4c41-a4b6-95ec19491807,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2dc690b-4c69-428a-a67e-8ad007c39548,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f59f7811-70b7-4c44-99f7-4f4fdce3ed22,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b35e3633-8893-4b0b-af1e-92e342557199,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70aeb960-426c-4805-b956-476bebccd926,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c806400-5fdc-4398-8475-37f700b3191f,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e03d1378-6889-43d5-a34c-f96132cffa88,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c482c813-1eb7-40dd-907a-845a7df112bf,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a630937b-8369-74ad-b68a-f940eb16ff0f
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23f3c1f4-0fc8-4804-a9e3-04cf25dd302e
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF1	NADH:ubiquinone oxidoreductase complex assembly factor 1	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4L2	NDUFA4 mitochondrial complex associated like 2	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	4	Completed	https://clinicaltrials.gov/study/NCT02864030,https://clinicaltrials.gov/study/NCT01961544
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dc35c59-f4f3-43b4-8251-0cf5c06cdc80
MONDO_0007254	breast cancer	CHEMBL3244648	METHOTREXATE SODIUM	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=68623ad0-a395-4847-88d4-48413c1f4fcf
EFO_0000305	breast carcinoma	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0349f98-42fa-4003-b6d8-a1db1401b0ef
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	4	Completed	https://clinicaltrials.gov/study/NCT01961544,https://clinicaltrials.gov/study/NCT02864030
MONDO_0004379	female breast carcinoma	CHEMBL1200694	SEVOFLURANE	Small molecule	Potassium channel subfamily K member 9 opener		KCNK9	potassium two pore domain channel subfamily K member 9	4	Completed	https://clinicaltrials.gov/study/NCT02005770
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23f3c1f4-0fc8-4804-a9e3-04cf25dd302e
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	4	Unknown status	https://clinicaltrials.gov/study/NCT03123770
EFO_0000305	breast carcinoma	CHEMBL34259	METHOTREXATE	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57b2face-9edd-4aea-bbc4-938249aa2267,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd035a9f-cd40-4314-b9d8-2294b8a924e2
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23f3c1f4-0fc8-4804-a9e3-04cf25dd302e
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS6	NADH:ubiquinone oxidoreductase subunit S6	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF4	NADH:ubiquinone oxidoreductase complex assembly factor 4	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=241f0b1e-8b95-470d-876f-bf1804daaf18
MONDO_0007254	breast cancer	CHEMBL742	KETAMINE	Small molecule	Glutamate [NMDA] receptor negative allosteric modulator	Negative allosteric modulator	GRIN2D	glutamate ionotropic receptor NMDA type subunit 2D	4	Unknown status	https://clinicaltrials.gov/study/NCT03676114
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB5	NADH:ubiquinone oxidoreductase subunit B5	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN9A	sodium voltage-gated channel alpha subunit 9	4	Completed	https://clinicaltrials.gov/study/NCT03360214
MONDO_0007254	breast cancer	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1d1d5818-1594-4f54-90a9-ae9a9afcdc67
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	4	Recruiting	https://clinicaltrials.gov/study/NCT05033769,https://clinicaltrials.gov/study/NCT05183126,https://clinicaltrials.gov/study/NCT06217185,https://clinicaltrials.gov/study/NCT05420454,https://clinicaltrials.gov/study/NCT04182568,https://clinicaltrials.gov/study/NCT04136782,https://clinicaltrials.gov/study/NCT03355157,https://clinicaltrials.gov/study/NCT05420467
EFO_0000305	breast carcinoma	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR1	estrogen receptor 1	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83d7a440-e904-4e36-afb5-cb02b1c919f7
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e1a3a8d-6a6b-46fd-90ae-c7ad9e9b364b,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6c24189-293f-42ca-b969-75870bb55af0,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4dbbb7c8-a4b5-484d-a2a4-4d925010fc44,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea28753a-8631-460a-bfdc-b101eb8ac84a,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=973efa93-7f9d-440a-a09f-521cf331b5e7,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d499be2-fdb5-4b9d-a7ce-3662ec9b2e34,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24d10449-2936-4cd3-b7db-a7683db721e4,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ffd3e34-537f-4f65-b00e-57c25bab3b01,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=566a00ae-47c0-4cd2-b602-79909bdfd9b1,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6cefbdb9-1141-4a53-9d05-f6fcc2746834,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=88d7cdd2-e650-4a16-adec-873927e03e93,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f10f730f-6479-4f6a-8edc-fa4bd2140c1b
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV1	NADH:ubiquinone oxidoreductase core subunit V1	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dc35c59-f4f3-43b4-8251-0cf5c06cdc80
MONDO_0007254	breast cancer	CHEMBL1200675	TOREMIFENE CITRATE	Small molecule	Estrogen receptor modulator		ESR1	estrogen receptor 1	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b3ebaa6-9cbe-405e-8f14-14ce8dcd2a68,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2cab8dd1-3a10-48e6-86ce-0e5275ed49e5
MONDO_0004379	female breast carcinoma	CHEMBL1200694	SEVOFLURANE	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRB2	gamma-aminobutyric acid type A receptor subunit beta2	4	Completed	https://clinicaltrials.gov/study/NCT02005770
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	4	Completed	https://clinicaltrials.gov/study/NCT02419742,https://clinicaltrials.gov/study/NCT01301729,https://clinicaltrials.gov/study/NCT02502864,https://clinicaltrials.gov/study/NCT02445586,https://clinicaltrials.gov/study/NCT00127933,https://clinicaltrials.gov/study/NCT01094184,https://clinicaltrials.gov/study/NCT01660542
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4dbbb7c8-a4b5-484d-a2a4-4d925010fc44,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=566a00ae-47c0-4cd2-b602-79909bdfd9b1,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e1a3a8d-6a6b-46fd-90ae-c7ad9e9b364b,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=88d7cdd2-e650-4a16-adec-873927e03e93,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d499be2-fdb5-4b9d-a7ce-3662ec9b2e34,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6c24189-293f-42ca-b969-75870bb55af0,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea28753a-8631-460a-bfdc-b101eb8ac84a,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f10f730f-6479-4f6a-8edc-fa4bd2140c1b,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6cefbdb9-1141-4a53-9d05-f6fcc2746834,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24d10449-2936-4cd3-b7db-a7683db721e4,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=973efa93-7f9d-440a-a09f-521cf331b5e7,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ffd3e34-537f-4f65-b00e-57c25bab3b01
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	4	Completed	https://clinicaltrials.gov/study/NCT00372476
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR2	estrogen receptor 2	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05191914,https://clinicaltrials.gov/study/NCT03591549
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR2	estrogen receptor 2	4	Terminated	https://clinicaltrials.gov/study/NCT04031885
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	4	Recruiting	https://clinicaltrials.gov/study/NCT03355157
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	4	Unknown status	https://clinicaltrials.gov/study/NCT03123770
MONDO_0007254	breast cancer	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17f85d17-ab71-4f5b-9fe3-0b8c822f69ff,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27dd5e6b-72cd-458d-a015-cf4dab5800da
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dc35c59-f4f3-43b4-8251-0cf5c06cdc80
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT04137640
EFO_0000305	breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022065lbl.pdf
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAB1	NADH:ubiquinone oxidoreductase subunit AB1	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	4	Completed	https://clinicaltrials.gov/study/NCT01301729,https://clinicaltrials.gov/study/NCT02419742,https://clinicaltrials.gov/study/NCT01094184
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF2	NADH:ubiquinone oxidoreductase complex assembly factor 2	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	4	Withdrawn	https://clinicaltrials.gov/study/NCT01156961
MONDO_0007254	breast cancer	CHEMBL4297844	TRASTUZUMAB DERUXTECAN	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 binding agent		ERBB2	erb-b2 receptor tyrosine kinase 2	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e67e73e-ddf4-4e4d-8b50-09d7514910b6
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636
EFO_0000305	breast carcinoma	CHEMBL3137318	TALAZOPARIB TOSYLATE	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	4	Recruiting	https://clinicaltrials.gov/study/NCT05033769
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS4	NADH:ubiquinone oxidoreductase subunit S4	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	4	Completed	https://clinicaltrials.gov/study/NCT02445586,https://clinicaltrials.gov/study/NCT02502864,https://clinicaltrials.gov/study/NCT00127933,https://clinicaltrials.gov/study/NCT02419742,https://clinicaltrials.gov/study/NCT01301729,https://clinicaltrials.gov/study/NCT01094184,https://clinicaltrials.gov/study/NCT01660542
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB2	NADH:ubiquinone oxidoreductase subunit B2	4	Completed	https://clinicaltrials.gov/study/NCT05840068
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49f9e774-52f9-40af-aecf-217c11e243ce,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6004fba9-49c0-4781-8134-44bf7cf196fd,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c550dd16-a5e8-44be-87f2-210c15bbb513,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffc0a4be-6091-4157-837e-3637c1e121a6
MONDO_0004379	female breast carcinoma	CHEMBL526	PROPOFOL	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRA5	gamma-aminobutyric acid type A receptor subunit alpha5	4	Completed	https://clinicaltrials.gov/study/NCT02005770
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	4	Completed	https://clinicaltrials.gov/study/NCT02502864,https://clinicaltrials.gov/study/NCT02419742,https://clinicaltrials.gov/study/NCT02445586,https://clinicaltrials.gov/study/NCT01301729,https://clinicaltrials.gov/study/NCT01094184,https://clinicaltrials.gov/study/NCT00127933,https://clinicaltrials.gov/study/NCT01660542
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	4	Recruiting	https://clinicaltrials.gov/study/NCT06217185,https://clinicaltrials.gov/study/NCT05033769,https://clinicaltrials.gov/study/NCT04136782,https://clinicaltrials.gov/study/NCT03355157,https://clinicaltrials.gov/study/NCT05420467,https://clinicaltrials.gov/study/NCT04182568,https://clinicaltrials.gov/study/NCT05183126,https://clinicaltrials.gov/study/NCT05420454
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24d10449-2936-4cd3-b7db-a7683db721e4,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ca3c0d4-e629-4d89-a969-3515a62886c6
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	4	Withdrawn	https://clinicaltrials.gov/study/NCT00774241
MONDO_0007254	breast cancer	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	4	Completed	https://clinicaltrials.gov/study/NCT01553903,https://clinicaltrials.gov/study/NCT00537771,https://clinicaltrials.gov/study/NCT02344940,https://clinicaltrials.gov/study/NCT01612871
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=241f0b1e-8b95-470d-876f-bf1804daaf18
MONDO_0007254	breast cancer	CHEMBL180022	NERATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d1e41dcf-e82a-47c2-a0ad-6c6eef621834
MONDO_0007254	breast cancer	CHEMBL4303669	ZOLEDRONIC ACID	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	4	Active, not recruiting	https://clinicaltrials.gov/study/NCT03664687
EFO_0000305	breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022065lbl.pdf
EFO_0000305	breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022065lbl.pdf
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	4	Completed	https://clinicaltrials.gov/study/NCT02658734
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	4	Completed	https://clinicaltrials.gov/study/NCT00372476
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49f9e774-52f9-40af-aecf-217c11e243ce,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffc0a4be-6091-4157-837e-3637c1e121a6,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c550dd16-a5e8-44be-87f2-210c15bbb513,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6004fba9-49c0-4781-8134-44bf7cf196fd
MONDO_0004379	female breast carcinoma	CHEMBL1200694	SEVOFLURANE	Small molecule	Glycine receptor (alpha-1/beta) positive modulator		GLRA1	glycine receptor alpha 1	4	Completed	https://clinicaltrials.gov/study/NCT02005770
MONDO_0007254	breast cancer	CHEMBL1201583	BEVACIZUMAB	Antibody	Vascular endothelial growth factor A inhibitor		VEGFA	vascular endothelial growth factor A	4	Completed	https://clinicaltrials.gov/study/NCT00121836,https://clinicaltrials.gov/study/NCT01094184
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	4	Recruiting	https://clinicaltrials.gov/study/NCT04136782,https://clinicaltrials.gov/study/NCT02627248,https://clinicaltrials.gov/study/NCT04182568,https://clinicaltrials.gov/study/NCT05420467,https://clinicaltrials.gov/study/NCT06217185,https://clinicaltrials.gov/study/NCT05420454
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV2	NADH:ubiquinone oxidoreductase core subunit V2	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF2	NADH:ubiquinone oxidoreductase complex assembly factor 2	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	4	Recruiting	https://clinicaltrials.gov/study/NCT04136782,https://clinicaltrials.gov/study/NCT04182568,https://clinicaltrials.gov/study/NCT06217185,https://clinicaltrials.gov/study/NCT05420454,https://clinicaltrials.gov/study/NCT05183126,https://clinicaltrials.gov/study/NCT05420467,https://clinicaltrials.gov/study/NCT05033769,https://clinicaltrials.gov/study/NCT03355157
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dc35c59-f4f3-43b4-8251-0cf5c06cdc80
MONDO_0007254	breast cancer	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	4	Completed	https://clinicaltrials.gov/study/NCT01127295,https://clinicaltrials.gov/study/NCT01612871,https://clinicaltrials.gov/study/NCT01553903,https://clinicaltrials.gov/study/NCT01743560
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dc35c59-f4f3-43b4-8251-0cf5c06cdc80
MONDO_0007254	breast cancer	CHEMBL1655	TOREMIFENE	Small molecule	Estrogen receptor modulator		ESR1	estrogen receptor 1	4	Unknown status	https://clinicaltrials.gov/study/NCT02089854
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA8	NADH:ubiquinone oxidoreductase subunit A8	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	4	Completed	https://clinicaltrials.gov/study/NCT01961544,https://clinicaltrials.gov/study/NCT02864030
MONDO_0004379	female breast carcinoma	CHEMBL526	PROPOFOL	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRA1	gamma-aminobutyric acid type A receptor subunit alpha1	4	Completed	https://clinicaltrials.gov/study/NCT02005770
EFO_0000305	breast carcinoma	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR2	estrogen receptor 2	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83d7a440-e904-4e36-afb5-cb02b1c919f7
EFO_0000305	breast carcinoma	CHEMBL3989921	NERATINIB MALEATE	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208051s000lbl.pdf
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f59f7811-70b7-4c44-99f7-4f4fdce3ed22,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a630937b-8369-74ad-b68a-f940eb16ff0f,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e03d1378-6889-43d5-a34c-f96132cffa88,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c482c813-1eb7-40dd-907a-845a7df112bf,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2dc690b-4c69-428a-a67e-8ad007c39548,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c806400-5fdc-4398-8475-37f700b3191f,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd0ca36d-1f54-4568-8d19-a7152addcd52,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b35e3633-8893-4b0b-af1e-92e342557199,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0ec4bcc-93ea-4c41-a4b6-95ec19491807,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70aeb960-426c-4805-b956-476bebccd926
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	4	Completed	https://clinicaltrials.gov/study/NCT02419742,https://clinicaltrials.gov/study/NCT00127933,https://clinicaltrials.gov/study/NCT01660542,https://clinicaltrials.gov/study/NCT02445586,https://clinicaltrials.gov/study/NCT02502864,https://clinicaltrials.gov/study/NCT01301729,https://clinicaltrials.gov/study/NCT01094184
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	4	Recruiting	https://clinicaltrials.gov/study/NCT05033769
MONDO_0007254	breast cancer	CHEMBL3647420	PYROTINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	4	Recruiting	https://clinicaltrials.gov/study/NCT06217185
MONDO_0007254	breast cancer	CHEMBL742	KETAMINE	Small molecule	Glutamate [NMDA] receptor negative allosteric modulator	Negative allosteric modulator	GRIN2C	glutamate ionotropic receptor NMDA type subunit 2C	4	Unknown status	https://clinicaltrials.gov/study/NCT03676114
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA10	NADH:ubiquinone oxidoreductase subunit A10	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT04137640
MONDO_0007254	breast cancer	CHEMBL3707227	ATEZOLIZUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6fa682c9-a312-4932-9831-f286908660ee
EFO_0000305	breast carcinoma	CHEMBL180022	NERATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208051s000lbl.pdf
EFO_0000305	breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49f9e774-52f9-40af-aecf-217c11e243ce,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c550dd16-a5e8-44be-87f2-210c15bbb513,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffc0a4be-6091-4157-837e-3637c1e121a6,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6004fba9-49c0-4781-8134-44bf7cf196fd
EFO_0000305	breast carcinoma	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	4	Recruiting	https://clinicaltrials.gov/study/NCT03355157,https://clinicaltrials.gov/study/NCT03270007,https://clinicaltrials.gov/study/NCT05131841
MONDO_0007254	breast cancer	CHEMBL469	KETOROLAC	Small molecule	Cyclooxygenase inhibitor		PTGS2	prostaglandin-endoperoxide synthase 2	4	Withdrawn	https://clinicaltrials.gov/study/NCT03007381
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05291910
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	4	Completed	https://clinicaltrials.gov/study/NCT02864030,https://clinicaltrials.gov/study/NCT01961544
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	4	Recruiting	https://clinicaltrials.gov/study/NCT05183126,https://clinicaltrials.gov/study/NCT04182568,https://clinicaltrials.gov/study/NCT04136782,https://clinicaltrials.gov/study/NCT06217185,https://clinicaltrials.gov/study/NCT05033769,https://clinicaltrials.gov/study/NCT05420467,https://clinicaltrials.gov/study/NCT03355157,https://clinicaltrials.gov/study/NCT05420454
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	4	Completed	https://clinicaltrials.gov/study/NCT01961544,https://clinicaltrials.gov/study/NCT02864030
EFO_0000305	breast carcinoma	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf
MONDO_0007254	breast cancer	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN4A	sodium voltage-gated channel alpha subunit 4	4	Completed	https://clinicaltrials.gov/study/NCT03360214
EFO_0000305	breast carcinoma	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=63560663-ecc4-4529-bbd7-c63c1877dfba,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6cfd29d7-f519-7b8c-4814-07b39f367f0d,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27355e18-e832-4639-93dc-d6995ff193d6,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ebda73d-82a3-4b17-8a81-a1f258003d32,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=82b77d74-085f-45ac-a7dd-1f5c038bf406,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32fd146f-7652-877f-cfd1-db9fa367406a,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0193faa4-9b02-4ccd-9751-de6124cc8c68,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e11b0a54-92bd-4790-8b80-f439f7093c01,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0800d19b-bdd8-47c9-81c3-67a92b81d07a,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b275f564-62f8-46de-a290-0b5bdc612988,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b73bf908-7979-4955-af20-0414388920da,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eb9ef121-71c7-436f-85d0-aa3649852915,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=63e54b62-a30d-4a56-9215-75e7a0b0bf02,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c391fe11-fd47-4a35-af6d-c823ab7b8838,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4818abc4-2797-4248-b7d7-5cb4b5cdcf6a,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=87b9906a-1e3f-4bd7-9f93-35d20a386315,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=13e802e6-3924-4122-ba3a-1966a164c48a,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=458f94b4-3ef7-4c73-bad2-017a10a924b6,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1524730f-e37d-478c-1956-b113b3ca42a8,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e92bf71-0ba2-4276-af81-5e61b9122044,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6bc22f65-4aaf-40a5-8f36-8b2419249ff5
EFO_0000305	breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022065lbl.pdf
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS7	NADH:ubiquinone oxidoreductase core subunit S7	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dc35c59-f4f3-43b4-8251-0cf5c06cdc80
MONDO_0007254	breast cancer	CHEMBL4297843	TORIPALIMAB	Antibody	Programmed cell death protein 1 antagonist		PDCD1	programmed cell death 1	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05291910
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA9	NADH:ubiquinone oxidoreductase subunit A9	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	4	Recruiting	https://clinicaltrials.gov/study/NCT04182568,https://clinicaltrials.gov/study/NCT05420467,https://clinicaltrials.gov/study/NCT04136782,https://clinicaltrials.gov/study/NCT02627248,https://clinicaltrials.gov/study/NCT05420454,https://clinicaltrials.gov/study/NCT06217185
MONDO_0007254	breast cancer	CHEMBL3989921	NERATINIB MALEATE	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d1e41dcf-e82a-47c2-a0ad-6c6eef621834
MONDO_0007254	breast cancer	CHEMBL1738	DEXRAZOXANE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f68a34ae-e17e-45b3-8c8e-8d7194b2124a,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b098c7f5-07a9-49a3-8e8a-f8adda671eca
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	4	Completed	https://clinicaltrials.gov/study/NCT02658734
MONDO_0007254	breast cancer	CHEMBL1098	BUPIVACAINE	Small molecule	Sodium channel protein type IV alpha subunit blocker		SCN4A	sodium voltage-gated channel alpha subunit 4	4	Completed	https://clinicaltrials.gov/study/NCT03360214
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	4	Unknown status	https://clinicaltrials.gov/study/NCT03123770
MONDO_0004379	female breast carcinoma	CHEMBL1200694	SEVOFLURANE	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRB3	gamma-aminobutyric acid type A receptor subunit beta3	4	Completed	https://clinicaltrials.gov/study/NCT02005770
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV3	NADH:ubiquinone oxidoreductase subunit V3	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	4	Recruiting	https://clinicaltrials.gov/study/NCT05033769
EFO_0000305	breast carcinoma	CHEMBL554	LAPATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022059lbl.pdf
EFO_0005537	triple-negative breast cancer	CHEMBL3545262	SACITUZUMAB GOVITECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	4		https://www.ema.europa.eu/en/medicines/human/EPAR/trodelvy,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761115s000lbl.pdf
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636
MONDO_0007254	breast cancer	CHEMBL180022	NERATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d1e41dcf-e82a-47c2-a0ad-6c6eef621834
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN4A	sodium voltage-gated channel alpha subunit 4	4	Recruiting	https://clinicaltrials.gov/study/NCT05072314
MONDO_0007254	breast cancer	CHEMBL1200396	BUPIVACAINE HYDROCHLORIDE	Small molecule	Sodium channel protein type IV alpha subunit blocker		SCN4A	sodium voltage-gated channel alpha subunit 4	4	Completed	https://clinicaltrials.gov/study/NCT03360214
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor		GPD2	glycerol-3-phosphate dehydrogenase 2	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	4	Recruiting	https://clinicaltrials.gov/study/NCT04136782,https://clinicaltrials.gov/study/NCT06217185,https://clinicaltrials.gov/study/NCT05420467,https://clinicaltrials.gov/study/NCT05033769,https://clinicaltrials.gov/study/NCT03355157,https://clinicaltrials.gov/study/NCT05420454,https://clinicaltrials.gov/study/NCT04182568,https://clinicaltrials.gov/study/NCT05183126
EFO_0000305	breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49f9e774-52f9-40af-aecf-217c11e243ce,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffc0a4be-6091-4157-837e-3637c1e121a6,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c550dd16-a5e8-44be-87f2-210c15bbb513,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6004fba9-49c0-4781-8134-44bf7cf196fd
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	4	Recruiting	https://clinicaltrials.gov/study/NCT05420467,https://clinicaltrials.gov/study/NCT04136782,https://clinicaltrials.gov/study/NCT05420454,https://clinicaltrials.gov/study/NCT04182568,https://clinicaltrials.gov/study/NCT02627248,https://clinicaltrials.gov/study/NCT06217185
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS4	NADH:ubiquinone oxidoreductase subunit S4	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0004379	female breast carcinoma	CHEMBL526	PROPOFOL	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRA6	gamma-aminobutyric acid type A receptor subunit alpha6	4	Completed	https://clinicaltrials.gov/study/NCT02005770
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e03d1378-6889-43d5-a34c-f96132cffa88,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b35e3633-8893-4b0b-af1e-92e342557199,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f59f7811-70b7-4c44-99f7-4f4fdce3ed22,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c482c813-1eb7-40dd-907a-845a7df112bf,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a630937b-8369-74ad-b68a-f940eb16ff0f,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2dc690b-4c69-428a-a67e-8ad007c39548,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd0ca36d-1f54-4568-8d19-a7152addcd52,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c806400-5fdc-4398-8475-37f700b3191f,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0ec4bcc-93ea-4c41-a4b6-95ec19491807,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70aeb960-426c-4805-b956-476bebccd926
MONDO_0007254	breast cancer	CHEMBL1201468	ESTROGENS, ESTERIFIED	Unknown	Estrogen receptor agonist		ESR1	estrogen receptor 1	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0141598-0bb2-4cf0-c9b8-6867b34bbb17
MONDO_0007254	breast cancer	CHEMBL554	LAPATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eee37f88-ec6a-4c30-b8aa-e2c71f93088c
MONDO_0007254	breast cancer	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	4	Recruiting	https://clinicaltrials.gov/study/NCT05161195,https://clinicaltrials.gov/study/NCT05452213
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	4	Completed	https://clinicaltrials.gov/study/NCT02419742,https://clinicaltrials.gov/study/NCT01301729,https://clinicaltrials.gov/study/NCT01094184
MONDO_0007254	breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	4	Recruiting	https://clinicaltrials.gov/study/NCT06169371,https://clinicaltrials.gov/study/NCT05362760
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	4	Recruiting	https://clinicaltrials.gov/study/NCT04136782,https://clinicaltrials.gov/study/NCT05420454,https://clinicaltrials.gov/study/NCT06217185,https://clinicaltrials.gov/study/NCT04182568,https://clinicaltrials.gov/study/NCT05420467,https://clinicaltrials.gov/study/NCT02627248
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23f3c1f4-0fc8-4804-a9e3-04cf25dd302e
EFO_0000305	breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6004fba9-49c0-4781-8134-44bf7cf196fd,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49f9e774-52f9-40af-aecf-217c11e243ce,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffc0a4be-6091-4157-837e-3637c1e121a6,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c550dd16-a5e8-44be-87f2-210c15bbb513
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA5	NADH:ubiquinone oxidoreductase subunit A5	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=241f0b1e-8b95-470d-876f-bf1804daaf18
EFO_0000305	breast carcinoma	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	4	Completed	https://clinicaltrials.gov/study/NCT02248571
MONDO_0007254	breast cancer	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN10A	sodium voltage-gated channel alpha subunit 10	4	Completed	https://clinicaltrials.gov/study/NCT03360214
MONDO_0007254	breast cancer	CHEMBL3989921	NERATINIB MALEATE	Small molecule	Receptor protein-tyrosine kinase erbB-4 inhibitor		ERBB4	erb-b2 receptor tyrosine kinase 4	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d1e41dcf-e82a-47c2-a0ad-6c6eef621834
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	4	Withdrawn	https://clinicaltrials.gov/study/NCT01156961
MONDO_0007254	breast cancer	CHEMBL834	PAMIDRONIC ACID	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	4	Completed	https://clinicaltrials.gov/study/NCT01907880
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c806400-5fdc-4398-8475-37f700b3191f,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a630937b-8369-74ad-b68a-f940eb16ff0f,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e03d1378-6889-43d5-a34c-f96132cffa88,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b35e3633-8893-4b0b-af1e-92e342557199,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd0ca36d-1f54-4568-8d19-a7152addcd52,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70aeb960-426c-4805-b956-476bebccd926,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2dc690b-4c69-428a-a67e-8ad007c39548,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0ec4bcc-93ea-4c41-a4b6-95ec19491807,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c482c813-1eb7-40dd-907a-845a7df112bf,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f59f7811-70b7-4c44-99f7-4f4fdce3ed22
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	4	Completed	https://clinicaltrials.gov/study/NCT02658734
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2dc690b-4c69-428a-a67e-8ad007c39548,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0ec4bcc-93ea-4c41-a4b6-95ec19491807,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c482c813-1eb7-40dd-907a-845a7df112bf,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c806400-5fdc-4398-8475-37f700b3191f,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b35e3633-8893-4b0b-af1e-92e342557199,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e03d1378-6889-43d5-a34c-f96132cffa88,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a630937b-8369-74ad-b68a-f940eb16ff0f,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd0ca36d-1f54-4568-8d19-a7152addcd52,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f59f7811-70b7-4c44-99f7-4f4fdce3ed22,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70aeb960-426c-4805-b956-476bebccd926
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ca3c0d4-e629-4d89-a969-3515a62886c6,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24d10449-2936-4cd3-b7db-a7683db721e4
MONDO_0007254	breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be4bc0de-0fdc-4d46-8d25-be43c79e6a06
MONDO_0007254	breast cancer	CHEMBL924	ZOLEDRONIC ACID ANHYDROUS	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	4	Terminated	https://clinicaltrials.gov/study/NCT00333229
MONDO_0007254	breast cancer	CHEMBL778	DEXMEDETOMIDINE	Small molecule	Adrenergic receptor alpha-2 agonist		ADRA2A	adrenoceptor alpha 2A	4	Recruiting	https://clinicaltrials.gov/study/NCT05732064
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dc35c59-f4f3-43b4-8251-0cf5c06cdc80
MONDO_0007254	breast cancer	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	4	Unknown status	https://clinicaltrials.gov/study/NCT01072318,https://clinicaltrials.gov/study/NCT01908556
EFO_0000305	breast carcinoma	CHEMBL1908360	EVEROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2150f73a-179b-4afc-b8ce-67c85cc72f04
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0ec4bcc-93ea-4c41-a4b6-95ec19491807,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e03d1378-6889-43d5-a34c-f96132cffa88,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c482c813-1eb7-40dd-907a-845a7df112bf,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f59f7811-70b7-4c44-99f7-4f4fdce3ed22,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2dc690b-4c69-428a-a67e-8ad007c39548,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70aeb960-426c-4805-b956-476bebccd926,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd0ca36d-1f54-4568-8d19-a7152addcd52,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c806400-5fdc-4398-8475-37f700b3191f,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a630937b-8369-74ad-b68a-f940eb16ff0f,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b35e3633-8893-4b0b-af1e-92e342557199
EFO_0000305	breast carcinoma	CHEMBL1201247	GOSERELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6bd94a89-f18a-45e5-d0a4-b343a4f0f03d
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	4	Completed	https://clinicaltrials.gov/study/NCT01961544,https://clinicaltrials.gov/study/NCT02864030
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB5	NADH:ubiquinone oxidoreductase subunit B5	4	Completed	https://clinicaltrials.gov/study/NCT05840068
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
MONDO_0007254	breast cancer	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	4	Completed	https://clinicaltrials.gov/study/NCT02344940,https://clinicaltrials.gov/study/NCT01553903,https://clinicaltrials.gov/study/NCT01127295,https://clinicaltrials.gov/study/NCT01612871,https://clinicaltrials.gov/study/NCT00537771
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	4	Completed	https://clinicaltrials.gov/study/NCT02658734
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05291910
MONDO_0007254	breast cancer	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	4	Completed	https://clinicaltrials.gov/study/NCT00121836,https://clinicaltrials.gov/study/NCT00127933
MONDO_0007254	breast cancer	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN3A	sodium voltage-gated channel alpha subunit 3	4	Completed	https://clinicaltrials.gov/study/NCT03360214
MONDO_0007254	breast cancer	CHEMBL1200778	DEXRAZOXANE HYDROCHLORIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f68a34ae-e17e-45b3-8c8e-8d7194b2124a,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b098c7f5-07a9-49a3-8e8a-f8adda671eca
MONDO_0007254	breast cancer	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa5e4446-19cd-4235-a382-5b48bf6c3b2f,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaeaef94-f3f5-4367-8ea2-b181d7be2da8
MONDO_0007254	breast cancer	CHEMBL4303669	ZOLEDRONIC ACID	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	4	Terminated	https://clinicaltrials.gov/study/NCT00333229
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	4	Unknown status	https://clinicaltrials.gov/study/NCT03123770
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dc35c59-f4f3-43b4-8251-0cf5c06cdc80
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT04137640
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	4	Recruiting	https://clinicaltrials.gov/study/NCT03270007,https://clinicaltrials.gov/study/NCT05131841,https://clinicaltrials.gov/study/NCT03355157
EFO_0000305	breast carcinoma	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17f85d17-ab71-4f5b-9fe3-0b8c822f69ff
MONDO_0007254	breast cancer	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	4	Recruiting	https://clinicaltrials.gov/study/NCT00900744,https://clinicaltrials.gov/study/NCT05525481,https://clinicaltrials.gov/study/NCT03355157,https://clinicaltrials.gov/study/NCT05161195
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6c24189-293f-42ca-b969-75870bb55af0,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=973efa93-7f9d-440a-a09f-521cf331b5e7,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6cefbdb9-1141-4a53-9d05-f6fcc2746834,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4dbbb7c8-a4b5-484d-a2a4-4d925010fc44,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24d10449-2936-4cd3-b7db-a7683db721e4,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d499be2-fdb5-4b9d-a7ce-3662ec9b2e34,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=566a00ae-47c0-4cd2-b602-79909bdfd9b1,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=88d7cdd2-e650-4a16-adec-873927e03e93,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e1a3a8d-6a6b-46fd-90ae-c7ad9e9b364b,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea28753a-8631-460a-bfdc-b101eb8ac84a,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ffd3e34-537f-4f65-b00e-57c25bab3b01,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f10f730f-6479-4f6a-8edc-fa4bd2140c1b
MONDO_0004379	female breast carcinoma	CHEMBL526	PROPOFOL	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRD	gamma-aminobutyric acid type A receptor subunit delta	4	Completed	https://clinicaltrials.gov/study/NCT02005770
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
EFO_0000305	breast carcinoma	CHEMBL1908360	EVEROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	4	Completed	https://clinicaltrials.gov/study/NCT02248571
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	4	Unknown status	https://clinicaltrials.gov/study/NCT00912639,https://clinicaltrials.gov/study/NCT02142790,https://clinicaltrials.gov/study/NCT02207361
MONDO_0004658	breast carcinoma in situ	CHEMBL1200675	TOREMIFENE CITRATE	Small molecule	Estrogen receptor modulator		ESR1	estrogen receptor 1	4	Withdrawn	https://clinicaltrials.gov/study/NCT03238703
EFO_0000305	breast carcinoma	CHEMBL3707266	RIBOCICLIB SUCCINATE	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209092s000lbl.pdf
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0ec4bcc-93ea-4c41-a4b6-95ec19491807,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70aeb960-426c-4805-b956-476bebccd926,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b35e3633-8893-4b0b-af1e-92e342557199,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c482c813-1eb7-40dd-907a-845a7df112bf,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e03d1378-6889-43d5-a34c-f96132cffa88,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2dc690b-4c69-428a-a67e-8ad007c39548,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f59f7811-70b7-4c44-99f7-4f4fdce3ed22,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c806400-5fdc-4398-8475-37f700b3191f,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a630937b-8369-74ad-b68a-f940eb16ff0f,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd0ca36d-1f54-4568-8d19-a7152addcd52
MONDO_0007254	breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	4	Terminated	https://clinicaltrials.gov/study/NCT04031885
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	4	Recruiting	https://clinicaltrials.gov/study/NCT04182568,https://clinicaltrials.gov/study/NCT05420454,https://clinicaltrials.gov/study/NCT04136782,https://clinicaltrials.gov/study/NCT05420467,https://clinicaltrials.gov/study/NCT06217185,https://clinicaltrials.gov/study/NCT02627248
MONDO_0007254	breast cancer	CHEMBL1738	DEXRAZOXANE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b098c7f5-07a9-49a3-8e8a-f8adda671eca,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f68a34ae-e17e-45b3-8c8e-8d7194b2124a
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND3	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4L	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24d10449-2936-4cd3-b7db-a7683db721e4,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ca3c0d4-e629-4d89-a969-3515a62886c6
MONDO_0007254	breast cancer	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	4	Active, not recruiting	https://clinicaltrials.gov/study/NCT04781959
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0ec4bcc-93ea-4c41-a4b6-95ec19491807,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e03d1378-6889-43d5-a34c-f96132cffa88,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70aeb960-426c-4805-b956-476bebccd926,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd0ca36d-1f54-4568-8d19-a7152addcd52,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a630937b-8369-74ad-b68a-f940eb16ff0f,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c806400-5fdc-4398-8475-37f700b3191f,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2dc690b-4c69-428a-a67e-8ad007c39548,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b35e3633-8893-4b0b-af1e-92e342557199,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f59f7811-70b7-4c44-99f7-4f4fdce3ed22,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c482c813-1eb7-40dd-907a-845a7df112bf
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND1	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	4	Unknown status	https://clinicaltrials.gov/study/NCT03123770
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	4	Completed	https://clinicaltrials.gov/study/NCT02502864,https://clinicaltrials.gov/study/NCT01301729,https://clinicaltrials.gov/study/NCT00127933,https://clinicaltrials.gov/study/NCT02445586,https://clinicaltrials.gov/study/NCT01094184,https://clinicaltrials.gov/study/NCT02419742,https://clinicaltrials.gov/study/NCT01660542
EFO_0000305	breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49f9e774-52f9-40af-aecf-217c11e243ce,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c550dd16-a5e8-44be-87f2-210c15bbb513,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6004fba9-49c0-4781-8134-44bf7cf196fd,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffc0a4be-6091-4157-837e-3637c1e121a6
EFO_0000305	breast carcinoma	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b2c7b4ba-831c-a80f-3078-145017268657,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5753679a-506c-4ac4-b8b2-b27c664d1d40,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1de8bba-3b1d-4c9d-ab8a-32d2c05e67c8,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b76b5bb-1d69-43f9-99c6-f39a0b6d8a26,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16145a4c-a3d0-404b-bd58-3f220a45ef73,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03dd3301-e9ce-40af-84e1-7b70fc6557b0,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=715ef37e-e700-4009-89ca-f5018c480c63
MONDO_0007254	breast cancer	CHEMBL3707266	RIBOCICLIB SUCCINATE	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaeaef94-f3f5-4367-8ea2-b181d7be2da8,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa5e4446-19cd-4235-a382-5b48bf6c3b2f
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ca3c0d4-e629-4d89-a969-3515a62886c6,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24d10449-2936-4cd3-b7db-a7683db721e4
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4	NDUFA4 mitochondrial complex associated	4	Completed	https://clinicaltrials.gov/study/NCT05840068
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23f3c1f4-0fc8-4804-a9e3-04cf25dd302e
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	4	Unknown status	https://clinicaltrials.gov/study/NCT03123770
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND5	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a630937b-8369-74ad-b68a-f940eb16ff0f,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f59f7811-70b7-4c44-99f7-4f4fdce3ed22,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2dc690b-4c69-428a-a67e-8ad007c39548,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd0ca36d-1f54-4568-8d19-a7152addcd52,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c806400-5fdc-4398-8475-37f700b3191f,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70aeb960-426c-4805-b956-476bebccd926,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e03d1378-6889-43d5-a34c-f96132cffa88,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c482c813-1eb7-40dd-907a-845a7df112bf,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b35e3633-8893-4b0b-af1e-92e342557199,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0ec4bcc-93ea-4c41-a4b6-95ec19491807
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6004fba9-49c0-4781-8134-44bf7cf196fd,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c550dd16-a5e8-44be-87f2-210c15bbb513,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49f9e774-52f9-40af-aecf-217c11e243ce,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffc0a4be-6091-4157-837e-3637c1e121a6
MONDO_0004658	breast carcinoma in situ	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	4	Withdrawn	https://clinicaltrials.gov/study/NCT03238703
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dc35c59-f4f3-43b4-8251-0cf5c06cdc80
EFO_0000305	breast carcinoma	CHEMBL180022	NERATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208051s000lbl.pdf
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA9	NADH:ubiquinone oxidoreductase subunit A9	4	Completed	https://clinicaltrials.gov/study/NCT05840068
EFO_0000305	breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffc0a4be-6091-4157-837e-3637c1e121a6,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6004fba9-49c0-4781-8134-44bf7cf196fd,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49f9e774-52f9-40af-aecf-217c11e243ce,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c550dd16-a5e8-44be-87f2-210c15bbb513
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB6	NADH:ubiquinone oxidoreductase subunit B6	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=241f0b1e-8b95-470d-876f-bf1804daaf18
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dc35c59-f4f3-43b4-8251-0cf5c06cdc80
MONDO_0007254	breast cancer	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	4	Recruiting	https://clinicaltrials.gov/study/NCT05420454,https://clinicaltrials.gov/study/NCT05420467,https://clinicaltrials.gov/study/NCT05036005
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	4	Recruiting	https://clinicaltrials.gov/study/NCT05131841,https://clinicaltrials.gov/study/NCT03355157,https://clinicaltrials.gov/study/NCT03270007
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT04137640
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB4	NADH:ubiquinone oxidoreductase subunit B4	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	4	Unknown status	https://clinicaltrials.gov/study/NCT03123770
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	4	Withdrawn	https://clinicaltrials.gov/study/NCT00774241
MONDO_0007254	breast cancer	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	4	Terminated	https://clinicaltrials.gov/study/NCT00087620
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR1	estrogen receptor 1	4	Recruiting	https://clinicaltrials.gov/study/NCT05362760,https://clinicaltrials.gov/study/NCT05631795,https://clinicaltrials.gov/study/NCT03355157,https://clinicaltrials.gov/study/NCT05161195
EFO_0000305	breast carcinoma	CHEMBL180022	NERATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-4 inhibitor		ERBB4	erb-b2 receptor tyrosine kinase 4	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208051s000lbl.pdf
EFO_0000305	breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49f9e774-52f9-40af-aecf-217c11e243ce,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c550dd16-a5e8-44be-87f2-210c15bbb513,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6004fba9-49c0-4781-8134-44bf7cf196fd,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffc0a4be-6091-4157-837e-3637c1e121a6
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24d10449-2936-4cd3-b7db-a7683db721e4,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ca3c0d4-e629-4d89-a969-3515a62886c6
MONDO_0007254	breast cancer	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN8A	sodium voltage-gated channel alpha subunit 8	4	Completed	https://clinicaltrials.gov/study/NCT03360214
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=566a00ae-47c0-4cd2-b602-79909bdfd9b1,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d499be2-fdb5-4b9d-a7ce-3662ec9b2e34,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24d10449-2936-4cd3-b7db-a7683db721e4,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6cefbdb9-1141-4a53-9d05-f6fcc2746834,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea28753a-8631-460a-bfdc-b101eb8ac84a,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=88d7cdd2-e650-4a16-adec-873927e03e93,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ffd3e34-537f-4f65-b00e-57c25bab3b01,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6c24189-293f-42ca-b969-75870bb55af0,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4dbbb7c8-a4b5-484d-a2a4-4d925010fc44,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=973efa93-7f9d-440a-a09f-521cf331b5e7,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f10f730f-6479-4f6a-8edc-fa4bd2140c1b,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e1a3a8d-6a6b-46fd-90ae-c7ad9e9b364b
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	4	Completed	https://clinicaltrials.gov/study/NCT02502864,https://clinicaltrials.gov/study/NCT01660542,https://clinicaltrials.gov/study/NCT02419742,https://clinicaltrials.gov/study/NCT01301729,https://clinicaltrials.gov/study/NCT01094184,https://clinicaltrials.gov/study/NCT02445586,https://clinicaltrials.gov/study/NCT00127933
MONDO_0004379	female breast carcinoma	CHEMBL1200694	SEVOFLURANE	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRA3	gamma-aminobutyric acid type A receptor subunit alpha3	4	Completed	https://clinicaltrials.gov/study/NCT02005770
MONDO_0007254	breast cancer	CHEMBL135	ESTRADIOL	Small molecule	Estrogen receptor alpha agonist		ESR1	estrogen receptor 1	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12fea717-3ee5-47af-ba43-2c6fd4d85d5b,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=596a20bd-d93d-4c48-e053-2991aa0ad4ca
MONDO_0007254	breast cancer	CHEMBL1201468	ESTROGENS, ESTERIFIED	Unknown	Estrogen receptor agonist		ESR2	estrogen receptor 2	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0141598-0bb2-4cf0-c9b8-6867b34bbb17
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05291910
MONDO_0004379	female breast carcinoma	CHEMBL1200694	SEVOFLURANE	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRP	gamma-aminobutyric acid type A receptor subunit pi	4	Completed	https://clinicaltrials.gov/study/NCT02005770
MONDO_0007254	breast cancer	CHEMBL742	KETAMINE	Small molecule	Glutamate [NMDA] receptor negative allosteric modulator	Negative allosteric modulator	GRIN2B	glutamate ionotropic receptor NMDA type subunit 2B	4	Unknown status	https://clinicaltrials.gov/study/NCT03676114
MONDO_0007254	breast cancer	CHEMBL395091	ESKETAMINE	Small molecule	Glutamate [NMDA] receptor negative allosteric modulator	Negative allosteric modulator	GRIN2C	glutamate ionotropic receptor NMDA type subunit 2C	4	Recruiting	https://clinicaltrials.gov/study/NCT05732064
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	4	Withdrawn	https://clinicaltrials.gov/study/NCT01156961
EFO_0000305	breast carcinoma	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3cd04ed6-7c5a-4c4a-9955-ee40839dfea0,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4fee8d4c-bb21-4773-b622-87f9a4ff333a,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c58c7013-50a0-4734-8a78-38ff20a3e7eb,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a96e22b2-eca3-4438-b959-dc5381085d31,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f40d2bcc-6b44-455c-8c03-001f39bfecd5,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d4f90d4-e535-4681-a863-3d774a2064e6,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=965c4cb1-f6b8-47ac-bf13-c36639aa908f,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ca9d4aff-ffdf-4a46-ad20-e47e5886a19e,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4f6df9c0-b3a1-4ba0-83b9-ba06c69c2e08,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=611e1f43-1442-4cbb-b7eb-b65de15c6c70,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=260cfda7-efe0-84b2-7f74-ea83c610c4ef,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=35c8037f-2601-4bd3-b423-2f53af7c0be3,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc0c084b-a122-736e-c136-c8cffc92f5f4,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e46ed5b8-83c9-4adb-890f-0fc612371eea,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5ad69fab-7469-419e-9c52-662e07e52c86,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6128eda4-ad33-4c23-8d93-5192421fd8d0,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=19251d0b-279a-49f5-99b2-0e74d7cca479,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4bd7e768-2d09-44e6-bacb-7390a5bc5dbc,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d4f43676-0746-4765-9689-3f1e3075fa6a,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ddc99d79-fb94-4a91-9c39-9dcdb3dd5d5b,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=188c6fd5-6695-4d8b-af43-61d9c26abfe9,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4a23dc55-9877-4b43-ac2c-cd628c0f5038,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d4550afa-977e-426e-814b-705435d2af81,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ca16f8de-d9a5-4c6c-957b-ae28497b67ac,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8d8cdd21-2403-4284-bdfc-d56d6e8ab117,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b33520de-f891-43f8-bd04-1b66795d3dd2,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7a36fd8-530e-4c63-97d5-0f80fab5880e,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03586c40-eb32-45c5-beb7-6762a6b78790,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7666def-a855-4ca3-a322-603a88a44101,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1448e72e-dc7f-4618-9b37-a82c59823839,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11628cdc-4e3c-4063-ee9f-c51e2386a820,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d7d3cfa-af46-48fd-afee-cddf39d2efde,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8e4f7179-81d7-4715-9cc1-babef97fcca0
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24d10449-2936-4cd3-b7db-a7683db721e4,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ca3c0d4-e629-4d89-a969-3515a62886c6
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86718885-da44-4d3d-b3ca-06cbcedcffd8
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV2	NADH:ubiquinone oxidoreductase core subunit V2	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05291910
MONDO_0007254	breast cancer	CHEMBL395091	ESKETAMINE	Small molecule	Glutamate [NMDA] receptor negative allosteric modulator	Negative allosteric modulator	GRIN2B	glutamate ionotropic receptor NMDA type subunit 2B	4	Recruiting	https://clinicaltrials.gov/study/NCT05732064
MONDO_0007254	breast cancer	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	4	Terminated	https://clinicaltrials.gov/study/NCT04657679
MONDO_0007254	breast cancer	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	4	Completed	https://clinicaltrials.gov/study/NCT02419742
EFO_0000304	breast adenocarcinoma	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	4	Suspended	https://clinicaltrials.gov/study/NCT05183828
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
MONDO_0007254	breast cancer	CHEMBL1889140	ROPIVACAINE HYDROCHLORIDE	Small molecule	Sodium channel alpha subunit blocker		SCN9A	sodium voltage-gated channel alpha subunit 9	4	Completed	https://clinicaltrials.gov/study/NCT03360214
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC1	NADH:ubiquinone oxidoreductase subunit C1	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dc35c59-f4f3-43b4-8251-0cf5c06cdc80
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c550dd16-a5e8-44be-87f2-210c15bbb513,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffc0a4be-6091-4157-837e-3637c1e121a6,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49f9e774-52f9-40af-aecf-217c11e243ce,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6004fba9-49c0-4781-8134-44bf7cf196fd
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	4	Recruiting	https://clinicaltrials.gov/study/NCT04136782,https://clinicaltrials.gov/study/NCT05420454,https://clinicaltrials.gov/study/NCT04182568,https://clinicaltrials.gov/study/NCT05420467,https://clinicaltrials.gov/study/NCT06217185,https://clinicaltrials.gov/study/NCT02627248
EFO_0000305	breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022065lbl.pdf
MONDO_0004379	female breast carcinoma	CHEMBL1200694	SEVOFLURANE	Small molecule	Potassium channel subfamily K member 18 opener		KCNK18	potassium two pore domain channel subfamily K member 18	4	Completed	https://clinicaltrials.gov/study/NCT02005770
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF3	NADH:ubiquinone oxidoreductase complex assembly factor 3	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0004379	female breast carcinoma	CHEMBL526	PROPOFOL	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRA2	gamma-aminobutyric acid type A receptor subunit alpha2	4	Completed	https://clinicaltrials.gov/study/NCT02005770
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS3	NADH:ubiquinone oxidoreductase core subunit S3	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	4	Completed	https://clinicaltrials.gov/study/NCT01301729,https://clinicaltrials.gov/study/NCT02419742,https://clinicaltrials.gov/study/NCT01094184
MONDO_0007254	breast cancer	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaeaef94-f3f5-4367-8ea2-b181d7be2da8,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa5e4446-19cd-4235-a382-5b48bf6c3b2f
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636
MONDO_0007254	breast cancer	CHEMBL1201649	ESTROGENS, CONJUGATED	Unknown	Estrogen receptor agonist		ESR1	estrogen receptor 1	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=751b6213-92d8-40f8-a2d5-83e8dad086dd
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dc35c59-f4f3-43b4-8251-0cf5c06cdc80
EFO_0000305	breast carcinoma	CHEMBL1201179	LAPATINIB DITOSYLATE	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022059lbl.pdf
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB4	NADH:ubiquinone oxidoreductase subunit B4	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	4	Recruiting	https://clinicaltrials.gov/study/NCT05452213,https://clinicaltrials.gov/study/NCT05161195
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23f3c1f4-0fc8-4804-a9e3-04cf25dd302e
MONDO_0007254	breast cancer	CHEMBL1201649	ESTROGENS, CONJUGATED	Unknown	Estrogen receptor agonist		ESR2	estrogen receptor 2	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=751b6213-92d8-40f8-a2d5-83e8dad086dd
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR1	estrogen receptor 1	4	Terminated	https://clinicaltrials.gov/study/NCT04031885
MONDO_0007254	breast cancer	CHEMBL877	TRANEXAMIC ACID	Small molecule	Plasminogen inhibitor		PLG	plasminogen	4	Recruiting	https://clinicaltrials.gov/study/NCT05807074
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6004fba9-49c0-4781-8134-44bf7cf196fd,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c550dd16-a5e8-44be-87f2-210c15bbb513,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49f9e774-52f9-40af-aecf-217c11e243ce,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffc0a4be-6091-4157-837e-3637c1e121a6
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT04137640
MONDO_0007254	breast cancer	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	4	Terminated	https://clinicaltrials.gov/study/NCT00171847,https://clinicaltrials.gov/study/NCT00241046
MONDO_0007254	breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be4bc0de-0fdc-4d46-8d25-be43c79e6a06
MONDO_0004658	breast carcinoma in situ	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	4	Withdrawn	https://clinicaltrials.gov/study/NCT03238703
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT04137640
EFO_0000305	breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49f9e774-52f9-40af-aecf-217c11e243ce,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6004fba9-49c0-4781-8134-44bf7cf196fd,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c550dd16-a5e8-44be-87f2-210c15bbb513,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffc0a4be-6091-4157-837e-3637c1e121a6
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	4	Recruiting	https://clinicaltrials.gov/study/NCT06217185,https://clinicaltrials.gov/study/NCT05420454,https://clinicaltrials.gov/study/NCT05420467,https://clinicaltrials.gov/study/NCT02627248,https://clinicaltrials.gov/study/NCT04136782,https://clinicaltrials.gov/study/NCT04182568
EFO_0006861	male breast carcinoma	CHEMBL4594273	ELACESTRANT HYDROCHLORIDE	Small molecule	Estrogen receptor alpha degrader		ESR1	estrogen receptor 1	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639s000lbl.pdf
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	4	Completed	https://clinicaltrials.gov/study/NCT00372476
EFO_0000305	breast carcinoma	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208716Orig1s000lbl.pdf
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB3	NADH:ubiquinone oxidoreductase subunit B3	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0004379	female breast carcinoma	CHEMBL526	PROPOFOL	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRB3	gamma-aminobutyric acid type A receptor subunit beta3	4	Completed	https://clinicaltrials.gov/study/NCT02005770
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	4	Unknown status	https://clinicaltrials.gov/study/NCT02207361,https://clinicaltrials.gov/study/NCT02142790,https://clinicaltrials.gov/study/NCT00912639
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor		GPD2	glycerol-3-phosphate dehydrogenase 2	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
MONDO_0007254	breast cancer	CHEMBL1395	METHYLTESTOSTERONE	Small molecule	Androgen Receptor agonist		AR	androgen receptor	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=77bb4ef4-c10e-4acc-8225-651d003f4561
MONDO_0007254	breast cancer	CHEMBL778	DEXMEDETOMIDINE	Small molecule	Adrenergic receptor alpha-2 agonist		ADRA2B	adrenoceptor alpha 2B	4	Recruiting	https://clinicaltrials.gov/study/NCT05732064
MONDO_0007254	breast cancer	CHEMBL3647420	PYROTINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	4	Recruiting	https://clinicaltrials.gov/study/NCT06217185
MONDO_0007254	breast cancer	CHEMBL1889140	ROPIVACAINE HYDROCHLORIDE	Small molecule	Sodium channel alpha subunit blocker		SCN2A	sodium voltage-gated channel alpha subunit 2	4	Completed	https://clinicaltrials.gov/study/NCT03360214
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05291910
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24d10449-2936-4cd3-b7db-a7683db721e4,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d499be2-fdb5-4b9d-a7ce-3662ec9b2e34,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e1a3a8d-6a6b-46fd-90ae-c7ad9e9b364b,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=566a00ae-47c0-4cd2-b602-79909bdfd9b1,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ffd3e34-537f-4f65-b00e-57c25bab3b01,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f10f730f-6479-4f6a-8edc-fa4bd2140c1b,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4dbbb7c8-a4b5-484d-a2a4-4d925010fc44,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6cefbdb9-1141-4a53-9d05-f6fcc2746834,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea28753a-8631-460a-bfdc-b101eb8ac84a,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=88d7cdd2-e650-4a16-adec-873927e03e93,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=973efa93-7f9d-440a-a09f-521cf331b5e7,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6c24189-293f-42ca-b969-75870bb55af0
EFO_0005537	triple-negative breast cancer	CHEMBL3545262	SACITUZUMAB GOVITECAN	Antibody drug conjugate	Tumor-associated calcium signal transducer 2 binding agent		TACSTD2	tumor associated calcium signal transducer 2	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761115s000lbl.pdf,https://www.ema.europa.eu/en/medicines/human/EPAR/trodelvy
MONDO_0007254	breast cancer	CHEMBL742	KETAMINE	Small molecule	Glutamate [NMDA] receptor negative allosteric modulator	Negative allosteric modulator	GRIN2A	glutamate ionotropic receptor NMDA type subunit 2A	4	Unknown status	https://clinicaltrials.gov/study/NCT03676114
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	4	Unknown status	https://clinicaltrials.gov/study/NCT02142790,https://clinicaltrials.gov/study/NCT00912639,https://clinicaltrials.gov/study/NCT02207361
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	4	Completed	https://clinicaltrials.gov/study/NCT02658734
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	4	Unknown status	https://clinicaltrials.gov/study/NCT00912639,https://clinicaltrials.gov/study/NCT02142790,https://clinicaltrials.gov/study/NCT02207361
MONDO_0007254	breast cancer	CHEMBL941	IMATINIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	4	Completed	https://clinicaltrials.gov/study/NCT00372476
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23f3c1f4-0fc8-4804-a9e3-04cf25dd302e
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA3	NADH:ubiquinone oxidoreductase subunit A3	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL941	IMATINIB	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	4	Completed	https://clinicaltrials.gov/study/NCT00372476
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA12	NADH:ubiquinone oxidoreductase subunit A12	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT04137640
MONDO_0004379	female breast carcinoma	CHEMBL526	PROPOFOL	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRG1	gamma-aminobutyric acid type A receptor subunit gamma1	4	Completed	https://clinicaltrials.gov/study/NCT02005770
EFO_0000305	breast carcinoma	CHEMBL3989921	NERATINIB MALEATE	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208051s000lbl.pdf
MONDO_0007254	breast cancer	CHEMBL1201193	LEVOBUPIVACAINE	Small molecule	Sodium channel protein type IV alpha subunit blocker		SCN4A	sodium voltage-gated channel alpha subunit 4	4	Terminated	https://clinicaltrials.gov/study/NCT03456661
MONDO_0004379	female breast carcinoma	CHEMBL1200694	SEVOFLURANE	Small molecule	Potassium channel subfamily K member 10 opener		KCNK10	potassium two pore domain channel subfamily K member 10	4	Completed	https://clinicaltrials.gov/study/NCT02005770
MONDO_0004658	breast carcinoma in situ	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	4	Withdrawn	https://clinicaltrials.gov/study/NCT03238703
MONDO_0004658	breast carcinoma in situ	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	4	Withdrawn	https://clinicaltrials.gov/study/NCT03238703
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF1	NADH:ubiquinone oxidoreductase complex assembly factor 1	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT04137640
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70aeb960-426c-4805-b956-476bebccd926,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c482c813-1eb7-40dd-907a-845a7df112bf,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e03d1378-6889-43d5-a34c-f96132cffa88,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b35e3633-8893-4b0b-af1e-92e342557199,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a630937b-8369-74ad-b68a-f940eb16ff0f,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2dc690b-4c69-428a-a67e-8ad007c39548,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c806400-5fdc-4398-8475-37f700b3191f,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f59f7811-70b7-4c44-99f7-4f4fdce3ed22,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0ec4bcc-93ea-4c41-a4b6-95ec19491807,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd0ca36d-1f54-4568-8d19-a7152addcd52
MONDO_0007254	breast cancer	CHEMBL1201247	GOSERELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT03591549
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	4	Unknown status	https://clinicaltrials.gov/study/NCT03123770
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA13	NADH:ubiquinone oxidoreductase subunit A13	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC2	NADH:ubiquinone oxidoreductase subunit C2	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	4	Completed	https://clinicaltrials.gov/study/NCT02445586
MONDO_0007254	breast cancer	CHEMBL3647420	PYROTINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT06245824,https://clinicaltrials.gov/study/NCT04929548
MONDO_0007254	breast cancer	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bd72fd53-ae0c-4080-9b7f-2d294b14cc86,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=151ce76c-2d44-4c82-850d-ab213bea4d6b
MONDO_0007254	breast cancer	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN11A	sodium voltage-gated channel alpha subunit 11	4	Completed	https://clinicaltrials.gov/study/NCT03360214
MONDO_0007254	breast cancer	CHEMBL1889140	ROPIVACAINE HYDROCHLORIDE	Small molecule	Sodium channel alpha subunit blocker		SCN3A	sodium voltage-gated channel alpha subunit 3	4	Completed	https://clinicaltrials.gov/study/NCT03360214
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	4	Completed	https://clinicaltrials.gov/study/NCT01094184,https://clinicaltrials.gov/study/NCT02419742,https://clinicaltrials.gov/study/NCT00127933,https://clinicaltrials.gov/study/NCT02445586,https://clinicaltrials.gov/study/NCT02502864,https://clinicaltrials.gov/study/NCT01301729,https://clinicaltrials.gov/study/NCT01660542
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	4	Recruiting	https://clinicaltrials.gov/study/NCT03355157,https://clinicaltrials.gov/study/NCT03270007,https://clinicaltrials.gov/study/NCT05131841
EFO_0000305	breast carcinoma	CHEMBL554	LAPATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022059lbl.pdf
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN1A	sodium voltage-gated channel alpha subunit 1	4	Completed	https://clinicaltrials.gov/study/NCT04248179
MONDO_0004379	female breast carcinoma	CHEMBL526	PROPOFOL	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRA4	gamma-aminobutyric acid type A receptor subunit alpha4	4	Completed	https://clinicaltrials.gov/study/NCT02005770
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23f3c1f4-0fc8-4804-a9e3-04cf25dd302e
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23f3c1f4-0fc8-4804-a9e3-04cf25dd302e
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB9	NADH:ubiquinone oxidoreductase subunit B9	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffc0a4be-6091-4157-837e-3637c1e121a6,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6004fba9-49c0-4781-8134-44bf7cf196fd,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c550dd16-a5e8-44be-87f2-210c15bbb513,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49f9e774-52f9-40af-aecf-217c11e243ce
MONDO_0004379	female breast carcinoma	CHEMBL1200694	SEVOFLURANE	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRG3	gamma-aminobutyric acid type A receptor subunit gamma3	4	Completed	https://clinicaltrials.gov/study/NCT02005770
MONDO_0004379	female breast carcinoma	CHEMBL1200694	SEVOFLURANE	Small molecule	Potassium channel subfamily K member 2 opener		KCNK2	potassium two pore domain channel subfamily K member 2	4	Completed	https://clinicaltrials.gov/study/NCT02005770
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	4	Recruiting	https://clinicaltrials.gov/study/NCT05033769
MONDO_0007254	breast cancer	CHEMBL395091	ESKETAMINE	Small molecule	Glutamate [NMDA] receptor negative allosteric modulator	Negative allosteric modulator	GRIN3B	glutamate ionotropic receptor NMDA type subunit 3B	4	Recruiting	https://clinicaltrials.gov/study/NCT05732064
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	4	Unknown status	https://clinicaltrials.gov/study/NCT03123770
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	4	Unknown status	https://clinicaltrials.gov/study/NCT00912639,https://clinicaltrials.gov/study/NCT02142790,https://clinicaltrials.gov/study/NCT02207361
MONDO_0007254	breast cancer	CHEMBL393220	ATORVASTATIN CALCIUM	Small molecule	HMG-CoA reductase inhibitor		HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4L2	NDUFA4 mitochondrial complex associated like 2	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	4	Withdrawn	https://clinicaltrials.gov/study/NCT00774241
MONDO_0007254	breast cancer	CHEMBL1116	RALOXIFENE HYDROCHLORIDE	Small molecule	Estrogen receptor beta modulator		ESR2	estrogen receptor 2	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcaaa6dc-74e8-4fb8-800c-5574bf0f8de9
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR1	estrogen receptor 1	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2fc17ba3-83c7-a2b4-8a75-6a0cb1e07682,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99cf8b69-4c23-4886-80e9-b23e348b5bd7
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	4	Completed	https://clinicaltrials.gov/study/NCT02658734
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	4	Recruiting	https://clinicaltrials.gov/study/NCT02627248,https://clinicaltrials.gov/study/NCT04182568,https://clinicaltrials.gov/study/NCT06217185,https://clinicaltrials.gov/study/NCT05420454,https://clinicaltrials.gov/study/NCT05420467,https://clinicaltrials.gov/study/NCT04136782
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA6	NADH:ubiquinone oxidoreductase subunit A6	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN7A	sodium voltage-gated channel alpha subunit 7	4	Recruiting	https://clinicaltrials.gov/study/NCT05072314
EFO_0000305	breast carcinoma	CHEMBL3137318	TALAZOPARIB TOSYLATE	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf
MONDO_0007254	breast cancer	CHEMBL3989921	NERATINIB MALEATE	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d1e41dcf-e82a-47c2-a0ad-6c6eef621834
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea28753a-8631-460a-bfdc-b101eb8ac84a,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=566a00ae-47c0-4cd2-b602-79909bdfd9b1,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=973efa93-7f9d-440a-a09f-521cf331b5e7,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ffd3e34-537f-4f65-b00e-57c25bab3b01,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24d10449-2936-4cd3-b7db-a7683db721e4,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6c24189-293f-42ca-b969-75870bb55af0,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6cefbdb9-1141-4a53-9d05-f6fcc2746834,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d499be2-fdb5-4b9d-a7ce-3662ec9b2e34,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4dbbb7c8-a4b5-484d-a2a4-4d925010fc44,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f10f730f-6479-4f6a-8edc-fa4bd2140c1b,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e1a3a8d-6a6b-46fd-90ae-c7ad9e9b364b,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=88d7cdd2-e650-4a16-adec-873927e03e93
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	4	Withdrawn	https://clinicaltrials.gov/study/NCT00774241
MONDO_0007254	breast cancer	CHEMBL778	DEXMEDETOMIDINE	Small molecule	Adrenergic receptor alpha-2 agonist		ADRA2C	adrenoceptor alpha 2C	4	Recruiting	https://clinicaltrials.gov/study/NCT05732064
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	4	Completed	https://clinicaltrials.gov/study/NCT02502864,https://clinicaltrials.gov/study/NCT01094184,https://clinicaltrials.gov/study/NCT01301729,https://clinicaltrials.gov/study/NCT01660542,https://clinicaltrials.gov/study/NCT00127933,https://clinicaltrials.gov/study/NCT02419742,https://clinicaltrials.gov/study/NCT02445586
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	4	Recruiting	https://clinicaltrials.gov/study/NCT05420467,https://clinicaltrials.gov/study/NCT05420454,https://clinicaltrials.gov/study/NCT05183126,https://clinicaltrials.gov/study/NCT05033769,https://clinicaltrials.gov/study/NCT04182568,https://clinicaltrials.gov/study/NCT06217185,https://clinicaltrials.gov/study/NCT04136782,https://clinicaltrials.gov/study/NCT03355157
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23f3c1f4-0fc8-4804-a9e3-04cf25dd302e
EFO_0000305	breast carcinoma	CHEMBL1201583	BEVACIZUMAB	Antibody	Vascular endothelial growth factor A inhibitor		VEGFA	vascular endothelial growth factor A	4	Completed	https://clinicaltrials.gov/study/NCT02248571
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA2	NADH:ubiquinone oxidoreductase subunit A2	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0004379	female breast carcinoma	CHEMBL526	PROPOFOL	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRE	gamma-aminobutyric acid type A receptor subunit epsilon	4	Completed	https://clinicaltrials.gov/study/NCT02005770
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4	NDUFA4 mitochondrial complex associated	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	4	Completed	https://clinicaltrials.gov/study/NCT01094184,https://clinicaltrials.gov/study/NCT01301729,https://clinicaltrials.gov/study/NCT02419742
MONDO_0007254	breast cancer	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	4	Recruiting	https://clinicaltrials.gov/study/NCT05161195
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA7	NADH:ubiquinone oxidoreductase subunit A7	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	4	Completed	https://clinicaltrials.gov/study/NCT02679755
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	4	Withdrawn	https://clinicaltrials.gov/study/NCT00774241
EFO_0000305	breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6004fba9-49c0-4781-8134-44bf7cf196fd,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffc0a4be-6091-4157-837e-3637c1e121a6,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c550dd16-a5e8-44be-87f2-210c15bbb513,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49f9e774-52f9-40af-aecf-217c11e243ce
EFO_0000305	breast carcinoma	CHEMBL359744	DOXORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0349f98-42fa-4003-b6d8-a1db1401b0ef
MONDO_0007254	breast cancer	CHEMBL941	IMATINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	4	Completed	https://clinicaltrials.gov/study/NCT00372476
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN7A	sodium voltage-gated channel alpha subunit 7	4	Completed	https://clinicaltrials.gov/study/NCT04248179
MONDO_0007254	breast cancer	CHEMBL3647420	PYROTINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT06245824,https://clinicaltrials.gov/study/NCT04929548
EFO_0000305	breast carcinoma	CHEMBL3989921	NERATINIB MALEATE	Small molecule	Receptor protein-tyrosine kinase erbB-4 inhibitor		ERBB4	erb-b2 receptor tyrosine kinase 4	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208051s000lbl.pdf
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB8	NADH:ubiquinone oxidoreductase subunit B8	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC2	NADH:ubiquinone oxidoreductase subunit C2	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	4	Recruiting	https://clinicaltrials.gov/study/NCT05033769
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN1A	sodium voltage-gated channel alpha subunit 1	4	Recruiting	https://clinicaltrials.gov/study/NCT05072314
MONDO_0007254	breast cancer	CHEMBL742	KETAMINE	Small molecule	Glutamate [NMDA] receptor negative allosteric modulator	Negative allosteric modulator	GRIN3A	glutamate ionotropic receptor NMDA type subunit 3A	4	Unknown status	https://clinicaltrials.gov/study/NCT03676114
MONDO_0007254	breast cancer	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	4	Recruiting	https://clinicaltrials.gov/study/NCT05161195,https://clinicaltrials.gov/study/NCT05525481,https://clinicaltrials.gov/study/NCT03355157,https://clinicaltrials.gov/study/NCT00900744
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	4	Recruiting	https://clinicaltrials.gov/study/NCT05033769
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	4	Completed	https://clinicaltrials.gov/study/NCT01961544,https://clinicaltrials.gov/study/NCT02864030
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	4	Withdrawn	https://clinicaltrials.gov/study/NCT00774241
MONDO_0007254	breast cancer	CHEMBL359744	DOXORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6bcde92b-e584-4919-866a-68847ea201ba,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00634b2b-4e48-4178-8877-28582af894ad
MONDO_0004379	female breast carcinoma	CHEMBL1200694	SEVOFLURANE	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRG1	gamma-aminobutyric acid type A receptor subunit gamma1	4	Completed	https://clinicaltrials.gov/study/NCT02005770
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB9	NADH:ubiquinone oxidoreductase subunit B9	4	Completed	https://clinicaltrials.gov/study/NCT05840068
MONDO_0007254	breast cancer	CHEMBL1200501	GOSERELIN ACETATE	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT03591549
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=241f0b1e-8b95-470d-876f-bf1804daaf18
MONDO_0007254	breast cancer	CHEMBL180022	NERATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-4 inhibitor		ERBB4	erb-b2 receptor tyrosine kinase 4	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d1e41dcf-e82a-47c2-a0ad-6c6eef621834
MONDO_0004379	female breast carcinoma	CHEMBL1200694	SEVOFLURANE	Small molecule	Potassium channel subfamily K member 3 opener		KCNK3	potassium two pore domain channel subfamily K member 3	4	Completed	https://clinicaltrials.gov/study/NCT02005770
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	4	Recruiting	https://clinicaltrials.gov/study/NCT06217185,https://clinicaltrials.gov/study/NCT05420467,https://clinicaltrials.gov/study/NCT02627248,https://clinicaltrials.gov/study/NCT04182568,https://clinicaltrials.gov/study/NCT05420454,https://clinicaltrials.gov/study/NCT04136782
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS8	NADH:ubiquinone oxidoreductase core subunit S8	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA12	NADH:ubiquinone oxidoreductase subunit A12	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	4	Withdrawn	https://clinicaltrials.gov/study/NCT00774241
MONDO_0007254	breast cancer	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00634b2b-4e48-4178-8877-28582af894ad,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6bcde92b-e584-4919-866a-68847ea201ba
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636
EFO_0000305	breast carcinoma	CHEMBL1655	TOREMIFENE	Small molecule	Estrogen receptor modulator		ESR1	estrogen receptor 1	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6ff9761-7442-4bff-9e50-858c03e27fd0,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2cab8dd1-3a10-48e6-86ce-0e5275ed49e5
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	4	Recruiting	https://clinicaltrials.gov/study/NCT04136782,https://clinicaltrials.gov/study/NCT05420454,https://clinicaltrials.gov/study/NCT06217185,https://clinicaltrials.gov/study/NCT04182568,https://clinicaltrials.gov/study/NCT05420467,https://clinicaltrials.gov/study/NCT02627248
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN10A	sodium voltage-gated channel alpha subunit 10	4	Recruiting	https://clinicaltrials.gov/study/NCT05072314
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	4	Completed	https://clinicaltrials.gov/study/NCT02658734
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	4	Unknown status	https://clinicaltrials.gov/study/NCT00912639,https://clinicaltrials.gov/study/NCT02142790,https://clinicaltrials.gov/study/NCT02207361
MONDO_0007254	breast cancer	CHEMBL1200675	TOREMIFENE CITRATE	Small molecule	Estrogen receptor modulator		ESR2	estrogen receptor 2	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2cab8dd1-3a10-48e6-86ce-0e5275ed49e5,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b3ebaa6-9cbe-405e-8f14-14ce8dcd2a68
MONDO_0007254	breast cancer	CHEMBL2396661	ALPELISIB	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b20b4e18-7a4b-4500-a08f-06c6dab0ee5b
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND6	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA8	NADH:ubiquinone oxidoreductase subunit A8	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05291910
MONDO_0007254	breast cancer	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN5A	sodium voltage-gated channel alpha subunit 5	4	Completed	https://clinicaltrials.gov/study/NCT03360214
MONDO_0007254	breast cancer	CHEMBL1201247	GOSERELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	4	Recruiting	https://clinicaltrials.gov/study/NCT05161195
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	4	Withdrawn	https://clinicaltrials.gov/study/NCT00774241
EFO_0000305	breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49f9e774-52f9-40af-aecf-217c11e243ce,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c550dd16-a5e8-44be-87f2-210c15bbb513,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffc0a4be-6091-4157-837e-3637c1e121a6,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6004fba9-49c0-4781-8134-44bf7cf196fd
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dc35c59-f4f3-43b4-8251-0cf5c06cdc80
EFO_0000305	breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49f9e774-52f9-40af-aecf-217c11e243ce,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c550dd16-a5e8-44be-87f2-210c15bbb513,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6004fba9-49c0-4781-8134-44bf7cf196fd,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffc0a4be-6091-4157-837e-3637c1e121a6
EFO_0000305	breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	4		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022065lbl.pdf
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV3	NADH:ubiquinone oxidoreductase subunit V3	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL3545262	SACITUZUMAB GOVITECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57a597d2-03f0-472e-b148-016d7169169d
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF4	NADH:ubiquinone oxidoreductase complex assembly factor 4	4	Not yet recruiting	https://clinicaltrials.gov/study/NCT05507398
MONDO_0007254	breast cancer	CHEMBL778	DEXMEDETOMIDINE	Small molecule	Adrenergic receptor alpha-2 agonist		ADRA2B	adrenoceptor alpha 2B	4	Terminated	https://clinicaltrials.gov/study/NCT03456661
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45e6dce4-92e2-4ad1-bf11-bbcefb753636,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f59f7811-70b7-4c44-99f7-4f4fdce3ed22,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b35e3633-8893-4b0b-af1e-92e342557199,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c482c813-1eb7-40dd-907a-845a7df112bf,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70aeb960-426c-4805-b956-476bebccd926,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a630937b-8369-74ad-b68a-f940eb16ff0f,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd0ca36d-1f54-4568-8d19-a7152addcd52,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c806400-5fdc-4398-8475-37f700b3191f,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0ec4bcc-93ea-4c41-a4b6-95ec19491807,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e03d1378-6889-43d5-a34c-f96132cffa88,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2dc690b-4c69-428a-a67e-8ad007c39548
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	4	Recruiting	https://clinicaltrials.gov/study/NCT05033769
MONDO_0007254	breast cancer	CHEMBL3707266	RIBOCICLIB SUCCINATE	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaeaef94-f3f5-4367-8ea2-b181d7be2da8,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa5e4446-19cd-4235-a382-5b48bf6c3b2f
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49f9e774-52f9-40af-aecf-217c11e243ce,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffc0a4be-6091-4157-837e-3637c1e121a6,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6004fba9-49c0-4781-8134-44bf7cf196fd,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c550dd16-a5e8-44be-87f2-210c15bbb513
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	4	Completed	https://clinicaltrials.gov/study/NCT01094184,https://clinicaltrials.gov/study/NCT01660542,https://clinicaltrials.gov/study/NCT00127933,https://clinicaltrials.gov/study/NCT01301729,https://clinicaltrials.gov/study/NCT02502864,https://clinicaltrials.gov/study/NCT02445586,https://clinicaltrials.gov/study/NCT02419742
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	4		https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dc35c59-f4f3-43b4-8251-0cf5c06cdc80
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	4	Unknown status	https://clinicaltrials.gov/study/NCT03123770
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	4	Completed	https://clinicaltrials.gov/study/NCT01961544,https://clinicaltrials.gov/study/NCT02864030
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS7	NADH:ubiquinone oxidoreductase core subunit S7	4	Completed	https://clinicaltrials.gov/study/NCT05840068
EFO_0000304	breast adenocarcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC6	histone deacetylase 6	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02115282
MONDO_0004658	breast carcinoma in situ	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Recruiting	https://clinicaltrials.gov/study/NCT04862585
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	3	Completed	https://clinicaltrials.gov/study/NCT01234337
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT06143553
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBA3C	tubulin alpha 3c	3	Completed	https://clinicaltrials.gov/study/NCT01953003,https://clinicaltrials.gov/study/NCT01091168,https://clinicaltrials.gov/study/NCT01095003
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Recruiting	https://clinicaltrials.gov/study/NCT05883852,https://clinicaltrials.gov/study/NCT05430399,https://clinicaltrials.gov/study/NCT05207514,https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT04540692,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT03671044,https://clinicaltrials.gov/study/NCT05720026,https://clinicaltrials.gov/study/NCT03949634,https://clinicaltrials.gov/study/NCT05296798,https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT05901428,https://clinicaltrials.gov/study/NCT04547907,https://clinicaltrials.gov/study/NCT05894239,https://clinicaltrials.gov/study/NCT05159193,https://clinicaltrials.gov/study/NCT04193059,https://clinicaltrials.gov/study/NCT05673629,https://clinicaltrials.gov/study/NCT03926091
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Completed	https://clinicaltrials.gov/study/NCT00337103,https://clinicaltrials.gov/study/NCT02225470,https://clinicaltrials.gov/study/NCT00388726
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Completed	https://clinicaltrials.gov/study/NCT00236899,https://clinicaltrials.gov/study/NCT01989676,https://clinicaltrials.gov/study/NCT04031703,https://clinicaltrials.gov/study/NCT00196872,https://clinicaltrials.gov/study/NCT03493854,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT03462251,https://clinicaltrials.gov/study/NCT01216111,https://clinicaltrials.gov/study/NCT00513292,https://clinicaltrials.gov/study/NCT02163694,https://clinicaltrials.gov/study/NCT00567554,https://clinicaltrials.gov/study/NCT03726879,https://clinicaltrials.gov/study/NCT01131195,https://clinicaltrials.gov/study/NCT00600340,https://clinicaltrials.gov/study/NCT00014222,https://clinicaltrials.gov/study/NCT01901146,https://clinicaltrials.gov/study/NCT00129922,https://clinicaltrials.gov/study/NCT00146549,https://clinicaltrials.gov/study/NCT00004125,https://clinicaltrials.gov/study/NCT00336791,https://clinicaltrials.gov/study/NCT01120184,https://clinicaltrials.gov/study/NCT03337724,https://clinicaltrials.gov/study/NCT00003013,https://clinicaltrials.gov/study/NCT00668616,https://clinicaltrials.gov/study/NCT01644890,https://clinicaltrials.gov/study/NCT04127019,https://clinicaltrials.gov/study/NCT00041119,https://clinicaltrials.gov/study/NCT01287624,https://clinicaltrials.gov/study/NCT03498716,https://clinicaltrials.gov/study/NCT01663727,https://clinicaltrials.gov/study/NCT02032277,https://clinicaltrials.gov/study/NCT01822314,https://clinicaltrials.gov/study/NCT00561119,https://clinicaltrials.gov/study/NCT01998906,https://clinicaltrials.gov/study/NCT02472964,https://clinicaltrials.gov/study/NCT02819518,https://clinicaltrials.gov/study/NCT01526369,https://clinicaltrials.gov/study/NCT02019277,https://clinicaltrials.gov/study/NCT00016406,https://clinicaltrials.gov/study/NCT00876395,https://clinicaltrials.gov/study/NCT00003440,https://clinicaltrials.gov/study/NCT00003088,https://clinicaltrials.gov/study/NCT02594371,https://clinicaltrials.gov/study/NCT00431080,https://clinicaltrials.gov/study/NCT02425891,https://clinicaltrials.gov/study/NCT01964391,https://clinicaltrials.gov/study/NCT01940497,https://clinicaltrials.gov/study/NCT02450058,https://clinicaltrials.gov/study/NCT04109066,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT00876486,https://clinicaltrials.gov/study/NCT00544232,https://clinicaltrials.gov/study/NCT00311636,https://clinicaltrials.gov/study/NCT00038402,https://clinicaltrials.gov/study/NCT01314833,https://clinicaltrials.gov/study/NCT01433614,https://clinicaltrials.gov/study/NCT01764022,https://clinicaltrials.gov/study/NCT00789581,https://clinicaltrials.gov/study/NCT00006459,https://clinicaltrials.gov/study/NCT00002953,https://clinicaltrials.gov/study/NCT00002662,https://clinicaltrials.gov/study/NCT00129389,https://clinicaltrials.gov/study/NCT00028990,https://clinicaltrials.gov/study/NCT03556358,https://clinicaltrials.gov/study/NCT00004067,https://clinicaltrials.gov/study/NCT02194166,https://clinicaltrials.gov/study/NCT00667251,https://clinicaltrials.gov/study/NCT00448591,https://clinicaltrials.gov/study/NCT00003972,https://clinicaltrials.gov/study/NCT01690702
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	3	Terminated	https://clinicaltrials.gov/study/NCT05134194,https://clinicaltrials.gov/study/NCT00440622,https://clinicaltrials.gov/study/NCT02054338
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Withdrawn	https://clinicaltrials.gov/study/NCT05474690,https://clinicaltrials.gov/study/NCT03811418,https://clinicaltrials.gov/study/NCT00041171
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Terminated	https://clinicaltrials.gov/study/NCT02144012,https://clinicaltrials.gov/study/NCT00912444,https://clinicaltrials.gov/study/NCT00625898,https://clinicaltrials.gov/study/NCT01200212,https://clinicaltrials.gov/study/NCT00053911
EFO_1000984	inflammatory breast carcinoma	CHEMBL1200778	DEXRAZOXANE HYDROCHLORIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	3	Terminated	https://clinicaltrials.gov/study/NCT00016276
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS7	NADH:ubiquinone oxidoreductase core subunit S7	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND3	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL1201509	GONADOTROPIN, CHORIONIC	Protein	Luteinizing hormone/Choriogonadotropin receptor agonist		LHCGR	luteinizing hormone/choriogonadotropin receptor	3	Unknown status	https://clinicaltrials.gov/study/NCT00808522
MONDO_0007254	breast cancer	CHEMBL691	ETHINYL ESTRADIOL	Small molecule	Estrogen receptor alpha agonist		ESR1	estrogen receptor 1	3	Terminated	https://clinicaltrials.gov/study/NCT00193726
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND1	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1	3	Completed	https://clinicaltrials.gov/study/NCT01101438
EFO_0000304	breast adenocarcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Completed	https://clinicaltrials.gov/study/NCT00785291,https://clinicaltrials.gov/study/NCT01935492
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	3	Terminated	https://clinicaltrials.gov/study/NCT02340221
MONDO_0007254	breast cancer	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Terminated	https://clinicaltrials.gov/study/NCT02730091,https://clinicaltrials.gov/study/NCT04478266,https://clinicaltrials.gov/study/NCT03050398
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Completed	https://clinicaltrials.gov/study/NCT01953003,https://clinicaltrials.gov/study/NCT01091168,https://clinicaltrials.gov/study/NCT01095003
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885,https://clinicaltrials.gov/study/NCT02003209,https://clinicaltrials.gov/study/NCT01275677
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Completed	https://clinicaltrials.gov/study/NCT00191152
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01275677,https://clinicaltrials.gov/study/NCT02003209,https://clinicaltrials.gov/study/NCT03199885
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652
EFO_0005537	triple-negative breast cancer	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02445391
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R2	phosphoinositide-3-kinase regulatory subunit 2	3	Completed	https://clinicaltrials.gov/study/NCT01610284
MONDO_0007254	breast cancer	CHEMBL1908360	EVEROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01674140,https://clinicaltrials.gov/study/NCT01805271
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Terminated	https://clinicaltrials.gov/study/NCT03786094,https://clinicaltrials.gov/study/NCT05134194
MONDO_0007254	breast cancer	CHEMBL547	ISOTRETINOIN	Small molecule	Retinoic acid receptor agonist		RARA	retinoic acid receptor alpha	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT05016349
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885,https://clinicaltrials.gov/study/NCT00433511
MONDO_0007254	breast cancer	CHEMBL4279455	LAROTAXEL	Small molecule	Tubulin stabiliser		TUBB1	tubulin beta 1 class VI	3	Completed	https://clinicaltrials.gov/study/NCT00081796
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Completed	https://clinicaltrials.gov/study/NCT00630032,https://clinicaltrials.gov/study/NCT00789581,https://clinicaltrials.gov/study/NCT00448591,https://clinicaltrials.gov/study/NCT00080301,https://clinicaltrials.gov/study/NCT00082433
EFO_0000432	breast ductal carcinoma in situ	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01272037,https://clinicaltrials.gov/study/NCT01357772
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Completed	https://clinicaltrials.gov/study/NCT00005970
MONDO_0007254	breast cancer	CHEMBL3545262	SACITUZUMAB GOVITECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	3	Recruiting	https://clinicaltrials.gov/study/NCT04595565,https://clinicaltrials.gov/study/NCT05840211,https://clinicaltrials.gov/study/NCT05633654,https://clinicaltrials.gov/study/NCT05552001,https://clinicaltrials.gov/study/NCT05382299
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Terminated	https://clinicaltrials.gov/study/NCT00520975,https://clinicaltrials.gov/study/NCT01303679,https://clinicaltrials.gov/study/NCT04335006,https://clinicaltrials.gov/study/NCT00002772,https://clinicaltrials.gov/study/NCT01200212,https://clinicaltrials.gov/study/NCT02054338
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Completed	https://clinicaltrials.gov/study/NCT00785291,https://clinicaltrials.gov/study/NCT01935492
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT05901935,https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT04665986
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Terminated	https://clinicaltrials.gov/study/NCT00625898,https://clinicaltrials.gov/study/NCT00053911,https://clinicaltrials.gov/study/NCT00912444,https://clinicaltrials.gov/study/NCT01200212,https://clinicaltrials.gov/study/NCT02144012
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1201179	LAPATINIB DITOSYLATE	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	3	Completed	https://clinicaltrials.gov/study/NCT00390455
EFO_0000304	breast adenocarcinoma	CHEMBL1200501	GOSERELIN ACETATE	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02115282
MONDO_0007254	breast cancer	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Suspended	https://clinicaltrials.gov/study/NCT00002696
MONDO_0007254	breast cancer	CHEMBL2177390	IPATASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT1	AKT serine/threonine kinase 1	3	Completed	https://clinicaltrials.gov/study/NCT03337724
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	3	Unknown status	https://clinicaltrials.gov/study/NCT00070278,https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT00039546
MONDO_0007254	breast cancer	CHEMBL2396661	ALPELISIB	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04208178,https://clinicaltrials.gov/study/NCT05063786
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA11	NADH:ubiquinone oxidoreductase subunit A11	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	3	Terminated	https://clinicaltrials.gov/study/NCT05134194,https://clinicaltrials.gov/study/NCT02054338,https://clinicaltrials.gov/study/NCT00440622
EFO_0005537	triple-negative breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	3	Suspended	https://clinicaltrials.gov/study/NCT03002103
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Withdrawn	https://clinicaltrials.gov/study/NCT05474690,https://clinicaltrials.gov/study/NCT00041171,https://clinicaltrials.gov/study/NCT03811418
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4L2	NDUFA4 mitochondrial complex associated like 2	3	Completed	https://clinicaltrials.gov/study/NCT01101438
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02221999
EFO_0000304	breast adenocarcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC7	histone deacetylase 7	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02115282
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Completed	https://clinicaltrials.gov/study/NCT00005970
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Completed	https://clinicaltrials.gov/study/NCT02125344,https://clinicaltrials.gov/study/NCT01583426
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Unknown status	https://clinicaltrials.gov/study/NCT02879513
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Recruiting	https://clinicaltrials.gov/study/NCT05374512
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06126640,https://clinicaltrials.gov/study/NCT06316531,https://clinicaltrials.gov/study/NCT06313086
MONDO_0007254	breast cancer	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT01645839
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA1	NADH:ubiquinone oxidoreductase subunit A1	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL997	IBANDRONIC ACID	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	3	Unknown status	https://clinicaltrials.gov/study/NCT00326820
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Withdrawn	https://clinicaltrials.gov/study/NCT02929576
MONDO_0007254	breast cancer	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	3	Recruiting	https://clinicaltrials.gov/study/NCT05207709,https://clinicaltrials.gov/study/NCT04964934,https://clinicaltrials.gov/study/NCT04862663,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT04055493,https://clinicaltrials.gov/study/NCT05827081
MONDO_0007254	breast cancer	CHEMBL924	ZOLEDRONIC ACID ANHYDROUS	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	3	Terminated	https://clinicaltrials.gov/study/NCT00372710
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND2	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA3	NADH:ubiquinone oxidoreductase subunit A3	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02214381,https://clinicaltrials.gov/study/NCT03595592,https://clinicaltrials.gov/study/NCT03168880,https://clinicaltrials.gov/study/NCT03725059,https://clinicaltrials.gov/study/NCT01996267,https://clinicaltrials.gov/study/NCT00070564,https://clinicaltrials.gov/study/NCT00433420,https://clinicaltrials.gov/study/NCT04732598,https://clinicaltrials.gov/study/NCT01646034,https://clinicaltrials.gov/study/NCT01358877,https://clinicaltrials.gov/study/NCT03315364,https://clinicaltrials.gov/study/NCT04494425,https://clinicaltrials.gov/study/NCT03734029
EFO_1000984	inflammatory breast carcinoma	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT05415215
MONDO_0007254	breast cancer	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT01645839
EFO_1000984	inflammatory breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Completed	https://clinicaltrials.gov/study/NCT02324088
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885,https://clinicaltrials.gov/study/NCT00433511
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA1	NADH:ubiquinone oxidoreductase subunit A1	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB9	NADH:ubiquinone oxidoreductase subunit B9	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04639986
MONDO_0007254	breast cancer	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Withdrawn	https://clinicaltrials.gov/study/NCT05474690,https://clinicaltrials.gov/study/NCT03811418,https://clinicaltrials.gov/study/NCT00053339
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03725059,https://clinicaltrials.gov/study/NCT04494425,https://clinicaltrials.gov/study/NCT01358877,https://clinicaltrials.gov/study/NCT00433420,https://clinicaltrials.gov/study/NCT03315364,https://clinicaltrials.gov/study/NCT04732598,https://clinicaltrials.gov/study/NCT01996267,https://clinicaltrials.gov/study/NCT03595592,https://clinicaltrials.gov/study/NCT00070564,https://clinicaltrials.gov/study/NCT03168880,https://clinicaltrials.gov/study/NCT03734029,https://clinicaltrials.gov/study/NCT02214381,https://clinicaltrials.gov/study/NCT01646034
EFO_0000304	breast adenocarcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC10	histone deacetylase 10	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02115282
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Withdrawn	https://clinicaltrials.gov/study/NCT05474690,https://clinicaltrials.gov/study/NCT00041171,https://clinicaltrials.gov/study/NCT03811418
MONDO_0007254	breast cancer	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN7A	sodium voltage-gated channel alpha subunit 7	3	Terminated	https://clinicaltrials.gov/study/NCT02525211
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Recruiting	https://clinicaltrials.gov/study/NCT05894239,https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT04547907,https://clinicaltrials.gov/study/NCT03926091,https://clinicaltrials.gov/study/NCT03949634,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT05673629,https://clinicaltrials.gov/study/NCT05430399,https://clinicaltrials.gov/study/NCT05296798,https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT04540692,https://clinicaltrials.gov/study/NCT05720026,https://clinicaltrials.gov/study/NCT05159193,https://clinicaltrials.gov/study/NCT05207514,https://clinicaltrials.gov/study/NCT05901428,https://clinicaltrials.gov/study/NCT05883852,https://clinicaltrials.gov/study/NCT04193059,https://clinicaltrials.gov/study/NCT03671044
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT05172518,https://clinicaltrials.gov/study/NCT04301739,https://clinicaltrials.gov/study/NCT06279364,https://clinicaltrials.gov/study/NCT05841381,https://clinicaltrials.gov/study/NCT05753865,https://clinicaltrials.gov/study/NCT05388500
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA8	NADH:ubiquinone oxidoreductase subunit A8	3	Completed	https://clinicaltrials.gov/study/NCT01101438
EFO_0000305	breast carcinoma	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Terminated	https://clinicaltrials.gov/study/NCT00520975
EFO_0005537	triple-negative breast cancer	CHEMBL3894860	TRILACICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04799249
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC1	NADH:ubiquinone oxidoreductase subunit C1	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT05104866,https://clinicaltrials.gov/study/NCT03734029,https://clinicaltrials.gov/study/NCT05063786,https://clinicaltrials.gov/study/NCT04639986
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC1	NADH:ubiquinone oxidoreductase subunit C1	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06313086,https://clinicaltrials.gov/study/NCT06316531,https://clinicaltrials.gov/study/NCT06126640
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN3A	sodium voltage-gated channel alpha subunit 3	3	Completed	https://clinicaltrials.gov/study/NCT04822597
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR2	estrogen receptor 2	3	Recruiting	https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT05438810,https://clinicaltrials.gov/study/NCT04263298,https://clinicaltrials.gov/study/NCT05077449,https://clinicaltrials.gov/study/NCT04646759,https://clinicaltrials.gov/study/NCT05654623,https://clinicaltrials.gov/study/NCT05696626,https://clinicaltrials.gov/study/NCT06105632,https://clinicaltrials.gov/study/NCT04650581,https://clinicaltrials.gov/study/NCT05207709,https://clinicaltrials.gov/study/NCT04862663,https://clinicaltrials.gov/study/NCT05054751,https://clinicaltrials.gov/study/NCT05038735,https://clinicaltrials.gov/study/NCT05646862,https://clinicaltrials.gov/study/NCT05306340,https://clinicaltrials.gov/study/NCT05501886
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT06255392
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Unknown status	https://clinicaltrials.gov/study/NCT02514681
MONDO_0007254	breast cancer	CHEMBL554	LAPATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Completed	https://clinicaltrials.gov/study/NCT01619111,https://clinicaltrials.gov/study/NCT01526369,https://clinicaltrials.gov/study/NCT00829166,https://clinicaltrials.gov/study/NCT01808573,https://clinicaltrials.gov/study/NCT00567554,https://clinicaltrials.gov/study/NCT00078572,https://clinicaltrials.gov/study/NCT03084939,https://clinicaltrials.gov/study/NCT00667251
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	3	Unknown status	https://clinicaltrials.gov/study/NCT02207335,https://clinicaltrials.gov/study/NCT00039546,https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT00070278
EFO_0000304	breast adenocarcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	3	Suspended	https://clinicaltrials.gov/study/NCT03002103
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01275677,https://clinicaltrials.gov/study/NCT03199885
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	3	Suspended	https://clinicaltrials.gov/study/NCT03002103
MONDO_0007254	breast cancer	CHEMBL413	SIROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT04736589
EFO_0005537	triple-negative breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	3	Recruiting	https://clinicaltrials.gov/study/NCT05760378
MONDO_0007254	breast cancer	CHEMBL4594550	SERPLULIMAB	Antibody	Programmed cell death protein 1 antagonist		PDCD1	programmed cell death 1	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT04301739
EFO_0000305	breast carcinoma	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Unknown status	https://clinicaltrials.gov/study/NCT02404051
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04148911,https://clinicaltrials.gov/study/NCT04085276
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	3	Suspended	https://clinicaltrials.gov/study/NCT03002103
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R5	phosphoinositide-3-kinase regulatory subunit 5	3	Completed	https://clinicaltrials.gov/study/NCT01610284
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT06103864,https://clinicaltrials.gov/study/NCT05382299,https://clinicaltrials.gov/study/NCT06268652,https://clinicaltrials.gov/study/NCT05814354,https://clinicaltrials.gov/study/NCT06143553,https://clinicaltrials.gov/study/NCT04722978
MONDO_0007254	breast cancer	CHEMBL185	FLUOROURACIL	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	3	Terminated	https://clinicaltrials.gov/study/NCT00053911,https://clinicaltrials.gov/study/NCT00625898
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04639986
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	3	Completed	https://clinicaltrials.gov/study/NCT02028507,https://clinicaltrials.gov/study/NCT01942135,https://clinicaltrials.gov/study/NCT01864746,https://clinicaltrials.gov/study/NCT02600923,https://clinicaltrials.gov/study/NCT03969121
MONDO_0004658	breast carcinoma in situ	CHEMBL384467	DEXAMETHASONE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	3	Recruiting	https://clinicaltrials.gov/study/NCT04862585
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	3	Suspended	https://clinicaltrials.gov/study/NCT03002103
EFO_1000984	inflammatory breast carcinoma	CHEMBL1738	DEXRAZOXANE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	3	Terminated	https://clinicaltrials.gov/study/NCT00016276
EFO_1000984	inflammatory breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Completed	https://clinicaltrials.gov/study/NCT02324088
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06313086,https://clinicaltrials.gov/study/NCT06316531,https://clinicaltrials.gov/study/NCT06126640
MONDO_0007254	breast cancer	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN1A	sodium voltage-gated channel alpha subunit 1	3	Terminated	https://clinicaltrials.gov/study/NCT02525211
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Completed	https://clinicaltrials.gov/study/NCT00789581,https://clinicaltrials.gov/study/NCT01663727,https://clinicaltrials.gov/study/NCT00003972,https://clinicaltrials.gov/study/NCT00028990,https://clinicaltrials.gov/study/NCT01526369,https://clinicaltrials.gov/study/NCT00336791,https://clinicaltrials.gov/study/NCT01940497,https://clinicaltrials.gov/study/NCT00876395,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT00567554,https://clinicaltrials.gov/study/NCT00876486,https://clinicaltrials.gov/study/NCT03337724,https://clinicaltrials.gov/study/NCT02594371,https://clinicaltrials.gov/study/NCT01690702,https://clinicaltrials.gov/study/NCT01287624,https://clinicaltrials.gov/study/NCT03556358,https://clinicaltrials.gov/study/NCT00003440,https://clinicaltrials.gov/study/NCT02032277,https://clinicaltrials.gov/study/NCT00003088,https://clinicaltrials.gov/study/NCT00667251,https://clinicaltrials.gov/study/NCT01901146,https://clinicaltrials.gov/study/NCT00002953,https://clinicaltrials.gov/study/NCT00513292,https://clinicaltrials.gov/study/NCT00016406,https://clinicaltrials.gov/study/NCT03498716,https://clinicaltrials.gov/study/NCT01989676,https://clinicaltrials.gov/study/NCT00041119,https://clinicaltrials.gov/study/NCT00311636,https://clinicaltrials.gov/study/NCT00003013,https://clinicaltrials.gov/study/NCT04127019,https://clinicaltrials.gov/study/NCT00004067,https://clinicaltrials.gov/study/NCT02819518,https://clinicaltrials.gov/study/NCT00196872,https://clinicaltrials.gov/study/NCT01764022,https://clinicaltrials.gov/study/NCT00236899,https://clinicaltrials.gov/study/NCT00561119,https://clinicaltrials.gov/study/NCT00668616,https://clinicaltrials.gov/study/NCT01964391,https://clinicaltrials.gov/study/NCT02472964,https://clinicaltrials.gov/study/NCT01644890,https://clinicaltrials.gov/study/NCT00002662,https://clinicaltrials.gov/study/NCT03493854,https://clinicaltrials.gov/study/NCT02163694,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT00038402,https://clinicaltrials.gov/study/NCT02019277,https://clinicaltrials.gov/study/NCT00006459,https://clinicaltrials.gov/study/NCT01998906,https://clinicaltrials.gov/study/NCT00431080,https://clinicaltrials.gov/study/NCT01131195,https://clinicaltrials.gov/study/NCT00448591,https://clinicaltrials.gov/study/NCT01120184,https://clinicaltrials.gov/study/NCT00014222,https://clinicaltrials.gov/study/NCT01314833,https://clinicaltrials.gov/study/NCT01216111,https://clinicaltrials.gov/study/NCT04031703,https://clinicaltrials.gov/study/NCT00146549,https://clinicaltrials.gov/study/NCT03462251,https://clinicaltrials.gov/study/NCT00129922,https://clinicaltrials.gov/study/NCT02194166,https://clinicaltrials.gov/study/NCT00544232,https://clinicaltrials.gov/study/NCT01433614,https://clinicaltrials.gov/study/NCT01822314,https://clinicaltrials.gov/study/NCT00129389,https://clinicaltrials.gov/study/NCT02450058,https://clinicaltrials.gov/study/NCT02425891,https://clinicaltrials.gov/study/NCT00600340,https://clinicaltrials.gov/study/NCT03726879,https://clinicaltrials.gov/study/NCT04109066,https://clinicaltrials.gov/study/NCT00004125
EFO_0000305	breast carcinoma	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Recruiting	https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT04307147,https://clinicaltrials.gov/study/NCT06268652,https://clinicaltrials.gov/study/NCT06143553,https://clinicaltrials.gov/study/NCT04400695
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	3	Completed	https://clinicaltrials.gov/study/NCT01234337
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Terminated	https://clinicaltrials.gov/study/NCT05134194,https://clinicaltrials.gov/study/NCT03786094
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885,https://clinicaltrials.gov/study/NCT01275677
EFO_0006861	male breast carcinoma	CHEMBL1201179	LAPATINIB DITOSYLATE	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00770809
EFO_0000305	breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Completed	https://clinicaltrials.gov/study/NCT00785291
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT05172518,https://clinicaltrials.gov/study/NCT05838066,https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT04665986
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Recruiting	https://clinicaltrials.gov/study/NCT02488967
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	3	Recruiting	https://clinicaltrials.gov/study/NCT05501886
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Completed	https://clinicaltrials.gov/study/NCT02555657,https://clinicaltrials.gov/study/NCT02225470,https://clinicaltrials.gov/study/NCT03901339,https://clinicaltrials.gov/study/NCT00776724,https://clinicaltrials.gov/study/NCT00868634,https://clinicaltrials.gov/study/NCT00146549,https://clinicaltrials.gov/study/NCT02574455,https://clinicaltrials.gov/study/NCT00103233,https://clinicaltrials.gov/study/NCT00431106,https://clinicaltrials.gov/study/NCT01007942
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Recruiting	https://clinicaltrials.gov/study/NCT05207514,https://clinicaltrials.gov/study/NCT03926091,https://clinicaltrials.gov/study/NCT03949634,https://clinicaltrials.gov/study/NCT05296798,https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT05430399,https://clinicaltrials.gov/study/NCT05720026,https://clinicaltrials.gov/study/NCT03671044,https://clinicaltrials.gov/study/NCT05901428,https://clinicaltrials.gov/study/NCT05883852,https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT05673629,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT05159193,https://clinicaltrials.gov/study/NCT04547907,https://clinicaltrials.gov/study/NCT05894239,https://clinicaltrials.gov/study/NCT04540692,https://clinicaltrials.gov/study/NCT04193059
MONDO_0007254	breast cancer	CHEMBL1276308	MIFEPRISTONE	Small molecule	Glucocorticoid receptor antagonist		NR3C1	nuclear receptor subfamily 3 group C member 1	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT05016349
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01275677,https://clinicaltrials.gov/study/NCT03199885
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Terminated	https://clinicaltrials.gov/study/NCT00520975
MONDO_0007254	breast cancer	CHEMBL637	VENLAFAXINE	Small molecule	Norepinephrine transporter inhibitor		SLC6A2	solute carrier family 6 member 2	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06106529
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00433511,https://clinicaltrials.gov/study/NCT03199885
MONDO_0007254	breast cancer	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN4A	sodium voltage-gated channel alpha subunit 4	3	Terminated	https://clinicaltrials.gov/study/NCT02525211
MONDO_0007254	breast cancer	CHEMBL190461	CANNABIDIOL	Small molecule	Cannabinoid CB1 receptor negative allosteric modulator		CNR1	cannabinoid receptor 1	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT05016349
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Withdrawn	https://clinicaltrials.gov/study/NCT05474690,https://clinicaltrials.gov/study/NCT00041171,https://clinicaltrials.gov/study/NCT03811418
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06081959,https://clinicaltrials.gov/study/NCT05901935,https://clinicaltrials.gov/study/NCT04665986,https://clinicaltrials.gov/study/NCT06343948,https://clinicaltrials.gov/study/NCT06079983
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND3	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3	3	Completed	https://clinicaltrials.gov/study/NCT01101438
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
MONDO_0007254	breast cancer	CHEMBL4297844	TRASTUZUMAB DERUXTECAN	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 binding agent		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03523585,https://clinicaltrials.gov/study/NCT03734029,https://clinicaltrials.gov/study/NCT04494425,https://clinicaltrials.gov/study/NCT03529110,https://clinicaltrials.gov/study/NCT04622319,https://clinicaltrials.gov/study/NCT04784715
MONDO_0007254	breast cancer	CHEMBL13	METOPROLOL	Small molecule	Beta-1 adrenergic receptor antagonist		ADRB1	adrenoceptor beta 1	3	Withdrawn	https://clinicaltrials.gov/study/NCT02269696
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Recruiting	https://clinicaltrials.gov/study/NCT06265428,https://clinicaltrials.gov/study/NCT05288777,https://clinicaltrials.gov/study/NCT04873362,https://clinicaltrials.gov/study/NCT05755048,https://clinicaltrials.gov/study/NCT04457596,https://clinicaltrials.gov/study/NCT05429684,https://clinicaltrials.gov/study/NCT03975647
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00006459
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Completed	https://clinicaltrials.gov/study/NCT03901339,https://clinicaltrials.gov/study/NCT00388726,https://clinicaltrials.gov/study/NCT00337103,https://clinicaltrials.gov/study/NCT02574455,https://clinicaltrials.gov/study/NCT02555657,https://clinicaltrials.gov/study/NCT02225470
MONDO_0007254	breast cancer	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	3	Completed	https://clinicaltrials.gov/study/NCT00241449,https://clinicaltrials.gov/study/NCT00002542,https://clinicaltrials.gov/study/NCT00002784,https://clinicaltrials.gov/study/NCT00605267,https://clinicaltrials.gov/study/NCT00002777,https://clinicaltrials.gov/study/NCT00929591,https://clinicaltrials.gov/study/NCT00003906,https://clinicaltrials.gov/study/NCT00286117,https://clinicaltrials.gov/study/NCT00072462,https://clinicaltrials.gov/study/NCT00002720,https://clinicaltrials.gov/study/NCT00784862,https://clinicaltrials.gov/study/NCT02278120,https://clinicaltrials.gov/study/NCT00793377,https://clinicaltrials.gov/study/NCT00849030,https://clinicaltrials.gov/study/NCT00002707,https://clinicaltrials.gov/study/NCT00433589,https://clinicaltrials.gov/study/NCT00002755,https://clinicaltrials.gov/study/NCT00201851,https://clinicaltrials.gov/study/NCT00309491,https://clinicaltrials.gov/study/NCT00002582,https://clinicaltrials.gov/study/NCT00002967,https://clinicaltrials.gov/study/NCT00171704,https://clinicaltrials.gov/study/NCT00295646,https://clinicaltrials.gov/study/NCT00053898,https://clinicaltrials.gov/study/NCT00002528,https://clinicaltrials.gov/study/NCT00814125,https://clinicaltrials.gov/study/NCT00152178,https://clinicaltrials.gov/study/NCT00293540,https://clinicaltrials.gov/study/NCT00002646,https://clinicaltrials.gov/study/NCT00590785,https://clinicaltrials.gov/study/NCT00003032,https://clinicaltrials.gov/study/NCT00002581,https://clinicaltrials.gov/study/NCT00002580,https://clinicaltrials.gov/study/NCT00002529,https://clinicaltrials.gov/study/NCT00047099,https://clinicaltrials.gov/study/NCT00002864,https://clinicaltrials.gov/study/NCT00003857,https://clinicaltrials.gov/study/NCT00002579,https://clinicaltrials.gov/study/NCT00291759,https://clinicaltrials.gov/study/NCT00032136,https://clinicaltrials.gov/study/NCT00949598,https://clinicaltrials.gov/study/NCT00004125,https://clinicaltrials.gov/study/NCT00003972,https://clinicaltrials.gov/study/NCT00003013,https://clinicaltrials.gov/study/NCT00309478,https://clinicaltrials.gov/study/NCT00004205,https://clinicaltrials.gov/study/NCT02995772
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652,https://clinicaltrials.gov/study/NCT05382299,https://clinicaltrials.gov/study/NCT05814354,https://clinicaltrials.gov/study/NCT06103864,https://clinicaltrials.gov/study/NCT04722978,https://clinicaltrials.gov/study/NCT06143553
EFO_1000984	inflammatory breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Completed	https://clinicaltrials.gov/study/NCT02324088
MONDO_0007254	breast cancer	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Unknown status	https://clinicaltrials.gov/study/NCT02514681
MONDO_0007254	breast cancer	CHEMBL384467	DEXAMETHASONE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	3	Recruiting	https://clinicaltrials.gov/study/NCT04862585,https://clinicaltrials.gov/study/NCT05306340
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	3	Suspended	https://clinicaltrials.gov/study/NCT03002103
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Unknown status	https://clinicaltrials.gov/study/NCT02879513
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	3	Recruiting	https://clinicaltrials.gov/study/NCT03820830,https://clinicaltrials.gov/study/NCT05207709,https://clinicaltrials.gov/study/NCT04964934,https://clinicaltrials.gov/study/NCT05429684,https://clinicaltrials.gov/study/NCT05909397,https://clinicaltrials.gov/study/NCT05501886,https://clinicaltrials.gov/study/NCT04862663
MONDO_0007254	breast cancer	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RA	interleukin 2 receptor subunit alpha	3	Completed	https://clinicaltrials.gov/study/NCT00008203
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Recruiting	https://clinicaltrials.gov/study/NCT05747794,https://clinicaltrials.gov/study/NCT04862585,https://clinicaltrials.gov/study/NCT03201861,https://clinicaltrials.gov/study/NCT06058377
EFO_0000304	breast adenocarcinoma	CHEMBL1201247	GOSERELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02115282
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	3	Recruiting	https://clinicaltrials.gov/study/NCT04964934,https://clinicaltrials.gov/study/NCT05909397,https://clinicaltrials.gov/study/NCT05429684,https://clinicaltrials.gov/study/NCT05501886,https://clinicaltrials.gov/study/NCT03820830,https://clinicaltrials.gov/study/NCT04862663,https://clinicaltrials.gov/study/NCT05207709
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Recruiting	https://clinicaltrials.gov/study/NCT05894239
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Recruiting	https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT05207514,https://clinicaltrials.gov/study/NCT05894239,https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT03949634,https://clinicaltrials.gov/study/NCT05159193,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT04540692,https://clinicaltrials.gov/study/NCT05673629,https://clinicaltrials.gov/study/NCT05883852,https://clinicaltrials.gov/study/NCT05296798,https://clinicaltrials.gov/study/NCT05901428,https://clinicaltrials.gov/study/NCT03926091,https://clinicaltrials.gov/study/NCT05720026,https://clinicaltrials.gov/study/NCT04193059,https://clinicaltrials.gov/study/NCT05430399,https://clinicaltrials.gov/study/NCT04547907,https://clinicaltrials.gov/study/NCT03671044
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT06255392
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT05104866,https://clinicaltrials.gov/study/NCT02641847,https://clinicaltrials.gov/study/NCT04639986,https://clinicaltrials.gov/study/NCT01646034,https://clinicaltrials.gov/study/NCT03734029
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Unknown status	https://clinicaltrials.gov/study/NCT00025688,https://clinicaltrials.gov/study/NCT01134523,https://clinicaltrials.gov/study/NCT01378533,https://clinicaltrials.gov/study/NCT00070278,https://clinicaltrials.gov/study/NCT02393833,https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT00629278,https://clinicaltrials.gov/study/NCT01019616,https://clinicaltrials.gov/study/NCT01084876,https://clinicaltrials.gov/study/NCT00005581,https://clinicaltrials.gov/study/NCT00289263,https://clinicaltrials.gov/study/NCT00039546,https://clinicaltrials.gov/study/NCT00486668,https://clinicaltrials.gov/study/NCT01547741
MONDO_0007254	breast cancer	CHEMBL1201066	VENLAFAXINE HYDROCHLORIDE	Small molecule	Serotonin transporter inhibitor		SLC6A4	solute carrier family 6 member 4	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06106529
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Completed	https://clinicaltrials.gov/study/NCT03197935,https://clinicaltrials.gov/study/NCT04177108,https://clinicaltrials.gov/study/NCT03125902
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06081959,https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT06343948,https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06279364
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	3	Terminated	https://clinicaltrials.gov/study/NCT02144012
MONDO_0007254	breast cancer	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03701334
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02003209,https://clinicaltrials.gov/study/NCT03588091,https://clinicaltrials.gov/study/NCT03863223,https://clinicaltrials.gov/study/NCT01646034,https://clinicaltrials.gov/study/NCT01358877,https://clinicaltrials.gov/study/NCT02641847,https://clinicaltrials.gov/study/NCT04024462
MONDO_0007254	breast cancer	CHEMBL480	LANSOPRAZOLE	Small molecule	Potassium-transporting ATPase inhibitor		ATP4A	ATPase H+/K+ transporting subunit alpha	3	Completed	https://clinicaltrials.gov/study/NCT04874935
MONDO_0007254	breast cancer	CHEMBL4279455	LAROTAXEL	Small molecule	Tubulin stabiliser		TUBB	tubulin beta class I	3	Completed	https://clinicaltrials.gov/study/NCT00081796
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT06255392
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA8	NADH:ubiquinone oxidoreductase subunit A8	3	Completed	https://clinicaltrials.gov/study/NCT01101438
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Terminated	https://clinicaltrials.gov/study/NCT00520975
MONDO_0007254	breast cancer	CHEMBL4297844	TRASTUZUMAB DERUXTECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	3	Recruiting	https://clinicaltrials.gov/study/NCT05113251,https://clinicaltrials.gov/study/NCT05950945
MONDO_0007254	breast cancer	CHEMBL4650316	GIREDESTRANT	Small molecule	Estrogen receptor alpha degrader		ESR1	estrogen receptor 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04546009
EFO_0000305	breast carcinoma	CHEMBL1201583	BEVACIZUMAB	Antibody	Vascular endothelial growth factor A inhibitor		VEGFA	vascular endothelial growth factor A	3	Completed	https://clinicaltrials.gov/study/NCT01935492,https://clinicaltrials.gov/study/NCT00785291
EFO_0000305	breast carcinoma	CHEMBL359744	DOXORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01275677
EFO_0000186	invasive breast ductal carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Completed	https://clinicaltrials.gov/study/NCT02620280
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	3	Suspended	https://clinicaltrials.gov/study/NCT03002103
EFO_0005537	triple-negative breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	3	Recruiting	https://clinicaltrials.gov/study/NCT05760378
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4L2	NDUFA4 mitochondrial complex associated like 2	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03734029,https://clinicaltrials.gov/study/NCT01646034,https://clinicaltrials.gov/study/NCT02641847,https://clinicaltrials.gov/study/NCT04639986,https://clinicaltrials.gov/study/NCT05104866
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR2	estrogen receptor 2	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT04337658
EFO_0000186	invasive breast ductal carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Completed	https://clinicaltrials.gov/study/NCT02620280
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN1A	sodium voltage-gated channel alpha subunit 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01916317
EFO_0000304	breast adenocarcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Completed	https://clinicaltrials.gov/study/NCT00005970
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Recruiting	https://clinicaltrials.gov/study/NCT05429684,https://clinicaltrials.gov/study/NCT05288777,https://clinicaltrials.gov/study/NCT04873362,https://clinicaltrials.gov/study/NCT04457596,https://clinicaltrials.gov/study/NCT05755048,https://clinicaltrials.gov/study/NCT06265428,https://clinicaltrials.gov/study/NCT03975647
MONDO_0007254	breast cancer	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Completed	https://clinicaltrials.gov/study/NCT04109066,https://clinicaltrials.gov/study/NCT03439046,https://clinicaltrials.gov/study/NCT02980965,https://clinicaltrials.gov/study/NCT00949598,https://clinicaltrials.gov/study/NCT00330317,https://clinicaltrials.gov/study/NCT00107263,https://clinicaltrials.gov/study/NCT00004205,https://clinicaltrials.gov/study/NCT02941926,https://clinicaltrials.gov/study/NCT00754845,https://clinicaltrials.gov/study/NCT00545077,https://clinicaltrials.gov/study/NCT02278120,https://clinicaltrials.gov/study/NCT02600923,https://clinicaltrials.gov/study/NCT00171704,https://clinicaltrials.gov/study/NCT00332852,https://clinicaltrials.gov/study/NCT00963729,https://clinicaltrials.gov/study/NCT00433589,https://clinicaltrials.gov/study/NCT01958021,https://clinicaltrials.gov/study/NCT00329940,https://clinicaltrials.gov/study/NCT02995772,https://clinicaltrials.gov/study/NCT00171314,https://clinicaltrials.gov/study/NCT00553410,https://clinicaltrials.gov/study/NCT03096847,https://clinicaltrials.gov/study/NCT00248170,https://clinicaltrials.gov/study/NCT00265759,https://clinicaltrials.gov/study/NCT00003140
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND5	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02810743,https://clinicaltrials.gov/study/NCT02000622,https://clinicaltrials.gov/study/NCT02032823
MONDO_0007254	breast cancer	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT04973319,https://clinicaltrials.gov/study/NCT04337658,https://clinicaltrials.gov/study/NCT05838066,https://clinicaltrials.gov/study/NCT05901935,https://clinicaltrials.gov/study/NCT05841381,https://clinicaltrials.gov/study/NCT05388500
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
EFO_0000553	invasive lobular carcinoma	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR1	estrogen receptor 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01953588
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04148911,https://clinicaltrials.gov/study/NCT04085276
MONDO_0007254	breast cancer	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Recruiting	https://clinicaltrials.gov/study/NCT04964934,https://clinicaltrials.gov/study/NCT04852887,https://clinicaltrials.gov/study/NCT04134598,https://clinicaltrials.gov/study/NCT04047758,https://clinicaltrials.gov/study/NCT05827081,https://clinicaltrials.gov/study/NCT05439499,https://clinicaltrials.gov/study/NCT05774951,https://clinicaltrials.gov/study/NCT05952557,https://clinicaltrials.gov/study/NCT05780567,https://clinicaltrials.gov/study/NCT05429684,https://clinicaltrials.gov/study/NCT05207709,https://clinicaltrials.gov/study/NCT05523609,https://clinicaltrials.gov/study/NCT04906395,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT05512364,https://clinicaltrials.gov/study/NCT04584853,https://clinicaltrials.gov/study/NCT05851014,https://clinicaltrials.gov/study/NCT05891093,https://clinicaltrials.gov/study/NCT05909397
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA5	NADH:ubiquinone oxidoreductase subunit A5	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Terminated	https://clinicaltrials.gov/study/NCT00002772,https://clinicaltrials.gov/study/NCT04335006,https://clinicaltrials.gov/study/NCT01200212,https://clinicaltrials.gov/study/NCT02054338,https://clinicaltrials.gov/study/NCT01303679,https://clinicaltrials.gov/study/NCT00520975
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	3	Recruiting	https://clinicaltrials.gov/study/NCT05501886
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885,https://clinicaltrials.gov/study/NCT01275677,https://clinicaltrials.gov/study/NCT02003209
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Completed	https://clinicaltrials.gov/study/NCT00191152
MONDO_0007254	breast cancer	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Terminated	https://clinicaltrials.gov/study/NCT00543127,https://clinicaltrials.gov/study/NCT00053911,https://clinicaltrials.gov/study/NCT02730091,https://clinicaltrials.gov/study/NCT02137837
MONDO_0007254	breast cancer	CHEMBL4303669	ZOLEDRONIC ACID	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00412022
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Suspended	https://clinicaltrials.gov/study/NCT03002103
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Recruiting	https://clinicaltrials.gov/study/NCT04193059,https://clinicaltrials.gov/study/NCT04137653,https://clinicaltrials.gov/study/NCT05113251,https://clinicaltrials.gov/study/NCT06018337,https://clinicaltrials.gov/study/NCT05382299,https://clinicaltrials.gov/study/NCT05555706,https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT04547907,https://clinicaltrials.gov/study/NCT04540692,https://clinicaltrials.gov/study/NCT05814354,https://clinicaltrials.gov/study/NCT04335669,https://clinicaltrials.gov/study/NCT05840211,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT05296798,https://clinicaltrials.gov/study/NCT05894239,https://clinicaltrials.gov/study/NCT03876886,https://clinicaltrials.gov/study/NCT05207709,https://clinicaltrials.gov/study/NCT06112379,https://clinicaltrials.gov/study/NCT06103864,https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT06143553,https://clinicaltrials.gov/study/NCT05374512,https://clinicaltrials.gov/study/NCT03949634,https://clinicaltrials.gov/study/NCT05429684,https://clinicaltrials.gov/study/NCT04862585
MONDO_0007254	breast cancer	CHEMBL924	ZOLEDRONIC ACID ANHYDROUS	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00412022
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV3	NADH:ubiquinone oxidoreductase subunit V3	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL1042	CHOLECALCIFEROL	Small molecule	Vitamin D receptor agonist		VDR	vitamin D receptor	3	Terminated	https://clinicaltrials.gov/study/NCT01608451
MONDO_0007254	breast cancer	CHEMBL1201179	LAPATINIB DITOSYLATE	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	3	Completed	https://clinicaltrials.gov/study/NCT00667251
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Recruiting	https://clinicaltrials.gov/study/NCT04296175,https://clinicaltrials.gov/study/NCT05862064
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Recruiting	https://clinicaltrials.gov/study/NCT04457596
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR1	estrogen receptor 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT05063786,https://clinicaltrials.gov/study/NCT04191499,https://clinicaltrials.gov/study/NCT01953588,https://clinicaltrials.gov/study/NCT02763566,https://clinicaltrials.gov/study/NCT02947685,https://clinicaltrials.gov/study/NCT03927456,https://clinicaltrials.gov/study/NCT04305496,https://clinicaltrials.gov/study/NCT01602380,https://clinicaltrials.gov/study/NCT03079011,https://clinicaltrials.gov/study/NCT00099437,https://clinicaltrials.gov/study/NCT05433480
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT05104866,https://clinicaltrials.gov/study/NCT04639986,https://clinicaltrials.gov/study/NCT03734029,https://clinicaltrials.gov/study/NCT05063786
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Completed	https://clinicaltrials.gov/study/NCT00005970
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01275677,https://clinicaltrials.gov/study/NCT03199885,https://clinicaltrials.gov/study/NCT02003209
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	3	Completed	https://clinicaltrials.gov/study/NCT00191152,https://clinicaltrials.gov/study/NCT02546934,https://clinicaltrials.gov/study/NCT00236899,https://clinicaltrials.gov/study/NCT00006459,https://clinicaltrials.gov/study/NCT02574455,https://clinicaltrials.gov/study/NCT02555657,https://clinicaltrials.gov/study/NCT03901339,https://clinicaltrials.gov/study/NCT00561119,https://clinicaltrials.gov/study/NCT00431106,https://clinicaltrials.gov/study/NCT02819518,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT01287624,https://clinicaltrials.gov/study/NCT00938652,https://clinicaltrials.gov/study/NCT00670878,https://clinicaltrials.gov/study/NCT00294385
MONDO_0007254	breast cancer	CHEMBL1098	BUPIVACAINE	Small molecule	Sodium channel protein type IV alpha subunit blocker		SCN4A	sodium voltage-gated channel alpha subunit 4	3	Unknown status	https://clinicaltrials.gov/study/NCT03063073,https://clinicaltrials.gov/study/NCT01314144
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Recruiting	https://clinicaltrials.gov/study/NCT05374512
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Recruiting	https://clinicaltrials.gov/study/NCT03975647,https://clinicaltrials.gov/study/NCT05429684,https://clinicaltrials.gov/study/NCT05755048,https://clinicaltrials.gov/study/NCT05288777,https://clinicaltrials.gov/study/NCT04457596,https://clinicaltrials.gov/study/NCT04873362,https://clinicaltrials.gov/study/NCT06265428
EFO_0000305	breast carcinoma	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Completed	https://clinicaltrials.gov/study/NCT02162667
MONDO_0007254	breast cancer	CHEMBL554	LAPATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04185649,https://clinicaltrials.gov/study/NCT01104571,https://clinicaltrials.gov/study/NCT03523585
MONDO_0007254	breast cancer	CHEMBL657	DIPHENHYDRAMINE	Small molecule	Histamine H1 receptor antagonist		HRH1	histamine receptor H1	3	Recruiting	https://clinicaltrials.gov/study/NCT04862585
MONDO_0007254	breast cancer	CHEMBL1014	CANDESARTAN CILEXETIL	Small molecule	Type-1 angiotensin II receptor antagonist		AGTR1	angiotensin II receptor type 1	3	Completed	https://clinicaltrials.gov/study/NCT00459771
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA6	NADH:ubiquinone oxidoreductase subunit A6	3	Completed	https://clinicaltrials.gov/study/NCT01101438
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02003209,https://clinicaltrials.gov/study/NCT03199885,https://clinicaltrials.gov/study/NCT01275677
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
EFO_0000304	breast adenocarcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Withdrawn	https://clinicaltrials.gov/study/NCT00041171,https://clinicaltrials.gov/study/NCT03811418,https://clinicaltrials.gov/study/NCT05474690
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Completed	https://clinicaltrials.gov/study/NCT02225470,https://clinicaltrials.gov/study/NCT03901339,https://clinicaltrials.gov/study/NCT00337103,https://clinicaltrials.gov/study/NCT00388726,https://clinicaltrials.gov/study/NCT02574455,https://clinicaltrials.gov/study/NCT02555657
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Completed	https://clinicaltrials.gov/study/NCT00005970
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Recruiting	https://clinicaltrials.gov/study/NCT05374512
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN3A	sodium voltage-gated channel alpha subunit 3	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01916317
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02221999
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Completed	https://clinicaltrials.gov/study/NCT01095003,https://clinicaltrials.gov/study/NCT01953003,https://clinicaltrials.gov/study/NCT01091168
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT06081959,https://clinicaltrials.gov/study/NCT06343948,https://clinicaltrials.gov/study/NCT06255392
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Unknown status	https://clinicaltrials.gov/study/NCT02393833,https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT00003679,https://clinicaltrials.gov/study/NCT00532727,https://clinicaltrials.gov/study/NCT00010140,https://clinicaltrials.gov/study/NCT00944424,https://clinicaltrials.gov/study/NCT01354522,https://clinicaltrials.gov/study/NCT01622361,https://clinicaltrials.gov/study/NCT00629278,https://clinicaltrials.gov/study/NCT01547741,https://clinicaltrials.gov/study/NCT01222052,https://clinicaltrials.gov/study/NCT00430001,https://clinicaltrials.gov/study/NCT01642771,https://clinicaltrials.gov/study/NCT01479036,https://clinicaltrials.gov/study/NCT00408408
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Recruiting	https://clinicaltrials.gov/study/NCT04457596
EFO_0000304	breast adenocarcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06343948,https://clinicaltrials.gov/study/NCT06081959
EFO_0000304	breast adenocarcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00433511,https://clinicaltrials.gov/study/NCT03199885
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Recruiting	https://clinicaltrials.gov/study/NCT05760378
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Completed	https://clinicaltrials.gov/study/NCT00337103,https://clinicaltrials.gov/study/NCT00388726,https://clinicaltrials.gov/study/NCT02225470
MONDO_0007254	breast cancer	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT01645839
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	3	Completed	https://clinicaltrials.gov/study/NCT03726879,https://clinicaltrials.gov/study/NCT03084939,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT01419197,https://clinicaltrials.gov/study/NCT00829166,https://clinicaltrials.gov/study/NCT01702571,https://clinicaltrials.gov/study/NCT01120184
MONDO_0007254	breast cancer	CHEMBL1200511	GONADORELIN ACETATE	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	3	Completed	https://clinicaltrials.gov/study/NCT00605267
EFO_0000305	breast carcinoma	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Recruiting	https://clinicaltrials.gov/study/NCT05760378
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04148911,https://clinicaltrials.gov/study/NCT04085276
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Recruiting	https://clinicaltrials.gov/study/NCT04307147,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT06143553,https://clinicaltrials.gov/study/NCT06268652,https://clinicaltrials.gov/study/NCT04400695
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Unknown status	https://clinicaltrials.gov/study/NCT01134523,https://clinicaltrials.gov/study/NCT00486668,https://clinicaltrials.gov/study/NCT00070278,https://clinicaltrials.gov/study/NCT01019616,https://clinicaltrials.gov/study/NCT00629278,https://clinicaltrials.gov/study/NCT00039546,https://clinicaltrials.gov/study/NCT00289263,https://clinicaltrials.gov/study/NCT01378533,https://clinicaltrials.gov/study/NCT01547741,https://clinicaltrials.gov/study/NCT00005581,https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT01084876,https://clinicaltrials.gov/study/NCT02393833,https://clinicaltrials.gov/study/NCT00025688
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04639986
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652,https://clinicaltrials.gov/study/NCT05374512,https://clinicaltrials.gov/study/NCT05814354,https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT02344472
EFO_0000305	breast carcinoma	CHEMBL1908360	EVEROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	3	Unknown status	https://clinicaltrials.gov/study/NCT02404051
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02221999
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06377852
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Withdrawn	https://clinicaltrials.gov/study/NCT00041171,https://clinicaltrials.gov/study/NCT05474690,https://clinicaltrials.gov/study/NCT03811418
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Withdrawn	https://clinicaltrials.gov/study/NCT03811418
MONDO_0007254	breast cancer	CHEMBL4297715	CAMRELIZUMAB	Antibody	Programmed cell death protein 1 antagonist		PDCD1	programmed cell death 1	3	Completed	https://clinicaltrials.gov/study/NCT04613674
EFO_0000304	breast adenocarcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885
MONDO_0004658	breast carcinoma in situ	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Recruiting	https://clinicaltrials.gov/study/NCT04862585
EFO_1000984	inflammatory breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT05415215
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT06143553
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	3	Completed	https://clinicaltrials.gov/study/NCT01234337
MONDO_0007254	breast cancer	CHEMBL3186534	RIVOCERANIB	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	3	Terminated	https://clinicaltrials.gov/study/NCT04335006
MONDO_0007254	breast cancer	CHEMBL271227	ABIRATERONE ACETATE	Small molecule	Cytochrome P450 17A1 inhibitor		CYP17A1	cytochrome P450 family 17 subfamily A member 1	3	Completed	https://clinicaltrials.gov/study/NCT01517802
MONDO_0007254	breast cancer	CHEMBL3989569	IBANDRONATE SODIUM	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	3	Completed	https://clinicaltrials.gov/study/NCT00127205
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Unknown status	https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT00430001
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Recruiting	https://clinicaltrials.gov/study/NCT04457596
EFO_0000305	breast carcinoma	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885,https://clinicaltrials.gov/study/NCT02003209,https://clinicaltrials.gov/study/NCT01275677
EFO_0005537	triple-negative breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	3	Suspended	https://clinicaltrials.gov/study/NCT03002103
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Completed	https://clinicaltrials.gov/study/NCT03197935,https://clinicaltrials.gov/study/NCT04177108,https://clinicaltrials.gov/study/NCT03125902
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Recruiting	https://clinicaltrials.gov/study/NCT05894239
EFO_1000984	inflammatory breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Completed	https://clinicaltrials.gov/study/NCT02324088
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Terminated	https://clinicaltrials.gov/study/NCT03786094,https://clinicaltrials.gov/study/NCT05134194
EFO_0000186	invasive breast ductal carcinoma	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR1	estrogen receptor 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01953588
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	3	Terminated	https://clinicaltrials.gov/study/NCT01633060
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Completed	https://clinicaltrials.gov/study/NCT00431106,https://clinicaltrials.gov/study/NCT02225470,https://clinicaltrials.gov/study/NCT00103233,https://clinicaltrials.gov/study/NCT00776724,https://clinicaltrials.gov/study/NCT00146549,https://clinicaltrials.gov/study/NCT01007942,https://clinicaltrials.gov/study/NCT03901339,https://clinicaltrials.gov/study/NCT00868634,https://clinicaltrials.gov/study/NCT02574455,https://clinicaltrials.gov/study/NCT02555657
MONDO_0007254	breast cancer	CHEMBL1201568	PEGFILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	3	Unknown status	https://clinicaltrials.gov/study/NCT00516425,https://clinicaltrials.gov/study/NCT02761460,https://clinicaltrials.gov/study/NCT03404752
MONDO_0007254	breast cancer	CHEMBL135	ESTRADIOL	Small molecule	Estrogen receptor alpha agonist		ESR1	estrogen receptor 1	3	Completed	https://clinicaltrials.gov/study/NCT00003771
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Completed	https://clinicaltrials.gov/study/NCT01935492,https://clinicaltrials.gov/study/NCT00785291
MONDO_0007254	breast cancer	CHEMBL34259	METHOTREXATE	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	3	Unknown status	https://clinicaltrials.gov/study/NCT01031030,https://clinicaltrials.gov/study/NCT02393833,https://clinicaltrials.gov/study/NCT00003680
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Completed	https://clinicaltrials.gov/study/NCT00005970
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Completed	https://clinicaltrials.gov/study/NCT00017095,https://clinicaltrials.gov/study/NCT01049425,https://clinicaltrials.gov/study/NCT02586025,https://clinicaltrials.gov/study/NCT00448591,https://clinicaltrials.gov/study/NCT01120184,https://clinicaltrials.gov/study/NCT00288002,https://clinicaltrials.gov/study/NCT03013504,https://clinicaltrials.gov/study/NCT02019277,https://clinicaltrials.gov/study/NCT02115204,https://clinicaltrials.gov/study/NCT00004125,https://clinicaltrials.gov/study/NCT00146549,https://clinicaltrials.gov/study/NCT00193011,https://clinicaltrials.gov/study/NCT00703326,https://clinicaltrials.gov/study/NCT05301010,https://clinicaltrials.gov/study/NCT00424606,https://clinicaltrials.gov/study/NCT00540800,https://clinicaltrials.gov/study/NCT02194166,https://clinicaltrials.gov/study/NCT03084237,https://clinicaltrials.gov/study/NCT00493870,https://clinicaltrials.gov/study/NCT00776724,https://clinicaltrials.gov/study/NCT00089479,https://clinicaltrials.gov/study/NCT03989037,https://clinicaltrials.gov/study/NCT00333775,https://clinicaltrials.gov/study/NCT04127019,https://clinicaltrials.gov/study/NCT00002662,https://clinicaltrials.gov/study/NCT00114816,https://clinicaltrials.gov/study/NCT00615602,https://clinicaltrials.gov/study/NCT00003519,https://clinicaltrials.gov/study/NCT00008411,https://clinicaltrials.gov/study/NCT01690702,https://clinicaltrials.gov/study/NCT00429871,https://clinicaltrials.gov/study/NCT00002707,https://clinicaltrials.gov/study/NCT00963729,https://clinicaltrials.gov/study/NCT00091442,https://clinicaltrials.gov/study/NCT02980965,https://clinicaltrials.gov/study/NCT00003782,https://clinicaltrials.gov/study/NCT00002544,https://clinicaltrials.gov/study/NCT00887536,https://clinicaltrials.gov/study/NCT00054587,https://clinicaltrials.gov/study/NCT02187744,https://clinicaltrials.gov/study/NCT01940497,https://clinicaltrials.gov/study/NCT00047099,https://clinicaltrials.gov/study/NCT02681003,https://clinicaltrials.gov/study/NCT00352378,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT01099436,https://clinicaltrials.gov/study/NCT00688740,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT04957212,https://clinicaltrials.gov/study/NCT00129935,https://clinicaltrials.gov/study/NCT03425656,https://clinicaltrials.gov/study/NCT05629949,https://clinicaltrials.gov/study/NCT00567554,https://clinicaltrials.gov/study/NCT00331097,https://clinicaltrials.gov/study/NCT01314833,https://clinicaltrials.gov/study/NCT00433589,https://clinicaltrials.gov/study/NCT00294385,https://clinicaltrials.gov/study/NCT00309556,https://clinicaltrials.gov/study/NCT02472964,https://clinicaltrials.gov/study/NCT01964391,https://clinicaltrials.gov/study/NCT01216111,https://clinicaltrials.gov/study/NCT00047255,https://clinicaltrials.gov/study/NCT00190489,https://clinicaltrials.gov/study/NCT01985724,https://clinicaltrials.gov/study/NCT04031703,https://clinicaltrials.gov/study/NCT03493854,https://clinicaltrials.gov/study/NCT00312208,https://clinicaltrials.gov/study/NCT00667251,https://clinicaltrials.gov/study/NCT00567190,https://clinicaltrials.gov/study/NCT00236899,https://clinicaltrials.gov/study/NCT00793377,https://clinicaltrials.gov/study/NCT00950300,https://clinicaltrials.gov/study/NCT00311636,https://clinicaltrials.gov/study/NCT00630032,https://clinicaltrials.gov/study/NCT00191152,https://clinicaltrials.gov/study/NCT04629846,https://clinicaltrials.gov/study/NCT02896855,https://clinicaltrials.gov/study/NCT00314977,https://clinicaltrials.gov/study/NCT00391092,https://clinicaltrials.gov/study/NCT00431080,https://clinicaltrials.gov/study/NCT02402712
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA7	NADH:ubiquinone oxidoreductase subunit A7	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Completed	https://clinicaltrials.gov/study/NCT00630032,https://clinicaltrials.gov/study/NCT00789581,https://clinicaltrials.gov/study/NCT00082433,https://clinicaltrials.gov/study/NCT00080301,https://clinicaltrials.gov/study/NCT00448591
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Completed	https://clinicaltrials.gov/study/NCT01583426,https://clinicaltrials.gov/study/NCT02125344
MONDO_0004658	breast carcinoma in situ	CHEMBL1790041	RANITIDINE	Small molecule	Histamine H2 receptor antagonist		HRH2	histamine receptor H2	3	Recruiting	https://clinicaltrials.gov/study/NCT04862585
MONDO_0007254	breast cancer	CHEMBL4650365	CAMIZESTRANT	Small molecule	Estrogen receptor alpha degrader		ESR1	estrogen receptor 1	3	Recruiting	https://clinicaltrials.gov/study/NCT05952557,https://clinicaltrials.gov/study/NCT04964934,https://clinicaltrials.gov/study/NCT05774951
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06079983
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Unknown status	https://clinicaltrials.gov/study/NCT02514681
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	3	Terminated	https://clinicaltrials.gov/study/NCT02340221
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Recruiting	https://clinicaltrials.gov/study/NCT03671044,https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT05430399,https://clinicaltrials.gov/study/NCT05673629,https://clinicaltrials.gov/study/NCT05720026,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT05894239,https://clinicaltrials.gov/study/NCT03949634,https://clinicaltrials.gov/study/NCT04547907,https://clinicaltrials.gov/study/NCT05883852,https://clinicaltrials.gov/study/NCT03926091,https://clinicaltrials.gov/study/NCT04540692,https://clinicaltrials.gov/study/NCT04193059,https://clinicaltrials.gov/study/NCT05159193,https://clinicaltrials.gov/study/NCT05296798,https://clinicaltrials.gov/study/NCT05207514,https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT05901428
EFO_1000984	inflammatory breast carcinoma	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Completed	https://clinicaltrials.gov/study/NCT02125344
MONDO_0007254	breast cancer	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	3	Recruiting	https://clinicaltrials.gov/study/NCT06103864,https://clinicaltrials.gov/study/NCT05633654,https://clinicaltrials.gov/study/NCT06112379,https://clinicaltrials.gov/study/NCT04335669,https://clinicaltrials.gov/study/NCT05629585
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Withdrawn	https://clinicaltrials.gov/study/NCT00041171,https://clinicaltrials.gov/study/NCT03811418,https://clinicaltrials.gov/study/NCT05474690
MONDO_0007254	breast cancer	CHEMBL4279455	LAROTAXEL	Small molecule	Tubulin stabiliser		TUBB2A	tubulin beta 2A class IIa	3	Completed	https://clinicaltrials.gov/study/NCT00081796
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Completed	https://clinicaltrials.gov/study/NCT03197935,https://clinicaltrials.gov/study/NCT03125902,https://clinicaltrials.gov/study/NCT04177108
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
MONDO_0007254	breast cancer	CHEMBL1201564	INTERFERON GAMMA-1B	Protein	Interferon gamma receptor agonist		IFNGR1	interferon gamma receptor 1	3	Completed	https://clinicaltrials.gov/study/NCT00008203
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT00006459
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	3	Unknown status	https://clinicaltrials.gov/study/NCT00039546,https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT00070278
EFO_0000186	invasive breast ductal carcinoma	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01953588
MONDO_0007254	breast cancer	CHEMBL1201565	EPOETIN ALFA	Protein	Erythropoietin receptor agonist		EPOR	erythropoietin receptor	3	Completed	https://clinicaltrials.gov/study/NCT00544232,https://clinicaltrials.gov/study/NCT00014222
MONDO_0007254	breast cancer	CHEMBL3707227	ATEZOLIZUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04732598,https://clinicaltrials.gov/study/NCT03595592,https://clinicaltrials.gov/study/NCT03281954,https://clinicaltrials.gov/study/NCT04740918
MONDO_0004658	breast carcinoma in situ	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Recruiting	https://clinicaltrials.gov/study/NCT04862585
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	3	Terminated	https://clinicaltrials.gov/study/NCT01633060
MONDO_0007254	breast cancer	CHEMBL1201199	LEUPROLIDE	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01674140,https://clinicaltrials.gov/study/NCT04711252,https://clinicaltrials.gov/study/NCT04546009
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT00191152
MONDO_0007254	breast cancer	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Terminated	https://clinicaltrials.gov/study/NCT00912444,https://clinicaltrials.gov/study/NCT00296010,https://clinicaltrials.gov/study/NCT00002772,https://clinicaltrials.gov/study/NCT00082095
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	3	Terminated	https://clinicaltrials.gov/study/NCT00440622,https://clinicaltrials.gov/study/NCT02054338,https://clinicaltrials.gov/study/NCT05134194
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04148911,https://clinicaltrials.gov/study/NCT04085276
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01275677,https://clinicaltrials.gov/study/NCT03199885,https://clinicaltrials.gov/study/NCT02003209
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Recruiting	https://clinicaltrials.gov/study/NCT04457596
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04622319,https://clinicaltrials.gov/study/NCT01772472,https://clinicaltrials.gov/study/NCT04740918,https://clinicaltrials.gov/study/NCT03529110
MONDO_0007254	breast cancer	CHEMBL3545111	HEMAY-022	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Recruiting	https://clinicaltrials.gov/study/NCT06313983,https://clinicaltrials.gov/study/NCT05122494
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Unknown status	https://clinicaltrials.gov/study/NCT00010140,https://clinicaltrials.gov/study/NCT01622361,https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT00944424,https://clinicaltrials.gov/study/NCT00003679,https://clinicaltrials.gov/study/NCT00430001,https://clinicaltrials.gov/study/NCT00629278,https://clinicaltrials.gov/study/NCT01479036,https://clinicaltrials.gov/study/NCT01642771,https://clinicaltrials.gov/study/NCT02393833,https://clinicaltrials.gov/study/NCT00532727,https://clinicaltrials.gov/study/NCT01354522,https://clinicaltrials.gov/study/NCT01547741,https://clinicaltrials.gov/study/NCT01222052
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA13	NADH:ubiquinone oxidoreductase subunit A13	3	Completed	https://clinicaltrials.gov/study/NCT01101438
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Completed	https://clinicaltrials.gov/study/NCT04177108,https://clinicaltrials.gov/study/NCT03197935,https://clinicaltrials.gov/study/NCT03125902
EFO_0000304	breast adenocarcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC5	histone deacetylase 5	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02115282
EFO_1000984	inflammatory breast carcinoma	CHEMBL1738	DEXRAZOXANE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	3	Terminated	https://clinicaltrials.gov/study/NCT00016276
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Withdrawn	https://clinicaltrials.gov/study/NCT03811418
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT04722978,https://clinicaltrials.gov/study/NCT06103864,https://clinicaltrials.gov/study/NCT06143553,https://clinicaltrials.gov/study/NCT05814354,https://clinicaltrials.gov/study/NCT05382299,https://clinicaltrials.gov/study/NCT06268652
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03734029,https://clinicaltrials.gov/study/NCT03595592,https://clinicaltrials.gov/study/NCT00433420,https://clinicaltrials.gov/study/NCT02214381,https://clinicaltrials.gov/study/NCT00070564,https://clinicaltrials.gov/study/NCT03168880,https://clinicaltrials.gov/study/NCT01646034,https://clinicaltrials.gov/study/NCT01358877,https://clinicaltrials.gov/study/NCT01996267,https://clinicaltrials.gov/study/NCT03315364,https://clinicaltrials.gov/study/NCT04494425,https://clinicaltrials.gov/study/NCT03725059,https://clinicaltrials.gov/study/NCT04732598
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Recruiting	https://clinicaltrials.gov/study/NCT05374512
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC10	histone deacetylase 10	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03538171
EFO_0000304	breast adenocarcinoma	CHEMBL3707227	ATEZOLIZUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885
MONDO_0007254	breast cancer	CHEMBL3647420	PYROTINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03588091,https://clinicaltrials.gov/study/NCT03863223,https://clinicaltrials.gov/study/NCT03980054,https://clinicaltrials.gov/study/NCT02973737
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Completed	https://clinicaltrials.gov/study/NCT00005970
MONDO_0007254	breast cancer	CHEMBL4297715	CAMRELIZUMAB	Antibody	Programmed cell death protein 1 antagonist		PDCD1	programmed cell death 1	3	Terminated	https://clinicaltrials.gov/study/NCT05134194
MONDO_0007254	breast cancer	CHEMBL554	LAPATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Unknown status	https://clinicaltrials.gov/study/NCT02394496,https://clinicaltrials.gov/study/NCT00486668,https://clinicaltrials.gov/study/NCT03080805,https://clinicaltrials.gov/study/NCT00688194
MONDO_0007254	breast cancer	CHEMBL778	DEXMEDETOMIDINE	Small molecule	Adrenergic receptor alpha-2 agonist		ADRA2A	adrenoceptor alpha 2A	3	Recruiting	https://clinicaltrials.gov/study/NCT05439005
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB8	NADH:ubiquinone oxidoreductase subunit B8	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL902	FAMOTIDINE	Small molecule	Histamine H2 receptor antagonist		HRH2	histamine receptor H2	3	Recruiting	https://clinicaltrials.gov/study/NCT04862585
MONDO_0007254	breast cancer	CHEMBL3647420	PYROTINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Recruiting	https://clinicaltrials.gov/study/NCT04646759,https://clinicaltrials.gov/study/NCT05910398,https://clinicaltrials.gov/study/NCT06278870,https://clinicaltrials.gov/study/NCT05346861,https://clinicaltrials.gov/study/NCT04254263,https://clinicaltrials.gov/study/NCT05424835,https://clinicaltrials.gov/study/NCT05429684
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Unknown status	https://clinicaltrials.gov/study/NCT02514681
EFO_0000304	breast adenocarcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
MONDO_0007254	breast cancer	CHEMBL25	ASPIRIN	Small molecule	Cyclooxygenase inhibitor		PTGS1	prostaglandin-endoperoxide synthase 1	3	Terminated	https://clinicaltrials.gov/study/NCT02927249
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR1	estrogen receptor 1	3	Recruiting	https://clinicaltrials.gov/study/NCT04646759,https://clinicaltrials.gov/study/NCT05306340,https://clinicaltrials.gov/study/NCT04862663,https://clinicaltrials.gov/study/NCT05077449,https://clinicaltrials.gov/study/NCT04263298,https://clinicaltrials.gov/study/NCT05207709,https://clinicaltrials.gov/study/NCT05646862,https://clinicaltrials.gov/study/NCT05654623,https://clinicaltrials.gov/study/NCT04650581,https://clinicaltrials.gov/study/NCT05501886,https://clinicaltrials.gov/study/NCT06105632,https://clinicaltrials.gov/study/NCT05054751,https://clinicaltrials.gov/study/NCT05038735,https://clinicaltrials.gov/study/NCT05438810,https://clinicaltrials.gov/study/NCT05696626,https://clinicaltrials.gov/study/NCT02344472
MONDO_0007254	breast cancer	CHEMBL185	FLUOROURACIL	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	3	Suspended	https://clinicaltrials.gov/study/NCT00002696
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT06343948,https://clinicaltrials.gov/study/NCT06081959
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	3	Recruiting	https://clinicaltrials.gov/study/NCT06112379
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885,https://clinicaltrials.gov/study/NCT00433511
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04799249
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Suspended	https://clinicaltrials.gov/study/NCT03002103
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04639986
MONDO_0007254	breast cancer	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Completed	https://clinicaltrials.gov/study/NCT00016432,https://clinicaltrials.gov/study/NCT00065325,https://clinicaltrials.gov/study/NCT02482753,https://clinicaltrials.gov/study/NCT00066573,https://clinicaltrials.gov/study/NCT02995772,https://clinicaltrials.gov/study/NCT02028507,https://clinicaltrials.gov/study/NCT04109066,https://clinicaltrials.gov/study/NCT01626222,https://clinicaltrials.gov/study/NCT00083174,https://clinicaltrials.gov/study/NCT00863655,https://clinicaltrials.gov/study/NCT00002777,https://clinicaltrials.gov/study/NCT03176238,https://clinicaltrials.gov/study/NCT00525096,https://clinicaltrials.gov/study/NCT00032136,https://clinicaltrials.gov/study/NCT01237327,https://clinicaltrials.gov/study/NCT00265759
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR1	estrogen receptor 1	3	Completed	https://clinicaltrials.gov/study/NCT00390455
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	3	Completed	https://clinicaltrials.gov/study/NCT00006459
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Terminated	https://clinicaltrials.gov/study/NCT05134194,https://clinicaltrials.gov/study/NCT02730091
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06081959,https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06343948,https://clinicaltrials.gov/study/NCT06079983
EFO_1000984	inflammatory breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Completed	https://clinicaltrials.gov/study/NCT02324088
MONDO_0007254	breast cancer	CHEMBL4297939	DATOPOTAMAB DERUXTECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT05104866
MONDO_0007254	breast cancer	CHEMBL38	TRETINOIN	Small molecule	Retinoic acid receptor agonist		RARB	retinoic acid receptor beta	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT05016349
MONDO_0007254	breast cancer	CHEMBL4650215	INAVOLISIB	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	3	Recruiting	https://clinicaltrials.gov/study/NCT05646862,https://clinicaltrials.gov/study/NCT05894239
EFO_0000304	breast adenocarcinoma	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01646034,https://clinicaltrials.gov/study/NCT03588091,https://clinicaltrials.gov/study/NCT04024462,https://clinicaltrials.gov/study/NCT01358877,https://clinicaltrials.gov/study/NCT03863223,https://clinicaltrials.gov/study/NCT02003209,https://clinicaltrials.gov/study/NCT02641847
EFO_0000305	breast carcinoma	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652
MONDO_0007254	breast cancer	CHEMBL3989868	TUCATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Recruiting	https://clinicaltrials.gov/study/NCT05132582,https://clinicaltrials.gov/study/NCT04457596,https://clinicaltrials.gov/study/NCT03975647
MONDO_0007254	breast cancer	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Enrolling by invitation	https://clinicaltrials.gov/study/NCT05645536
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02003209,https://clinicaltrials.gov/study/NCT03199885,https://clinicaltrials.gov/study/NCT01275677
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Unknown status	https://clinicaltrials.gov/study/NCT01642771,https://clinicaltrials.gov/study/NCT01354522,https://clinicaltrials.gov/study/NCT00003679,https://clinicaltrials.gov/study/NCT01222052,https://clinicaltrials.gov/study/NCT00629278,https://clinicaltrials.gov/study/NCT01622361,https://clinicaltrials.gov/study/NCT00944424,https://clinicaltrials.gov/study/NCT02393833,https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT00010140,https://clinicaltrials.gov/study/NCT01479036,https://clinicaltrials.gov/study/NCT00532727,https://clinicaltrials.gov/study/NCT01547741,https://clinicaltrials.gov/study/NCT00430001
MONDO_0007254	breast cancer	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01674140,https://clinicaltrials.gov/study/NCT04711252,https://clinicaltrials.gov/study/NCT01953588,https://clinicaltrials.gov/study/NCT02763566,https://clinicaltrials.gov/study/NCT02246621,https://clinicaltrials.gov/study/NCT02918084,https://clinicaltrials.gov/study/NCT02947685,https://clinicaltrials.gov/study/NCT01602380,https://clinicaltrials.gov/study/NCT00887380
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Recruiting	https://clinicaltrials.gov/study/NCT05862064,https://clinicaltrials.gov/study/NCT04296175
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	3	Completed	https://clinicaltrials.gov/study/NCT01610284
MONDO_0007254	breast cancer	CHEMBL924	ZOLEDRONIC ACID ANHYDROUS	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	3	Completed	https://clinicaltrials.gov/study/NCT00171314,https://clinicaltrials.gov/study/NCT01099436,https://clinicaltrials.gov/study/NCT00127205,https://clinicaltrials.gov/study/NCT00295646,https://clinicaltrials.gov/study/NCT00320710,https://clinicaltrials.gov/study/NCT00376740,https://clinicaltrials.gov/study/NCT00375505,https://clinicaltrials.gov/study/NCT00107263,https://clinicaltrials.gov/study/NCT00512993,https://clinicaltrials.gov/study/NCT00202059,https://clinicaltrials.gov/study/NCT00556374,https://clinicaltrials.gov/study/NCT00375427,https://clinicaltrials.gov/study/NCT00712985
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT00191152
MONDO_0007254	breast cancer	CHEMBL1200501	GOSERELIN ACETATE	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	3	Unknown status	https://clinicaltrials.gov/study/NCT00002460
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA9	NADH:ubiquinone oxidoreductase subunit A9	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT05838066,https://clinicaltrials.gov/study/NCT05283837,https://clinicaltrials.gov/study/NCT04337658
MONDO_0007254	breast cancer	CHEMBL1201199	LEUPROLIDE	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	3	Completed	https://clinicaltrials.gov/study/NCT01546649,https://clinicaltrials.gov/study/NCT02941926,https://clinicaltrials.gov/study/NCT00002580,https://clinicaltrials.gov/study/NCT02980965,https://clinicaltrials.gov/study/NCT00002582
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Recruiting	https://clinicaltrials.gov/study/NCT02488967
EFO_0000304	breast adenocarcinoma	CHEMBL359744	DOXORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00433511
MONDO_0007254	breast cancer	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RB	interleukin 2 receptor subunit beta	3	Completed	https://clinicaltrials.gov/study/NCT00008203
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT06255392
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Completed	https://clinicaltrials.gov/study/NCT02225470,https://clinicaltrials.gov/study/NCT00388726,https://clinicaltrials.gov/study/NCT00337103
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06079983
MONDO_0007254	breast cancer	CHEMBL279785	MARIMASTAT	Small molecule	Matrix metalloproteinase-2 inhibitor		MMP2	matrix metallopeptidase 2	3	Completed	https://clinicaltrials.gov/study/NCT00003010
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT05104866,https://clinicaltrials.gov/study/NCT02641847,https://clinicaltrials.gov/study/NCT01646034,https://clinicaltrials.gov/study/NCT03734029,https://clinicaltrials.gov/study/NCT04639986
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	3	Terminated	https://clinicaltrials.gov/study/NCT02054338,https://clinicaltrials.gov/study/NCT00440622,https://clinicaltrials.gov/study/NCT05134194
MONDO_0007254	breast cancer	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03701334
EFO_0000305	breast carcinoma	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Terminated	https://clinicaltrials.gov/study/NCT00520975
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652,https://clinicaltrials.gov/study/NCT06103864,https://clinicaltrials.gov/study/NCT05382299,https://clinicaltrials.gov/study/NCT04722978,https://clinicaltrials.gov/study/NCT06143553,https://clinicaltrials.gov/study/NCT05814354
MONDO_0007254	breast cancer	CHEMBL1201247	GOSERELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	3	Recruiting	https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT05827081,https://clinicaltrials.gov/study/NCT03664895,https://clinicaltrials.gov/study/NCT02535221,https://clinicaltrials.gov/study/NCT03936933,https://clinicaltrials.gov/study/NCT02914158,https://clinicaltrials.gov/study/NCT05439499,https://clinicaltrials.gov/study/NCT05438810
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT04665986,https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT05901935
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03529110,https://clinicaltrials.gov/study/NCT01772472,https://clinicaltrials.gov/study/NCT04622319,https://clinicaltrials.gov/study/NCT04740918
MONDO_0007254	breast cancer	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	3	Completed	https://clinicaltrials.gov/study/NCT02555657,https://clinicaltrials.gov/study/NCT02819518
EFO_0005537	triple-negative breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	3	Suspended	https://clinicaltrials.gov/study/NCT03002103
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Recruiting	https://clinicaltrials.gov/study/NCT03876886,https://clinicaltrials.gov/study/NCT04137653,https://clinicaltrials.gov/study/NCT05840211,https://clinicaltrials.gov/study/NCT04862585,https://clinicaltrials.gov/study/NCT05429684,https://clinicaltrials.gov/study/NCT05894239,https://clinicaltrials.gov/study/NCT04335669,https://clinicaltrials.gov/study/NCT06143553,https://clinicaltrials.gov/study/NCT05374512,https://clinicaltrials.gov/study/NCT05555706,https://clinicaltrials.gov/study/NCT05382299,https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT04547907,https://clinicaltrials.gov/study/NCT03949634,https://clinicaltrials.gov/study/NCT06112379,https://clinicaltrials.gov/study/NCT05113251,https://clinicaltrials.gov/study/NCT04540692,https://clinicaltrials.gov/study/NCT06018337,https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT05814354,https://clinicaltrials.gov/study/NCT06103864,https://clinicaltrials.gov/study/NCT04193059,https://clinicaltrials.gov/study/NCT05207709,https://clinicaltrials.gov/study/NCT05296798
MONDO_0007254	breast cancer	CHEMBL4475463	AMCENESTRANT	Small molecule	Estrogen receptor alpha degrader		ESR1	estrogen receptor 1	3	Terminated	https://clinicaltrials.gov/study/NCT04478266,https://clinicaltrials.gov/study/NCT05128773
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	3	Recruiting	https://clinicaltrials.gov/study/NCT06112379
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	3	Recruiting	https://clinicaltrials.gov/study/NCT05814354,https://clinicaltrials.gov/study/NCT06268652,https://clinicaltrials.gov/study/NCT05382299,https://clinicaltrials.gov/study/NCT04722978,https://clinicaltrials.gov/study/NCT06143553,https://clinicaltrials.gov/study/NCT06103864
MONDO_0007254	breast cancer	CHEMBL4303669	ZOLEDRONIC ACID	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	3	Unknown status	https://clinicaltrials.gov/study/NCT00326820,https://clinicaltrials.gov/study/NCT02595138,https://clinicaltrials.gov/study/NCT00072020
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Withdrawn	https://clinicaltrials.gov/study/NCT05474690,https://clinicaltrials.gov/study/NCT00041171,https://clinicaltrials.gov/study/NCT03811418
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT04665986,https://clinicaltrials.gov/study/NCT05901935,https://clinicaltrials.gov/study/NCT06255392
MONDO_0007254	breast cancer	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	3	Recruiting	https://clinicaltrials.gov/study/NCT04906395,https://clinicaltrials.gov/study/NCT02097459,https://clinicaltrials.gov/study/NCT05306340,https://clinicaltrials.gov/study/NCT05952557,https://clinicaltrials.gov/study/NCT05774951,https://clinicaltrials.gov/study/NCT05512364,https://clinicaltrials.gov/study/NCT04852887,https://clinicaltrials.gov/study/NCT04134598,https://clinicaltrials.gov/study/NCT02062489,https://clinicaltrials.gov/study/NCT05891093,https://clinicaltrials.gov/study/NCT03351062,https://clinicaltrials.gov/study/NCT05780567,https://clinicaltrials.gov/study/NCT02914158
MONDO_0007254	breast cancer	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	3	Completed	https://clinicaltrials.gov/study/NCT00668616,https://clinicaltrials.gov/study/NCT00002836,https://clinicaltrials.gov/study/NCT00002755,https://clinicaltrials.gov/study/NCT00014222,https://clinicaltrials.gov/study/NCT00016406,https://clinicaltrials.gov/study/NCT00003972,https://clinicaltrials.gov/study/NCT00017095,https://clinicaltrials.gov/study/NCT00002784,https://clinicaltrials.gov/study/NCT03343145,https://clinicaltrials.gov/study/NCT00003032,https://clinicaltrials.gov/study/NCT00002870,https://clinicaltrials.gov/study/NCT00590785
EFO_0005537	triple-negative breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	3	Recruiting	https://clinicaltrials.gov/study/NCT05760378
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Withdrawn	https://clinicaltrials.gov/study/NCT00041171,https://clinicaltrials.gov/study/NCT03811418,https://clinicaltrials.gov/study/NCT05474690
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Recruiting	https://clinicaltrials.gov/study/NCT03671044,https://clinicaltrials.gov/study/NCT03949634,https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT05207514,https://clinicaltrials.gov/study/NCT04193059,https://clinicaltrials.gov/study/NCT05673629,https://clinicaltrials.gov/study/NCT05894239,https://clinicaltrials.gov/study/NCT05430399,https://clinicaltrials.gov/study/NCT04547907,https://clinicaltrials.gov/study/NCT05159193,https://clinicaltrials.gov/study/NCT03926091,https://clinicaltrials.gov/study/NCT05296798,https://clinicaltrials.gov/study/NCT05883852,https://clinicaltrials.gov/study/NCT05720026,https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT04540692,https://clinicaltrials.gov/study/NCT05901428
MONDO_0007254	breast cancer	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	3	Completed	https://clinicaltrials.gov/study/NCT02032277,https://clinicaltrials.gov/study/NCT02163694
MONDO_0007254	breast cancer	CHEMBL554	LAPATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03523585,https://clinicaltrials.gov/study/NCT01104571,https://clinicaltrials.gov/study/NCT04185649
EFO_0000304	breast adenocarcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Completed	https://clinicaltrials.gov/study/NCT00431106,https://clinicaltrials.gov/study/NCT03901339,https://clinicaltrials.gov/study/NCT00103233,https://clinicaltrials.gov/study/NCT00868634,https://clinicaltrials.gov/study/NCT02225470,https://clinicaltrials.gov/study/NCT01007942,https://clinicaltrials.gov/study/NCT00146549,https://clinicaltrials.gov/study/NCT02555657,https://clinicaltrials.gov/study/NCT02574455,https://clinicaltrials.gov/study/NCT00776724
EFO_0000304	breast adenocarcinoma	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02115282,https://clinicaltrials.gov/study/NCT00310180
MONDO_0007254	breast cancer	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Unknown status	https://clinicaltrials.gov/study/NCT00253422,https://clinicaltrials.gov/study/NCT01402193,https://clinicaltrials.gov/study/NCT00902954,https://clinicaltrials.gov/study/NCT00541086,https://clinicaltrials.gov/study/NCT00688194,https://clinicaltrials.gov/study/NCT00893061
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Completed	https://clinicaltrials.gov/study/NCT01702571,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT01120184,https://clinicaltrials.gov/study/NCT01419197,https://clinicaltrials.gov/study/NCT03084939,https://clinicaltrials.gov/study/NCT03726879,https://clinicaltrials.gov/study/NCT00829166
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Completed	https://clinicaltrials.gov/study/NCT03726879,https://clinicaltrials.gov/study/NCT01120184,https://clinicaltrials.gov/study/NCT03084939,https://clinicaltrials.gov/study/NCT01419197,https://clinicaltrials.gov/study/NCT01702571,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT00829166
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04639986,https://clinicaltrials.gov/study/NCT05063786,https://clinicaltrials.gov/study/NCT05104866
MONDO_0007254	breast cancer	CHEMBL554	LAPATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Recruiting	https://clinicaltrials.gov/study/NCT05122494,https://clinicaltrials.gov/study/NCT06313983
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Completed	https://clinicaltrials.gov/study/NCT00091442,https://clinicaltrials.gov/study/NCT02896855,https://clinicaltrials.gov/study/NCT02681003,https://clinicaltrials.gov/study/NCT02472964,https://clinicaltrials.gov/study/NCT00493870,https://clinicaltrials.gov/study/NCT00887536,https://clinicaltrials.gov/study/NCT00047255,https://clinicaltrials.gov/study/NCT00047099,https://clinicaltrials.gov/study/NCT03989037,https://clinicaltrials.gov/study/NCT00314977,https://clinicaltrials.gov/study/NCT00193011,https://clinicaltrials.gov/study/NCT00114816,https://clinicaltrials.gov/study/NCT00431080,https://clinicaltrials.gov/study/NCT00002662,https://clinicaltrials.gov/study/NCT04957212,https://clinicaltrials.gov/study/NCT03013504,https://clinicaltrials.gov/study/NCT02402712,https://clinicaltrials.gov/study/NCT00567190,https://clinicaltrials.gov/study/NCT00703326,https://clinicaltrials.gov/study/NCT02187744,https://clinicaltrials.gov/study/NCT00963729,https://clinicaltrials.gov/study/NCT00615602,https://clinicaltrials.gov/study/NCT00448591,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT00129935,https://clinicaltrials.gov/study/NCT01099436,https://clinicaltrials.gov/study/NCT00352378,https://clinicaltrials.gov/study/NCT00294385,https://clinicaltrials.gov/study/NCT04031703,https://clinicaltrials.gov/study/NCT05301010,https://clinicaltrials.gov/study/NCT04127019,https://clinicaltrials.gov/study/NCT00146549,https://clinicaltrials.gov/study/NCT00667251,https://clinicaltrials.gov/study/NCT02586025,https://clinicaltrials.gov/study/NCT00002707,https://clinicaltrials.gov/study/NCT00429871,https://clinicaltrials.gov/study/NCT00002544,https://clinicaltrials.gov/study/NCT00017095,https://clinicaltrials.gov/study/NCT00391092,https://clinicaltrials.gov/study/NCT00311636,https://clinicaltrials.gov/study/NCT00191152,https://clinicaltrials.gov/study/NCT01216111,https://clinicaltrials.gov/study/NCT05629949,https://clinicaltrials.gov/study/NCT00630032,https://clinicaltrials.gov/study/NCT03084237,https://clinicaltrials.gov/study/NCT00333775,https://clinicaltrials.gov/study/NCT01049425,https://clinicaltrials.gov/study/NCT00003782,https://clinicaltrials.gov/study/NCT01940497,https://clinicaltrials.gov/study/NCT04629846,https://clinicaltrials.gov/study/NCT00567554,https://clinicaltrials.gov/study/NCT03493854,https://clinicaltrials.gov/study/NCT02019277,https://clinicaltrials.gov/study/NCT00793377,https://clinicaltrials.gov/study/NCT00688740,https://clinicaltrials.gov/study/NCT00331097,https://clinicaltrials.gov/study/NCT00950300,https://clinicaltrials.gov/study/NCT02980965,https://clinicaltrials.gov/study/NCT00288002,https://clinicaltrials.gov/study/NCT00190489,https://clinicaltrials.gov/study/NCT01120184,https://clinicaltrials.gov/study/NCT00089479,https://clinicaltrials.gov/study/NCT02115204,https://clinicaltrials.gov/study/NCT01690702,https://clinicaltrials.gov/study/NCT00236899,https://clinicaltrials.gov/study/NCT01964391,https://clinicaltrials.gov/study/NCT00008411,https://clinicaltrials.gov/study/NCT00540800,https://clinicaltrials.gov/study/NCT00433589,https://clinicaltrials.gov/study/NCT00309556,https://clinicaltrials.gov/study/NCT00003519,https://clinicaltrials.gov/study/NCT00054587,https://clinicaltrials.gov/study/NCT03425656,https://clinicaltrials.gov/study/NCT00424606,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT00776724,https://clinicaltrials.gov/study/NCT00004125,https://clinicaltrials.gov/study/NCT01985724,https://clinicaltrials.gov/study/NCT02194166,https://clinicaltrials.gov/study/NCT00312208,https://clinicaltrials.gov/study/NCT01314833
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Recruiting	https://clinicaltrials.gov/study/NCT06143553,https://clinicaltrials.gov/study/NCT04400695
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT05063786,https://clinicaltrials.gov/study/NCT05104866,https://clinicaltrials.gov/study/NCT04639986
MONDO_0007254	breast cancer	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	3	Unknown status	https://clinicaltrials.gov/study/NCT00006030,https://clinicaltrials.gov/study/NCT00003418,https://clinicaltrials.gov/study/NCT00003680,https://clinicaltrials.gov/study/NCT00912548,https://clinicaltrials.gov/study/NCT00003016,https://clinicaltrials.gov/study/NCT00629278,https://clinicaltrials.gov/study/NCT00003679,https://clinicaltrials.gov/study/NCT00010140,https://clinicaltrials.gov/study/NCT01622361,https://clinicaltrials.gov/study/NCT00541086,https://clinicaltrials.gov/study/NCT01758146,https://clinicaltrials.gov/study/NCT00963209,https://clinicaltrials.gov/study/NCT00003678,https://clinicaltrials.gov/study/NCT00002460,https://clinicaltrials.gov/study/NCT00893061
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Unknown status	https://clinicaltrials.gov/study/NCT00005581,https://clinicaltrials.gov/study/NCT01547741,https://clinicaltrials.gov/study/NCT00629278,https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT01019616,https://clinicaltrials.gov/study/NCT02393833,https://clinicaltrials.gov/study/NCT00289263,https://clinicaltrials.gov/study/NCT01134523,https://clinicaltrials.gov/study/NCT00039546,https://clinicaltrials.gov/study/NCT00486668,https://clinicaltrials.gov/study/NCT01084876,https://clinicaltrials.gov/study/NCT00070278,https://clinicaltrials.gov/study/NCT00025688,https://clinicaltrials.gov/study/NCT01378533
MONDO_0007254	breast cancer	CHEMBL488	AMINOGLUTETHIMIDE	Small molecule	Cytochrome P450 11A1 inhibitor		CYP11A1	cytochrome P450 family 11 subfamily A member 1	3	Completed	https://clinicaltrials.gov/study/NCT00309491
EFO_0000186	invasive breast ductal carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Completed	https://clinicaltrials.gov/study/NCT02620280
EFO_0000304	breast adenocarcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA2	NADH:ubiquinone oxidoreductase subunit A2	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND6	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6	3	Completed	https://clinicaltrials.gov/study/NCT01101438
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Completed	https://clinicaltrials.gov/study/NCT00005970
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN4A	sodium voltage-gated channel alpha subunit 4	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01916317
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Recruiting	https://clinicaltrials.gov/study/NCT05883852,https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT05673629,https://clinicaltrials.gov/study/NCT05720026,https://clinicaltrials.gov/study/NCT04193059,https://clinicaltrials.gov/study/NCT05430399,https://clinicaltrials.gov/study/NCT03949634,https://clinicaltrials.gov/study/NCT03671044,https://clinicaltrials.gov/study/NCT05901428,https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT05296798,https://clinicaltrials.gov/study/NCT04540692,https://clinicaltrials.gov/study/NCT05159193,https://clinicaltrials.gov/study/NCT05207514,https://clinicaltrials.gov/study/NCT04547907,https://clinicaltrials.gov/study/NCT05894239,https://clinicaltrials.gov/study/NCT03926091
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06079983
MONDO_0007254	breast cancer	CHEMBL1200775	LEUPROLIDE ACETATE	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	3	Completed	https://clinicaltrials.gov/study/NCT00002580,https://clinicaltrials.gov/study/NCT01546649,https://clinicaltrials.gov/study/NCT00002582
MONDO_0007254	breast cancer	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	3	Completed	https://clinicaltrials.gov/study/NCT02032277,https://clinicaltrials.gov/study/NCT02163694
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Recruiting	https://clinicaltrials.gov/study/NCT05747794,https://clinicaltrials.gov/study/NCT03201861,https://clinicaltrials.gov/study/NCT04862585,https://clinicaltrials.gov/study/NCT06058377
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Completed	https://clinicaltrials.gov/study/NCT00146549,https://clinicaltrials.gov/study/NCT00868634,https://clinicaltrials.gov/study/NCT03901339,https://clinicaltrials.gov/study/NCT00103233,https://clinicaltrials.gov/study/NCT00431106,https://clinicaltrials.gov/study/NCT02225470,https://clinicaltrials.gov/study/NCT01007942,https://clinicaltrials.gov/study/NCT02574455,https://clinicaltrials.gov/study/NCT00776724,https://clinicaltrials.gov/study/NCT02555657
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	3	Recruiting	https://clinicaltrials.gov/study/NCT05501886
EFO_0000304	breast adenocarcinoma	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00310180
MONDO_0007254	breast cancer	CHEMBL1201649	ESTROGENS, CONJUGATED	Unknown	Estrogen receptor agonist		ESR2	estrogen receptor 2	3	Terminated	https://clinicaltrials.gov/study/NCT00193726
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB1	NADH:ubiquinone oxidoreductase subunit B1	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652,https://clinicaltrials.gov/study/NCT05814354,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT05374512
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Recruiting	https://clinicaltrials.gov/study/NCT05760378
MONDO_0007254	breast cancer	CHEMBL2177390	IPATASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT1	AKT serine/threonine kinase 1	3	Recruiting	https://clinicaltrials.gov/study/NCT04650581
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT05104866,https://clinicaltrials.gov/study/NCT05063786,https://clinicaltrials.gov/study/NCT03734029,https://clinicaltrials.gov/study/NCT04639986
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	3	Terminated	https://clinicaltrials.gov/study/NCT04060862,https://clinicaltrials.gov/study/NCT04478266
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN2A	sodium voltage-gated channel alpha subunit 2	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01916317
EFO_0000305	breast carcinoma	CHEMBL902	FAMOTIDINE	Small molecule	Histamine H2 receptor antagonist		HRH2	histamine receptor H2	3	Recruiting	https://clinicaltrials.gov/study/NCT04862585
MONDO_0007254	breast cancer	CHEMBL1200480	OCTREOTIDE ACETATE	Protein	Somatostatin receptor agonist		SSTR3	somatostatin receptor 3	3	Completed	https://clinicaltrials.gov/study/NCT00002864
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04639986
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB5	NADH:ubiquinone oxidoreductase subunit B5	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Terminated	https://clinicaltrials.gov/study/NCT02144012
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB7	NADH:ubiquinone oxidoreductase subunit B7	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Withdrawn	https://clinicaltrials.gov/study/NCT05474690,https://clinicaltrials.gov/study/NCT03811418,https://clinicaltrials.gov/study/NCT00041171
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06081959,https://clinicaltrials.gov/study/NCT06343948,https://clinicaltrials.gov/study/NCT06079983
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT00191152
EFO_0000186	invasive breast ductal carcinoma	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR2	estrogen receptor 2	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01953588
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652
MONDO_0007254	breast cancer	CHEMBL2177390	IPATASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT2	AKT serine/threonine kinase 2	3	Completed	https://clinicaltrials.gov/study/NCT03337724
MONDO_0007254	breast cancer	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	3	Completed	https://clinicaltrials.gov/study/NCT00002836
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT00294385,https://clinicaltrials.gov/study/NCT02574455,https://clinicaltrials.gov/study/NCT00561119,https://clinicaltrials.gov/study/NCT00236899,https://clinicaltrials.gov/study/NCT00431106,https://clinicaltrials.gov/study/NCT01287624,https://clinicaltrials.gov/study/NCT00670878,https://clinicaltrials.gov/study/NCT02555657,https://clinicaltrials.gov/study/NCT02546934,https://clinicaltrials.gov/study/NCT03901339,https://clinicaltrials.gov/study/NCT02819518,https://clinicaltrials.gov/study/NCT00006459,https://clinicaltrials.gov/study/NCT00938652,https://clinicaltrials.gov/study/NCT00191152
MONDO_0007254	breast cancer	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	3	Recruiting	https://clinicaltrials.gov/study/NCT04852887,https://clinicaltrials.gov/study/NCT04584853,https://clinicaltrials.gov/study/NCT05952557,https://clinicaltrials.gov/study/NCT04906395,https://clinicaltrials.gov/study/NCT04134598,https://clinicaltrials.gov/study/NCT03351062,https://clinicaltrials.gov/study/NCT02097459,https://clinicaltrials.gov/study/NCT05891093,https://clinicaltrials.gov/study/NCT05512364,https://clinicaltrials.gov/study/NCT02062489,https://clinicaltrials.gov/study/NCT05774951,https://clinicaltrials.gov/study/NCT05306340,https://clinicaltrials.gov/study/NCT05780567,https://clinicaltrials.gov/study/NCT02914158
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04148911,https://clinicaltrials.gov/study/NCT04085276
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Completed	https://clinicaltrials.gov/study/NCT02225470,https://clinicaltrials.gov/study/NCT00337103,https://clinicaltrials.gov/study/NCT00388726
MONDO_0007254	breast cancer	CHEMBL328190	LASOFOXIFENE	Small molecule	Estrogen receptor modulator		ESR2	estrogen receptor 2	3	Recruiting	https://clinicaltrials.gov/study/NCT05696626
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Suspended	https://clinicaltrials.gov/study/NCT03777579
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN8A	sodium voltage-gated channel alpha subunit 8	3	Completed	https://clinicaltrials.gov/study/NCT04822597
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Recruiting	https://clinicaltrials.gov/study/NCT06143553,https://clinicaltrials.gov/study/NCT04400695
EFO_0000305	breast carcinoma	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	3	Completed	https://clinicaltrials.gov/study/NCT01935492,https://clinicaltrials.gov/study/NCT00191152
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF2	NADH:ubiquinone oxidoreductase complex assembly factor 2	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	3	Terminated	https://clinicaltrials.gov/study/NCT02340221
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03168880,https://clinicaltrials.gov/study/NCT01996267,https://clinicaltrials.gov/study/NCT03315364,https://clinicaltrials.gov/study/NCT03725059,https://clinicaltrials.gov/study/NCT04732598,https://clinicaltrials.gov/study/NCT01358877,https://clinicaltrials.gov/study/NCT01646034,https://clinicaltrials.gov/study/NCT02214381,https://clinicaltrials.gov/study/NCT03595592,https://clinicaltrials.gov/study/NCT04494425,https://clinicaltrials.gov/study/NCT00070564,https://clinicaltrials.gov/study/NCT03734029,https://clinicaltrials.gov/study/NCT00433420
MONDO_0007254	breast cancer	CHEMBL637	VENLAFAXINE	Small molecule	Serotonin transporter inhibitor		SLC6A4	solute carrier family 6 member 4	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06106529
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00006459
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01272037
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Unknown status	https://clinicaltrials.gov/study/NCT00629278,https://clinicaltrials.gov/study/NCT01642771,https://clinicaltrials.gov/study/NCT00532727,https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT00944424,https://clinicaltrials.gov/study/NCT01354522,https://clinicaltrials.gov/study/NCT02393833,https://clinicaltrials.gov/study/NCT00003679,https://clinicaltrials.gov/study/NCT00430001,https://clinicaltrials.gov/study/NCT01622361,https://clinicaltrials.gov/study/NCT01547741,https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT00010140,https://clinicaltrials.gov/study/NCT01222052,https://clinicaltrials.gov/study/NCT01479036
EFO_0005537	triple-negative breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	3	Suspended	https://clinicaltrials.gov/study/NCT03002103
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02221999
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Completed	https://clinicaltrials.gov/study/NCT00191152
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	3	Terminated	https://clinicaltrials.gov/study/NCT02340221
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Unknown status	https://clinicaltrials.gov/study/NCT00003679,https://clinicaltrials.gov/study/NCT02393833,https://clinicaltrials.gov/study/NCT00430001,https://clinicaltrials.gov/study/NCT00629278,https://clinicaltrials.gov/study/NCT01547741,https://clinicaltrials.gov/study/NCT00532727,https://clinicaltrials.gov/study/NCT00944424,https://clinicaltrials.gov/study/NCT01222052,https://clinicaltrials.gov/study/NCT01479036,https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT00010140,https://clinicaltrials.gov/study/NCT01622361,https://clinicaltrials.gov/study/NCT01354522,https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT01642771
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Completed	https://clinicaltrials.gov/study/NCT00191152
MONDO_0007254	breast cancer	CHEMBL18901	EFAPROXIRAL	Small molecule	Hemoglobin HbA negative modulator		HBB	hemoglobin subunit beta	3	Completed	https://clinicaltrials.gov/study/NCT00083304
EFO_1000984	inflammatory breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Completed	https://clinicaltrials.gov/study/NCT02324088
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Unknown status	https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT00430001
MONDO_0007254	breast cancer	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN4A	sodium voltage-gated channel alpha subunit 4	3	Completed	https://clinicaltrials.gov/study/NCT00547989,https://clinicaltrials.gov/study/NCT04327063,https://clinicaltrials.gov/study/NCT02408393
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Completed	https://clinicaltrials.gov/study/NCT00191152
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL554	LAPATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03500380
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R5	phosphoinositide-3-kinase regulatory subunit 5	3	Terminated	https://clinicaltrials.gov/study/NCT02340221
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06316531,https://clinicaltrials.gov/study/NCT06313086,https://clinicaltrials.gov/study/NCT06126640
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Terminated	https://clinicaltrials.gov/study/NCT00625898,https://clinicaltrials.gov/study/NCT00912444,https://clinicaltrials.gov/study/NCT02144012,https://clinicaltrials.gov/study/NCT00053911,https://clinicaltrials.gov/study/NCT01200212
MONDO_0007254	breast cancer	CHEMBL2325741	CAPIVASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT2	AKT serine/threonine kinase 2	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04305496
MONDO_0007254	breast cancer	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Completed	https://clinicaltrials.gov/study/NCT00314977,https://clinicaltrials.gov/study/NCT00002755,https://clinicaltrials.gov/study/NCT00002784,https://clinicaltrials.gov/study/NCT00688740,https://clinicaltrials.gov/study/NCT02995772,https://clinicaltrials.gov/study/NCT01998906,https://clinicaltrials.gov/study/NCT03726879,https://clinicaltrials.gov/study/NCT02032277,https://clinicaltrials.gov/study/NCT00129389,https://clinicaltrials.gov/study/NCT00091442,https://clinicaltrials.gov/study/NCT00312208,https://clinicaltrials.gov/study/NCT00929591,https://clinicaltrials.gov/study/NCT00002967,https://clinicaltrials.gov/study/NCT00590785,https://clinicaltrials.gov/study/NCT00004125,https://clinicaltrials.gov/study/NCT00002582,https://clinicaltrials.gov/study/NCT00014222,https://clinicaltrials.gov/study/NCT00266799,https://clinicaltrials.gov/study/NCT03493854,https://clinicaltrials.gov/study/NCT01940497,https://clinicaltrials.gov/study/NCT00793377,https://clinicaltrials.gov/study/NCT01964391,https://clinicaltrials.gov/study/NCT00041119,https://clinicaltrials.gov/study/NCT00002542,https://clinicaltrials.gov/study/NCT03425656,https://clinicaltrials.gov/study/NCT00493870,https://clinicaltrials.gov/study/NCT01099436,https://clinicaltrials.gov/study/NCT00003519,https://clinicaltrials.gov/study/NCT00003013,https://clinicaltrials.gov/study/NCT00336791,https://clinicaltrials.gov/study/NCT00016406,https://clinicaltrials.gov/study/NCT00002707,https://clinicaltrials.gov/study/NCT03498716,https://clinicaltrials.gov/study/NCT00024102,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT00003782,https://clinicaltrials.gov/study/NCT00311636,https://clinicaltrials.gov/study/NCT00003893,https://clinicaltrials.gov/study/NCT00087178,https://clinicaltrials.gov/study/NCT00004067,https://clinicaltrials.gov/study/NCT00789581,https://clinicaltrials.gov/study/NCT00002529,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT00003088,https://clinicaltrials.gov/study/NCT00887536
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT05063786,https://clinicaltrials.gov/study/NCT04639986,https://clinicaltrials.gov/study/NCT05104866
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02221999
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02810743,https://clinicaltrials.gov/study/NCT02000622,https://clinicaltrials.gov/study/NCT02032823
MONDO_0007254	breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02763566,https://clinicaltrials.gov/study/NCT02246621,https://clinicaltrials.gov/study/NCT03155997
MONDO_0007254	breast cancer	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN7A	sodium voltage-gated channel alpha subunit 7	3	Completed	https://clinicaltrials.gov/study/NCT00547989,https://clinicaltrials.gov/study/NCT04327063,https://clinicaltrials.gov/study/NCT02408393
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02221999
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Completed	https://clinicaltrials.gov/study/NCT00196872,https://clinicaltrials.gov/study/NCT02425891,https://clinicaltrials.gov/study/NCT01287624,https://clinicaltrials.gov/study/NCT00600340,https://clinicaltrials.gov/study/NCT03498716,https://clinicaltrials.gov/study/NCT00544232,https://clinicaltrials.gov/study/NCT02032277,https://clinicaltrials.gov/study/NCT01822314,https://clinicaltrials.gov/study/NCT00336791,https://clinicaltrials.gov/study/NCT00002953,https://clinicaltrials.gov/study/NCT02194166,https://clinicaltrials.gov/study/NCT03462251,https://clinicaltrials.gov/study/NCT00003440,https://clinicaltrials.gov/study/NCT02819518,https://clinicaltrials.gov/study/NCT01901146,https://clinicaltrials.gov/study/NCT02163694,https://clinicaltrials.gov/study/NCT00038402,https://clinicaltrials.gov/study/NCT00004125,https://clinicaltrials.gov/study/NCT02594371,https://clinicaltrials.gov/study/NCT00004067,https://clinicaltrials.gov/study/NCT00028990,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT00448591,https://clinicaltrials.gov/study/NCT00041119,https://clinicaltrials.gov/study/NCT00668616,https://clinicaltrials.gov/study/NCT00014222,https://clinicaltrials.gov/study/NCT00311636,https://clinicaltrials.gov/study/NCT00876395,https://clinicaltrials.gov/study/NCT01131195,https://clinicaltrials.gov/study/NCT03556358,https://clinicaltrials.gov/study/NCT01526369,https://clinicaltrials.gov/study/NCT01216111,https://clinicaltrials.gov/study/NCT00003088,https://clinicaltrials.gov/study/NCT01433614,https://clinicaltrials.gov/study/NCT00513292,https://clinicaltrials.gov/study/NCT01644890,https://clinicaltrials.gov/study/NCT00789581,https://clinicaltrials.gov/study/NCT00236899,https://clinicaltrials.gov/study/NCT00431080,https://clinicaltrials.gov/study/NCT01964391,https://clinicaltrials.gov/study/NCT02019277,https://clinicaltrials.gov/study/NCT01998906,https://clinicaltrials.gov/study/NCT00561119,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT03337724,https://clinicaltrials.gov/study/NCT01764022,https://clinicaltrials.gov/study/NCT00006459,https://clinicaltrials.gov/study/NCT03726879,https://clinicaltrials.gov/study/NCT01690702,https://clinicaltrials.gov/study/NCT02472964,https://clinicaltrials.gov/study/NCT00567554,https://clinicaltrials.gov/study/NCT01120184,https://clinicaltrials.gov/study/NCT04109066,https://clinicaltrials.gov/study/NCT02450058,https://clinicaltrials.gov/study/NCT01940497,https://clinicaltrials.gov/study/NCT00146549,https://clinicaltrials.gov/study/NCT00003013,https://clinicaltrials.gov/study/NCT04031703,https://clinicaltrials.gov/study/NCT00016406,https://clinicaltrials.gov/study/NCT01314833,https://clinicaltrials.gov/study/NCT00876486,https://clinicaltrials.gov/study/NCT00667251,https://clinicaltrials.gov/study/NCT00002662,https://clinicaltrials.gov/study/NCT04127019,https://clinicaltrials.gov/study/NCT00129389,https://clinicaltrials.gov/study/NCT00129922,https://clinicaltrials.gov/study/NCT01989676,https://clinicaltrials.gov/study/NCT01663727,https://clinicaltrials.gov/study/NCT00003972,https://clinicaltrials.gov/study/NCT03493854
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT06255392
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06081959,https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT06279364,https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06343948
EFO_0006861	male breast carcinoma	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00770809
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Withdrawn	https://clinicaltrials.gov/study/NCT03811418
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	3	Completed	https://clinicaltrials.gov/study/NCT01234337
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Recruiting	https://clinicaltrials.gov/study/NCT04457596
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF2	NADH:ubiquinone oxidoreductase complex assembly factor 2	3	Completed	https://clinicaltrials.gov/study/NCT01101438
EFO_0000305	breast carcinoma	CHEMBL1201583	BEVACIZUMAB	Antibody	Vascular endothelial growth factor A inhibitor		VEGFA	vascular endothelial growth factor A	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00601900
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT06255392
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT05901935,https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT04665986
EFO_0006861	male breast carcinoma	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Completed	https://clinicaltrials.gov/study/NCT01638247
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
MONDO_0007254	breast cancer	CHEMBL2325741	CAPIVASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT3	AKT serine/threonine kinase 3	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04305496
EFO_0000305	breast carcinoma	CHEMBL30	CIMETIDINE	Small molecule	Histamine H2 receptor antagonist		HRH2	histamine receptor H2	3	Recruiting	https://clinicaltrials.gov/study/NCT04862585
EFO_0000304	breast adenocarcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Completed	https://clinicaltrials.gov/study/NCT00191152,https://clinicaltrials.gov/study/NCT00431080,https://clinicaltrials.gov/study/NCT00311636,https://clinicaltrials.gov/study/NCT01049425,https://clinicaltrials.gov/study/NCT01985724,https://clinicaltrials.gov/study/NCT00003782,https://clinicaltrials.gov/study/NCT00703326,https://clinicaltrials.gov/study/NCT00002707,https://clinicaltrials.gov/study/NCT02115204,https://clinicaltrials.gov/study/NCT04127019,https://clinicaltrials.gov/study/NCT02586025,https://clinicaltrials.gov/study/NCT00017095,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT00950300,https://clinicaltrials.gov/study/NCT00091442,https://clinicaltrials.gov/study/NCT04031703,https://clinicaltrials.gov/study/NCT00333775,https://clinicaltrials.gov/study/NCT01120184,https://clinicaltrials.gov/study/NCT00776724,https://clinicaltrials.gov/study/NCT01690702,https://clinicaltrials.gov/study/NCT01964391,https://clinicaltrials.gov/study/NCT02187744,https://clinicaltrials.gov/study/NCT00003519,https://clinicaltrials.gov/study/NCT05629949,https://clinicaltrials.gov/study/NCT02019277,https://clinicaltrials.gov/study/NCT00312208,https://clinicaltrials.gov/study/NCT00288002,https://clinicaltrials.gov/study/NCT00667251,https://clinicaltrials.gov/study/NCT00433589,https://clinicaltrials.gov/study/NCT00448591,https://clinicaltrials.gov/study/NCT03493854,https://clinicaltrials.gov/study/NCT00047255,https://clinicaltrials.gov/study/NCT02472964,https://clinicaltrials.gov/study/NCT00331097,https://clinicaltrials.gov/study/NCT03013504,https://clinicaltrials.gov/study/NCT00793377,https://clinicaltrials.gov/study/NCT00146549,https://clinicaltrials.gov/study/NCT03425656,https://clinicaltrials.gov/study/NCT00540800,https://clinicaltrials.gov/study/NCT00190489,https://clinicaltrials.gov/study/NCT02681003,https://clinicaltrials.gov/study/NCT02980965,https://clinicaltrials.gov/study/NCT00429871,https://clinicaltrials.gov/study/NCT00615602,https://clinicaltrials.gov/study/NCT00054587,https://clinicaltrials.gov/study/NCT00193011,https://clinicaltrials.gov/study/NCT02896855,https://clinicaltrials.gov/study/NCT00002662,https://clinicaltrials.gov/study/NCT00129935,https://clinicaltrials.gov/study/NCT00004125,https://clinicaltrials.gov/study/NCT00567190,https://clinicaltrials.gov/study/NCT01314833,https://clinicaltrials.gov/study/NCT00089479,https://clinicaltrials.gov/study/NCT00567554,https://clinicaltrials.gov/study/NCT00294385,https://clinicaltrials.gov/study/NCT03989037,https://clinicaltrials.gov/study/NCT00047099,https://clinicaltrials.gov/study/NCT01099436,https://clinicaltrials.gov/study/NCT00630032,https://clinicaltrials.gov/study/NCT02402712,https://clinicaltrials.gov/study/NCT00352378,https://clinicaltrials.gov/study/NCT03084237,https://clinicaltrials.gov/study/NCT00236899,https://clinicaltrials.gov/study/NCT01216111,https://clinicaltrials.gov/study/NCT00114816,https://clinicaltrials.gov/study/NCT04629846,https://clinicaltrials.gov/study/NCT00424606,https://clinicaltrials.gov/study/NCT01940497,https://clinicaltrials.gov/study/NCT00309556,https://clinicaltrials.gov/study/NCT00391092,https://clinicaltrials.gov/study/NCT00314977,https://clinicaltrials.gov/study/NCT00008411,https://clinicaltrials.gov/study/NCT04957212,https://clinicaltrials.gov/study/NCT00963729,https://clinicaltrials.gov/study/NCT00002544,https://clinicaltrials.gov/study/NCT00493870,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT02194166,https://clinicaltrials.gov/study/NCT00887536,https://clinicaltrials.gov/study/NCT00688740,https://clinicaltrials.gov/study/NCT05301010
MONDO_0007254	breast cancer	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Terminated	https://clinicaltrials.gov/study/NCT04869943,https://clinicaltrials.gov/study/NCT00810706,https://clinicaltrials.gov/study/NCT05065411,https://clinicaltrials.gov/study/NCT00066807,https://clinicaltrials.gov/study/NCT01303679
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC9	histone deacetylase 9	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03538171
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Recruiting	https://clinicaltrials.gov/study/NCT04862585,https://clinicaltrials.gov/study/NCT05814354,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT05894239,https://clinicaltrials.gov/study/NCT03949634,https://clinicaltrials.gov/study/NCT04335669,https://clinicaltrials.gov/study/NCT05207709,https://clinicaltrials.gov/study/NCT04547907,https://clinicaltrials.gov/study/NCT05555706,https://clinicaltrials.gov/study/NCT05382299,https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT04193059,https://clinicaltrials.gov/study/NCT04137653,https://clinicaltrials.gov/study/NCT06018337,https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT05840211,https://clinicaltrials.gov/study/NCT06112379,https://clinicaltrials.gov/study/NCT06103864,https://clinicaltrials.gov/study/NCT03876886,https://clinicaltrials.gov/study/NCT05374512,https://clinicaltrials.gov/study/NCT04540692,https://clinicaltrials.gov/study/NCT06143553,https://clinicaltrials.gov/study/NCT05113251,https://clinicaltrials.gov/study/NCT05429684,https://clinicaltrials.gov/study/NCT05296798
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Completed	https://clinicaltrials.gov/study/NCT00103233,https://clinicaltrials.gov/study/NCT02225470
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Unknown status	https://clinicaltrials.gov/study/NCT00010140,https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT00532727,https://clinicaltrials.gov/study/NCT01547741,https://clinicaltrials.gov/study/NCT01642771,https://clinicaltrials.gov/study/NCT01622361,https://clinicaltrials.gov/study/NCT00629278,https://clinicaltrials.gov/study/NCT00944424,https://clinicaltrials.gov/study/NCT02393833,https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT01354522,https://clinicaltrials.gov/study/NCT00003679,https://clinicaltrials.gov/study/NCT01222052,https://clinicaltrials.gov/study/NCT00430001,https://clinicaltrials.gov/study/NCT01479036
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	3	Unknown status	https://clinicaltrials.gov/study/NCT00039546,https://clinicaltrials.gov/study/NCT00070278,https://clinicaltrials.gov/study/NCT02207335,https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT02514681
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00191152
MONDO_0007254	breast cancer	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	3	Completed	https://clinicaltrials.gov/study/NCT01645839
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Terminated	https://clinicaltrials.gov/study/NCT05134194,https://clinicaltrials.gov/study/NCT02730091
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT03901339,https://clinicaltrials.gov/study/NCT02546934,https://clinicaltrials.gov/study/NCT02819518,https://clinicaltrials.gov/study/NCT00670878,https://clinicaltrials.gov/study/NCT00938652,https://clinicaltrials.gov/study/NCT00236899,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT00431106,https://clinicaltrials.gov/study/NCT00294385,https://clinicaltrials.gov/study/NCT02555657,https://clinicaltrials.gov/study/NCT00191152,https://clinicaltrials.gov/study/NCT00006459,https://clinicaltrials.gov/study/NCT01287624,https://clinicaltrials.gov/study/NCT02574455,https://clinicaltrials.gov/study/NCT00561119
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Completed	https://clinicaltrials.gov/study/NCT00080301,https://clinicaltrials.gov/study/NCT00082433,https://clinicaltrials.gov/study/NCT00789581,https://clinicaltrials.gov/study/NCT00630032,https://clinicaltrials.gov/study/NCT00448591
MONDO_0007254	breast cancer	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	3	Terminated	https://clinicaltrials.gov/study/NCT00002772
MONDO_0007254	breast cancer	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01996267,https://clinicaltrials.gov/study/NCT02003209,https://clinicaltrials.gov/study/NCT03595592,https://clinicaltrials.gov/study/NCT02625441,https://clinicaltrials.gov/study/NCT03863223,https://clinicaltrials.gov/study/NCT03523585,https://clinicaltrials.gov/study/NCT01104571,https://clinicaltrials.gov/study/NCT03588091,https://clinicaltrials.gov/study/NCT04208178,https://clinicaltrials.gov/study/NCT04024462,https://clinicaltrials.gov/study/NCT02947685,https://clinicaltrials.gov/study/NCT05063786,https://clinicaltrials.gov/study/NCT01772472,https://clinicaltrials.gov/study/NCT01358877,https://clinicaltrials.gov/study/NCT04784715
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	3	Enrolling by invitation	https://clinicaltrials.gov/study/NCT04421963
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Unknown status	https://clinicaltrials.gov/study/NCT02514681
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
EFO_0000304	breast adenocarcinoma	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	3	Completed	https://clinicaltrials.gov/study/NCT00005970
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Completed	https://clinicaltrials.gov/study/NCT00005970
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Recruiting	https://clinicaltrials.gov/study/NCT06265428,https://clinicaltrials.gov/study/NCT05429684,https://clinicaltrials.gov/study/NCT03975647,https://clinicaltrials.gov/study/NCT05755048,https://clinicaltrials.gov/study/NCT04873362,https://clinicaltrials.gov/study/NCT04457596,https://clinicaltrials.gov/study/NCT05288777
MONDO_0007254	breast cancer	CHEMBL34259	METHOTREXATE	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	3	Suspended	https://clinicaltrials.gov/study/NCT00002696
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT05841381,https://clinicaltrials.gov/study/NCT05753865,https://clinicaltrials.gov/study/NCT05388500,https://clinicaltrials.gov/study/NCT04301739,https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06279364,https://clinicaltrials.gov/study/NCT05172518
MONDO_0007254	breast cancer	CHEMBL1201247	GOSERELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02003209,https://clinicaltrials.gov/study/NCT01674140
MONDO_0007254	breast cancer	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Recruiting	https://clinicaltrials.gov/study/NCT04906395,https://clinicaltrials.gov/study/NCT05952557,https://clinicaltrials.gov/study/NCT05306340,https://clinicaltrials.gov/study/NCT05891093,https://clinicaltrials.gov/study/NCT05774951,https://clinicaltrials.gov/study/NCT05827081,https://clinicaltrials.gov/study/NCT04852887,https://clinicaltrials.gov/study/NCT04134598,https://clinicaltrials.gov/study/NCT05512364,https://clinicaltrials.gov/study/NCT04584853,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT06105632
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4	NDUFA4 mitochondrial complex associated	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL1201179	LAPATINIB DITOSYLATE	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Completed	https://clinicaltrials.gov/study/NCT00667251
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
EFO_0000553	invasive lobular carcinoma	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR2	estrogen receptor 2	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01953588
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Completed	https://clinicaltrials.gov/study/NCT01953003,https://clinicaltrials.gov/study/NCT01095003,https://clinicaltrials.gov/study/NCT01091168
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Recruiting	https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT04540692,https://clinicaltrials.gov/study/NCT05883852,https://clinicaltrials.gov/study/NCT05894239,https://clinicaltrials.gov/study/NCT05207514,https://clinicaltrials.gov/study/NCT05673629,https://clinicaltrials.gov/study/NCT05430399,https://clinicaltrials.gov/study/NCT03926091,https://clinicaltrials.gov/study/NCT05720026,https://clinicaltrials.gov/study/NCT03671044,https://clinicaltrials.gov/study/NCT04547907,https://clinicaltrials.gov/study/NCT03949634,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT05296798,https://clinicaltrials.gov/study/NCT05159193,https://clinicaltrials.gov/study/NCT05901428,https://clinicaltrials.gov/study/NCT04193059
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB4	NADH:ubiquinone oxidoreductase subunit B4	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB6	NADH:ubiquinone oxidoreductase subunit B6	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT00561119,https://clinicaltrials.gov/study/NCT00294385,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT03901339,https://clinicaltrials.gov/study/NCT00236899,https://clinicaltrials.gov/study/NCT00431106,https://clinicaltrials.gov/study/NCT00006459,https://clinicaltrials.gov/study/NCT02546934,https://clinicaltrials.gov/study/NCT02819518,https://clinicaltrials.gov/study/NCT02574455,https://clinicaltrials.gov/study/NCT00191152,https://clinicaltrials.gov/study/NCT01287624,https://clinicaltrials.gov/study/NCT02555657,https://clinicaltrials.gov/study/NCT00670878,https://clinicaltrials.gov/study/NCT00938652
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
MONDO_0007254	breast cancer	CHEMBL25	ASPIRIN	Small molecule	Cyclooxygenase inhibitor		PTGS2	prostaglandin-endoperoxide synthase 2	3	Terminated	https://clinicaltrials.gov/study/NCT02927249
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04639986
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Terminated	https://clinicaltrials.gov/study/NCT00912444,https://clinicaltrials.gov/study/NCT02144012,https://clinicaltrials.gov/study/NCT00053911,https://clinicaltrials.gov/study/NCT00625898,https://clinicaltrials.gov/study/NCT01200212
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Withdrawn	https://clinicaltrials.gov/study/NCT02929576
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02641847,https://clinicaltrials.gov/study/NCT01646034,https://clinicaltrials.gov/study/NCT04639986,https://clinicaltrials.gov/study/NCT05104866,https://clinicaltrials.gov/study/NCT03734029
EFO_0005537	triple-negative breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	3	Suspended	https://clinicaltrials.gov/study/NCT03002103
MONDO_0007254	breast cancer	CHEMBL4650316	GIREDESTRANT	Small molecule	Estrogen receptor alpha degrader		ESR1	estrogen receptor 1	3	Recruiting	https://clinicaltrials.gov/study/NCT05296798,https://clinicaltrials.gov/study/NCT05306340,https://clinicaltrials.gov/study/NCT04961996
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885,https://clinicaltrials.gov/study/NCT00433511
MONDO_0007254	breast cancer	CHEMBL1200501	GOSERELIN ACETATE	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	3	Terminated	https://clinicaltrials.gov/study/NCT00053911
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS1	NADH:ubiquinone oxidoreductase core subunit S1	3	Completed	https://clinicaltrials.gov/study/NCT01101438
EFO_0000305	breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Completed	https://clinicaltrials.gov/study/NCT00785291
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Recruiting	https://clinicaltrials.gov/study/NCT04296175,https://clinicaltrials.gov/study/NCT05862064
MONDO_0007254	breast cancer	CHEMBL3039544	TECEMOTIDE	Protein	Mucin-1 vaccine antigen		MUC1	mucin 1, cell surface associated	3	Terminated	https://clinicaltrials.gov/study/NCT00925548
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Recruiting	https://clinicaltrials.gov/study/NCT04296175,https://clinicaltrials.gov/study/NCT05862064
MONDO_0007254	breast cancer	CHEMBL1201568	PEGFILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	3	Withdrawn	https://clinicaltrials.gov/study/NCT02768714
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R5	phosphoinositide-3-kinase regulatory subunit 5	3	Terminated	https://clinicaltrials.gov/study/NCT01633060
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02003209,https://clinicaltrials.gov/study/NCT01646034,https://clinicaltrials.gov/study/NCT04024462,https://clinicaltrials.gov/study/NCT03863223,https://clinicaltrials.gov/study/NCT03588091,https://clinicaltrials.gov/study/NCT01358877,https://clinicaltrials.gov/study/NCT02641847
EFO_1000984	inflammatory breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT05415215
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Withdrawn	https://clinicaltrials.gov/study/NCT03811418
MONDO_0007254	breast cancer	CHEMBL1201583	BEVACIZUMAB	Antibody	Vascular endothelial growth factor A inhibitor		VEGFA	vascular endothelial growth factor A	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04732598,https://clinicaltrials.gov/study/NCT00601900
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04639986,https://clinicaltrials.gov/study/NCT03734029,https://clinicaltrials.gov/study/NCT05104866,https://clinicaltrials.gov/study/NCT05063786
EFO_0000305	breast carcinoma	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00066690,https://clinicaltrials.gov/study/NCT00601900
MONDO_0007254	breast cancer	CHEMBL1201179	LAPATINIB DITOSYLATE	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Unknown status	https://clinicaltrials.gov/study/NCT00688194
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Recruiting	https://clinicaltrials.gov/study/NCT05814354,https://clinicaltrials.gov/study/NCT05429684,https://clinicaltrials.gov/study/NCT06112379,https://clinicaltrials.gov/study/NCT05555706,https://clinicaltrials.gov/study/NCT04862585,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT05840211,https://clinicaltrials.gov/study/NCT04335669,https://clinicaltrials.gov/study/NCT05894239,https://clinicaltrials.gov/study/NCT04193059,https://clinicaltrials.gov/study/NCT03949634,https://clinicaltrials.gov/study/NCT05207709,https://clinicaltrials.gov/study/NCT04137653,https://clinicaltrials.gov/study/NCT04540692,https://clinicaltrials.gov/study/NCT05382299,https://clinicaltrials.gov/study/NCT06103864,https://clinicaltrials.gov/study/NCT06143553,https://clinicaltrials.gov/study/NCT05374512,https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT04547907,https://clinicaltrials.gov/study/NCT05113251,https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT03876886,https://clinicaltrials.gov/study/NCT06018337,https://clinicaltrials.gov/study/NCT05296798
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Completed	https://clinicaltrials.gov/study/NCT00005970
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Unknown status	https://clinicaltrials.gov/study/NCT00430001,https://clinicaltrials.gov/study/NCT02514681
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Completed	https://clinicaltrials.gov/study/NCT01583426,https://clinicaltrials.gov/study/NCT02125344
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01275677,https://clinicaltrials.gov/study/NCT03199885,https://clinicaltrials.gov/study/NCT02003209
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Recruiting	https://clinicaltrials.gov/study/NCT05894239
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Completed	https://clinicaltrials.gov/study/NCT00388726,https://clinicaltrials.gov/study/NCT02225470,https://clinicaltrials.gov/study/NCT00337103
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Terminated	https://clinicaltrials.gov/study/NCT00625898,https://clinicaltrials.gov/study/NCT00912444,https://clinicaltrials.gov/study/NCT01200212,https://clinicaltrials.gov/study/NCT02144012,https://clinicaltrials.gov/study/NCT00053911
EFO_0005537	triple-negative breast cancer	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	3	Completed	https://clinicaltrials.gov/study/NCT03197935
EFO_0005537	triple-negative breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	3	Suspended	https://clinicaltrials.gov/study/NCT03002103
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Terminated	https://clinicaltrials.gov/study/NCT00016276
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT06255392
EFO_1000984	inflammatory breast carcinoma	CHEMBL185	FLUOROURACIL	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	3	Unknown status	https://clinicaltrials.gov/study/NCT02879513
MONDO_0007254	breast cancer	CHEMBL513	CARMUSTINE	Small molecule	Glutathione reductase inhibitor		GSR	glutathione-disulfide reductase	3	Terminated	https://clinicaltrials.gov/study/NCT00002772
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Withdrawn	https://clinicaltrials.gov/study/NCT05474690,https://clinicaltrials.gov/study/NCT00041171,https://clinicaltrials.gov/study/NCT03811418
MONDO_0007254	breast cancer	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN3A	sodium voltage-gated channel alpha subunit 3	3	Terminated	https://clinicaltrials.gov/study/NCT02525211
EFO_1000984	inflammatory breast carcinoma	CHEMBL359744	DOXORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Terminated	https://clinicaltrials.gov/study/NCT00016276
MONDO_0007254	breast cancer	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06377852
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Withdrawn	https://clinicaltrials.gov/study/NCT03811418
EFO_0000304	breast adenocarcinoma	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Withdrawn	https://clinicaltrials.gov/study/NCT02929576
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Completed	https://clinicaltrials.gov/study/NCT00789581,https://clinicaltrials.gov/study/NCT00080301,https://clinicaltrials.gov/study/NCT00630032,https://clinicaltrials.gov/study/NCT00082433,https://clinicaltrials.gov/study/NCT00448591
MONDO_0007254	breast cancer	CHEMBL4297843	TORIPALIMAB	Antibody	Programmed cell death protein 1 antagonist		PDCD1	programmed cell death 1	3	Suspended	https://clinicaltrials.gov/study/NCT03777579
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	3	Recruiting	https://clinicaltrials.gov/study/NCT05501886
EFO_1000984	inflammatory breast carcinoma	CHEMBL1200778	DEXRAZOXANE HYDROCHLORIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	3	Terminated	https://clinicaltrials.gov/study/NCT00016276
MONDO_0007254	breast cancer	CHEMBL4297939	DATOPOTAMAB DERUXTECAN	Antibody drug conjugate	Tumor-associated calcium signal transducer 2 binding agent		TACSTD2	tumor associated calcium signal transducer 2	3	Recruiting	https://clinicaltrials.gov/study/NCT06112379,https://clinicaltrials.gov/study/NCT05629585,https://clinicaltrials.gov/study/NCT06103864,https://clinicaltrials.gov/study/NCT05374512
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Recruiting	https://clinicaltrials.gov/study/NCT05374512
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
EFO_0005537	triple-negative breast cancer	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02954874
MONDO_0007254	breast cancer	CHEMBL4297844	TRASTUZUMAB DERUXTECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03734029,https://clinicaltrials.gov/study/NCT04494425,https://clinicaltrials.gov/study/NCT04784715,https://clinicaltrials.gov/study/NCT03523585,https://clinicaltrials.gov/study/NCT04622319,https://clinicaltrials.gov/study/NCT03529110
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02003209,https://clinicaltrials.gov/study/NCT01275677,https://clinicaltrials.gov/study/NCT03199885
EFO_1000984	inflammatory breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT05415215
MONDO_0007254	breast cancer	CHEMBL1237023	DENOSUMAB	Antibody	Tumor necrosis factor ligand superfamily member 11 inhibitor		TNFSF11	TNF superfamily member 11	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03324932
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Completed	https://clinicaltrials.gov/study/NCT00352378,https://clinicaltrials.gov/study/NCT00540800,https://clinicaltrials.gov/study/NCT00288002,https://clinicaltrials.gov/study/NCT04629846,https://clinicaltrials.gov/study/NCT00054587,https://clinicaltrials.gov/study/NCT00688740,https://clinicaltrials.gov/study/NCT05301010,https://clinicaltrials.gov/study/NCT04957212,https://clinicaltrials.gov/study/NCT00047255,https://clinicaltrials.gov/study/NCT02586025,https://clinicaltrials.gov/study/NCT00312208,https://clinicaltrials.gov/study/NCT00193011,https://clinicaltrials.gov/study/NCT03425656,https://clinicaltrials.gov/study/NCT00191152,https://clinicaltrials.gov/study/NCT01314833,https://clinicaltrials.gov/study/NCT00002544,https://clinicaltrials.gov/study/NCT00431080,https://clinicaltrials.gov/study/NCT00615602,https://clinicaltrials.gov/study/NCT01049425,https://clinicaltrials.gov/study/NCT00429871,https://clinicaltrials.gov/study/NCT03989037,https://clinicaltrials.gov/study/NCT02681003,https://clinicaltrials.gov/study/NCT00114816,https://clinicaltrials.gov/study/NCT02402712,https://clinicaltrials.gov/study/NCT02980965,https://clinicaltrials.gov/study/NCT02194166,https://clinicaltrials.gov/study/NCT00314977,https://clinicaltrials.gov/study/NCT00309556,https://clinicaltrials.gov/study/NCT00294385,https://clinicaltrials.gov/study/NCT03013504,https://clinicaltrials.gov/study/NCT01120184,https://clinicaltrials.gov/study/NCT00963729,https://clinicaltrials.gov/study/NCT01216111,https://clinicaltrials.gov/study/NCT00047099,https://clinicaltrials.gov/study/NCT00146549,https://clinicaltrials.gov/study/NCT00002662,https://clinicaltrials.gov/study/NCT02187744,https://clinicaltrials.gov/study/NCT01964391,https://clinicaltrials.gov/study/NCT00129935,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT00003519,https://clinicaltrials.gov/study/NCT03493854,https://clinicaltrials.gov/study/NCT02019277,https://clinicaltrials.gov/study/NCT00003782,https://clinicaltrials.gov/study/NCT00567554,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT05629949,https://clinicaltrials.gov/study/NCT01985724,https://clinicaltrials.gov/study/NCT00703326,https://clinicaltrials.gov/study/NCT00017095,https://clinicaltrials.gov/study/NCT00793377,https://clinicaltrials.gov/study/NCT00630032,https://clinicaltrials.gov/study/NCT00333775,https://clinicaltrials.gov/study/NCT00002707,https://clinicaltrials.gov/study/NCT00004125,https://clinicaltrials.gov/study/NCT01940497,https://clinicaltrials.gov/study/NCT00190489,https://clinicaltrials.gov/study/NCT00776724,https://clinicaltrials.gov/study/NCT00493870,https://clinicaltrials.gov/study/NCT00667251,https://clinicaltrials.gov/study/NCT04127019,https://clinicaltrials.gov/study/NCT02472964,https://clinicaltrials.gov/study/NCT00008411,https://clinicaltrials.gov/study/NCT04031703,https://clinicaltrials.gov/study/NCT00448591,https://clinicaltrials.gov/study/NCT00424606,https://clinicaltrials.gov/study/NCT01690702,https://clinicaltrials.gov/study/NCT00311636,https://clinicaltrials.gov/study/NCT00950300,https://clinicaltrials.gov/study/NCT00331097,https://clinicaltrials.gov/study/NCT00567190,https://clinicaltrials.gov/study/NCT00236899,https://clinicaltrials.gov/study/NCT00433589,https://clinicaltrials.gov/study/NCT00887536,https://clinicaltrials.gov/study/NCT02115204,https://clinicaltrials.gov/study/NCT01099436,https://clinicaltrials.gov/study/NCT00391092,https://clinicaltrials.gov/study/NCT00091442,https://clinicaltrials.gov/study/NCT00089479,https://clinicaltrials.gov/study/NCT02896855,https://clinicaltrials.gov/study/NCT03084237
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04639986,https://clinicaltrials.gov/study/NCT05104866,https://clinicaltrials.gov/study/NCT03734029,https://clinicaltrials.gov/study/NCT05063786
MONDO_0007254	breast cancer	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN8A	sodium voltage-gated channel alpha subunit 8	3	Completed	https://clinicaltrials.gov/study/NCT04327063,https://clinicaltrials.gov/study/NCT02408393,https://clinicaltrials.gov/study/NCT00547989
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT05838066,https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT05172518,https://clinicaltrials.gov/study/NCT04665986
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Completed	https://clinicaltrials.gov/study/NCT00080301,https://clinicaltrials.gov/study/NCT00789581,https://clinicaltrials.gov/study/NCT00082433,https://clinicaltrials.gov/study/NCT00630032,https://clinicaltrials.gov/study/NCT00448591
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Recruiting	https://clinicaltrials.gov/study/NCT06058377,https://clinicaltrials.gov/study/NCT03201861,https://clinicaltrials.gov/study/NCT04862585,https://clinicaltrials.gov/study/NCT05747794
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT05063786,https://clinicaltrials.gov/study/NCT05104866,https://clinicaltrials.gov/study/NCT04639986
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Unknown status	https://clinicaltrials.gov/study/NCT01642771,https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT01222052,https://clinicaltrials.gov/study/NCT00003679,https://clinicaltrials.gov/study/NCT00430001,https://clinicaltrials.gov/study/NCT00532727,https://clinicaltrials.gov/study/NCT01547741,https://clinicaltrials.gov/study/NCT01354522,https://clinicaltrials.gov/study/NCT00629278,https://clinicaltrials.gov/study/NCT02393833,https://clinicaltrials.gov/study/NCT01622361,https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT00944424,https://clinicaltrials.gov/study/NCT00010140,https://clinicaltrials.gov/study/NCT01479036
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Recruiting	https://clinicaltrials.gov/study/NCT05894239
MONDO_0007254	breast cancer	CHEMBL279785	MARIMASTAT	Small molecule	Matrix metalloproteinase 7 inhibitor		MMP7	matrix metallopeptidase 7	3	Completed	https://clinicaltrials.gov/study/NCT00003010
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT05063786,https://clinicaltrials.gov/study/NCT03734029,https://clinicaltrials.gov/study/NCT05104866,https://clinicaltrials.gov/study/NCT04639986
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Completed	https://clinicaltrials.gov/study/NCT03901339,https://clinicaltrials.gov/study/NCT00337103,https://clinicaltrials.gov/study/NCT00388726,https://clinicaltrials.gov/study/NCT02574455,https://clinicaltrials.gov/study/NCT02225470,https://clinicaltrials.gov/study/NCT02555657
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	3	Completed	https://clinicaltrials.gov/study/NCT01610284
MONDO_0007254	breast cancer	CHEMBL2177390	IPATASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT2	AKT serine/threonine kinase 2	3	Recruiting	https://clinicaltrials.gov/study/NCT04650581
EFO_0000304	breast adenocarcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC4	histone deacetylase 4	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02115282
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04799249
MONDO_0007254	breast cancer	CHEMBL3707227	ATEZOLIZUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	3	Completed	https://clinicaltrials.gov/study/NCT02425891,https://clinicaltrials.gov/study/NCT03498716,https://clinicaltrials.gov/study/NCT03726879
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Recruiting	https://clinicaltrials.gov/study/NCT06058377,https://clinicaltrials.gov/study/NCT03201861,https://clinicaltrials.gov/study/NCT05747794,https://clinicaltrials.gov/study/NCT04862585
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT06343948,https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06279364,https://clinicaltrials.gov/study/NCT06081959
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Recruiting	https://clinicaltrials.gov/study/NCT05374512
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS8	NADH:ubiquinone oxidoreductase core subunit S8	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Withdrawn	https://clinicaltrials.gov/study/NCT03811418
MONDO_0007254	breast cancer	CHEMBL939	GEFITINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	3	Completed	https://clinicaltrials.gov/study/NCT00357734
EFO_0000305	breast carcinoma	CHEMBL3301587	DURVALUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	3	Recruiting	https://clinicaltrials.gov/study/NCT06058377
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Recruiting	https://clinicaltrials.gov/study/NCT04862585,https://clinicaltrials.gov/study/NCT03201861,https://clinicaltrials.gov/study/NCT05747794,https://clinicaltrials.gov/study/NCT06058377
EFO_0005537	triple-negative breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	3	Recruiting	https://clinicaltrials.gov/study/NCT05760378
MONDO_0007254	breast cancer	CHEMBL34259	METHOTREXATE	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00301925
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Completed	https://clinicaltrials.gov/study/NCT00424606,https://clinicaltrials.gov/study/NCT00540800,https://clinicaltrials.gov/study/NCT00047099,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT00667251,https://clinicaltrials.gov/study/NCT01216111,https://clinicaltrials.gov/study/NCT00017095,https://clinicaltrials.gov/study/NCT03425656,https://clinicaltrials.gov/study/NCT00146549,https://clinicaltrials.gov/study/NCT02194166,https://clinicaltrials.gov/study/NCT03084237,https://clinicaltrials.gov/study/NCT02115204,https://clinicaltrials.gov/study/NCT00054587,https://clinicaltrials.gov/study/NCT00333775,https://clinicaltrials.gov/study/NCT00008411,https://clinicaltrials.gov/study/NCT00309556,https://clinicaltrials.gov/study/NCT00433589,https://clinicaltrials.gov/study/NCT01314833,https://clinicaltrials.gov/study/NCT00191152,https://clinicaltrials.gov/study/NCT04629846,https://clinicaltrials.gov/study/NCT00190489,https://clinicaltrials.gov/study/NCT00630032,https://clinicaltrials.gov/study/NCT02472964,https://clinicaltrials.gov/study/NCT00089479,https://clinicaltrials.gov/study/NCT04127019,https://clinicaltrials.gov/study/NCT00776724,https://clinicaltrials.gov/study/NCT00688740,https://clinicaltrials.gov/study/NCT00002662,https://clinicaltrials.gov/study/NCT00236899,https://clinicaltrials.gov/study/NCT02896855,https://clinicaltrials.gov/study/NCT01940497,https://clinicaltrials.gov/study/NCT00963729,https://clinicaltrials.gov/study/NCT00352378,https://clinicaltrials.gov/study/NCT00429871,https://clinicaltrials.gov/study/NCT03989037,https://clinicaltrials.gov/study/NCT04957212,https://clinicaltrials.gov/study/NCT00793377,https://clinicaltrials.gov/study/NCT02586025,https://clinicaltrials.gov/study/NCT03013504,https://clinicaltrials.gov/study/NCT01985724,https://clinicaltrials.gov/study/NCT00314977,https://clinicaltrials.gov/study/NCT00567554,https://clinicaltrials.gov/study/NCT00703326,https://clinicaltrials.gov/study/NCT00004125,https://clinicaltrials.gov/study/NCT00331097,https://clinicaltrials.gov/study/NCT00294385,https://clinicaltrials.gov/study/NCT00003519,https://clinicaltrials.gov/study/NCT00493870,https://clinicaltrials.gov/study/NCT05629949,https://clinicaltrials.gov/study/NCT00887536,https://clinicaltrials.gov/study/NCT00431080,https://clinicaltrials.gov/study/NCT01049425,https://clinicaltrials.gov/study/NCT00002544,https://clinicaltrials.gov/study/NCT01099436,https://clinicaltrials.gov/study/NCT01690702,https://clinicaltrials.gov/study/NCT00448591,https://clinicaltrials.gov/study/NCT02187744,https://clinicaltrials.gov/study/NCT01120184,https://clinicaltrials.gov/study/NCT00311636,https://clinicaltrials.gov/study/NCT04031703,https://clinicaltrials.gov/study/NCT00091442,https://clinicaltrials.gov/study/NCT02402712,https://clinicaltrials.gov/study/NCT02980965,https://clinicaltrials.gov/study/NCT00114816,https://clinicaltrials.gov/study/NCT03493854,https://clinicaltrials.gov/study/NCT00567190,https://clinicaltrials.gov/study/NCT01964391,https://clinicaltrials.gov/study/NCT00615602,https://clinicaltrials.gov/study/NCT00193011,https://clinicaltrials.gov/study/NCT02681003,https://clinicaltrials.gov/study/NCT00047255,https://clinicaltrials.gov/study/NCT00288002,https://clinicaltrials.gov/study/NCT05301010,https://clinicaltrials.gov/study/NCT00950300,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT00391092,https://clinicaltrials.gov/study/NCT00002707,https://clinicaltrials.gov/study/NCT00129935,https://clinicaltrials.gov/study/NCT02019277,https://clinicaltrials.gov/study/NCT00003782,https://clinicaltrials.gov/study/NCT00312208
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Completed	https://clinicaltrials.gov/study/NCT02225470,https://clinicaltrials.gov/study/NCT03901339,https://clinicaltrials.gov/study/NCT02574455,https://clinicaltrials.gov/study/NCT02555657,https://clinicaltrials.gov/study/NCT00388726,https://clinicaltrials.gov/study/NCT00337103
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Unknown status	https://clinicaltrials.gov/study/NCT02514681
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Unknown status	https://clinicaltrials.gov/study/NCT00039546,https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT01547741,https://clinicaltrials.gov/study/NCT01134523,https://clinicaltrials.gov/study/NCT00025688,https://clinicaltrials.gov/study/NCT00070278,https://clinicaltrials.gov/study/NCT00005581,https://clinicaltrials.gov/study/NCT00629278,https://clinicaltrials.gov/study/NCT02393833,https://clinicaltrials.gov/study/NCT00486668,https://clinicaltrials.gov/study/NCT01378533,https://clinicaltrials.gov/study/NCT00289263,https://clinicaltrials.gov/study/NCT01084876,https://clinicaltrials.gov/study/NCT01019616
MONDO_0007254	breast cancer	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN10A	sodium voltage-gated channel alpha subunit 10	3	Terminated	https://clinicaltrials.gov/study/NCT02525211
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT05838066,https://clinicaltrials.gov/study/NCT05172518,https://clinicaltrials.gov/study/NCT04665986
EFO_0000186	invasive breast ductal carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Completed	https://clinicaltrials.gov/study/NCT02620280
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Unknown status	https://clinicaltrials.gov/study/NCT00430001,https://clinicaltrials.gov/study/NCT02514681
MONDO_0007254	breast cancer	CHEMBL4802129	BALIXAFORTIDE	Protein	C-X-C chemokine receptor type 4 antagonist		CXCR4	C-X-C motif chemokine receptor 4	3	Terminated	https://clinicaltrials.gov/study/NCT03786094
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC2	NADH:ubiquinone oxidoreductase subunit C2	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	3	Completed	https://clinicaltrials.gov/study/NCT02278120,https://clinicaltrials.gov/study/NCT03096847,https://clinicaltrials.gov/study/NCT02941926,https://clinicaltrials.gov/study/NCT03439046,https://clinicaltrials.gov/study/NCT01958021,https://clinicaltrials.gov/study/NCT03462251,https://clinicaltrials.gov/study/NCT02422615
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04639986
EFO_0000304	breast adenocarcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC1	histone deacetylase 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02115282
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Completed	https://clinicaltrials.gov/study/NCT01583426,https://clinicaltrials.gov/study/NCT02125344
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R5	phosphoinositide-3-kinase regulatory subunit 5	3	Recruiting	https://clinicaltrials.gov/study/NCT05501886
MONDO_0007254	breast cancer	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06279364,https://clinicaltrials.gov/study/NCT04337658,https://clinicaltrials.gov/study/NCT06343948,https://clinicaltrials.gov/study/NCT06268327,https://clinicaltrials.gov/study/NCT05172518,https://clinicaltrials.gov/study/NCT06081959,https://clinicaltrials.gov/study/NCT05901935,https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06079983
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	3	Terminated	https://clinicaltrials.gov/study/NCT01633060
MONDO_0007254	breast cancer	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Completed	https://clinicaltrials.gov/study/NCT00022672,https://clinicaltrials.gov/study/NCT00148876,https://clinicaltrials.gov/study/NCT05301010,https://clinicaltrials.gov/study/NCT01104935,https://clinicaltrials.gov/study/NCT04629846,https://clinicaltrials.gov/study/NCT02896855,https://clinicaltrials.gov/study/NCT02187744,https://clinicaltrials.gov/study/NCT00146549,https://clinicaltrials.gov/study/NCT00309556,https://clinicaltrials.gov/study/NCT03989037,https://clinicaltrials.gov/study/NCT00567554,https://clinicaltrials.gov/study/NCT03084237,https://clinicaltrials.gov/study/NCT00513292,https://clinicaltrials.gov/study/NCT03013504,https://clinicaltrials.gov/study/NCT03493854,https://clinicaltrials.gov/study/NCT06107790,https://clinicaltrials.gov/study/NCT02402712,https://clinicaltrials.gov/study/NCT04957212,https://clinicaltrials.gov/study/NCT02586025,https://clinicaltrials.gov/study/NCT00381901,https://clinicaltrials.gov/study/NCT00047255,https://clinicaltrials.gov/study/NCT00003440,https://clinicaltrials.gov/study/NCT00615602,https://clinicaltrials.gov/study/NCT01998906,https://clinicaltrials.gov/study/NCT02019277,https://clinicaltrials.gov/study/NCT02194166,https://clinicaltrials.gov/study/NCT03433313,https://clinicaltrials.gov/study/NCT01964391,https://clinicaltrials.gov/study/NCT00567190,https://clinicaltrials.gov/study/NCT00054587,https://clinicaltrials.gov/study/NCT04109391,https://clinicaltrials.gov/study/NCT01926886,https://clinicaltrials.gov/study/NCT01940497,https://clinicaltrials.gov/study/NCT00639366,https://clinicaltrials.gov/study/NCT02472964,https://clinicaltrials.gov/study/NCT00950300,https://clinicaltrials.gov/study/NCT01875367,https://clinicaltrials.gov/study/NCT02040935,https://clinicaltrials.gov/study/NCT00038402,https://clinicaltrials.gov/study/NCT02149524,https://clinicaltrials.gov/study/NCT01901146,https://clinicaltrials.gov/study/NCT00004067,https://clinicaltrials.gov/study/NCT00391092,https://clinicaltrials.gov/study/NCT01950182,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT00288002,https://clinicaltrials.gov/study/NCT01120184,https://clinicaltrials.gov/study/NCT00667251,https://clinicaltrials.gov/study/NCT01989676,https://clinicaltrials.gov/study/NCT00876395,https://clinicaltrials.gov/study/NCT00103233,https://clinicaltrials.gov/study/NCT03556358,https://clinicaltrials.gov/study/NCT01007942,https://clinicaltrials.gov/study/NCT01810393,https://clinicaltrials.gov/study/NCT03726879,https://clinicaltrials.gov/study/NCT00448279,https://clinicaltrials.gov/study/NCT01764022,https://clinicaltrials.gov/study/NCT05629949,https://clinicaltrials.gov/study/NCT00045032,https://clinicaltrials.gov/study/NCT03425656,https://clinicaltrials.gov/study/NCT01526369,https://clinicaltrials.gov/study/NCT01026142
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Completed	https://clinicaltrials.gov/study/NCT01091168,https://clinicaltrials.gov/study/NCT01095003,https://clinicaltrials.gov/study/NCT01953003
EFO_0000305	breast carcinoma	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01275677
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS2	NADH:ubiquinone oxidoreductase core subunit S2	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04622319,https://clinicaltrials.gov/study/NCT04740918,https://clinicaltrials.gov/study/NCT03529110,https://clinicaltrials.gov/study/NCT01772472
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Recruiting	https://clinicaltrials.gov/study/NCT05760378
MONDO_0007254	breast cancer	CHEMBL3647420	PYROTINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	3	Recruiting	https://clinicaltrials.gov/study/NCT04254263,https://clinicaltrials.gov/study/NCT05424835,https://clinicaltrials.gov/study/NCT04646759,https://clinicaltrials.gov/study/NCT05429684,https://clinicaltrials.gov/study/NCT05346861,https://clinicaltrials.gov/study/NCT05910398,https://clinicaltrials.gov/study/NCT06278870
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Recruiting	https://clinicaltrials.gov/study/NCT05374512
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor		GPD2	glycerol-3-phosphate dehydrogenase 2	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	3	Completed	https://clinicaltrials.gov/study/NCT00006459
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Completed	https://clinicaltrials.gov/study/NCT02225470,https://clinicaltrials.gov/study/NCT00103233
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04024462,https://clinicaltrials.gov/study/NCT03588091,https://clinicaltrials.gov/study/NCT02641847,https://clinicaltrials.gov/study/NCT03863223,https://clinicaltrials.gov/study/NCT01358877,https://clinicaltrials.gov/study/NCT01646034,https://clinicaltrials.gov/study/NCT02003209
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Suspended	https://clinicaltrials.gov/study/NCT03777579
MONDO_0007254	breast cancer	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06223698,https://clinicaltrials.gov/study/NCT05257395
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT06343948,https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06279364,https://clinicaltrials.gov/study/NCT06081959
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBA3E	tubulin alpha 3e	3	Completed	https://clinicaltrials.gov/study/NCT01091168,https://clinicaltrials.gov/study/NCT01095003,https://clinicaltrials.gov/study/NCT01953003
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Withdrawn	https://clinicaltrials.gov/study/NCT02929576
MONDO_0007254	breast cancer	CHEMBL4297844	TRASTUZUMAB DERUXTECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	3	Completed	https://clinicaltrials.gov/study/NCT04739761
EFO_0000304	breast adenocarcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885
MONDO_0007254	breast cancer	CHEMBL2177390	IPATASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT1	AKT serine/threonine kinase 1	3	Terminated	https://clinicaltrials.gov/study/NCT04060862
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	3	Recruiting	https://clinicaltrials.gov/study/NCT06143553
MONDO_0007254	breast cancer	CHEMBL3647420	PYROTINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02973737,https://clinicaltrials.gov/study/NCT03980054,https://clinicaltrials.gov/study/NCT03588091,https://clinicaltrials.gov/study/NCT03863223
EFO_0000304	breast adenocarcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC9	histone deacetylase 9	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02115282
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV1	NADH:ubiquinone oxidoreductase core subunit V1	3	Completed	https://clinicaltrials.gov/study/NCT01101438
EFO_0000304	breast adenocarcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
MONDO_0007254	breast cancer	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	3	Withdrawn	https://clinicaltrials.gov/study/NCT03081234
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Completed	https://clinicaltrials.gov/study/NCT02225470,https://clinicaltrials.gov/study/NCT00103233
MONDO_0007254	breast cancer	CHEMBL1201566	DARBEPOETIN ALFA	Protein	Erythropoietin receptor agonist		EPOR	erythropoietin receptor	3	Completed	https://clinicaltrials.gov/study/NCT00544232
MONDO_0007254	breast cancer	CHEMBL2177390	IPATASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT3	AKT serine/threonine kinase 3	3	Completed	https://clinicaltrials.gov/study/NCT03337724
MONDO_0007254	breast cancer	CHEMBL1201179	LAPATINIB DITOSYLATE	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	3	Unknown status	https://clinicaltrials.gov/study/NCT00688194
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	3	Terminated	https://clinicaltrials.gov/study/NCT01633060
MONDO_0007254	breast cancer	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	3	Terminated	https://clinicaltrials.gov/study/NCT00066807,https://clinicaltrials.gov/study/NCT00053911,https://clinicaltrials.gov/study/NCT00002772,https://clinicaltrials.gov/study/NCT05128773
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02221999
MONDO_0007254	breast cancer	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Recruiting	https://clinicaltrials.gov/study/NCT05802225,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT04193059,https://clinicaltrials.gov/study/NCT05720026,https://clinicaltrials.gov/study/NCT05159193,https://clinicaltrials.gov/study/NCT06278870,https://clinicaltrials.gov/study/NCT05429684,https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT05113251,https://clinicaltrials.gov/study/NCT05883852,https://clinicaltrials.gov/study/NCT04514419,https://clinicaltrials.gov/study/NCT05132582
EFO_0000305	breast carcinoma	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00066690
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04639986,https://clinicaltrials.gov/study/NCT05104866,https://clinicaltrials.gov/study/NCT05063786
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	3	Recruiting	https://clinicaltrials.gov/study/NCT06143553
EFO_1000984	inflammatory breast carcinoma	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Terminated	https://clinicaltrials.gov/study/NCT00016276
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Recruiting	https://clinicaltrials.gov/study/NCT04457596
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Completed	https://clinicaltrials.gov/study/NCT00190489,https://clinicaltrials.gov/study/NCT00429871,https://clinicaltrials.gov/study/NCT00047255,https://clinicaltrials.gov/study/NCT00314977,https://clinicaltrials.gov/study/NCT04957212,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT02472964,https://clinicaltrials.gov/study/NCT00431080,https://clinicaltrials.gov/study/NCT02019277,https://clinicaltrials.gov/study/NCT01940497,https://clinicaltrials.gov/study/NCT03013504,https://clinicaltrials.gov/study/NCT03493854,https://clinicaltrials.gov/study/NCT00688740,https://clinicaltrials.gov/study/NCT00424606,https://clinicaltrials.gov/study/NCT00004125,https://clinicaltrials.gov/study/NCT00311636,https://clinicaltrials.gov/study/NCT00333775,https://clinicaltrials.gov/study/NCT00114816,https://clinicaltrials.gov/study/NCT04031703,https://clinicaltrials.gov/study/NCT00003519,https://clinicaltrials.gov/study/NCT00003782,https://clinicaltrials.gov/study/NCT00352378,https://clinicaltrials.gov/study/NCT02115204,https://clinicaltrials.gov/study/NCT00540800,https://clinicaltrials.gov/study/NCT02194166,https://clinicaltrials.gov/study/NCT03084237,https://clinicaltrials.gov/study/NCT00008411,https://clinicaltrials.gov/study/NCT00294385,https://clinicaltrials.gov/study/NCT03989037,https://clinicaltrials.gov/study/NCT02402712,https://clinicaltrials.gov/study/NCT00950300,https://clinicaltrials.gov/study/NCT00017095,https://clinicaltrials.gov/study/NCT01099436,https://clinicaltrials.gov/study/NCT00567190,https://clinicaltrials.gov/study/NCT01690702,https://clinicaltrials.gov/study/NCT01049425,https://clinicaltrials.gov/study/NCT02187744,https://clinicaltrials.gov/study/NCT00776724,https://clinicaltrials.gov/study/NCT05629949,https://clinicaltrials.gov/study/NCT03425656,https://clinicaltrials.gov/study/NCT00091442,https://clinicaltrials.gov/study/NCT00002707,https://clinicaltrials.gov/study/NCT00331097,https://clinicaltrials.gov/study/NCT00887536,https://clinicaltrials.gov/study/NCT00002662,https://clinicaltrials.gov/study/NCT02586025,https://clinicaltrials.gov/study/NCT01120184,https://clinicaltrials.gov/study/NCT00793377,https://clinicaltrials.gov/study/NCT02896855,https://clinicaltrials.gov/study/NCT00567554,https://clinicaltrials.gov/study/NCT00963729,https://clinicaltrials.gov/study/NCT00146549,https://clinicaltrials.gov/study/NCT00089479,https://clinicaltrials.gov/study/NCT00391092,https://clinicaltrials.gov/study/NCT04629846,https://clinicaltrials.gov/study/NCT00433589,https://clinicaltrials.gov/study/NCT00312208,https://clinicaltrials.gov/study/NCT04127019,https://clinicaltrials.gov/study/NCT02681003,https://clinicaltrials.gov/study/NCT00493870,https://clinicaltrials.gov/study/NCT00615602,https://clinicaltrials.gov/study/NCT00129935,https://clinicaltrials.gov/study/NCT00047099,https://clinicaltrials.gov/study/NCT00667251,https://clinicaltrials.gov/study/NCT00288002,https://clinicaltrials.gov/study/NCT00703326,https://clinicaltrials.gov/study/NCT00236899,https://clinicaltrials.gov/study/NCT00191152,https://clinicaltrials.gov/study/NCT01985724,https://clinicaltrials.gov/study/NCT05301010,https://clinicaltrials.gov/study/NCT01216111,https://clinicaltrials.gov/study/NCT00309556,https://clinicaltrials.gov/study/NCT02980965,https://clinicaltrials.gov/study/NCT00002544,https://clinicaltrials.gov/study/NCT01314833,https://clinicaltrials.gov/study/NCT00630032,https://clinicaltrials.gov/study/NCT00448591,https://clinicaltrials.gov/study/NCT01964391,https://clinicaltrials.gov/study/NCT00054587,https://clinicaltrials.gov/study/NCT00193011
MONDO_0007254	breast cancer	CHEMBL1201247	GOSERELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	3	Withdrawn	https://clinicaltrials.gov/study/NCT00888082
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	3	Suspended	https://clinicaltrials.gov/study/NCT03002103
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	3	Unknown status	https://clinicaltrials.gov/study/NCT00039546,https://clinicaltrials.gov/study/NCT00070278,https://clinicaltrials.gov/study/NCT00408408
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Suspended	https://clinicaltrials.gov/study/NCT03777579
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00769379
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	3	Unknown status	https://clinicaltrials.gov/study/NCT00039546,https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT02207335,https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT00070278
MONDO_0007254	breast cancer	CHEMBL3039558	ETIRINOTECAN PEGOL	Small molecule	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	3	Completed	https://clinicaltrials.gov/study/NCT01492101
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Suspended	https://clinicaltrials.gov/study/NCT03777579
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Completed	https://clinicaltrials.gov/study/NCT00829166,https://clinicaltrials.gov/study/NCT03726879,https://clinicaltrials.gov/study/NCT01120184,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT03084939,https://clinicaltrials.gov/study/NCT01419197,https://clinicaltrials.gov/study/NCT01702571
MONDO_0007254	breast cancer	CHEMBL4303669	ZOLEDRONIC ACID	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	3	Completed	https://clinicaltrials.gov/study/NCT00107263,https://clinicaltrials.gov/study/NCT00320710,https://clinicaltrials.gov/study/NCT00295646,https://clinicaltrials.gov/study/NCT00712985,https://clinicaltrials.gov/study/NCT00375505,https://clinicaltrials.gov/study/NCT00202059,https://clinicaltrials.gov/study/NCT00376740,https://clinicaltrials.gov/study/NCT00375427,https://clinicaltrials.gov/study/NCT01099436,https://clinicaltrials.gov/study/NCT00512993,https://clinicaltrials.gov/study/NCT00127205,https://clinicaltrials.gov/study/NCT00171314,https://clinicaltrials.gov/study/NCT00556374
EFO_0000186	invasive breast ductal carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Completed	https://clinicaltrials.gov/study/NCT02620280
EFO_0000304	breast adenocarcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04639986
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR2	estrogen receptor 2	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01953588,https://clinicaltrials.gov/study/NCT05063786,https://clinicaltrials.gov/study/NCT02947685,https://clinicaltrials.gov/study/NCT02763566,https://clinicaltrials.gov/study/NCT04305496,https://clinicaltrials.gov/study/NCT01602380,https://clinicaltrials.gov/study/NCT03927456,https://clinicaltrials.gov/study/NCT03079011,https://clinicaltrials.gov/study/NCT04191499,https://clinicaltrials.gov/study/NCT05433480,https://clinicaltrials.gov/study/NCT00099437
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Recruiting	https://clinicaltrials.gov/study/NCT05862064,https://clinicaltrials.gov/study/NCT04296175
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Completed	https://clinicaltrials.gov/study/NCT03125902,https://clinicaltrials.gov/study/NCT04177108,https://clinicaltrials.gov/study/NCT03197935
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00770809
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Recruiting	https://clinicaltrials.gov/study/NCT05894239
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT05063786,https://clinicaltrials.gov/study/NCT05104866,https://clinicaltrials.gov/study/NCT03734029,https://clinicaltrials.gov/study/NCT04639986
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT05814354,https://clinicaltrials.gov/study/NCT06103864,https://clinicaltrials.gov/study/NCT04722978,https://clinicaltrials.gov/study/NCT06143553,https://clinicaltrials.gov/study/NCT05382299,https://clinicaltrials.gov/study/NCT06268652
MONDO_0007254	breast cancer	CHEMBL1042	CHOLECALCIFEROL	Small molecule	Vitamin D receptor agonist		VDR	vitamin D receptor	3	Completed	https://clinicaltrials.gov/study/NCT01480869
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Completed	https://clinicaltrials.gov/study/NCT03726879,https://clinicaltrials.gov/study/NCT02163694,https://clinicaltrials.gov/study/NCT01764022,https://clinicaltrials.gov/study/NCT00129389,https://clinicaltrials.gov/study/NCT00006459,https://clinicaltrials.gov/study/NCT00544232,https://clinicaltrials.gov/study/NCT02594371,https://clinicaltrials.gov/study/NCT02194166,https://clinicaltrials.gov/study/NCT01216111,https://clinicaltrials.gov/study/NCT00876486,https://clinicaltrials.gov/study/NCT02032277,https://clinicaltrials.gov/study/NCT02425891,https://clinicaltrials.gov/study/NCT01901146,https://clinicaltrials.gov/study/NCT00028990,https://clinicaltrials.gov/study/NCT00003088,https://clinicaltrials.gov/study/NCT00016406,https://clinicaltrials.gov/study/NCT00311636,https://clinicaltrials.gov/study/NCT00003972,https://clinicaltrials.gov/study/NCT01526369,https://clinicaltrials.gov/study/NCT01131195,https://clinicaltrials.gov/study/NCT02819518,https://clinicaltrials.gov/study/NCT02450058,https://clinicaltrials.gov/study/NCT01690702,https://clinicaltrials.gov/study/NCT00336791,https://clinicaltrials.gov/study/NCT00513292,https://clinicaltrials.gov/study/NCT00129922,https://clinicaltrials.gov/study/NCT01120184,https://clinicaltrials.gov/study/NCT01433614,https://clinicaltrials.gov/study/NCT03462251,https://clinicaltrials.gov/study/NCT01940497,https://clinicaltrials.gov/study/NCT01287624,https://clinicaltrials.gov/study/NCT00004067,https://clinicaltrials.gov/study/NCT00196872,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT00002953,https://clinicaltrials.gov/study/NCT04109066,https://clinicaltrials.gov/study/NCT00038402,https://clinicaltrials.gov/study/NCT01822314,https://clinicaltrials.gov/study/NCT00448591,https://clinicaltrials.gov/study/NCT01663727,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT00876395,https://clinicaltrials.gov/study/NCT00567554,https://clinicaltrials.gov/study/NCT02019277,https://clinicaltrials.gov/study/NCT01314833,https://clinicaltrials.gov/study/NCT00002662,https://clinicaltrials.gov/study/NCT01989676,https://clinicaltrials.gov/study/NCT01964391,https://clinicaltrials.gov/study/NCT04031703,https://clinicaltrials.gov/study/NCT00431080,https://clinicaltrials.gov/study/NCT00667251,https://clinicaltrials.gov/study/NCT00561119,https://clinicaltrials.gov/study/NCT00236899,https://clinicaltrials.gov/study/NCT00014222,https://clinicaltrials.gov/study/NCT00668616,https://clinicaltrials.gov/study/NCT00041119,https://clinicaltrials.gov/study/NCT00003013,https://clinicaltrials.gov/study/NCT03498716,https://clinicaltrials.gov/study/NCT04127019,https://clinicaltrials.gov/study/NCT00146549,https://clinicaltrials.gov/study/NCT03493854,https://clinicaltrials.gov/study/NCT02472964,https://clinicaltrials.gov/study/NCT03556358,https://clinicaltrials.gov/study/NCT01998906,https://clinicaltrials.gov/study/NCT00600340,https://clinicaltrials.gov/study/NCT00003440,https://clinicaltrials.gov/study/NCT00789581,https://clinicaltrials.gov/study/NCT00004125,https://clinicaltrials.gov/study/NCT01644890,https://clinicaltrials.gov/study/NCT03337724
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Recruiting	https://clinicaltrials.gov/study/NCT02488967
MONDO_0007254	breast cancer	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN5A	sodium voltage-gated channel alpha subunit 5	3	Terminated	https://clinicaltrials.gov/study/NCT02525211
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Recruiting	https://clinicaltrials.gov/study/NCT04296175,https://clinicaltrials.gov/study/NCT05862064
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Recruiting	https://clinicaltrials.gov/study/NCT05760378
EFO_1000984	inflammatory breast carcinoma	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Completed	https://clinicaltrials.gov/study/NCT02125344
MONDO_0007254	breast cancer	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Enrolling by invitation	https://clinicaltrials.gov/study/NCT05645536
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
MONDO_0007254	breast cancer	CHEMBL180022	NERATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Completed	https://clinicaltrials.gov/study/NCT00878709,https://clinicaltrials.gov/study/NCT01808573
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN8A	sodium voltage-gated channel alpha subunit 8	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01916317
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Recruiting	https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT06268652,https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT05374512,https://clinicaltrials.gov/study/NCT05814354
MONDO_0007254	breast cancer	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN11A	sodium voltage-gated channel alpha subunit 11	3	Terminated	https://clinicaltrials.gov/study/NCT02525211
EFO_0000432	breast ductal carcinoma in situ	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01272037,https://clinicaltrials.gov/study/NCT01357772
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06316531,https://clinicaltrials.gov/study/NCT06313086,https://clinicaltrials.gov/study/NCT06126640
MONDO_0007254	breast cancer	CHEMBL1200501	GOSERELIN ACETATE	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01674140,https://clinicaltrials.gov/study/NCT02003209
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R2	phosphoinositide-3-kinase regulatory subunit 2	3	Terminated	https://clinicaltrials.gov/study/NCT01633060
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS3	NADH:ubiquinone oxidoreductase core subunit S3	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Recruiting	https://clinicaltrials.gov/study/NCT05894239
MONDO_0007254	breast cancer	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	3	Enrolling by invitation	https://clinicaltrials.gov/study/NCT05645536
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01646034,https://clinicaltrials.gov/study/NCT04639986,https://clinicaltrials.gov/study/NCT02641847,https://clinicaltrials.gov/study/NCT05104866,https://clinicaltrials.gov/study/NCT03734029
MONDO_0007254	breast cancer	CHEMBL547	ISOTRETINOIN	Small molecule	Retinoic acid receptor agonist		RARG	retinoic acid receptor gamma	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT05016349
EFO_0000304	breast adenocarcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC2	histone deacetylase 2	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02115282
EFO_0005537	triple-negative breast cancer	CHEMBL1201568	PEGFILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	3	Completed	https://clinicaltrials.gov/study/NCT03197935
EFO_0005537	triple-negative breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	3	Suspended	https://clinicaltrials.gov/study/NCT03002103
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04639986
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00191152
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS7	NADH:ubiquinone oxidoreductase core subunit S7	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Completed	https://clinicaltrials.gov/study/NCT00829166,https://clinicaltrials.gov/study/NCT01702571,https://clinicaltrials.gov/study/NCT01419197,https://clinicaltrials.gov/study/NCT03084939,https://clinicaltrials.gov/study/NCT03726879,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT01120184
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	3	Unknown status	https://clinicaltrials.gov/study/NCT00039546,https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT02207335,https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT00070278
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Terminated	https://clinicaltrials.gov/study/NCT00016276
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Unknown status	https://clinicaltrials.gov/study/NCT02514681
MONDO_0007254	breast cancer	CHEMBL924	ZOLEDRONIC ACID ANHYDROUS	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	3	Unknown status	https://clinicaltrials.gov/study/NCT00072020,https://clinicaltrials.gov/study/NCT00326820,https://clinicaltrials.gov/study/NCT02595138
MONDO_0007254	breast cancer	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT01645839
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03734029,https://clinicaltrials.gov/study/NCT04639986,https://clinicaltrials.gov/study/NCT02641847,https://clinicaltrials.gov/study/NCT01646034,https://clinicaltrials.gov/study/NCT05104866
EFO_0000304	breast adenocarcinoma	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00310180
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Terminated	https://clinicaltrials.gov/study/NCT02144012
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Terminated	https://clinicaltrials.gov/study/NCT00016276
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Suspended	https://clinicaltrials.gov/study/NCT03002103
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Terminated	https://clinicaltrials.gov/study/NCT01200212,https://clinicaltrials.gov/study/NCT02144012,https://clinicaltrials.gov/study/NCT00053911,https://clinicaltrials.gov/study/NCT00912444,https://clinicaltrials.gov/study/NCT00625898
MONDO_0007254	breast cancer	CHEMBL2108738	NIVOLUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	3	Completed	https://clinicaltrials.gov/study/NCT04109066
MONDO_0007254	breast cancer	CHEMBL778	DEXMEDETOMIDINE	Small molecule	Adrenergic receptor alpha-2 agonist		ADRA2C	adrenoceptor alpha 2C	3	Unknown status	https://clinicaltrials.gov/study/NCT03063073,https://clinicaltrials.gov/study/NCT03046238
MONDO_0007254	breast cancer	CHEMBL1738889	ENOBOSARM	Small molecule	Androgen Receptor modulator		AR	androgen receptor	3	Terminated	https://clinicaltrials.gov/study/NCT05065411,https://clinicaltrials.gov/study/NCT04869943
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBA1B	tubulin alpha 1b	3	Completed	https://clinicaltrials.gov/study/NCT01091168,https://clinicaltrials.gov/study/NCT01953003,https://clinicaltrials.gov/study/NCT01095003
EFO_0000304	breast adenocarcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652
EFO_0000305	breast carcinoma	CHEMBL1200501	GOSERELIN ACETATE	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02003209
MONDO_0007254	breast cancer	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN2A	sodium voltage-gated channel alpha subunit 2	3	Completed	https://clinicaltrials.gov/study/NCT00547989,https://clinicaltrials.gov/study/NCT04327063,https://clinicaltrials.gov/study/NCT02408393
EFO_0000186	invasive breast ductal carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Completed	https://clinicaltrials.gov/study/NCT02620280
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	3	Unknown status	https://clinicaltrials.gov/study/NCT00039546,https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT00070278
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Unknown status	https://clinicaltrials.gov/study/NCT02514681
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV3	NADH:ubiquinone oxidoreductase subunit V3	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT04665986,https://clinicaltrials.gov/study/NCT05172518,https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT05838066
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT06143553
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Terminated	https://clinicaltrials.gov/study/NCT05134194,https://clinicaltrials.gov/study/NCT02730091
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Unknown status	https://clinicaltrials.gov/study/NCT02879513
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00770809
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06079983
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Completed	https://clinicaltrials.gov/study/NCT00005970
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR1	estrogen receptor 1	3	Unknown status	https://clinicaltrials.gov/study/NCT00688194,https://clinicaltrials.gov/study/NCT02394496,https://clinicaltrials.gov/study/NCT00253422
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06081959,https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06343948,https://clinicaltrials.gov/study/NCT06079983
MONDO_0007254	breast cancer	CHEMBL3545262	SACITUZUMAB GOVITECAN	Antibody drug conjugate	Tumor-associated calcium signal transducer 2 binding agent		TACSTD2	tumor associated calcium signal transducer 2	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04639986
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04085276,https://clinicaltrials.gov/study/NCT04148911
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	3	Completed	https://clinicaltrials.gov/study/NCT00191152,https://clinicaltrials.gov/study/NCT01287624,https://clinicaltrials.gov/study/NCT00670878,https://clinicaltrials.gov/study/NCT00938652,https://clinicaltrials.gov/study/NCT03901339,https://clinicaltrials.gov/study/NCT02546934,https://clinicaltrials.gov/study/NCT02819518,https://clinicaltrials.gov/study/NCT00561119,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT02555657,https://clinicaltrials.gov/study/NCT02574455,https://clinicaltrials.gov/study/NCT00431106,https://clinicaltrials.gov/study/NCT00006459,https://clinicaltrials.gov/study/NCT00294385,https://clinicaltrials.gov/study/NCT00236899
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Terminated	https://clinicaltrials.gov/study/NCT00016276
EFO_1000984	inflammatory breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Completed	https://clinicaltrials.gov/study/NCT02324088
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	3	Suspended	https://clinicaltrials.gov/study/NCT03002103
MONDO_0007254	breast cancer	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03725059
MONDO_0007254	breast cancer	CHEMBL393220	ATORVASTATIN CALCIUM	Small molecule	HMG-CoA reductase inhibitor		HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase	3	Recruiting	https://clinicaltrials.gov/study/NCT04601116
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Terminated	https://clinicaltrials.gov/study/NCT00520975,https://clinicaltrials.gov/study/NCT02054338,https://clinicaltrials.gov/study/NCT01200212,https://clinicaltrials.gov/study/NCT00002772,https://clinicaltrials.gov/study/NCT04335006,https://clinicaltrials.gov/study/NCT01303679
MONDO_0007254	breast cancer	CHEMBL58	MITOXANTRONE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Completed	https://clinicaltrials.gov/study/NCT00002544,https://clinicaltrials.gov/study/NCT00003032,https://clinicaltrials.gov/study/NCT00003893
MONDO_0007254	breast cancer	CHEMBL1655	TOREMIFENE	Small molecule	Estrogen receptor modulator		ESR1	estrogen receptor 1	3	Completed	https://clinicaltrials.gov/study/NCT00002529
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Completed	https://clinicaltrials.gov/study/NCT00337103,https://clinicaltrials.gov/study/NCT02555657,https://clinicaltrials.gov/study/NCT02225470,https://clinicaltrials.gov/study/NCT02574455,https://clinicaltrials.gov/study/NCT03901339,https://clinicaltrials.gov/study/NCT00388726
MONDO_0007254	breast cancer	CHEMBL4279455	LAROTAXEL	Small molecule	Tubulin stabiliser		TUBB3	tubulin beta 3 class III	3	Completed	https://clinicaltrials.gov/study/NCT00081796
MONDO_0007254	breast cancer	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04024462,https://clinicaltrials.gov/study/NCT02641847,https://clinicaltrials.gov/study/NCT02214381,https://clinicaltrials.gov/study/NCT01358877,https://clinicaltrials.gov/study/NCT03725059,https://clinicaltrials.gov/study/NCT01646034,https://clinicaltrials.gov/study/NCT00070564,https://clinicaltrials.gov/study/NCT03595592
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Terminated	https://clinicaltrials.gov/study/NCT00912444,https://clinicaltrials.gov/study/NCT02144012,https://clinicaltrials.gov/study/NCT01200212,https://clinicaltrials.gov/study/NCT00625898,https://clinicaltrials.gov/study/NCT00053911
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06343948,https://clinicaltrials.gov/study/NCT06081959,https://clinicaltrials.gov/study/NCT05901935,https://clinicaltrials.gov/study/NCT04665986,https://clinicaltrials.gov/study/NCT06079983
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885,https://clinicaltrials.gov/study/NCT01275677
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS2	NADH:ubiquinone oxidoreductase core subunit S2	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02003209,https://clinicaltrials.gov/study/NCT01358877,https://clinicaltrials.gov/study/NCT03863223,https://clinicaltrials.gov/study/NCT04024462,https://clinicaltrials.gov/study/NCT03588091,https://clinicaltrials.gov/study/NCT02641847,https://clinicaltrials.gov/study/NCT01646034
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS5	NADH:ubiquinone oxidoreductase subunit S5	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL20883	TEGAFUR	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	3	Completed	https://clinicaltrials.gov/study/NCT00152178,https://clinicaltrials.gov/study/NCT00152191
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT00006459
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN9A	sodium voltage-gated channel alpha subunit 9	3	Completed	https://clinicaltrials.gov/study/NCT04822597
EFO_0000305	breast carcinoma	CHEMBL657	DIPHENHYDRAMINE	Small molecule	Histamine H1 receptor antagonist		HRH1	histamine receptor H1	3	Recruiting	https://clinicaltrials.gov/study/NCT04862585
EFO_0000305	breast carcinoma	CHEMBL1201247	GOSERELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02003209
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase B-raf inhibitor		BRAF	B-Raf proto-oncogene, serine/threonine kinase	3	Completed	https://clinicaltrials.gov/study/NCT01234337
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA10	NADH:ubiquinone oxidoreductase subunit A10	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04639986
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA5	NADH:ubiquinone oxidoreductase subunit A5	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT05753865,https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06279364,https://clinicaltrials.gov/study/NCT05388500,https://clinicaltrials.gov/study/NCT04301739,https://clinicaltrials.gov/study/NCT05172518,https://clinicaltrials.gov/study/NCT05841381
MONDO_0004658	breast carcinoma in situ	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Recruiting	https://clinicaltrials.gov/study/NCT04862585
EFO_0006861	male breast carcinoma	CHEMBL554	LAPATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00770809
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Recruiting	https://clinicaltrials.gov/study/NCT05760378
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Unknown status	https://clinicaltrials.gov/study/NCT02514681
MONDO_0007254	breast cancer	CHEMBL4279455	LAROTAXEL	Small molecule	Tubulin stabiliser		TUBB4A	tubulin beta 4A class IVa	3	Completed	https://clinicaltrials.gov/study/NCT00081796
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04799249
EFO_0000304	breast adenocarcinoma	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Recruiting	https://clinicaltrials.gov/study/NCT02488967
MONDO_0007254	breast cancer	CHEMBL1201247	GOSERELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	3	Terminated	https://clinicaltrials.gov/study/NCT00053911,https://clinicaltrials.gov/study/NCT04478266,https://clinicaltrials.gov/study/NCT00429403
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Recruiting	https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT05814354,https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT06268652,https://clinicaltrials.gov/study/NCT05374512
EFO_1000984	inflammatory breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT05415215
MONDO_0007254	breast cancer	CHEMBL1680	OCTREOTIDE	Protein	Somatostatin receptor agonist		SSTR4	somatostatin receptor 4	3	Completed	https://clinicaltrials.gov/study/NCT00002967,https://clinicaltrials.gov/study/NCT00002864
MONDO_0007254	breast cancer	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	3	Completed	https://clinicaltrials.gov/study/NCT00080301,https://clinicaltrials.gov/study/NCT00129935,https://clinicaltrials.gov/study/NCT00600340,https://clinicaltrials.gov/study/NCT00196872,https://clinicaltrials.gov/study/NCT02574455,https://clinicaltrials.gov/study/NCT00266799,https://clinicaltrials.gov/study/NCT00661102,https://clinicaltrials.gov/study/NCT00929240,https://clinicaltrials.gov/study/NCT00082433,https://clinicaltrials.gov/study/NCT01808573,https://clinicaltrials.gov/study/NCT00024102,https://clinicaltrials.gov/study/NCT01953003,https://clinicaltrials.gov/study/NCT02555657,https://clinicaltrials.gov/study/NCT00081796,https://clinicaltrials.gov/study/NCT00078572,https://clinicaltrials.gov/study/NCT00868634,https://clinicaltrials.gov/study/NCT01234337,https://clinicaltrials.gov/study/NCT02253459,https://clinicaltrials.gov/study/NCT03084939,https://clinicaltrials.gov/study/NCT00309556,https://clinicaltrials.gov/study/NCT03462251,https://clinicaltrials.gov/study/NCT00429871,https://clinicaltrials.gov/study/NCT00433589,https://clinicaltrials.gov/study/NCT00196859,https://clinicaltrials.gov/study/NCT00130533,https://clinicaltrials.gov/study/NCT03901339,https://clinicaltrials.gov/study/NCT02028507,https://clinicaltrials.gov/study/NCT01112826,https://clinicaltrials.gov/study/NCT01026142,https://clinicaltrials.gov/study/NCT00829166,https://clinicaltrials.gov/study/NCT00114816,https://clinicaltrials.gov/study/NCT01131195,https://clinicaltrials.gov/study/NCT00431106,https://clinicaltrials.gov/study/NCT01095003,https://clinicaltrials.gov/study/NCT01433614,https://clinicaltrials.gov/study/NCT00337103,https://clinicaltrials.gov/study/NCT00191152,https://clinicaltrials.gov/study/NCT00148876,https://clinicaltrials.gov/study/NCT00540800,https://clinicaltrials.gov/study/NCT00288002,https://clinicaltrials.gov/study/NCT00089479,https://clinicaltrials.gov/study/NCT00352378
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Completed	https://clinicaltrials.gov/study/NCT02819518,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT03726879,https://clinicaltrials.gov/study/NCT03498716,https://clinicaltrials.gov/study/NCT00668616,https://clinicaltrials.gov/study/NCT00002662,https://clinicaltrials.gov/study/NCT01131195,https://clinicaltrials.gov/study/NCT01964391,https://clinicaltrials.gov/study/NCT00561119,https://clinicaltrials.gov/study/NCT00431080,https://clinicaltrials.gov/study/NCT00336791,https://clinicaltrials.gov/study/NCT01901146,https://clinicaltrials.gov/study/NCT00003013,https://clinicaltrials.gov/study/NCT00311636,https://clinicaltrials.gov/study/NCT00876395,https://clinicaltrials.gov/study/NCT01287624,https://clinicaltrials.gov/study/NCT01663727,https://clinicaltrials.gov/study/NCT02425891,https://clinicaltrials.gov/study/NCT00146549,https://clinicaltrials.gov/study/NCT01216111,https://clinicaltrials.gov/study/NCT00014222,https://clinicaltrials.gov/study/NCT00003972,https://clinicaltrials.gov/study/NCT00513292,https://clinicaltrials.gov/study/NCT00544232,https://clinicaltrials.gov/study/NCT01940497,https://clinicaltrials.gov/study/NCT00196872,https://clinicaltrials.gov/study/NCT00600340,https://clinicaltrials.gov/study/NCT02032277,https://clinicaltrials.gov/study/NCT02194166,https://clinicaltrials.gov/study/NCT01690702,https://clinicaltrials.gov/study/NCT00016406,https://clinicaltrials.gov/study/NCT00004067,https://clinicaltrials.gov/study/NCT01998906,https://clinicaltrials.gov/study/NCT00038402,https://clinicaltrials.gov/study/NCT03337724,https://clinicaltrials.gov/study/NCT00876486,https://clinicaltrials.gov/study/NCT00041119,https://clinicaltrials.gov/study/NCT01120184,https://clinicaltrials.gov/study/NCT00004125,https://clinicaltrials.gov/study/NCT00028990,https://clinicaltrials.gov/study/NCT00567554,https://clinicaltrials.gov/study/NCT03462251,https://clinicaltrials.gov/study/NCT04031703,https://clinicaltrials.gov/study/NCT02594371,https://clinicaltrials.gov/study/NCT01989676,https://clinicaltrials.gov/study/NCT02472964,https://clinicaltrials.gov/study/NCT02019277,https://clinicaltrials.gov/study/NCT00129922,https://clinicaltrials.gov/study/NCT03556358,https://clinicaltrials.gov/study/NCT00236899,https://clinicaltrials.gov/study/NCT01526369,https://clinicaltrials.gov/study/NCT01764022,https://clinicaltrials.gov/study/NCT04127019,https://clinicaltrials.gov/study/NCT01822314,https://clinicaltrials.gov/study/NCT01433614,https://clinicaltrials.gov/study/NCT00789581,https://clinicaltrials.gov/study/NCT03493854,https://clinicaltrials.gov/study/NCT00003088,https://clinicaltrials.gov/study/NCT04109066,https://clinicaltrials.gov/study/NCT02450058,https://clinicaltrials.gov/study/NCT02163694,https://clinicaltrials.gov/study/NCT00129389,https://clinicaltrials.gov/study/NCT00667251,https://clinicaltrials.gov/study/NCT01314833,https://clinicaltrials.gov/study/NCT01644890,https://clinicaltrials.gov/study/NCT00006459,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT00002953,https://clinicaltrials.gov/study/NCT00448591,https://clinicaltrials.gov/study/NCT00003440
MONDO_0007254	breast cancer	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	3	Withdrawn	https://clinicaltrials.gov/study/NCT03081234
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB9	NADH:ubiquinone oxidoreductase subunit B9	3	Completed	https://clinicaltrials.gov/study/NCT01101438
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1094636	NIRAPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	3	Terminated	https://clinicaltrials.gov/study/NCT01905592
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT04665986,https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT06343948,https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT05901935,https://clinicaltrials.gov/study/NCT06081959
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC7	histone deacetylase 7	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03538171
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	3	Terminated	https://clinicaltrials.gov/study/NCT02054338,https://clinicaltrials.gov/study/NCT00440622,https://clinicaltrials.gov/study/NCT05134194
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
MONDO_0007254	breast cancer	CHEMBL359744	DOXORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Suspended	https://clinicaltrials.gov/study/NCT00002696
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Recruiting	https://clinicaltrials.gov/study/NCT05883852,https://clinicaltrials.gov/study/NCT05296798,https://clinicaltrials.gov/study/NCT03671044,https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT03926091,https://clinicaltrials.gov/study/NCT05894239,https://clinicaltrials.gov/study/NCT04540692,https://clinicaltrials.gov/study/NCT04547907,https://clinicaltrials.gov/study/NCT03949634,https://clinicaltrials.gov/study/NCT05720026,https://clinicaltrials.gov/study/NCT05207514,https://clinicaltrials.gov/study/NCT05159193,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT05430399,https://clinicaltrials.gov/study/NCT05673629,https://clinicaltrials.gov/study/NCT05901428,https://clinicaltrials.gov/study/NCT04193059,https://clinicaltrials.gov/study/NCT03264547
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN7A	sodium voltage-gated channel alpha subunit 7	3	Completed	https://clinicaltrials.gov/study/NCT04822597
MONDO_0007254	breast cancer	CHEMBL1417019	MITOXANTRONE HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Completed	https://clinicaltrials.gov/study/NCT00003893,https://clinicaltrials.gov/study/NCT00002544,https://clinicaltrials.gov/study/NCT00003032
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06126640,https://clinicaltrials.gov/study/NCT06316531,https://clinicaltrials.gov/study/NCT06313086
EFO_0000305	breast carcinoma	CHEMBL384467	DEXAMETHASONE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	3	Recruiting	https://clinicaltrials.gov/study/NCT04862585
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	3	Recruiting	https://clinicaltrials.gov/study/NCT06112379
MONDO_0007254	breast cancer	CHEMBL3545414	RIVOCERANIB MESYLATE	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	3	Recruiting	https://clinicaltrials.gov/study/NCT04296370
MONDO_0007254	breast cancer	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT01645839
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT05104866,https://clinicaltrials.gov/study/NCT02641847,https://clinicaltrials.gov/study/NCT04639986,https://clinicaltrials.gov/study/NCT01646034,https://clinicaltrials.gov/study/NCT03734029
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Completed	https://clinicaltrials.gov/study/NCT04177108,https://clinicaltrials.gov/study/NCT03197935,https://clinicaltrials.gov/study/NCT03125902
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Completed	https://clinicaltrials.gov/study/NCT02555657,https://clinicaltrials.gov/study/NCT03901339,https://clinicaltrials.gov/study/NCT02574455,https://clinicaltrials.gov/study/NCT00388726,https://clinicaltrials.gov/study/NCT02225470,https://clinicaltrials.gov/study/NCT00337103
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Completed	https://clinicaltrials.gov/study/NCT00103233,https://clinicaltrials.gov/study/NCT02225470
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Recruiting	https://clinicaltrials.gov/study/NCT04862585,https://clinicaltrials.gov/study/NCT06058377,https://clinicaltrials.gov/study/NCT05747794,https://clinicaltrials.gov/study/NCT03201861
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN10A	sodium voltage-gated channel alpha subunit 10	3	Completed	https://clinicaltrials.gov/study/NCT04822597
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04639986
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Completed	https://clinicaltrials.gov/study/NCT03901339,https://clinicaltrials.gov/study/NCT02555657,https://clinicaltrials.gov/study/NCT02225470,https://clinicaltrials.gov/study/NCT00337103,https://clinicaltrials.gov/study/NCT00388726,https://clinicaltrials.gov/study/NCT02574455
MONDO_0007254	breast cancer	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	3	Withdrawn	https://clinicaltrials.gov/study/NCT00053339
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Completed	https://clinicaltrials.gov/study/NCT00789581,https://clinicaltrials.gov/study/NCT00082433,https://clinicaltrials.gov/study/NCT00630032,https://clinicaltrials.gov/study/NCT00080301,https://clinicaltrials.gov/study/NCT00448591
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Unknown status	https://clinicaltrials.gov/study/NCT00010140,https://clinicaltrials.gov/study/NCT01479036,https://clinicaltrials.gov/study/NCT00944424,https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT01642771,https://clinicaltrials.gov/study/NCT01547741,https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT00430001,https://clinicaltrials.gov/study/NCT00003679,https://clinicaltrials.gov/study/NCT01622361,https://clinicaltrials.gov/study/NCT01222052,https://clinicaltrials.gov/study/NCT02393833,https://clinicaltrials.gov/study/NCT01354522,https://clinicaltrials.gov/study/NCT00532727,https://clinicaltrials.gov/study/NCT00629278
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN11A	sodium voltage-gated channel alpha subunit 11	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01916317
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Terminated	https://clinicaltrials.gov/study/NCT05134194,https://clinicaltrials.gov/study/NCT03786094
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC8	histone deacetylase 8	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03538171
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Completed	https://clinicaltrials.gov/study/NCT00005970
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652,https://clinicaltrials.gov/study/NCT06143553,https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT04307147
EFO_0000304	breast adenocarcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Recruiting	https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT06143553
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01646034,https://clinicaltrials.gov/study/NCT03863223,https://clinicaltrials.gov/study/NCT02641847,https://clinicaltrials.gov/study/NCT02003209,https://clinicaltrials.gov/study/NCT01358877,https://clinicaltrials.gov/study/NCT04024462,https://clinicaltrials.gov/study/NCT03588091
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Recruiting	https://clinicaltrials.gov/study/NCT02488967
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	3	Unknown status	https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT00070278,https://clinicaltrials.gov/study/NCT00039546,https://clinicaltrials.gov/study/NCT02207335
EFO_0000305	breast carcinoma	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Suspended	https://clinicaltrials.gov/study/NCT03002103
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Completed	https://clinicaltrials.gov/study/NCT01583426,https://clinicaltrials.gov/study/NCT02125344
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Terminated	https://clinicaltrials.gov/study/NCT00625898,https://clinicaltrials.gov/study/NCT00912444,https://clinicaltrials.gov/study/NCT01200212,https://clinicaltrials.gov/study/NCT02144012,https://clinicaltrials.gov/study/NCT00053911
MONDO_0007254	breast cancer	CHEMBL4297844	TRASTUZUMAB DERUXTECAN	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 binding agent		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Recruiting	https://clinicaltrials.gov/study/NCT05113251,https://clinicaltrials.gov/study/NCT05950945
MONDO_0007254	breast cancer	CHEMBL4650365	CAMIZESTRANT	Small molecule	Estrogen receptor alpha degrader		ESR1	estrogen receptor 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04711252
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB10	NADH:ubiquinone oxidoreductase subunit B10	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL1743062	RAMUCIRUMAB	Antibody	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	3	Completed	https://clinicaltrials.gov/study/NCT00703326
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT05172518,https://clinicaltrials.gov/study/NCT04665986,https://clinicaltrials.gov/study/NCT05838066
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN5A	sodium voltage-gated channel alpha subunit 5	3	Completed	https://clinicaltrials.gov/study/NCT04822597
MONDO_0007254	breast cancer	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	3	Completed	https://clinicaltrials.gov/study/NCT02032277,https://clinicaltrials.gov/study/NCT02163694
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Recruiting	https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT06143553
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT04665986,https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06081959,https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT06343948,https://clinicaltrials.gov/study/NCT05901935
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT06255392
EFO_0000304	breast adenocarcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01358877,https://clinicaltrials.gov/study/NCT03168880,https://clinicaltrials.gov/study/NCT00433420,https://clinicaltrials.gov/study/NCT03595592,https://clinicaltrials.gov/study/NCT03315364,https://clinicaltrials.gov/study/NCT01646034,https://clinicaltrials.gov/study/NCT04494425,https://clinicaltrials.gov/study/NCT04732598,https://clinicaltrials.gov/study/NCT00070564,https://clinicaltrials.gov/study/NCT01996267,https://clinicaltrials.gov/study/NCT03734029,https://clinicaltrials.gov/study/NCT03725059,https://clinicaltrials.gov/study/NCT02214381
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS6	NADH:ubiquinone oxidoreductase subunit S6	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL279785	MARIMASTAT	Small molecule	Matrix metalloproteinase 9 inhibitor		MMP9	matrix metallopeptidase 9	3	Completed	https://clinicaltrials.gov/study/NCT00003010
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Completed	https://clinicaltrials.gov/study/NCT00688740,https://clinicaltrials.gov/study/NCT00002707,https://clinicaltrials.gov/study/NCT04629846,https://clinicaltrials.gov/study/NCT00540800,https://clinicaltrials.gov/study/NCT01690702,https://clinicaltrials.gov/study/NCT02586025,https://clinicaltrials.gov/study/NCT00236899,https://clinicaltrials.gov/study/NCT00391092,https://clinicaltrials.gov/study/NCT00190489,https://clinicaltrials.gov/study/NCT00703326,https://clinicaltrials.gov/study/NCT00129935,https://clinicaltrials.gov/study/NCT00493870,https://clinicaltrials.gov/study/NCT00114816,https://clinicaltrials.gov/study/NCT00047099,https://clinicaltrials.gov/study/NCT00793377,https://clinicaltrials.gov/study/NCT01964391,https://clinicaltrials.gov/study/NCT02194166,https://clinicaltrials.gov/study/NCT00311636,https://clinicaltrials.gov/study/NCT00630032,https://clinicaltrials.gov/study/NCT00333775,https://clinicaltrials.gov/study/NCT00424606,https://clinicaltrials.gov/study/NCT01099436,https://clinicaltrials.gov/study/NCT00431080,https://clinicaltrials.gov/study/NCT00002662,https://clinicaltrials.gov/study/NCT00776724,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT01216111,https://clinicaltrials.gov/study/NCT03493854,https://clinicaltrials.gov/study/NCT00309556,https://clinicaltrials.gov/study/NCT00667251,https://clinicaltrials.gov/study/NCT00004125,https://clinicaltrials.gov/study/NCT00003782,https://clinicaltrials.gov/study/NCT01985724,https://clinicaltrials.gov/study/NCT05629949,https://clinicaltrials.gov/study/NCT00047255,https://clinicaltrials.gov/study/NCT03425656,https://clinicaltrials.gov/study/NCT02980965,https://clinicaltrials.gov/study/NCT02402712,https://clinicaltrials.gov/study/NCT02896855,https://clinicaltrials.gov/study/NCT00331097,https://clinicaltrials.gov/study/NCT01314833,https://clinicaltrials.gov/study/NCT03989037,https://clinicaltrials.gov/study/NCT00091442,https://clinicaltrials.gov/study/NCT00003519,https://clinicaltrials.gov/study/NCT00433589,https://clinicaltrials.gov/study/NCT00089479,https://clinicaltrials.gov/study/NCT00312208,https://clinicaltrials.gov/study/NCT00567554,https://clinicaltrials.gov/study/NCT00448591,https://clinicaltrials.gov/study/NCT00294385,https://clinicaltrials.gov/study/NCT04957212,https://clinicaltrials.gov/study/NCT00950300,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT00288002,https://clinicaltrials.gov/study/NCT02187744,https://clinicaltrials.gov/study/NCT00193011,https://clinicaltrials.gov/study/NCT01049425,https://clinicaltrials.gov/study/NCT05301010,https://clinicaltrials.gov/study/NCT00017095,https://clinicaltrials.gov/study/NCT00008411,https://clinicaltrials.gov/study/NCT00191152,https://clinicaltrials.gov/study/NCT00963729,https://clinicaltrials.gov/study/NCT03013504,https://clinicaltrials.gov/study/NCT00054587,https://clinicaltrials.gov/study/NCT00002544,https://clinicaltrials.gov/study/NCT03084237,https://clinicaltrials.gov/study/NCT02019277,https://clinicaltrials.gov/study/NCT01940497,https://clinicaltrials.gov/study/NCT00314977,https://clinicaltrials.gov/study/NCT02472964,https://clinicaltrials.gov/study/NCT00146549,https://clinicaltrials.gov/study/NCT00887536,https://clinicaltrials.gov/study/NCT00615602,https://clinicaltrials.gov/study/NCT00352378,https://clinicaltrials.gov/study/NCT04031703,https://clinicaltrials.gov/study/NCT02681003,https://clinicaltrials.gov/study/NCT02115204,https://clinicaltrials.gov/study/NCT04127019,https://clinicaltrials.gov/study/NCT01120184,https://clinicaltrials.gov/study/NCT00429871,https://clinicaltrials.gov/study/NCT00567190
EFO_1000984	inflammatory breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Completed	https://clinicaltrials.gov/study/NCT02324088
MONDO_0007254	breast cancer	CHEMBL513	CARMUSTINE	Small molecule	Glutathione reductase inhibitor		GSR	glutathione-disulfide reductase	3	Completed	https://clinicaltrials.gov/study/NCT00002836
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Completed	https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT03084939,https://clinicaltrials.gov/study/NCT01702571,https://clinicaltrials.gov/study/NCT01120184,https://clinicaltrials.gov/study/NCT00829166,https://clinicaltrials.gov/study/NCT03726879,https://clinicaltrials.gov/study/NCT01419197
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Unknown status	https://clinicaltrials.gov/study/NCT02393833,https://clinicaltrials.gov/study/NCT01479036,https://clinicaltrials.gov/study/NCT00532727,https://clinicaltrials.gov/study/NCT01642771,https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT00003679,https://clinicaltrials.gov/study/NCT00944424,https://clinicaltrials.gov/study/NCT01222052,https://clinicaltrials.gov/study/NCT00430001,https://clinicaltrials.gov/study/NCT00629278,https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT01547741,https://clinicaltrials.gov/study/NCT01622361,https://clinicaltrials.gov/study/NCT00010140,https://clinicaltrials.gov/study/NCT01354522
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT05172518,https://clinicaltrials.gov/study/NCT04665986,https://clinicaltrials.gov/study/NCT05838066
MONDO_0007254	breast cancer	CHEMBL3545262	SACITUZUMAB GOVITECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04639986
MONDO_0007254	breast cancer	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT04301739
MONDO_0004658	breast carcinoma in situ	CHEMBL902	FAMOTIDINE	Small molecule	Histamine H2 receptor antagonist		HRH2	histamine receptor H2	3	Recruiting	https://clinicaltrials.gov/study/NCT04862585
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT04665986,https://clinicaltrials.gov/study/NCT05838066,https://clinicaltrials.gov/study/NCT05172518
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Completed	https://clinicaltrials.gov/study/NCT00005970
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	3	Unknown status	https://clinicaltrials.gov/study/NCT00070278,https://clinicaltrials.gov/study/NCT00039546,https://clinicaltrials.gov/study/NCT00408408
MONDO_0007254	breast cancer	CHEMBL1042	CHOLECALCIFEROL	Small molecule	Vitamin D receptor agonist		VDR	vitamin D receptor	3	Unknown status	https://clinicaltrials.gov/study/NCT02786875
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC2	NADH:ubiquinone oxidoreductase subunit C2	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF1	NADH:ubiquinone oxidoreductase complex assembly factor 1	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Terminated	https://clinicaltrials.gov/study/NCT05134194,https://clinicaltrials.gov/study/NCT03786094
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	3	Terminated	https://clinicaltrials.gov/study/NCT00440622,https://clinicaltrials.gov/study/NCT05134194,https://clinicaltrials.gov/study/NCT02054338
MONDO_0007254	breast cancer	CHEMBL481	IRINOTECAN	Small molecule	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	3	Unknown status	https://clinicaltrials.gov/study/NCT01501669
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	3	Completed	https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT00938652,https://clinicaltrials.gov/study/NCT02555657,https://clinicaltrials.gov/study/NCT01287624,https://clinicaltrials.gov/study/NCT02574455,https://clinicaltrials.gov/study/NCT00191152,https://clinicaltrials.gov/study/NCT00670878,https://clinicaltrials.gov/study/NCT00006459,https://clinicaltrials.gov/study/NCT00294385,https://clinicaltrials.gov/study/NCT00236899,https://clinicaltrials.gov/study/NCT03901339,https://clinicaltrials.gov/study/NCT02546934,https://clinicaltrials.gov/study/NCT00561119,https://clinicaltrials.gov/study/NCT00431106,https://clinicaltrials.gov/study/NCT02819518
EFO_0000305	breast carcinoma	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Completed	https://clinicaltrials.gov/study/NCT01935492,https://clinicaltrials.gov/study/NCT00785291
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06079983
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06279364,https://clinicaltrials.gov/study/NCT05388500,https://clinicaltrials.gov/study/NCT04301739,https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT05172518,https://clinicaltrials.gov/study/NCT05841381,https://clinicaltrials.gov/study/NCT05753865
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	3	Completed	https://clinicaltrials.gov/study/NCT01234337
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Completed	https://clinicaltrials.gov/study/NCT00146549,https://clinicaltrials.gov/study/NCT01007942,https://clinicaltrials.gov/study/NCT03901339,https://clinicaltrials.gov/study/NCT00431106,https://clinicaltrials.gov/study/NCT00103233,https://clinicaltrials.gov/study/NCT02555657,https://clinicaltrials.gov/study/NCT00776724,https://clinicaltrials.gov/study/NCT02225470,https://clinicaltrials.gov/study/NCT02574455,https://clinicaltrials.gov/study/NCT00868634
MONDO_0007254	breast cancer	CHEMBL997	IBANDRONIC ACID	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	3	Completed	https://clinicaltrials.gov/study/NCT00196859,https://clinicaltrials.gov/study/NCT00127205
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase RAF inhibitor		RAF1	Raf-1 proto-oncogene, serine/threonine kinase	3	Completed	https://clinicaltrials.gov/study/NCT01234337
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Withdrawn	https://clinicaltrials.gov/study/NCT02929576
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03863223,https://clinicaltrials.gov/study/NCT03588091,https://clinicaltrials.gov/study/NCT02641847,https://clinicaltrials.gov/study/NCT01358877,https://clinicaltrials.gov/study/NCT04024462,https://clinicaltrials.gov/study/NCT01646034,https://clinicaltrials.gov/study/NCT02003209
MONDO_0007254	breast cancer	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	3	Terminated	https://clinicaltrials.gov/study/NCT03905343,https://clinicaltrials.gov/study/NCT03050398
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC1	histone deacetylase 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03538171
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Recruiting	https://clinicaltrials.gov/study/NCT06143553,https://clinicaltrials.gov/study/NCT04400695
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Recruiting	https://clinicaltrials.gov/study/NCT05894239
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF4	NADH:ubiquinone oxidoreductase complex assembly factor 4	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Terminated	https://clinicaltrials.gov/study/NCT03786094,https://clinicaltrials.gov/study/NCT05134194
EFO_0000304	breast adenocarcinoma	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Completed	https://clinicaltrials.gov/study/NCT00005970
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN10A	sodium voltage-gated channel alpha subunit 10	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01916317
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Recruiting	https://clinicaltrials.gov/study/NCT05382299,https://clinicaltrials.gov/study/NCT06103864,https://clinicaltrials.gov/study/NCT04547907,https://clinicaltrials.gov/study/NCT05555706,https://clinicaltrials.gov/study/NCT05814354,https://clinicaltrials.gov/study/NCT04335669,https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT03876886,https://clinicaltrials.gov/study/NCT06112379,https://clinicaltrials.gov/study/NCT04137653,https://clinicaltrials.gov/study/NCT03949634,https://clinicaltrials.gov/study/NCT05429684,https://clinicaltrials.gov/study/NCT05894239,https://clinicaltrials.gov/study/NCT06018337,https://clinicaltrials.gov/study/NCT05113251,https://clinicaltrials.gov/study/NCT05207709,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT05840211,https://clinicaltrials.gov/study/NCT04193059,https://clinicaltrials.gov/study/NCT04862585,https://clinicaltrials.gov/study/NCT05296798,https://clinicaltrials.gov/study/NCT05374512,https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT04540692,https://clinicaltrials.gov/study/NCT06143553
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Completed	https://clinicaltrials.gov/study/NCT00431106,https://clinicaltrials.gov/study/NCT02225470,https://clinicaltrials.gov/study/NCT01007942,https://clinicaltrials.gov/study/NCT00103233,https://clinicaltrials.gov/study/NCT00776724,https://clinicaltrials.gov/study/NCT00146549,https://clinicaltrials.gov/study/NCT00868634,https://clinicaltrials.gov/study/NCT03901339,https://clinicaltrials.gov/study/NCT02574455,https://clinicaltrials.gov/study/NCT02555657
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Withdrawn	https://clinicaltrials.gov/study/NCT03811418,https://clinicaltrials.gov/study/NCT05474690,https://clinicaltrials.gov/study/NCT00041171
MONDO_0007254	breast cancer	CHEMBL3545414	RIVOCERANIB MESYLATE	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT05889871
MONDO_0007254	breast cancer	CHEMBL1201247	GOSERELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	3	Unknown status	https://clinicaltrials.gov/study/NCT00002460,https://clinicaltrials.gov/study/NCT00912548,https://clinicaltrials.gov/study/NCT01352091
MONDO_0007254	breast cancer	CHEMBL4303669	ZOLEDRONIC ACID	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	3	Recruiting	https://clinicaltrials.gov/study/NCT05164952
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04148911,https://clinicaltrials.gov/study/NCT04085276
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT05382299,https://clinicaltrials.gov/study/NCT06268652,https://clinicaltrials.gov/study/NCT06103864,https://clinicaltrials.gov/study/NCT06143553,https://clinicaltrials.gov/study/NCT04722978,https://clinicaltrials.gov/study/NCT05814354
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN2A	sodium voltage-gated channel alpha subunit 2	3	Completed	https://clinicaltrials.gov/study/NCT04822597
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Completed	https://clinicaltrials.gov/study/NCT00668616,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT00567554,https://clinicaltrials.gov/study/NCT03498716,https://clinicaltrials.gov/study/NCT03337724,https://clinicaltrials.gov/study/NCT00146549,https://clinicaltrials.gov/study/NCT01901146,https://clinicaltrials.gov/study/NCT00513292,https://clinicaltrials.gov/study/NCT01433614,https://clinicaltrials.gov/study/NCT00448591,https://clinicaltrials.gov/study/NCT00038402,https://clinicaltrials.gov/study/NCT04109066,https://clinicaltrials.gov/study/NCT00311636,https://clinicaltrials.gov/study/NCT00544232,https://clinicaltrials.gov/study/NCT00129922,https://clinicaltrials.gov/study/NCT01822314,https://clinicaltrials.gov/study/NCT00667251,https://clinicaltrials.gov/study/NCT01764022,https://clinicaltrials.gov/study/NCT01216111,https://clinicaltrials.gov/study/NCT00004067,https://clinicaltrials.gov/study/NCT00129389,https://clinicaltrials.gov/study/NCT01131195,https://clinicaltrials.gov/study/NCT00876486,https://clinicaltrials.gov/study/NCT00431080,https://clinicaltrials.gov/study/NCT01940497,https://clinicaltrials.gov/study/NCT03493854,https://clinicaltrials.gov/study/NCT00014222,https://clinicaltrials.gov/study/NCT02472964,https://clinicaltrials.gov/study/NCT00196872,https://clinicaltrials.gov/study/NCT01287624,https://clinicaltrials.gov/study/NCT00003440,https://clinicaltrials.gov/study/NCT02819518,https://clinicaltrials.gov/study/NCT01663727,https://clinicaltrials.gov/study/NCT00236899,https://clinicaltrials.gov/study/NCT01644890,https://clinicaltrials.gov/study/NCT00028990,https://clinicaltrials.gov/study/NCT00561119,https://clinicaltrials.gov/study/NCT01314833,https://clinicaltrials.gov/study/NCT01998906,https://clinicaltrials.gov/study/NCT00006459,https://clinicaltrials.gov/study/NCT00003013,https://clinicaltrials.gov/study/NCT00016406,https://clinicaltrials.gov/study/NCT00003972,https://clinicaltrials.gov/study/NCT01526369,https://clinicaltrials.gov/study/NCT00004125,https://clinicaltrials.gov/study/NCT01989676,https://clinicaltrials.gov/study/NCT00002953,https://clinicaltrials.gov/study/NCT00876395,https://clinicaltrials.gov/study/NCT00002662,https://clinicaltrials.gov/study/NCT02163694,https://clinicaltrials.gov/study/NCT02450058,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT02194166,https://clinicaltrials.gov/study/NCT01964391,https://clinicaltrials.gov/study/NCT02425891,https://clinicaltrials.gov/study/NCT03462251,https://clinicaltrials.gov/study/NCT00003088,https://clinicaltrials.gov/study/NCT00041119,https://clinicaltrials.gov/study/NCT00336791,https://clinicaltrials.gov/study/NCT03556358,https://clinicaltrials.gov/study/NCT00600340,https://clinicaltrials.gov/study/NCT03726879,https://clinicaltrials.gov/study/NCT02594371,https://clinicaltrials.gov/study/NCT04127019,https://clinicaltrials.gov/study/NCT02019277,https://clinicaltrials.gov/study/NCT01690702,https://clinicaltrials.gov/study/NCT00789581,https://clinicaltrials.gov/study/NCT02032277,https://clinicaltrials.gov/study/NCT04031703,https://clinicaltrials.gov/study/NCT01120184
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06279364,https://clinicaltrials.gov/study/NCT04301739,https://clinicaltrials.gov/study/NCT05841381,https://clinicaltrials.gov/study/NCT05172518,https://clinicaltrials.gov/study/NCT05388500,https://clinicaltrials.gov/study/NCT05753865
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Recruiting	https://clinicaltrials.gov/study/NCT02488967
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT06343948,https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06081959,https://clinicaltrials.gov/study/NCT06279364
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Recruiting	https://clinicaltrials.gov/study/NCT05760378
MONDO_0007254	breast cancer	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	3	Recruiting	https://clinicaltrials.gov/study/NCT04862663,https://clinicaltrials.gov/study/NCT05827081,https://clinicaltrials.gov/study/NCT04964934,https://clinicaltrials.gov/study/NCT05207709,https://clinicaltrials.gov/study/NCT04055493,https://clinicaltrials.gov/study/NCT02344472
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBA4A	tubulin alpha 4a	3	Completed	https://clinicaltrials.gov/study/NCT01953003,https://clinicaltrials.gov/study/NCT01095003,https://clinicaltrials.gov/study/NCT01091168
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Terminated	https://clinicaltrials.gov/study/NCT02730091,https://clinicaltrials.gov/study/NCT05134194
MONDO_0007254	breast cancer	CHEMBL359744	DOXORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Terminated	https://clinicaltrials.gov/study/NCT00296010,https://clinicaltrials.gov/study/NCT00002772
EFO_0000304	breast adenocarcinoma	CHEMBL359744	DOXORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Recruiting	https://clinicaltrials.gov/study/NCT02488967
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04799249
EFO_1000984	inflammatory breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Completed	https://clinicaltrials.gov/study/NCT02324088
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR2	estrogen receptor 2	3	Completed	https://clinicaltrials.gov/study/NCT00390455
EFO_1000984	inflammatory breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Completed	https://clinicaltrials.gov/study/NCT02324088
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	3	Terminated	https://clinicaltrials.gov/study/NCT00440622,https://clinicaltrials.gov/study/NCT02054338,https://clinicaltrials.gov/study/NCT05134194
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06343948,https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06081959
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT02819518,https://clinicaltrials.gov/study/NCT02555657,https://clinicaltrials.gov/study/NCT03901339,https://clinicaltrials.gov/study/NCT00938652,https://clinicaltrials.gov/study/NCT01287624,https://clinicaltrials.gov/study/NCT00670878,https://clinicaltrials.gov/study/NCT02546934,https://clinicaltrials.gov/study/NCT00191152,https://clinicaltrials.gov/study/NCT00006459,https://clinicaltrials.gov/study/NCT02574455,https://clinicaltrials.gov/study/NCT00294385,https://clinicaltrials.gov/study/NCT00236899,https://clinicaltrials.gov/study/NCT00561119,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT00431106
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Completed	https://clinicaltrials.gov/study/NCT00703326,https://clinicaltrials.gov/study/NCT00311636,https://clinicaltrials.gov/study/NCT00309556,https://clinicaltrials.gov/study/NCT02472964,https://clinicaltrials.gov/study/NCT02019277,https://clinicaltrials.gov/study/NCT00054587,https://clinicaltrials.gov/study/NCT04031703,https://clinicaltrials.gov/study/NCT00887536,https://clinicaltrials.gov/study/NCT00331097,https://clinicaltrials.gov/study/NCT00004125,https://clinicaltrials.gov/study/NCT04957212,https://clinicaltrials.gov/study/NCT02115204,https://clinicaltrials.gov/study/NCT00493870,https://clinicaltrials.gov/study/NCT01314833,https://clinicaltrials.gov/study/NCT01216111,https://clinicaltrials.gov/study/NCT00950300,https://clinicaltrials.gov/study/NCT00008411,https://clinicaltrials.gov/study/NCT00688740,https://clinicaltrials.gov/study/NCT00312208,https://clinicaltrials.gov/study/NCT00191152,https://clinicaltrials.gov/study/NCT00002707,https://clinicaltrials.gov/study/NCT02194166,https://clinicaltrials.gov/study/NCT02402712,https://clinicaltrials.gov/study/NCT01964391,https://clinicaltrials.gov/study/NCT02586025,https://clinicaltrials.gov/study/NCT04127019,https://clinicaltrials.gov/study/NCT00793377,https://clinicaltrials.gov/study/NCT01985724,https://clinicaltrials.gov/study/NCT02980965,https://clinicaltrials.gov/study/NCT00615602,https://clinicaltrials.gov/study/NCT01940497,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT00002544,https://clinicaltrials.gov/study/NCT05301010,https://clinicaltrials.gov/study/NCT00424606,https://clinicaltrials.gov/study/NCT00433589,https://clinicaltrials.gov/study/NCT03989037,https://clinicaltrials.gov/study/NCT02896855,https://clinicaltrials.gov/study/NCT00391092,https://clinicaltrials.gov/study/NCT01690702,https://clinicaltrials.gov/study/NCT03084237,https://clinicaltrials.gov/study/NCT00114816,https://clinicaltrials.gov/study/NCT03425656,https://clinicaltrials.gov/study/NCT04629846,https://clinicaltrials.gov/study/NCT00448591,https://clinicaltrials.gov/study/NCT00047099,https://clinicaltrials.gov/study/NCT00567190,https://clinicaltrials.gov/study/NCT00190489,https://clinicaltrials.gov/study/NCT00017095,https://clinicaltrials.gov/study/NCT00429871,https://clinicaltrials.gov/study/NCT00091442,https://clinicaltrials.gov/study/NCT00288002,https://clinicaltrials.gov/study/NCT03013504,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT00314977,https://clinicaltrials.gov/study/NCT01120184,https://clinicaltrials.gov/study/NCT00089479,https://clinicaltrials.gov/study/NCT00667251,https://clinicaltrials.gov/study/NCT00630032,https://clinicaltrials.gov/study/NCT01049425,https://clinicaltrials.gov/study/NCT00431080,https://clinicaltrials.gov/study/NCT00333775,https://clinicaltrials.gov/study/NCT00129935,https://clinicaltrials.gov/study/NCT00236899,https://clinicaltrials.gov/study/NCT00047255,https://clinicaltrials.gov/study/NCT05629949,https://clinicaltrials.gov/study/NCT00294385,https://clinicaltrials.gov/study/NCT00963729,https://clinicaltrials.gov/study/NCT00352378,https://clinicaltrials.gov/study/NCT00146549,https://clinicaltrials.gov/study/NCT00540800,https://clinicaltrials.gov/study/NCT00003782,https://clinicaltrials.gov/study/NCT01099436,https://clinicaltrials.gov/study/NCT00193011,https://clinicaltrials.gov/study/NCT00776724,https://clinicaltrials.gov/study/NCT00567554,https://clinicaltrials.gov/study/NCT02187744,https://clinicaltrials.gov/study/NCT02681003,https://clinicaltrials.gov/study/NCT00002662,https://clinicaltrials.gov/study/NCT03493854,https://clinicaltrials.gov/study/NCT00003519
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Terminated	https://clinicaltrials.gov/study/NCT00016276
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT06279364,https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06081959,https://clinicaltrials.gov/study/NCT06343948
MONDO_0007254	breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03155997,https://clinicaltrials.gov/study/NCT02763566,https://clinicaltrials.gov/study/NCT02246621
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Recruiting	https://clinicaltrials.gov/study/NCT04307147,https://clinicaltrials.gov/study/NCT06268652,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT06143553
MONDO_0007254	breast cancer	CHEMBL3647420	PYROTINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Unknown status	https://clinicaltrials.gov/study/NCT03080805
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
MONDO_0007254	breast cancer	CHEMBL3989569	IBANDRONATE SODIUM	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	3	Unknown status	https://clinicaltrials.gov/study/NCT00326820
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06079983
EFO_0000305	breast carcinoma	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Completed	https://clinicaltrials.gov/study/NCT01935492
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF1	NADH:ubiquinone oxidoreductase complex assembly factor 1	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL34259	METHOTREXATE	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	3	Terminated	https://clinicaltrials.gov/study/NCT00296010
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Completed	https://clinicaltrials.gov/study/NCT00005970
EFO_0000186	invasive breast ductal carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Completed	https://clinicaltrials.gov/study/NCT02620280
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT05063786,https://clinicaltrials.gov/study/NCT04639986,https://clinicaltrials.gov/study/NCT05104866,https://clinicaltrials.gov/study/NCT03734029
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Unknown status	https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT00430001
MONDO_0007254	breast cancer	CHEMBL38	TRETINOIN	Small molecule	Retinoic acid receptor agonist		RARG	retinoic acid receptor gamma	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT05016349
EFO_0000305	breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Completed	https://clinicaltrials.gov/study/NCT00785291
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885,https://clinicaltrials.gov/study/NCT01275677,https://clinicaltrials.gov/study/NCT02003209
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN5A	sodium voltage-gated channel alpha subunit 5	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01916317
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Recruiting	https://clinicaltrials.gov/study/NCT05760378
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Recruiting	https://clinicaltrials.gov/study/NCT05760378
MONDO_0007254	breast cancer	CHEMBL1201199	LEUPROLIDE	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	3	Recruiting	https://clinicaltrials.gov/study/NCT05891093,https://clinicaltrials.gov/study/NCT03664895,https://clinicaltrials.gov/study/NCT05827081,https://clinicaltrials.gov/study/NCT05306340,https://clinicaltrials.gov/study/NCT05296798,https://clinicaltrials.gov/study/NCT02914158,https://clinicaltrials.gov/study/NCT04964934,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT04961996
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Recruiting	https://clinicaltrials.gov/study/NCT06265428,https://clinicaltrials.gov/study/NCT04457596,https://clinicaltrials.gov/study/NCT05288777,https://clinicaltrials.gov/study/NCT03975647,https://clinicaltrials.gov/study/NCT04873362,https://clinicaltrials.gov/study/NCT05755048,https://clinicaltrials.gov/study/NCT05429684
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04639986
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV1	NADH:ubiquinone oxidoreductase core subunit V1	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Terminated	https://clinicaltrials.gov/study/NCT02144012
MONDO_0007254	breast cancer	CHEMBL778	DEXMEDETOMIDINE	Small molecule	Adrenergic receptor alpha-2 agonist		ADRA2B	adrenoceptor alpha 2B	3	Unknown status	https://clinicaltrials.gov/study/NCT03063073,https://clinicaltrials.gov/study/NCT03046238
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R2	phosphoinositide-3-kinase regulatory subunit 2	3	Terminated	https://clinicaltrials.gov/study/NCT02340221
EFO_0000304	breast adenocarcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC3	histone deacetylase 3	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02115282
EFO_0000304	breast adenocarcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC11	histone deacetylase 11	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02115282
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885,https://clinicaltrials.gov/study/NCT01275677
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL3989868	TUCATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Recruiting	https://clinicaltrials.gov/study/NCT04457596
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02221999
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB10	NADH:ubiquinone oxidoreductase subunit B10	3	Completed	https://clinicaltrials.gov/study/NCT01101438
EFO_0000304	breast adenocarcinoma	CHEMBL1201583	BEVACIZUMAB	Antibody	Vascular endothelial growth factor A inhibitor		VEGFA	vascular endothelial growth factor A	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00433511
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT04665986,https://clinicaltrials.gov/study/NCT05901935
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	3	Terminated	https://clinicaltrials.gov/study/NCT02054338,https://clinicaltrials.gov/study/NCT00440622,https://clinicaltrials.gov/study/NCT05134194
EFO_0006861	male breast carcinoma	CHEMBL554	LAPATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00770809
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
MONDO_0007254	breast cancer	CHEMBL675	ALENDRONATE SODIUM	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	3	Completed	https://clinicaltrials.gov/study/NCT00122356
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	3	Completed	https://clinicaltrials.gov/study/NCT01610284
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
EFO_0000305	breast carcinoma	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652
MONDO_0007254	breast cancer	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN10A	sodium voltage-gated channel alpha subunit 10	3	Completed	https://clinicaltrials.gov/study/NCT00547989,https://clinicaltrials.gov/study/NCT02408393,https://clinicaltrials.gov/study/NCT04327063
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Recruiting	https://clinicaltrials.gov/study/NCT05760378
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Withdrawn	https://clinicaltrials.gov/study/NCT03811418
MONDO_0007254	breast cancer	CHEMBL4297950	BENEGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	3	Completed	https://clinicaltrials.gov/study/NCT04174599
MONDO_0007254	breast cancer	CHEMBL1680	OCTREOTIDE	Protein	Somatostatin receptor agonist		SSTR3	somatostatin receptor 3	3	Completed	https://clinicaltrials.gov/study/NCT00002967,https://clinicaltrials.gov/study/NCT00002864
MONDO_0007254	breast cancer	CHEMBL1655	TOREMIFENE	Small molecule	Estrogen receptor modulator		ESR2	estrogen receptor 2	3	Recruiting	https://clinicaltrials.gov/study/NCT02097459,https://clinicaltrials.gov/study/NCT05891093,https://clinicaltrials.gov/study/NCT03351062
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Terminated	https://clinicaltrials.gov/study/NCT02144012
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA9	NADH:ubiquinone oxidoreductase subunit A9	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL1201179	LAPATINIB DITOSYLATE	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01104571
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT06255392
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT06143553
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01772472,https://clinicaltrials.gov/study/NCT03529110,https://clinicaltrials.gov/study/NCT04740918,https://clinicaltrials.gov/study/NCT04622319
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Recruiting	https://clinicaltrials.gov/study/NCT03671044,https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT05673629,https://clinicaltrials.gov/study/NCT04547907,https://clinicaltrials.gov/study/NCT04193059,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT05894239,https://clinicaltrials.gov/study/NCT05430399,https://clinicaltrials.gov/study/NCT05901428,https://clinicaltrials.gov/study/NCT05883852,https://clinicaltrials.gov/study/NCT04540692,https://clinicaltrials.gov/study/NCT05159193,https://clinicaltrials.gov/study/NCT03926091,https://clinicaltrials.gov/study/NCT05720026,https://clinicaltrials.gov/study/NCT05296798,https://clinicaltrials.gov/study/NCT05207514,https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT03949634
MONDO_0007254	breast cancer	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	3	Unknown status	https://clinicaltrials.gov/study/NCT00003680,https://clinicaltrials.gov/study/NCT00629278,https://clinicaltrials.gov/study/NCT00010140,https://clinicaltrials.gov/study/NCT00963209,https://clinicaltrials.gov/study/NCT01758146,https://clinicaltrials.gov/study/NCT00003418,https://clinicaltrials.gov/study/NCT00003679,https://clinicaltrials.gov/study/NCT00912548,https://clinicaltrials.gov/study/NCT00541086,https://clinicaltrials.gov/study/NCT00003016,https://clinicaltrials.gov/study/NCT00893061,https://clinicaltrials.gov/study/NCT01622361,https://clinicaltrials.gov/study/NCT00006030,https://clinicaltrials.gov/study/NCT00002460,https://clinicaltrials.gov/study/NCT00003678
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4L	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT05814354,https://clinicaltrials.gov/study/NCT06103864,https://clinicaltrials.gov/study/NCT06268652,https://clinicaltrials.gov/study/NCT06143553,https://clinicaltrials.gov/study/NCT05382299,https://clinicaltrials.gov/study/NCT04722978
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Completed	https://clinicaltrials.gov/study/NCT00191152
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Suspended	https://clinicaltrials.gov/study/NCT03002103
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Completed	https://clinicaltrials.gov/study/NCT03125902,https://clinicaltrials.gov/study/NCT03197935,https://clinicaltrials.gov/study/NCT04177108
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	3	Suspended	https://clinicaltrials.gov/study/NCT03002103
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Withdrawn	https://clinicaltrials.gov/study/NCT05474690,https://clinicaltrials.gov/study/NCT00041171,https://clinicaltrials.gov/study/NCT03811418
MONDO_0007254	breast cancer	CHEMBL2325741	CAPIVASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT1	AKT serine/threonine kinase 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04305496
EFO_1000984	inflammatory breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Completed	https://clinicaltrials.gov/study/NCT02324088
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03588091,https://clinicaltrials.gov/study/NCT03863223,https://clinicaltrials.gov/study/NCT04024462,https://clinicaltrials.gov/study/NCT02641847,https://clinicaltrials.gov/study/NCT01358877,https://clinicaltrials.gov/study/NCT01646034,https://clinicaltrials.gov/study/NCT02003209
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00433420,https://clinicaltrials.gov/study/NCT03315364,https://clinicaltrials.gov/study/NCT00070564,https://clinicaltrials.gov/study/NCT03725059,https://clinicaltrials.gov/study/NCT01646034,https://clinicaltrials.gov/study/NCT02214381,https://clinicaltrials.gov/study/NCT01358877,https://clinicaltrials.gov/study/NCT03595592,https://clinicaltrials.gov/study/NCT03734029,https://clinicaltrials.gov/study/NCT04494425,https://clinicaltrials.gov/study/NCT01996267,https://clinicaltrials.gov/study/NCT04732598,https://clinicaltrials.gov/study/NCT03168880
MONDO_0007254	breast cancer	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN3A	sodium voltage-gated channel alpha subunit 3	3	Completed	https://clinicaltrials.gov/study/NCT02408393,https://clinicaltrials.gov/study/NCT04327063,https://clinicaltrials.gov/study/NCT00547989
EFO_0000304	breast adenocarcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
MONDO_0007254	breast cancer	CHEMBL554	LAPATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	3	Completed	https://clinicaltrials.gov/study/NCT00667251,https://clinicaltrials.gov/study/NCT01808573,https://clinicaltrials.gov/study/NCT00567554,https://clinicaltrials.gov/study/NCT01619111,https://clinicaltrials.gov/study/NCT01526369,https://clinicaltrials.gov/study/NCT03084939,https://clinicaltrials.gov/study/NCT00078572,https://clinicaltrials.gov/study/NCT00829166
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00670878,https://clinicaltrials.gov/study/NCT00294385,https://clinicaltrials.gov/study/NCT00431106,https://clinicaltrials.gov/study/NCT00561119,https://clinicaltrials.gov/study/NCT00236899,https://clinicaltrials.gov/study/NCT02819518,https://clinicaltrials.gov/study/NCT00006459,https://clinicaltrials.gov/study/NCT01287624,https://clinicaltrials.gov/study/NCT03901339,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT02574455,https://clinicaltrials.gov/study/NCT02546934,https://clinicaltrials.gov/study/NCT00938652,https://clinicaltrials.gov/study/NCT02555657,https://clinicaltrials.gov/study/NCT00191152
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Recruiting	https://clinicaltrials.gov/study/NCT05207514,https://clinicaltrials.gov/study/NCT04193059,https://clinicaltrials.gov/study/NCT05430399,https://clinicaltrials.gov/study/NCT05296798,https://clinicaltrials.gov/study/NCT05883852,https://clinicaltrials.gov/study/NCT05673629,https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT03949634,https://clinicaltrials.gov/study/NCT05720026,https://clinicaltrials.gov/study/NCT03926091,https://clinicaltrials.gov/study/NCT05159193,https://clinicaltrials.gov/study/NCT05901428,https://clinicaltrials.gov/study/NCT03671044,https://clinicaltrials.gov/study/NCT05894239,https://clinicaltrials.gov/study/NCT04540692,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT04547907
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Unknown status	https://clinicaltrials.gov/study/NCT00430001,https://clinicaltrials.gov/study/NCT00003679,https://clinicaltrials.gov/study/NCT02393833,https://clinicaltrials.gov/study/NCT01642771,https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT01354522,https://clinicaltrials.gov/study/NCT01479036,https://clinicaltrials.gov/study/NCT01547741,https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT00629278,https://clinicaltrials.gov/study/NCT00944424,https://clinicaltrials.gov/study/NCT01622361,https://clinicaltrials.gov/study/NCT00532727,https://clinicaltrials.gov/study/NCT00010140,https://clinicaltrials.gov/study/NCT01222052
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652,https://clinicaltrials.gov/study/NCT05814354,https://clinicaltrials.gov/study/NCT05374512,https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT02344472
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL554	LAPATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Completed	https://clinicaltrials.gov/study/NCT00390455
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Completed	https://clinicaltrials.gov/study/NCT00191152
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02221999
MONDO_0007254	breast cancer	CHEMBL409	BICALUTAMIDE	Small molecule	Androgen Receptor antagonist		AR	androgen receptor	3	Terminated	https://clinicaltrials.gov/study/NCT03055312
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Unknown status	https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT00430001
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02641847,https://clinicaltrials.gov/study/NCT03588091,https://clinicaltrials.gov/study/NCT03863223,https://clinicaltrials.gov/study/NCT01646034,https://clinicaltrials.gov/study/NCT01358877,https://clinicaltrials.gov/study/NCT02003209,https://clinicaltrials.gov/study/NCT04024462
MONDO_0007254	breast cancer	CHEMBL160	CYCLOSPORINE	Protein	Cyclophilin A modulator		PPIA	peptidylprolyl isomerase A	3	Completed	https://clinicaltrials.gov/study/NCT00008203
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Completed	https://clinicaltrials.gov/study/NCT01091168,https://clinicaltrials.gov/study/NCT01095003,https://clinicaltrials.gov/study/NCT01953003
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06343948,https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT05901935,https://clinicaltrials.gov/study/NCT06081959,https://clinicaltrials.gov/study/NCT04665986
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB3	NADH:ubiquinone oxidoreductase subunit B3	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Completed	https://clinicaltrials.gov/study/NCT01419197,https://clinicaltrials.gov/study/NCT03084939,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT03726879,https://clinicaltrials.gov/study/NCT01702571,https://clinicaltrials.gov/study/NCT00829166,https://clinicaltrials.gov/study/NCT01120184
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Recruiting	https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT05374512,https://clinicaltrials.gov/study/NCT06268652,https://clinicaltrials.gov/study/NCT05814354
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06377852
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Withdrawn	https://clinicaltrials.gov/study/NCT03811418,https://clinicaltrials.gov/study/NCT00041171,https://clinicaltrials.gov/study/NCT05474690
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Suspended	https://clinicaltrials.gov/study/NCT03777579
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Terminated	https://clinicaltrials.gov/study/NCT00053911,https://clinicaltrials.gov/study/NCT02144012,https://clinicaltrials.gov/study/NCT00912444,https://clinicaltrials.gov/study/NCT00625898,https://clinicaltrials.gov/study/NCT01200212
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR1	estrogen receptor 1	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT04337658
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00770809
MONDO_0007254	breast cancer	CHEMBL1082407	ENZALUTAMIDE	Small molecule	Androgen Receptor antagonist		AR	androgen receptor	3	Withdrawn	https://clinicaltrials.gov/study/NCT02929576
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Completed	https://clinicaltrials.gov/study/NCT02472964,https://clinicaltrials.gov/study/NCT00567554,https://clinicaltrials.gov/study/NCT02019277,https://clinicaltrials.gov/study/NCT04031703,https://clinicaltrials.gov/study/NCT00312208,https://clinicaltrials.gov/study/NCT01120184,https://clinicaltrials.gov/study/NCT02194166,https://clinicaltrials.gov/study/NCT02402712,https://clinicaltrials.gov/study/NCT01099436,https://clinicaltrials.gov/study/NCT00002544,https://clinicaltrials.gov/study/NCT00314977,https://clinicaltrials.gov/study/NCT03989037,https://clinicaltrials.gov/study/NCT00887536,https://clinicaltrials.gov/study/NCT00294385,https://clinicaltrials.gov/study/NCT00236899,https://clinicaltrials.gov/study/NCT00003519,https://clinicaltrials.gov/study/NCT00091442,https://clinicaltrials.gov/study/NCT00391092,https://clinicaltrials.gov/study/NCT05629949,https://clinicaltrials.gov/study/NCT00002707,https://clinicaltrials.gov/study/NCT00004125,https://clinicaltrials.gov/study/NCT00047099,https://clinicaltrials.gov/study/NCT00129935,https://clinicaltrials.gov/study/NCT01314833,https://clinicaltrials.gov/study/NCT00429871,https://clinicaltrials.gov/study/NCT01964391,https://clinicaltrials.gov/study/NCT00448591,https://clinicaltrials.gov/study/NCT00288002,https://clinicaltrials.gov/study/NCT00114816,https://clinicaltrials.gov/study/NCT00352378,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT00493870,https://clinicaltrials.gov/study/NCT00667251,https://clinicaltrials.gov/study/NCT00688740,https://clinicaltrials.gov/study/NCT00776724,https://clinicaltrials.gov/study/NCT00963729,https://clinicaltrials.gov/study/NCT04127019,https://clinicaltrials.gov/study/NCT03013504,https://clinicaltrials.gov/study/NCT00311636,https://clinicaltrials.gov/study/NCT00309556,https://clinicaltrials.gov/study/NCT00615602,https://clinicaltrials.gov/study/NCT00002662,https://clinicaltrials.gov/study/NCT00146549,https://clinicaltrials.gov/study/NCT00424606,https://clinicaltrials.gov/study/NCT02586025,https://clinicaltrials.gov/study/NCT00950300,https://clinicaltrials.gov/study/NCT04957212,https://clinicaltrials.gov/study/NCT02115204,https://clinicaltrials.gov/study/NCT00054587,https://clinicaltrials.gov/study/NCT00333775,https://clinicaltrials.gov/study/NCT01049425,https://clinicaltrials.gov/study/NCT00431080,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT00191152,https://clinicaltrials.gov/study/NCT00047255,https://clinicaltrials.gov/study/NCT03084237,https://clinicaltrials.gov/study/NCT02187744,https://clinicaltrials.gov/study/NCT00703326,https://clinicaltrials.gov/study/NCT00008411,https://clinicaltrials.gov/study/NCT00190489,https://clinicaltrials.gov/study/NCT03425656,https://clinicaltrials.gov/study/NCT02681003,https://clinicaltrials.gov/study/NCT00540800,https://clinicaltrials.gov/study/NCT00193011,https://clinicaltrials.gov/study/NCT00017095,https://clinicaltrials.gov/study/NCT00433589,https://clinicaltrials.gov/study/NCT00003782,https://clinicaltrials.gov/study/NCT00793377,https://clinicaltrials.gov/study/NCT01940497,https://clinicaltrials.gov/study/NCT01985724,https://clinicaltrials.gov/study/NCT03493854,https://clinicaltrials.gov/study/NCT00089479,https://clinicaltrials.gov/study/NCT02896855,https://clinicaltrials.gov/study/NCT04629846,https://clinicaltrials.gov/study/NCT00331097,https://clinicaltrials.gov/study/NCT02980965,https://clinicaltrials.gov/study/NCT01690702,https://clinicaltrials.gov/study/NCT05301010,https://clinicaltrials.gov/study/NCT00567190,https://clinicaltrials.gov/study/NCT00630032,https://clinicaltrials.gov/study/NCT01216111
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Terminated	https://clinicaltrials.gov/study/NCT00625898,https://clinicaltrials.gov/study/NCT01200212,https://clinicaltrials.gov/study/NCT00912444,https://clinicaltrials.gov/study/NCT00053911,https://clinicaltrials.gov/study/NCT02144012
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00770809
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBA1C	tubulin alpha 1c	3	Completed	https://clinicaltrials.gov/study/NCT01095003,https://clinicaltrials.gov/study/NCT01953003,https://clinicaltrials.gov/study/NCT01091168
MONDO_0007254	breast cancer	CHEMBL1237023	DENOSUMAB	Antibody	Tumor necrosis factor ligand superfamily member 11 inhibitor		TNFSF11	TNF superfamily member 11	3	Terminated	https://clinicaltrials.gov/study/NCT01077154
EFO_1000984	inflammatory breast carcinoma	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	3	Terminated	https://clinicaltrials.gov/study/NCT00016276
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Completed	https://clinicaltrials.gov/study/NCT00191152
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02641847,https://clinicaltrials.gov/study/NCT03588091,https://clinicaltrials.gov/study/NCT03863223,https://clinicaltrials.gov/study/NCT01646034,https://clinicaltrials.gov/study/NCT01358877,https://clinicaltrials.gov/study/NCT04024462,https://clinicaltrials.gov/study/NCT02003209
MONDO_0007254	breast cancer	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN9A	sodium voltage-gated channel alpha subunit 9	3	Terminated	https://clinicaltrials.gov/study/NCT02525211
MONDO_0007254	breast cancer	CHEMBL18901	EFAPROXIRAL	Small molecule	Hemoglobin HbA negative modulator		HBA1	hemoglobin subunit alpha 1	3	Completed	https://clinicaltrials.gov/study/NCT00083304
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN7A	sodium voltage-gated channel alpha subunit 7	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01916317
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT04665986,https://clinicaltrials.gov/study/NCT05172518,https://clinicaltrials.gov/study/NCT05838066
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
MONDO_0004658	breast carcinoma in situ	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Recruiting	https://clinicaltrials.gov/study/NCT04862585
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC5	histone deacetylase 5	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03538171
EFO_0005537	triple-negative breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	3	Recruiting	https://clinicaltrials.gov/study/NCT05760378
EFO_1000984	inflammatory breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT05415215
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Completed	https://clinicaltrials.gov/study/NCT00005970
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Recruiting	https://clinicaltrials.gov/study/NCT05760378
MONDO_0007254	breast cancer	CHEMBL4279455	LAROTAXEL	Small molecule	Tubulin stabiliser		TUBB4B	tubulin beta 4B class IVb	3	Completed	https://clinicaltrials.gov/study/NCT00081796
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT06255392
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA7	NADH:ubiquinone oxidoreductase subunit A7	3	Completed	https://clinicaltrials.gov/study/NCT01101438
EFO_0000186	invasive breast ductal carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Completed	https://clinicaltrials.gov/study/NCT02620280
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB2	NADH:ubiquinone oxidoreductase subunit B2	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT00561119,https://clinicaltrials.gov/study/NCT00938652,https://clinicaltrials.gov/study/NCT01287624,https://clinicaltrials.gov/study/NCT00431106,https://clinicaltrials.gov/study/NCT03901339,https://clinicaltrials.gov/study/NCT02574455,https://clinicaltrials.gov/study/NCT02546934,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT02555657,https://clinicaltrials.gov/study/NCT00006459,https://clinicaltrials.gov/study/NCT02819518,https://clinicaltrials.gov/study/NCT00670878,https://clinicaltrials.gov/study/NCT00191152,https://clinicaltrials.gov/study/NCT00294385,https://clinicaltrials.gov/study/NCT00236899
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC2	histone deacetylase 2	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03538171
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	3	Recruiting	https://clinicaltrials.gov/study/NCT06143553
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	3	Recruiting	https://clinicaltrials.gov/study/NCT05755048,https://clinicaltrials.gov/study/NCT04457596,https://clinicaltrials.gov/study/NCT05288777,https://clinicaltrials.gov/study/NCT05429684,https://clinicaltrials.gov/study/NCT03975647,https://clinicaltrials.gov/study/NCT06265428,https://clinicaltrials.gov/study/NCT04873362
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Recruiting	https://clinicaltrials.gov/study/NCT02488967
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04740918,https://clinicaltrials.gov/study/NCT03529110,https://clinicaltrials.gov/study/NCT01772472,https://clinicaltrials.gov/study/NCT04622319
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL554	LAPATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	3	Completed	https://clinicaltrials.gov/study/NCT00390455
MONDO_0007254	breast cancer	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Recruiting	https://clinicaltrials.gov/study/NCT05760612,https://clinicaltrials.gov/study/NCT04873362,https://clinicaltrials.gov/study/NCT05429684,https://clinicaltrials.gov/study/NCT04193059,https://clinicaltrials.gov/study/NCT05132582,https://clinicaltrials.gov/study/NCT05346861,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT05159193,https://clinicaltrials.gov/study/NCT05883852,https://clinicaltrials.gov/study/NCT04547907,https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT05113251,https://clinicaltrials.gov/study/NCT05720026,https://clinicaltrials.gov/study/NCT06278870
MONDO_0004658	breast carcinoma in situ	CHEMBL30	CIMETIDINE	Small molecule	Histamine H2 receptor antagonist		HRH2	histamine receptor H2	3	Recruiting	https://clinicaltrials.gov/study/NCT04862585
MONDO_0007254	breast cancer	CHEMBL547	ISOTRETINOIN	Small molecule	Retinoic acid receptor agonist		RARB	retinoic acid receptor beta	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT05016349
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Recruiting	https://clinicaltrials.gov/study/NCT06058377,https://clinicaltrials.gov/study/NCT03201861,https://clinicaltrials.gov/study/NCT04862585,https://clinicaltrials.gov/study/NCT05747794
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Terminated	https://clinicaltrials.gov/study/NCT00016276
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL554	LAPATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03500380
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Completed	https://clinicaltrials.gov/study/NCT00337103,https://clinicaltrials.gov/study/NCT02574455,https://clinicaltrials.gov/study/NCT02555657,https://clinicaltrials.gov/study/NCT02225470,https://clinicaltrials.gov/study/NCT00388726,https://clinicaltrials.gov/study/NCT03901339
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Unknown status	https://clinicaltrials.gov/study/NCT01547741,https://clinicaltrials.gov/study/NCT00003679,https://clinicaltrials.gov/study/NCT01479036,https://clinicaltrials.gov/study/NCT01622361,https://clinicaltrials.gov/study/NCT00532727,https://clinicaltrials.gov/study/NCT01642771,https://clinicaltrials.gov/study/NCT01354522,https://clinicaltrials.gov/study/NCT00629278,https://clinicaltrials.gov/study/NCT00944424,https://clinicaltrials.gov/study/NCT00430001,https://clinicaltrials.gov/study/NCT00010140,https://clinicaltrials.gov/study/NCT02393833,https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT01222052
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Completed	https://clinicaltrials.gov/study/NCT00191152
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT04665986,https://clinicaltrials.gov/study/NCT05901935
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	3	Terminated	https://clinicaltrials.gov/study/NCT02340221
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Recruiting	https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT05814354,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT05374512,https://clinicaltrials.gov/study/NCT06268652
MONDO_0007254	breast cancer	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06377852
EFO_0000304	breast adenocarcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04799249
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Recruiting	https://clinicaltrials.gov/study/NCT05862064,https://clinicaltrials.gov/study/NCT04296175
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	3	Completed	https://clinicaltrials.gov/study/NCT01234337
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00006459
MONDO_0007254	breast cancer	CHEMBL1201670	SARGRAMOSTIM	Protein	Granulocyte-macrophage colony-stimulating factor receptor agonist		CSF2RA	colony stimulating factor 2 receptor subunit alpha	3	Completed	https://clinicaltrials.gov/study/NCT00003972,https://clinicaltrials.gov/study/NCT01479244
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06343948,https://clinicaltrials.gov/study/NCT06081959,https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT05901935,https://clinicaltrials.gov/study/NCT04665986,https://clinicaltrials.gov/study/NCT06079983
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03588091,https://clinicaltrials.gov/study/NCT02641847,https://clinicaltrials.gov/study/NCT04024462,https://clinicaltrials.gov/study/NCT02003209,https://clinicaltrials.gov/study/NCT03863223,https://clinicaltrials.gov/study/NCT01358877,https://clinicaltrials.gov/study/NCT01646034
EFO_0000304	breast adenocarcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	3	Completed	https://clinicaltrials.gov/study/NCT01864746,https://clinicaltrials.gov/study/NCT02600923,https://clinicaltrials.gov/study/NCT03969121,https://clinicaltrials.gov/study/NCT02028507,https://clinicaltrials.gov/study/NCT01942135
MONDO_0007254	breast cancer	CHEMBL45	MELATONIN	Small molecule	Melatonin receptor agonist		MTNR1A	melatonin receptor 1A	3	Terminated	https://clinicaltrials.gov/study/NCT02332928
MONDO_0007254	breast cancer	CHEMBL2396661	ALPELISIB	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	3	Completed	https://clinicaltrials.gov/study/NCT03439046,https://clinicaltrials.gov/study/NCT02437318
MONDO_0007254	breast cancer	CHEMBL279785	MARIMASTAT	Small molecule	Matrix metalloproteinase 3 inhibitor		MMP3	matrix metallopeptidase 3	3	Completed	https://clinicaltrials.gov/study/NCT00003010
MONDO_0007254	breast cancer	CHEMBL554	LAPATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	3	Recruiting	https://clinicaltrials.gov/study/NCT06313983,https://clinicaltrials.gov/study/NCT05122494
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR1	estrogen receptor 1	3	Terminated	https://clinicaltrials.gov/study/NCT01633060,https://clinicaltrials.gov/study/NCT04060862,https://clinicaltrials.gov/study/NCT02137837,https://clinicaltrials.gov/study/NCT00543127,https://clinicaltrials.gov/study/NCT00010153,https://clinicaltrials.gov/study/NCT02340221,https://clinicaltrials.gov/study/NCT05065411
EFO_1000984	inflammatory breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Completed	https://clinicaltrials.gov/study/NCT02324088
EFO_0000304	breast adenocarcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
MONDO_0007254	breast cancer	CHEMBL4297840	TISLELIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	3	Recruiting	https://clinicaltrials.gov/study/NCT05207709
MONDO_0007254	breast cancer	CHEMBL1201649	ESTROGENS, CONJUGATED	Unknown	Estrogen receptor agonist		ESR1	estrogen receptor 1	3	Terminated	https://clinicaltrials.gov/study/NCT00193726
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Terminated	https://clinicaltrials.gov/study/NCT02730091,https://clinicaltrials.gov/study/NCT05134194
EFO_0000304	breast adenocarcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT05104866,https://clinicaltrials.gov/study/NCT05063786,https://clinicaltrials.gov/study/NCT04639986
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAB1	NADH:ubiquinone oxidoreductase subunit AB1	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL359744	DOXORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Recruiting	https://clinicaltrials.gov/study/NCT03949634
MONDO_0007254	breast cancer	CHEMBL4279455	LAROTAXEL	Small molecule	Tubulin stabiliser		TUBB8	tubulin beta 8 class VIII	3	Completed	https://clinicaltrials.gov/study/NCT00081796
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Completed	https://clinicaltrials.gov/study/NCT00191152
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Completed	https://clinicaltrials.gov/study/NCT00388726,https://clinicaltrials.gov/study/NCT02225470,https://clinicaltrials.gov/study/NCT00337103
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Unknown status	https://clinicaltrials.gov/study/NCT02879513
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Completed	https://clinicaltrials.gov/study/NCT00388726,https://clinicaltrials.gov/study/NCT00337103,https://clinicaltrials.gov/study/NCT02225470
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Withdrawn	https://clinicaltrials.gov/study/NCT02929576
MONDO_0007254	breast cancer	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Unknown status	https://clinicaltrials.gov/study/NCT01204801,https://clinicaltrials.gov/study/NCT01547741,https://clinicaltrials.gov/study/NCT00003679,https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT02393833,https://clinicaltrials.gov/study/NCT00294996,https://clinicaltrials.gov/study/NCT00516425,https://clinicaltrials.gov/study/NCT00629278,https://clinicaltrials.gov/study/NCT01622361,https://clinicaltrials.gov/study/NCT01354522,https://clinicaltrials.gov/study/NCT00486668
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	3	Completed	https://clinicaltrials.gov/study/NCT03286842
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	3	Terminated	https://clinicaltrials.gov/study/NCT05134194,https://clinicaltrials.gov/study/NCT00440622,https://clinicaltrials.gov/study/NCT02054338
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB5	NADH:ubiquinone oxidoreductase subunit B5	3	Completed	https://clinicaltrials.gov/study/NCT01101438
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01275677,https://clinicaltrials.gov/study/NCT02003209,https://clinicaltrials.gov/study/NCT03199885
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT05382299,https://clinicaltrials.gov/study/NCT06143553,https://clinicaltrials.gov/study/NCT05814354,https://clinicaltrials.gov/study/NCT04722978,https://clinicaltrials.gov/study/NCT06268652,https://clinicaltrials.gov/study/NCT06103864
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Completed	https://clinicaltrials.gov/study/NCT00785291,https://clinicaltrials.gov/study/NCT01935492
MONDO_0007254	breast cancer	CHEMBL3545262	SACITUZUMAB GOVITECAN	Antibody drug conjugate	Tumor-associated calcium signal transducer 2 binding agent		TACSTD2	tumor associated calcium signal transducer 2	3	Recruiting	https://clinicaltrials.gov/study/NCT05633654,https://clinicaltrials.gov/study/NCT05840211,https://clinicaltrials.gov/study/NCT05552001,https://clinicaltrials.gov/study/NCT05382299,https://clinicaltrials.gov/study/NCT04595565
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06126640,https://clinicaltrials.gov/study/NCT06316531,https://clinicaltrials.gov/study/NCT06313086
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND2	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Terminated	https://clinicaltrials.gov/study/NCT00053911,https://clinicaltrials.gov/study/NCT02144012,https://clinicaltrials.gov/study/NCT00625898,https://clinicaltrials.gov/study/NCT01200212,https://clinicaltrials.gov/study/NCT00912444
EFO_0005537	triple-negative breast cancer	CHEMBL2177390	IPATASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT1	AKT serine/threonine kinase 1	3	Completed	https://clinicaltrials.gov/study/NCT04177108
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Completed	https://clinicaltrials.gov/study/NCT00002707,https://clinicaltrials.gov/study/NCT00667251,https://clinicaltrials.gov/study/NCT00047255,https://clinicaltrials.gov/study/NCT03084237,https://clinicaltrials.gov/study/NCT03013504,https://clinicaltrials.gov/study/NCT01964391,https://clinicaltrials.gov/study/NCT03425656,https://clinicaltrials.gov/study/NCT00431080,https://clinicaltrials.gov/study/NCT00429871,https://clinicaltrials.gov/study/NCT03493854,https://clinicaltrials.gov/study/NCT00089479,https://clinicaltrials.gov/study/NCT01099436,https://clinicaltrials.gov/study/NCT02681003,https://clinicaltrials.gov/study/NCT00002662,https://clinicaltrials.gov/study/NCT02402712,https://clinicaltrials.gov/study/NCT00331097,https://clinicaltrials.gov/study/NCT00333775,https://clinicaltrials.gov/study/NCT00630032,https://clinicaltrials.gov/study/NCT02472964,https://clinicaltrials.gov/study/NCT01690702,https://clinicaltrials.gov/study/NCT02019277,https://clinicaltrials.gov/study/NCT00540800,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT00688740,https://clinicaltrials.gov/study/NCT00193011,https://clinicaltrials.gov/study/NCT00424606,https://clinicaltrials.gov/study/NCT00054587,https://clinicaltrials.gov/study/NCT00191152,https://clinicaltrials.gov/study/NCT00963729,https://clinicaltrials.gov/study/NCT00493870,https://clinicaltrials.gov/study/NCT00950300,https://clinicaltrials.gov/study/NCT00047099,https://clinicaltrials.gov/study/NCT01314833,https://clinicaltrials.gov/study/NCT00002544,https://clinicaltrials.gov/study/NCT02586025,https://clinicaltrials.gov/study/NCT04629846,https://clinicaltrials.gov/study/NCT04127019,https://clinicaltrials.gov/study/NCT00615602,https://clinicaltrials.gov/study/NCT04031703,https://clinicaltrials.gov/study/NCT02980965,https://clinicaltrials.gov/study/NCT00309556,https://clinicaltrials.gov/study/NCT00091442,https://clinicaltrials.gov/study/NCT00776724,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT00008411,https://clinicaltrials.gov/study/NCT02194166,https://clinicaltrials.gov/study/NCT00003519,https://clinicaltrials.gov/study/NCT04957212,https://clinicaltrials.gov/study/NCT00294385,https://clinicaltrials.gov/study/NCT00352378,https://clinicaltrials.gov/study/NCT00887536,https://clinicaltrials.gov/study/NCT00433589,https://clinicaltrials.gov/study/NCT01216111,https://clinicaltrials.gov/study/NCT00190489,https://clinicaltrials.gov/study/NCT00567190,https://clinicaltrials.gov/study/NCT00288002,https://clinicaltrials.gov/study/NCT00114816,https://clinicaltrials.gov/study/NCT00793377,https://clinicaltrials.gov/study/NCT00311636,https://clinicaltrials.gov/study/NCT00314977,https://clinicaltrials.gov/study/NCT05629949,https://clinicaltrials.gov/study/NCT00146549,https://clinicaltrials.gov/study/NCT00129935,https://clinicaltrials.gov/study/NCT01120184,https://clinicaltrials.gov/study/NCT01985724,https://clinicaltrials.gov/study/NCT00567554,https://clinicaltrials.gov/study/NCT00236899,https://clinicaltrials.gov/study/NCT00017095,https://clinicaltrials.gov/study/NCT02115204,https://clinicaltrials.gov/study/NCT01940497,https://clinicaltrials.gov/study/NCT00391092,https://clinicaltrials.gov/study/NCT02896855,https://clinicaltrials.gov/study/NCT00003782,https://clinicaltrials.gov/study/NCT02187744,https://clinicaltrials.gov/study/NCT00448591,https://clinicaltrials.gov/study/NCT05301010,https://clinicaltrials.gov/study/NCT00703326,https://clinicaltrials.gov/study/NCT00312208,https://clinicaltrials.gov/study/NCT01049425,https://clinicaltrials.gov/study/NCT00004125,https://clinicaltrials.gov/study/NCT03989037
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Unknown status	https://clinicaltrials.gov/study/NCT01222052,https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT01622361,https://clinicaltrials.gov/study/NCT01354522,https://clinicaltrials.gov/study/NCT01642771,https://clinicaltrials.gov/study/NCT00532727,https://clinicaltrials.gov/study/NCT01547741,https://clinicaltrials.gov/study/NCT00944424,https://clinicaltrials.gov/study/NCT00629278,https://clinicaltrials.gov/study/NCT00003679,https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT00010140,https://clinicaltrials.gov/study/NCT02393833,https://clinicaltrials.gov/study/NCT00430001,https://clinicaltrials.gov/study/NCT01479036
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Unknown status	https://clinicaltrials.gov/study/NCT00025688,https://clinicaltrials.gov/study/NCT00070278,https://clinicaltrials.gov/study/NCT01547741,https://clinicaltrials.gov/study/NCT01019616,https://clinicaltrials.gov/study/NCT00289263,https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT00486668,https://clinicaltrials.gov/study/NCT02393833,https://clinicaltrials.gov/study/NCT00005581,https://clinicaltrials.gov/study/NCT00629278,https://clinicaltrials.gov/study/NCT01378533,https://clinicaltrials.gov/study/NCT01084876,https://clinicaltrials.gov/study/NCT00039546,https://clinicaltrials.gov/study/NCT01134523
MONDO_0007254	breast cancer	CHEMBL4594298	ENCEQUIDAR	Small molecule	P-glycoprotein 1 inhibitor		ABCB1	ATP binding cassette subfamily B member 1	3	Completed	https://clinicaltrials.gov/study/NCT02594371
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	3	Recruiting	https://clinicaltrials.gov/study/NCT04457596
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB11	NADH:ubiquinone oxidoreductase subunit B11	3	Completed	https://clinicaltrials.gov/study/NCT01101438
EFO_1000984	inflammatory breast carcinoma	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Completed	https://clinicaltrials.gov/study/NCT02125344
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Completed	https://clinicaltrials.gov/study/NCT00191152
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02221999
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06079983
MONDO_0007254	breast cancer	CHEMBL1098	BUPIVACAINE	Small molecule	Sodium channel protein type IV alpha subunit blocker		SCN4A	sodium voltage-gated channel alpha subunit 4	3	Completed	https://clinicaltrials.gov/study/NCT00547989
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Recruiting	https://clinicaltrials.gov/study/NCT04307147,https://clinicaltrials.gov/study/NCT06268652,https://clinicaltrials.gov/study/NCT06143553,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT04400695
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06279364,https://clinicaltrials.gov/study/NCT04301739,https://clinicaltrials.gov/study/NCT05841381,https://clinicaltrials.gov/study/NCT05753865,https://clinicaltrials.gov/study/NCT05172518,https://clinicaltrials.gov/study/NCT05388500,https://clinicaltrials.gov/study/NCT06255392
EFO_0000304	breast adenocarcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Suspended	https://clinicaltrials.gov/study/NCT03002103
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	3	Unknown status	https://clinicaltrials.gov/study/NCT00039546,https://clinicaltrials.gov/study/NCT00070278,https://clinicaltrials.gov/study/NCT00408408
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Completed	https://clinicaltrials.gov/study/NCT01120184,https://clinicaltrials.gov/study/NCT00309556,https://clinicaltrials.gov/study/NCT03493854,https://clinicaltrials.gov/study/NCT02115204,https://clinicaltrials.gov/study/NCT04031703,https://clinicaltrials.gov/study/NCT02019277,https://clinicaltrials.gov/study/NCT00493870,https://clinicaltrials.gov/study/NCT00129935,https://clinicaltrials.gov/study/NCT00054587,https://clinicaltrials.gov/study/NCT00047099,https://clinicaltrials.gov/study/NCT00004125,https://clinicaltrials.gov/study/NCT00688740,https://clinicaltrials.gov/study/NCT00003782,https://clinicaltrials.gov/study/NCT00887536,https://clinicaltrials.gov/study/NCT03425656,https://clinicaltrials.gov/study/NCT00567554,https://clinicaltrials.gov/study/NCT00114816,https://clinicaltrials.gov/study/NCT00703326,https://clinicaltrials.gov/study/NCT00190489,https://clinicaltrials.gov/study/NCT04127019,https://clinicaltrials.gov/study/NCT01940497,https://clinicaltrials.gov/study/NCT00431080,https://clinicaltrials.gov/study/NCT00002707,https://clinicaltrials.gov/study/NCT02896855,https://clinicaltrials.gov/study/NCT00429871,https://clinicaltrials.gov/study/NCT01964391,https://clinicaltrials.gov/study/NCT00146549,https://clinicaltrials.gov/study/NCT00008411,https://clinicaltrials.gov/study/NCT00002544,https://clinicaltrials.gov/study/NCT02194166,https://clinicaltrials.gov/study/NCT00002662,https://clinicaltrials.gov/study/NCT01216111,https://clinicaltrials.gov/study/NCT00193011,https://clinicaltrials.gov/study/NCT00288002,https://clinicaltrials.gov/study/NCT00433589,https://clinicaltrials.gov/study/NCT00567190,https://clinicaltrials.gov/study/NCT05629949,https://clinicaltrials.gov/study/NCT00424606,https://clinicaltrials.gov/study/NCT00950300,https://clinicaltrials.gov/study/NCT00191152,https://clinicaltrials.gov/study/NCT00667251,https://clinicaltrials.gov/study/NCT02980965,https://clinicaltrials.gov/study/NCT00540800,https://clinicaltrials.gov/study/NCT00311636,https://clinicaltrials.gov/study/NCT02681003,https://clinicaltrials.gov/study/NCT01099436,https://clinicaltrials.gov/study/NCT04957212,https://clinicaltrials.gov/study/NCT00963729,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT00630032,https://clinicaltrials.gov/study/NCT00017095,https://clinicaltrials.gov/study/NCT01690702,https://clinicaltrials.gov/study/NCT00089479,https://clinicaltrials.gov/study/NCT00091442,https://clinicaltrials.gov/study/NCT03989037,https://clinicaltrials.gov/study/NCT02402712,https://clinicaltrials.gov/study/NCT05301010,https://clinicaltrials.gov/study/NCT00615602,https://clinicaltrials.gov/study/NCT03013504,https://clinicaltrials.gov/study/NCT00312208,https://clinicaltrials.gov/study/NCT00294385,https://clinicaltrials.gov/study/NCT01314833,https://clinicaltrials.gov/study/NCT00314977,https://clinicaltrials.gov/study/NCT00003519,https://clinicaltrials.gov/study/NCT00333775,https://clinicaltrials.gov/study/NCT00793377,https://clinicaltrials.gov/study/NCT02472964,https://clinicaltrials.gov/study/NCT00776724,https://clinicaltrials.gov/study/NCT03084237,https://clinicaltrials.gov/study/NCT00236899,https://clinicaltrials.gov/study/NCT00391092,https://clinicaltrials.gov/study/NCT00047255,https://clinicaltrials.gov/study/NCT00448591,https://clinicaltrials.gov/study/NCT00352378,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT02586025,https://clinicaltrials.gov/study/NCT00331097,https://clinicaltrials.gov/study/NCT02187744,https://clinicaltrials.gov/study/NCT04629846,https://clinicaltrials.gov/study/NCT01985724,https://clinicaltrials.gov/study/NCT01049425
MONDO_0007254	breast cancer	CHEMBL4297509	ELACESTRANT	Small molecule	Estrogen receptor alpha degrader		ESR1	estrogen receptor 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03778931
EFO_1000984	inflammatory breast carcinoma	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Terminated	https://clinicaltrials.gov/study/NCT00016276
MONDO_0007254	breast cancer	CHEMBL3545414	RIVOCERANIB MESYLATE	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	3	Terminated	https://clinicaltrials.gov/study/NCT04335006
MONDO_0007254	breast cancer	CHEMBL3545262	SACITUZUMAB GOVITECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	3	Completed	https://clinicaltrials.gov/study/NCT02574455,https://clinicaltrials.gov/study/NCT03901339
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04546009,https://clinicaltrials.gov/study/NCT04191499,https://clinicaltrials.gov/study/NCT04711252,https://clinicaltrials.gov/study/NCT03079011,https://clinicaltrials.gov/study/NCT02513394,https://clinicaltrials.gov/study/NCT02947685
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01772472,https://clinicaltrials.gov/study/NCT04740918,https://clinicaltrials.gov/study/NCT04622319,https://clinicaltrials.gov/study/NCT03529110
MONDO_0007254	breast cancer	CHEMBL481611	ODANACATIB	Small molecule	Cathepsin K inhibitor		CTSK	cathepsin K	3	Withdrawn	https://clinicaltrials.gov/study/NCT00692458
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	3	Completed	https://clinicaltrials.gov/study/NCT03286842
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Recruiting	https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT06143553,https://clinicaltrials.gov/study/NCT06268652,https://clinicaltrials.gov/study/NCT04307147
MONDO_0007254	breast cancer	CHEMBL45	MELATONIN	Small molecule	Melatonin receptor agonist		MTNR1B	melatonin receptor 1B	3	Terminated	https://clinicaltrials.gov/study/NCT02332928
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	3	Completed	https://clinicaltrials.gov/study/NCT00191152
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Completed	https://clinicaltrials.gov/study/NCT01583426,https://clinicaltrials.gov/study/NCT02125344
MONDO_0007254	breast cancer	CHEMBL554	LAPATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	3	Unknown status	https://clinicaltrials.gov/study/NCT03080805,https://clinicaltrials.gov/study/NCT02394496,https://clinicaltrials.gov/study/NCT00688194,https://clinicaltrials.gov/study/NCT00486668
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885,https://clinicaltrials.gov/study/NCT00433511
MONDO_0007254	breast cancer	CHEMBL3647420	PYROTINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT04736589,https://clinicaltrials.gov/study/NCT04973319,https://clinicaltrials.gov/study/NCT05841381
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Terminated	https://clinicaltrials.gov/study/NCT00912444,https://clinicaltrials.gov/study/NCT02144012,https://clinicaltrials.gov/study/NCT00053911,https://clinicaltrials.gov/study/NCT01200212,https://clinicaltrials.gov/study/NCT00625898
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Completed	https://clinicaltrials.gov/study/NCT00005970
MONDO_0007254	breast cancer	CHEMBL1200480	OCTREOTIDE ACETATE	Protein	Somatostatin receptor agonist		SSTR4	somatostatin receptor 4	3	Completed	https://clinicaltrials.gov/study/NCT00002864
MONDO_0007254	breast cancer	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Recruiting	https://clinicaltrials.gov/study/NCT04964934,https://clinicaltrials.gov/study/NCT04906395,https://clinicaltrials.gov/study/NCT05891093,https://clinicaltrials.gov/study/NCT04134598,https://clinicaltrials.gov/study/NCT05439499,https://clinicaltrials.gov/study/NCT05512364,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT05952557,https://clinicaltrials.gov/study/NCT04852887,https://clinicaltrials.gov/study/NCT02097459,https://clinicaltrials.gov/study/NCT04584853,https://clinicaltrials.gov/study/NCT05780567,https://clinicaltrials.gov/study/NCT05774951
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT05172518,https://clinicaltrials.gov/study/NCT05838066,https://clinicaltrials.gov/study/NCT04665986,https://clinicaltrials.gov/study/NCT06079983
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	3	Completed	https://clinicaltrials.gov/study/NCT00006459
MONDO_0007254	breast cancer	CHEMBL4303669	ZOLEDRONIC ACID	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	3	Terminated	https://clinicaltrials.gov/study/NCT00372710
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Completed	https://clinicaltrials.gov/study/NCT01583426,https://clinicaltrials.gov/study/NCT02125344
MONDO_0007254	breast cancer	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	3	Completed	https://clinicaltrials.gov/study/NCT00002646,https://clinicaltrials.gov/study/NCT00433589,https://clinicaltrials.gov/study/NCT00047099,https://clinicaltrials.gov/study/NCT00003857,https://clinicaltrials.gov/study/NCT00232661,https://clinicaltrials.gov/study/NCT00152178,https://clinicaltrials.gov/study/NCT00002707,https://clinicaltrials.gov/study/NCT00002967,https://clinicaltrials.gov/study/NCT00002542,https://clinicaltrials.gov/study/NCT00053898,https://clinicaltrials.gov/study/NCT00002580,https://clinicaltrials.gov/study/NCT00004125,https://clinicaltrials.gov/study/NCT00002579,https://clinicaltrials.gov/study/NCT00003906,https://clinicaltrials.gov/study/NCT00293540,https://clinicaltrials.gov/study/NCT00590785,https://clinicaltrials.gov/study/NCT02995772,https://clinicaltrials.gov/study/NCT00605267,https://clinicaltrials.gov/study/NCT00201851,https://clinicaltrials.gov/study/NCT00949598,https://clinicaltrials.gov/study/NCT00003013,https://clinicaltrials.gov/study/NCT00814125,https://clinicaltrials.gov/study/NCT00929591,https://clinicaltrials.gov/study/NCT00309491,https://clinicaltrials.gov/study/NCT00003032,https://clinicaltrials.gov/study/NCT02278120,https://clinicaltrials.gov/study/NCT00002777,https://clinicaltrials.gov/study/NCT00002528,https://clinicaltrials.gov/study/NCT00002720,https://clinicaltrials.gov/study/NCT00002784,https://clinicaltrials.gov/study/NCT00286117,https://clinicaltrials.gov/study/NCT00072462,https://clinicaltrials.gov/study/NCT00002529,https://clinicaltrials.gov/study/NCT00003972,https://clinicaltrials.gov/study/NCT00849030,https://clinicaltrials.gov/study/NCT00002582,https://clinicaltrials.gov/study/NCT00002864,https://clinicaltrials.gov/study/NCT00793377,https://clinicaltrials.gov/study/NCT00291759,https://clinicaltrials.gov/study/NCT00171704,https://clinicaltrials.gov/study/NCT00032136,https://clinicaltrials.gov/study/NCT00241449,https://clinicaltrials.gov/study/NCT00004205,https://clinicaltrials.gov/study/NCT00309478,https://clinicaltrials.gov/study/NCT00002581,https://clinicaltrials.gov/study/NCT00295646,https://clinicaltrials.gov/study/NCT00002755,https://clinicaltrials.gov/study/NCT00784862
MONDO_0007254	breast cancer	CHEMBL1161	MOMETASONE FUROATE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	3	Completed	https://clinicaltrials.gov/study/NCT01856543
EFO_0000305	breast carcinoma	CHEMBL1201334	TRIPTORELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00066690
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04639986
MONDO_0007254	breast cancer	CHEMBL1908360	EVEROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	3	Terminated	https://clinicaltrials.gov/study/NCT05065411,https://clinicaltrials.gov/study/NCT01773460,https://clinicaltrials.gov/study/NCT02137837
MONDO_0004658	breast carcinoma in situ	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Recruiting	https://clinicaltrials.gov/study/NCT04862585
EFO_0000304	breast adenocarcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	3	Unknown status	https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT00070278,https://clinicaltrials.gov/study/NCT00039546
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT05814354,https://clinicaltrials.gov/study/NCT05382299,https://clinicaltrials.gov/study/NCT04722978,https://clinicaltrials.gov/study/NCT06268652,https://clinicaltrials.gov/study/NCT06103864,https://clinicaltrials.gov/study/NCT06143553
EFO_0000304	breast adenocarcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Suspended	https://clinicaltrials.gov/study/NCT03777579
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV2	NADH:ubiquinone oxidoreductase core subunit V2	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	3	Recruiting	https://clinicaltrials.gov/study/NCT05891093,https://clinicaltrials.gov/study/NCT04565054,https://clinicaltrials.gov/study/NCT04584853,https://clinicaltrials.gov/study/NCT04862663,https://clinicaltrials.gov/study/NCT05696626,https://clinicaltrials.gov/study/NCT04961996,https://clinicaltrials.gov/study/NCT05952557,https://clinicaltrials.gov/study/NCT04964934
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Suspended	https://clinicaltrials.gov/study/NCT03002103
EFO_0005537	triple-negative breast cancer	CHEMBL4297715	CAMRELIZUMAB	Antibody	Programmed cell death protein 1 antagonist		PDCD1	programmed cell death 1	3	Recruiting	https://clinicaltrials.gov/study/NCT05862064,https://clinicaltrials.gov/study/NCT05999149,https://clinicaltrials.gov/study/NCT05760378
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB1	NADH:ubiquinone oxidoreductase subunit B1	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Completed	https://clinicaltrials.gov/study/NCT01120184,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT03084939,https://clinicaltrials.gov/study/NCT01419197,https://clinicaltrials.gov/study/NCT00829166,https://clinicaltrials.gov/study/NCT01702571,https://clinicaltrials.gov/study/NCT03726879
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT05382299,https://clinicaltrials.gov/study/NCT05814354,https://clinicaltrials.gov/study/NCT06268652,https://clinicaltrials.gov/study/NCT04722978,https://clinicaltrials.gov/study/NCT06143553,https://clinicaltrials.gov/study/NCT06103864
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Completed	https://clinicaltrials.gov/study/NCT04177108,https://clinicaltrials.gov/study/NCT03197935,https://clinicaltrials.gov/study/NCT03125902
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	3	Completed	https://clinicaltrials.gov/study/NCT00191152
EFO_1000984	inflammatory breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT05415215
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06079983
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Terminated	https://clinicaltrials.gov/study/NCT03786094,https://clinicaltrials.gov/study/NCT05134194
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	3	Unknown status	https://clinicaltrials.gov/study/NCT00039546,https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT02207335,https://clinicaltrials.gov/study/NCT00070278
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04799249
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	3	Unknown status	https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT00039546,https://clinicaltrials.gov/study/NCT02207335,https://clinicaltrials.gov/study/NCT00070278,https://clinicaltrials.gov/study/NCT02514681
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAB1	NADH:ubiquinone oxidoreductase subunit AB1	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0004658	breast carcinoma in situ	CHEMBL657	DIPHENHYDRAMINE	Small molecule	Histamine H1 receptor antagonist		HRH1	histamine receptor H1	3	Recruiting	https://clinicaltrials.gov/study/NCT04862585
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT05841381,https://clinicaltrials.gov/study/NCT05172518,https://clinicaltrials.gov/study/NCT04301739,https://clinicaltrials.gov/study/NCT06279364,https://clinicaltrials.gov/study/NCT05753865,https://clinicaltrials.gov/study/NCT05388500
EFO_1000984	inflammatory breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Completed	https://clinicaltrials.gov/study/NCT02324088
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor		GPD2	glycerol-3-phosphate dehydrogenase 2	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	3	Terminated	https://clinicaltrials.gov/study/NCT05065411
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Terminated	https://clinicaltrials.gov/study/NCT02144012
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Withdrawn	https://clinicaltrials.gov/study/NCT03811418
MONDO_0007254	breast cancer	CHEMBL2325741	CAPIVASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT1	AKT serine/threonine kinase 1	3	Recruiting	https://clinicaltrials.gov/study/NCT04862663
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB11	NADH:ubiquinone oxidoreductase subunit B11	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB7	NADH:ubiquinone oxidoreductase subunit B7	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Completed	https://clinicaltrials.gov/study/NCT02555657,https://clinicaltrials.gov/study/NCT00337103,https://clinicaltrials.gov/study/NCT03901339,https://clinicaltrials.gov/study/NCT02574455,https://clinicaltrials.gov/study/NCT02225470,https://clinicaltrials.gov/study/NCT00388726
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Recruiting	https://clinicaltrials.gov/study/NCT05760378
MONDO_0007254	breast cancer	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00301925,https://clinicaltrials.gov/study/NCT03523585,https://clinicaltrials.gov/study/NCT04185649,https://clinicaltrials.gov/study/NCT02973737,https://clinicaltrials.gov/study/NCT05104866,https://clinicaltrials.gov/study/NCT04639986,https://clinicaltrials.gov/study/NCT04494425,https://clinicaltrials.gov/study/NCT02767661,https://clinicaltrials.gov/study/NCT05063786,https://clinicaltrials.gov/study/NCT03734029
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS6	NADH:ubiquinone oxidoreductase subunit S6	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Recruiting	https://clinicaltrials.gov/study/NCT05894239
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB6	NADH:ubiquinone oxidoreductase subunit B6	3	Completed	https://clinicaltrials.gov/study/NCT01101438
EFO_0000304	breast adenocarcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
EFO_0000304	breast adenocarcinoma	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00433511
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02003209,https://clinicaltrials.gov/study/NCT01275677,https://clinicaltrials.gov/study/NCT03199885
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	3	Completed	https://clinicaltrials.gov/study/NCT00005970
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Unknown status	https://clinicaltrials.gov/study/NCT00944424,https://clinicaltrials.gov/study/NCT01479036,https://clinicaltrials.gov/study/NCT02393833,https://clinicaltrials.gov/study/NCT00629278,https://clinicaltrials.gov/study/NCT00430001,https://clinicaltrials.gov/study/NCT01354522,https://clinicaltrials.gov/study/NCT01547741,https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT01622361,https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT01222052,https://clinicaltrials.gov/study/NCT00010140,https://clinicaltrials.gov/study/NCT01642771,https://clinicaltrials.gov/study/NCT00532727,https://clinicaltrials.gov/study/NCT00003679
MONDO_0007254	breast cancer	CHEMBL1201460	DALTEPARIN SODIUM	Oligosaccharide	Antithrombin-III activator		SERPINC1	serpin family C member 1	3	Completed	https://clinicaltrials.gov/study/NCT00003674
MONDO_0007254	breast cancer	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN9A	sodium voltage-gated channel alpha subunit 9	3	Completed	https://clinicaltrials.gov/study/NCT00547989,https://clinicaltrials.gov/study/NCT02408393,https://clinicaltrials.gov/study/NCT04327063
MONDO_0007254	breast cancer	CHEMBL328190	LASOFOXIFENE	Small molecule	Estrogen receptor modulator		ESR1	estrogen receptor 1	3	Recruiting	https://clinicaltrials.gov/study/NCT05696626
MONDO_0007254	breast cancer	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	3	Terminated	https://clinicaltrials.gov/study/NCT00053911,https://clinicaltrials.gov/study/NCT05128773,https://clinicaltrials.gov/study/NCT00066807,https://clinicaltrials.gov/study/NCT00002772
EFO_0006861	male breast carcinoma	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	3	Completed	https://clinicaltrials.gov/study/NCT01638247
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Unknown status	https://clinicaltrials.gov/study/NCT02879513
EFO_0005537	triple-negative breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Vascular endothelial growth factor receptor 3 inhibitor		FLT4	fms related receptor tyrosine kinase 4	3	Recruiting	https://clinicaltrials.gov/study/NCT05760378
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS5	NADH:ubiquinone oxidoreductase subunit S5	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Recruiting	https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT05814354,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT06268652,https://clinicaltrials.gov/study/NCT05374512
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03529110,https://clinicaltrials.gov/study/NCT04740918,https://clinicaltrials.gov/study/NCT04622319,https://clinicaltrials.gov/study/NCT01772472
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04639986
MONDO_0007254	breast cancer	CHEMBL185	FLUOROURACIL	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01358877,https://clinicaltrials.gov/study/NCT00301925,https://clinicaltrials.gov/study/NCT00433420
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06343948,https://clinicaltrials.gov/study/NCT06081959,https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT06255392
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03863223,https://clinicaltrials.gov/study/NCT02003209,https://clinicaltrials.gov/study/NCT02641847,https://clinicaltrials.gov/study/NCT03588091,https://clinicaltrials.gov/study/NCT01646034,https://clinicaltrials.gov/study/NCT04024462,https://clinicaltrials.gov/study/NCT01358877
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT05838066,https://clinicaltrials.gov/study/NCT04665986,https://clinicaltrials.gov/study/NCT05172518,https://clinicaltrials.gov/study/NCT06079983
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS3	NADH:ubiquinone oxidoreductase core subunit S3	3	Completed	https://clinicaltrials.gov/study/NCT01101438
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	3	Suspended	https://clinicaltrials.gov/study/NCT03002103
MONDO_0007254	breast cancer	CHEMBL1200501	GOSERELIN ACETATE	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	3	Completed	https://clinicaltrials.gov/study/NCT00047099,https://clinicaltrials.gov/study/NCT00002582,https://clinicaltrials.gov/study/NCT01712893,https://clinicaltrials.gov/study/NCT00002580,https://clinicaltrials.gov/study/NCT05110170,https://clinicaltrials.gov/study/NCT01073865,https://clinicaltrials.gov/study/NCT00605267
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Completed	https://clinicaltrials.gov/study/NCT02225470,https://clinicaltrials.gov/study/NCT00103233
EFO_1000984	inflammatory breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Completed	https://clinicaltrials.gov/study/NCT02324088
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Completed	https://clinicaltrials.gov/study/NCT01953003,https://clinicaltrials.gov/study/NCT01091168,https://clinicaltrials.gov/study/NCT01095003
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Completed	https://clinicaltrials.gov/study/NCT03901339,https://clinicaltrials.gov/study/NCT02225470,https://clinicaltrials.gov/study/NCT01007942,https://clinicaltrials.gov/study/NCT00103233,https://clinicaltrials.gov/study/NCT00776724,https://clinicaltrials.gov/study/NCT02555657,https://clinicaltrials.gov/study/NCT02574455,https://clinicaltrials.gov/study/NCT00431106,https://clinicaltrials.gov/study/NCT00868634,https://clinicaltrials.gov/study/NCT00146549
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Unknown status	https://clinicaltrials.gov/study/NCT02879513
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00561119,https://clinicaltrials.gov/study/NCT02819518,https://clinicaltrials.gov/study/NCT00670878,https://clinicaltrials.gov/study/NCT03901339,https://clinicaltrials.gov/study/NCT00294385,https://clinicaltrials.gov/study/NCT00006459,https://clinicaltrials.gov/study/NCT01287624,https://clinicaltrials.gov/study/NCT00431106,https://clinicaltrials.gov/study/NCT02555657,https://clinicaltrials.gov/study/NCT00938652,https://clinicaltrials.gov/study/NCT02546934,https://clinicaltrials.gov/study/NCT02574455,https://clinicaltrials.gov/study/NCT00236899,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT00191152
MONDO_0007254	breast cancer	CHEMBL3707227	ATEZOLIZUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	3	Recruiting	https://clinicaltrials.gov/study/NCT04873362
EFO_0000304	breast adenocarcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04740918,https://clinicaltrials.gov/study/NCT01772472,https://clinicaltrials.gov/study/NCT03529110,https://clinicaltrials.gov/study/NCT04622319
EFO_0000305	breast carcinoma	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885,https://clinicaltrials.gov/study/NCT02003209
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT05838066,https://clinicaltrials.gov/study/NCT05172518,https://clinicaltrials.gov/study/NCT04665986
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Recruiting	https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT06143553,https://clinicaltrials.gov/study/NCT04307147,https://clinicaltrials.gov/study/NCT06268652,https://clinicaltrials.gov/study/NCT04400695
EFO_1000984	inflammatory breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Completed	https://clinicaltrials.gov/study/NCT02324088
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Completed	https://clinicaltrials.gov/study/NCT00005970
MONDO_0007254	breast cancer	CHEMBL118	CELECOXIB	Small molecule	Cyclooxygenase-2 inhibitor		PTGS2	prostaglandin-endoperoxide synthase 2	3	Terminated	https://clinicaltrials.gov/study/NCT00305643
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06081959,https://clinicaltrials.gov/study/NCT06279364,https://clinicaltrials.gov/study/NCT06343948,https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT06255392
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00191152
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC4	histone deacetylase 4	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03538171
EFO_1000984	inflammatory breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT05415215
MONDO_0007254	breast cancer	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT01645839
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT05838066,https://clinicaltrials.gov/study/NCT04665986,https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT05172518
MONDO_0007254	breast cancer	CHEMBL4279455	LAROTAXEL	Small molecule	Tubulin stabiliser		TUBB6	tubulin beta 6 class V	3	Completed	https://clinicaltrials.gov/study/NCT00081796
MONDO_0007254	breast cancer	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	3	Enrolling by invitation	https://clinicaltrials.gov/study/NCT05645536
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03588091,https://clinicaltrials.gov/study/NCT02641847,https://clinicaltrials.gov/study/NCT02003209,https://clinicaltrials.gov/study/NCT01358877,https://clinicaltrials.gov/study/NCT01646034,https://clinicaltrials.gov/study/NCT03863223,https://clinicaltrials.gov/study/NCT04024462
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06081959,https://clinicaltrials.gov/study/NCT06343948,https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT06255392
MONDO_0007254	breast cancer	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN8A	sodium voltage-gated channel alpha subunit 8	3	Terminated	https://clinicaltrials.gov/study/NCT02525211
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04799249
MONDO_0007254	breast cancer	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	3	Completed	https://clinicaltrials.gov/study/NCT02941926,https://clinicaltrials.gov/study/NCT01958021,https://clinicaltrials.gov/study/NCT03096847,https://clinicaltrials.gov/study/NCT02278120,https://clinicaltrials.gov/study/NCT02422615,https://clinicaltrials.gov/study/NCT03439046,https://clinicaltrials.gov/study/NCT03462251
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Recruiting	https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT06268652,https://clinicaltrials.gov/study/NCT06143553,https://clinicaltrials.gov/study/NCT04307147,https://clinicaltrials.gov/study/NCT04400695
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT05814354,https://clinicaltrials.gov/study/NCT05382299,https://clinicaltrials.gov/study/NCT06103864,https://clinicaltrials.gov/study/NCT06143553,https://clinicaltrials.gov/study/NCT04722978,https://clinicaltrials.gov/study/NCT06268652
EFO_0000305	breast carcinoma	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR1	estrogen receptor 1	3	Unknown status	https://clinicaltrials.gov/study/NCT02404051
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	3	Completed	https://clinicaltrials.gov/study/NCT01610284
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02003209,https://clinicaltrials.gov/study/NCT03199885,https://clinicaltrials.gov/study/NCT01275677
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	3	Completed	https://clinicaltrials.gov/study/NCT00191152
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Recruiting	https://clinicaltrials.gov/study/NCT05901428,https://clinicaltrials.gov/study/NCT04547907,https://clinicaltrials.gov/study/NCT05296798,https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT04540692,https://clinicaltrials.gov/study/NCT03671044,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT05883852,https://clinicaltrials.gov/study/NCT05894239,https://clinicaltrials.gov/study/NCT03926091,https://clinicaltrials.gov/study/NCT05673629,https://clinicaltrials.gov/study/NCT05207514,https://clinicaltrials.gov/study/NCT05430399,https://clinicaltrials.gov/study/NCT04193059,https://clinicaltrials.gov/study/NCT05159193,https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT05720026,https://clinicaltrials.gov/study/NCT03949634
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Completed	https://clinicaltrials.gov/study/NCT01935492,https://clinicaltrials.gov/study/NCT00785291
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02641847,https://clinicaltrials.gov/study/NCT05104866,https://clinicaltrials.gov/study/NCT04639986,https://clinicaltrials.gov/study/NCT01646034,https://clinicaltrials.gov/study/NCT03734029
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	3	Terminated	https://clinicaltrials.gov/study/NCT00440622,https://clinicaltrials.gov/study/NCT02054338,https://clinicaltrials.gov/study/NCT05134194
MONDO_0007254	breast cancer	CHEMBL1200501	GOSERELIN ACETATE	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	3	Recruiting	https://clinicaltrials.gov/study/NCT05438810,https://clinicaltrials.gov/study/NCT05439499,https://clinicaltrials.gov/study/NCT03664895,https://clinicaltrials.gov/study/NCT03936933
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT06143553
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Terminated	https://clinicaltrials.gov/study/NCT02144012,https://clinicaltrials.gov/study/NCT00625898,https://clinicaltrials.gov/study/NCT00912444,https://clinicaltrials.gov/study/NCT01200212,https://clinicaltrials.gov/study/NCT00053911
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
MONDO_0007254	breast cancer	CHEMBL1201334	TRIPTORELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	3	Completed	https://clinicaltrials.gov/study/NCT00311636
EFO_0000304	breast adenocarcinoma	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00310180
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Recruiting	https://clinicaltrials.gov/study/NCT05760378
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652
EFO_0005537	triple-negative breast cancer	CHEMBL3894860	TRILACICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04799249
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00006459
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Recruiting	https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT06143553
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Completed	https://clinicaltrials.gov/study/NCT03125902,https://clinicaltrials.gov/study/NCT04177108,https://clinicaltrials.gov/study/NCT03197935
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00770809
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R2	phosphoinositide-3-kinase regulatory subunit 2	3	Recruiting	https://clinicaltrials.gov/study/NCT05501886
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Recruiting	https://clinicaltrials.gov/study/NCT04457596
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Terminated	https://clinicaltrials.gov/study/NCT00016276
MONDO_0007254	breast cancer	CHEMBL1201334	TRIPTORELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	3	Terminated	https://clinicaltrials.gov/study/NCT00066807
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Unknown status	https://clinicaltrials.gov/study/NCT00039546,https://clinicaltrials.gov/study/NCT01547741,https://clinicaltrials.gov/study/NCT00289263,https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT01378533,https://clinicaltrials.gov/study/NCT02393833,https://clinicaltrials.gov/study/NCT00025688,https://clinicaltrials.gov/study/NCT00629278,https://clinicaltrials.gov/study/NCT01019616,https://clinicaltrials.gov/study/NCT00005581,https://clinicaltrials.gov/study/NCT01134523,https://clinicaltrials.gov/study/NCT01084876,https://clinicaltrials.gov/study/NCT00070278,https://clinicaltrials.gov/study/NCT00486668
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02221999
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Recruiting	https://clinicaltrials.gov/study/NCT05760378
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00191152
MONDO_0007254	breast cancer	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Completed	https://clinicaltrials.gov/study/NCT04629846,https://clinicaltrials.gov/study/NCT01026142,https://clinicaltrials.gov/study/NCT02896855,https://clinicaltrials.gov/study/NCT00567190,https://clinicaltrials.gov/study/NCT01120184,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT04957212,https://clinicaltrials.gov/study/NCT02586025,https://clinicaltrials.gov/study/NCT03493854,https://clinicaltrials.gov/study/NCT02019277,https://clinicaltrials.gov/study/NCT03726879,https://clinicaltrials.gov/study/NCT02402712
MONDO_0007254	breast cancer	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT01645839
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Completed	https://clinicaltrials.gov/study/NCT02187744,https://clinicaltrials.gov/study/NCT00003519,https://clinicaltrials.gov/study/NCT00309556,https://clinicaltrials.gov/study/NCT00567190,https://clinicaltrials.gov/study/NCT02115204,https://clinicaltrials.gov/study/NCT00887536,https://clinicaltrials.gov/study/NCT02896855,https://clinicaltrials.gov/study/NCT03084237,https://clinicaltrials.gov/study/NCT00089479,https://clinicaltrials.gov/study/NCT04031703,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT00129935,https://clinicaltrials.gov/study/NCT00429871,https://clinicaltrials.gov/study/NCT05629949,https://clinicaltrials.gov/study/NCT00793377,https://clinicaltrials.gov/study/NCT00391092,https://clinicaltrials.gov/study/NCT03493854,https://clinicaltrials.gov/study/NCT01216111,https://clinicaltrials.gov/study/NCT00433589,https://clinicaltrials.gov/study/NCT00667251,https://clinicaltrials.gov/study/NCT04127019,https://clinicaltrials.gov/study/NCT00424606,https://clinicaltrials.gov/study/NCT00193011,https://clinicaltrials.gov/study/NCT03013504,https://clinicaltrials.gov/study/NCT00288002,https://clinicaltrials.gov/study/NCT03425656,https://clinicaltrials.gov/study/NCT00333775,https://clinicaltrials.gov/study/NCT01690702,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT00002544,https://clinicaltrials.gov/study/NCT00688740,https://clinicaltrials.gov/study/NCT00431080,https://clinicaltrials.gov/study/NCT00294385,https://clinicaltrials.gov/study/NCT00008411,https://clinicaltrials.gov/study/NCT00047099,https://clinicaltrials.gov/study/NCT03989037,https://clinicaltrials.gov/study/NCT00236899,https://clinicaltrials.gov/study/NCT00191152,https://clinicaltrials.gov/study/NCT00540800,https://clinicaltrials.gov/study/NCT00004125,https://clinicaltrials.gov/study/NCT00312208,https://clinicaltrials.gov/study/NCT00352378,https://clinicaltrials.gov/study/NCT00003782,https://clinicaltrials.gov/study/NCT02586025,https://clinicaltrials.gov/study/NCT02472964,https://clinicaltrials.gov/study/NCT00002662,https://clinicaltrials.gov/study/NCT01049425,https://clinicaltrials.gov/study/NCT00448591,https://clinicaltrials.gov/study/NCT04629846,https://clinicaltrials.gov/study/NCT01940497,https://clinicaltrials.gov/study/NCT00054587,https://clinicaltrials.gov/study/NCT00493870,https://clinicaltrials.gov/study/NCT00190489,https://clinicaltrials.gov/study/NCT00114816,https://clinicaltrials.gov/study/NCT00615602,https://clinicaltrials.gov/study/NCT00002707,https://clinicaltrials.gov/study/NCT01120184,https://clinicaltrials.gov/study/NCT02402712,https://clinicaltrials.gov/study/NCT02681003,https://clinicaltrials.gov/study/NCT05301010,https://clinicaltrials.gov/study/NCT00311636,https://clinicaltrials.gov/study/NCT01314833,https://clinicaltrials.gov/study/NCT02980965,https://clinicaltrials.gov/study/NCT00950300,https://clinicaltrials.gov/study/NCT01099436,https://clinicaltrials.gov/study/NCT00703326,https://clinicaltrials.gov/study/NCT00776724,https://clinicaltrials.gov/study/NCT00630032,https://clinicaltrials.gov/study/NCT01964391,https://clinicaltrials.gov/study/NCT00963729,https://clinicaltrials.gov/study/NCT00567554,https://clinicaltrials.gov/study/NCT00017095,https://clinicaltrials.gov/study/NCT02019277,https://clinicaltrials.gov/study/NCT00146549,https://clinicaltrials.gov/study/NCT04957212,https://clinicaltrials.gov/study/NCT00091442,https://clinicaltrials.gov/study/NCT02194166,https://clinicaltrials.gov/study/NCT01985724,https://clinicaltrials.gov/study/NCT00331097,https://clinicaltrials.gov/study/NCT00047255,https://clinicaltrials.gov/study/NCT00314977
MONDO_0007254	breast cancer	CHEMBL30	CIMETIDINE	Small molecule	Histamine H2 receptor antagonist		HRH2	histamine receptor H2	3	Recruiting	https://clinicaltrials.gov/study/NCT04862585
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
EFO_0000305	breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Completed	https://clinicaltrials.gov/study/NCT00785291
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	3	Unknown status	https://clinicaltrials.gov/study/NCT02207335,https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT00070278,https://clinicaltrials.gov/study/NCT00039546,https://clinicaltrials.gov/study/NCT02514681
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04799249
EFO_0005537	triple-negative breast cancer	CHEMBL2177390	IPATASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT2	AKT serine/threonine kinase 2	3	Completed	https://clinicaltrials.gov/study/NCT04177108
EFO_0006861	male breast carcinoma	CHEMBL1201179	LAPATINIB DITOSYLATE	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00770809
MONDO_0007254	breast cancer	CHEMBL103	PROGESTERONE	Small molecule	Progesterone receptor agonist		PGR	progesterone receptor	3	Terminated	https://clinicaltrials.gov/study/NCT01608451
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT01287624,https://clinicaltrials.gov/study/NCT02546934,https://clinicaltrials.gov/study/NCT02819518,https://clinicaltrials.gov/study/NCT00006459,https://clinicaltrials.gov/study/NCT00431106,https://clinicaltrials.gov/study/NCT03901339,https://clinicaltrials.gov/study/NCT00938652,https://clinicaltrials.gov/study/NCT00191152,https://clinicaltrials.gov/study/NCT00561119,https://clinicaltrials.gov/study/NCT00236899,https://clinicaltrials.gov/study/NCT00294385,https://clinicaltrials.gov/study/NCT00670878,https://clinicaltrials.gov/study/NCT02574455,https://clinicaltrials.gov/study/NCT02555657
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Suspended	https://clinicaltrials.gov/study/NCT03777579
MONDO_0007254	breast cancer	CHEMBL1276308	MIFEPRISTONE	Small molecule	Progesterone receptor antagonist		PGR	progesterone receptor	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT05016349
MONDO_0007254	breast cancer	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06223698,https://clinicaltrials.gov/study/NCT05016349
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	3	Recruiting	https://clinicaltrials.gov/study/NCT05501886
EFO_0000305	breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Completed	https://clinicaltrials.gov/study/NCT00785291
EFO_0000305	breast carcinoma	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00601900
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Recruiting	https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT06268652,https://clinicaltrials.gov/study/NCT05814354,https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT05374512
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT04665986,https://clinicaltrials.gov/study/NCT05172518,https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT05838066
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF3	NADH:ubiquinone oxidoreductase complex assembly factor 3	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL180022	NERATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	3	Completed	https://clinicaltrials.gov/study/NCT01808573,https://clinicaltrials.gov/study/NCT00878709
EFO_0005537	triple-negative breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	3	Suspended	https://clinicaltrials.gov/study/NCT03002103
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Recruiting	https://clinicaltrials.gov/study/NCT05760378
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Unknown status	https://clinicaltrials.gov/study/NCT02879513
MONDO_0007254	breast cancer	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT05257395,https://clinicaltrials.gov/study/NCT06223698
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Recruiting	https://clinicaltrials.gov/study/NCT05374512
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06081959,https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT06279364,https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06343948
MONDO_0004658	breast carcinoma in situ	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Recruiting	https://clinicaltrials.gov/study/NCT04862585
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00433511,https://clinicaltrials.gov/study/NCT03199885
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR1	estrogen receptor 1	3	Completed	https://clinicaltrials.gov/study/NCT00635713,https://clinicaltrials.gov/study/NCT00327769,https://clinicaltrials.gov/study/NCT00256698,https://clinicaltrials.gov/study/NCT00065325,https://clinicaltrials.gov/study/NCT01300351,https://clinicaltrials.gov/study/NCT00075764,https://clinicaltrials.gov/study/NCT02028507,https://clinicaltrials.gov/study/NCT00545077,https://clinicaltrials.gov/study/NCT02437318,https://clinicaltrials.gov/study/NCT04109066,https://clinicaltrials.gov/study/NCT01610284,https://clinicaltrials.gov/study/NCT03462251,https://clinicaltrials.gov/study/NCT01942135,https://clinicaltrials.gov/study/NCT00241449,https://clinicaltrials.gov/study/NCT02422615,https://clinicaltrials.gov/study/NCT03439046
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Recruiting	https://clinicaltrials.gov/study/NCT04873362,https://clinicaltrials.gov/study/NCT05288777,https://clinicaltrials.gov/study/NCT05429684,https://clinicaltrials.gov/study/NCT06265428,https://clinicaltrials.gov/study/NCT04457596,https://clinicaltrials.gov/study/NCT03975647,https://clinicaltrials.gov/study/NCT05755048
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Withdrawn	https://clinicaltrials.gov/study/NCT03811418,https://clinicaltrials.gov/study/NCT00041171,https://clinicaltrials.gov/study/NCT05474690
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	3	Unknown status	https://clinicaltrials.gov/study/NCT00039546,https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT02207335,https://clinicaltrials.gov/study/NCT00070278,https://clinicaltrials.gov/study/NCT02514681
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Completed	https://clinicaltrials.gov/study/NCT02225470,https://clinicaltrials.gov/study/NCT00103233
MONDO_0007254	breast cancer	CHEMBL1655	TOREMIFENE	Small molecule	Estrogen receptor modulator		ESR1	estrogen receptor 1	3	Terminated	https://clinicaltrials.gov/study/NCT00010322
MONDO_0007254	breast cancer	CHEMBL3186534	RIVOCERANIB	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT05889871
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	3	Completed	https://clinicaltrials.gov/study/NCT01234337
MONDO_0007254	breast cancer	CHEMBL2177390	IPATASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT3	AKT serine/threonine kinase 3	3	Terminated	https://clinicaltrials.gov/study/NCT04060862
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Terminated	https://clinicaltrials.gov/study/NCT00520975
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Recruiting	https://clinicaltrials.gov/study/NCT02488967
MONDO_0007254	breast cancer	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	3	Recruiting	https://clinicaltrials.gov/study/NCT05374512,https://clinicaltrials.gov/study/NCT05122494,https://clinicaltrials.gov/study/NCT04335669,https://clinicaltrials.gov/study/NCT05288777,https://clinicaltrials.gov/study/NCT06268652,https://clinicaltrials.gov/study/NCT05814354,https://clinicaltrials.gov/study/NCT04307147,https://clinicaltrials.gov/study/NCT05840211,https://clinicaltrials.gov/study/NCT05424835,https://clinicaltrials.gov/study/NCT05429684,https://clinicaltrials.gov/study/NCT05629585,https://clinicaltrials.gov/study/NCT04646759,https://clinicaltrials.gov/study/NCT06143553,https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT04263298,https://clinicaltrials.gov/study/NCT03561740,https://clinicaltrials.gov/study/NCT05063136,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT04595565,https://clinicaltrials.gov/study/NCT06018337,https://clinicaltrials.gov/study/NCT05633654,https://clinicaltrials.gov/study/NCT06313983,https://clinicaltrials.gov/study/NCT05212454,https://clinicaltrials.gov/study/NCT06112379
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Terminated	https://clinicaltrials.gov/study/NCT00520975
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Recruiting	https://clinicaltrials.gov/study/NCT05894239
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Suspended	https://clinicaltrials.gov/study/NCT03777579
MONDO_0007254	breast cancer	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	3	Withdrawn	https://clinicaltrials.gov/study/NCT00053339
EFO_0000305	breast carcinoma	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Recruiting	https://clinicaltrials.gov/study/NCT01785420
EFO_0000305	breast carcinoma	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06079983
EFO_0000305	breast carcinoma	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Recruiting	https://clinicaltrials.gov/study/NCT06058377
EFO_0006861	male breast carcinoma	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	3	Completed	https://clinicaltrials.gov/study/NCT01638247
MONDO_0007254	breast cancer	CHEMBL2325741	CAPIVASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT2	AKT serine/threonine kinase 2	3	Recruiting	https://clinicaltrials.gov/study/NCT04862663
EFO_1000984	inflammatory breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Completed	https://clinicaltrials.gov/study/NCT02324088
MONDO_0007254	breast cancer	CHEMBL1231	OXYBUTYNIN	Small molecule	Muscarinic acetylcholine receptor M3 antagonist		CHRM3	cholinergic receptor muscarinic 3	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06106529
MONDO_0007254	breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	3	Recruiting	https://clinicaltrials.gov/study/NCT04862663,https://clinicaltrials.gov/study/NCT05696626,https://clinicaltrials.gov/study/NCT04961996,https://clinicaltrials.gov/study/NCT05891093,https://clinicaltrials.gov/study/NCT05952557,https://clinicaltrials.gov/study/NCT04964934,https://clinicaltrials.gov/study/NCT04584853,https://clinicaltrials.gov/study/NCT04565054
MONDO_0007254	breast cancer	CHEMBL1201179	LAPATINIB DITOSYLATE	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01104571
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT04665986,https://clinicaltrials.gov/study/NCT06081959,https://clinicaltrials.gov/study/NCT05901935,https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06343948
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	3	Terminated	https://clinicaltrials.gov/study/NCT01633060
EFO_0000304	breast adenocarcinoma	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	3	Completed	https://clinicaltrials.gov/study/NCT00005970
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00770809
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Completed	https://clinicaltrials.gov/study/NCT00191152
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Suspended	https://clinicaltrials.gov/study/NCT03777579
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00191152
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Completed	https://clinicaltrials.gov/study/NCT03462251,https://clinicaltrials.gov/study/NCT01131195,https://clinicaltrials.gov/study/NCT00513292,https://clinicaltrials.gov/study/NCT00876395,https://clinicaltrials.gov/study/NCT00038402,https://clinicaltrials.gov/study/NCT01287624,https://clinicaltrials.gov/study/NCT01216111,https://clinicaltrials.gov/study/NCT00567554,https://clinicaltrials.gov/study/NCT01901146,https://clinicaltrials.gov/study/NCT01690702,https://clinicaltrials.gov/study/NCT00431080,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT03498716,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT02163694,https://clinicaltrials.gov/study/NCT00236899,https://clinicaltrials.gov/study/NCT01120184,https://clinicaltrials.gov/study/NCT01964391,https://clinicaltrials.gov/study/NCT01940497,https://clinicaltrials.gov/study/NCT00006459,https://clinicaltrials.gov/study/NCT04031703,https://clinicaltrials.gov/study/NCT01989676,https://clinicaltrials.gov/study/NCT00146549,https://clinicaltrials.gov/study/NCT00041119,https://clinicaltrials.gov/study/NCT00667251,https://clinicaltrials.gov/study/NCT00311636,https://clinicaltrials.gov/study/NCT01998906,https://clinicaltrials.gov/study/NCT00016406,https://clinicaltrials.gov/study/NCT02472964,https://clinicaltrials.gov/study/NCT02194166,https://clinicaltrials.gov/study/NCT02019277,https://clinicaltrials.gov/study/NCT00336791,https://clinicaltrials.gov/study/NCT03556358,https://clinicaltrials.gov/study/NCT02819518,https://clinicaltrials.gov/study/NCT04109066,https://clinicaltrials.gov/study/NCT00003013,https://clinicaltrials.gov/study/NCT00129922,https://clinicaltrials.gov/study/NCT00544232,https://clinicaltrials.gov/study/NCT03726879,https://clinicaltrials.gov/study/NCT02425891,https://clinicaltrials.gov/study/NCT04127019,https://clinicaltrials.gov/study/NCT03493854,https://clinicaltrials.gov/study/NCT01764022,https://clinicaltrials.gov/study/NCT02594371,https://clinicaltrials.gov/study/NCT00600340,https://clinicaltrials.gov/study/NCT00004067,https://clinicaltrials.gov/study/NCT00002662,https://clinicaltrials.gov/study/NCT01526369,https://clinicaltrials.gov/study/NCT00014222,https://clinicaltrials.gov/study/NCT00002953,https://clinicaltrials.gov/study/NCT00448591,https://clinicaltrials.gov/study/NCT02032277,https://clinicaltrials.gov/study/NCT00004125,https://clinicaltrials.gov/study/NCT00129389,https://clinicaltrials.gov/study/NCT01822314,https://clinicaltrials.gov/study/NCT00028990,https://clinicaltrials.gov/study/NCT00003088,https://clinicaltrials.gov/study/NCT01433614,https://clinicaltrials.gov/study/NCT02450058,https://clinicaltrials.gov/study/NCT00668616,https://clinicaltrials.gov/study/NCT01314833,https://clinicaltrials.gov/study/NCT00876486,https://clinicaltrials.gov/study/NCT01663727,https://clinicaltrials.gov/study/NCT00561119,https://clinicaltrials.gov/study/NCT00789581,https://clinicaltrials.gov/study/NCT01644890,https://clinicaltrials.gov/study/NCT00003972,https://clinicaltrials.gov/study/NCT03337724,https://clinicaltrials.gov/study/NCT00003440,https://clinicaltrials.gov/study/NCT00196872
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Withdrawn	https://clinicaltrials.gov/study/NCT02929576
EFO_0000304	breast adenocarcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	3	Suspended	https://clinicaltrials.gov/study/NCT03002103
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
MONDO_0007254	breast cancer	CHEMBL3545262	SACITUZUMAB GOVITECAN	Antibody drug conjugate	Tumor-associated calcium signal transducer 2 binding agent		TACSTD2	tumor associated calcium signal transducer 2	3	Completed	https://clinicaltrials.gov/study/NCT03901339,https://clinicaltrials.gov/study/NCT02574455
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Completed	https://clinicaltrials.gov/study/NCT00448591,https://clinicaltrials.gov/study/NCT00630032,https://clinicaltrials.gov/study/NCT00789581,https://clinicaltrials.gov/study/NCT00080301,https://clinicaltrials.gov/study/NCT00082433
MONDO_0007254	breast cancer	CHEMBL4297844	TRASTUZUMAB DERUXTECAN	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 binding agent		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Completed	https://clinicaltrials.gov/study/NCT04739761
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Completed	https://clinicaltrials.gov/study/NCT02225470,https://clinicaltrials.gov/study/NCT00103233
MONDO_0007254	breast cancer	CHEMBL1536	ERGOCALCIFEROL	Small molecule	Vitamin D receptor agonist		VDR	vitamin D receptor	3	Unknown status	https://clinicaltrials.gov/study/NCT00944424
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06079983
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT05838066,https://clinicaltrials.gov/study/NCT04665986,https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT05172518
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	3	Unknown status	https://clinicaltrials.gov/study/NCT00070278,https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT00039546
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02003209,https://clinicaltrials.gov/study/NCT03199885,https://clinicaltrials.gov/study/NCT01275677
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	3	Unknown status	https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT00039546,https://clinicaltrials.gov/study/NCT00070278
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Withdrawn	https://clinicaltrials.gov/study/NCT03811418
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885,https://clinicaltrials.gov/study/NCT01275677
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT06143553
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4L	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L	3	Completed	https://clinicaltrials.gov/study/NCT01101438
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04639986
EFO_0000305	breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Completed	https://clinicaltrials.gov/study/NCT00785291
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Recruiting	https://clinicaltrials.gov/study/NCT05862064,https://clinicaltrials.gov/study/NCT04296175
MONDO_0007254	breast cancer	CHEMBL185	FLUOROURACIL	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	3	Completed	https://clinicaltrials.gov/study/NCT00431080,https://clinicaltrials.gov/study/NCT02995772,https://clinicaltrials.gov/study/NCT00311636,https://clinicaltrials.gov/study/NCT00002784,https://clinicaltrials.gov/study/NCT00038402,https://clinicaltrials.gov/study/NCT00152178,https://clinicaltrials.gov/study/NCT00963729,https://clinicaltrials.gov/study/NCT00002870,https://clinicaltrials.gov/study/NCT02450058,https://clinicaltrials.gov/study/NCT00002580,https://clinicaltrials.gov/study/NCT00950300,https://clinicaltrials.gov/study/NCT00129922,https://clinicaltrials.gov/study/NCT00055679,https://clinicaltrials.gov/study/NCT00003893,https://clinicaltrials.gov/study/NCT00331097,https://clinicaltrials.gov/study/NCT00003577,https://clinicaltrials.gov/study/NCT00309569,https://clinicaltrials.gov/study/NCT00047099,https://clinicaltrials.gov/study/NCT00002755,https://clinicaltrials.gov/study/NCT00054587,https://clinicaltrials.gov/study/NCT04127019,https://clinicaltrials.gov/study/NCT00630032,https://clinicaltrials.gov/study/NCT03888677,https://clinicaltrials.gov/study/NCT00002579,https://clinicaltrials.gov/study/NCT04031703,https://clinicaltrials.gov/study/NCT02115204,https://clinicaltrials.gov/study/NCT00014222,https://clinicaltrials.gov/study/NCT00929591,https://clinicaltrials.gov/study/NCT01314833,https://clinicaltrials.gov/study/NCT00129389,https://clinicaltrials.gov/study/NCT00003013,https://clinicaltrials.gov/study/NCT00002581,https://clinicaltrials.gov/study/NCT00615602,https://clinicaltrials.gov/study/NCT00152191,https://clinicaltrials.gov/study/NCT01216111,https://clinicaltrials.gov/study/NCT00776724,https://clinicaltrials.gov/study/NCT00017095,https://clinicaltrials.gov/study/NCT00309478,https://clinicaltrials.gov/study/NCT00003012,https://clinicaltrials.gov/study/NCT00002582,https://clinicaltrials.gov/study/NCT00193011,https://clinicaltrials.gov/study/NCT02980965,https://clinicaltrials.gov/study/NCT00002542,https://clinicaltrials.gov/study/NCT02681003,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT00688740,https://clinicaltrials.gov/study/NCT00087178,https://clinicaltrials.gov/study/NCT00336791,https://clinicaltrials.gov/study/NCT01985724
MONDO_0007254	breast cancer	CHEMBL1201568	PEGFILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	3	Completed	https://clinicaltrials.gov/study/NCT00117910,https://clinicaltrials.gov/study/NCT00887536
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Terminated	https://clinicaltrials.gov/study/NCT00625898,https://clinicaltrials.gov/study/NCT00912444,https://clinicaltrials.gov/study/NCT00053911,https://clinicaltrials.gov/study/NCT02144012,https://clinicaltrials.gov/study/NCT01200212
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Recruiting	https://clinicaltrials.gov/study/NCT04540692,https://clinicaltrials.gov/study/NCT06112379,https://clinicaltrials.gov/study/NCT04335669,https://clinicaltrials.gov/study/NCT06018337,https://clinicaltrials.gov/study/NCT05374512,https://clinicaltrials.gov/study/NCT03876886,https://clinicaltrials.gov/study/NCT04193059,https://clinicaltrials.gov/study/NCT05555706,https://clinicaltrials.gov/study/NCT04547907,https://clinicaltrials.gov/study/NCT04862585,https://clinicaltrials.gov/study/NCT05382299,https://clinicaltrials.gov/study/NCT04137653,https://clinicaltrials.gov/study/NCT05429684,https://clinicaltrials.gov/study/NCT05840211,https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT05207709,https://clinicaltrials.gov/study/NCT06103864,https://clinicaltrials.gov/study/NCT03949634,https://clinicaltrials.gov/study/NCT05113251,https://clinicaltrials.gov/study/NCT05894239,https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT05296798,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT05814354,https://clinicaltrials.gov/study/NCT06143553
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Recruiting	https://clinicaltrials.gov/study/NCT02488967
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Completed	https://clinicaltrials.gov/study/NCT02194166,https://clinicaltrials.gov/study/NCT02819518,https://clinicaltrials.gov/study/NCT04031703,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT03498716,https://clinicaltrials.gov/study/NCT01940497,https://clinicaltrials.gov/study/NCT00006459,https://clinicaltrials.gov/study/NCT00513292,https://clinicaltrials.gov/study/NCT00002662,https://clinicaltrials.gov/study/NCT00003088,https://clinicaltrials.gov/study/NCT00876486,https://clinicaltrials.gov/study/NCT00004067,https://clinicaltrials.gov/study/NCT01989676,https://clinicaltrials.gov/study/NCT00003972,https://clinicaltrials.gov/study/NCT01131195,https://clinicaltrials.gov/study/NCT01216111,https://clinicaltrials.gov/study/NCT00600340,https://clinicaltrials.gov/study/NCT04127019,https://clinicaltrials.gov/study/NCT00041119,https://clinicaltrials.gov/study/NCT00016406,https://clinicaltrials.gov/study/NCT02594371,https://clinicaltrials.gov/study/NCT00668616,https://clinicaltrials.gov/study/NCT00014222,https://clinicaltrials.gov/study/NCT01120184,https://clinicaltrials.gov/study/NCT00876395,https://clinicaltrials.gov/study/NCT00146549,https://clinicaltrials.gov/study/NCT01901146,https://clinicaltrials.gov/study/NCT02425891,https://clinicaltrials.gov/study/NCT00567554,https://clinicaltrials.gov/study/NCT01287624,https://clinicaltrials.gov/study/NCT00003013,https://clinicaltrials.gov/study/NCT03726879,https://clinicaltrials.gov/study/NCT00431080,https://clinicaltrials.gov/study/NCT00448591,https://clinicaltrials.gov/study/NCT00336791,https://clinicaltrials.gov/study/NCT02450058,https://clinicaltrials.gov/study/NCT01690702,https://clinicaltrials.gov/study/NCT00311636,https://clinicaltrials.gov/study/NCT03556358,https://clinicaltrials.gov/study/NCT00028990,https://clinicaltrials.gov/study/NCT04109066,https://clinicaltrials.gov/study/NCT01314833,https://clinicaltrials.gov/study/NCT00789581,https://clinicaltrials.gov/study/NCT03337724,https://clinicaltrials.gov/study/NCT02472964,https://clinicaltrials.gov/study/NCT02019277,https://clinicaltrials.gov/study/NCT01822314,https://clinicaltrials.gov/study/NCT00561119,https://clinicaltrials.gov/study/NCT00196872,https://clinicaltrials.gov/study/NCT00004125,https://clinicaltrials.gov/study/NCT01644890,https://clinicaltrials.gov/study/NCT01526369,https://clinicaltrials.gov/study/NCT01764022,https://clinicaltrials.gov/study/NCT03493854,https://clinicaltrials.gov/study/NCT00003440,https://clinicaltrials.gov/study/NCT01998906,https://clinicaltrials.gov/study/NCT01433614,https://clinicaltrials.gov/study/NCT00544232,https://clinicaltrials.gov/study/NCT00129389,https://clinicaltrials.gov/study/NCT02163694,https://clinicaltrials.gov/study/NCT00667251,https://clinicaltrials.gov/study/NCT00236899,https://clinicaltrials.gov/study/NCT00129922,https://clinicaltrials.gov/study/NCT03462251,https://clinicaltrials.gov/study/NCT01663727,https://clinicaltrials.gov/study/NCT02032277,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT00038402,https://clinicaltrials.gov/study/NCT00002953,https://clinicaltrials.gov/study/NCT01964391
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Terminated	https://clinicaltrials.gov/study/NCT00520975
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01646034,https://clinicaltrials.gov/study/NCT03734029,https://clinicaltrials.gov/study/NCT04639986,https://clinicaltrials.gov/study/NCT02641847,https://clinicaltrials.gov/study/NCT05104866
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03588091,https://clinicaltrials.gov/study/NCT02003209,https://clinicaltrials.gov/study/NCT04024462,https://clinicaltrials.gov/study/NCT01646034,https://clinicaltrials.gov/study/NCT02641847,https://clinicaltrials.gov/study/NCT01358877,https://clinicaltrials.gov/study/NCT03863223
MONDO_0007254	breast cancer	CHEMBL118	CELECOXIB	Small molecule	Cyclooxygenase-2 inhibitor		PTGS2	prostaglandin-endoperoxide synthase 2	3	Completed	https://clinicaltrials.gov/study/NCT00525096,https://clinicaltrials.gov/study/NCT02429427
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Completed	https://clinicaltrials.gov/study/NCT00080301,https://clinicaltrials.gov/study/NCT00448591,https://clinicaltrials.gov/study/NCT00630032,https://clinicaltrials.gov/study/NCT00789581,https://clinicaltrials.gov/study/NCT00082433
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Completed	https://clinicaltrials.gov/study/NCT03901339,https://clinicaltrials.gov/study/NCT02555657,https://clinicaltrials.gov/study/NCT00868634,https://clinicaltrials.gov/study/NCT00431106,https://clinicaltrials.gov/study/NCT02225470,https://clinicaltrials.gov/study/NCT01007942,https://clinicaltrials.gov/study/NCT00776724,https://clinicaltrials.gov/study/NCT00103233,https://clinicaltrials.gov/study/NCT02574455,https://clinicaltrials.gov/study/NCT00146549
MONDO_0007254	breast cancer	CHEMBL1059	PREGABALIN	Small molecule	Voltage-gated calcium channel modulator		CACNA2D1	calcium voltage-gated channel auxiliary subunit alpha2delta 1	3	Completed	https://clinicaltrials.gov/study/NCT03794388
EFO_0000304	breast adenocarcinoma	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00310180
EFO_0000305	breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Completed	https://clinicaltrials.gov/study/NCT00785291
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Unknown status	https://clinicaltrials.gov/study/NCT02879513
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04799249
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Recruiting	https://clinicaltrials.gov/study/NCT04457596
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Terminated	https://clinicaltrials.gov/study/NCT05134194,https://clinicaltrials.gov/study/NCT03786094
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Completed	https://clinicaltrials.gov/study/NCT00567554,https://clinicaltrials.gov/study/NCT00236899,https://clinicaltrials.gov/study/NCT00433589,https://clinicaltrials.gov/study/NCT03493854,https://clinicaltrials.gov/study/NCT03084237,https://clinicaltrials.gov/study/NCT00091442,https://clinicaltrials.gov/study/NCT01690702,https://clinicaltrials.gov/study/NCT00294385,https://clinicaltrials.gov/study/NCT00047255,https://clinicaltrials.gov/study/NCT01314833,https://clinicaltrials.gov/study/NCT00963729,https://clinicaltrials.gov/study/NCT00630032,https://clinicaltrials.gov/study/NCT03013504,https://clinicaltrials.gov/study/NCT01940497,https://clinicaltrials.gov/study/NCT01120184,https://clinicaltrials.gov/study/NCT01964391,https://clinicaltrials.gov/study/NCT00114816,https://clinicaltrials.gov/study/NCT00008411,https://clinicaltrials.gov/study/NCT00047099,https://clinicaltrials.gov/study/NCT01216111,https://clinicaltrials.gov/study/NCT00002662,https://clinicaltrials.gov/study/NCT00146549,https://clinicaltrials.gov/study/NCT00703326,https://clinicaltrials.gov/study/NCT00129935,https://clinicaltrials.gov/study/NCT05301010,https://clinicaltrials.gov/study/NCT02187744,https://clinicaltrials.gov/study/NCT04957212,https://clinicaltrials.gov/study/NCT02194166,https://clinicaltrials.gov/study/NCT00003782,https://clinicaltrials.gov/study/NCT00314977,https://clinicaltrials.gov/study/NCT02472964,https://clinicaltrials.gov/study/NCT00002707,https://clinicaltrials.gov/study/NCT04031703,https://clinicaltrials.gov/study/NCT04629846,https://clinicaltrials.gov/study/NCT00776724,https://clinicaltrials.gov/study/NCT02586025,https://clinicaltrials.gov/study/NCT02681003,https://clinicaltrials.gov/study/NCT04127019,https://clinicaltrials.gov/study/NCT00887536,https://clinicaltrials.gov/study/NCT00615602,https://clinicaltrials.gov/study/NCT00793377,https://clinicaltrials.gov/study/NCT00054587,https://clinicaltrials.gov/study/NCT00431080,https://clinicaltrials.gov/study/NCT02402712,https://clinicaltrials.gov/study/NCT00333775,https://clinicaltrials.gov/study/NCT02019277,https://clinicaltrials.gov/study/NCT00002544,https://clinicaltrials.gov/study/NCT03989037,https://clinicaltrials.gov/study/NCT00017095,https://clinicaltrials.gov/study/NCT00193011,https://clinicaltrials.gov/study/NCT02115204,https://clinicaltrials.gov/study/NCT00429871,https://clinicaltrials.gov/study/NCT00950300,https://clinicaltrials.gov/study/NCT00190489,https://clinicaltrials.gov/study/NCT00448591,https://clinicaltrials.gov/study/NCT00309556,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT03425656,https://clinicaltrials.gov/study/NCT00352378,https://clinicaltrials.gov/study/NCT01099436,https://clinicaltrials.gov/study/NCT00311636,https://clinicaltrials.gov/study/NCT05629949,https://clinicaltrials.gov/study/NCT00391092,https://clinicaltrials.gov/study/NCT01985724,https://clinicaltrials.gov/study/NCT00667251,https://clinicaltrials.gov/study/NCT00493870,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT00089479,https://clinicaltrials.gov/study/NCT00004125,https://clinicaltrials.gov/study/NCT00688740,https://clinicaltrials.gov/study/NCT00312208,https://clinicaltrials.gov/study/NCT00567190,https://clinicaltrials.gov/study/NCT00191152,https://clinicaltrials.gov/study/NCT00003519,https://clinicaltrials.gov/study/NCT00331097,https://clinicaltrials.gov/study/NCT01049425,https://clinicaltrials.gov/study/NCT02896855,https://clinicaltrials.gov/study/NCT00288002,https://clinicaltrials.gov/study/NCT02980965,https://clinicaltrials.gov/study/NCT00424606,https://clinicaltrials.gov/study/NCT00540800
MONDO_0007254	breast cancer	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN2A	sodium voltage-gated channel alpha subunit 2	3	Terminated	https://clinicaltrials.gov/study/NCT02525211
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Completed	https://clinicaltrials.gov/study/NCT00103233,https://clinicaltrials.gov/study/NCT02225470
EFO_0000304	breast adenocarcinoma	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Completed	https://clinicaltrials.gov/study/NCT00005970
MONDO_0007254	breast cancer	CHEMBL1201583	BEVACIZUMAB	Antibody	Vascular endothelial growth factor A inhibitor		VEGFA	vascular endothelial growth factor A	3	Unknown status	https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT00262067
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Unknown status	https://clinicaltrials.gov/study/NCT00430001,https://clinicaltrials.gov/study/NCT02514681
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Terminated	https://clinicaltrials.gov/study/NCT00520975
MONDO_0007254	breast cancer	CHEMBL1487	ATORVASTATIN	Small molecule	HMG-CoA reductase inhibitor		HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase	3	Recruiting	https://clinicaltrials.gov/study/NCT04601116
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Completed	https://clinicaltrials.gov/study/NCT00005970
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Recruiting	https://clinicaltrials.gov/study/NCT05159193,https://clinicaltrials.gov/study/NCT05894239,https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT04540692,https://clinicaltrials.gov/study/NCT03926091,https://clinicaltrials.gov/study/NCT05207514,https://clinicaltrials.gov/study/NCT05901428,https://clinicaltrials.gov/study/NCT05673629,https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT03671044,https://clinicaltrials.gov/study/NCT03949634,https://clinicaltrials.gov/study/NCT04547907,https://clinicaltrials.gov/study/NCT05720026,https://clinicaltrials.gov/study/NCT05430399,https://clinicaltrials.gov/study/NCT05883852,https://clinicaltrials.gov/study/NCT04193059,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT05296798
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT06143553
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Completed	https://clinicaltrials.gov/study/NCT01940497,https://clinicaltrials.gov/study/NCT00129935,https://clinicaltrials.gov/study/NCT00091442,https://clinicaltrials.gov/study/NCT00333775,https://clinicaltrials.gov/study/NCT00190489,https://clinicaltrials.gov/study/NCT00448591,https://clinicaltrials.gov/study/NCT00703326,https://clinicaltrials.gov/study/NCT01985724,https://clinicaltrials.gov/study/NCT02402712,https://clinicaltrials.gov/study/NCT00776724,https://clinicaltrials.gov/study/NCT00887536,https://clinicaltrials.gov/study/NCT01049425,https://clinicaltrials.gov/study/NCT00331097,https://clinicaltrials.gov/study/NCT00003519,https://clinicaltrials.gov/study/NCT00424606,https://clinicaltrials.gov/study/NCT00667251,https://clinicaltrials.gov/study/NCT00047099,https://clinicaltrials.gov/study/NCT00017095,https://clinicaltrials.gov/study/NCT03425656,https://clinicaltrials.gov/study/NCT00002544,https://clinicaltrials.gov/study/NCT02896855,https://clinicaltrials.gov/study/NCT00429871,https://clinicaltrials.gov/study/NCT01099436,https://clinicaltrials.gov/study/NCT00311636,https://clinicaltrials.gov/study/NCT02472964,https://clinicaltrials.gov/study/NCT00002662,https://clinicaltrials.gov/study/NCT02586025,https://clinicaltrials.gov/study/NCT02980965,https://clinicaltrials.gov/study/NCT00352378,https://clinicaltrials.gov/study/NCT03013504,https://clinicaltrials.gov/study/NCT00950300,https://clinicaltrials.gov/study/NCT01120184,https://clinicaltrials.gov/study/NCT00963729,https://clinicaltrials.gov/study/NCT00047255,https://clinicaltrials.gov/study/NCT00146549,https://clinicaltrials.gov/study/NCT00114816,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT00567554,https://clinicaltrials.gov/study/NCT04629846,https://clinicaltrials.gov/study/NCT02194166,https://clinicaltrials.gov/study/NCT00003782,https://clinicaltrials.gov/study/NCT03493854,https://clinicaltrials.gov/study/NCT00236899,https://clinicaltrials.gov/study/NCT02019277,https://clinicaltrials.gov/study/NCT00008411,https://clinicaltrials.gov/study/NCT02115204,https://clinicaltrials.gov/study/NCT04957212,https://clinicaltrials.gov/study/NCT04127019,https://clinicaltrials.gov/study/NCT00615602,https://clinicaltrials.gov/study/NCT05301010,https://clinicaltrials.gov/study/NCT00089479,https://clinicaltrials.gov/study/NCT00312208,https://clinicaltrials.gov/study/NCT02681003,https://clinicaltrials.gov/study/NCT00002707,https://clinicaltrials.gov/study/NCT00431080,https://clinicaltrials.gov/study/NCT00567190,https://clinicaltrials.gov/study/NCT02187744,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT00433589,https://clinicaltrials.gov/study/NCT00309556,https://clinicaltrials.gov/study/NCT00688740,https://clinicaltrials.gov/study/NCT00004125,https://clinicaltrials.gov/study/NCT00054587,https://clinicaltrials.gov/study/NCT01314833,https://clinicaltrials.gov/study/NCT00540800,https://clinicaltrials.gov/study/NCT00191152,https://clinicaltrials.gov/study/NCT00193011,https://clinicaltrials.gov/study/NCT00793377,https://clinicaltrials.gov/study/NCT04031703,https://clinicaltrials.gov/study/NCT00314977,https://clinicaltrials.gov/study/NCT00288002,https://clinicaltrials.gov/study/NCT05629949,https://clinicaltrials.gov/study/NCT00391092,https://clinicaltrials.gov/study/NCT01964391,https://clinicaltrials.gov/study/NCT00294385,https://clinicaltrials.gov/study/NCT00493870,https://clinicaltrials.gov/study/NCT03084237,https://clinicaltrials.gov/study/NCT01216111,https://clinicaltrials.gov/study/NCT01690702,https://clinicaltrials.gov/study/NCT03989037,https://clinicaltrials.gov/study/NCT00630032
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00191152
MONDO_0007254	breast cancer	CHEMBL4297939	DATOPOTAMAB DERUXTECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	3	Recruiting	https://clinicaltrials.gov/study/NCT05629585,https://clinicaltrials.gov/study/NCT05374512,https://clinicaltrials.gov/study/NCT06103864,https://clinicaltrials.gov/study/NCT06112379
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885,https://clinicaltrials.gov/study/NCT02003209,https://clinicaltrials.gov/study/NCT01275677
EFO_0000304	breast adenocarcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
EFO_1000984	inflammatory breast carcinoma	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT05415215
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Terminated	https://clinicaltrials.gov/study/NCT01200212,https://clinicaltrials.gov/study/NCT02054338,https://clinicaltrials.gov/study/NCT00002772,https://clinicaltrials.gov/study/NCT00520975,https://clinicaltrials.gov/study/NCT04335006,https://clinicaltrials.gov/study/NCT01303679
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Terminated	https://clinicaltrials.gov/study/NCT01200212,https://clinicaltrials.gov/study/NCT02144012,https://clinicaltrials.gov/study/NCT00912444,https://clinicaltrials.gov/study/NCT00625898,https://clinicaltrials.gov/study/NCT00053911
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF3	NADH:ubiquinone oxidoreductase complex assembly factor 3	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Withdrawn	https://clinicaltrials.gov/study/NCT00403182
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Withdrawn	https://clinicaltrials.gov/study/NCT00041171,https://clinicaltrials.gov/study/NCT03811418,https://clinicaltrials.gov/study/NCT05474690
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBA1A	tubulin alpha 1a	3	Completed	https://clinicaltrials.gov/study/NCT01953003,https://clinicaltrials.gov/study/NCT01095003,https://clinicaltrials.gov/study/NCT01091168
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	3	Completed	https://clinicaltrials.gov/study/NCT01610284
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Completed	https://clinicaltrials.gov/study/NCT01095003,https://clinicaltrials.gov/study/NCT01091168,https://clinicaltrials.gov/study/NCT01953003
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
MONDO_0007254	breast cancer	CHEMBL635	PREDNISONE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	3	Completed	https://clinicaltrials.gov/study/NCT01517802
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA13	NADH:ubiquinone oxidoreductase subunit A13	3	Completed	https://clinicaltrials.gov/study/NCT01101438
EFO_1000984	inflammatory breast carcinoma	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02221999
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	3	Suspended	https://clinicaltrials.gov/study/NCT03002103
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL359744	DOXORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Completed	https://clinicaltrials.gov/study/NCT00005970
MONDO_0007254	breast cancer	CHEMBL1201247	GOSERELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	3	Completed	https://clinicaltrials.gov/study/NCT01712893,https://clinicaltrials.gov/study/NCT01073865,https://clinicaltrials.gov/study/NCT00002580,https://clinicaltrials.gov/study/NCT02278120,https://clinicaltrials.gov/study/NCT00002582,https://clinicaltrials.gov/study/NCT02483767,https://clinicaltrials.gov/study/NCT01530607,https://clinicaltrials.gov/study/NCT05110170,https://clinicaltrials.gov/study/NCT00605267,https://clinicaltrials.gov/study/NCT00309478,https://clinicaltrials.gov/study/NCT00047099,https://clinicaltrials.gov/study/NCT00295646,https://clinicaltrials.gov/study/NCT02941926,https://clinicaltrials.gov/study/NCT03096847
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06079983
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Completed	https://clinicaltrials.gov/study/NCT00091442,https://clinicaltrials.gov/study/NCT00667251,https://clinicaltrials.gov/study/NCT01964391,https://clinicaltrials.gov/study/NCT00963729,https://clinicaltrials.gov/study/NCT03425656,https://clinicaltrials.gov/study/NCT05301010,https://clinicaltrials.gov/study/NCT00431080,https://clinicaltrials.gov/study/NCT00129935,https://clinicaltrials.gov/study/NCT00309556,https://clinicaltrials.gov/study/NCT00054587,https://clinicaltrials.gov/study/NCT01216111,https://clinicaltrials.gov/study/NCT02896855,https://clinicaltrials.gov/study/NCT00089479,https://clinicaltrials.gov/study/NCT00433589,https://clinicaltrials.gov/study/NCT01314833,https://clinicaltrials.gov/study/NCT00630032,https://clinicaltrials.gov/study/NCT03493854,https://clinicaltrials.gov/study/NCT00294385,https://clinicaltrials.gov/study/NCT02019277,https://clinicaltrials.gov/study/NCT01940497,https://clinicaltrials.gov/study/NCT00314977,https://clinicaltrials.gov/study/NCT03084237,https://clinicaltrials.gov/study/NCT00002544,https://clinicaltrials.gov/study/NCT00333775,https://clinicaltrials.gov/study/NCT02681003,https://clinicaltrials.gov/study/NCT00493870,https://clinicaltrials.gov/study/NCT00003519,https://clinicaltrials.gov/study/NCT05629949,https://clinicaltrials.gov/study/NCT00688740,https://clinicaltrials.gov/study/NCT02187744,https://clinicaltrials.gov/study/NCT00146549,https://clinicaltrials.gov/study/NCT00002662,https://clinicaltrials.gov/study/NCT00193011,https://clinicaltrials.gov/study/NCT00540800,https://clinicaltrials.gov/study/NCT00191152,https://clinicaltrials.gov/study/NCT03013504,https://clinicaltrials.gov/study/NCT03989037,https://clinicaltrials.gov/study/NCT00190489,https://clinicaltrials.gov/study/NCT00017095,https://clinicaltrials.gov/study/NCT04629846,https://clinicaltrials.gov/study/NCT00424606,https://clinicaltrials.gov/study/NCT00887536,https://clinicaltrials.gov/study/NCT00331097,https://clinicaltrials.gov/study/NCT00567190,https://clinicaltrials.gov/study/NCT00429871,https://clinicaltrials.gov/study/NCT00615602,https://clinicaltrials.gov/study/NCT00047255,https://clinicaltrials.gov/study/NCT00047099,https://clinicaltrials.gov/study/NCT02402712,https://clinicaltrials.gov/study/NCT04031703,https://clinicaltrials.gov/study/NCT02472964,https://clinicaltrials.gov/study/NCT00950300,https://clinicaltrials.gov/study/NCT00793377,https://clinicaltrials.gov/study/NCT02586025,https://clinicaltrials.gov/study/NCT00114816,https://clinicaltrials.gov/study/NCT01985724,https://clinicaltrials.gov/study/NCT00311636,https://clinicaltrials.gov/study/NCT00312208,https://clinicaltrials.gov/study/NCT00352378,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT00448591,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT00703326,https://clinicaltrials.gov/study/NCT00002707,https://clinicaltrials.gov/study/NCT00776724,https://clinicaltrials.gov/study/NCT01099436,https://clinicaltrials.gov/study/NCT00391092,https://clinicaltrials.gov/study/NCT01049425,https://clinicaltrials.gov/study/NCT02980965,https://clinicaltrials.gov/study/NCT02115204,https://clinicaltrials.gov/study/NCT04127019,https://clinicaltrials.gov/study/NCT04957212,https://clinicaltrials.gov/study/NCT00003782,https://clinicaltrials.gov/study/NCT01120184,https://clinicaltrials.gov/study/NCT00567554,https://clinicaltrials.gov/study/NCT01690702,https://clinicaltrials.gov/study/NCT02194166,https://clinicaltrials.gov/study/NCT00288002,https://clinicaltrials.gov/study/NCT00236899,https://clinicaltrials.gov/study/NCT00004125,https://clinicaltrials.gov/study/NCT00008411
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06081959,https://clinicaltrials.gov/study/NCT06279364,https://clinicaltrials.gov/study/NCT06343948,https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT06255392
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA10	NADH:ubiquinone oxidoreductase subunit A10	3	Completed	https://clinicaltrials.gov/study/NCT01101438
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Suspended	https://clinicaltrials.gov/study/NCT03002103
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Terminated	https://clinicaltrials.gov/study/NCT02054338,https://clinicaltrials.gov/study/NCT01200212,https://clinicaltrials.gov/study/NCT00002772,https://clinicaltrials.gov/study/NCT01303679,https://clinicaltrials.gov/study/NCT00520975,https://clinicaltrials.gov/study/NCT04335006
MONDO_0007254	breast cancer	CHEMBL359744	DOXORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Unknown status	https://clinicaltrials.gov/study/NCT00516425,https://clinicaltrials.gov/study/NCT00003679,https://clinicaltrials.gov/study/NCT00294996,https://clinicaltrials.gov/study/NCT00629278,https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT02393833
EFO_0000553	invasive lobular carcinoma	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01953588
EFO_0005537	triple-negative breast cancer	CHEMBL2177390	IPATASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT3	AKT serine/threonine kinase 3	3	Completed	https://clinicaltrials.gov/study/NCT04177108
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02003209,https://clinicaltrials.gov/study/NCT03199885,https://clinicaltrials.gov/study/NCT01275677
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Terminated	https://clinicaltrials.gov/study/NCT01200212,https://clinicaltrials.gov/study/NCT04335006,https://clinicaltrials.gov/study/NCT00002772,https://clinicaltrials.gov/study/NCT02054338,https://clinicaltrials.gov/study/NCT00520975,https://clinicaltrials.gov/study/NCT01303679
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Completed	https://clinicaltrials.gov/study/NCT00388726,https://clinicaltrials.gov/study/NCT02225470,https://clinicaltrials.gov/study/NCT00337103
MONDO_0007254	breast cancer	CHEMBL34259	METHOTREXATE	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	3	Completed	https://clinicaltrials.gov/study/NCT00003012,https://clinicaltrials.gov/study/NCT00003013,https://clinicaltrials.gov/study/NCT00152191,https://clinicaltrials.gov/study/NCT00309569,https://clinicaltrials.gov/study/NCT00002784,https://clinicaltrials.gov/study/NCT00002582,https://clinicaltrials.gov/study/NCT00544232,https://clinicaltrials.gov/study/NCT00309478,https://clinicaltrials.gov/study/NCT00003893,https://clinicaltrials.gov/study/NCT00002542,https://clinicaltrials.gov/study/NCT02115204,https://clinicaltrials.gov/study/NCT00003577,https://clinicaltrials.gov/study/NCT00002581,https://clinicaltrials.gov/study/NCT00022516,https://clinicaltrials.gov/study/NCT00311636,https://clinicaltrials.gov/study/NCT00002579,https://clinicaltrials.gov/study/NCT00002755,https://clinicaltrials.gov/study/NCT00331097,https://clinicaltrials.gov/study/NCT00193011,https://clinicaltrials.gov/study/NCT00002580,https://clinicaltrials.gov/study/NCT00152178
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Terminated	https://clinicaltrials.gov/study/NCT00016276
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02000622,https://clinicaltrials.gov/study/NCT02810743,https://clinicaltrials.gov/study/NCT02032823
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN4A	sodium voltage-gated channel alpha subunit 4	3	Completed	https://clinicaltrials.gov/study/NCT04822597
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN11A	sodium voltage-gated channel alpha subunit 11	3	Completed	https://clinicaltrials.gov/study/NCT04822597
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Recruiting	https://clinicaltrials.gov/study/NCT05374512,https://clinicaltrials.gov/study/NCT06103864,https://clinicaltrials.gov/study/NCT03949634,https://clinicaltrials.gov/study/NCT03876886,https://clinicaltrials.gov/study/NCT05840211,https://clinicaltrials.gov/study/NCT04193059,https://clinicaltrials.gov/study/NCT04547907,https://clinicaltrials.gov/study/NCT05894239,https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT05382299,https://clinicaltrials.gov/study/NCT04862585,https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT04335669,https://clinicaltrials.gov/study/NCT05429684,https://clinicaltrials.gov/study/NCT05207709,https://clinicaltrials.gov/study/NCT06018337,https://clinicaltrials.gov/study/NCT05814354,https://clinicaltrials.gov/study/NCT05555706,https://clinicaltrials.gov/study/NCT06112379,https://clinicaltrials.gov/study/NCT05113251,https://clinicaltrials.gov/study/NCT05296798,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT06143553,https://clinicaltrials.gov/study/NCT04137653,https://clinicaltrials.gov/study/NCT04540692
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	3	Recruiting	https://clinicaltrials.gov/study/NCT05501886
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Terminated	https://clinicaltrials.gov/study/NCT00520975
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA6	NADH:ubiquinone oxidoreductase subunit A6	3	Completed	https://clinicaltrials.gov/study/NCT01101438
EFO_0005537	triple-negative breast cancer	CHEMBL3707227	ATEZOLIZUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	3	Completed	https://clinicaltrials.gov/study/NCT03197935,https://clinicaltrials.gov/study/NCT04177108,https://clinicaltrials.gov/study/NCT03125902
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Unknown status	https://clinicaltrials.gov/study/NCT02879513
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02221999
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03529110,https://clinicaltrials.gov/study/NCT04622319,https://clinicaltrials.gov/study/NCT04740918,https://clinicaltrials.gov/study/NCT01772472
MONDO_0007254	breast cancer	CHEMBL4279455	LAROTAXEL	Small molecule	Tubulin stabiliser		TUBB2B	tubulin beta 2B class IIb	3	Completed	https://clinicaltrials.gov/study/NCT00081796
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT05104866,https://clinicaltrials.gov/study/NCT05063786,https://clinicaltrials.gov/study/NCT04639986
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN1A	sodium voltage-gated channel alpha subunit 1	3	Completed	https://clinicaltrials.gov/study/NCT04822597
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652
EFO_0000305	breast carcinoma	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Completed	https://clinicaltrials.gov/study/NCT00005970
EFO_0000305	breast carcinoma	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00601900,https://clinicaltrials.gov/study/NCT00066690
MONDO_0007254	breast cancer	CHEMBL1201146	NORETHINDRONE ACETATE	Small molecule	Progesterone receptor agonist		PGR	progesterone receptor	3	Completed	https://clinicaltrials.gov/study/NCT00003771
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06316531,https://clinicaltrials.gov/study/NCT06313086,https://clinicaltrials.gov/study/NCT06126640
MONDO_0007254	breast cancer	CHEMBL4594568	KN-026	Unknown	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT05838066
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Recruiting	https://clinicaltrials.gov/study/NCT04862585,https://clinicaltrials.gov/study/NCT06058377,https://clinicaltrials.gov/study/NCT05747794,https://clinicaltrials.gov/study/NCT03201861
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Unknown status	https://clinicaltrials.gov/study/NCT00025688,https://clinicaltrials.gov/study/NCT01378533,https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT02393833,https://clinicaltrials.gov/study/NCT01084876,https://clinicaltrials.gov/study/NCT00005581,https://clinicaltrials.gov/study/NCT00070278,https://clinicaltrials.gov/study/NCT00289263,https://clinicaltrials.gov/study/NCT01019616,https://clinicaltrials.gov/study/NCT00039546,https://clinicaltrials.gov/study/NCT00486668,https://clinicaltrials.gov/study/NCT01134523,https://clinicaltrials.gov/study/NCT01547741,https://clinicaltrials.gov/study/NCT00629278
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Recruiting	https://clinicaltrials.gov/study/NCT05883852,https://clinicaltrials.gov/study/NCT05901428,https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT04547907,https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT04193059,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT05430399,https://clinicaltrials.gov/study/NCT04540692,https://clinicaltrials.gov/study/NCT05207514,https://clinicaltrials.gov/study/NCT03671044,https://clinicaltrials.gov/study/NCT03949634,https://clinicaltrials.gov/study/NCT05720026,https://clinicaltrials.gov/study/NCT05894239,https://clinicaltrials.gov/study/NCT03926091,https://clinicaltrials.gov/study/NCT05296798,https://clinicaltrials.gov/study/NCT05673629,https://clinicaltrials.gov/study/NCT05159193
MONDO_0007254	breast cancer	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN1A	sodium voltage-gated channel alpha subunit 1	3	Completed	https://clinicaltrials.gov/study/NCT00547989,https://clinicaltrials.gov/study/NCT02408393,https://clinicaltrials.gov/study/NCT04327063
MONDO_0007254	breast cancer	CHEMBL3647420	PYROTINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	3	Unknown status	https://clinicaltrials.gov/study/NCT03080805
MONDO_0007254	breast cancer	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06223698
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Terminated	https://clinicaltrials.gov/study/NCT00520975,https://clinicaltrials.gov/study/NCT01303679,https://clinicaltrials.gov/study/NCT01200212,https://clinicaltrials.gov/study/NCT02054338,https://clinicaltrials.gov/study/NCT04335006,https://clinicaltrials.gov/study/NCT00002772
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00770809
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Terminated	https://clinicaltrials.gov/study/NCT00002772,https://clinicaltrials.gov/study/NCT01200212,https://clinicaltrials.gov/study/NCT02054338,https://clinicaltrials.gov/study/NCT00520975,https://clinicaltrials.gov/study/NCT04335006,https://clinicaltrials.gov/study/NCT01303679
MONDO_0007254	breast cancer	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	3	Terminated	https://clinicaltrials.gov/study/NCT03050398,https://clinicaltrials.gov/study/NCT03905343
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Recruiting	https://clinicaltrials.gov/study/NCT04547907,https://clinicaltrials.gov/study/NCT03926091,https://clinicaltrials.gov/study/NCT05720026,https://clinicaltrials.gov/study/NCT05207514,https://clinicaltrials.gov/study/NCT05673629,https://clinicaltrials.gov/study/NCT05894239,https://clinicaltrials.gov/study/NCT05159193,https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT05430399,https://clinicaltrials.gov/study/NCT03671044,https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT05901428,https://clinicaltrials.gov/study/NCT04540692,https://clinicaltrials.gov/study/NCT05883852,https://clinicaltrials.gov/study/NCT03949634,https://clinicaltrials.gov/study/NCT04193059,https://clinicaltrials.gov/study/NCT05296798,https://clinicaltrials.gov/study/NCT02344472
MONDO_0007254	breast cancer	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT01645839
MONDO_0007254	breast cancer	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Unknown status	https://clinicaltrials.gov/study/NCT00688194,https://clinicaltrials.gov/study/NCT00541086,https://clinicaltrials.gov/study/NCT00893061,https://clinicaltrials.gov/study/NCT01758146,https://clinicaltrials.gov/study/NCT00902954
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Unknown status	https://clinicaltrials.gov/study/NCT01084876,https://clinicaltrials.gov/study/NCT00289263,https://clinicaltrials.gov/study/NCT00025688,https://clinicaltrials.gov/study/NCT01547741,https://clinicaltrials.gov/study/NCT00629278,https://clinicaltrials.gov/study/NCT01019616,https://clinicaltrials.gov/study/NCT00005581,https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT00039546,https://clinicaltrials.gov/study/NCT02393833,https://clinicaltrials.gov/study/NCT01134523,https://clinicaltrials.gov/study/NCT00070278,https://clinicaltrials.gov/study/NCT00486668,https://clinicaltrials.gov/study/NCT01378533
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Terminated	https://clinicaltrials.gov/study/NCT02144012
EFO_1000984	inflammatory breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT05415215
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04085276,https://clinicaltrials.gov/study/NCT04148911
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Terminated	https://clinicaltrials.gov/study/NCT00053911,https://clinicaltrials.gov/study/NCT02144012,https://clinicaltrials.gov/study/NCT00625898,https://clinicaltrials.gov/study/NCT00912444,https://clinicaltrials.gov/study/NCT01200212
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	Serine/threonine-protein kinase mTOR inhibitor		MTOR	mechanistic target of rapamycin kinase	3	Recruiting	https://clinicaltrials.gov/study/NCT05501886
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Unknown status	https://clinicaltrials.gov/study/NCT00430001,https://clinicaltrials.gov/study/NCT00629278,https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT00003679,https://clinicaltrials.gov/study/NCT00010140,https://clinicaltrials.gov/study/NCT01547741,https://clinicaltrials.gov/study/NCT01222052,https://clinicaltrials.gov/study/NCT01479036,https://clinicaltrials.gov/study/NCT01354522,https://clinicaltrials.gov/study/NCT00944424,https://clinicaltrials.gov/study/NCT01622361,https://clinicaltrials.gov/study/NCT00532727,https://clinicaltrials.gov/study/NCT02393833,https://clinicaltrials.gov/study/NCT01642771
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Completed	https://clinicaltrials.gov/study/NCT00191152
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB2	NADH:ubiquinone oxidoreductase subunit B2	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Terminated	https://clinicaltrials.gov/study/NCT02144012
MONDO_0007254	breast cancer	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	3	Completed	https://clinicaltrials.gov/study/NCT01645839
EFO_0005537	triple-negative breast cancer	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Completed	https://clinicaltrials.gov/study/NCT03197935
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	3	Unknown status	https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT00039546,https://clinicaltrials.gov/study/NCT00070278
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01646034,https://clinicaltrials.gov/study/NCT03734029,https://clinicaltrials.gov/study/NCT04639986,https://clinicaltrials.gov/study/NCT05104866,https://clinicaltrials.gov/study/NCT02641847
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02221999
MONDO_0007254	breast cancer	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01674140,https://clinicaltrials.gov/study/NCT00002644,https://clinicaltrials.gov/study/NCT00066703,https://clinicaltrials.gov/study/NCT00412022,https://clinicaltrials.gov/study/NCT01579734,https://clinicaltrials.gov/study/NCT00601900
EFO_1000984	inflammatory breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT05415215
MONDO_0007254	breast cancer	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Completed	https://clinicaltrials.gov/study/NCT00286117,https://clinicaltrials.gov/study/NCT00327769,https://clinicaltrials.gov/study/NCT00814125,https://clinicaltrials.gov/study/NCT00291759,https://clinicaltrials.gov/study/NCT00605267,https://clinicaltrials.gov/study/NCT00053898,https://clinicaltrials.gov/study/NCT00248170,https://clinicaltrials.gov/study/NCT00066573,https://clinicaltrials.gov/study/NCT00849030,https://clinicaltrials.gov/study/NCT00072462,https://clinicaltrials.gov/study/NCT00301457,https://clinicaltrials.gov/study/NCT00784862,https://clinicaltrials.gov/study/NCT00295646,https://clinicaltrials.gov/study/NCT00078832,https://clinicaltrials.gov/study/NCT00075764,https://clinicaltrials.gov/study/NCT02278120,https://clinicaltrials.gov/study/NCT02995772,https://clinicaltrials.gov/study/NCT00022672,https://clinicaltrials.gov/study/NCT00232661,https://clinicaltrials.gov/study/NCT04109066,https://clinicaltrials.gov/study/NCT00295620,https://clinicaltrials.gov/study/NCT00256698,https://clinicaltrials.gov/study/NCT00635713,https://clinicaltrials.gov/study/NCT00265759
MONDO_0007254	breast cancer	CHEMBL1655	TOREMIFENE	Small molecule	Estrogen receptor modulator		ESR2	estrogen receptor 2	3	Completed	https://clinicaltrials.gov/study/NCT00002529
MONDO_0007254	breast cancer	CHEMBL3186534	RIVOCERANIB	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	3	Recruiting	https://clinicaltrials.gov/study/NCT04296370
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV2	NADH:ubiquinone oxidoreductase core subunit V2	3	Completed	https://clinicaltrials.gov/study/NCT01101438
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Completed	https://clinicaltrials.gov/study/NCT00191152
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Recruiting	https://clinicaltrials.gov/study/NCT05760378
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	3	Unknown status	https://clinicaltrials.gov/study/NCT00070278,https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT00039546,https://clinicaltrials.gov/study/NCT02207335,https://clinicaltrials.gov/study/NCT00408408
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06081959,https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT06343948
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT05388500,https://clinicaltrials.gov/study/NCT06279364,https://clinicaltrials.gov/study/NCT04301739,https://clinicaltrials.gov/study/NCT05172518,https://clinicaltrials.gov/study/NCT05753865,https://clinicaltrials.gov/study/NCT05841381,https://clinicaltrials.gov/study/NCT06255392
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04639986
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Recruiting	https://clinicaltrials.gov/study/NCT05883852,https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT04540692,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT05901428,https://clinicaltrials.gov/study/NCT05720026,https://clinicaltrials.gov/study/NCT03949634,https://clinicaltrials.gov/study/NCT04193059,https://clinicaltrials.gov/study/NCT05673629,https://clinicaltrials.gov/study/NCT03926091,https://clinicaltrials.gov/study/NCT05296798,https://clinicaltrials.gov/study/NCT05159193,https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT05894239,https://clinicaltrials.gov/study/NCT05207514,https://clinicaltrials.gov/study/NCT05430399,https://clinicaltrials.gov/study/NCT04547907,https://clinicaltrials.gov/study/NCT03671044
MONDO_0007254	breast cancer	CHEMBL924	ZOLEDRONIC ACID ANHYDROUS	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	3	Recruiting	https://clinicaltrials.gov/study/NCT05164952
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	3	Completed	https://clinicaltrials.gov/study/NCT03286842
MONDO_0007254	breast cancer	CHEMBL279785	MARIMASTAT	Small molecule	Matrix metalloproteinase-1 inhibitor		MMP1	matrix metallopeptidase 1	3	Completed	https://clinicaltrials.gov/study/NCT00003010
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT02555657,https://clinicaltrials.gov/study/NCT00006459,https://clinicaltrials.gov/study/NCT00191152,https://clinicaltrials.gov/study/NCT00431106,https://clinicaltrials.gov/study/NCT00561119,https://clinicaltrials.gov/study/NCT02574455,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT00938652,https://clinicaltrials.gov/study/NCT00670878,https://clinicaltrials.gov/study/NCT03901339,https://clinicaltrials.gov/study/NCT02819518,https://clinicaltrials.gov/study/NCT00294385,https://clinicaltrials.gov/study/NCT01287624,https://clinicaltrials.gov/study/NCT02546934,https://clinicaltrials.gov/study/NCT00236899
MONDO_0007254	breast cancer	CHEMBL1098	BUPIVACAINE	Small molecule	Sodium channel protein type IV alpha subunit blocker		SCN4A	sodium voltage-gated channel alpha subunit 4	3	Recruiting	https://clinicaltrials.gov/study/NCT03351348
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885,https://clinicaltrials.gov/study/NCT01275677,https://clinicaltrials.gov/study/NCT02003209
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT05901935,https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT04665986
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06081959,https://clinicaltrials.gov/study/NCT06343948,https://clinicaltrials.gov/study/NCT05901935,https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT04665986
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Completed	https://clinicaltrials.gov/study/NCT02125344,https://clinicaltrials.gov/study/NCT01583426
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT04665986,https://clinicaltrials.gov/study/NCT05172518,https://clinicaltrials.gov/study/NCT05838066
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Recruiting	https://clinicaltrials.gov/study/NCT04296175,https://clinicaltrials.gov/study/NCT05862064
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03595592,https://clinicaltrials.gov/study/NCT01358877,https://clinicaltrials.gov/study/NCT03734029,https://clinicaltrials.gov/study/NCT00433420,https://clinicaltrials.gov/study/NCT04732598,https://clinicaltrials.gov/study/NCT01996267,https://clinicaltrials.gov/study/NCT02214381,https://clinicaltrials.gov/study/NCT03168880,https://clinicaltrials.gov/study/NCT01646034,https://clinicaltrials.gov/study/NCT03315364,https://clinicaltrials.gov/study/NCT04494425,https://clinicaltrials.gov/study/NCT03725059,https://clinicaltrials.gov/study/NCT00070564
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	3	Terminated	https://clinicaltrials.gov/study/NCT01633060
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Completed	https://clinicaltrials.gov/study/NCT01099436,https://clinicaltrials.gov/study/NCT00054587,https://clinicaltrials.gov/study/NCT00190489,https://clinicaltrials.gov/study/NCT00002662,https://clinicaltrials.gov/study/NCT00309556,https://clinicaltrials.gov/study/NCT00008411,https://clinicaltrials.gov/study/NCT01314833,https://clinicaltrials.gov/study/NCT03084237,https://clinicaltrials.gov/study/NCT00433589,https://clinicaltrials.gov/study/NCT00429871,https://clinicaltrials.gov/study/NCT04031703,https://clinicaltrials.gov/study/NCT00003519,https://clinicaltrials.gov/study/NCT00114816,https://clinicaltrials.gov/study/NCT00314977,https://clinicaltrials.gov/study/NCT03425656,https://clinicaltrials.gov/study/NCT00567554,https://clinicaltrials.gov/study/NCT00002707,https://clinicaltrials.gov/study/NCT01120184,https://clinicaltrials.gov/study/NCT03989037,https://clinicaltrials.gov/study/NCT00424606,https://clinicaltrials.gov/study/NCT00950300,https://clinicaltrials.gov/study/NCT01940497,https://clinicaltrials.gov/study/NCT00331097,https://clinicaltrials.gov/study/NCT00311636,https://clinicaltrials.gov/study/NCT00146549,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT00047255,https://clinicaltrials.gov/study/NCT05629949,https://clinicaltrials.gov/study/NCT01690702,https://clinicaltrials.gov/study/NCT02896855,https://clinicaltrials.gov/study/NCT00431080,https://clinicaltrials.gov/study/NCT00004125,https://clinicaltrials.gov/study/NCT00191152,https://clinicaltrials.gov/study/NCT04629846,https://clinicaltrials.gov/study/NCT00391092,https://clinicaltrials.gov/study/NCT02194166,https://clinicaltrials.gov/study/NCT01985724,https://clinicaltrials.gov/study/NCT00236899,https://clinicaltrials.gov/study/NCT00193011,https://clinicaltrials.gov/study/NCT00887536,https://clinicaltrials.gov/study/NCT02681003,https://clinicaltrials.gov/study/NCT00312208,https://clinicaltrials.gov/study/NCT00540800,https://clinicaltrials.gov/study/NCT00047099,https://clinicaltrials.gov/study/NCT00567190,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT00333775,https://clinicaltrials.gov/study/NCT00493870,https://clinicaltrials.gov/study/NCT00288002,https://clinicaltrials.gov/study/NCT00776724,https://clinicaltrials.gov/study/NCT00089479,https://clinicaltrials.gov/study/NCT00667251,https://clinicaltrials.gov/study/NCT02019277,https://clinicaltrials.gov/study/NCT02115204,https://clinicaltrials.gov/study/NCT00294385,https://clinicaltrials.gov/study/NCT02402712,https://clinicaltrials.gov/study/NCT00003782,https://clinicaltrials.gov/study/NCT00793377,https://clinicaltrials.gov/study/NCT00688740,https://clinicaltrials.gov/study/NCT02586025,https://clinicaltrials.gov/study/NCT05301010,https://clinicaltrials.gov/study/NCT02187744,https://clinicaltrials.gov/study/NCT01049425,https://clinicaltrials.gov/study/NCT00703326,https://clinicaltrials.gov/study/NCT00002544,https://clinicaltrials.gov/study/NCT00615602,https://clinicaltrials.gov/study/NCT00630032,https://clinicaltrials.gov/study/NCT04127019,https://clinicaltrials.gov/study/NCT03493854,https://clinicaltrials.gov/study/NCT01216111,https://clinicaltrials.gov/study/NCT00963729,https://clinicaltrials.gov/study/NCT00448591,https://clinicaltrials.gov/study/NCT00091442,https://clinicaltrials.gov/study/NCT03013504,https://clinicaltrials.gov/study/NCT02472964,https://clinicaltrials.gov/study/NCT02980965,https://clinicaltrials.gov/study/NCT04957212,https://clinicaltrials.gov/study/NCT00129935,https://clinicaltrials.gov/study/NCT01964391,https://clinicaltrials.gov/study/NCT00352378,https://clinicaltrials.gov/study/NCT00017095
MONDO_0007254	breast cancer	CHEMBL4298178	TRASTUZUMAB DUOCARMAZINE	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 binding agent		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Completed	https://clinicaltrials.gov/study/NCT03262935
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02221999
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1094636	NIRAPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	3	Terminated	https://clinicaltrials.gov/study/NCT01905592
MONDO_0007254	breast cancer	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00412022,https://clinicaltrials.gov/study/NCT01579734,https://clinicaltrials.gov/study/NCT00002644,https://clinicaltrials.gov/study/NCT00601900,https://clinicaltrials.gov/study/NCT00066703,https://clinicaltrials.gov/study/NCT01674140
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Recruiting	https://clinicaltrials.gov/study/NCT05760378
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Completed	https://clinicaltrials.gov/study/NCT00005970
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Completed	https://clinicaltrials.gov/study/NCT00630032,https://clinicaltrials.gov/study/NCT00080301,https://clinicaltrials.gov/study/NCT00082433,https://clinicaltrials.gov/study/NCT00789581,https://clinicaltrials.gov/study/NCT00448591
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00770809
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Recruiting	https://clinicaltrials.gov/study/NCT05760378
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS8	NADH:ubiquinone oxidoreductase core subunit S8	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC6	histone deacetylase 6	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03538171
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06313086,https://clinicaltrials.gov/study/NCT06126640,https://clinicaltrials.gov/study/NCT06316531
MONDO_0007254	breast cancer	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	3	Completed	https://clinicaltrials.gov/study/NCT00002836
MONDO_0007254	breast cancer	CHEMBL4297509	ELACESTRANT	Small molecule	Estrogen receptor alpha degrader		ESR1	estrogen receptor 1	3	Recruiting	https://clinicaltrials.gov/study/NCT05512364
MONDO_0007254	breast cancer	CHEMBL1201564	INTERFERON GAMMA-1B	Protein	Interferon gamma receptor agonist		IFNGR2	interferon gamma receptor 2	3	Completed	https://clinicaltrials.gov/study/NCT00008203
MONDO_0007254	breast cancer	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Withdrawn	https://clinicaltrials.gov/study/NCT03811418,https://clinicaltrials.gov/study/NCT05474690
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA11	NADH:ubiquinone oxidoreductase subunit A11	3	Completed	https://clinicaltrials.gov/study/NCT01101438
EFO_0000304	breast adenocarcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC8	histone deacetylase 8	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02115282
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Completed	https://clinicaltrials.gov/study/NCT00191152
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00770809
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB3	NADH:ubiquinone oxidoreductase subunit B3	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Terminated	https://clinicaltrials.gov/study/NCT05134194,https://clinicaltrials.gov/study/NCT03786094
MONDO_0007254	breast cancer	CHEMBL1680	OCTREOTIDE	Protein	Somatostatin receptor agonist		SSTR5	somatostatin receptor 5	3	Completed	https://clinicaltrials.gov/study/NCT00002864,https://clinicaltrials.gov/study/NCT00002967
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT05104866,https://clinicaltrials.gov/study/NCT04639986,https://clinicaltrials.gov/study/NCT05063786
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	3	Terminated	https://clinicaltrials.gov/study/NCT00440622,https://clinicaltrials.gov/study/NCT02054338,https://clinicaltrials.gov/study/NCT05134194
EFO_0005537	triple-negative breast cancer	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	3	Recruiting	https://clinicaltrials.gov/study/NCT05760378
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR2	estrogen receptor 2	3	Unknown status	https://clinicaltrials.gov/study/NCT02394496,https://clinicaltrials.gov/study/NCT00253422,https://clinicaltrials.gov/study/NCT00688194
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA2	NADH:ubiquinone oxidoreductase subunit A2	3	Completed	https://clinicaltrials.gov/study/NCT01101438
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Completed	https://clinicaltrials.gov/study/NCT00191152
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Recruiting	https://clinicaltrials.gov/study/NCT05288777,https://clinicaltrials.gov/study/NCT03975647,https://clinicaltrials.gov/study/NCT05429684,https://clinicaltrials.gov/study/NCT04457596,https://clinicaltrials.gov/study/NCT06265428,https://clinicaltrials.gov/study/NCT05755048,https://clinicaltrials.gov/study/NCT04873362
MONDO_0007254	breast cancer	CHEMBL1790041	RANITIDINE	Small molecule	Histamine H2 receptor antagonist		HRH2	histamine receptor H2	3	Recruiting	https://clinicaltrials.gov/study/NCT04862585
MONDO_0007254	breast cancer	CHEMBL1201583	BEVACIZUMAB	Antibody	Vascular endothelial growth factor A inhibitor		VEGFA	vascular endothelial growth factor A	3	Completed	https://clinicaltrials.gov/study/NCT00028990,https://clinicaltrials.gov/study/NCT00887536,https://clinicaltrials.gov/study/NCT00448591,https://clinicaltrials.gov/study/NCT00868634,https://clinicaltrials.gov/study/NCT00929240,https://clinicaltrials.gov/study/NCT00391092,https://clinicaltrials.gov/study/NCT00600340,https://clinicaltrials.gov/study/NCT01663727,https://clinicaltrials.gov/study/NCT00545077,https://clinicaltrials.gov/study/NCT01131195,https://clinicaltrials.gov/study/NCT00281697,https://clinicaltrials.gov/study/NCT00567554,https://clinicaltrials.gov/study/NCT00333775,https://clinicaltrials.gov/study/NCT01250379,https://clinicaltrials.gov/study/NCT00528567,https://clinicaltrials.gov/study/NCT00109239
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Completed	https://clinicaltrials.gov/study/NCT00673335
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00006459
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT05172518,https://clinicaltrials.gov/study/NCT05838066,https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT04665986
MONDO_0007254	breast cancer	CHEMBL803	CYTARABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT01645839
MONDO_0007254	breast cancer	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Enrolling by invitation	https://clinicaltrials.gov/study/NCT05645536
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03725059,https://clinicaltrials.gov/study/NCT00070564,https://clinicaltrials.gov/study/NCT04732598,https://clinicaltrials.gov/study/NCT03168880,https://clinicaltrials.gov/study/NCT01646034,https://clinicaltrials.gov/study/NCT03595592,https://clinicaltrials.gov/study/NCT00433420,https://clinicaltrials.gov/study/NCT01358877,https://clinicaltrials.gov/study/NCT02214381,https://clinicaltrials.gov/study/NCT04494425,https://clinicaltrials.gov/study/NCT03734029,https://clinicaltrials.gov/study/NCT01996267,https://clinicaltrials.gov/study/NCT03315364
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT04665986,https://clinicaltrials.gov/study/NCT06343948,https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06081959,https://clinicaltrials.gov/study/NCT05901935,https://clinicaltrials.gov/study/NCT06079983
MONDO_0007254	breast cancer	CHEMBL1201139	MEGESTROL ACETATE	Small molecule	Progesterone receptor agonist		PGR	progesterone receptor	3	Completed	https://clinicaltrials.gov/study/NCT01237327
MONDO_0007254	breast cancer	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Unknown status	https://clinicaltrials.gov/study/NCT00486668,https://clinicaltrials.gov/study/NCT00637325,https://clinicaltrials.gov/study/NCT00629278,https://clinicaltrials.gov/study/NCT00430001,https://clinicaltrials.gov/study/NCT01084876,https://clinicaltrials.gov/study/NCT00712140,https://clinicaltrials.gov/study/NCT02514681
MONDO_0007254	breast cancer	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Terminated	https://clinicaltrials.gov/study/NCT00520975,https://clinicaltrials.gov/study/NCT00004935,https://clinicaltrials.gov/study/NCT00440622,https://clinicaltrials.gov/study/NCT02144012,https://clinicaltrials.gov/study/NCT00625898
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03734029,https://clinicaltrials.gov/study/NCT04639986,https://clinicaltrials.gov/study/NCT05063786,https://clinicaltrials.gov/study/NCT05104866
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04799249
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Completed	https://clinicaltrials.gov/study/NCT00388726,https://clinicaltrials.gov/study/NCT02225470,https://clinicaltrials.gov/study/NCT00337103
MONDO_0007254	breast cancer	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02918084,https://clinicaltrials.gov/study/NCT03538171,https://clinicaltrials.gov/study/NCT02947685,https://clinicaltrials.gov/study/NCT00066703,https://clinicaltrials.gov/study/NCT01674140
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Withdrawn	https://clinicaltrials.gov/study/NCT03811418,https://clinicaltrials.gov/study/NCT05474690,https://clinicaltrials.gov/study/NCT00041171
MONDO_0007254	breast cancer	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	3	Terminated	https://clinicaltrials.gov/study/NCT01655992,https://clinicaltrials.gov/study/NCT03326674,https://clinicaltrials.gov/study/NCT00082095,https://clinicaltrials.gov/study/NCT01200212,https://clinicaltrials.gov/study/NCT00440622,https://clinicaltrials.gov/study/NCT00305643,https://clinicaltrials.gov/study/NCT05134194
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4	NDUFA4 mitochondrial complex associated	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL2177390	IPATASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT2	AKT serine/threonine kinase 2	3	Terminated	https://clinicaltrials.gov/study/NCT04060862
EFO_0000305	breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Completed	https://clinicaltrials.gov/study/NCT00785291
EFO_0000305	breast carcinoma	CHEMBL1201583	BEVACIZUMAB	Antibody	Vascular endothelial growth factor A inhibitor		VEGFA	vascular endothelial growth factor A	3	Terminated	https://clinicaltrials.gov/study/NCT00520975
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Suspended	https://clinicaltrials.gov/study/NCT03002103
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT05172518,https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT05838066,https://clinicaltrials.gov/study/NCT04665986
MONDO_0007254	breast cancer	CHEMBL359744	DOXORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Completed	https://clinicaltrials.gov/study/NCT00003013,https://clinicaltrials.gov/study/NCT00002784,https://clinicaltrials.gov/study/NCT00002529,https://clinicaltrials.gov/study/NCT00003519,https://clinicaltrials.gov/study/NCT00004125,https://clinicaltrials.gov/study/NCT00014222,https://clinicaltrials.gov/study/NCT00091442,https://clinicaltrials.gov/study/NCT01099436,https://clinicaltrials.gov/study/NCT00002755,https://clinicaltrials.gov/study/NCT00311636,https://clinicaltrials.gov/study/NCT00929591,https://clinicaltrials.gov/study/NCT00041119,https://clinicaltrials.gov/study/NCT00003088,https://clinicaltrials.gov/study/NCT00002967,https://clinicaltrials.gov/study/NCT00003893,https://clinicaltrials.gov/study/NCT00002542,https://clinicaltrials.gov/study/NCT00002582
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Recruiting	https://clinicaltrials.gov/study/NCT04457596
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06316531,https://clinicaltrials.gov/study/NCT06313086,https://clinicaltrials.gov/study/NCT06126640
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Completed	https://clinicaltrials.gov/study/NCT00016406,https://clinicaltrials.gov/study/NCT03556358,https://clinicaltrials.gov/study/NCT00006459,https://clinicaltrials.gov/study/NCT00041119,https://clinicaltrials.gov/study/NCT01901146,https://clinicaltrials.gov/study/NCT00544232,https://clinicaltrials.gov/study/NCT01663727,https://clinicaltrials.gov/study/NCT00876395,https://clinicaltrials.gov/study/NCT01989676,https://clinicaltrials.gov/study/NCT01690702,https://clinicaltrials.gov/study/NCT01526369,https://clinicaltrials.gov/study/NCT00311636,https://clinicaltrials.gov/study/NCT01964391,https://clinicaltrials.gov/study/NCT00002953,https://clinicaltrials.gov/study/NCT02450058,https://clinicaltrials.gov/study/NCT00003013,https://clinicaltrials.gov/study/NCT02472964,https://clinicaltrials.gov/study/NCT00600340,https://clinicaltrials.gov/study/NCT01433614,https://clinicaltrials.gov/study/NCT03493854,https://clinicaltrials.gov/study/NCT03726879,https://clinicaltrials.gov/study/NCT01287624,https://clinicaltrials.gov/study/NCT00003440,https://clinicaltrials.gov/study/NCT00028990,https://clinicaltrials.gov/study/NCT00129922,https://clinicaltrials.gov/study/NCT04127019,https://clinicaltrials.gov/study/NCT00567554,https://clinicaltrials.gov/study/NCT01120184,https://clinicaltrials.gov/study/NCT01822314,https://clinicaltrials.gov/study/NCT01940497,https://clinicaltrials.gov/study/NCT01764022,https://clinicaltrials.gov/study/NCT00876486,https://clinicaltrials.gov/study/NCT00014222,https://clinicaltrials.gov/study/NCT00667251,https://clinicaltrials.gov/study/NCT00038402,https://clinicaltrials.gov/study/NCT02425891,https://clinicaltrials.gov/study/NCT00003972,https://clinicaltrials.gov/study/NCT03337724,https://clinicaltrials.gov/study/NCT01998906,https://clinicaltrials.gov/study/NCT04031703,https://clinicaltrials.gov/study/NCT00146549,https://clinicaltrials.gov/study/NCT03462251,https://clinicaltrials.gov/study/NCT00236899,https://clinicaltrials.gov/study/NCT03498716,https://clinicaltrials.gov/study/NCT02019277,https://clinicaltrials.gov/study/NCT02163694,https://clinicaltrials.gov/study/NCT00004125,https://clinicaltrials.gov/study/NCT02032277,https://clinicaltrials.gov/study/NCT00448591,https://clinicaltrials.gov/study/NCT01314833,https://clinicaltrials.gov/study/NCT00336791,https://clinicaltrials.gov/study/NCT00668616,https://clinicaltrials.gov/study/NCT00004067,https://clinicaltrials.gov/study/NCT02594371,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT00561119,https://clinicaltrials.gov/study/NCT00513292,https://clinicaltrials.gov/study/NCT02819518,https://clinicaltrials.gov/study/NCT00002662,https://clinicaltrials.gov/study/NCT01216111,https://clinicaltrials.gov/study/NCT04109066,https://clinicaltrials.gov/study/NCT01131195,https://clinicaltrials.gov/study/NCT00003088,https://clinicaltrials.gov/study/NCT00196872,https://clinicaltrials.gov/study/NCT00129389,https://clinicaltrials.gov/study/NCT00789581,https://clinicaltrials.gov/study/NCT01644890,https://clinicaltrials.gov/study/NCT00431080,https://clinicaltrials.gov/study/NCT02194166,https://clinicaltrials.gov/study/NCT01966471
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Terminated	https://clinicaltrials.gov/study/NCT00625898,https://clinicaltrials.gov/study/NCT02144012,https://clinicaltrials.gov/study/NCT00912444,https://clinicaltrials.gov/study/NCT00053911,https://clinicaltrials.gov/study/NCT01200212
MONDO_0007254	breast cancer	CHEMBL279785	MARIMASTAT	Small molecule	Matrix metalloproteinase 12 inhibitor		MMP12	matrix metallopeptidase 12	3	Completed	https://clinicaltrials.gov/study/NCT00003010
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	3	Terminated	https://clinicaltrials.gov/study/NCT05134194,https://clinicaltrials.gov/study/NCT02054338,https://clinicaltrials.gov/study/NCT00440622
MONDO_0007254	breast cancer	CHEMBL185	FLUOROURACIL	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	3	Unknown status	https://clinicaltrials.gov/study/NCT02393833,https://clinicaltrials.gov/study/NCT00629278,https://clinicaltrials.gov/study/NCT01222052,https://clinicaltrials.gov/study/NCT01031030,https://clinicaltrials.gov/study/NCT00003680,https://clinicaltrials.gov/study/NCT01642771,https://clinicaltrials.gov/study/NCT00005581
EFO_0005537	triple-negative breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	3	Suspended	https://clinicaltrials.gov/study/NCT03002103
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF4	NADH:ubiquinone oxidoreductase complex assembly factor 4	3	Completed	https://clinicaltrials.gov/study/NCT01101438
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01275677,https://clinicaltrials.gov/study/NCT03199885
EFO_0005537	triple-negative breast cancer	CHEMBL3707227	ATEZOLIZUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04148911
MONDO_0007254	breast cancer	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Unknown status	https://clinicaltrials.gov/study/NCT00003418,https://clinicaltrials.gov/study/NCT00253422,https://clinicaltrials.gov/study/NCT00902954,https://clinicaltrials.gov/study/NCT00893061,https://clinicaltrials.gov/study/NCT00541086,https://clinicaltrials.gov/study/NCT00688194
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT06143553
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Unknown status	https://clinicaltrials.gov/study/NCT02514681
MONDO_0007254	breast cancer	CHEMBL81	RALOXIFENE	Small molecule	Estrogen receptor beta modulator		ESR2	estrogen receptor 2	3	Completed	https://clinicaltrials.gov/study/NCT00003906
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	3	Enrolling by invitation	https://clinicaltrials.gov/study/NCT04421963
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT04301739,https://clinicaltrials.gov/study/NCT05753865,https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT05388500,https://clinicaltrials.gov/study/NCT06279364,https://clinicaltrials.gov/study/NCT05172518,https://clinicaltrials.gov/study/NCT05841381
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
MONDO_0007254	breast cancer	CHEMBL778	DEXMEDETOMIDINE	Small molecule	Adrenergic receptor alpha-2 agonist		ADRA2A	adrenoceptor alpha 2A	3	Unknown status	https://clinicaltrials.gov/study/NCT03046238,https://clinicaltrials.gov/study/NCT03063073
MONDO_0007254	breast cancer	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT05016349,https://clinicaltrials.gov/study/NCT06223698
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB8	NADH:ubiquinone oxidoreductase subunit B8	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Recruiting	https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT06143553
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Completed	https://clinicaltrials.gov/study/NCT00191152
MONDO_0007254	breast cancer	CHEMBL1655	TOREMIFENE	Small molecule	Estrogen receptor modulator		ESR2	estrogen receptor 2	3	Terminated	https://clinicaltrials.gov/study/NCT00010322
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03500380
EFO_0005537	triple-negative breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Vascular endothelial growth factor receptor 1 inhibitor		FLT1	fms related receptor tyrosine kinase 1	3	Recruiting	https://clinicaltrials.gov/study/NCT05760378
MONDO_0007254	breast cancer	CHEMBL1536	ERGOCALCIFEROL	Small molecule	Vitamin D receptor agonist		VDR	vitamin D receptor	3	Completed	https://clinicaltrials.gov/study/NCT01224678
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885,https://clinicaltrials.gov/study/NCT01275677
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Completed	https://clinicaltrials.gov/study/NCT00191152
MONDO_0007254	breast cancer	CHEMBL4297939	DATOPOTAMAB DERUXTECAN	Antibody drug conjugate	Tumor-associated calcium signal transducer 2 binding agent		TACSTD2	tumor associated calcium signal transducer 2	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT05104866
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Completed	https://clinicaltrials.gov/study/NCT00785291,https://clinicaltrials.gov/study/NCT01935492
MONDO_0007254	breast cancer	CHEMBL294199	CAPSAICIN	Small molecule	Vanilloid receptor opener		TRPV1	transient receptor potential cation channel subfamily V member 1	3	Completed	https://clinicaltrials.gov/study/NCT03794388
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04799249
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1201179	LAPATINIB DITOSYLATE	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Completed	https://clinicaltrials.gov/study/NCT00390455
MONDO_0007254	breast cancer	CHEMBL3647420	PYROTINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT05841381,https://clinicaltrials.gov/study/NCT04736589,https://clinicaltrials.gov/study/NCT04973319
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Terminated	https://clinicaltrials.gov/study/NCT00016276
MONDO_0007254	breast cancer	CHEMBL180022	NERATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-4 inhibitor		ERBB4	erb-b2 receptor tyrosine kinase 4	3	Completed	https://clinicaltrials.gov/study/NCT01808573,https://clinicaltrials.gov/study/NCT00878709
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04622319,https://clinicaltrials.gov/study/NCT01772472,https://clinicaltrials.gov/study/NCT04740918,https://clinicaltrials.gov/study/NCT03529110
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06081959,https://clinicaltrials.gov/study/NCT06343948,https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT06255392
EFO_0005537	triple-negative breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	3	Suspended	https://clinicaltrials.gov/study/NCT03002103
EFO_1000984	inflammatory breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Completed	https://clinicaltrials.gov/study/NCT02324088
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR2	estrogen receptor 2	3	Terminated	https://clinicaltrials.gov/study/NCT00543127,https://clinicaltrials.gov/study/NCT04060862,https://clinicaltrials.gov/study/NCT02340221,https://clinicaltrials.gov/study/NCT05065411,https://clinicaltrials.gov/study/NCT02137837,https://clinicaltrials.gov/study/NCT01633060,https://clinicaltrials.gov/study/NCT00010153
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02641847,https://clinicaltrials.gov/study/NCT01646034,https://clinicaltrials.gov/study/NCT01358877,https://clinicaltrials.gov/study/NCT03588091,https://clinicaltrials.gov/study/NCT03863223,https://clinicaltrials.gov/study/NCT04024462,https://clinicaltrials.gov/study/NCT02003209
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Unknown status	https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT00629278,https://clinicaltrials.gov/study/NCT01479036,https://clinicaltrials.gov/study/NCT00944424,https://clinicaltrials.gov/study/NCT00010140,https://clinicaltrials.gov/study/NCT00532727,https://clinicaltrials.gov/study/NCT01642771,https://clinicaltrials.gov/study/NCT00003679,https://clinicaltrials.gov/study/NCT01354522,https://clinicaltrials.gov/study/NCT01547741,https://clinicaltrials.gov/study/NCT01622361,https://clinicaltrials.gov/study/NCT01222052,https://clinicaltrials.gov/study/NCT00430001,https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT02393833
MONDO_0007254	breast cancer	CHEMBL1200480	OCTREOTIDE ACETATE	Protein	Somatostatin receptor agonist		SSTR1	somatostatin receptor 1	3	Completed	https://clinicaltrials.gov/study/NCT00002864
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Completed	https://clinicaltrials.gov/study/NCT01120184,https://clinicaltrials.gov/study/NCT03726879,https://clinicaltrials.gov/study/NCT01702571,https://clinicaltrials.gov/study/NCT01419197,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT03084939,https://clinicaltrials.gov/study/NCT00829166
MONDO_0007254	breast cancer	CHEMBL18901	EFAPROXIRAL	Small molecule	Hemoglobin HbA negative modulator		HBA2	hemoglobin subunit alpha 2	3	Completed	https://clinicaltrials.gov/study/NCT00083304
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Terminated	https://clinicaltrials.gov/study/NCT02144012
MONDO_0007254	breast cancer	CHEMBL359744	DOXORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02214381,https://clinicaltrials.gov/study/NCT00070564
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	3	Enrolling by invitation	https://clinicaltrials.gov/study/NCT04421963
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Terminated	https://clinicaltrials.gov/study/NCT02730091,https://clinicaltrials.gov/study/NCT05134194
EFO_0000304	breast adenocarcinoma	CHEMBL359744	DOXORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Completed	https://clinicaltrials.gov/study/NCT00005970
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04639986
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Unknown status	https://clinicaltrials.gov/study/NCT00010140,https://clinicaltrials.gov/study/NCT01354522,https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT01622361,https://clinicaltrials.gov/study/NCT01479036,https://clinicaltrials.gov/study/NCT00003679,https://clinicaltrials.gov/study/NCT00629278,https://clinicaltrials.gov/study/NCT01547741,https://clinicaltrials.gov/study/NCT00944424,https://clinicaltrials.gov/study/NCT01642771,https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT02393833,https://clinicaltrials.gov/study/NCT01222052,https://clinicaltrials.gov/study/NCT00532727,https://clinicaltrials.gov/study/NCT00430001
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR2	estrogen receptor 2	3	Completed	https://clinicaltrials.gov/study/NCT00545077,https://clinicaltrials.gov/study/NCT01300351,https://clinicaltrials.gov/study/NCT00256698,https://clinicaltrials.gov/study/NCT01942135,https://clinicaltrials.gov/study/NCT00241449,https://clinicaltrials.gov/study/NCT02422615,https://clinicaltrials.gov/study/NCT02437318,https://clinicaltrials.gov/study/NCT03462251,https://clinicaltrials.gov/study/NCT00065325,https://clinicaltrials.gov/study/NCT00075764,https://clinicaltrials.gov/study/NCT00635713,https://clinicaltrials.gov/study/NCT03439046,https://clinicaltrials.gov/study/NCT02028507,https://clinicaltrials.gov/study/NCT00327769,https://clinicaltrials.gov/study/NCT01610284,https://clinicaltrials.gov/study/NCT04109066
MONDO_0007254	breast cancer	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	3	Recruiting	https://clinicaltrials.gov/study/NCT05207514,https://clinicaltrials.gov/study/NCT05159193,https://clinicaltrials.gov/study/NCT04540692,https://clinicaltrials.gov/study/NCT03949634,https://clinicaltrials.gov/study/NCT05113251,https://clinicaltrials.gov/study/NCT06112379
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Recruiting	https://clinicaltrials.gov/study/NCT02488967
EFO_0000186	invasive breast ductal carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Completed	https://clinicaltrials.gov/study/NCT02620280
MONDO_0007254	breast cancer	CHEMBL488	AMINOGLUTETHIMIDE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Completed	https://clinicaltrials.gov/study/NCT00309491
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT05901935,https://clinicaltrials.gov/study/NCT06079983,https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT04665986
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	3	Completed	https://clinicaltrials.gov/study/NCT00006459
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Recruiting	https://clinicaltrials.gov/study/NCT05159193,https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT04540692,https://clinicaltrials.gov/study/NCT05894239,https://clinicaltrials.gov/study/NCT05673629,https://clinicaltrials.gov/study/NCT03949634,https://clinicaltrials.gov/study/NCT05430399,https://clinicaltrials.gov/study/NCT04193059,https://clinicaltrials.gov/study/NCT05901428,https://clinicaltrials.gov/study/NCT05720026,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT05207514,https://clinicaltrials.gov/study/NCT03671044,https://clinicaltrials.gov/study/NCT04547907,https://clinicaltrials.gov/study/NCT05296798,https://clinicaltrials.gov/study/NCT05883852,https://clinicaltrials.gov/study/NCT03926091
MONDO_0007254	breast cancer	CHEMBL1200480	OCTREOTIDE ACETATE	Protein	Somatostatin receptor agonist		SSTR2	somatostatin receptor 2	3	Completed	https://clinicaltrials.gov/study/NCT00002864
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	3	Terminated	https://clinicaltrials.gov/study/NCT04060862,https://clinicaltrials.gov/study/NCT04478266
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Unknown status	https://clinicaltrials.gov/study/NCT00430001,https://clinicaltrials.gov/study/NCT02514681
MONDO_0007254	breast cancer	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN11A	sodium voltage-gated channel alpha subunit 11	3	Completed	https://clinicaltrials.gov/study/NCT04327063,https://clinicaltrials.gov/study/NCT00547989,https://clinicaltrials.gov/study/NCT02408393
MONDO_0007254	breast cancer	CHEMBL1908360	EVEROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	3	Completed	https://clinicaltrials.gov/study/NCT01626222,https://clinicaltrials.gov/study/NCT02376985,https://clinicaltrials.gov/study/NCT00567554,https://clinicaltrials.gov/study/NCT00863655,https://clinicaltrials.gov/study/NCT00876395,https://clinicaltrials.gov/study/NCT02511639,https://clinicaltrials.gov/study/NCT03176238,https://clinicaltrials.gov/study/NCT01007942
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	3	Unknown status	https://clinicaltrials.gov/study/NCT00039546,https://clinicaltrials.gov/study/NCT02207335,https://clinicaltrials.gov/study/NCT00070278,https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT00408408
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652
MONDO_0007254	breast cancer	CHEMBL1201568	PEGFILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00070564,https://clinicaltrials.gov/study/NCT00433420,https://clinicaltrials.gov/study/NCT00301925
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	3	Unknown status	https://clinicaltrials.gov/study/NCT00070278,https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT00039546
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Recruiting	https://clinicaltrials.gov/study/NCT06058377,https://clinicaltrials.gov/study/NCT05747794,https://clinicaltrials.gov/study/NCT03201861,https://clinicaltrials.gov/study/NCT04862585
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652
MONDO_0007254	breast cancer	CHEMBL1077896	ROPIVACAINE	Small molecule	Sodium channel alpha subunit blocker		SCN5A	sodium voltage-gated channel alpha subunit 5	3	Completed	https://clinicaltrials.gov/study/NCT04327063,https://clinicaltrials.gov/study/NCT00547989,https://clinicaltrials.gov/study/NCT02408393
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Unknown status	https://clinicaltrials.gov/study/NCT00430001,https://clinicaltrials.gov/study/NCT02514681
EFO_1000984	inflammatory breast carcinoma	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	3	Terminated	https://clinicaltrials.gov/study/NCT00016276
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Terminated	https://clinicaltrials.gov/study/NCT05134194,https://clinicaltrials.gov/study/NCT02730091
MONDO_0007254	breast cancer	CHEMBL870	ALENDRONIC ACID	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	3	Completed	https://clinicaltrials.gov/study/NCT00122356
EFO_0000304	breast adenocarcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00433511,https://clinicaltrials.gov/study/NCT03199885
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Terminated	https://clinicaltrials.gov/study/NCT02730091,https://clinicaltrials.gov/study/NCT05134194
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04799249
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
MONDO_0007254	breast cancer	CHEMBL2325741	CAPIVASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT3	AKT serine/threonine kinase 3	3	Recruiting	https://clinicaltrials.gov/study/NCT04862663
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Completed	https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT01702571,https://clinicaltrials.gov/study/NCT03726879,https://clinicaltrials.gov/study/NCT01419197,https://clinicaltrials.gov/study/NCT03084939,https://clinicaltrials.gov/study/NCT01120184,https://clinicaltrials.gov/study/NCT00829166
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Withdrawn	https://clinicaltrials.gov/study/NCT02929576
EFO_0005537	triple-negative breast cancer	CHEMBL4297843	TORIPALIMAB	Antibody	Programmed cell death protein 1 antagonist		PDCD1	programmed cell death 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04085276
MONDO_0007254	breast cancer	CHEMBL778	DEXMEDETOMIDINE	Small molecule	Adrenergic receptor alpha-2 agonist		ADRA2C	adrenoceptor alpha 2C	3	Recruiting	https://clinicaltrials.gov/study/NCT05439005
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Recruiting	https://clinicaltrials.gov/study/NCT04137653,https://clinicaltrials.gov/study/NCT06018337,https://clinicaltrials.gov/study/NCT05894239,https://clinicaltrials.gov/study/NCT03949634,https://clinicaltrials.gov/study/NCT03876886,https://clinicaltrials.gov/study/NCT06143553,https://clinicaltrials.gov/study/NCT04540692,https://clinicaltrials.gov/study/NCT05555706,https://clinicaltrials.gov/study/NCT04862585,https://clinicaltrials.gov/study/NCT04335669,https://clinicaltrials.gov/study/NCT05814354,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT04193059,https://clinicaltrials.gov/study/NCT05382299,https://clinicaltrials.gov/study/NCT05113251,https://clinicaltrials.gov/study/NCT05840211,https://clinicaltrials.gov/study/NCT05207709,https://clinicaltrials.gov/study/NCT05296798,https://clinicaltrials.gov/study/NCT04547907,https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT06112379,https://clinicaltrials.gov/study/NCT06103864,https://clinicaltrials.gov/study/NCT05429684,https://clinicaltrials.gov/study/NCT05374512
MONDO_0007254	breast cancer	CHEMBL2396661	ALPELISIB	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	3	Recruiting	https://clinicaltrials.gov/study/NCT05646862,https://clinicaltrials.gov/study/NCT05038735,https://clinicaltrials.gov/study/NCT05501886
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT05838066,https://clinicaltrials.gov/study/NCT05172518,https://clinicaltrials.gov/study/NCT04665986,https://clinicaltrials.gov/study/NCT06079983
MONDO_0007254	breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	3	Terminated	https://clinicaltrials.gov/study/NCT05065411
MONDO_0007254	breast cancer	CHEMBL1201583	BEVACIZUMAB	Antibody	Vascular endothelial growth factor A inhibitor		VEGFA	vascular endothelial growth factor A	3	Terminated	https://clinicaltrials.gov/study/NCT01200212,https://clinicaltrials.gov/study/NCT00625898,https://clinicaltrials.gov/study/NCT01303679,https://clinicaltrials.gov/study/NCT00520975
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01272037
EFO_0000186	invasive breast ductal carcinoma	CHEMBL3707227	ATEZOLIZUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor	Inhibitor	CD274	CD274 molecule	3	Completed	https://clinicaltrials.gov/study/NCT02620280
EFO_0000304	breast adenocarcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Completed	https://clinicaltrials.gov/study/NCT00785291,https://clinicaltrials.gov/study/NCT01935492
MONDO_0007254	breast cancer	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	3	Unknown status	https://clinicaltrials.gov/study/NCT01642771,https://clinicaltrials.gov/study/NCT03080805,https://clinicaltrials.gov/study/NCT02207335,https://clinicaltrials.gov/study/NCT01354522,https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT01501669
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS4	NADH:ubiquinone oxidoreductase subunit S4	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04494425,https://clinicaltrials.gov/study/NCT00070564,https://clinicaltrials.gov/study/NCT02214381,https://clinicaltrials.gov/study/NCT01996267,https://clinicaltrials.gov/study/NCT01358877,https://clinicaltrials.gov/study/NCT03734029,https://clinicaltrials.gov/study/NCT03595592,https://clinicaltrials.gov/study/NCT01646034,https://clinicaltrials.gov/study/NCT00433420,https://clinicaltrials.gov/study/NCT03315364,https://clinicaltrials.gov/study/NCT04732598,https://clinicaltrials.gov/study/NCT03168880,https://clinicaltrials.gov/study/NCT03725059
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02221999
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01272037
EFO_0000304	breast adenocarcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA12	NADH:ubiquinone oxidoreductase subunit A12	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02513394,https://clinicaltrials.gov/study/NCT02947685,https://clinicaltrials.gov/study/NCT03079011,https://clinicaltrials.gov/study/NCT04711252,https://clinicaltrials.gov/study/NCT04191499,https://clinicaltrials.gov/study/NCT04546009
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC3	histone deacetylase 3	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03538171
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
MONDO_0007254	breast cancer	CHEMBL778	DEXMEDETOMIDINE	Small molecule	Adrenergic receptor alpha-2 agonist		ADRA2B	adrenoceptor alpha 2B	3	Recruiting	https://clinicaltrials.gov/study/NCT05439005
MONDO_0007254	breast cancer	CHEMBL4297829	SINTILIMAB	Antibody	Programmed cell death protein 1 antagonist		PDCD1	programmed cell death 1	3	Recruiting	https://clinicaltrials.gov/study/NCT05429684
MONDO_0007254	breast cancer	CHEMBL1680	OCTREOTIDE	Protein	Somatostatin receptor agonist		SSTR1	somatostatin receptor 1	3	Completed	https://clinicaltrials.gov/study/NCT00002967,https://clinicaltrials.gov/study/NCT00002864
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Completed	https://clinicaltrials.gov/study/NCT01953003,https://clinicaltrials.gov/study/NCT01091168,https://clinicaltrials.gov/study/NCT01095003
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885,https://clinicaltrials.gov/study/NCT01275677
EFO_0000304	breast adenocarcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB4	NADH:ubiquinone oxidoreductase subunit B4	3	Completed	https://clinicaltrials.gov/study/NCT01101438
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
EFO_0000305	breast carcinoma	CHEMBL3707227	ATEZOLIZUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor	Inhibitor	CD274	CD274 molecule	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03199885
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Recruiting	https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT06143553
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Unknown status	https://clinicaltrials.gov/study/NCT00003679,https://clinicaltrials.gov/study/NCT01354522,https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT00532727,https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT02393833,https://clinicaltrials.gov/study/NCT00944424,https://clinicaltrials.gov/study/NCT00629278,https://clinicaltrials.gov/study/NCT01547741,https://clinicaltrials.gov/study/NCT00010140,https://clinicaltrials.gov/study/NCT01479036,https://clinicaltrials.gov/study/NCT01222052,https://clinicaltrials.gov/study/NCT01642771,https://clinicaltrials.gov/study/NCT00430001,https://clinicaltrials.gov/study/NCT01622361
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02221999
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	3	Completed	https://clinicaltrials.gov/study/NCT00006459
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT05063786,https://clinicaltrials.gov/study/NCT05104866,https://clinicaltrials.gov/study/NCT04639986
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Terminated	https://clinicaltrials.gov/study/NCT00520975
EFO_1000984	inflammatory breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Completed	https://clinicaltrials.gov/study/NCT02324088
MONDO_0007254	breast cancer	CHEMBL3301587	DURVALUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor	Inhibitor	CD274	CD274 molecule	3	Recruiting	https://clinicaltrials.gov/study/NCT06103864,https://clinicaltrials.gov/study/NCT06112379,https://clinicaltrials.gov/study/NCT05629585
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Completed	https://clinicaltrials.gov/study/NCT01935492,https://clinicaltrials.gov/study/NCT00785291
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02221999
MONDO_0007254	breast cancer	CHEMBL1200775	LEUPROLIDE ACETATE	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01674140,https://clinicaltrials.gov/study/NCT04711252
EFO_0000304	breast adenocarcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01358877,https://clinicaltrials.gov/study/NCT02641847,https://clinicaltrials.gov/study/NCT03588091,https://clinicaltrials.gov/study/NCT01646034,https://clinicaltrials.gov/study/NCT04024462,https://clinicaltrials.gov/study/NCT02003209,https://clinicaltrials.gov/study/NCT03863223
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND1	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1	3	Completed	https://clinicaltrials.gov/study/NCT01101438
EFO_0000304	breast adenocarcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Unknown status	https://clinicaltrials.gov/study/NCT01134523,https://clinicaltrials.gov/study/NCT00005581,https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT01378533,https://clinicaltrials.gov/study/NCT00289263,https://clinicaltrials.gov/study/NCT01019616,https://clinicaltrials.gov/study/NCT00039546,https://clinicaltrials.gov/study/NCT02393833,https://clinicaltrials.gov/study/NCT01547741,https://clinicaltrials.gov/study/NCT00486668,https://clinicaltrials.gov/study/NCT00025688,https://clinicaltrials.gov/study/NCT00070278,https://clinicaltrials.gov/study/NCT01084876,https://clinicaltrials.gov/study/NCT00629278
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02221999
MONDO_0004658	breast carcinoma in situ	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Recruiting	https://clinicaltrials.gov/study/NCT04862585
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Recruiting	https://clinicaltrials.gov/study/NCT05374512
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	3	Unknown status	https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT02207335,https://clinicaltrials.gov/study/NCT00039546,https://clinicaltrials.gov/study/NCT00070278,https://clinicaltrials.gov/study/NCT00408408
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Recruiting	https://clinicaltrials.gov/study/NCT04457596,https://clinicaltrials.gov/study/NCT05429684,https://clinicaltrials.gov/study/NCT06265428,https://clinicaltrials.gov/study/NCT05288777,https://clinicaltrials.gov/study/NCT03975647,https://clinicaltrials.gov/study/NCT04873362,https://clinicaltrials.gov/study/NCT05755048
MONDO_0007254	breast cancer	CHEMBL4650215	INAVOLISIB	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04191499
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND6	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Terminated	https://clinicaltrials.gov/study/NCT02054338,https://clinicaltrials.gov/study/NCT04335006,https://clinicaltrials.gov/study/NCT00520975,https://clinicaltrials.gov/study/NCT01303679,https://clinicaltrials.gov/study/NCT00002772,https://clinicaltrials.gov/study/NCT01200212
EFO_0000305	breast carcinoma	CHEMBL1790041	RANITIDINE	Small molecule	Histamine H2 receptor antagonist		HRH2	histamine receptor H2	3	Recruiting	https://clinicaltrials.gov/study/NCT04862585
EFO_0000305	breast carcinoma	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR2	estrogen receptor 2	3	Unknown status	https://clinicaltrials.gov/study/NCT02404051
MONDO_0007254	breast cancer	CHEMBL1231	OXYBUTYNIN	Small molecule	Muscarinic acetylcholine receptor M2 antagonist		CHRM2	cholinergic receptor muscarinic 2	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06106529
MONDO_0007254	breast cancer	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03595592,https://clinicaltrials.gov/study/NCT02947685,https://clinicaltrials.gov/study/NCT04024462,https://clinicaltrials.gov/study/NCT04208178,https://clinicaltrials.gov/study/NCT01358877,https://clinicaltrials.gov/study/NCT02625441,https://clinicaltrials.gov/study/NCT02003209,https://clinicaltrials.gov/study/NCT05346224,https://clinicaltrials.gov/study/NCT04784715,https://clinicaltrials.gov/study/NCT01996267
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Terminated	https://clinicaltrials.gov/study/NCT05134194,https://clinicaltrials.gov/study/NCT02730091
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Completed	https://clinicaltrials.gov/study/NCT01985724,https://clinicaltrials.gov/study/NCT00146549,https://clinicaltrials.gov/study/NCT02019277,https://clinicaltrials.gov/study/NCT00424606,https://clinicaltrials.gov/study/NCT00004125,https://clinicaltrials.gov/study/NCT00703326,https://clinicaltrials.gov/study/NCT00311636,https://clinicaltrials.gov/study/NCT02586025,https://clinicaltrials.gov/study/NCT00002544,https://clinicaltrials.gov/study/NCT03013504,https://clinicaltrials.gov/study/NCT04629846,https://clinicaltrials.gov/study/NCT00615602,https://clinicaltrials.gov/study/NCT01120184,https://clinicaltrials.gov/study/NCT02402712,https://clinicaltrials.gov/study/NCT00667251,https://clinicaltrials.gov/study/NCT03989037,https://clinicaltrials.gov/study/NCT00776724,https://clinicaltrials.gov/study/NCT00688740,https://clinicaltrials.gov/study/NCT01216111,https://clinicaltrials.gov/study/NCT00391092,https://clinicaltrials.gov/study/NCT00191152,https://clinicaltrials.gov/study/NCT01964391,https://clinicaltrials.gov/study/NCT00193011,https://clinicaltrials.gov/study/NCT05629949,https://clinicaltrials.gov/study/NCT00352378,https://clinicaltrials.gov/study/NCT00312208,https://clinicaltrials.gov/study/NCT00294385,https://clinicaltrials.gov/study/NCT00017095,https://clinicaltrials.gov/study/NCT05301010,https://clinicaltrials.gov/study/NCT00047099,https://clinicaltrials.gov/study/NCT03493854,https://clinicaltrials.gov/study/NCT00129935,https://clinicaltrials.gov/study/NCT01099436,https://clinicaltrials.gov/study/NCT04127019,https://clinicaltrials.gov/study/NCT00054587,https://clinicaltrials.gov/study/NCT01314833,https://clinicaltrials.gov/study/NCT00114816,https://clinicaltrials.gov/study/NCT02187744,https://clinicaltrials.gov/study/NCT00793377,https://clinicaltrials.gov/study/NCT00008411,https://clinicaltrials.gov/study/NCT00288002,https://clinicaltrials.gov/study/NCT00630032,https://clinicaltrials.gov/study/NCT00003519,https://clinicaltrials.gov/study/NCT00002662,https://clinicaltrials.gov/study/NCT00089479,https://clinicaltrials.gov/study/NCT00448591,https://clinicaltrials.gov/study/NCT00431080,https://clinicaltrials.gov/study/NCT00314977,https://clinicaltrials.gov/study/NCT03084237,https://clinicaltrials.gov/study/NCT02115204,https://clinicaltrials.gov/study/NCT01940497,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT00963729,https://clinicaltrials.gov/study/NCT00493870,https://clinicaltrials.gov/study/NCT00091442,https://clinicaltrials.gov/study/NCT00887536,https://clinicaltrials.gov/study/NCT00003782,https://clinicaltrials.gov/study/NCT00429871,https://clinicaltrials.gov/study/NCT00333775,https://clinicaltrials.gov/study/NCT02472964,https://clinicaltrials.gov/study/NCT00950300,https://clinicaltrials.gov/study/NCT00567190,https://clinicaltrials.gov/study/NCT00540800,https://clinicaltrials.gov/study/NCT03425656,https://clinicaltrials.gov/study/NCT04031703,https://clinicaltrials.gov/study/NCT00190489,https://clinicaltrials.gov/study/NCT00567554,https://clinicaltrials.gov/study/NCT00309556,https://clinicaltrials.gov/study/NCT02194166,https://clinicaltrials.gov/study/NCT00236899,https://clinicaltrials.gov/study/NCT00433589,https://clinicaltrials.gov/study/NCT00047255,https://clinicaltrials.gov/study/NCT04957212,https://clinicaltrials.gov/study/NCT02980965,https://clinicaltrials.gov/study/NCT01049425,https://clinicaltrials.gov/study/NCT00002707,https://clinicaltrials.gov/study/NCT00331097,https://clinicaltrials.gov/study/NCT02896855,https://clinicaltrials.gov/study/NCT02681003,https://clinicaltrials.gov/study/NCT01690702,https://clinicaltrials.gov/study/NCT01966471
MONDO_0007254	breast cancer	CHEMBL1200501	GOSERELIN ACETATE	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	3	Withdrawn	https://clinicaltrials.gov/study/NCT00888082
MONDO_0007254	breast cancer	CHEMBL1007	GONADORELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	3	Completed	https://clinicaltrials.gov/study/NCT00605267
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT05104866,https://clinicaltrials.gov/study/NCT04639986,https://clinicaltrials.gov/study/NCT02641847,https://clinicaltrials.gov/study/NCT03734029,https://clinicaltrials.gov/study/NCT01646034
MONDO_0007254	breast cancer	CHEMBL1237023	DENOSUMAB	Antibody	Tumor necrosis factor ligand superfamily member 11 inhibitor		TNFSF11	TNF superfamily member 11	3	Completed	https://clinicaltrials.gov/study/NCT00556374
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Withdrawn	https://clinicaltrials.gov/study/NCT02929576
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS4	NADH:ubiquinone oxidoreductase subunit S4	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Recruiting	https://clinicaltrials.gov/study/NCT03201861
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Recruiting	https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT06143553
EFO_1000984	inflammatory breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT05415215
MONDO_0007254	breast cancer	CHEMBL1200775	LEUPROLIDE ACETATE	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	3	Recruiting	https://clinicaltrials.gov/study/NCT03664895,https://clinicaltrials.gov/study/NCT04964934
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Completed	https://clinicaltrials.gov/study/NCT01953003,https://clinicaltrials.gov/study/NCT01095003,https://clinicaltrials.gov/study/NCT01091168
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT04665986,https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT05901935,https://clinicaltrials.gov/study/NCT06079983
MONDO_0004658	breast carcinoma in situ	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02954874
MONDO_0007254	breast cancer	CHEMBL1200480	OCTREOTIDE ACETATE	Protein	Somatostatin receptor agonist		SSTR5	somatostatin receptor 5	3	Completed	https://clinicaltrials.gov/study/NCT00002864
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Terminated	https://clinicaltrials.gov/study/NCT02144012
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Unknown status	https://clinicaltrials.gov/study/NCT01622361,https://clinicaltrials.gov/study/NCT00430001,https://clinicaltrials.gov/study/NCT00010140,https://clinicaltrials.gov/study/NCT01479036,https://clinicaltrials.gov/study/NCT00944424,https://clinicaltrials.gov/study/NCT00629278,https://clinicaltrials.gov/study/NCT01642771,https://clinicaltrials.gov/study/NCT02514681,https://clinicaltrials.gov/study/NCT00532727,https://clinicaltrials.gov/study/NCT01222052,https://clinicaltrials.gov/study/NCT02393833,https://clinicaltrials.gov/study/NCT01547741,https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT01354522,https://clinicaltrials.gov/study/NCT00003679
MONDO_0007254	breast cancer	CHEMBL1201066	VENLAFAXINE HYDROCHLORIDE	Small molecule	Norepinephrine transporter inhibitor		SLC6A2	solute carrier family 6 member 2	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06106529
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01358877,https://clinicaltrials.gov/study/NCT02003209,https://clinicaltrials.gov/study/NCT03863223,https://clinicaltrials.gov/study/NCT04024462,https://clinicaltrials.gov/study/NCT01646034,https://clinicaltrials.gov/study/NCT03588091,https://clinicaltrials.gov/study/NCT02641847
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA12	NADH:ubiquinone oxidoreductase subunit A12	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Completed	https://clinicaltrials.gov/study/NCT00103233,https://clinicaltrials.gov/study/NCT02225470
EFO_0005537	triple-negative breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	3	Suspended	https://clinicaltrials.gov/study/NCT03002103
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT06081959,https://clinicaltrials.gov/study/NCT06255392,https://clinicaltrials.gov/study/NCT06343948,https://clinicaltrials.gov/study/NCT06079983
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Completed	https://clinicaltrials.gov/study/NCT02125344,https://clinicaltrials.gov/study/NCT01583426
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN9A	sodium voltage-gated channel alpha subunit 9	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01916317
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA3	NADH:ubiquinone oxidoreductase subunit A3	3	Completed	https://clinicaltrials.gov/study/NCT01101438
EFO_0000304	breast adenocarcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Suspended	https://clinicaltrials.gov/study/NCT02037529
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	3	Recruiting	https://clinicaltrials.gov/study/NCT05673629,https://clinicaltrials.gov/study/NCT05901428,https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT05296798,https://clinicaltrials.gov/study/NCT05720026,https://clinicaltrials.gov/study/NCT05894239,https://clinicaltrials.gov/study/NCT04540692,https://clinicaltrials.gov/study/NCT03949634,https://clinicaltrials.gov/study/NCT03926091,https://clinicaltrials.gov/study/NCT05430399,https://clinicaltrials.gov/study/NCT04547907,https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT04193059,https://clinicaltrials.gov/study/NCT05207514,https://clinicaltrials.gov/study/NCT05883852,https://clinicaltrials.gov/study/NCT05159193,https://clinicaltrials.gov/study/NCT03671044
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC11	histone deacetylase 11	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT03538171
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02641847,https://clinicaltrials.gov/study/NCT01646034,https://clinicaltrials.gov/study/NCT01358877,https://clinicaltrials.gov/study/NCT02003209,https://clinicaltrials.gov/study/NCT04024462,https://clinicaltrials.gov/study/NCT03863223,https://clinicaltrials.gov/study/NCT03588091
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Completed	https://clinicaltrials.gov/study/NCT00776724,https://clinicaltrials.gov/study/NCT02574455,https://clinicaltrials.gov/study/NCT00431106,https://clinicaltrials.gov/study/NCT02225470,https://clinicaltrials.gov/study/NCT02555657,https://clinicaltrials.gov/study/NCT01007942,https://clinicaltrials.gov/study/NCT03901339,https://clinicaltrials.gov/study/NCT00146549,https://clinicaltrials.gov/study/NCT00868634,https://clinicaltrials.gov/study/NCT00103233
MONDO_0007254	breast cancer	CHEMBL2177390	IPATASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT3	AKT serine/threonine kinase 3	3	Recruiting	https://clinicaltrials.gov/study/NCT04650581
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04148911,https://clinicaltrials.gov/study/NCT04085276
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02221999
MONDO_0007254	breast cancer	CHEMBL1655	TOREMIFENE	Small molecule	Estrogen receptor modulator		ESR1	estrogen receptor 1	3	Recruiting	https://clinicaltrials.gov/study/NCT05891093,https://clinicaltrials.gov/study/NCT03351062,https://clinicaltrials.gov/study/NCT02097459
MONDO_0007254	breast cancer	CHEMBL1201334	TRIPTORELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT00412022,https://clinicaltrials.gov/study/NCT00066703
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	3	Unknown status	https://clinicaltrials.gov/study/NCT00039546,https://clinicaltrials.gov/study/NCT00408408,https://clinicaltrials.gov/study/NCT00070278
EFO_0005537	triple-negative breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	3	Suspended	https://clinicaltrials.gov/study/NCT03002103
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Recruiting	https://clinicaltrials.gov/study/NCT04307147,https://clinicaltrials.gov/study/NCT06143553,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT06268652
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	3	Recruiting	https://clinicaltrials.gov/study/NCT04457596,https://clinicaltrials.gov/study/NCT05288777,https://clinicaltrials.gov/study/NCT05755048,https://clinicaltrials.gov/study/NCT04873362,https://clinicaltrials.gov/study/NCT03975647,https://clinicaltrials.gov/study/NCT06265428,https://clinicaltrials.gov/study/NCT05429684
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	3	Withdrawn	https://clinicaltrials.gov/study/NCT05474690,https://clinicaltrials.gov/study/NCT03811418,https://clinicaltrials.gov/study/NCT00041171
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	3	Completed	https://clinicaltrials.gov/study/NCT01610284
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02003209,https://clinicaltrials.gov/study/NCT01275677,https://clinicaltrials.gov/study/NCT03199885
EFO_0000305	breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Completed	https://clinicaltrials.gov/study/NCT00785291
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	3	Terminated	https://clinicaltrials.gov/study/NCT02340221
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	3	Terminated	https://clinicaltrials.gov/study/NCT00912444,https://clinicaltrials.gov/study/NCT00625898,https://clinicaltrials.gov/study/NCT00053911,https://clinicaltrials.gov/study/NCT02144012,https://clinicaltrials.gov/study/NCT01200212
MONDO_0007254	breast cancer	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT02246621,https://clinicaltrials.gov/study/NCT00601900,https://clinicaltrials.gov/study/NCT04546009,https://clinicaltrials.gov/study/NCT00382070,https://clinicaltrials.gov/study/NCT00412022,https://clinicaltrials.gov/study/NCT02918084,https://clinicaltrials.gov/study/NCT01064635,https://clinicaltrials.gov/study/NCT01674140,https://clinicaltrials.gov/study/NCT02947685,https://clinicaltrials.gov/study/NCT02763566
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	3	Recruiting	https://clinicaltrials.gov/study/NCT06143553
MONDO_0007254	breast cancer	CHEMBL1908360	EVEROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	3	Recruiting	https://clinicaltrials.gov/study/NCT06105632,https://clinicaltrials.gov/study/NCT05429684,https://clinicaltrials.gov/study/NCT05306340
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND5	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0004658	breast carcinoma in situ	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	3	Recruiting	https://clinicaltrials.gov/study/NCT04862585
EFO_0000305	breast carcinoma	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Recruiting	https://clinicaltrials.gov/study/NCT06268652
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	3	Recruiting	https://clinicaltrials.gov/study/NCT03264547,https://clinicaltrials.gov/study/NCT04547907,https://clinicaltrials.gov/study/NCT04400695,https://clinicaltrials.gov/study/NCT05296798,https://clinicaltrials.gov/study/NCT06143553,https://clinicaltrials.gov/study/NCT04540692,https://clinicaltrials.gov/study/NCT05429684,https://clinicaltrials.gov/study/NCT05113251,https://clinicaltrials.gov/study/NCT06103864,https://clinicaltrials.gov/study/NCT05840211,https://clinicaltrials.gov/study/NCT05555706,https://clinicaltrials.gov/study/NCT05207709,https://clinicaltrials.gov/study/NCT05814354,https://clinicaltrials.gov/study/NCT03949634,https://clinicaltrials.gov/study/NCT05894239,https://clinicaltrials.gov/study/NCT04335669,https://clinicaltrials.gov/study/NCT05374512,https://clinicaltrials.gov/study/NCT04862585,https://clinicaltrials.gov/study/NCT06018337,https://clinicaltrials.gov/study/NCT05382299,https://clinicaltrials.gov/study/NCT02344472,https://clinicaltrials.gov/study/NCT06112379,https://clinicaltrials.gov/study/NCT04137653,https://clinicaltrials.gov/study/NCT03876886,https://clinicaltrials.gov/study/NCT04193059
MONDO_0007254	breast cancer	CHEMBL38	TRETINOIN	Small molecule	Retinoic acid receptor agonist		RARA	retinoic acid receptor alpha	3	Not yet recruiting	https://clinicaltrials.gov/study/NCT05016349
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	3	Completed	https://clinicaltrials.gov/study/NCT00005970
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS1	NADH:ubiquinone oxidoreductase core subunit S1	3	Completed	https://clinicaltrials.gov/study/NCT01101438
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	3	Completed	https://clinicaltrials.gov/study/NCT00615602,https://clinicaltrials.gov/study/NCT00887536,https://clinicaltrials.gov/study/NCT00047099,https://clinicaltrials.gov/study/NCT00091442,https://clinicaltrials.gov/study/NCT02586025,https://clinicaltrials.gov/study/NCT00002662,https://clinicaltrials.gov/study/NCT01049425,https://clinicaltrials.gov/study/NCT00448591,https://clinicaltrials.gov/study/NCT00190489,https://clinicaltrials.gov/study/NCT02980965,https://clinicaltrials.gov/study/NCT00114816,https://clinicaltrials.gov/study/NCT00950300,https://clinicaltrials.gov/study/NCT03493854,https://clinicaltrials.gov/study/NCT04031703,https://clinicaltrials.gov/study/NCT00433589,https://clinicaltrials.gov/study/NCT00540800,https://clinicaltrials.gov/study/NCT00236899,https://clinicaltrials.gov/study/NCT01940497,https://clinicaltrials.gov/study/NCT00331097,https://clinicaltrials.gov/study/NCT00054587,https://clinicaltrials.gov/study/NCT00146549,https://clinicaltrials.gov/study/NCT02194166,https://clinicaltrials.gov/study/NCT01966471,https://clinicaltrials.gov/study/NCT00429871,https://clinicaltrials.gov/study/NCT00294385,https://clinicaltrials.gov/study/NCT02402712,https://clinicaltrials.gov/study/NCT00352378,https://clinicaltrials.gov/study/NCT00793377,https://clinicaltrials.gov/study/NCT00017095,https://clinicaltrials.gov/study/NCT00431080,https://clinicaltrials.gov/study/NCT00963729,https://clinicaltrials.gov/study/NCT00004125,https://clinicaltrials.gov/study/NCT00129935,https://clinicaltrials.gov/study/NCT00003519,https://clinicaltrials.gov/study/NCT00309556,https://clinicaltrials.gov/study/NCT05301010,https://clinicaltrials.gov/study/NCT04629846,https://clinicaltrials.gov/study/NCT03084237,https://clinicaltrials.gov/study/NCT02115204,https://clinicaltrials.gov/study/NCT00630032,https://clinicaltrials.gov/study/NCT00391092,https://clinicaltrials.gov/study/NCT00191152,https://clinicaltrials.gov/study/NCT01314833,https://clinicaltrials.gov/study/NCT02019277,https://clinicaltrials.gov/study/NCT00288002,https://clinicaltrials.gov/study/NCT04957212,https://clinicaltrials.gov/study/NCT00047255,https://clinicaltrials.gov/study/NCT02896855,https://clinicaltrials.gov/study/NCT00193011,https://clinicaltrials.gov/study/NCT03425656,https://clinicaltrials.gov/study/NCT00688740,https://clinicaltrials.gov/study/NCT01099436,https://clinicaltrials.gov/study/NCT00424606,https://clinicaltrials.gov/study/NCT03989037,https://clinicaltrials.gov/study/NCT01216111,https://clinicaltrials.gov/study/NCT00333775,https://clinicaltrials.gov/study/NCT00314977,https://clinicaltrials.gov/study/NCT05629949,https://clinicaltrials.gov/study/NCT00002544,https://clinicaltrials.gov/study/NCT02187744,https://clinicaltrials.gov/study/NCT00089479,https://clinicaltrials.gov/study/NCT01690702,https://clinicaltrials.gov/study/NCT00002707,https://clinicaltrials.gov/study/NCT00312208,https://clinicaltrials.gov/study/NCT00008411,https://clinicaltrials.gov/study/NCT00567554,https://clinicaltrials.gov/study/NCT02472964,https://clinicaltrials.gov/study/NCT01964391,https://clinicaltrials.gov/study/NCT01120184,https://clinicaltrials.gov/study/NCT00003782,https://clinicaltrials.gov/study/NCT00311636,https://clinicaltrials.gov/study/NCT04127019,https://clinicaltrials.gov/study/NCT00493870,https://clinicaltrials.gov/study/NCT00776724,https://clinicaltrials.gov/study/NCT01985724,https://clinicaltrials.gov/study/NCT00567190,https://clinicaltrials.gov/study/NCT03013504,https://clinicaltrials.gov/study/NCT00703326,https://clinicaltrials.gov/study/NCT02681003,https://clinicaltrials.gov/study/NCT00093795,https://clinicaltrials.gov/study/NCT00667251
MONDO_0007254	breast cancer	CHEMBL1680	OCTREOTIDE	Protein	Somatostatin receptor agonist		SSTR2	somatostatin receptor 2	3	Completed	https://clinicaltrials.gov/study/NCT00002967,https://clinicaltrials.gov/study/NCT00002864
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT04639986
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	3	Active, not recruiting	https://clinicaltrials.gov/study/NCT01646034,https://clinicaltrials.gov/study/NCT05104866,https://clinicaltrials.gov/study/NCT03734029,https://clinicaltrials.gov/study/NCT02641847,https://clinicaltrials.gov/study/NCT04639986
EFO_0000305	breast carcinoma	CHEMBL1201179	LAPATINIB DITOSYLATE	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Completed	https://clinicaltrials.gov/study/NCT01622868,https://clinicaltrials.gov/study/NCT00684983
EFO_0000304	breast adenocarcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Recruiting	https://clinicaltrials.gov/study/NCT04197687
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Unknown status	https://clinicaltrials.gov/study/NCT02175446
EFO_0000305	breast carcinoma	CHEMBL1201247	GOSERELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT02476786
EFO_0005537	triple-negative breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967
EFO_0005537	triple-negative breast cancer	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Withdrawn	https://clinicaltrials.gov/study/NCT05177796
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA8	NADH:ubiquinone oxidoreductase subunit A8	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF2	NADH:ubiquinone oxidoreductase complex assembly factor 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
EFO_0006861	male breast carcinoma	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT00096434
EFO_0005537	triple-negative breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT03932526
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA13	NADH:ubiquinone oxidoreductase subunit A13	2	Terminated	https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT02472353
MONDO_0007254	breast cancer	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT04891068
MONDO_0007254	breast cancer	CHEMBL4285417	CERALASERTIB	Small molecule	Serine-protein kinase ATR inhibitor		ATR	ATR serine/threonine kinase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03330847
MONDO_0007254	breast cancer	CHEMBL3137309	VENETOCLAX	Small molecule	Apoptosis regulator Bcl-2 inhibitor		BCL2	BCL2 apoptosis regulator	2	Terminated	https://clinicaltrials.gov/study/NCT03584009
MONDO_0007254	breast cancer	CHEMBL4297715	CAMRELIZUMAB	Antibody	Programmed cell death protein 1 antagonist		PDCD1	programmed cell death 1	2	Recruiting	https://clinicaltrials.gov/study/NCT04676997,https://clinicaltrials.gov/study/NCT05088057,https://clinicaltrials.gov/study/NCT05447702,https://clinicaltrials.gov/study/NCT05761470,https://clinicaltrials.gov/study/NCT04803539
MONDO_0007254	breast cancer	CHEMBL679	EPINEPHRINE	Small molecule	Adrenergic receptor agonist		ADRA1B	adrenoceptor alpha 1B	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04603911
MONDO_0007254	breast cancer	CHEMBL468	THALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		CUL4A	cullin 4A	2	Unknown status	https://clinicaltrials.gov/study/NCT02649101
MONDO_0007254	breast cancer	CHEMBL1289601	LENVATINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Recruiting	https://clinicaltrials.gov/study/NCT06110793,https://clinicaltrials.gov/study/NCT05286437,https://clinicaltrials.gov/study/NCT05181033
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT00002998,https://clinicaltrials.gov/study/NCT00003540,https://clinicaltrials.gov/study/NCT00059852,https://clinicaltrials.gov/study/NCT00662129,https://clinicaltrials.gov/study/NCT00005991,https://clinicaltrials.gov/study/NCT00006007
MONDO_0007254	breast cancer	CHEMBL655	MIDAZOLAM	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRA1	gamma-aminobutyric acid type A receptor subunit alpha1	2	Completed	https://clinicaltrials.gov/study/NCT03084536
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT00542451,https://clinicaltrials.gov/study/NCT01091428
EFO_0000305	breast carcinoma	CHEMBL384467	DEXAMETHASONE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	2	Terminated	https://clinicaltrials.gov/study/NCT00832338
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA12	NADH:ubiquinone oxidoreductase subunit A12	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0005537	triple-negative breast cancer	CHEMBL4298101	LADIRATUZUMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Terminated	https://clinicaltrials.gov/study/NCT00524459,https://clinicaltrials.gov/study/NCT00636441,https://clinicaltrials.gov/study/NCT00025493,https://clinicaltrials.gov/study/NCT00028483,https://clinicaltrials.gov/study/NCT03329378,https://clinicaltrials.gov/study/NCT00225056,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT01690325,https://clinicaltrials.gov/study/NCT00845910,https://clinicaltrials.gov/study/NCT03894007,https://clinicaltrials.gov/study/NCT00665457,https://clinicaltrials.gov/study/NCT00080626,https://clinicaltrials.gov/study/NCT00104624,https://clinicaltrials.gov/study/NCT00576901,https://clinicaltrials.gov/study/NCT00852332,https://clinicaltrials.gov/study/NCT00118053,https://clinicaltrials.gov/study/NCT01985841,https://clinicaltrials.gov/study/NCT00206453,https://clinicaltrials.gov/study/NCT00479856,https://clinicaltrials.gov/study/NCT00453635,https://clinicaltrials.gov/study/NCT00193024,https://clinicaltrials.gov/study/NCT00343512,https://clinicaltrials.gov/study/NCT02229149
MONDO_0007254	breast cancer	CHEMBL502835	NINTEDANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT01658462
MONDO_0007254	breast cancer	CHEMBL1743028	GLEMBATUMUMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT01997333,https://clinicaltrials.gov/study/NCT01156753
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Recruiting	https://clinicaltrials.gov/study/NCT05645380,https://clinicaltrials.gov/study/NCT05918328,https://clinicaltrials.gov/study/NCT05638594,https://clinicaltrials.gov/study/NCT05426486,https://clinicaltrials.gov/study/NCT06107673,https://clinicaltrials.gov/study/NCT04872985,https://clinicaltrials.gov/study/NCT05483439,https://clinicaltrials.gov/study/NCT05088057,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT05189067,https://clinicaltrials.gov/study/NCT03497702,https://clinicaltrials.gov/study/NCT03879577,https://clinicaltrials.gov/study/NCT05900206,https://clinicaltrials.gov/study/NCT05475678,https://clinicaltrials.gov/study/NCT03367676,https://clinicaltrials.gov/study/NCT04947189,https://clinicaltrials.gov/study/NCT04576143,https://clinicaltrials.gov/study/NCT04717531
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04517292,https://clinicaltrials.gov/study/NCT04502680,https://clinicaltrials.gov/study/NCT04913571,https://clinicaltrials.gov/study/NCT06308939,https://clinicaltrials.gov/study/NCT05263882,https://clinicaltrials.gov/study/NCT06202313
MONDO_0007254	breast cancer	CHEMBL1079175	MK-2206	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT3	AKT serine/threonine kinase 3	2	Withdrawn	https://clinicaltrials.gov/study/NCT01240941
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04290793,https://clinicaltrials.gov/study/NCT05872412,https://clinicaltrials.gov/study/NCT04194684,https://clinicaltrials.gov/study/NCT03959397,https://clinicaltrials.gov/study/NCT05444998,https://clinicaltrials.gov/study/NCT04301375,https://clinicaltrials.gov/study/NCT04900311,https://clinicaltrials.gov/study/NCT04907344,https://clinicaltrials.gov/study/NCT04498793,https://clinicaltrials.gov/study/NCT04639271,https://clinicaltrials.gov/study/NCT04499118,https://clinicaltrials.gov/study/NCT04946227,https://clinicaltrials.gov/study/NCT04659499
MONDO_0007254	breast cancer	CHEMBL3545414	RIVOCERANIB MESYLATE	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT04803539,https://clinicaltrials.gov/study/NCT04722718,https://clinicaltrials.gov/study/NCT05447702,https://clinicaltrials.gov/study/NCT05759572
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04907344,https://clinicaltrials.gov/study/NCT04301375,https://clinicaltrials.gov/study/NCT04499118,https://clinicaltrials.gov/study/NCT04659499,https://clinicaltrials.gov/study/NCT03959397,https://clinicaltrials.gov/study/NCT05872412,https://clinicaltrials.gov/study/NCT04290793,https://clinicaltrials.gov/study/NCT04946227,https://clinicaltrials.gov/study/NCT04639271,https://clinicaltrials.gov/study/NCT04194684,https://clinicaltrials.gov/study/NCT04498793,https://clinicaltrials.gov/study/NCT04900311,https://clinicaltrials.gov/study/NCT05444998
MONDO_0007254	breast cancer	CHEMBL4297736	PRALUZATAMAB RAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT04596150
MONDO_0007254	breast cancer	CHEMBL3545414	RIVOCERANIB MESYLATE	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Completed	https://clinicaltrials.gov/study/NCT02878057,https://clinicaltrials.gov/study/NCT03394287,https://clinicaltrials.gov/study/NCT01176669,https://clinicaltrials.gov/study/NCT03254654,https://clinicaltrials.gov/study/NCT03535961,https://clinicaltrials.gov/study/NCT03982485
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT00148681,https://clinicaltrials.gov/study/NCT00194779,https://clinicaltrials.gov/study/NCT00266110,https://clinicaltrials.gov/study/NCT00004237,https://clinicaltrials.gov/study/NCT00093808,https://clinicaltrials.gov/study/NCT00006682,https://clinicaltrials.gov/study/NCT01941771,https://clinicaltrials.gov/study/NCT00022152,https://clinicaltrials.gov/study/NCT00532623,https://clinicaltrials.gov/study/NCT00148668
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT00128856,https://clinicaltrials.gov/study/NCT00662129,https://clinicaltrials.gov/study/NCT01201265,https://clinicaltrials.gov/study/NCT00532857,https://clinicaltrials.gov/study/NCT00063570,https://clinicaltrials.gov/study/NCT00005991,https://clinicaltrials.gov/study/NCT00450762,https://clinicaltrials.gov/study/NCT00623233,https://clinicaltrials.gov/study/NCT00320541,https://clinicaltrials.gov/study/NCT00192101,https://clinicaltrials.gov/study/NCT00618826,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00191854,https://clinicaltrials.gov/study/NCT02435680,https://clinicaltrials.gov/study/NCT00540358,https://clinicaltrials.gov/study/NCT00493636,https://clinicaltrials.gov/study/NCT00378313,https://clinicaltrials.gov/study/NCT00201760,https://clinicaltrials.gov/study/NCT00191269,https://clinicaltrials.gov/study/NCT00813956,https://clinicaltrials.gov/study/NCT00002998,https://clinicaltrials.gov/study/NCT00480597,https://clinicaltrials.gov/study/NCT00059852,https://clinicaltrials.gov/study/NCT00191815,https://clinicaltrials.gov/study/NCT00193050,https://clinicaltrials.gov/study/NCT00191347,https://clinicaltrials.gov/study/NCT00532623,https://clinicaltrials.gov/study/NCT00503906,https://clinicaltrials.gov/study/NCT01045304,https://clinicaltrials.gov/study/NCT01550848,https://clinicaltrials.gov/study/NCT02263495,https://clinicaltrials.gov/study/NCT04464174,https://clinicaltrials.gov/study/NCT00006007,https://clinicaltrials.gov/study/NCT00191243,https://clinicaltrials.gov/study/NCT00193063,https://clinicaltrials.gov/study/NCT00846027,https://clinicaltrials.gov/study/NCT00110084,https://clinicaltrials.gov/study/NCT00244933,https://clinicaltrials.gov/study/NCT00316199,https://clinicaltrials.gov/study/NCT00193206,https://clinicaltrials.gov/study/NCT00003540,https://clinicaltrials.gov/study/NCT00191789,https://clinicaltrials.gov/study/NCT00894504,https://clinicaltrials.gov/study/NCT03025880,https://clinicaltrials.gov/study/NCT00334802,https://clinicaltrials.gov/study/NCT00601159,https://clinicaltrials.gov/study/NCT00191373,https://clinicaltrials.gov/study/NCT00403130,https://clinicaltrials.gov/study/NCT00193076,https://clinicaltrials.gov/study/NCT00754351,https://clinicaltrials.gov/study/NCT00212069,https://clinicaltrials.gov/study/NCT00192062,https://clinicaltrials.gov/study/NCT00191451,https://clinicaltrials.gov/study/NCT00325234,https://clinicaltrials.gov/study/NCT00695994
EFO_0000305	breast carcinoma	CHEMBL4302409	LUTETIUM OXODOTREOTIDE	Protein	Somatostatin receptor binding agent		SSTR2	somatostatin receptor 2	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04529044
MONDO_0007254	breast cancer	CHEMBL1743028	GLEMBATUMUMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT01156753,https://clinicaltrials.gov/study/NCT01997333
MONDO_0007254	breast cancer	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Completed	https://clinicaltrials.gov/study/NCT03121352,https://clinicaltrials.gov/study/NCT03051659,https://clinicaltrials.gov/study/NCT05112536,https://clinicaltrials.gov/study/NCT02768701,https://clinicaltrials.gov/study/NCT03988036,https://clinicaltrials.gov/study/NCT03289819,https://clinicaltrials.gov/study/NCT03222856,https://clinicaltrials.gov/study/NCT03139851,https://clinicaltrials.gov/study/NCT02447003,https://clinicaltrials.gov/study/NCT05159778,https://clinicaltrials.gov/study/NCT03025880,https://clinicaltrials.gov/study/NCT02730130
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Recruiting	https://clinicaltrials.gov/study/NCT06026657,https://clinicaltrials.gov/study/NCT03606967
EFO_0000305	breast carcinoma	CHEMBL4298037	RETIFANLIMAB	Antibody	Programmed cell death protein 1 antagonist		PDCD1	programmed cell death 1	2	Recruiting	https://clinicaltrials.gov/study/NCT04445844
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967,https://clinicaltrials.gov/study/NCT04266249,https://clinicaltrials.gov/study/NCT04090398
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4L	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0006861	male breast carcinoma	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05501704
EFO_0005537	triple-negative breast cancer	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03911973
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND5	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5	2	Unknown status	https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT02506777,https://clinicaltrials.gov/study/NCT02506790
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Unknown status	https://clinicaltrials.gov/study/NCT00398489,https://clinicaltrials.gov/study/NCT00801411,https://clinicaltrials.gov/study/NCT03876587,https://clinicaltrials.gov/study/NCT00006120,https://clinicaltrials.gov/study/NCT00033683,https://clinicaltrials.gov/study/NCT01270373,https://clinicaltrials.gov/study/NCT00669773,https://clinicaltrials.gov/study/NCT00994968,https://clinicaltrials.gov/study/NCT01907529,https://clinicaltrials.gov/study/NCT00250874,https://clinicaltrials.gov/study/NCT02947061,https://clinicaltrials.gov/study/NCT02144194,https://clinicaltrials.gov/study/NCT03147963,https://clinicaltrials.gov/study/NCT00012311,https://clinicaltrials.gov/study/NCT01939054,https://clinicaltrials.gov/study/NCT00721747,https://clinicaltrials.gov/study/NCT01351597,https://clinicaltrials.gov/study/NCT01526499,https://clinicaltrials.gov/study/NCT00957125,https://clinicaltrials.gov/study/NCT00003066,https://clinicaltrials.gov/study/NCT02685657,https://clinicaltrials.gov/study/NCT01352494,https://clinicaltrials.gov/study/NCT00026078
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Withdrawn	https://clinicaltrials.gov/study/NCT02215876,https://clinicaltrials.gov/study/NCT03637868
MONDO_0007254	breast cancer	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC1	histone deacetylase 1	2	Completed	https://clinicaltrials.gov/study/NCT00098397
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05536128,https://clinicaltrials.gov/study/NCT05128734
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Recruiting	https://clinicaltrials.gov/study/NCT06102824,https://clinicaltrials.gov/study/NCT05823623,https://clinicaltrials.gov/study/NCT03939871,https://clinicaltrials.gov/study/NCT04759248,https://clinicaltrials.gov/study/NCT04389073,https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT04605575,https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT05747326,https://clinicaltrials.gov/study/NCT04304352,https://clinicaltrials.gov/study/NCT05296577,https://clinicaltrials.gov/study/NCT04302441,https://clinicaltrials.gov/study/NCT04296162
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB10	NADH:ubiquinone oxidoreductase subunit B10	2	Unknown status	https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT02506777
MONDO_0007254	breast cancer	CHEMBL4297892	ANVATABART OPADOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBA1C	tubulin alpha 1c	2	Recruiting	https://clinicaltrials.gov/study/NCT04829604,https://clinicaltrials.gov/study/NCT05426486,https://clinicaltrials.gov/study/NCT05018702,https://clinicaltrials.gov/study/NCT05018676,https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA1	NADH:ubiquinone oxidoreductase subunit A1	2	Terminated	https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT01627067
MONDO_0007254	breast cancer	CHEMBL1200694	SEVOFLURANE	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRQ	gamma-aminobutyric acid type A receptor subunit theta	2	Completed	https://clinicaltrials.gov/study/NCT02839668
MONDO_0007254	breast cancer	CHEMBL3039558	ETIRINOTECAN PEGOL	Small molecule	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	2	Completed	https://clinicaltrials.gov/study/NCT00802945
EFO_0000305	breast carcinoma	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02632045
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
EFO_0000305	breast carcinoma	CHEMBL1201746	PRALATREXATE	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	2	Completed	https://clinicaltrials.gov/study/NCT01118624
EFO_0000305	breast carcinoma	CHEMBL841	LOPERAMIDE	Small molecule	Mu opioid receptor agonist		OPRM1	opioid receptor mu 1	2	Completed	https://clinicaltrials.gov/study/NCT02441946
EFO_0000305	breast carcinoma	CHEMBL3545262	SACITUZUMAB GOVITECAN	Antibody drug conjugate	Tumor-associated calcium signal transducer 2 binding agent		TACSTD2	tumor associated calcium signal transducer 2	2	Recruiting	https://clinicaltrials.gov/study/NCT03971409
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Recruiting	https://clinicaltrials.gov/study/NCT04266249
EFO_0006861	male breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Unknown status	https://clinicaltrials.gov/study/NCT01372579
EFO_0006861	male breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00095888
EFO_0006861	male breast carcinoma	CHEMBL535	SUNITINIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	2	Completed	https://clinicaltrials.gov/study/NCT00513695
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS6	NADH:ubiquinone oxidoreductase subunit S6	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL1059	PREGABALIN	Small molecule	Voltage-gated calcium channel modulator		CACNA2D1	calcium voltage-gated channel auxiliary subunit alpha2delta 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06150898
MONDO_0007254	breast cancer	CHEMBL2408045	SAPITINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Terminated	https://clinicaltrials.gov/study/NCT01151215
MONDO_0007254	breast cancer	CHEMBL4650411	OCIPERLIMAB	Antibody	T-cell immunoreceptor with Ig and ITIM domains inhibitor		TIGIT	T cell immunoreceptor with Ig and ITIM domains	2	Withdrawn	https://clinicaltrials.gov/study/NCT05809895
EFO_0005537	triple-negative breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		LYN	LYN proto-oncogene, Src family tyrosine kinase	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06355037
EFO_0006861	male breast carcinoma	CHEMBL1567	SUNITINIB MALATE	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	2	Completed	https://clinicaltrials.gov/study/NCT00513695
MONDO_0007254	breast cancer	CHEMBL4297763	GTI-2040	Unknown	Ribonucleotide reductase small subunit mRNA antisense inhibitor		RRM2	ribonucleotide reductase regulatory subunit M2	2	Completed	https://clinicaltrials.gov/study/NCT00068588
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05833919,https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT04303741
MONDO_0007254	breast cancer	CHEMBL180022	NERATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Terminated	https://clinicaltrials.gov/study/NCT04460430,https://clinicaltrials.gov/study/NCT03289039
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Unknown status	https://clinicaltrials.gov/study/NCT01730677,https://clinicaltrials.gov/study/NCT01528826,https://clinicaltrials.gov/study/NCT00159094,https://clinicaltrials.gov/study/NCT02607215,https://clinicaltrials.gov/study/NCT02768415,https://clinicaltrials.gov/study/NCT02144194,https://clinicaltrials.gov/study/NCT02544243,https://clinicaltrials.gov/study/NCT03423849
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05263882,https://clinicaltrials.gov/study/NCT04517292,https://clinicaltrials.gov/study/NCT04143906
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Withdrawn	https://clinicaltrials.gov/study/NCT02725541
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Recruiting	https://clinicaltrials.gov/study/NCT04924699
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05041101,https://clinicaltrials.gov/study/NCT03202316
MONDO_0007254	breast cancer	CHEMBL3813842	PAXALISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	2	Recruiting	https://clinicaltrials.gov/study/NCT03765983
EFO_0000305	breast carcinoma	CHEMBL491473	CEDIRANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Recruiting	https://clinicaltrials.gov/study/NCT04090567
MONDO_0007254	breast cancer	CHEMBL2103842	VARLITINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Completed	https://clinicaltrials.gov/study/NCT02338245
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Epidermal growth factor receptor inhibitor		ERBB3	erb-b2 receptor tyrosine kinase 3	2	Completed	https://clinicaltrials.gov/study/NCT00494481
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Epidermal growth factor receptor inhibitor		ERBB4	erb-b2 receptor tyrosine kinase 4	2	Terminated	https://clinicaltrials.gov/study/NCT00481845,https://clinicaltrials.gov/study/NCT01934335,https://clinicaltrials.gov/study/NCT00752986
MONDO_0007254	breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	2	Recruiting	https://clinicaltrials.gov/study/NCT05464173,https://clinicaltrials.gov/study/NCT04614194,https://clinicaltrials.gov/study/NCT05766410,https://clinicaltrials.gov/study/NCT04523857,https://clinicaltrials.gov/study/NCT05548127,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT05524584,https://clinicaltrials.gov/study/NCT05608252,https://clinicaltrials.gov/study/NCT05501704,https://clinicaltrials.gov/study/NCT05933395,https://clinicaltrials.gov/study/NCT04802759,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT05563220,https://clinicaltrials.gov/study/NCT04791384
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Enrolling by invitation	https://clinicaltrials.gov/study/NCT03580395
MONDO_0007254	breast cancer	CHEMBL481	IRINOTECAN	Small molecule	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	2	Terminated	https://clinicaltrials.gov/study/NCT00476827
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA2	NADH:ubiquinone oxidoreductase subunit A2	2	Recruiting	https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04559308
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR1	estrogen receptor 1	2	Terminated	https://clinicaltrials.gov/study/NCT02540330
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV2	NADH:ubiquinone oxidoreductase core subunit V2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
EFO_0006861	male breast carcinoma	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase RAF inhibitor		RAF1	Raf-1 proto-oncogene, serine/threonine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00096434
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Withdrawn	https://clinicaltrials.gov/study/NCT04351230
EFO_0006861	male breast carcinoma	CHEMBL1201670	SARGRAMOSTIM	Protein	Granulocyte-macrophage colony-stimulating factor receptor agonist		CSF2RA	colony stimulating factor 2 receptor subunit alpha	2	Completed	https://clinicaltrials.gov/study/NCT00343109,https://clinicaltrials.gov/study/NCT00003199
MONDO_0007254	breast cancer	CHEMBL522892	DOVITINIB	Small molecule	Fibroblast growth factor receptor 3 inhibitor		FGFR3	fibroblast growth factor receptor 3	2	Terminated	https://clinicaltrials.gov/study/NCT01528345
EFO_0005537	triple-negative breast cancer	CHEMBL2325741	CAPIVASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT1	AKT serine/threonine kinase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02208375
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBA4A	tubulin alpha 4a	2	Withdrawn	https://clinicaltrials.gov/study/NCT01227408
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC9	histone deacetylase 9	2	Withdrawn	https://clinicaltrials.gov/study/NCT02115594
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBA1B	tubulin alpha 1b	2	Completed	https://clinicaltrials.gov/study/NCT00284180
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT00003050,https://clinicaltrials.gov/study/NCT05112536,https://clinicaltrials.gov/study/NCT00662129,https://clinicaltrials.gov/study/NCT02628613,https://clinicaltrials.gov/study/NCT00007904,https://clinicaltrials.gov/study/NCT01855828,https://clinicaltrials.gov/study/NCT00002937,https://clinicaltrials.gov/study/NCT02783222,https://clinicaltrials.gov/study/NCT00580333,https://clinicaltrials.gov/study/NCT00194779,https://clinicaltrials.gov/study/NCT00475670,https://clinicaltrials.gov/study/NCT02225652,https://clinicaltrials.gov/study/NCT02280252,https://clinicaltrials.gov/study/NCT00005635,https://clinicaltrials.gov/study/NCT00629499,https://clinicaltrials.gov/study/NCT00191854,https://clinicaltrials.gov/study/NCT00193206,https://clinicaltrials.gov/study/NCT02954055,https://clinicaltrials.gov/study/NCT01740336,https://clinicaltrials.gov/study/NCT02938442,https://clinicaltrials.gov/study/NCT00004092,https://clinicaltrials.gov/study/NCT00146562,https://clinicaltrials.gov/study/NCT02370238,https://clinicaltrials.gov/study/NCT00467012,https://clinicaltrials.gov/study/NCT00251472,https://clinicaltrials.gov/study/NCT00394082,https://clinicaltrials.gov/study/NCT02365805,https://clinicaltrials.gov/study/NCT00019812,https://clinicaltrials.gov/study/NCT00002679,https://clinicaltrials.gov/study/NCT00503750,https://clinicaltrials.gov/study/NCT00971945,https://clinicaltrials.gov/study/NCT01779479,https://clinicaltrials.gov/study/NCT01818063,https://clinicaltrials.gov/study/NCT00645177,https://clinicaltrials.gov/study/NCT00930930,https://clinicaltrials.gov/study/NCT01036087,https://clinicaltrials.gov/study/NCT03644186,https://clinicaltrials.gov/study/NCT00256243,https://clinicaltrials.gov/study/NCT00856492,https://clinicaltrials.gov/study/NCT01008150,https://clinicaltrials.gov/study/NCT03248427,https://clinicaltrials.gov/study/NCT00274456,https://clinicaltrials.gov/study/NCT00004013,https://clinicaltrials.gov/study/NCT00919880,https://clinicaltrials.gov/study/NCT00093145,https://clinicaltrials.gov/study/NCT00370552,https://clinicaltrials.gov/study/NCT01827163,https://clinicaltrials.gov/study/NCT00096343,https://clinicaltrials.gov/study/NCT02909751,https://clinicaltrials.gov/study/NCT00096668,https://clinicaltrials.gov/study/NCT00773695,https://clinicaltrials.gov/study/NCT01594177,https://clinicaltrials.gov/study/NCT01572727,https://clinicaltrials.gov/study/NCT03193853,https://clinicaltrials.gov/study/NCT00482391,https://clinicaltrials.gov/study/NCT00618826,https://clinicaltrials.gov/study/NCT01256762,https://clinicaltrials.gov/study/NCT00136539,https://clinicaltrials.gov/study/NCT03887130,https://clinicaltrials.gov/study/NCT01593020,https://clinicaltrials.gov/study/NCT00003992,https://clinicaltrials.gov/study/NCT01565499,https://clinicaltrials.gov/study/NCT00096291,https://clinicaltrials.gov/study/NCT02685059,https://clinicaltrials.gov/study/NCT01446016,https://clinicaltrials.gov/study/NCT01106898,https://clinicaltrials.gov/study/NCT01023204,https://clinicaltrials.gov/study/NCT04408118,https://clinicaltrials.gov/study/NCT00001384,https://clinicaltrials.gov/study/NCT02263495,https://clinicaltrials.gov/study/NCT01204125,https://clinicaltrials.gov/study/NCT00546156,https://clinicaltrials.gov/study/NCT00403130,https://clinicaltrials.gov/study/NCT03982485,https://clinicaltrials.gov/study/NCT02474186,https://clinicaltrials.gov/study/NCT02132949,https://clinicaltrials.gov/study/NCT01656538,https://clinicaltrials.gov/study/NCT03121352,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT01421472,https://clinicaltrials.gov/study/NCT01204437,https://clinicaltrials.gov/study/NCT02301988,https://clinicaltrials.gov/study/NCT03326102,https://clinicaltrials.gov/study/NCT04224922,https://clinicaltrials.gov/study/NCT00052351,https://clinicaltrials.gov/study/NCT00003612,https://clinicaltrials.gov/study/NCT00006110,https://clinicaltrials.gov/study/NCT00320541,https://clinicaltrials.gov/study/NCT00072319,https://clinicaltrials.gov/study/NCT00915603,https://clinicaltrials.gov/study/NCT00532857,https://clinicaltrials.gov/study/NCT01688609,https://clinicaltrials.gov/study/NCT01847001,https://clinicaltrials.gov/study/NCT00001498,https://clinicaltrials.gov/study/NCT01190982,https://clinicaltrials.gov/study/NCT00003392,https://clinicaltrials.gov/study/NCT00944047,https://clinicaltrials.gov/study/NCT01705691,https://clinicaltrials.gov/study/NCT03072992,https://clinicaltrials.gov/study/NCT00028873,https://clinicaltrials.gov/study/NCT01792050,https://clinicaltrials.gov/study/NCT00479674,https://clinicaltrials.gov/study/NCT01722968,https://clinicaltrials.gov/study/NCT01506609,https://clinicaltrials.gov/study/NCT00110084,https://clinicaltrials.gov/study/NCT01959490,https://clinicaltrials.gov/study/NCT01320111,https://clinicaltrials.gov/study/NCT00723125,https://clinicaltrials.gov/study/NCT00846027,https://clinicaltrials.gov/study/NCT00542451,https://clinicaltrials.gov/study/NCT00003539,https://clinicaltrials.gov/study/NCT01672671,https://clinicaltrials.gov/study/NCT03853707,https://clinicaltrials.gov/study/NCT00675259,https://clinicaltrials.gov/study/NCT00002826,https://clinicaltrials.gov/study/NCT00316199,https://clinicaltrials.gov/study/NCT01307891,https://clinicaltrials.gov/study/NCT00635050,https://clinicaltrials.gov/study/NCT00503906,https://clinicaltrials.gov/study/NCT00654836,https://clinicaltrials.gov/study/NCT01969032,https://clinicaltrials.gov/study/NCT00559845,https://clinicaltrials.gov/study/NCT00148681,https://clinicaltrials.gov/study/NCT03289819,https://clinicaltrials.gov/study/NCT00334802,https://clinicaltrials.gov/study/NCT01432223,https://clinicaltrials.gov/study/NCT01835236,https://clinicaltrials.gov/study/NCT00407888,https://clinicaltrials.gov/study/NCT00392392,https://clinicaltrials.gov/study/NCT00915018,https://clinicaltrials.gov/study/NCT00378313,https://clinicaltrials.gov/study/NCT02687490,https://clinicaltrials.gov/study/NCT03301350,https://clinicaltrials.gov/study/NCT02229084,https://clinicaltrials.gov/study/NCT00618657,https://clinicaltrials.gov/study/NCT01816594,https://clinicaltrials.gov/study/NCT01203267,https://clinicaltrials.gov/study/NCT00128856,https://clinicaltrials.gov/study/NCT00511459,https://clinicaltrials.gov/study/NCT01973660,https://clinicaltrials.gov/study/NCT00254592,https://clinicaltrials.gov/study/NCT00455533,https://clinicaltrials.gov/study/NCT03742986,https://clinicaltrials.gov/study/NCT00394251,https://clinicaltrials.gov/study/NCT00768859,https://clinicaltrials.gov/study/NCT02789657,https://clinicaltrials.gov/study/NCT01276041,https://clinicaltrials.gov/study/NCT00795899,https://clinicaltrials.gov/study/NCT02698891,https://clinicaltrials.gov/study/NCT01989780,https://clinicaltrials.gov/study/NCT00499083,https://clinicaltrials.gov/study/NCT00003035,https://clinicaltrials.gov/study/NCT00005649,https://clinicaltrials.gov/study/NCT00436566,https://clinicaltrials.gov/study/NCT01186991,https://clinicaltrials.gov/study/NCT00006256,https://clinicaltrials.gov/study/NCT01423695,https://clinicaltrials.gov/study/NCT01617668,https://clinicaltrials.gov/study/NCT00733408,https://clinicaltrials.gov/study/NCT01982448,https://clinicaltrials.gov/study/NCT02073487
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC2	NADH:ubiquinone oxidoreductase subunit C2	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA1	NADH:ubiquinone oxidoreductase subunit A1	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA3	NADH:ubiquinone oxidoreductase subunit A3	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL4303201	CATEQUENTINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04975451
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB8	NADH:ubiquinone oxidoreductase subunit B8	2	Recruiting	https://clinicaltrials.gov/study/NCT04559308,https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA7	NADH:ubiquinone oxidoreductase subunit A7	2	Terminated	https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT02472353
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC11	histone deacetylase 11	2	Terminated	https://clinicaltrials.gov/study/NCT00777335
MONDO_0007254	breast cancer	CHEMBL4650316	GIREDESTRANT	Small molecule	Estrogen receptor alpha degrader		ESR1	estrogen receptor 1	2	Completed	https://clinicaltrials.gov/study/NCT04436744
MONDO_0007254	breast cancer	CHEMBL482968	ENMD-2076	Small molecule	Serine/threonine-protein kinase Aurora-A inhibitor		AURKA	aurora kinase A	2	Completed	https://clinicaltrials.gov/study/NCT01639248
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF2	NADH:ubiquinone oxidoreductase complex assembly factor 2	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB5	NADH:ubiquinone oxidoreductase subunit B5	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
MONDO_0007254	breast cancer	CHEMBL1200775	LEUPROLIDE ACETATE	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT02592746
MONDO_0021115	luminal B breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT03356860
EFO_0006861	male breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Unknown status	https://clinicaltrials.gov/study/NCT01372579
MONDO_0007254	breast cancer	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Unknown status	https://clinicaltrials.gov/study/NCT00499525
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT03530696
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB2	NADH:ubiquinone oxidoreductase subunit B2	2	Terminated	https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT01477060
MONDO_0007254	breast cancer	CHEMBL3545262	SACITUZUMAB GOVITECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	2	Withdrawn	https://clinicaltrials.gov/study/NCT05008510
MONDO_0007254	breast cancer	CHEMBL4650365	CAMIZESTRANT	Small molecule	Estrogen receptor alpha degrader		ESR1	estrogen receptor 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04214288
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Unknown status	https://clinicaltrials.gov/study/NCT02341911,https://clinicaltrials.gov/study/NCT02544243,https://clinicaltrials.gov/study/NCT01352494,https://clinicaltrials.gov/study/NCT00027989,https://clinicaltrials.gov/study/NCT03423849
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF1	NADH:ubiquinone oxidoreductase complex assembly factor 1	2	Completed	https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT04170465
EFO_0000305	breast carcinoma	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02849496
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Unknown status	https://clinicaltrials.gov/study/NCT03144947
EFO_0005537	triple-negative breast cancer	CHEMBL4303201	CATEQUENTINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Recruiting	https://clinicaltrials.gov/study/NCT05089643,https://clinicaltrials.gov/study/NCT04914390
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA13	NADH:ubiquinone oxidoreductase subunit A13	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Recruiting	https://clinicaltrials.gov/study/NCT04266249,https://clinicaltrials.gov/study/NCT05319873,https://clinicaltrials.gov/study/NCT06042569
EFO_0006861	male breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
EFO_0006861	male breast carcinoma	CHEMBL1201179	LAPATINIB DITOSYLATE	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Completed	https://clinicaltrials.gov/study/NCT00118157,https://clinicaltrials.gov/study/NCT00098605
EFO_0006861	male breast carcinoma	CHEMBL491473	CEDIRANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Completed	https://clinicaltrials.gov/study/NCT00244881
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	2	Withdrawn	https://clinicaltrials.gov/study/NCT04351230
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Unknown status	https://clinicaltrials.gov/study/NCT03412955,https://clinicaltrials.gov/study/NCT02175446
MONDO_0007254	breast cancer	CHEMBL112	ACETAMINOPHEN	Small molecule	Vanilloid receptor opener		TRPV1	transient receptor potential cation channel subfamily V member 1	2	Completed	https://clinicaltrials.gov/study/NCT02839668,https://clinicaltrials.gov/study/NCT03084536
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND2	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC6	histone deacetylase 6	2	Withdrawn	https://clinicaltrials.gov/study/NCT02115594
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND1	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05041101,https://clinicaltrials.gov/study/NCT03202316
MONDO_0007254	breast cancer	CHEMBL1201468	ESTROGENS, ESTERIFIED	Unknown	Estrogen receptor agonist		ESR2	estrogen receptor 2	2	Terminated	https://clinicaltrials.gov/study/NCT00131924
MONDO_0007254	breast cancer	CHEMBL1201748	CABAZITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT01693549
MONDO_0007254	breast cancer	CHEMBL2396661	ALPELISIB	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	2	Completed	https://clinicaltrials.gov/study/NCT01923168,https://clinicaltrials.gov/study/NCT02506556
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	2	Terminated	https://clinicaltrials.gov/study/NCT01934335,https://clinicaltrials.gov/study/NCT00752986,https://clinicaltrials.gov/study/NCT00481845
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Unknown status	https://clinicaltrials.gov/study/NCT03147963,https://clinicaltrials.gov/study/NCT00250874,https://clinicaltrials.gov/study/NCT00033683,https://clinicaltrials.gov/study/NCT00669773,https://clinicaltrials.gov/study/NCT00003066,https://clinicaltrials.gov/study/NCT01352494,https://clinicaltrials.gov/study/NCT00957125,https://clinicaltrials.gov/study/NCT03876587,https://clinicaltrials.gov/study/NCT00801411,https://clinicaltrials.gov/study/NCT01270373,https://clinicaltrials.gov/study/NCT00026078,https://clinicaltrials.gov/study/NCT00721747,https://clinicaltrials.gov/study/NCT01526499,https://clinicaltrials.gov/study/NCT00398489,https://clinicaltrials.gov/study/NCT01351597,https://clinicaltrials.gov/study/NCT02947061,https://clinicaltrials.gov/study/NCT01939054,https://clinicaltrials.gov/study/NCT01907529,https://clinicaltrials.gov/study/NCT00012311,https://clinicaltrials.gov/study/NCT02685657,https://clinicaltrials.gov/study/NCT00994968,https://clinicaltrials.gov/study/NCT02144194,https://clinicaltrials.gov/study/NCT00006120
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV2	NADH:ubiquinone oxidoreductase core subunit V2	2	Recruiting	https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04559308,https://clinicaltrials.gov/study/NCT03238495
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT00005614
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB7	NADH:ubiquinone oxidoreductase subunit B7	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4	NDUFA4 mitochondrial complex associated	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0006861	male breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Tyrosine-protein kinase LCK inhibitor		LCK	LCK proto-oncogene, Src family tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4	2	Completed	https://clinicaltrials.gov/study/NCT01885013
EFO_0005537	triple-negative breast cancer	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0005537	triple-negative breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03911973
MONDO_0007254	breast cancer	CHEMBL45	MELATONIN	Small molecule	Melatonin receptor agonist		MTNR1A	melatonin receptor 1A	2	Unknown status	https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT01557478,https://clinicaltrials.gov/study/NCT02506777
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Terminated	https://clinicaltrials.gov/study/NCT00049660,https://clinicaltrials.gov/study/NCT00694200,https://clinicaltrials.gov/study/NCT00169104,https://clinicaltrials.gov/study/NCT03358004,https://clinicaltrials.gov/study/NCT00453635,https://clinicaltrials.gov/study/NCT01161368,https://clinicaltrials.gov/study/NCT00130507,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT01185509,https://clinicaltrials.gov/study/NCT02585388,https://clinicaltrials.gov/study/NCT00754702,https://clinicaltrials.gov/study/NCT00194792,https://clinicaltrials.gov/study/NCT00088985,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT02213744,https://clinicaltrials.gov/study/NCT00176488
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE1B	phosphodiesterase 1B	2	Recruiting	https://clinicaltrials.gov/study/NCT06087237
EFO_0005537	triple-negative breast cancer	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Completed	https://clinicaltrials.gov/study/NCT02401347
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT03530696
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT00861705
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT00513695,https://clinicaltrials.gov/study/NCT02199418,https://clinicaltrials.gov/study/NCT02682693
EFO_0006318	breast ductal adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Terminated	https://clinicaltrials.gov/study/NCT01891357
EFO_0006861	male breast carcinoma	CHEMBL941	IMATINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT00045188
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT00265733,https://clinicaltrials.gov/study/NCT00148707
EFO_0005537	triple-negative breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FGR	FGR proto-oncogene, Src family tyrosine kinase	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06355037
MONDO_0007254	breast cancer	CHEMBL1201748	CABAZITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Terminated	https://clinicaltrials.gov/study/NCT01934894
MONDO_0007254	breast cancer	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	2	Completed	https://clinicaltrials.gov/study/NCT00004906,https://clinicaltrials.gov/study/NCT00015938,https://clinicaltrials.gov/study/NCT00194779,https://clinicaltrials.gov/study/NCT00003953,https://clinicaltrials.gov/study/NCT00003392,https://clinicaltrials.gov/study/NCT02225652,https://clinicaltrials.gov/study/NCT00407888,https://clinicaltrials.gov/study/NCT00002680,https://clinicaltrials.gov/study/NCT00004172,https://clinicaltrials.gov/study/NCT03301350,https://clinicaltrials.gov/study/NCT00072319,https://clinicaltrials.gov/study/NCT00005800,https://clinicaltrials.gov/study/NCT00007904,https://clinicaltrials.gov/study/NCT00020176,https://clinicaltrials.gov/study/NCT00002679,https://clinicaltrials.gov/study/NCT00004900,https://clinicaltrials.gov/study/NCT00004092,https://clinicaltrials.gov/study/NCT00001384,https://clinicaltrials.gov/study/NCT00049114,https://clinicaltrials.gov/study/NCT00003035,https://clinicaltrials.gov/study/NCT00041067,https://clinicaltrials.gov/study/NCT01416389,https://clinicaltrials.gov/study/NCT00404066
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS3	NADH:ubiquinone oxidoreductase core subunit S3	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT01941771,https://clinicaltrials.gov/study/NCT00093808,https://clinicaltrials.gov/study/NCT00266110,https://clinicaltrials.gov/study/NCT00022152,https://clinicaltrials.gov/study/NCT00004237,https://clinicaltrials.gov/study/NCT00532623,https://clinicaltrials.gov/study/NCT00006682,https://clinicaltrials.gov/study/NCT00148668,https://clinicaltrials.gov/study/NCT00194779,https://clinicaltrials.gov/study/NCT00148681
MONDO_0007254	breast cancer	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RB	interleukin 2 receptor subunit beta	2	Terminated	https://clinicaltrials.gov/study/NCT00784524,https://clinicaltrials.gov/study/NCT00376805
MONDO_0007254	breast cancer	CHEMBL1230314	ESTETROL	Small molecule	Estrogen receptor agonist		ESR1	estrogen receptor 1	2	Completed	https://clinicaltrials.gov/study/NCT00464516
MONDO_0007254	breast cancer	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC5	histone deacetylase 5	2	Completed	https://clinicaltrials.gov/study/NCT00098397
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Recruiting	https://clinicaltrials.gov/study/NCT04796324
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT00191373
EFO_0000304	breast adenocarcinoma	CHEMBL2146146	ATROPINE SULFATE	Small molecule	Muscarinic acetylcholine receptor M2 antagonist		CHRM2	cholinergic receptor muscarinic 2	2	Completed	https://clinicaltrials.gov/study/NCT03094052
EFO_0005537	triple-negative breast cancer	CHEMBL3813873	PEXIDARTINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA3	NADH:ubiquinone oxidoreductase subunit A3	2	Completed	https://clinicaltrials.gov/study/NCT01885013
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV3	NADH:ubiquinone oxidoreductase subunit V3	2	Completed	https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT00909506
EFO_0006861	male breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Unknown status	https://clinicaltrials.gov/study/NCT01372579
MONDO_0007254	breast cancer	CHEMBL1567	SUNITINIB MALATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Terminated	https://clinicaltrials.gov/study/NCT00824538
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	2	Withdrawn	https://clinicaltrials.gov/study/NCT00615524
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL180022	NERATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT02673398
EFO_1000984	inflammatory breast carcinoma	CHEMBL1567	SUNITINIB MALATE	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Completed	https://clinicaltrials.gov/study/NCT00513695
EFO_0006861	male breast carcinoma	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT00017394
EFO_0006861	male breast carcinoma	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT00017394
MONDO_0007254	breast cancer	CHEMBL3545068	COPANLISIB HYDROCHLORIDE	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03939897
EFO_0005537	triple-negative breast cancer	CHEMBL4298119	OLINVACIMAB	Antibody	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT04986852
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Completed	https://clinicaltrials.gov/study/NCT01466972,https://clinicaltrials.gov/study/NCT00509587
MONDO_0007254	breast cancer	CHEMBL522892	DOVITINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT01528345
EFO_1000984	inflammatory breast carcinoma	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01730833
MONDO_0007254	breast cancer	CHEMBL553	ERLOTINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Completed	https://clinicaltrials.gov/study/NCT00030537,https://clinicaltrials.gov/study/NCT00633750,https://clinicaltrials.gov/study/NCT00059852,https://clinicaltrials.gov/study/NCT00109265,https://clinicaltrials.gov/study/NCT00733408,https://clinicaltrials.gov/study/NCT00054275
MONDO_0007254	breast cancer	CHEMBL2108184	CROFELEMER	Small molecule	Anoctamin-1 blocker		ANO1	anoctamin 1	2	Completed	https://clinicaltrials.gov/study/NCT02910219
MONDO_0007254	breast cancer	CHEMBL4298101	LADIRATUZUMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT03424005
MONDO_0007254	breast cancer	CHEMBL45	MELATONIN	Small molecule	Melatonin receptor agonist		MTNR1B	melatonin receptor 1B	2	Unknown status	https://clinicaltrials.gov/study/NCT02506777,https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT01557478
MONDO_0007254	breast cancer	CHEMBL924	ZOLEDRONIC ACID ANHYDROUS	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	2	Completed	https://clinicaltrials.gov/study/NCT00247650,https://clinicaltrials.gov/study/NCT00903162,https://clinicaltrials.gov/study/NCT03358017,https://clinicaltrials.gov/study/NCT01344967,https://clinicaltrials.gov/study/NCT00525759,https://clinicaltrials.gov/study/NCT00213980,https://clinicaltrials.gov/study/NCT01367288,https://clinicaltrials.gov/study/NCT00295867
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Withdrawn	https://clinicaltrials.gov/study/NCT02725541
EFO_0006861	male breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Terminated	https://clinicaltrials.gov/study/NCT00095888
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT03018080,https://clinicaltrials.gov/study/NCT00119262,https://clinicaltrials.gov/study/NCT00513695
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04733118,https://clinicaltrials.gov/study/NCT01745965,https://clinicaltrials.gov/study/NCT01565200,https://clinicaltrials.gov/study/NCT04398914,https://clinicaltrials.gov/study/NCT01494662,https://clinicaltrials.gov/study/NCT02326974,https://clinicaltrials.gov/study/NCT01853748,https://clinicaltrials.gov/study/NCT03587740
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA8	NADH:ubiquinone oxidoreductase subunit A8	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT03644186,https://clinicaltrials.gov/study/NCT01023204,https://clinicaltrials.gov/study/NCT02132949,https://clinicaltrials.gov/study/NCT00773695,https://clinicaltrials.gov/study/NCT01740336,https://clinicaltrials.gov/study/NCT00378313,https://clinicaltrials.gov/study/NCT01722968,https://clinicaltrials.gov/study/NCT02687490,https://clinicaltrials.gov/study/NCT00028873,https://clinicaltrials.gov/study/NCT00001498,https://clinicaltrials.gov/study/NCT01106898,https://clinicaltrials.gov/study/NCT00003035,https://clinicaltrials.gov/study/NCT01779479,https://clinicaltrials.gov/study/NCT00274456,https://clinicaltrials.gov/study/NCT00482391,https://clinicaltrials.gov/study/NCT01204437,https://clinicaltrials.gov/study/NCT01959490,https://clinicaltrials.gov/study/NCT00370552,https://clinicaltrials.gov/study/NCT00511459,https://clinicaltrials.gov/study/NCT00019812,https://clinicaltrials.gov/study/NCT00846027,https://clinicaltrials.gov/study/NCT03248427,https://clinicaltrials.gov/study/NCT00403130,https://clinicaltrials.gov/study/NCT01423695,https://clinicaltrials.gov/study/NCT01617668,https://clinicaltrials.gov/study/NCT01688609,https://clinicaltrials.gov/study/NCT00194779,https://clinicaltrials.gov/study/NCT00479674,https://clinicaltrials.gov/study/NCT01594177,https://clinicaltrials.gov/study/NCT01989780,https://clinicaltrials.gov/study/NCT00919880,https://clinicaltrials.gov/study/NCT00618657,https://clinicaltrials.gov/study/NCT02954055,https://clinicaltrials.gov/study/NCT00072319,https://clinicaltrials.gov/study/NCT00003050,https://clinicaltrials.gov/study/NCT03072992,https://clinicaltrials.gov/study/NCT02474186,https://clinicaltrials.gov/study/NCT00675259,https://clinicaltrials.gov/study/NCT00542451,https://clinicaltrials.gov/study/NCT03853707,https://clinicaltrials.gov/study/NCT00146562,https://clinicaltrials.gov/study/NCT02685059,https://clinicaltrials.gov/study/NCT00003392,https://clinicaltrials.gov/study/NCT02698891,https://clinicaltrials.gov/study/NCT01446016,https://clinicaltrials.gov/study/NCT01969032,https://clinicaltrials.gov/study/NCT03742986,https://clinicaltrials.gov/study/NCT00467012,https://clinicaltrials.gov/study/NCT00503750,https://clinicaltrials.gov/study/NCT00971945,https://clinicaltrials.gov/study/NCT01186991,https://clinicaltrials.gov/study/NCT00546156,https://clinicaltrials.gov/study/NCT02789657,https://clinicaltrials.gov/study/NCT00635050,https://clinicaltrials.gov/study/NCT04408118,https://clinicaltrials.gov/study/NCT03982485,https://clinicaltrials.gov/study/NCT01593020,https://clinicaltrials.gov/study/NCT01672671,https://clinicaltrials.gov/study/NCT00407888,https://clinicaltrials.gov/study/NCT00618826,https://clinicaltrials.gov/study/NCT01572727,https://clinicaltrials.gov/study/NCT04224922,https://clinicaltrials.gov/study/NCT00193206,https://clinicaltrials.gov/study/NCT00256243,https://clinicaltrials.gov/study/NCT00191854,https://clinicaltrials.gov/study/NCT00455533,https://clinicaltrials.gov/study/NCT00005649,https://clinicaltrials.gov/study/NCT00795899,https://clinicaltrials.gov/study/NCT00559845,https://clinicaltrials.gov/study/NCT00003612,https://clinicaltrials.gov/study/NCT02365805,https://clinicaltrials.gov/study/NCT00334802,https://clinicaltrials.gov/study/NCT00003539,https://clinicaltrials.gov/study/NCT00580333,https://clinicaltrials.gov/study/NCT00002937,https://clinicaltrials.gov/study/NCT00768859,https://clinicaltrials.gov/study/NCT02909751,https://clinicaltrials.gov/study/NCT00128856,https://clinicaltrials.gov/study/NCT00002679,https://clinicaltrials.gov/study/NCT00003992,https://clinicaltrials.gov/study/NCT03326102,https://clinicaltrials.gov/study/NCT00436566,https://clinicaltrials.gov/study/NCT00316199,https://clinicaltrials.gov/study/NCT01008150,https://clinicaltrials.gov/study/NCT00723125,https://clinicaltrials.gov/study/NCT00503906,https://clinicaltrials.gov/study/NCT00096668,https://clinicaltrials.gov/study/NCT00002826,https://clinicaltrials.gov/study/NCT03193853,https://clinicaltrials.gov/study/NCT00110084,https://clinicaltrials.gov/study/NCT03289819,https://clinicaltrials.gov/study/NCT00662129,https://clinicaltrials.gov/study/NCT01656538,https://clinicaltrials.gov/study/NCT02370238,https://clinicaltrials.gov/study/NCT00006110,https://clinicaltrials.gov/study/NCT00394251,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00944047,https://clinicaltrials.gov/study/NCT01705691,https://clinicaltrials.gov/study/NCT01432223,https://clinicaltrials.gov/study/NCT00001384,https://clinicaltrials.gov/study/NCT01792050,https://clinicaltrials.gov/study/NCT00096291,https://clinicaltrials.gov/study/NCT00499083,https://clinicaltrials.gov/study/NCT00394082,https://clinicaltrials.gov/study/NCT00052351,https://clinicaltrials.gov/study/NCT01982448,https://clinicaltrials.gov/study/NCT01847001,https://clinicaltrials.gov/study/NCT01190982,https://clinicaltrials.gov/study/NCT00915018,https://clinicaltrials.gov/study/NCT01973660,https://clinicaltrials.gov/study/NCT01421472,https://clinicaltrials.gov/study/NCT02280252,https://clinicaltrials.gov/study/NCT02938442,https://clinicaltrials.gov/study/NCT00532857,https://clinicaltrials.gov/study/NCT01307891,https://clinicaltrials.gov/study/NCT00930930,https://clinicaltrials.gov/study/NCT01565499,https://clinicaltrials.gov/study/NCT02301988,https://clinicaltrials.gov/study/NCT00645177,https://clinicaltrials.gov/study/NCT00251472,https://clinicaltrials.gov/study/NCT01506609,https://clinicaltrials.gov/study/NCT05112536,https://clinicaltrials.gov/study/NCT01204125,https://clinicaltrials.gov/study/NCT00004013,https://clinicaltrials.gov/study/NCT00654836,https://clinicaltrials.gov/study/NCT00733408,https://clinicaltrials.gov/study/NCT02073487,https://clinicaltrials.gov/study/NCT00392392,https://clinicaltrials.gov/study/NCT01320111,https://clinicaltrials.gov/study/NCT00254592,https://clinicaltrials.gov/study/NCT00004092,https://clinicaltrials.gov/study/NCT01276041,https://clinicaltrials.gov/study/NCT01816594,https://clinicaltrials.gov/study/NCT02628613,https://clinicaltrials.gov/study/NCT00007904,https://clinicaltrials.gov/study/NCT00096343,https://clinicaltrials.gov/study/NCT01835236,https://clinicaltrials.gov/study/NCT00136539,https://clinicaltrials.gov/study/NCT02225652,https://clinicaltrials.gov/study/NCT03121352,https://clinicaltrials.gov/study/NCT00856492,https://clinicaltrials.gov/study/NCT01827163,https://clinicaltrials.gov/study/NCT01036087,https://clinicaltrials.gov/study/NCT01256762,https://clinicaltrials.gov/study/NCT01818063,https://clinicaltrials.gov/study/NCT00915603,https://clinicaltrials.gov/study/NCT02229084,https://clinicaltrials.gov/study/NCT00629499,https://clinicaltrials.gov/study/NCT00475670,https://clinicaltrials.gov/study/NCT02263495,https://clinicaltrials.gov/study/NCT03301350,https://clinicaltrials.gov/study/NCT00005635,https://clinicaltrials.gov/study/NCT01203267,https://clinicaltrials.gov/study/NCT00148681,https://clinicaltrials.gov/study/NCT02783222,https://clinicaltrials.gov/study/NCT00320541,https://clinicaltrials.gov/study/NCT00006256,https://clinicaltrials.gov/study/NCT01855828,https://clinicaltrials.gov/study/NCT00093145,https://clinicaltrials.gov/study/NCT03887130
EFO_0005537	triple-negative breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03639948
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBA3C	tubulin alpha 3c	2	Completed	https://clinicaltrials.gov/study/NCT00284180
MONDO_0007254	breast cancer	CHEMBL94657	PATUPILONE	Small molecule	Tubulin stabiliser		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT00450866
EFO_0006318	breast ductal adenocarcinoma	CHEMBL554	LAPATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01891357
MONDO_0007254	breast cancer	CHEMBL4297840	TISLELIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04913571,https://clinicaltrials.gov/study/NCT04498793
MONDO_0007254	breast cancer	CHEMBL3545154	POZIOTINIB	Small molecule	Epidermal growth factor receptor inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT02544997,https://clinicaltrials.gov/study/NCT02418689,https://clinicaltrials.gov/study/NCT02659514
MONDO_0007254	breast cancer	CHEMBL68055	ACOLBIFENE	Small molecule	Estrogen receptor modulator		ESR2	estrogen receptor 2	2	Completed	https://clinicaltrials.gov/study/NCT00853996
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		HCK	HCK proto-oncogene, Src family tyrosine kinase	2	Withdrawn	https://clinicaltrials.gov/study/NCT01410708
MONDO_0007254	breast cancer	CHEMBL1429	DESMOPRESSIN	Protein	Vasopressin receptor agonist		AVPR1B	arginine vasopressin receptor 1B	2	Completed	https://clinicaltrials.gov/study/NCT01606072
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Recruiting	https://clinicaltrials.gov/study/NCT06042569,https://clinicaltrials.gov/study/NCT04266249,https://clinicaltrials.gov/study/NCT05319873
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00674206,https://clinicaltrials.gov/study/NCT00470249,https://clinicaltrials.gov/study/NCT00323063,https://clinicaltrials.gov/study/NCT00532285,https://clinicaltrials.gov/study/NCT00159458,https://clinicaltrials.gov/study/NCT02213744,https://clinicaltrials.gov/study/NCT00095888,https://clinicaltrials.gov/study/NCT00462865,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT03674242,https://clinicaltrials.gov/study/NCT00679029
EFO_0000304	breast adenocarcinoma	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02957968
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Withdrawn	https://clinicaltrials.gov/study/NCT00615524
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967,https://clinicaltrials.gov/study/NCT06026657
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS4	NADH:ubiquinone oxidoreductase subunit S4	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS2	NADH:ubiquinone oxidoreductase core subunit S2	2	Completed	https://clinicaltrials.gov/study/NCT01885013
MONDO_0007254	breast cancer	CHEMBL1789844	IPILIMUMAB	Antibody	Cytotoxic T-lymphocyte protein 4 inhibitor		CTLA4	cytotoxic T-lymphocyte associated protein 4	2	Recruiting	https://clinicaltrials.gov/study/NCT03815890,https://clinicaltrials.gov/study/NCT03546686
MONDO_0007254	breast cancer	CHEMBL4297892	ANVATABART OPADOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBA4A	tubulin alpha 4a	2	Recruiting	https://clinicaltrials.gov/study/NCT05426486,https://clinicaltrials.gov/study/NCT05018702,https://clinicaltrials.gov/study/NCT04829604,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT05018676
MONDO_0007254	breast cancer	CHEMBL191413	REPARIXIN	Small molecule	Interleukin-8 receptor A modulator		CXCR1	C-X-C motif chemokine receptor 1	2	Terminated	https://clinicaltrials.gov/study/NCT01861054
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB3	NADH:ubiquinone oxidoreductase subunit B3	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0006861	male breast carcinoma	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT00017394
MONDO_0007254	breast cancer	CHEMBL1201670	SARGRAMOSTIM	Protein	Granulocyte-macrophage colony-stimulating factor receptor agonist		CSF2RA	colony stimulating factor 2 receptor subunit alpha	2	Completed	https://clinicaltrials.gov/study/NCT00266110,https://clinicaltrials.gov/study/NCT00524277,https://clinicaltrials.gov/study/NCT00429104,https://clinicaltrials.gov/study/NCT00254592,https://clinicaltrials.gov/study/NCT00001239,https://clinicaltrials.gov/study/NCT00052351,https://clinicaltrials.gov/study/NCT01570036,https://clinicaltrials.gov/study/NCT00256243,https://clinicaltrials.gov/study/NCT00179309,https://clinicaltrials.gov/study/NCT02297698
MONDO_0007254	breast cancer	CHEMBL185	FLUOROURACIL	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	2	Completed	https://clinicaltrials.gov/study/NCT02365805,https://clinicaltrials.gov/study/NCT02742051,https://clinicaltrials.gov/study/NCT00124111,https://clinicaltrials.gov/study/NCT00001498,https://clinicaltrials.gov/study/NCT00015886,https://clinicaltrials.gov/study/NCT00525759,https://clinicaltrials.gov/study/NCT01204437,https://clinicaltrials.gov/study/NCT00559845,https://clinicaltrials.gov/study/NCT01036087,https://clinicaltrials.gov/study/NCT02132949,https://clinicaltrials.gov/study/NCT01593020,https://clinicaltrials.gov/study/NCT02400567,https://clinicaltrials.gov/study/NCT02225652,https://clinicaltrials.gov/study/NCT00820547,https://clinicaltrials.gov/study/NCT01855828,https://clinicaltrials.gov/study/NCT00773695,https://clinicaltrials.gov/study/NCT00036868,https://clinicaltrials.gov/study/NCT02846428
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Unknown status	https://clinicaltrials.gov/study/NCT00499603,https://clinicaltrials.gov/study/NCT03429972,https://clinicaltrials.gov/study/NCT01428414,https://clinicaltrials.gov/study/NCT01625429,https://clinicaltrials.gov/study/NCT01276769,https://clinicaltrials.gov/study/NCT00533936,https://clinicaltrials.gov/study/NCT02230319,https://clinicaltrials.gov/study/NCT00777673,https://clinicaltrials.gov/study/NCT00499525,https://clinicaltrials.gov/study/NCT02694224,https://clinicaltrials.gov/study/NCT02059876,https://clinicaltrials.gov/study/NCT01647672,https://clinicaltrials.gov/study/NCT00404404,https://clinicaltrials.gov/study/NCT00006120,https://clinicaltrials.gov/study/NCT02041338,https://clinicaltrials.gov/study/NCT03348098,https://clinicaltrials.gov/study/NCT01309607,https://clinicaltrials.gov/study/NCT00154882,https://clinicaltrials.gov/study/NCT03735082,https://clinicaltrials.gov/study/NCT01321775,https://clinicaltrials.gov/study/NCT02423603,https://clinicaltrials.gov/study/NCT01830244
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05263882,https://clinicaltrials.gov/study/NCT04517292,https://clinicaltrials.gov/study/NCT04143906
MONDO_0007254	breast cancer	CHEMBL1742982	AFLIBERCEPT	Protein	Vascular endothelial growth factor A inhibitor		VEGFA	vascular endothelial growth factor A	2	Completed	https://clinicaltrials.gov/study/NCT00369655
MONDO_0007254	breast cancer	CHEMBL2103879	GANETESPIB	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AA1	heat shock protein 90 alpha family class A member 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01560416
EFO_0006861	male breast carcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC11	histone deacetylase 11	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01349959
EFO_0006861	male breast carcinoma	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		PSEN2	presenilin 2	2	Terminated	https://clinicaltrials.gov/study/NCT01151449
MONDO_0007254	breast cancer	CHEMBL1417019	MITOXANTRONE HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Unknown status	https://clinicaltrials.gov/study/NCT00002498,https://clinicaltrials.gov/study/NCT00010075
MONDO_0007254	breast cancer	CHEMBL1620	DIPHENHYDRAMINE HYDROCHLORIDE	Small molecule	Histamine H1 receptor antagonist		HRH1	histamine receptor H1	2	Completed	https://clinicaltrials.gov/study/NCT01332630
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA4	EPH receptor A4	2	Completed	https://clinicaltrials.gov/study/NCT00494481
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Recruiting	https://clinicaltrials.gov/study/NCT04717531,https://clinicaltrials.gov/study/NCT03497702,https://clinicaltrials.gov/study/NCT03879577,https://clinicaltrials.gov/study/NCT05483439,https://clinicaltrials.gov/study/NCT05475678,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT04947189,https://clinicaltrials.gov/study/NCT05900206,https://clinicaltrials.gov/study/NCT05638594,https://clinicaltrials.gov/study/NCT05426486,https://clinicaltrials.gov/study/NCT05645380,https://clinicaltrials.gov/study/NCT05088057,https://clinicaltrials.gov/study/NCT04576143,https://clinicaltrials.gov/study/NCT05189067,https://clinicaltrials.gov/study/NCT06107673,https://clinicaltrials.gov/study/NCT03367676,https://clinicaltrials.gov/study/NCT04872985,https://clinicaltrials.gov/study/NCT05918328
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Unknown status	https://clinicaltrials.gov/study/NCT01321775,https://clinicaltrials.gov/study/NCT02694224,https://clinicaltrials.gov/study/NCT01276769,https://clinicaltrials.gov/study/NCT00154882,https://clinicaltrials.gov/study/NCT00404404,https://clinicaltrials.gov/study/NCT02041338,https://clinicaltrials.gov/study/NCT02059876,https://clinicaltrials.gov/study/NCT01625429,https://clinicaltrials.gov/study/NCT01647672,https://clinicaltrials.gov/study/NCT00777673,https://clinicaltrials.gov/study/NCT03735082,https://clinicaltrials.gov/study/NCT03348098,https://clinicaltrials.gov/study/NCT02423603,https://clinicaltrials.gov/study/NCT00006120,https://clinicaltrials.gov/study/NCT03429972,https://clinicaltrials.gov/study/NCT00533936,https://clinicaltrials.gov/study/NCT00499603,https://clinicaltrials.gov/study/NCT01309607,https://clinicaltrials.gov/study/NCT01830244,https://clinicaltrials.gov/study/NCT01428414,https://clinicaltrials.gov/study/NCT02230319,https://clinicaltrials.gov/study/NCT00499525
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB4	NADH:ubiquinone oxidoreductase subunit B4	2	Completed	https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT04143282
EFO_0000304	breast adenocarcinoma	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT04197687
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS5	NADH:ubiquinone oxidoreductase subunit S5	2	Completed	https://clinicaltrials.gov/study/NCT01885013
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Terminated	https://clinicaltrials.gov/study/NCT01498588
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT06026657,https://clinicaltrials.gov/study/NCT03606967
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND6	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6	2	Unknown status	https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT02506777,https://clinicaltrials.gov/study/NCT02506790
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF2	NADH:ubiquinone oxidoreductase complex assembly factor 2	2	Completed	https://clinicaltrials.gov/study/NCT01885013
MONDO_0007254	breast cancer	CHEMBL1567	SUNITINIB MALATE	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	2	Terminated	https://clinicaltrials.gov/study/NCT00824538
MONDO_0007254	breast cancer	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03964532,https://clinicaltrials.gov/study/NCT03901469
EFO_0006861	male breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Unknown status	https://clinicaltrials.gov/study/NCT01372579
EFO_0006861	male breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
MONDO_0007254	breast cancer	CHEMBL1743051	ONARTUZUMAB	Antibody	Hepatocyte growth factor receptor antagonist		MET	MET proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01186991
MONDO_0007254	breast cancer	CHEMBL1237022	TOCILIZUMAB	Antibody	Interleukin-6 receptor alpha subunit inhibitor		IL6R	interleukin 6 receptor	2	Completed	https://clinicaltrials.gov/study/NCT04871854
MONDO_0007254	breast cancer	CHEMBL2103842	VARLITINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT02338245
MONDO_0007254	breast cancer	CHEMBL3813842	PAXALISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R5	phosphoinositide-3-kinase regulatory subunit 5	2	Recruiting	https://clinicaltrials.gov/study/NCT03765983
EFO_0005537	triple-negative breast cancer	CHEMBL5095033	IBCASERTIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Recruiting	https://clinicaltrials.gov/study/NCT05336721
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05833919
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC4	histone deacetylase 4	2	Withdrawn	https://clinicaltrials.gov/study/NCT02115594
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT00148070,https://clinicaltrials.gov/study/NCT00027885,https://clinicaltrials.gov/study/NCT00559754,https://clinicaltrials.gov/study/NCT02005549,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT01038804,https://clinicaltrials.gov/study/NCT00464646,https://clinicaltrials.gov/study/NCT00203502,https://clinicaltrials.gov/study/NCT00976989,https://clinicaltrials.gov/study/NCT01485926,https://clinicaltrials.gov/study/NCT00044993,https://clinicaltrials.gov/study/NCT00039520,https://clinicaltrials.gov/study/NCT00006682,https://clinicaltrials.gov/study/NCT00428922,https://clinicaltrials.gov/study/NCT00004888,https://clinicaltrials.gov/study/NCT03742986,https://clinicaltrials.gov/study/NCT00248703,https://clinicaltrials.gov/study/NCT01367028,https://clinicaltrials.gov/study/NCT02748213,https://clinicaltrials.gov/study/NCT02909751,https://clinicaltrials.gov/study/NCT00201708,https://clinicaltrials.gov/study/NCT01208480,https://clinicaltrials.gov/study/NCT00365365,https://clinicaltrials.gov/study/NCT00604435,https://clinicaltrials.gov/study/NCT00475670,https://clinicaltrials.gov/study/NCT00209092,https://clinicaltrials.gov/study/NCT00206518,https://clinicaltrials.gov/study/NCT00524810,https://clinicaltrials.gov/study/NCT00212095,https://clinicaltrials.gov/study/NCT03735966,https://clinicaltrials.gov/study/NCT00820547,https://clinicaltrials.gov/study/NCT00193050,https://clinicaltrials.gov/study/NCT01671319,https://clinicaltrials.gov/study/NCT00003352,https://clinicaltrials.gov/study/NCT01527487,https://clinicaltrials.gov/study/NCT00820872,https://clinicaltrials.gov/study/NCT00525759,https://clinicaltrials.gov/study/NCT00214864,https://clinicaltrials.gov/study/NCT00379015,https://clinicaltrials.gov/study/NCT00179309,https://clinicaltrials.gov/study/NCT00155259,https://clinicaltrials.gov/study/NCT02137083,https://clinicaltrials.gov/study/NCT00841828,https://clinicaltrials.gov/study/NCT00004175,https://clinicaltrials.gov/study/NCT00005800,https://clinicaltrials.gov/study/NCT00041067,https://clinicaltrials.gov/study/NCT00258375,https://clinicaltrials.gov/study/NCT00773695,https://clinicaltrials.gov/study/NCT00146042,https://clinicaltrials.gov/study/NCT02846428,https://clinicaltrials.gov/study/NCT00003565,https://clinicaltrials.gov/study/NCT00494481,https://clinicaltrials.gov/study/NCT01142778,https://clinicaltrials.gov/study/NCT00679341,https://clinicaltrials.gov/study/NCT00198237,https://clinicaltrials.gov/study/NCT00645866,https://clinicaltrials.gov/study/NCT00004906,https://clinicaltrials.gov/study/NCT00003953,https://clinicaltrials.gov/study/NCT00148668,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT01540110,https://clinicaltrials.gov/study/NCT00365417,https://clinicaltrials.gov/study/NCT00527449,https://clinicaltrials.gov/study/NCT00015938,https://clinicaltrials.gov/study/NCT00088998,https://clinicaltrials.gov/study/NCT00193180,https://clinicaltrials.gov/study/NCT00545688,https://clinicaltrials.gov/study/NCT00600249,https://clinicaltrials.gov/study/NCT00404066,https://clinicaltrials.gov/study/NCT00054275,https://clinicaltrials.gov/study/NCT02229084,https://clinicaltrials.gov/study/NCT00232479,https://clinicaltrials.gov/study/NCT03140553,https://clinicaltrials.gov/study/NCT00079118,https://clinicaltrials.gov/study/NCT00193089,https://clinicaltrials.gov/study/NCT00015886,https://clinicaltrials.gov/study/NCT00695994,https://clinicaltrials.gov/study/NCT01658462,https://clinicaltrials.gov/study/NCT00107510,https://clinicaltrials.gov/study/NCT03887130,https://clinicaltrials.gov/study/NCT00247481,https://clinicaltrials.gov/study/NCT00077857,https://clinicaltrials.gov/study/NCT00123929,https://clinicaltrials.gov/study/NCT04664972,https://clinicaltrials.gov/study/NCT00203372,https://clinicaltrials.gov/study/NCT01792050,https://clinicaltrials.gov/study/NCT00712881,https://clinicaltrials.gov/study/NCT01446016,https://clinicaltrials.gov/study/NCT00319618,https://clinicaltrials.gov/study/NCT00499122,https://clinicaltrials.gov/study/NCT00191243,https://clinicaltrials.gov/study/NCT01150513,https://clinicaltrials.gov/study/NCT00068341,https://clinicaltrials.gov/study/NCT02365805,https://clinicaltrials.gov/study/NCT00028873,https://clinicaltrials.gov/study/NCT00193115,https://clinicaltrials.gov/study/NCT02132949,https://clinicaltrials.gov/study/NCT02834403,https://clinicaltrials.gov/study/NCT00217672,https://clinicaltrials.gov/study/NCT02041351,https://clinicaltrials.gov/study/NCT00364611,https://clinicaltrials.gov/study/NCT00490646,https://clinicaltrials.gov/study/NCT00274456,https://clinicaltrials.gov/study/NCT00055861,https://clinicaltrials.gov/study/NCT00432172,https://clinicaltrials.gov/study/NCT00769470,https://clinicaltrials.gov/study/NCT00005908,https://clinicaltrials.gov/study/NCT00212082,https://clinicaltrials.gov/study/NCT00066443,https://clinicaltrials.gov/study/NCT00005963,https://clinicaltrials.gov/study/NCT00193037,https://clinicaltrials.gov/study/NCT00206466,https://clinicaltrials.gov/study/NCT02838225,https://clinicaltrials.gov/study/NCT00493649,https://clinicaltrials.gov/study/NCT00206505,https://clinicaltrials.gov/study/NCT01396655,https://clinicaltrials.gov/study/NCT01959490,https://clinicaltrials.gov/study/NCT00149214,https://clinicaltrials.gov/study/NCT00754351,https://clinicaltrials.gov/study/NCT00006104,https://clinicaltrials.gov/study/NCT00941330,https://clinicaltrials.gov/study/NCT01025349,https://clinicaltrials.gov/study/NCT00129376
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Unknown status	https://clinicaltrials.gov/study/NCT00398489,https://clinicaltrials.gov/study/NCT02947061,https://clinicaltrials.gov/study/NCT01526499,https://clinicaltrials.gov/study/NCT01907529,https://clinicaltrials.gov/study/NCT01270373,https://clinicaltrials.gov/study/NCT00026078,https://clinicaltrials.gov/study/NCT00003066,https://clinicaltrials.gov/study/NCT00721747,https://clinicaltrials.gov/study/NCT00006120,https://clinicaltrials.gov/study/NCT02685657,https://clinicaltrials.gov/study/NCT00250874,https://clinicaltrials.gov/study/NCT03147963,https://clinicaltrials.gov/study/NCT00801411,https://clinicaltrials.gov/study/NCT00012311,https://clinicaltrials.gov/study/NCT01351597,https://clinicaltrials.gov/study/NCT00669773,https://clinicaltrials.gov/study/NCT03876587,https://clinicaltrials.gov/study/NCT00033683,https://clinicaltrials.gov/study/NCT02144194,https://clinicaltrials.gov/study/NCT00994968,https://clinicaltrials.gov/study/NCT01352494,https://clinicaltrials.gov/study/NCT01939054,https://clinicaltrials.gov/study/NCT00957125
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Suspended	https://clinicaltrials.gov/study/NCT04419181,https://clinicaltrials.gov/study/NCT02897050
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND2	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2	2	Recruiting	https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04559308,https://clinicaltrials.gov/study/NCT03238495
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03587740,https://clinicaltrials.gov/study/NCT04398914,https://clinicaltrials.gov/study/NCT01494662,https://clinicaltrials.gov/study/NCT01853748,https://clinicaltrials.gov/study/NCT04733118,https://clinicaltrials.gov/study/NCT01565200,https://clinicaltrials.gov/study/NCT01745965,https://clinicaltrials.gov/study/NCT02326974
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03567720,https://clinicaltrials.gov/study/NCT04262804,https://clinicaltrials.gov/study/NCT04297267,https://clinicaltrials.gov/study/NCT01815242,https://clinicaltrials.gov/study/NCT02252887
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBB1	tubulin beta 1 class VI	2	Withdrawn	https://clinicaltrials.gov/study/NCT01227408
MONDO_0007254	breast cancer	CHEMBL4297844	TRASTUZUMAB DERUXTECAN	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 binding agent		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT04752059
MONDO_0007254	breast cancer	CHEMBL52885	ENMD-981693	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR3	fibroblast growth factor receptor 3	2	Completed	https://clinicaltrials.gov/study/NCT00306631
MONDO_0007254	breast cancer	CHEMBL256147	TILARGININE	Small molecule	Nitric oxide synthase inhibitor		NOS1	nitric oxide synthase 1	2	Completed	https://clinicaltrials.gov/study/NCT02834403
EFO_0000305	breast carcinoma	CHEMBL2146883	COBIMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 1 inhibitor		MAP2K1	mitogen-activated protein kinase kinase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03202316
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Terminated	https://clinicaltrials.gov/study/NCT00832338
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		SRC	SRC proto-oncogene, non-receptor tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT00817531,https://clinicaltrials.gov/study/NCT05198843,https://clinicaltrials.gov/study/NCT00780676
EFO_0000305	breast carcinoma	CHEMBL3218576	COPANLISIB	Small molecule	PI3-kinase p110-delta subunit inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03939897
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT00119262,https://clinicaltrials.gov/study/NCT03018080,https://clinicaltrials.gov/study/NCT00513695
EFO_0000305	breast carcinoma	CHEMBL1184904	RETASPIMYCIN	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AA1	heat shock protein 90 alpha family class A member 1	2	Terminated	https://clinicaltrials.gov/study/NCT00817362
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA8	NADH:ubiquinone oxidoreductase subunit A8	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0005537	triple-negative breast cancer	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Completed	https://clinicaltrials.gov/study/NCT02648477
MONDO_0007254	breast cancer	CHEMBL1237	LISINOPRIL ANHYDROUS	Small molecule	Angiotensin-converting enzyme inhibitor		ACE	angiotensin I converting enzyme	2	Completed	https://clinicaltrials.gov/study/NCT01009918
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT02199418,https://clinicaltrials.gov/study/NCT00513695,https://clinicaltrials.gov/study/NCT02682693
MONDO_0007254	breast cancer	CHEMBL1201568	PEGFILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	2	Completed	https://clinicaltrials.gov/study/NCT01648322,https://clinicaltrials.gov/study/NCT02698891,https://clinicaltrials.gov/study/NCT00253500,https://clinicaltrials.gov/study/NCT04554056,https://clinicaltrials.gov/study/NCT00256360,https://clinicaltrials.gov/study/NCT00146562,https://clinicaltrials.gov/study/NCT00856492,https://clinicaltrials.gov/study/NCT00107510,https://clinicaltrials.gov/study/NCT00394251,https://clinicaltrials.gov/study/NCT00124111,https://clinicaltrials.gov/study/NCT00261313,https://clinicaltrials.gov/study/NCT01671319,https://clinicaltrials.gov/study/NCT02650193,https://clinicaltrials.gov/study/NCT03301350,https://clinicaltrials.gov/study/NCT00066443,https://clinicaltrials.gov/study/NCT00404066,https://clinicaltrials.gov/study/NCT01416389,https://clinicaltrials.gov/study/NCT01712009,https://clinicaltrials.gov/study/NCT03575520,https://clinicaltrials.gov/study/NCT01827163,https://clinicaltrials.gov/study/NCT01847001,https://clinicaltrials.gov/study/NCT02834403
MONDO_0007254	breast cancer	CHEMBL4297844	TRASTUZUMAB DERUXTECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	2	Completed	https://clinicaltrials.gov/study/NCT04752059
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Terminated	https://clinicaltrials.gov/study/NCT01161368,https://clinicaltrials.gov/study/NCT00130507,https://clinicaltrials.gov/study/NCT00088985,https://clinicaltrials.gov/study/NCT00453635,https://clinicaltrials.gov/study/NCT00694200,https://clinicaltrials.gov/study/NCT01185509,https://clinicaltrials.gov/study/NCT00049660,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT02213744,https://clinicaltrials.gov/study/NCT00194792,https://clinicaltrials.gov/study/NCT00754702,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT00169104,https://clinicaltrials.gov/study/NCT02585388,https://clinicaltrials.gov/study/NCT00176488,https://clinicaltrials.gov/study/NCT03358004
MONDO_0007254	breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Vascular endothelial growth factor receptor 1 inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04733417
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA11	NADH:ubiquinone oxidoreductase subunit A11	2	Recruiting	https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04559308
MONDO_0007254	breast cancer	CHEMBL1536	ERGOCALCIFEROL	Small molecule	Vitamin D receptor agonist		VDR	vitamin D receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01472445,https://clinicaltrials.gov/study/NCT00172068,https://clinicaltrials.gov/study/NCT01988090
MONDO_0007254	breast cancer	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		APH1A	aph-1 homolog A, gamma-secretase subunit	2	Terminated	https://clinicaltrials.gov/study/NCT01151449
MONDO_0007254	breast cancer	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Unknown status	https://clinicaltrials.gov/study/NCT00499525
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE3A	phosphodiesterase 3A	2	Recruiting	https://clinicaltrials.gov/study/NCT06087237
EFO_1000984	inflammatory breast carcinoma	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Completed	https://clinicaltrials.gov/study/NCT00049114,https://clinicaltrials.gov/study/NCT00513695
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHB4	EPH receptor B4	2	Completed	https://clinicaltrials.gov/study/NCT00494481
MONDO_0007254	breast cancer	CHEMBL1082407	ENZALUTAMIDE	Small molecule	Androgen Receptor antagonist		AR	androgen receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT06099769
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Terminated	https://clinicaltrials.gov/study/NCT00765765,https://clinicaltrials.gov/study/NCT00790894,https://clinicaltrials.gov/study/NCT00079326
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04001829,https://clinicaltrials.gov/study/NCT02568839
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT00265733,https://clinicaltrials.gov/study/NCT00148707
MONDO_0007254	breast cancer	CHEMBL3544954	ZOPTARELIN DOXORUBICIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01698281
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Terminated	https://clinicaltrials.gov/study/NCT01498588
EFO_0000304	breast adenocarcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Recruiting	https://clinicaltrials.gov/study/NCT04197687
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Recruiting	https://clinicaltrials.gov/study/NCT04266249,https://clinicaltrials.gov/study/NCT05319873,https://clinicaltrials.gov/study/NCT06042569
MONDO_0007254	breast cancer	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Terminated	https://clinicaltrials.gov/study/NCT01394211,https://clinicaltrials.gov/study/NCT00481845,https://clinicaltrials.gov/study/NCT00555477,https://clinicaltrials.gov/study/NCT00206414,https://clinicaltrials.gov/study/NCT00684216,https://clinicaltrials.gov/study/NCT01151215,https://clinicaltrials.gov/study/NCT00661531,https://clinicaltrials.gov/study/NCT02000596,https://clinicaltrials.gov/study/NCT02269670,https://clinicaltrials.gov/study/NCT01368263,https://clinicaltrials.gov/study/NCT00303615,https://clinicaltrials.gov/study/NCT02585388,https://clinicaltrials.gov/study/NCT00573755,https://clinicaltrials.gov/study/NCT03874325
MONDO_0007254	breast cancer	CHEMBL4594611	PATRITUMAB DERUXTECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	2	Completed	https://clinicaltrials.gov/study/NCT02980341
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04262804,https://clinicaltrials.gov/study/NCT00431704,https://clinicaltrials.gov/study/NCT03414658
EFO_0005537	triple-negative breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04683679,https://clinicaltrials.gov/study/NCT03801369
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Unknown status	https://clinicaltrials.gov/study/NCT01372579
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04345913
EFO_0000305	breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Fibroblast growth factor receptor 1 inhibitor		FGFR1	fibroblast growth factor receptor 1	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
EFO_0005537	triple-negative breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03639948
EFO_0000432	breast ductal carcinoma in situ	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Terminated	https://clinicaltrials.gov/study/NCT00461344
MONDO_0007254	breast cancer	CHEMBL1201748	CABAZITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Terminated	https://clinicaltrials.gov/study/NCT01934894
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS4	NADH:ubiquinone oxidoreductase subunit S4	2	Unknown status	https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT02506777
MONDO_0007254	breast cancer	CHEMBL1655	TOREMIFENE	Small molecule	Estrogen receptor modulator		ESR1	estrogen receptor 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05472792
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT00027989
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04502680
MONDO_0007254	breast cancer	CHEMBL225072	PEMETREXED	Small molecule	GAR transformylase inhibitor		GART	phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase	2	Completed	https://clinicaltrials.gov/study/NCT00006007,https://clinicaltrials.gov/study/NCT00102219,https://clinicaltrials.gov/study/NCT00149214,https://clinicaltrials.gov/study/NCT00065533,https://clinicaltrials.gov/study/NCT00063570,https://clinicaltrials.gov/study/NCT00325234,https://clinicaltrials.gov/study/NCT00191347
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS1	NADH:ubiquinone oxidoreductase core subunit S1	2	Completed	https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT02028221
MONDO_0007254	breast cancer	CHEMBL359744	DOXORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT00295893,https://clinicaltrials.gov/study/NCT00003042
MONDO_0007254	breast cancer	CHEMBL4303201	CATEQUENTINIB	Small molecule	Vascular endothelial growth factor receptor 3 inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Recruiting	https://clinicaltrials.gov/study/NCT04936295,https://clinicaltrials.gov/study/NCT05558722,https://clinicaltrials.gov/study/NCT05296577,https://clinicaltrials.gov/study/NCT04452370,https://clinicaltrials.gov/study/NCT04877821,https://clinicaltrials.gov/study/NCT04624711
EFO_0005537	triple-negative breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Suspended	https://clinicaltrials.gov/study/NCT04095689
MONDO_0007254	breast cancer	CHEMBL1200978	ARSENIC TRIOXIDE	Small molecule	Thioredoxin reductase 1 inhibitor		TXNRD1	thioredoxin reductase 1	2	Withdrawn	https://clinicaltrials.gov/study/NCT00075413
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Recruiting	https://clinicaltrials.gov/study/NCT06042569,https://clinicaltrials.gov/study/NCT04266249,https://clinicaltrials.gov/study/NCT05319873
MONDO_0007254	breast cancer	CHEMBL468	THALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		CUL4A	cullin 4A	2	Terminated	https://clinicaltrials.gov/study/NCT00193102
EFO_0006861	male breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
EFO_0006861	male breast carcinoma	CHEMBL939	GEFITINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Completed	https://clinicaltrials.gov/study/NCT00024154
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA9	NADH:ubiquinone oxidoreductase subunit A9	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS5	NADH:ubiquinone oxidoreductase subunit S5	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0005537	triple-negative breast cancer	CHEMBL3545132	MIRVETUXIMAB SORAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT03106077
EFO_0005537	triple-negative breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03911973
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT01881230
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4	NDUFA4 mitochondrial complex associated	2	Terminated	https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT01627067
MONDO_0007254	breast cancer	CHEMBL4297715	CAMRELIZUMAB	Antibody	Programmed cell death protein 1 antagonist		PDCD1	programmed cell death 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04303741
MONDO_0007254	breast cancer	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01149083
EFO_0005537	triple-negative breast cancer	CHEMBL3545262	SACITUZUMAB GOVITECAN	Antibody drug conjugate	Tumor-associated calcium signal transducer 2 binding agent		TACSTD2	tumor associated calcium signal transducer 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04454437,https://clinicaltrials.gov/study/NCT04958785
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Withdrawn	https://clinicaltrials.gov/study/NCT01818999,https://clinicaltrials.gov/study/NCT02067416
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT00005614
MONDO_0007254	breast cancer	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT06193525,https://clinicaltrials.gov/study/NCT04892693,https://clinicaltrials.gov/study/NCT03990896,https://clinicaltrials.gov/study/NCT05288127,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04756765,https://clinicaltrials.gov/study/NCT04039230,https://clinicaltrials.gov/study/NCT04849364
EFO_1000984	inflammatory breast carcinoma	CHEMBL1789941	RUXOLITINIB	Small molecule	Tyrosine-protein kinase JAK2 inhibitor		JAK2	Janus kinase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02876302
MONDO_0007254	breast cancer	CHEMBL4297939	DATOPOTAMAB DERUXTECAN	Antibody drug conjugate	Tumor-associated calcium signal transducer 2 binding agent		TACSTD2	tumor associated calcium signal transducer 2	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT05866432
MONDO_0007254	breast cancer	CHEMBL52885	ENMD-981693	Small molecule	SRC inhibitor		FYN	FYN proto-oncogene, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00306631
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05833919
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA2	EPH receptor A2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999
MONDO_0007254	breast cancer	CHEMBL185	FLUOROURACIL	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	2	Unknown status	https://clinicaltrials.gov/study/NCT00002498,https://clinicaltrials.gov/study/NCT00010075,https://clinicaltrials.gov/study/NCT00499603,https://clinicaltrials.gov/study/NCT01270373,https://clinicaltrials.gov/study/NCT01231802,https://clinicaltrials.gov/study/NCT00012311,https://clinicaltrials.gov/study/NCT00033683,https://clinicaltrials.gov/study/NCT02115152,https://clinicaltrials.gov/study/NCT00533936
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC2	histone deacetylase 2	2	Completed	https://clinicaltrials.gov/study/NCT00828854,https://clinicaltrials.gov/study/NCT03291886,https://clinicaltrials.gov/study/NCT02708680,https://clinicaltrials.gov/study/NCT00676663
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT05900206,https://clinicaltrials.gov/study/NCT05918328,https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT05659056,https://clinicaltrials.gov/study/NCT04893109,https://clinicaltrials.gov/study/NCT05447702,https://clinicaltrials.gov/study/NCT05629429,https://clinicaltrials.gov/study/NCT05325632,https://clinicaltrials.gov/study/NCT03150576,https://clinicaltrials.gov/study/NCT04780347,https://clinicaltrials.gov/study/NCT05020860,https://clinicaltrials.gov/study/NCT04243616,https://clinicaltrials.gov/study/NCT04355858,https://clinicaltrials.gov/study/NCT04329065,https://clinicaltrials.gov/study/NCT03907800,https://clinicaltrials.gov/study/NCT05633914,https://clinicaltrials.gov/study/NCT03571633,https://clinicaltrials.gov/study/NCT04771871,https://clinicaltrials.gov/study/NCT05189067,https://clinicaltrials.gov/study/NCT05761470,https://clinicaltrials.gov/study/NCT04090398,https://clinicaltrials.gov/study/NCT06245889,https://clinicaltrials.gov/study/NCT04917900,https://clinicaltrials.gov/study/NCT03412643,https://clinicaltrials.gov/study/NCT04877821,https://clinicaltrials.gov/study/NCT05383196,https://clinicaltrials.gov/study/NCT05174832,https://clinicaltrials.gov/study/NCT03048942,https://clinicaltrials.gov/study/NCT05728268,https://clinicaltrials.gov/study/NCT05681728,https://clinicaltrials.gov/study/NCT05749575,https://clinicaltrials.gov/study/NCT05889390,https://clinicaltrials.gov/study/NCT01817452,https://clinicaltrials.gov/study/NCT04722718,https://clinicaltrials.gov/study/NCT04443348,https://clinicaltrials.gov/study/NCT04872985,https://clinicaltrials.gov/study/NCT04676997,https://clinicaltrials.gov/study/NCT05346107,https://clinicaltrials.gov/study/NCT05582538,https://clinicaltrials.gov/study/NCT05068141,https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT05353361,https://clinicaltrials.gov/study/NCT04425018,https://clinicaltrials.gov/study/NCT04159142,https://clinicaltrials.gov/study/NCT04576143,https://clinicaltrials.gov/study/NCT05749016,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT05852691,https://clinicaltrials.gov/study/NCT04537286
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND2	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04345913
EFO_0005537	triple-negative breast cancer	CHEMBL1908360	EVEROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04395989
EFO_0005537	triple-negative breast cancer	CHEMBL3545262	SACITUZUMAB GOVITECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04454437,https://clinicaltrials.gov/study/NCT04958785
MONDO_0007254	breast cancer	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBA1A	tubulin alpha 1a	2	Withdrawn	https://clinicaltrials.gov/study/NCT01227408
MONDO_0007254	breast cancer	CHEMBL554	LAPATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Withdrawn	https://clinicaltrials.gov/study/NCT01005641,https://clinicaltrials.gov/study/NCT00455039,https://clinicaltrials.gov/study/NCT01985893,https://clinicaltrials.gov/study/NCT00343759
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB6	NADH:ubiquinone oxidoreductase subunit B6	2	Recruiting	https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04559308
MONDO_0007254	breast cancer	CHEMBL1201649	ESTROGENS, CONJUGATED	Unknown	Estrogen receptor agonist		ESR2	estrogen receptor 2	2	Recruiting	https://clinicaltrials.gov/study/NCT04821141
MONDO_0007254	breast cancer	CHEMBL1751	DIGOXIN	Small molecule	Sodium/potassium-transporting ATPase inhibitor		ATP1A4	ATPase Na+/K+ transporting subunit alpha 4	2	Terminated	https://clinicaltrials.gov/study/NCT01887288
MONDO_0007254	breast cancer	CHEMBL603	ZAFIRLUKAST	Small molecule	Cysteinyl leukotriene receptor 1 antagonist		CYSLTR1	cysteinyl leukotriene receptor 1	2	Terminated	https://clinicaltrials.gov/study/NCT02950480
MONDO_0007254	breast cancer	CHEMBL191413	REPARIXIN	Small molecule	Interleukin-8 receptor A modulator		CXCR1	C-X-C motif chemokine receptor 1	2	Completed	https://clinicaltrials.gov/study/NCT02370238
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Withdrawn	https://clinicaltrials.gov/study/NCT03841747,https://clinicaltrials.gov/study/NCT01169870,https://clinicaltrials.gov/study/NCT03058939,https://clinicaltrials.gov/study/NCT02067416,https://clinicaltrials.gov/study/NCT03872505,https://clinicaltrials.gov/study/NCT02053597,https://clinicaltrials.gov/study/NCT05809895,https://clinicaltrials.gov/study/NCT00397761,https://clinicaltrials.gov/study/NCT04038489,https://clinicaltrials.gov/study/NCT01163929,https://clinicaltrials.gov/study/NCT03554109
EFO_0000305	breast carcinoma	CHEMBL409	BICALUTAMIDE	Small molecule	Androgen Receptor antagonist		AR	androgen receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03650894
MONDO_0007254	breast cancer	CHEMBL4297571	PENPULIMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05726175
EFO_0005537	triple-negative breast cancer	CHEMBL4297831	SPARTALIZUMAB	Antibody	Programmed cell death protein 1 antagonist		PDCD1	programmed cell death 1	2	Completed	https://clinicaltrials.gov/study/NCT03499899
MONDO_0007254	breast cancer	CHEMBL723	CARVEDILOL	Small molecule	Adrenergic receptor alpha-1 antagonist		ADRA1D	adrenoceptor alpha 1D	2	Completed	https://clinicaltrials.gov/study/NCT01009918,https://clinicaltrials.gov/study/NCT02177175
MONDO_0007254	breast cancer	CHEMBL2177390	IPATASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT3	AKT serine/threonine kinase 3	2	Recruiting	https://clinicaltrials.gov/study/NCT04920708,https://clinicaltrials.gov/study/NCT04802759,https://clinicaltrials.gov/study/NCT05332561,https://clinicaltrials.gov/study/NCT03424005
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA8	NADH:ubiquinone oxidoreductase subunit A8	2	Completed	https://clinicaltrials.gov/study/NCT01885013
EFO_0000305	breast carcinoma	CHEMBL483158	ALISERTIB	Small molecule	Serine/threonine-protein kinase Aurora-A inhibitor		AURKA	aurora kinase A	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02187991,https://clinicaltrials.gov/study/NCT02860000
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Unknown status	https://clinicaltrials.gov/study/NCT01372579
MONDO_0007254	breast cancer	CHEMBL1789844	IPILIMUMAB	Antibody	Cytotoxic T-lymphocyte protein 4 inhibitor		CTLA4	cytotoxic T-lymphocyte associated protein 4	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06342037
MONDO_0021115	luminal B breast carcinoma	CHEMBL3990016	OLECLUMAB	Antibody	5'-nucleotidase inhibitor		NT5E	5'-nucleotidase ecto	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03875573
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Recruiting	https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT05638594,https://clinicaltrials.gov/study/NCT05918328,https://clinicaltrials.gov/study/NCT05645380,https://clinicaltrials.gov/study/NCT05900206,https://clinicaltrials.gov/study/NCT04872985,https://clinicaltrials.gov/study/NCT05088057,https://clinicaltrials.gov/study/NCT04576143,https://clinicaltrials.gov/study/NCT04947189,https://clinicaltrials.gov/study/NCT06107673,https://clinicaltrials.gov/study/NCT04717531,https://clinicaltrials.gov/study/NCT05189067,https://clinicaltrials.gov/study/NCT05426486,https://clinicaltrials.gov/study/NCT05475678,https://clinicaltrials.gov/study/NCT03879577,https://clinicaltrials.gov/study/NCT05483439,https://clinicaltrials.gov/study/NCT03497702,https://clinicaltrials.gov/study/NCT03367676
EFO_0006861	male breast carcinoma	CHEMBL1567	SUNITINIB MALATE	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00513695
EFO_0005537	triple-negative breast cancer	CHEMBL4297892	ANVATABART OPADOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0000304	breast adenocarcinoma	CHEMBL1200665	DIPHENOXYLATE HYDROCHLORIDE	Small molecule	Mu opioid receptor agonist		OPRM1	opioid receptor mu 1	2	Completed	https://clinicaltrials.gov/study/NCT03094052
EFO_0005537	triple-negative breast cancer	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Completed	https://clinicaltrials.gov/study/NCT01818063,https://clinicaltrials.gov/study/NCT01306032
EFO_0005537	triple-negative breast cancer	CHEMBL4298101	LADIRATUZUMAB VEDOTIN	Antibody drug conjugate	Zinc transporter ZIP6 binding agent		SLC39A6	solute carrier family 39 member 6	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0006861	male breast carcinoma	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		APH1A	aph-1 homolog A, gamma-secretase subunit	2	Terminated	https://clinicaltrials.gov/study/NCT01151449
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS3	NADH:ubiquinone oxidoreductase core subunit S3	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT01881230
EFO_1000984	inflammatory breast carcinoma	CHEMBL1567	SUNITINIB MALATE	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00513695
MONDO_0007254	breast cancer	CHEMBL1535	HYDROXYCHLOROQUINE	Small molecule	Toll-like receptor 9 antagonist		TLR9	toll like receptor 9	2	Completed	https://clinicaltrials.gov/study/NCT03774472
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04502680
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Unknown status	https://clinicaltrials.gov/study/NCT01351597,https://clinicaltrials.gov/study/NCT02144194,https://clinicaltrials.gov/study/NCT02685657,https://clinicaltrials.gov/study/NCT00398489,https://clinicaltrials.gov/study/NCT00003066,https://clinicaltrials.gov/study/NCT01939054,https://clinicaltrials.gov/study/NCT00033683,https://clinicaltrials.gov/study/NCT01526499,https://clinicaltrials.gov/study/NCT01907529,https://clinicaltrials.gov/study/NCT00250874,https://clinicaltrials.gov/study/NCT03876587,https://clinicaltrials.gov/study/NCT00994968,https://clinicaltrials.gov/study/NCT00026078,https://clinicaltrials.gov/study/NCT00006120,https://clinicaltrials.gov/study/NCT00012311,https://clinicaltrials.gov/study/NCT01352494,https://clinicaltrials.gov/study/NCT02947061,https://clinicaltrials.gov/study/NCT01270373,https://clinicaltrials.gov/study/NCT00801411,https://clinicaltrials.gov/study/NCT00669773,https://clinicaltrials.gov/study/NCT00957125,https://clinicaltrials.gov/study/NCT03147963,https://clinicaltrials.gov/study/NCT00721747
MONDO_0007254	breast cancer	CHEMBL1201748	CABAZITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT01693549
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Recruiting	https://clinicaltrials.gov/study/NCT04796324
MONDO_0007254	breast cancer	CHEMBL941	IMATINIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT00323063
EFO_0000304	breast adenocarcinoma	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01730833
EFO_0000305	breast carcinoma	CHEMBL1743001	CIXUTUMUMAB	Antibody	Insulin-like growth factor I receptor antagonist		IGF1R	insulin like growth factor 1 receptor	2	Completed	https://clinicaltrials.gov/study/NCT00684983
MONDO_0007254	breast cancer	CHEMBL1173655	AFATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT01594177
MONDO_0007254	breast cancer	CHEMBL191	LOSARTAN	Small molecule	Type-1 angiotensin II receptor antagonist		AGTR1	angiotensin II receptor type 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05097248
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Terminated	https://clinicaltrials.gov/study/NCT00453635,https://clinicaltrials.gov/study/NCT03329378,https://clinicaltrials.gov/study/NCT00206453,https://clinicaltrials.gov/study/NCT00479856,https://clinicaltrials.gov/study/NCT00852332,https://clinicaltrials.gov/study/NCT00636441,https://clinicaltrials.gov/study/NCT00104624,https://clinicaltrials.gov/study/NCT00025493,https://clinicaltrials.gov/study/NCT00343512,https://clinicaltrials.gov/study/NCT00225056,https://clinicaltrials.gov/study/NCT03894007,https://clinicaltrials.gov/study/NCT00118053,https://clinicaltrials.gov/study/NCT01985841,https://clinicaltrials.gov/study/NCT00193024,https://clinicaltrials.gov/study/NCT00665457,https://clinicaltrials.gov/study/NCT01690325,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT00845910,https://clinicaltrials.gov/study/NCT00028483,https://clinicaltrials.gov/study/NCT00080626,https://clinicaltrials.gov/study/NCT00524459,https://clinicaltrials.gov/study/NCT00576901
MONDO_0007254	breast cancer	CHEMBL742	KETAMINE	Small molecule	Glutamate [NMDA] receptor negative allosteric modulator		GRIN2A	glutamate ionotropic receptor NMDA type subunit 2A	2	Completed	https://clinicaltrials.gov/study/NCT00304850,https://clinicaltrials.gov/study/NCT05727098
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA12	NADH:ubiquinone oxidoreductase subunit A12	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
EFO_0006861	male breast carcinoma	CHEMBL535	SUNITINIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	2	Completed	https://clinicaltrials.gov/study/NCT00513695
EFO_0005537	triple-negative breast cancer	CHEMBL3187723	BINIMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 1 inhibitor		MAP2K1	mitogen-activated protein kinase kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT03106415
EFO_0000305	breast carcinoma	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	2	Recruiting	https://clinicaltrials.gov/study/NCT02778685
EFO_0000305	breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
EFO_0006861	male breast carcinoma	CHEMBL4297763	GTI-2040	Unknown	Ribonucleotide reductase small subunit mRNA antisense inhibitor		RRM2	ribonucleotide reductase regulatory subunit M2	2	Completed	https://clinicaltrials.gov/study/NCT00068588
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB4	NADH:ubiquinone oxidoreductase subunit B4	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_1000984	inflammatory breast carcinoma	CHEMBL535	SUNITINIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	2	Completed	https://clinicaltrials.gov/study/NCT00513695
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03609047,https://clinicaltrials.gov/study/NCT04172259,https://clinicaltrials.gov/study/NCT02624973,https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT02339532,https://clinicaltrials.gov/study/NCT03161353,https://clinicaltrials.gov/study/NCT02547987,https://clinicaltrials.gov/study/NCT00496795,https://clinicaltrials.gov/study/NCT00295893,https://clinicaltrials.gov/study/NCT01779206,https://clinicaltrials.gov/study/NCT02568839
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT00006261
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Withdrawn	https://clinicaltrials.gov/study/NCT00615524
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA10	NADH:ubiquinone oxidoreductase subunit A10	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL468	THALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		CRBN	cereblon	2	Unknown status	https://clinicaltrials.gov/study/NCT02649101
EFO_0000305	breast carcinoma	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	2	Withdrawn	https://clinicaltrials.gov/study/NCT04351230
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FRK	fyn related Src family tyrosine kinase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01471106
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT00027989
MONDO_0007254	breast cancer	CHEMBL3545396	BMS-690514	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT01068704
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	2	Recruiting	https://clinicaltrials.gov/study/NCT03698383
MONDO_0007254	breast cancer	CHEMBL1642	IMATINIB MESYLATE	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00338728,https://clinicaltrials.gov/study/NCT00087152
MONDO_0007254	breast cancer	CHEMBL3545071	SERIBANTUMAB	Antibody	Receptor tyrosine-protein kinase erbB-3 inhibitor		ERBB3	erb-b2 receptor tyrosine kinase 3	2	Terminated	https://clinicaltrials.gov/study/NCT03241810
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Recruiting	https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT04304352,https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT04296162,https://clinicaltrials.gov/study/NCT04605575,https://clinicaltrials.gov/study/NCT04302441,https://clinicaltrials.gov/study/NCT05296577,https://clinicaltrials.gov/study/NCT04759248,https://clinicaltrials.gov/study/NCT06102824,https://clinicaltrials.gov/study/NCT04389073,https://clinicaltrials.gov/study/NCT03939871,https://clinicaltrials.gov/study/NCT05747326,https://clinicaltrials.gov/study/NCT05823623
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT00191373
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Recruiting	https://clinicaltrials.gov/study/NCT05583110
EFO_0005537	triple-negative breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967
EFO_0006861	male breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Unknown status	https://clinicaltrials.gov/study/NCT01372579
EFO_0005537	triple-negative breast cancer	CHEMBL4298101	LADIRATUZUMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Terminated	https://clinicaltrials.gov/study/NCT00665457,https://clinicaltrials.gov/study/NCT01690325,https://clinicaltrials.gov/study/NCT00852332,https://clinicaltrials.gov/study/NCT00845910,https://clinicaltrials.gov/study/NCT00343512,https://clinicaltrials.gov/study/NCT03329378,https://clinicaltrials.gov/study/NCT00225056,https://clinicaltrials.gov/study/NCT00080626,https://clinicaltrials.gov/study/NCT00636441,https://clinicaltrials.gov/study/NCT00524459,https://clinicaltrials.gov/study/NCT00193024,https://clinicaltrials.gov/study/NCT00453635,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT00118053,https://clinicaltrials.gov/study/NCT00028483,https://clinicaltrials.gov/study/NCT00025493,https://clinicaltrials.gov/study/NCT03894007,https://clinicaltrials.gov/study/NCT00479856,https://clinicaltrials.gov/study/NCT00576901,https://clinicaltrials.gov/study/NCT00206453,https://clinicaltrials.gov/study/NCT01985841,https://clinicaltrials.gov/study/NCT00104624,https://clinicaltrials.gov/study/NCT02229149
EFO_0005537	triple-negative breast cancer	CHEMBL3545132	MIRVETUXIMAB SORAVTANSINE	Antibody drug conjugate	Folate receptor alpha binding agent		FOLR1	folate receptor alpha	2	Completed	https://clinicaltrials.gov/study/NCT03106077
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4	NDUFA4 mitochondrial complex associated	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_1000984	inflammatory breast carcinoma	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RB	interleukin 2 receptor subunit beta	2	Completed	https://clinicaltrials.gov/study/NCT00003199
EFO_0000305	breast carcinoma	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR1	estrogen receptor 1	2	Withdrawn	https://clinicaltrials.gov/study/NCT03803761,https://clinicaltrials.gov/study/NCT05191004
EFO_0006861	male breast carcinoma	CHEMBL1567	SUNITINIB MALATE	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	2	Completed	https://clinicaltrials.gov/study/NCT00513695
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06202313,https://clinicaltrials.gov/study/NCT05263882,https://clinicaltrials.gov/study/NCT06308939,https://clinicaltrials.gov/study/NCT04502680,https://clinicaltrials.gov/study/NCT04517292,https://clinicaltrials.gov/study/NCT04913571
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF1	NADH:ubiquinone oxidoreductase complex assembly factor 1	2	Recruiting	https://clinicaltrials.gov/study/NCT04559308,https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT01042379
EFO_1000984	inflammatory breast carcinoma	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Recruiting	https://clinicaltrials.gov/study/NCT03515798
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Terminated	https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT02213744,https://clinicaltrials.gov/study/NCT00169104,https://clinicaltrials.gov/study/NCT00453635,https://clinicaltrials.gov/study/NCT03358004,https://clinicaltrials.gov/study/NCT01185509,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT00176488,https://clinicaltrials.gov/study/NCT00049660,https://clinicaltrials.gov/study/NCT00694200,https://clinicaltrials.gov/study/NCT01161368,https://clinicaltrials.gov/study/NCT00754702,https://clinicaltrials.gov/study/NCT00130507,https://clinicaltrials.gov/study/NCT02585388,https://clinicaltrials.gov/study/NCT00088985,https://clinicaltrials.gov/study/NCT00194792
MONDO_0003982	bilateral breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT00877500
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00410813,https://clinicaltrials.gov/study/NCT00767520,https://clinicaltrials.gov/study/NCT00546104,https://clinicaltrials.gov/study/NCT00696072,https://clinicaltrials.gov/study/NCT00754325
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Suspended	https://clinicaltrials.gov/study/NCT04675827,https://clinicaltrials.gov/study/NCT04419181
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Terminated	https://clinicaltrials.gov/study/NCT00481845,https://clinicaltrials.gov/study/NCT01934335,https://clinicaltrials.gov/study/NCT00752986
MONDO_0007254	breast cancer	CHEMBL4297522	PEMIGATINIB	Small molecule	Fibroblast growth factor receptor 3 inhibitor		FGFR3	fibroblast growth factor receptor 3	2	Recruiting	https://clinicaltrials.gov/study/NCT05560334
EFO_0006861	male breast carcinoma	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RB	interleukin 2 receptor subunit beta	2	Completed	https://clinicaltrials.gov/study/NCT00003199,https://clinicaltrials.gov/study/NCT00006228
MONDO_0007254	breast cancer	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 6 inhibitor		HDAC6	histone deacetylase 6	2	Completed	https://clinicaltrials.gov/study/NCT00262834,https://clinicaltrials.gov/study/NCT00365599
MONDO_0007254	breast cancer	CHEMBL134	CLONIDINE	Small molecule	Adrenergic receptor alpha-2 agonist		ADRA2C	adrenoceptor alpha 2C	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04603911
MONDO_0007254	breast cancer	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Suspended	https://clinicaltrials.gov/study/NCT04675827,https://clinicaltrials.gov/study/NCT04419181
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Withdrawn	https://clinicaltrials.gov/study/NCT05177796
MONDO_0007254	breast cancer	CHEMBL34259	METHOTREXATE	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	2	Terminated	https://clinicaltrials.gov/study/NCT00194792,https://clinicaltrials.gov/study/NCT00074269,https://clinicaltrials.gov/study/NCT01067989,https://clinicaltrials.gov/study/NCT00925652
EFO_0005537	triple-negative breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Suspended	https://clinicaltrials.gov/study/NCT04095689
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Withdrawn	https://clinicaltrials.gov/study/NCT05177796
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Unknown status	https://clinicaltrials.gov/study/NCT01372579
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS3	NADH:ubiquinone oxidoreductase core subunit S3	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1200694	SEVOFLURANE	Small molecule	Potassium channel subfamily K member 2 opener		KCNK2	potassium two pore domain channel subfamily K member 2	2	Completed	https://clinicaltrials.gov/study/NCT02839668
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Fibroblast growth factor receptor 3 inhibitor		FGFR3	fibroblast growth factor receptor 3	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
EFO_1000984	inflammatory breast carcinoma	CHEMBL393220	ATORVASTATIN CALCIUM	Small molecule	HMG-CoA reductase inhibitor		HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase	2	Completed	https://clinicaltrials.gov/study/NCT03872388
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1201179	LAPATINIB DITOSYLATE	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Completed	https://clinicaltrials.gov/study/NCT00684983
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA9	NADH:ubiquinone oxidoreductase subunit A9	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06078384
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Terminated	https://clinicaltrials.gov/study/NCT02978716
MONDO_0007254	breast cancer	CHEMBL1094636	NIRAPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Completed	https://clinicaltrials.gov/study/NCT04240106
EFO_0006861	male breast carcinoma	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Completed	https://clinicaltrials.gov/study/NCT00096434
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT00879086,https://clinicaltrials.gov/study/NCT00593827,https://clinicaltrials.gov/study/NCT00490646,https://clinicaltrials.gov/study/NCT00751868,https://clinicaltrials.gov/study/NCT00633464,https://clinicaltrials.gov/study/NCT01446016,https://clinicaltrials.gov/study/NCT00866905,https://clinicaltrials.gov/study/NCT00821886,https://clinicaltrials.gov/study/NCT00020904,https://clinicaltrials.gov/study/NCT01027208,https://clinicaltrials.gov/study/NCT00077376,https://clinicaltrials.gov/study/NCT00455533,https://clinicaltrials.gov/study/NCT01097642,https://clinicaltrials.gov/study/NCT00045097,https://clinicaltrials.gov/study/NCT00627978,https://clinicaltrials.gov/study/NCT01019577,https://clinicaltrials.gov/study/NCT00370552,https://clinicaltrials.gov/study/NCT00080262,https://clinicaltrials.gov/study/NCT01416389,https://clinicaltrials.gov/study/NCT01075100
EFO_0006861	male breast carcinoma	CHEMBL225072	PEMETREXED	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	2	Completed	https://clinicaltrials.gov/study/NCT00106002
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS8	NADH:ubiquinone oxidoreductase core subunit S8	2	Terminated	https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT04899349
EFO_0006861	male breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Terminated	https://clinicaltrials.gov/study/NCT00095888
MONDO_0007254	breast cancer	CHEMBL502835	NINTEDANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Completed	https://clinicaltrials.gov/study/NCT01658462
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02208375
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA8	NADH:ubiquinone oxidoreductase subunit A8	2	Completed	https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT01310231
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
MONDO_0007254	breast cancer	CHEMBL393220	ATORVASTATIN CALCIUM	Small molecule	HMG-CoA reductase inhibitor		HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase	2	Recruiting	https://clinicaltrials.gov/study/NCT05103644
MONDO_0007254	breast cancer	CHEMBL52885	ENMD-981693	Small molecule	SRC inhibitor		YES1	YES proto-oncogene 1, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00306631
MONDO_0007254	breast cancer	CHEMBL1751	DIGOXIN	Small molecule	Sodium/potassium-transporting ATPase inhibitor		ATP1A4	ATPase Na+/K+ transporting subunit alpha 4	2	Completed	https://clinicaltrials.gov/study/NCT01763931
MONDO_0007254	breast cancer	CHEMBL1200721	ESTRAMUSTINE PHOSPHATE SODIUM	Small molecule	Estrogen receptor beta modulator		ESR2	estrogen receptor 2	2	Unknown status	https://clinicaltrials.gov/study/NCT00003066
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND3	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL521851	PICTILISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	2	Completed	https://clinicaltrials.gov/study/NCT01437566,https://clinicaltrials.gov/study/NCT01740336
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Terminated	https://clinicaltrials.gov/study/NCT00453635,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT00049660,https://clinicaltrials.gov/study/NCT00088985,https://clinicaltrials.gov/study/NCT00169104,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT03358004,https://clinicaltrials.gov/study/NCT02585388,https://clinicaltrials.gov/study/NCT00754702,https://clinicaltrials.gov/study/NCT00694200,https://clinicaltrials.gov/study/NCT01161368,https://clinicaltrials.gov/study/NCT00194792,https://clinicaltrials.gov/study/NCT00176488,https://clinicaltrials.gov/study/NCT00130507,https://clinicaltrials.gov/study/NCT02213744,https://clinicaltrials.gov/study/NCT01185509
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Terminated	https://clinicaltrials.gov/study/NCT02598310,https://clinicaltrials.gov/study/NCT00542191,https://clinicaltrials.gov/study/NCT00434356,https://clinicaltrials.gov/study/NCT00934895,https://clinicaltrials.gov/study/NCT00194792,https://clinicaltrials.gov/study/NCT01194869,https://clinicaltrials.gov/study/NCT00456846,https://clinicaltrials.gov/study/NCT01745367,https://clinicaltrials.gov/study/NCT00479856,https://clinicaltrials.gov/study/NCT01147016,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT00679029,https://clinicaltrials.gov/study/NCT00691912,https://clinicaltrials.gov/study/NCT01009983,https://clinicaltrials.gov/study/NCT03329378,https://clinicaltrials.gov/study/NCT01207102,https://clinicaltrials.gov/study/NCT00607438,https://clinicaltrials.gov/study/NCT01120158,https://clinicaltrials.gov/study/NCT00622466,https://clinicaltrials.gov/study/NCT01069796,https://clinicaltrials.gov/study/NCT00536939,https://clinicaltrials.gov/study/NCT01329627,https://clinicaltrials.gov/study/NCT00589238,https://clinicaltrials.gov/study/NCT00356681,https://clinicaltrials.gov/study/NCT02322814,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT04066790,https://clinicaltrials.gov/study/NCT00756470,https://clinicaltrials.gov/study/NCT00532285,https://clinicaltrials.gov/study/NCT01416558,https://clinicaltrials.gov/study/NCT03894007
MONDO_0007254	breast cancer	CHEMBL1445	FLUOXYMESTERONE	Small molecule	Androgen Receptor agonist		AR	androgen receptor	2	Terminated	https://clinicaltrials.gov/study/NCT00303615
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04502680
MONDO_0007254	breast cancer	CHEMBL679	EPINEPHRINE	Small molecule	Adrenergic receptor agonist		ADRA2B	adrenoceptor alpha 2B	2	Completed	https://clinicaltrials.gov/study/NCT02525718
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT00005800,https://clinicaltrials.gov/study/NCT01025349,https://clinicaltrials.gov/study/NCT00527449,https://clinicaltrials.gov/study/NCT00206518,https://clinicaltrials.gov/study/NCT00006682,https://clinicaltrials.gov/study/NCT00493649,https://clinicaltrials.gov/study/NCT00193050,https://clinicaltrials.gov/study/NCT00525759,https://clinicaltrials.gov/study/NCT00712881,https://clinicaltrials.gov/study/NCT03735966,https://clinicaltrials.gov/study/NCT00679341,https://clinicaltrials.gov/study/NCT00028873,https://clinicaltrials.gov/study/NCT00193115,https://clinicaltrials.gov/study/NCT00248703,https://clinicaltrials.gov/study/NCT02132949,https://clinicaltrials.gov/study/NCT01959490,https://clinicaltrials.gov/study/NCT00217672,https://clinicaltrials.gov/study/NCT00232479,https://clinicaltrials.gov/study/NCT01671319,https://clinicaltrials.gov/study/NCT00193180,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT02041351,https://clinicaltrials.gov/study/NCT00475670,https://clinicaltrials.gov/study/NCT00039520,https://clinicaltrials.gov/study/NCT00107510,https://clinicaltrials.gov/study/NCT03140553,https://clinicaltrials.gov/study/NCT00432172,https://clinicaltrials.gov/study/NCT01150513,https://clinicaltrials.gov/study/NCT00499122,https://clinicaltrials.gov/study/NCT00559754,https://clinicaltrials.gov/study/NCT00364611,https://clinicaltrials.gov/study/NCT00404066,https://clinicaltrials.gov/study/NCT00645866,https://clinicaltrials.gov/study/NCT00015938,https://clinicaltrials.gov/study/NCT00258375,https://clinicaltrials.gov/study/NCT00524810,https://clinicaltrials.gov/study/NCT01367028,https://clinicaltrials.gov/study/NCT00212082,https://clinicaltrials.gov/study/NCT00209092,https://clinicaltrials.gov/study/NCT00365417,https://clinicaltrials.gov/study/NCT00820547,https://clinicaltrials.gov/study/NCT00319618,https://clinicaltrials.gov/study/NCT00088998,https://clinicaltrials.gov/study/NCT01658462,https://clinicaltrials.gov/study/NCT01446016,https://clinicaltrials.gov/study/NCT00003953,https://clinicaltrials.gov/study/NCT00066443,https://clinicaltrials.gov/study/NCT00769470,https://clinicaltrials.gov/study/NCT00494481,https://clinicaltrials.gov/study/NCT00820872,https://clinicaltrials.gov/study/NCT00365365,https://clinicaltrials.gov/study/NCT00079118,https://clinicaltrials.gov/study/NCT00203372,https://clinicaltrials.gov/study/NCT00841828,https://clinicaltrials.gov/study/NCT01396655,https://clinicaltrials.gov/study/NCT01540110,https://clinicaltrials.gov/study/NCT00129376,https://clinicaltrials.gov/study/NCT00004906,https://clinicaltrials.gov/study/NCT00155259,https://clinicaltrials.gov/study/NCT00941330,https://clinicaltrials.gov/study/NCT02838225,https://clinicaltrials.gov/study/NCT01485926,https://clinicaltrials.gov/study/NCT00004888,https://clinicaltrials.gov/study/NCT00206466,https://clinicaltrials.gov/study/NCT00004175,https://clinicaltrials.gov/study/NCT00206505,https://clinicaltrials.gov/study/NCT00191243,https://clinicaltrials.gov/study/NCT00754351,https://clinicaltrials.gov/study/NCT00214864,https://clinicaltrials.gov/study/NCT00054275,https://clinicaltrials.gov/study/NCT00976989,https://clinicaltrials.gov/study/NCT00247481,https://clinicaltrials.gov/study/NCT02748213,https://clinicaltrials.gov/study/NCT04664972,https://clinicaltrials.gov/study/NCT03887130,https://clinicaltrials.gov/study/NCT00003352,https://clinicaltrials.gov/study/NCT00068341,https://clinicaltrials.gov/study/NCT00027885,https://clinicaltrials.gov/study/NCT00464646,https://clinicaltrials.gov/study/NCT00193089,https://clinicaltrials.gov/study/NCT00604435,https://clinicaltrials.gov/study/NCT02137083,https://clinicaltrials.gov/study/NCT02005549,https://clinicaltrials.gov/study/NCT00149214,https://clinicaltrials.gov/study/NCT00077857,https://clinicaltrials.gov/study/NCT00193037,https://clinicaltrials.gov/study/NCT00773695,https://clinicaltrials.gov/study/NCT00148668,https://clinicaltrials.gov/study/NCT00003565,https://clinicaltrials.gov/study/NCT00123929,https://clinicaltrials.gov/study/NCT02365805,https://clinicaltrials.gov/study/NCT00490646,https://clinicaltrials.gov/study/NCT00041067,https://clinicaltrials.gov/study/NCT00379015,https://clinicaltrials.gov/study/NCT01038804,https://clinicaltrials.gov/study/NCT00600249,https://clinicaltrials.gov/study/NCT00203502,https://clinicaltrials.gov/study/NCT01527487,https://clinicaltrials.gov/study/NCT00198237,https://clinicaltrials.gov/study/NCT00146042,https://clinicaltrials.gov/study/NCT00006104,https://clinicaltrials.gov/study/NCT01142778,https://clinicaltrials.gov/study/NCT01208480,https://clinicaltrials.gov/study/NCT00148070,https://clinicaltrials.gov/study/NCT00428922,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT02909751,https://clinicaltrials.gov/study/NCT00274456,https://clinicaltrials.gov/study/NCT00055861,https://clinicaltrials.gov/study/NCT00005908,https://clinicaltrials.gov/study/NCT02834403,https://clinicaltrials.gov/study/NCT00201708,https://clinicaltrials.gov/study/NCT00212095,https://clinicaltrials.gov/study/NCT00179309,https://clinicaltrials.gov/study/NCT01792050,https://clinicaltrials.gov/study/NCT02229084,https://clinicaltrials.gov/study/NCT02846428,https://clinicaltrials.gov/study/NCT00005963,https://clinicaltrials.gov/study/NCT00015886,https://clinicaltrials.gov/study/NCT00695994,https://clinicaltrials.gov/study/NCT00545688,https://clinicaltrials.gov/study/NCT00044993,https://clinicaltrials.gov/study/NCT03742986
MONDO_0007254	breast cancer	CHEMBL1094636	NIRAPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05601440,https://clinicaltrials.gov/study/NCT04837209
MONDO_0007254	breast cancer	CHEMBL1276308	MIFEPRISTONE	Small molecule	Glucocorticoid receptor antagonist		NR3C1	nuclear receptor subfamily 3 group C member 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02788981,https://clinicaltrials.gov/study/NCT03225547
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBA3E	tubulin alpha 3e	2	Withdrawn	https://clinicaltrials.gov/study/NCT00450515
EFO_0005537	triple-negative breast cancer	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05438706
MONDO_0007254	breast cancer	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Unknown status	https://clinicaltrials.gov/study/NCT02025712,https://clinicaltrials.gov/study/NCT00687648,https://clinicaltrials.gov/study/NCT02646735,https://clinicaltrials.gov/study/NCT02676986,https://clinicaltrials.gov/study/NCT02917005,https://clinicaltrials.gov/study/NCT01648608,https://clinicaltrials.gov/study/NCT02592746
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT01908101,https://clinicaltrials.gov/study/NCT01269346,https://clinicaltrials.gov/study/NCT00246090,https://clinicaltrials.gov/study/NCT00965523,https://clinicaltrials.gov/study/NCT01439282,https://clinicaltrials.gov/study/NCT02481050,https://clinicaltrials.gov/study/NCT05206656,https://clinicaltrials.gov/study/NCT01268150,https://clinicaltrials.gov/study/NCT03051659,https://clinicaltrials.gov/study/NCT00879086
MONDO_0007254	breast cancer	CHEMBL1201247	GOSERELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT00398489,https://clinicaltrials.gov/study/NCT02072512,https://clinicaltrials.gov/study/NCT01266213,https://clinicaltrials.gov/study/NCT02313051,https://clinicaltrials.gov/study/NCT02917005
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Unknown status	https://clinicaltrials.gov/study/NCT02790580
EFO_0005537	triple-negative breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03911973
EFO_0005537	triple-negative breast cancer	CHEMBL3647420	PYROTINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04395989
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01881230
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04502680
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02414646
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND3	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
EFO_0005537	triple-negative breast cancer	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	2	Completed	https://clinicaltrials.gov/study/NCT01306032,https://clinicaltrials.gov/study/NCT01818063
EFO_0005537	triple-negative breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT02413320,https://clinicaltrials.gov/study/NCT03154749
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF3	NADH:ubiquinone oxidoreductase complex assembly factor 3	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT04924699
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01898117,https://clinicaltrials.gov/study/NCT01057069,https://clinicaltrials.gov/study/NCT03125928,https://clinicaltrials.gov/study/NCT01853748,https://clinicaltrials.gov/study/NCT02187991,https://clinicaltrials.gov/study/NCT02546232,https://clinicaltrials.gov/study/NCT00609791,https://clinicaltrials.gov/study/NCT01815242,https://clinicaltrials.gov/study/NCT04192331,https://clinicaltrials.gov/study/NCT05498896,https://clinicaltrials.gov/study/NCT01779206,https://clinicaltrials.gov/study/NCT04172259,https://clinicaltrials.gov/study/NCT04083963,https://clinicaltrials.gov/study/NCT04251169,https://clinicaltrials.gov/study/NCT03609047,https://clinicaltrials.gov/study/NCT02788981,https://clinicaltrials.gov/study/NCT02883062,https://clinicaltrials.gov/study/NCT04418154,https://clinicaltrials.gov/study/NCT04734262,https://clinicaltrials.gov/study/NCT04398914,https://clinicaltrials.gov/study/NCT03950570,https://clinicaltrials.gov/study/NCT03387085,https://clinicaltrials.gov/study/NCT03747120,https://clinicaltrials.gov/study/NCT02734290,https://clinicaltrials.gov/study/NCT03616886,https://clinicaltrials.gov/study/NCT02752685,https://clinicaltrials.gov/study/NCT02779855,https://clinicaltrials.gov/study/NCT00295893,https://clinicaltrials.gov/study/NCT03567720,https://clinicaltrials.gov/study/NCT04538742,https://clinicaltrials.gov/study/NCT00616967,https://clinicaltrials.gov/study/NCT01730833,https://clinicaltrials.gov/study/NCT01796197,https://clinicaltrials.gov/study/NCT04603183,https://clinicaltrials.gov/study/NCT04215146,https://clinicaltrials.gov/study/NCT00003042,https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT03568422
MONDO_0007254	breast cancer	CHEMBL4303201	CATEQUENTINIB	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT05296577,https://clinicaltrials.gov/study/NCT04936295,https://clinicaltrials.gov/study/NCT04624711,https://clinicaltrials.gov/study/NCT04452370,https://clinicaltrials.gov/study/NCT04877821,https://clinicaltrials.gov/study/NCT05558722
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Recruiting	https://clinicaltrials.gov/study/NCT05319873,https://clinicaltrials.gov/study/NCT06042569,https://clinicaltrials.gov/study/NCT04266249
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA7	NADH:ubiquinone oxidoreductase subunit A7	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS4	NADH:ubiquinone oxidoreductase subunit S4	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT01320111,https://clinicaltrials.gov/study/NCT00101400,https://clinicaltrials.gov/study/NCT00548899,https://clinicaltrials.gov/study/NCT00634634,https://clinicaltrials.gov/study/NCT00493636
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB1	NADH:ubiquinone oxidoreductase subunit B1	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000432	breast ductal carcinoma in situ	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Terminated	https://clinicaltrials.gov/study/NCT00461344
MONDO_0007254	breast cancer	CHEMBL489	AFIMOXIFENE	Small molecule	Estrogen receptor modulator		ESR1	estrogen receptor 1	2	Completed	https://clinicaltrials.gov/study/NCT03931928
EFO_0006861	male breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
EFO_0005537	triple-negative breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03639948
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS2	NADH:ubiquinone oxidoreductase core subunit S2	2	Recruiting	https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT04559308,https://clinicaltrials.gov/study/NCT01042379
EFO_0006861	male breast carcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC4	histone deacetylase 4	2	Completed	https://clinicaltrials.gov/study/NCT00098397
MONDO_0007254	breast cancer	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Completed	https://clinicaltrials.gov/study/NCT00081510,https://clinicaltrials.gov/study/NCT01989780,https://clinicaltrials.gov/study/NCT00186121,https://clinicaltrials.gov/study/NCT00629616,https://clinicaltrials.gov/study/NCT02441946,https://clinicaltrials.gov/study/NCT00244959,https://clinicaltrials.gov/study/NCT02291913,https://clinicaltrials.gov/study/NCT02440230,https://clinicaltrials.gov/study/NCT00128843,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00077025,https://clinicaltrials.gov/study/NCT04436744,https://clinicaltrials.gov/study/NCT00066378,https://clinicaltrials.gov/study/NCT00921115,https://clinicaltrials.gov/study/NCT04294225,https://clinicaltrials.gov/study/NCT00004906,https://clinicaltrials.gov/study/NCT02549430,https://clinicaltrials.gov/study/NCT00570323,https://clinicaltrials.gov/study/NCT00357110,https://clinicaltrials.gov/study/NCT00005908,https://clinicaltrials.gov/study/NCT01972984,https://clinicaltrials.gov/study/NCT00274469,https://clinicaltrials.gov/study/NCT04075604,https://clinicaltrials.gov/study/NCT00049062,https://clinicaltrials.gov/study/NCT03481998,https://clinicaltrials.gov/study/NCT00354640,https://clinicaltrials.gov/study/NCT00287534,https://clinicaltrials.gov/study/NCT00235937,https://clinicaltrials.gov/study/NCT00259090,https://clinicaltrials.gov/study/NCT00057941,https://clinicaltrials.gov/study/NCT03555877,https://clinicaltrials.gov/study/NCT00405938,https://clinicaltrials.gov/study/NCT00871858,https://clinicaltrials.gov/study/NCT00255463,https://clinicaltrials.gov/study/NCT00004900,https://clinicaltrials.gov/study/NCT00728949
MONDO_0007254	breast cancer	CHEMBL355200	ENILURACIL	Small molecule	Dihydropyrimidine dehydrogenase inhibitor		DPYD	dihydropyrimidine dehydrogenase	2	Unknown status	https://clinicaltrials.gov/study/NCT01231802
MONDO_0007254	breast cancer	CHEMBL3707227	ATEZOLIZUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor	Inhibitor	CD274	CD274 molecule	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06342037,https://clinicaltrials.gov/study/NCT04819243
MONDO_0007254	breast cancer	CHEMBL679	EPINEPHRINE	Small molecule	Adrenergic receptor agonist		ADRA2A	adrenoceptor alpha 2A	2	Completed	https://clinicaltrials.gov/study/NCT02525718
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Withdrawn	https://clinicaltrials.gov/study/NCT02725541
MONDO_0007254	breast cancer	CHEMBL502835	NINTEDANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Completed	https://clinicaltrials.gov/study/NCT01658462
EFO_0000305	breast carcinoma	CHEMBL4297545	LUTETIUM OXODOTREOTIDE LU-177	Protein	Somatostatin receptor binding agent		SSTR2	somatostatin receptor 2	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04529044
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Recruiting	https://clinicaltrials.gov/study/NCT05483439,https://clinicaltrials.gov/study/NCT03367676,https://clinicaltrials.gov/study/NCT05088057,https://clinicaltrials.gov/study/NCT05918328,https://clinicaltrials.gov/study/NCT03497702,https://clinicaltrials.gov/study/NCT04576143,https://clinicaltrials.gov/study/NCT04872985,https://clinicaltrials.gov/study/NCT06107673,https://clinicaltrials.gov/study/NCT05426486,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT04717531,https://clinicaltrials.gov/study/NCT05189067,https://clinicaltrials.gov/study/NCT04947189,https://clinicaltrials.gov/study/NCT05900206,https://clinicaltrials.gov/study/NCT05475678,https://clinicaltrials.gov/study/NCT05645380,https://clinicaltrials.gov/study/NCT03879577,https://clinicaltrials.gov/study/NCT05638594
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4L	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA2	NADH:ubiquinone oxidoreductase subunit A2	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02414646
MONDO_0007254	breast cancer	CHEMBL3813873	PEXIDARTINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF3	NADH:ubiquinone oxidoreductase complex assembly factor 3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT00006261
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134,https://clinicaltrials.gov/study/NCT06291064,https://clinicaltrials.gov/study/NCT04290793,https://clinicaltrials.gov/study/NCT04034823
MONDO_0007254	breast cancer	CHEMBL1201334	TRIPTORELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	2	Terminated	https://clinicaltrials.gov/study/NCT02113553,https://clinicaltrials.gov/study/NCT00090844,https://clinicaltrials.gov/study/NCT00194792
MONDO_0007254	breast cancer	CHEMBL1201167	CARVEDILOL PHOSPHATE	Small molecule	Adrenergic receptor alpha-1 antagonist		ADRA1B	adrenoceptor alpha 1B	2	Completed	https://clinicaltrials.gov/study/NCT01009918
MONDO_0007254	breast cancer	CHEMBL939	GEFITINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT01732276
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT00532623,https://clinicaltrials.gov/study/NCT00093808,https://clinicaltrials.gov/study/NCT00266110,https://clinicaltrials.gov/study/NCT00006682,https://clinicaltrials.gov/study/NCT00148681,https://clinicaltrials.gov/study/NCT00022152,https://clinicaltrials.gov/study/NCT00148668,https://clinicaltrials.gov/study/NCT01941771,https://clinicaltrials.gov/study/NCT00194779,https://clinicaltrials.gov/study/NCT00004237
EFO_0006861	male breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00095888
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT02978716
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Terminated	https://clinicaltrials.gov/study/NCT00194792,https://clinicaltrials.gov/study/NCT00088985,https://clinicaltrials.gov/study/NCT00049660,https://clinicaltrials.gov/study/NCT03358004,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT00476827
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Terminated	https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT00088985,https://clinicaltrials.gov/study/NCT03358004,https://clinicaltrials.gov/study/NCT00049660,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT00194792
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL2325741	CAPIVASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT3	AKT serine/threonine kinase 3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02208375
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Recruiting	https://clinicaltrials.gov/study/NCT06042569,https://clinicaltrials.gov/study/NCT05319873,https://clinicaltrials.gov/study/NCT04266249
MONDO_0007254	breast cancer	CHEMBL1042	CHOLECALCIFEROL	Small molecule	Vitamin D receptor agonist		VDR	vitamin D receptor	2	Terminated	https://clinicaltrials.gov/study/NCT00172068,https://clinicaltrials.gov/study/NCT01988090
MONDO_0007254	breast cancer	CHEMBL1234354	PF-04691502	Small molecule	PI3-kinase class I inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	2	Terminated	https://clinicaltrials.gov/study/NCT01430585
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS8	NADH:ubiquinone oxidoreductase core subunit S8	2	Recruiting	https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT04559308
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06291064,https://clinicaltrials.gov/study/NCT04290793,https://clinicaltrials.gov/study/NCT04034823,https://clinicaltrials.gov/study/NCT06348134
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB8	NADH:ubiquinone oxidoreductase subunit B8	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1922094	APITOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R5	phosphoinositide-3-kinase regulatory subunit 5	2	Completed	https://clinicaltrials.gov/study/NCT01437566
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC1	histone deacetylase 1	2	Withdrawn	https://clinicaltrials.gov/study/NCT02115594
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF3	NADH:ubiquinone oxidoreductase complex assembly factor 3	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA2	NADH:ubiquinone oxidoreductase subunit A2	2	Terminated	https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT02360059
MONDO_0007254	breast cancer	CHEMBL27	PROPRANOLOL	Small molecule	Beta-2 adrenergic receptor antagonist		ADRB2	adrenoceptor beta 2	2	Completed	https://clinicaltrials.gov/study/NCT01847001
MONDO_0007254	breast cancer	CHEMBL679	EPINEPHRINE	Small molecule	Adrenergic receptor agonist		ADRA1A	adrenoceptor alpha 1A	2	Completed	https://clinicaltrials.gov/study/NCT02525718
MONDO_0007254	breast cancer	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04059484,https://clinicaltrials.gov/study/NCT00003042,https://clinicaltrials.gov/study/NCT03161353,https://clinicaltrials.gov/study/NCT02206984,https://clinicaltrials.gov/study/NCT02624973,https://clinicaltrials.gov/study/NCT02668666,https://clinicaltrials.gov/study/NCT04129216,https://clinicaltrials.gov/study/NCT04272801,https://clinicaltrials.gov/study/NCT03917082,https://clinicaltrials.gov/study/NCT02890082,https://clinicaltrials.gov/study/NCT04997941,https://clinicaltrials.gov/study/NCT01196936,https://clinicaltrials.gov/study/NCT02747004,https://clinicaltrials.gov/study/NCT02764541,https://clinicaltrials.gov/study/NCT05133674,https://clinicaltrials.gov/study/NCT03219476,https://clinicaltrials.gov/study/NCT05035836
EFO_0005537	triple-negative breast cancer	CHEMBL3545262	SACITUZUMAB GOVITECAN	Antibody drug conjugate	Tumor-associated calcium signal transducer 2 binding agent		TACSTD2	tumor associated calcium signal transducer 2	2	Recruiting	https://clinicaltrials.gov/study/NCT03971409,https://clinicaltrials.gov/study/NCT05101096
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Recruiting	https://clinicaltrials.gov/study/NCT05834582,https://clinicaltrials.gov/study/NCT03606967,https://clinicaltrials.gov/study/NCT05192798,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT05227664,https://clinicaltrials.gov/study/NCT04138719
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02208375
EFO_0006861	male breast carcinoma	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT00861705
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND5	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1487	ATORVASTATIN	Small molecule	HMG-CoA reductase inhibitor		HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase	2	Unknown status	https://clinicaltrials.gov/study/NCT00914017,https://clinicaltrials.gov/study/NCT02958852
EFO_0005537	triple-negative breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Suspended	https://clinicaltrials.gov/study/NCT04095689
EFO_0006861	male breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND5	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL384467	DEXAMETHASONE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04603911
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05444998,https://clinicaltrials.gov/study/NCT04946227,https://clinicaltrials.gov/study/NCT04900311,https://clinicaltrials.gov/study/NCT04907344,https://clinicaltrials.gov/study/NCT03959397,https://clinicaltrials.gov/study/NCT04290793,https://clinicaltrials.gov/study/NCT04498793,https://clinicaltrials.gov/study/NCT04301375,https://clinicaltrials.gov/study/NCT04499118,https://clinicaltrials.gov/study/NCT04659499,https://clinicaltrials.gov/study/NCT04194684,https://clinicaltrials.gov/study/NCT05872412,https://clinicaltrials.gov/study/NCT04639271
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Terminated	https://clinicaltrials.gov/study/NCT03894007,https://clinicaltrials.gov/study/NCT01702558,https://clinicaltrials.gov/study/NCT03709082
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Vascular endothelial growth factor receptor 1 inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Unknown status	https://clinicaltrials.gov/study/NCT02790580
EFO_0005537	triple-negative breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC6	histone deacetylase 6	2	Terminated	https://clinicaltrials.gov/study/NCT01234532
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND1	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1	2	Recruiting	https://clinicaltrials.gov/study/NCT04559308,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC3	histone deacetylase 3	2	Withdrawn	https://clinicaltrials.gov/study/NCT02115594
MONDO_0007254	breast cancer	CHEMBL2396661	ALPELISIB	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT05625087,https://clinicaltrials.gov/study/NCT04762979,https://clinicaltrials.gov/study/NCT05230810,https://clinicaltrials.gov/study/NCT05101564,https://clinicaltrials.gov/study/NCT05933395,https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT05563220
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR2	estrogen receptor 2	2	Completed	https://clinicaltrials.gov/study/NCT02049957,https://clinicaltrials.gov/study/NCT03481998,https://clinicaltrials.gov/study/NCT00093002,https://clinicaltrials.gov/study/NCT03007979,https://clinicaltrials.gov/study/NCT02384239,https://clinicaltrials.gov/study/NCT00921115,https://clinicaltrials.gov/study/NCT02491983,https://clinicaltrials.gov/study/NCT00626106,https://clinicaltrials.gov/study/NCT00057941,https://clinicaltrials.gov/study/NCT00728949,https://clinicaltrials.gov/study/NCT00201864,https://clinicaltrials.gov/study/NCT00313170,https://clinicaltrials.gov/study/NCT00570323,https://clinicaltrials.gov/study/NCT02291913,https://clinicaltrials.gov/study/NCT03555877,https://clinicaltrials.gov/study/NCT02953860,https://clinicaltrials.gov/study/NCT00534417,https://clinicaltrials.gov/study/NCT00423917,https://clinicaltrials.gov/study/NCT01437566,https://clinicaltrials.gov/study/NCT01797120,https://clinicaltrials.gov/study/NCT00357110,https://clinicaltrials.gov/study/NCT02675231,https://clinicaltrials.gov/study/NCT01989780,https://clinicaltrials.gov/study/NCT00146601,https://clinicaltrials.gov/study/NCT02137083,https://clinicaltrials.gov/study/NCT02536742,https://clinicaltrials.gov/study/NCT01160718,https://clinicaltrials.gov/study/NCT02549430,https://clinicaltrials.gov/study/NCT00754325,https://clinicaltrials.gov/study/NCT00012025,https://clinicaltrials.gov/study/NCT00871858,https://clinicaltrials.gov/study/NCT00082810,https://clinicaltrials.gov/study/NCT02630693,https://clinicaltrials.gov/study/NCT00570921,https://clinicaltrials.gov/study/NCT00274469,https://clinicaltrials.gov/study/NCT00405938,https://clinicaltrials.gov/study/NCT00454805,https://clinicaltrials.gov/study/NCT00305448,https://clinicaltrials.gov/study/NCT02692755,https://clinicaltrials.gov/study/NCT00629616,https://clinicaltrials.gov/study/NCT00811369,https://clinicaltrials.gov/study/NCT00451555,https://clinicaltrials.gov/study/NCT00259090,https://clinicaltrials.gov/study/NCT00234403
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	2	Completed	https://clinicaltrials.gov/study/NCT02273973
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA6	NADH:ubiquinone oxidoreductase subunit A6	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000432	breast ductal carcinoma in situ	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Terminated	https://clinicaltrials.gov/study/NCT00461344
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02530489,https://clinicaltrials.gov/study/NCT02957968,https://clinicaltrials.gov/study/NCT01730833
EFO_0000305	breast carcinoma	CHEMBL483158	ALISERTIB	Small molecule	Serine/threonine-protein kinase Aurora-A inhibitor		AURKA	aurora kinase A	2	Completed	https://clinicaltrials.gov/study/NCT01091428
MONDO_0007254	breast cancer	CHEMBL1201748	CABAZITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT01693549
MONDO_0007254	breast cancer	CHEMBL288441	BOSUTINIB	Small molecule	Tyrosine-protein kinase Lyn inhibitor		LYN	LYN proto-oncogene, Src family tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT00793546,https://clinicaltrials.gov/study/NCT00880009
MONDO_0007254	breast cancer	CHEMBL1491	AMLODIPINE	Small molecule	Voltage-gated L-type calcium channel blocker		CACNA1F	calcium voltage-gated channel subunit alpha1 F	2	Completed	https://clinicaltrials.gov/study/NCT02834403
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB1	NADH:ubiquinone oxidoreductase subunit B1	2	Completed	https://clinicaltrials.gov/study/NCT04170465
EFO_0000305	breast carcinoma	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT04266249,https://clinicaltrials.gov/study/NCT05319873
MONDO_0007254	breast cancer	CHEMBL223360	LINIFANIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	2	Completed	https://clinicaltrials.gov/study/NCT00645177
MONDO_0007254	breast cancer	CHEMBL271227	ABIRATERONE ACETATE	Small molecule	Cytochrome P450 17A1 inhibitor		CYP17A1	cytochrome P450 family 17 subfamily A member 1	2	Withdrawn	https://clinicaltrials.gov/study/NCT01814865
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00159458,https://clinicaltrials.gov/study/NCT00674206,https://clinicaltrials.gov/study/NCT00679029,https://clinicaltrials.gov/study/NCT00462865,https://clinicaltrials.gov/study/NCT00470249,https://clinicaltrials.gov/study/NCT00095888,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT03674242,https://clinicaltrials.gov/study/NCT02213744,https://clinicaltrials.gov/study/NCT00532285,https://clinicaltrials.gov/study/NCT00323063
MONDO_0007254	breast cancer	CHEMBL1567	SUNITINIB MALATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT00482755
MONDO_0007254	breast cancer	CHEMBL2396661	ALPELISIB	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	2	Terminated	https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT04862143,https://clinicaltrials.gov/study/NCT03386162
MONDO_0007254	breast cancer	CHEMBL3349607	PASIREOTIDE	Protein	Somatostatin receptor 3 agonist		SSTR3	somatostatin receptor 3	2	Completed	https://clinicaltrials.gov/study/NCT01356862
EFO_0005537	triple-negative breast cancer	CHEMBL4298101	LADIRATUZUMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT01908101
EFO_1000984	inflammatory breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02623972
MONDO_0007254	breast cancer	CHEMBL4650316	GIREDESTRANT	Small molecule	Estrogen receptor alpha degrader		ESR1	estrogen receptor 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05708235
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4L2	NDUFA4 mitochondrial complex associated like 2	2	Completed	https://clinicaltrials.gov/study/NCT01885013
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT03530696
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	Serine/threonine-protein kinase mTOR inhibitor		MTOR	mechanistic target of rapamycin kinase	2	Recruiting	https://clinicaltrials.gov/study/NCT03698383
EFO_0005537	triple-negative breast cancer	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04683679,https://clinicaltrials.gov/study/NCT03213041,https://clinicaltrials.gov/study/NCT06027268,https://clinicaltrials.gov/study/NCT05756166
EFO_0000305	breast carcinoma	CHEMBL1201247	GOSERELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
MONDO_0007254	breast cancer	CHEMBL572881	MOTESANIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	2	Terminated	https://clinicaltrials.gov/study/NCT00356681
MONDO_0003982	bilateral breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT00877500
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT06026657,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT05601440,https://clinicaltrials.gov/study/NCT04739670,https://clinicaltrials.gov/study/NCT06102824,https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT05181462
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Completed	https://clinicaltrials.gov/study/NCT00494481
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Unknown status	https://clinicaltrials.gov/study/NCT01352494,https://clinicaltrials.gov/study/NCT00006120,https://clinicaltrials.gov/study/NCT00669773,https://clinicaltrials.gov/study/NCT00721747,https://clinicaltrials.gov/study/NCT00250874,https://clinicaltrials.gov/study/NCT02685657,https://clinicaltrials.gov/study/NCT00801411,https://clinicaltrials.gov/study/NCT02947061,https://clinicaltrials.gov/study/NCT01907529,https://clinicaltrials.gov/study/NCT00398489,https://clinicaltrials.gov/study/NCT00003066,https://clinicaltrials.gov/study/NCT03876587,https://clinicaltrials.gov/study/NCT00026078,https://clinicaltrials.gov/study/NCT01939054,https://clinicaltrials.gov/study/NCT00033683,https://clinicaltrials.gov/study/NCT01526499,https://clinicaltrials.gov/study/NCT01270373,https://clinicaltrials.gov/study/NCT00957125,https://clinicaltrials.gov/study/NCT00994968,https://clinicaltrials.gov/study/NCT03147963,https://clinicaltrials.gov/study/NCT00012311,https://clinicaltrials.gov/study/NCT02144194,https://clinicaltrials.gov/study/NCT01351597
EFO_0005537	triple-negative breast cancer	CHEMBL4297715	CAMRELIZUMAB	Antibody	Programmed cell death protein 1 antagonist		PDCD1	programmed cell death 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04129996
MONDO_0007254	breast cancer	CHEMBL742	KETAMINE	Small molecule	Glutamate [NMDA] receptor negative allosteric modulator		GRIN1	glutamate ionotropic receptor NMDA type subunit 1	2	Completed	https://clinicaltrials.gov/study/NCT05727098,https://clinicaltrials.gov/study/NCT00304850
MONDO_0007254	breast cancer	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT04872985,https://clinicaltrials.gov/study/NCT05386524,https://clinicaltrials.gov/study/NCT05346107,https://clinicaltrials.gov/study/NCT05645380,https://clinicaltrials.gov/study/NCT05889390,https://clinicaltrials.gov/study/NCT05088057,https://clinicaltrials.gov/study/NCT05748834,https://clinicaltrials.gov/study/NCT04443348,https://clinicaltrials.gov/study/NCT03497702,https://clinicaltrials.gov/study/NCT04159818,https://clinicaltrials.gov/study/NCT03412643,https://clinicaltrials.gov/study/NCT03933319,https://clinicaltrials.gov/study/NCT05020860,https://clinicaltrials.gov/study/NCT06245889,https://clinicaltrials.gov/study/NCT04243616
MONDO_0007254	breast cancer	CHEMBL105442	CI-1040	Small molecule	Dual specificity mitogen-activated protein kinase kinase 2 inhibitor		MAP2K2	mitogen-activated protein kinase kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT00033384
MONDO_0007254	breast cancer	CHEMBL134	CLONIDINE	Small molecule	Adrenergic receptor alpha-2 agonist		ADRA2B	adrenoceptor alpha 2B	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04603911
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
EFO_0000305	breast carcinoma	CHEMBL1200501	GOSERELIN ACETATE	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01776008
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE6H	phosphodiesterase 6H	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT06176339,https://clinicaltrials.gov/study/NCT06186700
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT00045097,https://clinicaltrials.gov/study/NCT00821886,https://clinicaltrials.gov/study/NCT01416389,https://clinicaltrials.gov/study/NCT00751868,https://clinicaltrials.gov/study/NCT00077376,https://clinicaltrials.gov/study/NCT00490646,https://clinicaltrials.gov/study/NCT00879086,https://clinicaltrials.gov/study/NCT01075100,https://clinicaltrials.gov/study/NCT00633464,https://clinicaltrials.gov/study/NCT00080262,https://clinicaltrials.gov/study/NCT00627978,https://clinicaltrials.gov/study/NCT00866905,https://clinicaltrials.gov/study/NCT01097642,https://clinicaltrials.gov/study/NCT01446016,https://clinicaltrials.gov/study/NCT00593827,https://clinicaltrials.gov/study/NCT00455533,https://clinicaltrials.gov/study/NCT00370552,https://clinicaltrials.gov/study/NCT01019577,https://clinicaltrials.gov/study/NCT01027208,https://clinicaltrials.gov/study/NCT00020904
EFO_0006861	male breast carcinoma	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT00017394
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC2	NADH:ubiquinone oxidoreductase subunit C2	2	Completed	https://clinicaltrials.gov/study/NCT01885013
EFO_0000432	breast ductal carcinoma in situ	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Terminated	https://clinicaltrials.gov/study/NCT00461344
EFO_0000432	breast ductal carcinoma in situ	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Terminated	https://clinicaltrials.gov/study/NCT00461344
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
EFO_0000186	invasive breast ductal carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02779855
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR1	estrogen receptor 1	2	Completed	https://clinicaltrials.gov/study/NCT02675231,https://clinicaltrials.gov/study/NCT00626106,https://clinicaltrials.gov/study/NCT00259090,https://clinicaltrials.gov/study/NCT00454805,https://clinicaltrials.gov/study/NCT02291913,https://clinicaltrials.gov/study/NCT00570921,https://clinicaltrials.gov/study/NCT01160718,https://clinicaltrials.gov/study/NCT00728949,https://clinicaltrials.gov/study/NCT00629616,https://clinicaltrials.gov/study/NCT00871858,https://clinicaltrials.gov/study/NCT00305448,https://clinicaltrials.gov/study/NCT00057941,https://clinicaltrials.gov/study/NCT00754325,https://clinicaltrials.gov/study/NCT02692755,https://clinicaltrials.gov/study/NCT01437566,https://clinicaltrials.gov/study/NCT00357110,https://clinicaltrials.gov/study/NCT00405938,https://clinicaltrials.gov/study/NCT00570323,https://clinicaltrials.gov/study/NCT02491983,https://clinicaltrials.gov/study/NCT00423917,https://clinicaltrials.gov/study/NCT00811369,https://clinicaltrials.gov/study/NCT02953860,https://clinicaltrials.gov/study/NCT00201864,https://clinicaltrials.gov/study/NCT02549430,https://clinicaltrials.gov/study/NCT00921115,https://clinicaltrials.gov/study/NCT00093002,https://clinicaltrials.gov/study/NCT00012025,https://clinicaltrials.gov/study/NCT00451555,https://clinicaltrials.gov/study/NCT00534417,https://clinicaltrials.gov/study/NCT02384239,https://clinicaltrials.gov/study/NCT02049957,https://clinicaltrials.gov/study/NCT01797120,https://clinicaltrials.gov/study/NCT02630693,https://clinicaltrials.gov/study/NCT03481998,https://clinicaltrials.gov/study/NCT02137083,https://clinicaltrials.gov/study/NCT00313170,https://clinicaltrials.gov/study/NCT00082810,https://clinicaltrials.gov/study/NCT01989780,https://clinicaltrials.gov/study/NCT00274469,https://clinicaltrials.gov/study/NCT00146601,https://clinicaltrials.gov/study/NCT03007979,https://clinicaltrials.gov/study/NCT02536742,https://clinicaltrials.gov/study/NCT00234403,https://clinicaltrials.gov/study/NCT03555877
MONDO_0007254	breast cancer	CHEMBL1738889	ENOBOSARM	Small molecule	Androgen Receptor modulator		AR	androgen receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01616758,https://clinicaltrials.gov/study/NCT02368691
MONDO_0007254	breast cancer	CHEMBL1200694	SEVOFLURANE	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRB1	gamma-aminobutyric acid type A receptor subunit beta1	2	Completed	https://clinicaltrials.gov/study/NCT02839668
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT00499525,https://clinicaltrials.gov/study/NCT00954135
EFO_0005537	triple-negative breast cancer	CHEMBL1614701	SELUMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 2 inhibitor		MAP2K2	mitogen-activated protein kinase kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT03801369
EFO_0005537	triple-negative breast cancer	CHEMBL3545132	MIRVETUXIMAB SORAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT03106077
MONDO_0007254	breast cancer	CHEMBL1743028	GLEMBATUMUMAB VEDOTIN	Antibody drug conjugate	Transmembrane glycoprotein NMB binding agent		GPNMB	glycoprotein nmb	2	Completed	https://clinicaltrials.gov/study/NCT01156753,https://clinicaltrials.gov/study/NCT01997333
MONDO_0007254	breast cancer	CHEMBL554	LAPATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT02238509,https://clinicaltrials.gov/study/NCT01283789,https://clinicaltrials.gov/study/NCT01730677,https://clinicaltrials.gov/study/NCT03085368,https://clinicaltrials.gov/study/NCT00842998,https://clinicaltrials.gov/study/NCT01309607
EFO_0006861	male breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Unknown status	https://clinicaltrials.gov/study/NCT01372579
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Recruiting	https://clinicaltrials.gov/study/NCT05383196,https://clinicaltrials.gov/study/NCT03515798
EFO_0005537	triple-negative breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT02413320,https://clinicaltrials.gov/study/NCT03154749
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL180022	NERATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-4 inhibitor		ERBB4	erb-b2 receptor tyrosine kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT02673398
EFO_0000305	breast carcinoma	CHEMBL3301587	DURVALUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor	Inhibitor	CD274	CD274 molecule	2	Completed	https://clinicaltrials.gov/study/NCT02536794
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		HCK	HCK proto-oncogene, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00767520,https://clinicaltrials.gov/study/NCT00546104,https://clinicaltrials.gov/study/NCT00754325,https://clinicaltrials.gov/study/NCT00410813,https://clinicaltrials.gov/study/NCT00696072
EFO_0005537	triple-negative breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT03932526
MONDO_0007254	breast cancer	CHEMBL1237022	TOCILIZUMAB	Antibody	Interleukin-6 receptor alpha subunit inhibitor		IL6R	interleukin 6 receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT05846789,https://clinicaltrials.gov/study/NCT03424005
MONDO_0007254	breast cancer	CHEMBL3647420	PYROTINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Terminated	https://clinicaltrials.gov/study/NCT04066790
MONDO_0007254	breast cancer	CHEMBL4303214	FRUQUINTINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04577963
EFO_0000432	breast ductal carcinoma in situ	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Terminated	https://clinicaltrials.gov/study/NCT00461344
MONDO_0007254	breast cancer	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Completed	https://clinicaltrials.gov/study/NCT01506609,https://clinicaltrials.gov/study/NCT01818063
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Unknown status	https://clinicaltrials.gov/study/NCT02607215,https://clinicaltrials.gov/study/NCT02768415,https://clinicaltrials.gov/study/NCT00159094,https://clinicaltrials.gov/study/NCT02144194,https://clinicaltrials.gov/study/NCT03423849,https://clinicaltrials.gov/study/NCT01730677,https://clinicaltrials.gov/study/NCT02544243,https://clinicaltrials.gov/study/NCT01528826
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB8	NADH:ubiquinone oxidoreductase subunit B8	2	Terminated	https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT01477060
MONDO_0007254	breast cancer	CHEMBL4279455	LAROTAXEL	Small molecule	Tubulin stabiliser		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT00387907,https://clinicaltrials.gov/study/NCT00087958
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF2	NADH:ubiquinone oxidoreductase complex assembly factor 2	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Unknown status	https://clinicaltrials.gov/study/NCT03144947
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB1	NADH:ubiquinone oxidoreductase subunit B1	2	Unknown status	https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT02506777,https://clinicaltrials.gov/study/NCT02506790
MONDO_0007254	breast cancer	CHEMBL1567	SUNITINIB MALATE	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	2	Completed	https://clinicaltrials.gov/study/NCT00482755
MONDO_0007254	breast cancer	CHEMBL491473	CEDIRANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Completed	https://clinicaltrials.gov/study/NCT00454805
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02530489,https://clinicaltrials.gov/study/NCT02957968,https://clinicaltrials.gov/study/NCT01730833
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04502680
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA1	NADH:ubiquinone oxidoreductase subunit A1	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL1743022	FRESOLIMUMAB	Antibody	Transforming growth factor beta-1 inhibitor		TGFB1	transforming growth factor beta 1	2	Completed	https://clinicaltrials.gov/study/NCT01401062
MONDO_0007254	breast cancer	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Fibroblast growth factor receptor 3 inhibitor		FGFR3	fibroblast growth factor receptor 3	2	Completed	https://clinicaltrials.gov/study/NCT00509587
EFO_0005537	triple-negative breast cancer	CHEMBL27	PROPRANOLOL	Small molecule	Beta-2 adrenergic receptor antagonist		ADRB2	adrenoceptor beta 2	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05741164
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00323063,https://clinicaltrials.gov/study/NCT00679029,https://clinicaltrials.gov/study/NCT00470249,https://clinicaltrials.gov/study/NCT00095888
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05833919
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Suspended	https://clinicaltrials.gov/study/NCT02897050,https://clinicaltrials.gov/study/NCT04419181
MONDO_0007254	breast cancer	CHEMBL3707227	ATEZOLIZUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor	Inhibitor	CD274	CD274 molecule	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03125928,https://clinicaltrials.gov/study/NCT03417544,https://clinicaltrials.gov/study/NCT05498896,https://clinicaltrials.gov/study/NCT03756298,https://clinicaltrials.gov/study/NCT01898117,https://clinicaltrials.gov/study/NCT02883062,https://clinicaltrials.gov/study/NCT03483012,https://clinicaltrials.gov/study/NCT03395899,https://clinicaltrials.gov/study/NCT04434040
MONDO_0007254	breast cancer	CHEMBL4297892	ANVATABART OPADOTIN	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 binding agent		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT04829604,https://clinicaltrials.gov/study/NCT05426486,https://clinicaltrials.gov/study/NCT05018676,https://clinicaltrials.gov/study/NCT05018702,https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Unknown status	https://clinicaltrials.gov/study/NCT02544243,https://clinicaltrials.gov/study/NCT01528826,https://clinicaltrials.gov/study/NCT02768415,https://clinicaltrials.gov/study/NCT01730677,https://clinicaltrials.gov/study/NCT03423849,https://clinicaltrials.gov/study/NCT02144194,https://clinicaltrials.gov/study/NCT00159094,https://clinicaltrials.gov/study/NCT02607215
MONDO_0007254	breast cancer	CHEMBL521851	PICTILISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	2	Completed	https://clinicaltrials.gov/study/NCT01740336,https://clinicaltrials.gov/study/NCT01437566
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05833919
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Withdrawn	https://clinicaltrials.gov/study/NCT05177796,https://clinicaltrials.gov/study/NCT05233696
MONDO_0007254	breast cancer	CHEMBL522892	DOVITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Terminated	https://clinicaltrials.gov/study/NCT01528345
MONDO_0007254	breast cancer	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	2	Withdrawn	https://clinicaltrials.gov/study/NCT03058939
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB9	NADH:ubiquinone oxidoreductase subunit B9	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL2304041	SAGOPILONE	Small molecule	Tubulin stabiliser		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT00288249
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA10	EPH receptor A10	2	Terminated	https://clinicaltrials.gov/study/NCT01934335,https://clinicaltrials.gov/study/NCT00752986,https://clinicaltrials.gov/study/NCT00481845
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHB4	EPH receptor B4	2	Terminated	https://clinicaltrials.gov/study/NCT01934335,https://clinicaltrials.gov/study/NCT00752986,https://clinicaltrials.gov/study/NCT00481845
MONDO_0007254	breast cancer	CHEMBL4297736	PRALUZATAMAB RAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT04596150
MONDO_0007254	breast cancer	CHEMBL1091644	LINSITINIB	Small molecule	Insulin receptor inhibitor		INSR	insulin receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01205685
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04398914,https://clinicaltrials.gov/study/NCT03587740,https://clinicaltrials.gov/study/NCT01745965,https://clinicaltrials.gov/study/NCT04733118,https://clinicaltrials.gov/study/NCT01494662,https://clinicaltrials.gov/study/NCT01853748,https://clinicaltrials.gov/study/NCT01565200,https://clinicaltrials.gov/study/NCT02326974
MONDO_0007254	breast cancer	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02188745,https://clinicaltrials.gov/study/NCT03633331,https://clinicaltrials.gov/study/NCT02712723,https://clinicaltrials.gov/study/NCT05569811,https://clinicaltrials.gov/study/NCT04603183,https://clinicaltrials.gov/study/NCT04129216,https://clinicaltrials.gov/study/NCT04293393,https://clinicaltrials.gov/study/NCT03161353,https://clinicaltrials.gov/study/NCT03747042,https://clinicaltrials.gov/study/NCT05035836,https://clinicaltrials.gov/study/NCT03900637,https://clinicaltrials.gov/study/NCT00999804,https://clinicaltrials.gov/study/NCT03671330,https://clinicaltrials.gov/study/NCT01872260,https://clinicaltrials.gov/study/NCT03056755,https://clinicaltrials.gov/study/NCT04272801,https://clinicaltrials.gov/study/NCT03219476,https://clinicaltrials.gov/study/NCT03822468,https://clinicaltrials.gov/study/NCT02624973,https://clinicaltrials.gov/study/NCT02764541,https://clinicaltrials.gov/study/NCT04059484
MONDO_0007254	breast cancer	CHEMBL46	ONDANSETRON	Small molecule	Serotonin 3a (5-HT3a) receptor antagonist		HTR3A	5-hydroxytryptamine receptor 3A	2	Unknown status	https://clinicaltrials.gov/study/NCT02234466
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE4D	phosphodiesterase 4D	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT06186700,https://clinicaltrials.gov/study/NCT06176339
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT02978495
MONDO_0007254	breast cancer	CHEMBL1201167	CARVEDILOL PHOSPHATE	Small molecule	Adrenergic receptor alpha-1 antagonist		ADRA1D	adrenoceptor alpha 1D	2	Completed	https://clinicaltrials.gov/study/NCT01009918
EFO_1000984	inflammatory breast carcinoma	CHEMBL1567	SUNITINIB MALATE	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT00513695
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967,https://clinicaltrials.gov/study/NCT06026657
MONDO_0007254	breast cancer	CHEMBL2107818	ALDOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Withdrawn	https://clinicaltrials.gov/study/NCT03554109
MONDO_0007254	breast cancer	CHEMBL939	GEFITINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Withdrawn	https://clinicaltrials.gov/study/NCT00252811
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4	NDUFA4 mitochondrial complex associated	2	Completed	https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT00930579
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT00321633
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04001829,https://clinicaltrials.gov/study/NCT02568839
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Unknown status	https://clinicaltrials.gov/study/NCT00250874,https://clinicaltrials.gov/study/NCT01907529,https://clinicaltrials.gov/study/NCT00398489,https://clinicaltrials.gov/study/NCT03147963,https://clinicaltrials.gov/study/NCT00957125,https://clinicaltrials.gov/study/NCT01526499,https://clinicaltrials.gov/study/NCT00721747,https://clinicaltrials.gov/study/NCT00012311,https://clinicaltrials.gov/study/NCT00033683,https://clinicaltrials.gov/study/NCT01351597,https://clinicaltrials.gov/study/NCT00026078,https://clinicaltrials.gov/study/NCT03876587,https://clinicaltrials.gov/study/NCT00003066,https://clinicaltrials.gov/study/NCT01939054,https://clinicaltrials.gov/study/NCT00669773,https://clinicaltrials.gov/study/NCT00801411,https://clinicaltrials.gov/study/NCT02144194,https://clinicaltrials.gov/study/NCT02947061,https://clinicaltrials.gov/study/NCT02685657,https://clinicaltrials.gov/study/NCT00006120,https://clinicaltrials.gov/study/NCT00994968,https://clinicaltrials.gov/study/NCT01270373,https://clinicaltrials.gov/study/NCT01352494
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS4	NADH:ubiquinone oxidoreductase subunit S4	2	Completed	https://clinicaltrials.gov/study/NCT01885013
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT01091428,https://clinicaltrials.gov/study/NCT00542451
EFO_0000305	breast carcinoma	CHEMBL3218576	COPANLISIB	Small molecule	PI3-kinase p110-delta subunit inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	2	Withdrawn	https://clinicaltrials.gov/study/NCT03803761
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT05809895,https://clinicaltrials.gov/study/NCT00005614
EFO_0005537	triple-negative breast cancer	CHEMBL3545132	MIRVETUXIMAB SORAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT03106077
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	2	Recruiting	https://clinicaltrials.gov/study/NCT06245889,https://clinicaltrials.gov/study/NCT03025035,https://clinicaltrials.gov/study/NCT05498155,https://clinicaltrials.gov/study/NCT03182634,https://clinicaltrials.gov/study/NCT03150576,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT06298084,https://clinicaltrials.gov/study/NCT05174832,https://clinicaltrials.gov/study/NCT05629429,https://clinicaltrials.gov/study/NCT05033756,https://clinicaltrials.gov/study/NCT05332561,https://clinicaltrials.gov/study/NCT05203445
EFO_0006861	male breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT00077376
EFO_0006861	male breast carcinoma	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase B-raf inhibitor		BRAF	B-Raf proto-oncogene, serine/threonine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00096434
MONDO_0007254	breast cancer	CHEMBL3644587	2X-121	Small molecule	Tankyrase 1/2 inhibitor		TNKS	tankyrase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03562832
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT05181462,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT05601440,https://clinicaltrials.gov/study/NCT06102824,https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT06026657,https://clinicaltrials.gov/study/NCT04739670
MONDO_0007254	breast cancer	CHEMBL4297736	PRALUZATAMAB RAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT04596150
MONDO_0007254	breast cancer	CHEMBL226267	ARZOXIFENE	Small molecule	Estrogen receptor modulator		ESR2	estrogen receptor 2	2	Completed	https://clinicaltrials.gov/study/NCT00253539,https://clinicaltrials.gov/study/NCT00003428,https://clinicaltrials.gov/study/NCT00005879
MONDO_0007254	breast cancer	CHEMBL1921976	ORTERONEL	Small molecule	Cytochrome P450 17A1 inhibitor		CYP17A1	cytochrome P450 family 17 subfamily A member 1	2	Completed	https://clinicaltrials.gov/study/NCT01990209
EFO_0000305	breast carcinoma	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06179303
MONDO_0007254	breast cancer	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT00012311,https://clinicaltrials.gov/study/NCT00777673
MONDO_0007254	breast cancer	CHEMBL1976040	ADAVOSERTIB	Small molecule	Serine/threonine-protein kinase WEE1 inhibitor		WEE1	WEE1 G2 checkpoint kinase	2	Completed	https://clinicaltrials.gov/study/NCT03012477
MONDO_0007254	breast cancer	CHEMBL185	FLUOROURACIL	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03387085
MONDO_0007254	breast cancer	CHEMBL502835	NINTEDANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Terminated	https://clinicaltrials.gov/study/NCT02389764
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Withdrawn	https://clinicaltrials.gov/study/NCT00615524
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Terminated	https://clinicaltrials.gov/study/NCT00049660,https://clinicaltrials.gov/study/NCT03358004,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT00088985,https://clinicaltrials.gov/study/NCT00194792,https://clinicaltrials.gov/study/NCT00476827
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03202316,https://clinicaltrials.gov/study/NCT05041101
EFO_0000305	breast carcinoma	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR2	estrogen receptor 2	2	Terminated	https://clinicaltrials.gov/study/NCT00183963
EFO_0005537	triple-negative breast cancer	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Completed	https://clinicaltrials.gov/study/NCT02413320,https://clinicaltrials.gov/study/NCT02648477,https://clinicaltrials.gov/study/NCT02456857,https://clinicaltrials.gov/study/NCT01818063
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04345913
EFO_0000305	breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967
EFO_0005537	triple-negative breast cancer	CHEMBL4297892	ANVATABART OPADOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBA1B	tubulin alpha 1b	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0006861	male breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00095888
MONDO_0007254	breast cancer	CHEMBL1091644	LINSITINIB	Small molecule	Insulin receptor inhibitor		INSR	insulin receptor	2	Withdrawn	https://clinicaltrials.gov/study/NCT01013506
MONDO_0007254	breast cancer	CHEMBL4303201	CATEQUENTINIB	Small molecule	Vascular endothelial growth factor receptor 3 inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04975451
EFO_0006861	male breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Unknown status	https://clinicaltrials.gov/study/NCT01372579
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02654119
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND5	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	2	Completed	https://clinicaltrials.gov/study/NCT00684983
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT00662129,https://clinicaltrials.gov/study/NCT00003540,https://clinicaltrials.gov/study/NCT00002998,https://clinicaltrials.gov/study/NCT00005991,https://clinicaltrials.gov/study/NCT00006007,https://clinicaltrials.gov/study/NCT00059852
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB3	NADH:ubiquinone oxidoreductase subunit B3	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND5	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_1000984	inflammatory breast carcinoma	CHEMBL1567	SUNITINIB MALATE	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	2	Completed	https://clinicaltrials.gov/study/NCT00513695
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT00265733,https://clinicaltrials.gov/study/NCT00148707
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA3	NADH:ubiquinone oxidoreductase subunit A3	2	Unknown status	https://clinicaltrials.gov/study/NCT02506777,https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT02506790
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV1	NADH:ubiquinone oxidoreductase core subunit V1	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND1	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1	2	Terminated	https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT01627067
MONDO_0007254	breast cancer	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC6	histone deacetylase 6	2	Completed	https://clinicaltrials.gov/study/NCT00098397
EFO_1000984	inflammatory breast carcinoma	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02411656
MONDO_0007254	breast cancer	CHEMBL3545262	SACITUZUMAB GOVITECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05520723,https://clinicaltrials.gov/study/NCT04448886,https://clinicaltrials.gov/study/NCT05113966,https://clinicaltrials.gov/study/NCT04434040
MONDO_0007254	breast cancer	CHEMBL4297584	TENALISIB	Small molecule	PI3-kinase p110-delta subunit inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	2	Recruiting	https://clinicaltrials.gov/study/NCT06189209
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS5	NADH:ubiquinone oxidoreductase subunit S5	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA1	NADH:ubiquinone oxidoreductase subunit A1	2	Unknown status	https://clinicaltrials.gov/study/NCT02506777,https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT03192293
MONDO_0007254	breast cancer	CHEMBL3137318	TALAZOPARIB TOSYLATE	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT04756765
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
MONDO_0007254	breast cancer	CHEMBL25	ASPIRIN	Small molecule	Cyclooxygenase inhibitor		PTGS2	prostaglandin-endoperoxide synthase 2	2	Withdrawn	https://clinicaltrials.gov/study/NCT04038489,https://clinicaltrials.gov/study/NCT03794596
EFO_0005537	triple-negative breast cancer	CHEMBL3545068	COPANLISIB HYDROCHLORIDE	Small molecule	PI3-kinase p110-delta subunit inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04345913
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT01908101
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Recruiting	https://clinicaltrials.gov/study/NCT04266249
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT00020176,https://clinicaltrials.gov/study/NCT01105650,https://clinicaltrials.gov/study/NCT00429572
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00074269,https://clinicaltrials.gov/study/NCT00376805
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04143906,https://clinicaltrials.gov/study/NCT05263882,https://clinicaltrials.gov/study/NCT04517292
EFO_0000553	invasive lobular carcinoma	CHEMBL1201247	GOSERELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT04551495
EFO_0005537	triple-negative breast cancer	CHEMBL1079175	MK-2206	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT2	AKT serine/threonine kinase 2	2	Terminated	https://clinicaltrials.gov/study/NCT01319539
EFO_0006861	male breast carcinoma	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT00017394
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA8	EPH receptor A8	2	Terminated	https://clinicaltrials.gov/study/NCT00481845,https://clinicaltrials.gov/study/NCT01934335,https://clinicaltrials.gov/study/NCT00752986
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	Bcr/Abl fusion protein		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01471106
MONDO_0007254	breast cancer	CHEMBL2220486	LUCITANIB	Small molecule	Fibroblast growth factor receptor 1 inhibitor		FGFR1	fibroblast growth factor receptor 1	2	Completed	https://clinicaltrials.gov/study/NCT02053636
MONDO_0007254	breast cancer	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Terminated	https://clinicaltrials.gov/study/NCT00722072,https://clinicaltrials.gov/study/NCT00622466,https://clinicaltrials.gov/study/NCT00573755
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT00431704,https://clinicaltrials.gov/study/NCT03414658,https://clinicaltrials.gov/study/NCT04262804
EFO_0005537	triple-negative breast cancer	CHEMBL3813873	PEXIDARTINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4	2	Unknown status	https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT02506777,https://clinicaltrials.gov/study/NCT03192293
MONDO_0007254	breast cancer	CHEMBL231616	TRIAPINE	Small molecule	Ribonucleotide reductase inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Terminated	https://clinicaltrials.gov/study/NCT00095888
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Recruiting	https://clinicaltrials.gov/study/NCT04877821,https://clinicaltrials.gov/study/NCT03150576,https://clinicaltrials.gov/study/NCT05633914,https://clinicaltrials.gov/study/NCT05346107,https://clinicaltrials.gov/study/NCT04780347,https://clinicaltrials.gov/study/NCT04893109,https://clinicaltrials.gov/study/NCT01817452,https://clinicaltrials.gov/study/NCT05325632,https://clinicaltrials.gov/study/NCT04090398,https://clinicaltrials.gov/study/NCT03412643,https://clinicaltrials.gov/study/NCT05852691,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT04425018,https://clinicaltrials.gov/study/NCT04771871,https://clinicaltrials.gov/study/NCT04722718,https://clinicaltrials.gov/study/NCT04243616,https://clinicaltrials.gov/study/NCT05353361,https://clinicaltrials.gov/study/NCT04329065,https://clinicaltrials.gov/study/NCT04872985,https://clinicaltrials.gov/study/NCT05582538,https://clinicaltrials.gov/study/NCT05659056,https://clinicaltrials.gov/study/NCT05900206,https://clinicaltrials.gov/study/NCT05020860,https://clinicaltrials.gov/study/NCT04676997,https://clinicaltrials.gov/study/NCT05761470,https://clinicaltrials.gov/study/NCT05749016,https://clinicaltrials.gov/study/NCT04443348,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT05681728,https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT05728268,https://clinicaltrials.gov/study/NCT05889390,https://clinicaltrials.gov/study/NCT04576143,https://clinicaltrials.gov/study/NCT04355858,https://clinicaltrials.gov/study/NCT04537286,https://clinicaltrials.gov/study/NCT06245889,https://clinicaltrials.gov/study/NCT04159142,https://clinicaltrials.gov/study/NCT05068141,https://clinicaltrials.gov/study/NCT05383196,https://clinicaltrials.gov/study/NCT03907800,https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT05749575,https://clinicaltrials.gov/study/NCT05174832,https://clinicaltrials.gov/study/NCT05447702,https://clinicaltrials.gov/study/NCT03048942,https://clinicaltrials.gov/study/NCT05189067,https://clinicaltrials.gov/study/NCT05918328,https://clinicaltrials.gov/study/NCT04917900,https://clinicaltrials.gov/study/NCT05629429,https://clinicaltrials.gov/study/NCT03571633
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA13	NADH:ubiquinone oxidoreductase subunit A13	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND1	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1	2	Completed	https://clinicaltrials.gov/study/NCT01885013
EFO_0000305	breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Recruiting	https://clinicaltrials.gov/study/NCT06026657,https://clinicaltrials.gov/study/NCT03606967
EFO_0000305	breast carcinoma	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	2	Recruiting	https://clinicaltrials.gov/study/NCT06298084,https://clinicaltrials.gov/study/NCT03598257,https://clinicaltrials.gov/study/NCT04090567
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
EFO_0005537	triple-negative breast cancer	CHEMBL1079175	MK-2206	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT3	AKT serine/threonine kinase 3	2	Terminated	https://clinicaltrials.gov/study/NCT01319539
MONDO_0007254	breast cancer	CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist		IFNAR2	interferon alpha and beta receptor subunit 2	2	Enrolling by invitation	https://clinicaltrials.gov/study/NCT03328026
MONDO_0007254	breast cancer	CHEMBL1230609	FORETINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01138384,https://clinicaltrials.gov/study/NCT01147484
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01730833,https://clinicaltrials.gov/study/NCT02876302
EFO_0006861	male breast carcinoma	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Completed	https://clinicaltrials.gov/study/NCT00513695,https://clinicaltrials.gov/study/NCT00119262
EFO_0006861	male breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Terminated	https://clinicaltrials.gov/study/NCT00095888
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Terminated	https://clinicaltrials.gov/study/NCT00790894,https://clinicaltrials.gov/study/NCT00765765,https://clinicaltrials.gov/study/NCT00079326
MONDO_0007254	breast cancer	CHEMBL1922094	APITOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	2	Completed	https://clinicaltrials.gov/study/NCT01437566
EFO_1000984	inflammatory breast carcinoma	CHEMBL1738758	ONVANSERTIB	Small molecule	Serine/threonine-protein kinase PLK1 inhibitor		PLK1	polo like kinase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05383196
MONDO_0007254	breast cancer	CHEMBL3264002	AVUTOMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 1 inhibitor		MAP2K1	mitogen-activated protein kinase kinase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05608252
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		SRC	SRC proto-oncogene, non-receptor tyrosine kinase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01471106
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS8	NADH:ubiquinone oxidoreductase core subunit S8	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0006861	male breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Terminated	https://clinicaltrials.gov/study/NCT00095888
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT00020176,https://clinicaltrials.gov/study/NCT01105650,https://clinicaltrials.gov/study/NCT00429572
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT02199418
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB9	NADH:ubiquinone oxidoreductase subunit B9	2	Completed	https://clinicaltrials.gov/study/NCT01885013
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT01091428,https://clinicaltrials.gov/study/NCT00542451
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	2	Withdrawn	https://clinicaltrials.gov/study/NCT04220476,https://clinicaltrials.gov/study/NCT03377101
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Withdrawn	https://clinicaltrials.gov/study/NCT05177796,https://clinicaltrials.gov/study/NCT05233696
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA11	NADH:ubiquinone oxidoreductase subunit A11	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
MONDO_0007254	breast cancer	CHEMBL180022	NERATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-4 inhibitor		ERBB4	erb-b2 receptor tyrosine kinase 4	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05154396
MONDO_0007254	breast cancer	CHEMBL482968	ENMD-2076	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Completed	https://clinicaltrials.gov/study/NCT01639248
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
EFO_0000305	breast carcinoma	CHEMBL2109637	HUHMFG1	Antibody	Mucin-1 other		MUC1	mucin 1, cell surface associated	2	Terminated	https://clinicaltrials.gov/study/NCT00770354
EFO_0000432	breast ductal carcinoma in situ	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Terminated	https://clinicaltrials.gov/study/NCT00461344
EFO_0005537	triple-negative breast cancer	CHEMBL5095033	IBCASERTIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT05336721
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Withdrawn	https://clinicaltrials.gov/study/NCT01410708
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		LCK	LCK proto-oncogene, Src family tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT00817531,https://clinicaltrials.gov/study/NCT00780676,https://clinicaltrials.gov/study/NCT05198843
EFO_0000305	breast carcinoma	CHEMBL113	CAFFEINE	Small molecule	Adenosine receptor antagonist		ADORA2A	adenosine A2a receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03768492
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Recruiting	https://clinicaltrials.gov/study/NCT04266249,https://clinicaltrials.gov/study/NCT06042569,https://clinicaltrials.gov/study/NCT05319873
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Tyrosine-protein kinase TIE-2 inhibitor		TEK	TEK receptor tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT01934335,https://clinicaltrials.gov/study/NCT00481845,https://clinicaltrials.gov/study/NCT00752986
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA9	NADH:ubiquinone oxidoreductase subunit A9	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0005537	triple-negative breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0000305	breast carcinoma	CHEMBL113	CAFFEINE	Small molecule	Adenosine receptor antagonist		ADORA2B	adenosine A2b receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03768492
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Completed	https://clinicaltrials.gov/study/NCT00201760,https://clinicaltrials.gov/study/NCT00059852,https://clinicaltrials.gov/study/NCT02435680,https://clinicaltrials.gov/study/NCT00601159,https://clinicaltrials.gov/study/NCT00128856,https://clinicaltrials.gov/study/NCT00334802,https://clinicaltrials.gov/study/NCT00894504,https://clinicaltrials.gov/study/NCT00191854,https://clinicaltrials.gov/study/NCT00813956,https://clinicaltrials.gov/study/NCT00191243,https://clinicaltrials.gov/study/NCT00191373,https://clinicaltrials.gov/study/NCT00532623,https://clinicaltrials.gov/study/NCT00316199,https://clinicaltrials.gov/study/NCT00618826,https://clinicaltrials.gov/study/NCT01201265,https://clinicaltrials.gov/study/NCT03025880,https://clinicaltrials.gov/study/NCT00480597,https://clinicaltrials.gov/study/NCT02263495,https://clinicaltrials.gov/study/NCT00695994,https://clinicaltrials.gov/study/NCT00191269,https://clinicaltrials.gov/study/NCT00532857,https://clinicaltrials.gov/study/NCT00191815,https://clinicaltrials.gov/study/NCT01045304,https://clinicaltrials.gov/study/NCT00193050,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00378313,https://clinicaltrials.gov/study/NCT00754351,https://clinicaltrials.gov/study/NCT00244933,https://clinicaltrials.gov/study/NCT00193063,https://clinicaltrials.gov/study/NCT00063570,https://clinicaltrials.gov/study/NCT00212069,https://clinicaltrials.gov/study/NCT00191451,https://clinicaltrials.gov/study/NCT00002998,https://clinicaltrials.gov/study/NCT00191789,https://clinicaltrials.gov/study/NCT00662129,https://clinicaltrials.gov/study/NCT00005991,https://clinicaltrials.gov/study/NCT00503906,https://clinicaltrials.gov/study/NCT00623233,https://clinicaltrials.gov/study/NCT00003540,https://clinicaltrials.gov/study/NCT04464174,https://clinicaltrials.gov/study/NCT00403130,https://clinicaltrials.gov/study/NCT01550848,https://clinicaltrials.gov/study/NCT00540358,https://clinicaltrials.gov/study/NCT00846027,https://clinicaltrials.gov/study/NCT00193206,https://clinicaltrials.gov/study/NCT00110084,https://clinicaltrials.gov/study/NCT00450762,https://clinicaltrials.gov/study/NCT00193076,https://clinicaltrials.gov/study/NCT00320541,https://clinicaltrials.gov/study/NCT00191347,https://clinicaltrials.gov/study/NCT00006007,https://clinicaltrials.gov/study/NCT00493636,https://clinicaltrials.gov/study/NCT00192062,https://clinicaltrials.gov/study/NCT00325234,https://clinicaltrials.gov/study/NCT00192101
MONDO_0007254	breast cancer	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	2	Suspended	https://clinicaltrials.gov/study/NCT02897050
EFO_0005537	triple-negative breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967
MONDO_0007254	breast cancer	CHEMBL94657	PATUPILONE	Small molecule	Tubulin stabiliser		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT00450866
EFO_1000307	Invasive Breast Carcinoma	CHEMBL3707227	ATEZOLIZUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor	Inhibitor	CD274	CD274 molecule	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03206203
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT00482755,https://clinicaltrials.gov/study/NCT00662025,https://clinicaltrials.gov/study/NCT00270413
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Unknown status	https://clinicaltrials.gov/study/NCT01907529,https://clinicaltrials.gov/study/NCT03876587,https://clinicaltrials.gov/study/NCT00003066,https://clinicaltrials.gov/study/NCT03147963,https://clinicaltrials.gov/study/NCT01939054,https://clinicaltrials.gov/study/NCT00026078,https://clinicaltrials.gov/study/NCT00006120,https://clinicaltrials.gov/study/NCT00957125,https://clinicaltrials.gov/study/NCT00801411,https://clinicaltrials.gov/study/NCT01526499,https://clinicaltrials.gov/study/NCT00669773,https://clinicaltrials.gov/study/NCT01352494,https://clinicaltrials.gov/study/NCT00033683,https://clinicaltrials.gov/study/NCT00398489,https://clinicaltrials.gov/study/NCT01351597,https://clinicaltrials.gov/study/NCT00994968,https://clinicaltrials.gov/study/NCT01270373,https://clinicaltrials.gov/study/NCT02685657,https://clinicaltrials.gov/study/NCT02144194,https://clinicaltrials.gov/study/NCT00721747,https://clinicaltrials.gov/study/NCT00250874,https://clinicaltrials.gov/study/NCT02947061,https://clinicaltrials.gov/study/NCT00012311
MONDO_0007254	breast cancer	CHEMBL1504	TRIAMCINOLONE ACETONIDE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05190770
MONDO_0007254	breast cancer	CHEMBL2325741	CAPIVASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT3	AKT serine/threonine kinase 3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT02208375
EFO_0005537	triple-negative breast cancer	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Completed	https://clinicaltrials.gov/study/NCT03106415,https://clinicaltrials.gov/study/NCT02971761,https://clinicaltrials.gov/study/NCT02648477
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06078384
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA10	NADH:ubiquinone oxidoreductase subunit A10	2	Unknown status	https://clinicaltrials.gov/study/NCT02506777,https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT03192293
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAB1	NADH:ubiquinone oxidoreductase subunit AB1	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04517292,https://clinicaltrials.gov/study/NCT05263882,https://clinicaltrials.gov/study/NCT04913571,https://clinicaltrials.gov/study/NCT04502680,https://clinicaltrials.gov/study/NCT06202313,https://clinicaltrials.gov/study/NCT06308939
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA11	NADH:ubiquinone oxidoreductase subunit A11	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02624973,https://clinicaltrials.gov/study/NCT04172259,https://clinicaltrials.gov/study/NCT01779206,https://clinicaltrials.gov/study/NCT03609047,https://clinicaltrials.gov/study/NCT00496795,https://clinicaltrials.gov/study/NCT00295893,https://clinicaltrials.gov/study/NCT02547987,https://clinicaltrials.gov/study/NCT03161353,https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT02339532,https://clinicaltrials.gov/study/NCT02568839
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Terminated	https://clinicaltrials.gov/study/NCT00832338
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT00006261
MONDO_0007254	breast cancer	CHEMBL4298178	TRASTUZUMAB DUOCARMAZINE	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 binding agent		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT04983238
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01881230
MONDO_0007254	breast cancer	CHEMBL1200694	SEVOFLURANE	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRG2	gamma-aminobutyric acid type A receptor subunit gamma2	2	Completed	https://clinicaltrials.gov/study/NCT02839668
MONDO_0007254	breast cancer	CHEMBL4297584	TENALISIB	Small molecule	PI3-kinase p110-gamma subunit inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	2	Recruiting	https://clinicaltrials.gov/study/NCT06189209
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Withdrawn	https://clinicaltrials.gov/study/NCT05177796
MONDO_0007254	breast cancer	CHEMBL489	AFIMOXIFENE	Small molecule	Estrogen-related receptor gamma antagonist		ESRRG	estrogen related receptor gamma	2	Completed	https://clinicaltrials.gov/study/NCT03931928
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA9	NADH:ubiquinone oxidoreductase subunit A9	2	Terminated	https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT02472353
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE8A	phosphodiesterase 8A	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT06186700,https://clinicaltrials.gov/study/NCT06176339
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT03742986,https://clinicaltrials.gov/study/NCT00217672,https://clinicaltrials.gov/study/NCT00079118,https://clinicaltrials.gov/study/NCT01792050,https://clinicaltrials.gov/study/NCT00015938,https://clinicaltrials.gov/study/NCT00645866,https://clinicaltrials.gov/study/NCT00214864,https://clinicaltrials.gov/study/NCT01485926,https://clinicaltrials.gov/study/NCT00148668,https://clinicaltrials.gov/study/NCT00206518,https://clinicaltrials.gov/study/NCT00039520,https://clinicaltrials.gov/study/NCT00712881,https://clinicaltrials.gov/study/NCT02005549,https://clinicaltrials.gov/study/NCT00604435,https://clinicaltrials.gov/study/NCT00088998,https://clinicaltrials.gov/study/NCT00066443,https://clinicaltrials.gov/study/NCT00206466,https://clinicaltrials.gov/study/NCT00247481,https://clinicaltrials.gov/study/NCT00004888,https://clinicaltrials.gov/study/NCT00232479,https://clinicaltrials.gov/study/NCT00494481,https://clinicaltrials.gov/study/NCT02846428,https://clinicaltrials.gov/study/NCT00005800,https://clinicaltrials.gov/study/NCT00490646,https://clinicaltrials.gov/study/NCT02365805,https://clinicaltrials.gov/study/NCT00524810,https://clinicaltrials.gov/study/NCT00319618,https://clinicaltrials.gov/study/NCT00004906,https://clinicaltrials.gov/study/NCT00054275,https://clinicaltrials.gov/study/NCT00198237,https://clinicaltrials.gov/study/NCT00179309,https://clinicaltrials.gov/study/NCT00003565,https://clinicaltrials.gov/study/NCT00193089,https://clinicaltrials.gov/study/NCT00428922,https://clinicaltrials.gov/study/NCT00149214,https://clinicaltrials.gov/study/NCT00123929,https://clinicaltrials.gov/study/NCT00193180,https://clinicaltrials.gov/study/NCT00976989,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT02229084,https://clinicaltrials.gov/study/NCT01367028,https://clinicaltrials.gov/study/NCT01142778,https://clinicaltrials.gov/study/NCT03140553,https://clinicaltrials.gov/study/NCT00191243,https://clinicaltrials.gov/study/NCT00005963,https://clinicaltrials.gov/study/NCT01540110,https://clinicaltrials.gov/study/NCT00212082,https://clinicaltrials.gov/study/NCT00201708,https://clinicaltrials.gov/study/NCT00545688,https://clinicaltrials.gov/study/NCT02748213,https://clinicaltrials.gov/study/NCT00203502,https://clinicaltrials.gov/study/NCT00365365,https://clinicaltrials.gov/study/NCT00493649,https://clinicaltrials.gov/study/NCT02909751,https://clinicaltrials.gov/study/NCT00464646,https://clinicaltrials.gov/study/NCT00107510,https://clinicaltrials.gov/study/NCT00077857,https://clinicaltrials.gov/study/NCT01150513,https://clinicaltrials.gov/study/NCT00499122,https://clinicaltrials.gov/study/NCT00193037,https://clinicaltrials.gov/study/NCT02838225,https://clinicaltrials.gov/study/NCT00475670,https://clinicaltrials.gov/study/NCT00055861,https://clinicaltrials.gov/study/NCT00027885,https://clinicaltrials.gov/study/NCT00003352,https://clinicaltrials.gov/study/NCT00206505,https://clinicaltrials.gov/study/NCT03735966,https://clinicaltrials.gov/study/NCT01527487,https://clinicaltrials.gov/study/NCT00044993,https://clinicaltrials.gov/study/NCT00148070,https://clinicaltrials.gov/study/NCT00209092,https://clinicaltrials.gov/study/NCT01446016,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT00258375,https://clinicaltrials.gov/study/NCT00193050,https://clinicaltrials.gov/study/NCT00379015,https://clinicaltrials.gov/study/NCT00559754,https://clinicaltrials.gov/study/NCT00155259,https://clinicaltrials.gov/study/NCT00003953,https://clinicaltrials.gov/study/NCT04664972,https://clinicaltrials.gov/study/NCT01038804,https://clinicaltrials.gov/study/NCT00679341,https://clinicaltrials.gov/study/NCT00248703,https://clinicaltrials.gov/study/NCT00754351,https://clinicaltrials.gov/study/NCT02834403,https://clinicaltrials.gov/study/NCT00364611,https://clinicaltrials.gov/study/NCT00820547,https://clinicaltrials.gov/study/NCT01208480,https://clinicaltrials.gov/study/NCT00600249,https://clinicaltrials.gov/study/NCT02132949,https://clinicaltrials.gov/study/NCT00004175,https://clinicaltrials.gov/study/NCT00820872,https://clinicaltrials.gov/study/NCT00015886,https://clinicaltrials.gov/study/NCT00005908,https://clinicaltrials.gov/study/NCT00941330,https://clinicaltrials.gov/study/NCT02137083,https://clinicaltrials.gov/study/NCT01959490,https://clinicaltrials.gov/study/NCT00212095,https://clinicaltrials.gov/study/NCT00041067,https://clinicaltrials.gov/study/NCT00841828,https://clinicaltrials.gov/study/NCT03887130,https://clinicaltrials.gov/study/NCT00129376,https://clinicaltrials.gov/study/NCT00146042,https://clinicaltrials.gov/study/NCT02041351,https://clinicaltrials.gov/study/NCT00028873,https://clinicaltrials.gov/study/NCT00527449,https://clinicaltrials.gov/study/NCT01658462,https://clinicaltrials.gov/study/NCT00695994,https://clinicaltrials.gov/study/NCT00006104,https://clinicaltrials.gov/study/NCT00203372,https://clinicaltrials.gov/study/NCT00068341,https://clinicaltrials.gov/study/NCT00769470,https://clinicaltrials.gov/study/NCT00404066,https://clinicaltrials.gov/study/NCT00365417,https://clinicaltrials.gov/study/NCT00525759,https://clinicaltrials.gov/study/NCT00773695,https://clinicaltrials.gov/study/NCT00274456,https://clinicaltrials.gov/study/NCT01671319,https://clinicaltrials.gov/study/NCT00432172,https://clinicaltrials.gov/study/NCT00193115,https://clinicaltrials.gov/study/NCT01025349,https://clinicaltrials.gov/study/NCT00006682,https://clinicaltrials.gov/study/NCT01396655
MONDO_0007254	breast cancer	CHEMBL4297856	ZIMBERELIMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06238921
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Withdrawn	https://clinicaltrials.gov/study/NCT01229605,https://clinicaltrials.gov/study/NCT01825265,https://clinicaltrials.gov/study/NCT00964704,https://clinicaltrials.gov/study/NCT00678626,https://clinicaltrials.gov/study/NCT00434031,https://clinicaltrials.gov/study/NCT00006261,https://clinicaltrials.gov/study/NCT02067416
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT00321633
EFO_0000305	breast carcinoma	CHEMBL377559	RETASPIMYCIN HYDROCHLORIDE	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AB1	heat shock protein 90 alpha family class B member 1	2	Terminated	https://clinicaltrials.gov/study/NCT00817362
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB2	NADH:ubiquinone oxidoreductase subunit B2	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04001829,https://clinicaltrials.gov/study/NCT02568839
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Recruiting	https://clinicaltrials.gov/study/NCT05583110
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Suspended	https://clinicaltrials.gov/study/NCT02897050,https://clinicaltrials.gov/study/NCT04419181
MONDO_0007254	breast cancer	CHEMBL4297545	LUTETIUM OXODOTREOTIDE LU-177	Protein	Somatostatin receptor binding agent		SSTR5	somatostatin receptor 5	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04529044
MONDO_0007254	breast cancer	CHEMBL3184679	AZD-4547	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR4	fibroblast growth factor receptor 4	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999
EFO_0006318	breast ductal adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Terminated	https://clinicaltrials.gov/study/NCT01891357
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT00119262,https://clinicaltrials.gov/study/NCT03018080,https://clinicaltrials.gov/study/NCT00513695
MONDO_0007254	breast cancer	CHEMBL517712	ATROPINE	Small molecule	Muscarinic acetylcholine receptor M2 antagonist		CHRM2	cholinergic receptor muscarinic 2	2	Completed	https://clinicaltrials.gov/study/NCT02839668
EFO_0005537	triple-negative breast cancer	CHEMBL1201583	BEVACIZUMAB	Antibody	Vascular endothelial growth factor A inhibitor		VEGFA	vascular endothelial growth factor A	2	Recruiting	https://clinicaltrials.gov/study/NCT05192798,https://clinicaltrials.gov/study/NCT06125080
MONDO_0007254	breast cancer	CHEMBL15770	SULINDAC	Small molecule	Cyclooxygenase inhibitor		PTGS2	prostaglandin-endoperoxide synthase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT04542135
MONDO_0007254	breast cancer	CHEMBL1743028	GLEMBATUMUMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT01997333,https://clinicaltrials.gov/study/NCT01156753
MONDO_0007254	breast cancer	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT00301899,https://clinicaltrials.gov/study/NCT02491892,https://clinicaltrials.gov/study/NCT02132949,https://clinicaltrials.gov/study/NCT03644186,https://clinicaltrials.gov/study/NCT01491737,https://clinicaltrials.gov/study/NCT01565083,https://clinicaltrials.gov/study/NCT01597414,https://clinicaltrials.gov/study/NCT01847001,https://clinicaltrials.gov/study/NCT01855828,https://clinicaltrials.gov/study/NCT01276041,https://clinicaltrials.gov/study/NCT00976989,https://clinicaltrials.gov/study/NCT02411344,https://clinicaltrials.gov/study/NCT02789657,https://clinicaltrials.gov/study/NCT01904903,https://clinicaltrials.gov/study/NCT00943670,https://clinicaltrials.gov/study/NCT02909751,https://clinicaltrials.gov/study/NCT03742986,https://clinicaltrials.gov/study/NCT03674112,https://clinicaltrials.gov/study/NCT01835236,https://clinicaltrials.gov/study/NCT02073487,https://clinicaltrials.gov/study/NCT03988036,https://clinicaltrials.gov/study/NCT00545688,https://clinicaltrials.gov/study/NCT01959490,https://clinicaltrials.gov/study/NCT01674062,https://clinicaltrials.gov/study/NCT02536339
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT00148681,https://clinicaltrials.gov/study/NCT00022152,https://clinicaltrials.gov/study/NCT00006682,https://clinicaltrials.gov/study/NCT00266110,https://clinicaltrials.gov/study/NCT00532623,https://clinicaltrials.gov/study/NCT01941771,https://clinicaltrials.gov/study/NCT00148668,https://clinicaltrials.gov/study/NCT00093808,https://clinicaltrials.gov/study/NCT00004237,https://clinicaltrials.gov/study/NCT00194779
MONDO_0007254	breast cancer	CHEMBL637	VENLAFAXINE	Small molecule	Norepinephrine transporter inhibitor		SLC6A2	solute carrier family 6 member 2	2	Completed	https://clinicaltrials.gov/study/NCT00198250
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE6D	phosphodiesterase 6D	2	Recruiting	https://clinicaltrials.gov/study/NCT06087237
MONDO_0007254	breast cancer	CHEMBL553	ERLOTINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Terminated	https://clinicaltrials.gov/study/NCT00739063,https://clinicaltrials.gov/study/NCT00570258,https://clinicaltrials.gov/study/NCT00597597,https://clinicaltrials.gov/study/NCT00611715,https://clinicaltrials.gov/study/NCT01205685
MONDO_0007254	breast cancer	CHEMBL4298178	TRASTUZUMAB DUOCARMAZINE	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 binding agent		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0000305	breast carcinoma	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		LCK	LCK proto-oncogene, Src family tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT05198843
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS1	NADH:ubiquinone oxidoreductase core subunit S1	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND3	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FRK	fyn related Src family tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT00780676,https://clinicaltrials.gov/study/NCT00817531,https://clinicaltrials.gov/study/NCT05198843
MONDO_0007254	breast cancer	CHEMBL522892	DOVITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01528345
MONDO_0007254	breast cancer	CHEMBL4297181	SAMOTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	2	Completed	https://clinicaltrials.gov/study/NCT04032080
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04345913
EFO_0005537	triple-negative breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC9	histone deacetylase 9	2	Terminated	https://clinicaltrials.gov/study/NCT01234532
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA5	NADH:ubiquinone oxidoreductase subunit A5	2	Recruiting	https://clinicaltrials.gov/study/NCT04559308,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04300790
MONDO_0007254	breast cancer	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 3 inhibitor		HDAC3	histone deacetylase 3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT00616967
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB9	NADH:ubiquinone oxidoreductase subunit B9	2	Terminated	https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT02472353
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBB6	tubulin beta 6 class V	2	Withdrawn	https://clinicaltrials.gov/study/NCT01227408
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Terminated	https://clinicaltrials.gov/study/NCT02681523,https://clinicaltrials.gov/study/NCT01912963,https://clinicaltrials.gov/study/NCT02000596,https://clinicaltrials.gov/study/NCT01534455,https://clinicaltrials.gov/study/NCT01498588,https://clinicaltrials.gov/study/NCT03795012
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Withdrawn	https://clinicaltrials.gov/study/NCT03032614
MONDO_0007254	breast cancer	CHEMBL359744	DOXORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Completed	https://clinicaltrials.gov/study/NCT00052351,https://clinicaltrials.gov/study/NCT00007904,https://clinicaltrials.gov/study/NCT00005991,https://clinicaltrials.gov/study/NCT00004237,https://clinicaltrials.gov/study/NCT00712881,https://clinicaltrials.gov/study/NCT00003953,https://clinicaltrials.gov/study/NCT00284336,https://clinicaltrials.gov/study/NCT00002679,https://clinicaltrials.gov/study/NCT00004906,https://clinicaltrials.gov/study/NCT00608972,https://clinicaltrials.gov/study/NCT00004175,https://clinicaltrials.gov/study/NCT00194779,https://clinicaltrials.gov/study/NCT00005908,https://clinicaltrials.gov/study/NCT00049114,https://clinicaltrials.gov/study/NCT00006110,https://clinicaltrials.gov/study/NCT00482391,https://clinicaltrials.gov/study/NCT00004092,https://clinicaltrials.gov/study/NCT00128856,https://clinicaltrials.gov/study/NCT00004888,https://clinicaltrials.gov/study/NCT00005980,https://clinicaltrials.gov/study/NCT00027885,https://clinicaltrials.gov/study/NCT00003035,https://clinicaltrials.gov/study/NCT00044993,https://clinicaltrials.gov/study/NCT00499083,https://clinicaltrials.gov/study/NCT00407888,https://clinicaltrials.gov/study/NCT00436566,https://clinicaltrials.gov/study/NCT00960336,https://clinicaltrials.gov/study/NCT00003992,https://clinicaltrials.gov/study/NCT00856492,https://clinicaltrials.gov/study/NCT00003050
MONDO_0007254	breast cancer	CHEMBL1200694	SEVOFLURANE	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRA1	gamma-aminobutyric acid type A receptor subunit alpha1	2	Completed	https://clinicaltrials.gov/study/NCT02839668
MONDO_0007254	breast cancer	CHEMBL4297522	PEMIGATINIB	Small molecule	Fibroblast growth factor receptor 2 inhibitor		FGFR2	fibroblast growth factor receptor 2	2	Recruiting	https://clinicaltrials.gov/study/NCT05560334
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBA1C	tubulin alpha 1c	2	Withdrawn	https://clinicaltrials.gov/study/NCT00450515
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT00943670,https://clinicaltrials.gov/study/NCT01196052,https://clinicaltrials.gov/study/NCT00679341,https://clinicaltrials.gov/study/NCT03530696,https://clinicaltrials.gov/study/NCT02924883,https://clinicaltrials.gov/study/NCT01904903,https://clinicaltrials.gov/study/NCT01835236,https://clinicaltrials.gov/study/NCT02073487,https://clinicaltrials.gov/study/NCT00679211,https://clinicaltrials.gov/study/NCT00509769
MONDO_0007254	breast cancer	CHEMBL359744	DOXORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Terminated	https://clinicaltrials.gov/study/NCT01147016,https://clinicaltrials.gov/study/NCT00589238,https://clinicaltrials.gov/study/NCT00679029,https://clinicaltrials.gov/study/NCT00448266,https://clinicaltrials.gov/study/NCT00524459,https://clinicaltrials.gov/study/NCT00665457
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Unknown status	https://clinicaltrials.gov/study/NCT01647672,https://clinicaltrials.gov/study/NCT00499603,https://clinicaltrials.gov/study/NCT01321775,https://clinicaltrials.gov/study/NCT02041338,https://clinicaltrials.gov/study/NCT00777673,https://clinicaltrials.gov/study/NCT01309607,https://clinicaltrials.gov/study/NCT03735082,https://clinicaltrials.gov/study/NCT01276769,https://clinicaltrials.gov/study/NCT03348098,https://clinicaltrials.gov/study/NCT00533936,https://clinicaltrials.gov/study/NCT01625429,https://clinicaltrials.gov/study/NCT02230319,https://clinicaltrials.gov/study/NCT02423603,https://clinicaltrials.gov/study/NCT02059876,https://clinicaltrials.gov/study/NCT01428414,https://clinicaltrials.gov/study/NCT01830244,https://clinicaltrials.gov/study/NCT00006120,https://clinicaltrials.gov/study/NCT03429972,https://clinicaltrials.gov/study/NCT02694224,https://clinicaltrials.gov/study/NCT00499525,https://clinicaltrials.gov/study/NCT00404404,https://clinicaltrials.gov/study/NCT00154882
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS1	NADH:ubiquinone oxidoreductase core subunit S1	2	Terminated	https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT02360059
MONDO_0007254	breast cancer	CHEMBL2107881	REGRAMOSTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	2	Completed	https://clinicaltrials.gov/study/NCT00524277
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Unknown status	https://clinicaltrials.gov/study/NCT00159094,https://clinicaltrials.gov/study/NCT01730677,https://clinicaltrials.gov/study/NCT01528826,https://clinicaltrials.gov/study/NCT02544243,https://clinicaltrials.gov/study/NCT03423849,https://clinicaltrials.gov/study/NCT02607215,https://clinicaltrials.gov/study/NCT02768415,https://clinicaltrials.gov/study/NCT02144194
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Recruiting	https://clinicaltrials.gov/study/NCT04266249
EFO_0006861	male breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00095888
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS1	NADH:ubiquinone oxidoreductase core subunit S1	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01881230
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA13	NADH:ubiquinone oxidoreductase subunit A13	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor		GPD2	glycerol-3-phosphate dehydrogenase 2	2	Terminated	https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT01477060
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHB1	EPH receptor B1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999
EFO_0005537	triple-negative breast cancer	CHEMBL4298101	LADIRATUZUMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Unknown status	https://clinicaltrials.gov/study/NCT01372579
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Completed	https://clinicaltrials.gov/study/NCT00101400,https://clinicaltrials.gov/study/NCT01320111,https://clinicaltrials.gov/study/NCT00493636,https://clinicaltrials.gov/study/NCT00548899,https://clinicaltrials.gov/study/NCT00634634
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA9	NADH:ubiquinone oxidoreductase subunit A9	2	Unknown status	https://clinicaltrials.gov/study/NCT02506777,https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT03192293
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Unknown status	https://clinicaltrials.gov/study/NCT03412955
MONDO_0007254	breast cancer	CHEMBL3894860	TRILACICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	2	Completed	https://clinicaltrials.gov/study/NCT05112536
MONDO_0007254	breast cancer	CHEMBL4297545	LUTETIUM OXODOTREOTIDE LU-177	Protein	Somatostatin receptor binding agent		SSTR3	somatostatin receptor 3	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04529044
MONDO_0007254	breast cancer	CHEMBL522892	DOVITINIB	Small molecule	Fibroblast growth factor receptor 3 inhibitor		FGFR3	fibroblast growth factor receptor 3	2	Completed	https://clinicaltrials.gov/study/NCT00958971,https://clinicaltrials.gov/study/NCT01262027
MONDO_0007254	breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Recruiting	https://clinicaltrials.gov/study/NCT04355858
MONDO_0007254	breast cancer	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00509587
MONDO_0007254	breast cancer	CHEMBL679	EPINEPHRINE	Small molecule	Adrenergic receptor agonist		ADRA2C	adrenoceptor alpha 2C	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04603911
MONDO_0007254	breast cancer	CHEMBL522892	DOVITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Terminated	https://clinicaltrials.gov/study/NCT01528345
MONDO_0007254	breast cancer	CHEMBL3264610	SEVITERONEL	Small molecule	Cytochrome P450 17A1 inhibitor		CYP17A1	cytochrome P450 family 17 subfamily A member 1	2	Recruiting	https://clinicaltrials.gov/study/NCT04947189
EFO_0005537	triple-negative breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		YES1	YES proto-oncogene 1, Src family tyrosine kinase	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06355037
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02208375
MONDO_0007254	breast cancer	CHEMBL1770916	NIROGACESTAT	Small molecule	Gamma-secretase inhibitor		APH1B	aph-1 homolog B, gamma-secretase subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT02338531
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Tyrosine-protein kinase SRC inhibitor		SRC	SRC proto-oncogene, non-receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00494481
MONDO_0007254	breast cancer	CHEMBL4298124	DOSTARLIMAB	Antibody	Programmed cell death protein 1 antagonist		PDCD1	programmed cell death 1	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04837209
MONDO_0007254	breast cancer	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	2	Completed	https://clinicaltrials.gov/study/NCT03248427,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT03477396,https://clinicaltrials.gov/study/NCT03613220,https://clinicaltrials.gov/study/NCT03555877,https://clinicaltrials.gov/study/NCT03078751
EFO_0000305	breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
MONDO_0007254	breast cancer	CHEMBL2304041	SAGOPILONE	Small molecule	Tubulin stabiliser		TUBA3E	tubulin alpha 3e	2	Completed	https://clinicaltrials.gov/study/NCT00288249
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Terminated	https://clinicaltrials.gov/study/NCT00176488,https://clinicaltrials.gov/study/NCT00088985,https://clinicaltrials.gov/study/NCT00130507,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT00694200,https://clinicaltrials.gov/study/NCT02585388,https://clinicaltrials.gov/study/NCT00453635,https://clinicaltrials.gov/study/NCT00169104,https://clinicaltrials.gov/study/NCT03358004,https://clinicaltrials.gov/study/NCT02213744,https://clinicaltrials.gov/study/NCT01185509,https://clinicaltrials.gov/study/NCT01161368,https://clinicaltrials.gov/study/NCT00754702,https://clinicaltrials.gov/study/NCT00049660,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT00194792
EFO_0006861	male breast carcinoma	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT00096434
EFO_0000305	breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Tyrosine-protein kinase ITK/TSK inhibitor		ITK	IL2 inducible T cell kinase	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
EFO_0000305	breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Fibroblast growth factor receptor 1 inhibitor		FGFR1	fibroblast growth factor receptor 1	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
EFO_0000432	breast ductal carcinoma in situ	CHEMBL489	AFIMOXIFENE	Small molecule	Estrogen-related receptor gamma antagonist		ESRRG	estrogen related receptor gamma	2	Completed	https://clinicaltrials.gov/study/NCT00952731
EFO_1000307	Invasive Breast Carcinoma	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	2	Recruiting	https://clinicaltrials.gov/study/NCT05693766
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL2325741	CAPIVASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT2	AKT serine/threonine kinase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02208375
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05833919
MONDO_0007254	breast cancer	CHEMBL491473	CEDIRANIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00454805
MONDO_0007254	breast cancer	CHEMBL723	CARVEDILOL	Small molecule	Adrenergic receptor alpha-1 antagonist		ADRA1A	adrenoceptor alpha 1A	2	Recruiting	https://clinicaltrials.gov/study/NCT03879629
EFO_0006861	male breast carcinoma	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	2	Recruiting	https://clinicaltrials.gov/study/NCT05501704
EFO_0000432	breast ductal carcinoma in situ	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02779855
EFO_0005537	triple-negative breast cancer	CHEMBL4303201	CATEQUENTINIB	Small molecule	Vascular endothelial growth factor receptor 3 inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Recruiting	https://clinicaltrials.gov/study/NCT04914390,https://clinicaltrials.gov/study/NCT05089643
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01463072,https://clinicaltrials.gov/study/NCT02603679,https://clinicaltrials.gov/study/NCT03179904,https://clinicaltrials.gov/study/NCT03101748,https://clinicaltrials.gov/study/NCT04216472,https://clinicaltrials.gov/study/NCT04001829,https://clinicaltrials.gov/study/NCT02530489,https://clinicaltrials.gov/study/NCT02436993,https://clinicaltrials.gov/study/NCT02187991
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT03530696
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB7	NADH:ubiquinone oxidoreductase subunit B7	2	Terminated	https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT01477060
MONDO_0007254	breast cancer	CHEMBL3545185	SELINEXOR	Small molecule	Exportin-1 inhibitor		XPO1	exportin 1	2	Completed	https://clinicaltrials.gov/study/NCT02402764
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Recruiting	https://clinicaltrials.gov/study/NCT03879577,https://clinicaltrials.gov/study/NCT05475678,https://clinicaltrials.gov/study/NCT04947189,https://clinicaltrials.gov/study/NCT04872985,https://clinicaltrials.gov/study/NCT05426486,https://clinicaltrials.gov/study/NCT05088057,https://clinicaltrials.gov/study/NCT05189067,https://clinicaltrials.gov/study/NCT05645380,https://clinicaltrials.gov/study/NCT05918328,https://clinicaltrials.gov/study/NCT03367676,https://clinicaltrials.gov/study/NCT05900206,https://clinicaltrials.gov/study/NCT04717531,https://clinicaltrials.gov/study/NCT06107673,https://clinicaltrials.gov/study/NCT05483439,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT04576143,https://clinicaltrials.gov/study/NCT03497702,https://clinicaltrials.gov/study/NCT05638594
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Vascular endothelial growth factor receptor 1 inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Terminated	https://clinicaltrials.gov/study/NCT00434356,https://clinicaltrials.gov/study/NCT00570908,https://clinicaltrials.gov/study/NCT00824538
MONDO_0007254	breast cancer	CHEMBL3647420	PYROTINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04659499,https://clinicaltrials.gov/study/NCT04900311,https://clinicaltrials.gov/study/NCT06362096,https://clinicaltrials.gov/study/NCT04858516,https://clinicaltrials.gov/study/NCT05621434,https://clinicaltrials.gov/study/NCT05020964,https://clinicaltrials.gov/study/NCT04088110,https://clinicaltrials.gov/study/NCT04236310,https://clinicaltrials.gov/study/NCT05806671,https://clinicaltrials.gov/study/NCT03997539,https://clinicaltrials.gov/study/NCT05255523,https://clinicaltrials.gov/study/NCT04963595,https://clinicaltrials.gov/study/NCT04246502,https://clinicaltrials.gov/study/NCT05577923,https://clinicaltrials.gov/study/NCT04290793,https://clinicaltrials.gov/study/NCT03993964,https://clinicaltrials.gov/study/NCT04639271,https://clinicaltrials.gov/study/NCT03919253,https://clinicaltrials.gov/study/NCT04255056,https://clinicaltrials.gov/study/NCT04303988,https://clinicaltrials.gov/study/NCT04158856
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT00148668,https://clinicaltrials.gov/study/NCT01835236,https://clinicaltrials.gov/study/NCT02954055,https://clinicaltrials.gov/study/NCT00148681,https://clinicaltrials.gov/study/NCT01941771,https://clinicaltrials.gov/study/NCT00480597,https://clinicaltrials.gov/study/NCT03887130,https://clinicaltrials.gov/study/NCT02362958,https://clinicaltrials.gov/study/NCT00041067,https://clinicaltrials.gov/study/NCT00192062,https://clinicaltrials.gov/study/NCT00266110,https://clinicaltrials.gov/study/NCT03321981,https://clinicaltrials.gov/study/NCT00006682,https://clinicaltrials.gov/study/NCT00193089,https://clinicaltrials.gov/study/NCT03254654,https://clinicaltrials.gov/study/NCT03007992,https://clinicaltrials.gov/study/NCT01565083,https://clinicaltrials.gov/study/NCT00022152,https://clinicaltrials.gov/study/NCT00503750,https://clinicaltrials.gov/study/NCT00004237,https://clinicaltrials.gov/study/NCT02628613,https://clinicaltrials.gov/study/NCT00670982,https://clinicaltrials.gov/study/NCT00015938,https://clinicaltrials.gov/study/NCT00325234,https://clinicaltrials.gov/study/NCT01242449,https://clinicaltrials.gov/study/NCT01439191,https://clinicaltrials.gov/study/NCT04903652,https://clinicaltrials.gov/study/NCT01305941,https://clinicaltrials.gov/study/NCT01520103,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00093808,https://clinicaltrials.gov/study/NCT00401427,https://clinicaltrials.gov/study/NCT00194779,https://clinicaltrials.gov/study/NCT00532623
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05041101
EFO_0006861	male breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT00077376
EFO_0000305	breast carcinoma	CHEMBL1421	DASATINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Terminated	https://clinicaltrials.gov/study/NCT05198843
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS4	NADH:ubiquinone oxidoreductase subunit S4	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967,https://clinicaltrials.gov/study/NCT06026657
EFO_0000305	breast carcinoma	CHEMBL4302409	LUTETIUM OXODOTREOTIDE	Protein	Somatostatin receptor binding agent		SSTR3	somatostatin receptor 3	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04529044
EFO_0006318	breast ductal adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Terminated	https://clinicaltrials.gov/study/NCT01891357
MONDO_0007254	breast cancer	CHEMBL3301587	DURVALUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor	Inhibitor	CD274	CD274 molecule	2	Completed	https://clinicaltrials.gov/study/NCT03167619,https://clinicaltrials.gov/study/NCT02685059
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT02199418
EFO_1000984	inflammatory breast carcinoma	CHEMBL1567	SUNITINIB MALATE	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Completed	https://clinicaltrials.gov/study/NCT00513695
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA10	NADH:ubiquinone oxidoreductase subunit A10	2	Terminated	https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT01627067
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV2	NADH:ubiquinone oxidoreductase core subunit V2	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB7	NADH:ubiquinone oxidoreductase subunit B7	2	Completed	https://clinicaltrials.gov/study/NCT01885013
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Unknown status	https://clinicaltrials.gov/study/NCT02175446
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Withdrawn	https://clinicaltrials.gov/study/NCT04351230
MONDO_0007254	breast cancer	CHEMBL2304041	SAGOPILONE	Small molecule	Tubulin stabiliser		TUBA1B	tubulin alpha 1b	2	Completed	https://clinicaltrials.gov/study/NCT00288249
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4L	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
EFO_0000305	breast carcinoma	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		BLK	BLK proto-oncogene, Src family tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT05198843
MONDO_0007254	breast cancer	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04858516,https://clinicaltrials.gov/study/NCT06364267
MONDO_0007254	breast cancer	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Serine/threonine-protein kinase RAF inhibitor		RAF1	Raf-1 proto-oncogene, serine/threonine kinase	2	Unknown status	https://clinicaltrials.gov/study/NCT00499525
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Unknown status	https://clinicaltrials.gov/study/NCT02768415,https://clinicaltrials.gov/study/NCT03423849,https://clinicaltrials.gov/study/NCT01528826,https://clinicaltrials.gov/study/NCT02544243,https://clinicaltrials.gov/study/NCT02144194,https://clinicaltrials.gov/study/NCT02607215,https://clinicaltrials.gov/study/NCT01730677,https://clinicaltrials.gov/study/NCT00159094
MONDO_0044915	salivary duct carcinoma	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Recruiting	https://clinicaltrials.gov/study/NCT02628067
EFO_0005537	triple-negative breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04395989,https://clinicaltrials.gov/study/NCT04129996
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA6	NADH:ubiquinone oxidoreductase subunit A6	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Recruiting	https://clinicaltrials.gov/study/NCT04872985,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT06107673,https://clinicaltrials.gov/study/NCT05900206,https://clinicaltrials.gov/study/NCT05189067,https://clinicaltrials.gov/study/NCT04947189,https://clinicaltrials.gov/study/NCT05475678,https://clinicaltrials.gov/study/NCT05426486,https://clinicaltrials.gov/study/NCT05088057,https://clinicaltrials.gov/study/NCT05638594,https://clinicaltrials.gov/study/NCT05483439,https://clinicaltrials.gov/study/NCT04576143,https://clinicaltrials.gov/study/NCT05645380,https://clinicaltrials.gov/study/NCT03879577,https://clinicaltrials.gov/study/NCT05918328,https://clinicaltrials.gov/study/NCT04717531,https://clinicaltrials.gov/study/NCT03367676,https://clinicaltrials.gov/study/NCT03497702
MONDO_0007254	breast cancer	CHEMBL483158	ALISERTIB	Small molecule	Serine/threonine-protein kinase Aurora-A inhibitor		AURKA	aurora kinase A	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06369285
EFO_0000305	breast carcinoma	CHEMBL1079175	MK-2206	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT2	AKT serine/threonine kinase 2	2	Terminated	https://clinicaltrials.gov/study/NCT01776008
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Terminated	https://clinicaltrials.gov/study/NCT00832338
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04303741,https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT05833919
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT00006682,https://clinicaltrials.gov/study/NCT00015938,https://clinicaltrials.gov/study/NCT01520103,https://clinicaltrials.gov/study/NCT00193089,https://clinicaltrials.gov/study/NCT02628613,https://clinicaltrials.gov/study/NCT00148681,https://clinicaltrials.gov/study/NCT03321981,https://clinicaltrials.gov/study/NCT00670982,https://clinicaltrials.gov/study/NCT03887130,https://clinicaltrials.gov/study/NCT00266110,https://clinicaltrials.gov/study/NCT00004237,https://clinicaltrials.gov/study/NCT00022152,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00325234,https://clinicaltrials.gov/study/NCT00194779,https://clinicaltrials.gov/study/NCT00093808,https://clinicaltrials.gov/study/NCT01565083,https://clinicaltrials.gov/study/NCT01941771,https://clinicaltrials.gov/study/NCT00148668,https://clinicaltrials.gov/study/NCT03007992,https://clinicaltrials.gov/study/NCT01242449,https://clinicaltrials.gov/study/NCT03254654,https://clinicaltrials.gov/study/NCT00480597,https://clinicaltrials.gov/study/NCT00041067,https://clinicaltrials.gov/study/NCT02954055,https://clinicaltrials.gov/study/NCT00401427,https://clinicaltrials.gov/study/NCT00532623,https://clinicaltrials.gov/study/NCT02362958,https://clinicaltrials.gov/study/NCT01439191,https://clinicaltrials.gov/study/NCT00503750,https://clinicaltrials.gov/study/NCT00192062,https://clinicaltrials.gov/study/NCT01305941,https://clinicaltrials.gov/study/NCT04903652,https://clinicaltrials.gov/study/NCT01835236
MONDO_0007254	breast cancer	CHEMBL52885	ENMD-981693	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR1	fibroblast growth factor receptor 1	2	Completed	https://clinicaltrials.gov/study/NCT00306631
MONDO_0007254	breast cancer	CHEMBL635	PREDNISONE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	2	Completed	https://clinicaltrials.gov/study/NCT01381874
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02530489,https://clinicaltrials.gov/study/NCT04216472,https://clinicaltrials.gov/study/NCT02436993,https://clinicaltrials.gov/study/NCT02187991,https://clinicaltrials.gov/study/NCT03101748,https://clinicaltrials.gov/study/NCT01463072,https://clinicaltrials.gov/study/NCT03179904,https://clinicaltrials.gov/study/NCT04001829,https://clinicaltrials.gov/study/NCT02603679
EFO_0000305	breast carcinoma	CHEMBL4302409	LUTETIUM OXODOTREOTIDE	Protein	Somatostatin receptor binding agent		SSTR5	somatostatin receptor 5	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04529044
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF2	NADH:ubiquinone oxidoreductase complex assembly factor 2	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL94657	PATUPILONE	Small molecule	Tubulin stabiliser		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT00450866
EFO_0000305	breast carcinoma	CHEMBL180022	NERATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03101748
MONDO_0007254	breast cancer	CHEMBL289228	TIPIFARNIB	Small molecule	Protein farnesyltransferase inhibitor		FNTA	farnesyltransferase, CAAX box, subunit alpha	2	Completed	https://clinicaltrials.gov/study/NCT00049114,https://clinicaltrials.gov/study/NCT00077363,https://clinicaltrials.gov/study/NCT00050141,https://clinicaltrials.gov/study/NCT00082810,https://clinicaltrials.gov/study/NCT00052728
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Unknown status	https://clinicaltrials.gov/study/NCT03144947
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Completed	https://clinicaltrials.gov/study/NCT00005991,https://clinicaltrials.gov/study/NCT00002998,https://clinicaltrials.gov/study/NCT00662129,https://clinicaltrials.gov/study/NCT00059852,https://clinicaltrials.gov/study/NCT00006007,https://clinicaltrials.gov/study/NCT00003540
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE7A	phosphodiesterase 7A	2	Recruiting	https://clinicaltrials.gov/study/NCT06087237
EFO_0006861	male breast carcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC9	histone deacetylase 9	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01349959
EFO_0000305	breast carcinoma	CHEMBL1201583	BEVACIZUMAB	Antibody	Vascular endothelial growth factor A inhibitor		VEGFA	vascular endothelial growth factor A	2	Unknown status	https://clinicaltrials.gov/study/NCT02175446
MONDO_0007254	breast cancer	CHEMBL3813873	PEXIDARTINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967,https://clinicaltrials.gov/study/NCT06027268
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	2	Unknown status	https://clinicaltrials.gov/study/NCT00954135,https://clinicaltrials.gov/study/NCT00499525
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS4	NADH:ubiquinone oxidoreductase subunit S4	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL1879463	DACTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	2	Withdrawn	https://clinicaltrials.gov/study/NCT01288092
EFO_0005537	triple-negative breast cancer	CHEMBL4297939	DATOPOTAMAB DERUXTECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT06176261
MONDO_0007254	breast cancer	CHEMBL288441	BOSUTINIB	Small molecule	Tyrosine-protein kinase SRC inhibitor		SRC	SRC proto-oncogene, non-receptor tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT00880009,https://clinicaltrials.gov/study/NCT00793546
EFO_0006861	male breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00095888
MONDO_0007254	breast cancer	CHEMBL2360464	PEMETREXED DISODIUM	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	2	Completed	https://clinicaltrials.gov/study/NCT00006007
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Enrolling by invitation	https://clinicaltrials.gov/study/NCT03580395
MONDO_0007254	breast cancer	CHEMBL2109477	SELICRELUMAB	Antibody	Tumor necrosis factor receptor superfamily member 5 agonist		CD40	CD40 molecule	2	Recruiting	https://clinicaltrials.gov/study/NCT03424005
MONDO_0007254	breast cancer	CHEMBL4298101	LADIRATUZUMAB VEDOTIN	Antibody drug conjugate	Zinc transporter ZIP6 binding agent		SLC39A6	solute carrier family 39 member 6	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT03424005
EFO_0006861	male breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Unknown status	https://clinicaltrials.gov/study/NCT01372579
EFO_0006861	male breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
EFO_0000305	breast carcinoma	CHEMBL491473	CEDIRANIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Recruiting	https://clinicaltrials.gov/study/NCT04090567
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBA3E	tubulin alpha 3e	2	Withdrawn	https://clinicaltrials.gov/study/NCT01227408
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Recruiting	https://clinicaltrials.gov/study/NCT05583110
MONDO_0007254	breast cancer	CHEMBL1201199	LEUPROLIDE	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	2	Withdrawn	https://clinicaltrials.gov/study/NCT03058939
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND6	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6	2	Recruiting	https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT04559308
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05041101
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Completed	https://clinicaltrials.gov/study/NCT00191373
MONDO_0007254	breast cancer	CHEMBL1789844	IPILIMUMAB	Antibody	Cytotoxic T-lymphocyte protein 4 inhibitor		CTLA4	cytotoxic T-lymphocyte associated protein 4	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03789110,https://clinicaltrials.gov/study/NCT03650894,https://clinicaltrials.gov/study/NCT03818685
MONDO_0007254	breast cancer	CHEMBL1642	IMATINIB MESYLATE	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	2	Terminated	https://clinicaltrials.gov/study/NCT00323063
MONDO_0007254	breast cancer	CHEMBL1201753	PITAVASTATIN	Small molecule	HMG-CoA reductase inhibitor		HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04705909
EFO_0005537	triple-negative breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT00002998,https://clinicaltrials.gov/study/NCT00006007,https://clinicaltrials.gov/study/NCT00003540,https://clinicaltrials.gov/study/NCT00005991,https://clinicaltrials.gov/study/NCT00059852,https://clinicaltrials.gov/study/NCT00662129
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Terminated	https://clinicaltrials.gov/study/NCT00095888,https://clinicaltrials.gov/study/NCT00323063,https://clinicaltrials.gov/study/NCT00679029,https://clinicaltrials.gov/study/NCT00470249
MONDO_0007254	breast cancer	CHEMBL19019	NALTREXONE	Small molecule	Opioid receptors; mu/kappa/delta antagonist		OPRM1	opioid receptor mu 1	2	Terminated	https://clinicaltrials.gov/study/NCT00379197
MONDO_0007254	breast cancer	CHEMBL483158	ALISERTIB	Small molecule	Serine/threonine-protein kinase Aurora-A inhibitor		AURKA	aurora kinase A	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02187991
MONDO_0007254	breast cancer	CHEMBL4297736	PRALUZATAMAB RAVTANSINE	Antibody drug conjugate	CD166 antigen binding agent		ALCAM	activated leukocyte cell adhesion molecule	2	Completed	https://clinicaltrials.gov/study/NCT04596150
MONDO_0007254	breast cancer	CHEMBL645	BISOPROLOL	Small molecule	Beta-1 adrenergic receptor antagonist		ADRB1	adrenoceptor beta 1	2	Completed	https://clinicaltrials.gov/study/NCT04588935
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01815242,https://clinicaltrials.gov/study/NCT04297267,https://clinicaltrials.gov/study/NCT02252887,https://clinicaltrials.gov/study/NCT04262804,https://clinicaltrials.gov/study/NCT03567720
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT00490646,https://clinicaltrials.gov/study/NCT00633464,https://clinicaltrials.gov/study/NCT01019577,https://clinicaltrials.gov/study/NCT00751868,https://clinicaltrials.gov/study/NCT00045097,https://clinicaltrials.gov/study/NCT00080262,https://clinicaltrials.gov/study/NCT01416389,https://clinicaltrials.gov/study/NCT00455533,https://clinicaltrials.gov/study/NCT00866905,https://clinicaltrials.gov/study/NCT00627978,https://clinicaltrials.gov/study/NCT00879086,https://clinicaltrials.gov/study/NCT01446016,https://clinicaltrials.gov/study/NCT01075100,https://clinicaltrials.gov/study/NCT01097642,https://clinicaltrials.gov/study/NCT00077376,https://clinicaltrials.gov/study/NCT00020904,https://clinicaltrials.gov/study/NCT00821886,https://clinicaltrials.gov/study/NCT00593827,https://clinicaltrials.gov/study/NCT00370552,https://clinicaltrials.gov/study/NCT01027208
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4	NDUFA4 mitochondrial complex associated	2	Recruiting	https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT04559308,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL468	THALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		RBX1	ring-box 1	2	Terminated	https://clinicaltrials.gov/study/NCT00193102
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05833919
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT01269346,https://clinicaltrials.gov/study/NCT03051659,https://clinicaltrials.gov/study/NCT01908101,https://clinicaltrials.gov/study/NCT02481050,https://clinicaltrials.gov/study/NCT05206656,https://clinicaltrials.gov/study/NCT00246090,https://clinicaltrials.gov/study/NCT01268150,https://clinicaltrials.gov/study/NCT00965523,https://clinicaltrials.gov/study/NCT01439282,https://clinicaltrials.gov/study/NCT00879086
MONDO_0007254	breast cancer	CHEMBL94657	PATUPILONE	Small molecule	Tubulin stabiliser		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT00450866
MONDO_0007254	breast cancer	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Completed	https://clinicaltrials.gov/study/NCT00530868,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00696072,https://clinicaltrials.gov/study/NCT00238316,https://clinicaltrials.gov/study/NCT00338728,https://clinicaltrials.gov/study/NCT00238290,https://clinicaltrials.gov/study/NCT02692755,https://clinicaltrials.gov/study/NCT00194779,https://clinicaltrials.gov/study/NCT03397537,https://clinicaltrials.gov/study/NCT02400567,https://clinicaltrials.gov/study/NCT01698918,https://clinicaltrials.gov/study/NCT02005887,https://clinicaltrials.gov/study/NCT00090857,https://clinicaltrials.gov/study/NCT03481998,https://clinicaltrials.gov/study/NCT01068704,https://clinicaltrials.gov/study/NCT00291135,https://clinicaltrials.gov/study/NCT02291913,https://clinicaltrials.gov/study/NCT03644186,https://clinicaltrials.gov/study/NCT03555877,https://clinicaltrials.gov/study/NCT02549430,https://clinicaltrials.gov/study/NCT03054363,https://clinicaltrials.gov/study/NCT03613220,https://clinicaltrials.gov/study/NCT00721409,https://clinicaltrials.gov/study/NCT00634634,https://clinicaltrials.gov/study/NCT03819010,https://clinicaltrials.gov/study/NCT02742051,https://clinicaltrials.gov/study/NCT02520063,https://clinicaltrials.gov/study/NCT00728949,https://clinicaltrials.gov/study/NCT02273973,https://clinicaltrials.gov/study/NCT02491983,https://clinicaltrials.gov/study/NCT02296801,https://clinicaltrials.gov/study/NCT03306472,https://clinicaltrials.gov/study/NCT02806050,https://clinicaltrials.gov/study/NCT01439711,https://clinicaltrials.gov/study/NCT01989780,https://clinicaltrials.gov/study/NCT03248427,https://clinicaltrials.gov/study/NCT03774472,https://clinicaltrials.gov/study/NCT00084396,https://clinicaltrials.gov/study/NCT01275859,https://clinicaltrials.gov/study/NCT00161291,https://clinicaltrials.gov/study/NCT00535418,https://clinicaltrials.gov/study/NCT00305825,https://clinicaltrials.gov/study/NCT01654185,https://clinicaltrials.gov/study/NCT00903162,https://clinicaltrials.gov/study/NCT00532272,https://clinicaltrials.gov/study/NCT00247650,https://clinicaltrials.gov/study/NCT04294225,https://clinicaltrials.gov/study/NCT00333047,https://clinicaltrials.gov/study/NCT00867217,https://clinicaltrials.gov/study/NCT02344550,https://clinicaltrials.gov/study/NCT00134680,https://clinicaltrials.gov/study/NCT00579826,https://clinicaltrials.gov/study/NCT03007979,https://clinicaltrials.gov/study/NCT03628066,https://clinicaltrials.gov/study/NCT00199134,https://clinicaltrials.gov/study/NCT00208273
MONDO_0007254	breast cancer	CHEMBL502835	NINTEDANIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR3	fibroblast growth factor receptor 3	2	Terminated	https://clinicaltrials.gov/study/NCT02389764
EFO_0000305	breast carcinoma	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Terminated	https://clinicaltrials.gov/study/NCT04108858
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Recruiting	https://clinicaltrials.gov/study/NCT04266249,https://clinicaltrials.gov/study/NCT05319873,https://clinicaltrials.gov/study/NCT06042569
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT06026657,https://clinicaltrials.gov/study/NCT03606967
MONDO_0007254	breast cancer	CHEMBL1234354	PF-04691502	Small molecule	PI3-kinase class I inhibitor		PIK3R5	phosphoinositide-3-kinase regulatory subunit 5	2	Terminated	https://clinicaltrials.gov/study/NCT01430585
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R2	phosphoinositide-3-kinase regulatory subunit 2	2	Completed	https://clinicaltrials.gov/study/NCT01790932,https://clinicaltrials.gov/study/NCT02404844,https://clinicaltrials.gov/study/NCT01629615,https://clinicaltrials.gov/study/NCT01572727,https://clinicaltrials.gov/study/NCT01816594,https://clinicaltrials.gov/study/NCT01923168
MONDO_0007254	breast cancer	CHEMBL572881	MOTESANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Terminated	https://clinicaltrials.gov/study/NCT00356681
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04345913
MONDO_0007254	breast cancer	CHEMBL3701238	FUTIBATINIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR4	fibroblast growth factor receptor 4	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04024436
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE9A	phosphodiesterase 9A	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT06186700,https://clinicaltrials.gov/study/NCT06176339
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB2	NADH:ubiquinone oxidoreductase subunit B2	2	Completed	https://clinicaltrials.gov/study/NCT01885013
MONDO_0004658	breast carcinoma in situ	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Completed	https://clinicaltrials.gov/study/NCT02598557
EFO_0000305	breast carcinoma	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Unknown status	https://clinicaltrials.gov/study/NCT03144947
EFO_0005537	triple-negative breast cancer	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Completed	https://clinicaltrials.gov/study/NCT02648477
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02883062,https://clinicaltrials.gov/study/NCT04395989,https://clinicaltrials.gov/study/NCT02593175,https://clinicaltrials.gov/study/NCT04129996,https://clinicaltrials.gov/study/NCT04770272,https://clinicaltrials.gov/study/NCT02530489,https://clinicaltrials.gov/study/NCT01750073,https://clinicaltrials.gov/study/NCT04958785,https://clinicaltrials.gov/study/NCT02315196,https://clinicaltrials.gov/study/NCT02876107,https://clinicaltrials.gov/study/NCT04216472
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA3	NADH:ubiquinone oxidoreductase subunit A3	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL1289601	LENVATINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT06110793,https://clinicaltrials.gov/study/NCT05286437,https://clinicaltrials.gov/study/NCT05181033
MONDO_0007254	breast cancer	CHEMBL2364649	MARGETUXIMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04262804
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02339532,https://clinicaltrials.gov/study/NCT03161353,https://clinicaltrials.gov/study/NCT04172259,https://clinicaltrials.gov/study/NCT02568839,https://clinicaltrials.gov/study/NCT01779206,https://clinicaltrials.gov/study/NCT03609047,https://clinicaltrials.gov/study/NCT02624973,https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT00496795,https://clinicaltrials.gov/study/NCT00295893,https://clinicaltrials.gov/study/NCT02547987
EFO_0005537	triple-negative breast cancer	CHEMBL3186534	RIVOCERANIB	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT03932526
EFO_0006861	male breast carcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC11	histone deacetylase 11	2	Completed	https://clinicaltrials.gov/study/NCT00098397
MONDO_0007254	breast cancer	CHEMBL2109355	DUSIGITUMAB	Antibody	Insulin-like growth factor II inhibitor		IGF2	insulin like growth factor 2	2	Completed	https://clinicaltrials.gov/study/NCT01446159
EFO_0005537	triple-negative breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03911973
MONDO_0007254	breast cancer	CHEMBL4475463	AMCENESTRANT	Small molecule	Estrogen receptor alpha degrader		ESR1	estrogen receptor 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03284957,https://clinicaltrials.gov/study/NCT04059484
MONDO_0007254	breast cancer	CHEMBL4297892	ANVATABART OPADOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBA1A	tubulin alpha 1a	2	Recruiting	https://clinicaltrials.gov/study/NCT05018702,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04829604,https://clinicaltrials.gov/study/NCT05018676,https://clinicaltrials.gov/study/NCT05426486
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Recruiting	https://clinicaltrials.gov/study/NCT04304352,https://clinicaltrials.gov/study/NCT03939871,https://clinicaltrials.gov/study/NCT04389073,https://clinicaltrials.gov/study/NCT04759248,https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT06102824,https://clinicaltrials.gov/study/NCT04302441,https://clinicaltrials.gov/study/NCT05296577,https://clinicaltrials.gov/study/NCT05747326,https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT05823623,https://clinicaltrials.gov/study/NCT04296162,https://clinicaltrials.gov/study/NCT04605575
EFO_0000305	breast carcinoma	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134,https://clinicaltrials.gov/study/NCT06179303
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Unknown status	https://clinicaltrials.gov/study/NCT03412955,https://clinicaltrials.gov/study/NCT02175446
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04733118,https://clinicaltrials.gov/study/NCT01745965,https://clinicaltrials.gov/study/NCT01494662,https://clinicaltrials.gov/study/NCT03587740,https://clinicaltrials.gov/study/NCT04398914,https://clinicaltrials.gov/study/NCT02326974,https://clinicaltrials.gov/study/NCT01853748,https://clinicaltrials.gov/study/NCT01565200
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02414646
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Withdrawn	https://clinicaltrials.gov/study/NCT02725541
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAB1	NADH:ubiquinone oxidoreductase subunit AB1	2	Completed	https://clinicaltrials.gov/study/NCT01885013
MONDO_0007254	breast cancer	CHEMBL4297181	SAMOTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	2	Completed	https://clinicaltrials.gov/study/NCT04032080
EFO_0000432	breast ductal carcinoma in situ	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02779855
MONDO_0007254	breast cancer	CHEMBL1614701	SELUMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 2 inhibitor		MAP2K2	mitogen-activated protein kinase kinase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999
MONDO_0007254	breast cancer	CHEMBL1655	TOREMIFENE	Small molecule	Estrogen receptor modulator		ESR1	estrogen receptor 1	2	Unknown status	https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT02132000
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor		GPD2	glycerol-3-phosphate dehydrogenase 2	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	2	Terminated	https://clinicaltrials.gov/study/NCT01887288,https://clinicaltrials.gov/study/NCT00347438,https://clinicaltrials.gov/study/NCT01290718,https://clinicaltrials.gov/study/NCT03858972,https://clinicaltrials.gov/study/NCT00479856,https://clinicaltrials.gov/study/NCT00437294,https://clinicaltrials.gov/study/NCT02120417,https://clinicaltrials.gov/study/NCT00148720,https://clinicaltrials.gov/study/NCT01067989,https://clinicaltrials.gov/study/NCT00227656,https://clinicaltrials.gov/study/NCT01702558,https://clinicaltrials.gov/study/NCT00216073,https://clinicaltrials.gov/study/NCT00193102,https://clinicaltrials.gov/study/NCT00665457,https://clinicaltrials.gov/study/NCT00496366,https://clinicaltrials.gov/study/NCT00657137,https://clinicaltrials.gov/study/NCT00130507,https://clinicaltrials.gov/study/NCT01069796,https://clinicaltrials.gov/study/NCT02213744,https://clinicaltrials.gov/study/NCT00434941,https://clinicaltrials.gov/study/NCT03358004,https://clinicaltrials.gov/study/NCT01873833,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT00570908,https://clinicaltrials.gov/study/NCT00576901,https://clinicaltrials.gov/study/NCT00225056,https://clinicaltrials.gov/study/NCT00977379,https://clinicaltrials.gov/study/NCT00194792,https://clinicaltrials.gov/study/NCT03322215,https://clinicaltrials.gov/study/NCT00049660,https://clinicaltrials.gov/study/NCT00845910,https://clinicaltrials.gov/study/NCT00462865,https://clinicaltrials.gov/study/NCT00684216
EFO_0000305	breast carcinoma	CHEMBL1201583	BEVACIZUMAB	Antibody	Vascular endothelial growth factor A inhibitor		VEGFA	vascular endothelial growth factor A	2	Completed	https://clinicaltrials.gov/study/NCT00054132,https://clinicaltrials.gov/study/NCT02456857
MONDO_0007254	breast cancer	CHEMBL635	PREDNISONE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	2	Withdrawn	https://clinicaltrials.gov/study/NCT01814865
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Withdrawn	https://clinicaltrials.gov/study/NCT02067416,https://clinicaltrials.gov/study/NCT00006261,https://clinicaltrials.gov/study/NCT01825265,https://clinicaltrials.gov/study/NCT01229605,https://clinicaltrials.gov/study/NCT00964704,https://clinicaltrials.gov/study/NCT00678626,https://clinicaltrials.gov/study/NCT00434031
EFO_0005537	triple-negative breast cancer	CHEMBL3545132	MIRVETUXIMAB SORAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT03106077
MONDO_0007254	breast cancer	CHEMBL1234354	PF-04691502	Small molecule	PI3-kinase class I inhibitor		PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	2	Terminated	https://clinicaltrials.gov/study/NCT01430585
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA3	NADH:ubiquinone oxidoreductase subunit A3	2	Completed	https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT02488564
EFO_0005537	triple-negative breast cancer	CHEMBL1201670	SARGRAMOSTIM	Protein	Granulocyte-macrophage colony-stimulating factor receptor agonist		CSF2RA	colony stimulating factor 2 receptor subunit alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT05455658
EFO_0006861	male breast carcinoma	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT00017394
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	Ephrin type-A receptor 2 inhibitor		EPHA2	EPH receptor A2	2	Terminated	https://clinicaltrials.gov/study/NCT05198843,https://clinicaltrials.gov/study/NCT00817531,https://clinicaltrials.gov/study/NCT00780676
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND1	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL20684	ABT-751	Small molecule	Tubulin beta inhibitor		TUBB8B	tubulin beta 8B	2	Completed	https://clinicaltrials.gov/study/NCT00063102
MONDO_0007254	breast cancer	CHEMBL1201748	CABAZITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT01693549
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT02978495
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Recruiting	https://clinicaltrials.gov/study/NCT05823623,https://clinicaltrials.gov/study/NCT05296577
MONDO_0007254	breast cancer	CHEMBL679	EPINEPHRINE	Small molecule	Adrenergic receptor agonist		ADRA1A	adrenoceptor alpha 1A	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04603911
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF4	NADH:ubiquinone oxidoreductase complex assembly factor 4	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT03530696
MONDO_0007254	breast cancer	CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist		IFNAR2	interferon alpha and beta receptor subunit 2	2	Terminated	https://clinicaltrials.gov/study/NCT00227656
MONDO_0007254	breast cancer	CHEMBL112	ACETAMINOPHEN	Small molecule	Anandamide amidohydrolase inhibitor		FAAH	fatty acid amide hydrolase	2	Completed	https://clinicaltrials.gov/study/NCT02839668,https://clinicaltrials.gov/study/NCT03084536
EFO_0000305	breast carcinoma	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Terminated	https://clinicaltrials.gov/study/NCT01498588
MONDO_0004379	female breast carcinoma	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR1	estrogen receptor 1	2	Terminated	https://clinicaltrials.gov/study/NCT02540330
EFO_0005537	triple-negative breast cancer	CHEMBL3545414	RIVOCERANIB MESYLATE	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT03932526
MONDO_0007254	breast cancer	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Serine/threonine-protein kinase B-raf inhibitor		BRAF	B-Raf proto-oncogene, serine/threonine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT00622466,https://clinicaltrials.gov/study/NCT00573755,https://clinicaltrials.gov/study/NCT00722072
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS1	NADH:ubiquinone oxidoreductase core subunit S1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBB2B	tubulin beta 2B class IIb	2	Withdrawn	https://clinicaltrials.gov/study/NCT01227408
EFO_0006861	male breast carcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC10	histone deacetylase 10	2	Completed	https://clinicaltrials.gov/study/NCT00098397
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT01835236,https://clinicaltrials.gov/study/NCT00006682,https://clinicaltrials.gov/study/NCT00093808,https://clinicaltrials.gov/study/NCT01242449,https://clinicaltrials.gov/study/NCT04903652,https://clinicaltrials.gov/study/NCT03254654,https://clinicaltrials.gov/study/NCT00503750,https://clinicaltrials.gov/study/NCT00670982,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT03887130,https://clinicaltrials.gov/study/NCT00192062,https://clinicaltrials.gov/study/NCT00532623,https://clinicaltrials.gov/study/NCT00041067,https://clinicaltrials.gov/study/NCT00401427,https://clinicaltrials.gov/study/NCT00004237,https://clinicaltrials.gov/study/NCT00480597,https://clinicaltrials.gov/study/NCT00148668,https://clinicaltrials.gov/study/NCT00194779,https://clinicaltrials.gov/study/NCT02954055,https://clinicaltrials.gov/study/NCT00325234,https://clinicaltrials.gov/study/NCT00015938,https://clinicaltrials.gov/study/NCT00266110,https://clinicaltrials.gov/study/NCT03007992,https://clinicaltrials.gov/study/NCT00022152,https://clinicaltrials.gov/study/NCT01439191,https://clinicaltrials.gov/study/NCT01565083,https://clinicaltrials.gov/study/NCT02362958,https://clinicaltrials.gov/study/NCT00193089,https://clinicaltrials.gov/study/NCT01520103,https://clinicaltrials.gov/study/NCT01305941,https://clinicaltrials.gov/study/NCT02628613,https://clinicaltrials.gov/study/NCT00148681,https://clinicaltrials.gov/study/NCT03321981,https://clinicaltrials.gov/study/NCT01941771
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Suspended	https://clinicaltrials.gov/study/NCT04419181,https://clinicaltrials.gov/study/NCT02897050
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT00063570,https://clinicaltrials.gov/study/NCT00325234,https://clinicaltrials.gov/study/NCT00191789,https://clinicaltrials.gov/study/NCT00191451,https://clinicaltrials.gov/study/NCT00894504,https://clinicaltrials.gov/study/NCT00623233,https://clinicaltrials.gov/study/NCT00191243,https://clinicaltrials.gov/study/NCT04464174,https://clinicaltrials.gov/study/NCT00316199,https://clinicaltrials.gov/study/NCT00695994,https://clinicaltrials.gov/study/NCT00403130,https://clinicaltrials.gov/study/NCT03025880,https://clinicaltrials.gov/study/NCT00191854,https://clinicaltrials.gov/study/NCT00059852,https://clinicaltrials.gov/study/NCT00128856,https://clinicaltrials.gov/study/NCT00191347,https://clinicaltrials.gov/study/NCT01550848,https://clinicaltrials.gov/study/NCT00191373,https://clinicaltrials.gov/study/NCT00813956,https://clinicaltrials.gov/study/NCT00618826,https://clinicaltrials.gov/study/NCT01045304,https://clinicaltrials.gov/study/NCT02435680,https://clinicaltrials.gov/study/NCT00201760,https://clinicaltrials.gov/study/NCT00192062,https://clinicaltrials.gov/study/NCT00193063,https://clinicaltrials.gov/study/NCT00450762,https://clinicaltrials.gov/study/NCT00002998,https://clinicaltrials.gov/study/NCT00003540,https://clinicaltrials.gov/study/NCT00532857,https://clinicaltrials.gov/study/NCT00244933,https://clinicaltrials.gov/study/NCT02263495,https://clinicaltrials.gov/study/NCT00601159,https://clinicaltrials.gov/study/NCT00503906,https://clinicaltrials.gov/study/NCT00532623,https://clinicaltrials.gov/study/NCT00191815,https://clinicaltrials.gov/study/NCT00378313,https://clinicaltrials.gov/study/NCT00193076,https://clinicaltrials.gov/study/NCT00334802,https://clinicaltrials.gov/study/NCT00320541,https://clinicaltrials.gov/study/NCT00212069,https://clinicaltrials.gov/study/NCT00110084,https://clinicaltrials.gov/study/NCT00191269,https://clinicaltrials.gov/study/NCT00846027,https://clinicaltrials.gov/study/NCT00006007,https://clinicaltrials.gov/study/NCT00192101,https://clinicaltrials.gov/study/NCT00754351,https://clinicaltrials.gov/study/NCT01201265,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00005991,https://clinicaltrials.gov/study/NCT00480597,https://clinicaltrials.gov/study/NCT00193206,https://clinicaltrials.gov/study/NCT00540358,https://clinicaltrials.gov/study/NCT00662129,https://clinicaltrials.gov/study/NCT00193050,https://clinicaltrials.gov/study/NCT00493636
EFO_0000432	breast ductal carcinoma in situ	CHEMBL489	AFIMOXIFENE	Small molecule	Estrogen receptor modulator		ESR1	estrogen receptor 1	2	Recruiting	https://clinicaltrials.gov/study/NCT04009044,https://clinicaltrials.gov/study/NCT02993159
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT02682693,https://clinicaltrials.gov/study/NCT00513695,https://clinicaltrials.gov/study/NCT02199418
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR1	estrogen receptor 1	2	Withdrawn	https://clinicaltrials.gov/study/NCT05191004,https://clinicaltrials.gov/study/NCT03377101,https://clinicaltrials.gov/study/NCT02115594,https://clinicaltrials.gov/study/NCT04901299
MONDO_0007254	breast cancer	CHEMBL575448	BMS-754807	Small molecule	Insulin-like growth factor I receptor inhibitor		IGF1R	insulin like growth factor 1 receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01225172
MONDO_0007254	breast cancer	CHEMBL1200778	DEXRAZOXANE HYDROCHLORIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	2	Terminated	https://clinicaltrials.gov/study/NCT00955890
MONDO_0007254	breast cancer	CHEMBL1655	TOREMIFENE	Small molecule	Estrogen receptor modulator		ESR2	estrogen receptor 2	2	Unknown status	https://clinicaltrials.gov/study/NCT02132000,https://clinicaltrials.gov/study/NCT02506790
MONDO_0007254	breast cancer	CHEMBL1234354	PF-04691502	Small molecule	PI3-kinase class I inhibitor		PIK3R2	phosphoinositide-3-kinase regulatory subunit 2	2	Terminated	https://clinicaltrials.gov/study/NCT01430585
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT00284180
MONDO_0007254	breast cancer	CHEMBL3701238	FUTIBATINIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR2	fibroblast growth factor receptor 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04024436
MONDO_0007254	breast cancer	CHEMBL256147	TILARGININE	Small molecule	Nitric oxide synthase inhibitor		NOS2	nitric oxide synthase 2	2	Completed	https://clinicaltrials.gov/study/NCT02834403
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Recruiting	https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT04576143,https://clinicaltrials.gov/study/NCT03497702,https://clinicaltrials.gov/study/NCT04947189,https://clinicaltrials.gov/study/NCT05900206,https://clinicaltrials.gov/study/NCT04872985,https://clinicaltrials.gov/study/NCT06107673,https://clinicaltrials.gov/study/NCT03879577,https://clinicaltrials.gov/study/NCT05645380,https://clinicaltrials.gov/study/NCT05189067,https://clinicaltrials.gov/study/NCT05918328,https://clinicaltrials.gov/study/NCT05475678,https://clinicaltrials.gov/study/NCT05638594,https://clinicaltrials.gov/study/NCT04717531,https://clinicaltrials.gov/study/NCT05426486,https://clinicaltrials.gov/study/NCT03367676,https://clinicaltrials.gov/study/NCT05483439,https://clinicaltrials.gov/study/NCT05088057
MONDO_0007254	breast cancer	CHEMBL4297181	SAMOTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R2	phosphoinositide-3-kinase regulatory subunit 2	2	Completed	https://clinicaltrials.gov/study/NCT04032080
EFO_1000984	inflammatory breast carcinoma	CHEMBL535	SUNITINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT00513695
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBA1B	tubulin alpha 1b	2	Completed	https://clinicaltrials.gov/study/NCT00265733,https://clinicaltrials.gov/study/NCT00148707
EFO_0005537	triple-negative breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC7	histone deacetylase 7	2	Terminated	https://clinicaltrials.gov/study/NCT01234532
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03125928,https://clinicaltrials.gov/study/NCT04172259,https://clinicaltrials.gov/study/NCT02752685,https://clinicaltrials.gov/study/NCT04538742,https://clinicaltrials.gov/study/NCT02734290,https://clinicaltrials.gov/study/NCT03616886,https://clinicaltrials.gov/study/NCT03567720,https://clinicaltrials.gov/study/NCT00609791,https://clinicaltrials.gov/study/NCT00295893,https://clinicaltrials.gov/study/NCT03387085,https://clinicaltrials.gov/study/NCT01898117,https://clinicaltrials.gov/study/NCT03609047,https://clinicaltrials.gov/study/NCT04192331,https://clinicaltrials.gov/study/NCT03950570,https://clinicaltrials.gov/study/NCT01853748,https://clinicaltrials.gov/study/NCT04603183,https://clinicaltrials.gov/study/NCT04083963,https://clinicaltrials.gov/study/NCT04398914,https://clinicaltrials.gov/study/NCT04734262,https://clinicaltrials.gov/study/NCT04418154,https://clinicaltrials.gov/study/NCT01796197,https://clinicaltrials.gov/study/NCT01730833,https://clinicaltrials.gov/study/NCT02788981,https://clinicaltrials.gov/study/NCT01815242,https://clinicaltrials.gov/study/NCT05498896,https://clinicaltrials.gov/study/NCT02187991,https://clinicaltrials.gov/study/NCT04215146,https://clinicaltrials.gov/study/NCT02883062,https://clinicaltrials.gov/study/NCT00616967,https://clinicaltrials.gov/study/NCT03568422,https://clinicaltrials.gov/study/NCT00003042,https://clinicaltrials.gov/study/NCT02546232,https://clinicaltrials.gov/study/NCT02779855,https://clinicaltrials.gov/study/NCT04251169,https://clinicaltrials.gov/study/NCT03747120,https://clinicaltrials.gov/study/NCT01057069,https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT01779206
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT00101400,https://clinicaltrials.gov/study/NCT00493636,https://clinicaltrials.gov/study/NCT00634634,https://clinicaltrials.gov/study/NCT00548899,https://clinicaltrials.gov/study/NCT01320111
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Recruiting	https://clinicaltrials.gov/study/NCT05426486,https://clinicaltrials.gov/study/NCT05088057,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT04576143,https://clinicaltrials.gov/study/NCT04947189,https://clinicaltrials.gov/study/NCT05900206,https://clinicaltrials.gov/study/NCT04717531,https://clinicaltrials.gov/study/NCT03497702,https://clinicaltrials.gov/study/NCT06107673,https://clinicaltrials.gov/study/NCT03367676,https://clinicaltrials.gov/study/NCT03879577,https://clinicaltrials.gov/study/NCT05918328,https://clinicaltrials.gov/study/NCT04872985,https://clinicaltrials.gov/study/NCT05475678,https://clinicaltrials.gov/study/NCT05483439,https://clinicaltrials.gov/study/NCT05638594,https://clinicaltrials.gov/study/NCT05645380,https://clinicaltrials.gov/study/NCT05189067
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04517292,https://clinicaltrials.gov/study/NCT05263882,https://clinicaltrials.gov/study/NCT04143906
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA5	NADH:ubiquinone oxidoreductase subunit A5	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1200694	SEVOFLURANE	Small molecule	Potassium channel subfamily K member 18 opener		KCNK18	potassium two pore domain channel subfamily K member 18	2	Completed	https://clinicaltrials.gov/study/NCT02839668
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Terminated	https://clinicaltrials.gov/study/NCT00790894,https://clinicaltrials.gov/study/NCT00765765,https://clinicaltrials.gov/study/NCT00079326
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBA1A	tubulin alpha 1a	2	Completed	https://clinicaltrials.gov/study/NCT00148707,https://clinicaltrials.gov/study/NCT00265733
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL3545369	EPACADOSTAT	Small molecule	Indoleamine 2,3-dioxygenase inhibitor		IDO1	indoleamine 2,3-dioxygenase 1	2	Withdrawn	https://clinicaltrials.gov/study/NCT03432676
EFO_0005537	triple-negative breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT03154749,https://clinicaltrials.gov/study/NCT02413320
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND1	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB4	NADH:ubiquinone oxidoreductase subunit B4	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000553	invasive lobular carcinoma	CHEMBL1983268	ENTRECTINIB	Small molecule	Neurotrophic tyrosine kinase receptor inhibitor		NTRK2	neurotrophic receptor tyrosine kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT04551495
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV2	NADH:ubiquinone oxidoreductase core subunit V2	2	Terminated	https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT01477060
MONDO_0007254	breast cancer	CHEMBL1655	TOREMIFENE	Small molecule	Estrogen receptor modulator		ESR2	estrogen receptor 2	2	Recruiting	https://clinicaltrials.gov/study/NCT05472792
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Withdrawn	https://clinicaltrials.gov/study/NCT02067416,https://clinicaltrials.gov/study/NCT01229605,https://clinicaltrials.gov/study/NCT01825265,https://clinicaltrials.gov/study/NCT00434031,https://clinicaltrials.gov/study/NCT00006261,https://clinicaltrials.gov/study/NCT00678626,https://clinicaltrials.gov/study/NCT00964704
EFO_0005537	triple-negative breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03639948
MONDO_0007254	breast cancer	CHEMBL1094636	NIRAPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05232006,https://clinicaltrials.gov/study/NCT05461690
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Fibroblast growth factor receptor 3 inhibitor		FGFR3	fibroblast growth factor receptor 3	2	Withdrawn	https://clinicaltrials.gov/study/NCT00615524
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02326974,https://clinicaltrials.gov/study/NCT01565200,https://clinicaltrials.gov/study/NCT01745965,https://clinicaltrials.gov/study/NCT03587740,https://clinicaltrials.gov/study/NCT04398914,https://clinicaltrials.gov/study/NCT01494662,https://clinicaltrials.gov/study/NCT01853748,https://clinicaltrials.gov/study/NCT04733118
MONDO_0007254	breast cancer	CHEMBL491473	CEDIRANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT00454805
EFO_0005537	triple-negative breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV2	NADH:ubiquinone oxidoreductase core subunit V2	2	Unknown status	https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT02506777
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS8	NADH:ubiquinone oxidoreductase core subunit S8	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Recruiting	https://clinicaltrials.gov/study/NCT05570253,https://clinicaltrials.gov/study/NCT05402722
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Unknown status	https://clinicaltrials.gov/study/NCT01372579
EFO_0000305	breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Terminated	https://clinicaltrials.gov/study/NCT00752986,https://clinicaltrials.gov/study/NCT01934335,https://clinicaltrials.gov/study/NCT00481845
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05041101
EFO_1000984	inflammatory breast carcinoma	CHEMBL359744	DOXORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Completed	https://clinicaltrials.gov/study/NCT00513695,https://clinicaltrials.gov/study/NCT00049114
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT00733408,https://clinicaltrials.gov/study/NCT01881230,https://clinicaltrials.gov/study/NCT01818063,https://clinicaltrials.gov/study/NCT02413320,https://clinicaltrials.gov/study/NCT03853707,https://clinicaltrials.gov/study/NCT03057600,https://clinicaltrials.gov/study/NCT02689427
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB1	NADH:ubiquinone oxidoreductase subunit B1	2	Recruiting	https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT04559308,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT03238495
MONDO_0007254	breast cancer	CHEMBL1289494	TIVOZANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Terminated	https://clinicaltrials.gov/study/NCT01745367
MONDO_0007254	breast cancer	CHEMBL2108029	ERTUMAXOMAB	Antibody	T-cell surface glycoprotein CD3 epsilon chain cross-linking agent		CD3E	CD3 epsilon subunit of T-cell receptor complex	2	Terminated	https://clinicaltrials.gov/study/NCT00452140,https://clinicaltrials.gov/study/NCT00351858,https://clinicaltrials.gov/study/NCT00522457
MONDO_0007254	breast cancer	CHEMBL3545414	RIVOCERANIB MESYLATE	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Enrolling by invitation	https://clinicaltrials.gov/study/NCT03580395
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	2	Recruiting	https://clinicaltrials.gov/study/NCT03698383
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Unknown status	https://clinicaltrials.gov/study/NCT01372579
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Terminated	https://clinicaltrials.gov/study/NCT02978716
EFO_0000553	invasive lobular carcinoma	CHEMBL1983268	ENTRECTINIB	Small molecule	Proto-oncogene tyrosine-protein kinase ROS inhibitor		ROS1	ROS proto-oncogene 1, receptor tyrosine kinase	2	Recruiting	https://clinicaltrials.gov/study/NCT04551495
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS3	NADH:ubiquinone oxidoreductase core subunit S3	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Tyrosine-protein kinase TIE-2 inhibitor		TEK	TEK receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00494481
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF2	NADH:ubiquinone oxidoreductase complex assembly factor 2	2	Terminated	https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT02360059
MONDO_0007254	breast cancer	CHEMBL1738758	ONVANSERTIB	Small molecule	Serine/threonine-protein kinase PLK1 inhibitor		PLK1	polo like kinase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05383196
MONDO_0007254	breast cancer	CHEMBL1200675	TOREMIFENE CITRATE	Small molecule	Estrogen receptor modulator		ESR2	estrogen receptor 2	2	Unknown status	https://clinicaltrials.gov/study/NCT02132000
MONDO_0007254	breast cancer	CHEMBL112	ACETAMINOPHEN	Small molecule	Cyclooxygenase inhibitor		PTGS2	prostaglandin-endoperoxide synthase 2	2	Completed	https://clinicaltrials.gov/study/NCT03084536,https://clinicaltrials.gov/study/NCT02839668
MONDO_0007254	breast cancer	CHEMBL572881	MOTESANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Terminated	https://clinicaltrials.gov/study/NCT00356681
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00074269,https://clinicaltrials.gov/study/NCT00376805
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND3	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase RAF inhibitor		RAF1	Raf-1 proto-oncogene, serine/threonine kinase	2	Unknown status	https://clinicaltrials.gov/study/NCT00499525,https://clinicaltrials.gov/study/NCT00954135
EFO_0000305	breast carcinoma	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT02296801,https://clinicaltrials.gov/study/NCT02894398,https://clinicaltrials.gov/study/NCT03007979,https://clinicaltrials.gov/study/NCT03809988,https://clinicaltrials.gov/study/NCT04256941
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT02682693,https://clinicaltrials.gov/study/NCT00513695,https://clinicaltrials.gov/study/NCT02199418
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT00214864,https://clinicaltrials.gov/study/NCT00493649,https://clinicaltrials.gov/study/NCT01025349,https://clinicaltrials.gov/study/NCT01038804,https://clinicaltrials.gov/study/NCT00247481,https://clinicaltrials.gov/study/NCT00041067,https://clinicaltrials.gov/study/NCT00123929,https://clinicaltrials.gov/study/NCT01396655,https://clinicaltrials.gov/study/NCT04664972,https://clinicaltrials.gov/study/NCT01150513,https://clinicaltrials.gov/study/NCT00193050,https://clinicaltrials.gov/study/NCT00198237,https://clinicaltrials.gov/study/NCT00028873,https://clinicaltrials.gov/study/NCT00193180,https://clinicaltrials.gov/study/NCT03742986,https://clinicaltrials.gov/study/NCT00365365,https://clinicaltrials.gov/study/NCT00004906,https://clinicaltrials.gov/study/NCT02846428,https://clinicaltrials.gov/study/NCT00404066,https://clinicaltrials.gov/study/NCT02005549,https://clinicaltrials.gov/study/NCT03887130,https://clinicaltrials.gov/study/NCT00769470,https://clinicaltrials.gov/study/NCT00149214,https://clinicaltrials.gov/study/NCT00015938,https://clinicaltrials.gov/study/NCT01658462,https://clinicaltrials.gov/study/NCT00129376,https://clinicaltrials.gov/study/NCT00645866,https://clinicaltrials.gov/study/NCT00079118,https://clinicaltrials.gov/study/NCT00773695,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00066443,https://clinicaltrials.gov/study/NCT00193089,https://clinicaltrials.gov/study/NCT00155259,https://clinicaltrials.gov/study/NCT00212082,https://clinicaltrials.gov/study/NCT00475670,https://clinicaltrials.gov/study/NCT00712881,https://clinicaltrials.gov/study/NCT00055861,https://clinicaltrials.gov/study/NCT00841828,https://clinicaltrials.gov/study/NCT00068341,https://clinicaltrials.gov/study/NCT02132949,https://clinicaltrials.gov/study/NCT01208480,https://clinicaltrials.gov/study/NCT00209092,https://clinicaltrials.gov/study/NCT00754351,https://clinicaltrials.gov/study/NCT00604435,https://clinicaltrials.gov/study/NCT00148070,https://clinicaltrials.gov/study/NCT00005963,https://clinicaltrials.gov/study/NCT00044993,https://clinicaltrials.gov/study/NCT00003565,https://clinicaltrials.gov/study/NCT00527449,https://clinicaltrials.gov/study/NCT00003352,https://clinicaltrials.gov/study/NCT02834403,https://clinicaltrials.gov/study/NCT00258375,https://clinicaltrials.gov/study/NCT00179309,https://clinicaltrials.gov/study/NCT01671319,https://clinicaltrials.gov/study/NCT03140553,https://clinicaltrials.gov/study/NCT00600249,https://clinicaltrials.gov/study/NCT00820872,https://clinicaltrials.gov/study/NCT00248703,https://clinicaltrials.gov/study/NCT00499122,https://clinicaltrials.gov/study/NCT00193115,https://clinicaltrials.gov/study/NCT00054275,https://clinicaltrials.gov/study/NCT00464646,https://clinicaltrials.gov/study/NCT00039520,https://clinicaltrials.gov/study/NCT00679341,https://clinicaltrials.gov/study/NCT00365417,https://clinicaltrials.gov/study/NCT00490646,https://clinicaltrials.gov/study/NCT00525759,https://clinicaltrials.gov/study/NCT00015886,https://clinicaltrials.gov/study/NCT02041351,https://clinicaltrials.gov/study/NCT00274456,https://clinicaltrials.gov/study/NCT00524810,https://clinicaltrials.gov/study/NCT00217672,https://clinicaltrials.gov/study/NCT00695994,https://clinicaltrials.gov/study/NCT00432172,https://clinicaltrials.gov/study/NCT00006104,https://clinicaltrials.gov/study/NCT00077857,https://clinicaltrials.gov/study/NCT00107510,https://clinicaltrials.gov/study/NCT01959490,https://clinicaltrials.gov/study/NCT00203502,https://clinicaltrials.gov/study/NCT00206466,https://clinicaltrials.gov/study/NCT02909751,https://clinicaltrials.gov/study/NCT00005908,https://clinicaltrials.gov/study/NCT00005800,https://clinicaltrials.gov/study/NCT01540110,https://clinicaltrials.gov/study/NCT00006682,https://clinicaltrials.gov/study/NCT00379015,https://clinicaltrials.gov/study/NCT00148668,https://clinicaltrials.gov/study/NCT01142778,https://clinicaltrials.gov/study/NCT00364611,https://clinicaltrials.gov/study/NCT00820547,https://clinicaltrials.gov/study/NCT00004175,https://clinicaltrials.gov/study/NCT00004888,https://clinicaltrials.gov/study/NCT01485926,https://clinicaltrials.gov/study/NCT00319618,https://clinicaltrials.gov/study/NCT00146042,https://clinicaltrials.gov/study/NCT03735966,https://clinicaltrials.gov/study/NCT00494481,https://clinicaltrials.gov/study/NCT01527487,https://clinicaltrials.gov/study/NCT00976989,https://clinicaltrials.gov/study/NCT00203372,https://clinicaltrials.gov/study/NCT00193037,https://clinicaltrials.gov/study/NCT00559754,https://clinicaltrials.gov/study/NCT00027885,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT00941330,https://clinicaltrials.gov/study/NCT01367028,https://clinicaltrials.gov/study/NCT00003953,https://clinicaltrials.gov/study/NCT00232479,https://clinicaltrials.gov/study/NCT00191243,https://clinicaltrials.gov/study/NCT02137083,https://clinicaltrials.gov/study/NCT00088998,https://clinicaltrials.gov/study/NCT02748213,https://clinicaltrials.gov/study/NCT00206518,https://clinicaltrials.gov/study/NCT02365805,https://clinicaltrials.gov/study/NCT00201708,https://clinicaltrials.gov/study/NCT01792050,https://clinicaltrials.gov/study/NCT02229084,https://clinicaltrials.gov/study/NCT00212095,https://clinicaltrials.gov/study/NCT00428922,https://clinicaltrials.gov/study/NCT02838225,https://clinicaltrials.gov/study/NCT00545688,https://clinicaltrials.gov/study/NCT00206505,https://clinicaltrials.gov/study/NCT01446016
MONDO_0007254	breast cancer	CHEMBL4298006	ENVAFOLIMAB	Antibody	Programmed cell death 1 ligand 1 binding agent	Inhibitor	CD274	CD274 molecule	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04034823
MONDO_0007254	breast cancer	CHEMBL4279455	LAROTAXEL	Small molecule	Tubulin stabiliser		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT00387907,https://clinicaltrials.gov/study/NCT00087958
EFO_0005537	triple-negative breast cancer	CHEMBL2108658	TREMELIMUMAB	Antibody	Cytotoxic T-lymphocyte protein 4 inhibitor		CTLA4	cytotoxic T-lymphocyte associated protein 4	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Withdrawn	https://clinicaltrials.gov/study/NCT04351230
MONDO_0007254	breast cancer	CHEMBL1201179	LAPATINIB DITOSYLATE	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT00482391,https://clinicaltrials.gov/study/NCT01688609,https://clinicaltrials.gov/study/NCT00820872,https://clinicaltrials.gov/study/NCT01622868,https://clinicaltrials.gov/study/NCT00967031,https://clinicaltrials.gov/study/NCT00436566,https://clinicaltrials.gov/study/NCT00769470
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Recruiting	https://clinicaltrials.gov/study/NCT05068141,https://clinicaltrials.gov/study/NCT04771871,https://clinicaltrials.gov/study/NCT05346107,https://clinicaltrials.gov/study/NCT03150576,https://clinicaltrials.gov/study/NCT03571633,https://clinicaltrials.gov/study/NCT05852691,https://clinicaltrials.gov/study/NCT04872985,https://clinicaltrials.gov/study/NCT05749575,https://clinicaltrials.gov/study/NCT04676997,https://clinicaltrials.gov/study/NCT01817452,https://clinicaltrials.gov/study/NCT05659056,https://clinicaltrials.gov/study/NCT05918328,https://clinicaltrials.gov/study/NCT05633914,https://clinicaltrials.gov/study/NCT05761470,https://clinicaltrials.gov/study/NCT04159142,https://clinicaltrials.gov/study/NCT05020860,https://clinicaltrials.gov/study/NCT04425018,https://clinicaltrials.gov/study/NCT03907800,https://clinicaltrials.gov/study/NCT05353361,https://clinicaltrials.gov/study/NCT05728268,https://clinicaltrials.gov/study/NCT03412643,https://clinicaltrials.gov/study/NCT04243616,https://clinicaltrials.gov/study/NCT05900206,https://clinicaltrials.gov/study/NCT04877821,https://clinicaltrials.gov/study/NCT04443348,https://clinicaltrials.gov/study/NCT04090398,https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT04537286,https://clinicaltrials.gov/study/NCT04722718,https://clinicaltrials.gov/study/NCT04355858,https://clinicaltrials.gov/study/NCT04329065,https://clinicaltrials.gov/study/NCT05383196,https://clinicaltrials.gov/study/NCT06245889,https://clinicaltrials.gov/study/NCT05447702,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04576143,https://clinicaltrials.gov/study/NCT04893109,https://clinicaltrials.gov/study/NCT05325632,https://clinicaltrials.gov/study/NCT05681728,https://clinicaltrials.gov/study/NCT05749016,https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT05582538,https://clinicaltrials.gov/study/NCT05889390,https://clinicaltrials.gov/study/NCT05629429,https://clinicaltrials.gov/study/NCT05189067,https://clinicaltrials.gov/study/NCT03048942,https://clinicaltrials.gov/study/NCT05174832,https://clinicaltrials.gov/study/NCT04917900,https://clinicaltrials.gov/study/NCT04780347,https://clinicaltrials.gov/study/NCT03424005
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS3	NADH:ubiquinone oxidoreductase core subunit S3	2	Completed	https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT02488564
MONDO_0007254	breast cancer	CHEMBL1544	LIOTHYRONINE	Small molecule	Thyroid hormone receptor agonist		THRA	thyroid hormone receptor alpha	2	Terminated	https://clinicaltrials.gov/study/NCT03787303
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
MONDO_0007254	breast cancer	CHEMBL384467	DEXAMETHASONE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	2	Recruiting	https://clinicaltrials.gov/study/NCT04947189
EFO_0005537	triple-negative breast cancer	CHEMBL3989868	TUCATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04262804,https://clinicaltrials.gov/study/NCT00431704,https://clinicaltrials.gov/study/NCT03414658
MONDO_0007254	breast cancer	CHEMBL223360	LINIFANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Completed	https://clinicaltrials.gov/study/NCT00645177
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Enrolling by invitation	https://clinicaltrials.gov/study/NCT03580395
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Unknown status	https://clinicaltrials.gov/study/NCT03144947
MONDO_0007254	breast cancer	CHEMBL3644587	2X-121	Small molecule	Tankyrase 1/2 inhibitor		TNKS2	tankyrase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03562832
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT00006261
MONDO_0007254	breast cancer	CHEMBL2105694	TELAPRISTONE ACETATE	Small molecule	Progesterone receptor modulator		PGR	progesterone receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT01800422
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Epidermal growth factor receptor inhibitor		ERBB4	erb-b2 receptor tyrosine kinase 4	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999
MONDO_0007254	breast cancer	CHEMBL1201748	CABAZITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT01693549
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT00284180
EFO_0009780	HER2 negative breast carcinoma	CHEMBL4297715	CAMRELIZUMAB	Antibody	Programmed cell death protein 1 antagonist		PDCD1	programmed cell death 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05085626,https://clinicaltrials.gov/study/NCT05656131
EFO_0005537	triple-negative breast cancer	CHEMBL3186534	RIVOCERANIB	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT03775928,https://clinicaltrials.gov/study/NCT05192798,https://clinicaltrials.gov/study/NCT05556200
MONDO_0007254	breast cancer	CHEMBL491473	CEDIRANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Completed	https://clinicaltrials.gov/study/NCT00454805
EFO_0005537	triple-negative breast cancer	CHEMBL3186534	RIVOCERANIB	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Completed	https://clinicaltrials.gov/study/NCT03243838
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06078384
EFO_0005537	triple-negative breast cancer	CHEMBL4298178	TRASTUZUMAB DUOCARMAZINE	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 binding agent		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0006861	male breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
EFO_0005537	triple-negative breast cancer	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02595905
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT02199418
MONDO_0007254	breast cancer	CHEMBL4297181	SAMOTOLISIB	Small molecule	Serine/threonine-protein kinase mTOR inhibitor		MTOR	mechanistic target of rapamycin kinase	2	Completed	https://clinicaltrials.gov/study/NCT04032080
MONDO_0007254	breast cancer	CHEMBL2146883	COBIMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 1 inhibitor		MAP2K1	mitogen-activated protein kinase kinase 1	2	Terminated	https://clinicaltrials.gov/study/NCT02322814
MONDO_0007254	breast cancer	CHEMBL4650256	ZANIDATAMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC2	NADH:ubiquinone oxidoreductase subunit C2	2	Unknown status	https://clinicaltrials.gov/study/NCT02506777,https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT02506790
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Recruiting	https://clinicaltrials.gov/study/NCT04090398,https://clinicaltrials.gov/study/NCT04266249,https://clinicaltrials.gov/study/NCT03606967
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Terminated	https://clinicaltrials.gov/study/NCT00832338
MONDO_0007254	breast cancer	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	2	Terminated	https://clinicaltrials.gov/study/NCT01194427,https://clinicaltrials.gov/study/NCT04190056,https://clinicaltrials.gov/study/NCT00096369,https://clinicaltrials.gov/study/NCT00290654,https://clinicaltrials.gov/study/NCT02269670,https://clinicaltrials.gov/study/NCT00206492,https://clinicaltrials.gov/study/NCT00684216,https://clinicaltrials.gov/study/NCT02322853
MONDO_0007254	breast cancer	CHEMBL1743028	GLEMBATUMUMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT01997333,https://clinicaltrials.gov/study/NCT01156753
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC2	NADH:ubiquinone oxidoreductase subunit C2	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0005537	triple-negative breast cancer	CHEMBL3137318	TALAZOPARIB TOSYLATE	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Completed	https://clinicaltrials.gov/study/NCT02401347
EFO_0005537	triple-negative breast cancer	CHEMBL3545132	MIRVETUXIMAB SORAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT03106077
EFO_0006318	breast ductal adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Terminated	https://clinicaltrials.gov/study/NCT01891357
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA3	NADH:ubiquinone oxidoreductase subunit A3	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT04559308,https://clinicaltrials.gov/study/NCT04300790
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHB3	EPH receptor B3	2	Terminated	https://clinicaltrials.gov/study/NCT00752986,https://clinicaltrials.gov/study/NCT01934335,https://clinicaltrials.gov/study/NCT00481845
EFO_1000984	inflammatory breast carcinoma	CHEMBL1487	ATORVASTATIN	Small molecule	HMG-CoA reductase inhibitor		HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase	2	Completed	https://clinicaltrials.gov/study/NCT03872388
MONDO_0007254	breast cancer	CHEMBL3301587	DURVALUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor	Inhibitor	CD274	CD274 molecule	2	Terminated	https://clinicaltrials.gov/study/NCT03874325
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03609047,https://clinicaltrials.gov/study/NCT00295893,https://clinicaltrials.gov/study/NCT03161353,https://clinicaltrials.gov/study/NCT02624973,https://clinicaltrials.gov/study/NCT02568839,https://clinicaltrials.gov/study/NCT00496795,https://clinicaltrials.gov/study/NCT02547987,https://clinicaltrials.gov/study/NCT02339532,https://clinicaltrials.gov/study/NCT01779206,https://clinicaltrials.gov/study/NCT04172259,https://clinicaltrials.gov/study/NCT02299999
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00548899,https://clinicaltrials.gov/study/NCT00634634,https://clinicaltrials.gov/study/NCT00101400,https://clinicaltrials.gov/study/NCT01320111,https://clinicaltrials.gov/study/NCT00493636
MONDO_0007254	breast cancer	CHEMBL3545068	COPANLISIB HYDROCHLORIDE	Small molecule	PI3-kinase p110-delta subunit inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03939897
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT00044993,https://clinicaltrials.gov/study/NCT02748213,https://clinicaltrials.gov/study/NCT00123929,https://clinicaltrials.gov/study/NCT02365805,https://clinicaltrials.gov/study/NCT00193089,https://clinicaltrials.gov/study/NCT00499122,https://clinicaltrials.gov/study/NCT00976989,https://clinicaltrials.gov/study/NCT00148668,https://clinicaltrials.gov/study/NCT00028873,https://clinicaltrials.gov/study/NCT00319618,https://clinicaltrials.gov/study/NCT01150513,https://clinicaltrials.gov/study/NCT02838225,https://clinicaltrials.gov/study/NCT00379015,https://clinicaltrials.gov/study/NCT00527449,https://clinicaltrials.gov/study/NCT00206505,https://clinicaltrials.gov/study/NCT00193115,https://clinicaltrials.gov/study/NCT00193180,https://clinicaltrials.gov/study/NCT00198237,https://clinicaltrials.gov/study/NCT00364611,https://clinicaltrials.gov/study/NCT00107510,https://clinicaltrials.gov/study/NCT00179309,https://clinicaltrials.gov/study/NCT00079118,https://clinicaltrials.gov/study/NCT00005800,https://clinicaltrials.gov/study/NCT00232479,https://clinicaltrials.gov/study/NCT00003565,https://clinicaltrials.gov/study/NCT00525759,https://clinicaltrials.gov/study/NCT00005963,https://clinicaltrials.gov/study/NCT00432172,https://clinicaltrials.gov/study/NCT00206518,https://clinicaltrials.gov/study/NCT01396655,https://clinicaltrials.gov/study/NCT01792050,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT00712881,https://clinicaltrials.gov/study/NCT00941330,https://clinicaltrials.gov/study/NCT03140553,https://clinicaltrials.gov/study/NCT00212082,https://clinicaltrials.gov/study/NCT00206466,https://clinicaltrials.gov/study/NCT00679341,https://clinicaltrials.gov/study/NCT00004906,https://clinicaltrials.gov/study/NCT00695994,https://clinicaltrials.gov/study/NCT00129376,https://clinicaltrials.gov/study/NCT00769470,https://clinicaltrials.gov/study/NCT00003953,https://clinicaltrials.gov/study/NCT00006104,https://clinicaltrials.gov/study/NCT01142778,https://clinicaltrials.gov/study/NCT00004175,https://clinicaltrials.gov/study/NCT01540110,https://clinicaltrials.gov/study/NCT00027885,https://clinicaltrials.gov/study/NCT01671319,https://clinicaltrials.gov/study/NCT00820547,https://clinicaltrials.gov/study/NCT02909751,https://clinicaltrials.gov/study/NCT00212095,https://clinicaltrials.gov/study/NCT00754351,https://clinicaltrials.gov/study/NCT00155259,https://clinicaltrials.gov/study/NCT00015938,https://clinicaltrials.gov/study/NCT00191243,https://clinicaltrials.gov/study/NCT02005549,https://clinicaltrials.gov/study/NCT00214864,https://clinicaltrials.gov/study/NCT00088998,https://clinicaltrials.gov/study/NCT00600249,https://clinicaltrials.gov/study/NCT00003352,https://clinicaltrials.gov/study/NCT00068341,https://clinicaltrials.gov/study/NCT03742986,https://clinicaltrials.gov/study/NCT01208480,https://clinicaltrials.gov/study/NCT02834403,https://clinicaltrials.gov/study/NCT00464646,https://clinicaltrials.gov/study/NCT00247481,https://clinicaltrials.gov/study/NCT00604435,https://clinicaltrials.gov/study/NCT00274456,https://clinicaltrials.gov/study/NCT00645866,https://clinicaltrials.gov/study/NCT00258375,https://clinicaltrials.gov/study/NCT02137083,https://clinicaltrials.gov/study/NCT00039520,https://clinicaltrials.gov/study/NCT00146042,https://clinicaltrials.gov/study/NCT00209092,https://clinicaltrials.gov/study/NCT01038804,https://clinicaltrials.gov/study/NCT00545688,https://clinicaltrials.gov/study/NCT00490646,https://clinicaltrials.gov/study/NCT01658462,https://clinicaltrials.gov/study/NCT00475670,https://clinicaltrials.gov/study/NCT00193037,https://clinicaltrials.gov/study/NCT00077857,https://clinicaltrials.gov/study/NCT02041351,https://clinicaltrials.gov/study/NCT00203372,https://clinicaltrials.gov/study/NCT01485926,https://clinicaltrials.gov/study/NCT00193050,https://clinicaltrials.gov/study/NCT00149214,https://clinicaltrials.gov/study/NCT02132949,https://clinicaltrials.gov/study/NCT00201708,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00055861,https://clinicaltrials.gov/study/NCT00404066,https://clinicaltrials.gov/study/NCT00559754,https://clinicaltrials.gov/study/NCT01527487,https://clinicaltrials.gov/study/NCT00493649,https://clinicaltrials.gov/study/NCT00054275,https://clinicaltrials.gov/study/NCT00066443,https://clinicaltrials.gov/study/NCT00217672,https://clinicaltrials.gov/study/NCT01959490,https://clinicaltrials.gov/study/NCT00004888,https://clinicaltrials.gov/study/NCT00203502,https://clinicaltrials.gov/study/NCT00148070,https://clinicaltrials.gov/study/NCT00841828,https://clinicaltrials.gov/study/NCT00524810,https://clinicaltrials.gov/study/NCT02229084,https://clinicaltrials.gov/study/NCT03735966,https://clinicaltrials.gov/study/NCT00773695,https://clinicaltrials.gov/study/NCT00015886,https://clinicaltrials.gov/study/NCT04664972,https://clinicaltrials.gov/study/NCT00005908,https://clinicaltrials.gov/study/NCT00006682,https://clinicaltrials.gov/study/NCT02846428,https://clinicaltrials.gov/study/NCT01367028,https://clinicaltrials.gov/study/NCT03887130,https://clinicaltrials.gov/study/NCT00494481,https://clinicaltrials.gov/study/NCT00248703,https://clinicaltrials.gov/study/NCT00365417,https://clinicaltrials.gov/study/NCT01446016,https://clinicaltrials.gov/study/NCT00428922,https://clinicaltrials.gov/study/NCT00820872,https://clinicaltrials.gov/study/NCT01025349,https://clinicaltrials.gov/study/NCT00365365,https://clinicaltrials.gov/study/NCT00041067
EFO_0005537	triple-negative breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03911973
EFO_0000305	breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967
MONDO_0007254	breast cancer	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04236310
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA5	NADH:ubiquinone oxidoreductase subunit A5	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Unknown status	https://clinicaltrials.gov/study/NCT03144947
MONDO_0007254	breast cancer	CHEMBL723	CARVEDILOL	Small molecule	Adrenergic receptor alpha-1 antagonist		ADRA1B	adrenoceptor alpha 1B	2	Completed	https://clinicaltrials.gov/study/NCT01009918,https://clinicaltrials.gov/study/NCT02177175
MONDO_0007254	breast cancer	CHEMBL409	BICALUTAMIDE	Small molecule	Androgen Receptor antagonist		AR	androgen receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT03090165
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Terminated	https://clinicaltrials.gov/study/NCT00832338
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Tyrosine-protein kinase SRC inhibitor		SRC	SRC proto-oncogene, non-receptor tyrosine kinase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999
MONDO_0007254	breast cancer	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	2	Terminated	https://clinicaltrials.gov/study/NCT00006032,https://clinicaltrials.gov/study/NCT00020722,https://clinicaltrials.gov/study/NCT00810017
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Withdrawn	https://clinicaltrials.gov/study/NCT02067416,https://clinicaltrials.gov/study/NCT01229605,https://clinicaltrials.gov/study/NCT00964704,https://clinicaltrials.gov/study/NCT00434031,https://clinicaltrials.gov/study/NCT01825265,https://clinicaltrials.gov/study/NCT00006261,https://clinicaltrials.gov/study/NCT00678626
EFO_0005537	triple-negative breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Suspended	https://clinicaltrials.gov/study/NCT04095689
EFO_0005537	triple-negative breast cancer	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT04266249
EFO_1000984	inflammatory breast carcinoma	CHEMBL535	SUNITINIB	Small molecule	Platelet-derived growth factor receptor alpha inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Completed	https://clinicaltrials.gov/study/NCT00513695
MONDO_0007254	breast cancer	CHEMBL1908360	EVEROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	2	Withdrawn	https://clinicaltrials.gov/study/NCT05079360,https://clinicaltrials.gov/study/NCT01825265,https://clinicaltrials.gov/study/NCT00855114
MONDO_0007254	breast cancer	CHEMBL3813873	PEXIDARTINIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL502835	NINTEDANIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR2	fibroblast growth factor receptor 2	2	Completed	https://clinicaltrials.gov/study/NCT01658462
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00470249,https://clinicaltrials.gov/study/NCT00095888,https://clinicaltrials.gov/study/NCT00679029,https://clinicaltrials.gov/study/NCT00323063
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Terminated	https://clinicaltrials.gov/study/NCT03894007,https://clinicaltrials.gov/study/NCT01702558,https://clinicaltrials.gov/study/NCT03709082
MONDO_0007254	breast cancer	CHEMBL3301587	DURVALUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor	Inhibitor	CD274	CD274 molecule	2	Recruiting	https://clinicaltrials.gov/study/NCT05498155,https://clinicaltrials.gov/study/NCT05215106,https://clinicaltrials.gov/study/NCT05582538,https://clinicaltrials.gov/study/NCT03820141,https://clinicaltrials.gov/study/NCT05720260,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT05795101
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04345913
MONDO_0007254	breast cancer	CHEMBL679	EPINEPHRINE	Small molecule	Adrenergic receptor agonist		ADRB3	adrenoceptor beta 3	2	Completed	https://clinicaltrials.gov/study/NCT02525718
MONDO_0007254	breast cancer	CHEMBL109480	TANESPIMYCIN	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AB1	heat shock protein 90 alpha family class B member 1	2	Terminated	https://clinicaltrials.gov/study/NCT00096109
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT00247481,https://clinicaltrials.gov/study/NCT00039520,https://clinicaltrials.gov/study/NCT00527449,https://clinicaltrials.gov/study/NCT00209092,https://clinicaltrials.gov/study/NCT00214864,https://clinicaltrials.gov/study/NCT00212082,https://clinicaltrials.gov/study/NCT01527487,https://clinicaltrials.gov/study/NCT00428922,https://clinicaltrials.gov/study/NCT00712881,https://clinicaltrials.gov/study/NCT00148668,https://clinicaltrials.gov/study/NCT00604435,https://clinicaltrials.gov/study/NCT00005908,https://clinicaltrials.gov/study/NCT00365417,https://clinicaltrials.gov/study/NCT00464646,https://clinicaltrials.gov/study/NCT00545688,https://clinicaltrials.gov/study/NCT00524810,https://clinicaltrials.gov/study/NCT00248703,https://clinicaltrials.gov/study/NCT00003352,https://clinicaltrials.gov/study/NCT02132949,https://clinicaltrials.gov/study/NCT00004175,https://clinicaltrials.gov/study/NCT00559754,https://clinicaltrials.gov/study/NCT04664972,https://clinicaltrials.gov/study/NCT00077857,https://clinicaltrials.gov/study/NCT00054275,https://clinicaltrials.gov/study/NCT01208480,https://clinicaltrials.gov/study/NCT00820872,https://clinicaltrials.gov/study/NCT00773695,https://clinicaltrials.gov/study/NCT00068341,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT01025349,https://clinicaltrials.gov/study/NCT00198237,https://clinicaltrials.gov/study/NCT00976989,https://clinicaltrials.gov/study/NCT00232479,https://clinicaltrials.gov/study/NCT00379015,https://clinicaltrials.gov/study/NCT02041351,https://clinicaltrials.gov/study/NCT02229084,https://clinicaltrials.gov/study/NCT00193050,https://clinicaltrials.gov/study/NCT00041067,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00203372,https://clinicaltrials.gov/study/NCT00149214,https://clinicaltrials.gov/study/NCT00015938,https://clinicaltrials.gov/study/NCT00044993,https://clinicaltrials.gov/study/NCT00003953,https://clinicaltrials.gov/study/NCT00146042,https://clinicaltrials.gov/study/NCT00319618,https://clinicaltrials.gov/study/NCT01671319,https://clinicaltrials.gov/study/NCT00525759,https://clinicaltrials.gov/study/NCT02838225,https://clinicaltrials.gov/study/NCT00475670,https://clinicaltrials.gov/study/NCT00066443,https://clinicaltrials.gov/study/NCT03140553,https://clinicaltrials.gov/study/NCT01792050,https://clinicaltrials.gov/study/NCT01485926,https://clinicaltrials.gov/study/NCT00274456,https://clinicaltrials.gov/study/NCT00201708,https://clinicaltrials.gov/study/NCT02748213,https://clinicaltrials.gov/study/NCT00494481,https://clinicaltrials.gov/study/NCT00006104,https://clinicaltrials.gov/study/NCT01367028,https://clinicaltrials.gov/study/NCT00148070,https://clinicaltrials.gov/study/NCT01540110,https://clinicaltrials.gov/study/NCT01038804,https://clinicaltrials.gov/study/NCT01142778,https://clinicaltrials.gov/study/NCT00027885,https://clinicaltrials.gov/study/NCT03735966,https://clinicaltrials.gov/study/NCT03742986,https://clinicaltrials.gov/study/NCT01150513,https://clinicaltrials.gov/study/NCT00107510,https://clinicaltrials.gov/study/NCT00645866,https://clinicaltrials.gov/study/NCT00404066,https://clinicaltrials.gov/study/NCT00004888,https://clinicaltrials.gov/study/NCT00179309,https://clinicaltrials.gov/study/NCT01658462,https://clinicaltrials.gov/study/NCT00088998,https://clinicaltrials.gov/study/NCT00191243,https://clinicaltrials.gov/study/NCT00212095,https://clinicaltrials.gov/study/NCT00432172,https://clinicaltrials.gov/study/NCT00841828,https://clinicaltrials.gov/study/NCT01446016,https://clinicaltrials.gov/study/NCT00364611,https://clinicaltrials.gov/study/NCT00941330,https://clinicaltrials.gov/study/NCT00005963,https://clinicaltrials.gov/study/NCT00193089,https://clinicaltrials.gov/study/NCT00123929,https://clinicaltrials.gov/study/NCT00006682,https://clinicaltrials.gov/study/NCT00055861,https://clinicaltrials.gov/study/NCT00695994,https://clinicaltrials.gov/study/NCT01396655,https://clinicaltrials.gov/study/NCT02846428,https://clinicaltrials.gov/study/NCT00493649,https://clinicaltrials.gov/study/NCT00206466,https://clinicaltrials.gov/study/NCT00193180,https://clinicaltrials.gov/study/NCT00129376,https://clinicaltrials.gov/study/NCT00155259,https://clinicaltrials.gov/study/NCT00028873,https://clinicaltrials.gov/study/NCT00769470,https://clinicaltrials.gov/study/NCT02834403,https://clinicaltrials.gov/study/NCT00005800,https://clinicaltrials.gov/study/NCT00499122,https://clinicaltrials.gov/study/NCT00079118,https://clinicaltrials.gov/study/NCT00258375,https://clinicaltrials.gov/study/NCT00365365,https://clinicaltrials.gov/study/NCT02137083,https://clinicaltrials.gov/study/NCT01959490,https://clinicaltrials.gov/study/NCT00193037,https://clinicaltrials.gov/study/NCT02005549,https://clinicaltrials.gov/study/NCT00206505,https://clinicaltrials.gov/study/NCT00217672,https://clinicaltrials.gov/study/NCT00193115,https://clinicaltrials.gov/study/NCT00203502,https://clinicaltrials.gov/study/NCT00004906,https://clinicaltrials.gov/study/NCT00490646,https://clinicaltrials.gov/study/NCT00003565,https://clinicaltrials.gov/study/NCT00206518,https://clinicaltrials.gov/study/NCT03887130,https://clinicaltrials.gov/study/NCT02365805,https://clinicaltrials.gov/study/NCT00754351,https://clinicaltrials.gov/study/NCT00679341,https://clinicaltrials.gov/study/NCT02909751,https://clinicaltrials.gov/study/NCT00820547,https://clinicaltrials.gov/study/NCT00600249,https://clinicaltrials.gov/study/NCT00015886
MONDO_0007254	breast cancer	CHEMBL2177390	IPATASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT1	AKT serine/threonine kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT04464174,https://clinicaltrials.gov/study/NCT02301988,https://clinicaltrials.gov/study/NCT03853707
MONDO_0007254	breast cancer	CHEMBL325041	BORTEZOMIB	Small molecule	26S proteosome inhibitor		PSMB5	proteasome 20S subunit beta 5	2	Completed	https://clinicaltrials.gov/study/NCT00025584,https://clinicaltrials.gov/study/NCT00028639
EFO_0000304	breast adenocarcinoma	CHEMBL841	LOPERAMIDE	Small molecule	Mu opioid receptor agonist		OPRM1	opioid receptor mu 1	2	Completed	https://clinicaltrials.gov/study/NCT03094052
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Recruiting	https://clinicaltrials.gov/study/NCT04266249,https://clinicaltrials.gov/study/NCT03606967,https://clinicaltrials.gov/study/NCT04090398
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS5	NADH:ubiquinone oxidoreductase subunit S5	2	Recruiting	https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT04559308,https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04251169,https://clinicaltrials.gov/study/NCT02734290,https://clinicaltrials.gov/study/NCT03387085,https://clinicaltrials.gov/study/NCT04734262,https://clinicaltrials.gov/study/NCT02779855,https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT04398914,https://clinicaltrials.gov/study/NCT00003042,https://clinicaltrials.gov/study/NCT05498896,https://clinicaltrials.gov/study/NCT02788981,https://clinicaltrials.gov/study/NCT01796197,https://clinicaltrials.gov/study/NCT03616886,https://clinicaltrials.gov/study/NCT00609791,https://clinicaltrials.gov/study/NCT01730833,https://clinicaltrials.gov/study/NCT00295893,https://clinicaltrials.gov/study/NCT04083963,https://clinicaltrials.gov/study/NCT01815242,https://clinicaltrials.gov/study/NCT03950570,https://clinicaltrials.gov/study/NCT04215146,https://clinicaltrials.gov/study/NCT04172259,https://clinicaltrials.gov/study/NCT04603183,https://clinicaltrials.gov/study/NCT03568422,https://clinicaltrials.gov/study/NCT00616967,https://clinicaltrials.gov/study/NCT01779206,https://clinicaltrials.gov/study/NCT03609047,https://clinicaltrials.gov/study/NCT03567720,https://clinicaltrials.gov/study/NCT03747120,https://clinicaltrials.gov/study/NCT03125928,https://clinicaltrials.gov/study/NCT02883062,https://clinicaltrials.gov/study/NCT01853748,https://clinicaltrials.gov/study/NCT02546232,https://clinicaltrials.gov/study/NCT01898117,https://clinicaltrials.gov/study/NCT02752685,https://clinicaltrials.gov/study/NCT01057069,https://clinicaltrials.gov/study/NCT02187991,https://clinicaltrials.gov/study/NCT04538742,https://clinicaltrials.gov/study/NCT04418154,https://clinicaltrials.gov/study/NCT04192331
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC7	histone deacetylase 7	2	Terminated	https://clinicaltrials.gov/study/NCT00777335
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT03997539,https://clinicaltrials.gov/study/NCT04143906,https://clinicaltrials.gov/study/NCT04922008,https://clinicaltrials.gov/study/NCT06229067,https://clinicaltrials.gov/study/NCT04963595
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Withdrawn	https://clinicaltrials.gov/study/NCT05809895,https://clinicaltrials.gov/study/NCT00005614
MONDO_0007254	breast cancer	CHEMBL939	GEFITINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Terminated	https://clinicaltrials.gov/study/NCT00206414,https://clinicaltrials.gov/study/NCT00206492,https://clinicaltrials.gov/study/NCT00082667
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02593175,https://clinicaltrials.gov/study/NCT04216472,https://clinicaltrials.gov/study/NCT01750073,https://clinicaltrials.gov/study/NCT02876107,https://clinicaltrials.gov/study/NCT04395989,https://clinicaltrials.gov/study/NCT04958785,https://clinicaltrials.gov/study/NCT04770272,https://clinicaltrials.gov/study/NCT02883062,https://clinicaltrials.gov/study/NCT02315196,https://clinicaltrials.gov/study/NCT02530489,https://clinicaltrials.gov/study/NCT04129996
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT02978716
MONDO_0007254	breast cancer	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Tyrosine-protein kinase LCK inhibitor		LCK	LCK proto-oncogene, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00509587
MONDO_0007254	breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02747004,https://clinicaltrials.gov/study/NCT04352777,https://clinicaltrials.gov/study/NCT04293393,https://clinicaltrials.gov/study/NCT04227327,https://clinicaltrials.gov/study/NCT04603183,https://clinicaltrials.gov/study/NCT03284957,https://clinicaltrials.gov/study/NCT04432454,https://clinicaltrials.gov/study/NCT03939897
EFO_0005537	triple-negative breast cancer	CHEMBL4297892	ANVATABART OPADOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0006861	male breast carcinoma	CHEMBL491473	CEDIRANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT00244881
EFO_0000305	breast carcinoma	CHEMBL4297883	IVUXOLIMAB	Antibody	Tumor necrosis factor receptor superfamily member 4 agonist		TNFRSF4	TNF receptor superfamily member 4	2	Recruiting	https://clinicaltrials.gov/study/NCT03971409
EFO_0005537	triple-negative breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967
MONDO_0007254	breast cancer	CHEMBL1173655	AFATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-4 inhibitor		ERBB4	erb-b2 receptor tyrosine kinase 4	2	Unknown status	https://clinicaltrials.gov/study/NCT02511847
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	2	Recruiting	https://clinicaltrials.gov/study/NCT04924699
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA4	EPH receptor A4	2	Terminated	https://clinicaltrials.gov/study/NCT00752986,https://clinicaltrials.gov/study/NCT01934335,https://clinicaltrials.gov/study/NCT00481845
MONDO_0007254	breast cancer	CHEMBL481	IRINOTECAN	Small molecule	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL1535	HYDROXYCHLOROQUINE	Small molecule	Toll-like receptor 7 antagonist		TLR7	toll like receptor 7	2	Terminated	https://clinicaltrials.gov/study/NCT00765765
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND2	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2	2	Completed	https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT00909506
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04502680
MONDO_0007254	breast cancer	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	2	Recruiting	https://clinicaltrials.gov/study/NCT05747326,https://clinicaltrials.gov/study/NCT04803539,https://clinicaltrials.gov/study/NCT04443348,https://clinicaltrials.gov/study/NCT04296162,https://clinicaltrials.gov/study/NCT04389073,https://clinicaltrials.gov/study/NCT04355858,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT04780347,https://clinicaltrials.gov/study/NCT04304352,https://clinicaltrials.gov/study/NCT04383275,https://clinicaltrials.gov/study/NCT05845138,https://clinicaltrials.gov/study/NCT04768426,https://clinicaltrials.gov/study/NCT03204734,https://clinicaltrials.gov/study/NCT05411380,https://clinicaltrials.gov/study/NCT05292742,https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT04849364,https://clinicaltrials.gov/study/NCT04571437,https://clinicaltrials.gov/study/NCT05575804,https://clinicaltrials.gov/study/NCT05163223,https://clinicaltrials.gov/study/NCT05042791,https://clinicaltrials.gov/study/NCT05390476,https://clinicaltrials.gov/study/NCT04789096,https://clinicaltrials.gov/study/NCT06085742,https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT05861271,https://clinicaltrials.gov/study/NCT06102824,https://clinicaltrials.gov/study/NCT04159142,https://clinicaltrials.gov/study/NCT06245889,https://clinicaltrials.gov/study/NCT04965064,https://clinicaltrials.gov/study/NCT04095390,https://clinicaltrials.gov/study/NCT04302441,https://clinicaltrials.gov/study/NCT03923166
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT00284180
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA10	NADH:ubiquinone oxidoreductase subunit A10	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE5A	phosphodiesterase 5A	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT06176339,https://clinicaltrials.gov/study/NCT06186700
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02414646
EFO_0005537	triple-negative breast cancer	CHEMBL4297892	ANVATABART OPADOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Recruiting	https://clinicaltrials.gov/study/NCT06075953
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4L2	NDUFA4 mitochondrial complex associated like 2	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000432	breast ductal carcinoma in situ	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Terminated	https://clinicaltrials.gov/study/NCT00461344
EFO_0006861	male breast carcinoma	CHEMBL491473	CEDIRANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT00244881
MONDO_0007254	breast cancer	CHEMBL131	PREDNISOLONE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	2	Unknown status	https://clinicaltrials.gov/study/NCT00687648
MONDO_0007254	breast cancer	CHEMBL1567	SUNITINIB MALATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT00482755
MONDO_0007254	breast cancer	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01872260,https://clinicaltrials.gov/study/NCT03822468,https://clinicaltrials.gov/study/NCT03671330,https://clinicaltrials.gov/study/NCT02632045,https://clinicaltrials.gov/study/NCT02712723,https://clinicaltrials.gov/study/NCT03944434,https://clinicaltrials.gov/study/NCT05384119
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02624973,https://clinicaltrials.gov/study/NCT00295893,https://clinicaltrials.gov/study/NCT03161353,https://clinicaltrials.gov/study/NCT02339532,https://clinicaltrials.gov/study/NCT01779206,https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT04172259,https://clinicaltrials.gov/study/NCT00496795,https://clinicaltrials.gov/study/NCT02547987,https://clinicaltrials.gov/study/NCT02568839,https://clinicaltrials.gov/study/NCT03609047
MONDO_0007254	breast cancer	CHEMBL4297892	ANVATABART OPADOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Recruiting	https://clinicaltrials.gov/study/NCT04829604,https://clinicaltrials.gov/study/NCT05018702,https://clinicaltrials.gov/study/NCT05018676,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT05426486
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC3	histone deacetylase 3	2	Terminated	https://clinicaltrials.gov/study/NCT00777335
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA5	NADH:ubiquinone oxidoreductase subunit A5	2	Completed	https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT05053841
MONDO_0007254	breast cancer	CHEMBL2220486	LUCITANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Completed	https://clinicaltrials.gov/study/NCT02053636
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Terminated	https://clinicaltrials.gov/study/NCT00532285,https://clinicaltrials.gov/study/NCT01745367,https://clinicaltrials.gov/study/NCT01194869,https://clinicaltrials.gov/study/NCT01416558,https://clinicaltrials.gov/study/NCT01329627,https://clinicaltrials.gov/study/NCT02322814,https://clinicaltrials.gov/study/NCT02598310,https://clinicaltrials.gov/study/NCT01009983,https://clinicaltrials.gov/study/NCT00456846,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT03894007,https://clinicaltrials.gov/study/NCT00691912,https://clinicaltrials.gov/study/NCT00622466,https://clinicaltrials.gov/study/NCT00194792,https://clinicaltrials.gov/study/NCT00607438,https://clinicaltrials.gov/study/NCT00434356,https://clinicaltrials.gov/study/NCT00589238,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT00356681,https://clinicaltrials.gov/study/NCT03329378,https://clinicaltrials.gov/study/NCT00479856,https://clinicaltrials.gov/study/NCT00536939,https://clinicaltrials.gov/study/NCT00934895,https://clinicaltrials.gov/study/NCT01147016,https://clinicaltrials.gov/study/NCT01120158,https://clinicaltrials.gov/study/NCT01207102,https://clinicaltrials.gov/study/NCT00679029,https://clinicaltrials.gov/study/NCT01069796,https://clinicaltrials.gov/study/NCT04066790,https://clinicaltrials.gov/study/NCT00542191,https://clinicaltrials.gov/study/NCT00756470
EFO_0000305	breast carcinoma	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06179303,https://clinicaltrials.gov/study/NCT06348134
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02286687
EFO_0005537	triple-negative breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Vascular endothelial growth factor receptor 1 inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05670925
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT00634634,https://clinicaltrials.gov/study/NCT00101400,https://clinicaltrials.gov/study/NCT00548899,https://clinicaltrials.gov/study/NCT00493636,https://clinicaltrials.gov/study/NCT01320111
MONDO_0007254	breast cancer	CHEMBL1873475	IBRUTINIB	Small molecule	Tyrosine-protein kinase BTK inhibitor		BTK	Bruton tyrosine kinase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03379428
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Terminated	https://clinicaltrials.gov/study/NCT00225056,https://clinicaltrials.gov/study/NCT01690325,https://clinicaltrials.gov/study/NCT00453635,https://clinicaltrials.gov/study/NCT03894007,https://clinicaltrials.gov/study/NCT00845910,https://clinicaltrials.gov/study/NCT00118053,https://clinicaltrials.gov/study/NCT00206453,https://clinicaltrials.gov/study/NCT01985841,https://clinicaltrials.gov/study/NCT03329378,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT00193024,https://clinicaltrials.gov/study/NCT00025493,https://clinicaltrials.gov/study/NCT00852332,https://clinicaltrials.gov/study/NCT00028483,https://clinicaltrials.gov/study/NCT00524459,https://clinicaltrials.gov/study/NCT00665457,https://clinicaltrials.gov/study/NCT00576901,https://clinicaltrials.gov/study/NCT00080626,https://clinicaltrials.gov/study/NCT00479856,https://clinicaltrials.gov/study/NCT00104624,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT00343512,https://clinicaltrials.gov/study/NCT00636441
EFO_0000304	breast adenocarcinoma	CHEMBL180022	NERATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Completed	https://clinicaltrials.gov/study/NCT03094052
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV1	NADH:ubiquinone oxidoreductase core subunit V1	2	Completed	https://clinicaltrials.gov/study/NCT01885013
MONDO_0007254	breast cancer	CHEMBL180022	NERATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Withdrawn	https://clinicaltrials.gov/study/NCT04901299
MONDO_0007254	breast cancer	CHEMBL306823	SODIUM DICHLOROACETATE	Small molecule	Pyruvate dehydrogenase kinase inhibitor		PDK1	pyruvate dehydrogenase kinase 1	2	Terminated	https://clinicaltrials.gov/study/NCT01029925
MONDO_0007254	breast cancer	CHEMBL4297736	PRALUZATAMAB RAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBA1A	tubulin alpha 1a	2	Completed	https://clinicaltrials.gov/study/NCT04596150
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Recruiting	https://clinicaltrials.gov/study/NCT05546255,https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT05458674,https://clinicaltrials.gov/study/NCT06102824,https://clinicaltrials.gov/study/NCT05810870,https://clinicaltrials.gov/study/NCT04624711,https://clinicaltrials.gov/study/NCT05530057,https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT03424005
EFO_0000305	breast carcinoma	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	2	Terminated	https://clinicaltrials.gov/study/NCT00183963
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01105650,https://clinicaltrials.gov/study/NCT00429572,https://clinicaltrials.gov/study/NCT00020176
MONDO_0007254	breast cancer	CHEMBL4298025	ZENOCUTUZUMAB	Antibody	ErbB-2/ErbB-3 heterodimer inhibitor		ERBB3	erb-b2 receptor tyrosine kinase 3	2	Completed	https://clinicaltrials.gov/study/NCT03321981
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR1	estrogen receptor 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04999540,https://clinicaltrials.gov/study/NCT05986071,https://clinicaltrials.gov/study/NCT05536128,https://clinicaltrials.gov/study/NCT05806671,https://clinicaltrials.gov/study/NCT05577923,https://clinicaltrials.gov/study/NCT05808582,https://clinicaltrials.gov/study/NCT05806047
MONDO_0007254	breast cancer	CHEMBL502835	NINTEDANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT01658462
EFO_0005537	triple-negative breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03639948
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR2	estrogen receptor 2	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05536128,https://clinicaltrials.gov/study/NCT04999540,https://clinicaltrials.gov/study/NCT05808582,https://clinicaltrials.gov/study/NCT05577923,https://clinicaltrials.gov/study/NCT05986071,https://clinicaltrials.gov/study/NCT05806047,https://clinicaltrials.gov/study/NCT05806671
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05041101,https://clinicaltrials.gov/study/NCT03202316
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA3	NADH:ubiquinone oxidoreductase subunit A3	2	Terminated	https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT02360059
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Recruiting	https://clinicaltrials.gov/study/NCT05530057,https://clinicaltrials.gov/study/NCT05546255,https://clinicaltrials.gov/study/NCT04624711
MONDO_0007254	breast cancer	CHEMBL2364626	RALIMETINIB	Small molecule	MAP kinase p38 alpha inhibitor		MAPK14	mitogen-activated protein kinase 14	2	Terminated	https://clinicaltrials.gov/study/NCT02322853
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00509587,https://clinicaltrials.gov/study/NCT01466972
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT01196052,https://clinicaltrials.gov/study/NCT00679341,https://clinicaltrials.gov/study/NCT01835236,https://clinicaltrials.gov/study/NCT00509769,https://clinicaltrials.gov/study/NCT02073487,https://clinicaltrials.gov/study/NCT00679211,https://clinicaltrials.gov/study/NCT03530696,https://clinicaltrials.gov/study/NCT02924883,https://clinicaltrials.gov/study/NCT00943670,https://clinicaltrials.gov/study/NCT01904903
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF2	NADH:ubiquinone oxidoreductase complex assembly factor 2	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03747120,https://clinicaltrials.gov/study/NCT02734290,https://clinicaltrials.gov/study/NCT03567720,https://clinicaltrials.gov/study/NCT02752685,https://clinicaltrials.gov/study/NCT04373031,https://clinicaltrials.gov/study/NCT03632941,https://clinicaltrials.gov/study/NCT03366844,https://clinicaltrials.gov/study/NCT04251169,https://clinicaltrials.gov/study/NCT04448886,https://clinicaltrials.gov/study/NCT03393845,https://clinicaltrials.gov/study/NCT03225547
MONDO_0007254	breast cancer	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT00509587
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT06026657,https://clinicaltrials.gov/study/NCT03606967
MONDO_0007254	breast cancer	CHEMBL4112930	PAMIPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Completed	https://clinicaltrials.gov/study/NCT03575065
EFO_0000305	breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF2	NADH:ubiquinone oxidoreductase complex assembly factor 2	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02568839,https://clinicaltrials.gov/study/NCT04001829
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1173055	RUCAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Completed	https://clinicaltrials.gov/study/NCT00664781
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04946227,https://clinicaltrials.gov/study/NCT04301375,https://clinicaltrials.gov/study/NCT04639271,https://clinicaltrials.gov/study/NCT04907344,https://clinicaltrials.gov/study/NCT05872412,https://clinicaltrials.gov/study/NCT04498793,https://clinicaltrials.gov/study/NCT04290793,https://clinicaltrials.gov/study/NCT04499118,https://clinicaltrials.gov/study/NCT05444998,https://clinicaltrials.gov/study/NCT04194684,https://clinicaltrials.gov/study/NCT03959397,https://clinicaltrials.gov/study/NCT04900311,https://clinicaltrials.gov/study/NCT04659499
EFO_0000305	breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Withdrawn	https://clinicaltrials.gov/study/NCT05233696,https://clinicaltrials.gov/study/NCT05177796
EFO_0006861	male breast carcinoma	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT00017394
EFO_0006861	male breast carcinoma	CHEMBL217092	SARACATINIB	Small molecule	Tyrosine-protein kinase SRC inhibitor		SRC	SRC proto-oncogene, non-receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00559507
MONDO_0007254	breast cancer	CHEMBL3545211	SR16234	Small molecule	Estrogen receptor alpha antagonist		ESR1	estrogen receptor 1	2	Completed	https://clinicaltrials.gov/study/NCT00166543
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Terminated	https://clinicaltrials.gov/study/NCT02624700,https://clinicaltrials.gov/study/NCT01194869,https://clinicaltrials.gov/study/NCT00573755,https://clinicaltrials.gov/study/NCT00722072,https://clinicaltrials.gov/study/NCT00632541,https://clinicaltrials.gov/study/NCT00622466,https://clinicaltrials.gov/study/NCT00607438,https://clinicaltrials.gov/study/NCT00525161
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT00284180
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Recruiting	https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT06102824,https://clinicaltrials.gov/study/NCT05458674,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT05810870,https://clinicaltrials.gov/study/NCT05546255,https://clinicaltrials.gov/study/NCT05530057,https://clinicaltrials.gov/study/NCT04624711,https://clinicaltrials.gov/study/NCT04745975
EFO_1000984	inflammatory breast carcinoma	CHEMBL289228	TIPIFARNIB	Small molecule	Protein farnesyltransferase inhibitor		FNTB	farnesyltransferase, CAAX box, subunit beta	2	Completed	https://clinicaltrials.gov/study/NCT00049114
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA6	NADH:ubiquinone oxidoreductase subunit A6	2	Recruiting	https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04559308
MONDO_0007254	breast cancer	CHEMBL1607	TOPOTECAN HYDROCHLORIDE	Small molecule	DNA topoisomerase I, mitochondrial inhibitor		TOP1MT	DNA topoisomerase I mitochondrial	2	Terminated	https://clinicaltrials.gov/study/NCT00006032
EFO_0006861	male breast carcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC9	histone deacetylase 9	2	Completed	https://clinicaltrials.gov/study/NCT00098397
MONDO_0007254	breast cancer	CHEMBL1098	BUPIVACAINE	Small molecule	Sodium channel protein type IV alpha subunit blocker		SCN4A	sodium voltage-gated channel alpha subunit 4	2	Completed	https://clinicaltrials.gov/study/NCT05727098,https://clinicaltrials.gov/study/NCT03084536,https://clinicaltrials.gov/study/NCT02525718
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	2	Terminated	https://clinicaltrials.gov/study/NCT03709082,https://clinicaltrials.gov/study/NCT03894007,https://clinicaltrials.gov/study/NCT01702558
MONDO_0007254	breast cancer	CHEMBL2108738	NIVOLUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Completed	https://clinicaltrials.gov/study/NCT04075604,https://clinicaltrials.gov/study/NCT03742986,https://clinicaltrials.gov/study/NCT04659551,https://clinicaltrials.gov/study/NCT03316586,https://clinicaltrials.gov/study/NCT03409198
MONDO_0007254	breast cancer	CHEMBL4650989	TALETRECTINIB	Small molecule	Neurotrophic tyrosine kinase receptor inhibitor		NTRK1	neurotrophic receptor tyrosine kinase 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06214793
MONDO_0007254	breast cancer	CHEMBL4594456	CADONILIMAB	Antibody	Cytotoxic T-lymphocyte protein 4 inhibitor		CTLA4	cytotoxic T-lymphocyte associated protein 4	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06202313
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor		GPD2	glycerol-3-phosphate dehydrogenase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01881230
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT00191373
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Withdrawn	https://clinicaltrials.gov/study/NCT02067416,https://clinicaltrials.gov/study/NCT01818999
MONDO_0007254	breast cancer	CHEMBL1042	CHOLECALCIFEROL	Small molecule	Vitamin D receptor agonist		VDR	vitamin D receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01747720
MONDO_0007254	breast cancer	CHEMBL2304041	SAGOPILONE	Small molecule	Tubulin stabiliser		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT00288249
EFO_0000305	breast carcinoma	CHEMBL3707227	ATEZOLIZUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor	Inhibitor	CD274	CD274 molecule	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02849496,https://clinicaltrials.gov/study/NCT02530489,https://clinicaltrials.gov/study/NCT03202316
EFO_0005537	triple-negative breast cancer	CHEMBL4594298	ENCEQUIDAR	Small molecule	P-glycoprotein 1 inhibitor		ABCB1	ATP binding cassette subfamily B member 1	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL3545414	RIVOCERANIB MESYLATE	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04303741
MONDO_0007254	breast cancer	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05872412,https://clinicaltrials.gov/study/NCT05097248,https://clinicaltrials.gov/study/NCT04498793
EFO_0000553	invasive lobular carcinoma	CHEMBL1983268	ENTRECTINIB	Small molecule	Neurotrophic tyrosine kinase receptor inhibitor		NTRK3	neurotrophic receptor tyrosine kinase 3	2	Recruiting	https://clinicaltrials.gov/study/NCT04551495
EFO_0000305	breast carcinoma	CHEMBL1201583	BEVACIZUMAB	Antibody	Vascular endothelial growth factor A inhibitor		VEGFA	vascular endothelial growth factor A	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02436993
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4	NDUFA4 mitochondrial complex associated	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	2	Terminated	https://clinicaltrials.gov/study/NCT00824538,https://clinicaltrials.gov/study/NCT00570908,https://clinicaltrials.gov/study/NCT00434356
EFO_0006861	male breast carcinoma	CHEMBL554	LAPATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01868503
EFO_0006861	male breast carcinoma	CHEMBL535	SUNITINIB	Small molecule	Vascular endothelial growth factor receptor 1 inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT00513695
EFO_0006861	male breast carcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC8	histone deacetylase 8	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01349959
MONDO_0003982	bilateral breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT00877500
EFO_0005537	triple-negative breast cancer	CHEMBL4650256	ZANIDATAMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00323063,https://clinicaltrials.gov/study/NCT00679029,https://clinicaltrials.gov/study/NCT00470249,https://clinicaltrials.gov/study/NCT00095888
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05833919
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Recruiting	https://clinicaltrials.gov/study/NCT05402722,https://clinicaltrials.gov/study/NCT05570253
EFO_0005537	triple-negative breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Suspended	https://clinicaltrials.gov/study/NCT04095689
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FGR	FGR proto-oncogene, Src family tyrosine kinase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01471106
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAB1	NADH:ubiquinone oxidoreductase subunit AB1	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Recruiting	https://clinicaltrials.gov/study/NCT06102824,https://clinicaltrials.gov/study/NCT04304352,https://clinicaltrials.gov/study/NCT04389073,https://clinicaltrials.gov/study/NCT05823623,https://clinicaltrials.gov/study/NCT04296162,https://clinicaltrials.gov/study/NCT05747326,https://clinicaltrials.gov/study/NCT04759248,https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT03939871,https://clinicaltrials.gov/study/NCT04605575,https://clinicaltrials.gov/study/NCT04302441,https://clinicaltrials.gov/study/NCT05296577
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA3	EPH receptor A3	2	Terminated	https://clinicaltrials.gov/study/NCT00481845,https://clinicaltrials.gov/study/NCT01934335,https://clinicaltrials.gov/study/NCT00752986
EFO_0006861	male breast carcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC2	histone deacetylase 2	2	Completed	https://clinicaltrials.gov/study/NCT00098397
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR2	estrogen receptor 2	2	Unknown status	https://clinicaltrials.gov/study/NCT02000193,https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT00927511,https://clinicaltrials.gov/study/NCT02216786,https://clinicaltrials.gov/study/NCT01266213,https://clinicaltrials.gov/study/NCT02072512,https://clinicaltrials.gov/study/NCT02646735,https://clinicaltrials.gov/study/NCT02958852
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		BLK	BLK proto-oncogene, Src family tyrosine kinase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01471106
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Platelet-derived growth factor receptor alpha inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Terminated	https://clinicaltrials.gov/study/NCT00570908,https://clinicaltrials.gov/study/NCT00434356,https://clinicaltrials.gov/study/NCT00824538
MONDO_0007254	breast cancer	CHEMBL1094636	NIRAPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Terminated	https://clinicaltrials.gov/study/NCT02826512
MONDO_0007254	breast cancer	CHEMBL1201566	DARBEPOETIN ALFA	Protein	Erythropoietin receptor agonist		EPOR	erythropoietin receptor	2	Completed	https://clinicaltrials.gov/study/NCT00261313,https://clinicaltrials.gov/study/NCT00146562
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Suspended	https://clinicaltrials.gov/study/NCT04419181,https://clinicaltrials.gov/study/NCT04675827
MONDO_0007254	breast cancer	CHEMBL429910	DAPAGLIFLOZIN	Small molecule	Sodium/glucose cotransporter 2 inhibitor		SLC5A2	solute carrier family 5 member 2	2	Terminated	https://clinicaltrials.gov/study/NCT04899349
EFO_0005537	triple-negative breast cancer	CHEMBL2103879	GANETESPIB	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AA1	heat shock protein 90 alpha family class A member 1	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0005537	triple-negative breast cancer	CHEMBL1421	DASATINIB	Small molecule	Bcr/Abl fusion protein		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06355037
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Unknown status	https://clinicaltrials.gov/study/NCT02175446
MONDO_0007254	breast cancer	CHEMBL4303214	FRUQUINTINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04577963
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Unknown status	https://clinicaltrials.gov/study/NCT01372579
EFO_0000305	breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Fibroblast growth factor receptor 1 inhibitor		FGFR1	fibroblast growth factor receptor 1	2	Withdrawn	https://clinicaltrials.gov/study/NCT00615524
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Unknown status	https://clinicaltrials.gov/study/NCT00954135,https://clinicaltrials.gov/study/NCT00499525
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE6G	phosphodiesterase 6G	2	Recruiting	https://clinicaltrials.gov/study/NCT06087237
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00470249,https://clinicaltrials.gov/study/NCT00159458,https://clinicaltrials.gov/study/NCT00679029,https://clinicaltrials.gov/study/NCT00674206,https://clinicaltrials.gov/study/NCT03674242,https://clinicaltrials.gov/study/NCT02213744,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT00323063,https://clinicaltrials.gov/study/NCT00462865,https://clinicaltrials.gov/study/NCT00095888,https://clinicaltrials.gov/study/NCT00532285
MONDO_0007254	breast cancer	CHEMBL1201568	PEGFILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01498588,https://clinicaltrials.gov/study/NCT00080626,https://clinicaltrials.gov/study/NCT03329378,https://clinicaltrials.gov/study/NCT00679029
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB10	NADH:ubiquinone oxidoreductase subunit B10	2	Recruiting	https://clinicaltrials.gov/study/NCT04559308,https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT03238495
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA5	EPH receptor A5	2	Terminated	https://clinicaltrials.gov/study/NCT00481845,https://clinicaltrials.gov/study/NCT01934335,https://clinicaltrials.gov/study/NCT00752986
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAB1	NADH:ubiquinone oxidoreductase subunit AB1	2	Recruiting	https://clinicaltrials.gov/study/NCT04559308,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT03238495
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02654119
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Withdrawn	https://clinicaltrials.gov/study/NCT00006261
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	2	Completed	https://clinicaltrials.gov/study/NCT02273973
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT05833919,https://clinicaltrials.gov/study/NCT04303741
EFO_0005537	triple-negative breast cancer	CHEMBL3833373	AVELUMAB	Antibody	Programmed cell death 1 ligand 1 other	Inhibitor	CD274	CD274 molecule	2	Recruiting	https://clinicaltrials.gov/study/NCT03971409
EFO_0005537	triple-negative breast cancer	CHEMBL1201670	SARGRAMOSTIM	Protein	Granulocyte-macrophage colony-stimulating factor receptor agonist		CSF2RA	colony stimulating factor 2 receptor subunit alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03012100
EFO_0005537	triple-negative breast cancer	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	2	Unknown status	https://clinicaltrials.gov/study/NCT03044730
MONDO_0007254	breast cancer	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Suspended	https://clinicaltrials.gov/study/NCT00738777
MONDO_0007254	breast cancer	CHEMBL4297829	SINTILIMAB	Antibody	Programmed cell death protein 1 antagonist		PDCD1	programmed cell death 1	2	Recruiting	https://clinicaltrials.gov/study/NCT04877821,https://clinicaltrials.gov/study/NCT04722718,https://clinicaltrials.gov/study/NCT05386524
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	2	Recruiting	https://clinicaltrials.gov/study/NCT03698383
MONDO_0007254	breast cancer	CHEMBL2325741	CAPIVASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT3	AKT serine/threonine kinase 3	2	Recruiting	https://clinicaltrials.gov/study/NCT03182634,https://clinicaltrials.gov/study/NCT05720260,https://clinicaltrials.gov/study/NCT05563220
MONDO_0007254	breast cancer	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	2	Withdrawn	https://clinicaltrials.gov/study/NCT03058939
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT00284180
EFO_0005537	triple-negative breast cancer	CHEMBL3894860	TRILACICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	2	Terminated	https://clinicaltrials.gov/study/NCT02978716
MONDO_0007254	breast cancer	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
MONDO_0007254	breast cancer	CHEMBL180022	NERATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT01008150,https://clinicaltrials.gov/study/NCT04366713,https://clinicaltrials.gov/study/NCT02673398,https://clinicaltrials.gov/study/NCT02400476,https://clinicaltrials.gov/study/NCT00777101,https://clinicaltrials.gov/study/NCT00915018
MONDO_0007254	breast cancer	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT00509587
MONDO_0007254	breast cancer	CHEMBL4279455	LAROTAXEL	Small molecule	Tubulin stabiliser		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT00087958,https://clinicaltrials.gov/study/NCT00387907
MONDO_0007254	breast cancer	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Withdrawn	https://clinicaltrials.gov/study/NCT03841747,https://clinicaltrials.gov/study/NCT05809895
MONDO_0007254	breast cancer	CHEMBL522892	DOVITINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Terminated	https://clinicaltrials.gov/study/NCT01528345
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Recruiting	https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT04302441,https://clinicaltrials.gov/study/NCT06102824,https://clinicaltrials.gov/study/NCT04759248,https://clinicaltrials.gov/study/NCT04605575,https://clinicaltrials.gov/study/NCT05823623,https://clinicaltrials.gov/study/NCT05296577,https://clinicaltrials.gov/study/NCT04296162,https://clinicaltrials.gov/study/NCT04304352,https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT05747326,https://clinicaltrials.gov/study/NCT04389073,https://clinicaltrials.gov/study/NCT03939871
MONDO_0007254	breast cancer	CHEMBL554	LAPATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT00470704,https://clinicaltrials.gov/study/NCT00999804
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT05809895,https://clinicaltrials.gov/study/NCT00005614
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT02614833
MONDO_0007254	breast cancer	CHEMBL223360	LINIFANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT00645177
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Withdrawn	https://clinicaltrials.gov/study/NCT00964704,https://clinicaltrials.gov/study/NCT00678626,https://clinicaltrials.gov/study/NCT01825265,https://clinicaltrials.gov/study/NCT00434031,https://clinicaltrials.gov/study/NCT02067416,https://clinicaltrials.gov/study/NCT00006261,https://clinicaltrials.gov/study/NCT01229605
EFO_0006861	male breast carcinoma	CHEMBL535	SUNITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Completed	https://clinicaltrials.gov/study/NCT00513695
EFO_0006861	male breast carcinoma	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT00017394
MONDO_0007254	breast cancer	CHEMBL1237023	DENOSUMAB	Antibody	Tumor necrosis factor ligand superfamily member 11 inhibitor		TNFSF11	TNF superfamily member 11	2	Terminated	https://clinicaltrials.gov/study/NCT01545648,https://clinicaltrials.gov/study/NCT01952054
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04858516
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT06026657,https://clinicaltrials.gov/study/NCT03606967
EFO_0006861	male breast carcinoma	CHEMBL225072	PEMETREXED	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	2	Completed	https://clinicaltrials.gov/study/NCT00106002
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Terminated	https://clinicaltrials.gov/study/NCT02000596,https://clinicaltrials.gov/study/NCT01912963,https://clinicaltrials.gov/study/NCT03795012,https://clinicaltrials.gov/study/NCT02681523,https://clinicaltrials.gov/study/NCT01534455,https://clinicaltrials.gov/study/NCT01498588
MONDO_0007254	breast cancer	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Completed	https://clinicaltrials.gov/study/NCT00509587
MONDO_0007254	breast cancer	CHEMBL1201139	MEGESTROL ACETATE	Small molecule	Progesterone receptor agonist		PGR	progesterone receptor	2	Completed	https://clinicaltrials.gov/study/NCT03306472,https://clinicaltrials.gov/study/NCT00002680
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC1	NADH:ubiquinone oxidoreductase subunit C1	2	Completed	https://clinicaltrials.gov/study/NCT04170465
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB1	NADH:ubiquinone oxidoreductase subunit B1	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Terminated	https://clinicaltrials.gov/study/NCT00049660,https://clinicaltrials.gov/study/NCT00194792,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT00088985,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT03358004
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FGR	FGR proto-oncogene, Src family tyrosine kinase	2	Withdrawn	https://clinicaltrials.gov/study/NCT01410708
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04345913
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04770272,https://clinicaltrials.gov/study/NCT02876107,https://clinicaltrials.gov/study/NCT04129996,https://clinicaltrials.gov/study/NCT02315196,https://clinicaltrials.gov/study/NCT02883062,https://clinicaltrials.gov/study/NCT02593175,https://clinicaltrials.gov/study/NCT04958785,https://clinicaltrials.gov/study/NCT04395989,https://clinicaltrials.gov/study/NCT01750073,https://clinicaltrials.gov/study/NCT02530489,https://clinicaltrials.gov/study/NCT04216472
MONDO_0021115	luminal B breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT03356860
MONDO_0007254	breast cancer	CHEMBL941	IMATINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Terminated	https://clinicaltrials.gov/study/NCT00323063
EFO_1000984	inflammatory breast carcinoma	CHEMBL535	SUNITINIB	Small molecule	Vascular endothelial growth factor receptor 1 inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT00513695
EFO_1000984	inflammatory breast carcinoma	CHEMBL1201670	SARGRAMOSTIM	Protein	Granulocyte-macrophage colony-stimulating factor receptor agonist		CSF2RA	colony stimulating factor 2 receptor subunit alpha	2	Completed	https://clinicaltrials.gov/study/NCT00003199
MONDO_0007254	breast cancer	CHEMBL503	LOVASTATIN	Small molecule	HMG-CoA reductase inhibitor		HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase	2	Terminated	https://clinicaltrials.gov/study/NCT00285857,https://clinicaltrials.gov/study/NCT00902668
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Terminated	https://clinicaltrials.gov/study/NCT00780676,https://clinicaltrials.gov/study/NCT00817531,https://clinicaltrials.gov/study/NCT05198843
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase RAF inhibitor		RAF1	Raf-1 proto-oncogene, serine/threonine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT00573755,https://clinicaltrials.gov/study/NCT02624700,https://clinicaltrials.gov/study/NCT00525161,https://clinicaltrials.gov/study/NCT00632541,https://clinicaltrials.gov/study/NCT00622466,https://clinicaltrials.gov/study/NCT01194869,https://clinicaltrials.gov/study/NCT00722072,https://clinicaltrials.gov/study/NCT00607438
MONDO_0007254	breast cancer	CHEMBL359744	DOXORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Withdrawn	https://clinicaltrials.gov/study/NCT02067416,https://clinicaltrials.gov/study/NCT00006261,https://clinicaltrials.gov/study/NCT03554109
MONDO_0007254	breast cancer	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Tyrosine-protein kinase LCK inhibitor		LCK	LCK proto-oncogene, Src family tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
MONDO_0007254	breast cancer	CHEMBL2364649	MARGETUXIMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Withdrawn	https://clinicaltrials.gov/study/NCT05227131
MONDO_0007254	breast cancer	CHEMBL3707227	ATEZOLIZUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor	Inhibitor	CD274	CD274 molecule	2	Terminated	https://clinicaltrials.gov/study/NCT03147040,https://clinicaltrials.gov/study/NCT03894007,https://clinicaltrials.gov/study/NCT03952325,https://clinicaltrials.gov/study/NCT04690855,https://clinicaltrials.gov/study/NCT02322814
MONDO_0007254	breast cancer	CHEMBL3186534	RIVOCERANIB	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT05759572,https://clinicaltrials.gov/study/NCT04803539,https://clinicaltrials.gov/study/NCT04722718,https://clinicaltrials.gov/study/NCT05447702
EFO_0005537	triple-negative breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Suspended	https://clinicaltrials.gov/study/NCT04095689
MONDO_0007254	breast cancer	CHEMBL328190	LASOFOXIFENE	Small molecule	Estrogen receptor modulator		ESR2	estrogen receptor 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04432454,https://clinicaltrials.gov/study/NCT03781063
EFO_0006861	male breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT00077376
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB6	NADH:ubiquinone oxidoreductase subunit B6	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB3	NADH:ubiquinone oxidoreductase subunit B3	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00679029,https://clinicaltrials.gov/study/NCT00323063,https://clinicaltrials.gov/study/NCT00470249,https://clinicaltrials.gov/study/NCT00095888
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT00027989
EFO_0005537	triple-negative breast cancer	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		APH1A	aph-1 homolog A, gamma-secretase subunit	2	Terminated	https://clinicaltrials.gov/study/NCT01151449
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT00861705
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND2	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2	2	Completed	https://clinicaltrials.gov/study/NCT01885013
EFO_0000305	breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
EFO_0000305	breast carcinoma	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT02441946,https://clinicaltrials.gov/study/NCT04256941
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Unknown status	https://clinicaltrials.gov/study/NCT03144947
MONDO_0007254	breast cancer	CHEMBL1230609	FORETINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Completed	https://clinicaltrials.gov/study/NCT01138384,https://clinicaltrials.gov/study/NCT01147484
MONDO_0007254	breast cancer	CHEMBL1567	SUNITINIB MALATE	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	2	Terminated	https://clinicaltrials.gov/study/NCT00824538
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Tyrosine-protein kinase BRK inhibitor		PTK6	protein tyrosine kinase 6	2	Terminated	https://clinicaltrials.gov/study/NCT01934335,https://clinicaltrials.gov/study/NCT00481845,https://clinicaltrials.gov/study/NCT00752986
MONDO_0007254	breast cancer	CHEMBL4302409	LUTETIUM OXODOTREOTIDE	Protein	Somatostatin receptor binding agent		SSTR5	somatostatin receptor 5	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04529044
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06291064,https://clinicaltrials.gov/study/NCT06348134,https://clinicaltrials.gov/study/NCT04034823,https://clinicaltrials.gov/study/NCT04290793
EFO_1000984	inflammatory breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02623972
EFO_0006861	male breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00095888
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND1	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL2105717	CABOZANTINIB	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01441947
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Unknown status	https://clinicaltrials.gov/study/NCT02175446,https://clinicaltrials.gov/study/NCT03412955
MONDO_0007254	breast cancer	CHEMBL2105717	CABOZANTINIB	Small molecule	Hepatocyte growth factor receptor inhibitor		MET	MET proto-oncogene, receptor tyrosine kinase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01441947
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS4	NADH:ubiquinone oxidoreductase subunit S4	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF4	NADH:ubiquinone oxidoreductase complex assembly factor 4	2	Terminated	https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT01627067
MONDO_0007254	breast cancer	CHEMBL4594568	KN-026	Unknown	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04165993
MONDO_0007254	breast cancer	CHEMBL46740	BAZEDOXIFENE	Small molecule	Estrogen receptor modulator		ESR2	estrogen receptor 2	2	Recruiting	https://clinicaltrials.gov/study/NCT04821141
MONDO_0007254	breast cancer	CHEMBL1567	SUNITINIB MALATE	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00482755
MONDO_0007254	breast cancer	CHEMBL4650215	INAVOLISIB	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05708235
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS5	NADH:ubiquinone oxidoreductase subunit S5	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA10	NADH:ubiquinone oxidoreductase subunit A10	2	Completed	https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT01310231
MONDO_0007254	breast cancer	CHEMBL1200396	BUPIVACAINE HYDROCHLORIDE	Small molecule	Sodium channel protein type IV alpha subunit blocker		SCN4A	sodium voltage-gated channel alpha subunit 4	2	Completed	https://clinicaltrials.gov/study/NCT05727098
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4L	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L	2	Terminated	https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT01627067
MONDO_0007254	breast cancer	CHEMBL997	IBANDRONIC ACID	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	2	Completed	https://clinicaltrials.gov/study/NCT02616744
MONDO_0007254	breast cancer	CHEMBL134	CLONIDINE	Small molecule	Adrenergic receptor alpha-2 agonist		ADRA2A	adrenoceptor alpha 2A	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04603911
EFO_0000305	breast carcinoma	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Terminated	https://clinicaltrials.gov/study/NCT02774681,https://clinicaltrials.gov/study/NCT02907918,https://clinicaltrials.gov/study/NCT00817362,https://clinicaltrials.gov/study/NCT04108858
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF2	NADH:ubiquinone oxidoreductase complex assembly factor 2	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS6	NADH:ubiquinone oxidoreductase subunit S6	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_1000984	inflammatory breast carcinoma	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RA	interleukin 2 receptor subunit alpha	2	Completed	https://clinicaltrials.gov/study/NCT00003199
EFO_0005537	triple-negative breast cancer	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04755868
EFO_0006861	male breast carcinoma	CHEMBL1642	IMATINIB MESYLATE	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00045188
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB7	NADH:ubiquinone oxidoreductase subunit B7	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1922094	APITOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	2	Completed	https://clinicaltrials.gov/study/NCT01437566
MONDO_0007254	breast cancer	CHEMBL3545262	SACITUZUMAB GOVITECAN	Antibody drug conjugate	Tumor-associated calcium signal transducer 2 binding agent		TACSTD2	tumor associated calcium signal transducer 2	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06263543,https://clinicaltrials.gov/study/NCT06236269,https://clinicaltrials.gov/study/NCT06081244,https://clinicaltrials.gov/study/NCT06238921
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT02624973,https://clinicaltrials.gov/study/NCT02208375,https://clinicaltrials.gov/study/NCT04053322,https://clinicaltrials.gov/study/NCT03330847
MONDO_0007254	breast cancer	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Terminated	https://clinicaltrials.gov/study/NCT03499353,https://clinicaltrials.gov/study/NCT04690855
MONDO_0007254	breast cancer	CHEMBL1567	SUNITINIB MALATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Completed	https://clinicaltrials.gov/study/NCT00482755
MONDO_0007254	breast cancer	CHEMBL4297545	LUTETIUM OXODOTREOTIDE LU-177	Protein	Somatostatin receptor binding agent		SSTR2	somatostatin receptor 2	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04529044
MONDO_0007254	breast cancer	CHEMBL1535	HYDROXYCHLOROQUINE	Small molecule	Toll-like receptor 9 antagonist		TLR9	toll like receptor 9	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03032406
MONDO_0007254	breast cancer	CHEMBL1790041	RANITIDINE	Small molecule	Histamine H2 receptor antagonist		HRH2	histamine receptor H2	2	Completed	https://clinicaltrials.gov/study/NCT01332630
EFO_0000305	breast carcinoma	CHEMBL1079175	MK-2206	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT1	AKT serine/threonine kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT01277757
EFO_0005537	triple-negative breast cancer	CHEMBL4297883	IVUXOLIMAB	Antibody	Tumor necrosis factor receptor superfamily member 4 agonist		TNFRSF4	TNF receptor superfamily member 4	2	Recruiting	https://clinicaltrials.gov/study/NCT03971409
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Withdrawn	https://clinicaltrials.gov/study/NCT02215876,https://clinicaltrials.gov/study/NCT03637868
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT01352494,https://clinicaltrials.gov/study/NCT03423849,https://clinicaltrials.gov/study/NCT00027989,https://clinicaltrials.gov/study/NCT02544243,https://clinicaltrials.gov/study/NCT02341911
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT06027268,https://clinicaltrials.gov/study/NCT03606967
MONDO_0007254	breast cancer	CHEMBL2218894	FLUVASTATIN SODIUM	Small molecule	HMG-CoA reductase inhibitor		HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase	2	Completed	https://clinicaltrials.gov/study/NCT00416403
MONDO_0007254	breast cancer	CHEMBL2304041	SAGOPILONE	Small molecule	Tubulin stabiliser		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT00288249
MONDO_0007254	breast cancer	CHEMBL4298101	LADIRATUZUMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT03424005
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS7	NADH:ubiquinone oxidoreductase core subunit S7	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0005537	triple-negative breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS1	NADH:ubiquinone oxidoreductase core subunit S1	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Recruiting	https://clinicaltrials.gov/study/NCT06107673,https://clinicaltrials.gov/study/NCT04576143,https://clinicaltrials.gov/study/NCT03879577,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT05088057,https://clinicaltrials.gov/study/NCT05900206,https://clinicaltrials.gov/study/NCT05189067,https://clinicaltrials.gov/study/NCT05638594,https://clinicaltrials.gov/study/NCT04717531,https://clinicaltrials.gov/study/NCT05918328,https://clinicaltrials.gov/study/NCT05426486,https://clinicaltrials.gov/study/NCT05483439,https://clinicaltrials.gov/study/NCT03497702,https://clinicaltrials.gov/study/NCT03367676,https://clinicaltrials.gov/study/NCT05475678,https://clinicaltrials.gov/study/NCT04947189,https://clinicaltrials.gov/study/NCT05645380,https://clinicaltrials.gov/study/NCT04872985
MONDO_0007254	breast cancer	CHEMBL4297736	PRALUZATAMAB RAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT04596150
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT02073487,https://clinicaltrials.gov/study/NCT02924883,https://clinicaltrials.gov/study/NCT01904903,https://clinicaltrials.gov/study/NCT00509769,https://clinicaltrials.gov/study/NCT00943670,https://clinicaltrials.gov/study/NCT00679211,https://clinicaltrials.gov/study/NCT00679341,https://clinicaltrials.gov/study/NCT03530696,https://clinicaltrials.gov/study/NCT01835236,https://clinicaltrials.gov/study/NCT01196052
MONDO_0004379	female breast carcinoma	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR2	estrogen receptor 2	2	Terminated	https://clinicaltrials.gov/study/NCT02540330
MONDO_0007254	breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04733417
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Suspended	https://clinicaltrials.gov/study/NCT02897050,https://clinicaltrials.gov/study/NCT04419181
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		SRMS	src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites	2	Completed	https://clinicaltrials.gov/study/NCT00410813,https://clinicaltrials.gov/study/NCT00754325,https://clinicaltrials.gov/study/NCT00546104,https://clinicaltrials.gov/study/NCT00767520,https://clinicaltrials.gov/study/NCT00696072
MONDO_0007254	breast cancer	CHEMBL2325741	CAPIVASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT1	AKT serine/threonine kinase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT02208375
MONDO_0007254	breast cancer	CHEMBL1200694	SEVOFLURANE	Small molecule	Potassium channel subfamily K member 10 opener		KCNK10	potassium two pore domain channel subfamily K member 10	2	Completed	https://clinicaltrials.gov/study/NCT02839668
MONDO_0007254	breast cancer	CHEMBL1201583	BEVACIZUMAB	Antibody	Vascular endothelial growth factor A inhibitor		VEGFA	vascular endothelial growth factor A	2	Recruiting	https://clinicaltrials.gov/study/NCT05180006,https://clinicaltrials.gov/study/NCT05769010,https://clinicaltrials.gov/study/NCT05386524,https://clinicaltrials.gov/study/NCT04739670,https://clinicaltrials.gov/study/NCT05357417,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT05303038,https://clinicaltrials.gov/study/NCT04389073
MONDO_0021115	luminal B breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT03356860
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	2	Withdrawn	https://clinicaltrials.gov/study/NCT01410708
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT02978495
MONDO_0007254	breast cancer	CHEMBL20883	TEGAFUR	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	2	Terminated	https://clinicaltrials.gov/study/NCT00005608
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT00429572,https://clinicaltrials.gov/study/NCT01105650,https://clinicaltrials.gov/study/NCT00020176
EFO_0006861	male breast carcinoma	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT00017394
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00462865,https://clinicaltrials.gov/study/NCT00470249,https://clinicaltrials.gov/study/NCT00323063,https://clinicaltrials.gov/study/NCT00159458,https://clinicaltrials.gov/study/NCT00679029,https://clinicaltrials.gov/study/NCT00674206,https://clinicaltrials.gov/study/NCT02213744,https://clinicaltrials.gov/study/NCT00532285,https://clinicaltrials.gov/study/NCT03674242,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT00095888
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT01908101
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF1	NADH:ubiquinone oxidoreductase complex assembly factor 1	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL76222	REBIMASTAT	Small molecule	Matrix metalloproteinase 13 inhibitor		MMP13	matrix metallopeptidase 13	2	Terminated	https://clinicaltrials.gov/study/NCT00036621
MONDO_0007254	breast cancer	CHEMBL1201066	VENLAFAXINE HYDROCHLORIDE	Small molecule	Norepinephrine transporter inhibitor		SLC6A2	solute carrier family 6 member 2	2	Completed	https://clinicaltrials.gov/study/NCT00198250
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBB4A	tubulin beta 4A class IVa	2	Withdrawn	https://clinicaltrials.gov/study/NCT01227408
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Recruiting	https://clinicaltrials.gov/study/NCT05823623,https://clinicaltrials.gov/study/NCT05296577
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05041101,https://clinicaltrials.gov/study/NCT03202316
EFO_0000432	breast ductal carcinoma in situ	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	2	Terminated	https://clinicaltrials.gov/study/NCT03535506
EFO_1000984	inflammatory breast carcinoma	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT02682693
EFO_0005537	triple-negative breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967
EFO_0005537	triple-negative breast cancer	CHEMBL1201568	PEGFILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03639948
MONDO_0003982	bilateral breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT00877500
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Unknown status	https://clinicaltrials.gov/study/NCT03412955
MONDO_0007254	breast cancer	CHEMBL3188267	CAPMATINIB	Small molecule	Hepatocyte growth factor receptor inhibitor		MET	MET proto-oncogene, receptor tyrosine kinase	2	Recruiting	https://clinicaltrials.gov/study/NCT05243641
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	Adenosine A2 receptor antagonist		ADORA2A	adenosine A2a receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT06176339,https://clinicaltrials.gov/study/NCT06186700
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA11	NADH:ubiquinone oxidoreductase subunit A11	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL657	DIPHENHYDRAMINE	Small molecule	Histamine H1 receptor antagonist		HRH1	histamine receptor H1	2	Completed	https://clinicaltrials.gov/study/NCT01332630
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		LCK	LCK proto-oncogene, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00767520,https://clinicaltrials.gov/study/NCT00410813,https://clinicaltrials.gov/study/NCT00754325,https://clinicaltrials.gov/study/NCT00546104,https://clinicaltrials.gov/study/NCT00696072
MONDO_0007254	breast cancer	CHEMBL52885	ENMD-981693	Small molecule	SRC inhibitor		FGR	FGR proto-oncogene, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00306631
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND2	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2	2	Unknown status	https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT02506777,https://clinicaltrials.gov/study/NCT02506790
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE7B	phosphodiesterase 7B	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT06176339,https://clinicaltrials.gov/study/NCT06186700
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Tyrosine-protein kinase LCK inhibitor		LCK	LCK proto-oncogene, Src family tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02187991,https://clinicaltrials.gov/study/NCT03101748,https://clinicaltrials.gov/study/NCT03179904,https://clinicaltrials.gov/study/NCT01463072,https://clinicaltrials.gov/study/NCT04216472,https://clinicaltrials.gov/study/NCT02603679,https://clinicaltrials.gov/study/NCT04001829,https://clinicaltrials.gov/study/NCT02436993,https://clinicaltrials.gov/study/NCT02530489
EFO_0005537	triple-negative breast cancer	CHEMBL359744	DOXORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01750073,https://clinicaltrials.gov/study/NCT02315196
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Recruiting	https://clinicaltrials.gov/study/NCT04138719,https://clinicaltrials.gov/study/NCT05192798,https://clinicaltrials.gov/study/NCT03606967,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT05834582,https://clinicaltrials.gov/study/NCT05227664
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Withdrawn	https://clinicaltrials.gov/study/NCT05177796
MONDO_0007254	breast cancer	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Unknown status	https://clinicaltrials.gov/study/NCT02685657,https://clinicaltrials.gov/study/NCT00006433,https://clinicaltrials.gov/study/NCT02506777,https://clinicaltrials.gov/study/NCT00994968,https://clinicaltrials.gov/study/NCT01210768,https://clinicaltrials.gov/study/NCT02790580,https://clinicaltrials.gov/study/NCT00027989,https://clinicaltrials.gov/study/NCT03071926,https://clinicaltrials.gov/study/NCT00801411,https://clinicaltrials.gov/study/NCT01784120,https://clinicaltrials.gov/study/NCT00518583,https://clinicaltrials.gov/study/NCT00777673,https://clinicaltrials.gov/study/NCT01176799,https://clinicaltrials.gov/study/NCT00012311,https://clinicaltrials.gov/study/NCT01270373,https://clinicaltrials.gov/study/NCT00533936,https://clinicaltrials.gov/study/NCT01670500,https://clinicaltrials.gov/study/NCT00669773,https://clinicaltrials.gov/study/NCT00036985,https://clinicaltrials.gov/study/NCT00159094,https://clinicaltrials.gov/study/NCT01415336,https://clinicaltrials.gov/study/NCT00003165,https://clinicaltrials.gov/study/NCT00721747,https://clinicaltrials.gov/study/NCT00250874
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1094636	NIRAPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT04584255
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04001829,https://clinicaltrials.gov/study/NCT02568839
MONDO_0007254	breast cancer	CHEMBL45	MELATONIN	Small molecule	Melatonin receptor agonist		MTNR1B	melatonin receptor 1B	2	Completed	https://clinicaltrials.gov/study/NCT01965522
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE4B	phosphodiesterase 4B	2	Recruiting	https://clinicaltrials.gov/study/NCT06087237
MONDO_0007254	breast cancer	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC4	histone deacetylase 4	2	Completed	https://clinicaltrials.gov/study/NCT00098397
MONDO_0007254	breast cancer	CHEMBL468	THALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		DDB1	damage specific DNA binding protein 1	2	Terminated	https://clinicaltrials.gov/study/NCT00193102
MONDO_0007254	breast cancer	CHEMBL1201139	MEGESTROL ACETATE	Small molecule	Progesterone receptor agonist		PGR	progesterone receptor	2	Terminated	https://clinicaltrials.gov/study/NCT02269670
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02603679,https://clinicaltrials.gov/study/NCT03101748,https://clinicaltrials.gov/study/NCT01463072,https://clinicaltrials.gov/study/NCT02436993,https://clinicaltrials.gov/study/NCT04216472,https://clinicaltrials.gov/study/NCT02530489,https://clinicaltrials.gov/study/NCT03179904,https://clinicaltrials.gov/study/NCT02187991,https://clinicaltrials.gov/study/NCT04001829
MONDO_0007254	breast cancer	CHEMBL2146883	COBIMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 2 inhibitor		MAP2K2	mitogen-activated protein kinase kinase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03395899
EFO_0000432	breast ductal carcinoma in situ	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	2	Terminated	https://clinicaltrials.gov/study/NCT03535506
MONDO_0007254	breast cancer	CHEMBL76222	REBIMASTAT	Small molecule	Matrix metalloproteinase 8 inhibitor		MMP8	matrix metallopeptidase 8	2	Terminated	https://clinicaltrials.gov/study/NCT00036621
MONDO_0007254	breast cancer	CHEMBL45	MELATONIN	Small molecule	Melatonin receptor agonist		MTNR1B	melatonin receptor 1B	2	Recruiting	https://clinicaltrials.gov/study/NCT02288806
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT01908101
MONDO_0007254	breast cancer	CHEMBL841	LOPERAMIDE	Small molecule	Mu opioid receptor agonist		OPRM1	opioid receptor mu 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05520723,https://clinicaltrials.gov/study/NCT02747004
EFO_0006861	male breast carcinoma	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Completed	https://clinicaltrials.gov/study/NCT03018080
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHB6	EPH receptor B6	2	Terminated	https://clinicaltrials.gov/study/NCT00481845,https://clinicaltrials.gov/study/NCT00752986,https://clinicaltrials.gov/study/NCT01934335
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC1	NADH:ubiquinone oxidoreductase subunit C1	2	Completed	https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT04143282
EFO_0005537	triple-negative breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04129996,https://clinicaltrials.gov/study/NCT04395989
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04143906,https://clinicaltrials.gov/study/NCT05263882,https://clinicaltrials.gov/study/NCT04517292
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Terminated	https://clinicaltrials.gov/study/NCT03709082,https://clinicaltrials.gov/study/NCT03894007,https://clinicaltrials.gov/study/NCT01702558
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB9	NADH:ubiquinone oxidoreductase subunit B9	2	Completed	https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT01589367
EFO_0000305	breast carcinoma	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01149083,https://clinicaltrials.gov/study/NCT02595905
MONDO_0007254	breast cancer	CHEMBL1922094	APITOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R2	phosphoinositide-3-kinase regulatory subunit 2	2	Completed	https://clinicaltrials.gov/study/NCT01437566
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Terminated	https://clinicaltrials.gov/study/NCT01534455,https://clinicaltrials.gov/study/NCT01498588,https://clinicaltrials.gov/study/NCT03795012,https://clinicaltrials.gov/study/NCT01912963,https://clinicaltrials.gov/study/NCT02681523,https://clinicaltrials.gov/study/NCT02000596
MONDO_0007254	breast cancer	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT00321633
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT00212082,https://clinicaltrials.gov/study/NCT00198237,https://clinicaltrials.gov/study/NCT00820547,https://clinicaltrials.gov/study/NCT00005800,https://clinicaltrials.gov/study/NCT00545688,https://clinicaltrials.gov/study/NCT00525759,https://clinicaltrials.gov/study/NCT01671319,https://clinicaltrials.gov/study/NCT00191243,https://clinicaltrials.gov/study/NCT00319618,https://clinicaltrials.gov/study/NCT00006682,https://clinicaltrials.gov/study/NCT02838225,https://clinicaltrials.gov/study/NCT00193115,https://clinicaltrials.gov/study/NCT00232479,https://clinicaltrials.gov/study/NCT00754351,https://clinicaltrials.gov/study/NCT03742986,https://clinicaltrials.gov/study/NCT00055861,https://clinicaltrials.gov/study/NCT01792050,https://clinicaltrials.gov/study/NCT00004906,https://clinicaltrials.gov/study/NCT00769470,https://clinicaltrials.gov/study/NCT01367028,https://clinicaltrials.gov/study/NCT00039520,https://clinicaltrials.gov/study/NCT02041351,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT00004888,https://clinicaltrials.gov/study/NCT00841828,https://clinicaltrials.gov/study/NCT00212095,https://clinicaltrials.gov/study/NCT00464646,https://clinicaltrials.gov/study/NCT00003565,https://clinicaltrials.gov/study/NCT00527449,https://clinicaltrials.gov/study/NCT00820872,https://clinicaltrials.gov/study/NCT00179309,https://clinicaltrials.gov/study/NCT01150513,https://clinicaltrials.gov/study/NCT00129376,https://clinicaltrials.gov/study/NCT00365365,https://clinicaltrials.gov/study/NCT02132949,https://clinicaltrials.gov/study/NCT00193180,https://clinicaltrials.gov/study/NCT01025349,https://clinicaltrials.gov/study/NCT00679341,https://clinicaltrials.gov/study/NCT00146042,https://clinicaltrials.gov/study/NCT00107510,https://clinicaltrials.gov/study/NCT01038804,https://clinicaltrials.gov/study/NCT00248703,https://clinicaltrials.gov/study/NCT00258375,https://clinicaltrials.gov/study/NCT00193089,https://clinicaltrials.gov/study/NCT00149214,https://clinicaltrials.gov/study/NCT00274456,https://clinicaltrials.gov/study/NCT00976989,https://clinicaltrials.gov/study/NCT02909751,https://clinicaltrials.gov/study/NCT01527487,https://clinicaltrials.gov/study/NCT02834403,https://clinicaltrials.gov/study/NCT00123929,https://clinicaltrials.gov/study/NCT00028873,https://clinicaltrials.gov/study/NCT01658462,https://clinicaltrials.gov/study/NCT00524810,https://clinicaltrials.gov/study/NCT00044993,https://clinicaltrials.gov/study/NCT00712881,https://clinicaltrials.gov/study/NCT00773695,https://clinicaltrials.gov/study/NCT03140553,https://clinicaltrials.gov/study/NCT00054275,https://clinicaltrials.gov/study/NCT00068341,https://clinicaltrials.gov/study/NCT00003352,https://clinicaltrials.gov/study/NCT00077857,https://clinicaltrials.gov/study/NCT00209092,https://clinicaltrials.gov/study/NCT00600249,https://clinicaltrials.gov/study/NCT00148070,https://clinicaltrials.gov/study/NCT02229084,https://clinicaltrials.gov/study/NCT00604435,https://clinicaltrials.gov/study/NCT03735966,https://clinicaltrials.gov/study/NCT00203502,https://clinicaltrials.gov/study/NCT01208480,https://clinicaltrials.gov/study/NCT04664972,https://clinicaltrials.gov/study/NCT01142778,https://clinicaltrials.gov/study/NCT00006104,https://clinicaltrials.gov/study/NCT00155259,https://clinicaltrials.gov/study/NCT01540110,https://clinicaltrials.gov/study/NCT00490646,https://clinicaltrials.gov/study/NCT00559754,https://clinicaltrials.gov/study/NCT00645866,https://clinicaltrials.gov/study/NCT02137083,https://clinicaltrials.gov/study/NCT00005963,https://clinicaltrials.gov/study/NCT00214864,https://clinicaltrials.gov/study/NCT00005908,https://clinicaltrials.gov/study/NCT00206505,https://clinicaltrials.gov/study/NCT00003953,https://clinicaltrials.gov/study/NCT00364611,https://clinicaltrials.gov/study/NCT00206518,https://clinicaltrials.gov/study/NCT00404066,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00193037,https://clinicaltrials.gov/study/NCT00475670,https://clinicaltrials.gov/study/NCT00148668,https://clinicaltrials.gov/study/NCT00499122,https://clinicaltrials.gov/study/NCT01396655,https://clinicaltrials.gov/study/NCT02846428,https://clinicaltrials.gov/study/NCT01959490,https://clinicaltrials.gov/study/NCT00365417,https://clinicaltrials.gov/study/NCT00217672,https://clinicaltrials.gov/study/NCT00941330,https://clinicaltrials.gov/study/NCT02365805,https://clinicaltrials.gov/study/NCT00379015,https://clinicaltrials.gov/study/NCT00432172,https://clinicaltrials.gov/study/NCT00201708,https://clinicaltrials.gov/study/NCT00494481,https://clinicaltrials.gov/study/NCT00041067,https://clinicaltrials.gov/study/NCT00247481,https://clinicaltrials.gov/study/NCT00428922,https://clinicaltrials.gov/study/NCT01446016,https://clinicaltrials.gov/study/NCT00203372,https://clinicaltrials.gov/study/NCT00493649,https://clinicaltrials.gov/study/NCT00206466,https://clinicaltrials.gov/study/NCT00695994,https://clinicaltrials.gov/study/NCT01485926,https://clinicaltrials.gov/study/NCT00079118,https://clinicaltrials.gov/study/NCT00066443,https://clinicaltrials.gov/study/NCT00193050,https://clinicaltrials.gov/study/NCT00015886,https://clinicaltrials.gov/study/NCT00015938,https://clinicaltrials.gov/study/NCT02005549,https://clinicaltrials.gov/study/NCT00004175,https://clinicaltrials.gov/study/NCT00027885,https://clinicaltrials.gov/study/NCT00088998,https://clinicaltrials.gov/study/NCT02748213,https://clinicaltrials.gov/study/NCT03887130
EFO_0000305	breast carcinoma	CHEMBL3218576	COPANLISIB	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	2	Withdrawn	https://clinicaltrials.gov/study/NCT03803761
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT00455533,https://clinicaltrials.gov/study/NCT00020904,https://clinicaltrials.gov/study/NCT00821886,https://clinicaltrials.gov/study/NCT00370552,https://clinicaltrials.gov/study/NCT00490646,https://clinicaltrials.gov/study/NCT00045097,https://clinicaltrials.gov/study/NCT01019577,https://clinicaltrials.gov/study/NCT01075100,https://clinicaltrials.gov/study/NCT00879086,https://clinicaltrials.gov/study/NCT01027208,https://clinicaltrials.gov/study/NCT00627978,https://clinicaltrials.gov/study/NCT01416389,https://clinicaltrials.gov/study/NCT00593827,https://clinicaltrials.gov/study/NCT00633464,https://clinicaltrials.gov/study/NCT00077376,https://clinicaltrials.gov/study/NCT01097642,https://clinicaltrials.gov/study/NCT00866905,https://clinicaltrials.gov/study/NCT00751868,https://clinicaltrials.gov/study/NCT00080262,https://clinicaltrials.gov/study/NCT01446016
EFO_0005537	triple-negative breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT03154749,https://clinicaltrials.gov/study/NCT02413320
EFO_0005537	triple-negative breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03911973
EFO_1000984	inflammatory breast carcinoma	CHEMBL1237023	DENOSUMAB	Antibody	Tumor necrosis factor ligand superfamily member 11 inhibitor		TNFSF11	TNF superfamily member 11	2	Completed	https://clinicaltrials.gov/study/NCT02682693
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00376805,https://clinicaltrials.gov/study/NCT00074269
MONDO_0007254	breast cancer	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT00003042,https://clinicaltrials.gov/study/NCT05520723
MONDO_0007254	breast cancer	CHEMBL4594217	CANAGLIFLOZIN	Small molecule	Sodium/glucose cotransporter 2 inhibitor		SLC5A2	solute carrier family 5 member 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05090358
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB10	NADH:ubiquinone oxidoreductase subunit B10	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04345913
EFO_0005537	triple-negative breast cancer	CHEMBL3137336	UPROSERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT2	AKT serine/threonine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT01964924
EFO_0000305	breast carcinoma	CHEMBL113	CAFFEINE	Small molecule	Adenosine receptor antagonist		ADORA1	adenosine A1 receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03768492
MONDO_0007254	breast cancer	CHEMBL3894860	TRILACICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Terminated	https://clinicaltrials.gov/study/NCT00832338
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Recruiting	https://clinicaltrials.gov/study/NCT05645380,https://clinicaltrials.gov/study/NCT05189067,https://clinicaltrials.gov/study/NCT05918328,https://clinicaltrials.gov/study/NCT04872985,https://clinicaltrials.gov/study/NCT03879577,https://clinicaltrials.gov/study/NCT05638594,https://clinicaltrials.gov/study/NCT04947189,https://clinicaltrials.gov/study/NCT05483439,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT05900206,https://clinicaltrials.gov/study/NCT04576143,https://clinicaltrials.gov/study/NCT05475678,https://clinicaltrials.gov/study/NCT04717531,https://clinicaltrials.gov/study/NCT05088057,https://clinicaltrials.gov/study/NCT03367676,https://clinicaltrials.gov/study/NCT06107673,https://clinicaltrials.gov/study/NCT05426486,https://clinicaltrials.gov/study/NCT03497702
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC1	histone deacetylase 1	2	Terminated	https://clinicaltrials.gov/study/NCT00777335
MONDO_0007254	breast cancer	CHEMBL517712	ATROPINE	Small molecule	Muscarinic acetylcholine receptor M1 antagonist		CHRM1	cholinergic receptor muscarinic 1	2	Completed	https://clinicaltrials.gov/study/NCT02839668
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB5	NADH:ubiquinone oxidoreductase subunit B5	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0005537	triple-negative breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Suspended	https://clinicaltrials.gov/study/NCT04095689
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB10	NADH:ubiquinone oxidoreductase subunit B10	2	Terminated	https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT04899349
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02252887,https://clinicaltrials.gov/study/NCT04297267,https://clinicaltrials.gov/study/NCT04262804,https://clinicaltrials.gov/study/NCT03567720,https://clinicaltrials.gov/study/NCT01815242
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB6	NADH:ubiquinone oxidoreductase subunit B6	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC1	NADH:ubiquinone oxidoreductase subunit C1	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL2108738	NIVOLUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03487666,https://clinicaltrials.gov/study/NCT03818685,https://clinicaltrials.gov/study/NCT02499367,https://clinicaltrials.gov/study/NCT03650894,https://clinicaltrials.gov/study/NCT03414684,https://clinicaltrials.gov/study/NCT03789110
MONDO_0007254	breast cancer	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01149083
MONDO_0007254	breast cancer	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	2	Completed	https://clinicaltrials.gov/study/NCT01818063,https://clinicaltrials.gov/study/NCT01506609
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE6B	phosphodiesterase 6B	2	Recruiting	https://clinicaltrials.gov/study/NCT06087237
EFO_0006861	male breast carcinoma	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT00017394
EFO_0006861	male breast carcinoma	CHEMBL231616	TRIAPINE	Small molecule	Ribonucleotide reductase inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Terminated	https://clinicaltrials.gov/study/NCT00095888
MONDO_0007254	breast cancer	CHEMBL15770	SULINDAC	Small molecule	Cyclooxygenase inhibitor		PTGS1	prostaglandin-endoperoxide synthase 1	2	Completed	https://clinicaltrials.gov/study/NCT00039520
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	2	Completed	https://clinicaltrials.gov/study/NCT01572727,https://clinicaltrials.gov/study/NCT02404844,https://clinicaltrials.gov/study/NCT01923168,https://clinicaltrials.gov/study/NCT01629615,https://clinicaltrials.gov/study/NCT01790932,https://clinicaltrials.gov/study/NCT01816594
EFO_0000186	invasive breast ductal carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02779855
MONDO_0007254	breast cancer	CHEMBL118	CELECOXIB	Small molecule	Cyclooxygenase-2 inhibitor		PTGS2	prostaglandin-endoperoxide synthase 2	2	Terminated	https://clinicaltrials.gov/study/NCT00088972,https://clinicaltrials.gov/study/NCT01067989,https://clinicaltrials.gov/study/NCT00101062,https://clinicaltrials.gov/study/NCT00665457,https://clinicaltrials.gov/study/NCT00045591
EFO_0005537	triple-negative breast cancer	CHEMBL3545414	RIVOCERANIB MESYLATE	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT03650738
MONDO_0007254	breast cancer	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Serine/threonine-protein kinase RAF inhibitor		RAF1	Raf-1 proto-oncogene, serine/threonine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT00622466,https://clinicaltrials.gov/study/NCT00722072,https://clinicaltrials.gov/study/NCT00573755
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase RAF inhibitor		RAF1	Raf-1 proto-oncogene, serine/threonine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01320111,https://clinicaltrials.gov/study/NCT00634634,https://clinicaltrials.gov/study/NCT00493636,https://clinicaltrials.gov/study/NCT00548899,https://clinicaltrials.gov/study/NCT00101400
EFO_0005537	triple-negative breast cancer	CHEMBL4297723	CEMIPLIMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL1536	ERGOCALCIFEROL	Small molecule	Vitamin D receptor agonist		VDR	vitamin D receptor	2	Completed	https://clinicaltrials.gov/study/NCT01965522,https://clinicaltrials.gov/study/NCT00656019,https://clinicaltrials.gov/study/NCT04091178,https://clinicaltrials.gov/study/NCT04166253
MONDO_0007254	breast cancer	CHEMBL2304041	SAGOPILONE	Small molecule	Tubulin stabiliser		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT00288249
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05263882,https://clinicaltrials.gov/study/NCT04517292,https://clinicaltrials.gov/study/NCT04143906
MONDO_0007254	breast cancer	CHEMBL3647420	PYROTINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03691051,https://clinicaltrials.gov/study/NCT04001621,https://clinicaltrials.gov/study/NCT04126525,https://clinicaltrials.gov/study/NCT04398914,https://clinicaltrials.gov/study/NCT04486911,https://clinicaltrials.gov/study/NCT04293276
MONDO_0007254	breast cancer	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	2	Completed	https://clinicaltrials.gov/study/NCT00004906,https://clinicaltrials.gov/study/NCT00004900,https://clinicaltrials.gov/study/NCT01589159,https://clinicaltrials.gov/study/NCT03535961,https://clinicaltrials.gov/study/NCT00693719,https://clinicaltrials.gov/study/NCT00006260
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00679029,https://clinicaltrials.gov/study/NCT00159458,https://clinicaltrials.gov/study/NCT00323063,https://clinicaltrials.gov/study/NCT00095888,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT00470249,https://clinicaltrials.gov/study/NCT03674242,https://clinicaltrials.gov/study/NCT00674206,https://clinicaltrials.gov/study/NCT00462865,https://clinicaltrials.gov/study/NCT02213744,https://clinicaltrials.gov/study/NCT00532285
EFO_0005537	triple-negative breast cancer	CHEMBL1614701	SELUMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 1 inhibitor		MAP2K1	mitogen-activated protein kinase kinase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT03801369
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT03853707,https://clinicaltrials.gov/study/NCT00733408,https://clinicaltrials.gov/study/NCT01818063,https://clinicaltrials.gov/study/NCT01881230,https://clinicaltrials.gov/study/NCT02689427,https://clinicaltrials.gov/study/NCT03057600,https://clinicaltrials.gov/study/NCT02413320
MONDO_0007254	breast cancer	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 3 inhibitor		HDAC3	histone deacetylase 3	2	Terminated	https://clinicaltrials.gov/study/NCT01194427,https://clinicaltrials.gov/study/NCT04190056
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT00006261
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	2	Recruiting	https://clinicaltrials.gov/study/NCT05766410,https://clinicaltrials.gov/study/NCT02760030,https://clinicaltrials.gov/study/NCT05563220,https://clinicaltrials.gov/study/NCT04920708,https://clinicaltrials.gov/study/NCT04946864,https://clinicaltrials.gov/study/NCT04318223,https://clinicaltrials.gov/study/NCT05069038,https://clinicaltrials.gov/study/NCT04567420,https://clinicaltrials.gov/study/NCT04841148,https://clinicaltrials.gov/study/NCT04802759,https://clinicaltrials.gov/study/NCT03439735,https://clinicaltrials.gov/study/NCT04247633,https://clinicaltrials.gov/study/NCT05190094,https://clinicaltrials.gov/study/NCT04563507,https://clinicaltrials.gov/study/NCT04985266,https://clinicaltrials.gov/study/NCT05076695
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Withdrawn	https://clinicaltrials.gov/study/NCT02067416,https://clinicaltrials.gov/study/NCT03554109,https://clinicaltrials.gov/study/NCT05809895,https://clinicaltrials.gov/study/NCT02053597,https://clinicaltrials.gov/study/NCT01163929,https://clinicaltrials.gov/study/NCT04038489,https://clinicaltrials.gov/study/NCT03872505,https://clinicaltrials.gov/study/NCT03841747,https://clinicaltrials.gov/study/NCT01169870,https://clinicaltrials.gov/study/NCT03058939,https://clinicaltrials.gov/study/NCT00397761
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT02199418,https://clinicaltrials.gov/study/NCT00513695,https://clinicaltrials.gov/study/NCT02682693
EFO_1000984	inflammatory breast carcinoma	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01730833
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Recruiting	https://clinicaltrials.gov/study/NCT04266249,https://clinicaltrials.gov/study/NCT06042569,https://clinicaltrials.gov/study/NCT05319873
MONDO_0007254	breast cancer	CHEMBL4297892	ANVATABART OPADOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Recruiting	https://clinicaltrials.gov/study/NCT05426486,https://clinicaltrials.gov/study/NCT05018702,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT05018676,https://clinicaltrials.gov/study/NCT04829604
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Withdrawn	https://clinicaltrials.gov/study/NCT05233696,https://clinicaltrials.gov/study/NCT05177796
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Completed	https://clinicaltrials.gov/study/NCT00191373
EFO_0005537	triple-negative breast cancer	CHEMBL180022	NERATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04303741,https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT05833919
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Withdrawn	https://clinicaltrials.gov/study/NCT00450515
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Withdrawn	https://clinicaltrials.gov/study/NCT00450515
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Recruiting	https://clinicaltrials.gov/study/NCT06075953
MONDO_0007254	breast cancer	CHEMBL1186894	AMRUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Withdrawn	https://clinicaltrials.gov/study/NCT00380835
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT00148707,https://clinicaltrials.gov/study/NCT00265733
MONDO_0007254	breast cancer	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Terminated	https://clinicaltrials.gov/study/NCT00542191,https://clinicaltrials.gov/study/NCT00465673,https://clinicaltrials.gov/study/NCT03329378,https://clinicaltrials.gov/study/NCT01329627,https://clinicaltrials.gov/study/NCT00431795,https://clinicaltrials.gov/study/NCT01120171,https://clinicaltrials.gov/study/NCT00679029,https://clinicaltrials.gov/study/NCT00636441,https://clinicaltrials.gov/study/NCT00903656,https://clinicaltrials.gov/study/NCT01990352,https://clinicaltrials.gov/study/NCT00448266,https://clinicaltrials.gov/study/NCT02096588,https://clinicaltrials.gov/study/NCT00691912,https://clinicaltrials.gov/study/NCT00665457,https://clinicaltrials.gov/study/NCT00574236,https://clinicaltrials.gov/study/NCT01147016,https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT00589238,https://clinicaltrials.gov/study/NCT01498588,https://clinicaltrials.gov/study/NCT00524459
EFO_0005537	triple-negative breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT05670925
EFO_0000305	breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Fibroblast growth factor receptor 3 inhibitor		FGFR3	fibroblast growth factor receptor 3	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA5	NADH:ubiquinone oxidoreductase subunit A5	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Terminated	https://clinicaltrials.gov/study/NCT03709082,https://clinicaltrials.gov/study/NCT01702558,https://clinicaltrials.gov/study/NCT03894007
MONDO_0007254	breast cancer	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Suspended	https://clinicaltrials.gov/study/NCT02897050,https://clinicaltrials.gov/study/NCT04419181
MONDO_0007254	breast cancer	CHEMBL3647420	PYROTINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT05834764,https://clinicaltrials.gov/study/NCT05769010,https://clinicaltrials.gov/study/NCT05426486,https://clinicaltrials.gov/study/NCT04605575,https://clinicaltrials.gov/study/NCT06001086,https://clinicaltrials.gov/study/NCT04872985,https://clinicaltrials.gov/study/NCT03923179,https://clinicaltrials.gov/study/NCT03923166,https://clinicaltrials.gov/study/NCT05659056,https://clinicaltrials.gov/study/NCT05353361,https://clinicaltrials.gov/study/NCT05800756,https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT05429294,https://clinicaltrials.gov/study/NCT05638594,https://clinicaltrials.gov/study/NCT05635487,https://clinicaltrials.gov/study/NCT04034589,https://clinicaltrials.gov/study/NCT04717531,https://clinicaltrials.gov/study/NCT05042791,https://clinicaltrials.gov/study/NCT06254690,https://clinicaltrials.gov/study/NCT06152822,https://clinicaltrials.gov/study/NCT05575804,https://clinicaltrials.gov/study/NCT04095390,https://clinicaltrials.gov/study/NCT04407988,https://clinicaltrials.gov/study/NCT05823623,https://clinicaltrials.gov/study/NCT04917900,https://clinicaltrials.gov/study/NCT04033172,https://clinicaltrials.gov/study/NCT04997798,https://clinicaltrials.gov/study/NCT05861271,https://clinicaltrials.gov/study/NCT05880927,https://clinicaltrials.gov/study/NCT04355858,https://clinicaltrials.gov/study/NCT05076695,https://clinicaltrials.gov/study/NCT05228951,https://clinicaltrials.gov/study/NCT05292742
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL180022	NERATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Completed	https://clinicaltrials.gov/study/NCT02673398
MONDO_0007254	breast cancer	CHEMBL1201748	CABAZITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Terminated	https://clinicaltrials.gov/study/NCT01934894
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR1	estrogen receptor 1	2	Suspended	https://clinicaltrials.gov/study/NCT00738777
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FRK	fyn related Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00546104,https://clinicaltrials.gov/study/NCT00754325,https://clinicaltrials.gov/study/NCT00410813,https://clinicaltrials.gov/study/NCT00696072,https://clinicaltrials.gov/study/NCT00767520
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA10	NADH:ubiquinone oxidoreductase subunit A10	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1201748	CABAZITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT01693549
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN7A	sodium voltage-gated channel alpha subunit 7	2	Completed	https://clinicaltrials.gov/study/NCT02839668,https://clinicaltrials.gov/study/NCT01204242
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Unknown status	https://clinicaltrials.gov/study/NCT03144947
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		SRMS	src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01471106
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF3	NADH:ubiquinone oxidoreductase complex assembly factor 3	2	Terminated	https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT04899349
MONDO_0007254	breast cancer	CHEMBL1491	AMLODIPINE	Small molecule	Voltage-gated L-type calcium channel blocker		CACNA1C	calcium voltage-gated channel subunit alpha1 C	2	Completed	https://clinicaltrials.gov/study/NCT02834403
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV3	NADH:ubiquinone oxidoreductase subunit V3	2	Unknown status	https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT02506777,https://clinicaltrials.gov/study/NCT03192293
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Epidermal growth factor receptor inhibitor		EGFR	epidermal growth factor receptor	2	Terminated	https://clinicaltrials.gov/study/NCT00481845,https://clinicaltrials.gov/study/NCT00752986,https://clinicaltrials.gov/study/NCT01934335
MONDO_0007254	breast cancer	CHEMBL3349607	PASIREOTIDE	Protein	Somatostatin receptor 2 agonist		SSTR2	somatostatin receptor 2	2	Completed	https://clinicaltrials.gov/study/NCT01356862
MONDO_0007254	breast cancer	CHEMBL1536	ERGOCALCIFEROL	Small molecule	Vitamin D receptor agonist		VDR	vitamin D receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT02288806
MONDO_0007254	breast cancer	CHEMBL522892	DOVITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Completed	https://clinicaltrials.gov/study/NCT01262027,https://clinicaltrials.gov/study/NCT00958971
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		SRMS	src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites	2	Terminated	https://clinicaltrials.gov/study/NCT00780676,https://clinicaltrials.gov/study/NCT00817531,https://clinicaltrials.gov/study/NCT05198843
MONDO_0007254	breast cancer	CHEMBL298734	LONAFARNIB	Small molecule	Protein farnesyltransferase inhibitor		FNTB	farnesyltransferase, CAAX box, subunit beta	2	Terminated	https://clinicaltrials.gov/study/NCT00773474
MONDO_0007254	breast cancer	CHEMBL940	GABAPENTIN	Small molecule	Voltage-gated calcium channel modulator		CACNA2D1	calcium voltage-gated channel auxiliary subunit alpha2delta 1	2	Completed	https://clinicaltrials.gov/study/NCT03084536
MONDO_0007254	breast cancer	CHEMBL94657	PATUPILONE	Small molecule	Tubulin stabiliser		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT00450866
EFO_0006861	male breast carcinoma	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Completed	https://clinicaltrials.gov/study/NCT00096434
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04001829,https://clinicaltrials.gov/study/NCT02568839
EFO_0000305	breast carcinoma	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	2	Recruiting	https://clinicaltrials.gov/study/NCT04305834
EFO_0000305	breast carcinoma	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Recruiting	https://clinicaltrials.gov/study/NCT02476786,https://clinicaltrials.gov/study/NCT05150652
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Unknown status	https://clinicaltrials.gov/study/NCT02175446
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS1	NADH:ubiquinone oxidoreductase core subunit S1	2	Recruiting	https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT04559308
MONDO_0007254	breast cancer	CHEMBL180022	NERATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01494662,https://clinicaltrials.gov/study/NCT03812393,https://clinicaltrials.gov/study/NCT03377387
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Withdrawn	https://clinicaltrials.gov/study/NCT02067416,https://clinicaltrials.gov/study/NCT01818999
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05033756,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT05174832,https://clinicaltrials.gov/study/NCT06298084,https://clinicaltrials.gov/study/NCT06245889,https://clinicaltrials.gov/study/NCT05332561,https://clinicaltrials.gov/study/NCT05498155,https://clinicaltrials.gov/study/NCT05203445,https://clinicaltrials.gov/study/NCT05629429,https://clinicaltrials.gov/study/NCT03182634,https://clinicaltrials.gov/study/NCT03025035,https://clinicaltrials.gov/study/NCT03150576
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE7B	phosphodiesterase 7B	2	Recruiting	https://clinicaltrials.gov/study/NCT06087237
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967,https://clinicaltrials.gov/study/NCT06027268
EFO_0005537	triple-negative breast cancer	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01750073
MONDO_0007254	breast cancer	CHEMBL1200694	SEVOFLURANE	Small molecule	Potassium channel subfamily K member 9 opener		KCNK9	potassium two pore domain channel subfamily K member 9	2	Completed	https://clinicaltrials.gov/study/NCT02839668
MONDO_0007254	breast cancer	CHEMBL4298050	TIRAGOLUMAB	Antibody	T-cell immunoreceptor with Ig and ITIM domains inhibitor		TIGIT	T cell immunoreceptor with Ig and ITIM domains	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06342037
MONDO_0007254	breast cancer	CHEMBL225072	PEMETREXED	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	2	Unknown status	https://clinicaltrials.gov/study/NCT02829008
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT00148707,https://clinicaltrials.gov/study/NCT00265733
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT02978495
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Recruiting	https://clinicaltrials.gov/study/NCT04266249,https://clinicaltrials.gov/study/NCT03606967,https://clinicaltrials.gov/study/NCT04090398
MONDO_0007254	breast cancer	CHEMBL131	PREDNISOLONE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	2	Completed	https://clinicaltrials.gov/study/NCT01381874
MONDO_0007254	breast cancer	CHEMBL4279455	LAROTAXEL	Small molecule	Tubulin stabiliser		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT00087958,https://clinicaltrials.gov/study/NCT00387907
MONDO_0007254	breast cancer	CHEMBL52885	ENMD-981693	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Completed	https://clinicaltrials.gov/study/NCT00306631
EFO_0000305	breast carcinoma	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05133674,https://clinicaltrials.gov/study/NCT02311933,https://clinicaltrials.gov/study/NCT02668666
MONDO_0007254	breast cancer	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	2	Unknown status	https://clinicaltrials.gov/study/NCT01492556,https://clinicaltrials.gov/study/NCT00012311
EFO_0000186	invasive breast ductal carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02779855
MONDO_0007254	breast cancer	CHEMBL1230609	FORETINIB	Small molecule	Hepatocyte growth factor receptor inhibitor		MET	MET proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01138384,https://clinicaltrials.gov/study/NCT01147484
MONDO_0007254	breast cancer	CHEMBL4303201	CATEQUENTINIB	Small molecule	Vascular endothelial growth factor receptor 3 inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT05206656
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Recruiting	https://clinicaltrials.gov/study/NCT04796324
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Withdrawn	https://clinicaltrials.gov/study/NCT03032614
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT00027989
MONDO_0007254	breast cancer	CHEMBL2109402	MM-121	Antibody	Receptor tyrosine-protein kinase erbB-3 antagonist		ERBB3	erb-b2 receptor tyrosine kinase 3	2	Completed	https://clinicaltrials.gov/study/NCT01151046,https://clinicaltrials.gov/study/NCT01421472
MONDO_0007254	breast cancer	CHEMBL27	PROPRANOLOL	Small molecule	Beta-1 adrenergic receptor antagonist		ADRB1	adrenoceptor beta 1	2	Terminated	https://clinicaltrials.gov/study/NCT02596867
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT00254592,https://clinicaltrials.gov/study/NCT00146562,https://clinicaltrials.gov/study/NCT03853707,https://clinicaltrials.gov/study/NCT03248427,https://clinicaltrials.gov/study/NCT00407888,https://clinicaltrials.gov/study/NCT01320111,https://clinicaltrials.gov/study/NCT00436566,https://clinicaltrials.gov/study/NCT00005635,https://clinicaltrials.gov/study/NCT02365805,https://clinicaltrials.gov/study/NCT02263495,https://clinicaltrials.gov/study/NCT00110084,https://clinicaltrials.gov/study/NCT02628613,https://clinicaltrials.gov/study/NCT01722968,https://clinicaltrials.gov/study/NCT01792050,https://clinicaltrials.gov/study/NCT01617668,https://clinicaltrials.gov/study/NCT00455533,https://clinicaltrials.gov/study/NCT00148681,https://clinicaltrials.gov/study/NCT01276041,https://clinicaltrials.gov/study/NCT00378313,https://clinicaltrials.gov/study/NCT00256243,https://clinicaltrials.gov/study/NCT00475670,https://clinicaltrials.gov/study/NCT00773695,https://clinicaltrials.gov/study/NCT02909751,https://clinicaltrials.gov/study/NCT01432223,https://clinicaltrials.gov/study/NCT02938442,https://clinicaltrials.gov/study/NCT03121352,https://clinicaltrials.gov/study/NCT00542451,https://clinicaltrials.gov/study/NCT02687490,https://clinicaltrials.gov/study/NCT00052351,https://clinicaltrials.gov/study/NCT03289819,https://clinicaltrials.gov/study/NCT00629499,https://clinicaltrials.gov/study/NCT00971945,https://clinicaltrials.gov/study/NCT00546156,https://clinicaltrials.gov/study/NCT00096291,https://clinicaltrials.gov/study/NCT01989780,https://clinicaltrials.gov/study/NCT00005649,https://clinicaltrials.gov/study/NCT01506609,https://clinicaltrials.gov/study/NCT00334802,https://clinicaltrials.gov/study/NCT00662129,https://clinicaltrials.gov/study/NCT03644186,https://clinicaltrials.gov/study/NCT01818063,https://clinicaltrials.gov/study/NCT01256762,https://clinicaltrials.gov/study/NCT03742986,https://clinicaltrials.gov/study/NCT00503906,https://clinicaltrials.gov/study/NCT00004092,https://clinicaltrials.gov/study/NCT01190982,https://clinicaltrials.gov/study/NCT01106898,https://clinicaltrials.gov/study/NCT01423695,https://clinicaltrials.gov/study/NCT00675259,https://clinicaltrials.gov/study/NCT05112536,https://clinicaltrials.gov/study/NCT00001498,https://clinicaltrials.gov/study/NCT00193206,https://clinicaltrials.gov/study/NCT00532857,https://clinicaltrials.gov/study/NCT00482391,https://clinicaltrials.gov/study/NCT04408118,https://clinicaltrials.gov/study/NCT00467012,https://clinicaltrials.gov/study/NCT01036087,https://clinicaltrials.gov/study/NCT00001384,https://clinicaltrials.gov/study/NCT00394251,https://clinicaltrials.gov/study/NCT00795899,https://clinicaltrials.gov/study/NCT00096668,https://clinicaltrials.gov/study/NCT01656538,https://clinicaltrials.gov/study/NCT01307891,https://clinicaltrials.gov/study/NCT01835236,https://clinicaltrials.gov/study/NCT01969032,https://clinicaltrials.gov/study/NCT00191854,https://clinicaltrials.gov/study/NCT00002937,https://clinicaltrials.gov/study/NCT00723125,https://clinicaltrials.gov/study/NCT00403130,https://clinicaltrials.gov/study/NCT01008150,https://clinicaltrials.gov/study/NCT02229084,https://clinicaltrials.gov/study/NCT00072319,https://clinicaltrials.gov/study/NCT01705691,https://clinicaltrials.gov/study/NCT00194779,https://clinicaltrials.gov/study/NCT00654836,https://clinicaltrials.gov/study/NCT00003612,https://clinicaltrials.gov/study/NCT01779479,https://clinicaltrials.gov/study/NCT02685059,https://clinicaltrials.gov/study/NCT00093145,https://clinicaltrials.gov/study/NCT02301988,https://clinicaltrials.gov/study/NCT00580333,https://clinicaltrials.gov/study/NCT01740336,https://clinicaltrials.gov/study/NCT01847001,https://clinicaltrials.gov/study/NCT00559845,https://clinicaltrials.gov/study/NCT02370238,https://clinicaltrials.gov/study/NCT00919880,https://clinicaltrials.gov/study/NCT00003035,https://clinicaltrials.gov/study/NCT02783222,https://clinicaltrials.gov/study/NCT00096343,https://clinicaltrials.gov/study/NCT01572727,https://clinicaltrials.gov/study/NCT01827163,https://clinicaltrials.gov/study/NCT00003392,https://clinicaltrials.gov/study/NCT03982485,https://clinicaltrials.gov/study/NCT03887130,https://clinicaltrials.gov/study/NCT00316199,https://clinicaltrials.gov/study/NCT00394082,https://clinicaltrials.gov/study/NCT00002679,https://clinicaltrials.gov/study/NCT02789657,https://clinicaltrials.gov/study/NCT01186991,https://clinicaltrials.gov/study/NCT01593020,https://clinicaltrials.gov/study/NCT01982448,https://clinicaltrials.gov/study/NCT03326102,https://clinicaltrials.gov/study/NCT01816594,https://clinicaltrials.gov/study/NCT00136539,https://clinicaltrials.gov/study/NCT00006256,https://clinicaltrials.gov/study/NCT00944047,https://clinicaltrials.gov/study/NCT01959490,https://clinicaltrials.gov/study/NCT00733408,https://clinicaltrials.gov/study/NCT00320541,https://clinicaltrials.gov/study/NCT00846027,https://clinicaltrials.gov/study/NCT00915603,https://clinicaltrials.gov/study/NCT02225652,https://clinicaltrials.gov/study/NCT01565499,https://clinicaltrials.gov/study/NCT02132949,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00274456,https://clinicaltrials.gov/study/NCT00003992,https://clinicaltrials.gov/study/NCT00915018,https://clinicaltrials.gov/study/NCT02474186,https://clinicaltrials.gov/study/NCT03301350,https://clinicaltrials.gov/study/NCT00499083,https://clinicaltrials.gov/study/NCT00930930,https://clinicaltrials.gov/study/NCT00002826,https://clinicaltrials.gov/study/NCT01672671,https://clinicaltrials.gov/study/NCT00019812,https://clinicaltrials.gov/study/NCT03072992,https://clinicaltrials.gov/study/NCT00511459,https://clinicaltrials.gov/study/NCT01023204,https://clinicaltrials.gov/study/NCT00004013,https://clinicaltrials.gov/study/NCT02698891,https://clinicaltrials.gov/study/NCT00128856,https://clinicaltrials.gov/study/NCT00645177,https://clinicaltrials.gov/study/NCT01203267,https://clinicaltrials.gov/study/NCT00618657,https://clinicaltrials.gov/study/NCT01446016,https://clinicaltrials.gov/study/NCT00028873,https://clinicaltrials.gov/study/NCT01688609,https://clinicaltrials.gov/study/NCT01421472,https://clinicaltrials.gov/study/NCT02280252,https://clinicaltrials.gov/study/NCT00006110,https://clinicaltrials.gov/study/NCT01204125,https://clinicaltrials.gov/study/NCT00618826,https://clinicaltrials.gov/study/NCT01204437,https://clinicaltrials.gov/study/NCT01855828,https://clinicaltrials.gov/study/NCT00503750,https://clinicaltrials.gov/study/NCT02954055,https://clinicaltrials.gov/study/NCT00007904,https://clinicaltrials.gov/study/NCT01594177,https://clinicaltrials.gov/study/NCT04224922,https://clinicaltrials.gov/study/NCT02073487,https://clinicaltrials.gov/study/NCT00856492,https://clinicaltrials.gov/study/NCT00370552,https://clinicaltrials.gov/study/NCT00768859,https://clinicaltrials.gov/study/NCT00635050,https://clinicaltrials.gov/study/NCT00003050,https://clinicaltrials.gov/study/NCT00003539,https://clinicaltrials.gov/study/NCT03193853,https://clinicaltrials.gov/study/NCT00479674,https://clinicaltrials.gov/study/NCT00392392,https://clinicaltrials.gov/study/NCT01973660,https://clinicaltrials.gov/study/NCT00251472
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF1	NADH:ubiquinone oxidoreductase complex assembly factor 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
EFO_0000305	breast carcinoma	CHEMBL2108738	NIVOLUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03650894
MONDO_0007254	breast cancer	CHEMBL1200501	GOSERELIN ACETATE	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT00398489
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB11	NADH:ubiquinone oxidoreductase subunit B11	2	Completed	https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT02028221
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS2	NADH:ubiquinone oxidoreductase core subunit S2	2	Completed	https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT00909506
MONDO_0007254	breast cancer	CHEMBL52885	ENMD-981693	Small molecule	SRC inhibitor		FRK	fyn related Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00306631
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Suspended	https://clinicaltrials.gov/study/NCT04419181,https://clinicaltrials.gov/study/NCT04675827
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Withdrawn	https://clinicaltrials.gov/study/NCT03872505,https://clinicaltrials.gov/study/NCT03058939,https://clinicaltrials.gov/study/NCT01163929,https://clinicaltrials.gov/study/NCT03554109,https://clinicaltrials.gov/study/NCT04038489,https://clinicaltrials.gov/study/NCT01169870,https://clinicaltrials.gov/study/NCT05809895,https://clinicaltrials.gov/study/NCT02053597,https://clinicaltrials.gov/study/NCT00397761,https://clinicaltrials.gov/study/NCT03841747,https://clinicaltrials.gov/study/NCT02067416
MONDO_0007254	breast cancer	CHEMBL1201827	PANITUMUMAB	Antibody	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01009983
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4L	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
EFO_0005537	triple-negative breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT03932526
MONDO_0007254	breast cancer	CHEMBL3833373	AVELUMAB	Antibody	Programmed cell death 1 ligand 1 other	Inhibitor	CD274	CD274 molecule	2	Recruiting	https://clinicaltrials.gov/study/NCT04841148
MONDO_0007254	breast cancer	CHEMBL1922094	APITOLISIB	Small molecule	Serine/threonine-protein kinase mTOR inhibitor		MTOR	mechanistic target of rapamycin kinase	2	Completed	https://clinicaltrials.gov/study/NCT01437566
MONDO_0007254	breast cancer	CHEMBL3647420	PYROTINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT03735966,https://clinicaltrials.gov/study/NCT04903652
MONDO_0007254	breast cancer	CHEMBL2220486	LUCITANIB	Small molecule	Fibroblast growth factor receptor 2 inhibitor		FGFR2	fibroblast growth factor receptor 2	2	Terminated	https://clinicaltrials.gov/study/NCT02202746
MONDO_0007254	breast cancer	CHEMBL4297190	SURUFATINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05186545
EFO_0000305	breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967
MONDO_0007254	breast cancer	CHEMBL1201748	CABAZITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Recruiting	https://clinicaltrials.gov/study/NCT03048942
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS7	NADH:ubiquinone oxidoreductase core subunit S7	2	Unknown status	https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT02506777
MONDO_0007254	breast cancer	CHEMBL1751	DIGOXIN	Small molecule	Sodium/potassium-transporting ATPase inhibitor		ATP1A3	ATPase Na+/K+ transporting subunit alpha 3	2	Terminated	https://clinicaltrials.gov/study/NCT01887288
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC4	histone deacetylase 4	2	Completed	https://clinicaltrials.gov/study/NCT00676663,https://clinicaltrials.gov/study/NCT02708680,https://clinicaltrials.gov/study/NCT00828854,https://clinicaltrials.gov/study/NCT03291886
MONDO_0007254	breast cancer	CHEMBL480	LANSOPRAZOLE	Small molecule	Potassium-transporting ATPase inhibitor		ATP4A	ATPase H+/K+ transporting subunit alpha	2	Withdrawn	https://clinicaltrials.gov/study/NCT03794596
MONDO_0007254	breast cancer	CHEMBL1201748	CABAZITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Terminated	https://clinicaltrials.gov/study/NCT01934894
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Terminated	https://clinicaltrials.gov/study/NCT02978716
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA10	NADH:ubiquinone oxidoreductase subunit A10	2	Completed	https://clinicaltrials.gov/study/NCT04170465
EFO_0005537	triple-negative breast cancer	CHEMBL2103875	TRAMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor		MAP2K1	mitogen-activated protein kinase kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT01964924
MONDO_0007254	breast cancer	CHEMBL1201748	CABAZITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Recruiting	https://clinicaltrials.gov/study/NCT03048942
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA6	NADH:ubiquinone oxidoreductase subunit A6	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA1	NADH:ubiquinone oxidoreductase subunit A1	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA12	NADH:ubiquinone oxidoreductase subunit A12	2	Completed	https://clinicaltrials.gov/study/NCT01885013
MONDO_0007254	breast cancer	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC11	histone deacetylase 11	2	Completed	https://clinicaltrials.gov/study/NCT00098397
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV3	NADH:ubiquinone oxidoreductase subunit V3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
MONDO_0007254	breast cancer	CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist		IFNAR1	interferon alpha and beta receptor subunit 1	2	Enrolling by invitation	https://clinicaltrials.gov/study/NCT03328026
MONDO_0007254	breast cancer	CHEMBL4297509	ELACESTRANT	Small molecule	Estrogen receptor alpha degrader		ESR1	estrogen receptor 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05596409,https://clinicaltrials.gov/study/NCT05963997,https://clinicaltrials.gov/study/NCT05563220,https://clinicaltrials.gov/study/NCT04791384
EFO_0000186	invasive breast ductal carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02779855
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Withdrawn	https://clinicaltrials.gov/study/NCT04351230
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB5	NADH:ubiquinone oxidoreductase subunit B5	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
MONDO_0007254	breast cancer	CHEMBL1201179	LAPATINIB DITOSYLATE	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Completed	https://clinicaltrials.gov/study/NCT01688609,https://clinicaltrials.gov/study/NCT01622868,https://clinicaltrials.gov/study/NCT00436566,https://clinicaltrials.gov/study/NCT00769470,https://clinicaltrials.gov/study/NCT00820872,https://clinicaltrials.gov/study/NCT00967031,https://clinicaltrials.gov/study/NCT00482391
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT01779206,https://clinicaltrials.gov/study/NCT00295893,https://clinicaltrials.gov/study/NCT04172259,https://clinicaltrials.gov/study/NCT03609047,https://clinicaltrials.gov/study/NCT02568839,https://clinicaltrials.gov/study/NCT03161353,https://clinicaltrials.gov/study/NCT02339532,https://clinicaltrials.gov/study/NCT02547987,https://clinicaltrials.gov/study/NCT00496795,https://clinicaltrials.gov/study/NCT02624973
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4L2	NDUFA4 mitochondrial complex associated like 2	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04143906,https://clinicaltrials.gov/study/NCT06229067,https://clinicaltrials.gov/study/NCT03997539,https://clinicaltrials.gov/study/NCT04922008,https://clinicaltrials.gov/study/NCT04963595
MONDO_0007254	breast cancer	CHEMBL3989868	TUCATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04538742,https://clinicaltrials.gov/study/NCT04539938,https://clinicaltrials.gov/study/NCT04721977
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT02614833
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV2	NADH:ubiquinone oxidoreductase core subunit V2	2	Completed	https://clinicaltrials.gov/study/NCT01885013
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
MONDO_0007254	breast cancer	CHEMBL3184679	AZD-4547	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR3	fibroblast growth factor receptor 3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999
MONDO_0003982	bilateral breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT00877500
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Suspended	https://clinicaltrials.gov/study/NCT02897050,https://clinicaltrials.gov/study/NCT04419181
MONDO_0007254	breast cancer	CHEMBL3701238	FUTIBATINIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR1	fibroblast growth factor receptor 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04024436
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT00193089,https://clinicaltrials.gov/study/NCT00325234,https://clinicaltrials.gov/study/NCT00041067,https://clinicaltrials.gov/study/NCT03254654,https://clinicaltrials.gov/study/NCT00670982,https://clinicaltrials.gov/study/NCT00401427,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT01565083,https://clinicaltrials.gov/study/NCT03007992,https://clinicaltrials.gov/study/NCT00022152,https://clinicaltrials.gov/study/NCT00148681,https://clinicaltrials.gov/study/NCT00004237,https://clinicaltrials.gov/study/NCT03887130,https://clinicaltrials.gov/study/NCT00148668,https://clinicaltrials.gov/study/NCT00503750,https://clinicaltrials.gov/study/NCT01835236,https://clinicaltrials.gov/study/NCT01439191,https://clinicaltrials.gov/study/NCT00266110,https://clinicaltrials.gov/study/NCT01305941,https://clinicaltrials.gov/study/NCT01520103,https://clinicaltrials.gov/study/NCT03321981,https://clinicaltrials.gov/study/NCT00192062,https://clinicaltrials.gov/study/NCT04903652,https://clinicaltrials.gov/study/NCT00480597,https://clinicaltrials.gov/study/NCT00194779,https://clinicaltrials.gov/study/NCT00015938,https://clinicaltrials.gov/study/NCT02628613,https://clinicaltrials.gov/study/NCT00093808,https://clinicaltrials.gov/study/NCT02954055,https://clinicaltrials.gov/study/NCT00006682,https://clinicaltrials.gov/study/NCT01941771,https://clinicaltrials.gov/study/NCT00532623,https://clinicaltrials.gov/study/NCT01242449,https://clinicaltrials.gov/study/NCT02362958
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Withdrawn	https://clinicaltrials.gov/study/NCT04351230
MONDO_0007254	breast cancer	CHEMBL2108702	IMETELSTAT SODIUM	Oligonucleotide	Telomerase reverse transcriptase inhibitor		TERT	telomerase reverse transcriptase	2	Completed	https://clinicaltrials.gov/study/NCT01256762
MONDO_0007254	breast cancer	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	2	Recruiting	https://clinicaltrials.gov/study/NCT05563220,https://clinicaltrials.gov/study/NCT03285412,https://clinicaltrials.gov/study/NCT05625087,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT05900206,https://clinicaltrials.gov/study/NCT05296746,https://clinicaltrials.gov/study/NCT05664893,https://clinicaltrials.gov/study/NCT04802759,https://clinicaltrials.gov/study/NCT05467891,https://clinicaltrials.gov/study/NCT05573555,https://clinicaltrials.gov/study/NCT03090165,https://clinicaltrials.gov/study/NCT05816655,https://clinicaltrials.gov/study/NCT05766410
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor		GPD2	glycerol-3-phosphate dehydrogenase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0005537	triple-negative breast cancer	CHEMBL135	ESTRADIOL	Small molecule	Estrogen receptor alpha agonist		ESR1	estrogen receptor 1	2	Enrolling by invitation	https://clinicaltrials.gov/study/NCT03941730
MONDO_0007254	breast cancer	CHEMBL924	ZOLEDRONIC ACID ANHYDROUS	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	2	Unknown status	https://clinicaltrials.gov/study/NCT01654367
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV3	NADH:ubiquinone oxidoreductase subunit V3	2	Terminated	https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT04899349
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04502680
MONDO_0007254	breast cancer	CHEMBL76222	REBIMASTAT	Small molecule	Matrix metalloproteinase-1 inhibitor		MMP1	matrix metallopeptidase 1	2	Terminated	https://clinicaltrials.gov/study/NCT00036621
MONDO_0007254	breast cancer	CHEMBL3545154	POZIOTINIB	Small molecule	Epidermal growth factor receptor inhibitor		ERBB3	erb-b2 receptor tyrosine kinase 3	2	Completed	https://clinicaltrials.gov/study/NCT02659514,https://clinicaltrials.gov/study/NCT02418689,https://clinicaltrials.gov/study/NCT02544997
MONDO_0007254	breast cancer	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 1 inhibitor		HDAC1	histone deacetylase 1	2	Completed	https://clinicaltrials.gov/study/NCT00262834,https://clinicaltrials.gov/study/NCT00365599
EFO_0006861	male breast carcinoma	CHEMBL2107313	BECATECARIN	Small molecule	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	2	Completed	https://clinicaltrials.gov/study/NCT00005817
MONDO_0007254	breast cancer	CHEMBL1234354	PF-04691502	Small molecule	Serine/threonine-protein kinase mTOR inhibitor		MTOR	mechanistic target of rapamycin kinase	2	Terminated	https://clinicaltrials.gov/study/NCT01430585
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB3	NADH:ubiquinone oxidoreductase subunit B3	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT04559308,https://clinicaltrials.gov/study/NCT03238495
MONDO_0021115	luminal B breast carcinoma	CHEMBL3301587	DURVALUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor	Inhibitor	CD274	CD274 molecule	2	Completed	https://clinicaltrials.gov/study/NCT03356860
EFO_0000432	breast ductal carcinoma in situ	CHEMBL489	AFIMOXIFENE	Small molecule	Estrogen receptor modulator		ESR2	estrogen receptor 2	2	Completed	https://clinicaltrials.gov/study/NCT00952731
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT06027268,https://clinicaltrials.gov/study/NCT03606967
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04001829,https://clinicaltrials.gov/study/NCT02568839
EFO_0000305	breast carcinoma	CHEMBL2396661	ALPELISIB	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04216472
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01471106
MONDO_0007254	breast cancer	CHEMBL1201247	GOSERELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT05720260,https://clinicaltrials.gov/study/NCT05607004,https://clinicaltrials.gov/study/NCT02476786
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT00119262,https://clinicaltrials.gov/study/NCT00513695,https://clinicaltrials.gov/study/NCT03018080
EFO_0005537	triple-negative breast cancer	CHEMBL3545132	MIRVETUXIMAB SORAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBA3E	tubulin alpha 3e	2	Completed	https://clinicaltrials.gov/study/NCT03106077
MONDO_0007254	breast cancer	CHEMBL1173055	RUCAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	2	Completed	https://clinicaltrials.gov/study/NCT01074970,https://clinicaltrials.gov/study/NCT02505048
EFO_0006861	male breast carcinoma	CHEMBL1642	IMATINIB MESYLATE	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT00045188
MONDO_0007254	breast cancer	CHEMBL2220486	LUCITANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT02053636
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Terminated	https://clinicaltrials.gov/study/NCT01985841,https://clinicaltrials.gov/study/NCT00193024,https://clinicaltrials.gov/study/NCT03329378,https://clinicaltrials.gov/study/NCT00225056,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT01690325,https://clinicaltrials.gov/study/NCT00453635,https://clinicaltrials.gov/study/NCT00576901,https://clinicaltrials.gov/study/NCT00028483,https://clinicaltrials.gov/study/NCT00479856,https://clinicaltrials.gov/study/NCT03894007,https://clinicaltrials.gov/study/NCT00206453,https://clinicaltrials.gov/study/NCT00636441,https://clinicaltrials.gov/study/NCT00665457,https://clinicaltrials.gov/study/NCT00025493,https://clinicaltrials.gov/study/NCT00104624,https://clinicaltrials.gov/study/NCT00524459,https://clinicaltrials.gov/study/NCT00118053,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT00343512,https://clinicaltrials.gov/study/NCT00080626,https://clinicaltrials.gov/study/NCT00852332,https://clinicaltrials.gov/study/NCT00845910
MONDO_0007254	breast cancer	CHEMBL4297563	PACMILIMAB	Antibody	Programmed cell death 1 ligand 1 binding agent	Inhibitor	CD274	CD274 molecule	2	Completed	https://clinicaltrials.gov/study/NCT04596150
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06308939,https://clinicaltrials.gov/study/NCT05263882,https://clinicaltrials.gov/study/NCT06202313,https://clinicaltrials.gov/study/NCT04502680,https://clinicaltrials.gov/study/NCT04517292,https://clinicaltrials.gov/study/NCT04913571
MONDO_0007254	breast cancer	CHEMBL20684	ABT-751	Small molecule	Tubulin beta inhibitor		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT00063102
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT01908101
EFO_0006861	male breast carcinoma	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 3 inhibitor		HDAC3	histone deacetylase 3	2	Terminated	https://clinicaltrials.gov/study/NCT00132002
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05041101,https://clinicaltrials.gov/study/NCT03202316
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Withdrawn	https://clinicaltrials.gov/study/NCT03841747,https://clinicaltrials.gov/study/NCT03554109,https://clinicaltrials.gov/study/NCT04038489,https://clinicaltrials.gov/study/NCT02053597,https://clinicaltrials.gov/study/NCT03872505,https://clinicaltrials.gov/study/NCT00397761,https://clinicaltrials.gov/study/NCT01169870,https://clinicaltrials.gov/study/NCT03058939,https://clinicaltrials.gov/study/NCT02067416,https://clinicaltrials.gov/study/NCT01163929,https://clinicaltrials.gov/study/NCT05809895
MONDO_0007254	breast cancer	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Withdrawn	https://clinicaltrials.gov/study/NCT01240941,https://clinicaltrials.gov/study/NCT00935558,https://clinicaltrials.gov/study/NCT00080613,https://clinicaltrials.gov/study/NCT00615524,https://clinicaltrials.gov/study/NCT00057993,https://clinicaltrials.gov/study/NCT01005641,https://clinicaltrials.gov/study/NCT05079360
MONDO_0007254	breast cancer	CHEMBL1201583	BEVACIZUMAB	Antibody	Vascular endothelial growth factor A inhibitor		VEGFA	vascular endothelial growth factor A	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04303988,https://clinicaltrials.gov/study/NCT05398861
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA5	NADH:ubiquinone oxidoreductase subunit A5	2	Terminated	https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT04899349
MONDO_0007254	breast cancer	CHEMBL278020	NEOSTIGMINE	Small molecule	Acetylcholinesterase inhibitor		ACHE	acetylcholinesterase (Yt blood group)	2	Completed	https://clinicaltrials.gov/study/NCT02839668
MONDO_0007254	breast cancer	CHEMBL3707324	UTOMILUMAB	Antibody	Tumor necrosis factor receptor superfamily member 9 agonist		TNFRSF9	TNF receptor superfamily member 9	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03414658
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Terminated	https://clinicaltrials.gov/study/NCT00832338
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Enrolling by invitation	https://clinicaltrials.gov/study/NCT03580395
MONDO_0007254	breast cancer	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		APH1B	aph-1 homolog B, gamma-secretase subunit	2	Terminated	https://clinicaltrials.gov/study/NCT01151449
MONDO_0007254	breast cancer	CHEMBL467399	BIIB021	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AB1	heat shock protein 90 alpha family class B member 1	2	Completed	https://clinicaltrials.gov/study/NCT01004081
EFO_0005537	triple-negative breast cancer	CHEMBL4297939	DATOPOTAMAB DERUXTECAN	Antibody drug conjugate	Tumor-associated calcium signal transducer 2 binding agent		TACSTD2	tumor associated calcium signal transducer 2	2	Recruiting	https://clinicaltrials.gov/study/NCT06176261,https://clinicaltrials.gov/study/NCT01042379
EFO_0005537	triple-negative breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT03932526
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Recruiting	https://clinicaltrials.gov/study/NCT05583110
EFO_0006861	male breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Unknown status	https://clinicaltrials.gov/study/NCT01372579
MONDO_0007254	breast cancer	CHEMBL288441	BOSUTINIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT00793546,https://clinicaltrials.gov/study/NCT00880009
MONDO_0007254	breast cancer	CHEMBL3186534	RIVOCERANIB	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04303741
MONDO_0007254	breast cancer	CHEMBL2108184	CROFELEMER	Small molecule	Cystic fibrosis transmembrane conductance regulator inhibitor		CFTR	CF transmembrane conductance regulator	2	Completed	https://clinicaltrials.gov/study/NCT02910219
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02568839,https://clinicaltrials.gov/study/NCT04172259,https://clinicaltrials.gov/study/NCT00496795,https://clinicaltrials.gov/study/NCT01779206,https://clinicaltrials.gov/study/NCT02339532,https://clinicaltrials.gov/study/NCT03609047,https://clinicaltrials.gov/study/NCT03161353,https://clinicaltrials.gov/study/NCT00295893,https://clinicaltrials.gov/study/NCT02624973,https://clinicaltrials.gov/study/NCT02547987,https://clinicaltrials.gov/study/NCT02299999
EFO_0005537	triple-negative breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT02413320,https://clinicaltrials.gov/study/NCT03154749
EFO_0000305	breast carcinoma	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		SRMS	src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites	2	Terminated	https://clinicaltrials.gov/study/NCT05198843
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00470249,https://clinicaltrials.gov/study/NCT00095888,https://clinicaltrials.gov/study/NCT00679029,https://clinicaltrials.gov/study/NCT00323063
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Recruiting	https://clinicaltrials.gov/study/NCT04266249
MONDO_0007254	breast cancer	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Withdrawn	https://clinicaltrials.gov/study/NCT00057993,https://clinicaltrials.gov/study/NCT00964704,https://clinicaltrials.gov/study/NCT03203616,https://clinicaltrials.gov/study/NCT03058939,https://clinicaltrials.gov/study/NCT00434031,https://clinicaltrials.gov/study/NCT01985893,https://clinicaltrials.gov/study/NCT00054470
EFO_0006861	male breast carcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC1	histone deacetylase 1	2	Completed	https://clinicaltrials.gov/study/NCT00098397
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00470249,https://clinicaltrials.gov/study/NCT00095888,https://clinicaltrials.gov/study/NCT00679029,https://clinicaltrials.gov/study/NCT00323063
MONDO_0007254	breast cancer	CHEMBL2109635	SAR-566658	Antibody drug conjugate	Mucin-1 binding agent		MUC1	mucin 1, cell surface associated	2	Terminated	https://clinicaltrials.gov/study/NCT02984683
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Withdrawn	https://clinicaltrials.gov/study/NCT00434031,https://clinicaltrials.gov/study/NCT01229605,https://clinicaltrials.gov/study/NCT02067416,https://clinicaltrials.gov/study/NCT00964704,https://clinicaltrials.gov/study/NCT01825265,https://clinicaltrials.gov/study/NCT00678626,https://clinicaltrials.gov/study/NCT00006261
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA9	NADH:ubiquinone oxidoreductase subunit A9	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS6	NADH:ubiquinone oxidoreductase subunit S6	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04502680
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT00431704,https://clinicaltrials.gov/study/NCT04262804,https://clinicaltrials.gov/study/NCT03414658
EFO_0006861	male breast carcinoma	CHEMBL1201179	LAPATINIB DITOSYLATE	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT00118157,https://clinicaltrials.gov/study/NCT00098605
EFO_0005537	triple-negative breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03639948
EFO_0005537	triple-negative breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Suspended	https://clinicaltrials.gov/study/NCT04095689
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04502680
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT00284180
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Withdrawn	https://clinicaltrials.gov/study/NCT00450515
EFO_1000984	inflammatory breast carcinoma	CHEMBL535	SUNITINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00513695
MONDO_0007254	breast cancer	CHEMBL4297844	TRASTUZUMAB DERUXTECAN	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 binding agent		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05704829,https://clinicaltrials.gov/study/NCT05982678,https://clinicaltrials.gov/study/NCT06172127
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA9	NADH:ubiquinone oxidoreductase subunit A9	2	Recruiting	https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04559308,https://clinicaltrials.gov/study/NCT03238495
MONDO_0007254	breast cancer	CHEMBL4297844	TRASTUZUMAB DERUXTECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05982678,https://clinicaltrials.gov/study/NCT05704829,https://clinicaltrials.gov/study/NCT06172127
MONDO_0007254	breast cancer	CHEMBL27	PROPRANOLOL	Small molecule	Beta-2 adrenergic receptor antagonist		ADRB2	adrenoceptor beta 2	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05741164
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Withdrawn	https://clinicaltrials.gov/study/NCT02725541
MONDO_0007254	breast cancer	CHEMBL1789941	RUXOLITINIB	Small molecule	Tyrosine-protein kinase JAK1 inhibitor		JAK1	Janus kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT02066532,https://clinicaltrials.gov/study/NCT01594216
MONDO_0007254	breast cancer	CHEMBL25	ASPIRIN	Small molecule	Cyclooxygenase inhibitor		PTGS1	prostaglandin-endoperoxide synthase 1	2	Completed	https://clinicaltrials.gov/study/NCT02834403
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV1	NADH:ubiquinone oxidoreductase core subunit V1	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL4594611	PATRITUMAB DERUXTECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	2	Recruiting	https://clinicaltrials.gov/study/NCT06298084
EFO_0000304	breast adenocarcinoma	CHEMBL2146146	ATROPINE SULFATE	Small molecule	Muscarinic acetylcholine receptor M3 antagonist		CHRM3	cholinergic receptor muscarinic 3	2	Completed	https://clinicaltrials.gov/study/NCT03094052
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB1	NADH:ubiquinone oxidoreductase subunit B1	2	Terminated	https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT01477060
MONDO_0007254	breast cancer	CHEMBL2304041	SAGOPILONE	Small molecule	Tubulin stabiliser		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT00288249
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF1	NADH:ubiquinone oxidoreductase complex assembly factor 1	2	Completed	https://clinicaltrials.gov/study/NCT01885013
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS7	NADH:ubiquinone oxidoreductase core subunit S7	2	Completed	https://clinicaltrials.gov/study/NCT04170465
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA11	NADH:ubiquinone oxidoreductase subunit A11	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL180022	NERATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT03182634,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT05388149,https://clinicaltrials.gov/study/NCT05243641,https://clinicaltrials.gov/study/NCT04886531,https://clinicaltrials.gov/study/NCT04965064,https://clinicaltrials.gov/study/NCT05933395
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA2	NADH:ubiquinone oxidoreductase subunit A2	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT00542451,https://clinicaltrials.gov/study/NCT01091428
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA8	EPH receptor A8	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Epidermal growth factor receptor inhibitor		ERBB3	erb-b2 receptor tyrosine kinase 3	2	Terminated	https://clinicaltrials.gov/study/NCT00481845,https://clinicaltrials.gov/study/NCT00752986,https://clinicaltrials.gov/study/NCT01934335
MONDO_0007254	breast cancer	CHEMBL554	LAPATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Terminated	https://clinicaltrials.gov/study/NCT00225758,https://clinicaltrials.gov/study/NCT01873833,https://clinicaltrials.gov/study/NCT01934894,https://clinicaltrials.gov/study/NCT00754702,https://clinicaltrials.gov/study/NCT00479856,https://clinicaltrials.gov/study/NCT01534455,https://clinicaltrials.gov/study/NCT00756470,https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT01161368,https://clinicaltrials.gov/study/NCT00496366,https://clinicaltrials.gov/study/NCT00903656,https://clinicaltrials.gov/study/NCT00657137,https://clinicaltrials.gov/study/NCT00499681,https://clinicaltrials.gov/study/NCT00759642
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT00005614,https://clinicaltrials.gov/study/NCT05809895
MONDO_0007254	breast cancer	CHEMBL502835	NINTEDANIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR3	fibroblast growth factor receptor 3	2	Completed	https://clinicaltrials.gov/study/NCT01658462
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Withdrawn	https://clinicaltrials.gov/study/NCT00006261
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA11	NADH:ubiquinone oxidoreductase subunit A11	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA8	EPH receptor A8	2	Completed	https://clinicaltrials.gov/study/NCT00494481
EFO_0005537	triple-negative breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT03154749,https://clinicaltrials.gov/study/NCT02413320
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS3	NADH:ubiquinone oxidoreductase core subunit S3	2	Terminated	https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT01477060
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA6	NADH:ubiquinone oxidoreductase subunit A6	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Terminated	https://clinicaltrials.gov/study/NCT00074269,https://clinicaltrials.gov/study/NCT00376805
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	Ephrin type-A receptor 2 inhibitor		EPHA2	EPH receptor A2	2	Completed	https://clinicaltrials.gov/study/NCT00754325,https://clinicaltrials.gov/study/NCT00410813,https://clinicaltrials.gov/study/NCT00546104,https://clinicaltrials.gov/study/NCT00696072,https://clinicaltrials.gov/study/NCT00767520
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Withdrawn	https://clinicaltrials.gov/study/NCT04351230
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Terminated	https://clinicaltrials.gov/study/NCT00622466,https://clinicaltrials.gov/study/NCT00479856,https://clinicaltrials.gov/study/NCT00607438,https://clinicaltrials.gov/study/NCT00194792,https://clinicaltrials.gov/study/NCT01147016,https://clinicaltrials.gov/study/NCT03329378,https://clinicaltrials.gov/study/NCT02598310,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT00456846,https://clinicaltrials.gov/study/NCT00542191,https://clinicaltrials.gov/study/NCT01207102,https://clinicaltrials.gov/study/NCT00691912,https://clinicaltrials.gov/study/NCT01009983,https://clinicaltrials.gov/study/NCT01194869,https://clinicaltrials.gov/study/NCT00679029,https://clinicaltrials.gov/study/NCT00589238,https://clinicaltrials.gov/study/NCT01745367,https://clinicaltrials.gov/study/NCT00356681,https://clinicaltrials.gov/study/NCT00434356,https://clinicaltrials.gov/study/NCT01416558,https://clinicaltrials.gov/study/NCT00756470,https://clinicaltrials.gov/study/NCT01069796,https://clinicaltrials.gov/study/NCT00532285,https://clinicaltrials.gov/study/NCT03894007,https://clinicaltrials.gov/study/NCT00536939,https://clinicaltrials.gov/study/NCT00934895,https://clinicaltrials.gov/study/NCT02322814,https://clinicaltrials.gov/study/NCT01120158,https://clinicaltrials.gov/study/NCT04066790,https://clinicaltrials.gov/study/NCT01329627
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA12	NADH:ubiquinone oxidoreductase subunit A12	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000432	breast ductal carcinoma in situ	CHEMBL46740	BAZEDOXIFENE	Small molecule	Estrogen receptor modulator		ESR2	estrogen receptor 2	2	Recruiting	https://clinicaltrials.gov/study/NCT02694809
MONDO_0007254	breast cancer	CHEMBL383824	ALVESPIMYCIN	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AB1	heat shock protein 90 alpha family class B member 1	2	Terminated	https://clinicaltrials.gov/study/NCT00780000
EFO_0005537	triple-negative breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Suspended	https://clinicaltrials.gov/study/NCT04095689
EFO_0000305	breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Fibroblast growth factor receptor 3 inhibitor		FGFR3	fibroblast growth factor receptor 3	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
EFO_0005537	triple-negative breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967
EFO_0005537	triple-negative breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03639948
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04297267,https://clinicaltrials.gov/study/NCT04262804,https://clinicaltrials.gov/study/NCT03567720,https://clinicaltrials.gov/study/NCT02252887,https://clinicaltrials.gov/study/NCT01815242
EFO_0005537	triple-negative breast cancer	CHEMBL5095033	IBCASERTIB	Small molecule	Serine/threonine-protein kinase Aurora-B inhibitor		AURKB	aurora kinase B	2	Recruiting	https://clinicaltrials.gov/study/NCT05336721
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA8	NADH:ubiquinone oxidoreductase subunit A8	2	Recruiting	https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT04559308
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT00005614
EFO_0006861	male breast carcinoma	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 1 inhibitor		HDAC1	histone deacetylase 1	2	Terminated	https://clinicaltrials.gov/study/NCT00132002
MONDO_0007254	breast cancer	CHEMBL2220486	LUCITANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT02053636
MONDO_0007254	breast cancer	CHEMBL655	MIDAZOLAM	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRG1	gamma-aminobutyric acid type A receptor subunit gamma1	2	Completed	https://clinicaltrials.gov/study/NCT03084536
MONDO_0007254	breast cancer	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	2	Terminated	https://clinicaltrials.gov/study/NCT00206492,https://clinicaltrials.gov/study/NCT00290654,https://clinicaltrials.gov/study/NCT02269670,https://clinicaltrials.gov/study/NCT01194427,https://clinicaltrials.gov/study/NCT00684216,https://clinicaltrials.gov/study/NCT00096369,https://clinicaltrials.gov/study/NCT04190056,https://clinicaltrials.gov/study/NCT02322853
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Withdrawn	https://clinicaltrials.gov/study/NCT01825265,https://clinicaltrials.gov/study/NCT00006261,https://clinicaltrials.gov/study/NCT01229605,https://clinicaltrials.gov/study/NCT00678626,https://clinicaltrials.gov/study/NCT00964704,https://clinicaltrials.gov/study/NCT02067416,https://clinicaltrials.gov/study/NCT00434031
EFO_0000305	breast carcinoma	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02568839,https://clinicaltrials.gov/study/NCT03101748,https://clinicaltrials.gov/study/NCT02436993,https://clinicaltrials.gov/study/NCT03179904
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT00212082,https://clinicaltrials.gov/study/NCT00214864,https://clinicaltrials.gov/study/NCT01658462,https://clinicaltrials.gov/study/NCT00198237,https://clinicaltrials.gov/study/NCT00494481,https://clinicaltrials.gov/study/NCT00247481,https://clinicaltrials.gov/study/NCT00027885,https://clinicaltrials.gov/study/NCT00201708,https://clinicaltrials.gov/study/NCT00028873,https://clinicaltrials.gov/study/NCT01150513,https://clinicaltrials.gov/study/NCT00475670,https://clinicaltrials.gov/study/NCT00191243,https://clinicaltrials.gov/study/NCT00209092,https://clinicaltrials.gov/study/NCT00404066,https://clinicaltrials.gov/study/NCT02137083,https://clinicaltrials.gov/study/NCT00365365,https://clinicaltrials.gov/study/NCT00524810,https://clinicaltrials.gov/study/NCT00015938,https://clinicaltrials.gov/study/NCT00068341,https://clinicaltrials.gov/study/NCT00193050,https://clinicaltrials.gov/study/NCT00148070,https://clinicaltrials.gov/study/NCT01038804,https://clinicaltrials.gov/study/NCT00365417,https://clinicaltrials.gov/study/NCT00039520,https://clinicaltrials.gov/study/NCT04664972,https://clinicaltrials.gov/study/NCT00645866,https://clinicaltrials.gov/study/NCT00005800,https://clinicaltrials.gov/study/NCT02005549,https://clinicaltrials.gov/study/NCT00193037,https://clinicaltrials.gov/study/NCT00003565,https://clinicaltrials.gov/study/NCT00432172,https://clinicaltrials.gov/study/NCT02132949,https://clinicaltrials.gov/study/NCT00149214,https://clinicaltrials.gov/study/NCT01025349,https://clinicaltrials.gov/study/NCT00604435,https://clinicaltrials.gov/study/NCT01792050,https://clinicaltrials.gov/study/NCT00066443,https://clinicaltrials.gov/study/NCT02838225,https://clinicaltrials.gov/study/NCT00319618,https://clinicaltrials.gov/study/NCT02846428,https://clinicaltrials.gov/study/NCT01485926,https://clinicaltrials.gov/study/NCT00015886,https://clinicaltrials.gov/study/NCT00712881,https://clinicaltrials.gov/study/NCT00274456,https://clinicaltrials.gov/study/NCT00941330,https://clinicaltrials.gov/study/NCT02365805,https://clinicaltrials.gov/study/NCT00107510,https://clinicaltrials.gov/study/NCT00129376,https://clinicaltrials.gov/study/NCT00003953,https://clinicaltrials.gov/study/NCT02748213,https://clinicaltrials.gov/study/NCT00559754,https://clinicaltrials.gov/study/NCT00428922,https://clinicaltrials.gov/study/NCT03742986,https://clinicaltrials.gov/study/NCT02041351,https://clinicaltrials.gov/study/NCT00203372,https://clinicaltrials.gov/study/NCT01446016,https://clinicaltrials.gov/study/NCT00079118,https://clinicaltrials.gov/study/NCT00679341,https://clinicaltrials.gov/study/NCT01671319,https://clinicaltrials.gov/study/NCT00525759,https://clinicaltrials.gov/study/NCT00212095,https://clinicaltrials.gov/study/NCT00203502,https://clinicaltrials.gov/study/NCT00820872,https://clinicaltrials.gov/study/NCT00055861,https://clinicaltrials.gov/study/NCT00499122,https://clinicaltrials.gov/study/NCT00123929,https://clinicaltrials.gov/study/NCT00193089,https://clinicaltrials.gov/study/NCT00003352,https://clinicaltrials.gov/study/NCT01540110,https://clinicaltrials.gov/study/NCT00206505,https://clinicaltrials.gov/study/NCT00148668,https://clinicaltrials.gov/study/NCT00206518,https://clinicaltrials.gov/study/NCT00146042,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT00773695,https://clinicaltrials.gov/study/NCT00545688,https://clinicaltrials.gov/study/NCT00379015,https://clinicaltrials.gov/study/NCT01208480,https://clinicaltrials.gov/study/NCT00054275,https://clinicaltrials.gov/study/NCT00754351,https://clinicaltrials.gov/study/NCT00005908,https://clinicaltrials.gov/study/NCT00527449,https://clinicaltrials.gov/study/NCT00004175,https://clinicaltrials.gov/study/NCT00206466,https://clinicaltrials.gov/study/NCT00004888,https://clinicaltrials.gov/study/NCT00217672,https://clinicaltrials.gov/study/NCT00493649,https://clinicaltrials.gov/study/NCT00600249,https://clinicaltrials.gov/study/NCT00006104,https://clinicaltrials.gov/study/NCT00464646,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00005963,https://clinicaltrials.gov/study/NCT03140553,https://clinicaltrials.gov/study/NCT00155259,https://clinicaltrials.gov/study/NCT02229084,https://clinicaltrials.gov/study/NCT00248703,https://clinicaltrials.gov/study/NCT00769470,https://clinicaltrials.gov/study/NCT03735966,https://clinicaltrials.gov/study/NCT00077857,https://clinicaltrials.gov/study/NCT01396655,https://clinicaltrials.gov/study/NCT00041067,https://clinicaltrials.gov/study/NCT02909751,https://clinicaltrials.gov/study/NCT01527487,https://clinicaltrials.gov/study/NCT00841828,https://clinicaltrials.gov/study/NCT00490646,https://clinicaltrials.gov/study/NCT00820547,https://clinicaltrials.gov/study/NCT01367028,https://clinicaltrials.gov/study/NCT00193115,https://clinicaltrials.gov/study/NCT01959490,https://clinicaltrials.gov/study/NCT00232479,https://clinicaltrials.gov/study/NCT00258375,https://clinicaltrials.gov/study/NCT00006682,https://clinicaltrials.gov/study/NCT03887130,https://clinicaltrials.gov/study/NCT00364611,https://clinicaltrials.gov/study/NCT00179309,https://clinicaltrials.gov/study/NCT02834403,https://clinicaltrials.gov/study/NCT00004906,https://clinicaltrials.gov/study/NCT01142778,https://clinicaltrials.gov/study/NCT00695994,https://clinicaltrials.gov/study/NCT00044993,https://clinicaltrials.gov/study/NCT00088998,https://clinicaltrials.gov/study/NCT00193180,https://clinicaltrials.gov/study/NCT00976989
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB6	NADH:ubiquinone oxidoreductase subunit B6	2	Completed	https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT01266486
MONDO_0007254	breast cancer	CHEMBL2304041	SAGOPILONE	Small molecule	Tubulin stabiliser		TUBA1C	tubulin alpha 1c	2	Completed	https://clinicaltrials.gov/study/NCT00288249
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Fibroblast growth factor receptor 1 inhibitor		FGFR1	fibroblast growth factor receptor 1	2	Completed	https://clinicaltrials.gov/study/NCT01466972,https://clinicaltrials.gov/study/NCT00509587
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Recruiting	https://clinicaltrials.gov/study/NCT03515798,https://clinicaltrials.gov/study/NCT05383196
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA5	NADH:ubiquinone oxidoreductase subunit A5	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL467399	BIIB021	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AA1	heat shock protein 90 alpha family class A member 1	2	Completed	https://clinicaltrials.gov/study/NCT01004081
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Terminated	https://clinicaltrials.gov/study/NCT00079326,https://clinicaltrials.gov/study/NCT00790894,https://clinicaltrials.gov/study/NCT00765765
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Terminated	https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT03358004,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT00049660,https://clinicaltrials.gov/study/NCT00088985,https://clinicaltrials.gov/study/NCT00194792
MONDO_0007254	breast cancer	CHEMBL1201560	PEGINTERFERON ALFA-2A	Protein	Interferon alpha/beta receptor agonist		IFNAR1	interferon alpha and beta receptor subunit 1	2	Terminated	https://clinicaltrials.gov/study/NCT00227656
EFO_0000305	breast carcinoma	CHEMBL1421	DASATINIB	Small molecule	Bcr/Abl fusion protein		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT05198843
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Terminated	https://clinicaltrials.gov/study/NCT01498588
EFO_0000305	breast carcinoma	CHEMBL1184904	RETASPIMYCIN	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AB1	heat shock protein 90 alpha family class B member 1	2	Terminated	https://clinicaltrials.gov/study/NCT00817362
MONDO_0007254	breast cancer	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Completed	https://clinicaltrials.gov/study/NCT00128843,https://clinicaltrials.gov/study/NCT00010010,https://clinicaltrials.gov/study/NCT00201773,https://clinicaltrials.gov/study/NCT00201864,https://clinicaltrials.gov/study/NCT02598557,https://clinicaltrials.gov/study/NCT00767520,https://clinicaltrials.gov/study/NCT01381874,https://clinicaltrials.gov/study/NCT00200174,https://clinicaltrials.gov/study/NCT01783444,https://clinicaltrials.gov/study/NCT01594216,https://clinicaltrials.gov/study/NCT01698918,https://clinicaltrials.gov/study/NCT04659551,https://clinicaltrials.gov/study/NCT01234857,https://clinicaltrials.gov/study/NCT00810797,https://clinicaltrials.gov/study/NCT01831076,https://clinicaltrials.gov/study/NCT01151046,https://clinicaltrials.gov/study/NCT02028364,https://clinicaltrials.gov/study/NCT00676663,https://clinicaltrials.gov/study/NCT01004081,https://clinicaltrials.gov/study/NCT01989780,https://clinicaltrials.gov/study/NCT00728949,https://clinicaltrials.gov/study/NCT04465097,https://clinicaltrials.gov/study/NCT00941330,https://clinicaltrials.gov/study/NCT03555877,https://clinicaltrials.gov/study/NCT02549430,https://clinicaltrials.gov/study/NCT03291886,https://clinicaltrials.gov/study/NCT02049957,https://clinicaltrials.gov/study/NCT02069093,https://clinicaltrials.gov/study/NCT03312738,https://clinicaltrials.gov/study/NCT00626106,https://clinicaltrials.gov/study/NCT02291913,https://clinicaltrials.gov/study/NCT01654185,https://clinicaltrials.gov/study/NCT02440230,https://clinicaltrials.gov/study/NCT00432172
EFO_0006861	male breast carcinoma	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT00017394
EFO_0000305	breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
EFO_0000305	breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03609047,https://clinicaltrials.gov/study/NCT01779206,https://clinicaltrials.gov/study/NCT00616967,https://clinicaltrials.gov/study/NCT04172259,https://clinicaltrials.gov/study/NCT04215146,https://clinicaltrials.gov/study/NCT01730833,https://clinicaltrials.gov/study/NCT03616886,https://clinicaltrials.gov/study/NCT03387085,https://clinicaltrials.gov/study/NCT02788981,https://clinicaltrials.gov/study/NCT02187991,https://clinicaltrials.gov/study/NCT03747120,https://clinicaltrials.gov/study/NCT02734290,https://clinicaltrials.gov/study/NCT05498896,https://clinicaltrials.gov/study/NCT01057069,https://clinicaltrials.gov/study/NCT02779855,https://clinicaltrials.gov/study/NCT04603183,https://clinicaltrials.gov/study/NCT03125928,https://clinicaltrials.gov/study/NCT04192331,https://clinicaltrials.gov/study/NCT04398914,https://clinicaltrials.gov/study/NCT01815242,https://clinicaltrials.gov/study/NCT02752685,https://clinicaltrials.gov/study/NCT01898117,https://clinicaltrials.gov/study/NCT02546232,https://clinicaltrials.gov/study/NCT04418154,https://clinicaltrials.gov/study/NCT00003042,https://clinicaltrials.gov/study/NCT03568422,https://clinicaltrials.gov/study/NCT00295893,https://clinicaltrials.gov/study/NCT02883062,https://clinicaltrials.gov/study/NCT00609791,https://clinicaltrials.gov/study/NCT01796197,https://clinicaltrials.gov/study/NCT01853748,https://clinicaltrials.gov/study/NCT03567720,https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT04251169,https://clinicaltrials.gov/study/NCT04083963,https://clinicaltrials.gov/study/NCT04538742,https://clinicaltrials.gov/study/NCT04734262,https://clinicaltrials.gov/study/NCT03950570
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Suspended	https://clinicaltrials.gov/study/NCT04419181,https://clinicaltrials.gov/study/NCT02897050
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT03530696
MONDO_0007254	breast cancer	CHEMBL225072	PEMETREXED	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	2	Unknown status	https://clinicaltrials.gov/study/NCT02829008
MONDO_0007254	breast cancer	CHEMBL1201649	ESTROGENS, CONJUGATED	Unknown	Estrogen receptor agonist		ESR2	estrogen receptor 2	2	Withdrawn	https://clinicaltrials.gov/study/NCT05079360
MONDO_0007254	breast cancer	CHEMBL4298101	LADIRATUZUMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT03424005
MONDO_0007254	breast cancer	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	2	Completed	https://clinicaltrials.gov/study/NCT01124695,https://clinicaltrials.gov/study/NCT00253539,https://clinicaltrials.gov/study/NCT00007904,https://clinicaltrials.gov/study/NCT02291913,https://clinicaltrials.gov/study/NCT00194779,https://clinicaltrials.gov/study/NCT00003099,https://clinicaltrials.gov/study/NCT00003953,https://clinicaltrials.gov/study/NCT00002679,https://clinicaltrials.gov/study/NCT03045653,https://clinicaltrials.gov/study/NCT00002680,https://clinicaltrials.gov/study/NCT02806544,https://clinicaltrials.gov/study/NCT00728949,https://clinicaltrials.gov/study/NCT00003050,https://clinicaltrials.gov/study/NCT00052728,https://clinicaltrials.gov/study/NCT02404844,https://clinicaltrials.gov/study/NCT01614210,https://clinicaltrials.gov/study/NCT00003992,https://clinicaltrials.gov/study/NCT00295100,https://clinicaltrials.gov/study/NCT00499083,https://clinicaltrials.gov/study/NCT02866955,https://clinicaltrials.gov/study/NCT00287534,https://clinicaltrials.gov/study/NCT02630693,https://clinicaltrials.gov/study/NCT01220076,https://clinicaltrials.gov/study/NCT00365599,https://clinicaltrials.gov/study/NCT00080743,https://clinicaltrials.gov/study/NCT00005908,https://clinicaltrials.gov/study/NCT02988986,https://clinicaltrials.gov/study/NCT02384239,https://clinicaltrials.gov/study/NCT01831076,https://clinicaltrials.gov/study/NCT00003035
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Completed	https://clinicaltrials.gov/study/NCT00662025,https://clinicaltrials.gov/study/NCT00482755,https://clinicaltrials.gov/study/NCT00270413
EFO_0005537	triple-negative breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03639948
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Recruiting	https://clinicaltrials.gov/study/NCT05583110
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05536128,https://clinicaltrials.gov/study/NCT05128734
MONDO_0007254	breast cancer	CHEMBL1535	HYDROXYCHLOROQUINE	Small molecule	Toll-like receptor 9 antagonist		TLR9	toll like receptor 9	2	Terminated	https://clinicaltrials.gov/study/NCT00765765
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE6D	phosphodiesterase 6D	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT06186700,https://clinicaltrials.gov/study/NCT06176339
MONDO_0007254	breast cancer	CHEMBL146032	LONAPRISAN	Small molecule	Progesterone receptor antagonist		PGR	progesterone receptor	2	Completed	https://clinicaltrials.gov/study/NCT00555919
MONDO_0007254	breast cancer	CHEMBL3218576	COPANLISIB	Small molecule	PI3-kinase p110-delta subunit inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03939897
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT03140553,https://clinicaltrials.gov/study/NCT00525759,https://clinicaltrials.gov/study/NCT00364611,https://clinicaltrials.gov/study/NCT00003565,https://clinicaltrials.gov/study/NCT00123929,https://clinicaltrials.gov/study/NCT00490646,https://clinicaltrials.gov/study/NCT00006682,https://clinicaltrials.gov/study/NCT00193089,https://clinicaltrials.gov/study/NCT00248703,https://clinicaltrials.gov/study/NCT00559754,https://clinicaltrials.gov/study/NCT00820547,https://clinicaltrials.gov/study/NCT00006104,https://clinicaltrials.gov/study/NCT00149214,https://clinicaltrials.gov/study/NCT01792050,https://clinicaltrials.gov/study/NCT00015886,https://clinicaltrials.gov/study/NCT00941330,https://clinicaltrials.gov/study/NCT00005800,https://clinicaltrials.gov/study/NCT00494481,https://clinicaltrials.gov/study/NCT00206505,https://clinicaltrials.gov/study/NCT00193115,https://clinicaltrials.gov/study/NCT01150513,https://clinicaltrials.gov/study/NCT00054275,https://clinicaltrials.gov/study/NCT00214864,https://clinicaltrials.gov/study/NCT02229084,https://clinicaltrials.gov/study/NCT00193050,https://clinicaltrials.gov/study/NCT00155259,https://clinicaltrials.gov/study/NCT00428922,https://clinicaltrials.gov/study/NCT00148668,https://clinicaltrials.gov/study/NCT00712881,https://clinicaltrials.gov/study/NCT00319618,https://clinicaltrials.gov/study/NCT03887130,https://clinicaltrials.gov/study/NCT00079118,https://clinicaltrials.gov/study/NCT00604435,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00432172,https://clinicaltrials.gov/study/NCT00191243,https://clinicaltrials.gov/study/NCT01658462,https://clinicaltrials.gov/study/NCT01671319,https://clinicaltrials.gov/study/NCT00015938,https://clinicaltrials.gov/study/NCT00274456,https://clinicaltrials.gov/study/NCT02834403,https://clinicaltrials.gov/study/NCT00769470,https://clinicaltrials.gov/study/NCT01959490,https://clinicaltrials.gov/study/NCT00527449,https://clinicaltrials.gov/study/NCT00209092,https://clinicaltrials.gov/study/NCT00107510,https://clinicaltrials.gov/study/NCT00066443,https://clinicaltrials.gov/study/NCT01025349,https://clinicaltrials.gov/study/NCT01485926,https://clinicaltrials.gov/study/NCT00055861,https://clinicaltrials.gov/study/NCT00976989,https://clinicaltrials.gov/study/NCT01396655,https://clinicaltrials.gov/study/NCT00129376,https://clinicaltrials.gov/study/NCT00004906,https://clinicaltrials.gov/study/NCT01367028,https://clinicaltrials.gov/study/NCT00464646,https://clinicaltrials.gov/study/NCT03742986,https://clinicaltrials.gov/study/NCT01540110,https://clinicaltrials.gov/study/NCT00039520,https://clinicaltrials.gov/study/NCT04664972,https://clinicaltrials.gov/study/NCT02132949,https://clinicaltrials.gov/study/NCT00193180,https://clinicaltrials.gov/study/NCT00545688,https://clinicaltrials.gov/study/NCT00820872,https://clinicaltrials.gov/study/NCT02041351,https://clinicaltrials.gov/study/NCT00146042,https://clinicaltrials.gov/study/NCT00198237,https://clinicaltrials.gov/study/NCT00203372,https://clinicaltrials.gov/study/NCT00044993,https://clinicaltrials.gov/study/NCT01038804,https://clinicaltrials.gov/study/NCT00679341,https://clinicaltrials.gov/study/NCT00524810,https://clinicaltrials.gov/study/NCT00206518,https://clinicaltrials.gov/study/NCT00212095,https://clinicaltrials.gov/study/NCT00645866,https://clinicaltrials.gov/study/NCT00379015,https://clinicaltrials.gov/study/NCT00754351,https://clinicaltrials.gov/study/NCT00203502,https://clinicaltrials.gov/study/NCT02137083,https://clinicaltrials.gov/study/NCT00217672,https://clinicaltrials.gov/study/NCT03735966,https://clinicaltrials.gov/study/NCT00773695,https://clinicaltrials.gov/study/NCT01208480,https://clinicaltrials.gov/study/NCT01142778,https://clinicaltrials.gov/study/NCT00493649,https://clinicaltrials.gov/study/NCT00088998,https://clinicaltrials.gov/study/NCT00365417,https://clinicaltrials.gov/study/NCT00247481,https://clinicaltrials.gov/study/NCT00027885,https://clinicaltrials.gov/study/NCT00148070,https://clinicaltrials.gov/study/NCT00005908,https://clinicaltrials.gov/study/NCT02838225,https://clinicaltrials.gov/study/NCT02909751,https://clinicaltrials.gov/study/NCT00077857,https://clinicaltrials.gov/study/NCT00179309,https://clinicaltrials.gov/study/NCT00003953,https://clinicaltrials.gov/study/NCT00003352,https://clinicaltrials.gov/study/NCT00365365,https://clinicaltrials.gov/study/NCT02005549,https://clinicaltrials.gov/study/NCT00499122,https://clinicaltrials.gov/study/NCT00695994,https://clinicaltrials.gov/study/NCT00258375,https://clinicaltrials.gov/study/NCT00004888,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT02365805,https://clinicaltrials.gov/study/NCT00600249,https://clinicaltrials.gov/study/NCT00841828,https://clinicaltrials.gov/study/NCT00475670,https://clinicaltrials.gov/study/NCT01527487,https://clinicaltrials.gov/study/NCT01446016,https://clinicaltrials.gov/study/NCT00201708,https://clinicaltrials.gov/study/NCT00041067,https://clinicaltrials.gov/study/NCT02748213,https://clinicaltrials.gov/study/NCT00404066,https://clinicaltrials.gov/study/NCT00206466,https://clinicaltrials.gov/study/NCT00193037,https://clinicaltrials.gov/study/NCT00068341,https://clinicaltrials.gov/study/NCT00004175,https://clinicaltrials.gov/study/NCT00232479,https://clinicaltrials.gov/study/NCT02846428,https://clinicaltrials.gov/study/NCT00005963,https://clinicaltrials.gov/study/NCT00212082,https://clinicaltrials.gov/study/NCT00028873
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT00265733,https://clinicaltrials.gov/study/NCT00148707
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHB3	EPH receptor B3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999
EFO_0000305	breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Tyrosine-protein kinase ITK/TSK inhibitor		ITK	IL2 inducible T cell kinase	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Unknown status	https://clinicaltrials.gov/study/NCT00033683,https://clinicaltrials.gov/study/NCT00006120,https://clinicaltrials.gov/study/NCT03876587,https://clinicaltrials.gov/study/NCT01526499,https://clinicaltrials.gov/study/NCT01351597,https://clinicaltrials.gov/study/NCT00250874,https://clinicaltrials.gov/study/NCT03147963,https://clinicaltrials.gov/study/NCT00003066,https://clinicaltrials.gov/study/NCT00994968,https://clinicaltrials.gov/study/NCT00801411,https://clinicaltrials.gov/study/NCT01352494,https://clinicaltrials.gov/study/NCT00721747,https://clinicaltrials.gov/study/NCT02144194,https://clinicaltrials.gov/study/NCT01907529,https://clinicaltrials.gov/study/NCT01270373,https://clinicaltrials.gov/study/NCT00026078,https://clinicaltrials.gov/study/NCT00398489,https://clinicaltrials.gov/study/NCT00669773,https://clinicaltrials.gov/study/NCT00012311,https://clinicaltrials.gov/study/NCT02947061,https://clinicaltrials.gov/study/NCT00957125,https://clinicaltrials.gov/study/NCT01939054,https://clinicaltrials.gov/study/NCT02685657
EFO_0000305	breast carcinoma	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Completed	https://clinicaltrials.gov/study/NCT02282345
EFO_0000305	breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
EFO_0000432	breast ductal carcinoma in situ	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	2	Completed	https://clinicaltrials.gov/study/NCT00952731
EFO_0000305	breast carcinoma	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR2	estrogen receptor 2	2	Completed	https://clinicaltrials.gov/study/NCT01142401,https://clinicaltrials.gov/study/NCT02894398,https://clinicaltrials.gov/study/NCT03007979,https://clinicaltrials.gov/study/NCT04256941
MONDO_0007254	breast cancer	CHEMBL4298101	LADIRATUZUMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Recruiting	https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE6C	phosphodiesterase 6C	2	Recruiting	https://clinicaltrials.gov/study/NCT06087237
MONDO_0007254	breast cancer	CHEMBL1770916	NIROGACESTAT	Small molecule	Gamma-secretase inhibitor		PSENEN	presenilin enhancer, gamma-secretase subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT02338531
MONDO_0007254	breast cancer	CHEMBL1201199	LEUPROLIDE	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	2	Terminated	https://clinicaltrials.gov/study/NCT00498901
MONDO_0007254	breast cancer	CHEMBL1230609	FORETINIB	Small molecule	Tyrosine-protein kinase TIE-2 inhibitor		TEK	TEK receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01147484,https://clinicaltrials.gov/study/NCT01138384
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT05809895,https://clinicaltrials.gov/study/NCT00005614
MONDO_0007254	breast cancer	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Unknown status	https://clinicaltrials.gov/study/NCT01170143,https://clinicaltrials.gov/study/NCT00533936,https://clinicaltrials.gov/study/NCT02059876,https://clinicaltrials.gov/study/NCT00250874,https://clinicaltrials.gov/study/NCT02214004,https://clinicaltrials.gov/study/NCT00842998,https://clinicaltrials.gov/study/NCT02238509,https://clinicaltrials.gov/study/NCT01428414,https://clinicaltrials.gov/study/NCT01321775,https://clinicaltrials.gov/study/NCT03085368,https://clinicaltrials.gov/study/NCT00398489
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT00751868,https://clinicaltrials.gov/study/NCT01027208,https://clinicaltrials.gov/study/NCT01019577,https://clinicaltrials.gov/study/NCT01097642,https://clinicaltrials.gov/study/NCT00866905,https://clinicaltrials.gov/study/NCT00077376,https://clinicaltrials.gov/study/NCT00080262,https://clinicaltrials.gov/study/NCT01416389,https://clinicaltrials.gov/study/NCT00370552,https://clinicaltrials.gov/study/NCT00045097,https://clinicaltrials.gov/study/NCT00879086,https://clinicaltrials.gov/study/NCT01446016,https://clinicaltrials.gov/study/NCT00627978,https://clinicaltrials.gov/study/NCT00490646,https://clinicaltrials.gov/study/NCT00020904,https://clinicaltrials.gov/study/NCT00593827,https://clinicaltrials.gov/study/NCT00633464,https://clinicaltrials.gov/study/NCT01075100,https://clinicaltrials.gov/study/NCT00821886,https://clinicaltrials.gov/study/NCT00455533
MONDO_0007254	breast cancer	CHEMBL1230609	FORETINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Completed	https://clinicaltrials.gov/study/NCT01138384,https://clinicaltrials.gov/study/NCT01147484
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02654119
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Withdrawn	https://clinicaltrials.gov/study/NCT03432676
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT01196052,https://clinicaltrials.gov/study/NCT00679341,https://clinicaltrials.gov/study/NCT00679211,https://clinicaltrials.gov/study/NCT01835236,https://clinicaltrials.gov/study/NCT02924883,https://clinicaltrials.gov/study/NCT00943670,https://clinicaltrials.gov/study/NCT02073487,https://clinicaltrials.gov/study/NCT03530696,https://clinicaltrials.gov/study/NCT00509769,https://clinicaltrials.gov/study/NCT01904903
MONDO_0007254	breast cancer	CHEMBL20883	TEGAFUR	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	2	Unknown status	https://clinicaltrials.gov/study/NCT01492543,https://clinicaltrials.gov/study/NCT00994968
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04034823,https://clinicaltrials.gov/study/NCT04290793,https://clinicaltrials.gov/study/NCT06291064,https://clinicaltrials.gov/study/NCT06348134
MONDO_0007254	breast cancer	CHEMBL502835	NINTEDANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Terminated	https://clinicaltrials.gov/study/NCT02389764
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Recruiting	https://clinicaltrials.gov/study/NCT05296577,https://clinicaltrials.gov/study/NCT05823623
MONDO_0007254	breast cancer	CHEMBL742	KETAMINE	Small molecule	Glutamate [NMDA] receptor negative allosteric modulator		GRIN2B	glutamate ionotropic receptor NMDA type subunit 2B	2	Completed	https://clinicaltrials.gov/study/NCT00304850,https://clinicaltrials.gov/study/NCT05727098
MONDO_0007254	breast cancer	CHEMBL1535	HYDROXYCHLOROQUINE	Small molecule	Toll-like receptor 9 antagonist		TLR9	toll like receptor 9	2	Recruiting	https://clinicaltrials.gov/study/NCT06328387,https://clinicaltrials.gov/study/NCT04523857
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB4	NADH:ubiquinone oxidoreductase subunit B4	2	Recruiting	https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT04559308,https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT01904903,https://clinicaltrials.gov/study/NCT01835236,https://clinicaltrials.gov/study/NCT00679341,https://clinicaltrials.gov/study/NCT02073487,https://clinicaltrials.gov/study/NCT00509769,https://clinicaltrials.gov/study/NCT00679211,https://clinicaltrials.gov/study/NCT01196052,https://clinicaltrials.gov/study/NCT02924883,https://clinicaltrials.gov/study/NCT00943670,https://clinicaltrials.gov/study/NCT03530696
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT06027268,https://clinicaltrials.gov/study/NCT03606967
EFO_0000305	breast carcinoma	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		SRC	SRC proto-oncogene, non-receptor tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT05198843
EFO_0000305	breast carcinoma	CHEMBL325041	BORTEZOMIB	Small molecule	26S proteosome inhibitor		PSMB5	proteasome 20S subunit beta 5	2	Completed	https://clinicaltrials.gov/study/NCT01142401
MONDO_0007254	breast cancer	CHEMBL34259	METHOTREXATE	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	2	Completed	https://clinicaltrials.gov/study/NCT01204437,https://clinicaltrials.gov/study/NCT00001498,https://clinicaltrials.gov/study/NCT00194779,https://clinicaltrials.gov/study/NCT00124111,https://clinicaltrials.gov/study/NCT00036868,https://clinicaltrials.gov/study/NCT00083031,https://clinicaltrials.gov/study/NCT00577122
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
EFO_0000305	breast carcinoma	CHEMBL2103875	TRAMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor		MAP2K2	mitogen-activated protein kinase kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT01964924
MONDO_0003982	bilateral breast carcinoma	CHEMBL1201670	SARGRAMOSTIM	Protein	Granulocyte-macrophage colony-stimulating factor receptor agonist		CSF2RA	colony stimulating factor 2 receptor subunit alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03012100
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL226267	ARZOXIFENE	Small molecule	Estrogen receptor modulator		ESR2	estrogen receptor 2	2	Completed	https://clinicaltrials.gov/study/NCT00253539
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Withdrawn	https://clinicaltrials.gov/study/NCT05177796
EFO_0005537	triple-negative breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Suspended	https://clinicaltrials.gov/study/NCT04095689
EFO_0005537	triple-negative breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Suspended	https://clinicaltrials.gov/study/NCT04095689
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Terminated	https://clinicaltrials.gov/study/NCT02585388,https://clinicaltrials.gov/study/NCT00194792,https://clinicaltrials.gov/study/NCT00049660,https://clinicaltrials.gov/study/NCT01185509,https://clinicaltrials.gov/study/NCT00453635,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT03358004,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT00169104,https://clinicaltrials.gov/study/NCT00176488,https://clinicaltrials.gov/study/NCT02213744,https://clinicaltrials.gov/study/NCT01161368,https://clinicaltrials.gov/study/NCT00130507,https://clinicaltrials.gov/study/NCT00694200,https://clinicaltrials.gov/study/NCT00088985,https://clinicaltrials.gov/study/NCT00754702
MONDO_0007254	breast cancer	CHEMBL4297892	ANVATABART OPADOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBA1B	tubulin alpha 1b	2	Recruiting	https://clinicaltrials.gov/study/NCT04829604,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT05018676,https://clinicaltrials.gov/study/NCT05426486,https://clinicaltrials.gov/study/NCT05018702
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134,https://clinicaltrials.gov/study/NCT04034823,https://clinicaltrials.gov/study/NCT06291064,https://clinicaltrials.gov/study/NCT04290793
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT02365805,https://clinicaltrials.gov/study/NCT00003953,https://clinicaltrials.gov/study/NCT00212082,https://clinicaltrials.gov/study/NCT01446016,https://clinicaltrials.gov/study/NCT01150513,https://clinicaltrials.gov/study/NCT00006682,https://clinicaltrials.gov/study/NCT00054275,https://clinicaltrials.gov/study/NCT00198237,https://clinicaltrials.gov/study/NCT00248703,https://clinicaltrials.gov/study/NCT00600249,https://clinicaltrials.gov/study/NCT00212095,https://clinicaltrials.gov/study/NCT00146042,https://clinicaltrials.gov/study/NCT04664972,https://clinicaltrials.gov/study/NCT00712881,https://clinicaltrials.gov/study/NCT01792050,https://clinicaltrials.gov/study/NCT00079118,https://clinicaltrials.gov/study/NCT00004175,https://clinicaltrials.gov/study/NCT02846428,https://clinicaltrials.gov/study/NCT03742986,https://clinicaltrials.gov/study/NCT00193050,https://clinicaltrials.gov/study/NCT00695994,https://clinicaltrials.gov/study/NCT00769470,https://clinicaltrials.gov/study/NCT01038804,https://clinicaltrials.gov/study/NCT00191243,https://clinicaltrials.gov/study/NCT00464646,https://clinicaltrials.gov/study/NCT00490646,https://clinicaltrials.gov/study/NCT02748213,https://clinicaltrials.gov/study/NCT00475670,https://clinicaltrials.gov/study/NCT00107510,https://clinicaltrials.gov/study/NCT01367028,https://clinicaltrials.gov/study/NCT00077857,https://clinicaltrials.gov/study/NCT00365417,https://clinicaltrials.gov/study/NCT00525759,https://clinicaltrials.gov/study/NCT00149214,https://clinicaltrials.gov/study/NCT00841828,https://clinicaltrials.gov/study/NCT00015886,https://clinicaltrials.gov/study/NCT00015938,https://clinicaltrials.gov/study/NCT00039520,https://clinicaltrials.gov/study/NCT00428922,https://clinicaltrials.gov/study/NCT00193089,https://clinicaltrials.gov/study/NCT00041067,https://clinicaltrials.gov/study/NCT00193180,https://clinicaltrials.gov/study/NCT01671319,https://clinicaltrials.gov/study/NCT00404066,https://clinicaltrials.gov/study/NCT00679341,https://clinicaltrials.gov/study/NCT00155259,https://clinicaltrials.gov/study/NCT00006104,https://clinicaltrials.gov/study/NCT00028873,https://clinicaltrials.gov/study/NCT00206466,https://clinicaltrials.gov/study/NCT00004888,https://clinicaltrials.gov/study/NCT02137083,https://clinicaltrials.gov/study/NCT00206518,https://clinicaltrials.gov/study/NCT02132949,https://clinicaltrials.gov/study/NCT00274456,https://clinicaltrials.gov/study/NCT00179309,https://clinicaltrials.gov/study/NCT00005963,https://clinicaltrials.gov/study/NCT00214864,https://clinicaltrials.gov/study/NCT01142778,https://clinicaltrials.gov/study/NCT03887130,https://clinicaltrials.gov/study/NCT00545688,https://clinicaltrials.gov/study/NCT00148070,https://clinicaltrials.gov/study/NCT00493649,https://clinicaltrials.gov/study/NCT02229084,https://clinicaltrials.gov/study/NCT00365365,https://clinicaltrials.gov/study/NCT01485926,https://clinicaltrials.gov/study/NCT00003352,https://clinicaltrials.gov/study/NCT00976989,https://clinicaltrials.gov/study/NCT01527487,https://clinicaltrials.gov/study/NCT00319618,https://clinicaltrials.gov/study/NCT00129376,https://clinicaltrials.gov/study/NCT00364611,https://clinicaltrials.gov/study/NCT00003565,https://clinicaltrials.gov/study/NCT01540110,https://clinicaltrials.gov/study/NCT00206505,https://clinicaltrials.gov/study/NCT02834403,https://clinicaltrials.gov/study/NCT00604435,https://clinicaltrials.gov/study/NCT00201708,https://clinicaltrials.gov/study/NCT03735966,https://clinicaltrials.gov/study/NCT00820872,https://clinicaltrials.gov/study/NCT00193115,https://clinicaltrials.gov/study/NCT00148668,https://clinicaltrials.gov/study/NCT00379015,https://clinicaltrials.gov/study/NCT00209092,https://clinicaltrials.gov/study/NCT01025349,https://clinicaltrials.gov/study/NCT00004906,https://clinicaltrials.gov/study/NCT00044993,https://clinicaltrials.gov/study/NCT00773695,https://clinicaltrials.gov/study/NCT00754351,https://clinicaltrials.gov/study/NCT00524810,https://clinicaltrials.gov/study/NCT00203372,https://clinicaltrials.gov/study/NCT00494481,https://clinicaltrials.gov/study/NCT00005908,https://clinicaltrials.gov/study/NCT00217672,https://clinicaltrials.gov/study/NCT01396655,https://clinicaltrials.gov/study/NCT00645866,https://clinicaltrials.gov/study/NCT02041351,https://clinicaltrials.gov/study/NCT00193037,https://clinicaltrials.gov/study/NCT02005549,https://clinicaltrials.gov/study/NCT03140553,https://clinicaltrials.gov/study/NCT00005800,https://clinicaltrials.gov/study/NCT02838225,https://clinicaltrials.gov/study/NCT00123929,https://clinicaltrials.gov/study/NCT00247481,https://clinicaltrials.gov/study/NCT00232479,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT01208480,https://clinicaltrials.gov/study/NCT00088998,https://clinicaltrials.gov/study/NCT00068341,https://clinicaltrials.gov/study/NCT00258375,https://clinicaltrials.gov/study/NCT01959490,https://clinicaltrials.gov/study/NCT00055861,https://clinicaltrials.gov/study/NCT00941330,https://clinicaltrials.gov/study/NCT00527449,https://clinicaltrials.gov/study/NCT01658462,https://clinicaltrials.gov/study/NCT00203502,https://clinicaltrials.gov/study/NCT00066443,https://clinicaltrials.gov/study/NCT00027885,https://clinicaltrials.gov/study/NCT00820547,https://clinicaltrials.gov/study/NCT00559754,https://clinicaltrials.gov/study/NCT02909751,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT00499122,https://clinicaltrials.gov/study/NCT00432172
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Recruiting	https://clinicaltrials.gov/study/NCT04624711,https://clinicaltrials.gov/study/NCT05530057,https://clinicaltrials.gov/study/NCT05546255
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Terminated	https://clinicaltrials.gov/study/NCT03709082,https://clinicaltrials.gov/study/NCT03894007,https://clinicaltrials.gov/study/NCT01702558
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT00284180
MONDO_0007254	breast cancer	CHEMBL1144	PRAVASTATIN	Small molecule	HMG-CoA reductase inhibitor		HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase	2	Recruiting	https://clinicaltrials.gov/study/NCT04356209
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02414646
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS8	NADH:ubiquinone oxidoreductase core subunit S8	2	Completed	https://clinicaltrials.gov/study/NCT04170465
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA7	NADH:ubiquinone oxidoreductase subunit A7	2	Completed	https://clinicaltrials.gov/study/NCT01885013
EFO_0000304	breast adenocarcinoma	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Completed	https://clinicaltrials.gov/study/NCT03106415
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT01908101
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor		GPD2	glycerol-3-phosphate dehydrogenase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	2	Terminated	https://clinicaltrials.gov/study/NCT00183963
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT01908101
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
EFO_0006861	male breast carcinoma	CHEMBL1567	SUNITINIB MALATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Completed	https://clinicaltrials.gov/study/NCT00513695
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1042	CHOLECALCIFEROL	Small molecule	Vitamin D receptor agonist		VDR	vitamin D receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01097278
MONDO_0003982	bilateral breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT00877500
EFO_0000305	breast carcinoma	CHEMBL1201247	GOSERELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01776008,https://clinicaltrials.gov/study/NCT02907918
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Terminated	https://clinicaltrials.gov/study/NCT00790894,https://clinicaltrials.gov/study/NCT00079326,https://clinicaltrials.gov/study/NCT00765765
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA2	NADH:ubiquinone oxidoreductase subunit A2	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL1742982	AFLIBERCEPT	Protein	Placenta growth factor inhibitor		PGF	placental growth factor	2	Completed	https://clinicaltrials.gov/study/NCT00369655
MONDO_0007254	breast cancer	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	2	Completed	https://clinicaltrials.gov/study/NCT00693719,https://clinicaltrials.gov/study/NCT00004900,https://clinicaltrials.gov/study/NCT00006260,https://clinicaltrials.gov/study/NCT03535961,https://clinicaltrials.gov/study/NCT00004906,https://clinicaltrials.gov/study/NCT01589159
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Completed	https://clinicaltrials.gov/study/NCT00509587,https://clinicaltrials.gov/study/NCT01466972
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAB1	NADH:ubiquinone oxidoreductase subunit AB1	2	Unknown status	https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT02506777
MONDO_0007254	breast cancer	CHEMBL1200775	LEUPROLIDE ACETATE	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	2	Terminated	https://clinicaltrials.gov/study/NCT00498901
MONDO_0007254	breast cancer	CHEMBL2325741	CAPIVASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT2	AKT serine/threonine kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT03182634,https://clinicaltrials.gov/study/NCT05563220,https://clinicaltrials.gov/study/NCT05720260
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV3	NADH:ubiquinone oxidoreductase subunit V3	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT04559308
MONDO_0007254	breast cancer	CHEMBL4297181	SAMOTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	2	Completed	https://clinicaltrials.gov/study/NCT04032080
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Withdrawn	https://clinicaltrials.gov/study/NCT00678626,https://clinicaltrials.gov/study/NCT01825265,https://clinicaltrials.gov/study/NCT00964704,https://clinicaltrials.gov/study/NCT02067416,https://clinicaltrials.gov/study/NCT00434031,https://clinicaltrials.gov/study/NCT01229605,https://clinicaltrials.gov/study/NCT00006261
MONDO_0007254	breast cancer	CHEMBL502835	NINTEDANIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR4	fibroblast growth factor receptor 4	2	Completed	https://clinicaltrials.gov/study/NCT01658462
MONDO_0007254	breast cancer	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		PSENEN	presenilin enhancer, gamma-secretase subunit	2	Terminated	https://clinicaltrials.gov/study/NCT01151449
EFO_0000305	breast carcinoma	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	2	Completed	https://clinicaltrials.gov/study/NCT02441946,https://clinicaltrials.gov/study/NCT04256941
MONDO_0007254	breast cancer	CHEMBL1922094	APITOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	2	Completed	https://clinicaltrials.gov/study/NCT01437566
EFO_1000307	Invasive Breast Carcinoma	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT04569747
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02876302,https://clinicaltrials.gov/study/NCT01730833
EFO_0005537	triple-negative breast cancer	CHEMBL3218576	COPANLISIB	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04345913
EFO_0005537	triple-negative breast cancer	CHEMBL1421	DASATINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06355037
EFO_0000305	breast carcinoma	CHEMBL1079175	MK-2206	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT3	AKT serine/threonine kinase 3	2	Completed	https://clinicaltrials.gov/study/NCT01277757
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Tyrosine-protein kinase LCK inhibitor		LCK	LCK proto-oncogene, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01466972,https://clinicaltrials.gov/study/NCT00509587
EFO_0000305	breast carcinoma	CHEMBL1908360	EVEROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	2	Completed	https://clinicaltrials.gov/study/NCT02456857
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02436993,https://clinicaltrials.gov/study/NCT04001829,https://clinicaltrials.gov/study/NCT04216472,https://clinicaltrials.gov/study/NCT02530489,https://clinicaltrials.gov/study/NCT03101748,https://clinicaltrials.gov/study/NCT02603679,https://clinicaltrials.gov/study/NCT01463072,https://clinicaltrials.gov/study/NCT02187991,https://clinicaltrials.gov/study/NCT03179904
MONDO_0007254	breast cancer	CHEMBL1079175	MK-2206	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT2	AKT serine/threonine kinase 2	2	Withdrawn	https://clinicaltrials.gov/study/NCT01240941
MONDO_0007254	breast cancer	CHEMBL1079742	ERLOTINIB HYDROCHLORIDE	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Terminated	https://clinicaltrials.gov/study/NCT00611715,https://clinicaltrials.gov/study/NCT00739063
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	2	Completed	https://clinicaltrials.gov/study/NCT02404844,https://clinicaltrials.gov/study/NCT01572727,https://clinicaltrials.gov/study/NCT01629615,https://clinicaltrials.gov/study/NCT01816594,https://clinicaltrials.gov/study/NCT01790932,https://clinicaltrials.gov/study/NCT01923168
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		SRC	SRC proto-oncogene, non-receptor tyrosine kinase	2	Withdrawn	https://clinicaltrials.gov/study/NCT01410708
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Completed	https://clinicaltrials.gov/study/NCT00662129,https://clinicaltrials.gov/study/NCT00003540,https://clinicaltrials.gov/study/NCT00059852,https://clinicaltrials.gov/study/NCT00005991,https://clinicaltrials.gov/study/NCT00006007,https://clinicaltrials.gov/study/NCT00002998
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB10	NADH:ubiquinone oxidoreductase subunit B10	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBA1B	tubulin alpha 1b	2	Withdrawn	https://clinicaltrials.gov/study/NCT00450515
MONDO_0007254	breast cancer	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	2	Suspended	https://clinicaltrials.gov/study/NCT00738777
MONDO_0007254	breast cancer	CHEMBL1743006	DALOTUZUMAB	Antibody	Insulin-like growth factor I receptor antagonist		IGF1R	insulin like growth factor 1 receptor	2	Completed	https://clinicaltrials.gov/study/NCT01234857
MONDO_0007254	breast cancer	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Terminated	https://clinicaltrials.gov/study/NCT00573755,https://clinicaltrials.gov/study/NCT00722072,https://clinicaltrials.gov/study/NCT00622466
EFO_0006861	male breast carcinoma	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	2	Completed	https://clinicaltrials.gov/study/NCT00119262,https://clinicaltrials.gov/study/NCT00118157,https://clinicaltrials.gov/study/NCT00003199
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Unknown status	https://clinicaltrials.gov/study/NCT00954135,https://clinicaltrials.gov/study/NCT00499525
EFO_0000305	breast carcinoma	CHEMBL1789941	RUXOLITINIB	Small molecule	Tyrosine-protein kinase JAK2 inhibitor		JAK2	Janus kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT02066532
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06078384
EFO_1000984	inflammatory breast carcinoma	CHEMBL535	SUNITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Completed	https://clinicaltrials.gov/study/NCT00513695
EFO_0005537	triple-negative breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FRK	fyn related Src family tyrosine kinase	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06355037
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA7	NADH:ubiquinone oxidoreductase subunit A7	2	Unknown status	https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT02506777
EFO_0006861	male breast carcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC6	histone deacetylase 6	2	Completed	https://clinicaltrials.gov/study/NCT00098397
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT00005614
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN11A	sodium voltage-gated channel alpha subunit 11	2	Completed	https://clinicaltrials.gov/study/NCT02839668,https://clinicaltrials.gov/study/NCT01204242
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02654119
EFO_0005537	triple-negative breast cancer	CHEMBL3545132	MIRVETUXIMAB SORAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT03106077
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1094636	NIRAPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06201234
EFO_0000305	breast carcinoma	CHEMBL1501	FLUOCINONIDE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	2	Completed	https://clinicaltrials.gov/study/NCT01422408
EFO_0000305	breast carcinoma	CHEMBL1503	OMEPRAZOLE	Small molecule	Potassium-transporting ATPase inhibitor		ATP4A	ATPase H+/K+ transporting subunit alpha	2	Completed	https://clinicaltrials.gov/study/NCT02595372
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC10	histone deacetylase 10	2	Completed	https://clinicaltrials.gov/study/NCT03291886,https://clinicaltrials.gov/study/NCT00828854,https://clinicaltrials.gov/study/NCT00676663,https://clinicaltrials.gov/study/NCT02708680
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04502680,https://clinicaltrials.gov/study/NCT05263882,https://clinicaltrials.gov/study/NCT06308939,https://clinicaltrials.gov/study/NCT04913571,https://clinicaltrials.gov/study/NCT04517292,https://clinicaltrials.gov/study/NCT06202313
MONDO_0007254	breast cancer	CHEMBL118	CELECOXIB	Small molecule	Cyclooxygenase-2 inhibitor		PTGS2	prostaglandin-endoperoxide synthase 2	2	Completed	https://clinicaltrials.gov/study/NCT03084536,https://clinicaltrials.gov/study/NCT00135018,https://clinicaltrials.gov/study/NCT00201773,https://clinicaltrials.gov/study/NCT00291694,https://clinicaltrials.gov/study/NCT01695226,https://clinicaltrials.gov/study/NCT00056082,https://clinicaltrials.gov/study/NCT00006381
MONDO_0007254	breast cancer	CHEMBL1751	DIGOXIN	Small molecule	Sodium/potassium-transporting ATPase inhibitor		ATP1A2	ATPase Na+/K+ transporting subunit alpha 2	2	Terminated	https://clinicaltrials.gov/study/NCT01887288
MONDO_0007254	breast cancer	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Fibroblast growth factor receptor 1 inhibitor		FGFR1	fibroblast growth factor receptor 1	2	Completed	https://clinicaltrials.gov/study/NCT00509587
MONDO_0007254	breast cancer	CHEMBL1098	BUPIVACAINE	Small molecule	Sodium channel protein type IV alpha subunit blocker		SCN4A	sodium voltage-gated channel alpha subunit 4	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04603911
MONDO_0007254	breast cancer	CHEMBL1082407	ENZALUTAMIDE	Small molecule	Androgen Receptor antagonist		AR	androgen receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT02676986
MONDO_0007254	breast cancer	CHEMBL1908360	EVEROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03284957,https://clinicaltrials.gov/study/NCT03032406,https://clinicaltrials.gov/study/NCT02531932
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Withdrawn	https://clinicaltrials.gov/study/NCT00450515
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND5	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5	2	Terminated	https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT02360059
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS6	NADH:ubiquinone oxidoreductase subunit S6	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB10	NADH:ubiquinone oxidoreductase subunit B10	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF4	NADH:ubiquinone oxidoreductase complex assembly factor 4	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
MONDO_0021115	luminal B breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT03356860
EFO_0005537	triple-negative breast cancer	CHEMBL3707227	ATEZOLIZUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor	Inhibitor	CD274	CD274 molecule	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02883062,https://clinicaltrials.gov/study/NCT04770272,https://clinicaltrials.gov/study/NCT02530489
MONDO_0007254	breast cancer	CHEMBL655	MIDAZOLAM	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRG2	gamma-aminobutyric acid type A receptor subunit gamma2	2	Completed	https://clinicaltrials.gov/study/NCT03084536
MONDO_0007254	breast cancer	CHEMBL1276308	MIFEPRISTONE	Small molecule	Progesterone receptor antagonist		PGR	progesterone receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT06099769
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB11	NADH:ubiquinone oxidoreductase subunit B11	2	Recruiting	https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT04559308
MONDO_0007254	breast cancer	CHEMBL3647420	PYROTINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT03876587,https://clinicaltrials.gov/study/NCT03412383
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Tyrosine-protein kinase ITK/TSK inhibitor		ITK	IL2 inducible T cell kinase	2	Withdrawn	https://clinicaltrials.gov/study/NCT00615524
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA6	NADH:ubiquinone oxidoreductase subunit A6	2	Completed	https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02339532,https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT00295893,https://clinicaltrials.gov/study/NCT02547987,https://clinicaltrials.gov/study/NCT03161353,https://clinicaltrials.gov/study/NCT00496795,https://clinicaltrials.gov/study/NCT02624973,https://clinicaltrials.gov/study/NCT02568839,https://clinicaltrials.gov/study/NCT04172259,https://clinicaltrials.gov/study/NCT01779206,https://clinicaltrials.gov/study/NCT03609047
EFO_0000305	breast carcinoma	CHEMBL4297844	TRASTUZUMAB DERUXTECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	2	Recruiting	https://clinicaltrials.gov/study/NCT04553770
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT00027989
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		LCK	LCK proto-oncogene, Src family tyrosine kinase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01471106
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS6	NADH:ubiquinone oxidoreductase subunit S6	2	Unknown status	https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT02506777,https://clinicaltrials.gov/study/NCT02506790
MONDO_0044915	salivary duct carcinoma	CHEMBL1200969	DUTASTERIDE	Small molecule	Steroid 5-alpha-reductase inhibitor		SRD5A1	steroid 5 alpha-reductase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05513365
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Terminated	https://clinicaltrials.gov/study/NCT00570908,https://clinicaltrials.gov/study/NCT00824538,https://clinicaltrials.gov/study/NCT00434356
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE6G	phosphodiesterase 6G	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT06186700,https://clinicaltrials.gov/study/NCT06176339
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBA4A	tubulin alpha 4a	2	Withdrawn	https://clinicaltrials.gov/study/NCT00450515
MONDO_0007254	breast cancer	CHEMBL180022	NERATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT05933395,https://clinicaltrials.gov/study/NCT04886531,https://clinicaltrials.gov/study/NCT04965064,https://clinicaltrials.gov/study/NCT05243641,https://clinicaltrials.gov/study/NCT05388149,https://clinicaltrials.gov/study/NCT03182634
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Withdrawn	https://clinicaltrials.gov/study/NCT01410708
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05444998,https://clinicaltrials.gov/study/NCT03959397,https://clinicaltrials.gov/study/NCT04498793,https://clinicaltrials.gov/study/NCT04907344,https://clinicaltrials.gov/study/NCT04639271,https://clinicaltrials.gov/study/NCT04900311,https://clinicaltrials.gov/study/NCT04290793,https://clinicaltrials.gov/study/NCT04499118,https://clinicaltrials.gov/study/NCT05872412,https://clinicaltrials.gov/study/NCT04659499,https://clinicaltrials.gov/study/NCT04946227,https://clinicaltrials.gov/study/NCT04301375,https://clinicaltrials.gov/study/NCT04194684
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Withdrawn	https://clinicaltrials.gov/study/NCT00450515
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT01908101
EFO_0000305	breast carcinoma	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05837455,https://clinicaltrials.gov/study/NCT06179303
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF1	NADH:ubiquinone oxidoreductase complex assembly factor 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000432	breast ductal carcinoma in situ	CHEMBL46740	BAZEDOXIFENE	Small molecule	Estrogen receptor modulator		ESR1	estrogen receptor 1	2	Recruiting	https://clinicaltrials.gov/study/NCT02694809
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC2	NADH:ubiquinone oxidoreductase subunit C2	2	Terminated	https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT01477060
MONDO_0007254	breast cancer	CHEMBL2105717	CABOZANTINIB	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Completed	https://clinicaltrials.gov/study/NCT01738438,https://clinicaltrials.gov/study/NCT03316586
MONDO_0007254	breast cancer	CHEMBL2304041	SAGOPILONE	Small molecule	Tubulin stabiliser		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT00288249
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Terminated	https://clinicaltrials.gov/study/NCT00118053,https://clinicaltrials.gov/study/NCT00104624,https://clinicaltrials.gov/study/NCT00665457,https://clinicaltrials.gov/study/NCT00852332,https://clinicaltrials.gov/study/NCT01985841,https://clinicaltrials.gov/study/NCT00028483,https://clinicaltrials.gov/study/NCT00524459,https://clinicaltrials.gov/study/NCT00453635,https://clinicaltrials.gov/study/NCT00343512,https://clinicaltrials.gov/study/NCT00636441,https://clinicaltrials.gov/study/NCT03329378,https://clinicaltrials.gov/study/NCT00845910,https://clinicaltrials.gov/study/NCT03894007,https://clinicaltrials.gov/study/NCT00576901,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT00080626,https://clinicaltrials.gov/study/NCT00225056,https://clinicaltrials.gov/study/NCT01690325,https://clinicaltrials.gov/study/NCT00206453,https://clinicaltrials.gov/study/NCT00193024,https://clinicaltrials.gov/study/NCT00025493,https://clinicaltrials.gov/study/NCT00479856
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Enrolling by invitation	https://clinicaltrials.gov/study/NCT03580395
MONDO_0021115	luminal B breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT03356860
EFO_0005537	triple-negative breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Suspended	https://clinicaltrials.gov/study/NCT04095689
MONDO_0007254	breast cancer	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT00258960,https://clinicaltrials.gov/study/NCT00401427,https://clinicaltrials.gov/study/NCT00024154,https://clinicaltrials.gov/study/NCT00136539,https://clinicaltrials.gov/study/NCT00365365,https://clinicaltrials.gov/study/NCT00256243,https://clinicaltrials.gov/study/NCT00795899,https://clinicaltrials.gov/study/NCT00134680,https://clinicaltrials.gov/study/NCT00392392,https://clinicaltrials.gov/study/NCT01847001,https://clinicaltrials.gov/study/NCT00266110,https://clinicaltrials.gov/study/NCT00254592,https://clinicaltrials.gov/study/NCT02297698,https://clinicaltrials.gov/study/NCT01835236,https://clinicaltrials.gov/study/NCT00841828,https://clinicaltrials.gov/study/NCT00915018,https://clinicaltrials.gov/study/NCT00548184,https://clinicaltrials.gov/study/NCT00036868,https://clinicaltrials.gov/study/NCT01106898,https://clinicaltrials.gov/study/NCT00005635,https://clinicaltrials.gov/study/NCT01959490,https://clinicaltrials.gov/study/NCT00193089,https://clinicaltrials.gov/study/NCT00003612,https://clinicaltrials.gov/study/NCT02066532,https://clinicaltrials.gov/study/NCT00006110,https://clinicaltrials.gov/study/NCT00971737,https://clinicaltrials.gov/study/NCT02748213,https://clinicaltrials.gov/study/NCT00482391,https://clinicaltrials.gov/study/NCT03644186,https://clinicaltrials.gov/study/NCT01367028,https://clinicaltrials.gov/study/NCT01485926,https://clinicaltrials.gov/study/NCT00093808,https://clinicaltrials.gov/study/NCT00303108,https://clinicaltrials.gov/study/NCT00912340,https://clinicaltrials.gov/study/NCT00404066,https://clinicaltrials.gov/study/NCT02909751,https://clinicaltrials.gov/study/NCT00542451,https://clinicaltrials.gov/study/NCT00004888,https://clinicaltrials.gov/study/NCT00379015,https://clinicaltrials.gov/study/NCT00769470,https://clinicaltrials.gov/study/NCT00201760,https://clinicaltrials.gov/study/NCT00712881,https://clinicaltrials.gov/study/NCT01816594,https://clinicaltrials.gov/study/NCT02675231,https://clinicaltrials.gov/study/NCT00194779,https://clinicaltrials.gov/study/NCT00847171,https://clinicaltrials.gov/study/NCT00068341,https://clinicaltrials.gov/study/NCT00796978,https://clinicaltrials.gov/study/NCT00490646,https://clinicaltrials.gov/study/NCT00629499,https://clinicaltrials.gov/study/NCT00736970,https://clinicaltrials.gov/study/NCT00503750,https://clinicaltrials.gov/study/NCT00532857,https://clinicaltrials.gov/study/NCT01904903,https://clinicaltrials.gov/study/NCT00429247,https://clinicaltrials.gov/study/NCT00493649,https://clinicaltrials.gov/study/NCT00093145,https://clinicaltrials.gov/study/NCT00284180,https://clinicaltrials.gov/study/NCT00411788,https://clinicaltrials.gov/study/NCT00003539,https://clinicaltrials.gov/study/NCT00821886,https://clinicaltrials.gov/study/NCT03674112,https://clinicaltrials.gov/study/NCT00475670,https://clinicaltrials.gov/study/NCT00004013,https://clinicaltrials.gov/study/NCT00768859,https://clinicaltrials.gov/study/NCT02789657,https://clinicaltrials.gov/study/NCT01674062,https://clinicaltrials.gov/study/NCT02073487,https://clinicaltrials.gov/study/NCT00238290,https://clinicaltrials.gov/study/NCT02132949,https://clinicaltrials.gov/study/NCT00407888,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT01276041,https://clinicaltrials.gov/study/NCT00191451,https://clinicaltrials.gov/study/NCT01827163,https://clinicaltrials.gov/study/NCT03988036,https://clinicaltrials.gov/study/NCT03140553,https://clinicaltrials.gov/study/NCT00146042,https://clinicaltrials.gov/study/NCT03321981,https://clinicaltrials.gov/study/NCT00003992,https://clinicaltrials.gov/study/NCT01305941,https://clinicaltrials.gov/study/NCT00006104,https://clinicaltrials.gov/study/NCT00006381,https://clinicaltrials.gov/study/NCT01242449,https://clinicaltrials.gov/study/NCT00191373,https://clinicaltrials.gov/study/NCT00679341,https://clinicaltrials.gov/study/NCT01565083,https://clinicaltrials.gov/study/NCT00297596,https://clinicaltrials.gov/study/NCT01401959,https://clinicaltrials.gov/study/NCT01004172,https://clinicaltrials.gov/study/NCT00436566,https://clinicaltrials.gov/study/NCT01597414,https://clinicaltrials.gov/study/NCT01423695,https://clinicaltrials.gov/study/NCT02536339,https://clinicaltrials.gov/study/NCT00944047,https://clinicaltrials.gov/study/NCT00885755,https://clinicaltrials.gov/study/NCT00232479,https://clinicaltrials.gov/study/NCT00193063,https://clinicaltrials.gov/study/NCT00041067,https://clinicaltrials.gov/study/NCT03735966,https://clinicaltrials.gov/study/NCT01491737,https://clinicaltrials.gov/study/NCT00428922,https://clinicaltrials.gov/study/NCT00670982,https://clinicaltrials.gov/study/NCT01008150,https://clinicaltrials.gov/study/NCT00193076,https://clinicaltrials.gov/study/NCT00464646,https://clinicaltrials.gov/study/NCT00717405,https://clinicaltrials.gov/study/NCT01973660,https://clinicaltrials.gov/study/NCT00148668,https://clinicaltrials.gov/study/NCT00303992,https://clinicaltrials.gov/study/NCT00976989,https://clinicaltrials.gov/study/NCT00429104,https://clinicaltrials.gov/study/NCT01975142,https://clinicaltrials.gov/study/NCT01855828,https://clinicaltrials.gov/study/NCT00943410,https://clinicaltrials.gov/study/NCT01688609,https://clinicaltrials.gov/study/NCT00444587,https://clinicaltrials.gov/study/NCT00182793,https://clinicaltrials.gov/study/NCT00545688,https://clinicaltrials.gov/study/NCT02448420,https://clinicaltrials.gov/study/NCT01142778,https://clinicaltrials.gov/study/NCT02614794,https://clinicaltrials.gov/study/NCT00618657,https://clinicaltrials.gov/study/NCT00387907,https://clinicaltrials.gov/study/NCT00148681,https://clinicaltrials.gov/study/NCT00107393,https://clinicaltrials.gov/study/NCT00811135,https://clinicaltrials.gov/study/NCT01570036,https://clinicaltrials.gov/study/NCT00019812,https://clinicaltrials.gov/study/NCT00820872,https://clinicaltrials.gov/study/NCT00006228,https://clinicaltrials.gov/study/NCT00301899,https://clinicaltrials.gov/study/NCT02091960,https://clinicaltrials.gov/study/NCT00364611,https://clinicaltrials.gov/study/NCT01594177,https://clinicaltrials.gov/study/NCT03742986,https://clinicaltrials.gov/study/NCT00077376
EFO_0005537	triple-negative breast cancer	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Completed	https://clinicaltrials.gov/study/NCT02401347
EFO_0006318	breast ductal adenocarcinoma	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Terminated	https://clinicaltrials.gov/study/NCT01891357
MONDO_0007254	breast cancer	CHEMBL1094636	NIRAPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Terminated	https://clinicaltrials.gov/study/NCT02826512
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC4	histone deacetylase 4	2	Terminated	https://clinicaltrials.gov/study/NCT00777335
MONDO_0007254	breast cancer	CHEMBL742	KETAMINE	Small molecule	Glutamate [NMDA] receptor negative allosteric modulator		GRIN3A	glutamate ionotropic receptor NMDA type subunit 3A	2	Completed	https://clinicaltrials.gov/study/NCT00304850,https://clinicaltrials.gov/study/NCT05727098
MONDO_0007254	breast cancer	CHEMBL1429	DESMOPRESSIN	Protein	Vasopressin receptor agonist		AVPR1A	arginine vasopressin receptor 1A	2	Completed	https://clinicaltrials.gov/study/NCT01606072
EFO_0005537	triple-negative breast cancer	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL655	MIDAZOLAM	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRA2	gamma-aminobutyric acid type A receptor subunit alpha2	2	Completed	https://clinicaltrials.gov/study/NCT03084536
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Recruiting	https://clinicaltrials.gov/study/NCT05189067,https://clinicaltrials.gov/study/NCT03497702,https://clinicaltrials.gov/study/NCT05638594,https://clinicaltrials.gov/study/NCT05475678,https://clinicaltrials.gov/study/NCT04872985,https://clinicaltrials.gov/study/NCT05426486,https://clinicaltrials.gov/study/NCT05088057,https://clinicaltrials.gov/study/NCT04717531,https://clinicaltrials.gov/study/NCT03367676,https://clinicaltrials.gov/study/NCT04576143,https://clinicaltrials.gov/study/NCT06107673,https://clinicaltrials.gov/study/NCT05483439,https://clinicaltrials.gov/study/NCT05645380,https://clinicaltrials.gov/study/NCT04947189,https://clinicaltrials.gov/study/NCT05900206,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT05918328,https://clinicaltrials.gov/study/NCT03879577
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Terminated	https://clinicaltrials.gov/study/NCT00570908,https://clinicaltrials.gov/study/NCT00434356,https://clinicaltrials.gov/study/NCT00824538
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE6C	phosphodiesterase 6C	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT06186700,https://clinicaltrials.gov/study/NCT06176339
MONDO_0007254	breast cancer	CHEMBL180022	NERATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-4 inhibitor		ERBB4	erb-b2 receptor tyrosine kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT00915018,https://clinicaltrials.gov/study/NCT01008150,https://clinicaltrials.gov/study/NCT04366713,https://clinicaltrials.gov/study/NCT02673398,https://clinicaltrials.gov/study/NCT02400476,https://clinicaltrials.gov/study/NCT00777101
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Terminated	https://clinicaltrials.gov/study/NCT01120158,https://clinicaltrials.gov/study/NCT00532285,https://clinicaltrials.gov/study/NCT01745367,https://clinicaltrials.gov/study/NCT00542191,https://clinicaltrials.gov/study/NCT01329627,https://clinicaltrials.gov/study/NCT02322814,https://clinicaltrials.gov/study/NCT00679029,https://clinicaltrials.gov/study/NCT02598310,https://clinicaltrials.gov/study/NCT01147016,https://clinicaltrials.gov/study/NCT01416558,https://clinicaltrials.gov/study/NCT03329378,https://clinicaltrials.gov/study/NCT01009983,https://clinicaltrials.gov/study/NCT00934895,https://clinicaltrials.gov/study/NCT00607438,https://clinicaltrials.gov/study/NCT00622466,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT03894007,https://clinicaltrials.gov/study/NCT01207102,https://clinicaltrials.gov/study/NCT00691912,https://clinicaltrials.gov/study/NCT00356681,https://clinicaltrials.gov/study/NCT00194792,https://clinicaltrials.gov/study/NCT00456846,https://clinicaltrials.gov/study/NCT00536939,https://clinicaltrials.gov/study/NCT01069796,https://clinicaltrials.gov/study/NCT04066790,https://clinicaltrials.gov/study/NCT00589238,https://clinicaltrials.gov/study/NCT00479856,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT00756470,https://clinicaltrials.gov/study/NCT00434356,https://clinicaltrials.gov/study/NCT01194869
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Withdrawn	https://clinicaltrials.gov/study/NCT00450515
MONDO_0007254	breast cancer	CHEMBL1789844	IPILIMUMAB	Antibody	Cytotoxic T-lymphocyte protein 4 inhibitor		CTLA4	cytotoxic T-lymphocyte associated protein 4	2	Completed	https://clinicaltrials.gov/study/NCT03409198
MONDO_0007254	breast cancer	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Terminated	https://clinicaltrials.gov/study/NCT00674557,https://clinicaltrials.gov/study/NCT00194792,https://clinicaltrials.gov/study/NCT00793546,https://clinicaltrials.gov/study/NCT00684216,https://clinicaltrials.gov/study/NCT03874325,https://clinicaltrials.gov/study/NCT00573755,https://clinicaltrials.gov/study/NCT01627067
MONDO_0007254	breast cancer	CHEMBL4297736	PRALUZATAMAB RAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT04596150
MONDO_0007254	breast cancer	CHEMBL4303669	ZOLEDRONIC ACID	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	2	Completed	https://clinicaltrials.gov/study/NCT00247650,https://clinicaltrials.gov/study/NCT01344967,https://clinicaltrials.gov/study/NCT00903162,https://clinicaltrials.gov/study/NCT00295867,https://clinicaltrials.gov/study/NCT00213980,https://clinicaltrials.gov/study/NCT03358017,https://clinicaltrials.gov/study/NCT00525759,https://clinicaltrials.gov/study/NCT01367288
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02436993,https://clinicaltrials.gov/study/NCT04216472,https://clinicaltrials.gov/study/NCT02603679,https://clinicaltrials.gov/study/NCT02530489,https://clinicaltrials.gov/study/NCT03179904,https://clinicaltrials.gov/study/NCT01463072,https://clinicaltrials.gov/study/NCT02187991,https://clinicaltrials.gov/study/NCT03101748,https://clinicaltrials.gov/study/NCT04001829
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND2	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB11	NADH:ubiquinone oxidoreductase subunit B11	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0006861	male breast carcinoma	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT00096434
EFO_0005537	triple-negative breast cancer	CHEMBL4297985	MAGROLIMAB	Antibody	Leukocyte surface antigen CD47 inhibitor		CD47	CD47 molecule	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04958785
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT02790580
EFO_0005537	triple-negative breast cancer	CHEMBL3894860	TRILACICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	2	Recruiting	https://clinicaltrials.gov/study/NCT06027268,https://clinicaltrials.gov/study/NCT01042379
EFO_0005537	triple-negative breast cancer	CHEMBL4297715	CAMRELIZUMAB	Antibody	Programmed cell death protein 1 antagonist		PDCD1	programmed cell death 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05556200,https://clinicaltrials.gov/study/NCT05749588,https://clinicaltrials.gov/study/NCT05670925
MONDO_0007254	breast cancer	CHEMBL191413	REPARIXIN	Small molecule	Interleukin-8 receptor B modulator		CXCR2	C-X-C motif chemokine receptor 2	2	Completed	https://clinicaltrials.gov/study/NCT02370238
EFO_1000984	inflammatory breast carcinoma	CHEMBL1567	SUNITINIB MALATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Completed	https://clinicaltrials.gov/study/NCT00513695
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02252887,https://clinicaltrials.gov/study/NCT04262804,https://clinicaltrials.gov/study/NCT04297267,https://clinicaltrials.gov/study/NCT01815242,https://clinicaltrials.gov/study/NCT03567720
EFO_0000305	breast carcinoma	CHEMBL1201247	GOSERELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02592083,https://clinicaltrials.gov/study/NCT02603679
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC2	NADH:ubiquinone oxidoreductase subunit C2	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1201748	CABAZITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Terminated	https://clinicaltrials.gov/study/NCT01934894
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04290793,https://clinicaltrials.gov/study/NCT04034823,https://clinicaltrials.gov/study/NCT06348134,https://clinicaltrials.gov/study/NCT06291064
EFO_0006318	breast ductal adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Terminated	https://clinicaltrials.gov/study/NCT01891357
EFO_1000984	inflammatory breast carcinoma	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	2	Completed	https://clinicaltrials.gov/study/NCT00003199
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS7	NADH:ubiquinone oxidoreductase core subunit S7	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Terminated	https://clinicaltrials.gov/study/NCT01161368,https://clinicaltrials.gov/study/NCT00754702,https://clinicaltrials.gov/study/NCT00194792,https://clinicaltrials.gov/study/NCT00169104,https://clinicaltrials.gov/study/NCT00453635,https://clinicaltrials.gov/study/NCT02213744,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT03358004,https://clinicaltrials.gov/study/NCT02585388,https://clinicaltrials.gov/study/NCT00088985,https://clinicaltrials.gov/study/NCT00176488,https://clinicaltrials.gov/study/NCT00130507,https://clinicaltrials.gov/study/NCT00694200,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT01185509,https://clinicaltrials.gov/study/NCT00049660
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		SRMS	src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites	2	Withdrawn	https://clinicaltrials.gov/study/NCT01410708
MONDO_0007254	breast cancer	CHEMBL1642	IMATINIB MESYLATE	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	2	Completed	https://clinicaltrials.gov/study/NCT00087152,https://clinicaltrials.gov/study/NCT00338728
MONDO_0007254	breast cancer	CHEMBL3544911	PREXASERTIB	Small molecule	Serine/threonine-protein kinase Chk1 inhibitor		CHEK1	checkpoint kinase 1	2	Terminated	https://clinicaltrials.gov/study/NCT02203513
MONDO_0007254	breast cancer	CHEMBL1230609	FORETINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT01147484,https://clinicaltrials.gov/study/NCT01138384
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE4C	phosphodiesterase 4C	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT06176339,https://clinicaltrials.gov/study/NCT06186700
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Terminated	https://clinicaltrials.gov/study/NCT00832338
MONDO_0007254	breast cancer	CHEMBL2108738	NIVOLUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Recruiting	https://clinicaltrials.gov/study/NCT04159818,https://clinicaltrials.gov/study/NCT03815890,https://clinicaltrials.gov/study/NCT03546686
MONDO_0007254	breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05708235
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04301375,https://clinicaltrials.gov/study/NCT04498793,https://clinicaltrials.gov/study/NCT04499118,https://clinicaltrials.gov/study/NCT03959397,https://clinicaltrials.gov/study/NCT04946227,https://clinicaltrials.gov/study/NCT04900311,https://clinicaltrials.gov/study/NCT04639271,https://clinicaltrials.gov/study/NCT04907344,https://clinicaltrials.gov/study/NCT05872412,https://clinicaltrials.gov/study/NCT04290793,https://clinicaltrials.gov/study/NCT04194684,https://clinicaltrials.gov/study/NCT04659499,https://clinicaltrials.gov/study/NCT05444998
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF1	NADH:ubiquinone oxidoreductase complex assembly factor 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Terminated	https://clinicaltrials.gov/study/NCT00722072,https://clinicaltrials.gov/study/NCT00632541,https://clinicaltrials.gov/study/NCT00525161,https://clinicaltrials.gov/study/NCT00622466,https://clinicaltrials.gov/study/NCT00607438,https://clinicaltrials.gov/study/NCT00573755,https://clinicaltrials.gov/study/NCT01194869,https://clinicaltrials.gov/study/NCT02624700
MONDO_0044915	salivary duct carcinoma	CHEMBL1289601	LENVATINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Completed	https://clinicaltrials.gov/study/NCT02860936
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT00006682,https://clinicaltrials.gov/study/NCT00022152,https://clinicaltrials.gov/study/NCT00093808,https://clinicaltrials.gov/study/NCT00004237,https://clinicaltrials.gov/study/NCT01941771,https://clinicaltrials.gov/study/NCT00532623,https://clinicaltrials.gov/study/NCT00148681,https://clinicaltrials.gov/study/NCT00194779,https://clinicaltrials.gov/study/NCT00266110,https://clinicaltrials.gov/study/NCT00148668
EFO_0000432	breast ductal carcinoma in situ	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02779855
MONDO_0007254	breast cancer	CHEMBL1730601	GIMERACIL	Small molecule	Dihydropyrimidine dehydrogenase inhibitor		DPYD	dihydropyrimidine dehydrogenase	2	Unknown status	https://clinicaltrials.gov/study/NCT01492543,https://clinicaltrials.gov/study/NCT00994968
EFO_0005537	triple-negative breast cancer	CHEMBL4303201	CATEQUENTINIB	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT05089643,https://clinicaltrials.gov/study/NCT04914390
EFO_0005537	triple-negative breast cancer	CHEMBL4297892	ANVATABART OPADOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT00879086,https://clinicaltrials.gov/study/NCT02481050,https://clinicaltrials.gov/study/NCT01908101,https://clinicaltrials.gov/study/NCT01269346,https://clinicaltrials.gov/study/NCT00965523,https://clinicaltrials.gov/study/NCT03051659,https://clinicaltrials.gov/study/NCT01439282,https://clinicaltrials.gov/study/NCT00246090,https://clinicaltrials.gov/study/NCT05206656,https://clinicaltrials.gov/study/NCT01268150
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Withdrawn	https://clinicaltrials.gov/study/NCT05177796
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Unknown status	https://clinicaltrials.gov/study/NCT01372579
MONDO_0007254	breast cancer	CHEMBL482968	ENMD-2076	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01639248
MONDO_0007254	breast cancer	CHEMBL1751	DIGOXIN	Small molecule	Sodium/potassium-transporting ATPase inhibitor		ATP1A1	ATPase Na+/K+ transporting subunit alpha 1	2	Terminated	https://clinicaltrials.gov/study/NCT01887288
MONDO_0007254	breast cancer	CHEMBL481	IRINOTECAN	Small molecule	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	2	Unknown status	https://clinicaltrials.gov/study/NCT02030678
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT00513695,https://clinicaltrials.gov/study/NCT00119262,https://clinicaltrials.gov/study/NCT03018080
MONDO_0007254	breast cancer	CHEMBL1751	DIGOXIN	Small molecule	Sodium/potassium-transporting ATPase inhibitor		ATP1A1	ATPase Na+/K+ transporting subunit alpha 1	2	Completed	https://clinicaltrials.gov/study/NCT01763931
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC5	histone deacetylase 5	2	Terminated	https://clinicaltrials.gov/study/NCT00777335
MONDO_0007254	breast cancer	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Suspended	https://clinicaltrials.gov/study/NCT04419181,https://clinicaltrials.gov/study/NCT04675827
MONDO_0007254	breast cancer	CHEMBL359744	DOXORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Unknown status	https://clinicaltrials.gov/study/NCT00027989,https://clinicaltrials.gov/study/NCT00012311,https://clinicaltrials.gov/study/NCT00159094,https://clinicaltrials.gov/study/NCT00006433,https://clinicaltrials.gov/study/NCT00994968,https://clinicaltrials.gov/study/NCT00801411,https://clinicaltrials.gov/study/NCT00518583,https://clinicaltrials.gov/study/NCT00036985,https://clinicaltrials.gov/study/NCT00533936
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Unknown status	https://clinicaltrials.gov/study/NCT01270373,https://clinicaltrials.gov/study/NCT00398489,https://clinicaltrials.gov/study/NCT01939054,https://clinicaltrials.gov/study/NCT00012311,https://clinicaltrials.gov/study/NCT00994968,https://clinicaltrials.gov/study/NCT00957125,https://clinicaltrials.gov/study/NCT01352494,https://clinicaltrials.gov/study/NCT02947061,https://clinicaltrials.gov/study/NCT00003066,https://clinicaltrials.gov/study/NCT00669773,https://clinicaltrials.gov/study/NCT00033683,https://clinicaltrials.gov/study/NCT01907529,https://clinicaltrials.gov/study/NCT02144194,https://clinicaltrials.gov/study/NCT00801411,https://clinicaltrials.gov/study/NCT03876587,https://clinicaltrials.gov/study/NCT01351597,https://clinicaltrials.gov/study/NCT00026078,https://clinicaltrials.gov/study/NCT01526499,https://clinicaltrials.gov/study/NCT00006120,https://clinicaltrials.gov/study/NCT00721747,https://clinicaltrials.gov/study/NCT03147963,https://clinicaltrials.gov/study/NCT02685657,https://clinicaltrials.gov/study/NCT00250874
MONDO_0007254	breast cancer	CHEMBL3647420	PYROTINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04290793,https://clinicaltrials.gov/study/NCT05577923,https://clinicaltrials.gov/study/NCT05621434,https://clinicaltrials.gov/study/NCT05020964,https://clinicaltrials.gov/study/NCT04088110,https://clinicaltrials.gov/study/NCT03997539,https://clinicaltrials.gov/study/NCT06362096,https://clinicaltrials.gov/study/NCT04639271,https://clinicaltrials.gov/study/NCT03993964,https://clinicaltrials.gov/study/NCT04963595,https://clinicaltrials.gov/study/NCT04158856,https://clinicaltrials.gov/study/NCT04900311,https://clinicaltrials.gov/study/NCT05255523,https://clinicaltrials.gov/study/NCT04659499,https://clinicaltrials.gov/study/NCT04303988,https://clinicaltrials.gov/study/NCT04246502,https://clinicaltrials.gov/study/NCT04255056,https://clinicaltrials.gov/study/NCT05806671,https://clinicaltrials.gov/study/NCT03919253,https://clinicaltrials.gov/study/NCT04858516,https://clinicaltrials.gov/study/NCT04236310
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF4	NADH:ubiquinone oxidoreductase complex assembly factor 4	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL25	ASPIRIN	Small molecule	Cyclooxygenase inhibitor		PTGS2	prostaglandin-endoperoxide synthase 2	2	Completed	https://clinicaltrials.gov/study/NCT02834403
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Unknown status	https://clinicaltrials.gov/study/NCT02230319,https://clinicaltrials.gov/study/NCT00006120,https://clinicaltrials.gov/study/NCT02694224,https://clinicaltrials.gov/study/NCT03429972,https://clinicaltrials.gov/study/NCT00533936,https://clinicaltrials.gov/study/NCT01276769,https://clinicaltrials.gov/study/NCT03348098,https://clinicaltrials.gov/study/NCT02041338,https://clinicaltrials.gov/study/NCT01830244,https://clinicaltrials.gov/study/NCT01321775,https://clinicaltrials.gov/study/NCT00499525,https://clinicaltrials.gov/study/NCT01647672,https://clinicaltrials.gov/study/NCT03735082,https://clinicaltrials.gov/study/NCT02059876,https://clinicaltrials.gov/study/NCT00777673,https://clinicaltrials.gov/study/NCT00404404,https://clinicaltrials.gov/study/NCT01428414,https://clinicaltrials.gov/study/NCT00154882,https://clinicaltrials.gov/study/NCT00499603,https://clinicaltrials.gov/study/NCT02423603,https://clinicaltrials.gov/study/NCT01309607,https://clinicaltrials.gov/study/NCT01625429
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC7	histone deacetylase 7	2	Completed	https://clinicaltrials.gov/study/NCT00828854,https://clinicaltrials.gov/study/NCT00676663,https://clinicaltrials.gov/study/NCT03291886,https://clinicaltrials.gov/study/NCT02708680
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND2	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL1237023	DENOSUMAB	Antibody	Tumor necrosis factor ligand superfamily member 11 inhibitor		TNFSF11	TNF superfamily member 11	2	Terminated	https://clinicaltrials.gov/study/NCT03070002
EFO_0000305	breast carcinoma	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02592083,https://clinicaltrials.gov/study/NCT02603679,https://clinicaltrials.gov/study/NCT02668666
EFO_0000305	breast carcinoma	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02849496
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		LYN	LYN proto-oncogene, Src family tyrosine kinase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01471106
MONDO_0007254	breast cancer	CHEMBL4297892	ANVATABART OPADOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT05018676,https://clinicaltrials.gov/study/NCT05018702,https://clinicaltrials.gov/study/NCT05426486,https://clinicaltrials.gov/study/NCT04829604
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Terminated	https://clinicaltrials.gov/study/NCT00832338
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Recruiting	https://clinicaltrials.gov/study/NCT05192798,https://clinicaltrials.gov/study/NCT04138719,https://clinicaltrials.gov/study/NCT03606967,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT05227664,https://clinicaltrials.gov/study/NCT05834582
MONDO_0007254	breast cancer	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	2	Unknown status	https://clinicaltrials.gov/study/NCT00499525
MONDO_0007254	breast cancer	CHEMBL1201748	CABAZITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Recruiting	https://clinicaltrials.gov/study/NCT03048942
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA10	EPH receptor A10	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999
MONDO_0007254	breast cancer	CHEMBL1879463	DACTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	2	Withdrawn	https://clinicaltrials.gov/study/NCT01288092
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4L2	NDUFA4 mitochondrial complex associated like 2	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA9	NADH:ubiquinone oxidoreductase subunit A9	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4	NDUFA4 mitochondrial complex associated	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04290793,https://clinicaltrials.gov/study/NCT04034823,https://clinicaltrials.gov/study/NCT06348134,https://clinicaltrials.gov/study/NCT06291064
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT02978495
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	2	Completed	https://clinicaltrials.gov/study/NCT00253539
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBA1C	tubulin alpha 1c	2	Completed	https://clinicaltrials.gov/study/NCT00284180
MONDO_0007254	breast cancer	CHEMBL553	ERLOTINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Withdrawn	https://clinicaltrials.gov/study/NCT01013506
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT01908101
EFO_0006861	male breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00095888
MONDO_0007254	breast cancer	CHEMBL522892	DOVITINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Completed	https://clinicaltrials.gov/study/NCT01262027,https://clinicaltrials.gov/study/NCT00958971
MONDO_0007254	breast cancer	CHEMBL105442	CI-1040	Small molecule	Dual specificity mitogen-activated protein kinase kinase 1 inhibitor		MAP2K1	mitogen-activated protein kinase kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT00033384
MONDO_0007254	breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05708235
MONDO_0007254	breast cancer	CHEMBL3813842	PAXALISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R2	phosphoinositide-3-kinase regulatory subunit 2	2	Recruiting	https://clinicaltrials.gov/study/NCT03765983
MONDO_0007254	breast cancer	CHEMBL393220	ATORVASTATIN CALCIUM	Small molecule	HMG-CoA reductase inhibitor		HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase	2	Completed	https://clinicaltrials.gov/study/NCT01988571,https://clinicaltrials.gov/study/NCT03358017,https://clinicaltrials.gov/study/NCT00816244
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS7	NADH:ubiquinone oxidoreductase core subunit S7	2	Completed	https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT00909506
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB3	NADH:ubiquinone oxidoreductase subunit B3	2	Completed	https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT01266486
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT02978716
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Unknown status	https://clinicaltrials.gov/study/NCT03412955
EFO_0005537	triple-negative breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04395989,https://clinicaltrials.gov/study/NCT04129996
MONDO_0007254	breast cancer	CHEMBL4297950	BENEGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	2	Completed	https://clinicaltrials.gov/study/NCT01648322
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC3	histone deacetylase 3	2	Completed	https://clinicaltrials.gov/study/NCT00777049
MONDO_0007254	breast cancer	CHEMBL4302409	LUTETIUM OXODOTREOTIDE	Protein	Somatostatin receptor binding agent		SSTR2	somatostatin receptor 2	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04529044
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE2A	phosphodiesterase 2A	2	Recruiting	https://clinicaltrials.gov/study/NCT06087237
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN4A	sodium voltage-gated channel alpha subunit 4	2	Completed	https://clinicaltrials.gov/study/NCT01204242,https://clinicaltrials.gov/study/NCT02839668
MONDO_0007254	breast cancer	CHEMBL491473	CEDIRANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT00454805
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	2	Completed	https://clinicaltrials.gov/study/NCT03184090,https://clinicaltrials.gov/study/NCT03644186,https://clinicaltrials.gov/study/NCT03530696,https://clinicaltrials.gov/study/NCT02400567,https://clinicaltrials.gov/study/NCT02806050,https://clinicaltrials.gov/study/NCT04075604,https://clinicaltrials.gov/study/NCT02630693,https://clinicaltrials.gov/study/NCT03628066,https://clinicaltrials.gov/study/NCT04494958,https://clinicaltrials.gov/study/NCT03774472,https://clinicaltrials.gov/study/NCT03819010,https://clinicaltrials.gov/study/NCT03007979,https://clinicaltrials.gov/study/NCT02491983,https://clinicaltrials.gov/study/NCT02692755,https://clinicaltrials.gov/study/NCT02536742,https://clinicaltrials.gov/study/NCT02040857,https://clinicaltrials.gov/study/NCT02549430,https://clinicaltrials.gov/study/NCT02384239,https://clinicaltrials.gov/study/NCT04436744,https://clinicaltrials.gov/study/NCT02448420,https://clinicaltrials.gov/study/NCT03065621,https://clinicaltrials.gov/study/NCT02296801,https://clinicaltrials.gov/study/NCT03054363
MONDO_0007254	breast cancer	CHEMBL1201167	CARVEDILOL PHOSPHATE	Small molecule	Adrenergic receptor beta antagonist		ADRB2	adrenoceptor beta 2	2	Completed	https://clinicaltrials.gov/study/NCT01009918
MONDO_0007254	breast cancer	CHEMBL2304041	SAGOPILONE	Small molecule	Tubulin stabiliser		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT00288249
EFO_0000304	breast adenocarcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	2	Recruiting	https://clinicaltrials.gov/study/NCT04197687
EFO_0000305	breast carcinoma	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR2	estrogen receptor 2	2	Recruiting	https://clinicaltrials.gov/study/NCT02476786,https://clinicaltrials.gov/study/NCT05319873,https://clinicaltrials.gov/study/NCT05554354,https://clinicaltrials.gov/study/NCT02778685,https://clinicaltrials.gov/study/NCT04762979
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT00321633
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1094636	NIRAPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06201234
MONDO_0007254	breast cancer	CHEMBL482968	ENMD-2076	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	2	Completed	https://clinicaltrials.gov/study/NCT01639248
MONDO_0007254	breast cancer	CHEMBL160	CYCLOSPORINE	Protein	Cyclophilin A modulator		PPIA	peptidylprolyl isomerase A	2	Terminated	https://clinicaltrials.gov/study/NCT00074269
MONDO_0007254	breast cancer	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	2	Terminated	https://clinicaltrials.gov/study/NCT01919229
EFO_0000432	breast ductal carcinoma in situ	CHEMBL489	AFIMOXIFENE	Small molecule	Estrogen-related receptor gamma antagonist		ESRRG	estrogen related receptor gamma	2	Recruiting	https://clinicaltrials.gov/study/NCT02993159,https://clinicaltrials.gov/study/NCT04009044
EFO_0000305	breast carcinoma	CHEMBL4297545	LUTETIUM OXODOTREOTIDE LU-177	Protein	Somatostatin receptor binding agent		SSTR5	somatostatin receptor 5	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04529044
EFO_0006861	male breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Fibroblast growth factor receptor 1 inhibitor		FGFR1	fibroblast growth factor receptor 1	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
MONDO_0007254	breast cancer	CHEMBL521851	PICTILISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R2	phosphoinositide-3-kinase regulatory subunit 2	2	Completed	https://clinicaltrials.gov/study/NCT01740336,https://clinicaltrials.gov/study/NCT01437566
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02568839,https://clinicaltrials.gov/study/NCT04001829
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
EFO_0006861	male breast carcinoma	CHEMBL1201179	LAPATINIB DITOSYLATE	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01868503
EFO_0006861	male breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
MONDO_0021115	luminal B breast carcinoma	CHEMBL3301587	DURVALUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor	Inhibitor	CD274	CD274 molecule	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03875573
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS2	NADH:ubiquinone oxidoreductase core subunit S2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
EFO_1000984	inflammatory breast carcinoma	CHEMBL1567	SUNITINIB MALATE	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	2	Completed	https://clinicaltrials.gov/study/NCT00513695
MONDO_0007254	breast cancer	CHEMBL1200775	LEUPROLIDE ACETATE	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03900637
MONDO_0007254	breast cancer	CHEMBL2103839	RIDAFOROLIMUS	Small molecule	Serine/threonine-protein kinase mTOR inhibitor		MTOR	mechanistic target of rapamycin kinase	2	Completed	https://clinicaltrials.gov/study/NCT00736970,https://clinicaltrials.gov/study/NCT01234857
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHB2	EPH receptor B2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999
MONDO_0007254	breast cancer	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05133674,https://clinicaltrials.gov/study/NCT04272801,https://clinicaltrials.gov/study/NCT02764541,https://clinicaltrials.gov/study/NCT02747004,https://clinicaltrials.gov/study/NCT05035836,https://clinicaltrials.gov/study/NCT04997941,https://clinicaltrials.gov/study/NCT04129216,https://clinicaltrials.gov/study/NCT01196936,https://clinicaltrials.gov/study/NCT02206984,https://clinicaltrials.gov/study/NCT04059484,https://clinicaltrials.gov/study/NCT03219476,https://clinicaltrials.gov/study/NCT00003042,https://clinicaltrials.gov/study/NCT03917082,https://clinicaltrials.gov/study/NCT02668666,https://clinicaltrials.gov/study/NCT03161353
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	Adenosine A2 receptor antagonist		ADORA2B	adenosine A2b receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT06087237
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB7	NADH:ubiquinone oxidoreductase subunit B7	2	Recruiting	https://clinicaltrials.gov/study/NCT04559308,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT04300790
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV1	NADH:ubiquinone oxidoreductase core subunit V1	2	Unknown status	https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT02506777
MONDO_0007254	breast cancer	CHEMBL1628688	ZIBOTENTAN	Small molecule	Endothelin receptor ET-A antagonist		EDNRA	endothelin receptor type A	2	Withdrawn	https://clinicaltrials.gov/study/NCT01134497
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Suspended	https://clinicaltrials.gov/study/NCT04419181,https://clinicaltrials.gov/study/NCT04675827
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Unknown status	https://clinicaltrials.gov/study/NCT00027989,https://clinicaltrials.gov/study/NCT01352494,https://clinicaltrials.gov/study/NCT02341911,https://clinicaltrials.gov/study/NCT03423849,https://clinicaltrials.gov/study/NCT02544243
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBA3C	tubulin alpha 3c	2	Withdrawn	https://clinicaltrials.gov/study/NCT01227408
MONDO_0007254	breast cancer	CHEMBL52885	ENMD-981693	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR2	fibroblast growth factor receptor 2	2	Completed	https://clinicaltrials.gov/study/NCT00306631
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF4	NADH:ubiquinone oxidoreductase complex assembly factor 4	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1091644	LINSITINIB	Small molecule	Insulin-like growth factor I receptor inhibitor		IGF1R	insulin like growth factor 1 receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01205685
MONDO_0007254	breast cancer	CHEMBL3989514	IRINOTECAN HYDROCHLORIDE	Small molecule	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	2	Completed	https://clinicaltrials.gov/study/NCT00617539,https://clinicaltrials.gov/study/NCT00275041,https://clinicaltrials.gov/study/NCT00003351,https://clinicaltrials.gov/study/NCT00303992,https://clinicaltrials.gov/study/NCT00693719,https://clinicaltrials.gov/study/NCT00079118,https://clinicaltrials.gov/study/NCT00004182
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Withdrawn	https://clinicaltrials.gov/study/NCT04351230
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Recruiting	https://clinicaltrials.gov/study/NCT04266249
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Unknown status	https://clinicaltrials.gov/study/NCT02175446
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Platelet-derived growth factor receptor alpha inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Completed	https://clinicaltrials.gov/study/NCT00270413,https://clinicaltrials.gov/study/NCT00662025,https://clinicaltrials.gov/study/NCT00482755
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05833919,https://clinicaltrials.gov/study/NCT04303741,https://clinicaltrials.gov/study/NCT02299999
EFO_0006861	male breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT00077376
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB11	NADH:ubiquinone oxidoreductase subunit B11	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0006861	male breast carcinoma	CHEMBL359744	DOXORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT00861705
EFO_0005537	triple-negative breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT04683679,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT03801369
EFO_0005537	triple-negative breast cancer	CHEMBL1201583	BEVACIZUMAB	Antibody	Vascular endothelial growth factor A inhibitor		VEGFA	vascular endothelial growth factor A	2	Completed	https://clinicaltrials.gov/study/NCT00733408,https://clinicaltrials.gov/study/NCT02456857
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS2	NADH:ubiquinone oxidoreductase core subunit S2	2	Terminated	https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT01627067
EFO_0006861	male breast carcinoma	CHEMBL1201583	BEVACIZUMAB	Antibody	Vascular endothelial growth factor A inhibitor		VEGFA	vascular endothelial growth factor A	2	Completed	https://clinicaltrials.gov/study/NCT00017394,https://clinicaltrials.gov/study/NCT00119262
EFO_0005537	triple-negative breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03639948
EFO_0006861	male breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00095888
MONDO_0007254	breast cancer	CHEMBL4297736	PRALUZATAMAB RAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBA4A	tubulin alpha 4a	2	Completed	https://clinicaltrials.gov/study/NCT04596150
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB7	NADH:ubiquinone oxidoreductase subunit B7	2	Unknown status	https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT02506777
MONDO_0007254	breast cancer	CHEMBL2108585	CONTUSUGENE LADENOVEC	Gene	Cellular tumor antigen p53 exogenous gene		TP53	tumor protein p53	2	Completed	https://clinicaltrials.gov/study/NCT00044993
MONDO_0007254	breast cancer	CHEMBL2108658	TREMELIMUMAB	Antibody	Cytotoxic T-lymphocyte protein 4 inhibitor		CTLA4	cytotoxic T-lymphocyte associated protein 4	2	Terminated	https://clinicaltrials.gov/study/NCT03430466
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBA3E	tubulin alpha 3e	2	Completed	https://clinicaltrials.gov/study/NCT00148707,https://clinicaltrials.gov/study/NCT00265733
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Withdrawn	https://clinicaltrials.gov/study/NCT00615524
MONDO_0007254	breast cancer	CHEMBL4297736	PRALUZATAMAB RAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT04596150
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE8B	phosphodiesterase 8B	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT06186700,https://clinicaltrials.gov/study/NCT06176339
MONDO_0007254	breast cancer	CHEMBL522892	DOVITINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT01262027,https://clinicaltrials.gov/study/NCT00958971
EFO_0006861	male breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT00077376
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Withdrawn	https://clinicaltrials.gov/study/NCT02067416,https://clinicaltrials.gov/study/NCT04038489,https://clinicaltrials.gov/study/NCT05809895,https://clinicaltrials.gov/study/NCT03872505,https://clinicaltrials.gov/study/NCT03554109,https://clinicaltrials.gov/study/NCT01169870,https://clinicaltrials.gov/study/NCT00397761,https://clinicaltrials.gov/study/NCT03058939,https://clinicaltrials.gov/study/NCT02053597,https://clinicaltrials.gov/study/NCT01163929,https://clinicaltrials.gov/study/NCT03841747
EFO_0000432	breast ductal carcinoma in situ	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Terminated	https://clinicaltrials.gov/study/NCT00461344
EFO_0000305	breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL135	ESTRADIOL	Small molecule	Estrogen receptor alpha agonist		ESR1	estrogen receptor 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT00080756
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF4	NADH:ubiquinone oxidoreductase complex assembly factor 4	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0005537	triple-negative breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02208375
EFO_0000305	breast carcinoma	CHEMBL1201182	TEMSIROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	2	Completed	https://clinicaltrials.gov/study/NCT00376688
MONDO_0007254	breast cancer	CHEMBL1184904	RETASPIMYCIN	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AB1	heat shock protein 90 alpha family class B member 1	2	Terminated	https://clinicaltrials.gov/study/NCT00817362
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA6	NADH:ubiquinone oxidoreductase subunit A6	2	Terminated	https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT01477060
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743001	CIXUTUMUMAB	Antibody	Insulin-like growth factor I receptor antagonist		IGF1R	insulin like growth factor 1 receptor	2	Completed	https://clinicaltrials.gov/study/NCT00684983
EFO_1000984	inflammatory breast carcinoma	CHEMBL1789844	IPILIMUMAB	Antibody	Cytotoxic T-lymphocyte protein 4 inhibitor		CTLA4	cytotoxic T-lymphocyte associated protein 4	2	Terminated	https://clinicaltrials.gov/study/NCT02892734
MONDO_0007254	breast cancer	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Fibroblast growth factor receptor 3 inhibitor		FGFR3	fibroblast growth factor receptor 3	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB1	NADH:ubiquinone oxidoreductase subunit B1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL2336325	VISTUSERTIB	Small molecule	Serine/threonine-protein kinase mTOR inhibitor		MTOR	mechanistic target of rapamycin kinase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02208375
MONDO_0007254	breast cancer	CHEMBL1201568	PEGFILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT03571633
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB10	NADH:ubiquinone oxidoreductase subunit B10	2	Completed	https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT01589367
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4	2	Completed	https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT01266486
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC1	NADH:ubiquinone oxidoreductase subunit C1	2	Recruiting	https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT04559308
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Unknown status	https://clinicaltrials.gov/study/NCT00027989
MONDO_0007254	breast cancer	CHEMBL2177390	IPATASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT3	AKT serine/threonine kinase 3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05498896,https://clinicaltrials.gov/study/NCT03395899
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Unknown status	https://clinicaltrials.gov/study/NCT00499525,https://clinicaltrials.gov/study/NCT03735082,https://clinicaltrials.gov/study/NCT01428414,https://clinicaltrials.gov/study/NCT01276769,https://clinicaltrials.gov/study/NCT01830244,https://clinicaltrials.gov/study/NCT00006120,https://clinicaltrials.gov/study/NCT02041338,https://clinicaltrials.gov/study/NCT00777673,https://clinicaltrials.gov/study/NCT02423603,https://clinicaltrials.gov/study/NCT02059876,https://clinicaltrials.gov/study/NCT03348098,https://clinicaltrials.gov/study/NCT00154882,https://clinicaltrials.gov/study/NCT01321775,https://clinicaltrials.gov/study/NCT02694224,https://clinicaltrials.gov/study/NCT00404404,https://clinicaltrials.gov/study/NCT01309607,https://clinicaltrials.gov/study/NCT01625429,https://clinicaltrials.gov/study/NCT01647672,https://clinicaltrials.gov/study/NCT02230319,https://clinicaltrials.gov/study/NCT00533936,https://clinicaltrials.gov/study/NCT00499603,https://clinicaltrials.gov/study/NCT03429972
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Unknown status	https://clinicaltrials.gov/study/NCT03144947
MONDO_0007254	breast cancer	CHEMBL135	ESTRADIOL	Small molecule	Estrogen receptor alpha agonist		ESR1	estrogen receptor 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02238808,https://clinicaltrials.gov/study/NCT02188745
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase B-raf inhibitor		BRAF	B-Raf proto-oncogene, serine/threonine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT00622466,https://clinicaltrials.gov/study/NCT00525161,https://clinicaltrials.gov/study/NCT00722072,https://clinicaltrials.gov/study/NCT00573755,https://clinicaltrials.gov/study/NCT00632541,https://clinicaltrials.gov/study/NCT02624700,https://clinicaltrials.gov/study/NCT01194869,https://clinicaltrials.gov/study/NCT00607438
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB6	NADH:ubiquinone oxidoreductase subunit B6	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01550848,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00192062,https://clinicaltrials.gov/study/NCT01201265,https://clinicaltrials.gov/study/NCT00063570,https://clinicaltrials.gov/study/NCT00325234,https://clinicaltrials.gov/study/NCT00191347,https://clinicaltrials.gov/study/NCT00191269,https://clinicaltrials.gov/study/NCT00193050,https://clinicaltrials.gov/study/NCT00003540,https://clinicaltrials.gov/study/NCT00316199,https://clinicaltrials.gov/study/NCT00192101,https://clinicaltrials.gov/study/NCT00601159,https://clinicaltrials.gov/study/NCT00503906,https://clinicaltrials.gov/study/NCT00540358,https://clinicaltrials.gov/study/NCT00110084,https://clinicaltrials.gov/study/NCT00493636,https://clinicaltrials.gov/study/NCT00128856,https://clinicaltrials.gov/study/NCT00212069,https://clinicaltrials.gov/study/NCT00193076,https://clinicaltrials.gov/study/NCT00191789,https://clinicaltrials.gov/study/NCT02435680,https://clinicaltrials.gov/study/NCT00191373,https://clinicaltrials.gov/study/NCT00193206,https://clinicaltrials.gov/study/NCT00006007,https://clinicaltrials.gov/study/NCT00191451,https://clinicaltrials.gov/study/NCT00059852,https://clinicaltrials.gov/study/NCT00403130,https://clinicaltrials.gov/study/NCT00754351,https://clinicaltrials.gov/study/NCT00320541,https://clinicaltrials.gov/study/NCT00005991,https://clinicaltrials.gov/study/NCT00191854,https://clinicaltrials.gov/study/NCT03025880,https://clinicaltrials.gov/study/NCT00244933,https://clinicaltrials.gov/study/NCT00618826,https://clinicaltrials.gov/study/NCT00813956,https://clinicaltrials.gov/study/NCT00894504,https://clinicaltrials.gov/study/NCT00662129,https://clinicaltrials.gov/study/NCT02263495,https://clinicaltrials.gov/study/NCT00532857,https://clinicaltrials.gov/study/NCT00002998,https://clinicaltrials.gov/study/NCT00623233,https://clinicaltrials.gov/study/NCT01045304,https://clinicaltrials.gov/study/NCT00846027,https://clinicaltrials.gov/study/NCT00191815,https://clinicaltrials.gov/study/NCT04464174,https://clinicaltrials.gov/study/NCT00695994,https://clinicaltrials.gov/study/NCT00334802,https://clinicaltrials.gov/study/NCT00450762,https://clinicaltrials.gov/study/NCT00201760,https://clinicaltrials.gov/study/NCT00378313,https://clinicaltrials.gov/study/NCT00532623,https://clinicaltrials.gov/study/NCT00480597,https://clinicaltrials.gov/study/NCT00193063,https://clinicaltrials.gov/study/NCT00191243
MONDO_0007254	breast cancer	CHEMBL964	DISULFIRAM	Small molecule	Aldehyde dehydrogenase inhibitor		ALDH2	aldehyde dehydrogenase 2 family member	2	Recruiting	https://clinicaltrials.gov/study/NCT03323346
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01815242,https://clinicaltrials.gov/study/NCT03567720,https://clinicaltrials.gov/study/NCT02252887,https://clinicaltrials.gov/study/NCT04297267,https://clinicaltrials.gov/study/NCT04262804
EFO_0000305	breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967
EFO_0000305	breast carcinoma	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR2	estrogen receptor 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03179904,https://clinicaltrials.gov/study/NCT02860000,https://clinicaltrials.gov/study/NCT03939897,https://clinicaltrials.gov/study/NCT02632045
MONDO_0007254	breast cancer	CHEMBL679	EPINEPHRINE	Small molecule	Adrenergic receptor agonist		ADRB2	adrenoceptor beta 2	2	Completed	https://clinicaltrials.gov/study/NCT02525718
EFO_0000305	breast carcinoma	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT04256941
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor		GPD2	glycerol-3-phosphate dehydrogenase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS7	NADH:ubiquinone oxidoreductase core subunit S7	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02530489,https://clinicaltrials.gov/study/NCT01750073,https://clinicaltrials.gov/study/NCT02876107,https://clinicaltrials.gov/study/NCT04395989,https://clinicaltrials.gov/study/NCT04770272,https://clinicaltrials.gov/study/NCT02883062,https://clinicaltrials.gov/study/NCT04216472,https://clinicaltrials.gov/study/NCT02593175,https://clinicaltrials.gov/study/NCT02315196,https://clinicaltrials.gov/study/NCT04958785,https://clinicaltrials.gov/study/NCT04129996
MONDO_0007254	breast cancer	CHEMBL3349607	PASIREOTIDE	Protein	Somatostatin receptor 5 agonist		SSTR5	somatostatin receptor 5	2	Completed	https://clinicaltrials.gov/study/NCT01356862
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT00861705
EFO_0006861	male breast carcinoma	CHEMBL491473	CEDIRANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Completed	https://clinicaltrials.gov/study/NCT00244881
MONDO_0007254	breast cancer	CHEMBL502835	NINTEDANIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR4	fibroblast growth factor receptor 4	2	Terminated	https://clinicaltrials.gov/study/NCT02389764
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA12	NADH:ubiquinone oxidoreductase subunit A12	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT04303741,https://clinicaltrials.gov/study/NCT05833919
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA1	EPH receptor A1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	2	Withdrawn	https://clinicaltrials.gov/study/NCT03032614
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		YES1	YES proto-oncogene 1, Src family tyrosine kinase	2	Withdrawn	https://clinicaltrials.gov/study/NCT01410708
MONDO_0007254	breast cancer	CHEMBL3707227	ATEZOLIZUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor	Inhibitor	CD274	CD274 molecule	2	Completed	https://clinicaltrials.gov/study/NCT03853707,https://clinicaltrials.gov/study/NCT03464942,https://clinicaltrials.gov/study/NCT04408118,https://clinicaltrials.gov/study/NCT03164993,https://clinicaltrials.gov/study/NCT02708680,https://clinicaltrials.gov/study/NCT02924883
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Unknown status	https://clinicaltrials.gov/study/NCT02544243,https://clinicaltrials.gov/study/NCT02341911,https://clinicaltrials.gov/study/NCT00027989,https://clinicaltrials.gov/study/NCT03423849,https://clinicaltrials.gov/study/NCT01352494
MONDO_0007254	breast cancer	CHEMBL1234354	PF-04691502	Small molecule	PI3-kinase class I inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	2	Terminated	https://clinicaltrials.gov/study/NCT01430585
MONDO_0007254	breast cancer	CHEMBL2325741	CAPIVASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT3	AKT serine/threonine kinase 3	2	Unknown status	https://clinicaltrials.gov/study/NCT02423603
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC1	NADH:ubiquinone oxidoreductase subunit C1	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05041101
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT00321633
EFO_0000305	breast carcinoma	CHEMBL554	LAPATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Completed	https://clinicaltrials.gov/study/NCT00684983,https://clinicaltrials.gov/study/NCT01622868
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Unknown status	https://clinicaltrials.gov/study/NCT03144947
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND2	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
EFO_0005537	triple-negative breast cancer	CHEMBL3545262	SACITUZUMAB GOVITECAN	Antibody drug conjugate	Tumor-associated calcium signal transducer 2 binding agent		TACSTD2	tumor associated calcium signal transducer 2	2	Withdrawn	https://clinicaltrials.gov/study/NCT02161679
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4L2	NDUFA4 mitochondrial complex associated like 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Unknown status	https://clinicaltrials.gov/study/NCT01372579
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Terminated	https://clinicaltrials.gov/study/NCT00622466,https://clinicaltrials.gov/study/NCT00607438,https://clinicaltrials.gov/study/NCT00573755,https://clinicaltrials.gov/study/NCT00632541,https://clinicaltrials.gov/study/NCT02624700,https://clinicaltrials.gov/study/NCT01194869,https://clinicaltrials.gov/study/NCT00525161,https://clinicaltrials.gov/study/NCT00722072
MONDO_0007254	breast cancer	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01057069,https://clinicaltrials.gov/study/NCT00003042,https://clinicaltrials.gov/study/NCT02499367,https://clinicaltrials.gov/study/NCT01796197,https://clinicaltrials.gov/study/NCT00295893,https://clinicaltrials.gov/study/NCT04293393,https://clinicaltrials.gov/study/NCT05498896,https://clinicaltrials.gov/study/NCT03609047,https://clinicaltrials.gov/study/NCT04083963,https://clinicaltrials.gov/study/NCT04172259,https://clinicaltrials.gov/study/NCT02299999
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Unknown status	https://clinicaltrials.gov/study/NCT00499603,https://clinicaltrials.gov/study/NCT00404404,https://clinicaltrials.gov/study/NCT03429972,https://clinicaltrials.gov/study/NCT01428414,https://clinicaltrials.gov/study/NCT00154882,https://clinicaltrials.gov/study/NCT01625429,https://clinicaltrials.gov/study/NCT01647672,https://clinicaltrials.gov/study/NCT03348098,https://clinicaltrials.gov/study/NCT00777673,https://clinicaltrials.gov/study/NCT00006120,https://clinicaltrials.gov/study/NCT02230319,https://clinicaltrials.gov/study/NCT02694224,https://clinicaltrials.gov/study/NCT00533936,https://clinicaltrials.gov/study/NCT01276769,https://clinicaltrials.gov/study/NCT03735082,https://clinicaltrials.gov/study/NCT02423603,https://clinicaltrials.gov/study/NCT00499525,https://clinicaltrials.gov/study/NCT02041338,https://clinicaltrials.gov/study/NCT02059876,https://clinicaltrials.gov/study/NCT01321775,https://clinicaltrials.gov/study/NCT01309607,https://clinicaltrials.gov/study/NCT01830244
MONDO_0007254	breast cancer	CHEMBL571209	INDOXIMOD	Small molecule	mTORC1 activator		MTOR	mechanistic target of rapamycin kinase	2	Completed	https://clinicaltrials.gov/study/NCT01792050
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor		GPD2	glycerol-3-phosphate dehydrogenase 2	2	Completed	https://clinicaltrials.gov/study/NCT01885013
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Terminated	https://clinicaltrials.gov/study/NCT00824538,https://clinicaltrials.gov/study/NCT00434356,https://clinicaltrials.gov/study/NCT00570908
MONDO_0007254	breast cancer	CHEMBL1289494	TIVOZANIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT01745367
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		HCK	HCK proto-oncogene, Src family tyrosine kinase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01471106
MONDO_0007254	breast cancer	CHEMBL52885	ENMD-981693	Small molecule	SRC inhibitor		SRMS	src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites	2	Completed	https://clinicaltrials.gov/study/NCT00306631
MONDO_0007254	breast cancer	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06134375,https://clinicaltrials.gov/study/NCT03492918,https://clinicaltrials.gov/study/NCT04946227,https://clinicaltrials.gov/study/NCT06371807,https://clinicaltrials.gov/study/NCT05741164,https://clinicaltrials.gov/study/NCT03971045,https://clinicaltrials.gov/study/NCT06081244,https://clinicaltrials.gov/study/NCT06353997
EFO_0000305	breast carcinoma	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02632045
MONDO_0007254	breast cancer	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03487666,https://clinicaltrials.gov/study/NCT03818685,https://clinicaltrials.gov/study/NCT03756298,https://clinicaltrials.gov/study/NCT05833919,https://clinicaltrials.gov/study/NCT03377387,https://clinicaltrials.gov/study/NCT03691051,https://clinicaltrials.gov/study/NCT01494662,https://clinicaltrials.gov/study/NCT04721977,https://clinicaltrials.gov/study/NCT04001621,https://clinicaltrials.gov/study/NCT03387085,https://clinicaltrials.gov/study/NCT02734290,https://clinicaltrials.gov/study/NCT02491697,https://clinicaltrials.gov/study/NCT04262804
MONDO_0007254	breast cancer	CHEMBL4298101	LADIRATUZUMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT03424005
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Unknown status	https://clinicaltrials.gov/study/NCT02175446
EFO_0000305	breast carcinoma	CHEMBL4297545	LUTETIUM OXODOTREOTIDE LU-177	Protein	Somatostatin receptor binding agent		SSTR1	somatostatin receptor 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04529044
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA1	NADH:ubiquinone oxidoreductase subunit A1	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0005537	triple-negative breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Vascular endothelial growth factor receptor 1 inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04395989,https://clinicaltrials.gov/study/NCT04129996
EFO_0005537	triple-negative breast cancer	CHEMBL3545132	MIRVETUXIMAB SORAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBA1B	tubulin alpha 1b	2	Completed	https://clinicaltrials.gov/study/NCT03106077
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA9	NADH:ubiquinone oxidoreductase subunit A9	2	Completed	https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT04143282
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB7	NADH:ubiquinone oxidoreductase subunit B7	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL1064	SIMVASTATIN	Small molecule	HMG-CoA reductase inhibitor		HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03324425
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Completed	https://clinicaltrials.gov/study/NCT01105650,https://clinicaltrials.gov/study/NCT00429572,https://clinicaltrials.gov/study/NCT00020176
MONDO_0007254	breast cancer	CHEMBL2177390	IPATASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT3	AKT serine/threonine kinase 3	2	Completed	https://clinicaltrials.gov/study/NCT04464174,https://clinicaltrials.gov/study/NCT02301988,https://clinicaltrials.gov/study/NCT03853707
MONDO_0007254	breast cancer	CHEMBL383824	ALVESPIMYCIN	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AA1	heat shock protein 90 alpha family class A member 1	2	Terminated	https://clinicaltrials.gov/study/NCT00780000
MONDO_0007254	breast cancer	CHEMBL225072	PEMETREXED	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	2	Completed	https://clinicaltrials.gov/study/NCT00063570,https://clinicaltrials.gov/study/NCT00006007,https://clinicaltrials.gov/study/NCT00191347,https://clinicaltrials.gov/study/NCT00149214,https://clinicaltrials.gov/study/NCT00325234,https://clinicaltrials.gov/study/NCT00102219,https://clinicaltrials.gov/study/NCT00065533
EFO_0005537	triple-negative breast cancer	CHEMBL4303201	CATEQUENTINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Recruiting	https://clinicaltrials.gov/study/NCT05089643,https://clinicaltrials.gov/study/NCT04914390
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Unknown status	https://clinicaltrials.gov/study/NCT02947061,https://clinicaltrials.gov/study/NCT00003066,https://clinicaltrials.gov/study/NCT03876587,https://clinicaltrials.gov/study/NCT00721747,https://clinicaltrials.gov/study/NCT00006120,https://clinicaltrials.gov/study/NCT01351597,https://clinicaltrials.gov/study/NCT01907529,https://clinicaltrials.gov/study/NCT00250874,https://clinicaltrials.gov/study/NCT01270373,https://clinicaltrials.gov/study/NCT00026078,https://clinicaltrials.gov/study/NCT00957125,https://clinicaltrials.gov/study/NCT01939054,https://clinicaltrials.gov/study/NCT02144194,https://clinicaltrials.gov/study/NCT00398489,https://clinicaltrials.gov/study/NCT03147963,https://clinicaltrials.gov/study/NCT02685657,https://clinicaltrials.gov/study/NCT00033683,https://clinicaltrials.gov/study/NCT00669773,https://clinicaltrials.gov/study/NCT00801411,https://clinicaltrials.gov/study/NCT00994968,https://clinicaltrials.gov/study/NCT01526499,https://clinicaltrials.gov/study/NCT00012311,https://clinicaltrials.gov/study/NCT01352494
MONDO_0007254	breast cancer	CHEMBL58	MITOXANTRONE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Completed	https://clinicaltrials.gov/study/NCT00003068,https://clinicaltrials.gov/study/NCT00004237
MONDO_0007254	breast cancer	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	2	Terminated	https://clinicaltrials.gov/study/NCT01919229
MONDO_0007254	breast cancer	CHEMBL384467	DEXAMETHASONE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	2	Completed	https://clinicaltrials.gov/study/NCT01332630,https://clinicaltrials.gov/study/NCT00404066,https://clinicaltrials.gov/study/NCT02069093,https://clinicaltrials.gov/study/NCT02525718,https://clinicaltrials.gov/study/NCT01698918
MONDO_0007254	breast cancer	CHEMBL1417019	MITOXANTRONE HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Completed	https://clinicaltrials.gov/study/NCT00003068,https://clinicaltrials.gov/study/NCT00004237
MONDO_0007254	breast cancer	CHEMBL4297181	SAMOTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	2	Completed	https://clinicaltrials.gov/study/NCT04032080
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01730833,https://clinicaltrials.gov/study/NCT02530489,https://clinicaltrials.gov/study/NCT02957968
MONDO_0007254	breast cancer	CHEMBL45	MELATONIN	Small molecule	Melatonin receptor agonist		MTNR1A	melatonin receptor 1A	2	Completed	https://clinicaltrials.gov/study/NCT01965522
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06291064,https://clinicaltrials.gov/study/NCT04034823,https://clinicaltrials.gov/study/NCT06348134,https://clinicaltrials.gov/study/NCT04290793
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01745965,https://clinicaltrials.gov/study/NCT01565200,https://clinicaltrials.gov/study/NCT04733118,https://clinicaltrials.gov/study/NCT01494662,https://clinicaltrials.gov/study/NCT04398914,https://clinicaltrials.gov/study/NCT01853748,https://clinicaltrials.gov/study/NCT02326974,https://clinicaltrials.gov/study/NCT03587740
MONDO_0007254	breast cancer	CHEMBL2408045	SAPITINIB	Small molecule	Receptor tyrosine-protein kinase erbB-3 inhibitor		ERBB3	erb-b2 receptor tyrosine kinase 3	2	Terminated	https://clinicaltrials.gov/study/NCT01151215
MONDO_0007254	breast cancer	CHEMBL27	PROPRANOLOL	Small molecule	Beta-1 adrenergic receptor antagonist		ADRB1	adrenoceptor beta 1	2	Completed	https://clinicaltrials.gov/study/NCT01847001
MONDO_0007254	breast cancer	CHEMBL1234354	PF-04691502	Small molecule	PI3-kinase class I inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	2	Terminated	https://clinicaltrials.gov/study/NCT01430585
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
EFO_0000305	breast carcinoma	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03939897
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA8	NADH:ubiquinone oxidoreductase subunit A8	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV3	NADH:ubiquinone oxidoreductase subunit V3	2	Completed	https://clinicaltrials.gov/study/NCT01885013
EFO_0005537	triple-negative breast cancer	CHEMBL553	ERLOTINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Completed	https://clinicaltrials.gov/study/NCT00733408
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04345913
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT03530696
EFO_0006861	male breast carcinoma	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	2	Completed	https://clinicaltrials.gov/study/NCT00119262,https://clinicaltrials.gov/study/NCT00118157,https://clinicaltrials.gov/study/NCT00003199
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Recruiting	https://clinicaltrials.gov/study/NCT05583110
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Recruiting	https://clinicaltrials.gov/study/NCT05192798,https://clinicaltrials.gov/study/NCT04138719,https://clinicaltrials.gov/study/NCT05227664,https://clinicaltrials.gov/study/NCT03606967,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT05834582
EFO_0005537	triple-negative breast cancer	CHEMBL4298101	LADIRATUZUMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04345913
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND3	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3	2	Recruiting	https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT04559308
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT01818063,https://clinicaltrials.gov/study/NCT00733408,https://clinicaltrials.gov/study/NCT02689427,https://clinicaltrials.gov/study/NCT01881230,https://clinicaltrials.gov/study/NCT03057600,https://clinicaltrials.gov/study/NCT03853707,https://clinicaltrials.gov/study/NCT02413320
EFO_0006861	male breast carcinoma	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Serine/threonine-protein kinase RAF inhibitor		RAF1	Raf-1 proto-oncogene, serine/threonine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00096434
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
MONDO_0007254	breast cancer	CHEMBL941	IMATINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT00323063
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT02682693,https://clinicaltrials.gov/study/NCT00513695,https://clinicaltrials.gov/study/NCT02199418
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Epidermal growth factor receptor inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT00494481
MONDO_0007254	breast cancer	CHEMBL4594611	PATRITUMAB DERUXTECAN	Antibody drug conjugate	Receptor tyrosine-protein kinase erbB-3 binding agent		ERBB3	erb-b2 receptor tyrosine kinase 3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05569811
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT02549430,https://clinicaltrials.gov/study/NCT02536742,https://clinicaltrials.gov/study/NCT03054363,https://clinicaltrials.gov/study/NCT02384239,https://clinicaltrials.gov/study/NCT03065621,https://clinicaltrials.gov/study/NCT03628066,https://clinicaltrials.gov/study/NCT03819010,https://clinicaltrials.gov/study/NCT03644186,https://clinicaltrials.gov/study/NCT03184090,https://clinicaltrials.gov/study/NCT02040857,https://clinicaltrials.gov/study/NCT02630693,https://clinicaltrials.gov/study/NCT04494958,https://clinicaltrials.gov/study/NCT04436744,https://clinicaltrials.gov/study/NCT04075604,https://clinicaltrials.gov/study/NCT03007979,https://clinicaltrials.gov/study/NCT03530696,https://clinicaltrials.gov/study/NCT02448420,https://clinicaltrials.gov/study/NCT02806050,https://clinicaltrials.gov/study/NCT02692755,https://clinicaltrials.gov/study/NCT03774472,https://clinicaltrials.gov/study/NCT02296801,https://clinicaltrials.gov/study/NCT02400567,https://clinicaltrials.gov/study/NCT02491983
MONDO_0007254	breast cancer	CHEMBL2108568	TREBANANIB	Protein	Angiopoietin-2 inhibitor		ANGPT2	angiopoietin 2	2	Completed	https://clinicaltrials.gov/study/NCT00511459
MONDO_0007254	breast cancer	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Terminated	https://clinicaltrials.gov/study/NCT00722072,https://clinicaltrials.gov/study/NCT00573755,https://clinicaltrials.gov/study/NCT00622466
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT06026657,https://clinicaltrials.gov/study/NCT03606967
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA2	NADH:ubiquinone oxidoreductase subunit A2	2	Completed	https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Terminated	https://clinicaltrials.gov/study/NCT00194792,https://clinicaltrials.gov/study/NCT00542191,https://clinicaltrials.gov/study/NCT01329627,https://clinicaltrials.gov/study/NCT02598310,https://clinicaltrials.gov/study/NCT03329378,https://clinicaltrials.gov/study/NCT00691912,https://clinicaltrials.gov/study/NCT00607438,https://clinicaltrials.gov/study/NCT01147016,https://clinicaltrials.gov/study/NCT00589238,https://clinicaltrials.gov/study/NCT00356681,https://clinicaltrials.gov/study/NCT00479856,https://clinicaltrials.gov/study/NCT01194869,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT00434356,https://clinicaltrials.gov/study/NCT00456846,https://clinicaltrials.gov/study/NCT00536939,https://clinicaltrials.gov/study/NCT01069796,https://clinicaltrials.gov/study/NCT00756470,https://clinicaltrials.gov/study/NCT00679029,https://clinicaltrials.gov/study/NCT00532285,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT02322814,https://clinicaltrials.gov/study/NCT03894007,https://clinicaltrials.gov/study/NCT01207102,https://clinicaltrials.gov/study/NCT01745367,https://clinicaltrials.gov/study/NCT01120158,https://clinicaltrials.gov/study/NCT00622466,https://clinicaltrials.gov/study/NCT01416558,https://clinicaltrials.gov/study/NCT01009983,https://clinicaltrials.gov/study/NCT00934895,https://clinicaltrials.gov/study/NCT04066790
MONDO_0007254	breast cancer	CHEMBL679	EPINEPHRINE	Small molecule	Adrenergic receptor agonist		ADRA1D	adrenoceptor alpha 1D	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04603911
MONDO_0007254	breast cancer	CHEMBL4297185	DAROLUTAMIDE	Small molecule	Androgen Receptor antagonist		AR	androgen receptor	2	Completed	https://clinicaltrials.gov/study/NCT03383679
EFO_0000305	breast carcinoma	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03179904
EFO_0000432	breast ductal carcinoma in situ	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Terminated	https://clinicaltrials.gov/study/NCT00461344
EFO_0000305	breast carcinoma	CHEMBL491473	CEDIRANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT04090567
EFO_0000305	breast carcinoma	CHEMBL1079175	MK-2206	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT1	AKT serine/threonine kinase 1	2	Terminated	https://clinicaltrials.gov/study/NCT01776008
EFO_0000304	breast adenocarcinoma	CHEMBL517712	ATROPINE	Small molecule	Muscarinic acetylcholine receptor M3 antagonist		CHRM3	cholinergic receptor muscarinic 3	2	Completed	https://clinicaltrials.gov/study/NCT03094052
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Terminated	https://clinicaltrials.gov/study/NCT02978716
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Recruiting	https://clinicaltrials.gov/study/NCT06027268,https://clinicaltrials.gov/study/NCT03606967
EFO_0005537	triple-negative breast cancer	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT03971409
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02547987,https://clinicaltrials.gov/study/NCT00295893,https://clinicaltrials.gov/study/NCT01779206,https://clinicaltrials.gov/study/NCT02624973,https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT03609047,https://clinicaltrials.gov/study/NCT00496795,https://clinicaltrials.gov/study/NCT04172259,https://clinicaltrials.gov/study/NCT02568839,https://clinicaltrials.gov/study/NCT03161353,https://clinicaltrials.gov/study/NCT02339532
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT00879086,https://clinicaltrials.gov/study/NCT03051659,https://clinicaltrials.gov/study/NCT00965523,https://clinicaltrials.gov/study/NCT01268150,https://clinicaltrials.gov/study/NCT01269346,https://clinicaltrials.gov/study/NCT02481050,https://clinicaltrials.gov/study/NCT05206656,https://clinicaltrials.gov/study/NCT00246090,https://clinicaltrials.gov/study/NCT01908101,https://clinicaltrials.gov/study/NCT01439282
MONDO_0007254	breast cancer	CHEMBL4297545	LUTETIUM OXODOTREOTIDE LU-177	Protein	Somatostatin receptor binding agent		SSTR1	somatostatin receptor 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04529044
MONDO_0007254	breast cancer	CHEMBL502835	NINTEDANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT01658462
MONDO_0007254	breast cancer	CHEMBL3264610	SEVITERONEL	Small molecule	Androgen Receptor antagonist		AR	androgen receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT04947189
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Recruiting	https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT05810870,https://clinicaltrials.gov/study/NCT05530057,https://clinicaltrials.gov/study/NCT05546255,https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT05458674,https://clinicaltrials.gov/study/NCT06102824,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT04624711
MONDO_0007254	breast cancer	CHEMBL27	PROPRANOLOL	Small molecule	Beta-1 adrenergic receptor antagonist		ADRB1	adrenoceptor beta 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05741164
MONDO_0007254	breast cancer	CHEMBL1173655	AFATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-4 inhibitor		ERBB4	erb-b2 receptor tyrosine kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT01594177
MONDO_0007254	breast cancer	CHEMBL1879463	DACTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R5	phosphoinositide-3-kinase regulatory subunit 5	2	Withdrawn	https://clinicaltrials.gov/study/NCT01288092
MONDO_0007254	breast cancer	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		NCSTN	nicastrin	2	Terminated	https://clinicaltrials.gov/study/NCT01151449
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Terminated	https://clinicaltrials.gov/study/NCT00636441,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT00028483,https://clinicaltrials.gov/study/NCT03894007,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT00453635,https://clinicaltrials.gov/study/NCT00225056,https://clinicaltrials.gov/study/NCT00845910,https://clinicaltrials.gov/study/NCT01690325,https://clinicaltrials.gov/study/NCT00080626,https://clinicaltrials.gov/study/NCT01985841,https://clinicaltrials.gov/study/NCT00104624,https://clinicaltrials.gov/study/NCT03329378,https://clinicaltrials.gov/study/NCT00524459,https://clinicaltrials.gov/study/NCT00343512,https://clinicaltrials.gov/study/NCT00479856,https://clinicaltrials.gov/study/NCT00025493,https://clinicaltrials.gov/study/NCT00206453,https://clinicaltrials.gov/study/NCT00193024,https://clinicaltrials.gov/study/NCT00118053,https://clinicaltrials.gov/study/NCT00852332,https://clinicaltrials.gov/study/NCT00576901,https://clinicaltrials.gov/study/NCT00665457
MONDO_0007254	breast cancer	CHEMBL2108738	NIVOLUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Terminated	https://clinicaltrials.gov/study/NCT03952325
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS4	NADH:ubiquinone oxidoreductase subunit S4	2	Recruiting	https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT04559308,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04300790
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND3	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3	2	Unknown status	https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT02506777,https://clinicaltrials.gov/study/NCT03192293
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS5	NADH:ubiquinone oxidoreductase subunit S5	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL20684	ABT-751	Small molecule	Tubulin beta inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT00063102
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT00006682,https://clinicaltrials.gov/study/NCT00976989,https://clinicaltrials.gov/study/NCT04664972,https://clinicaltrials.gov/study/NCT01527487,https://clinicaltrials.gov/study/NCT00179309,https://clinicaltrials.gov/study/NCT00203502,https://clinicaltrials.gov/study/NCT00319618,https://clinicaltrials.gov/study/NCT00055861,https://clinicaltrials.gov/study/NCT00039520,https://clinicaltrials.gov/study/NCT00432172,https://clinicaltrials.gov/study/NCT01142778,https://clinicaltrials.gov/study/NCT00545688,https://clinicaltrials.gov/study/NCT00027885,https://clinicaltrials.gov/study/NCT00006104,https://clinicaltrials.gov/study/NCT02132949,https://clinicaltrials.gov/study/NCT03140553,https://clinicaltrials.gov/study/NCT00841828,https://clinicaltrials.gov/study/NCT01025349,https://clinicaltrials.gov/study/NCT00248703,https://clinicaltrials.gov/study/NCT03887130,https://clinicaltrials.gov/study/NCT00003565,https://clinicaltrials.gov/study/NCT01671319,https://clinicaltrials.gov/study/NCT01540110,https://clinicaltrials.gov/study/NCT00209092,https://clinicaltrials.gov/study/NCT02137083,https://clinicaltrials.gov/study/NCT00464646,https://clinicaltrials.gov/study/NCT00604435,https://clinicaltrials.gov/study/NCT00258375,https://clinicaltrials.gov/study/NCT00123929,https://clinicaltrials.gov/study/NCT00004175,https://clinicaltrials.gov/study/NCT00003352,https://clinicaltrials.gov/study/NCT00428922,https://clinicaltrials.gov/study/NCT00206518,https://clinicaltrials.gov/study/NCT00490646,https://clinicaltrials.gov/study/NCT00494481,https://clinicaltrials.gov/study/NCT00365417,https://clinicaltrials.gov/study/NCT00015886,https://clinicaltrials.gov/study/NCT00364611,https://clinicaltrials.gov/study/NCT00203372,https://clinicaltrials.gov/study/NCT00193115,https://clinicaltrials.gov/study/NCT00206505,https://clinicaltrials.gov/study/NCT00214864,https://clinicaltrials.gov/study/NCT00155259,https://clinicaltrials.gov/study/NCT00077857,https://clinicaltrials.gov/study/NCT00191243,https://clinicaltrials.gov/study/NCT00820547,https://clinicaltrials.gov/study/NCT00206466,https://clinicaltrials.gov/study/NCT00004906,https://clinicaltrials.gov/study/NCT00028873,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT00769470,https://clinicaltrials.gov/study/NCT00003953,https://clinicaltrials.gov/study/NCT00941330,https://clinicaltrials.gov/study/NCT01485926,https://clinicaltrials.gov/study/NCT02846428,https://clinicaltrials.gov/study/NCT00404066,https://clinicaltrials.gov/study/NCT00679341,https://clinicaltrials.gov/study/NCT00212095,https://clinicaltrials.gov/study/NCT00088998,https://clinicaltrials.gov/study/NCT00695994,https://clinicaltrials.gov/study/NCT02909751,https://clinicaltrials.gov/study/NCT00054275,https://clinicaltrials.gov/study/NCT00005963,https://clinicaltrials.gov/study/NCT01038804,https://clinicaltrials.gov/study/NCT02041351,https://clinicaltrials.gov/study/NCT00475670,https://clinicaltrials.gov/study/NCT00146042,https://clinicaltrials.gov/study/NCT00559754,https://clinicaltrials.gov/study/NCT01208480,https://clinicaltrials.gov/study/NCT00129376,https://clinicaltrials.gov/study/NCT00524810,https://clinicaltrials.gov/study/NCT00525759,https://clinicaltrials.gov/study/NCT00193089,https://clinicaltrials.gov/study/NCT00493649,https://clinicaltrials.gov/study/NCT01150513,https://clinicaltrials.gov/study/NCT01959490,https://clinicaltrials.gov/study/NCT00527449,https://clinicaltrials.gov/study/NCT03742986,https://clinicaltrials.gov/study/NCT00107510,https://clinicaltrials.gov/study/NCT00212082,https://clinicaltrials.gov/study/NCT01367028,https://clinicaltrials.gov/study/NCT02838225,https://clinicaltrials.gov/study/NCT00645866,https://clinicaltrials.gov/study/NCT00005800,https://clinicaltrials.gov/study/NCT00015938,https://clinicaltrials.gov/study/NCT00365365,https://clinicaltrials.gov/study/NCT00232479,https://clinicaltrials.gov/study/NCT01446016,https://clinicaltrials.gov/study/NCT00600249,https://clinicaltrials.gov/study/NCT00247481,https://clinicaltrials.gov/study/NCT00148070,https://clinicaltrials.gov/study/NCT00044993,https://clinicaltrials.gov/study/NCT00379015,https://clinicaltrials.gov/study/NCT02229084,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00193037,https://clinicaltrials.gov/study/NCT00712881,https://clinicaltrials.gov/study/NCT01396655,https://clinicaltrials.gov/study/NCT00079118,https://clinicaltrials.gov/study/NCT00005908,https://clinicaltrials.gov/study/NCT00274456,https://clinicaltrials.gov/study/NCT00041067,https://clinicaltrials.gov/study/NCT00193180,https://clinicaltrials.gov/study/NCT00149214,https://clinicaltrials.gov/study/NCT00148668,https://clinicaltrials.gov/study/NCT02365805,https://clinicaltrials.gov/study/NCT00754351,https://clinicaltrials.gov/study/NCT00068341,https://clinicaltrials.gov/study/NCT02834403,https://clinicaltrials.gov/study/NCT00499122,https://clinicaltrials.gov/study/NCT00066443,https://clinicaltrials.gov/study/NCT01792050,https://clinicaltrials.gov/study/NCT00193050,https://clinicaltrials.gov/study/NCT00201708,https://clinicaltrials.gov/study/NCT00217672,https://clinicaltrials.gov/study/NCT03735966,https://clinicaltrials.gov/study/NCT00004888,https://clinicaltrials.gov/study/NCT00820872,https://clinicaltrials.gov/study/NCT02748213,https://clinicaltrials.gov/study/NCT01658462,https://clinicaltrials.gov/study/NCT02005549,https://clinicaltrials.gov/study/NCT00198237,https://clinicaltrials.gov/study/NCT00773695
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Terminated	https://clinicaltrials.gov/study/NCT00576901,https://clinicaltrials.gov/study/NCT00845910,https://clinicaltrials.gov/study/NCT00636441,https://clinicaltrials.gov/study/NCT01690325,https://clinicaltrials.gov/study/NCT01985841,https://clinicaltrials.gov/study/NCT00852332,https://clinicaltrials.gov/study/NCT00665457,https://clinicaltrials.gov/study/NCT00080626,https://clinicaltrials.gov/study/NCT00118053,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT00206453,https://clinicaltrials.gov/study/NCT00193024,https://clinicaltrials.gov/study/NCT03329378,https://clinicaltrials.gov/study/NCT00453635,https://clinicaltrials.gov/study/NCT00025493,https://clinicaltrials.gov/study/NCT03894007,https://clinicaltrials.gov/study/NCT00104624,https://clinicaltrials.gov/study/NCT00225056,https://clinicaltrials.gov/study/NCT00028483,https://clinicaltrials.gov/study/NCT00479856,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT00524459,https://clinicaltrials.gov/study/NCT00343512
EFO_0000432	breast ductal carcinoma in situ	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02779855
EFO_0005537	triple-negative breast cancer	CHEMBL3545262	SACITUZUMAB GOVITECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	2	Withdrawn	https://clinicaltrials.gov/study/NCT02161679
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Recruiting	https://clinicaltrials.gov/study/NCT05583110
EFO_0006861	male breast carcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC3	histone deacetylase 3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01349959
EFO_0005537	triple-negative breast cancer	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03639948,https://clinicaltrials.gov/study/NCT02411656,https://clinicaltrials.gov/study/NCT04024800
EFO_0006861	male breast carcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC7	histone deacetylase 7	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01349959
MONDO_0007254	breast cancer	CHEMBL1201748	CABAZITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Recruiting	https://clinicaltrials.gov/study/NCT03048942
MONDO_0007254	breast cancer	CHEMBL435191	EDOTECARIN	Small molecule	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	2	Completed	https://clinicaltrials.gov/study/NCT00070031
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS1	NADH:ubiquinone oxidoreductase core subunit S1	2	Unknown status	https://clinicaltrials.gov/study/NCT02506777,https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT02506790
MONDO_0007254	breast cancer	CHEMBL4303669	ZOLEDRONIC ACID	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06374459
MONDO_0007254	breast cancer	CHEMBL1200694	SEVOFLURANE	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRA2	gamma-aminobutyric acid type A receptor subunit alpha2	2	Completed	https://clinicaltrials.gov/study/NCT02839668
MONDO_0007254	breast cancer	CHEMBL4302409	LUTETIUM OXODOTREOTIDE	Protein	Somatostatin receptor binding agent		SSTR3	somatostatin receptor 3	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04529044
MONDO_0007254	breast cancer	CHEMBL468	THALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		RBX1	ring-box 1	2	Unknown status	https://clinicaltrials.gov/study/NCT02649101
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT00321633
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04303741,https://clinicaltrials.gov/study/NCT05833919,https://clinicaltrials.gov/study/NCT02299999
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Unknown status	https://clinicaltrials.gov/study/NCT01939054,https://clinicaltrials.gov/study/NCT02685657,https://clinicaltrials.gov/study/NCT00003066,https://clinicaltrials.gov/study/NCT00957125,https://clinicaltrials.gov/study/NCT01526499,https://clinicaltrials.gov/study/NCT01270373,https://clinicaltrials.gov/study/NCT00033683,https://clinicaltrials.gov/study/NCT00250874,https://clinicaltrials.gov/study/NCT01351597,https://clinicaltrials.gov/study/NCT00994968,https://clinicaltrials.gov/study/NCT00398489,https://clinicaltrials.gov/study/NCT00801411,https://clinicaltrials.gov/study/NCT00721747,https://clinicaltrials.gov/study/NCT02947061,https://clinicaltrials.gov/study/NCT03876587,https://clinicaltrials.gov/study/NCT00669773,https://clinicaltrials.gov/study/NCT00026078,https://clinicaltrials.gov/study/NCT02144194,https://clinicaltrials.gov/study/NCT00012311,https://clinicaltrials.gov/study/NCT01352494,https://clinicaltrials.gov/study/NCT01907529,https://clinicaltrials.gov/study/NCT03147963,https://clinicaltrials.gov/study/NCT00006120
EFO_0000305	breast carcinoma	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02668666,https://clinicaltrials.gov/study/NCT02603679,https://clinicaltrials.gov/study/NCT02592083
MONDO_0007254	breast cancer	CHEMBL1879463	DACTOLISIB	Small molecule	Serine/threonine-protein kinase mTOR inhibitor		MTOR	mechanistic target of rapamycin kinase	2	Withdrawn	https://clinicaltrials.gov/study/NCT01288092
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Withdrawn	https://clinicaltrials.gov/study/NCT02725541
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Suspended	https://clinicaltrials.gov/study/NCT02897050,https://clinicaltrials.gov/study/NCT04419181
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Withdrawn	https://clinicaltrials.gov/study/NCT00615524
MONDO_0007254	breast cancer	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 2 inhibitor		HDAC2	histone deacetylase 2	2	Completed	https://clinicaltrials.gov/study/NCT00262834,https://clinicaltrials.gov/study/NCT00365599
EFO_0006861	male breast carcinoma	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		APH1B	aph-1 homolog B, gamma-secretase subunit	2	Terminated	https://clinicaltrials.gov/study/NCT01151449
EFO_0006861	male breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Unknown status	https://clinicaltrials.gov/study/NCT01372579
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02654119
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06078384
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND3	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01730833,https://clinicaltrials.gov/study/NCT02876302
MONDO_0007254	breast cancer	CHEMBL1184904	RETASPIMYCIN	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AA1	heat shock protein 90 alpha family class A member 1	2	Terminated	https://clinicaltrials.gov/study/NCT00817362
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1201179	LAPATINIB DITOSYLATE	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT00684983
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor		GPD2	glycerol-3-phosphate dehydrogenase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04216472,https://clinicaltrials.gov/study/NCT02883062,https://clinicaltrials.gov/study/NCT04958785,https://clinicaltrials.gov/study/NCT02876107,https://clinicaltrials.gov/study/NCT01750073,https://clinicaltrials.gov/study/NCT04770272,https://clinicaltrials.gov/study/NCT04395989,https://clinicaltrials.gov/study/NCT04129996,https://clinicaltrials.gov/study/NCT02530489,https://clinicaltrials.gov/study/NCT02315196,https://clinicaltrials.gov/study/NCT02593175
EFO_0006861	male breast carcinoma	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Completed	https://clinicaltrials.gov/study/NCT00096434
MONDO_0044915	salivary duct carcinoma	CHEMBL1082407	ENZALUTAMIDE	Small molecule	Androgen Receptor antagonist		AR	androgen receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT02749903
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04770272,https://clinicaltrials.gov/study/NCT01750073,https://clinicaltrials.gov/study/NCT04129996,https://clinicaltrials.gov/study/NCT02883062,https://clinicaltrials.gov/study/NCT04216472,https://clinicaltrials.gov/study/NCT02315196,https://clinicaltrials.gov/study/NCT04958785,https://clinicaltrials.gov/study/NCT02593175,https://clinicaltrials.gov/study/NCT02530489,https://clinicaltrials.gov/study/NCT02876107,https://clinicaltrials.gov/study/NCT04395989
MONDO_0007254	breast cancer	CHEMBL3707227	ATEZOLIZUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor	Inhibitor	CD274	CD274 molecule	2	Recruiting	https://clinicaltrials.gov/study/NCT05180006,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT05332561,https://clinicaltrials.gov/study/NCT04759248,https://clinicaltrials.gov/study/NCT04802759,https://clinicaltrials.gov/study/NCT04739670
MONDO_0007254	breast cancer	CHEMBL409	BICALUTAMIDE	Small molecule	Androgen Receptor antagonist		AR	androgen receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02605486,https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT03650894
MONDO_0007254	breast cancer	CHEMBL1491	AMLODIPINE	Small molecule	Voltage-gated L-type calcium channel blocker		CACNA1D	calcium voltage-gated channel subunit alpha1 D	2	Completed	https://clinicaltrials.gov/study/NCT02834403
EFO_1000984	inflammatory breast carcinoma	CHEMBL535	SUNITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT00513695
MONDO_0044915	salivary duct carcinoma	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03614364
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	2	Unknown status	https://clinicaltrials.gov/study/NCT02917005,https://clinicaltrials.gov/study/NCT02592746
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS3	NADH:ubiquinone oxidoreductase core subunit S3	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT04559308,https://clinicaltrials.gov/study/NCT03238495
MONDO_0007254	breast cancer	CHEMBL2177390	IPATASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT1	AKT serine/threonine kinase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT04920708,https://clinicaltrials.gov/study/NCT04802759,https://clinicaltrials.gov/study/NCT05332561,https://clinicaltrials.gov/study/NCT03424005
EFO_0000305	breast carcinoma	CHEMBL1079175	MK-2206	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT3	AKT serine/threonine kinase 3	2	Terminated	https://clinicaltrials.gov/study/NCT01776008
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01471106
MONDO_0007254	breast cancer	CHEMBL2105756	TIVOZANIB HYDROCHLORIDE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Terminated	https://clinicaltrials.gov/study/NCT01745367
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04538742,https://clinicaltrials.gov/study/NCT04398914,https://clinicaltrials.gov/study/NCT04192331,https://clinicaltrials.gov/study/NCT01815242,https://clinicaltrials.gov/study/NCT01779206,https://clinicaltrials.gov/study/NCT04734262,https://clinicaltrials.gov/study/NCT02734290,https://clinicaltrials.gov/study/NCT03747120,https://clinicaltrials.gov/study/NCT03387085,https://clinicaltrials.gov/study/NCT02788981,https://clinicaltrials.gov/study/NCT04418154,https://clinicaltrials.gov/study/NCT00003042,https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT01796197,https://clinicaltrials.gov/study/NCT03125928,https://clinicaltrials.gov/study/NCT02883062,https://clinicaltrials.gov/study/NCT05498896,https://clinicaltrials.gov/study/NCT00609791,https://clinicaltrials.gov/study/NCT03568422,https://clinicaltrials.gov/study/NCT02187991,https://clinicaltrials.gov/study/NCT01853748,https://clinicaltrials.gov/study/NCT01057069,https://clinicaltrials.gov/study/NCT00616967,https://clinicaltrials.gov/study/NCT04603183,https://clinicaltrials.gov/study/NCT04215146,https://clinicaltrials.gov/study/NCT02546232,https://clinicaltrials.gov/study/NCT00295893,https://clinicaltrials.gov/study/NCT04172259,https://clinicaltrials.gov/study/NCT04251169,https://clinicaltrials.gov/study/NCT03616886,https://clinicaltrials.gov/study/NCT04083963,https://clinicaltrials.gov/study/NCT03950570,https://clinicaltrials.gov/study/NCT02779855,https://clinicaltrials.gov/study/NCT01730833,https://clinicaltrials.gov/study/NCT01898117,https://clinicaltrials.gov/study/NCT03609047,https://clinicaltrials.gov/study/NCT02752685,https://clinicaltrials.gov/study/NCT03567720
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Platelet-derived growth factor receptor alpha inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Unknown status	https://clinicaltrials.gov/study/NCT02790580
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Recruiting	https://clinicaltrials.gov/study/NCT04266249,https://clinicaltrials.gov/study/NCT04090398,https://clinicaltrials.gov/study/NCT03606967
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB10	NADH:ubiquinone oxidoreductase subunit B10	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Completed	https://clinicaltrials.gov/study/NCT01194440
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967,https://clinicaltrials.gov/study/NCT06027268
MONDO_0007254	breast cancer	CHEMBL4297844	TRASTUZUMAB DERUXTECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04539938,https://clinicaltrials.gov/study/NCT03248492,https://clinicaltrials.gov/study/NCT04538742
EFO_0006318	breast ductal adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Terminated	https://clinicaltrials.gov/study/NCT01891357
MONDO_0007254	breast cancer	CHEMBL834	PAMIDRONIC ACID	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	2	Completed	https://clinicaltrials.gov/study/NCT00004906
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA2	EPH receptor A2	2	Completed	https://clinicaltrials.gov/study/NCT00494481
MONDO_0007254	breast cancer	CHEMBL4594611	PATRITUMAB DERUXTECAN	Antibody drug conjugate	Receptor tyrosine-protein kinase erbB-3 binding agent		ERBB3	erb-b2 receptor tyrosine kinase 3	2	Recruiting	https://clinicaltrials.gov/study/NCT06298084,https://clinicaltrials.gov/study/NCT04965766,https://clinicaltrials.gov/study/NCT04699630
EFO_0005537	triple-negative breast cancer	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	2	Completed	https://clinicaltrials.gov/study/NCT03853707
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF2	NADH:ubiquinone oxidoreductase complex assembly factor 2	2	Unknown status	https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT02506777
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBA1C	tubulin alpha 1c	2	Completed	https://clinicaltrials.gov/study/NCT00265733,https://clinicaltrials.gov/study/NCT00148707
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Completed	https://clinicaltrials.gov/study/NCT02978495
MONDO_0021115	luminal B breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT03356860
MONDO_0007254	breast cancer	CHEMBL3545396	BMS-690514	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT01068704
MONDO_0007254	breast cancer	CHEMBL1237023	DENOSUMAB	Antibody	Tumor necrosis factor ligand superfamily member 11 inhibitor		TNFSF11	TNF superfamily member 11	2	Completed	https://clinicaltrials.gov/study/NCT02366130,https://clinicaltrials.gov/study/NCT02613416
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist	Antagonist	ESR2	estrogen receptor 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03939897,https://clinicaltrials.gov/study/NCT04224272,https://clinicaltrials.gov/study/NCT03781063,https://clinicaltrials.gov/study/NCT04352777,https://clinicaltrials.gov/study/NCT03393845,https://clinicaltrials.gov/study/NCT01441947,https://clinicaltrials.gov/study/NCT02738866,https://clinicaltrials.gov/study/NCT00585507,https://clinicaltrials.gov/study/NCT04059484,https://clinicaltrials.gov/study/NCT02632045,https://clinicaltrials.gov/study/NCT04024436,https://clinicaltrials.gov/study/NCT04214288,https://clinicaltrials.gov/study/NCT05090358,https://clinicaltrials.gov/study/NCT03147287,https://clinicaltrials.gov/study/NCT04053322,https://clinicaltrials.gov/study/NCT01560416,https://clinicaltrials.gov/study/NCT04524000,https://clinicaltrials.gov/study/NCT02955394,https://clinicaltrials.gov/study/NCT03633331,https://clinicaltrials.gov/study/NCT02206984,https://clinicaltrials.gov/study/NCT04576455,https://clinicaltrials.gov/study/NCT05574881,https://clinicaltrials.gov/study/NCT03056755,https://clinicaltrials.gov/study/NCT04603183,https://clinicaltrials.gov/study/NCT05384119
MONDO_0007254	breast cancer	CHEMBL409	BICALUTAMIDE	Small molecule	Androgen Receptor antagonist		AR	androgen receptor	2	Terminated	https://clinicaltrials.gov/study/NCT02348281
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Epidermal growth factor receptor inhibitor		EGFR	epidermal growth factor receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999
MONDO_0007254	breast cancer	CHEMBL45	MELATONIN	Small molecule	Melatonin receptor agonist		MTNR1A	melatonin receptor 1A	2	Recruiting	https://clinicaltrials.gov/study/NCT02288806
MONDO_0007254	breast cancer	CHEMBL1535	HYDROXYCHLOROQUINE	Small molecule	Toll-like receptor 7 antagonist		TLR7	toll like receptor 7	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03032406
MONDO_0007254	breast cancer	CHEMBL468	THALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		DDB1	damage specific DNA binding protein 1	2	Unknown status	https://clinicaltrials.gov/study/NCT02649101
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC9	histone deacetylase 9	2	Terminated	https://clinicaltrials.gov/study/NCT00777335
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB6	NADH:ubiquinone oxidoreductase subunit B6	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC1	NADH:ubiquinone oxidoreductase subunit C1	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0000432	breast ductal carcinoma in situ	CHEMBL924	ZOLEDRONIC ACID ANHYDROUS	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	2	Completed	https://clinicaltrials.gov/study/NCT01194440
EFO_0005537	triple-negative breast cancer	CHEMBL1421	DASATINIB	Small molecule	Ephrin type-A receptor 2 inhibitor		EPHA2	EPH receptor A2	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06355037
MONDO_0007254	breast cancer	CHEMBL1276308	MIFEPRISTONE	Small molecule	Glucocorticoid receptor antagonist		NR3C1	nuclear receptor subfamily 3 group C member 1	2	Completed	https://clinicaltrials.gov/study/NCT01898312
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB9	NADH:ubiquinone oxidoreductase subunit B9	2	Unknown status	https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT02506777
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT00027989
EFO_0006861	male breast carcinoma	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	2	Completed	https://clinicaltrials.gov/study/NCT00068588
MONDO_0007254	breast cancer	CHEMBL3545414	RIVOCERANIB MESYLATE	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT02768415,https://clinicaltrials.gov/study/NCT03086785,https://clinicaltrials.gov/study/NCT03348098,https://clinicaltrials.gov/study/NCT03457467,https://clinicaltrials.gov/study/NCT03735082
MONDO_0007254	breast cancer	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Unknown status	https://clinicaltrials.gov/study/NCT02607215,https://clinicaltrials.gov/study/NCT01730677,https://clinicaltrials.gov/study/NCT01528826,https://clinicaltrials.gov/study/NCT02144194,https://clinicaltrials.gov/study/NCT03423849,https://clinicaltrials.gov/study/NCT00159094,https://clinicaltrials.gov/study/NCT02768415,https://clinicaltrials.gov/study/NCT02544243
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV2	NADH:ubiquinone oxidoreductase core subunit V2	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Suspended	https://clinicaltrials.gov/study/NCT04419181,https://clinicaltrials.gov/study/NCT02897050
MONDO_0007254	breast cancer	CHEMBL4466233	PEMRAMETOSTAT	Small molecule	Protein arginine N-methyltransferase 5 inhibitor		PRMT5	protein arginine methyltransferase 5	2	Completed	https://clinicaltrials.gov/study/NCT04676516
MONDO_0007254	breast cancer	CHEMBL384467	DEXAMETHASONE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	2	Withdrawn	https://clinicaltrials.gov/study/NCT01825265
MONDO_0007254	breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	2	Terminated	https://clinicaltrials.gov/study/NCT03130439
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT06102824,https://clinicaltrials.gov/study/NCT05601440,https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT04739670,https://clinicaltrials.gov/study/NCT06026657,https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT05181462,https://clinicaltrials.gov/study/NCT03424005
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBB	tubulin beta class I	2	Withdrawn	https://clinicaltrials.gov/study/NCT01227408
MONDO_0007254	breast cancer	CHEMBL3544911	PREXASERTIB	Small molecule	Serine/threonine-protein kinase Chk2 inhibitor		CHEK2	checkpoint kinase 2	2	Terminated	https://clinicaltrials.gov/study/NCT02203513
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04172259,https://clinicaltrials.gov/study/NCT02547987,https://clinicaltrials.gov/study/NCT03161353,https://clinicaltrials.gov/study/NCT01779206,https://clinicaltrials.gov/study/NCT02339532,https://clinicaltrials.gov/study/NCT00496795,https://clinicaltrials.gov/study/NCT02624973,https://clinicaltrials.gov/study/NCT00295893,https://clinicaltrials.gov/study/NCT02568839,https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT03609047
EFO_0006861	male breast carcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC4	histone deacetylase 4	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01349959
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA7	EPH receptor A7	2	Completed	https://clinicaltrials.gov/study/NCT00494481
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT00542451,https://clinicaltrials.gov/study/NCT01091428
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT00321633
EFO_0000305	breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Tyrosine-protein kinase LCK inhibitor		LCK	LCK proto-oncogene, Src family tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
MONDO_0007254	breast cancer	CHEMBL3545396	BMS-690514	Small molecule	Receptor protein-tyrosine kinase erbB-4 inhibitor		ERBB4	erb-b2 receptor tyrosine kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT01068704
EFO_0000304	breast adenocarcinoma	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT03094052
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV3	NADH:ubiquinone oxidoreductase subunit V3	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Unknown status	https://clinicaltrials.gov/study/NCT03144947
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Unknown status	https://clinicaltrials.gov/study/NCT03412955
EFO_0006861	male breast carcinoma	CHEMBL554	LAPATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Terminated	https://clinicaltrials.gov/study/NCT01868503
EFO_0006861	male breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Unknown status	https://clinicaltrials.gov/study/NCT01372579
MONDO_0007254	breast cancer	CHEMBL4594568	KN-026	Unknown	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT04881929
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT02199418
MONDO_0007254	breast cancer	CHEMBL4298085	FIANLIMAB	Antibody	Lymphocyte activation gene 3 protein inhibitor		LAG3	lymphocyte activating 3	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL2105756	TIVOZANIB HYDROCHLORIDE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Terminated	https://clinicaltrials.gov/study/NCT01745367
MONDO_0007254	breast cancer	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 1 inhibitor		HDAC1	histone deacetylase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT00616967
MONDO_0007254	breast cancer	CHEMBL1201583	BEVACIZUMAB	Antibody	Vascular endothelial growth factor A inhibitor		VEGFA	vascular endothelial growth factor A	2	Withdrawn	https://clinicaltrials.gov/study/NCT00964704,https://clinicaltrials.gov/study/NCT05359874
EFO_0005537	triple-negative breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC4	histone deacetylase 4	2	Terminated	https://clinicaltrials.gov/study/NCT01234532
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Recruiting	https://clinicaltrials.gov/study/NCT04924699
MONDO_0007254	breast cancer	CHEMBL742	KETAMINE	Small molecule	Glutamate [NMDA] receptor negative allosteric modulator		GRIN2D	glutamate ionotropic receptor NMDA type subunit 2D	2	Completed	https://clinicaltrials.gov/study/NCT00304850,https://clinicaltrials.gov/study/NCT05727098
EFO_0000432	breast ductal carcinoma in situ	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Terminated	https://clinicaltrials.gov/study/NCT00461344
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Recruiting	https://clinicaltrials.gov/study/NCT05296577,https://clinicaltrials.gov/study/NCT05823623
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Terminated	https://clinicaltrials.gov/study/NCT00159458,https://clinicaltrials.gov/study/NCT02213744,https://clinicaltrials.gov/study/NCT00462865,https://clinicaltrials.gov/study/NCT00674206,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT00679029,https://clinicaltrials.gov/study/NCT00095888,https://clinicaltrials.gov/study/NCT00532285,https://clinicaltrials.gov/study/NCT03674242,https://clinicaltrials.gov/study/NCT00470249,https://clinicaltrials.gov/study/NCT00323063
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Terminated	https://clinicaltrials.gov/study/NCT01498588
MONDO_0007254	breast cancer	CHEMBL3545262	SACITUZUMAB GOVITECAN	Antibody drug conjugate	Tumor-associated calcium signal transducer 2 binding agent		TACSTD2	tumor associated calcium signal transducer 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05113966,https://clinicaltrials.gov/study/NCT04448886,https://clinicaltrials.gov/study/NCT05520723,https://clinicaltrials.gov/study/NCT04434040
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND5	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5	2	Completed	https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT00930579
EFO_0006861	male breast carcinoma	CHEMBL1642	IMATINIB MESYLATE	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00045188
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05833919,https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT04303741
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS2	NADH:ubiquinone oxidoreductase core subunit S2	2	Completed	https://clinicaltrials.gov/study/NCT04170465
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02654119
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT02682693,https://clinicaltrials.gov/study/NCT02199418,https://clinicaltrials.gov/study/NCT00513695
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00376805,https://clinicaltrials.gov/study/NCT00074269
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1094636	NIRAPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT03368729
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02547987,https://clinicaltrials.gov/study/NCT03161353,https://clinicaltrials.gov/study/NCT00295893,https://clinicaltrials.gov/study/NCT04172259,https://clinicaltrials.gov/study/NCT02624973,https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT00496795,https://clinicaltrials.gov/study/NCT02339532,https://clinicaltrials.gov/study/NCT02568839,https://clinicaltrials.gov/study/NCT01779206,https://clinicaltrials.gov/study/NCT03609047
MONDO_0007254	breast cancer	CHEMBL1496	ROSUVASTATIN	Small molecule	HMG-CoA reductase inhibitor		HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase	2	Completed	https://clinicaltrials.gov/study/NCT01299038
MONDO_0007254	breast cancer	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Terminated	https://clinicaltrials.gov/study/NCT03952325,https://clinicaltrials.gov/study/NCT04190056,https://clinicaltrials.gov/study/NCT03051672
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC1	histone deacetylase 1	2	Completed	https://clinicaltrials.gov/study/NCT03291886,https://clinicaltrials.gov/study/NCT00676663,https://clinicaltrials.gov/study/NCT00828854,https://clinicaltrials.gov/study/NCT02708680
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Recruiting	https://clinicaltrials.gov/study/NCT04159142,https://clinicaltrials.gov/study/NCT04893109,https://clinicaltrials.gov/study/NCT05582538,https://clinicaltrials.gov/study/NCT03907800,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT05020860,https://clinicaltrials.gov/study/NCT04676997,https://clinicaltrials.gov/study/NCT05852691,https://clinicaltrials.gov/study/NCT05761470,https://clinicaltrials.gov/study/NCT05189067,https://clinicaltrials.gov/study/NCT01817452,https://clinicaltrials.gov/study/NCT03048942,https://clinicaltrials.gov/study/NCT06245889,https://clinicaltrials.gov/study/NCT05681728,https://clinicaltrials.gov/study/NCT03150576,https://clinicaltrials.gov/study/NCT04780347,https://clinicaltrials.gov/study/NCT05325632,https://clinicaltrials.gov/study/NCT04243616,https://clinicaltrials.gov/study/NCT05749575,https://clinicaltrials.gov/study/NCT04877821,https://clinicaltrials.gov/study/NCT04537286,https://clinicaltrials.gov/study/NCT03412643,https://clinicaltrials.gov/study/NCT03571633,https://clinicaltrials.gov/study/NCT05353361,https://clinicaltrials.gov/study/NCT05728268,https://clinicaltrials.gov/study/NCT04090398,https://clinicaltrials.gov/study/NCT04355858,https://clinicaltrials.gov/study/NCT05346107,https://clinicaltrials.gov/study/NCT04425018,https://clinicaltrials.gov/study/NCT05174832,https://clinicaltrials.gov/study/NCT05629429,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT05447702,https://clinicaltrials.gov/study/NCT05383196,https://clinicaltrials.gov/study/NCT04329065,https://clinicaltrials.gov/study/NCT05889390,https://clinicaltrials.gov/study/NCT05068141,https://clinicaltrials.gov/study/NCT04576143,https://clinicaltrials.gov/study/NCT05633914,https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT04872985,https://clinicaltrials.gov/study/NCT04917900,https://clinicaltrials.gov/study/NCT04771871,https://clinicaltrials.gov/study/NCT05749016,https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT04722718,https://clinicaltrials.gov/study/NCT05918328,https://clinicaltrials.gov/study/NCT05659056,https://clinicaltrials.gov/study/NCT05900206,https://clinicaltrials.gov/study/NCT04443348
MONDO_0007254	breast cancer	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator	Antagonist	ESR1	estrogen receptor 1	2	Recruiting	https://clinicaltrials.gov/study/NCT02476786,https://clinicaltrials.gov/study/NCT03879577,https://clinicaltrials.gov/study/NCT05826964,https://clinicaltrials.gov/study/NCT05101564,https://clinicaltrials.gov/study/NCT05659563,https://clinicaltrials.gov/study/NCT05150652,https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT04985266,https://clinicaltrials.gov/study/NCT05501704,https://clinicaltrials.gov/study/NCT05463601,https://clinicaltrials.gov/study/NCT05472792
MONDO_0007254	breast cancer	CHEMBL298734	LONAFARNIB	Small molecule	Protein farnesyltransferase inhibitor		FNTB	farnesyltransferase, CAAX box, subunit beta	2	Completed	https://clinicaltrials.gov/study/NCT00081510
MONDO_0007254	breast cancer	CHEMBL286738	IROSUSTAT	Small molecule	Steryl-sulfatase inhibitor		STS	steroid sulfatase	2	Terminated	https://clinicaltrials.gov/study/NCT01230970
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Recruiting	https://clinicaltrials.gov/study/NCT03428802
MONDO_0007254	breast cancer	CHEMBL521851	PICTILISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	2	Completed	https://clinicaltrials.gov/study/NCT01740336,https://clinicaltrials.gov/study/NCT01437566
MONDO_0007254	breast cancer	CHEMBL1908360	EVEROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	2	Unknown status	https://clinicaltrials.gov/study/NCT00466102,https://clinicaltrials.gov/study/NCT02313051,https://clinicaltrials.gov/study/NCT00499603,https://clinicaltrials.gov/study/NCT02216786,https://clinicaltrials.gov/study/NCT02025712
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL386630	TESTOSTERONE	Small molecule	Androgen Receptor agonist		AR	androgen receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT00080756
EFO_0006861	male breast carcinoma	CHEMBL2107313	BECATECARIN	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	2	Completed	https://clinicaltrials.gov/study/NCT00005817
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND6	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6	2	Completed	https://clinicaltrials.gov/study/NCT01885013
EFO_0005537	triple-negative breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Suspended	https://clinicaltrials.gov/study/NCT04095689
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967,https://clinicaltrials.gov/study/NCT06027268
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Withdrawn	https://clinicaltrials.gov/study/NCT00615524
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Recruiting	https://clinicaltrials.gov/study/NCT06042569,https://clinicaltrials.gov/study/NCT04266249,https://clinicaltrials.gov/study/NCT05319873
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHB6	EPH receptor B6	2	Completed	https://clinicaltrials.gov/study/NCT00494481
MONDO_0007254	breast cancer	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC2	histone deacetylase 2	2	Completed	https://clinicaltrials.gov/study/NCT00098397
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA5	NADH:ubiquinone oxidoreductase subunit A5	2	Completed	https://clinicaltrials.gov/study/NCT01885013
EFO_0005537	triple-negative breast cancer	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03911973
EFO_0005537	triple-negative breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Recruiting	https://clinicaltrials.gov/study/NCT05670925
EFO_0000432	breast ductal carcinoma in situ	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02779855
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Recruiting	https://clinicaltrials.gov/study/NCT06042569,https://clinicaltrials.gov/study/NCT05319873,https://clinicaltrials.gov/study/NCT04266249
EFO_0000305	breast carcinoma	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Withdrawn	https://clinicaltrials.gov/study/NCT05177796
EFO_1000984	inflammatory breast carcinoma	CHEMBL3301587	DURVALUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	2	Recruiting	https://clinicaltrials.gov/study/NCT05795101
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06078384
EFO_0006318	breast ductal adenocarcinoma	CHEMBL554	LAPATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Terminated	https://clinicaltrials.gov/study/NCT01891357
MONDO_0007254	breast cancer	CHEMBL1200694	SEVOFLURANE	Small molecule	Glycine receptor (alpha-1/beta) positive modulator		GLRA1	glycine receptor alpha 1	2	Completed	https://clinicaltrials.gov/study/NCT02839668
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHB3	EPH receptor B3	2	Completed	https://clinicaltrials.gov/study/NCT00494481
EFO_0005537	triple-negative breast cancer	CHEMBL3187723	BINIMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 2 inhibitor		MAP2K2	mitogen-activated protein kinase kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT03971409
MONDO_0007254	breast cancer	CHEMBL1289494	TIVOZANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Terminated	https://clinicaltrials.gov/study/NCT01745367
MONDO_0007254	breast cancer	CHEMBL4475463	AMCENESTRANT	Small molecule	Estrogen receptor alpha degrader	Antagonist	ESR1	estrogen receptor 1	2	Terminated	https://clinicaltrials.gov/study/NCT04191382
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE1B	phosphodiesterase 1B	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT06186700,https://clinicaltrials.gov/study/NCT06176339
MONDO_0007254	breast cancer	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Terminated	https://clinicaltrials.gov/study/NCT04690855,https://clinicaltrials.gov/study/NCT03499353
MONDO_0007254	breast cancer	CHEMBL3545396	BMS-690514	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Completed	https://clinicaltrials.gov/study/NCT01068704
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Fibroblast growth factor receptor 1 inhibitor		FGFR1	fibroblast growth factor receptor 1	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	2	Terminated	https://clinicaltrials.gov/study/NCT03322215,https://clinicaltrials.gov/study/NCT03709082
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Terminated	https://clinicaltrials.gov/study/NCT03894007,https://clinicaltrials.gov/study/NCT03709082,https://clinicaltrials.gov/study/NCT01702558
MONDO_0007254	breast cancer	CHEMBL223360	LINIFANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT00645177
MONDO_0007254	breast cancer	CHEMBL679	EPINEPHRINE	Small molecule	Adrenergic receptor agonist		ADRB1	adrenoceptor beta 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04603911
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT00006261
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS1	NADH:ubiquinone oxidoreductase core subunit S1	2	Completed	https://clinicaltrials.gov/study/NCT04170465
EFO_0000305	breast carcinoma	CHEMBL3833373	AVELUMAB	Antibody	Programmed cell death 1 ligand 1 other		CD274	CD274 molecule	2	Recruiting	https://clinicaltrials.gov/study/NCT03971409
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB5	NADH:ubiquinone oxidoreductase subunit B5	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL4302409	LUTETIUM OXODOTREOTIDE	Protein	Somatostatin receptor binding agent		SSTR1	somatostatin receptor 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04529044
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT00542451,https://clinicaltrials.gov/study/NCT01091428
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1094636	NIRAPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT04584255
EFO_0005537	triple-negative breast cancer	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06078384,https://clinicaltrials.gov/study/NCT05539365,https://clinicaltrials.gov/study/NCT05741164
MONDO_0007254	breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT04355858
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0005537	triple-negative breast cancer	CHEMBL4297892	ANVATABART OPADOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS6	NADH:ubiquinone oxidoreductase subunit S6	2	Completed	https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT05053841
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF2	NADH:ubiquinone oxidoreductase complex assembly factor 2	2	Recruiting	https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT04559308,https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA7	EPH receptor A7	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Unknown status	https://clinicaltrials.gov/study/NCT00954135,https://clinicaltrials.gov/study/NCT00499525
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHB4	EPH receptor B4	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999
MONDO_0007254	breast cancer	CHEMBL502835	NINTEDANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Terminated	https://clinicaltrials.gov/study/NCT02389764
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	2	Completed	https://clinicaltrials.gov/study/NCT01629615,https://clinicaltrials.gov/study/NCT01923168,https://clinicaltrials.gov/study/NCT01816594,https://clinicaltrials.gov/study/NCT01790932,https://clinicaltrials.gov/study/NCT01572727,https://clinicaltrials.gov/study/NCT02404844
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC1	histone deacetylase 1	2	Completed	https://clinicaltrials.gov/study/NCT00777049
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Unknown status	https://clinicaltrials.gov/study/NCT01372579
MONDO_0007254	breast cancer	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT00509587
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA10	NADH:ubiquinone oxidoreductase subunit A10	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT01908101
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA13	NADH:ubiquinone oxidoreductase subunit A13	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA3	NADH:ubiquinone oxidoreductase subunit A3	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000304	breast adenocarcinoma	CHEMBL2146146	ATROPINE SULFATE	Small molecule	Muscarinic acetylcholine receptor M1 antagonist		CHRM1	cholinergic receptor muscarinic 1	2	Completed	https://clinicaltrials.gov/study/NCT03094052
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT02199418
EFO_0005537	triple-negative breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03639948
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Terminated	https://clinicaltrials.gov/study/NCT02978716
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02414646
EFO_0006861	male breast carcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC3	histone deacetylase 3	2	Completed	https://clinicaltrials.gov/study/NCT00098397
MONDO_0007254	breast cancer	CHEMBL1201748	CABAZITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Terminated	https://clinicaltrials.gov/study/NCT01934894
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA10	NADH:ubiquinone oxidoreductase subunit A10	2	Recruiting	https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT04559308,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04300790
MONDO_0007254	breast cancer	CHEMBL20684	ABT-751	Small molecule	Tubulin beta inhibitor		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT00063102
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	Adenosine A2 receptor antagonist		ADORA2A	adenosine A2a receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT06087237
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT00232479,https://clinicaltrials.gov/study/NCT00028873,https://clinicaltrials.gov/study/NCT00545688,https://clinicaltrials.gov/study/NCT02365805,https://clinicaltrials.gov/study/NCT02834403,https://clinicaltrials.gov/study/NCT00149214,https://clinicaltrials.gov/study/NCT00123929,https://clinicaltrials.gov/study/NCT01025349,https://clinicaltrials.gov/study/NCT00428922,https://clinicaltrials.gov/study/NCT00006682,https://clinicaltrials.gov/study/NCT00217672,https://clinicaltrials.gov/study/NCT00148668,https://clinicaltrials.gov/study/NCT00004888,https://clinicaltrials.gov/study/NCT00193050,https://clinicaltrials.gov/study/NCT04664972,https://clinicaltrials.gov/study/NCT01671319,https://clinicaltrials.gov/study/NCT00003352,https://clinicaltrials.gov/study/NCT00379015,https://clinicaltrials.gov/study/NCT00769470,https://clinicaltrials.gov/study/NCT01446016,https://clinicaltrials.gov/study/NCT00493649,https://clinicaltrials.gov/study/NCT00004906,https://clinicaltrials.gov/study/NCT00604435,https://clinicaltrials.gov/study/NCT00404066,https://clinicaltrials.gov/study/NCT00193180,https://clinicaltrials.gov/study/NCT00005963,https://clinicaltrials.gov/study/NCT00600249,https://clinicaltrials.gov/study/NCT00041067,https://clinicaltrials.gov/study/NCT03140553,https://clinicaltrials.gov/study/NCT02748213,https://clinicaltrials.gov/study/NCT00079118,https://clinicaltrials.gov/study/NCT00248703,https://clinicaltrials.gov/study/NCT02838225,https://clinicaltrials.gov/study/NCT00490646,https://clinicaltrials.gov/study/NCT01540110,https://clinicaltrials.gov/study/NCT00066443,https://clinicaltrials.gov/study/NCT00773695,https://clinicaltrials.gov/study/NCT00212082,https://clinicaltrials.gov/study/NCT00475670,https://clinicaltrials.gov/study/NCT01150513,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT02132949,https://clinicaltrials.gov/study/NCT00054275,https://clinicaltrials.gov/study/NCT01959490,https://clinicaltrials.gov/study/NCT02137083,https://clinicaltrials.gov/study/NCT01792050,https://clinicaltrials.gov/study/NCT00179309,https://clinicaltrials.gov/study/NCT00820872,https://clinicaltrials.gov/study/NCT00499122,https://clinicaltrials.gov/study/NCT00364611,https://clinicaltrials.gov/study/NCT00941330,https://clinicaltrials.gov/study/NCT00319618,https://clinicaltrials.gov/study/NCT00976989,https://clinicaltrials.gov/study/NCT00146042,https://clinicaltrials.gov/study/NCT00055861,https://clinicaltrials.gov/study/NCT00027885,https://clinicaltrials.gov/study/NCT00191243,https://clinicaltrials.gov/study/NCT03742986,https://clinicaltrials.gov/study/NCT00068341,https://clinicaltrials.gov/study/NCT01208480,https://clinicaltrials.gov/study/NCT00201708,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT01485926,https://clinicaltrials.gov/study/NCT00524810,https://clinicaltrials.gov/study/NCT00527449,https://clinicaltrials.gov/study/NCT00077857,https://clinicaltrials.gov/study/NCT00003565,https://clinicaltrials.gov/study/NCT00193089,https://clinicaltrials.gov/study/NCT03887130,https://clinicaltrials.gov/study/NCT00820547,https://clinicaltrials.gov/study/NCT00214864,https://clinicaltrials.gov/study/NCT02229084,https://clinicaltrials.gov/study/NCT00206466,https://clinicaltrials.gov/study/NCT01038804,https://clinicaltrials.gov/study/NCT00005800,https://clinicaltrials.gov/study/NCT00015938,https://clinicaltrials.gov/study/NCT00193115,https://clinicaltrials.gov/study/NCT00464646,https://clinicaltrials.gov/study/NCT00203372,https://clinicaltrials.gov/study/NCT00559754,https://clinicaltrials.gov/study/NCT00494481,https://clinicaltrials.gov/study/NCT00039520,https://clinicaltrials.gov/study/NCT00365365,https://clinicaltrials.gov/study/NCT00206518,https://clinicaltrials.gov/study/NCT02909751,https://clinicaltrials.gov/study/NCT00754351,https://clinicaltrials.gov/study/NCT00148070,https://clinicaltrials.gov/study/NCT00193037,https://clinicaltrials.gov/study/NCT01142778,https://clinicaltrials.gov/study/NCT00258375,https://clinicaltrials.gov/study/NCT00015886,https://clinicaltrials.gov/study/NCT02005549,https://clinicaltrials.gov/study/NCT00129376,https://clinicaltrials.gov/study/NCT00712881,https://clinicaltrials.gov/study/NCT00247481,https://clinicaltrials.gov/study/NCT00107510,https://clinicaltrials.gov/study/NCT00044993,https://clinicaltrials.gov/study/NCT00525759,https://clinicaltrials.gov/study/NCT01396655,https://clinicaltrials.gov/study/NCT00209092,https://clinicaltrials.gov/study/NCT00005908,https://clinicaltrials.gov/study/NCT00695994,https://clinicaltrials.gov/study/NCT00088998,https://clinicaltrials.gov/study/NCT00004175,https://clinicaltrials.gov/study/NCT00006104,https://clinicaltrials.gov/study/NCT00203502,https://clinicaltrials.gov/study/NCT00274456,https://clinicaltrials.gov/study/NCT00003953,https://clinicaltrials.gov/study/NCT02846428,https://clinicaltrials.gov/study/NCT02041351,https://clinicaltrials.gov/study/NCT00212095,https://clinicaltrials.gov/study/NCT00198237,https://clinicaltrials.gov/study/NCT00841828,https://clinicaltrials.gov/study/NCT00645866,https://clinicaltrials.gov/study/NCT01367028,https://clinicaltrials.gov/study/NCT00155259,https://clinicaltrials.gov/study/NCT00679341,https://clinicaltrials.gov/study/NCT01658462,https://clinicaltrials.gov/study/NCT00432172,https://clinicaltrials.gov/study/NCT03735966,https://clinicaltrials.gov/study/NCT01527487,https://clinicaltrials.gov/study/NCT00365417,https://clinicaltrials.gov/study/NCT00206505
EFO_0005537	triple-negative breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT05670925
EFO_0006861	male breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Tyrosine-protein kinase ITK/TSK inhibitor		ITK	IL2 inducible T cell kinase	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
MONDO_0007254	breast cancer	CHEMBL1201748	CABAZITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Terminated	https://clinicaltrials.gov/study/NCT01934894
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Unknown status	https://clinicaltrials.gov/study/NCT03412955,https://clinicaltrials.gov/study/NCT02175446
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Terminated	https://clinicaltrials.gov/study/NCT00636441,https://clinicaltrials.gov/study/NCT01985841,https://clinicaltrials.gov/study/NCT00576901,https://clinicaltrials.gov/study/NCT03329378,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT00225056,https://clinicaltrials.gov/study/NCT00852332,https://clinicaltrials.gov/study/NCT03894007,https://clinicaltrials.gov/study/NCT00665457,https://clinicaltrials.gov/study/NCT00118053,https://clinicaltrials.gov/study/NCT00193024,https://clinicaltrials.gov/study/NCT00025493,https://clinicaltrials.gov/study/NCT00028483,https://clinicaltrials.gov/study/NCT00206453,https://clinicaltrials.gov/study/NCT00453635,https://clinicaltrials.gov/study/NCT00080626,https://clinicaltrials.gov/study/NCT00343512,https://clinicaltrials.gov/study/NCT00524459,https://clinicaltrials.gov/study/NCT00479856,https://clinicaltrials.gov/study/NCT01690325,https://clinicaltrials.gov/study/NCT00104624,https://clinicaltrials.gov/study/NCT00845910,https://clinicaltrials.gov/study/NCT00476827
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Completed	https://clinicaltrials.gov/study/NCT03167619,https://clinicaltrials.gov/study/NCT03205761
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Unknown status	https://clinicaltrials.gov/study/NCT00499525,https://clinicaltrials.gov/study/NCT00954135
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		LYN	LYN proto-oncogene, Src family tyrosine kinase	2	Withdrawn	https://clinicaltrials.gov/study/NCT01410708
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	Ephrin type-A receptor 2 inhibitor		EPHA2	EPH receptor A2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01471106
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT00494481
MONDO_0007254	breast cancer	CHEMBL256147	TILARGININE	Small molecule	Nitric oxide synthase inhibitor		NOS3	nitric oxide synthase 3	2	Completed	https://clinicaltrials.gov/study/NCT02834403
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Terminated	https://clinicaltrials.gov/study/NCT03795012,https://clinicaltrials.gov/study/NCT02681523,https://clinicaltrials.gov/study/NCT01498588,https://clinicaltrials.gov/study/NCT02000596,https://clinicaltrials.gov/study/NCT01912963,https://clinicaltrials.gov/study/NCT01534455
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT02544243,https://clinicaltrials.gov/study/NCT00027989,https://clinicaltrials.gov/study/NCT03423849,https://clinicaltrials.gov/study/NCT01352494,https://clinicaltrials.gov/study/NCT02341911
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Withdrawn	https://clinicaltrials.gov/study/NCT03032614
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Withdrawn	https://clinicaltrials.gov/study/NCT00678626,https://clinicaltrials.gov/study/NCT00964704,https://clinicaltrials.gov/study/NCT02067416,https://clinicaltrials.gov/study/NCT00434031,https://clinicaltrials.gov/study/NCT01229605,https://clinicaltrials.gov/study/NCT01825265,https://clinicaltrials.gov/study/NCT00006261
MONDO_0007254	breast cancer	CHEMBL4298025	ZENOCUTUZUMAB	Antibody	ErbB-2/ErbB-3 heterodimer inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT03321981
MONDO_0007254	breast cancer	CHEMBL3989868	TUCATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT05748834,https://clinicaltrials.gov/study/NCT05041842,https://clinicaltrials.gov/study/NCT05458674,https://clinicaltrials.gov/study/NCT04789096,https://clinicaltrials.gov/study/NCT05892068,https://clinicaltrials.gov/study/NCT05230810,https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05263882,https://clinicaltrials.gov/study/NCT04517292,https://clinicaltrials.gov/study/NCT04143906
MONDO_0007254	breast cancer	CHEMBL1201167	CARVEDILOL PHOSPHATE	Small molecule	Adrenergic receptor beta antagonist		ADRB3	adrenoceptor beta 3	2	Completed	https://clinicaltrials.gov/study/NCT01009918
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT05498155,https://clinicaltrials.gov/study/NCT05033756,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT06245889,https://clinicaltrials.gov/study/NCT05629429,https://clinicaltrials.gov/study/NCT03150576,https://clinicaltrials.gov/study/NCT05203445,https://clinicaltrials.gov/study/NCT03025035,https://clinicaltrials.gov/study/NCT06298084,https://clinicaltrials.gov/study/NCT05332561,https://clinicaltrials.gov/study/NCT05174832,https://clinicaltrials.gov/study/NCT03182634
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4L2	NDUFA4 mitochondrial complex associated like 2	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT01908101
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS6	NADH:ubiquinone oxidoreductase subunit S6	2	Recruiting	https://clinicaltrials.gov/study/NCT04559308,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT01042379
EFO_0005537	triple-negative breast cancer	CHEMBL1908360	EVEROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	2	Completed	https://clinicaltrials.gov/study/NCT02456857
EFO_0005537	triple-negative breast cancer	CHEMBL2325741	CAPIVASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT2	AKT serine/threonine kinase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02208375
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS3	NADH:ubiquinone oxidoreductase core subunit S3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Withdrawn	https://clinicaltrials.gov/study/NCT04351230
EFO_0006861	male breast carcinoma	CHEMBL535	SUNITINIB	Small molecule	Platelet-derived growth factor receptor alpha inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Completed	https://clinicaltrials.gov/study/NCT00513695
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Enrolling by invitation	https://clinicaltrials.gov/study/NCT03580395
MONDO_0007254	breast cancer	CHEMBL4650316	GIREDESTRANT	Small molecule	Estrogen receptor alpha degrader	Antagonist	ESR1	estrogen receptor 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05896566,https://clinicaltrials.gov/study/NCT04802759,https://clinicaltrials.gov/study/NCT05659563
MONDO_0007254	breast cancer	CHEMBL482968	ENMD-2076	Small molecule	Fibroblast growth factor receptor 3 inhibitor		FGFR3	fibroblast growth factor receptor 3	2	Completed	https://clinicaltrials.gov/study/NCT01639248
MONDO_0007254	breast cancer	CHEMBL650	METHYLPREDNISOLONE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	2	Completed	https://clinicaltrials.gov/study/NCT01105650
MONDO_0007254	breast cancer	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04301375,https://clinicaltrials.gov/study/NCT04246502,https://clinicaltrials.gov/study/NCT05983094,https://clinicaltrials.gov/study/NCT04900311
MONDO_0007254	breast cancer	CHEMBL2325741	CAPIVASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT2	AKT serine/threonine kinase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02208375,https://clinicaltrials.gov/study/NCT02299999
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05263882,https://clinicaltrials.gov/study/NCT04502680,https://clinicaltrials.gov/study/NCT06202313,https://clinicaltrials.gov/study/NCT06308939,https://clinicaltrials.gov/study/NCT04517292,https://clinicaltrials.gov/study/NCT04913571
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999
MONDO_0007254	breast cancer	CHEMBL4650365	CAMIZESTRANT	Small molecule	Estrogen receptor alpha degrader	Antagonist	ESR1	estrogen receptor 1	2	Completed	https://clinicaltrials.gov/study/NCT04588298
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Unknown status	https://clinicaltrials.gov/study/NCT03412955
MONDO_0007254	breast cancer	CHEMBL1095097	EPLERENONE	Small molecule	Mineralocorticoid receptor antagonist		NR3C2	nuclear receptor subfamily 3 group C member 2	2	Terminated	https://clinicaltrials.gov/study/NCT01708798
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT02435680,https://clinicaltrials.gov/study/NCT00325234,https://clinicaltrials.gov/study/NCT00191789,https://clinicaltrials.gov/study/NCT00191373,https://clinicaltrials.gov/study/NCT00320541,https://clinicaltrials.gov/study/NCT00193050,https://clinicaltrials.gov/study/NCT00493636,https://clinicaltrials.gov/study/NCT00201760,https://clinicaltrials.gov/study/NCT00193063,https://clinicaltrials.gov/study/NCT00003540,https://clinicaltrials.gov/study/NCT00063570,https://clinicaltrials.gov/study/NCT00191815,https://clinicaltrials.gov/study/NCT01045304,https://clinicaltrials.gov/study/NCT00403130,https://clinicaltrials.gov/study/NCT00002998,https://clinicaltrials.gov/study/NCT03025880,https://clinicaltrials.gov/study/NCT00695994,https://clinicaltrials.gov/study/NCT00662129,https://clinicaltrials.gov/study/NCT01201265,https://clinicaltrials.gov/study/NCT00532857,https://clinicaltrials.gov/study/NCT00601159,https://clinicaltrials.gov/study/NCT00316199,https://clinicaltrials.gov/study/NCT00006007,https://clinicaltrials.gov/study/NCT00846027,https://clinicaltrials.gov/study/NCT00191347,https://clinicaltrials.gov/study/NCT00110084,https://clinicaltrials.gov/study/NCT00192101,https://clinicaltrials.gov/study/NCT02263495,https://clinicaltrials.gov/study/NCT01550848,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00192062,https://clinicaltrials.gov/study/NCT00191451,https://clinicaltrials.gov/study/NCT00813956,https://clinicaltrials.gov/study/NCT00378313,https://clinicaltrials.gov/study/NCT00005991,https://clinicaltrials.gov/study/NCT00480597,https://clinicaltrials.gov/study/NCT00193206,https://clinicaltrials.gov/study/NCT00540358,https://clinicaltrials.gov/study/NCT00244933,https://clinicaltrials.gov/study/NCT00191269,https://clinicaltrials.gov/study/NCT00212069,https://clinicaltrials.gov/study/NCT00450762,https://clinicaltrials.gov/study/NCT00618826,https://clinicaltrials.gov/study/NCT04464174,https://clinicaltrials.gov/study/NCT00503906,https://clinicaltrials.gov/study/NCT00191243,https://clinicaltrials.gov/study/NCT00623233,https://clinicaltrials.gov/study/NCT00754351,https://clinicaltrials.gov/study/NCT00532623,https://clinicaltrials.gov/study/NCT00059852,https://clinicaltrials.gov/study/NCT00193076,https://clinicaltrials.gov/study/NCT00334802,https://clinicaltrials.gov/study/NCT00191854,https://clinicaltrials.gov/study/NCT00894504,https://clinicaltrials.gov/study/NCT00128856
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT00321633
MONDO_0007254	breast cancer	CHEMBL2109512	MCS-110	Antibody	Macrophage colony-stimulating factor 1 inhibitor		CSF1	colony stimulating factor 1	2	Completed	https://clinicaltrials.gov/study/NCT02435680
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05041101,https://clinicaltrials.gov/study/NCT03202316
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Terminated	https://clinicaltrials.gov/study/NCT03329378,https://clinicaltrials.gov/study/NCT00456846,https://clinicaltrials.gov/study/NCT01069796,https://clinicaltrials.gov/study/NCT00691912,https://clinicaltrials.gov/study/NCT00934895,https://clinicaltrials.gov/study/NCT00589238,https://clinicaltrials.gov/study/NCT00356681,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT00479856,https://clinicaltrials.gov/study/NCT01120158,https://clinicaltrials.gov/study/NCT00607438,https://clinicaltrials.gov/study/NCT01416558,https://clinicaltrials.gov/study/NCT04066790,https://clinicaltrials.gov/study/NCT00622466,https://clinicaltrials.gov/study/NCT03894007,https://clinicaltrials.gov/study/NCT00434356,https://clinicaltrials.gov/study/NCT01147016,https://clinicaltrials.gov/study/NCT00542191,https://clinicaltrials.gov/study/NCT00756470,https://clinicaltrials.gov/study/NCT00532285,https://clinicaltrials.gov/study/NCT01745367,https://clinicaltrials.gov/study/NCT02322814,https://clinicaltrials.gov/study/NCT00536939,https://clinicaltrials.gov/study/NCT01207102,https://clinicaltrials.gov/study/NCT01329627,https://clinicaltrials.gov/study/NCT00194792,https://clinicaltrials.gov/study/NCT01009983,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT02598310,https://clinicaltrials.gov/study/NCT00679029,https://clinicaltrials.gov/study/NCT01194869
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB4	NADH:ubiquinone oxidoreductase subunit B4	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 3 inhibitor		HDAC3	histone deacetylase 3	2	Completed	https://clinicaltrials.gov/study/NCT00365599,https://clinicaltrials.gov/study/NCT00262834
EFO_0000304	breast adenocarcinoma	CHEMBL517712	ATROPINE	Small molecule	Muscarinic acetylcholine receptor M1 antagonist		CHRM1	cholinergic receptor muscarinic 1	2	Completed	https://clinicaltrials.gov/study/NCT03094052
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND1	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0005537	triple-negative breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03639948
EFO_0006861	male breast carcinoma	CHEMBL1336	SORAFENIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00096434
MONDO_0007254	breast cancer	CHEMBL1173655	AFATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Unknown status	https://clinicaltrials.gov/study/NCT02511847
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT00593827,https://clinicaltrials.gov/study/NCT00077376,https://clinicaltrials.gov/study/NCT00455533,https://clinicaltrials.gov/study/NCT00490646,https://clinicaltrials.gov/study/NCT01446016,https://clinicaltrials.gov/study/NCT00045097,https://clinicaltrials.gov/study/NCT00370552,https://clinicaltrials.gov/study/NCT00627978,https://clinicaltrials.gov/study/NCT01027208,https://clinicaltrials.gov/study/NCT01097642,https://clinicaltrials.gov/study/NCT00821886,https://clinicaltrials.gov/study/NCT00751868,https://clinicaltrials.gov/study/NCT01019577,https://clinicaltrials.gov/study/NCT00866905,https://clinicaltrials.gov/study/NCT00020904,https://clinicaltrials.gov/study/NCT01416389,https://clinicaltrials.gov/study/NCT00633464,https://clinicaltrials.gov/study/NCT00879086,https://clinicaltrials.gov/study/NCT00080262,https://clinicaltrials.gov/study/NCT01075100
MONDO_0007254	breast cancer	CHEMBL4303525	OMAVELOXOLONE	Small molecule	Nuclear factor erythroid 2-related factor 2 activator		NFE2L2	NFE2 like bZIP transcription factor 2	2	Completed	https://clinicaltrials.gov/study/NCT02142959
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist	Antagonist	ESR2	estrogen receptor 2	2	Terminated	https://clinicaltrials.gov/study/NCT03289039,https://clinicaltrials.gov/study/NCT00752986,https://clinicaltrials.gov/study/NCT05085002,https://clinicaltrials.gov/study/NCT03322215,https://clinicaltrials.gov/study/NCT02000596,https://clinicaltrials.gov/study/NCT03430466,https://clinicaltrials.gov/study/NCT00570258,https://clinicaltrials.gov/study/NCT01528345,https://clinicaltrials.gov/study/NCT00206414,https://clinicaltrials.gov/study/NCT03584009,https://clinicaltrials.gov/study/NCT02269670,https://clinicaltrials.gov/study/NCT03241810,https://clinicaltrials.gov/study/NCT04862143,https://clinicaltrials.gov/study/NCT02569801,https://clinicaltrials.gov/study/NCT00138125,https://clinicaltrials.gov/study/NCT00722072,https://clinicaltrials.gov/study/NCT04899349
MONDO_0007254	breast cancer	CHEMBL4650215	INAVOLISIB	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT04849364,https://clinicaltrials.gov/study/NCT05332561,https://clinicaltrials.gov/study/NCT04802759,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT05306041
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Withdrawn	https://clinicaltrials.gov/study/NCT05809895,https://clinicaltrials.gov/study/NCT03058939,https://clinicaltrials.gov/study/NCT01163929,https://clinicaltrials.gov/study/NCT03554109,https://clinicaltrials.gov/study/NCT04038489,https://clinicaltrials.gov/study/NCT02053597,https://clinicaltrials.gov/study/NCT03841747,https://clinicaltrials.gov/study/NCT00397761,https://clinicaltrials.gov/study/NCT03872505,https://clinicaltrials.gov/study/NCT01169870,https://clinicaltrials.gov/study/NCT02067416
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT00006007,https://clinicaltrials.gov/study/NCT00005991,https://clinicaltrials.gov/study/NCT00002998,https://clinicaltrials.gov/study/NCT00662129,https://clinicaltrials.gov/study/NCT00059852,https://clinicaltrials.gov/study/NCT00003540
MONDO_0007254	breast cancer	CHEMBL415606	DEGARELIX	Protein	Gonadotropin-releasing hormone receptor antagonist		GNRHR	gonadotropin releasing hormone receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT05501704
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC2	histone deacetylase 2	2	Completed	https://clinicaltrials.gov/study/NCT00777049
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT04408118,https://clinicaltrials.gov/study/NCT03853707,https://clinicaltrials.gov/study/NCT01969032,https://clinicaltrials.gov/study/NCT01446016,https://clinicaltrials.gov/study/NCT00479674,https://clinicaltrials.gov/study/NCT00645177,https://clinicaltrials.gov/study/NCT00002679,https://clinicaltrials.gov/study/NCT04224922,https://clinicaltrials.gov/study/NCT02370238,https://clinicaltrials.gov/study/NCT00028873,https://clinicaltrials.gov/study/NCT02365805,https://clinicaltrials.gov/study/NCT01432223,https://clinicaltrials.gov/study/NCT01705691,https://clinicaltrials.gov/study/NCT02225652,https://clinicaltrials.gov/study/NCT02783222,https://clinicaltrials.gov/study/NCT02229084,https://clinicaltrials.gov/study/NCT02301988,https://clinicaltrials.gov/study/NCT00455533,https://clinicaltrials.gov/study/NCT00475670,https://clinicaltrials.gov/study/NCT01565499,https://clinicaltrials.gov/study/NCT00795899,https://clinicaltrials.gov/study/NCT00580333,https://clinicaltrials.gov/study/NCT00193206,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00482391,https://clinicaltrials.gov/study/NCT01973660,https://clinicaltrials.gov/study/NCT00003035,https://clinicaltrials.gov/study/NCT01672671,https://clinicaltrials.gov/study/NCT02789657,https://clinicaltrials.gov/study/NCT01276041,https://clinicaltrials.gov/study/NCT05112536,https://clinicaltrials.gov/study/NCT00733408,https://clinicaltrials.gov/study/NCT00503750,https://clinicaltrials.gov/study/NCT00096291,https://clinicaltrials.gov/study/NCT01688609,https://clinicaltrials.gov/study/NCT03326102,https://clinicaltrials.gov/study/NCT00194779,https://clinicaltrials.gov/study/NCT00394251,https://clinicaltrials.gov/study/NCT02687490,https://clinicaltrials.gov/study/NCT03289819,https://clinicaltrials.gov/study/NCT02685059,https://clinicaltrials.gov/study/NCT00052351,https://clinicaltrials.gov/study/NCT00499083,https://clinicaltrials.gov/study/NCT01959490,https://clinicaltrials.gov/study/NCT00436566,https://clinicaltrials.gov/study/NCT00096343,https://clinicaltrials.gov/study/NCT01847001,https://clinicaltrials.gov/study/NCT00629499,https://clinicaltrials.gov/study/NCT01835236,https://clinicaltrials.gov/study/NCT00110084,https://clinicaltrials.gov/study/NCT00546156,https://clinicaltrials.gov/study/NCT00003612,https://clinicaltrials.gov/study/NCT00136539,https://clinicaltrials.gov/study/NCT00403130,https://clinicaltrials.gov/study/NCT02909751,https://clinicaltrials.gov/study/NCT00618657,https://clinicaltrials.gov/study/NCT01989780,https://clinicaltrials.gov/study/NCT03121352,https://clinicaltrials.gov/study/NCT00559845,https://clinicaltrials.gov/study/NCT00002937,https://clinicaltrials.gov/study/NCT02938442,https://clinicaltrials.gov/study/NCT00007904,https://clinicaltrials.gov/study/NCT01779479,https://clinicaltrials.gov/study/NCT01656538,https://clinicaltrials.gov/study/NCT00392392,https://clinicaltrials.gov/study/NCT00618826,https://clinicaltrials.gov/study/NCT01827163,https://clinicaltrials.gov/study/NCT00675259,https://clinicaltrials.gov/study/NCT00930930,https://clinicaltrials.gov/study/NCT00005649,https://clinicaltrials.gov/study/NCT00503906,https://clinicaltrials.gov/study/NCT01855828,https://clinicaltrials.gov/study/NCT01816594,https://clinicaltrials.gov/study/NCT01204125,https://clinicaltrials.gov/study/NCT02132949,https://clinicaltrials.gov/study/NCT00768859,https://clinicaltrials.gov/study/NCT00662129,https://clinicaltrials.gov/study/NCT00001498,https://clinicaltrials.gov/study/NCT01792050,https://clinicaltrials.gov/study/NCT01256762,https://clinicaltrials.gov/study/NCT00394082,https://clinicaltrials.gov/study/NCT00003392,https://clinicaltrials.gov/study/NCT00128856,https://clinicaltrials.gov/study/NCT03982485,https://clinicaltrials.gov/study/NCT01203267,https://clinicaltrials.gov/study/NCT00093145,https://clinicaltrials.gov/study/NCT01320111,https://clinicaltrials.gov/study/NCT00001384,https://clinicaltrials.gov/study/NCT01423695,https://clinicaltrials.gov/study/NCT02628613,https://clinicaltrials.gov/study/NCT03248427,https://clinicaltrials.gov/study/NCT01106898,https://clinicaltrials.gov/study/NCT00191854,https://clinicaltrials.gov/study/NCT00146562,https://clinicaltrials.gov/study/NCT02474186,https://clinicaltrials.gov/study/NCT00532857,https://clinicaltrials.gov/study/NCT01307891,https://clinicaltrials.gov/study/NCT00915018,https://clinicaltrials.gov/study/NCT00096668,https://clinicaltrials.gov/study/NCT00654836,https://clinicaltrials.gov/study/NCT00256243,https://clinicaltrials.gov/study/NCT01740336,https://clinicaltrials.gov/study/NCT01722968,https://clinicaltrials.gov/study/NCT00006256,https://clinicaltrials.gov/study/NCT00856492,https://clinicaltrials.gov/study/NCT01008150,https://clinicaltrials.gov/study/NCT00334802,https://clinicaltrials.gov/study/NCT00019812,https://clinicaltrials.gov/study/NCT00635050,https://clinicaltrials.gov/study/NCT01190982,https://clinicaltrials.gov/study/NCT00003050,https://clinicaltrials.gov/study/NCT00407888,https://clinicaltrials.gov/study/NCT01506609,https://clinicaltrials.gov/study/NCT03301350,https://clinicaltrials.gov/study/NCT03887130,https://clinicaltrials.gov/study/NCT00944047,https://clinicaltrials.gov/study/NCT00148681,https://clinicaltrials.gov/study/NCT00004092,https://clinicaltrials.gov/study/NCT00002826,https://clinicaltrials.gov/study/NCT00773695,https://clinicaltrials.gov/study/NCT01594177,https://clinicaltrials.gov/study/NCT00919880,https://clinicaltrials.gov/study/NCT00005635,https://clinicaltrials.gov/study/NCT00251472,https://clinicaltrials.gov/study/NCT00274456,https://clinicaltrials.gov/study/NCT00320541,https://clinicaltrials.gov/study/NCT00971945,https://clinicaltrials.gov/study/NCT01023204,https://clinicaltrials.gov/study/NCT00846027,https://clinicaltrials.gov/study/NCT01617668,https://clinicaltrials.gov/study/NCT00006110,https://clinicaltrials.gov/study/NCT00004013,https://clinicaltrials.gov/study/NCT01593020,https://clinicaltrials.gov/study/NCT02954055,https://clinicaltrials.gov/study/NCT03742986,https://clinicaltrials.gov/study/NCT03644186,https://clinicaltrials.gov/study/NCT01204437,https://clinicaltrials.gov/study/NCT00254592,https://clinicaltrials.gov/study/NCT00915603,https://clinicaltrials.gov/study/NCT00370552,https://clinicaltrials.gov/study/NCT01982448,https://clinicaltrials.gov/study/NCT00003539,https://clinicaltrials.gov/study/NCT00316199,https://clinicaltrials.gov/study/NCT00723125,https://clinicaltrials.gov/study/NCT00072319,https://clinicaltrials.gov/study/NCT02698891,https://clinicaltrials.gov/study/NCT01818063,https://clinicaltrials.gov/study/NCT01421472,https://clinicaltrials.gov/study/NCT03072992,https://clinicaltrials.gov/study/NCT02280252,https://clinicaltrials.gov/study/NCT00467012,https://clinicaltrials.gov/study/NCT00003992,https://clinicaltrials.gov/study/NCT01036087,https://clinicaltrials.gov/study/NCT02073487,https://clinicaltrials.gov/study/NCT03193853,https://clinicaltrials.gov/study/NCT02263495,https://clinicaltrials.gov/study/NCT01186991,https://clinicaltrials.gov/study/NCT00378313,https://clinicaltrials.gov/study/NCT00542451,https://clinicaltrials.gov/study/NCT01572727,https://clinicaltrials.gov/study/NCT00511459
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02414646
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1173055	RUCAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	2	Completed	https://clinicaltrials.gov/study/NCT00664781
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT00570908,https://clinicaltrials.gov/study/NCT00434356,https://clinicaltrials.gov/study/NCT00824538
EFO_0005537	triple-negative breast cancer	CHEMBL3545132	MIRVETUXIMAB SORAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBA1C	tubulin alpha 1c	2	Completed	https://clinicaltrials.gov/study/NCT03106077
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134,https://clinicaltrials.gov/study/NCT04290793,https://clinicaltrials.gov/study/NCT06291064,https://clinicaltrials.gov/study/NCT04034823
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4L	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L	2	Unknown status	https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT02506777
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV3	NADH:ubiquinone oxidoreductase subunit V3	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL2105756	TIVOZANIB HYDROCHLORIDE	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Terminated	https://clinicaltrials.gov/study/NCT01745367
EFO_0006861	male breast carcinoma	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01349959
EFO_0006861	male breast carcinoma	CHEMBL231616	TRIAPINE	Small molecule	Ribonucleotide reductase inhibitor		RRM2B	ribonucleotide reductase regulatory TP53 inducible subunit M2B	2	Terminated	https://clinicaltrials.gov/study/NCT00095888
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Enrolling by invitation	https://clinicaltrials.gov/study/NCT03580395
MONDO_0007254	breast cancer	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT00499525
EFO_0000305	breast carcinoma	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Completed	https://clinicaltrials.gov/study/NCT03164993,https://clinicaltrials.gov/study/NCT01885013,https://clinicaltrials.gov/study/NCT02456857
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA2	NADH:ubiquinone oxidoreductase subunit A2	2	Unknown status	https://clinicaltrials.gov/study/NCT02506777,https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT03192293
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Unknown status	https://clinicaltrials.gov/study/NCT03423849,https://clinicaltrials.gov/study/NCT02607215,https://clinicaltrials.gov/study/NCT02544243,https://clinicaltrials.gov/study/NCT02144194,https://clinicaltrials.gov/study/NCT00159094,https://clinicaltrials.gov/study/NCT02768415,https://clinicaltrials.gov/study/NCT01730677,https://clinicaltrials.gov/study/NCT01528826
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1201670	SARGRAMOSTIM	Protein	Granulocyte-macrophage colony-stimulating factor receptor agonist		CSF2RA	colony stimulating factor 2 receptor subunit alpha	2	Completed	https://clinicaltrials.gov/study/NCT02636582
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT01196052,https://clinicaltrials.gov/study/NCT00509769,https://clinicaltrials.gov/study/NCT00679211,https://clinicaltrials.gov/study/NCT01904903,https://clinicaltrials.gov/study/NCT01835236,https://clinicaltrials.gov/study/NCT02924883,https://clinicaltrials.gov/study/NCT03530696,https://clinicaltrials.gov/study/NCT00943670,https://clinicaltrials.gov/study/NCT00679341,https://clinicaltrials.gov/study/NCT02073487
MONDO_0007254	breast cancer	CHEMBL2220486	LUCITANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Terminated	https://clinicaltrials.gov/study/NCT02202746
EFO_0000304	breast adenocarcinoma	CHEMBL517712	ATROPINE	Small molecule	Muscarinic acetylcholine receptor M2 antagonist		CHRM2	cholinergic receptor muscarinic 2	2	Completed	https://clinicaltrials.gov/study/NCT03094052
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA5	NADH:ubiquinone oxidoreductase subunit A5	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0006861	male breast carcinoma	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT00096434
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Completed	https://clinicaltrials.gov/study/NCT01881230
MONDO_0007254	breast cancer	CHEMBL1201583	BEVACIZUMAB	Antibody	Vascular endothelial growth factor A inhibitor		VEGFA	vascular endothelial growth factor A	2	Terminated	https://clinicaltrials.gov/study/NCT00536939,https://clinicaltrials.gov/study/NCT00434356,https://clinicaltrials.gov/study/NCT00356681,https://clinicaltrials.gov/study/NCT01120158,https://clinicaltrials.gov/study/NCT01069796,https://clinicaltrials.gov/study/NCT00845910,https://clinicaltrials.gov/study/NCT00632541,https://clinicaltrials.gov/study/NCT00694200,https://clinicaltrials.gov/study/NCT01690325,https://clinicaltrials.gov/study/NCT00461773,https://clinicaltrials.gov/study/NCT00576901,https://clinicaltrials.gov/study/NCT00925652,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT00517361,https://clinicaltrials.gov/study/NCT00679029
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04034823,https://clinicaltrials.gov/study/NCT04290793,https://clinicaltrials.gov/study/NCT06291064,https://clinicaltrials.gov/study/NCT06348134
MONDO_0007254	breast cancer	CHEMBL1201748	CABAZITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT01693549
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT01466972,https://clinicaltrials.gov/study/NCT00509587
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Suspended	https://clinicaltrials.gov/study/NCT02897050,https://clinicaltrials.gov/study/NCT04419181
MONDO_0007254	breast cancer	CHEMBL491473	CEDIRANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT00454805
MONDO_0007254	breast cancer	CHEMBL4297787	MONALIZUMAB	Antibody	NKG2-A/NKG2-B type II integral membrane protein inhibitor		KLRC1	killer cell lectin like receptor C1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04307329
MONDO_0007254	breast cancer	CHEMBL231616	TRIAPINE	Small molecule	Ribonucleotide reductase inhibitor		RRM2B	ribonucleotide reductase regulatory TP53 inducible subunit M2B	2	Terminated	https://clinicaltrials.gov/study/NCT00095888
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Epidermal growth factor receptor inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Terminated	https://clinicaltrials.gov/study/NCT01934335,https://clinicaltrials.gov/study/NCT00752986,https://clinicaltrials.gov/study/NCT00481845
MONDO_0007254	breast cancer	CHEMBL4303201	CATEQUENTINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Recruiting	https://clinicaltrials.gov/study/NCT04452370,https://clinicaltrials.gov/study/NCT05558722,https://clinicaltrials.gov/study/NCT04624711,https://clinicaltrials.gov/study/NCT05296577,https://clinicaltrials.gov/study/NCT04936295,https://clinicaltrials.gov/study/NCT04877821
MONDO_0007254	breast cancer	CHEMBL482968	ENMD-2076	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Completed	https://clinicaltrials.gov/study/NCT01639248
MONDO_0007254	breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	2	Completed	https://clinicaltrials.gov/study/NCT02831530,https://clinicaltrials.gov/study/NCT02441946,https://clinicaltrials.gov/study/NCT03703466,https://clinicaltrials.gov/study/NCT02675231,https://clinicaltrials.gov/study/NCT02308020,https://clinicaltrials.gov/study/NCT02102490
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02339532,https://clinicaltrials.gov/study/NCT03161353,https://clinicaltrials.gov/study/NCT02568839,https://clinicaltrials.gov/study/NCT03609047,https://clinicaltrials.gov/study/NCT02547987,https://clinicaltrials.gov/study/NCT04172259,https://clinicaltrials.gov/study/NCT01779206,https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT00496795,https://clinicaltrials.gov/study/NCT00295893,https://clinicaltrials.gov/study/NCT02624973
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT04464174,https://clinicaltrials.gov/study/NCT01669252,https://clinicaltrials.gov/study/NCT01269346,https://clinicaltrials.gov/study/NCT01268150,https://clinicaltrials.gov/study/NCT01908101,https://clinicaltrials.gov/study/NCT01827787,https://clinicaltrials.gov/study/NCT01527487,https://clinicaltrials.gov/study/NCT01401959,https://clinicaltrials.gov/study/NCT01705691,https://clinicaltrials.gov/study/NCT03051659,https://clinicaltrials.gov/study/NCT00246090,https://clinicaltrials.gov/study/NCT01941407,https://clinicaltrials.gov/study/NCT01427933,https://clinicaltrials.gov/study/NCT05206656,https://clinicaltrials.gov/study/NCT01439282,https://clinicaltrials.gov/study/NCT01593020,https://clinicaltrials.gov/study/NCT00879086,https://clinicaltrials.gov/study/NCT02263495,https://clinicaltrials.gov/study/NCT00965523,https://clinicaltrials.gov/study/NCT02481050,https://clinicaltrials.gov/study/NCT03222856
MONDO_0007254	breast cancer	CHEMBL2325741	CAPIVASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT1	AKT serine/threonine kinase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05720260,https://clinicaltrials.gov/study/NCT03182634,https://clinicaltrials.gov/study/NCT05563220
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Recruiting	https://clinicaltrials.gov/study/NCT04717531,https://clinicaltrials.gov/study/NCT03497702,https://clinicaltrials.gov/study/NCT05645380,https://clinicaltrials.gov/study/NCT05918328,https://clinicaltrials.gov/study/NCT04872985,https://clinicaltrials.gov/study/NCT03367676,https://clinicaltrials.gov/study/NCT04947189,https://clinicaltrials.gov/study/NCT05426486,https://clinicaltrials.gov/study/NCT05475678,https://clinicaltrials.gov/study/NCT03879577,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT06107673,https://clinicaltrials.gov/study/NCT05189067,https://clinicaltrials.gov/study/NCT05483439,https://clinicaltrials.gov/study/NCT04576143,https://clinicaltrials.gov/study/NCT05900206,https://clinicaltrials.gov/study/NCT05638594,https://clinicaltrials.gov/study/NCT05088057
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01745965,https://clinicaltrials.gov/study/NCT01565200,https://clinicaltrials.gov/study/NCT04733118,https://clinicaltrials.gov/study/NCT01853748,https://clinicaltrials.gov/study/NCT02326974,https://clinicaltrials.gov/study/NCT04398914,https://clinicaltrials.gov/study/NCT03587740,https://clinicaltrials.gov/study/NCT01494662
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT00212069,https://clinicaltrials.gov/study/NCT02435680,https://clinicaltrials.gov/study/NCT00192101,https://clinicaltrials.gov/study/NCT00623233,https://clinicaltrials.gov/study/NCT00005991,https://clinicaltrials.gov/study/NCT00503906,https://clinicaltrials.gov/study/NCT00191243,https://clinicaltrials.gov/study/NCT01045304,https://clinicaltrials.gov/study/NCT00191815,https://clinicaltrials.gov/study/NCT00193206,https://clinicaltrials.gov/study/NCT00128856,https://clinicaltrials.gov/study/NCT00403130,https://clinicaltrials.gov/study/NCT00618826,https://clinicaltrials.gov/study/NCT00244933,https://clinicaltrials.gov/study/NCT00003540,https://clinicaltrials.gov/study/NCT00191373,https://clinicaltrials.gov/study/NCT00540358,https://clinicaltrials.gov/study/NCT00894504,https://clinicaltrials.gov/study/NCT00754351,https://clinicaltrials.gov/study/NCT00450762,https://clinicaltrials.gov/study/NCT00193063,https://clinicaltrials.gov/study/NCT00325234,https://clinicaltrials.gov/study/NCT00191854,https://clinicaltrials.gov/study/NCT00480597,https://clinicaltrials.gov/study/NCT00493636,https://clinicaltrials.gov/study/NCT00059852,https://clinicaltrials.gov/study/NCT00201760,https://clinicaltrials.gov/study/NCT00191347,https://clinicaltrials.gov/study/NCT00193050,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00063570,https://clinicaltrials.gov/study/NCT00006007,https://clinicaltrials.gov/study/NCT00378313,https://clinicaltrials.gov/study/NCT00662129,https://clinicaltrials.gov/study/NCT00110084,https://clinicaltrials.gov/study/NCT00316199,https://clinicaltrials.gov/study/NCT03025880,https://clinicaltrials.gov/study/NCT01550848,https://clinicaltrials.gov/study/NCT00846027,https://clinicaltrials.gov/study/NCT00193076,https://clinicaltrials.gov/study/NCT00695994,https://clinicaltrials.gov/study/NCT04464174,https://clinicaltrials.gov/study/NCT01201265,https://clinicaltrials.gov/study/NCT00191451,https://clinicaltrials.gov/study/NCT00813956,https://clinicaltrials.gov/study/NCT00532857,https://clinicaltrials.gov/study/NCT00192062,https://clinicaltrials.gov/study/NCT00320541,https://clinicaltrials.gov/study/NCT00002998,https://clinicaltrials.gov/study/NCT00334802,https://clinicaltrials.gov/study/NCT02263495,https://clinicaltrials.gov/study/NCT00191789,https://clinicaltrials.gov/study/NCT00601159,https://clinicaltrials.gov/study/NCT00532623,https://clinicaltrials.gov/study/NCT00191269
MONDO_0007254	breast cancer	CHEMBL1023	BEXAROTENE	Small molecule	Retinoid X receptor agonist		RXRB	retinoid X receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT00003752
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT00879086,https://clinicaltrials.gov/study/NCT01908101,https://clinicaltrials.gov/study/NCT02481050,https://clinicaltrials.gov/study/NCT01527487,https://clinicaltrials.gov/study/NCT01439282,https://clinicaltrials.gov/study/NCT05206656,https://clinicaltrials.gov/study/NCT00246090,https://clinicaltrials.gov/study/NCT01269346,https://clinicaltrials.gov/study/NCT01669252,https://clinicaltrials.gov/study/NCT02263495,https://clinicaltrials.gov/study/NCT01593020,https://clinicaltrials.gov/study/NCT01268150,https://clinicaltrials.gov/study/NCT04464174,https://clinicaltrials.gov/study/NCT03222856,https://clinicaltrials.gov/study/NCT00965523,https://clinicaltrials.gov/study/NCT01401959,https://clinicaltrials.gov/study/NCT01827787,https://clinicaltrials.gov/study/NCT01427933,https://clinicaltrials.gov/study/NCT03051659,https://clinicaltrials.gov/study/NCT01941407,https://clinicaltrials.gov/study/NCT01705691
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	2	Completed	https://clinicaltrials.gov/study/NCT02404844,https://clinicaltrials.gov/study/NCT01923168,https://clinicaltrials.gov/study/NCT01816594,https://clinicaltrials.gov/study/NCT01790932,https://clinicaltrials.gov/study/NCT01572727,https://clinicaltrials.gov/study/NCT01629615
MONDO_0007254	breast cancer	CHEMBL3989401	PAMIDRONATE DISODIUM	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	2	Completed	https://clinicaltrials.gov/study/NCT00004906
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Recruiting	https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT05447702,https://clinicaltrials.gov/study/NCT05900206,https://clinicaltrials.gov/study/NCT04443348,https://clinicaltrials.gov/study/NCT04355858,https://clinicaltrials.gov/study/NCT03150576,https://clinicaltrials.gov/study/NCT04576143,https://clinicaltrials.gov/study/NCT06245889,https://clinicaltrials.gov/study/NCT04425018,https://clinicaltrials.gov/study/NCT05068141,https://clinicaltrials.gov/study/NCT05383196,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT05749575,https://clinicaltrials.gov/study/NCT04537286,https://clinicaltrials.gov/study/NCT03907800,https://clinicaltrials.gov/study/NCT04243616,https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT04893109,https://clinicaltrials.gov/study/NCT05629429,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT05728268,https://clinicaltrials.gov/study/NCT05749016,https://clinicaltrials.gov/study/NCT05761470,https://clinicaltrials.gov/study/NCT03571633,https://clinicaltrials.gov/study/NCT05582538,https://clinicaltrials.gov/study/NCT04159142,https://clinicaltrials.gov/study/NCT01817452,https://clinicaltrials.gov/study/NCT04780347,https://clinicaltrials.gov/study/NCT04722718,https://clinicaltrials.gov/study/NCT05659056,https://clinicaltrials.gov/study/NCT05852691,https://clinicaltrials.gov/study/NCT04329065,https://clinicaltrials.gov/study/NCT04771871,https://clinicaltrials.gov/study/NCT05633914,https://clinicaltrials.gov/study/NCT05918328,https://clinicaltrials.gov/study/NCT05889390,https://clinicaltrials.gov/study/NCT03412643,https://clinicaltrials.gov/study/NCT04877821,https://clinicaltrials.gov/study/NCT04090398,https://clinicaltrials.gov/study/NCT04676997,https://clinicaltrials.gov/study/NCT05174832,https://clinicaltrials.gov/study/NCT04872985,https://clinicaltrials.gov/study/NCT05189067,https://clinicaltrials.gov/study/NCT05681728,https://clinicaltrials.gov/study/NCT05346107,https://clinicaltrials.gov/study/NCT05020860,https://clinicaltrials.gov/study/NCT04917900,https://clinicaltrials.gov/study/NCT03048942,https://clinicaltrials.gov/study/NCT05325632,https://clinicaltrials.gov/study/NCT05353361
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00074269,https://clinicaltrials.gov/study/NCT00376805
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA2	NADH:ubiquinone oxidoreductase subunit A2	2	Completed	https://clinicaltrials.gov/study/NCT01885013
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Unknown status	https://clinicaltrials.gov/study/NCT03144947
EFO_0000305	breast carcinoma	CHEMBL3137336	UPROSERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT2	AKT serine/threonine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT01964924
EFO_0005537	triple-negative breast cancer	CHEMBL4297892	ANVATABART OPADOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBA3E	tubulin alpha 3e	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0006861	male breast carcinoma	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT00017394
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT00006007,https://clinicaltrials.gov/study/NCT00003540,https://clinicaltrials.gov/study/NCT00002998,https://clinicaltrials.gov/study/NCT00059852,https://clinicaltrials.gov/study/NCT00005991,https://clinicaltrials.gov/study/NCT00662129
EFO_0006861	male breast carcinoma	CHEMBL535	SUNITINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00513695
MONDO_0007254	breast cancer	CHEMBL4297462	CFI-400945	Small molecule	Serine/threonine-protein kinase PLK4 inhibitor		PLK4	polo like kinase 4	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04176848,https://clinicaltrials.gov/study/NCT03624543
MONDO_0007254	breast cancer	CHEMBL135	ESTRADIOL	Small molecule	Estrogen receptor alpha agonist	Antagonist	ESR1	estrogen receptor 1	2	Completed	https://clinicaltrials.gov/study/NCT01923298,https://clinicaltrials.gov/study/NCT04150731
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Withdrawn	https://clinicaltrials.gov/study/NCT00005614
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	2	Completed	https://clinicaltrials.gov/study/NCT01923168,https://clinicaltrials.gov/study/NCT01790932,https://clinicaltrials.gov/study/NCT02404844,https://clinicaltrials.gov/study/NCT01816594,https://clinicaltrials.gov/study/NCT01629615,https://clinicaltrials.gov/study/NCT01572727
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Terminated	https://clinicaltrials.gov/study/NCT01329627,https://clinicaltrials.gov/study/NCT01745367,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT03894007,https://clinicaltrials.gov/study/NCT01194869,https://clinicaltrials.gov/study/NCT01009983,https://clinicaltrials.gov/study/NCT00434356,https://clinicaltrials.gov/study/NCT01416558,https://clinicaltrials.gov/study/NCT00679029,https://clinicaltrials.gov/study/NCT04066790,https://clinicaltrials.gov/study/NCT00456846,https://clinicaltrials.gov/study/NCT01069796,https://clinicaltrials.gov/study/NCT00622466,https://clinicaltrials.gov/study/NCT00589238,https://clinicaltrials.gov/study/NCT00356681,https://clinicaltrials.gov/study/NCT00542191,https://clinicaltrials.gov/study/NCT00536939,https://clinicaltrials.gov/study/NCT01120158,https://clinicaltrials.gov/study/NCT00607438,https://clinicaltrials.gov/study/NCT02322814,https://clinicaltrials.gov/study/NCT00479856,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT01147016,https://clinicaltrials.gov/study/NCT00691912,https://clinicaltrials.gov/study/NCT00756470,https://clinicaltrials.gov/study/NCT00532285,https://clinicaltrials.gov/study/NCT02598310,https://clinicaltrials.gov/study/NCT03329378,https://clinicaltrials.gov/study/NCT00934895,https://clinicaltrials.gov/study/NCT01207102,https://clinicaltrials.gov/study/NCT00194792
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Withdrawn	https://clinicaltrials.gov/study/NCT00006261,https://clinicaltrials.gov/study/NCT02067416,https://clinicaltrials.gov/study/NCT01229605,https://clinicaltrials.gov/study/NCT00678626,https://clinicaltrials.gov/study/NCT01825265,https://clinicaltrials.gov/study/NCT00434031,https://clinicaltrials.gov/study/NCT00964704
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC11	histone deacetylase 11	2	Completed	https://clinicaltrials.gov/study/NCT00777049
MONDO_0007254	breast cancer	CHEMBL3187723	BINIMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 1 inhibitor		MAP2K1	mitogen-activated protein kinase kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT04494958
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT00246090,https://clinicaltrials.gov/study/NCT00879086,https://clinicaltrials.gov/study/NCT02481050,https://clinicaltrials.gov/study/NCT03051659,https://clinicaltrials.gov/study/NCT04464174,https://clinicaltrials.gov/study/NCT01527487,https://clinicaltrials.gov/study/NCT02263495,https://clinicaltrials.gov/study/NCT03222856,https://clinicaltrials.gov/study/NCT01401959,https://clinicaltrials.gov/study/NCT01268150,https://clinicaltrials.gov/study/NCT01705691,https://clinicaltrials.gov/study/NCT01941407,https://clinicaltrials.gov/study/NCT00965523,https://clinicaltrials.gov/study/NCT01908101,https://clinicaltrials.gov/study/NCT01269346,https://clinicaltrials.gov/study/NCT01827787,https://clinicaltrials.gov/study/NCT05206656,https://clinicaltrials.gov/study/NCT01593020,https://clinicaltrials.gov/study/NCT01669252,https://clinicaltrials.gov/study/NCT01439282,https://clinicaltrials.gov/study/NCT01427933
MONDO_0007254	breast cancer	CHEMBL1922094	APITOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	2	Completed	https://clinicaltrials.gov/study/NCT01437566
MONDO_0007254	breast cancer	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Tyrosine-protein kinase ITK/TSK inhibitor		ITK	IL2 inducible T cell kinase	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
MONDO_0007254	breast cancer	CHEMBL288441	BOSUTINIB	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	2	Terminated	https://clinicaltrials.gov/study/NCT00793546,https://clinicaltrials.gov/study/NCT00880009
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Unknown status	https://clinicaltrials.gov/study/NCT03144947
EFO_0000305	breast carcinoma	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02595905,https://clinicaltrials.gov/study/NCT01149083
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF4	NADH:ubiquinone oxidoreductase complex assembly factor 4	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0005537	triple-negative breast cancer	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT00861705
MONDO_0007254	breast cancer	CHEMBL1567	SUNITINIB MALATE	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Completed	https://clinicaltrials.gov/study/NCT00482755
MONDO_0007254	breast cancer	CHEMBL4297190	SURUFATINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Recruiting	https://clinicaltrials.gov/study/NCT05186545
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT00532623,https://clinicaltrials.gov/study/NCT00148668,https://clinicaltrials.gov/study/NCT00194779,https://clinicaltrials.gov/study/NCT00266110,https://clinicaltrials.gov/study/NCT00148681,https://clinicaltrials.gov/study/NCT00093808,https://clinicaltrials.gov/study/NCT00006682,https://clinicaltrials.gov/study/NCT00004237,https://clinicaltrials.gov/study/NCT01941771,https://clinicaltrials.gov/study/NCT00022152
MONDO_0007254	breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04733417
MONDO_0007254	breast cancer	CHEMBL723	CARVEDILOL	Small molecule	Adrenergic receptor beta antagonist		ADRB1	adrenoceptor beta 1	2	Recruiting	https://clinicaltrials.gov/study/NCT03879629
EFO_0000305	breast carcinoma	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	2	Terminated	https://clinicaltrials.gov/study/NCT00148720
EFO_0000305	breast carcinoma	CHEMBL1789844	IPILIMUMAB	Antibody	Cytotoxic T-lymphocyte protein 4 inhibitor		CTLA4	cytotoxic T-lymphocyte associated protein 4	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03650894
EFO_0000305	breast carcinoma	CHEMBL491473	CEDIRANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT04090567
EFO_0005537	triple-negative breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC11	histone deacetylase 11	2	Terminated	https://clinicaltrials.gov/study/NCT01234532
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	2	Completed	https://clinicaltrials.gov/study/NCT00494481
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04034823,https://clinicaltrials.gov/study/NCT06348134,https://clinicaltrials.gov/study/NCT04290793,https://clinicaltrials.gov/study/NCT06291064
MONDO_0007254	breast cancer	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Withdrawn	https://clinicaltrials.gov/study/NCT00935558,https://clinicaltrials.gov/study/NCT01814865,https://clinicaltrials.gov/study/NCT00217659
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT00002998,https://clinicaltrials.gov/study/NCT00059852,https://clinicaltrials.gov/study/NCT00450762,https://clinicaltrials.gov/study/NCT00532623,https://clinicaltrials.gov/study/NCT00846027,https://clinicaltrials.gov/study/NCT00480597,https://clinicaltrials.gov/study/NCT02435680,https://clinicaltrials.gov/study/NCT00320541,https://clinicaltrials.gov/study/NCT00754351,https://clinicaltrials.gov/study/NCT00623233,https://clinicaltrials.gov/study/NCT00191854,https://clinicaltrials.gov/study/NCT00110084,https://clinicaltrials.gov/study/NCT00894504,https://clinicaltrials.gov/study/NCT00005991,https://clinicaltrials.gov/study/NCT00403130,https://clinicaltrials.gov/study/NCT00192062,https://clinicaltrials.gov/study/NCT00334802,https://clinicaltrials.gov/study/NCT04464174,https://clinicaltrials.gov/study/NCT01201265,https://clinicaltrials.gov/study/NCT00695994,https://clinicaltrials.gov/study/NCT00532857,https://clinicaltrials.gov/study/NCT03025880,https://clinicaltrials.gov/study/NCT01550848,https://clinicaltrials.gov/study/NCT00244933,https://clinicaltrials.gov/study/NCT00618826,https://clinicaltrials.gov/study/NCT00191815,https://clinicaltrials.gov/study/NCT00378313,https://clinicaltrials.gov/study/NCT00325234,https://clinicaltrials.gov/study/NCT02263495,https://clinicaltrials.gov/study/NCT00601159,https://clinicaltrials.gov/study/NCT00193206,https://clinicaltrials.gov/study/NCT00540358,https://clinicaltrials.gov/study/NCT00503906,https://clinicaltrials.gov/study/NCT00192101,https://clinicaltrials.gov/study/NCT00193050,https://clinicaltrials.gov/study/NCT00063570,https://clinicaltrials.gov/study/NCT00193063,https://clinicaltrials.gov/study/NCT01045304,https://clinicaltrials.gov/study/NCT00201760,https://clinicaltrials.gov/study/NCT00128856,https://clinicaltrials.gov/study/NCT00316199,https://clinicaltrials.gov/study/NCT00006007,https://clinicaltrials.gov/study/NCT00191789,https://clinicaltrials.gov/study/NCT00191243,https://clinicaltrials.gov/study/NCT00191347,https://clinicaltrials.gov/study/NCT00212069,https://clinicaltrials.gov/study/NCT00493636,https://clinicaltrials.gov/study/NCT00191373,https://clinicaltrials.gov/study/NCT00191269,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00003540,https://clinicaltrials.gov/study/NCT00813956,https://clinicaltrials.gov/study/NCT00191451,https://clinicaltrials.gov/study/NCT00193076,https://clinicaltrials.gov/study/NCT00662129
MONDO_0007254	breast cancer	CHEMBL1879463	DACTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	2	Withdrawn	https://clinicaltrials.gov/study/NCT01288092
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Terminated	https://clinicaltrials.gov/study/NCT00434356,https://clinicaltrials.gov/study/NCT00824538,https://clinicaltrials.gov/study/NCT00570908
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND5	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5	2	Completed	https://clinicaltrials.gov/study/NCT04170465
EFO_0006861	male breast carcinoma	CHEMBL1201583	BEVACIZUMAB	Antibody	Vascular endothelial growth factor A inhibitor		VEGFA	vascular endothelial growth factor A	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT00861705
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS5	NADH:ubiquinone oxidoreductase subunit S5	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999
MONDO_0007254	breast cancer	CHEMBL1770916	NIROGACESTAT	Small molecule	Gamma-secretase inhibitor		APH1A	aph-1 homolog A, gamma-secretase subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT02338531
MONDO_0007254	breast cancer	CHEMBL180022	NERATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Completed	https://clinicaltrials.gov/study/NCT02673398,https://clinicaltrials.gov/study/NCT00777101,https://clinicaltrials.gov/study/NCT02400476,https://clinicaltrials.gov/study/NCT00915018,https://clinicaltrials.gov/study/NCT01008150,https://clinicaltrials.gov/study/NCT04366713
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS3	NADH:ubiquinone oxidoreductase core subunit S3	2	Unknown status	https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT02506777
MONDO_0007254	breast cancer	CHEMBL4297736	PRALUZATAMAB RAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT04596150
MONDO_0007254	breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Vascular endothelial growth factor receptor 1 inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT04355858
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC1	NADH:ubiquinone oxidoreductase subunit C1	2	Unknown status	https://clinicaltrials.gov/study/NCT02506777,https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT02506790
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Tyrosine-protein kinase TIE-2 inhibitor		TEK	TEK receptor tyrosine kinase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT01427933,https://clinicaltrials.gov/study/NCT01593020,https://clinicaltrials.gov/study/NCT02481050,https://clinicaltrials.gov/study/NCT01827787,https://clinicaltrials.gov/study/NCT01941407,https://clinicaltrials.gov/study/NCT01439282,https://clinicaltrials.gov/study/NCT03222856,https://clinicaltrials.gov/study/NCT01705691,https://clinicaltrials.gov/study/NCT05206656,https://clinicaltrials.gov/study/NCT00246090,https://clinicaltrials.gov/study/NCT03051659,https://clinicaltrials.gov/study/NCT01527487,https://clinicaltrials.gov/study/NCT01669252,https://clinicaltrials.gov/study/NCT02263495,https://clinicaltrials.gov/study/NCT04464174,https://clinicaltrials.gov/study/NCT01268150,https://clinicaltrials.gov/study/NCT01269346,https://clinicaltrials.gov/study/NCT00879086,https://clinicaltrials.gov/study/NCT00965523,https://clinicaltrials.gov/study/NCT01908101,https://clinicaltrials.gov/study/NCT01401959
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4L	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L	2	Completed	https://clinicaltrials.gov/study/NCT04170465
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01009788
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Withdrawn	https://clinicaltrials.gov/study/NCT05233696,https://clinicaltrials.gov/study/NCT05177796
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB6	NADH:ubiquinone oxidoreductase subunit B6	2	Unknown status	https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT02506777,https://clinicaltrials.gov/study/NCT03192293
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF3	NADH:ubiquinone oxidoreductase complex assembly factor 3	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL2146883	COBIMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 2 inhibitor		MAP2K2	mitogen-activated protein kinase kinase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03202316
EFO_0000432	breast ductal carcinoma in situ	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Terminated	https://clinicaltrials.gov/study/NCT00461344
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE4D	phosphodiesterase 4D	2	Recruiting	https://clinicaltrials.gov/study/NCT06087237
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT00005614,https://clinicaltrials.gov/study/NCT05809895
MONDO_0007254	breast cancer	CHEMBL1098	BUPIVACAINE	Small molecule	Sodium channel protein type IV alpha subunit blocker		SCN4A	sodium voltage-gated channel alpha subunit 4	2	Recruiting	https://clinicaltrials.gov/study/NCT03504865
EFO_0000305	breast carcinoma	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist	Antagonist	ESR2	estrogen receptor 2	2	Withdrawn	https://clinicaltrials.gov/study/NCT05191004,https://clinicaltrials.gov/study/NCT03803761
EFO_0000305	breast carcinoma	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03101748,https://clinicaltrials.gov/study/NCT02568839,https://clinicaltrials.gov/study/NCT02436993
EFO_0000186	invasive breast ductal carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02779855
MONDO_0007254	breast cancer	CHEMBL1738889	ENOBOSARM	Small molecule	Androgen Receptor modulator		AR	androgen receptor	2	Withdrawn	https://clinicaltrials.gov/study/NCT02746328
EFO_0006861	male breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00095888
EFO_0006861	male breast carcinoma	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Completed	https://clinicaltrials.gov/study/NCT00096434
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE4A	phosphodiesterase 4A	2	Recruiting	https://clinicaltrials.gov/study/NCT06087237
MONDO_0007254	breast cancer	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02339532,https://clinicaltrials.gov/study/NCT01745965,https://clinicaltrials.gov/study/NCT00295893,https://clinicaltrials.gov/study/NCT04262804,https://clinicaltrials.gov/study/NCT01565200,https://clinicaltrials.gov/study/NCT03417544,https://clinicaltrials.gov/study/NCT03755141,https://clinicaltrials.gov/study/NCT04398914,https://clinicaltrials.gov/study/NCT05574881,https://clinicaltrials.gov/study/NCT03161353,https://clinicaltrials.gov/study/NCT01796197,https://clinicaltrials.gov/study/NCT00431704,https://clinicaltrials.gov/study/NCT04172259,https://clinicaltrials.gov/study/NCT02252887,https://clinicaltrials.gov/study/NCT00470704,https://clinicaltrials.gov/study/NCT00999804,https://clinicaltrials.gov/study/NCT01730833,https://clinicaltrials.gov/study/NCT03379428,https://clinicaltrials.gov/study/NCT02624973,https://clinicaltrials.gov/study/NCT04721977,https://clinicaltrials.gov/study/NCT01340430,https://clinicaltrials.gov/study/NCT04733118,https://clinicaltrials.gov/study/NCT01853748,https://clinicaltrials.gov/study/NCT01937117,https://clinicaltrials.gov/study/NCT03747120,https://clinicaltrials.gov/study/NCT03414658,https://clinicaltrials.gov/study/NCT02568839,https://clinicaltrials.gov/study/NCT03125928,https://clinicaltrials.gov/study/NCT02827877,https://clinicaltrials.gov/study/NCT04307329
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Recruiting	https://clinicaltrials.gov/study/NCT04924699
MONDO_0007254	breast cancer	CHEMBL4297723	CEMIPLIMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Suspended	https://clinicaltrials.gov/study/NCT04916002
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA13	NADH:ubiquinone oxidoreductase subunit A13	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05833919,https://clinicaltrials.gov/study/NCT04303741,https://clinicaltrials.gov/study/NCT02299999
MONDO_0007254	breast cancer	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Completed	https://clinicaltrials.gov/study/NCT01818063,https://clinicaltrials.gov/study/NCT01506609
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Withdrawn	https://clinicaltrials.gov/study/NCT00964704,https://clinicaltrials.gov/study/NCT01825265,https://clinicaltrials.gov/study/NCT00434031,https://clinicaltrials.gov/study/NCT02067416,https://clinicaltrials.gov/study/NCT00678626,https://clinicaltrials.gov/study/NCT00006261,https://clinicaltrials.gov/study/NCT01229605
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT03959397,https://clinicaltrials.gov/study/NCT04194684,https://clinicaltrials.gov/study/NCT04499118,https://clinicaltrials.gov/study/NCT04639271,https://clinicaltrials.gov/study/NCT04290793,https://clinicaltrials.gov/study/NCT04301375,https://clinicaltrials.gov/study/NCT04946227,https://clinicaltrials.gov/study/NCT04907344,https://clinicaltrials.gov/study/NCT04900311,https://clinicaltrials.gov/study/NCT04659499,https://clinicaltrials.gov/study/NCT05872412,https://clinicaltrials.gov/study/NCT05444998,https://clinicaltrials.gov/study/NCT04498793
EFO_0000305	breast carcinoma	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FYN	FYN proto-oncogene, Src family tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT05198843
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Withdrawn	https://clinicaltrials.gov/study/NCT03032614
EFO_0005537	triple-negative breast cancer	CHEMBL328190	LASOFOXIFENE	Small molecule	Estrogen receptor modulator	Antagonist	ESR1	estrogen receptor 1	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0000305	breast carcinoma	CHEMBL1201568	PEGFILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01498588
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT00191373
MONDO_0007254	breast cancer	CHEMBL1567	SUNITINIB MALATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Terminated	https://clinicaltrials.gov/study/NCT00824538
MONDO_0007254	breast cancer	CHEMBL384467	DEXAMETHASONE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	2	Unknown status	https://clinicaltrials.gov/study/NCT02234466
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Suspended	https://clinicaltrials.gov/study/NCT02897050,https://clinicaltrials.gov/study/NCT04419181
MONDO_0007254	breast cancer	CHEMBL52885	ENMD-981693	Small molecule	SRC inhibitor		LYN	LYN proto-oncogene, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00306631
EFO_0000304	breast adenocarcinoma	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Completed	https://clinicaltrials.gov/study/NCT02282345
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT00284180
MONDO_0007254	breast cancer	CHEMBL522892	DOVITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Completed	https://clinicaltrials.gov/study/NCT00958971,https://clinicaltrials.gov/study/NCT01262027
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT02682693,https://clinicaltrials.gov/study/NCT02199418,https://clinicaltrials.gov/study/NCT00513695
MONDO_0007254	breast cancer	CHEMBL1743028	GLEMBATUMUMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT01997333,https://clinicaltrials.gov/study/NCT01156753
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA7	EPH receptor A7	2	Terminated	https://clinicaltrials.gov/study/NCT00752986,https://clinicaltrials.gov/study/NCT01934335,https://clinicaltrials.gov/study/NCT00481845
MONDO_0007254	breast cancer	CHEMBL4279455	LAROTAXEL	Small molecule	Tubulin stabiliser		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT00087958,https://clinicaltrials.gov/study/NCT00387907
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT02614833
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Recruiting	https://clinicaltrials.gov/study/NCT05530057,https://clinicaltrials.gov/study/NCT04624711,https://clinicaltrials.gov/study/NCT05546255
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA2	EPH receptor A2	2	Terminated	https://clinicaltrials.gov/study/NCT01934335,https://clinicaltrials.gov/study/NCT00481845,https://clinicaltrials.gov/study/NCT00752986
MONDO_0007254	breast cancer	CHEMBL300138	ENZASTAURIN	Small molecule	Protein kinase C beta inhibitor		PRKCB	protein kinase C beta	2	Completed	https://clinicaltrials.gov/study/NCT00451555
EFO_0000304	breast adenocarcinoma	CHEMBL3187723	BINIMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 2 inhibitor		MAP2K2	mitogen-activated protein kinase kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT03106415
EFO_0000432	breast ductal carcinoma in situ	CHEMBL395429	OXYTOCIN	Protein	Oxytocin receptor agonist		OXTR	oxytocin receptor	2	Terminated	https://clinicaltrials.gov/study/NCT02127073
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Withdrawn	https://clinicaltrials.gov/study/NCT02215876,https://clinicaltrials.gov/study/NCT03637868
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4	NDUFA4 mitochondrial complex associated	2	Completed	https://clinicaltrials.gov/study/NCT04170465
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA12	NADH:ubiquinone oxidoreductase subunit A12	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1201247	GOSERELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT03444025,https://clinicaltrials.gov/study/NCT06348134
EFO_0005537	triple-negative breast cancer	CHEMBL481	IRINOTECAN	Small molecule	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02414646
EFO_0006861	male breast carcinoma	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	2	Completed	https://clinicaltrials.gov/study/NCT00096434
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT01881230,https://clinicaltrials.gov/study/NCT03853707,https://clinicaltrials.gov/study/NCT01818063,https://clinicaltrials.gov/study/NCT03057600,https://clinicaltrials.gov/study/NCT02689427,https://clinicaltrials.gov/study/NCT00733408,https://clinicaltrials.gov/study/NCT02413320
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND3	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Recruiting	https://clinicaltrials.gov/study/NCT05296577,https://clinicaltrials.gov/study/NCT05823623
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT00295893,https://clinicaltrials.gov/study/NCT03609047,https://clinicaltrials.gov/study/NCT02339532,https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT03161353,https://clinicaltrials.gov/study/NCT02568839,https://clinicaltrials.gov/study/NCT01779206,https://clinicaltrials.gov/study/NCT02624973,https://clinicaltrials.gov/study/NCT00496795,https://clinicaltrials.gov/study/NCT04172259,https://clinicaltrials.gov/study/NCT02547987
EFO_0005537	triple-negative breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02208375
MONDO_0007254	breast cancer	CHEMBL1743019	FIGITUMUMAB	Antibody	Insulin-like growth factor I receptor antagonist		IGF1R	insulin like growth factor 1 receptor	2	Withdrawn	https://clinicaltrials.gov/study/NCT00678626
MONDO_0007254	breast cancer	CHEMBL502835	NINTEDANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Terminated	https://clinicaltrials.gov/study/NCT02389764
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	2	Unknown status	https://clinicaltrials.gov/study/NCT02917005,https://clinicaltrials.gov/study/NCT02592746
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Tyrosine-protein kinase SRC inhibitor		SRC	SRC proto-oncogene, non-receptor tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT00752986,https://clinicaltrials.gov/study/NCT00481845,https://clinicaltrials.gov/study/NCT01934335
MONDO_0007254	breast cancer	CHEMBL572881	MOTESANIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT00356681
EFO_0000305	breast carcinoma	CHEMBL4297844	TRASTUZUMAB DERUXTECAN	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 binding agent		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT04553770
MONDO_0007254	breast cancer	CHEMBL4298037	RETIFANLIMAB	Antibody	Programmed cell death protein 1 antagonist		PDCD1	programmed cell death 1	2	Enrolling by invitation	https://clinicaltrials.gov/study/NCT03328026
EFO_0005537	triple-negative breast cancer	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		PSEN2	presenilin 2	2	Terminated	https://clinicaltrials.gov/study/NCT01151449
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Recruiting	https://clinicaltrials.gov/study/NCT06042569,https://clinicaltrials.gov/study/NCT04266249,https://clinicaltrials.gov/study/NCT05319873
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0005537	triple-negative breast cancer	CHEMBL4297892	ANVATABART OPADOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04538742,https://clinicaltrials.gov/study/NCT02624973,https://clinicaltrials.gov/study/NCT03417544,https://clinicaltrials.gov/study/NCT03747120,https://clinicaltrials.gov/study/NCT02252887,https://clinicaltrials.gov/study/NCT05574881,https://clinicaltrials.gov/study/NCT01730833,https://clinicaltrials.gov/study/NCT02326974,https://clinicaltrials.gov/study/NCT04733118,https://clinicaltrials.gov/study/NCT02568839,https://clinicaltrials.gov/study/NCT04172259,https://clinicaltrials.gov/study/NCT04398914,https://clinicaltrials.gov/study/NCT01796197,https://clinicaltrials.gov/study/NCT01937117,https://clinicaltrials.gov/study/NCT02827877,https://clinicaltrials.gov/study/NCT02339532,https://clinicaltrials.gov/study/NCT03161353,https://clinicaltrials.gov/study/NCT03125928
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	2	Terminated	https://clinicaltrials.gov/study/NCT03322215,https://clinicaltrials.gov/study/NCT03709082
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS7	NADH:ubiquinone oxidoreductase core subunit S7	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	2	Completed	https://clinicaltrials.gov/study/NCT00684983
EFO_0005537	triple-negative breast cancer	CHEMBL4297715	CAMRELIZUMAB	Antibody	Programmed cell death protein 1 antagonist		PDCD1	programmed cell death 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05438706
EFO_0000305	breast carcinoma	CHEMBL4302409	LUTETIUM OXODOTREOTIDE	Protein	Somatostatin receptor binding agent		SSTR4	somatostatin receptor 4	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04529044
MONDO_0007254	breast cancer	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Serine/threonine-protein kinase B-raf inhibitor		BRAF	B-Raf proto-oncogene, serine/threonine kinase	2	Unknown status	https://clinicaltrials.gov/study/NCT00499525
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FYN	FYN proto-oncogene, Src family tyrosine kinase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01471106
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Suspended	https://clinicaltrials.gov/study/NCT02897050,https://clinicaltrials.gov/study/NCT04419181
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02654119,https://clinicaltrials.gov/study/NCT02827877
MONDO_0007254	breast cancer	CHEMBL679	EPINEPHRINE	Small molecule	Adrenergic receptor agonist		ADRA1B	adrenoceptor alpha 1B	2	Completed	https://clinicaltrials.gov/study/NCT02525718
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA13	NADH:ubiquinone oxidoreductase subunit A13	2	Completed	https://clinicaltrials.gov/study/NCT04170465
EFO_0005537	triple-negative breast cancer	CHEMBL2177390	IPATASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT1	AKT serine/threonine kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT03853707
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB3	NADH:ubiquinone oxidoreductase subunit B3	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	2	Withdrawn	https://clinicaltrials.gov/study/NCT02725541
MONDO_0007254	breast cancer	CHEMBL1230609	FORETINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Completed	https://clinicaltrials.gov/study/NCT01147484,https://clinicaltrials.gov/study/NCT01138384
MONDO_0007254	breast cancer	CHEMBL2220486	LUCITANIB	Small molecule	Fibroblast growth factor receptor 2 inhibitor		FGFR2	fibroblast growth factor receptor 2	2	Completed	https://clinicaltrials.gov/study/NCT02053636
EFO_0005537	triple-negative breast cancer	CHEMBL3545414	RIVOCERANIB MESYLATE	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Completed	https://clinicaltrials.gov/study/NCT03243838
MONDO_0007254	breast cancer	CHEMBL2304041	SAGOPILONE	Small molecule	Tubulin stabiliser		TUBA1A	tubulin alpha 1a	2	Completed	https://clinicaltrials.gov/study/NCT00288249
MONDO_0007254	breast cancer	CHEMBL502835	NINTEDANIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR2	fibroblast growth factor receptor 2	2	Terminated	https://clinicaltrials.gov/study/NCT02389764
MONDO_0007254	breast cancer	CHEMBL742	KETAMINE	Small molecule	Glutamate [NMDA] receptor negative allosteric modulator		GRIN2C	glutamate ionotropic receptor NMDA type subunit 2C	2	Completed	https://clinicaltrials.gov/study/NCT00304850,https://clinicaltrials.gov/study/NCT05727098
EFO_0005537	triple-negative breast cancer	CHEMBL3187723	BINIMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 1 inhibitor		MAP2K1	mitogen-activated protein kinase kinase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT03971409
MONDO_0007254	breast cancer	CHEMBL2336325	VISTUSERTIB	Small molecule	Serine/threonine-protein kinase mTOR inhibitor		MTOR	mechanistic target of rapamycin kinase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT02208375
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE1A	phosphodiesterase 1A	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT06186700,https://clinicaltrials.gov/study/NCT06176339
MONDO_0007254	breast cancer	CHEMBL571209	INDOXIMOD	Small molecule	mTORC1 activator		MLST8	MTOR associated protein, LST8 homolog	2	Completed	https://clinicaltrials.gov/study/NCT01792050
MONDO_0007254	breast cancer	CHEMBL20684	ABT-751	Small molecule	Tubulin beta inhibitor		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT00063102
EFO_0006861	male breast carcinoma	CHEMBL217092	SARACATINIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00559507
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04001829,https://clinicaltrials.gov/study/NCT02568839
EFO_0000432	breast ductal carcinoma in situ	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02779855
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT00321633
MONDO_0007254	breast cancer	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	2	Terminated	https://clinicaltrials.gov/study/NCT00169104,https://clinicaltrials.gov/study/NCT00074269,https://clinicaltrials.gov/study/NCT00665457
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	2	Terminated	https://clinicaltrials.gov/study/NCT00824538,https://clinicaltrials.gov/study/NCT00434356,https://clinicaltrials.gov/study/NCT00570908
MONDO_0007254	breast cancer	CHEMBL1789941	RUXOLITINIB	Small molecule	Tyrosine-protein kinase JAK2 inhibitor		JAK2	Janus kinase 2	2	Terminated	https://clinicaltrials.gov/study/NCT02120417,https://clinicaltrials.gov/study/NCT01562873
MONDO_0007254	breast cancer	CHEMBL553	ERLOTINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT00491816
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA4	EPH receptor A4	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04034823,https://clinicaltrials.gov/study/NCT04290793,https://clinicaltrials.gov/study/NCT06348134,https://clinicaltrials.gov/study/NCT06291064
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC7	histone deacetylase 7	2	Completed	https://clinicaltrials.gov/study/NCT00777049
MONDO_0007254	breast cancer	CHEMBL723	CARVEDILOL	Small molecule	Adrenergic receptor beta antagonist		ADRB1	adrenoceptor beta 1	2	Completed	https://clinicaltrials.gov/study/NCT02177175,https://clinicaltrials.gov/study/NCT01009918
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT00005614
MONDO_0007254	breast cancer	CHEMBL2219773	CUSTIRSEN SODIUM	Oligonucleotide	Clusterin mRNA antisense inhibitor		CLU	clusterin	2	Completed	https://clinicaltrials.gov/study/NCT00258375
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	2	Completed	https://clinicaltrials.gov/study/NCT00548899,https://clinicaltrials.gov/study/NCT00101400,https://clinicaltrials.gov/study/NCT00634634,https://clinicaltrials.gov/study/NCT00493636,https://clinicaltrials.gov/study/NCT01320111
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	2	Unknown status	https://clinicaltrials.gov/study/NCT02681562
EFO_0000304	breast adenocarcinoma	CHEMBL180022	NERATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT03094052
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB6	NADH:ubiquinone oxidoreductase subunit B6	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Recruiting	https://clinicaltrials.gov/study/NCT06042569,https://clinicaltrials.gov/study/NCT04266249,https://clinicaltrials.gov/study/NCT05319873
EFO_0000304	breast adenocarcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Recruiting	https://clinicaltrials.gov/study/NCT04197687
MONDO_0007254	breast cancer	CHEMBL4297723	CEMIPLIMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT05259696,https://clinicaltrials.gov/study/NCT04243616
MONDO_0007254	breast cancer	CHEMBL1023	BEXAROTENE	Small molecule	Retinoid X receptor agonist		RXRA	retinoid X receptor alpha	2	Completed	https://clinicaltrials.gov/study/NCT00003752
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Unknown status	https://clinicaltrials.gov/study/NCT00006120,https://clinicaltrials.gov/study/NCT01428414,https://clinicaltrials.gov/study/NCT00154882,https://clinicaltrials.gov/study/NCT00404404,https://clinicaltrials.gov/study/NCT02230319,https://clinicaltrials.gov/study/NCT01276769,https://clinicaltrials.gov/study/NCT00777673,https://clinicaltrials.gov/study/NCT02423603,https://clinicaltrials.gov/study/NCT01830244,https://clinicaltrials.gov/study/NCT03429972,https://clinicaltrials.gov/study/NCT01625429,https://clinicaltrials.gov/study/NCT01309607,https://clinicaltrials.gov/study/NCT03735082,https://clinicaltrials.gov/study/NCT02041338,https://clinicaltrials.gov/study/NCT00499603,https://clinicaltrials.gov/study/NCT02059876,https://clinicaltrials.gov/study/NCT02694224,https://clinicaltrials.gov/study/NCT03348098,https://clinicaltrials.gov/study/NCT00499525,https://clinicaltrials.gov/study/NCT01647672,https://clinicaltrials.gov/study/NCT00533936,https://clinicaltrials.gov/study/NCT01321775
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Recruiting	https://clinicaltrials.gov/study/NCT05583110
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01463072,https://clinicaltrials.gov/study/NCT03101748,https://clinicaltrials.gov/study/NCT02530489,https://clinicaltrials.gov/study/NCT02187991,https://clinicaltrials.gov/study/NCT04216472,https://clinicaltrials.gov/study/NCT02603679,https://clinicaltrials.gov/study/NCT03179904,https://clinicaltrials.gov/study/NCT02436993,https://clinicaltrials.gov/study/NCT04001829
EFO_0000305	breast carcinoma	CHEMBL1421	DASATINIB	Small molecule	Ephrin type-A receptor 2 inhibitor		EPHA2	EPH receptor A2	2	Terminated	https://clinicaltrials.gov/study/NCT05198843
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Withdrawn	https://clinicaltrials.gov/study/NCT02067416,https://clinicaltrials.gov/study/NCT01818999
MONDO_0007254	breast cancer	CHEMBL135	ESTRADIOL	Small molecule	Estrogen receptor alpha agonist	Antagonist	ESR1	estrogen receptor 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05716516,https://clinicaltrials.gov/study/NCT01984138
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA11	NADH:ubiquinone oxidoreductase subunit A11	2	Unknown status	https://clinicaltrials.gov/study/NCT02506777,https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT03192293
EFO_0006861	male breast carcinoma	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	2	Completed	https://clinicaltrials.gov/study/NCT00119262,https://clinicaltrials.gov/study/NCT00513695
MONDO_0007254	breast cancer	CHEMBL3581693	BRILANESTRANT	Small molecule	Estrogen receptor alpha antagonist	Antagonist	ESR1	estrogen receptor 1	2	Terminated	https://clinicaltrials.gov/study/NCT02569801
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02876302,https://clinicaltrials.gov/study/NCT01730833
MONDO_0007254	breast cancer	CHEMBL112	ACETAMINOPHEN	Small molecule	Cyclooxygenase inhibitor		PTGS1	prostaglandin-endoperoxide synthase 1	2	Completed	https://clinicaltrials.gov/study/NCT03084536,https://clinicaltrials.gov/study/NCT02839668
MONDO_0007254	breast cancer	CHEMBL1201199	LEUPROLIDE	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT03879577,https://clinicaltrials.gov/study/NCT03497702
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND3	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3	2	Terminated	https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT01627067
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Terminated	https://clinicaltrials.gov/study/NCT01985841,https://clinicaltrials.gov/study/NCT00118053,https://clinicaltrials.gov/study/NCT00104624,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT03329378,https://clinicaltrials.gov/study/NCT00025493,https://clinicaltrials.gov/study/NCT00479856,https://clinicaltrials.gov/study/NCT00193024,https://clinicaltrials.gov/study/NCT01690325,https://clinicaltrials.gov/study/NCT00080626,https://clinicaltrials.gov/study/NCT00852332,https://clinicaltrials.gov/study/NCT00343512,https://clinicaltrials.gov/study/NCT00206453,https://clinicaltrials.gov/study/NCT00225056,https://clinicaltrials.gov/study/NCT00524459,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT00453635,https://clinicaltrials.gov/study/NCT00665457,https://clinicaltrials.gov/study/NCT00028483,https://clinicaltrials.gov/study/NCT00845910,https://clinicaltrials.gov/study/NCT00576901,https://clinicaltrials.gov/study/NCT00636441,https://clinicaltrials.gov/study/NCT03894007
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Withdrawn	https://clinicaltrials.gov/study/NCT01818999,https://clinicaltrials.gov/study/NCT02067416
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Recruiting	https://clinicaltrials.gov/study/NCT05810870,https://clinicaltrials.gov/study/NCT05546255,https://clinicaltrials.gov/study/NCT04624711,https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT05458674,https://clinicaltrials.gov/study/NCT05530057,https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT06102824
MONDO_0007254	breast cancer	CHEMBL1201583	BEVACIZUMAB	Antibody	Vascular endothelial growth factor A inhibitor		VEGFA	vascular endothelial growth factor A	2	Completed	https://clinicaltrials.gov/study/NCT00394082,https://clinicaltrials.gov/study/NCT00479674,https://clinicaltrials.gov/study/NCT00467012,https://clinicaltrials.gov/study/NCT00392392,https://clinicaltrials.gov/study/NCT01190345,https://clinicaltrials.gov/study/NCT00254592,https://clinicaltrials.gov/study/NCT00662129,https://clinicaltrials.gov/study/NCT00083031,https://clinicaltrials.gov/study/NCT01989780,https://clinicaltrials.gov/study/NCT00546156,https://clinicaltrials.gov/study/NCT00559845,https://clinicaltrials.gov/study/NCT00670982,https://clinicaltrials.gov/study/NCT00559754,https://clinicaltrials.gov/study/NCT00217672,https://clinicaltrials.gov/study/NCT00055861,https://clinicaltrials.gov/study/NCT00820547,https://clinicaltrials.gov/study/NCT00027885,https://clinicaltrials.gov/study/NCT01722968,https://clinicaltrials.gov/study/NCT01004172,https://clinicaltrials.gov/study/NCT00654836,https://clinicaltrials.gov/study/NCT00618657,https://clinicaltrials.gov/study/NCT00915603,https://clinicaltrials.gov/study/NCT00723125,https://clinicaltrials.gov/study/NCT00305825,https://clinicaltrials.gov/study/NCT00846027,https://clinicaltrials.gov/study/NCT00675259,https://clinicaltrials.gov/study/NCT00394251,https://clinicaltrials.gov/study/NCT01201265,https://clinicaltrials.gov/study/NCT00161291,https://clinicaltrials.gov/study/NCT00811135,https://clinicaltrials.gov/study/NCT00464646,https://clinicaltrials.gov/study/NCT00320541,https://clinicaltrials.gov/study/NCT00203502,https://clinicaltrials.gov/study/NCT00365365,https://clinicaltrials.gov/study/NCT01186991,https://clinicaltrials.gov/study/NCT00754351,https://clinicaltrials.gov/study/NCT02005549,https://clinicaltrials.gov/study/NCT00773695,https://clinicaltrials.gov/study/NCT00618826,https://clinicaltrials.gov/study/NCT00016549,https://clinicaltrials.gov/study/NCT04408118,https://clinicaltrials.gov/study/NCT00608972,https://clinicaltrials.gov/study/NCT00503906,https://clinicaltrials.gov/study/NCT00203372,https://clinicaltrials.gov/study/NCT00428922,https://clinicaltrials.gov/study/NCT00405938,https://clinicaltrials.gov/study/NCT01959490,https://clinicaltrials.gov/study/NCT00088998,https://clinicaltrials.gov/study/NCT01025349,https://clinicaltrials.gov/study/NCT03577743,https://clinicaltrials.gov/study/NCT00423917,https://clinicaltrials.gov/study/NCT01658033,https://clinicaltrials.gov/study/NCT01256762,https://clinicaltrials.gov/study/NCT00511459,https://clinicaltrials.gov/study/NCT00717405,https://clinicaltrials.gov/study/NCT00623233,https://clinicaltrials.gov/study/NCT00733408,https://clinicaltrials.gov/study/NCT00364611,https://clinicaltrials.gov/study/NCT00472693,https://clinicaltrials.gov/study/NCT00580333,https://clinicaltrials.gov/study/NCT01208480,https://clinicaltrials.gov/study/NCT00365417,https://clinicaltrials.gov/study/NCT00370552,https://clinicaltrials.gov/study/NCT00240071,https://clinicaltrials.gov/study/NCT00445406,https://clinicaltrials.gov/study/NCT01142778,https://clinicaltrials.gov/study/NCT00403130,https://clinicaltrials.gov/study/NCT00856492,https://clinicaltrials.gov/study/NCT01367028
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Withdrawn	https://clinicaltrials.gov/study/NCT05809895,https://clinicaltrials.gov/study/NCT00005614
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04034823,https://clinicaltrials.gov/study/NCT04290793,https://clinicaltrials.gov/study/NCT06291064,https://clinicaltrials.gov/study/NCT06348134
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Terminated	https://clinicaltrials.gov/study/NCT03709082,https://clinicaltrials.gov/study/NCT01702558,https://clinicaltrials.gov/study/NCT03894007
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA7	NADH:ubiquinone oxidoreductase subunit A7	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL3647420	PYROTINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04293276,https://clinicaltrials.gov/study/NCT04398914,https://clinicaltrials.gov/study/NCT04486911,https://clinicaltrials.gov/study/NCT04001621,https://clinicaltrials.gov/study/NCT03691051,https://clinicaltrials.gov/study/NCT04126525
EFO_0006861	male breast carcinoma	CHEMBL1201179	LAPATINIB DITOSYLATE	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Terminated	https://clinicaltrials.gov/study/NCT01868503
MONDO_0007254	breast cancer	CHEMBL25	ASPIRIN	Small molecule	Cyclooxygenase inhibitor		PTGS1	prostaglandin-endoperoxide synthase 1	2	Withdrawn	https://clinicaltrials.gov/study/NCT04038489,https://clinicaltrials.gov/study/NCT03794596
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Unknown status	https://clinicaltrials.gov/study/NCT02175446
EFO_0000305	breast carcinoma	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06179303
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA6	NADH:ubiquinone oxidoreductase subunit A6	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0005537	triple-negative breast cancer	CHEMBL1079742	ERLOTINIB HYDROCHLORIDE	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Completed	https://clinicaltrials.gov/study/NCT00733408
MONDO_0007254	breast cancer	CHEMBL1289494	TIVOZANIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Terminated	https://clinicaltrials.gov/study/NCT01745367
MONDO_0007254	breast cancer	CHEMBL223360	LINIFANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Completed	https://clinicaltrials.gov/study/NCT00645177
EFO_0005537	triple-negative breast cancer	CHEMBL4297892	ANVATABART OPADOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBA1A	tubulin alpha 1a	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT04329065,https://clinicaltrials.gov/study/NCT05891561,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT03412643,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT05749016,https://clinicaltrials.gov/study/NCT05900206,https://clinicaltrials.gov/study/NCT05041842,https://clinicaltrials.gov/study/NCT05483439,https://clinicaltrials.gov/study/NCT04802759,https://clinicaltrials.gov/study/NCT05020860,https://clinicaltrials.gov/study/NCT03820141,https://clinicaltrials.gov/study/NCT05292742,https://clinicaltrials.gov/study/NCT04569747,https://clinicaltrials.gov/study/NCT04578106,https://clinicaltrials.gov/study/NCT05638594,https://clinicaltrials.gov/study/NCT05325632,https://clinicaltrials.gov/study/NCT01817452,https://clinicaltrials.gov/study/NCT04425018,https://clinicaltrials.gov/study/NCT05332561,https://clinicaltrials.gov/study/NCT05426486,https://clinicaltrials.gov/study/NCT05353361,https://clinicaltrials.gov/study/NCT04717531,https://clinicaltrials.gov/study/NCT05954143,https://clinicaltrials.gov/study/NCT05180006,https://clinicaltrials.gov/study/NCT04993014
EFO_0000305	breast carcinoma	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		HCK	HCK proto-oncogene, Src family tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT05198843
EFO_0006861	male breast carcinoma	CHEMBL941	IMATINIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00045188
MONDO_0007254	breast cancer	CHEMBL4297843	TORIPALIMAB	Antibody	Programmed cell death protein 1 antagonist		PDCD1	programmed cell death 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04418154
EFO_0000304	breast adenocarcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT04197687
MONDO_0007254	breast cancer	CHEMBL1756	ESTRAMUSTINE PHOSPHATE	Small molecule	Estrogen receptor beta modulator	Antagonist	ESR2	estrogen receptor 2	2	Unknown status	https://clinicaltrials.gov/study/NCT00003066
EFO_0006861	male breast carcinoma	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator	Antagonist	ESR1	estrogen receptor 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05501704
EFO_0005537	triple-negative breast cancer	CHEMBL3545414	RIVOCERANIB MESYLATE	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT05192798,https://clinicaltrials.gov/study/NCT03775928,https://clinicaltrials.gov/study/NCT05556200
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA7	NADH:ubiquinone oxidoreductase subunit A7	2	Recruiting	https://clinicaltrials.gov/study/NCT04559308,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT03238495
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Unknown status	https://clinicaltrials.gov/study/NCT03412955,https://clinicaltrials.gov/study/NCT02175446
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Terminated	https://clinicaltrials.gov/study/NCT00765765,https://clinicaltrials.gov/study/NCT00079326,https://clinicaltrials.gov/study/NCT00790894
MONDO_0007254	breast cancer	CHEMBL4297939	DATOPOTAMAB DERUXTECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT05866432
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC8	histone deacetylase 8	2	Completed	https://clinicaltrials.gov/study/NCT00777049
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN5A	sodium voltage-gated channel alpha subunit 5	2	Completed	https://clinicaltrials.gov/study/NCT02839668,https://clinicaltrials.gov/study/NCT01204242
MONDO_0007254	breast cancer	CHEMBL103	PROGESTERONE	Small molecule	Progesterone receptor agonist		PGR	progesterone receptor	2	Completed	https://clinicaltrials.gov/study/NCT00577122
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00376805,https://clinicaltrials.gov/study/NCT00074269
MONDO_0007254	breast cancer	CHEMBL4650989	TALETRECTINIB	Small molecule	Neurotrophic tyrosine kinase receptor inhibitor		NTRK3	neurotrophic receptor tyrosine kinase 3	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06214793
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Tyrosine-protein kinase ITK/TSK inhibitor		ITK	IL2 inducible T cell kinase	2	Completed	https://clinicaltrials.gov/study/NCT00509587,https://clinicaltrials.gov/study/NCT01466972
MONDO_0007254	breast cancer	CHEMBL52885	ENMD-981693	Small molecule	Serine/threonine-protein kinase Aurora-A inhibitor		AURKA	aurora kinase A	2	Completed	https://clinicaltrials.gov/study/NCT00306631
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4L2	NDUFA4 mitochondrial complex associated like 2	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1201334	TRIPTORELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	2	Completed	https://clinicaltrials.gov/study/NCT02005887,https://clinicaltrials.gov/study/NCT03397537,https://clinicaltrials.gov/study/NCT04659551
MONDO_0007254	breast cancer	CHEMBL1201334	TRIPTORELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT05896566
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT00861705
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS2	NADH:ubiquinone oxidoreductase core subunit S2	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03567720,https://clinicaltrials.gov/study/NCT01815242,https://clinicaltrials.gov/study/NCT04297267,https://clinicaltrials.gov/study/NCT04262804,https://clinicaltrials.gov/study/NCT02252887
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Recruiting	https://clinicaltrials.gov/study/NCT05570253,https://clinicaltrials.gov/study/NCT05402722
MONDO_0007254	breast cancer	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00095888,https://clinicaltrials.gov/study/NCT00323063,https://clinicaltrials.gov/study/NCT00470249,https://clinicaltrials.gov/study/NCT00679029
EFO_0006861	male breast carcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC8	histone deacetylase 8	2	Completed	https://clinicaltrials.gov/study/NCT00098397
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT01466972,https://clinicaltrials.gov/study/NCT00509587
MONDO_0007254	breast cancer	CHEMBL3301587	DURVALUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03616886,https://clinicaltrials.gov/study/NCT04176848,https://clinicaltrials.gov/study/NCT04538742,https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT04053322
MONDO_0007254	breast cancer	CHEMBL4650989	TALETRECTINIB	Small molecule	Neurotrophic tyrosine kinase receptor inhibitor		NTRK2	neurotrophic receptor tyrosine kinase 2	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06214793
MONDO_0007254	breast cancer	CHEMBL1567	SUNITINIB MALATE	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT00824538
MONDO_0007254	breast cancer	CHEMBL20684	ABT-751	Small molecule	Tubulin beta inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT00063102
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02568839,https://clinicaltrials.gov/study/NCT04001829
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Withdrawn	https://clinicaltrials.gov/study/NCT05177796
EFO_0005537	triple-negative breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Recruiting	https://clinicaltrials.gov/study/NCT05670925
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND6	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000304	breast adenocarcinoma	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02957968
MONDO_0007254	breast cancer	CHEMBL185	FLUOROURACIL	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	2	Terminated	https://clinicaltrials.gov/study/NCT01937507,https://clinicaltrials.gov/study/NCT00756470,https://clinicaltrials.gov/study/NCT01985841
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4	NDUFA4 mitochondrial complex associated	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC4	histone deacetylase 4	2	Completed	https://clinicaltrials.gov/study/NCT00777049
EFO_0006861	male breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
MONDO_0007254	breast cancer	CHEMBL1201748	CABAZITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Recruiting	https://clinicaltrials.gov/study/NCT03048942
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04053322,https://clinicaltrials.gov/study/NCT03330847,https://clinicaltrials.gov/study/NCT02624973,https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT02208375
MONDO_0007254	breast cancer	CHEMBL2146883	COBIMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 2 inhibitor		MAP2K2	mitogen-activated protein kinase kinase 2	2	Terminated	https://clinicaltrials.gov/study/NCT02322814
MONDO_0007254	breast cancer	CHEMBL1200501	GOSERELIN ACETATE	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	2	Withdrawn	https://clinicaltrials.gov/study/NCT00217659
MONDO_0007254	breast cancer	CHEMBL1879463	DACTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R2	phosphoinositide-3-kinase regulatory subunit 2	2	Withdrawn	https://clinicaltrials.gov/study/NCT01288092
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT00321633
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT02199418
EFO_0000305	breast carcinoma	CHEMBL3301587	DURVALUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967
EFO_0000305	breast carcinoma	CHEMBL4297545	LUTETIUM OXODOTREOTIDE LU-177	Protein	Somatostatin receptor binding agent		SSTR3	somatostatin receptor 3	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04529044
MONDO_0007254	breast cancer	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RA	interleukin 2 receptor subunit alpha	2	Completed	https://clinicaltrials.gov/study/NCT00006228,https://clinicaltrials.gov/study/NCT01105650
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Terminated	https://clinicaltrials.gov/study/NCT03709082,https://clinicaltrials.gov/study/NCT03894007,https://clinicaltrials.gov/study/NCT01702558
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist	Antagonist	ESR1	estrogen receptor 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03781063,https://clinicaltrials.gov/study/NCT03393845,https://clinicaltrials.gov/study/NCT02632045,https://clinicaltrials.gov/study/NCT00585507,https://clinicaltrials.gov/study/NCT03147287,https://clinicaltrials.gov/study/NCT03633331,https://clinicaltrials.gov/study/NCT03056755,https://clinicaltrials.gov/study/NCT04214288,https://clinicaltrials.gov/study/NCT04603183,https://clinicaltrials.gov/study/NCT04576455,https://clinicaltrials.gov/study/NCT02738866,https://clinicaltrials.gov/study/NCT01441947,https://clinicaltrials.gov/study/NCT02955394,https://clinicaltrials.gov/study/NCT04524000,https://clinicaltrials.gov/study/NCT04352777,https://clinicaltrials.gov/study/NCT04024436,https://clinicaltrials.gov/study/NCT01560416,https://clinicaltrials.gov/study/NCT04059484,https://clinicaltrials.gov/study/NCT04224272,https://clinicaltrials.gov/study/NCT05384119,https://clinicaltrials.gov/study/NCT05574881,https://clinicaltrials.gov/study/NCT02206984,https://clinicaltrials.gov/study/NCT03939897,https://clinicaltrials.gov/study/NCT04053322,https://clinicaltrials.gov/study/NCT05090358
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC2	NADH:ubiquinone oxidoreductase subunit C2	2	Completed	https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT04170465
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB5	NADH:ubiquinone oxidoreductase subunit B5	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Terminated	https://clinicaltrials.gov/study/NCT02978716
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	2	Withdrawn	https://clinicaltrials.gov/study/NCT04351230
MONDO_0007254	breast cancer	CHEMBL1743001	CIXUTUMUMAB	Antibody	Insulin-like growth factor I receptor antagonist		IGF1R	insulin like growth factor 1 receptor	2	Completed	https://clinicaltrials.gov/study/NCT00728949
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967,https://clinicaltrials.gov/study/NCT04266249,https://clinicaltrials.gov/study/NCT04090398
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		SRC	SRC proto-oncogene, non-receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00754325,https://clinicaltrials.gov/study/NCT00767520,https://clinicaltrials.gov/study/NCT00410813,https://clinicaltrials.gov/study/NCT00696072,https://clinicaltrials.gov/study/NCT00546104
MONDO_0007254	breast cancer	CHEMBL3545097	SAPANISERTIB	Small molecule	Serine/threonine-protein kinase mTOR inhibitor		MTOR	mechanistic target of rapamycin kinase	2	Completed	https://clinicaltrials.gov/study/NCT02049957,https://clinicaltrials.gov/study/NCT02988986,https://clinicaltrials.gov/study/NCT03193853
MONDO_0007254	breast cancer	CHEMBL3545262	SACITUZUMAB GOVITECAN	Antibody drug conjugate	Tumor-associated calcium signal transducer 2 binding agent		TACSTD2	tumor associated calcium signal transducer 2	2	Recruiting	https://clinicaltrials.gov/study/NCT04468061,https://clinicaltrials.gov/study/NCT05332561,https://clinicaltrials.gov/study/NCT04230109,https://clinicaltrials.gov/study/NCT06102824,https://clinicaltrials.gov/study/NCT05675579,https://clinicaltrials.gov/study/NCT06100874,https://clinicaltrials.gov/study/NCT04039230,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT06328387
EFO_0005537	triple-negative breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT03154749,https://clinicaltrials.gov/study/NCT02413320
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA2	NADH:ubiquinone oxidoreductase subunit A2	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		PSEN1	presenilin 1	2	Terminated	https://clinicaltrials.gov/study/NCT01151449
EFO_0005537	triple-negative breast cancer	CHEMBL359744	DOXORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Completed	https://clinicaltrials.gov/study/NCT02456857,https://clinicaltrials.gov/study/NCT02648477
MONDO_0007254	breast cancer	CHEMBL1276308	MIFEPRISTONE	Small molecule	Progesterone receptor antagonist		PGR	progesterone receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03225547,https://clinicaltrials.gov/study/NCT02788981
MONDO_0007254	breast cancer	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Unknown status	https://clinicaltrials.gov/study/NCT00687648,https://clinicaltrials.gov/study/NCT02313051,https://clinicaltrials.gov/study/NCT02214004,https://clinicaltrials.gov/study/NCT03507465,https://clinicaltrials.gov/study/NCT00954135,https://clinicaltrials.gov/study/NCT02958852,https://clinicaltrials.gov/study/NCT00280930,https://clinicaltrials.gov/study/NCT01709370
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Recruiting	https://clinicaltrials.gov/study/NCT04924699
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Withdrawn	https://clinicaltrials.gov/study/NCT02725541
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04001829,https://clinicaltrials.gov/study/NCT02568839
EFO_0000305	breast carcinoma	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Recruiting	https://clinicaltrials.gov/study/NCT04553770,https://clinicaltrials.gov/study/NCT02476786,https://clinicaltrials.gov/study/NCT05150652
EFO_0000305	breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999
MONDO_0007254	breast cancer	CHEMBL1922094	APITOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	2	Completed	https://clinicaltrials.gov/study/NCT01437566
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FRK	fyn related Src family tyrosine kinase	2	Withdrawn	https://clinicaltrials.gov/study/NCT01410708
EFO_0000305	breast carcinoma	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	2	Recruiting	https://clinicaltrials.gov/study/NCT02778685
MONDO_0007254	breast cancer	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT04891068
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT01427933,https://clinicaltrials.gov/study/NCT02263495,https://clinicaltrials.gov/study/NCT01269346,https://clinicaltrials.gov/study/NCT01593020,https://clinicaltrials.gov/study/NCT02481050,https://clinicaltrials.gov/study/NCT01908101,https://clinicaltrials.gov/study/NCT04464174,https://clinicaltrials.gov/study/NCT01669252,https://clinicaltrials.gov/study/NCT01941407,https://clinicaltrials.gov/study/NCT01827787,https://clinicaltrials.gov/study/NCT00965523,https://clinicaltrials.gov/study/NCT01705691,https://clinicaltrials.gov/study/NCT00879086,https://clinicaltrials.gov/study/NCT03051659,https://clinicaltrials.gov/study/NCT00246090,https://clinicaltrials.gov/study/NCT01268150,https://clinicaltrials.gov/study/NCT01401959,https://clinicaltrials.gov/study/NCT03222856,https://clinicaltrials.gov/study/NCT05206656,https://clinicaltrials.gov/study/NCT01439282,https://clinicaltrials.gov/study/NCT01527487
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT02199418
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND6	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL58	MITOXANTRONE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Terminated	https://clinicaltrials.gov/study/NCT04927481
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Withdrawn	https://clinicaltrials.gov/study/NCT00005614,https://clinicaltrials.gov/study/NCT05809895
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02624973,https://clinicaltrials.gov/study/NCT02547987,https://clinicaltrials.gov/study/NCT01779206,https://clinicaltrials.gov/study/NCT02568839,https://clinicaltrials.gov/study/NCT00496795,https://clinicaltrials.gov/study/NCT03609047,https://clinicaltrials.gov/study/NCT04172259,https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT00295893,https://clinicaltrials.gov/study/NCT03161353,https://clinicaltrials.gov/study/NCT02339532
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC10	histone deacetylase 10	2	Terminated	https://clinicaltrials.gov/study/NCT00777335
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Unknown status	https://clinicaltrials.gov/study/NCT02790580
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB4	NADH:ubiquinone oxidoreductase subunit B4	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB9	NADH:ubiquinone oxidoreductase subunit B9	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator	Antagonist	ESR1	estrogen receptor 1	2	Completed	https://clinicaltrials.gov/study/NCT00253539
MONDO_0007254	breast cancer	CHEMBL2364649	MARGETUXIMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT01828021
EFO_0006861	male breast carcinoma	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	2	Recruiting	https://clinicaltrials.gov/study/NCT05501704
EFO_0005537	triple-negative breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT02413320,https://clinicaltrials.gov/study/NCT03154749
MONDO_0007254	breast cancer	CHEMBL1079742	ERLOTINIB HYDROCHLORIDE	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Withdrawn	https://clinicaltrials.gov/study/NCT01013506
MONDO_0007254	breast cancer	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		PSEN2	presenilin 2	2	Terminated	https://clinicaltrials.gov/study/NCT01151449
EFO_0005537	triple-negative breast cancer	CHEMBL4298101	LADIRATUZUMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0005537	triple-negative breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Suspended	https://clinicaltrials.gov/study/NCT04095689
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT00971945,https://clinicaltrials.gov/study/NCT05112536,https://clinicaltrials.gov/study/NCT02280252,https://clinicaltrials.gov/study/NCT00096668,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT01506609,https://clinicaltrials.gov/study/NCT01855828,https://clinicaltrials.gov/study/NCT01816594,https://clinicaltrials.gov/study/NCT01705691,https://clinicaltrials.gov/study/NCT01432223,https://clinicaltrials.gov/study/NCT02073487,https://clinicaltrials.gov/study/NCT00675259,https://clinicaltrials.gov/study/NCT01835236,https://clinicaltrials.gov/study/NCT00004013,https://clinicaltrials.gov/study/NCT00662129,https://clinicaltrials.gov/study/NCT00096291,https://clinicaltrials.gov/study/NCT01818063,https://clinicaltrials.gov/study/NCT03742986,https://clinicaltrials.gov/study/NCT02685059,https://clinicaltrials.gov/study/NCT00194779,https://clinicaltrials.gov/study/NCT00394251,https://clinicaltrials.gov/study/NCT00944047,https://clinicaltrials.gov/study/NCT00930930,https://clinicaltrials.gov/study/NCT00003392,https://clinicaltrials.gov/study/NCT00532857,https://clinicaltrials.gov/study/NCT00254592,https://clinicaltrials.gov/study/NCT00007904,https://clinicaltrials.gov/study/NCT00001498,https://clinicaltrials.gov/study/NCT00768859,https://clinicaltrials.gov/study/NCT01421472,https://clinicaltrials.gov/study/NCT01106898,https://clinicaltrials.gov/study/NCT00072319,https://clinicaltrials.gov/study/NCT00005649,https://clinicaltrials.gov/study/NCT01204437,https://clinicaltrials.gov/study/NCT00475670,https://clinicaltrials.gov/study/NCT01982448,https://clinicaltrials.gov/study/NCT00003035,https://clinicaltrials.gov/study/NCT04408118,https://clinicaltrials.gov/study/NCT03853707,https://clinicaltrials.gov/study/NCT00618657,https://clinicaltrials.gov/study/NCT00542451,https://clinicaltrials.gov/study/NCT00455533,https://clinicaltrials.gov/study/NCT01320111,https://clinicaltrials.gov/study/NCT03289819,https://clinicaltrials.gov/study/NCT00003050,https://clinicaltrials.gov/study/NCT00193206,https://clinicaltrials.gov/study/NCT02687490,https://clinicaltrials.gov/study/NCT00052351,https://clinicaltrials.gov/study/NCT02698891,https://clinicaltrials.gov/study/NCT03644186,https://clinicaltrials.gov/study/NCT02954055,https://clinicaltrials.gov/study/NCT00511459,https://clinicaltrials.gov/study/NCT01307891,https://clinicaltrials.gov/study/NCT01594177,https://clinicaltrials.gov/study/NCT01203267,https://clinicaltrials.gov/study/NCT01276041,https://clinicaltrials.gov/study/NCT00392392,https://clinicaltrials.gov/study/NCT02263495,https://clinicaltrials.gov/study/NCT01190982,https://clinicaltrials.gov/study/NCT00773695,https://clinicaltrials.gov/study/NCT02474186,https://clinicaltrials.gov/study/NCT00146562,https://clinicaltrials.gov/study/NCT00503906,https://clinicaltrials.gov/study/NCT00915018,https://clinicaltrials.gov/study/NCT00856492,https://clinicaltrials.gov/study/NCT00503750,https://clinicaltrials.gov/study/NCT02628613,https://clinicaltrials.gov/study/NCT01656538,https://clinicaltrials.gov/study/NCT01204125,https://clinicaltrials.gov/study/NCT01672671,https://clinicaltrials.gov/study/NCT03072992,https://clinicaltrials.gov/study/NCT00028873,https://clinicaltrials.gov/study/NCT00003612,https://clinicaltrials.gov/study/NCT00467012,https://clinicaltrials.gov/study/NCT01008150,https://clinicaltrials.gov/study/NCT01722968,https://clinicaltrials.gov/study/NCT00001384,https://clinicaltrials.gov/study/NCT00403130,https://clinicaltrials.gov/study/NCT00136539,https://clinicaltrials.gov/study/NCT02783222,https://clinicaltrials.gov/study/NCT00006110,https://clinicaltrials.gov/study/NCT02938442,https://clinicaltrials.gov/study/NCT01023204,https://clinicaltrials.gov/study/NCT00002826,https://clinicaltrials.gov/study/NCT02370238,https://clinicaltrials.gov/study/NCT00635050,https://clinicaltrials.gov/study/NCT02789657,https://clinicaltrials.gov/study/NCT03887130,https://clinicaltrials.gov/study/NCT01989780,https://clinicaltrials.gov/study/NCT00274456,https://clinicaltrials.gov/study/NCT01973660,https://clinicaltrials.gov/study/NCT00148681,https://clinicaltrials.gov/study/NCT00795899,https://clinicaltrials.gov/study/NCT03121352,https://clinicaltrials.gov/study/NCT00002679,https://clinicaltrials.gov/study/NCT01779479,https://clinicaltrials.gov/study/NCT00919880,https://clinicaltrials.gov/study/NCT00316199,https://clinicaltrials.gov/study/NCT00019812,https://clinicaltrials.gov/study/NCT00334802,https://clinicaltrials.gov/study/NCT00436566,https://clinicaltrials.gov/study/NCT03982485,https://clinicaltrials.gov/study/NCT00003539,https://clinicaltrials.gov/study/NCT02909751,https://clinicaltrials.gov/study/NCT01969032,https://clinicaltrials.gov/study/NCT00407888,https://clinicaltrials.gov/study/NCT00629499,https://clinicaltrials.gov/study/NCT04224922,https://clinicaltrials.gov/study/NCT00003992,https://clinicaltrials.gov/study/NCT00654836,https://clinicaltrials.gov/study/NCT01827163,https://clinicaltrials.gov/study/NCT00559845,https://clinicaltrials.gov/study/NCT01186991,https://clinicaltrials.gov/study/NCT00004092,https://clinicaltrials.gov/study/NCT01792050,https://clinicaltrials.gov/study/NCT01423695,https://clinicaltrials.gov/study/NCT00546156,https://clinicaltrials.gov/study/NCT03326102,https://clinicaltrials.gov/study/NCT01959490,https://clinicaltrials.gov/study/NCT01446016,https://clinicaltrials.gov/study/NCT00915603,https://clinicaltrials.gov/study/NCT00093145,https://clinicaltrials.gov/study/NCT02132949,https://clinicaltrials.gov/study/NCT00191854,https://clinicaltrials.gov/study/NCT03248427,https://clinicaltrials.gov/study/NCT00128856,https://clinicaltrials.gov/study/NCT00005635,https://clinicaltrials.gov/study/NCT01617668,https://clinicaltrials.gov/study/NCT00723125,https://clinicaltrials.gov/study/NCT01256762,https://clinicaltrials.gov/study/NCT00499083,https://clinicaltrials.gov/study/NCT01740336,https://clinicaltrials.gov/study/NCT02365805,https://clinicaltrials.gov/study/NCT01036087,https://clinicaltrials.gov/study/NCT00096343,https://clinicaltrials.gov/study/NCT00846027,https://clinicaltrials.gov/study/NCT00580333,https://clinicaltrials.gov/study/NCT01847001,https://clinicaltrials.gov/study/NCT00733408,https://clinicaltrials.gov/study/NCT03301350,https://clinicaltrials.gov/study/NCT00618826,https://clinicaltrials.gov/study/NCT00320541,https://clinicaltrials.gov/study/NCT01688609,https://clinicaltrials.gov/study/NCT00479674,https://clinicaltrials.gov/study/NCT02301988,https://clinicaltrials.gov/study/NCT00378313,https://clinicaltrials.gov/study/NCT00006256,https://clinicaltrials.gov/study/NCT00251472,https://clinicaltrials.gov/study/NCT00110084,https://clinicaltrials.gov/study/NCT00370552,https://clinicaltrials.gov/study/NCT00256243,https://clinicaltrials.gov/study/NCT02225652,https://clinicaltrials.gov/study/NCT01565499,https://clinicaltrials.gov/study/NCT01593020,https://clinicaltrials.gov/study/NCT00394082,https://clinicaltrials.gov/study/NCT00002937,https://clinicaltrials.gov/study/NCT00645177,https://clinicaltrials.gov/study/NCT00482391,https://clinicaltrials.gov/study/NCT01572727,https://clinicaltrials.gov/study/NCT02229084,https://clinicaltrials.gov/study/NCT03193853
MONDO_0007254	breast cancer	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	2	Terminated	https://clinicaltrials.gov/study/NCT00573755,https://clinicaltrials.gov/study/NCT00722072,https://clinicaltrials.gov/study/NCT00622466
MONDO_0007254	breast cancer	CHEMBL4279455	LAROTAXEL	Small molecule	Tubulin stabiliser		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT00387907,https://clinicaltrials.gov/study/NCT00087958
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	2	Completed	https://clinicaltrials.gov/study/NCT03167619,https://clinicaltrials.gov/study/NCT03205761
EFO_0005537	triple-negative breast cancer	CHEMBL4297840	TISLELIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Recruiting	https://clinicaltrials.gov/study/NCT04914390,https://clinicaltrials.gov/study/NCT04501523
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT00431704,https://clinicaltrials.gov/study/NCT04262804,https://clinicaltrials.gov/study/NCT03414658
MONDO_0007254	breast cancer	CHEMBL679	EPINEPHRINE	Small molecule	Adrenergic receptor agonist		ADRA2A	adrenoceptor alpha 2A	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04603911
MONDO_0007254	breast cancer	CHEMBL1234354	PF-04691502	Small molecule	PI3-kinase class I inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	2	Terminated	https://clinicaltrials.gov/study/NCT01430585
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB3	NADH:ubiquinone oxidoreductase subunit B3	2	Completed	https://clinicaltrials.gov/study/NCT01885013
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT02978495
MONDO_0007254	breast cancer	CHEMBL3894860	TRILACICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0005537	triple-negative breast cancer	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Withdrawn	https://clinicaltrials.gov/study/NCT00450515
MONDO_0007254	breast cancer	CHEMBL3894860	TRILACICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05113966
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02624973,https://clinicaltrials.gov/study/NCT04053322,https://clinicaltrials.gov/study/NCT02208375,https://clinicaltrials.gov/study/NCT03330847,https://clinicaltrials.gov/study/NCT02299999
EFO_0005537	triple-negative breast cancer	CHEMBL3894860	TRILACICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	2	Terminated	https://clinicaltrials.gov/study/NCT02978716
EFO_0000305	breast carcinoma	CHEMBL4285417	CERALASERTIB	Small molecule	Serine-protein kinase ATR inhibitor		ATR	ATR serine/threonine kinase	2	Recruiting	https://clinicaltrials.gov/study/NCT04090567
EFO_0000305	breast carcinoma	CHEMBL553	ERLOTINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Completed	https://clinicaltrials.gov/study/NCT00054132
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA2	NADH:ubiquinone oxidoreductase subunit A2	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Recruiting	https://clinicaltrials.gov/study/NCT05570253,https://clinicaltrials.gov/study/NCT05402722
MONDO_0007254	breast cancer	CHEMBL522892	DOVITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Terminated	https://clinicaltrials.gov/study/NCT01528345
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Recruiting	https://clinicaltrials.gov/study/NCT05823623,https://clinicaltrials.gov/study/NCT04304352,https://clinicaltrials.gov/study/NCT05296577,https://clinicaltrials.gov/study/NCT06102824,https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT04759248,https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT04302441,https://clinicaltrials.gov/study/NCT04605575,https://clinicaltrials.gov/study/NCT05747326,https://clinicaltrials.gov/study/NCT04296162,https://clinicaltrials.gov/study/NCT03939871,https://clinicaltrials.gov/study/NCT04389073
EFO_0000305	breast carcinoma	CHEMBL4594611	PATRITUMAB DERUXTECAN	Antibody drug conjugate	Receptor tyrosine-protein kinase erbB-3 binding agent		ERBB3	erb-b2 receptor tyrosine kinase 3	2	Recruiting	https://clinicaltrials.gov/study/NCT06298084
MONDO_0007254	breast cancer	CHEMBL2220486	LUCITANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Terminated	https://clinicaltrials.gov/study/NCT02202746
MONDO_0007254	breast cancer	CHEMBL637	VENLAFAXINE	Small molecule	Serotonin transporter inhibitor		SLC6A4	solute carrier family 6 member 4	2	Completed	https://clinicaltrials.gov/study/NCT00198250
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA1	NADH:ubiquinone oxidoreductase subunit A1	2	Completed	https://clinicaltrials.gov/study/NCT01885013
MONDO_0007254	breast cancer	CHEMBL1276308	MIFEPRISTONE	Small molecule	Glucocorticoid receptor antagonist		NR3C1	nuclear receptor subfamily 3 group C member 1	2	Recruiting	https://clinicaltrials.gov/study/NCT06099769
MONDO_0007254	breast cancer	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Withdrawn	https://clinicaltrials.gov/study/NCT03058939
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBA1A	tubulin alpha 1a	2	Withdrawn	https://clinicaltrials.gov/study/NCT00450515
EFO_0005537	triple-negative breast cancer	CHEMBL4297892	ANVATABART OPADOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBA1C	tubulin alpha 1c	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT01881230
MONDO_0007254	breast cancer	CHEMBL4302409	LUTETIUM OXODOTREOTIDE	Protein	Somatostatin receptor binding agent		SSTR1	somatostatin receptor 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04529044
MONDO_0007254	breast cancer	CHEMBL1567	SUNITINIB MALATE	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Terminated	https://clinicaltrials.gov/study/NCT00824538
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE4B	phosphodiesterase 4B	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT06186700,https://clinicaltrials.gov/study/NCT06176339
MONDO_0007254	breast cancer	CHEMBL415606	DEGARELIX	Protein	Gonadotropin-releasing hormone receptor antagonist		GNRHR	gonadotropin releasing hormone receptor	2	Completed	https://clinicaltrials.gov/study/NCT02005887
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND6	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FYN	FYN proto-oncogene, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00546104,https://clinicaltrials.gov/study/NCT00696072,https://clinicaltrials.gov/study/NCT00410813,https://clinicaltrials.gov/study/NCT00754325,https://clinicaltrials.gov/study/NCT00767520
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Terminated	https://clinicaltrials.gov/study/NCT00832338
MONDO_0007254	breast cancer	CHEMBL2304041	SAGOPILONE	Small molecule	Tubulin stabiliser		TUBA3C	tubulin alpha 3c	2	Completed	https://clinicaltrials.gov/study/NCT00288249
EFO_0000432	breast ductal carcinoma in situ	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Terminated	https://clinicaltrials.gov/study/NCT00461344
MONDO_0007254	breast cancer	CHEMBL3989514	IRINOTECAN HYDROCHLORIDE	Small molecule	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03328884
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Unknown status	https://clinicaltrials.gov/study/NCT02681562
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB6	NADH:ubiquinone oxidoreductase subunit B6	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1201199	LEUPROLIDE	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03944434,https://clinicaltrials.gov/study/NCT03900637,https://clinicaltrials.gov/study/NCT04576455,https://clinicaltrials.gov/study/NCT03056755
EFO_0005537	triple-negative breast cancer	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Unknown status	https://clinicaltrials.gov/study/NCT03044730
MONDO_0007254	breast cancer	CHEMBL2325741	CAPIVASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT1	AKT serine/threonine kinase 1	2	Unknown status	https://clinicaltrials.gov/study/NCT02423603
EFO_0006861	male breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Fibroblast growth factor receptor 3 inhibitor		FGFR3	fibroblast growth factor receptor 3	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Withdrawn	https://clinicaltrials.gov/study/NCT03032614
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS5	NADH:ubiquinone oxidoreductase subunit S5	2	Completed	https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT00930579
MONDO_0007254	breast cancer	CHEMBL2336325	VISTUSERTIB	Small molecule	Serine/threonine-protein kinase mTOR inhibitor		MTOR	mechanistic target of rapamycin kinase	2	Unknown status	https://clinicaltrials.gov/study/NCT02216786
MONDO_0007254	breast cancer	CHEMBL655	MIDAZOLAM	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRA3	gamma-aminobutyric acid type A receptor subunit alpha3	2	Completed	https://clinicaltrials.gov/study/NCT03084536
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00323063,https://clinicaltrials.gov/study/NCT00679029,https://clinicaltrials.gov/study/NCT00462865,https://clinicaltrials.gov/study/NCT03674242,https://clinicaltrials.gov/study/NCT02213744,https://clinicaltrials.gov/study/NCT00532285,https://clinicaltrials.gov/study/NCT00470249,https://clinicaltrials.gov/study/NCT00159458,https://clinicaltrials.gov/study/NCT00095888,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT00674206
MONDO_0007254	breast cancer	CHEMBL2177390	IPATASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT2	AKT serine/threonine kinase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05498896,https://clinicaltrials.gov/study/NCT03395899
MONDO_0007254	breast cancer	CHEMBL1201583	BEVACIZUMAB	Antibody	Vascular endothelial growth factor A inhibitor		VEGFA	vascular endothelial growth factor A	2	Unknown status	https://clinicaltrials.gov/study/NCT02829008,https://clinicaltrials.gov/study/NCT02175446,https://clinicaltrials.gov/study/NCT01321775,https://clinicaltrials.gov/study/NCT00777673,https://clinicaltrials.gov/study/NCT00378638,https://clinicaltrials.gov/study/NCT00957125,https://clinicaltrials.gov/study/NCT00404404
MONDO_0007254	breast cancer	CHEMBL4279455	LAROTAXEL	Small molecule	Tubulin stabiliser		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT00087958,https://clinicaltrials.gov/study/NCT00387907
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05263882,https://clinicaltrials.gov/study/NCT04517292,https://clinicaltrials.gov/study/NCT04143906
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT05181462,https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT04739670,https://clinicaltrials.gov/study/NCT06026657,https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT06102824,https://clinicaltrials.gov/study/NCT05601440
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4L2	NDUFA4 mitochondrial complex associated like 2	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04559308,https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT03238495
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT02682693,https://clinicaltrials.gov/study/NCT02199418,https://clinicaltrials.gov/study/NCT00513695
EFO_0000305	breast carcinoma	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03179904
MONDO_0007254	breast cancer	CHEMBL2325741	CAPIVASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT1	AKT serine/threonine kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT02077569
MONDO_0007254	breast cancer	CHEMBL4650374	APG-2575	Unknown	Apoptosis regulator Bcl-2 inhibitor		BCL2	BCL2 apoptosis regulator	2	Recruiting	https://clinicaltrials.gov/study/NCT04946864
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Recruiting	https://clinicaltrials.gov/study/NCT05296577,https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT04302441,https://clinicaltrials.gov/study/NCT04389073,https://clinicaltrials.gov/study/NCT05747326,https://clinicaltrials.gov/study/NCT04304352,https://clinicaltrials.gov/study/NCT06102824,https://clinicaltrials.gov/study/NCT04296162,https://clinicaltrials.gov/study/NCT03939871,https://clinicaltrials.gov/study/NCT04605575,https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT04759248,https://clinicaltrials.gov/study/NCT05823623
MONDO_0007254	breast cancer	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator	Antagonist	ESR1	estrogen receptor 1	2	Suspended	https://clinicaltrials.gov/study/NCT00738777
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT00861705
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT00429572,https://clinicaltrials.gov/study/NCT00020176,https://clinicaltrials.gov/study/NCT01105650
MONDO_0007254	breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04733417
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND6	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0005537	triple-negative breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Vascular endothelial growth factor receptor 3 inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04395989,https://clinicaltrials.gov/study/NCT04129996
MONDO_0007254	breast cancer	CHEMBL1614701	SELUMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 1 inhibitor		MAP2K1	mitogen-activated protein kinase kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT01160718
MONDO_0007254	breast cancer	CHEMBL1200694	SEVOFLURANE	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRA4	gamma-aminobutyric acid type A receptor subunit alpha4	2	Completed	https://clinicaltrials.gov/study/NCT02839668
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Epidermal growth factor receptor inhibitor		ERBB3	erb-b2 receptor tyrosine kinase 3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999
MONDO_0007254	breast cancer	CHEMBL3301587	DURVALUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	2	Withdrawn	https://clinicaltrials.gov/study/NCT03872505
MONDO_0007254	breast cancer	CHEMBL3545396	BMS-690514	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Completed	https://clinicaltrials.gov/study/NCT01068704
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Withdrawn	https://clinicaltrials.gov/study/NCT03872505,https://clinicaltrials.gov/study/NCT03841747,https://clinicaltrials.gov/study/NCT02067416,https://clinicaltrials.gov/study/NCT00397761,https://clinicaltrials.gov/study/NCT04038489,https://clinicaltrials.gov/study/NCT02053597,https://clinicaltrials.gov/study/NCT05809895,https://clinicaltrials.gov/study/NCT01163929,https://clinicaltrials.gov/study/NCT01169870,https://clinicaltrials.gov/study/NCT03554109,https://clinicaltrials.gov/study/NCT03058939
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA12	NADH:ubiquinone oxidoreductase subunit A12	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT04559308
EFO_1000984	inflammatory breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02623972
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06229067,https://clinicaltrials.gov/study/NCT04963595,https://clinicaltrials.gov/study/NCT04922008,https://clinicaltrials.gov/study/NCT03997539,https://clinicaltrials.gov/study/NCT04143906
EFO_0000432	breast ductal carcinoma in situ	CHEMBL4303669	ZOLEDRONIC ACID	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	2	Completed	https://clinicaltrials.gov/study/NCT01194440
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Unknown status	https://clinicaltrials.gov/study/NCT02175446
EFO_0000305	breast carcinoma	CHEMBL2108658	TREMELIMUMAB	Antibody	Cytotoxic T-lymphocyte protein 4 inhibitor		CTLA4	cytotoxic T-lymphocyte associated protein 4	2	Completed	https://clinicaltrials.gov/study/NCT02536794
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor		GPD2	glycerol-3-phosphate dehydrogenase 2	2	Unknown status	https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT02506777,https://clinicaltrials.gov/study/NCT02506790
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Recruiting	https://clinicaltrials.gov/study/NCT05383196,https://clinicaltrials.gov/study/NCT03515798
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00679029,https://clinicaltrials.gov/study/NCT00532285,https://clinicaltrials.gov/study/NCT00470249,https://clinicaltrials.gov/study/NCT00159458,https://clinicaltrials.gov/study/NCT00095888,https://clinicaltrials.gov/study/NCT00674206,https://clinicaltrials.gov/study/NCT00462865,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT02213744,https://clinicaltrials.gov/study/NCT00323063,https://clinicaltrials.gov/study/NCT03674242
MONDO_0007254	breast cancer	CHEMBL413	SIROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	2	Terminated	https://clinicaltrials.gov/study/NCT02642094
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT00321633
EFO_0005537	triple-negative breast cancer	CHEMBL3545132	MIRVETUXIMAB SORAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT03106077
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS4	NADH:ubiquinone oxidoreductase subunit S4	2	Completed	https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT01589367
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Completed	https://clinicaltrials.gov/study/NCT01881230
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF1	NADH:ubiquinone oxidoreductase complex assembly factor 1	2	Unknown status	https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT02506777
EFO_0006861	male breast carcinoma	CHEMBL359744	DOXORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Completed	https://clinicaltrials.gov/study/NCT00119262,https://clinicaltrials.gov/study/NCT00513695
EFO_0006861	male breast carcinoma	CHEMBL554	LAPATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Completed	https://clinicaltrials.gov/study/NCT00098605,https://clinicaltrials.gov/study/NCT00118157
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Withdrawn	https://clinicaltrials.gov/study/NCT02215876,https://clinicaltrials.gov/study/NCT03637868
MONDO_0007254	breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	2	Recruiting	https://clinicaltrials.gov/study/NCT05766410,https://clinicaltrials.gov/study/NCT05464173,https://clinicaltrials.gov/study/NCT05563220,https://clinicaltrials.gov/study/NCT04802759,https://clinicaltrials.gov/study/NCT05524584,https://clinicaltrials.gov/study/NCT05933395,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT05501704,https://clinicaltrials.gov/study/NCT05608252,https://clinicaltrials.gov/study/NCT04523857,https://clinicaltrials.gov/study/NCT05548127,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04791384,https://clinicaltrials.gov/study/NCT04614194
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT02789657,https://clinicaltrials.gov/study/NCT00005649,https://clinicaltrials.gov/study/NCT01779479,https://clinicaltrials.gov/study/NCT02474186,https://clinicaltrials.gov/study/NCT00407888,https://clinicaltrials.gov/study/NCT03326102,https://clinicaltrials.gov/study/NCT01982448,https://clinicaltrials.gov/study/NCT00499083,https://clinicaltrials.gov/study/NCT02225652,https://clinicaltrials.gov/study/NCT01656538,https://clinicaltrials.gov/study/NCT00378313,https://clinicaltrials.gov/study/NCT00146562,https://clinicaltrials.gov/study/NCT00479674,https://clinicaltrials.gov/study/NCT01204437,https://clinicaltrials.gov/study/NCT01973660,https://clinicaltrials.gov/study/NCT03742986,https://clinicaltrials.gov/study/NCT00007904,https://clinicaltrials.gov/study/NCT00251472,https://clinicaltrials.gov/study/NCT02687490,https://clinicaltrials.gov/study/NCT00618826,https://clinicaltrials.gov/study/NCT02909751,https://clinicaltrials.gov/study/NCT03853707,https://clinicaltrials.gov/study/NCT00148681,https://clinicaltrials.gov/study/NCT00629499,https://clinicaltrials.gov/study/NCT01446016,https://clinicaltrials.gov/study/NCT00475670,https://clinicaltrials.gov/study/NCT00274456,https://clinicaltrials.gov/study/NCT05112536,https://clinicaltrials.gov/study/NCT00455533,https://clinicaltrials.gov/study/NCT00096668,https://clinicaltrials.gov/study/NCT01847001,https://clinicaltrials.gov/study/NCT01106898,https://clinicaltrials.gov/study/NCT01688609,https://clinicaltrials.gov/study/NCT00846027,https://clinicaltrials.gov/study/NCT01190982,https://clinicaltrials.gov/study/NCT00254592,https://clinicaltrials.gov/study/NCT00320541,https://clinicaltrials.gov/study/NCT02229084,https://clinicaltrials.gov/study/NCT04224922,https://clinicaltrials.gov/study/NCT01565499,https://clinicaltrials.gov/study/NCT04408118,https://clinicaltrials.gov/study/NCT01506609,https://clinicaltrials.gov/study/NCT00930930,https://clinicaltrials.gov/study/NCT00618657,https://clinicaltrials.gov/study/NCT00096343,https://clinicaltrials.gov/study/NCT00915018,https://clinicaltrials.gov/study/NCT01835236,https://clinicaltrials.gov/study/NCT01423695,https://clinicaltrials.gov/study/NCT00856492,https://clinicaltrials.gov/study/NCT01969032,https://clinicaltrials.gov/study/NCT00542451,https://clinicaltrials.gov/study/NCT00003035,https://clinicaltrials.gov/study/NCT00052351,https://clinicaltrials.gov/study/NCT02365805,https://clinicaltrials.gov/study/NCT01855828,https://clinicaltrials.gov/study/NCT00136539,https://clinicaltrials.gov/study/NCT01276041,https://clinicaltrials.gov/study/NCT00768859,https://clinicaltrials.gov/study/NCT03193853,https://clinicaltrials.gov/study/NCT01594177,https://clinicaltrials.gov/study/NCT03248427,https://clinicaltrials.gov/study/NCT00635050,https://clinicaltrials.gov/study/NCT02783222,https://clinicaltrials.gov/study/NCT00334802,https://clinicaltrials.gov/study/NCT01959490,https://clinicaltrials.gov/study/NCT00191854,https://clinicaltrials.gov/study/NCT01036087,https://clinicaltrials.gov/study/NCT01572727,https://clinicaltrials.gov/study/NCT00256243,https://clinicaltrials.gov/study/NCT00193206,https://clinicaltrials.gov/study/NCT00003392,https://clinicaltrials.gov/study/NCT01740336,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00093145,https://clinicaltrials.gov/study/NCT01186991,https://clinicaltrials.gov/study/NCT00394082,https://clinicaltrials.gov/study/NCT02073487,https://clinicaltrials.gov/study/NCT00645177,https://clinicaltrials.gov/study/NCT00003992,https://clinicaltrials.gov/study/NCT00546156,https://clinicaltrials.gov/study/NCT01421472,https://clinicaltrials.gov/study/NCT00005635,https://clinicaltrials.gov/study/NCT00316199,https://clinicaltrials.gov/study/NCT01989780,https://clinicaltrials.gov/study/NCT00028873,https://clinicaltrials.gov/study/NCT03072992,https://clinicaltrials.gov/study/NCT00003539,https://clinicaltrials.gov/study/NCT02263495,https://clinicaltrials.gov/study/NCT00370552,https://clinicaltrials.gov/study/NCT00006110,https://clinicaltrials.gov/study/NCT02301988,https://clinicaltrials.gov/study/NCT00723125,https://clinicaltrials.gov/study/NCT00773695,https://clinicaltrials.gov/study/NCT01792050,https://clinicaltrials.gov/study/NCT00072319,https://clinicaltrials.gov/study/NCT03644186,https://clinicaltrials.gov/study/NCT01672671,https://clinicaltrials.gov/study/NCT01256762,https://clinicaltrials.gov/study/NCT03121352,https://clinicaltrials.gov/study/NCT01307891,https://clinicaltrials.gov/study/NCT00003612,https://clinicaltrials.gov/study/NCT00795899,https://clinicaltrials.gov/study/NCT00128856,https://clinicaltrials.gov/study/NCT00001498,https://clinicaltrials.gov/study/NCT02685059,https://clinicaltrials.gov/study/NCT00002937,https://clinicaltrials.gov/study/NCT00482391,https://clinicaltrials.gov/study/NCT00003050,https://clinicaltrials.gov/study/NCT00944047,https://clinicaltrials.gov/study/NCT01593020,https://clinicaltrials.gov/study/NCT01204125,https://clinicaltrials.gov/study/NCT00971945,https://clinicaltrials.gov/study/NCT00467012,https://clinicaltrials.gov/study/NCT00503906,https://clinicaltrials.gov/study/NCT00654836,https://clinicaltrials.gov/study/NCT02954055,https://clinicaltrials.gov/study/NCT00002826,https://clinicaltrials.gov/study/NCT01827163,https://clinicaltrials.gov/study/NCT03887130,https://clinicaltrials.gov/study/NCT03301350,https://clinicaltrials.gov/study/NCT00580333,https://clinicaltrials.gov/study/NCT00006256,https://clinicaltrials.gov/study/NCT00559845,https://clinicaltrials.gov/study/NCT00436566,https://clinicaltrials.gov/study/NCT01432223,https://clinicaltrials.gov/study/NCT00675259,https://clinicaltrials.gov/study/NCT01816594,https://clinicaltrials.gov/study/NCT00110084,https://clinicaltrials.gov/study/NCT02280252,https://clinicaltrials.gov/study/NCT00002679,https://clinicaltrials.gov/study/NCT00532857,https://clinicaltrials.gov/study/NCT01008150,https://clinicaltrials.gov/study/NCT00004092,https://clinicaltrials.gov/study/NCT02938442,https://clinicaltrials.gov/study/NCT00392392,https://clinicaltrials.gov/study/NCT00194779,https://clinicaltrials.gov/study/NCT03982485,https://clinicaltrials.gov/study/NCT00403130,https://clinicaltrials.gov/study/NCT03289819,https://clinicaltrials.gov/study/NCT00662129,https://clinicaltrials.gov/study/NCT00733408,https://clinicaltrials.gov/study/NCT00096291,https://clinicaltrials.gov/study/NCT02698891,https://clinicaltrials.gov/study/NCT00394251,https://clinicaltrials.gov/study/NCT01818063,https://clinicaltrials.gov/study/NCT00915603,https://clinicaltrials.gov/study/NCT01023204,https://clinicaltrials.gov/study/NCT01722968,https://clinicaltrials.gov/study/NCT01320111,https://clinicaltrials.gov/study/NCT02132949,https://clinicaltrials.gov/study/NCT00019812,https://clinicaltrials.gov/study/NCT00001384,https://clinicaltrials.gov/study/NCT00919880,https://clinicaltrials.gov/study/NCT00503750,https://clinicaltrials.gov/study/NCT02628613,https://clinicaltrials.gov/study/NCT01203267,https://clinicaltrials.gov/study/NCT02370238,https://clinicaltrials.gov/study/NCT00511459,https://clinicaltrials.gov/study/NCT00004013,https://clinicaltrials.gov/study/NCT01705691,https://clinicaltrials.gov/study/NCT01617668
MONDO_0007254	breast cancer	CHEMBL4303201	CATEQUENTINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Recruiting	https://clinicaltrials.gov/study/NCT04624711,https://clinicaltrials.gov/study/NCT04452370,https://clinicaltrials.gov/study/NCT04936295,https://clinicaltrials.gov/study/NCT05296577,https://clinicaltrials.gov/study/NCT04877821,https://clinicaltrials.gov/study/NCT05558722
MONDO_0007254	breast cancer	CHEMBL1200675	TOREMIFENE CITRATE	Small molecule	Estrogen receptor modulator	Antagonist	ESR1	estrogen receptor 1	2	Unknown status	https://clinicaltrials.gov/study/NCT02132000
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	2	Completed	https://clinicaltrials.gov/study/NCT02273973
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA12	NADH:ubiquinone oxidoreductase subunit A12	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0005537	triple-negative breast cancer	CHEMBL3545132	MIRVETUXIMAB SORAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT03106077
EFO_0000305	breast carcinoma	CHEMBL135	ESTRADIOL	Small molecule	Estrogen receptor alpha agonist	Antagonist	ESR1	estrogen receptor 1	2	Enrolling by invitation	https://clinicaltrials.gov/study/NCT03941730
MONDO_0007254	breast cancer	CHEMBL377559	RETASPIMYCIN HYDROCHLORIDE	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AB1	heat shock protein 90 alpha family class B member 1	2	Terminated	https://clinicaltrials.gov/study/NCT00817362
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND2	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2	2	Completed	https://clinicaltrials.gov/study/NCT04170465
EFO_0000186	invasive breast ductal carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02779855
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	Ephrin type-A receptor 2 inhibitor		EPHA2	EPH receptor A2	2	Withdrawn	https://clinicaltrials.gov/study/NCT01410708
MONDO_0007254	breast cancer	CHEMBL1007	GONADORELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04293393
MONDO_0007254	breast cancer	CHEMBL25	ASPIRIN	Small molecule	Cyclooxygenase inhibitor		PTGS1	prostaglandin-endoperoxide synthase 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04188119,https://clinicaltrials.gov/study/NCT03491410
EFO_0000305	breast carcinoma	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator	Antagonist	ESR1	estrogen receptor 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05133674,https://clinicaltrials.gov/study/NCT02592083,https://clinicaltrials.gov/study/NCT02603679,https://clinicaltrials.gov/study/NCT02668666,https://clinicaltrials.gov/study/NCT02311933
MONDO_0007254	breast cancer	CHEMBL58	MITOXANTRONE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Unknown status	https://clinicaltrials.gov/study/NCT00002498,https://clinicaltrials.gov/study/NCT02596373,https://clinicaltrials.gov/study/NCT00010075
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02654119
EFO_0000305	breast carcinoma	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Completed	https://clinicaltrials.gov/study/NCT02894398
EFO_0000305	breast carcinoma	CHEMBL3137336	UPROSERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT1	AKT serine/threonine kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT01964924
MONDO_0007254	breast cancer	CHEMBL1079175	MK-2206	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT1	AKT serine/threonine kinase 1	2	Withdrawn	https://clinicaltrials.gov/study/NCT01240941
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	2	Terminated	https://clinicaltrials.gov/study/NCT05198843,https://clinicaltrials.gov/study/NCT00780676,https://clinicaltrials.gov/study/NCT00817531
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBA3C	tubulin alpha 3c	2	Completed	https://clinicaltrials.gov/study/NCT00148707,https://clinicaltrials.gov/study/NCT00265733
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04034823,https://clinicaltrials.gov/study/NCT04290793,https://clinicaltrials.gov/study/NCT06348134,https://clinicaltrials.gov/study/NCT06291064
MONDO_0007254	breast cancer	CHEMBL1200694	SEVOFLURANE	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRE	gamma-aminobutyric acid type A receptor subunit epsilon	2	Completed	https://clinicaltrials.gov/study/NCT02839668
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Recruiting	https://clinicaltrials.gov/study/NCT05810870,https://clinicaltrials.gov/study/NCT05530057,https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT05458674,https://clinicaltrials.gov/study/NCT06102824,https://clinicaltrials.gov/study/NCT04624711,https://clinicaltrials.gov/study/NCT05546255,https://clinicaltrials.gov/study/NCT03424005
MONDO_0007254	breast cancer	CHEMBL1201827	PANITUMUMAB	Antibody	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Completed	https://clinicaltrials.gov/study/NCT00894504,https://clinicaltrials.gov/study/NCT01036087
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS4	NADH:ubiquinone oxidoreductase subunit S4	2	Terminated	https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT01627067
MONDO_0007254	breast cancer	CHEMBL15770	SULINDAC	Small molecule	Cyclooxygenase inhibitor		PTGS2	prostaglandin-endoperoxide synthase 2	2	Completed	https://clinicaltrials.gov/study/NCT00039520
MONDO_0007254	breast cancer	CHEMBL20684	ABT-751	Small molecule	Tubulin beta inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT00063102
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Withdrawn	https://clinicaltrials.gov/study/NCT03032614
EFO_0000186	invasive breast ductal carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02779855
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00323063,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT00532285,https://clinicaltrials.gov/study/NCT03674242,https://clinicaltrials.gov/study/NCT00462865,https://clinicaltrials.gov/study/NCT00674206,https://clinicaltrials.gov/study/NCT02213744,https://clinicaltrials.gov/study/NCT00095888,https://clinicaltrials.gov/study/NCT00159458,https://clinicaltrials.gov/study/NCT00679029,https://clinicaltrials.gov/study/NCT00470249
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC2	NADH:ubiquinone oxidoreductase subunit C2	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Unknown status	https://clinicaltrials.gov/study/NCT01372579
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	Bcr/Abl fusion protein		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00754325,https://clinicaltrials.gov/study/NCT00410813,https://clinicaltrials.gov/study/NCT00546104,https://clinicaltrials.gov/study/NCT00696072,https://clinicaltrials.gov/study/NCT00767520
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Withdrawn	https://clinicaltrials.gov/study/NCT02067416,https://clinicaltrials.gov/study/NCT00006261,https://clinicaltrials.gov/study/NCT00678626,https://clinicaltrials.gov/study/NCT01825265,https://clinicaltrials.gov/study/NCT00434031,https://clinicaltrials.gov/study/NCT01229605,https://clinicaltrials.gov/study/NCT00964704
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF4	NADH:ubiquinone oxidoreductase complex assembly factor 4	2	Unknown status	https://clinicaltrials.gov/study/NCT02506777,https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT03192293
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA3	EPH receptor A3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999
MONDO_0007254	breast cancer	CHEMBL3137318	TALAZOPARIB TOSYLATE	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT04756765
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Terminated	https://clinicaltrials.gov/study/NCT01498588
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC1	NADH:ubiquinone oxidoreductase subunit C1	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	2	Terminated	https://clinicaltrials.gov/study/NCT03130439
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02883062,https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT04251169,https://clinicaltrials.gov/study/NCT00295893,https://clinicaltrials.gov/study/NCT04603183,https://clinicaltrials.gov/study/NCT00609791,https://clinicaltrials.gov/study/NCT03568422,https://clinicaltrials.gov/study/NCT02788981,https://clinicaltrials.gov/study/NCT00003042,https://clinicaltrials.gov/study/NCT02734290,https://clinicaltrials.gov/study/NCT03747120,https://clinicaltrials.gov/study/NCT03616886,https://clinicaltrials.gov/study/NCT01779206,https://clinicaltrials.gov/study/NCT04215146,https://clinicaltrials.gov/study/NCT03125928,https://clinicaltrials.gov/study/NCT04083963,https://clinicaltrials.gov/study/NCT03567720,https://clinicaltrials.gov/study/NCT01815242,https://clinicaltrials.gov/study/NCT04398914,https://clinicaltrials.gov/study/NCT03950570,https://clinicaltrials.gov/study/NCT03387085,https://clinicaltrials.gov/study/NCT00616967,https://clinicaltrials.gov/study/NCT01057069,https://clinicaltrials.gov/study/NCT02752685,https://clinicaltrials.gov/study/NCT02779855,https://clinicaltrials.gov/study/NCT05498896,https://clinicaltrials.gov/study/NCT04192331,https://clinicaltrials.gov/study/NCT04734262,https://clinicaltrials.gov/study/NCT04538742,https://clinicaltrials.gov/study/NCT02546232,https://clinicaltrials.gov/study/NCT04172259,https://clinicaltrials.gov/study/NCT01730833,https://clinicaltrials.gov/study/NCT02187991,https://clinicaltrials.gov/study/NCT03609047,https://clinicaltrials.gov/study/NCT01796197,https://clinicaltrials.gov/study/NCT01853748,https://clinicaltrials.gov/study/NCT04418154,https://clinicaltrials.gov/study/NCT01898117
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Recruiting	https://clinicaltrials.gov/study/NCT05570253,https://clinicaltrials.gov/study/NCT05402722
MONDO_0007254	breast cancer	CHEMBL4303201	CATEQUENTINIB	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Completed	https://clinicaltrials.gov/study/NCT05206656
EFO_0005537	triple-negative breast cancer	CHEMBL3137318	TALAZOPARIB TOSYLATE	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Completed	https://clinicaltrials.gov/study/NCT02401347
EFO_0006318	breast ductal adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Terminated	https://clinicaltrials.gov/study/NCT01891357
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT00005614
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04922008,https://clinicaltrials.gov/study/NCT04963595,https://clinicaltrials.gov/study/NCT03997539,https://clinicaltrials.gov/study/NCT06229067,https://clinicaltrials.gov/study/NCT04143906
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA1	NADH:ubiquinone oxidoreductase subunit A1	2	Completed	https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT00930579
MONDO_0007254	breast cancer	CHEMBL1200694	SEVOFLURANE	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRB2	gamma-aminobutyric acid type A receptor subunit beta2	2	Completed	https://clinicaltrials.gov/study/NCT02839668
MONDO_0007254	breast cancer	CHEMBL1289601	LENVATINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT06110793,https://clinicaltrials.gov/study/NCT05181033,https://clinicaltrials.gov/study/NCT05286437
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		BLK	BLK proto-oncogene, Src family tyrosine kinase	2	Withdrawn	https://clinicaltrials.gov/study/NCT01410708
MONDO_0007254	breast cancer	CHEMBL34259	METHOTREXATE	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	2	Withdrawn	https://clinicaltrials.gov/study/NCT01227408,https://clinicaltrials.gov/study/NCT00003536
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	2	Withdrawn	https://clinicaltrials.gov/study/NCT04351230
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV2	NADH:ubiquinone oxidoreductase core subunit V2	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02530489,https://clinicaltrials.gov/study/NCT02957968,https://clinicaltrials.gov/study/NCT01730833
MONDO_0007254	breast cancer	CHEMBL3894860	TRILACICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT05112536
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	2	Recruiting	https://clinicaltrials.gov/study/NCT03698383
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		YES1	YES proto-oncogene 1, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00546104,https://clinicaltrials.gov/study/NCT00767520,https://clinicaltrials.gov/study/NCT00754325,https://clinicaltrials.gov/study/NCT00696072,https://clinicaltrials.gov/study/NCT00410813
MONDO_0007254	breast cancer	CHEMBL68055	ACOLBIFENE	Small molecule	Estrogen receptor modulator	Antagonist	ESR1	estrogen receptor 1	2	Completed	https://clinicaltrials.gov/study/NCT00853996
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT00494481
MONDO_0007254	breast cancer	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Completed	https://clinicaltrials.gov/study/NCT00001384,https://clinicaltrials.gov/study/NCT00580333,https://clinicaltrials.gov/study/NCT00003992,https://clinicaltrials.gov/study/NCT00005980,https://clinicaltrials.gov/study/NCT00002679,https://clinicaltrials.gov/study/NCT00256243,https://clinicaltrials.gov/study/NCT00254592,https://clinicaltrials.gov/study/NCT00005908,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT00563953,https://clinicaltrials.gov/study/NCT02938442,https://clinicaltrials.gov/study/NCT00404066,https://clinicaltrials.gov/study/NCT00148681,https://clinicaltrials.gov/study/NCT03164993,https://clinicaltrials.gov/study/NCT00003352,https://clinicaltrials.gov/study/NCT00455533,https://clinicaltrials.gov/study/NCT00191789,https://clinicaltrials.gov/study/NCT01396655,https://clinicaltrials.gov/study/NCT00123929,https://clinicaltrials.gov/study/NCT00128856,https://clinicaltrials.gov/study/NCT01818063,https://clinicaltrials.gov/study/NCT01847001,https://clinicaltrials.gov/study/NCT01969032,https://clinicaltrials.gov/study/NCT00499083,https://clinicaltrials.gov/study/NCT00004237,https://clinicaltrials.gov/study/NCT00044993,https://clinicaltrials.gov/study/NCT00006110,https://clinicaltrials.gov/study/NCT00365365,https://clinicaltrials.gov/study/NCT00206466,https://clinicaltrials.gov/study/NCT00559845,https://clinicaltrials.gov/study/NCT00005800,https://clinicaltrials.gov/study/NCT00394251,https://clinicaltrials.gov/study/NCT00712881,https://clinicaltrials.gov/study/NCT01206881,https://clinicaltrials.gov/study/NCT00482391,https://clinicaltrials.gov/study/NCT01669239,https://clinicaltrials.gov/study/NCT00102219,https://clinicaltrials.gov/study/NCT00608972,https://clinicaltrials.gov/study/NCT00284336,https://clinicaltrials.gov/study/NCT03742986,https://clinicaltrials.gov/study/NCT01705691,https://clinicaltrials.gov/study/NCT00201708,https://clinicaltrials.gov/study/NCT00193115,https://clinicaltrials.gov/study/NCT00258960,https://clinicaltrials.gov/study/NCT00004092,https://clinicaltrials.gov/study/NCT00004175,https://clinicaltrials.gov/study/NCT00146562,https://clinicaltrials.gov/study/NCT04664972,https://clinicaltrials.gov/study/NCT02838225,https://clinicaltrials.gov/study/NCT00524810,https://clinicaltrials.gov/study/NCT00007904,https://clinicaltrials.gov/study/NCT01593020,https://clinicaltrials.gov/study/NCT00546156,https://clinicaltrials.gov/study/NCT01672671,https://clinicaltrials.gov/study/NCT00004888,https://clinicaltrials.gov/study/NCT00436566,https://clinicaltrials.gov/study/NCT00206518,https://clinicaltrials.gov/study/NCT00944047,https://clinicaltrials.gov/study/NCT00096291,https://clinicaltrials.gov/study/NCT05112536,https://clinicaltrials.gov/study/NCT02132949,https://clinicaltrials.gov/study/NCT00499122,https://clinicaltrials.gov/study/NCT00004906,https://clinicaltrials.gov/study/NCT00049114,https://clinicaltrials.gov/study/NCT01008150,https://clinicaltrials.gov/study/NCT00149214,https://clinicaltrials.gov/study/NCT03248427,https://clinicaltrials.gov/study/NCT00303108,https://clinicaltrials.gov/study/NCT03409198,https://clinicaltrials.gov/study/NCT00129376,https://clinicaltrials.gov/study/NCT00027885,https://clinicaltrials.gov/study/NCT00407888,https://clinicaltrials.gov/study/NCT00203372,https://clinicaltrials.gov/study/NCT00003035,https://clinicaltrials.gov/study/NCT00960336,https://clinicaltrials.gov/study/NCT03575520,https://clinicaltrials.gov/study/NCT00052351,https://clinicaltrials.gov/study/NCT01959490,https://clinicaltrials.gov/study/NCT00005991,https://clinicaltrials.gov/study/NCT03301350,https://clinicaltrials.gov/study/NCT00136539,https://clinicaltrials.gov/study/NCT00212082,https://clinicaltrials.gov/study/NCT00856492,https://clinicaltrials.gov/study/NCT00003050,https://clinicaltrials.gov/study/NCT00193037,https://clinicaltrials.gov/study/NCT00365417,https://clinicaltrials.gov/study/NCT02229084,https://clinicaltrials.gov/study/NCT00194779,https://clinicaltrials.gov/study/NCT00003953,https://clinicaltrials.gov/study/NCT00001498
EFO_0005537	triple-negative breast cancer	CHEMBL2396661	ALPELISIB	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04216472
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE3A	phosphodiesterase 3A	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT06186700,https://clinicaltrials.gov/study/NCT06176339
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA5	EPH receptor A5	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999
EFO_0005537	triple-negative breast cancer	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB9	NADH:ubiquinone oxidoreductase subunit B9	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT04559308,https://clinicaltrials.gov/study/NCT03238495
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB4	NADH:ubiquinone oxidoreductase subunit B4	2	Unknown status	https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT02506777
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Withdrawn	https://clinicaltrials.gov/study/NCT00006261,https://clinicaltrials.gov/study/NCT00964704,https://clinicaltrials.gov/study/NCT00434031,https://clinicaltrials.gov/study/NCT00678626,https://clinicaltrials.gov/study/NCT02067416,https://clinicaltrials.gov/study/NCT01825265,https://clinicaltrials.gov/study/NCT01229605
MONDO_0007254	breast cancer	CHEMBL225072	PEMETREXED	Small molecule	GAR transformylase inhibitor		GART	phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase	2	Unknown status	https://clinicaltrials.gov/study/NCT02829008
EFO_0006861	male breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00095888
EFO_0005537	triple-negative breast cancer	CHEMBL4297892	ANVATABART OPADOTIN	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 binding agent		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4L	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L	2	Recruiting	https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04559308
MONDO_0007254	breast cancer	CHEMBL429910	DAPAGLIFLOZIN	Small molecule	Sodium/glucose cotransporter 2 inhibitor		SLC5A2	solute carrier family 5 member 2	2	Recruiting	https://clinicaltrials.gov/study/NCT05025735,https://clinicaltrials.gov/study/NCT06341842
MONDO_0007254	breast cancer	CHEMBL19019	NALTREXONE	Small molecule	Opioid receptors; mu/kappa/delta antagonist		OPRK1	opioid receptor kappa 1	2	Terminated	https://clinicaltrials.gov/study/NCT00379197
MONDO_0007254	breast cancer	CHEMBL2304041	SAGOPILONE	Small molecule	Tubulin stabiliser		TUBA4A	tubulin alpha 4a	2	Completed	https://clinicaltrials.gov/study/NCT00288249
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN1A	sodium voltage-gated channel alpha subunit 1	2	Completed	https://clinicaltrials.gov/study/NCT01204242,https://clinicaltrials.gov/study/NCT02839668
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC3	histone deacetylase 3	2	Completed	https://clinicaltrials.gov/study/NCT00828854,https://clinicaltrials.gov/study/NCT02708680,https://clinicaltrials.gov/study/NCT00676663,https://clinicaltrials.gov/study/NCT03291886
EFO_0005537	triple-negative breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC3	histone deacetylase 3	2	Terminated	https://clinicaltrials.gov/study/NCT01234532
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Recruiting	https://clinicaltrials.gov/study/NCT05834582,https://clinicaltrials.gov/study/NCT04138719,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT03606967,https://clinicaltrials.gov/study/NCT05227664,https://clinicaltrials.gov/study/NCT05192798
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND5	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL4297829	SINTILIMAB	Antibody	Programmed cell death protein 1 antagonist		PDCD1	programmed cell death 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06308939,https://clinicaltrials.gov/study/NCT04809779
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND3	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF3	NADH:ubiquinone oxidoreductase complex assembly factor 3	2	Unknown status	https://clinicaltrials.gov/study/NCT02506777,https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT02506790
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Terminated	https://clinicaltrials.gov/study/NCT03795012,https://clinicaltrials.gov/study/NCT01498588,https://clinicaltrials.gov/study/NCT01912963,https://clinicaltrials.gov/study/NCT01534455,https://clinicaltrials.gov/study/NCT02681523,https://clinicaltrials.gov/study/NCT02000596
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Terminated	https://clinicaltrials.gov/study/NCT00080626,https://clinicaltrials.gov/study/NCT00104624,https://clinicaltrials.gov/study/NCT00479856,https://clinicaltrials.gov/study/NCT03329378,https://clinicaltrials.gov/study/NCT01690325,https://clinicaltrials.gov/study/NCT00524459,https://clinicaltrials.gov/study/NCT00025493,https://clinicaltrials.gov/study/NCT00453635,https://clinicaltrials.gov/study/NCT00225056,https://clinicaltrials.gov/study/NCT00028483,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT00193024,https://clinicaltrials.gov/study/NCT00118053,https://clinicaltrials.gov/study/NCT00206453,https://clinicaltrials.gov/study/NCT00343512,https://clinicaltrials.gov/study/NCT00665457,https://clinicaltrials.gov/study/NCT00852332,https://clinicaltrials.gov/study/NCT00576901,https://clinicaltrials.gov/study/NCT00845910,https://clinicaltrials.gov/study/NCT00636441,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT03894007,https://clinicaltrials.gov/study/NCT01985841
EFO_0000305	breast carcinoma	CHEMBL3218576	COPANLISIB	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	2	Terminated	https://clinicaltrials.gov/study/NCT04108858
MONDO_0007254	breast cancer	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator	Antagonist	ESR1	estrogen receptor 1	2	Recruiting	https://clinicaltrials.gov/study/NCT04985266,https://clinicaltrials.gov/study/NCT05472792,https://clinicaltrials.gov/study/NCT05659563,https://clinicaltrials.gov/study/NCT05463601,https://clinicaltrials.gov/study/NCT03879577,https://clinicaltrials.gov/study/NCT05826964,https://clinicaltrials.gov/study/NCT05101564,https://clinicaltrials.gov/study/NCT02476786,https://clinicaltrials.gov/study/NCT05150652,https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT05501704
MONDO_0007254	breast cancer	CHEMBL1200694	SEVOFLURANE	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRG1	gamma-aminobutyric acid type A receptor subunit gamma1	2	Completed	https://clinicaltrials.gov/study/NCT02839668
MONDO_0007254	breast cancer	CHEMBL1201167	CARVEDILOL PHOSPHATE	Small molecule	Adrenergic receptor beta antagonist		ADRB1	adrenoceptor beta 1	2	Completed	https://clinicaltrials.gov/study/NCT01009918
EFO_0000305	breast carcinoma	CHEMBL113	CAFFEINE	Small molecule	Adenosine receptor antagonist		ADORA3	adenosine A3 receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03768492
EFO_0000305	breast carcinoma	CHEMBL3707227	ATEZOLIZUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	2	Completed	https://clinicaltrials.gov/study/NCT03164993
EFO_0006861	male breast carcinoma	CHEMBL491473	CEDIRANIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00244881
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04345913
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT01038804,https://clinicaltrials.gov/study/NCT02909751,https://clinicaltrials.gov/study/NCT00129376,https://clinicaltrials.gov/study/NCT02846428,https://clinicaltrials.gov/study/NCT01792050,https://clinicaltrials.gov/study/NCT00365417,https://clinicaltrials.gov/study/NCT00039520,https://clinicaltrials.gov/study/NCT00079118,https://clinicaltrials.gov/study/NCT02365805,https://clinicaltrials.gov/study/NCT02838225,https://clinicaltrials.gov/study/NCT00525759,https://clinicaltrials.gov/study/NCT00193037,https://clinicaltrials.gov/study/NCT00217672,https://clinicaltrials.gov/study/NCT00212095,https://clinicaltrials.gov/study/NCT00524810,https://clinicaltrials.gov/study/NCT00212082,https://clinicaltrials.gov/study/NCT00004888,https://clinicaltrials.gov/study/NCT00179309,https://clinicaltrials.gov/study/NCT00247481,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT00003953,https://clinicaltrials.gov/study/NCT00054275,https://clinicaltrials.gov/study/NCT00475670,https://clinicaltrials.gov/study/NCT00379015,https://clinicaltrials.gov/study/NCT00028873,https://clinicaltrials.gov/study/NCT00206505,https://clinicaltrials.gov/study/NCT00123929,https://clinicaltrials.gov/study/NCT00203502,https://clinicaltrials.gov/study/NCT02132949,https://clinicaltrials.gov/study/NCT00068341,https://clinicaltrials.gov/study/NCT00695994,https://clinicaltrials.gov/study/NCT00679341,https://clinicaltrials.gov/study/NCT00527449,https://clinicaltrials.gov/study/NCT00107510,https://clinicaltrials.gov/study/NCT02834403,https://clinicaltrials.gov/study/NCT00464646,https://clinicaltrials.gov/study/NCT00066443,https://clinicaltrials.gov/study/NCT00015886,https://clinicaltrials.gov/study/NCT01527487,https://clinicaltrials.gov/study/NCT00428922,https://clinicaltrials.gov/study/NCT00148668,https://clinicaltrials.gov/study/NCT00006104,https://clinicaltrials.gov/study/NCT02229084,https://clinicaltrials.gov/study/NCT01658462,https://clinicaltrials.gov/study/NCT03887130,https://clinicaltrials.gov/study/NCT01446016,https://clinicaltrials.gov/study/NCT00027885,https://clinicaltrials.gov/study/NCT01959490,https://clinicaltrials.gov/study/NCT00712881,https://clinicaltrials.gov/study/NCT00201708,https://clinicaltrials.gov/study/NCT00604435,https://clinicaltrials.gov/study/NCT00004906,https://clinicaltrials.gov/study/NCT00193115,https://clinicaltrials.gov/study/NCT00769470,https://clinicaltrials.gov/study/NCT01150513,https://clinicaltrials.gov/study/NCT00193180,https://clinicaltrials.gov/study/NCT00820872,https://clinicaltrials.gov/study/NCT00773695,https://clinicaltrials.gov/study/NCT00499122,https://clinicaltrials.gov/study/NCT00088998,https://clinicaltrials.gov/study/NCT00365365,https://clinicaltrials.gov/study/NCT00820547,https://clinicaltrials.gov/study/NCT00155259,https://clinicaltrials.gov/study/NCT01396655,https://clinicaltrials.gov/study/NCT00600249,https://clinicaltrials.gov/study/NCT00206466,https://clinicaltrials.gov/study/NCT02005549,https://clinicaltrials.gov/study/NCT00209092,https://clinicaltrials.gov/study/NCT01671319,https://clinicaltrials.gov/study/NCT01367028,https://clinicaltrials.gov/study/NCT00545688,https://clinicaltrials.gov/study/NCT00041067,https://clinicaltrials.gov/study/NCT00248703,https://clinicaltrials.gov/study/NCT00005908,https://clinicaltrials.gov/study/NCT00364611,https://clinicaltrials.gov/study/NCT04664972,https://clinicaltrials.gov/study/NCT00003565,https://clinicaltrials.gov/study/NCT00198237,https://clinicaltrials.gov/study/NCT00203372,https://clinicaltrials.gov/study/NCT00149214,https://clinicaltrials.gov/study/NCT00404066,https://clinicaltrials.gov/study/NCT01485926,https://clinicaltrials.gov/study/NCT00193089,https://clinicaltrials.gov/study/NCT00055861,https://clinicaltrials.gov/study/NCT00319618,https://clinicaltrials.gov/study/NCT00559754,https://clinicaltrials.gov/study/NCT01142778,https://clinicaltrials.gov/study/NCT03735966,https://clinicaltrials.gov/study/NCT00494481,https://clinicaltrials.gov/study/NCT00077857,https://clinicaltrials.gov/study/NCT03140553,https://clinicaltrials.gov/study/NCT00146042,https://clinicaltrials.gov/study/NCT00432172,https://clinicaltrials.gov/study/NCT00232479,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00044993,https://clinicaltrials.gov/study/NCT00841828,https://clinicaltrials.gov/study/NCT00258375,https://clinicaltrials.gov/study/NCT00148070,https://clinicaltrials.gov/study/NCT00274456,https://clinicaltrials.gov/study/NCT00015938,https://clinicaltrials.gov/study/NCT02137083,https://clinicaltrials.gov/study/NCT00005963,https://clinicaltrials.gov/study/NCT01025349,https://clinicaltrials.gov/study/NCT00976989,https://clinicaltrials.gov/study/NCT00006682,https://clinicaltrials.gov/study/NCT01208480,https://clinicaltrials.gov/study/NCT00493649,https://clinicaltrials.gov/study/NCT00004175,https://clinicaltrials.gov/study/NCT00206518,https://clinicaltrials.gov/study/NCT02041351,https://clinicaltrials.gov/study/NCT00193050,https://clinicaltrials.gov/study/NCT00214864,https://clinicaltrials.gov/study/NCT00490646,https://clinicaltrials.gov/study/NCT00003352,https://clinicaltrials.gov/study/NCT03742986,https://clinicaltrials.gov/study/NCT00645866,https://clinicaltrials.gov/study/NCT00754351,https://clinicaltrials.gov/study/NCT00941330,https://clinicaltrials.gov/study/NCT02748213,https://clinicaltrials.gov/study/NCT00191243,https://clinicaltrials.gov/study/NCT01540110,https://clinicaltrials.gov/study/NCT00005800
EFO_0005537	triple-negative breast cancer	CHEMBL3186534	RIVOCERANIB	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT03650738
EFO_0000432	breast ductal carcinoma in situ	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Terminated	https://clinicaltrials.gov/study/NCT00461344
EFO_0000553	invasive lobular carcinoma	CHEMBL1983268	ENTRECTINIB	Small molecule	Neurotrophic tyrosine kinase receptor inhibitor		NTRK1	neurotrophic receptor tyrosine kinase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT04551495
MONDO_0007254	breast cancer	CHEMBL1201748	CABAZITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Recruiting	https://clinicaltrials.gov/study/NCT03048942
MONDO_0007254	breast cancer	CHEMBL4285417	CERALASERTIB	Small molecule	Serine-protein kinase ATR inhibitor		ATR	ATR serine/threonine kinase	2	Recruiting	https://clinicaltrials.gov/study/NCT05582538,https://clinicaltrials.gov/study/NCT03182634
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Enrolling by invitation	https://clinicaltrials.gov/study/NCT03580395
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Terminated	https://clinicaltrials.gov/study/NCT00159458,https://clinicaltrials.gov/study/NCT00679029,https://clinicaltrials.gov/study/NCT00323063,https://clinicaltrials.gov/study/NCT00095888,https://clinicaltrials.gov/study/NCT00532285,https://clinicaltrials.gov/study/NCT00470249,https://clinicaltrials.gov/study/NCT00462865,https://clinicaltrials.gov/study/NCT02213744,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT03674242,https://clinicaltrials.gov/study/NCT00674206
MONDO_0007254	breast cancer	CHEMBL4594611	PATRITUMAB DERUXTECAN	Antibody drug conjugate	Receptor tyrosine-protein kinase erbB-3 binding agent		ERBB3	erb-b2 receptor tyrosine kinase 3	2	Completed	https://clinicaltrials.gov/study/NCT02980341
MONDO_0007254	breast cancer	CHEMBL502835	NINTEDANIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR1	fibroblast growth factor receptor 1	2	Terminated	https://clinicaltrials.gov/study/NCT02389764
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS6	NADH:ubiquinone oxidoreductase subunit S6	2	Terminated	https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT02472353
MONDO_0007254	breast cancer	CHEMBL1789941	RUXOLITINIB	Small molecule	Tyrosine-protein kinase JAK1 inhibitor		JAK1	Janus kinase 1	2	Terminated	https://clinicaltrials.gov/study/NCT01562873,https://clinicaltrials.gov/study/NCT02120417
MONDO_0007254	breast cancer	CHEMBL4297856	ZIMBERELIMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05632848
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Recruiting	https://clinicaltrials.gov/study/NCT05900206,https://clinicaltrials.gov/study/NCT03497702,https://clinicaltrials.gov/study/NCT04576143,https://clinicaltrials.gov/study/NCT05088057,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT05483439,https://clinicaltrials.gov/study/NCT05918328,https://clinicaltrials.gov/study/NCT05638594,https://clinicaltrials.gov/study/NCT04872985,https://clinicaltrials.gov/study/NCT03879577,https://clinicaltrials.gov/study/NCT05189067,https://clinicaltrials.gov/study/NCT04947189,https://clinicaltrials.gov/study/NCT06107673,https://clinicaltrials.gov/study/NCT04717531,https://clinicaltrials.gov/study/NCT03367676,https://clinicaltrials.gov/study/NCT05426486,https://clinicaltrials.gov/study/NCT05645380,https://clinicaltrials.gov/study/NCT05475678
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Withdrawn	https://clinicaltrials.gov/study/NCT02215876,https://clinicaltrials.gov/study/NCT03637868
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1094636	NIRAPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT03368729
MONDO_0007254	breast cancer	CHEMBL1743079	TEPROTUMUMAB	Antibody	Insulin-like growth factor I receptor antagonist		IGF1R	insulin like growth factor 1 receptor	2	Terminated	https://clinicaltrials.gov/study/NCT00796107
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03587740,https://clinicaltrials.gov/study/NCT02326974,https://clinicaltrials.gov/study/NCT04398914,https://clinicaltrials.gov/study/NCT01565200,https://clinicaltrials.gov/study/NCT04733118,https://clinicaltrials.gov/study/NCT01745965,https://clinicaltrials.gov/study/NCT01494662,https://clinicaltrials.gov/study/NCT01853748
MONDO_0007254	breast cancer	CHEMBL180022	NERATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-4 inhibitor		ERBB4	erb-b2 receptor tyrosine kinase 4	2	Terminated	https://clinicaltrials.gov/study/NCT03289039,https://clinicaltrials.gov/study/NCT04460430
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB11	NADH:ubiquinone oxidoreductase subunit B11	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
EFO_0000304	breast adenocarcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Recruiting	https://clinicaltrials.gov/study/NCT04197687
EFO_0006861	male breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
MONDO_0007254	breast cancer	CHEMBL1173055	RUCAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Completed	https://clinicaltrials.gov/study/NCT01074970,https://clinicaltrials.gov/study/NCT02505048
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA6	EPH receptor A6	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999
EFO_0000305	breast carcinoma	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist	Antagonist	ESR1	estrogen receptor 1	2	Completed	https://clinicaltrials.gov/study/NCT01142401,https://clinicaltrials.gov/study/NCT02894398,https://clinicaltrials.gov/study/NCT04256941,https://clinicaltrials.gov/study/NCT03007979
EFO_0000305	breast carcinoma	CHEMBL3218576	COPANLISIB	Small molecule	PI3-kinase p110-delta subunit inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	2	Terminated	https://clinicaltrials.gov/study/NCT04108858
EFO_0000305	breast carcinoma	CHEMBL3989868	TUCATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT05319873
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA10	NADH:ubiquinone oxidoreductase subunit A10	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02414646
MONDO_0007254	breast cancer	CHEMBL2325741	CAPIVASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT2	AKT serine/threonine kinase 2	2	Unknown status	https://clinicaltrials.gov/study/NCT02423603
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Withdrawn	https://clinicaltrials.gov/study/NCT01229605,https://clinicaltrials.gov/study/NCT00678626,https://clinicaltrials.gov/study/NCT00964704,https://clinicaltrials.gov/study/NCT00006261,https://clinicaltrials.gov/study/NCT02067416,https://clinicaltrials.gov/study/NCT01825265,https://clinicaltrials.gov/study/NCT00434031
MONDO_0007254	breast cancer	CHEMBL359744	DOXORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT05748834,https://clinicaltrials.gov/study/NCT04872985
MONDO_0007254	breast cancer	CHEMBL4475463	AMCENESTRANT	Small molecule	Estrogen receptor alpha degrader	Antagonist	ESR1	estrogen receptor 1	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA6	NADH:ubiquinone oxidoreductase subunit A6	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1201247	GOSERELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	2	Withdrawn	https://clinicaltrials.gov/study/NCT01013506,https://clinicaltrials.gov/study/NCT00217659,https://clinicaltrials.gov/study/NCT01240941
MONDO_0007254	breast cancer	CHEMBL180022	NERATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-4 inhibitor		ERBB4	erb-b2 receptor tyrosine kinase 4	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03377387,https://clinicaltrials.gov/study/NCT01494662,https://clinicaltrials.gov/study/NCT03812393
EFO_0006861	male breast carcinoma	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		PSENEN	presenilin enhancer, gamma-secretase subunit	2	Terminated	https://clinicaltrials.gov/study/NCT01151449
MONDO_0007254	breast cancer	CHEMBL2220486	LUCITANIB	Small molecule	Fibroblast growth factor receptor 1 inhibitor		FGFR1	fibroblast growth factor receptor 1	2	Terminated	https://clinicaltrials.gov/study/NCT02202746
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB3	NADH:ubiquinone oxidoreductase subunit B3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
MONDO_0007254	breast cancer	CHEMBL4297843	TORIPALIMAB	Antibody	Programmed cell death protein 1 antagonist		PDCD1	programmed cell death 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05749575,https://clinicaltrials.gov/study/NCT06178159,https://clinicaltrials.gov/study/NCT04389073
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Withdrawn	https://clinicaltrials.gov/study/NCT00006261,https://clinicaltrials.gov/study/NCT00678626,https://clinicaltrials.gov/study/NCT02067416,https://clinicaltrials.gov/study/NCT00434031,https://clinicaltrials.gov/study/NCT01825265,https://clinicaltrials.gov/study/NCT00964704,https://clinicaltrials.gov/study/NCT01229605
MONDO_0007254	breast cancer	CHEMBL964	DISULFIRAM	Small molecule	Aldehyde dehydrogenase inhibitor		ALDH2	aldehyde dehydrogenase 2 family member	2	Withdrawn	https://clinicaltrials.gov/study/NCT04265274
MONDO_0007254	breast cancer	CHEMBL1201066	VENLAFAXINE HYDROCHLORIDE	Small molecule	Serotonin transporter inhibitor		SLC6A4	solute carrier family 6 member 4	2	Completed	https://clinicaltrials.gov/study/NCT00198250
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB8	NADH:ubiquinone oxidoreductase subunit B8	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL4298101	LADIRATUZUMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT03424005
MONDO_0007254	breast cancer	CHEMBL2103879	GANETESPIB	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AA1	heat shock protein 90 alpha family class A member 1	2	Completed	https://clinicaltrials.gov/study/NCT01677455,https://clinicaltrials.gov/study/NCT01273896
EFO_0000305	breast carcinoma	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	2	Completed	https://clinicaltrials.gov/study/NCT04256941
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00323063,https://clinicaltrials.gov/study/NCT00095888,https://clinicaltrials.gov/study/NCT00679029,https://clinicaltrials.gov/study/NCT00470249
MONDO_0007254	breast cancer	CHEMBL4298101	LADIRATUZUMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Recruiting	https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT03997539,https://clinicaltrials.gov/study/NCT04143906,https://clinicaltrials.gov/study/NCT04922008,https://clinicaltrials.gov/study/NCT04963595,https://clinicaltrials.gov/study/NCT06229067
EFO_0000305	breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAB1	NADH:ubiquinone oxidoreductase subunit AB1	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0005537	triple-negative breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03639948
EFO_0006861	male breast carcinoma	CHEMBL1201568	PEGFILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	2	Completed	https://clinicaltrials.gov/study/NCT00119262
MONDO_0007254	breast cancer	CHEMBL3545154	POZIOTINIB	Small molecule	Epidermal growth factor receptor inhibitor		ERBB4	erb-b2 receptor tyrosine kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT02659514,https://clinicaltrials.gov/study/NCT02418689,https://clinicaltrials.gov/study/NCT02544997
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV2	NADH:ubiquinone oxidoreductase core subunit V2	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	2	Recruiting	https://clinicaltrials.gov/study/NCT05766410,https://clinicaltrials.gov/study/NCT04318223,https://clinicaltrials.gov/study/NCT05190094,https://clinicaltrials.gov/study/NCT03439735,https://clinicaltrials.gov/study/NCT05076695,https://clinicaltrials.gov/study/NCT04920708,https://clinicaltrials.gov/study/NCT04567420,https://clinicaltrials.gov/study/NCT05563220,https://clinicaltrials.gov/study/NCT04802759,https://clinicaltrials.gov/study/NCT04946864,https://clinicaltrials.gov/study/NCT04247633,https://clinicaltrials.gov/study/NCT04841148,https://clinicaltrials.gov/study/NCT04563507,https://clinicaltrials.gov/study/NCT05069038,https://clinicaltrials.gov/study/NCT04985266,https://clinicaltrials.gov/study/NCT02760030
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT02199418
MONDO_0007254	breast cancer	CHEMBL2360464	PEMETREXED DISODIUM	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	2	Completed	https://clinicaltrials.gov/study/NCT00006007
MONDO_0007254	breast cancer	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	2	Recruiting	https://clinicaltrials.gov/study/NCT03923179,https://clinicaltrials.gov/study/NCT04452370
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT03609047,https://clinicaltrials.gov/study/NCT02568839,https://clinicaltrials.gov/study/NCT02339532,https://clinicaltrials.gov/study/NCT01779206,https://clinicaltrials.gov/study/NCT04172259,https://clinicaltrials.gov/study/NCT00496795,https://clinicaltrials.gov/study/NCT00295893,https://clinicaltrials.gov/study/NCT02624973,https://clinicaltrials.gov/study/NCT03161353,https://clinicaltrials.gov/study/NCT02547987
MONDO_0007254	breast cancer	CHEMBL1091644	LINSITINIB	Small molecule	Insulin-like growth factor I receptor inhibitor		IGF1R	insulin like growth factor 1 receptor	2	Withdrawn	https://clinicaltrials.gov/study/NCT01013506
MONDO_0007254	breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Recruiting	https://clinicaltrials.gov/study/NCT04355858
MONDO_0007254	breast cancer	CHEMBL1738	DEXRAZOXANE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	2	Terminated	https://clinicaltrials.gov/study/NCT00955890
MONDO_0007254	breast cancer	CHEMBL3833373	AVELUMAB	Antibody	Programmed cell death 1 ligand 1 other		CD274	CD274 molecule	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04188119
MONDO_0007254	breast cancer	CHEMBL1614701	SELUMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 1 inhibitor		MAP2K1	mitogen-activated protein kinase kinase 1	2	Terminated	https://clinicaltrials.gov/study/NCT00780676
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC2	histone deacetylase 2	2	Withdrawn	https://clinicaltrials.gov/study/NCT02115594
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB2	NADH:ubiquinone oxidoreductase subunit B2	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	2	Unknown status	https://clinicaltrials.gov/study/NCT00012311,https://clinicaltrials.gov/study/NCT01492556
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT02614833
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT00618826,https://clinicaltrials.gov/study/NCT00493636,https://clinicaltrials.gov/study/NCT00192101,https://clinicaltrials.gov/study/NCT00325234,https://clinicaltrials.gov/study/NCT00191815,https://clinicaltrials.gov/study/NCT00193076,https://clinicaltrials.gov/study/NCT01201265,https://clinicaltrials.gov/study/NCT00191451,https://clinicaltrials.gov/study/NCT01550848,https://clinicaltrials.gov/study/NCT00006007,https://clinicaltrials.gov/study/NCT00002998,https://clinicaltrials.gov/study/NCT00532857,https://clinicaltrials.gov/study/NCT00532623,https://clinicaltrials.gov/study/NCT00662129,https://clinicaltrials.gov/study/NCT00754351,https://clinicaltrials.gov/study/NCT00191347,https://clinicaltrials.gov/study/NCT00540358,https://clinicaltrials.gov/study/NCT00063570,https://clinicaltrials.gov/study/NCT00846027,https://clinicaltrials.gov/study/NCT00320541,https://clinicaltrials.gov/study/NCT00244933,https://clinicaltrials.gov/study/NCT00193063,https://clinicaltrials.gov/study/NCT00813956,https://clinicaltrials.gov/study/NCT00193050,https://clinicaltrials.gov/study/NCT00334802,https://clinicaltrials.gov/study/NCT01045304,https://clinicaltrials.gov/study/NCT00695994,https://clinicaltrials.gov/study/NCT00191789,https://clinicaltrials.gov/study/NCT02263495,https://clinicaltrials.gov/study/NCT03025880,https://clinicaltrials.gov/study/NCT00201760,https://clinicaltrials.gov/study/NCT00894504,https://clinicaltrials.gov/study/NCT00601159,https://clinicaltrials.gov/study/NCT00005991,https://clinicaltrials.gov/study/NCT00128856,https://clinicaltrials.gov/study/NCT00191373,https://clinicaltrials.gov/study/NCT00193206,https://clinicaltrials.gov/study/NCT00316199,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00191269,https://clinicaltrials.gov/study/NCT00110084,https://clinicaltrials.gov/study/NCT04464174,https://clinicaltrials.gov/study/NCT00450762,https://clinicaltrials.gov/study/NCT00003540,https://clinicaltrials.gov/study/NCT00503906,https://clinicaltrials.gov/study/NCT00623233,https://clinicaltrials.gov/study/NCT00212069,https://clinicaltrials.gov/study/NCT00192062,https://clinicaltrials.gov/study/NCT00480597,https://clinicaltrials.gov/study/NCT00191854,https://clinicaltrials.gov/study/NCT00191243,https://clinicaltrials.gov/study/NCT02435680,https://clinicaltrials.gov/study/NCT00378313,https://clinicaltrials.gov/study/NCT00059852,https://clinicaltrials.gov/study/NCT00403130
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R5	phosphoinositide-3-kinase regulatory subunit 5	2	Completed	https://clinicaltrials.gov/study/NCT02273973
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04345913
EFO_0005537	triple-negative breast cancer	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		APH1B	aph-1 homolog B, gamma-secretase subunit	2	Terminated	https://clinicaltrials.gov/study/NCT01151449
EFO_0006861	male breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT00077376
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02414646
EFO_0006861	male breast carcinoma	CHEMBL535	SUNITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT00513695
MONDO_0007254	breast cancer	CHEMBL1201247	GOSERELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	2	Terminated	https://clinicaltrials.gov/study/NCT04862143,https://clinicaltrials.gov/study/NCT01368263,https://clinicaltrials.gov/study/NCT00498901,https://clinicaltrials.gov/study/NCT01205685
MONDO_0007254	breast cancer	CHEMBL1237023	DENOSUMAB	Antibody	Tumor necrosis factor ligand superfamily member 11 inhibitor		TNFSF11	TNF superfamily member 11	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06374459
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB5	NADH:ubiquinone oxidoreductase subunit B5	2	Completed	https://clinicaltrials.gov/study/NCT04170465
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT03018080,https://clinicaltrials.gov/study/NCT00119262,https://clinicaltrials.gov/study/NCT00513695
MONDO_0007254	breast cancer	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Unknown status	https://clinicaltrials.gov/study/NCT00499525
MONDO_0007254	breast cancer	CHEMBL1200554	TRIPTORELIN PAMOATE	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	2	Terminated	https://clinicaltrials.gov/study/NCT00194792
MONDO_0007254	breast cancer	CHEMBL1200694	SEVOFLURANE	Small molecule	Potassium channel subfamily K member 3 opener		KCNK3	potassium two pore domain channel subfamily K member 3	2	Completed	https://clinicaltrials.gov/study/NCT02839668
MONDO_0007254	breast cancer	CHEMBL1628227	DOXEPIN	Small molecule	Norepinephrine transporter inhibitor		SLC6A2	solute carrier family 6 member 2	2	Unknown status	https://clinicaltrials.gov/study/NCT02447211
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04345913
EFO_0005537	triple-negative breast cancer	CHEMBL2325741	CAPIVASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT3	AKT serine/threonine kinase 3	2	Recruiting	https://clinicaltrials.gov/study/NCT03801369
EFO_0005537	triple-negative breast cancer	CHEMBL3545132	MIRVETUXIMAB SORAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBA3C	tubulin alpha 3c	2	Completed	https://clinicaltrials.gov/study/NCT03106077
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHB2	EPH receptor B2	2	Terminated	https://clinicaltrials.gov/study/NCT01934335,https://clinicaltrials.gov/study/NCT00752986,https://clinicaltrials.gov/study/NCT00481845
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Recruiting	https://clinicaltrials.gov/study/NCT05319873,https://clinicaltrials.gov/study/NCT06042569,https://clinicaltrials.gov/study/NCT04266249
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Recruiting	https://clinicaltrials.gov/study/NCT04266249,https://clinicaltrials.gov/study/NCT06042569,https://clinicaltrials.gov/study/NCT05319873
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN9A	sodium voltage-gated channel alpha subunit 9	2	Completed	https://clinicaltrials.gov/study/NCT02839668,https://clinicaltrials.gov/study/NCT01204242
MONDO_0007254	breast cancer	CHEMBL81	RALOXIFENE	Small molecule	Estrogen receptor beta modulator	Antagonist	ESR2	estrogen receptor 2	2	Completed	https://clinicaltrials.gov/study/NCT00019500,https://clinicaltrials.gov/study/NCT00200174
EFO_1000984	inflammatory breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02623972
MONDO_0007254	breast cancer	CHEMBL3833373	AVELUMAB	Antibody	Programmed cell death 1 ligand 1 other		CD274	CD274 molecule	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03147287,https://clinicaltrials.gov/study/NCT03387085,https://clinicaltrials.gov/study/NCT04215146,https://clinicaltrials.gov/study/NCT03573648,https://clinicaltrials.gov/study/NCT03964532,https://clinicaltrials.gov/study/NCT03414658
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Unknown status	https://clinicaltrials.gov/study/NCT02144194,https://clinicaltrials.gov/study/NCT01939054,https://clinicaltrials.gov/study/NCT00026078,https://clinicaltrials.gov/study/NCT00721747,https://clinicaltrials.gov/study/NCT00003066,https://clinicaltrials.gov/study/NCT00801411,https://clinicaltrials.gov/study/NCT03876587,https://clinicaltrials.gov/study/NCT01907529,https://clinicaltrials.gov/study/NCT02685657,https://clinicaltrials.gov/study/NCT00669773,https://clinicaltrials.gov/study/NCT00012311,https://clinicaltrials.gov/study/NCT02947061,https://clinicaltrials.gov/study/NCT00398489,https://clinicaltrials.gov/study/NCT01351597,https://clinicaltrials.gov/study/NCT00994968,https://clinicaltrials.gov/study/NCT00957125,https://clinicaltrials.gov/study/NCT01270373,https://clinicaltrials.gov/study/NCT00006120,https://clinicaltrials.gov/study/NCT01352494,https://clinicaltrials.gov/study/NCT03147963,https://clinicaltrials.gov/study/NCT00250874,https://clinicaltrials.gov/study/NCT00033683,https://clinicaltrials.gov/study/NCT01526499
MONDO_0007254	breast cancer	CHEMBL2146883	COBIMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 1 inhibitor		MAP2K1	mitogen-activated protein kinase kinase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03395899
MONDO_0007254	breast cancer	CHEMBL4297844	TRASTUZUMAB DERUXTECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	2	Recruiting	https://clinicaltrials.gov/study/NCT05710666,https://clinicaltrials.gov/study/NCT05900206,https://clinicaltrials.gov/study/NCT06328387,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT05744375,https://clinicaltrials.gov/study/NCT06102824,https://clinicaltrials.gov/study/NCT05795101
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Unknown status	https://clinicaltrials.gov/study/NCT00027989
MONDO_0007254	breast cancer	CHEMBL1200501	GOSERELIN ACETATE	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01368263
MONDO_0007254	breast cancer	CHEMBL3647420	PYROTINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT05769010,https://clinicaltrials.gov/study/NCT04355858,https://clinicaltrials.gov/study/NCT04997798,https://clinicaltrials.gov/study/NCT03923179,https://clinicaltrials.gov/study/NCT05823623,https://clinicaltrials.gov/study/NCT05861271,https://clinicaltrials.gov/study/NCT04033172,https://clinicaltrials.gov/study/NCT05638594,https://clinicaltrials.gov/study/NCT06152822,https://clinicaltrials.gov/study/NCT05292742,https://clinicaltrials.gov/study/NCT05076695,https://clinicaltrials.gov/study/NCT04095390,https://clinicaltrials.gov/study/NCT04407988,https://clinicaltrials.gov/study/NCT04605575,https://clinicaltrials.gov/study/NCT04717531,https://clinicaltrials.gov/study/NCT04034589,https://clinicaltrials.gov/study/NCT05880927,https://clinicaltrials.gov/study/NCT04872985,https://clinicaltrials.gov/study/NCT05659056,https://clinicaltrials.gov/study/NCT05429294,https://clinicaltrials.gov/study/NCT06254690,https://clinicaltrials.gov/study/NCT05575804,https://clinicaltrials.gov/study/NCT05635487,https://clinicaltrials.gov/study/NCT05228951,https://clinicaltrials.gov/study/NCT05834764,https://clinicaltrials.gov/study/NCT06001086,https://clinicaltrials.gov/study/NCT04917900,https://clinicaltrials.gov/study/NCT03923166,https://clinicaltrials.gov/study/NCT05426486,https://clinicaltrials.gov/study/NCT05353361,https://clinicaltrials.gov/study/NCT05042791,https://clinicaltrials.gov/study/NCT05800756,https://clinicaltrials.gov/study/NCT04681911
EFO_0005537	triple-negative breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967
MONDO_0007254	breast cancer	CHEMBL185	FLUOROURACIL	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	2	Withdrawn	https://clinicaltrials.gov/study/NCT03554109
EFO_0005537	triple-negative breast cancer	CHEMBL3545262	SACITUZUMAB GOVITECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	2	Recruiting	https://clinicaltrials.gov/study/NCT05101096,https://clinicaltrials.gov/study/NCT03971409
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04963595,https://clinicaltrials.gov/study/NCT03997539,https://clinicaltrials.gov/study/NCT06229067,https://clinicaltrials.gov/study/NCT04922008,https://clinicaltrials.gov/study/NCT04143906
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE3B	phosphodiesterase 3B	2	Recruiting	https://clinicaltrials.gov/study/NCT06087237
EFO_0005537	triple-negative breast cancer	CHEMBL2325741	CAPIVASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT2	AKT serine/threonine kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT03801369
EFO_0005537	triple-negative breast cancer	CHEMBL4297844	TRASTUZUMAB DERUXTECAN	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 binding agent		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05953168
EFO_0005537	triple-negative breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT03154749,https://clinicaltrials.gov/study/NCT02413320
EFO_0006861	male breast carcinoma	CHEMBL1567	SUNITINIB MALATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT00513695
EFO_0000304	breast adenocarcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Recruiting	https://clinicaltrials.gov/study/NCT04197687
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA13	NADH:ubiquinone oxidoreductase subunit A13	2	Unknown status	https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT02506777,https://clinicaltrials.gov/study/NCT03192293
MONDO_0007254	breast cancer	CHEMBL924	ZOLEDRONIC ACID ANHYDROUS	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	2	Terminated	https://clinicaltrials.gov/study/NCT00172068,https://clinicaltrials.gov/study/NCT02347163
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT05198843,https://clinicaltrials.gov/study/NCT00780676,https://clinicaltrials.gov/study/NCT00817531
MONDO_0007254	breast cancer	CHEMBL1743024	GANITUMAB	Antibody	Insulin-like growth factor I receptor antagonist		IGF1R	insulin like growth factor 1 receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Terminated	https://clinicaltrials.gov/study/NCT01702558,https://clinicaltrials.gov/study/NCT03709082,https://clinicaltrials.gov/study/NCT03894007
MONDO_0007254	breast cancer	CHEMBL3184679	AZD-4547	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR2	fibroblast growth factor receptor 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT04903652,https://clinicaltrials.gov/study/NCT00401427,https://clinicaltrials.gov/study/NCT03254654,https://clinicaltrials.gov/study/NCT01305941,https://clinicaltrials.gov/study/NCT00148668,https://clinicaltrials.gov/study/NCT02362958,https://clinicaltrials.gov/study/NCT00193089,https://clinicaltrials.gov/study/NCT00266110,https://clinicaltrials.gov/study/NCT01565083,https://clinicaltrials.gov/study/NCT03321981,https://clinicaltrials.gov/study/NCT00325234,https://clinicaltrials.gov/study/NCT00192062,https://clinicaltrials.gov/study/NCT00670982,https://clinicaltrials.gov/study/NCT00148681,https://clinicaltrials.gov/study/NCT00004237,https://clinicaltrials.gov/study/NCT01520103,https://clinicaltrials.gov/study/NCT00503750,https://clinicaltrials.gov/study/NCT00022152,https://clinicaltrials.gov/study/NCT01835236,https://clinicaltrials.gov/study/NCT03007992,https://clinicaltrials.gov/study/NCT01242449,https://clinicaltrials.gov/study/NCT01941771,https://clinicaltrials.gov/study/NCT00015938,https://clinicaltrials.gov/study/NCT00532623,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT01439191,https://clinicaltrials.gov/study/NCT00041067,https://clinicaltrials.gov/study/NCT02628613,https://clinicaltrials.gov/study/NCT00194779,https://clinicaltrials.gov/study/NCT03887130,https://clinicaltrials.gov/study/NCT00480597,https://clinicaltrials.gov/study/NCT00006682,https://clinicaltrials.gov/study/NCT02954055,https://clinicaltrials.gov/study/NCT00093808
MONDO_0007254	breast cancer	CHEMBL679	EPINEPHRINE	Small molecule	Adrenergic receptor agonist		ADRB1	adrenoceptor beta 1	2	Completed	https://clinicaltrials.gov/study/NCT02525718
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA11	NADH:ubiquinone oxidoreductase subunit A11	2	Terminated	https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT02472353
MONDO_0007254	breast cancer	CHEMBL2220442	FLUVASTATIN	Small molecule	HMG-CoA reductase inhibitor		HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase	2	Completed	https://clinicaltrials.gov/study/NCT00416403
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05601440,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT04739670,https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT05181462,https://clinicaltrials.gov/study/NCT06102824,https://clinicaltrials.gov/study/NCT06026657
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Unknown status	https://clinicaltrials.gov/study/NCT01372579
MONDO_0007254	breast cancer	CHEMBL1581	PERINDOPRIL	Small molecule	Angiotensin-converting enzyme inhibitor		ACE	angiotensin I converting enzyme	2	Completed	https://clinicaltrials.gov/study/NCT04588935
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01853748,https://clinicaltrials.gov/study/NCT01565200,https://clinicaltrials.gov/study/NCT04733118,https://clinicaltrials.gov/study/NCT01494662,https://clinicaltrials.gov/study/NCT02326974,https://clinicaltrials.gov/study/NCT01745965,https://clinicaltrials.gov/study/NCT04398914,https://clinicaltrials.gov/study/NCT03587740
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT00191373
EFO_0000304	breast adenocarcinoma	CHEMBL1201294	DIPHENOXYLATE	Small molecule	Mu opioid receptor agonist		OPRM1	opioid receptor mu 1	2	Completed	https://clinicaltrials.gov/study/NCT03094052
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Unknown status	https://clinicaltrials.gov/study/NCT01372579
EFO_0005537	triple-negative breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R2	phosphoinositide-3-kinase regulatory subunit 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03911973
EFO_0005537	triple-negative breast cancer	CHEMBL1201827	PANITUMUMAB	Antibody	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Withdrawn	https://clinicaltrials.gov/study/NCT05177796
EFO_0000305	breast carcinoma	CHEMBL377559	RETASPIMYCIN HYDROCHLORIDE	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AA1	heat shock protein 90 alpha family class A member 1	2	Terminated	https://clinicaltrials.gov/study/NCT00817362
MONDO_0007254	breast cancer	CHEMBL2105756	TIVOZANIB HYDROCHLORIDE	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT01745367
MONDO_0007254	breast cancer	CHEMBL2364649	MARGETUXIMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT04425018
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE10A	phosphodiesterase 10A	2	Recruiting	https://clinicaltrials.gov/study/NCT06087237
EFO_0005537	triple-negative breast cancer	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0006861	male breast carcinoma	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 2 inhibitor		HDAC2	histone deacetylase 2	2	Terminated	https://clinicaltrials.gov/study/NCT00132002
EFO_0005537	triple-negative breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04395989,https://clinicaltrials.gov/study/NCT04129996
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT02978716
EFO_0005537	triple-negative breast cancer	CHEMBL4298037	RETIFANLIMAB	Antibody	Programmed cell death protein 1 antagonist		PDCD1	programmed cell death 1	2	Recruiting	https://clinicaltrials.gov/study/NCT04445844
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV1	NADH:ubiquinone oxidoreductase core subunit V1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Tyrosine-protein kinase BRK inhibitor		PTK6	protein tyrosine kinase 6	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999
MONDO_0007254	breast cancer	CHEMBL1642	IMATINIB MESYLATE	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00338728,https://clinicaltrials.gov/study/NCT00087152
MONDO_0007254	breast cancer	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC9	histone deacetylase 9	2	Completed	https://clinicaltrials.gov/study/NCT00098397
MONDO_0007254	breast cancer	CHEMBL679	EPINEPHRINE	Small molecule	Adrenergic receptor agonist		ADRA1D	adrenoceptor alpha 1D	2	Completed	https://clinicaltrials.gov/study/NCT02525718
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS6	NADH:ubiquinone oxidoreductase subunit S6	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 2 inhibitor		HDAC2	histone deacetylase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT00616967
MONDO_0044915	salivary duct carcinoma	CHEMBL1289601	LENVATINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT02860936
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS3	NADH:ubiquinone oxidoreductase core subunit S3	2	Completed	https://clinicaltrials.gov/study/NCT01885013
MONDO_0007254	breast cancer	CHEMBL1201577	CETUXIMAB	Antibody	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Completed	https://clinicaltrials.gov/study/NCT00633464,https://clinicaltrials.gov/study/NCT01097642,https://clinicaltrials.gov/study/NCT00600249,https://clinicaltrials.gov/study/NCT00275041,https://clinicaltrials.gov/study/NCT00232505
MONDO_0007254	breast cancer	CHEMBL1234354	PF-04691502	Small molecule	PI3-kinase class I inhibitor		PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	2	Terminated	https://clinicaltrials.gov/study/NCT01430585
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND2	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2	2	Terminated	https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT04899349
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHB6	EPH receptor B6	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC1	NADH:ubiquinone oxidoreductase subunit C1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC2	NADH:ubiquinone oxidoreductase subunit C2	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0000432	breast ductal carcinoma in situ	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator	Antagonist	ESR1	estrogen receptor 1	2	Completed	https://clinicaltrials.gov/study/NCT00952731
MONDO_0007254	breast cancer	CHEMBL1094636	NIRAPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Completed	https://clinicaltrials.gov/study/NCT04240106
MONDO_0007254	breast cancer	CHEMBL723	CARVEDILOL	Small molecule	Adrenergic receptor alpha-1 antagonist		ADRA1A	adrenoceptor alpha 1A	2	Completed	https://clinicaltrials.gov/study/NCT02177175,https://clinicaltrials.gov/study/NCT01009918
MONDO_0007254	breast cancer	CHEMBL4297840	TISLELIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04734262,https://clinicaltrials.gov/study/NCT04577963
EFO_0000305	breast carcinoma	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT06298084,https://clinicaltrials.gov/study/NCT03598257,https://clinicaltrials.gov/study/NCT04090567
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBA1A	tubulin alpha 1a	2	Completed	https://clinicaltrials.gov/study/NCT00284180
MONDO_0007254	breast cancer	CHEMBL3218576	COPANLISIB	Small molecule	PI3-kinase p110-delta subunit inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	2	Withdrawn	https://clinicaltrials.gov/study/NCT03377101
MONDO_0007254	breast cancer	CHEMBL3833373	AVELUMAB	Antibody	Programmed cell death 1 ligand 1 other		CD274	CD274 molecule	2	Withdrawn	https://clinicaltrials.gov/study/NCT03554109,https://clinicaltrials.gov/study/NCT03794596
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE6A	phosphodiesterase 6A	2	Recruiting	https://clinicaltrials.gov/study/NCT06087237
EFO_1000984	inflammatory breast carcinoma	CHEMBL4297844	TRASTUZUMAB DERUXTECAN	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 binding agent		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT05795101
MONDO_0007254	breast cancer	CHEMBL180022	NERATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05154396
EFO_0005537	triple-negative breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT02413320,https://clinicaltrials.gov/study/NCT03154749
MONDO_0007254	breast cancer	CHEMBL1835207	APRICOXIB	Small molecule	Cyclooxygenase-2 inhibitor		PTGS2	prostaglandin-endoperoxide synthase 2	2	Terminated	https://clinicaltrials.gov/study/NCT00657137
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC6	histone deacetylase 6	2	Completed	https://clinicaltrials.gov/study/NCT00777049
MONDO_0007254	breast cancer	CHEMBL56337	EPALRESTAT	Small molecule	Aldose reductase inhibitor		AKR1B1	aldo-keto reductase family 1 member B	2	Terminated	https://clinicaltrials.gov/study/NCT03244358
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT00767520,https://clinicaltrials.gov/study/NCT00696072,https://clinicaltrials.gov/study/NCT00410813,https://clinicaltrials.gov/study/NCT00546104,https://clinicaltrials.gov/study/NCT00754325
EFO_0000304	breast adenocarcinoma	CHEMBL180022	NERATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-4 inhibitor		ERBB4	erb-b2 receptor tyrosine kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT03094052
EFO_0000305	breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Tyrosine-protein kinase LCK inhibitor		LCK	LCK proto-oncogene, Src family tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
MONDO_0044915	salivary duct carcinoma	CHEMBL1289601	LENVATINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT02860936
EFO_0005537	triple-negative breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Suspended	https://clinicaltrials.gov/study/NCT04095689
MONDO_0007254	breast cancer	CHEMBL225072	PEMETREXED	Small molecule	GAR transformylase inhibitor		GART	phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase	2	Terminated	https://clinicaltrials.gov/study/NCT02624700
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05041101
EFO_0000432	breast ductal carcinoma in situ	CHEMBL4297509	ELACESTRANT	Small molecule	Estrogen receptor alpha degrader	Antagonist	ESR1	estrogen receptor 1	2	Recruiting	https://clinicaltrials.gov/study/NCT06075953
EFO_0000304	breast adenocarcinoma	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT04197687
MONDO_0007254	breast cancer	CHEMBL1370	BUDESONIDE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	2	Completed	https://clinicaltrials.gov/study/NCT02400476
MONDO_0007254	breast cancer	CHEMBL4303669	ZOLEDRONIC ACID	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	2	Terminated	https://clinicaltrials.gov/study/NCT00172068,https://clinicaltrials.gov/study/NCT02347163
MONDO_0007254	breast cancer	CHEMBL1200694	SEVOFLURANE	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRB3	gamma-aminobutyric acid type A receptor subunit beta3	2	Completed	https://clinicaltrials.gov/study/NCT02839668
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA8	NADH:ubiquinone oxidoreductase subunit A8	2	Terminated	https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT02360059
MONDO_0007254	breast cancer	CHEMBL1743028	GLEMBATUMUMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT01156753,https://clinicaltrials.gov/study/NCT01997333
MONDO_0007254	breast cancer	CHEMBL2408045	SAPITINIB	Small molecule	Receptor tyrosine-protein kinase erbB-3 inhibitor		ERBB3	erb-b2 receptor tyrosine kinase 3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT01908101
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC2	NADH:ubiquinone oxidoreductase subunit C2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT02978495
MONDO_0007254	breast cancer	CHEMBL482968	ENMD-2076	Small molecule	Serine/threonine-protein kinase Aurora-B inhibitor		AURKB	aurora kinase B	2	Completed	https://clinicaltrials.gov/study/NCT01639248
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Completed	https://clinicaltrials.gov/study/NCT01881230
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4	2	Recruiting	https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04559308,https://clinicaltrials.gov/study/NCT03238495
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02827877
MONDO_0007254	breast cancer	CHEMBL2408045	SAPITINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01151215
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Terminated	https://clinicaltrials.gov/study/NCT00462865,https://clinicaltrials.gov/study/NCT00674206,https://clinicaltrials.gov/study/NCT02213744,https://clinicaltrials.gov/study/NCT00323063,https://clinicaltrials.gov/study/NCT00679029,https://clinicaltrials.gov/study/NCT00095888,https://clinicaltrials.gov/study/NCT00470249,https://clinicaltrials.gov/study/NCT00532285,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT03674242,https://clinicaltrials.gov/study/NCT00159458
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02876302,https://clinicaltrials.gov/study/NCT01730833
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FYN	FYN proto-oncogene, Src family tyrosine kinase	2	Withdrawn	https://clinicaltrials.gov/study/NCT01410708
MONDO_0007254	breast cancer	CHEMBL84	TOPOTECAN	Small molecule	DNA topoisomerase I, mitochondrial inhibitor		TOP1MT	DNA topoisomerase I mitochondrial	2	Terminated	https://clinicaltrials.gov/study/NCT00006032
MONDO_0007254	breast cancer	CHEMBL2108359	NIMOTUZUMAB	Antibody	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT01939054
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01009788
EFO_0005537	triple-negative breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT03932526
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB9	NADH:ubiquinone oxidoreductase subunit B9	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	2	Withdrawn	https://clinicaltrials.gov/study/NCT00450515,https://clinicaltrials.gov/study/NCT00960544,https://clinicaltrials.gov/study/NCT05227131,https://clinicaltrials.gov/study/NCT00964704,https://clinicaltrials.gov/study/NCT00397761,https://clinicaltrials.gov/study/NCT01227408
MONDO_0007254	breast cancer	CHEMBL4297715	CAMRELIZUMAB	Antibody	Programmed cell death protein 1 antagonist		PDCD1	programmed cell death 1	2	Enrolling by invitation	https://clinicaltrials.gov/study/NCT05576389
MONDO_0007254	breast cancer	CHEMBL4594401	RAFUTROMBOPAG	Small molecule	Thrombopoietin receptor agonist		MPL	MPL proto-oncogene, thrombopoietin receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT05394285
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB8	NADH:ubiquinone oxidoreductase subunit B8	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB4	NADH:ubiquinone oxidoreductase subunit B4	2	Terminated	https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT01627067
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB3	NADH:ubiquinone oxidoreductase subunit B3	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL4297892	ANVATABART OPADOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Recruiting	https://clinicaltrials.gov/study/NCT05018676,https://clinicaltrials.gov/study/NCT05426486,https://clinicaltrials.gov/study/NCT05018702,https://clinicaltrials.gov/study/NCT04829604,https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBA4A	tubulin alpha 4a	2	Completed	https://clinicaltrials.gov/study/NCT00265733,https://clinicaltrials.gov/study/NCT00148707
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	2	Completed	https://clinicaltrials.gov/study/NCT00662025,https://clinicaltrials.gov/study/NCT00482755,https://clinicaltrials.gov/study/NCT00270413
EFO_0006861	male breast carcinoma	CHEMBL941	IMATINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00045188
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF3	NADH:ubiquinone oxidoreductase complex assembly factor 3	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1023	BEXAROTENE	Small molecule	Retinoid X receptor agonist		RXRG	retinoid X receptor gamma	2	Completed	https://clinicaltrials.gov/study/NCT00003752
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT00266110,https://clinicaltrials.gov/study/NCT00148681,https://clinicaltrials.gov/study/NCT00006682,https://clinicaltrials.gov/study/NCT00093808,https://clinicaltrials.gov/study/NCT00194779,https://clinicaltrials.gov/study/NCT00532623,https://clinicaltrials.gov/study/NCT00022152,https://clinicaltrials.gov/study/NCT00004237,https://clinicaltrials.gov/study/NCT00148668,https://clinicaltrials.gov/study/NCT01941771
EFO_0006861	male breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Fibroblast growth factor receptor 3 inhibitor		FGFR3	fibroblast growth factor receptor 3	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
MONDO_0007254	breast cancer	CHEMBL260538	ULIPRISTAL ACETATE	Small molecule	Progesterone receptor modulator		PGR	progesterone receptor	2	Completed	https://clinicaltrials.gov/study/NCT02408770
EFO_0005537	triple-negative breast cancer	CHEMBL4298085	FIANLIMAB	Antibody	Lymphocyte activation gene 3 protein inhibitor		LAG3	lymphocyte activating 3	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL1201649	ESTROGENS, CONJUGATED	Unknown	Estrogen receptor agonist	Antagonist	ESR1	estrogen receptor 1	2	Recruiting	https://clinicaltrials.gov/study/NCT04821141
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	2	Completed	https://clinicaltrials.gov/study/NCT02273973
MONDO_0007254	breast cancer	CHEMBL306823	SODIUM DICHLOROACETATE	Small molecule	Pyruvate dehydrogenase kinase inhibitor		PDK2	pyruvate dehydrogenase kinase 2	2	Terminated	https://clinicaltrials.gov/study/NCT01029925
MONDO_0007254	breast cancer	CHEMBL742	KETAMINE	Small molecule	Glutamate [NMDA] receptor negative allosteric modulator		GRIN3B	glutamate ionotropic receptor NMDA type subunit 3B	2	Completed	https://clinicaltrials.gov/study/NCT05727098,https://clinicaltrials.gov/study/NCT00304850
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV2	NADH:ubiquinone oxidoreductase core subunit V2	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Withdrawn	https://clinicaltrials.gov/study/NCT05177796,https://clinicaltrials.gov/study/NCT05233696
MONDO_0007254	breast cancer	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4L	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND6	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT00148707,https://clinicaltrials.gov/study/NCT00265733
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Withdrawn	https://clinicaltrials.gov/study/NCT00450515
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05128734,https://clinicaltrials.gov/study/NCT05536128
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Completed	https://clinicaltrials.gov/study/NCT02282345
EFO_0005537	triple-negative breast cancer	CHEMBL3647420	PYROTINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04395989
EFO_0005537	triple-negative breast cancer	CHEMBL3894860	TRILACICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	2	Recruiting	https://clinicaltrials.gov/study/NCT06027268,https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL1879463	DACTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	2	Withdrawn	https://clinicaltrials.gov/study/NCT01288092
EFO_0005537	triple-negative breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04395989,https://clinicaltrials.gov/study/NCT04129996
EFO_0005537	triple-negative breast cancer	CHEMBL180022	NERATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL2087361	ICOTINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Terminated	https://clinicaltrials.gov/study/NCT02362230
MONDO_0007254	breast cancer	CHEMBL3701238	FUTIBATINIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR3	fibroblast growth factor receptor 3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04024436
EFO_0005537	triple-negative breast cancer	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02315196,https://clinicaltrials.gov/study/NCT01750073
MONDO_0007254	breast cancer	CHEMBL3813842	PAXALISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	2	Recruiting	https://clinicaltrials.gov/study/NCT03765983
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	2	Completed	https://clinicaltrials.gov/study/NCT00662025,https://clinicaltrials.gov/study/NCT00482755,https://clinicaltrials.gov/study/NCT00270413
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE3B	phosphodiesterase 3B	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT06176339,https://clinicaltrials.gov/study/NCT06186700
EFO_0005537	triple-negative breast cancer	CHEMBL1421	DASATINIB	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06355037
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Recruiting	https://clinicaltrials.gov/study/NCT04266249
EFO_1000984	inflammatory breast carcinoma	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT02682693
MONDO_0007254	breast cancer	CHEMBL1230609	FORETINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT01138384,https://clinicaltrials.gov/study/NCT01147484
MONDO_0007254	breast cancer	CHEMBL571209	INDOXIMOD	Small molecule	mTORC1 activator		RPTOR	regulatory associated protein of MTOR complex 1	2	Completed	https://clinicaltrials.gov/study/NCT01792050
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC6	histone deacetylase 6	2	Terminated	https://clinicaltrials.gov/study/NCT00777335
EFO_0005537	triple-negative breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT03154749,https://clinicaltrials.gov/study/NCT02413320
MONDO_0007254	breast cancer	CHEMBL3264002	AVUTOMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 2 inhibitor		MAP2K2	mitogen-activated protein kinase kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT05608252
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS2	NADH:ubiquinone oxidoreductase core subunit S2	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0005537	triple-negative breast cancer	CHEMBL3545132	MIRVETUXIMAB SORAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT03106077
EFO_0000432	breast ductal carcinoma in situ	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Terminated	https://clinicaltrials.gov/study/NCT00461344
MONDO_0007254	breast cancer	CHEMBL1201583	BEVACIZUMAB	Antibody	Vascular endothelial growth factor A inhibitor		VEGFA	vascular endothelial growth factor A	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03395899,https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT03387085
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT01904903,https://clinicaltrials.gov/study/NCT02924883,https://clinicaltrials.gov/study/NCT01196052,https://clinicaltrials.gov/study/NCT02073487,https://clinicaltrials.gov/study/NCT00679211,https://clinicaltrials.gov/study/NCT01835236,https://clinicaltrials.gov/study/NCT00943670,https://clinicaltrials.gov/study/NCT00679341,https://clinicaltrials.gov/study/NCT03530696,https://clinicaltrials.gov/study/NCT00509769
MONDO_0007254	breast cancer	CHEMBL4297840	TISLELIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Withdrawn	https://clinicaltrials.gov/study/NCT05809895
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT00733408,https://clinicaltrials.gov/study/NCT03057600,https://clinicaltrials.gov/study/NCT01818063,https://clinicaltrials.gov/study/NCT02413320,https://clinicaltrials.gov/study/NCT01881230,https://clinicaltrials.gov/study/NCT03853707,https://clinicaltrials.gov/study/NCT02689427
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Terminated	https://clinicaltrials.gov/study/NCT00679029,https://clinicaltrials.gov/study/NCT00323063,https://clinicaltrials.gov/study/NCT00095888,https://clinicaltrials.gov/study/NCT00470249
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	2	Withdrawn	https://clinicaltrials.gov/study/NCT04351230
EFO_0005537	triple-negative breast cancer	CHEMBL180022	NERATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-4 inhibitor		ERBB4	erb-b2 receptor tyrosine kinase 4	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL502835	NINTEDANIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR1	fibroblast growth factor receptor 1	2	Completed	https://clinicaltrials.gov/study/NCT01658462
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS4	NADH:ubiquinone oxidoreductase subunit S4	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN2A	sodium voltage-gated channel alpha subunit 2	2	Completed	https://clinicaltrials.gov/study/NCT02839668,https://clinicaltrials.gov/study/NCT01204242
EFO_0006861	male breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00095888
EFO_0006861	male breast carcinoma	CHEMBL1567	SUNITINIB MALATE	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Completed	https://clinicaltrials.gov/study/NCT00513695
EFO_0000305	breast carcinoma	CHEMBL3039498	GRAPIPRANT	Small molecule	Prostanoid EP4 receptor antagonist		PTGER4	prostaglandin E receptor 4	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05041101
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04345913
EFO_0005537	triple-negative breast cancer	CHEMBL4285417	CERALASERTIB	Small molecule	Serine-protein kinase ATR inhibitor		ATR	ATR serine/threonine kinase	2	Recruiting	https://clinicaltrials.gov/study/NCT03801369
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Recruiting	https://clinicaltrials.gov/study/NCT05823623,https://clinicaltrials.gov/study/NCT05296577
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB3	NADH:ubiquinone oxidoreductase subunit B3	2	Unknown status	https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT02506777
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Withdrawn	https://clinicaltrials.gov/study/NCT02215876,https://clinicaltrials.gov/study/NCT03637868
MONDO_0007254	breast cancer	CHEMBL4594611	PATRITUMAB DERUXTECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05569811
MONDO_0007254	breast cancer	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05467891,https://clinicaltrials.gov/study/NCT05463601,https://clinicaltrials.gov/study/NCT05472792,https://clinicaltrials.gov/study/NCT04614194,https://clinicaltrials.gov/study/NCT05900206,https://clinicaltrials.gov/study/NCT03906669,https://clinicaltrials.gov/study/NCT04571437,https://clinicaltrials.gov/study/NCT04282031,https://clinicaltrials.gov/study/NCT03497702,https://clinicaltrials.gov/study/NCT04985266,https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT05800756,https://clinicaltrials.gov/study/NCT05766410,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT05286437,https://clinicaltrials.gov/study/NCT04563507,https://clinicaltrials.gov/study/NCT03879577,https://clinicaltrials.gov/study/NCT05638594,https://clinicaltrials.gov/study/NCT05150652,https://clinicaltrials.gov/study/NCT05411380,https://clinicaltrials.gov/study/NCT05190094,https://clinicaltrials.gov/study/NCT04886531,https://clinicaltrials.gov/study/NCT05181033,https://clinicaltrials.gov/study/NCT04095390,https://clinicaltrials.gov/study/NCT04568616
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT01908101
EFO_0000304	breast adenocarcinoma	CHEMBL3545092	CR 1447	Small molecule	Estrogen receptor beta agonist	Antagonist	ESR2	estrogen receptor 2	2	Terminated	https://clinicaltrials.gov/study/NCT02067741
EFO_0006861	male breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00095888
EFO_0005537	triple-negative breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R5	phosphoinositide-3-kinase regulatory subunit 5	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03911973
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA7	NADH:ubiquinone oxidoreductase subunit A7	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
MONDO_0004379	female breast carcinoma	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02942355
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT00265733,https://clinicaltrials.gov/study/NCT00148707
MONDO_0007254	breast cancer	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT00622466,https://clinicaltrials.gov/study/NCT00722072,https://clinicaltrials.gov/study/NCT00573755
EFO_0006861	male breast carcinoma	CHEMBL491473	CEDIRANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT00244881
EFO_1000984	inflammatory breast carcinoma	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02876302,https://clinicaltrials.gov/study/NCT02623972
EFO_0000304	breast adenocarcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Recruiting	https://clinicaltrials.gov/study/NCT04197687
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04345913
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT02790580
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT00662025,https://clinicaltrials.gov/study/NCT00482755,https://clinicaltrials.gov/study/NCT00270413
MONDO_0007254	breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04733417
MONDO_0007254	breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04227327,https://clinicaltrials.gov/study/NCT04603183,https://clinicaltrials.gov/study/NCT04432454,https://clinicaltrials.gov/study/NCT03284957,https://clinicaltrials.gov/study/NCT04293393,https://clinicaltrials.gov/study/NCT04352777,https://clinicaltrials.gov/study/NCT02747004,https://clinicaltrials.gov/study/NCT03939897
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT06026657,https://clinicaltrials.gov/study/NCT06102824,https://clinicaltrials.gov/study/NCT05181462,https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT04739670,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT05601440,https://clinicaltrials.gov/study/NCT04681911
EFO_0000305	breast carcinoma	CHEMBL1421	DASATINIB	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	2	Terminated	https://clinicaltrials.gov/study/NCT05198843
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT00003992,https://clinicaltrials.gov/study/NCT01186991,https://clinicaltrials.gov/study/NCT01446016,https://clinicaltrials.gov/study/NCT01036087,https://clinicaltrials.gov/study/NCT00915018,https://clinicaltrials.gov/study/NCT00559845,https://clinicaltrials.gov/study/NCT00256243,https://clinicaltrials.gov/study/NCT00403130,https://clinicaltrials.gov/study/NCT00455533,https://clinicaltrials.gov/study/NCT00274456,https://clinicaltrials.gov/study/NCT03742986,https://clinicaltrials.gov/study/NCT02698891,https://clinicaltrials.gov/study/NCT00532857,https://clinicaltrials.gov/study/NCT00511459,https://clinicaltrials.gov/study/NCT02783222,https://clinicaltrials.gov/study/NCT00675259,https://clinicaltrials.gov/study/NCT00629499,https://clinicaltrials.gov/study/NCT02938442,https://clinicaltrials.gov/study/NCT04408118,https://clinicaltrials.gov/study/NCT00136539,https://clinicaltrials.gov/study/NCT01307891,https://clinicaltrials.gov/study/NCT00006256,https://clinicaltrials.gov/study/NCT00320541,https://clinicaltrials.gov/study/NCT00003392,https://clinicaltrials.gov/study/NCT02789657,https://clinicaltrials.gov/study/NCT02280252,https://clinicaltrials.gov/study/NCT03248427,https://clinicaltrials.gov/study/NCT01276041,https://clinicaltrials.gov/study/NCT00499083,https://clinicaltrials.gov/study/NCT00019812,https://clinicaltrials.gov/study/NCT01204437,https://clinicaltrials.gov/study/NCT03121352,https://clinicaltrials.gov/study/NCT00407888,https://clinicaltrials.gov/study/NCT00392392,https://clinicaltrials.gov/study/NCT01190982,https://clinicaltrials.gov/study/NCT02365805,https://clinicaltrials.gov/study/NCT03193853,https://clinicaltrials.gov/study/NCT00542451,https://clinicaltrials.gov/study/NCT01969032,https://clinicaltrials.gov/study/NCT00110084,https://clinicaltrials.gov/study/NCT01023204,https://clinicaltrials.gov/study/NCT02909751,https://clinicaltrials.gov/study/NCT01705691,https://clinicaltrials.gov/study/NCT00002679,https://clinicaltrials.gov/study/NCT00846027,https://clinicaltrials.gov/study/NCT00194779,https://clinicaltrials.gov/study/NCT05112536,https://clinicaltrials.gov/study/NCT00662129,https://clinicaltrials.gov/study/NCT01572727,https://clinicaltrials.gov/study/NCT04224922,https://clinicaltrials.gov/study/NCT00001498,https://clinicaltrials.gov/study/NCT00503750,https://clinicaltrials.gov/study/NCT00773695,https://clinicaltrials.gov/study/NCT01204125,https://clinicaltrials.gov/study/NCT00096291,https://clinicaltrials.gov/study/NCT00394082,https://clinicaltrials.gov/study/NCT01989780,https://clinicaltrials.gov/study/NCT00334802,https://clinicaltrials.gov/study/NCT01617668,https://clinicaltrials.gov/study/NCT00004092,https://clinicaltrials.gov/study/NCT00251472,https://clinicaltrials.gov/study/NCT00475670,https://clinicaltrials.gov/study/NCT00394251,https://clinicaltrials.gov/study/NCT00007904,https://clinicaltrials.gov/study/NCT01847001,https://clinicaltrials.gov/study/NCT03301350,https://clinicaltrials.gov/study/NCT02225652,https://clinicaltrials.gov/study/NCT00503906,https://clinicaltrials.gov/study/NCT03982485,https://clinicaltrials.gov/study/NCT00093145,https://clinicaltrials.gov/study/NCT00930930,https://clinicaltrials.gov/study/NCT00001384,https://clinicaltrials.gov/study/NCT00128856,https://clinicaltrials.gov/study/NCT03072992,https://clinicaltrials.gov/study/NCT00479674,https://clinicaltrials.gov/study/NCT01722968,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00004013,https://clinicaltrials.gov/study/NCT00096668,https://clinicaltrials.gov/study/NCT00467012,https://clinicaltrials.gov/study/NCT00002937,https://clinicaltrials.gov/study/NCT01672671,https://clinicaltrials.gov/study/NCT01835236,https://clinicaltrials.gov/study/NCT01792050,https://clinicaltrials.gov/study/NCT00096343,https://clinicaltrials.gov/study/NCT02229084,https://clinicaltrials.gov/study/NCT02954055,https://clinicaltrials.gov/study/NCT00005635,https://clinicaltrials.gov/study/NCT03887130,https://clinicaltrials.gov/study/NCT00856492,https://clinicaltrials.gov/study/NCT03289819,https://clinicaltrials.gov/study/NCT01855828,https://clinicaltrials.gov/study/NCT00919880,https://clinicaltrials.gov/study/NCT03326102,https://clinicaltrials.gov/study/NCT00436566,https://clinicaltrials.gov/study/NCT01593020,https://clinicaltrials.gov/study/NCT02685059,https://clinicaltrials.gov/study/NCT02073487,https://clinicaltrials.gov/study/NCT01959490,https://clinicaltrials.gov/study/NCT02301988,https://clinicaltrials.gov/study/NCT00580333,https://clinicaltrials.gov/study/NCT00546156,https://clinicaltrials.gov/study/NCT01688609,https://clinicaltrials.gov/study/NCT00002826,https://clinicaltrials.gov/study/NCT00645177,https://clinicaltrials.gov/study/NCT00733408,https://clinicaltrials.gov/study/NCT00003035,https://clinicaltrials.gov/study/NCT00003050,https://clinicaltrials.gov/study/NCT00768859,https://clinicaltrials.gov/study/NCT01432223,https://clinicaltrials.gov/study/NCT00944047,https://clinicaltrials.gov/study/NCT02474186,https://clinicaltrials.gov/study/NCT01506609,https://clinicaltrials.gov/study/NCT01656538,https://clinicaltrials.gov/study/NCT00618826,https://clinicaltrials.gov/study/NCT01982448,https://clinicaltrials.gov/study/NCT01816594,https://clinicaltrials.gov/study/NCT03853707,https://clinicaltrials.gov/study/NCT00028873,https://clinicaltrials.gov/study/NCT01421472,https://clinicaltrials.gov/study/NCT02687490,https://clinicaltrials.gov/study/NCT02628613,https://clinicaltrials.gov/study/NCT02263495,https://clinicaltrials.gov/study/NCT01423695,https://clinicaltrials.gov/study/NCT00915603,https://clinicaltrials.gov/study/NCT02370238,https://clinicaltrials.gov/study/NCT00003612,https://clinicaltrials.gov/study/NCT00146562,https://clinicaltrials.gov/study/NCT00795899,https://clinicaltrials.gov/study/NCT00635050,https://clinicaltrials.gov/study/NCT00482391,https://clinicaltrials.gov/study/NCT00148681,https://clinicaltrials.gov/study/NCT01818063,https://clinicaltrials.gov/study/NCT00072319,https://clinicaltrials.gov/study/NCT01740336,https://clinicaltrials.gov/study/NCT01565499,https://clinicaltrials.gov/study/NCT00191854,https://clinicaltrials.gov/study/NCT01594177,https://clinicaltrials.gov/study/NCT00005649,https://clinicaltrials.gov/study/NCT00052351,https://clinicaltrials.gov/study/NCT01008150,https://clinicaltrials.gov/study/NCT01256762,https://clinicaltrials.gov/study/NCT00723125,https://clinicaltrials.gov/study/NCT00654836,https://clinicaltrials.gov/study/NCT00254592,https://clinicaltrials.gov/study/NCT00316199,https://clinicaltrials.gov/study/NCT00003539,https://clinicaltrials.gov/study/NCT01203267,https://clinicaltrials.gov/study/NCT01973660,https://clinicaltrials.gov/study/NCT01320111,https://clinicaltrials.gov/study/NCT00618657,https://clinicaltrials.gov/study/NCT00370552,https://clinicaltrials.gov/study/NCT03644186,https://clinicaltrials.gov/study/NCT00006110,https://clinicaltrials.gov/study/NCT00193206,https://clinicaltrials.gov/study/NCT01827163,https://clinicaltrials.gov/study/NCT02132949,https://clinicaltrials.gov/study/NCT01779479,https://clinicaltrials.gov/study/NCT00378313,https://clinicaltrials.gov/study/NCT00971945,https://clinicaltrials.gov/study/NCT01106898
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Unknown status	https://clinicaltrials.gov/study/NCT01372579
EFO_0000304	breast adenocarcinoma	CHEMBL4594557	EFTILAGIMOD ALFA	Unknown	Lymphocyte activation gene 3 protein vaccine antigen		LAG3	lymphocyte activating 3	2	Completed	https://clinicaltrials.gov/study/NCT02614833
MONDO_0021115	luminal B breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT03356860
MONDO_0007254	breast cancer	CHEMBL3545154	POZIOTINIB	Small molecule	Epidermal growth factor receptor inhibitor		EGFR	epidermal growth factor receptor	2	Completed	https://clinicaltrials.gov/study/NCT02418689,https://clinicaltrials.gov/study/NCT02544997,https://clinicaltrials.gov/study/NCT02659514
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Suspended	https://clinicaltrials.gov/study/NCT04675827,https://clinicaltrials.gov/study/NCT04419181
EFO_0000305	breast carcinoma	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT03971409
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS2	NADH:ubiquinone oxidoreductase core subunit S2	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1770916	NIROGACESTAT	Small molecule	Gamma-secretase inhibitor		NCSTN	nicastrin	2	Withdrawn	https://clinicaltrials.gov/study/NCT02338531
MONDO_0007254	breast cancer	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Unknown status	https://clinicaltrials.gov/study/NCT03145961
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Terminated	https://clinicaltrials.gov/study/NCT03329378,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT01690325,https://clinicaltrials.gov/study/NCT00524459,https://clinicaltrials.gov/study/NCT03894007,https://clinicaltrials.gov/study/NCT00636441,https://clinicaltrials.gov/study/NCT00206453,https://clinicaltrials.gov/study/NCT00665457,https://clinicaltrials.gov/study/NCT00845910,https://clinicaltrials.gov/study/NCT01985841,https://clinicaltrials.gov/study/NCT00118053,https://clinicaltrials.gov/study/NCT00453635,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT00852332,https://clinicaltrials.gov/study/NCT00479856,https://clinicaltrials.gov/study/NCT00028483,https://clinicaltrials.gov/study/NCT00576901,https://clinicaltrials.gov/study/NCT00104624,https://clinicaltrials.gov/study/NCT00343512,https://clinicaltrials.gov/study/NCT00025493,https://clinicaltrials.gov/study/NCT00080626,https://clinicaltrials.gov/study/NCT00225056,https://clinicaltrials.gov/study/NCT00193024
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Recruiting	https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT05810870,https://clinicaltrials.gov/study/NCT04624711,https://clinicaltrials.gov/study/NCT05530057,https://clinicaltrials.gov/study/NCT05546255,https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT05458674,https://clinicaltrials.gov/study/NCT06102824
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Withdrawn	https://clinicaltrials.gov/study/NCT02067416,https://clinicaltrials.gov/study/NCT01818999
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL554	LAPATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT00684983
EFO_0006861	male breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00095888
EFO_0000432	breast ductal carcinoma in situ	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Terminated	https://clinicaltrials.gov/study/NCT00461344
EFO_0005537	triple-negative breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		SRMS	src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06355037
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Recruiting	https://clinicaltrials.gov/study/NCT03515798,https://clinicaltrials.gov/study/NCT05383196
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Withdrawn	https://clinicaltrials.gov/study/NCT00006261
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT00002998,https://clinicaltrials.gov/study/NCT00003540,https://clinicaltrials.gov/study/NCT00006007,https://clinicaltrials.gov/study/NCT00059852,https://clinicaltrials.gov/study/NCT00005991,https://clinicaltrials.gov/study/NCT00662129
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Suspended	https://clinicaltrials.gov/study/NCT02897050,https://clinicaltrials.gov/study/NCT04419181
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC11	histone deacetylase 11	2	Withdrawn	https://clinicaltrials.gov/study/NCT02115594
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAB1	NADH:ubiquinone oxidoreductase subunit AB1	2	Completed	https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT01310231
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT02365805,https://clinicaltrials.gov/study/NCT02225652,https://clinicaltrials.gov/study/NCT00654836,https://clinicaltrials.gov/study/NCT00503750,https://clinicaltrials.gov/study/NCT01722968,https://clinicaltrials.gov/study/NCT01740336,https://clinicaltrials.gov/study/NCT00128856,https://clinicaltrials.gov/study/NCT03301350,https://clinicaltrials.gov/study/NCT00773695,https://clinicaltrials.gov/study/NCT02687490,https://clinicaltrials.gov/study/NCT00191854,https://clinicaltrials.gov/study/NCT01973660,https://clinicaltrials.gov/study/NCT01572727,https://clinicaltrials.gov/study/NCT00005649,https://clinicaltrials.gov/study/NCT02698891,https://clinicaltrials.gov/study/NCT00723125,https://clinicaltrials.gov/study/NCT01688609,https://clinicaltrials.gov/study/NCT00394082,https://clinicaltrials.gov/study/NCT01969032,https://clinicaltrials.gov/study/NCT00003035,https://clinicaltrials.gov/study/NCT00580333,https://clinicaltrials.gov/study/NCT02280252,https://clinicaltrials.gov/study/NCT00006110,https://clinicaltrials.gov/study/NCT03121352,https://clinicaltrials.gov/study/NCT00003050,https://clinicaltrials.gov/study/NCT02301988,https://clinicaltrials.gov/study/NCT02263495,https://clinicaltrials.gov/study/NCT00003612,https://clinicaltrials.gov/study/NCT00436566,https://clinicaltrials.gov/study/NCT01432223,https://clinicaltrials.gov/study/NCT03326102,https://clinicaltrials.gov/study/NCT01705691,https://clinicaltrials.gov/study/NCT00856492,https://clinicaltrials.gov/study/NCT02073487,https://clinicaltrials.gov/study/NCT00503906,https://clinicaltrials.gov/study/NCT00003539,https://clinicaltrials.gov/study/NCT00733408,https://clinicaltrials.gov/study/NCT00455533,https://clinicaltrials.gov/study/NCT00004013,https://clinicaltrials.gov/study/NCT02474186,https://clinicaltrials.gov/study/NCT03982485,https://clinicaltrials.gov/study/NCT00002826,https://clinicaltrials.gov/study/NCT01855828,https://clinicaltrials.gov/study/NCT01036087,https://clinicaltrials.gov/study/NCT00005635,https://clinicaltrials.gov/study/NCT00511459,https://clinicaltrials.gov/study/NCT00394251,https://clinicaltrials.gov/study/NCT00618826,https://clinicaltrials.gov/study/NCT00052351,https://clinicaltrials.gov/study/NCT02938442,https://clinicaltrials.gov/study/NCT00006256,https://clinicaltrials.gov/study/NCT02909751,https://clinicaltrials.gov/study/NCT04224922,https://clinicaltrials.gov/study/NCT00007904,https://clinicaltrials.gov/study/NCT00193206,https://clinicaltrials.gov/study/NCT02783222,https://clinicaltrials.gov/study/NCT00542451,https://clinicaltrials.gov/study/NCT01106898,https://clinicaltrials.gov/study/NCT01190982,https://clinicaltrials.gov/study/NCT00316199,https://clinicaltrials.gov/study/NCT00003992,https://clinicaltrials.gov/study/NCT03248427,https://clinicaltrials.gov/study/NCT02132949,https://clinicaltrials.gov/study/NCT00532857,https://clinicaltrials.gov/study/NCT01204437,https://clinicaltrials.gov/study/NCT00919880,https://clinicaltrials.gov/study/NCT01023204,https://clinicaltrials.gov/study/NCT00096343,https://clinicaltrials.gov/study/NCT00407888,https://clinicaltrials.gov/study/NCT01827163,https://clinicaltrials.gov/study/NCT05112536,https://clinicaltrials.gov/study/NCT00274456,https://clinicaltrials.gov/study/NCT00001384,https://clinicaltrials.gov/study/NCT00846027,https://clinicaltrials.gov/study/NCT01835236,https://clinicaltrials.gov/study/NCT00001498,https://clinicaltrials.gov/study/NCT01982448,https://clinicaltrials.gov/study/NCT01423695,https://clinicaltrials.gov/study/NCT01792050,https://clinicaltrials.gov/study/NCT04408118,https://clinicaltrials.gov/study/NCT00334802,https://clinicaltrials.gov/study/NCT01594177,https://clinicaltrials.gov/study/NCT00944047,https://clinicaltrials.gov/study/NCT00546156,https://clinicaltrials.gov/study/NCT00093145,https://clinicaltrials.gov/study/NCT00768859,https://clinicaltrials.gov/study/NCT00645177,https://clinicaltrials.gov/study/NCT03742986,https://clinicaltrials.gov/study/NCT00971945,https://clinicaltrials.gov/study/NCT00467012,https://clinicaltrials.gov/study/NCT02370238,https://clinicaltrials.gov/study/NCT00370552,https://clinicaltrials.gov/study/NCT00019812,https://clinicaltrials.gov/study/NCT00256243,https://clinicaltrials.gov/study/NCT01276041,https://clinicaltrials.gov/study/NCT00662129,https://clinicaltrials.gov/study/NCT01565499,https://clinicaltrials.gov/study/NCT01672671,https://clinicaltrials.gov/study/NCT01186991,https://clinicaltrials.gov/study/NCT02789657,https://clinicaltrials.gov/study/NCT01203267,https://clinicaltrials.gov/study/NCT03193853,https://clinicaltrials.gov/study/NCT00378313,https://clinicaltrials.gov/study/NCT00002937,https://clinicaltrials.gov/study/NCT00254592,https://clinicaltrials.gov/study/NCT00096291,https://clinicaltrials.gov/study/NCT00072319,https://clinicaltrials.gov/study/NCT00403130,https://clinicaltrials.gov/study/NCT00004092,https://clinicaltrials.gov/study/NCT03072992,https://clinicaltrials.gov/study/NCT01847001,https://clinicaltrials.gov/study/NCT00482391,https://clinicaltrials.gov/study/NCT01446016,https://clinicaltrials.gov/study/NCT01779479,https://clinicaltrials.gov/study/NCT00635050,https://clinicaltrials.gov/study/NCT00251472,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00475670,https://clinicaltrials.gov/study/NCT00136539,https://clinicaltrials.gov/study/NCT01256762,https://clinicaltrials.gov/study/NCT01593020,https://clinicaltrials.gov/study/NCT00392392,https://clinicaltrials.gov/study/NCT00110084,https://clinicaltrials.gov/study/NCT01818063,https://clinicaltrials.gov/study/NCT00795899,https://clinicaltrials.gov/study/NCT01656538,https://clinicaltrials.gov/study/NCT03289819,https://clinicaltrials.gov/study/NCT03853707,https://clinicaltrials.gov/study/NCT00479674,https://clinicaltrials.gov/study/NCT01204125,https://clinicaltrials.gov/study/NCT03887130,https://clinicaltrials.gov/study/NCT02229084,https://clinicaltrials.gov/study/NCT02628613,https://clinicaltrials.gov/study/NCT00028873,https://clinicaltrials.gov/study/NCT00629499,https://clinicaltrials.gov/study/NCT00915603,https://clinicaltrials.gov/study/NCT00146562,https://clinicaltrials.gov/study/NCT00003392,https://clinicaltrials.gov/study/NCT00499083,https://clinicaltrials.gov/study/NCT01421472,https://clinicaltrials.gov/study/NCT03644186,https://clinicaltrials.gov/study/NCT00930930,https://clinicaltrials.gov/study/NCT00002679,https://clinicaltrials.gov/study/NCT00194779,https://clinicaltrials.gov/study/NCT01816594,https://clinicaltrials.gov/study/NCT01320111,https://clinicaltrials.gov/study/NCT00675259,https://clinicaltrials.gov/study/NCT00096668,https://clinicaltrials.gov/study/NCT02954055,https://clinicaltrials.gov/study/NCT00915018,https://clinicaltrials.gov/study/NCT01959490,https://clinicaltrials.gov/study/NCT00559845,https://clinicaltrials.gov/study/NCT00320541,https://clinicaltrials.gov/study/NCT00618657,https://clinicaltrials.gov/study/NCT01307891,https://clinicaltrials.gov/study/NCT01989780,https://clinicaltrials.gov/study/NCT02685059,https://clinicaltrials.gov/study/NCT00148681,https://clinicaltrials.gov/study/NCT01617668,https://clinicaltrials.gov/study/NCT01008150,https://clinicaltrials.gov/study/NCT01506609
MONDO_0007254	breast cancer	CHEMBL4303201	CATEQUENTINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT05206656
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA9	NADH:ubiquinone oxidoreductase subunit A9	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHB1	EPH receptor B1	2	Terminated	https://clinicaltrials.gov/study/NCT00481845,https://clinicaltrials.gov/study/NCT00752986,https://clinicaltrials.gov/study/NCT01934335
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT02614833
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Recruiting	https://clinicaltrials.gov/study/NCT04090398,https://clinicaltrials.gov/study/NCT04266249,https://clinicaltrials.gov/study/NCT03606967
MONDO_0007254	breast cancer	CHEMBL1094636	NIRAPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT04837209,https://clinicaltrials.gov/study/NCT05601440
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Completed	https://clinicaltrials.gov/study/NCT00493636,https://clinicaltrials.gov/study/NCT00101400,https://clinicaltrials.gov/study/NCT01320111,https://clinicaltrials.gov/study/NCT00548899,https://clinicaltrials.gov/study/NCT00634634
MONDO_0007254	breast cancer	CHEMBL4594273	ELACESTRANT HYDROCHLORIDE	Small molecule	Estrogen receptor alpha degrader	Antagonist	ESR1	estrogen receptor 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05963997
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB2	NADH:ubiquinone oxidoreductase subunit B2	2	Recruiting	https://clinicaltrials.gov/study/NCT04559308,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT03238495
MONDO_0007254	breast cancer	CHEMBL481	IRINOTECAN	Small molecule	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03562390,https://clinicaltrials.gov/study/NCT00248287,https://clinicaltrials.gov/study/NCT03328884
EFO_0005537	triple-negative breast cancer	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Completed	https://clinicaltrials.gov/study/NCT02648477
EFO_0005537	triple-negative breast cancer	CHEMBL1738889	ENOBOSARM	Small molecule	Androgen Receptor modulator		AR	androgen receptor	2	Completed	https://clinicaltrials.gov/study/NCT02971761
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB5	NADH:ubiquinone oxidoreductase subunit B5	2	Completed	https://clinicaltrials.gov/study/NCT01885013
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT00191373
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT00284180
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC1	NADH:ubiquinone oxidoreductase subunit C1	2	Completed	https://clinicaltrials.gov/study/NCT01885013
EFO_0005537	triple-negative breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967
EFO_0006861	male breast carcinoma	CHEMBL1567	SUNITINIB MALATE	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT00513695
MONDO_0007254	breast cancer	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
EFO_0000305	breast carcinoma	CHEMBL513	CARMUSTINE	Small molecule	Glutathione reductase inhibitor		GSR	glutathione-disulfide reductase	2	Unknown status	https://clinicaltrials.gov/study/NCT02670109
EFO_0000432	breast ductal carcinoma in situ	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator	Antagonist	ESR1	estrogen receptor 1	2	Recruiting	https://clinicaltrials.gov/study/NCT02993159,https://clinicaltrials.gov/study/NCT06075953,https://clinicaltrials.gov/study/NCT04666961
MONDO_0007254	breast cancer	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134,https://clinicaltrials.gov/study/NCT05512416,https://clinicaltrials.gov/study/NCT05469750
MONDO_0007254	breast cancer	CHEMBL15770	SULINDAC	Small molecule	Cyclooxygenase inhibitor		PTGS1	prostaglandin-endoperoxide synthase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT04542135
EFO_0005537	triple-negative breast cancer	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Suspended	https://clinicaltrials.gov/study/NCT04095689
MONDO_0007254	breast cancer	CHEMBL306823	SODIUM DICHLOROACETATE	Small molecule	Pyruvate dehydrogenase kinase inhibitor		PDK3	pyruvate dehydrogenase kinase 3	2	Terminated	https://clinicaltrials.gov/study/NCT01029925
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS6	NADH:ubiquinone oxidoreductase subunit S6	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL4298101	LADIRATUZUMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Recruiting	https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL52885	ENMD-981693	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR4	fibroblast growth factor receptor 4	2	Completed	https://clinicaltrials.gov/study/NCT00306631
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT00509587,https://clinicaltrials.gov/study/NCT01466972
MONDO_0007254	breast cancer	CHEMBL409	BICALUTAMIDE	Small molecule	Androgen Receptor antagonist		AR	androgen receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT02910050
EFO_0000305	breast carcinoma	CHEMBL1064	SIMVASTATIN	Small molecule	HMG-CoA reductase inhibitor		HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase	2	Completed	https://clinicaltrials.gov/study/NCT03454529
MONDO_0007254	breast cancer	CHEMBL4303214	FRUQUINTINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04577963
MONDO_0007254	breast cancer	CHEMBL384467	DEXAMETHASONE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	2	Terminated	https://clinicaltrials.gov/study/NCT00215748,https://clinicaltrials.gov/study/NCT01698281
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Recruiting	https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT04605575,https://clinicaltrials.gov/study/NCT03939871,https://clinicaltrials.gov/study/NCT04389073,https://clinicaltrials.gov/study/NCT05747326,https://clinicaltrials.gov/study/NCT04304352,https://clinicaltrials.gov/study/NCT04302441,https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT04759248,https://clinicaltrials.gov/study/NCT05823623,https://clinicaltrials.gov/study/NCT06102824,https://clinicaltrials.gov/study/NCT04296162,https://clinicaltrials.gov/study/NCT05296577
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT00499122,https://clinicaltrials.gov/study/NCT02838225,https://clinicaltrials.gov/study/NCT00077857,https://clinicaltrials.gov/study/NCT00201708,https://clinicaltrials.gov/study/NCT00003352,https://clinicaltrials.gov/study/NCT00004906,https://clinicaltrials.gov/study/NCT00005908,https://clinicaltrials.gov/study/NCT00820872,https://clinicaltrials.gov/study/NCT00203372,https://clinicaltrials.gov/study/NCT00600249,https://clinicaltrials.gov/study/NCT01025349,https://clinicaltrials.gov/study/NCT00155259,https://clinicaltrials.gov/study/NCT03140553,https://clinicaltrials.gov/study/NCT01396655,https://clinicaltrials.gov/study/NCT01671319,https://clinicaltrials.gov/study/NCT00820547,https://clinicaltrials.gov/study/NCT01446016,https://clinicaltrials.gov/study/NCT00088998,https://clinicaltrials.gov/study/NCT00365417,https://clinicaltrials.gov/study/NCT00066443,https://clinicaltrials.gov/study/NCT02041351,https://clinicaltrials.gov/study/NCT00976989,https://clinicaltrials.gov/study/NCT00247481,https://clinicaltrials.gov/study/NCT02909751,https://clinicaltrials.gov/study/NCT00005963,https://clinicaltrials.gov/study/NCT01540110,https://clinicaltrials.gov/study/NCT00148668,https://clinicaltrials.gov/study/NCT00712881,https://clinicaltrials.gov/study/NCT00004888,https://clinicaltrials.gov/study/NCT00193115,https://clinicaltrials.gov/study/NCT00039520,https://clinicaltrials.gov/study/NCT00604435,https://clinicaltrials.gov/study/NCT00754351,https://clinicaltrials.gov/study/NCT00379015,https://clinicaltrials.gov/study/NCT00006682,https://clinicaltrials.gov/study/NCT02365805,https://clinicaltrials.gov/study/NCT01367028,https://clinicaltrials.gov/study/NCT00179309,https://clinicaltrials.gov/study/NCT00193180,https://clinicaltrials.gov/study/NCT00524810,https://clinicaltrials.gov/study/NCT00149214,https://clinicaltrials.gov/study/NCT00193037,https://clinicaltrials.gov/study/NCT00055861,https://clinicaltrials.gov/study/NCT00003565,https://clinicaltrials.gov/study/NCT00203502,https://clinicaltrials.gov/study/NCT00054275,https://clinicaltrials.gov/study/NCT02137083,https://clinicaltrials.gov/study/NCT00068341,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00206518,https://clinicaltrials.gov/study/NCT00027885,https://clinicaltrials.gov/study/NCT00527449,https://clinicaltrials.gov/study/NCT00015886,https://clinicaltrials.gov/study/NCT00432172,https://clinicaltrials.gov/study/NCT02748213,https://clinicaltrials.gov/study/NCT00206466,https://clinicaltrials.gov/study/NCT01142778,https://clinicaltrials.gov/study/NCT00214864,https://clinicaltrials.gov/study/NCT00198237,https://clinicaltrials.gov/study/NCT00006104,https://clinicaltrials.gov/study/NCT00248703,https://clinicaltrials.gov/study/NCT00005800,https://clinicaltrials.gov/study/NCT00028873,https://clinicaltrials.gov/study/NCT00319618,https://clinicaltrials.gov/study/NCT02834403,https://clinicaltrials.gov/study/NCT00773695,https://clinicaltrials.gov/study/NCT00559754,https://clinicaltrials.gov/study/NCT01792050,https://clinicaltrials.gov/study/NCT00365365,https://clinicaltrials.gov/study/NCT00679341,https://clinicaltrials.gov/study/NCT00015938,https://clinicaltrials.gov/study/NCT01038804,https://clinicaltrials.gov/study/NCT00475670,https://clinicaltrials.gov/study/NCT01527487,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT00191243,https://clinicaltrials.gov/study/NCT01150513,https://clinicaltrials.gov/study/NCT00769470,https://clinicaltrials.gov/study/NCT00364611,https://clinicaltrials.gov/study/NCT00217672,https://clinicaltrials.gov/study/NCT01959490,https://clinicaltrials.gov/study/NCT00494481,https://clinicaltrials.gov/study/NCT04664972,https://clinicaltrials.gov/study/NCT03887130,https://clinicaltrials.gov/study/NCT00041067,https://clinicaltrials.gov/study/NCT02229084,https://clinicaltrials.gov/study/NCT00232479,https://clinicaltrials.gov/study/NCT00545688,https://clinicaltrials.gov/study/NCT00004175,https://clinicaltrials.gov/study/NCT00490646,https://clinicaltrials.gov/study/NCT00123929,https://clinicaltrials.gov/study/NCT00129376,https://clinicaltrials.gov/study/NCT00003953,https://clinicaltrials.gov/study/NCT03735966,https://clinicaltrials.gov/study/NCT00148070,https://clinicaltrials.gov/study/NCT00193050,https://clinicaltrials.gov/study/NCT00212095,https://clinicaltrials.gov/study/NCT00645866,https://clinicaltrials.gov/study/NCT00525759,https://clinicaltrials.gov/study/NCT00274456,https://clinicaltrials.gov/study/NCT00107510,https://clinicaltrials.gov/study/NCT00209092,https://clinicaltrials.gov/study/NCT00079118,https://clinicaltrials.gov/study/NCT00841828,https://clinicaltrials.gov/study/NCT03742986,https://clinicaltrials.gov/study/NCT00941330,https://clinicaltrials.gov/study/NCT02846428,https://clinicaltrials.gov/study/NCT01208480,https://clinicaltrials.gov/study/NCT00206505,https://clinicaltrials.gov/study/NCT00493649,https://clinicaltrials.gov/study/NCT02005549,https://clinicaltrials.gov/study/NCT02132949,https://clinicaltrials.gov/study/NCT00146042,https://clinicaltrials.gov/study/NCT00428922,https://clinicaltrials.gov/study/NCT00464646,https://clinicaltrials.gov/study/NCT00212082,https://clinicaltrials.gov/study/NCT01485926,https://clinicaltrials.gov/study/NCT00193089,https://clinicaltrials.gov/study/NCT00044993,https://clinicaltrials.gov/study/NCT01658462,https://clinicaltrials.gov/study/NCT00695994,https://clinicaltrials.gov/study/NCT00258375,https://clinicaltrials.gov/study/NCT00404066
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE4A	phosphodiesterase 4A	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT06186700,https://clinicaltrials.gov/study/NCT06176339
EFO_0000305	breast carcinoma	CHEMBL180022	NERATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-4 inhibitor		ERBB4	erb-b2 receptor tyrosine kinase 4	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03101748
EFO_0005537	triple-negative breast cancer	CHEMBL2325741	CAPIVASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT3	AKT serine/threonine kinase 3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02208375
EFO_0006861	male breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT00077376
EFO_0000432	breast ductal carcinoma in situ	CHEMBL489	AFIMOXIFENE	Small molecule	Estrogen receptor modulator	Antagonist	ESR1	estrogen receptor 1	2	Completed	https://clinicaltrials.gov/study/NCT00952731
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHB1	EPH receptor B1	2	Completed	https://clinicaltrials.gov/study/NCT00494481
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Recruiting	https://clinicaltrials.gov/study/NCT05402722,https://clinicaltrials.gov/study/NCT05570253
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT02978716
MONDO_0007254	breast cancer	CHEMBL3545262	SACITUZUMAB GOVITECAN	Antibody drug conjugate	Tumor-associated calcium signal transducer 2 binding agent		TACSTD2	tumor associated calcium signal transducer 2	2	Withdrawn	https://clinicaltrials.gov/study/NCT05008510
MONDO_0007254	breast cancer	CHEMBL4297828	SHR-1316	Unknown	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	2	Recruiting	https://clinicaltrials.gov/study/NCT06149130
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT00148707,https://clinicaltrials.gov/study/NCT00265733
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB5	NADH:ubiquinone oxidoreductase subunit B5	2	Completed	https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT01589367
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE10A	phosphodiesterase 10A	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT06186700,https://clinicaltrials.gov/study/NCT06176339
MONDO_0007254	breast cancer	CHEMBL1743028	GLEMBATUMUMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT01997333,https://clinicaltrials.gov/study/NCT01156753
MONDO_0007254	breast cancer	CHEMBL4650276	SHR3680	Small molecule	Androgen Receptor antagonist		AR	androgen receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT04355858
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00074269,https://clinicaltrials.gov/study/NCT00376805
MONDO_0007254	breast cancer	CHEMBL1200694	SEVOFLURANE	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRA3	gamma-aminobutyric acid type A receptor subunit alpha3	2	Completed	https://clinicaltrials.gov/study/NCT02839668
MONDO_0007254	breast cancer	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RB	interleukin 2 receptor subunit beta	2	Completed	https://clinicaltrials.gov/study/NCT01105650,https://clinicaltrials.gov/study/NCT00006228
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Recruiting	https://clinicaltrials.gov/study/NCT04796324
MONDO_0007254	breast cancer	CHEMBL226267	ARZOXIFENE	Small molecule	Estrogen receptor modulator	Antagonist	ESR1	estrogen receptor 1	2	Completed	https://clinicaltrials.gov/study/NCT00005879,https://clinicaltrials.gov/study/NCT00253539,https://clinicaltrials.gov/study/NCT00003428
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA11	NADH:ubiquinone oxidoreductase subunit A11	2	Completed	https://clinicaltrials.gov/study/NCT01885013
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND5	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF3	NADH:ubiquinone oxidoreductase complex assembly factor 3	2	Completed	https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT01589367
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
MONDO_0007254	breast cancer	CHEMBL2177390	IPATASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT1	AKT serine/threonine kinase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03395899,https://clinicaltrials.gov/study/NCT05498896
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Withdrawn	https://clinicaltrials.gov/study/NCT04351230
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02568839,https://clinicaltrials.gov/study/NCT04001829
EFO_0006861	male breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00095888
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE8A	phosphodiesterase 8A	2	Recruiting	https://clinicaltrials.gov/study/NCT06087237
MONDO_0007254	breast cancer	CHEMBL1201748	CABAZITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Recruiting	https://clinicaltrials.gov/study/NCT03048942
MONDO_0007254	breast cancer	CHEMBL2109355	DUSIGITUMAB	Antibody	Insulin-like growth factor I inhibitor		IGF1	insulin like growth factor 1	2	Completed	https://clinicaltrials.gov/study/NCT01446159
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist	Antagonist	ESR2	estrogen receptor 2	2	Recruiting	https://clinicaltrials.gov/study/NCT05608252,https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT04796623,https://clinicaltrials.gov/study/NCT05305924,https://clinicaltrials.gov/study/NCT04282031,https://clinicaltrials.gov/study/NCT02476786,https://clinicaltrials.gov/study/NCT05524584,https://clinicaltrials.gov/study/NCT05186545,https://clinicaltrials.gov/study/NCT03182634,https://clinicaltrials.gov/study/NCT05963984,https://clinicaltrials.gov/study/NCT05720260,https://clinicaltrials.gov/study/NCT03939871,https://clinicaltrials.gov/study/NCT05411380,https://clinicaltrials.gov/study/NCT04034589,https://clinicaltrials.gov/study/NCT06110793,https://clinicaltrials.gov/study/NCT04567420,https://clinicaltrials.gov/study/NCT05759546,https://clinicaltrials.gov/study/NCT05230810,https://clinicaltrials.gov/study/NCT05816655,https://clinicaltrials.gov/study/NCT02760030,https://clinicaltrials.gov/study/NCT05181033,https://clinicaltrials.gov/study/NCT05472792,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT05601440,https://clinicaltrials.gov/study/NCT05933395,https://clinicaltrials.gov/study/NCT04920708,https://clinicaltrials.gov/study/NCT04762979,https://clinicaltrials.gov/study/NCT05463601,https://clinicaltrials.gov/study/NCT05759572,https://clinicaltrials.gov/study/NCT04936295,https://clinicaltrials.gov/study/NCT05467891,https://clinicaltrials.gov/study/NCT04033172,https://clinicaltrials.gov/study/NCT05076695,https://clinicaltrials.gov/study/NCT05101564,https://clinicaltrials.gov/study/NCT04985266
MONDO_0007254	breast cancer	CHEMBL3647420	PYROTINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Terminated	https://clinicaltrials.gov/study/NCT04066790
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA6	NADH:ubiquinone oxidoreductase subunit A6	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT03367676,https://clinicaltrials.gov/study/NCT05325632,https://clinicaltrials.gov/study/NCT01817452,https://clinicaltrials.gov/study/NCT04578106,https://clinicaltrials.gov/study/NCT05180006,https://clinicaltrials.gov/study/NCT04717531,https://clinicaltrials.gov/study/NCT04789096,https://clinicaltrials.gov/study/NCT05800756,https://clinicaltrials.gov/study/NCT03412643,https://clinicaltrials.gov/study/NCT04817540,https://clinicaltrials.gov/study/NCT04893109,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT05332561,https://clinicaltrials.gov/study/NCT04569747,https://clinicaltrials.gov/study/NCT03879577,https://clinicaltrials.gov/study/NCT06100874,https://clinicaltrials.gov/study/NCT03765983,https://clinicaltrials.gov/study/NCT04329065,https://clinicaltrials.gov/study/NCT05483439,https://clinicaltrials.gov/study/NCT04993014,https://clinicaltrials.gov/study/NCT03698383,https://clinicaltrials.gov/study/NCT03907800,https://clinicaltrials.gov/study/NCT05900206,https://clinicaltrials.gov/study/NCT04886531,https://clinicaltrials.gov/study/NCT05189067,https://clinicaltrials.gov/study/NCT05292742,https://clinicaltrials.gov/study/NCT04917900,https://clinicaltrials.gov/study/NCT03820141,https://clinicaltrials.gov/study/NCT05076695,https://clinicaltrials.gov/study/NCT04997798,https://clinicaltrials.gov/study/NCT05020860,https://clinicaltrials.gov/study/NCT05041842,https://clinicaltrials.gov/study/NCT04802759,https://clinicaltrials.gov/study/NCT05426486,https://clinicaltrials.gov/study/NCT05885776,https://clinicaltrials.gov/study/NCT05638594,https://clinicaltrials.gov/study/NCT05918328,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT04296162,https://clinicaltrials.gov/study/NCT03571633,https://clinicaltrials.gov/study/NCT04383275,https://clinicaltrials.gov/study/NCT05659056,https://clinicaltrials.gov/study/NCT04425018,https://clinicaltrials.gov/study/NCT04759248,https://clinicaltrials.gov/study/NCT05458674
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Recruiting	https://clinicaltrials.gov/study/NCT05530057,https://clinicaltrials.gov/study/NCT04624711,https://clinicaltrials.gov/study/NCT05546255,https://clinicaltrials.gov/study/NCT05458674,https://clinicaltrials.gov/study/NCT05810870,https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT06102824,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT04745975
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT04739670,https://clinicaltrials.gov/study/NCT05601440,https://clinicaltrials.gov/study/NCT05181462,https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT06026657,https://clinicaltrials.gov/study/NCT06102824
MONDO_0007254	breast cancer	CHEMBL1173055	RUCAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Completed	https://clinicaltrials.gov/study/NCT02505048,https://clinicaltrials.gov/study/NCT01074970
MONDO_0007254	breast cancer	CHEMBL4303201	CATEQUENTINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04975451
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS2	NADH:ubiquinone oxidoreductase core subunit S2	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Recruiting	https://clinicaltrials.gov/study/NCT05383196,https://clinicaltrials.gov/study/NCT03515798
MONDO_0007254	breast cancer	CHEMBL1098	BUPIVACAINE	Small molecule	Sodium channel protein type IV alpha subunit blocker		SCN4A	sodium voltage-gated channel alpha subunit 4	2	Withdrawn	https://clinicaltrials.gov/study/NCT03393117
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT02481050,https://clinicaltrials.gov/study/NCT01439282,https://clinicaltrials.gov/study/NCT05206656,https://clinicaltrials.gov/study/NCT00246090,https://clinicaltrials.gov/study/NCT01908101,https://clinicaltrials.gov/study/NCT01269346,https://clinicaltrials.gov/study/NCT00965523,https://clinicaltrials.gov/study/NCT01268150,https://clinicaltrials.gov/study/NCT00879086,https://clinicaltrials.gov/study/NCT03051659
EFO_0000305	breast carcinoma	CHEMBL491473	CEDIRANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT04090567
MONDO_0007254	breast cancer	CHEMBL3349607	PASIREOTIDE	Protein	Somatostatin receptor 1 agonist		SSTR1	somatostatin receptor 1	2	Completed	https://clinicaltrials.gov/study/NCT01356862
MONDO_0007254	breast cancer	CHEMBL4297892	ANVATABART OPADOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Recruiting	https://clinicaltrials.gov/study/NCT05426486,https://clinicaltrials.gov/study/NCT05018676,https://clinicaltrials.gov/study/NCT04829604,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT05018702
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA8	NADH:ubiquinone oxidoreductase subunit A8	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Withdrawn	https://clinicaltrials.gov/study/NCT02215876,https://clinicaltrials.gov/study/NCT03637868
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA8	NADH:ubiquinone oxidoreductase subunit A8	2	Completed	https://clinicaltrials.gov/study/NCT04170465
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAB1	NADH:ubiquinone oxidoreductase subunit AB1	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL939	GEFITINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Completed	https://clinicaltrials.gov/study/NCT00255463,https://clinicaltrials.gov/study/NCT00077025,https://clinicaltrials.gov/study/NCT00319618,https://clinicaltrials.gov/study/NCT00049062,https://clinicaltrials.gov/study/NCT00066378,https://clinicaltrials.gov/study/NCT00234403,https://clinicaltrials.gov/study/NCT00239343,https://clinicaltrials.gov/study/NCT00066339,https://clinicaltrials.gov/study/NCT00428896,https://clinicaltrials.gov/study/NCT00247481,https://clinicaltrials.gov/study/NCT00637026,https://clinicaltrials.gov/study/NCT00057941,https://clinicaltrials.gov/study/NCT00632723,https://clinicaltrials.gov/study/NCT00080743,https://clinicaltrials.gov/study/NCT00024154
EFO_0000432	breast ductal carcinoma in situ	CHEMBL489	AFIMOXIFENE	Small molecule	Estrogen receptor modulator	Antagonist	ESR2	estrogen receptor 2	2	Recruiting	https://clinicaltrials.gov/study/NCT04009044,https://clinicaltrials.gov/study/NCT02993159
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Withdrawn	https://clinicaltrials.gov/study/NCT04351230
EFO_0000305	breast carcinoma	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02595905,https://clinicaltrials.gov/study/NCT01149083
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT02978716
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT00861705
MONDO_0004379	female breast carcinoma	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02942355
MONDO_0007254	breast cancer	CHEMBL521851	PICTILISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R5	phosphoinositide-3-kinase regulatory subunit 5	2	Completed	https://clinicaltrials.gov/study/NCT01740336,https://clinicaltrials.gov/study/NCT01437566
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB2	NADH:ubiquinone oxidoreductase subunit B2	2	Unknown status	https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT02506777
MONDO_0007254	breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT04355858
MONDO_0007254	breast cancer	CHEMBL1201468	ESTROGENS, ESTERIFIED	Unknown	Estrogen receptor agonist	Antagonist	ESR1	estrogen receptor 1	2	Terminated	https://clinicaltrials.gov/study/NCT00131924
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist	Antagonist	ESR1	estrogen receptor 1	2	Unknown status	https://clinicaltrials.gov/study/NCT02646735,https://clinicaltrials.gov/study/NCT00927511,https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT02958852,https://clinicaltrials.gov/study/NCT02216786,https://clinicaltrials.gov/study/NCT02072512,https://clinicaltrials.gov/study/NCT01266213,https://clinicaltrials.gov/study/NCT02000193
MONDO_0007254	breast cancer	CHEMBL1567	SUNITINIB MALATE	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Terminated	https://clinicaltrials.gov/study/NCT00824538
MONDO_0007254	breast cancer	CHEMBL2304041	SAGOPILONE	Small molecule	Tubulin stabiliser		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT00288249
EFO_0005537	triple-negative breast cancer	CHEMBL4298101	LADIRATUZUMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0005537	triple-negative breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT03932526
MONDO_0007254	breast cancer	CHEMBL554	LAPATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT02362958,https://clinicaltrials.gov/study/NCT01138384,https://clinicaltrials.gov/study/NCT00206427,https://clinicaltrials.gov/study/NCT00777101,https://clinicaltrials.gov/study/NCT00548184,https://clinicaltrials.gov/study/NCT02073487,https://clinicaltrials.gov/study/NCT00694252,https://clinicaltrials.gov/study/NCT00404066,https://clinicaltrials.gov/study/NCT01485926,https://clinicaltrials.gov/study/NCT01068704,https://clinicaltrials.gov/study/NCT00482391,https://clinicaltrials.gov/study/NCT00841828,https://clinicaltrials.gov/study/NCT01262469,https://clinicaltrials.gov/study/NCT01827163,https://clinicaltrials.gov/study/NCT00477464,https://clinicaltrials.gov/study/NCT00820872,https://clinicaltrials.gov/study/NCT02338245,https://clinicaltrials.gov/study/NCT00299286,https://clinicaltrials.gov/study/NCT01275859,https://clinicaltrials.gov/study/NCT00436566,https://clinicaltrials.gov/study/NCT00721630,https://clinicaltrials.gov/study/NCT00967031,https://clinicaltrials.gov/study/NCT00044330,https://clinicaltrials.gov/study/NCT01973660,https://clinicaltrials.gov/study/NCT00769470,https://clinicaltrials.gov/study/NCT01688609,https://clinicaltrials.gov/study/NCT01622868
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Recruiting	https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT05458674,https://clinicaltrials.gov/study/NCT05546255,https://clinicaltrials.gov/study/NCT04624711,https://clinicaltrials.gov/study/NCT05530057,https://clinicaltrials.gov/study/NCT06102824,https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT05810870
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Recruiting	https://clinicaltrials.gov/study/NCT04924699
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Recruiting	https://clinicaltrials.gov/study/NCT03497702,https://clinicaltrials.gov/study/NCT04576143,https://clinicaltrials.gov/study/NCT03879577,https://clinicaltrials.gov/study/NCT05900206,https://clinicaltrials.gov/study/NCT05645380,https://clinicaltrials.gov/study/NCT05483439,https://clinicaltrials.gov/study/NCT05475678,https://clinicaltrials.gov/study/NCT06107673,https://clinicaltrials.gov/study/NCT05918328,https://clinicaltrials.gov/study/NCT05426486,https://clinicaltrials.gov/study/NCT04872985,https://clinicaltrials.gov/study/NCT03367676,https://clinicaltrials.gov/study/NCT04717531,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT05088057,https://clinicaltrials.gov/study/NCT04947189,https://clinicaltrials.gov/study/NCT05189067,https://clinicaltrials.gov/study/NCT05638594
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Unknown status	https://clinicaltrials.gov/study/NCT02790580
EFO_0000305	breast carcinoma	CHEMBL1079175	MK-2206	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT2	AKT serine/threonine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT01277757
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01194869,https://clinicaltrials.gov/study/NCT00573755,https://clinicaltrials.gov/study/NCT00525161,https://clinicaltrials.gov/study/NCT02624700,https://clinicaltrials.gov/study/NCT00607438,https://clinicaltrials.gov/study/NCT00632541,https://clinicaltrials.gov/study/NCT00722072,https://clinicaltrials.gov/study/NCT00622466
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	Bcr/Abl fusion protein		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT00780676,https://clinicaltrials.gov/study/NCT05198843,https://clinicaltrials.gov/study/NCT00817531
MONDO_0007254	breast cancer	CHEMBL1544	LIOTHYRONINE	Small molecule	Thyroid hormone receptor agonist		THRB	thyroid hormone receptor beta	2	Terminated	https://clinicaltrials.gov/study/NCT03787303
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Recruiting	https://clinicaltrials.gov/study/NCT04924699
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05872412,https://clinicaltrials.gov/study/NCT04194684,https://clinicaltrials.gov/study/NCT05444998,https://clinicaltrials.gov/study/NCT04301375,https://clinicaltrials.gov/study/NCT04907344,https://clinicaltrials.gov/study/NCT04498793,https://clinicaltrials.gov/study/NCT04659499,https://clinicaltrials.gov/study/NCT04499118,https://clinicaltrials.gov/study/NCT04900311,https://clinicaltrials.gov/study/NCT04639271,https://clinicaltrials.gov/study/NCT04946227,https://clinicaltrials.gov/study/NCT03959397,https://clinicaltrials.gov/study/NCT04290793
MONDO_0007254	breast cancer	CHEMBL298734	LONAFARNIB	Small molecule	Protein farnesyltransferase inhibitor		FNTA	farnesyltransferase, CAAX box, subunit alpha	2	Completed	https://clinicaltrials.gov/study/NCT00081510
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBB2A	tubulin beta 2A class IIa	2	Withdrawn	https://clinicaltrials.gov/study/NCT01227408
MONDO_0007254	breast cancer	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	2	Terminated	https://clinicaltrials.gov/study/NCT00020722,https://clinicaltrials.gov/study/NCT00006032,https://clinicaltrials.gov/study/NCT00810017
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Recruiting	https://clinicaltrials.gov/study/NCT05823623,https://clinicaltrials.gov/study/NCT05296577
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE5A	phosphodiesterase 5A	2	Recruiting	https://clinicaltrials.gov/study/NCT06087237
MONDO_0007254	breast cancer	CHEMBL924	ZOLEDRONIC ACID ANHYDROUS	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06374459
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Terminated	https://clinicaltrials.gov/study/NCT01498588
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Terminated	https://clinicaltrials.gov/study/NCT01498588
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT06026657,https://clinicaltrials.gov/study/NCT03606967
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT03057600,https://clinicaltrials.gov/study/NCT01818063,https://clinicaltrials.gov/study/NCT00733408,https://clinicaltrials.gov/study/NCT02689427,https://clinicaltrials.gov/study/NCT01881230,https://clinicaltrials.gov/study/NCT02413320,https://clinicaltrials.gov/study/NCT03853707
EFO_0005537	triple-negative breast cancer	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	2	Recruiting	https://clinicaltrials.gov/study/NCT05089643,https://clinicaltrials.gov/study/NCT03775928,https://clinicaltrials.gov/study/NCT05336721,https://clinicaltrials.gov/study/NCT04501523
EFO_0006861	male breast carcinoma	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT00017394
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Withdrawn	https://clinicaltrials.gov/study/NCT04351230
EFO_0005537	triple-negative breast cancer	CHEMBL1421	DASATINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06355037
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB9	NADH:ubiquinone oxidoreductase subunit B9	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
EFO_0005537	triple-negative breast cancer	CHEMBL3137336	UPROSERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT3	AKT serine/threonine kinase 3	2	Completed	https://clinicaltrials.gov/study/NCT01964924
EFO_0006861	male breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Unknown status	https://clinicaltrials.gov/study/NCT01372579
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT00513695,https://clinicaltrials.gov/study/NCT00119262,https://clinicaltrials.gov/study/NCT03018080
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC2	NADH:ubiquinone oxidoreductase subunit C2	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL1201167	CARVEDILOL PHOSPHATE	Small molecule	Adrenergic receptor alpha-1 antagonist		ADRA1A	adrenoceptor alpha 1A	2	Completed	https://clinicaltrials.gov/study/NCT01009918
MONDO_0007254	breast cancer	CHEMBL1201748	CABAZITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Recruiting	https://clinicaltrials.gov/study/NCT03048942
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB11	NADH:ubiquinone oxidoreductase subunit B11	2	Unknown status	https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT02506777
MONDO_0007254	breast cancer	CHEMBL217092	SARACATINIB	Small molecule	Tyrosine-protein kinase SRC inhibitor		SRC	SRC proto-oncogene, non-receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00559507
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE1A	phosphodiesterase 1A	2	Recruiting	https://clinicaltrials.gov/study/NCT06087237
MONDO_0007254	breast cancer	CHEMBL1201179	LAPATINIB DITOSYLATE	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01873833,https://clinicaltrials.gov/study/NCT00499681
MONDO_0007254	breast cancer	CHEMBL223360	LINIFANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT00645177
MONDO_0007254	breast cancer	CHEMBL3186534	RIVOCERANIB	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Completed	https://clinicaltrials.gov/study/NCT01176669,https://clinicaltrials.gov/study/NCT03394287,https://clinicaltrials.gov/study/NCT02878057,https://clinicaltrials.gov/study/NCT03982485,https://clinicaltrials.gov/study/NCT03254654,https://clinicaltrials.gov/study/NCT03535961
MONDO_0007254	breast cancer	CHEMBL4112930	PAMIPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Completed	https://clinicaltrials.gov/study/NCT03575065
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT02544243,https://clinicaltrials.gov/study/NCT00027989,https://clinicaltrials.gov/study/NCT03423849,https://clinicaltrials.gov/study/NCT01352494,https://clinicaltrials.gov/study/NCT02341911
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	2	Terminated	https://clinicaltrials.gov/study/NCT01194869,https://clinicaltrials.gov/study/NCT00622466,https://clinicaltrials.gov/study/NCT00525161,https://clinicaltrials.gov/study/NCT00573755,https://clinicaltrials.gov/study/NCT00632541,https://clinicaltrials.gov/study/NCT00607438,https://clinicaltrials.gov/study/NCT02624700,https://clinicaltrials.gov/study/NCT00722072
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4	NDUFA4 mitochondrial complex associated	2	Unknown status	https://clinicaltrials.gov/study/NCT02506777,https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT02506790
MONDO_0007254	breast cancer	CHEMBL723	CARVEDILOL	Small molecule	Adrenergic receptor alpha-1 antagonist		ADRA1D	adrenoceptor alpha 1D	2	Recruiting	https://clinicaltrials.gov/study/NCT03879629
MONDO_0007254	breast cancer	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	2	Completed	https://clinicaltrials.gov/study/NCT01589159,https://clinicaltrials.gov/study/NCT02846428,https://clinicaltrials.gov/study/NCT03853707,https://clinicaltrials.gov/study/NCT01077726,https://clinicaltrials.gov/study/NCT01941771,https://clinicaltrials.gov/study/NCT00107276,https://clinicaltrials.gov/study/NCT00204776,https://clinicaltrials.gov/study/NCT00093808,https://clinicaltrials.gov/study/NCT01969032,https://clinicaltrials.gov/study/NCT00077363,https://clinicaltrials.gov/study/NCT00005649,https://clinicaltrials.gov/study/NCT02748213,https://clinicaltrials.gov/study/NCT00493636,https://clinicaltrials.gov/study/NCT00209092,https://clinicaltrials.gov/study/NCT00534417,https://clinicaltrials.gov/study/NCT04366713,https://clinicaltrials.gov/study/NCT00562718,https://clinicaltrials.gov/study/NCT01997333,https://clinicaltrials.gov/study/NCT04464174,https://clinicaltrials.gov/study/NCT00068588,https://clinicaltrials.gov/study/NCT00194779,https://clinicaltrials.gov/study/NCT00198237,https://clinicaltrials.gov/study/NCT00885755,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00087152,https://clinicaltrials.gov/study/NCT00477464,https://clinicaltrials.gov/study/NCT00088998,https://clinicaltrials.gov/study/NCT00196820,https://clinicaltrials.gov/study/NCT00480597,https://clinicaltrials.gov/study/NCT00418028,https://clinicaltrials.gov/study/NCT00662025,https://clinicaltrials.gov/study/NCT01783444,https://clinicaltrials.gov/study/NCT00155259,https://clinicaltrials.gov/study/NCT00365417,https://clinicaltrials.gov/study/NCT00214864,https://clinicaltrials.gov/study/NCT02005549,https://clinicaltrials.gov/study/NCT00107393,https://clinicaltrials.gov/study/NCT00645866,https://clinicaltrials.gov/study/NCT02474186,https://clinicaltrials.gov/study/NCT00077857,https://clinicaltrials.gov/study/NCT00265733,https://clinicaltrials.gov/study/NCT01262469,https://clinicaltrials.gov/study/NCT00216021,https://clinicaltrials.gov/study/NCT00005908,https://clinicaltrials.gov/study/NCT02614794,https://clinicaltrials.gov/study/NCT00967031,https://clinicaltrials.gov/study/NCT01234402,https://clinicaltrials.gov/study/NCT03887130,https://clinicaltrials.gov/study/NCT02362958,https://clinicaltrials.gov/study/NCT00721630,https://clinicaltrials.gov/study/NCT02338245,https://clinicaltrials.gov/study/NCT00532714,https://clinicaltrials.gov/study/NCT00916578,https://clinicaltrials.gov/study/NCT00263705,https://clinicaltrials.gov/study/NCT00777101,https://clinicaltrials.gov/study/NCT02954055,https://clinicaltrials.gov/study/NCT02664103,https://clinicaltrials.gov/study/NCT01891227,https://clinicaltrials.gov/study/NCT01204437,https://clinicaltrials.gov/study/NCT01439282,https://clinicaltrials.gov/study/NCT01380808,https://clinicaltrials.gov/study/NCT03383679,https://clinicaltrials.gov/study/NCT00274768,https://clinicaltrials.gov/study/NCT00811135
MONDO_0007254	breast cancer	CHEMBL841	LOPERAMIDE	Small molecule	Mu opioid receptor agonist		OPRM1	opioid receptor mu 1	2	Recruiting	https://clinicaltrials.gov/study/NCT04736186
EFO_0000305	breast carcinoma	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT00542451,https://clinicaltrials.gov/study/NCT01548677,https://clinicaltrials.gov/study/NCT00191373,https://clinicaltrials.gov/study/NCT02066532
MONDO_0044915	salivary duct carcinoma	CHEMBL1200969	DUTASTERIDE	Small molecule	Steroid 5-alpha-reductase inhibitor		SRD5A2	steroid 5 alpha-reductase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT05513365
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB7	NADH:ubiquinone oxidoreductase subunit B7	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS5	NADH:ubiquinone oxidoreductase subunit S5	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0006861	male breast carcinoma	CHEMBL1336	SORAFENIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT00096434
EFO_0005537	triple-negative breast cancer	CHEMBL3301587	DURVALUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT03801369
EFO_0005537	triple-negative breast cancer	CHEMBL3218576	COPANLISIB	Small molecule	PI3-kinase p110-delta subunit inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04345913
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV1	NADH:ubiquinone oxidoreductase core subunit V1	2	Terminated	https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT02360059
EFO_0005537	triple-negative breast cancer	CHEMBL2103879	GANETESPIB	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AB1	heat shock protein 90 alpha family class B member 1	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02957968,https://clinicaltrials.gov/study/NCT01730833,https://clinicaltrials.gov/study/NCT02530489
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT06102824,https://clinicaltrials.gov/study/NCT06026657,https://clinicaltrials.gov/study/NCT05601440,https://clinicaltrials.gov/study/NCT04739670,https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT05181462,https://clinicaltrials.gov/study/NCT03424005
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01009788
MONDO_0007254	breast cancer	CHEMBL1372	OXIGLUTATIONE	Small molecule	Glutathione reductase 		GSR	glutathione-disulfide reductase	2	Completed	https://clinicaltrials.gov/study/NCT00499122
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04001829,https://clinicaltrials.gov/study/NCT02568839
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Terminated	https://clinicaltrials.gov/study/NCT00765765,https://clinicaltrials.gov/study/NCT00790894,https://clinicaltrials.gov/study/NCT00079326
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT01091428,https://clinicaltrials.gov/study/NCT00542451
MONDO_0007254	breast cancer	CHEMBL3833344	GANCOTAMAB	Antibody	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Terminated	https://clinicaltrials.gov/study/NCT02213744
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV2	NADH:ubiquinone oxidoreductase core subunit V2	2	Completed	https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT00909506
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBB8	tubulin beta 8 class VIII	2	Withdrawn	https://clinicaltrials.gov/study/NCT01227408
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB2	NADH:ubiquinone oxidoreductase subunit B2	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Unknown status	https://clinicaltrials.gov/study/NCT02175446
EFO_0005537	triple-negative breast cancer	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0005537	triple-negative breast cancer	CHEMBL3813873	PEXIDARTINIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0006861	male breast carcinoma	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT00096434
EFO_0009780	HER2 negative breast carcinoma	CHEMBL4297939	DATOPOTAMAB DERUXTECAN	Antibody drug conjugate	Tumor-associated calcium signal transducer 2 binding agent		TACSTD2	tumor associated calcium signal transducer 2	2	Recruiting	https://clinicaltrials.gov/study/NCT06176261
EFO_0006861	male breast carcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC5	histone deacetylase 5	2	Completed	https://clinicaltrials.gov/study/NCT00098397
EFO_0006861	male breast carcinoma	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT00077376,https://clinicaltrials.gov/study/NCT00024154,https://clinicaltrials.gov/study/NCT00006228
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS5	NADH:ubiquinone oxidoreductase subunit S5	2	Terminated	https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT01627067
MONDO_0007254	breast cancer	CHEMBL4297892	ANVATABART OPADOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Recruiting	https://clinicaltrials.gov/study/NCT05018676,https://clinicaltrials.gov/study/NCT04829604,https://clinicaltrials.gov/study/NCT05018702,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT05426486
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT00194779,https://clinicaltrials.gov/study/NCT00022152,https://clinicaltrials.gov/study/NCT00093808,https://clinicaltrials.gov/study/NCT00266110,https://clinicaltrials.gov/study/NCT00148668,https://clinicaltrials.gov/study/NCT00006682,https://clinicaltrials.gov/study/NCT00004237,https://clinicaltrials.gov/study/NCT00148681,https://clinicaltrials.gov/study/NCT00532623,https://clinicaltrials.gov/study/NCT01941771
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT00005614,https://clinicaltrials.gov/study/NCT05809895
MONDO_0007254	breast cancer	CHEMBL3408947	OCIFISERTIB	Small molecule	Serine/threonine-protein kinase PLK4 inhibitor		PLK4	polo like kinase 4	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03624543,https://clinicaltrials.gov/study/NCT04176848
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Recruiting	https://clinicaltrials.gov/study/NCT04796324
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	2	Completed	https://clinicaltrials.gov/study/NCT01816594,https://clinicaltrials.gov/study/NCT01923168,https://clinicaltrials.gov/study/NCT01629615,https://clinicaltrials.gov/study/NCT02404844,https://clinicaltrials.gov/study/NCT01790932,https://clinicaltrials.gov/study/NCT01572727
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Recruiting	https://clinicaltrials.gov/study/NCT06075953,https://clinicaltrials.gov/study/NCT04666961
MONDO_0007254	breast cancer	CHEMBL554	LAPATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Terminated	https://clinicaltrials.gov/study/NCT01934894,https://clinicaltrials.gov/study/NCT00479856,https://clinicaltrials.gov/study/NCT00903656,https://clinicaltrials.gov/study/NCT00756470,https://clinicaltrials.gov/study/NCT00496366,https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT01161368,https://clinicaltrials.gov/study/NCT00754702,https://clinicaltrials.gov/study/NCT01873833,https://clinicaltrials.gov/study/NCT00759642,https://clinicaltrials.gov/study/NCT00225758,https://clinicaltrials.gov/study/NCT00499681,https://clinicaltrials.gov/study/NCT01534455,https://clinicaltrials.gov/study/NCT00657137
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
MONDO_0003982	bilateral breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT00877500
EFO_0000305	breast carcinoma	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Terminated	https://clinicaltrials.gov/study/NCT02907918,https://clinicaltrials.gov/study/NCT00770354
MONDO_0007254	breast cancer	CHEMBL1064	SIMVASTATIN	Small molecule	HMG-CoA reductase inhibitor		HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase	2	Terminated	https://clinicaltrials.gov/study/NCT02096588
MONDO_0007254	breast cancer	CHEMBL180022	NERATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Withdrawn	https://clinicaltrials.gov/study/NCT04901299
MONDO_0007254	breast cancer	CHEMBL52885	ENMD-981693	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Completed	https://clinicaltrials.gov/study/NCT00306631
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE8B	phosphodiesterase 8B	2	Recruiting	https://clinicaltrials.gov/study/NCT06087237
EFO_0000305	breast carcinoma	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03101748
EFO_0005537	triple-negative breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC10	histone deacetylase 10	2	Terminated	https://clinicaltrials.gov/study/NCT01234532
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Recruiting	https://clinicaltrials.gov/study/NCT06027268,https://clinicaltrials.gov/study/NCT03606967
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04345913
EFO_0005537	triple-negative breast cancer	CHEMBL2325741	CAPIVASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT1	AKT serine/threonine kinase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT03801369
EFO_0005537	triple-negative breast cancer	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		NCSTN	nicastrin	2	Terminated	https://clinicaltrials.gov/study/NCT01151449
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL3989868	TUCATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT05583110
EFO_0000305	breast carcinoma	CHEMBL3545068	COPANLISIB HYDROCHLORIDE	Small molecule	PI3-kinase p110-delta subunit inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03939897
MONDO_0007254	breast cancer	CHEMBL522892	DOVITINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00958971,https://clinicaltrials.gov/study/NCT01262027
EFO_0000432	breast ductal carcinoma in situ	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Terminated	https://clinicaltrials.gov/study/NCT00461344
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF1	NADH:ubiquinone oxidoreductase complex assembly factor 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC8	histone deacetylase 8	2	Completed	https://clinicaltrials.gov/study/NCT00098397
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134,https://clinicaltrials.gov/study/NCT06291064,https://clinicaltrials.gov/study/NCT04034823,https://clinicaltrials.gov/study/NCT04290793
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	Adenosine A2 receptor antagonist		ADORA2B	adenosine A2b receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT06186700,https://clinicaltrials.gov/study/NCT06176339
EFO_0000432	breast ductal carcinoma in situ	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Terminated	https://clinicaltrials.gov/study/NCT00461344
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Terminated	https://clinicaltrials.gov/study/NCT00206453,https://clinicaltrials.gov/study/NCT01985841,https://clinicaltrials.gov/study/NCT00028483,https://clinicaltrials.gov/study/NCT00636441,https://clinicaltrials.gov/study/NCT00080626,https://clinicaltrials.gov/study/NCT03894007,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT00852332,https://clinicaltrials.gov/study/NCT03329378,https://clinicaltrials.gov/study/NCT00193024,https://clinicaltrials.gov/study/NCT00524459,https://clinicaltrials.gov/study/NCT00104624,https://clinicaltrials.gov/study/NCT00343512,https://clinicaltrials.gov/study/NCT01690325,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT00845910,https://clinicaltrials.gov/study/NCT00225056,https://clinicaltrials.gov/study/NCT00118053,https://clinicaltrials.gov/study/NCT00025493,https://clinicaltrials.gov/study/NCT00453635,https://clinicaltrials.gov/study/NCT00665457,https://clinicaltrials.gov/study/NCT00479856,https://clinicaltrials.gov/study/NCT00576901
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV1	NADH:ubiquinone oxidoreductase core subunit V1	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Recruiting	https://clinicaltrials.gov/study/NCT04624711,https://clinicaltrials.gov/study/NCT05530057,https://clinicaltrials.gov/study/NCT05546255
EFO_0005537	triple-negative breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		LCK	LCK proto-oncogene, Src family tyrosine kinase	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06355037
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA1	NADH:ubiquinone oxidoreductase subunit A1	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL2408045	SAPITINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999
EFO_0006861	male breast carcinoma	CHEMBL554	LAPATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT00118157,https://clinicaltrials.gov/study/NCT00098605
EFO_0006861	male breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00095888
MONDO_0007254	breast cancer	CHEMBL1200694	SEVOFLURANE	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRG3	gamma-aminobutyric acid type A receptor subunit gamma3	2	Completed	https://clinicaltrials.gov/study/NCT02839668
EFO_0000305	breast carcinoma	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Recruiting	https://clinicaltrials.gov/study/NCT02778685,https://clinicaltrials.gov/study/NCT03213041
EFO_0000305	breast carcinoma	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT03598257,https://clinicaltrials.gov/study/NCT06298084,https://clinicaltrials.gov/study/NCT04090567
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT02481050,https://clinicaltrials.gov/study/NCT01908101,https://clinicaltrials.gov/study/NCT01439282,https://clinicaltrials.gov/study/NCT03051659,https://clinicaltrials.gov/study/NCT00879086,https://clinicaltrials.gov/study/NCT00246090,https://clinicaltrials.gov/study/NCT00965523,https://clinicaltrials.gov/study/NCT01268150,https://clinicaltrials.gov/study/NCT05206656,https://clinicaltrials.gov/study/NCT01269346
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04963595,https://clinicaltrials.gov/study/NCT04922008,https://clinicaltrials.gov/study/NCT06229067,https://clinicaltrials.gov/study/NCT04143906,https://clinicaltrials.gov/study/NCT03997539
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04143906,https://clinicaltrials.gov/study/NCT05263882,https://clinicaltrials.gov/study/NCT04517292
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT02978495
EFO_0006861	male breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
MONDO_0021115	luminal B breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT03356860
MONDO_0007254	breast cancer	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	2	Unknown status	https://clinicaltrials.gov/study/NCT01662128,https://clinicaltrials.gov/study/NCT02592746,https://clinicaltrials.gov/study/NCT01609127,https://clinicaltrials.gov/study/NCT01939054,https://clinicaltrials.gov/study/NCT01231802,https://clinicaltrials.gov/study/NCT02838238,https://clinicaltrials.gov/study/NCT03507465,https://clinicaltrials.gov/study/NCT02595320,https://clinicaltrials.gov/study/NCT03423849,https://clinicaltrials.gov/study/NCT02947061,https://clinicaltrials.gov/study/NCT00589901,https://clinicaltrials.gov/study/NCT01924078,https://clinicaltrials.gov/study/NCT00717951,https://clinicaltrials.gov/study/NCT00026442,https://clinicaltrials.gov/study/NCT02115152,https://clinicaltrials.gov/study/NCT01928680,https://clinicaltrials.gov/study/NCT01415336
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Unknown status	https://clinicaltrials.gov/study/NCT03412955,https://clinicaltrials.gov/study/NCT02175446
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB11	NADH:ubiquinone oxidoreductase subunit B11	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Terminated	https://clinicaltrials.gov/study/NCT04066790,https://clinicaltrials.gov/study/NCT00934895,https://clinicaltrials.gov/study/NCT00691912,https://clinicaltrials.gov/study/NCT00536939,https://clinicaltrials.gov/study/NCT00456846,https://clinicaltrials.gov/study/NCT03894007,https://clinicaltrials.gov/study/NCT01416558,https://clinicaltrials.gov/study/NCT00542191,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT00679029,https://clinicaltrials.gov/study/NCT02322814,https://clinicaltrials.gov/study/NCT01147016,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT01009983,https://clinicaltrials.gov/study/NCT00756470,https://clinicaltrials.gov/study/NCT03329378,https://clinicaltrials.gov/study/NCT01207102,https://clinicaltrials.gov/study/NCT01194869,https://clinicaltrials.gov/study/NCT01745367,https://clinicaltrials.gov/study/NCT00622466,https://clinicaltrials.gov/study/NCT00589238,https://clinicaltrials.gov/study/NCT01069796,https://clinicaltrials.gov/study/NCT02598310,https://clinicaltrials.gov/study/NCT00607438,https://clinicaltrials.gov/study/NCT01329627,https://clinicaltrials.gov/study/NCT00532285,https://clinicaltrials.gov/study/NCT00356681,https://clinicaltrials.gov/study/NCT00434356,https://clinicaltrials.gov/study/NCT00194792,https://clinicaltrials.gov/study/NCT00479856,https://clinicaltrials.gov/study/NCT01120158
MONDO_0021115	luminal B breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT03356860
EFO_0000304	breast adenocarcinoma	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02957968
EFO_0000553	invasive lobular carcinoma	CHEMBL1983268	ENTRECTINIB	Small molecule	ALK tyrosine kinase receptor inhibitor		ALK	ALK receptor tyrosine kinase	2	Recruiting	https://clinicaltrials.gov/study/NCT04551495
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01730833,https://clinicaltrials.gov/study/NCT02957968,https://clinicaltrials.gov/study/NCT02530489
EFO_0005537	triple-negative breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03639948
EFO_0000305	breast carcinoma	CHEMBL135	ESTRADIOL	Small molecule	Estrogen receptor alpha agonist	Antagonist	ESR1	estrogen receptor 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06179303
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS3	NADH:ubiquinone oxidoreductase core subunit S3	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06078384
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT01908101
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB10	NADH:ubiquinone oxidoreductase subunit B10	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1201748	CABAZITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT01693549
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Unknown status	https://clinicaltrials.gov/study/NCT01372579
EFO_0005537	triple-negative breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC1	histone deacetylase 1	2	Terminated	https://clinicaltrials.gov/study/NCT01234532
EFO_0006861	male breast carcinoma	CHEMBL2107313	BECATECARIN	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	2	Completed	https://clinicaltrials.gov/study/NCT00005817
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT03018080,https://clinicaltrials.gov/study/NCT00513695,https://clinicaltrials.gov/study/NCT00119262
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04262804,https://clinicaltrials.gov/study/NCT03414658,https://clinicaltrials.gov/study/NCT00431704
MONDO_0007254	breast cancer	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC10	histone deacetylase 10	2	Completed	https://clinicaltrials.gov/study/NCT00098397
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Recruiting	https://clinicaltrials.gov/study/NCT04796324
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		BLK	BLK proto-oncogene, Src family tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT05198843,https://clinicaltrials.gov/study/NCT00817531,https://clinicaltrials.gov/study/NCT00780676
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS1	NADH:ubiquinone oxidoreductase core subunit S1	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT00321633
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT00006261
EFO_0000304	breast adenocarcinoma	CHEMBL3187723	BINIMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 1 inhibitor		MAP2K1	mitogen-activated protein kinase kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT03106415
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Terminated	https://clinicaltrials.gov/study/NCT02000596,https://clinicaltrials.gov/study/NCT01534455,https://clinicaltrials.gov/study/NCT03795012,https://clinicaltrials.gov/study/NCT01498588,https://clinicaltrials.gov/study/NCT01912963,https://clinicaltrials.gov/study/NCT02681523
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R2	phosphoinositide-3-kinase regulatory subunit 2	2	Completed	https://clinicaltrials.gov/study/NCT02273973
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT00325234,https://clinicaltrials.gov/study/NCT03321981,https://clinicaltrials.gov/study/NCT00193089,https://clinicaltrials.gov/study/NCT00022152,https://clinicaltrials.gov/study/NCT01242449,https://clinicaltrials.gov/study/NCT04903652,https://clinicaltrials.gov/study/NCT03254654,https://clinicaltrials.gov/study/NCT00148681,https://clinicaltrials.gov/study/NCT00401427,https://clinicaltrials.gov/study/NCT00006682,https://clinicaltrials.gov/study/NCT00670982,https://clinicaltrials.gov/study/NCT00192062,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00148668,https://clinicaltrials.gov/study/NCT00093808,https://clinicaltrials.gov/study/NCT01565083,https://clinicaltrials.gov/study/NCT03007992,https://clinicaltrials.gov/study/NCT00015938,https://clinicaltrials.gov/study/NCT00041067,https://clinicaltrials.gov/study/NCT02954055,https://clinicaltrials.gov/study/NCT00266110,https://clinicaltrials.gov/study/NCT01520103,https://clinicaltrials.gov/study/NCT00480597,https://clinicaltrials.gov/study/NCT03887130,https://clinicaltrials.gov/study/NCT01835236,https://clinicaltrials.gov/study/NCT00532623,https://clinicaltrials.gov/study/NCT00194779,https://clinicaltrials.gov/study/NCT01305941,https://clinicaltrials.gov/study/NCT02362958,https://clinicaltrials.gov/study/NCT00004237,https://clinicaltrials.gov/study/NCT00503750,https://clinicaltrials.gov/study/NCT01439191,https://clinicaltrials.gov/study/NCT01941771,https://clinicaltrials.gov/study/NCT02628613
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT06026657,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT04739670,https://clinicaltrials.gov/study/NCT06102824,https://clinicaltrials.gov/study/NCT05601440,https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT05181462
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Withdrawn	https://clinicaltrials.gov/study/NCT05177796
EFO_0000305	breast carcinoma	CHEMBL1201179	LAPATINIB DITOSYLATE	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT01622868,https://clinicaltrials.gov/study/NCT00684983
EFO_0005537	triple-negative breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT03932526
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Completed	https://clinicaltrials.gov/study/NCT03205761,https://clinicaltrials.gov/study/NCT03167619
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04262804,https://clinicaltrials.gov/study/NCT00431704,https://clinicaltrials.gov/study/NCT03414658
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02530489,https://clinicaltrials.gov/study/NCT01730833,https://clinicaltrials.gov/study/NCT02957968
MONDO_0007254	breast cancer	CHEMBL76222	REBIMASTAT	Small molecule	Matrix metalloproteinase 14 inhibitor		MMP14	matrix metallopeptidase 14	2	Terminated	https://clinicaltrials.gov/study/NCT00036621
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Recruiting	https://clinicaltrials.gov/study/NCT05181462,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT06026657,https://clinicaltrials.gov/study/NCT06102824,https://clinicaltrials.gov/study/NCT05601440,https://clinicaltrials.gov/study/NCT04739670
MONDO_0007254	breast cancer	CHEMBL2360464	PEMETREXED DISODIUM	Small molecule	GAR transformylase inhibitor		GART	phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase	2	Completed	https://clinicaltrials.gov/study/NCT00006007
EFO_0006861	male breast carcinoma	CHEMBL1642	IMATINIB MESYLATE	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	2	Completed	https://clinicaltrials.gov/study/NCT00045188
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05041101
MONDO_0007254	breast cancer	CHEMBL160	CYCLOSPORINE	Protein	Cyclophilin A modulator		PPIA	peptidylprolyl isomerase A	2	Completed	https://clinicaltrials.gov/study/NCT00020176,https://clinicaltrials.gov/study/NCT01105650
MONDO_0007254	breast cancer	CHEMBL1614650	EXATECAN	Small molecule	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	2	Completed	https://clinicaltrials.gov/study/NCT00004046
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Unknown status	https://clinicaltrials.gov/study/NCT01730677,https://clinicaltrials.gov/study/NCT02144194,https://clinicaltrials.gov/study/NCT01528826,https://clinicaltrials.gov/study/NCT03423849,https://clinicaltrials.gov/study/NCT02607215,https://clinicaltrials.gov/study/NCT00159094,https://clinicaltrials.gov/study/NCT02768415,https://clinicaltrials.gov/study/NCT02544243
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE2A	phosphodiesterase 2A	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT06186700,https://clinicaltrials.gov/study/NCT06176339
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Unknown status	https://clinicaltrials.gov/study/NCT00669773,https://clinicaltrials.gov/study/NCT00250874,https://clinicaltrials.gov/study/NCT00994968,https://clinicaltrials.gov/study/NCT03876587,https://clinicaltrials.gov/study/NCT00033683,https://clinicaltrials.gov/study/NCT00026078,https://clinicaltrials.gov/study/NCT02685657,https://clinicaltrials.gov/study/NCT02144194,https://clinicaltrials.gov/study/NCT01351597,https://clinicaltrials.gov/study/NCT01939054,https://clinicaltrials.gov/study/NCT00003066,https://clinicaltrials.gov/study/NCT03147963,https://clinicaltrials.gov/study/NCT00012311,https://clinicaltrials.gov/study/NCT00721747,https://clinicaltrials.gov/study/NCT00957125,https://clinicaltrials.gov/study/NCT00398489,https://clinicaltrials.gov/study/NCT00801411,https://clinicaltrials.gov/study/NCT02947061,https://clinicaltrials.gov/study/NCT01526499,https://clinicaltrials.gov/study/NCT01907529,https://clinicaltrials.gov/study/NCT01270373,https://clinicaltrials.gov/study/NCT01352494,https://clinicaltrials.gov/study/NCT00006120
MONDO_0007254	breast cancer	CHEMBL1094636	NIRAPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05232006,https://clinicaltrials.gov/study/NCT05461690
EFO_1000984	inflammatory breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02623972
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Recruiting	https://clinicaltrials.gov/study/NCT04796324
MONDO_0007254	breast cancer	CHEMBL1491	AMLODIPINE	Small molecule	Voltage-gated L-type calcium channel blocker		CACNA1S	calcium voltage-gated channel subunit alpha1 S	2	Completed	https://clinicaltrials.gov/study/NCT02834403
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC8	histone deacetylase 8	2	Terminated	https://clinicaltrials.gov/study/NCT00777335
MONDO_0007254	breast cancer	CHEMBL52885	ENMD-981693	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Completed	https://clinicaltrials.gov/study/NCT00306631
EFO_0000305	breast carcinoma	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist	Antagonist	ESR1	estrogen receptor 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06179303
MONDO_0007254	breast cancer	CHEMBL328190	LASOFOXIFENE	Small molecule	Estrogen receptor modulator	Antagonist	ESR1	estrogen receptor 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04432454,https://clinicaltrials.gov/study/NCT03781063
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT02614833
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05041101
EFO_0005537	triple-negative breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Suspended	https://clinicaltrials.gov/study/NCT04095689
MONDO_0007254	breast cancer	CHEMBL473417	VISMODEGIB	Small molecule	Smoothened homolog inhibitor		SMO	smoothened, frizzled class receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT02694224
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Unknown status	https://clinicaltrials.gov/study/NCT01372579
EFO_0005537	triple-negative breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03639948
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB2	NADH:ubiquinone oxidoreductase subunit B2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
EFO_0005537	triple-negative breast cancer	CHEMBL4298101	LADIRATUZUMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0006861	male breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Unknown status	https://clinicaltrials.gov/study/NCT01372579
MONDO_0007254	breast cancer	CHEMBL1567	SUNITINIB MALATE	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Completed	https://clinicaltrials.gov/study/NCT00482755
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Withdrawn	https://clinicaltrials.gov/study/NCT02067416,https://clinicaltrials.gov/study/NCT00006261,https://clinicaltrials.gov/study/NCT01229605,https://clinicaltrials.gov/study/NCT00434031,https://clinicaltrials.gov/study/NCT00964704,https://clinicaltrials.gov/study/NCT01825265,https://clinicaltrials.gov/study/NCT00678626
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00095888,https://clinicaltrials.gov/study/NCT00470249,https://clinicaltrials.gov/study/NCT00323063,https://clinicaltrials.gov/study/NCT00679029
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL4298124	DOSTARLIMAB	Antibody	Programmed cell death protein 1 antagonist		PDCD1	programmed cell death 1	2	Recruiting	https://clinicaltrials.gov/study/NCT04584255
MONDO_0007254	breast cancer	CHEMBL723	CARVEDILOL	Small molecule	Adrenergic receptor beta antagonist		ADRB3	adrenoceptor beta 3	2	Recruiting	https://clinicaltrials.gov/study/NCT03879629
MONDO_0007254	breast cancer	CHEMBL1082407	ENZALUTAMIDE	Small molecule	Androgen Receptor antagonist		AR	androgen receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02750358,https://clinicaltrials.gov/study/NCT02955394,https://clinicaltrials.gov/study/NCT02007512
MONDO_0007254	breast cancer	CHEMBL94657	PATUPILONE	Small molecule	Tubulin stabiliser		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT00450866
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB3	NADH:ubiquinone oxidoreductase subunit B3	2	Terminated	https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT01627067
MONDO_0007254	breast cancer	CHEMBL522892	DOVITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT00958971,https://clinicaltrials.gov/study/NCT01262027
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA12	NADH:ubiquinone oxidoreductase subunit A12	2	Terminated	https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT01627067
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS2	NADH:ubiquinone oxidoreductase core subunit S2	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0006861	male breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Tyrosine-protein kinase LCK inhibitor		LCK	LCK proto-oncogene, Src family tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT01446016,https://clinicaltrials.gov/study/NCT00020904,https://clinicaltrials.gov/study/NCT00045097,https://clinicaltrials.gov/study/NCT01416389,https://clinicaltrials.gov/study/NCT00879086,https://clinicaltrials.gov/study/NCT00370552,https://clinicaltrials.gov/study/NCT00077376,https://clinicaltrials.gov/study/NCT00080262,https://clinicaltrials.gov/study/NCT00593827,https://clinicaltrials.gov/study/NCT00627978,https://clinicaltrials.gov/study/NCT00455533,https://clinicaltrials.gov/study/NCT00633464,https://clinicaltrials.gov/study/NCT01075100,https://clinicaltrials.gov/study/NCT00866905,https://clinicaltrials.gov/study/NCT00821886,https://clinicaltrials.gov/study/NCT01027208,https://clinicaltrials.gov/study/NCT00490646,https://clinicaltrials.gov/study/NCT01097642,https://clinicaltrials.gov/study/NCT01019577,https://clinicaltrials.gov/study/NCT00751868
MONDO_0007254	breast cancer	CHEMBL4297545	LUTETIUM OXODOTREOTIDE LU-177	Protein	Somatostatin receptor binding agent		SSTR4	somatostatin receptor 4	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04529044
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R5	phosphoinositide-3-kinase regulatory subunit 5	2	Recruiting	https://clinicaltrials.gov/study/NCT03698383
MONDO_0007254	breast cancer	CHEMBL837	7-ETHYL-10-HYDROXYCAMPTOTHECIN	Small molecule	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	2	Completed	https://clinicaltrials.gov/study/NCT00951054
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT01550848,https://clinicaltrials.gov/study/NCT00059852,https://clinicaltrials.gov/study/NCT00128856,https://clinicaltrials.gov/study/NCT00493636,https://clinicaltrials.gov/study/NCT00005991,https://clinicaltrials.gov/study/NCT00192062,https://clinicaltrials.gov/study/NCT00450762,https://clinicaltrials.gov/study/NCT00813956,https://clinicaltrials.gov/study/NCT00754351,https://clinicaltrials.gov/study/NCT00193206,https://clinicaltrials.gov/study/NCT00480597,https://clinicaltrials.gov/study/NCT00212069,https://clinicaltrials.gov/study/NCT00618826,https://clinicaltrials.gov/study/NCT00193050,https://clinicaltrials.gov/study/NCT00191269,https://clinicaltrials.gov/study/NCT02435680,https://clinicaltrials.gov/study/NCT00316199,https://clinicaltrials.gov/study/NCT00006007,https://clinicaltrials.gov/study/NCT00540358,https://clinicaltrials.gov/study/NCT00191243,https://clinicaltrials.gov/study/NCT00334802,https://clinicaltrials.gov/study/NCT00378313,https://clinicaltrials.gov/study/NCT03025880,https://clinicaltrials.gov/study/NCT00002998,https://clinicaltrials.gov/study/NCT04464174,https://clinicaltrials.gov/study/NCT00191451,https://clinicaltrials.gov/study/NCT00503906,https://clinicaltrials.gov/study/NCT02263495,https://clinicaltrials.gov/study/NCT00191815,https://clinicaltrials.gov/study/NCT01201265,https://clinicaltrials.gov/study/NCT00325234,https://clinicaltrials.gov/study/NCT00532623,https://clinicaltrials.gov/study/NCT00623233,https://clinicaltrials.gov/study/NCT00320541,https://clinicaltrials.gov/study/NCT00201760,https://clinicaltrials.gov/study/NCT00192101,https://clinicaltrials.gov/study/NCT00532857,https://clinicaltrials.gov/study/NCT00193063,https://clinicaltrials.gov/study/NCT00662129,https://clinicaltrials.gov/study/NCT00191373,https://clinicaltrials.gov/study/NCT00695994,https://clinicaltrials.gov/study/NCT00191854,https://clinicaltrials.gov/study/NCT00244933,https://clinicaltrials.gov/study/NCT00110084,https://clinicaltrials.gov/study/NCT00846027,https://clinicaltrials.gov/study/NCT00063570,https://clinicaltrials.gov/study/NCT00193076,https://clinicaltrials.gov/study/NCT00191347,https://clinicaltrials.gov/study/NCT00003540,https://clinicaltrials.gov/study/NCT00191789,https://clinicaltrials.gov/study/NCT01045304,https://clinicaltrials.gov/study/NCT00894504,https://clinicaltrials.gov/study/NCT00601159,https://clinicaltrials.gov/study/NCT00403130
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT02614833
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0006861	male breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT00077376
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB8	NADH:ubiquinone oxidoreductase subunit B8	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
EFO_0009780	HER2 negative breast carcinoma	CHEMBL4297939	DATOPOTAMAB DERUXTECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	2	Recruiting	https://clinicaltrials.gov/study/NCT06176261
EFO_0005537	triple-negative breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT03154749,https://clinicaltrials.gov/study/NCT02413320
EFO_0006861	male breast carcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC2	histone deacetylase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01349959
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF3	NADH:ubiquinone oxidoreductase complex assembly factor 3	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL377559	RETASPIMYCIN HYDROCHLORIDE	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AA1	heat shock protein 90 alpha family class A member 1	2	Terminated	https://clinicaltrials.gov/study/NCT00817362
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	2	Completed	https://clinicaltrials.gov/study/NCT00509587,https://clinicaltrials.gov/study/NCT01466972
MONDO_0007254	breast cancer	CHEMBL52885	ENMD-981693	Small molecule	SRC inhibitor		SRC	SRC proto-oncogene, non-receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00306631
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Terminated	https://clinicaltrials.gov/study/NCT00088985,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT00049660,https://clinicaltrials.gov/study/NCT00194792,https://clinicaltrials.gov/study/NCT03358004
EFO_0006861	male breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Unknown status	https://clinicaltrials.gov/study/NCT01372579
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT00027989
MONDO_0007254	breast cancer	CHEMBL154	NAPROXEN	Small molecule	Cyclooxygenase inhibitor		PTGS2	prostaglandin-endoperoxide synthase 2	2	Completed	https://clinicaltrials.gov/study/NCT01712009
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT01908101,https://clinicaltrials.gov/study/NCT00246090,https://clinicaltrials.gov/study/NCT01269346,https://clinicaltrials.gov/study/NCT03051659,https://clinicaltrials.gov/study/NCT01439282,https://clinicaltrials.gov/study/NCT00965523,https://clinicaltrials.gov/study/NCT01268150,https://clinicaltrials.gov/study/NCT02481050,https://clinicaltrials.gov/study/NCT05206656,https://clinicaltrials.gov/study/NCT00879086
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT00490646,https://clinicaltrials.gov/study/NCT00003352,https://clinicaltrials.gov/study/NCT00248703,https://clinicaltrials.gov/study/NCT00604435,https://clinicaltrials.gov/study/NCT02132949,https://clinicaltrials.gov/study/NCT02846428,https://clinicaltrials.gov/study/NCT00494481,https://clinicaltrials.gov/study/NCT00004906,https://clinicaltrials.gov/study/NCT00365417,https://clinicaltrials.gov/study/NCT00493649,https://clinicaltrials.gov/study/NCT00232479,https://clinicaltrials.gov/study/NCT01367028,https://clinicaltrials.gov/study/NCT00274456,https://clinicaltrials.gov/study/NCT03140553,https://clinicaltrials.gov/study/NCT00203372,https://clinicaltrials.gov/study/NCT00525759,https://clinicaltrials.gov/study/NCT00193180,https://clinicaltrials.gov/study/NCT02748213,https://clinicaltrials.gov/study/NCT00712881,https://clinicaltrials.gov/study/NCT00191243,https://clinicaltrials.gov/study/NCT02838225,https://clinicaltrials.gov/study/NCT01658462,https://clinicaltrials.gov/study/NCT00123929,https://clinicaltrials.gov/study/NCT00524810,https://clinicaltrials.gov/study/NCT01671319,https://clinicaltrials.gov/study/NCT00155259,https://clinicaltrials.gov/study/NCT00217672,https://clinicaltrials.gov/study/NCT01959490,https://clinicaltrials.gov/study/NCT02041351,https://clinicaltrials.gov/study/NCT00006104,https://clinicaltrials.gov/study/NCT00015938,https://clinicaltrials.gov/study/NCT00005963,https://clinicaltrials.gov/study/NCT00976989,https://clinicaltrials.gov/study/NCT00005908,https://clinicaltrials.gov/study/NCT00055861,https://clinicaltrials.gov/study/NCT00841828,https://clinicaltrials.gov/study/NCT00193050,https://clinicaltrials.gov/study/NCT00054275,https://clinicaltrials.gov/study/NCT00068341,https://clinicaltrials.gov/study/NCT00027885,https://clinicaltrials.gov/study/NCT02005549,https://clinicaltrials.gov/study/NCT00028873,https://clinicaltrials.gov/study/NCT00941330,https://clinicaltrials.gov/study/NCT00319618,https://clinicaltrials.gov/study/NCT02137083,https://clinicaltrials.gov/study/NCT00365365,https://clinicaltrials.gov/study/NCT00464646,https://clinicaltrials.gov/study/NCT02365805,https://clinicaltrials.gov/study/NCT00212095,https://clinicaltrials.gov/study/NCT01396655,https://clinicaltrials.gov/study/NCT00206518,https://clinicaltrials.gov/study/NCT01025349,https://clinicaltrials.gov/study/NCT00379015,https://clinicaltrials.gov/study/NCT00209092,https://clinicaltrials.gov/study/NCT00545688,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT00193089,https://clinicaltrials.gov/study/NCT00107510,https://clinicaltrials.gov/study/NCT00527449,https://clinicaltrials.gov/study/NCT01038804,https://clinicaltrials.gov/study/NCT00206505,https://clinicaltrials.gov/study/NCT00193115,https://clinicaltrials.gov/study/NCT00206466,https://clinicaltrials.gov/study/NCT02834403,https://clinicaltrials.gov/study/NCT00004888,https://clinicaltrials.gov/study/NCT00006682,https://clinicaltrials.gov/study/NCT00198237,https://clinicaltrials.gov/study/NCT00041067,https://clinicaltrials.gov/study/NCT00820872,https://clinicaltrials.gov/study/NCT00258375,https://clinicaltrials.gov/study/NCT00003953,https://clinicaltrials.gov/study/NCT02909751,https://clinicaltrials.gov/study/NCT00077857,https://clinicaltrials.gov/study/NCT00364611,https://clinicaltrials.gov/study/NCT03742986,https://clinicaltrials.gov/study/NCT00005800,https://clinicaltrials.gov/study/NCT03735966,https://clinicaltrials.gov/study/NCT00203502,https://clinicaltrials.gov/study/NCT00679341,https://clinicaltrials.gov/study/NCT00079118,https://clinicaltrials.gov/study/NCT01208480,https://clinicaltrials.gov/study/NCT00201708,https://clinicaltrials.gov/study/NCT00179309,https://clinicaltrials.gov/study/NCT00773695,https://clinicaltrials.gov/study/NCT00559754,https://clinicaltrials.gov/study/NCT01150513,https://clinicaltrials.gov/study/NCT00003565,https://clinicaltrials.gov/study/NCT00769470,https://clinicaltrials.gov/study/NCT00404066,https://clinicaltrials.gov/study/NCT00044993,https://clinicaltrials.gov/study/NCT00004175,https://clinicaltrials.gov/study/NCT01485926,https://clinicaltrials.gov/study/NCT00645866,https://clinicaltrials.gov/study/NCT00428922,https://clinicaltrials.gov/study/NCT00129376,https://clinicaltrials.gov/study/NCT03887130,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00015886,https://clinicaltrials.gov/study/NCT00695994,https://clinicaltrials.gov/study/NCT00499122,https://clinicaltrials.gov/study/NCT00148070,https://clinicaltrials.gov/study/NCT00600249,https://clinicaltrials.gov/study/NCT01142778,https://clinicaltrials.gov/study/NCT00039520,https://clinicaltrials.gov/study/NCT00066443,https://clinicaltrials.gov/study/NCT01527487,https://clinicaltrials.gov/study/NCT00148668,https://clinicaltrials.gov/study/NCT00088998,https://clinicaltrials.gov/study/NCT00754351,https://clinicaltrials.gov/study/NCT02229084,https://clinicaltrials.gov/study/NCT00214864,https://clinicaltrials.gov/study/NCT01792050,https://clinicaltrials.gov/study/NCT00475670,https://clinicaltrials.gov/study/NCT00193037,https://clinicaltrials.gov/study/NCT01446016,https://clinicaltrials.gov/study/NCT00820547,https://clinicaltrials.gov/study/NCT04664972,https://clinicaltrials.gov/study/NCT00212082,https://clinicaltrials.gov/study/NCT01540110,https://clinicaltrials.gov/study/NCT00432172,https://clinicaltrials.gov/study/NCT00247481,https://clinicaltrials.gov/study/NCT00146042,https://clinicaltrials.gov/study/NCT00149214
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Terminated	https://clinicaltrials.gov/study/NCT03329378,https://clinicaltrials.gov/study/NCT00118053,https://clinicaltrials.gov/study/NCT00845910,https://clinicaltrials.gov/study/NCT00453635,https://clinicaltrials.gov/study/NCT01690325,https://clinicaltrials.gov/study/NCT03894007,https://clinicaltrials.gov/study/NCT00852332,https://clinicaltrials.gov/study/NCT00028483,https://clinicaltrials.gov/study/NCT00225056,https://clinicaltrials.gov/study/NCT00025493,https://clinicaltrials.gov/study/NCT00576901,https://clinicaltrials.gov/study/NCT00479856,https://clinicaltrials.gov/study/NCT00104624,https://clinicaltrials.gov/study/NCT00343512,https://clinicaltrials.gov/study/NCT01985841,https://clinicaltrials.gov/study/NCT00524459,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT00665457,https://clinicaltrials.gov/study/NCT00206453,https://clinicaltrials.gov/study/NCT00080626,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT00636441,https://clinicaltrials.gov/study/NCT00193024
EFO_0000305	breast carcinoma	CHEMBL359744	DOXORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Completed	https://clinicaltrials.gov/study/NCT02456857
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Unknown status	https://clinicaltrials.gov/study/NCT02768415,https://clinicaltrials.gov/study/NCT01528826,https://clinicaltrials.gov/study/NCT01730677,https://clinicaltrials.gov/study/NCT03423849,https://clinicaltrials.gov/study/NCT02544243,https://clinicaltrials.gov/study/NCT02144194,https://clinicaltrials.gov/study/NCT02607215,https://clinicaltrials.gov/study/NCT00159094
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT00191373
EFO_0000432	breast ductal carcinoma in situ	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02779855
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4L2	NDUFA4 mitochondrial complex associated like 2	2	Unknown status	https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT02506777
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05833919
MONDO_0007254	breast cancer	CHEMBL2325741	CAPIVASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT2	AKT serine/threonine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT02077569
MONDO_0007254	breast cancer	CHEMBL521851	PICTILISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	2	Completed	https://clinicaltrials.gov/study/NCT01740336,https://clinicaltrials.gov/study/NCT01437566
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Terminated	https://clinicaltrials.gov/study/NCT00088985,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT00194792,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT00049660,https://clinicaltrials.gov/study/NCT03358004
MONDO_0007254	breast cancer	CHEMBL596	FENTANYL	Small molecule	Mu opioid receptor agonist		OPRM1	opioid receptor mu 1	2	Completed	https://clinicaltrials.gov/study/NCT03084536
EFO_0006861	male breast carcinoma	CHEMBL1567	SUNITINIB MALATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT00513695
EFO_0006861	male breast carcinoma	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01349959
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Terminated	https://clinicaltrials.gov/study/NCT00722072,https://clinicaltrials.gov/study/NCT01194869,https://clinicaltrials.gov/study/NCT00525161,https://clinicaltrials.gov/study/NCT02624700,https://clinicaltrials.gov/study/NCT00622466,https://clinicaltrials.gov/study/NCT00607438,https://clinicaltrials.gov/study/NCT00632541,https://clinicaltrials.gov/study/NCT00573755
MONDO_0007254	breast cancer	CHEMBL191413	REPARIXIN	Small molecule	Interleukin-8 receptor B modulator		CXCR2	C-X-C motif chemokine receptor 2	2	Terminated	https://clinicaltrials.gov/study/NCT01861054
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBA1B	tubulin alpha 1b	2	Withdrawn	https://clinicaltrials.gov/study/NCT01227408
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Withdrawn	https://clinicaltrials.gov/study/NCT02067416,https://clinicaltrials.gov/study/NCT00678626,https://clinicaltrials.gov/study/NCT00964704,https://clinicaltrials.gov/study/NCT01825265,https://clinicaltrials.gov/study/NCT01229605,https://clinicaltrials.gov/study/NCT00006261,https://clinicaltrials.gov/study/NCT00434031
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF3	NADH:ubiquinone oxidoreductase complex assembly factor 3	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL1743030	ICRUCUMAB	Antibody	Vascular endothelial growth factor receptor 1 antagonist		FLT1	fms related receptor tyrosine kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT01234402
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT00006261
MONDO_0007254	breast cancer	CHEMBL142703	VILDAGLIPTIN	Small molecule	Dipeptidyl peptidase IV inhibitor		DPP4	dipeptidyl peptidase 4	2	Recruiting	https://clinicaltrials.gov/study/NCT04300790
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Unknown status	https://clinicaltrials.gov/study/NCT00012311,https://clinicaltrials.gov/study/NCT02144194,https://clinicaltrials.gov/study/NCT00250874,https://clinicaltrials.gov/study/NCT01526499,https://clinicaltrials.gov/study/NCT00398489,https://clinicaltrials.gov/study/NCT01351597,https://clinicaltrials.gov/study/NCT01270373,https://clinicaltrials.gov/study/NCT01907529,https://clinicaltrials.gov/study/NCT02685657,https://clinicaltrials.gov/study/NCT00026078,https://clinicaltrials.gov/study/NCT00801411,https://clinicaltrials.gov/study/NCT03876587,https://clinicaltrials.gov/study/NCT00006120,https://clinicaltrials.gov/study/NCT00957125,https://clinicaltrials.gov/study/NCT03147963,https://clinicaltrials.gov/study/NCT00994968,https://clinicaltrials.gov/study/NCT00033683,https://clinicaltrials.gov/study/NCT00003066,https://clinicaltrials.gov/study/NCT00721747,https://clinicaltrials.gov/study/NCT01352494,https://clinicaltrials.gov/study/NCT01939054,https://clinicaltrials.gov/study/NCT00669773,https://clinicaltrials.gov/study/NCT02947061
MONDO_0007254	breast cancer	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04900311,https://clinicaltrials.gov/study/NCT05020964,https://clinicaltrials.gov/study/NCT04290793,https://clinicaltrials.gov/study/NCT05621434,https://clinicaltrials.gov/study/NCT04922008,https://clinicaltrials.gov/study/NCT05983094,https://clinicaltrials.gov/study/NCT04034823,https://clinicaltrials.gov/study/NCT04301375,https://clinicaltrials.gov/study/NCT04088110,https://clinicaltrials.gov/study/NCT04158856,https://clinicaltrials.gov/study/NCT04639271,https://clinicaltrials.gov/study/NCT04246502,https://clinicaltrials.gov/study/NCT05577923,https://clinicaltrials.gov/study/NCT04858516,https://clinicaltrials.gov/study/NCT04236310
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA13	NADH:ubiquinone oxidoreductase subunit A13	2	Completed	https://clinicaltrials.gov/study/NCT01885013
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03202316,https://clinicaltrials.gov/study/NCT05041101
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Terminated	https://clinicaltrials.gov/study/NCT01498588
MONDO_0007254	breast cancer	CHEMBL1487	ATORVASTATIN	Small molecule	HMG-CoA reductase inhibitor		HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase	2	Recruiting	https://clinicaltrials.gov/study/NCT05103644
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4L	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L	2	Completed	https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT01310231
EFO_0000305	breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967
EFO_0000305	breast carcinoma	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		LYN	LYN proto-oncogene, Src family tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT05198843
MONDO_0007254	breast cancer	CHEMBL328190	LASOFOXIFENE	Small molecule	Estrogen receptor modulator	Antagonist	ESR2	estrogen receptor 2	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Withdrawn	https://clinicaltrials.gov/study/NCT03032614
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04262804,https://clinicaltrials.gov/study/NCT01815242,https://clinicaltrials.gov/study/NCT04297267,https://clinicaltrials.gov/study/NCT03567720,https://clinicaltrials.gov/study/NCT02252887
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Recruiting	https://clinicaltrials.gov/study/NCT05353361,https://clinicaltrials.gov/study/NCT04877821,https://clinicaltrials.gov/study/NCT04722718,https://clinicaltrials.gov/study/NCT04425018,https://clinicaltrials.gov/study/NCT05728268,https://clinicaltrials.gov/study/NCT05633914,https://clinicaltrials.gov/study/NCT05325632,https://clinicaltrials.gov/study/NCT04872985,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT04917900,https://clinicaltrials.gov/study/NCT05852691,https://clinicaltrials.gov/study/NCT05346107,https://clinicaltrials.gov/study/NCT01817452,https://clinicaltrials.gov/study/NCT05749016,https://clinicaltrials.gov/study/NCT05681728,https://clinicaltrials.gov/study/NCT04243616,https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT05189067,https://clinicaltrials.gov/study/NCT03150576,https://clinicaltrials.gov/study/NCT03412643,https://clinicaltrials.gov/study/NCT05659056,https://clinicaltrials.gov/study/NCT04537286,https://clinicaltrials.gov/study/NCT04090398,https://clinicaltrials.gov/study/NCT05918328,https://clinicaltrials.gov/study/NCT05174832,https://clinicaltrials.gov/study/NCT04893109,https://clinicaltrials.gov/study/NCT04443348,https://clinicaltrials.gov/study/NCT03048942,https://clinicaltrials.gov/study/NCT05889390,https://clinicaltrials.gov/study/NCT05020860,https://clinicaltrials.gov/study/NCT04780347,https://clinicaltrials.gov/study/NCT05629429,https://clinicaltrials.gov/study/NCT05582538,https://clinicaltrials.gov/study/NCT05383196,https://clinicaltrials.gov/study/NCT05900206,https://clinicaltrials.gov/study/NCT03571633,https://clinicaltrials.gov/study/NCT04576143,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT05749575,https://clinicaltrials.gov/study/NCT05068141,https://clinicaltrials.gov/study/NCT04771871,https://clinicaltrials.gov/study/NCT06245889,https://clinicaltrials.gov/study/NCT04329065,https://clinicaltrials.gov/study/NCT05447702,https://clinicaltrials.gov/study/NCT04355858,https://clinicaltrials.gov/study/NCT03907800,https://clinicaltrials.gov/study/NCT05761470,https://clinicaltrials.gov/study/NCT04676997,https://clinicaltrials.gov/study/NCT04159142
MONDO_0007254	breast cancer	CHEMBL94657	PATUPILONE	Small molecule	Tubulin stabiliser		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT00450866
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC2	histone deacetylase 2	2	Terminated	https://clinicaltrials.gov/study/NCT00777335
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT00027989,https://clinicaltrials.gov/study/NCT02341911,https://clinicaltrials.gov/study/NCT02544243,https://clinicaltrials.gov/study/NCT03423849,https://clinicaltrials.gov/study/NCT01352494
EFO_0000305	breast carcinoma	CHEMBL1789941	RUXOLITINIB	Small molecule	Tyrosine-protein kinase JAK1 inhibitor		JAK1	Janus kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT02066532
EFO_0005537	triple-negative breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FYN	FYN proto-oncogene, Src family tyrosine kinase	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06355037
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB11	NADH:ubiquinone oxidoreductase subunit B11	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Withdrawn	https://clinicaltrials.gov/study/NCT05233696,https://clinicaltrials.gov/study/NCT03644589,https://clinicaltrials.gov/study/NCT05177796
EFO_0006861	male breast carcinoma	CHEMBL1567	SUNITINIB MALATE	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Completed	https://clinicaltrials.gov/study/NCT00513695
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA5	NADH:ubiquinone oxidoreductase subunit A5	2	Unknown status	https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT02506777,https://clinicaltrials.gov/study/NCT02506790
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB9	NADH:ubiquinone oxidoreductase subunit B9	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBA3C	tubulin alpha 3c	2	Withdrawn	https://clinicaltrials.gov/study/NCT00450515
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT00490646,https://clinicaltrials.gov/study/NCT01792050,https://clinicaltrials.gov/study/NCT00499122,https://clinicaltrials.gov/study/NCT00179309,https://clinicaltrials.gov/study/NCT03887130,https://clinicaltrials.gov/study/NCT00004175,https://clinicaltrials.gov/study/NCT02132949,https://clinicaltrials.gov/study/NCT00248703,https://clinicaltrials.gov/study/NCT00247481,https://clinicaltrials.gov/study/NCT00039520,https://clinicaltrials.gov/study/NCT00191243,https://clinicaltrials.gov/study/NCT01540110,https://clinicaltrials.gov/study/NCT00545688,https://clinicaltrials.gov/study/NCT00695994,https://clinicaltrials.gov/study/NCT00976989,https://clinicaltrials.gov/study/NCT00054275,https://clinicaltrials.gov/study/NCT00600249,https://clinicaltrials.gov/study/NCT01038804,https://clinicaltrials.gov/study/NCT00769470,https://clinicaltrials.gov/study/NCT01671319,https://clinicaltrials.gov/study/NCT00005908,https://clinicaltrials.gov/study/NCT02041351,https://clinicaltrials.gov/study/NCT02748213,https://clinicaltrials.gov/study/NCT00494481,https://clinicaltrials.gov/study/NCT04664972,https://clinicaltrials.gov/study/NCT00027885,https://clinicaltrials.gov/study/NCT00212082,https://clinicaltrials.gov/study/NCT00005963,https://clinicaltrials.gov/study/NCT00841828,https://clinicaltrials.gov/study/NCT03742986,https://clinicaltrials.gov/study/NCT00005800,https://clinicaltrials.gov/study/NCT00319618,https://clinicaltrials.gov/study/NCT02137083,https://clinicaltrials.gov/study/NCT00148070,https://clinicaltrials.gov/study/NCT00015886,https://clinicaltrials.gov/study/NCT00773695,https://clinicaltrials.gov/study/NCT00679341,https://clinicaltrials.gov/study/NCT00041067,https://clinicaltrials.gov/study/NCT00206466,https://clinicaltrials.gov/study/NCT00365417,https://clinicaltrials.gov/study/NCT02834403,https://clinicaltrials.gov/study/NCT00258375,https://clinicaltrials.gov/study/NCT00055861,https://clinicaltrials.gov/study/NCT01396655,https://clinicaltrials.gov/study/NCT02365805,https://clinicaltrials.gov/study/NCT00146042,https://clinicaltrials.gov/study/NCT00212095,https://clinicaltrials.gov/study/NCT00198237,https://clinicaltrials.gov/study/NCT00193037,https://clinicaltrials.gov/study/NCT00364611,https://clinicaltrials.gov/study/NCT00379015,https://clinicaltrials.gov/study/NCT00754351,https://clinicaltrials.gov/study/NCT00028873,https://clinicaltrials.gov/study/NCT00201708,https://clinicaltrials.gov/study/NCT00193115,https://clinicaltrials.gov/study/NCT01446016,https://clinicaltrials.gov/study/NCT00006682,https://clinicaltrials.gov/study/NCT00217672,https://clinicaltrials.gov/study/NCT03140553,https://clinicaltrials.gov/study/NCT00206518,https://clinicaltrials.gov/study/NCT00107510,https://clinicaltrials.gov/study/NCT00820872,https://clinicaltrials.gov/study/NCT00432172,https://clinicaltrials.gov/study/NCT02838225,https://clinicaltrials.gov/study/NCT00232479,https://clinicaltrials.gov/study/NCT00004888,https://clinicaltrials.gov/study/NCT01208480,https://clinicaltrials.gov/study/NCT01025349,https://clinicaltrials.gov/study/NCT00006104,https://clinicaltrials.gov/study/NCT00068341,https://clinicaltrials.gov/study/NCT00148668,https://clinicaltrials.gov/study/NCT00493649,https://clinicaltrials.gov/study/NCT00524810,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT00820547,https://clinicaltrials.gov/study/NCT01367028,https://clinicaltrials.gov/study/NCT00077857,https://clinicaltrials.gov/study/NCT00527449,https://clinicaltrials.gov/study/NCT00604435,https://clinicaltrials.gov/study/NCT00464646,https://clinicaltrials.gov/study/NCT00274456,https://clinicaltrials.gov/study/NCT00149214,https://clinicaltrials.gov/study/NCT00203502,https://clinicaltrials.gov/study/NCT01150513,https://clinicaltrials.gov/study/NCT00193180,https://clinicaltrials.gov/study/NCT01658462,https://clinicaltrials.gov/study/NCT00123929,https://clinicaltrials.gov/study/NCT00155259,https://clinicaltrials.gov/study/NCT00941330,https://clinicaltrials.gov/study/NCT03735966,https://clinicaltrials.gov/study/NCT00066443,https://clinicaltrials.gov/study/NCT00003953,https://clinicaltrials.gov/study/NCT01959490,https://clinicaltrials.gov/study/NCT00428922,https://clinicaltrials.gov/study/NCT02005549,https://clinicaltrials.gov/study/NCT00193050,https://clinicaltrials.gov/study/NCT01142778,https://clinicaltrials.gov/study/NCT00559754,https://clinicaltrials.gov/study/NCT00404066,https://clinicaltrials.gov/study/NCT00015938,https://clinicaltrials.gov/study/NCT00079118,https://clinicaltrials.gov/study/NCT00206505,https://clinicaltrials.gov/study/NCT00044993,https://clinicaltrials.gov/study/NCT01485926,https://clinicaltrials.gov/study/NCT00129376,https://clinicaltrials.gov/study/NCT00214864,https://clinicaltrials.gov/study/NCT00003352,https://clinicaltrials.gov/study/NCT00193089,https://clinicaltrials.gov/study/NCT00203372,https://clinicaltrials.gov/study/NCT02846428,https://clinicaltrials.gov/study/NCT00088998,https://clinicaltrials.gov/study/NCT00645866,https://clinicaltrials.gov/study/NCT00525759,https://clinicaltrials.gov/study/NCT02909751,https://clinicaltrials.gov/study/NCT00712881,https://clinicaltrials.gov/study/NCT00365365,https://clinicaltrials.gov/study/NCT01527487,https://clinicaltrials.gov/study/NCT00209092,https://clinicaltrials.gov/study/NCT00003565,https://clinicaltrials.gov/study/NCT02229084,https://clinicaltrials.gov/study/NCT00004906,https://clinicaltrials.gov/study/NCT00475670,https://clinicaltrials.gov/study/NCT03839823
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT00005614,https://clinicaltrials.gov/study/NCT05809895
MONDO_0007254	breast cancer	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RA	interleukin 2 receptor subunit alpha	2	Terminated	https://clinicaltrials.gov/study/NCT00376805,https://clinicaltrials.gov/study/NCT00784524
MONDO_0007254	breast cancer	CHEMBL2105661	LITRONESIB	Small molecule	Kinesin-like protein 1 inhibitor		KIF11	kinesin family member 11	2	Completed	https://clinicaltrials.gov/study/NCT01416389
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT06026657,https://clinicaltrials.gov/study/NCT03606967
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA3	EPH receptor A3	2	Completed	https://clinicaltrials.gov/study/NCT00494481
MONDO_0007254	breast cancer	CHEMBL2105717	CABOZANTINIB	Small molecule	Hepatocyte growth factor receptor inhibitor		MET	MET proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT03316586,https://clinicaltrials.gov/study/NCT01738438
EFO_0005537	triple-negative breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03639948
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAB1	NADH:ubiquinone oxidoreductase subunit AB1	2	Terminated	https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT01627067
MONDO_0007254	breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT02441946,https://clinicaltrials.gov/study/NCT03703466,https://clinicaltrials.gov/study/NCT02308020,https://clinicaltrials.gov/study/NCT02675231,https://clinicaltrials.gov/study/NCT02102490,https://clinicaltrials.gov/study/NCT02831530
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Suspended	https://clinicaltrials.gov/study/NCT04419181,https://clinicaltrials.gov/study/NCT02897050
EFO_0000305	breast carcinoma	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator	Antagonist	ESR1	estrogen receptor 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05150652,https://clinicaltrials.gov/study/NCT02476786
EFO_0005537	triple-negative breast cancer	CHEMBL2177390	IPATASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT2	AKT serine/threonine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT03853707
MONDO_0007254	breast cancer	CHEMBL2304041	SAGOPILONE	Small molecule	Tubulin stabiliser		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT00288249
EFO_0006861	male breast carcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC6	histone deacetylase 6	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01349959
MONDO_0007254	breast cancer	CHEMBL289228	TIPIFARNIB	Small molecule	Protein farnesyltransferase inhibitor		FNTA	farnesyltransferase, CAAX box, subunit alpha	2	Withdrawn	https://clinicaltrials.gov/study/NCT00054470
MONDO_0007254	breast cancer	CHEMBL3545396	BMS-690514	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT01068704
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND6	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6	2	Terminated	https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT02472353
EFO_0005537	triple-negative breast cancer	CHEMBL3545132	MIRVETUXIMAB SORAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBA1A	tubulin alpha 1a	2	Completed	https://clinicaltrials.gov/study/NCT03106077
MONDO_0003982	bilateral breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT00877500
EFO_0006861	male breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Tyrosine-protein kinase ITK/TSK inhibitor		ITK	IL2 inducible T cell kinase	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
EFO_0006861	male breast carcinoma	CHEMBL415606	DEGARELIX	Protein	Gonadotropin-releasing hormone receptor antagonist		GNRHR	gonadotropin releasing hormone receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT05501704
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA10	EPH receptor A10	2	Completed	https://clinicaltrials.gov/study/NCT00494481
MONDO_0007254	breast cancer	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Terminated	https://clinicaltrials.gov/study/NCT00622466,https://clinicaltrials.gov/study/NCT00573755,https://clinicaltrials.gov/study/NCT00722072
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Terminated	https://clinicaltrials.gov/study/NCT01534455,https://clinicaltrials.gov/study/NCT02681523,https://clinicaltrials.gov/study/NCT01912963,https://clinicaltrials.gov/study/NCT03795012,https://clinicaltrials.gov/study/NCT02000596,https://clinicaltrials.gov/study/NCT01498588
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Recruiting	https://clinicaltrials.gov/study/NCT03497702,https://clinicaltrials.gov/study/NCT04576143,https://clinicaltrials.gov/study/NCT04717531,https://clinicaltrials.gov/study/NCT06107673,https://clinicaltrials.gov/study/NCT03879577,https://clinicaltrials.gov/study/NCT03367676,https://clinicaltrials.gov/study/NCT05900206,https://clinicaltrials.gov/study/NCT04872985,https://clinicaltrials.gov/study/NCT04947189,https://clinicaltrials.gov/study/NCT05638594,https://clinicaltrials.gov/study/NCT05483439,https://clinicaltrials.gov/study/NCT05475678,https://clinicaltrials.gov/study/NCT05426486,https://clinicaltrials.gov/study/NCT05189067,https://clinicaltrials.gov/study/NCT05088057,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT05918328,https://clinicaltrials.gov/study/NCT05645380
EFO_0000305	breast carcinoma	CHEMBL3137336	UPROSERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT3	AKT serine/threonine kinase 3	2	Completed	https://clinicaltrials.gov/study/NCT01964924
EFO_0000305	breast carcinoma	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Unknown status	https://clinicaltrials.gov/study/NCT03144947
EFO_0000305	breast carcinoma	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Terminated	https://clinicaltrials.gov/study/NCT01394211,https://clinicaltrials.gov/study/NCT01776008,https://clinicaltrials.gov/study/NCT00661531
MONDO_0007254	breast cancer	CHEMBL2048484	CANAGLIFLOZIN ANHYDROUS	Small molecule	Sodium/glucose cotransporter 2 inhibitor		SLC5A2	solute carrier family 5 member 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05090358
MONDO_0007254	breast cancer	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02712723,https://clinicaltrials.gov/study/NCT01872260,https://clinicaltrials.gov/study/NCT03944434,https://clinicaltrials.gov/study/NCT02632045,https://clinicaltrials.gov/study/NCT03671330,https://clinicaltrials.gov/study/NCT03822468,https://clinicaltrials.gov/study/NCT05384119
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL554	LAPATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Completed	https://clinicaltrials.gov/study/NCT00684983
EFO_0000186	invasive breast ductal carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02779855
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE6H	phosphodiesterase 6H	2	Recruiting	https://clinicaltrials.gov/study/NCT06087237
EFO_0006861	male breast carcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC7	histone deacetylase 7	2	Completed	https://clinicaltrials.gov/study/NCT00098397
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT00191373
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Recruiting	https://clinicaltrials.gov/study/NCT06042569,https://clinicaltrials.gov/study/NCT05319873,https://clinicaltrials.gov/study/NCT04266249
MONDO_0007254	breast cancer	CHEMBL1201670	SARGRAMOSTIM	Protein	Granulocyte-macrophage colony-stimulating factor receptor agonist		CSF2RA	colony stimulating factor 2 receptor subunit alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03012100
MONDO_0007254	breast cancer	CHEMBL4594611	PATRITUMAB DERUXTECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	2	Recruiting	https://clinicaltrials.gov/study/NCT04965766,https://clinicaltrials.gov/study/NCT06298084,https://clinicaltrials.gov/study/NCT04699630
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01881230
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Terminated	https://clinicaltrials.gov/study/NCT00049660,https://clinicaltrials.gov/study/NCT00088985,https://clinicaltrials.gov/study/NCT03358004,https://clinicaltrials.gov/study/NCT00194792,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT02229149
MONDO_0007254	breast cancer	CHEMBL1289601	LENVATINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Unknown status	https://clinicaltrials.gov/study/NCT03168074
MONDO_0007254	breast cancer	CHEMBL19019	NALTREXONE	Small molecule	Opioid receptors; mu/kappa/delta antagonist		OPRD1	opioid receptor delta 1	2	Terminated	https://clinicaltrials.gov/study/NCT00379197
MONDO_0007254	breast cancer	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01149083
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Withdrawn	https://clinicaltrials.gov/study/NCT03637868,https://clinicaltrials.gov/study/NCT02215876
MONDO_0007254	breast cancer	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_1000984	inflammatory breast carcinoma	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	2	Completed	https://clinicaltrials.gov/study/NCT03872388
MONDO_0007254	breast cancer	CHEMBL52885	ENMD-981693	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT00306631
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02286687
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN3A	sodium voltage-gated channel alpha subunit 3	2	Completed	https://clinicaltrials.gov/study/NCT01204242,https://clinicaltrials.gov/study/NCT02839668
EFO_0005537	triple-negative breast cancer	CHEMBL328190	LASOFOXIFENE	Small molecule	Estrogen receptor modulator	Antagonist	ESR2	estrogen receptor 2	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Withdrawn	https://clinicaltrials.gov/study/NCT05177796
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01105650,https://clinicaltrials.gov/study/NCT00020176,https://clinicaltrials.gov/study/NCT00429572
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAB1	NADH:ubiquinone oxidoreductase subunit AB1	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Recruiting	https://clinicaltrials.gov/study/NCT05601440,https://clinicaltrials.gov/study/NCT06026657,https://clinicaltrials.gov/study/NCT05181462,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT06102824,https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT04739670
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT00005614
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB9	NADH:ubiquinone oxidoreductase subunit B9	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL4297736	PRALUZATAMAB RAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBA3E	tubulin alpha 3e	2	Completed	https://clinicaltrials.gov/study/NCT04596150
EFO_0000304	breast adenocarcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Recruiting	https://clinicaltrials.gov/study/NCT04197687
MONDO_0007254	breast cancer	CHEMBL4297892	ANVATABART OPADOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	2	Recruiting	https://clinicaltrials.gov/study/NCT05426486,https://clinicaltrials.gov/study/NCT04829604,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT05018676,https://clinicaltrials.gov/study/NCT05018702
EFO_0000305	breast carcinoma	CHEMBL3545068	COPANLISIB HYDROCHLORIDE	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03939897
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4L	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL4297892	ANVATABART OPADOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Recruiting	https://clinicaltrials.gov/study/NCT04829604,https://clinicaltrials.gov/study/NCT05426486,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT05018702,https://clinicaltrials.gov/study/NCT05018676
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND5	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5	2	Completed	https://clinicaltrials.gov/study/NCT01885013
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV1	NADH:ubiquinone oxidoreductase core subunit V1	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_1000984	inflammatory breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02623972
EFO_0006861	male breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00095888
EFO_0006318	breast ductal adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Terminated	https://clinicaltrials.gov/study/NCT01891357
MONDO_0007254	breast cancer	CHEMBL300138	ENZASTAURIN	Small molecule	Protein kinase C beta inhibitor		PRKCB	protein kinase C beta	2	Terminated	https://clinicaltrials.gov/study/NCT00437294,https://clinicaltrials.gov/study/NCT00536939
EFO_0005537	triple-negative breast cancer	CHEMBL4297728	CIRMTUZUMAB	Antibody	Inactive tyrosine-protein kinase transmembrane receptor ROR1 inhibitor		ROR1	receptor tyrosine kinase like orphan receptor 1	2	Completed	https://clinicaltrials.gov/study/NCT04504916
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT06027268,https://clinicaltrials.gov/study/NCT03606967
MONDO_0007254	breast cancer	CHEMBL3218576	COPANLISIB	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	2	Withdrawn	https://clinicaltrials.gov/study/NCT03377101
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Withdrawn	https://clinicaltrials.gov/study/NCT02067416,https://clinicaltrials.gov/study/NCT01818999
MONDO_0007254	breast cancer	CHEMBL2105756	TIVOZANIB HYDROCHLORIDE	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01745367
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Recruiting	https://clinicaltrials.gov/study/NCT05426486,https://clinicaltrials.gov/study/NCT05483439,https://clinicaltrials.gov/study/NCT03367676,https://clinicaltrials.gov/study/NCT05645380,https://clinicaltrials.gov/study/NCT06107673,https://clinicaltrials.gov/study/NCT04717531,https://clinicaltrials.gov/study/NCT04576143,https://clinicaltrials.gov/study/NCT05918328,https://clinicaltrials.gov/study/NCT05900206,https://clinicaltrials.gov/study/NCT04872985,https://clinicaltrials.gov/study/NCT03879577,https://clinicaltrials.gov/study/NCT05638594,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT03497702,https://clinicaltrials.gov/study/NCT05088057,https://clinicaltrials.gov/study/NCT05189067,https://clinicaltrials.gov/study/NCT04947189,https://clinicaltrials.gov/study/NCT05475678
MONDO_0007254	breast cancer	CHEMBL3990016	OLECLUMAB	Antibody	5'-nucleotidase inhibitor		NT5E	5'-nucleotidase ecto	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03616886
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS7	NADH:ubiquinone oxidoreductase core subunit S7	2	Terminated	https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT04899349
EFO_0006861	male breast carcinoma	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT00017394
MONDO_0007254	breast cancer	CHEMBL1770916	NIROGACESTAT	Small molecule	Gamma-secretase inhibitor		PSEN1	presenilin 1	2	Withdrawn	https://clinicaltrials.gov/study/NCT02338531
MONDO_0044915	salivary duct carcinoma	CHEMBL1200969	DUTASTERIDE	Small molecule	Steroid 5-alpha-reductase inhibitor		SRD5A3	steroid 5 alpha-reductase 3	2	Recruiting	https://clinicaltrials.gov/study/NCT05513365
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT01097642,https://clinicaltrials.gov/study/NCT01027208,https://clinicaltrials.gov/study/NCT00020904,https://clinicaltrials.gov/study/NCT00627978,https://clinicaltrials.gov/study/NCT00879086,https://clinicaltrials.gov/study/NCT00045097,https://clinicaltrials.gov/study/NCT00080262,https://clinicaltrials.gov/study/NCT00455533,https://clinicaltrials.gov/study/NCT01075100,https://clinicaltrials.gov/study/NCT00866905,https://clinicaltrials.gov/study/NCT00751868,https://clinicaltrials.gov/study/NCT01446016,https://clinicaltrials.gov/study/NCT00821886,https://clinicaltrials.gov/study/NCT00593827,https://clinicaltrials.gov/study/NCT00077376,https://clinicaltrials.gov/study/NCT01019577,https://clinicaltrials.gov/study/NCT00370552,https://clinicaltrials.gov/study/NCT01416389,https://clinicaltrials.gov/study/NCT00633464,https://clinicaltrials.gov/study/NCT00490646
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS6	NADH:ubiquinone oxidoreductase subunit S6	2	Completed	https://clinicaltrials.gov/study/NCT01885013
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT00321633
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Recruiting	https://clinicaltrials.gov/study/NCT05319873,https://clinicaltrials.gov/study/NCT06042569,https://clinicaltrials.gov/study/NCT04266249
EFO_0000305	breast carcinoma	CHEMBL554	LAPATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT01622868,https://clinicaltrials.gov/study/NCT00684983
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Recruiting	https://clinicaltrials.gov/study/NCT04624711,https://clinicaltrials.gov/study/NCT05546255,https://clinicaltrials.gov/study/NCT05530057
MONDO_0007254	breast cancer	CHEMBL2396661	ALPELISIB	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04524000,https://clinicaltrials.gov/study/NCT05090358,https://clinicaltrials.gov/study/NCT01872260,https://clinicaltrials.gov/study/NCT03056755,https://clinicaltrials.gov/study/NCT03284957
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT01019577,https://clinicaltrials.gov/study/NCT00866905,https://clinicaltrials.gov/study/NCT00080262,https://clinicaltrials.gov/study/NCT01097642,https://clinicaltrials.gov/study/NCT01416389,https://clinicaltrials.gov/study/NCT00627978,https://clinicaltrials.gov/study/NCT01027208,https://clinicaltrials.gov/study/NCT00455533,https://clinicaltrials.gov/study/NCT00593827,https://clinicaltrials.gov/study/NCT00490646,https://clinicaltrials.gov/study/NCT00077376,https://clinicaltrials.gov/study/NCT00370552,https://clinicaltrials.gov/study/NCT01446016,https://clinicaltrials.gov/study/NCT00045097,https://clinicaltrials.gov/study/NCT00020904,https://clinicaltrials.gov/study/NCT01075100,https://clinicaltrials.gov/study/NCT00633464,https://clinicaltrials.gov/study/NCT00751868,https://clinicaltrials.gov/study/NCT00879086,https://clinicaltrials.gov/study/NCT00821886
EFO_0000305	breast carcinoma	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05150652,https://clinicaltrials.gov/study/NCT02778685,https://clinicaltrials.gov/study/NCT05447910
EFO_0000304	breast adenocarcinoma	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01730833
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT01908101
EFO_0000305	breast carcinoma	CHEMBL3187723	BINIMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 2 inhibitor		MAP2K2	mitogen-activated protein kinase kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT03971409,https://clinicaltrials.gov/study/NCT05554354
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Recruiting	https://clinicaltrials.gov/study/NCT04090398,https://clinicaltrials.gov/study/NCT03606967,https://clinicaltrials.gov/study/NCT04266249
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT02413320,https://clinicaltrials.gov/study/NCT03853707,https://clinicaltrials.gov/study/NCT03057600,https://clinicaltrials.gov/study/NCT01818063,https://clinicaltrials.gov/study/NCT02689427,https://clinicaltrials.gov/study/NCT01881230,https://clinicaltrials.gov/study/NCT00733408
EFO_0006861	male breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Unknown status	https://clinicaltrials.gov/study/NCT01372579
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT03530696
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Recruiting	https://clinicaltrials.gov/study/NCT05570253,https://clinicaltrials.gov/study/NCT05402722
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT01194869,https://clinicaltrials.gov/study/NCT00622466,https://clinicaltrials.gov/study/NCT00573755,https://clinicaltrials.gov/study/NCT00607438,https://clinicaltrials.gov/study/NCT00632541,https://clinicaltrials.gov/study/NCT02624700,https://clinicaltrials.gov/study/NCT00525161,https://clinicaltrials.gov/study/NCT00722072
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT03530696
EFO_0005537	triple-negative breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03639948
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00376805,https://clinicaltrials.gov/study/NCT00074269
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC5	histone deacetylase 5	2	Withdrawn	https://clinicaltrials.gov/study/NCT02115594
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB2	NADH:ubiquinone oxidoreductase subunit B2	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC2	NADH:ubiquinone oxidoreductase subunit C2	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT04559308,https://clinicaltrials.gov/study/NCT03238495
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT02481050,https://clinicaltrials.gov/study/NCT00965523,https://clinicaltrials.gov/study/NCT01269346,https://clinicaltrials.gov/study/NCT00879086,https://clinicaltrials.gov/study/NCT03051659,https://clinicaltrials.gov/study/NCT05206656,https://clinicaltrials.gov/study/NCT01908101,https://clinicaltrials.gov/study/NCT01268150,https://clinicaltrials.gov/study/NCT00246090,https://clinicaltrials.gov/study/NCT01439282
MONDO_0007254	breast cancer	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05501704,https://clinicaltrials.gov/study/NCT05467891,https://clinicaltrials.gov/study/NCT05190094,https://clinicaltrials.gov/study/NCT05472792,https://clinicaltrials.gov/study/NCT04985266,https://clinicaltrials.gov/study/NCT05411380,https://clinicaltrials.gov/study/NCT04886531,https://clinicaltrials.gov/study/NCT05524584,https://clinicaltrials.gov/study/NCT05150652,https://clinicaltrials.gov/study/NCT02476786,https://clinicaltrials.gov/study/NCT06086704,https://clinicaltrials.gov/study/NCT05896566
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Unknown status	https://clinicaltrials.gov/study/NCT02175446,https://clinicaltrials.gov/study/NCT03412955
EFO_0000305	breast carcinoma	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02971748
MONDO_0007254	breast cancer	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	2	Recruiting	https://clinicaltrials.gov/study/NCT05573555,https://clinicaltrials.gov/study/NCT05900206,https://clinicaltrials.gov/study/NCT05296746,https://clinicaltrials.gov/study/NCT05625087,https://clinicaltrials.gov/study/NCT05563220,https://clinicaltrials.gov/study/NCT03090165,https://clinicaltrials.gov/study/NCT05664893,https://clinicaltrials.gov/study/NCT04802759,https://clinicaltrials.gov/study/NCT03285412,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT05467891,https://clinicaltrials.gov/study/NCT05816655,https://clinicaltrials.gov/study/NCT05766410
MONDO_0007254	breast cancer	CHEMBL1908360	EVEROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	2	Completed	https://clinicaltrials.gov/study/NCT01305941,https://clinicaltrials.gov/study/NCT03312738,https://clinicaltrials.gov/study/NCT01931163,https://clinicaltrials.gov/study/NCT00912340,https://clinicaltrials.gov/study/NCT01698918,https://clinicaltrials.gov/study/NCT01127763,https://clinicaltrials.gov/study/NCT00915603,https://clinicaltrials.gov/study/NCT02742051,https://clinicaltrials.gov/study/NCT01520103,https://clinicaltrials.gov/study/NCT02028364,https://clinicaltrials.gov/study/NCT02069093,https://clinicaltrials.gov/study/NCT02344550,https://clinicaltrials.gov/study/NCT00930930,https://clinicaltrials.gov/study/NCT00570921,https://clinicaltrials.gov/study/NCT01797120,https://clinicaltrials.gov/study/NCT02520063,https://clinicaltrials.gov/study/NCT02291913,https://clinicaltrials.gov/study/NCT02387099,https://clinicaltrials.gov/study/NCT01783444,https://clinicaltrials.gov/study/NCT00255788
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT00027989,https://clinicaltrials.gov/study/NCT02544243,https://clinicaltrials.gov/study/NCT02341911,https://clinicaltrials.gov/study/NCT03423849,https://clinicaltrials.gov/study/NCT01352494
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV3	NADH:ubiquinone oxidoreductase subunit V3	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS8	NADH:ubiquinone oxidoreductase core subunit S8	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT00431704,https://clinicaltrials.gov/study/NCT03414658,https://clinicaltrials.gov/study/NCT04262804
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00674206,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT00679029,https://clinicaltrials.gov/study/NCT00462865,https://clinicaltrials.gov/study/NCT00095888,https://clinicaltrials.gov/study/NCT00470249,https://clinicaltrials.gov/study/NCT00323063,https://clinicaltrials.gov/study/NCT00159458,https://clinicaltrials.gov/study/NCT02213744,https://clinicaltrials.gov/study/NCT00532285,https://clinicaltrials.gov/study/NCT03674242
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND6	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02568839,https://clinicaltrials.gov/study/NCT04001829
EFO_0000305	breast carcinoma	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist	Antagonist	ESR2	estrogen receptor 2	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06179303
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND2	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Recruiting	https://clinicaltrials.gov/study/NCT04796324
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967,https://clinicaltrials.gov/study/NCT04138719,https://clinicaltrials.gov/study/NCT05192798,https://clinicaltrials.gov/study/NCT05227664,https://clinicaltrials.gov/study/NCT05834582,https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL180022	NERATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-4 inhibitor		ERBB4	erb-b2 receptor tyrosine kinase 4	2	Recruiting	https://clinicaltrials.gov/study/NCT05388149,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT05933395,https://clinicaltrials.gov/study/NCT03182634,https://clinicaltrials.gov/study/NCT04965064,https://clinicaltrials.gov/study/NCT04886531,https://clinicaltrials.gov/study/NCT05243641
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT03530696
EFO_0006861	male breast carcinoma	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT00017394
EFO_0006861	male breast carcinoma	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT00017394
EFO_0005537	triple-negative breast cancer	CHEMBL4297844	TRASTUZUMAB DERUXTECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05953168
MONDO_0007254	breast cancer	CHEMBL3989868	TUCATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Withdrawn	https://clinicaltrials.gov/study/NCT05227131
MONDO_0007254	breast cancer	CHEMBL468	THALIDOMIDE	Small molecule	CRL4(CRBN) E3 ubiquitin ligase inhibitor		CRBN	cereblon	2	Terminated	https://clinicaltrials.gov/study/NCT00193102
EFO_1000984	inflammatory breast carcinoma	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Terminated	https://clinicaltrials.gov/study/NCT03184558
MONDO_0007254	breast cancer	CHEMBL1200501	GOSERELIN ACETATE	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	2	Completed	https://clinicaltrials.gov/study/NCT00010010,https://clinicaltrials.gov/study/NCT00303524,https://clinicaltrials.gov/study/NCT00322348
MONDO_0007254	breast cancer	CHEMBL154	NAPROXEN	Small molecule	Cyclooxygenase inhibitor		PTGS1	prostaglandin-endoperoxide synthase 1	2	Completed	https://clinicaltrials.gov/study/NCT01712009
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist	Antagonist	ESR1	estrogen receptor 1	2	Terminated	https://clinicaltrials.gov/study/NCT03430466,https://clinicaltrials.gov/study/NCT03322215,https://clinicaltrials.gov/study/NCT02000596,https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT04862143,https://clinicaltrials.gov/study/NCT05085002,https://clinicaltrials.gov/study/NCT01528345,https://clinicaltrials.gov/study/NCT03289039,https://clinicaltrials.gov/study/NCT03241810,https://clinicaltrials.gov/study/NCT00206414,https://clinicaltrials.gov/study/NCT03584009,https://clinicaltrials.gov/study/NCT02269670,https://clinicaltrials.gov/study/NCT00752986,https://clinicaltrials.gov/study/NCT00722072,https://clinicaltrials.gov/study/NCT02569801,https://clinicaltrials.gov/study/NCT00570258,https://clinicaltrials.gov/study/NCT00138125
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT00006007,https://clinicaltrials.gov/study/NCT00662129,https://clinicaltrials.gov/study/NCT00005991,https://clinicaltrials.gov/study/NCT00003540,https://clinicaltrials.gov/study/NCT00002998,https://clinicaltrials.gov/study/NCT00059852
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02764541,https://clinicaltrials.gov/study/NCT02624973,https://clinicaltrials.gov/study/NCT02738866,https://clinicaltrials.gov/study/NCT02605486,https://clinicaltrials.gov/study/NCT05384119,https://clinicaltrials.gov/study/NCT03573648,https://clinicaltrials.gov/study/NCT04224272,https://clinicaltrials.gov/study/NCT03284957,https://clinicaltrials.gov/study/NCT02668666,https://clinicaltrials.gov/study/NCT03633331,https://clinicaltrials.gov/study/NCT03147287,https://clinicaltrials.gov/study/NCT03609047
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R5	phosphoinositide-3-kinase regulatory subunit 5	2	Completed	https://clinicaltrials.gov/study/NCT02404844,https://clinicaltrials.gov/study/NCT01923168,https://clinicaltrials.gov/study/NCT01629615,https://clinicaltrials.gov/study/NCT01790932,https://clinicaltrials.gov/study/NCT01816594,https://clinicaltrials.gov/study/NCT01572727
EFO_0005537	triple-negative breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04683679,https://clinicaltrials.gov/study/NCT03801369
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03567720,https://clinicaltrials.gov/study/NCT02252887,https://clinicaltrials.gov/study/NCT01815242,https://clinicaltrials.gov/study/NCT04297267,https://clinicaltrials.gov/study/NCT04262804
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS8	NADH:ubiquinone oxidoreductase core subunit S8	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT00194779,https://clinicaltrials.gov/study/NCT00532623,https://clinicaltrials.gov/study/NCT00266110,https://clinicaltrials.gov/study/NCT00148681,https://clinicaltrials.gov/study/NCT00022152,https://clinicaltrials.gov/study/NCT00148668,https://clinicaltrials.gov/study/NCT00006682,https://clinicaltrials.gov/study/NCT00093808,https://clinicaltrials.gov/study/NCT00004237,https://clinicaltrials.gov/study/NCT01941771
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT02689427,https://clinicaltrials.gov/study/NCT00733408,https://clinicaltrials.gov/study/NCT03057600,https://clinicaltrials.gov/study/NCT01881230,https://clinicaltrials.gov/study/NCT03853707,https://clinicaltrials.gov/study/NCT01818063,https://clinicaltrials.gov/study/NCT02413320
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4	NDUFA4 mitochondrial complex associated	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0006861	male breast carcinoma	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 6 inhibitor		HDAC6	histone deacetylase 6	2	Terminated	https://clinicaltrials.gov/study/NCT00132002
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA7	NADH:ubiquinone oxidoreductase subunit A7	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1086218	VALSPODAR	Protein	P-glycoprotein 1 inhibitor		ABCB1	ATP binding cassette subfamily B member 1	2	Completed	https://clinicaltrials.gov/study/NCT00002937,https://clinicaltrials.gov/study/NCT00002826
MONDO_0007254	breast cancer	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Fibroblast growth factor receptor 1 inhibitor		FGFR1	fibroblast growth factor receptor 1	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01471106
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4L2	NDUFA4 mitochondrial complex associated like 2	2	Terminated	https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT02472353
EFO_0005537	triple-negative breast cancer	CHEMBL3137336	UPROSERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT1	AKT serine/threonine kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT01964924
EFO_1000984	inflammatory breast carcinoma	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator	Antagonist	ESR1	estrogen receptor 1	2	Completed	https://clinicaltrials.gov/study/NCT00003199
MONDO_0007254	breast cancer	CHEMBL180022	NERATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Terminated	https://clinicaltrials.gov/study/NCT04460430,https://clinicaltrials.gov/study/NCT03289039
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC8	histone deacetylase 8	2	Withdrawn	https://clinicaltrials.gov/study/NCT02115594
MONDO_0007254	breast cancer	CHEMBL4297828	SHR-1316	Unknown	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06229067,https://clinicaltrials.gov/study/NCT04303988
MONDO_0007254	breast cancer	CHEMBL572881	MOTESANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Terminated	https://clinicaltrials.gov/study/NCT00356681
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE1C	phosphodiesterase 1C	2	Recruiting	https://clinicaltrials.gov/study/NCT06087237
MONDO_0007254	breast cancer	CHEMBL3218576	COPANLISIB	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03939897
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT00006261
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	2	Terminated	https://clinicaltrials.gov/study/NCT03367689
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT02628613,https://clinicaltrials.gov/study/NCT00004237,https://clinicaltrials.gov/study/NCT00093808,https://clinicaltrials.gov/study/NCT03007992,https://clinicaltrials.gov/study/NCT00022152,https://clinicaltrials.gov/study/NCT02954055,https://clinicaltrials.gov/study/NCT00041067,https://clinicaltrials.gov/study/NCT01242449,https://clinicaltrials.gov/study/NCT00194779,https://clinicaltrials.gov/study/NCT01305941,https://clinicaltrials.gov/study/NCT02362958,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00532623,https://clinicaltrials.gov/study/NCT00006682,https://clinicaltrials.gov/study/NCT00193089,https://clinicaltrials.gov/study/NCT01439191,https://clinicaltrials.gov/study/NCT00192062,https://clinicaltrials.gov/study/NCT03887130,https://clinicaltrials.gov/study/NCT00148681,https://clinicaltrials.gov/study/NCT00401427,https://clinicaltrials.gov/study/NCT01941771,https://clinicaltrials.gov/study/NCT03254654,https://clinicaltrials.gov/study/NCT03321981,https://clinicaltrials.gov/study/NCT00670982,https://clinicaltrials.gov/study/NCT00503750,https://clinicaltrials.gov/study/NCT00148668,https://clinicaltrials.gov/study/NCT00325234,https://clinicaltrials.gov/study/NCT04903652,https://clinicaltrials.gov/study/NCT01520103,https://clinicaltrials.gov/study/NCT01565083,https://clinicaltrials.gov/study/NCT00480597,https://clinicaltrials.gov/study/NCT00015938,https://clinicaltrials.gov/study/NCT01835236,https://clinicaltrials.gov/study/NCT00266110
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Terminated	https://clinicaltrials.gov/study/NCT03367689
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Terminated	https://clinicaltrials.gov/study/NCT00481845,https://clinicaltrials.gov/study/NCT00752986,https://clinicaltrials.gov/study/NCT01934335
EFO_0000305	breast carcinoma	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator	Antagonist	ESR1	estrogen receptor 1	2	Recruiting	https://clinicaltrials.gov/study/NCT02476786,https://clinicaltrials.gov/study/NCT05150652
MONDO_0007254	breast cancer	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator	Antagonist	ESR1	estrogen receptor 1	2	Unknown status	https://clinicaltrials.gov/study/NCT03211572,https://clinicaltrials.gov/study/NCT02132000,https://clinicaltrials.gov/study/NCT00033683,https://clinicaltrials.gov/study/NCT00077168,https://clinicaltrials.gov/study/NCT00398489
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA5	NADH:ubiquinone oxidoreductase subunit A5	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL306823	SODIUM DICHLOROACETATE	Small molecule	Pyruvate dehydrogenase kinase inhibitor		PDK4	pyruvate dehydrogenase kinase 4	2	Terminated	https://clinicaltrials.gov/study/NCT01029925
EFO_0005537	triple-negative breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT03932526
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Withdrawn	https://clinicaltrials.gov/study/NCT04351230
EFO_0005537	triple-negative breast cancer	CHEMBL3707324	UTOMILUMAB	Antibody	Tumor necrosis factor receptor superfamily member 9 agonist		TNFRSF9	TNF receptor superfamily member 9	2	Recruiting	https://clinicaltrials.gov/study/NCT03971409
MONDO_0007254	breast cancer	CHEMBL1230314	ESTETROL	Small molecule	Estrogen receptor agonist	Antagonist	ESR2	estrogen receptor 2	2	Completed	https://clinicaltrials.gov/study/NCT00464516
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB4	NADH:ubiquinone oxidoreductase subunit B4	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS5	NADH:ubiquinone oxidoreductase subunit S5	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB2	NADH:ubiquinone oxidoreductase subunit B2	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Recruiting	https://clinicaltrials.gov/study/NCT05383196,https://clinicaltrials.gov/study/NCT03515798
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	2	Suspended	https://clinicaltrials.gov/study/NCT04419181,https://clinicaltrials.gov/study/NCT04675827
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Withdrawn	https://clinicaltrials.gov/study/NCT00450515
EFO_0005537	triple-negative breast cancer	CHEMBL4298101	LADIRATUZUMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	2	Completed	https://clinicaltrials.gov/study/NCT02273973
MONDO_0007254	breast cancer	CHEMBL554	LAPATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Completed	https://clinicaltrials.gov/study/NCT02073487,https://clinicaltrials.gov/study/NCT02362958,https://clinicaltrials.gov/study/NCT00769470,https://clinicaltrials.gov/study/NCT00967031,https://clinicaltrials.gov/study/NCT00721630,https://clinicaltrials.gov/study/NCT00777101,https://clinicaltrials.gov/study/NCT00820872,https://clinicaltrials.gov/study/NCT00299286,https://clinicaltrials.gov/study/NCT01275859,https://clinicaltrials.gov/study/NCT00404066,https://clinicaltrials.gov/study/NCT02338245,https://clinicaltrials.gov/study/NCT01622868,https://clinicaltrials.gov/study/NCT00482391,https://clinicaltrials.gov/study/NCT01068704,https://clinicaltrials.gov/study/NCT00548184,https://clinicaltrials.gov/study/NCT01688609,https://clinicaltrials.gov/study/NCT01138384,https://clinicaltrials.gov/study/NCT00477464,https://clinicaltrials.gov/study/NCT01973660,https://clinicaltrials.gov/study/NCT00436566,https://clinicaltrials.gov/study/NCT01485926,https://clinicaltrials.gov/study/NCT00206427,https://clinicaltrials.gov/study/NCT00694252,https://clinicaltrials.gov/study/NCT00044330,https://clinicaltrials.gov/study/NCT01827163,https://clinicaltrials.gov/study/NCT01262469,https://clinicaltrials.gov/study/NCT00841828
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Suspended	https://clinicaltrials.gov/study/NCT04419181,https://clinicaltrials.gov/study/NCT04675827
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Recruiting	https://clinicaltrials.gov/study/NCT05546255,https://clinicaltrials.gov/study/NCT05530057,https://clinicaltrials.gov/study/NCT04624711
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Withdrawn	https://clinicaltrials.gov/study/NCT00005614
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Unknown status	https://clinicaltrials.gov/study/NCT03144947
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Recruiting	https://clinicaltrials.gov/study/NCT04924699
MONDO_0007254	breast cancer	CHEMBL2108568	TREBANANIB	Protein	Angiopoietin-1 inhibitor		ANGPT1	angiopoietin 1	2	Completed	https://clinicaltrials.gov/study/NCT00511459
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Withdrawn	https://clinicaltrials.gov/study/NCT00005614
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Unknown status	https://clinicaltrials.gov/study/NCT02685657,https://clinicaltrials.gov/study/NCT00669773,https://clinicaltrials.gov/study/NCT00003066,https://clinicaltrials.gov/study/NCT01526499,https://clinicaltrials.gov/study/NCT01351597,https://clinicaltrials.gov/study/NCT00006120,https://clinicaltrials.gov/study/NCT00012311,https://clinicaltrials.gov/study/NCT02144194,https://clinicaltrials.gov/study/NCT01270373,https://clinicaltrials.gov/study/NCT03876587,https://clinicaltrials.gov/study/NCT00398489,https://clinicaltrials.gov/study/NCT00957125,https://clinicaltrials.gov/study/NCT00250874,https://clinicaltrials.gov/study/NCT01939054,https://clinicaltrials.gov/study/NCT00033683,https://clinicaltrials.gov/study/NCT01907529,https://clinicaltrials.gov/study/NCT03147963,https://clinicaltrials.gov/study/NCT00721747,https://clinicaltrials.gov/study/NCT01352494,https://clinicaltrials.gov/study/NCT02947061,https://clinicaltrials.gov/study/NCT00026078,https://clinicaltrials.gov/study/NCT00801411,https://clinicaltrials.gov/study/NCT00994968
EFO_0005537	triple-negative breast cancer	CHEMBL2103875	TRAMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor		MAP2K2	mitogen-activated protein kinase kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT01964924
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA10	NADH:ubiquinone oxidoreductase subunit A10	2	Completed	https://clinicaltrials.gov/study/NCT01885013
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Terminated	https://clinicaltrials.gov/study/NCT00832338
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04345913
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02654119
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01881230
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03414658,https://clinicaltrials.gov/study/NCT04262804,https://clinicaltrials.gov/study/NCT00431704
MONDO_0007254	breast cancer	CHEMBL572881	MOTESANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	2	Terminated	https://clinicaltrials.gov/study/NCT00356681
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor		GPD2	glycerol-3-phosphate dehydrogenase 2	2	Completed	https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT02488564
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT05583110,https://clinicaltrials.gov/study/NCT03368729
EFO_0000304	breast adenocarcinoma	CHEMBL1201670	SARGRAMOSTIM	Protein	Granulocyte-macrophage colony-stimulating factor receptor agonist		CSF2RA	colony stimulating factor 2 receptor subunit alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT04197687
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND6	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6	2	Completed	https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT04143282
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06202313,https://clinicaltrials.gov/study/NCT04913571,https://clinicaltrials.gov/study/NCT04502680,https://clinicaltrials.gov/study/NCT06308939,https://clinicaltrials.gov/study/NCT05263882,https://clinicaltrials.gov/study/NCT04517292
EFO_0006861	male breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Fibroblast growth factor receptor 1 inhibitor		FGFR1	fibroblast growth factor receptor 1	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC1	NADH:ubiquinone oxidoreductase subunit C1	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL4297190	SURUFATINIB	Small molecule	Fibroblast growth factor receptor 1 inhibitor		FGFR1	fibroblast growth factor receptor 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05186545
EFO_0005537	triple-negative breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		HCK	HCK proto-oncogene, Src family tyrosine kinase	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06355037
MONDO_0007254	breast cancer	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Completed	https://clinicaltrials.gov/study/NCT00509587
MONDO_0007254	breast cancer	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Withdrawn	https://clinicaltrials.gov/study/NCT04220476,https://clinicaltrials.gov/study/NCT01013506,https://clinicaltrials.gov/study/NCT03058939,https://clinicaltrials.gov/study/NCT00935558
EFO_0000304	breast adenocarcinoma	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05447910
EFO_0000305	breast carcinoma	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FGR	FGR proto-oncogene, Src family tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT05198843
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Recruiting	https://clinicaltrials.gov/study/NCT04266249,https://clinicaltrials.gov/study/NCT05319873,https://clinicaltrials.gov/study/NCT06042569
MONDO_0007254	breast cancer	CHEMBL1064	SIMVASTATIN	Small molecule	HMG-CoA reductase inhibitor		HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase	2	Unknown status	https://clinicaltrials.gov/study/NCT00807950,https://clinicaltrials.gov/study/NCT03192293
MONDO_0007254	breast cancer	CHEMBL1738	DEXRAZOXANE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	2	Terminated	https://clinicaltrials.gov/study/NCT00955890
MONDO_0007254	breast cancer	CHEMBL2107818	ALDOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03387085
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA11	NADH:ubiquinone oxidoreductase subunit A11	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1642	IMATINIB MESYLATE	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT00338728,https://clinicaltrials.gov/study/NCT00087152
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Terminated	https://clinicaltrials.gov/study/NCT00074269,https://clinicaltrials.gov/study/NCT00376805
EFO_0000305	breast carcinoma	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03939897
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC9	histone deacetylase 9	2	Completed	https://clinicaltrials.gov/study/NCT00777049
MONDO_0007254	breast cancer	CHEMBL522892	DOVITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT00958971,https://clinicaltrials.gov/study/NCT01262027
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT00005614,https://clinicaltrials.gov/study/NCT05809895
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA2	NADH:ubiquinone oxidoreductase subunit A2	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1201199	LEUPROLIDE	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT02592746
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05833919
EFO_0000305	breast carcinoma	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	2	Withdrawn	https://clinicaltrials.gov/study/NCT04351230
MONDO_0007254	breast cancer	CHEMBL46740	BAZEDOXIFENE	Small molecule	Estrogen receptor modulator	Antagonist	ESR1	estrogen receptor 1	2	Recruiting	https://clinicaltrials.gov/study/NCT04821141
MONDO_0007254	breast cancer	CHEMBL1173655	AFATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT02511847
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA1	NADH:ubiquinone oxidoreductase subunit A1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
MONDO_0007254	breast cancer	CHEMBL1200694	SEVOFLURANE	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRP	gamma-aminobutyric acid type A receptor subunit pi	2	Completed	https://clinicaltrials.gov/study/NCT02839668
MONDO_0007254	breast cancer	CHEMBL4297892	ANVATABART OPADOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Recruiting	https://clinicaltrials.gov/study/NCT05018702,https://clinicaltrials.gov/study/NCT04829604,https://clinicaltrials.gov/study/NCT05426486,https://clinicaltrials.gov/study/NCT05018676,https://clinicaltrials.gov/study/NCT01042379
EFO_0005537	triple-negative breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC2	histone deacetylase 2	2	Terminated	https://clinicaltrials.gov/study/NCT01234532
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT01908101
EFO_0000305	breast carcinoma	CHEMBL491473	CEDIRANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Recruiting	https://clinicaltrials.gov/study/NCT04090567
MONDO_0007254	breast cancer	CHEMBL1064	SIMVASTATIN	Small molecule	HMG-CoA reductase inhibitor		HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase	2	Completed	https://clinicaltrials.gov/study/NCT00354640,https://clinicaltrials.gov/study/NCT00334542,https://clinicaltrials.gov/study/NCT03454529,https://clinicaltrials.gov/study/NCT01500577
MONDO_0007254	breast cancer	CHEMBL1743022	FRESOLIMUMAB	Antibody	Transforming growth factor beta-2 inhibitor		TGFB2	transforming growth factor beta 2	2	Completed	https://clinicaltrials.gov/study/NCT01401062
MONDO_0007254	breast cancer	CHEMBL4279455	LAROTAXEL	Small molecule	Tubulin stabiliser		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT00087958,https://clinicaltrials.gov/study/NCT00387907
EFO_0006861	male breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT00077376
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB10	NADH:ubiquinone oxidoreductase subunit B10	2	Completed	https://clinicaltrials.gov/study/NCT01885013
EFO_0000305	breast carcinoma	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	2	Terminated	https://clinicaltrials.gov/study/NCT02774681,https://clinicaltrials.gov/study/NCT02907918
MONDO_0007254	breast cancer	CHEMBL3894860	TRILACICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05113966
EFO_0006861	male breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF1	NADH:ubiquinone oxidoreductase complex assembly factor 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA1	EPH receptor A1	2	Terminated	https://clinicaltrials.gov/study/NCT01934335,https://clinicaltrials.gov/study/NCT00481845,https://clinicaltrials.gov/study/NCT00752986
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06078384
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Unknown status	https://clinicaltrials.gov/study/NCT03144947
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		HCK	HCK proto-oncogene, Src family tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT05198843,https://clinicaltrials.gov/study/NCT00817531,https://clinicaltrials.gov/study/NCT00780676
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB2	NADH:ubiquinone oxidoreductase subunit B2	2	Completed	https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT02488564
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Unknown status	https://clinicaltrials.gov/study/NCT03412955
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA1	EPH receptor A1	2	Completed	https://clinicaltrials.gov/study/NCT00494481
EFO_0006861	male breast carcinoma	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		NCSTN	nicastrin	2	Terminated	https://clinicaltrials.gov/study/NCT01151449
MONDO_0007254	breast cancer	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator	Antagonist	ESR1	estrogen receptor 1	2	Unknown status	https://clinicaltrials.gov/study/NCT03211572,https://clinicaltrials.gov/study/NCT00077168,https://clinicaltrials.gov/study/NCT00398489,https://clinicaltrials.gov/study/NCT02132000,https://clinicaltrials.gov/study/NCT00033683
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Recruiting	https://clinicaltrials.gov/study/NCT04796324
MONDO_0007254	breast cancer	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04819243
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Terminated	https://clinicaltrials.gov/study/NCT00074269,https://clinicaltrials.gov/study/NCT00376805
MONDO_0007254	breast cancer	CHEMBL225072	PEMETREXED	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	2	Terminated	https://clinicaltrials.gov/study/NCT02624700
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Terminated	https://clinicaltrials.gov/study/NCT02000596,https://clinicaltrials.gov/study/NCT03795012,https://clinicaltrials.gov/study/NCT01498588,https://clinicaltrials.gov/study/NCT01912963,https://clinicaltrials.gov/study/NCT01534455,https://clinicaltrials.gov/study/NCT02681523
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	2	Completed	https://clinicaltrials.gov/study/NCT02273973
MONDO_0007254	breast cancer	CHEMBL1742991	BENRALIZUMAB	Antibody	Interleukin-5 receptor subunit alpha inhibitor		IL5RA	interleukin 5 receptor subunit alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT05966584
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND3	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3	2	Completed	https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT01310231
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Suspended	https://clinicaltrials.gov/study/NCT04419181,https://clinicaltrials.gov/study/NCT04675827
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02654119
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05041101
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC8	histone deacetylase 8	2	Completed	https://clinicaltrials.gov/study/NCT00676663,https://clinicaltrials.gov/study/NCT02708680,https://clinicaltrials.gov/study/NCT00828854,https://clinicaltrials.gov/study/NCT03291886
MONDO_0007254	breast cancer	CHEMBL3813842	PAXALISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	2	Recruiting	https://clinicaltrials.gov/study/NCT03765983
MONDO_0007254	breast cancer	CHEMBL1201179	LAPATINIB DITOSYLATE	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Terminated	https://clinicaltrials.gov/study/NCT00499681,https://clinicaltrials.gov/study/NCT01873833
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Recruiting	https://clinicaltrials.gov/study/NCT05020860,https://clinicaltrials.gov/study/NCT04780347,https://clinicaltrials.gov/study/NCT04425018,https://clinicaltrials.gov/study/NCT05189067,https://clinicaltrials.gov/study/NCT03907800,https://clinicaltrials.gov/study/NCT04443348,https://clinicaltrials.gov/study/NCT04893109,https://clinicaltrials.gov/study/NCT05068141,https://clinicaltrials.gov/study/NCT04771871,https://clinicaltrials.gov/study/NCT05174832,https://clinicaltrials.gov/study/NCT05346107,https://clinicaltrials.gov/study/NCT04576143,https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT03150576,https://clinicaltrials.gov/study/NCT05325632,https://clinicaltrials.gov/study/NCT05383196,https://clinicaltrials.gov/study/NCT04722718,https://clinicaltrials.gov/study/NCT04877821,https://clinicaltrials.gov/study/NCT06245889,https://clinicaltrials.gov/study/NCT05889390,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT05633914,https://clinicaltrials.gov/study/NCT05728268,https://clinicaltrials.gov/study/NCT04355858,https://clinicaltrials.gov/study/NCT04159142,https://clinicaltrials.gov/study/NCT03412643,https://clinicaltrials.gov/study/NCT04329065,https://clinicaltrials.gov/study/NCT05852691,https://clinicaltrials.gov/study/NCT04243616,https://clinicaltrials.gov/study/NCT05659056,https://clinicaltrials.gov/study/NCT01817452,https://clinicaltrials.gov/study/NCT05749016,https://clinicaltrials.gov/study/NCT05447702,https://clinicaltrials.gov/study/NCT05353361,https://clinicaltrials.gov/study/NCT04676997,https://clinicaltrials.gov/study/NCT05900206,https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT03571633,https://clinicaltrials.gov/study/NCT05582538,https://clinicaltrials.gov/study/NCT05681728,https://clinicaltrials.gov/study/NCT04917900,https://clinicaltrials.gov/study/NCT05918328,https://clinicaltrials.gov/study/NCT05749575,https://clinicaltrials.gov/study/NCT05761470,https://clinicaltrials.gov/study/NCT04872985,https://clinicaltrials.gov/study/NCT04537286,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04090398,https://clinicaltrials.gov/study/NCT05629429,https://clinicaltrials.gov/study/NCT03048942
MONDO_0007254	breast cancer	CHEMBL3813842	PAXALISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	2	Recruiting	https://clinicaltrials.gov/study/NCT03765983
MONDO_0007254	breast cancer	CHEMBL77305	RUBITECAN	Small molecule	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	2	Completed	https://clinicaltrials.gov/study/NCT00005873
EFO_0000305	breast carcinoma	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02849496
MONDO_0007254	breast cancer	CHEMBL3647420	PYROTINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Completed	https://clinicaltrials.gov/study/NCT03735966,https://clinicaltrials.gov/study/NCT04903652
MONDO_0007254	breast cancer	CHEMBL554	LAPATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT00999804,https://clinicaltrials.gov/study/NCT00470704
EFO_0000305	breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967
EFO_0005537	triple-negative breast cancer	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Completed	https://clinicaltrials.gov/study/NCT01818063,https://clinicaltrials.gov/study/NCT01306032
EFO_0006861	male breast carcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC10	histone deacetylase 10	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01349959
MONDO_0007254	breast cancer	CHEMBL180022	NERATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05154396
EFO_0006861	male breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Unknown status	https://clinicaltrials.gov/study/NCT01372579
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Recruiting	https://clinicaltrials.gov/study/NCT05583110
EFO_1000984	inflammatory breast carcinoma	CHEMBL3809489	BEMCENTINIB	Small molecule	Tyrosine-protein kinase receptor UFO inhibitor		AXL	AXL receptor tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT03184558
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	2	Recruiting	https://clinicaltrials.gov/study/NCT03698383
MONDO_0007254	breast cancer	CHEMBL941	IMATINIB	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	2	Terminated	https://clinicaltrials.gov/study/NCT00323063
EFO_0000304	breast adenocarcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Recruiting	https://clinicaltrials.gov/study/NCT04197687
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT01908101
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB11	NADH:ubiquinone oxidoreductase subunit B11	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL480	LANSOPRAZOLE	Small molecule	Potassium-transporting ATPase inhibitor		ATP4A	ATPase H+/K+ transporting subunit alpha	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04188119
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT01091428,https://clinicaltrials.gov/study/NCT00542451
MONDO_0007254	breast cancer	CHEMBL1201748	CABAZITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Recruiting	https://clinicaltrials.gov/study/NCT03048942
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA6	EPH receptor A6	2	Terminated	https://clinicaltrials.gov/study/NCT00752986,https://clinicaltrials.gov/study/NCT01934335,https://clinicaltrials.gov/study/NCT00481845
MONDO_0007254	breast cancer	CHEMBL1201649	ESTROGENS, CONJUGATED	Unknown	Estrogen receptor agonist	Antagonist	ESR1	estrogen receptor 1	2	Withdrawn	https://clinicaltrials.gov/study/NCT05079360
MONDO_0007254	breast cancer	CHEMBL76222	REBIMASTAT	Small molecule	Matrix metalloproteinase 9 inhibitor		MMP9	matrix metallopeptidase 9	2	Terminated	https://clinicaltrials.gov/study/NCT00036621
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA6	NADH:ubiquinone oxidoreductase subunit A6	2	Unknown status	https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT02506777,https://clinicaltrials.gov/study/NCT03192293
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Recruiting	https://clinicaltrials.gov/study/NCT05402722,https://clinicaltrials.gov/study/NCT05570253
EFO_0005537	triple-negative breast cancer	CHEMBL2177390	IPATASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT3	AKT serine/threonine kinase 3	2	Completed	https://clinicaltrials.gov/study/NCT03853707
MONDO_0007254	breast cancer	CHEMBL4297736	PRALUZATAMAB RAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBA3C	tubulin alpha 3c	2	Completed	https://clinicaltrials.gov/study/NCT04596150
EFO_0000305	breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
EFO_0000305	breast carcinoma	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Completed	https://clinicaltrials.gov/study/NCT02894398,https://clinicaltrials.gov/study/NCT02441946,https://clinicaltrials.gov/study/NCT04256941,https://clinicaltrials.gov/study/NCT04294225
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Withdrawn	https://clinicaltrials.gov/study/NCT02067416,https://clinicaltrials.gov/study/NCT01818999
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Recruiting	https://clinicaltrials.gov/study/NCT04266249,https://clinicaltrials.gov/study/NCT03606967,https://clinicaltrials.gov/study/NCT04090398
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Recruiting	https://clinicaltrials.gov/study/NCT04924699
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT02614833
EFO_0000305	breast carcinoma	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03179904
MONDO_0007254	breast cancer	CHEMBL1743022	FRESOLIMUMAB	Antibody	Transforming growth factor beta-3 inhibitor		TGFB3	transforming growth factor beta 3	2	Completed	https://clinicaltrials.gov/study/NCT01401062
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	2	Withdrawn	https://clinicaltrials.gov/study/NCT03377101,https://clinicaltrials.gov/study/NCT04220476
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND5	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04559308,https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT03238495
MONDO_0007254	breast cancer	CHEMBL1201748	CABAZITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT01693549
EFO_0000305	breast carcinoma	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06179303
EFO_0006861	male breast carcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC5	histone deacetylase 5	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01349959
EFO_0006861	male breast carcinoma	CHEMBL535	SUNITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Completed	https://clinicaltrials.gov/study/NCT00513695
MONDO_0007254	breast cancer	CHEMBL1922094	APITOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	2	Completed	https://clinicaltrials.gov/study/NCT01437566
EFO_0005537	triple-negative breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967
MONDO_0007254	breast cancer	CHEMBL4297181	SAMOTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	2	Completed	https://clinicaltrials.gov/study/NCT04032080
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV1	NADH:ubiquinone oxidoreductase core subunit V1	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04059484,https://clinicaltrials.gov/study/NCT04272801,https://clinicaltrials.gov/study/NCT03219476,https://clinicaltrials.gov/study/NCT02188745,https://clinicaltrials.gov/study/NCT02007512,https://clinicaltrials.gov/study/NCT04129216
MONDO_0007254	breast cancer	CHEMBL1201247	GOSERELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03822468,https://clinicaltrials.gov/study/NCT02624973,https://clinicaltrials.gov/study/NCT03056755,https://clinicaltrials.gov/study/NCT03671330
MONDO_0007254	breast cancer	CHEMBL27	PROPRANOLOL	Small molecule	Beta-2 adrenergic receptor antagonist		ADRB2	adrenoceptor beta 2	2	Terminated	https://clinicaltrials.gov/study/NCT02596867
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04922008,https://clinicaltrials.gov/study/NCT04143906,https://clinicaltrials.gov/study/NCT04963595,https://clinicaltrials.gov/study/NCT03997539,https://clinicaltrials.gov/study/NCT06229067
MONDO_0007254	breast cancer	CHEMBL135	ESTRADIOL	Small molecule	Estrogen receptor alpha agonist	Antagonist	ESR1	estrogen receptor 1	2	Terminated	https://clinicaltrials.gov/study/NCT00661531,https://clinicaltrials.gov/study/NCT01083641
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA9	NADH:ubiquinone oxidoreductase subunit A9	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL76222	REBIMASTAT	Small molecule	Matrix metalloproteinase-2 inhibitor		MMP2	matrix metallopeptidase 2	2	Terminated	https://clinicaltrials.gov/study/NCT00036621
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04290793,https://clinicaltrials.gov/study/NCT04034823,https://clinicaltrials.gov/study/NCT06348134,https://clinicaltrials.gov/study/NCT06291064
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Terminated	https://clinicaltrials.gov/study/NCT03795012,https://clinicaltrials.gov/study/NCT01534455,https://clinicaltrials.gov/study/NCT02000596,https://clinicaltrials.gov/study/NCT01912963,https://clinicaltrials.gov/study/NCT01498588,https://clinicaltrials.gov/study/NCT02681523
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		LYN	LYN proto-oncogene, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00754325,https://clinicaltrials.gov/study/NCT00546104,https://clinicaltrials.gov/study/NCT00696072,https://clinicaltrials.gov/study/NCT00767520,https://clinicaltrials.gov/study/NCT00410813
MONDO_0007254	breast cancer	CHEMBL1976040	ADAVOSERTIB	Small molecule	Serine/threonine-protein kinase WEE1 inhibitor		WEE1	WEE1 G2 checkpoint kinase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03330847
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS8	NADH:ubiquinone oxidoreductase core subunit S8	2	Unknown status	https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT02506777,https://clinicaltrials.gov/study/NCT03192293
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT00027989
MONDO_0007254	breast cancer	CHEMBL1116	RALOXIFENE HYDROCHLORIDE	Small molecule	Estrogen receptor beta modulator	Antagonist	ESR2	estrogen receptor 2	2	Completed	https://clinicaltrials.gov/study/NCT00200174
MONDO_0007254	breast cancer	CHEMBL4650256	ZANIDATAMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05035836,https://clinicaltrials.gov/study/NCT04224272
EFO_1000984	inflammatory breast carcinoma	CHEMBL1567	SUNITINIB MALATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT00513695
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL2325741	CAPIVASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT1	AKT serine/threonine kinase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02208375
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02876302,https://clinicaltrials.gov/study/NCT01730833
MONDO_0007254	breast cancer	CHEMBL723	CARVEDILOL	Small molecule	Adrenergic receptor beta antagonist		ADRB3	adrenoceptor beta 3	2	Completed	https://clinicaltrials.gov/study/NCT01009918,https://clinicaltrials.gov/study/NCT02177175
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB6	NADH:ubiquinone oxidoreductase subunit B6	2	Completed	https://clinicaltrials.gov/study/NCT01885013
EFO_0000305	breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
EFO_0000305	breast carcinoma	CHEMBL554	LAPATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Terminated	https://clinicaltrials.gov/study/NCT01272141
EFO_0005537	triple-negative breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT02413320,https://clinicaltrials.gov/study/NCT03154749
EFO_0000305	breast carcinoma	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FRK	fyn related Src family tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT05198843
MONDO_0007254	breast cancer	CHEMBL34259	METHOTREXATE	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	2	Recruiting	https://clinicaltrials.gov/study/NCT06085742
EFO_0006861	male breast carcinoma	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Terminated	https://clinicaltrials.gov/study/NCT00832338
MONDO_0007254	breast cancer	CHEMBL217092	SARACATINIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00559507
MONDO_0007254	breast cancer	CHEMBL554	LAPATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Unknown status	https://clinicaltrials.gov/study/NCT01283789,https://clinicaltrials.gov/study/NCT01730677,https://clinicaltrials.gov/study/NCT02238509,https://clinicaltrials.gov/study/NCT03085368,https://clinicaltrials.gov/study/NCT00842998,https://clinicaltrials.gov/study/NCT01309607
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor		GPD2	glycerol-3-phosphate dehydrogenase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT04559308,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT03238495
MONDO_0007254	breast cancer	CHEMBL679	EPINEPHRINE	Small molecule	Adrenergic receptor agonist		ADRB3	adrenoceptor beta 3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04603911
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS8	NADH:ubiquinone oxidoreductase core subunit S8	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03587740,https://clinicaltrials.gov/study/NCT01745965,https://clinicaltrials.gov/study/NCT02326974,https://clinicaltrials.gov/study/NCT01494662,https://clinicaltrials.gov/study/NCT01565200,https://clinicaltrials.gov/study/NCT04733118,https://clinicaltrials.gov/study/NCT01853748,https://clinicaltrials.gov/study/NCT04398914
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Withdrawn	https://clinicaltrials.gov/study/NCT03032614
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT01268150,https://clinicaltrials.gov/study/NCT05206656,https://clinicaltrials.gov/study/NCT02481050,https://clinicaltrials.gov/study/NCT01439282,https://clinicaltrials.gov/study/NCT00879086,https://clinicaltrials.gov/study/NCT03051659,https://clinicaltrials.gov/study/NCT01908101,https://clinicaltrials.gov/study/NCT00965523,https://clinicaltrials.gov/study/NCT01269346,https://clinicaltrials.gov/study/NCT00246090
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Withdrawn	https://clinicaltrials.gov/study/NCT04351230
MONDO_0007254	breast cancer	CHEMBL109480	TANESPIMYCIN	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AA1	heat shock protein 90 alpha family class A member 1	2	Terminated	https://clinicaltrials.gov/study/NCT00096109
EFO_0000553	invasive lobular carcinoma	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Recruiting	https://clinicaltrials.gov/study/NCT04551495
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01730833,https://clinicaltrials.gov/study/NCT02530489,https://clinicaltrials.gov/study/NCT02957968
MONDO_0007254	breast cancer	CHEMBL3647420	PYROTINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Unknown status	https://clinicaltrials.gov/study/NCT03412383,https://clinicaltrials.gov/study/NCT03876587
EFO_0000305	breast carcinoma	CHEMBL1421	DASATINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT05198843
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	2	Unknown status	https://clinicaltrials.gov/study/NCT02790580
EFO_0000304	breast adenocarcinoma	CHEMBL3545092	CR 1447	Small molecule	Androgen Receptor agonist		AR	androgen receptor	2	Terminated	https://clinicaltrials.gov/study/NCT02067741
EFO_0000305	breast carcinoma	CHEMBL3545262	SACITUZUMAB GOVITECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	2	Recruiting	https://clinicaltrials.gov/study/NCT03971409
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB8	NADH:ubiquinone oxidoreductase subunit B8	2	Completed	https://clinicaltrials.gov/study/NCT01885013
EFO_0000305	breast carcinoma	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	2	Completed	https://clinicaltrials.gov/study/NCT03809988,https://clinicaltrials.gov/study/NCT02894398,https://clinicaltrials.gov/study/NCT04256941,https://clinicaltrials.gov/study/NCT02296801,https://clinicaltrials.gov/study/NCT03007979
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4L	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L	2	Completed	https://clinicaltrials.gov/study/NCT01885013
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB11	NADH:ubiquinone oxidoreductase subunit B11	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1614701	SELUMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 2 inhibitor		MAP2K2	mitogen-activated protein kinase kinase 2	2	Unknown status	https://clinicaltrials.gov/study/NCT02685657
MONDO_0007254	breast cancer	CHEMBL481	IRINOTECAN	Small molecule	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	2	Completed	https://clinicaltrials.gov/study/NCT02312622,https://clinicaltrials.gov/study/NCT00003351,https://clinicaltrials.gov/study/NCT00693719,https://clinicaltrials.gov/study/NCT00532714,https://clinicaltrials.gov/study/NCT00617539,https://clinicaltrials.gov/study/NCT00303992,https://clinicaltrials.gov/study/NCT00079118,https://clinicaltrials.gov/study/NCT00004182,https://clinicaltrials.gov/study/NCT00275041
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA3	NADH:ubiquinone oxidoreductase subunit A3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Terminated	https://clinicaltrials.gov/study/NCT03329378,https://clinicaltrials.gov/study/NCT01985841,https://clinicaltrials.gov/study/NCT00453635,https://clinicaltrials.gov/study/NCT00479856,https://clinicaltrials.gov/study/NCT00343512,https://clinicaltrials.gov/study/NCT00080626,https://clinicaltrials.gov/study/NCT00665457,https://clinicaltrials.gov/study/NCT00636441,https://clinicaltrials.gov/study/NCT00845910,https://clinicaltrials.gov/study/NCT00025493,https://clinicaltrials.gov/study/NCT00225056,https://clinicaltrials.gov/study/NCT00193024,https://clinicaltrials.gov/study/NCT00852332,https://clinicaltrials.gov/study/NCT00524459,https://clinicaltrials.gov/study/NCT03894007,https://clinicaltrials.gov/study/NCT00028483,https://clinicaltrials.gov/study/NCT00576901,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT00118053,https://clinicaltrials.gov/study/NCT01690325,https://clinicaltrials.gov/study/NCT00104624,https://clinicaltrials.gov/study/NCT00206453
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT01520103,https://clinicaltrials.gov/study/NCT03887130,https://clinicaltrials.gov/study/NCT00266110,https://clinicaltrials.gov/study/NCT00041067,https://clinicaltrials.gov/study/NCT03321981,https://clinicaltrials.gov/study/NCT01439191,https://clinicaltrials.gov/study/NCT00325234,https://clinicaltrials.gov/study/NCT00015938,https://clinicaltrials.gov/study/NCT00006682,https://clinicaltrials.gov/study/NCT00004237,https://clinicaltrials.gov/study/NCT00480597,https://clinicaltrials.gov/study/NCT03254654,https://clinicaltrials.gov/study/NCT01305941,https://clinicaltrials.gov/study/NCT00148681,https://clinicaltrials.gov/study/NCT04903652,https://clinicaltrials.gov/study/NCT02628613,https://clinicaltrials.gov/study/NCT03007992,https://clinicaltrials.gov/study/NCT00193089,https://clinicaltrials.gov/study/NCT00401427,https://clinicaltrials.gov/study/NCT00192062,https://clinicaltrials.gov/study/NCT01565083,https://clinicaltrials.gov/study/NCT00532623,https://clinicaltrials.gov/study/NCT00670982,https://clinicaltrials.gov/study/NCT00148668,https://clinicaltrials.gov/study/NCT00194779,https://clinicaltrials.gov/study/NCT00022152,https://clinicaltrials.gov/study/NCT02362958,https://clinicaltrials.gov/study/NCT00503750,https://clinicaltrials.gov/study/NCT01242449,https://clinicaltrials.gov/study/NCT00093808,https://clinicaltrials.gov/study/NCT01835236,https://clinicaltrials.gov/study/NCT02954055,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT01941771
EFO_0005537	triple-negative breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Suspended	https://clinicaltrials.gov/study/NCT04095689
EFO_0005537	triple-negative breast cancer	CHEMBL2336325	VISTUSERTIB	Small molecule	Serine/threonine-protein kinase mTOR inhibitor		MTOR	mechanistic target of rapamycin kinase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02208375
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04858516
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Withdrawn	https://clinicaltrials.gov/study/NCT01169870,https://clinicaltrials.gov/study/NCT01163929,https://clinicaltrials.gov/study/NCT03554109,https://clinicaltrials.gov/study/NCT00397761,https://clinicaltrials.gov/study/NCT05809895,https://clinicaltrials.gov/study/NCT02053597,https://clinicaltrials.gov/study/NCT03841747,https://clinicaltrials.gov/study/NCT03872505,https://clinicaltrials.gov/study/NCT04038489,https://clinicaltrials.gov/study/NCT02067416,https://clinicaltrials.gov/study/NCT03058939
EFO_0000305	breast carcinoma	CHEMBL554	LAPATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01272141
EFO_0005537	triple-negative breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03639948
MONDO_0007254	breast cancer	CHEMBL1173655	AFATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Completed	https://clinicaltrials.gov/study/NCT01594177
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT01565083,https://clinicaltrials.gov/study/NCT01305941,https://clinicaltrials.gov/study/NCT00006682,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00194779,https://clinicaltrials.gov/study/NCT00532623,https://clinicaltrials.gov/study/NCT00266110,https://clinicaltrials.gov/study/NCT00148668,https://clinicaltrials.gov/study/NCT00015938,https://clinicaltrials.gov/study/NCT02954055,https://clinicaltrials.gov/study/NCT03321981,https://clinicaltrials.gov/study/NCT00004237,https://clinicaltrials.gov/study/NCT00022152,https://clinicaltrials.gov/study/NCT00401427,https://clinicaltrials.gov/study/NCT00041067,https://clinicaltrials.gov/study/NCT02628613,https://clinicaltrials.gov/study/NCT01941771,https://clinicaltrials.gov/study/NCT00325234,https://clinicaltrials.gov/study/NCT00480597,https://clinicaltrials.gov/study/NCT00670982,https://clinicaltrials.gov/study/NCT00148681,https://clinicaltrials.gov/study/NCT00093808,https://clinicaltrials.gov/study/NCT00192062,https://clinicaltrials.gov/study/NCT01242449,https://clinicaltrials.gov/study/NCT01439191,https://clinicaltrials.gov/study/NCT04903652,https://clinicaltrials.gov/study/NCT03254654,https://clinicaltrials.gov/study/NCT01520103,https://clinicaltrials.gov/study/NCT03887130,https://clinicaltrials.gov/study/NCT00193089,https://clinicaltrials.gov/study/NCT01835236,https://clinicaltrials.gov/study/NCT03007992,https://clinicaltrials.gov/study/NCT02362958,https://clinicaltrials.gov/study/NCT00503750
MONDO_0007254	breast cancer	CHEMBL4297181	SAMOTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R5	phosphoinositide-3-kinase regulatory subunit 5	2	Completed	https://clinicaltrials.gov/study/NCT04032080
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Withdrawn	https://clinicaltrials.gov/study/NCT03554109,https://clinicaltrials.gov/study/NCT02053597,https://clinicaltrials.gov/study/NCT04038489,https://clinicaltrials.gov/study/NCT03872505,https://clinicaltrials.gov/study/NCT01169870,https://clinicaltrials.gov/study/NCT03841747,https://clinicaltrials.gov/study/NCT00397761,https://clinicaltrials.gov/study/NCT01163929,https://clinicaltrials.gov/study/NCT03058939,https://clinicaltrials.gov/study/NCT02067416,https://clinicaltrials.gov/study/NCT05809895
MONDO_0007254	breast cancer	CHEMBL20684	ABT-751	Small molecule	Tubulin beta inhibitor		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT00063102
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03567720,https://clinicaltrials.gov/study/NCT01815242,https://clinicaltrials.gov/study/NCT04297267,https://clinicaltrials.gov/study/NCT04262804,https://clinicaltrials.gov/study/NCT02252887
MONDO_0007254	breast cancer	CHEMBL846	CALCITRIOL	Small molecule	Vitamin D receptor agonist		VDR	vitamin D receptor	2	Completed	https://clinicaltrials.gov/study/NCT01293682
EFO_0005537	triple-negative breast cancer	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Withdrawn	https://clinicaltrials.gov/study/NCT05177796
EFO_0005537	triple-negative breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	Serine/threonine-protein kinase mTOR inhibitor		MTOR	mechanistic target of rapamycin kinase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03911973
EFO_0005537	triple-negative breast cancer	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		PSENEN	presenilin enhancer, gamma-secretase subunit	2	Terminated	https://clinicaltrials.gov/study/NCT01151449
EFO_1000984	inflammatory breast carcinoma	CHEMBL1789941	RUXOLITINIB	Small molecule	Tyrosine-protein kinase JAK1 inhibitor		JAK1	Janus kinase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02876302
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor		GPD2	glycerol-3-phosphate dehydrogenase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Withdrawn	https://clinicaltrials.gov/study/NCT05177796,https://clinicaltrials.gov/study/NCT05233696
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB8	NADH:ubiquinone oxidoreductase subunit B8	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Unknown status	https://clinicaltrials.gov/study/NCT03144947
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS1	NADH:ubiquinone oxidoreductase core subunit S1	2	Completed	https://clinicaltrials.gov/study/NCT01885013
EFO_0000305	breast carcinoma	CHEMBL2103875	TRAMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor		MAP2K1	mitogen-activated protein kinase kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT01964924
MONDO_0007254	breast cancer	CHEMBL109	VALPROIC ACID	Small molecule	Succinate semialdehyde dehydrogenase inhibitor		ALDH5A1	aldehyde dehydrogenase 5 family member A1	2	Terminated	https://clinicaltrials.gov/study/NCT01900730,https://clinicaltrials.gov/study/NCT00395655
MONDO_0007254	breast cancer	CHEMBL1789941	RUXOLITINIB	Small molecule	Tyrosine-protein kinase JAK2 inhibitor		JAK2	Janus kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT02066532,https://clinicaltrials.gov/study/NCT01594216
MONDO_0007254	breast cancer	CHEMBL4297715	CAMRELIZUMAB	Antibody	Programmed cell death protein 1 antagonist		PDCD1	programmed cell death 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04907344,https://clinicaltrials.gov/study/NCT05097248
EFO_0006861	male breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Unknown status	https://clinicaltrials.gov/study/NCT01372579
EFO_0005537	triple-negative breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT03932526
MONDO_0007254	breast cancer	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Tyrosine-protein kinase ITK/TSK inhibitor		ITK	IL2 inducible T cell kinase	2	Completed	https://clinicaltrials.gov/study/NCT00509587
MONDO_0007254	breast cancer	CHEMBL723	CARVEDILOL	Small molecule	Adrenergic receptor beta antagonist		ADRB2	adrenoceptor beta 2	2	Completed	https://clinicaltrials.gov/study/NCT01009918,https://clinicaltrials.gov/study/NCT02177175
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Completed	https://clinicaltrials.gov/study/NCT00894504,https://clinicaltrials.gov/study/NCT00191373,https://clinicaltrials.gov/study/NCT01201265,https://clinicaltrials.gov/study/NCT00813956,https://clinicaltrials.gov/study/NCT00110084,https://clinicaltrials.gov/study/NCT00191854,https://clinicaltrials.gov/study/NCT00493636,https://clinicaltrials.gov/study/NCT02435680,https://clinicaltrials.gov/study/NCT02263495,https://clinicaltrials.gov/study/NCT00191243,https://clinicaltrials.gov/study/NCT00191347,https://clinicaltrials.gov/study/NCT00320541,https://clinicaltrials.gov/study/NCT00192101,https://clinicaltrials.gov/study/NCT00003540,https://clinicaltrials.gov/study/NCT00846027,https://clinicaltrials.gov/study/NCT00005991,https://clinicaltrials.gov/study/NCT01045304,https://clinicaltrials.gov/study/NCT00325234,https://clinicaltrials.gov/study/NCT00191815,https://clinicaltrials.gov/study/NCT00662129,https://clinicaltrials.gov/study/NCT00623233,https://clinicaltrials.gov/study/NCT00193206,https://clinicaltrials.gov/study/NCT00212069,https://clinicaltrials.gov/study/NCT04464174,https://clinicaltrials.gov/study/NCT00193050,https://clinicaltrials.gov/study/NCT00191269,https://clinicaltrials.gov/study/NCT03025880,https://clinicaltrials.gov/study/NCT00540358,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00503906,https://clinicaltrials.gov/study/NCT00128856,https://clinicaltrials.gov/study/NCT00754351,https://clinicaltrials.gov/study/NCT00191789,https://clinicaltrials.gov/study/NCT00532857,https://clinicaltrials.gov/study/NCT00244933,https://clinicaltrials.gov/study/NCT00695994,https://clinicaltrials.gov/study/NCT00316199,https://clinicaltrials.gov/study/NCT00403130,https://clinicaltrials.gov/study/NCT00450762,https://clinicaltrials.gov/study/NCT00378313,https://clinicaltrials.gov/study/NCT00063570,https://clinicaltrials.gov/study/NCT00201760,https://clinicaltrials.gov/study/NCT00059852,https://clinicaltrials.gov/study/NCT00006007,https://clinicaltrials.gov/study/NCT00191451,https://clinicaltrials.gov/study/NCT00334802,https://clinicaltrials.gov/study/NCT00480597,https://clinicaltrials.gov/study/NCT01550848,https://clinicaltrials.gov/study/NCT00618826,https://clinicaltrials.gov/study/NCT00601159,https://clinicaltrials.gov/study/NCT00193076,https://clinicaltrials.gov/study/NCT00192062,https://clinicaltrials.gov/study/NCT00532623,https://clinicaltrials.gov/study/NCT00002998,https://clinicaltrials.gov/study/NCT00193063
MONDO_0007254	breast cancer	CHEMBL34259	METHOTREXATE	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999
MONDO_0007254	breast cancer	CHEMBL655	MIDAZOLAM	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRG3	gamma-aminobutyric acid type A receptor subunit gamma3	2	Completed	https://clinicaltrials.gov/study/NCT03084536
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB4	NADH:ubiquinone oxidoreductase subunit B4	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS7	NADH:ubiquinone oxidoreductase core subunit S7	2	Completed	https://clinicaltrials.gov/study/NCT01885013
MONDO_0003982	bilateral breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT00877500
MONDO_0003936	invasive tubular breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT02199418
MONDO_0007254	breast cancer	CHEMBL1289601	LENVATINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT03168074
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04963595,https://clinicaltrials.gov/study/NCT04143906,https://clinicaltrials.gov/study/NCT03997539,https://clinicaltrials.gov/study/NCT04922008,https://clinicaltrials.gov/study/NCT06229067
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Withdrawn	https://clinicaltrials.gov/study/NCT02067416,https://clinicaltrials.gov/study/NCT01818999
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT00020176,https://clinicaltrials.gov/study/NCT01105650,https://clinicaltrials.gov/study/NCT00429572
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Terminated	https://clinicaltrials.gov/study/NCT00691912,https://clinicaltrials.gov/study/NCT00542191,https://clinicaltrials.gov/study/NCT02322814,https://clinicaltrials.gov/study/NCT00679029,https://clinicaltrials.gov/study/NCT01069796,https://clinicaltrials.gov/study/NCT00194792,https://clinicaltrials.gov/study/NCT00456846,https://clinicaltrials.gov/study/NCT01009983,https://clinicaltrials.gov/study/NCT01745367,https://clinicaltrials.gov/study/NCT01147016,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT00356681,https://clinicaltrials.gov/study/NCT01416558,https://clinicaltrials.gov/study/NCT03894007,https://clinicaltrials.gov/study/NCT02598310,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT00434356,https://clinicaltrials.gov/study/NCT00536939,https://clinicaltrials.gov/study/NCT00934895,https://clinicaltrials.gov/study/NCT00756470,https://clinicaltrials.gov/study/NCT00589238,https://clinicaltrials.gov/study/NCT04066790,https://clinicaltrials.gov/study/NCT01194869,https://clinicaltrials.gov/study/NCT01207102,https://clinicaltrials.gov/study/NCT00532285,https://clinicaltrials.gov/study/NCT00607438,https://clinicaltrials.gov/study/NCT01120158,https://clinicaltrials.gov/study/NCT03329378,https://clinicaltrials.gov/study/NCT01329627,https://clinicaltrials.gov/study/NCT00622466,https://clinicaltrials.gov/study/NCT00479856
MONDO_0007254	breast cancer	CHEMBL1567	SUNITINIB MALATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Terminated	https://clinicaltrials.gov/study/NCT00824538
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Recruiting	https://clinicaltrials.gov/study/NCT05546255,https://clinicaltrials.gov/study/NCT05530057,https://clinicaltrials.gov/study/NCT04624711
EFO_0005537	triple-negative breast cancer	CHEMBL4297892	ANVATABART OPADOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBA4A	tubulin alpha 4a	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0000305	breast carcinoma	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		YES1	YES proto-oncogene 1, Src family tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT05198843
EFO_0006861	male breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
MONDO_0007254	breast cancer	CHEMBL288441	BOSUTINIB	Small molecule	Tyrosine-protein kinase HCK inhibitor		HCK	HCK proto-oncogene, Src family tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT00793546,https://clinicaltrials.gov/study/NCT00880009
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Recruiting	https://clinicaltrials.gov/study/NCT05192798,https://clinicaltrials.gov/study/NCT04138719,https://clinicaltrials.gov/study/NCT05834582,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT05227664,https://clinicaltrials.gov/study/NCT03606967
MONDO_0007254	breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Vascular endothelial growth factor receptor 3 inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04733417
MONDO_0007254	breast cancer	CHEMBL180022	NERATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-4 inhibitor		ERBB4	erb-b2 receptor tyrosine kinase 4	2	Withdrawn	https://clinicaltrials.gov/study/NCT04901299
EFO_0005537	triple-negative breast cancer	CHEMBL2103882	TIVANTINIB	Small molecule	Hepatocyte growth factor receptor inhibitor		MET	MET proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01575522
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Recruiting	https://clinicaltrials.gov/study/NCT05823623,https://clinicaltrials.gov/study/NCT04605575,https://clinicaltrials.gov/study/NCT04389073,https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT05747326,https://clinicaltrials.gov/study/NCT05296577,https://clinicaltrials.gov/study/NCT04302441,https://clinicaltrials.gov/study/NCT03939871,https://clinicaltrials.gov/study/NCT04304352,https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT04759248,https://clinicaltrials.gov/study/NCT04296162,https://clinicaltrials.gov/study/NCT06102824
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT03423849,https://clinicaltrials.gov/study/NCT02341911,https://clinicaltrials.gov/study/NCT00027989,https://clinicaltrials.gov/study/NCT01352494,https://clinicaltrials.gov/study/NCT02544243
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	2	Completed	https://clinicaltrials.gov/study/NCT03530696
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01779206,https://clinicaltrials.gov/study/NCT02547987,https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT03609047,https://clinicaltrials.gov/study/NCT00295893,https://clinicaltrials.gov/study/NCT02339532,https://clinicaltrials.gov/study/NCT03161353,https://clinicaltrials.gov/study/NCT04172259,https://clinicaltrials.gov/study/NCT02624973,https://clinicaltrials.gov/study/NCT00496795,https://clinicaltrials.gov/study/NCT02568839
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT00321633
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT00005614
MONDO_0007254	breast cancer	CHEMBL1487	ATORVASTATIN	Small molecule	HMG-CoA reductase inhibitor		HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase	2	Completed	https://clinicaltrials.gov/study/NCT01988571,https://clinicaltrials.gov/study/NCT03358017,https://clinicaltrials.gov/study/NCT00816244
MONDO_0007254	breast cancer	CHEMBL2109321	CAROTUXIMAB	Antibody	Endoglin inhibitor		ENG	endoglin	2	Completed	https://clinicaltrials.gov/study/NCT02520063
MONDO_0007254	breast cancer	CHEMBL3184679	AZD-4547	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR1	fibroblast growth factor receptor 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04192331,https://clinicaltrials.gov/study/NCT04172259,https://clinicaltrials.gov/study/NCT02779855,https://clinicaltrials.gov/study/NCT04538742,https://clinicaltrials.gov/study/NCT02752685,https://clinicaltrials.gov/study/NCT01815242,https://clinicaltrials.gov/study/NCT03609047,https://clinicaltrials.gov/study/NCT02546232,https://clinicaltrials.gov/study/NCT01796197,https://clinicaltrials.gov/study/NCT01779206,https://clinicaltrials.gov/study/NCT01730833,https://clinicaltrials.gov/study/NCT04215146,https://clinicaltrials.gov/study/NCT04734262,https://clinicaltrials.gov/study/NCT00616967,https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT04083963,https://clinicaltrials.gov/study/NCT04418154,https://clinicaltrials.gov/study/NCT04603183,https://clinicaltrials.gov/study/NCT02187991,https://clinicaltrials.gov/study/NCT05498896,https://clinicaltrials.gov/study/NCT01057069,https://clinicaltrials.gov/study/NCT02788981,https://clinicaltrials.gov/study/NCT04251169,https://clinicaltrials.gov/study/NCT03567720,https://clinicaltrials.gov/study/NCT01853748,https://clinicaltrials.gov/study/NCT01898117,https://clinicaltrials.gov/study/NCT03387085,https://clinicaltrials.gov/study/NCT03568422,https://clinicaltrials.gov/study/NCT02883062,https://clinicaltrials.gov/study/NCT02734290,https://clinicaltrials.gov/study/NCT00003042,https://clinicaltrials.gov/study/NCT04398914,https://clinicaltrials.gov/study/NCT03125928,https://clinicaltrials.gov/study/NCT03950570,https://clinicaltrials.gov/study/NCT00295893,https://clinicaltrials.gov/study/NCT03616886,https://clinicaltrials.gov/study/NCT03747120,https://clinicaltrials.gov/study/NCT00609791
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Recruiting	https://clinicaltrials.gov/study/NCT04872985,https://clinicaltrials.gov/study/NCT05426486,https://clinicaltrials.gov/study/NCT03367676,https://clinicaltrials.gov/study/NCT05483439,https://clinicaltrials.gov/study/NCT04947189,https://clinicaltrials.gov/study/NCT05638594,https://clinicaltrials.gov/study/NCT03879577,https://clinicaltrials.gov/study/NCT05475678,https://clinicaltrials.gov/study/NCT05918328,https://clinicaltrials.gov/study/NCT04576143,https://clinicaltrials.gov/study/NCT05900206,https://clinicaltrials.gov/study/NCT06107673,https://clinicaltrials.gov/study/NCT03497702,https://clinicaltrials.gov/study/NCT05088057,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT05189067,https://clinicaltrials.gov/study/NCT04717531,https://clinicaltrials.gov/study/NCT05645380
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT01527487,https://clinicaltrials.gov/study/NCT00493649,https://clinicaltrials.gov/study/NCT00201708,https://clinicaltrials.gov/study/NCT00003352,https://clinicaltrials.gov/study/NCT00006104,https://clinicaltrials.gov/study/NCT00066443,https://clinicaltrials.gov/study/NCT01485926,https://clinicaltrials.gov/study/NCT00005800,https://clinicaltrials.gov/study/NCT00679341,https://clinicaltrials.gov/study/NCT00079118,https://clinicaltrials.gov/study/NCT00203372,https://clinicaltrials.gov/study/NCT02137083,https://clinicaltrials.gov/study/NCT01396655,https://clinicaltrials.gov/study/NCT00006682,https://clinicaltrials.gov/study/NCT00499122,https://clinicaltrials.gov/study/NCT00054275,https://clinicaltrials.gov/study/NCT00193089,https://clinicaltrials.gov/study/NCT00941330,https://clinicaltrials.gov/study/NCT02132949,https://clinicaltrials.gov/study/NCT00179309,https://clinicaltrials.gov/study/NCT00773695,https://clinicaltrials.gov/study/NCT00212095,https://clinicaltrials.gov/study/NCT02229084,https://clinicaltrials.gov/study/NCT01208480,https://clinicaltrials.gov/study/NCT01150513,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT00527449,https://clinicaltrials.gov/study/NCT00155259,https://clinicaltrials.gov/study/NCT00524810,https://clinicaltrials.gov/study/NCT00148668,https://clinicaltrials.gov/study/NCT00545688,https://clinicaltrials.gov/study/NCT00525759,https://clinicaltrials.gov/study/NCT00198237,https://clinicaltrials.gov/study/NCT00123929,https://clinicaltrials.gov/study/NCT01367028,https://clinicaltrials.gov/study/NCT00015938,https://clinicaltrials.gov/study/NCT00365365,https://clinicaltrials.gov/study/NCT00248703,https://clinicaltrials.gov/study/NCT00559754,https://clinicaltrials.gov/study/NCT00206505,https://clinicaltrials.gov/study/NCT00258375,https://clinicaltrials.gov/study/NCT00193180,https://clinicaltrials.gov/study/NCT03887130,https://clinicaltrials.gov/study/NCT04664972,https://clinicaltrials.gov/study/NCT00068341,https://clinicaltrials.gov/study/NCT00044993,https://clinicaltrials.gov/study/NCT00003565,https://clinicaltrials.gov/study/NCT00754351,https://clinicaltrials.gov/study/NCT00475670,https://clinicaltrials.gov/study/NCT00191243,https://clinicaltrials.gov/study/NCT03735966,https://clinicaltrials.gov/study/NCT00088998,https://clinicaltrials.gov/study/NCT00146042,https://clinicaltrials.gov/study/NCT01446016,https://clinicaltrials.gov/study/NCT03742986,https://clinicaltrials.gov/study/NCT00004906,https://clinicaltrials.gov/study/NCT02909751,https://clinicaltrials.gov/study/NCT00841828,https://clinicaltrials.gov/study/NCT02365805,https://clinicaltrials.gov/study/NCT00820872,https://clinicaltrials.gov/study/NCT00645866,https://clinicaltrials.gov/study/NCT02834403,https://clinicaltrials.gov/study/NCT01038804,https://clinicaltrials.gov/study/NCT00209092,https://clinicaltrials.gov/study/NCT00695994,https://clinicaltrials.gov/study/NCT00319618,https://clinicaltrials.gov/study/NCT01540110,https://clinicaltrials.gov/study/NCT00274456,https://clinicaltrials.gov/study/NCT00600249,https://clinicaltrials.gov/study/NCT00247481,https://clinicaltrials.gov/study/NCT00212082,https://clinicaltrials.gov/study/NCT00005908,https://clinicaltrials.gov/study/NCT00206518,https://clinicaltrials.gov/study/NCT02846428,https://clinicaltrials.gov/study/NCT01959490,https://clinicaltrials.gov/study/NCT00365417,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00428922,https://clinicaltrials.gov/study/NCT00214864,https://clinicaltrials.gov/study/NCT01792050,https://clinicaltrials.gov/study/NCT00976989,https://clinicaltrials.gov/study/NCT00464646,https://clinicaltrials.gov/study/NCT01671319,https://clinicaltrials.gov/study/NCT03140553,https://clinicaltrials.gov/study/NCT00217672,https://clinicaltrials.gov/study/NCT00494481,https://clinicaltrials.gov/study/NCT00364611,https://clinicaltrials.gov/study/NCT00077857,https://clinicaltrials.gov/study/NCT00129376,https://clinicaltrials.gov/study/NCT00490646,https://clinicaltrials.gov/study/NCT00193037,https://clinicaltrials.gov/study/NCT00404066,https://clinicaltrials.gov/study/NCT01658462,https://clinicaltrials.gov/study/NCT00028873,https://clinicaltrials.gov/study/NCT02838225,https://clinicaltrials.gov/study/NCT00148070,https://clinicaltrials.gov/study/NCT00149214,https://clinicaltrials.gov/study/NCT00604435,https://clinicaltrials.gov/study/NCT00712881,https://clinicaltrials.gov/study/NCT02005549,https://clinicaltrials.gov/study/NCT00004175,https://clinicaltrials.gov/study/NCT00107510,https://clinicaltrials.gov/study/NCT00769470,https://clinicaltrials.gov/study/NCT01142778,https://clinicaltrials.gov/study/NCT02041351,https://clinicaltrials.gov/study/NCT00193115,https://clinicaltrials.gov/study/NCT00005963,https://clinicaltrials.gov/study/NCT00232479,https://clinicaltrials.gov/study/NCT00004888,https://clinicaltrials.gov/study/NCT00027885,https://clinicaltrials.gov/study/NCT01025349,https://clinicaltrials.gov/study/NCT00003953,https://clinicaltrials.gov/study/NCT00055861,https://clinicaltrials.gov/study/NCT00015886,https://clinicaltrials.gov/study/NCT00039520,https://clinicaltrials.gov/study/NCT00206466,https://clinicaltrials.gov/study/NCT00041067,https://clinicaltrials.gov/study/NCT00193050,https://clinicaltrials.gov/study/NCT00432172,https://clinicaltrials.gov/study/NCT00379015,https://clinicaltrials.gov/study/NCT00820547,https://clinicaltrials.gov/study/NCT02748213,https://clinicaltrials.gov/study/NCT00203502
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT02978495
MONDO_0004379	female breast carcinoma	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02942355
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB7	NADH:ubiquinone oxidoreductase subunit B7	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
MONDO_0007254	breast cancer	CHEMBL1276308	MIFEPRISTONE	Small molecule	Progesterone receptor antagonist		PGR	progesterone receptor	2	Completed	https://clinicaltrials.gov/study/NCT01898312
MONDO_0007254	breast cancer	CHEMBL834	PAMIDRONIC ACID	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	2	Terminated	https://clinicaltrials.gov/study/NCT01067989
EFO_0000305	breast carcinoma	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134,https://clinicaltrials.gov/study/NCT06179303
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04345913
EFO_0005537	triple-negative breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT03154749,https://clinicaltrials.gov/study/NCT02413320
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist	Antagonist	ESR1	estrogen receptor 1	2	Recruiting	https://clinicaltrials.gov/study/NCT02760030,https://clinicaltrials.gov/study/NCT05759572,https://clinicaltrials.gov/study/NCT05230810,https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT05305924,https://clinicaltrials.gov/study/NCT04796623,https://clinicaltrials.gov/study/NCT05076695,https://clinicaltrials.gov/study/NCT05933395,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT05411380,https://clinicaltrials.gov/study/NCT06110793,https://clinicaltrials.gov/study/NCT05181033,https://clinicaltrials.gov/study/NCT03939871,https://clinicaltrials.gov/study/NCT05472792,https://clinicaltrials.gov/study/NCT05608252,https://clinicaltrials.gov/study/NCT05963984,https://clinicaltrials.gov/study/NCT04034589,https://clinicaltrials.gov/study/NCT04985266,https://clinicaltrials.gov/study/NCT04936295,https://clinicaltrials.gov/study/NCT05601440,https://clinicaltrials.gov/study/NCT04033172,https://clinicaltrials.gov/study/NCT05463601,https://clinicaltrials.gov/study/NCT05759546,https://clinicaltrials.gov/study/NCT05816655,https://clinicaltrials.gov/study/NCT05720260,https://clinicaltrials.gov/study/NCT04920708,https://clinicaltrials.gov/study/NCT05524584,https://clinicaltrials.gov/study/NCT04282031,https://clinicaltrials.gov/study/NCT04762979,https://clinicaltrials.gov/study/NCT05101564,https://clinicaltrials.gov/study/NCT04567420,https://clinicaltrials.gov/study/NCT02476786,https://clinicaltrials.gov/study/NCT05467891,https://clinicaltrials.gov/study/NCT05186545,https://clinicaltrials.gov/study/NCT03182634
EFO_0005537	triple-negative breast cancer	CHEMBL2107862	RINTATOLIMOD	Oligonucleotide	Toll-like receptor 3 agonist		TLR3	toll like receptor 3	2	Recruiting	https://clinicaltrials.gov/study/NCT05756166
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Completed	https://clinicaltrials.gov/study/NCT00429572,https://clinicaltrials.gov/study/NCT01105650,https://clinicaltrials.gov/study/NCT00020176
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT00321633
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04216472,https://clinicaltrials.gov/study/NCT02315196,https://clinicaltrials.gov/study/NCT01750073,https://clinicaltrials.gov/study/NCT02593175,https://clinicaltrials.gov/study/NCT02876107,https://clinicaltrials.gov/study/NCT04958785,https://clinicaltrials.gov/study/NCT04395989,https://clinicaltrials.gov/study/NCT04770272,https://clinicaltrials.gov/study/NCT04129996,https://clinicaltrials.gov/study/NCT02530489,https://clinicaltrials.gov/study/NCT02883062
MONDO_0007254	breast cancer	CHEMBL1289494	TIVOZANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01745367
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA6	EPH receptor A6	2	Completed	https://clinicaltrials.gov/study/NCT00494481
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		YES1	YES proto-oncogene 1, Src family tyrosine kinase	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01471106
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT00662129,https://clinicaltrials.gov/study/NCT00005991,https://clinicaltrials.gov/study/NCT00003540,https://clinicaltrials.gov/study/NCT00006007,https://clinicaltrials.gov/study/NCT00059852,https://clinicaltrials.gov/study/NCT00002998
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00074269,https://clinicaltrials.gov/study/NCT00376805
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Unknown status	https://clinicaltrials.gov/study/NCT00012311,https://clinicaltrials.gov/study/NCT02685657,https://clinicaltrials.gov/study/NCT01907529,https://clinicaltrials.gov/study/NCT02947061,https://clinicaltrials.gov/study/NCT03147963,https://clinicaltrials.gov/study/NCT01351597,https://clinicaltrials.gov/study/NCT00003066,https://clinicaltrials.gov/study/NCT00801411,https://clinicaltrials.gov/study/NCT00398489,https://clinicaltrials.gov/study/NCT01526499,https://clinicaltrials.gov/study/NCT01270373,https://clinicaltrials.gov/study/NCT00033683,https://clinicaltrials.gov/study/NCT01352494,https://clinicaltrials.gov/study/NCT00957125,https://clinicaltrials.gov/study/NCT01939054,https://clinicaltrials.gov/study/NCT00994968,https://clinicaltrials.gov/study/NCT00250874,https://clinicaltrials.gov/study/NCT02144194,https://clinicaltrials.gov/study/NCT03876587,https://clinicaltrials.gov/study/NCT00006120,https://clinicaltrials.gov/study/NCT00669773,https://clinicaltrials.gov/study/NCT00026078,https://clinicaltrials.gov/study/NCT00721747
EFO_0005537	triple-negative breast cancer	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Terminated	https://clinicaltrials.gov/study/NCT01234532
MONDO_0007254	breast cancer	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05607004,https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT02476786,https://clinicaltrials.gov/study/NCT05411380,https://clinicaltrials.gov/study/NCT04997798,https://clinicaltrials.gov/study/NCT05463601,https://clinicaltrials.gov/study/NCT05150652,https://clinicaltrials.gov/study/NCT05472792,https://clinicaltrials.gov/study/NCT04985266,https://clinicaltrials.gov/study/NCT05467891
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV1	NADH:ubiquinone oxidoreductase core subunit V1	2	Completed	https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT01310231
MONDO_0007254	breast cancer	CHEMBL3813842	PAXALISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT03765983
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN10A	sodium voltage-gated channel alpha subunit 10	2	Completed	https://clinicaltrials.gov/study/NCT02839668,https://clinicaltrials.gov/study/NCT01204242
EFO_0000305	breast carcinoma	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Completed	https://clinicaltrials.gov/study/NCT02282345
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Withdrawn	https://clinicaltrials.gov/study/NCT03032614
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03202316,https://clinicaltrials.gov/study/NCT05041101
EFO_1000307	Invasive Breast Carcinoma	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT04569747
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Terminated	https://clinicaltrials.gov/study/NCT00765765,https://clinicaltrials.gov/study/NCT00079326,https://clinicaltrials.gov/study/NCT00790894
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE7A	phosphodiesterase 7A	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT06186700,https://clinicaltrials.gov/study/NCT06176339
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01815242,https://clinicaltrials.gov/study/NCT02252887,https://clinicaltrials.gov/study/NCT04297267,https://clinicaltrials.gov/study/NCT04262804,https://clinicaltrials.gov/study/NCT03567720
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT00005614,https://clinicaltrials.gov/study/NCT05809895
EFO_0000304	breast adenocarcinoma	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02957968
EFO_0005537	triple-negative breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02208375
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Withdrawn	https://clinicaltrials.gov/study/NCT02215876,https://clinicaltrials.gov/study/NCT03637868
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Terminated	https://clinicaltrials.gov/study/NCT00832338
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Unknown status	https://clinicaltrials.gov/study/NCT01372579
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Unknown status	https://clinicaltrials.gov/study/NCT03412955
MONDO_0007254	breast cancer	CHEMBL4297736	PRALUZATAMAB RAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT04596150
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase B-raf inhibitor		BRAF	B-Raf proto-oncogene, serine/threonine kinase	2	Unknown status	https://clinicaltrials.gov/study/NCT00499525,https://clinicaltrials.gov/study/NCT00954135
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Unknown status	https://clinicaltrials.gov/study/NCT00027989
MONDO_0007254	breast cancer	CHEMBL2103879	GANETESPIB	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AB1	heat shock protein 90 alpha family class B member 1	2	Completed	https://clinicaltrials.gov/study/NCT01677455,https://clinicaltrials.gov/study/NCT01273896
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134,https://clinicaltrials.gov/study/NCT06291064,https://clinicaltrials.gov/study/NCT04034823,https://clinicaltrials.gov/study/NCT04290793
MONDO_0007254	breast cancer	CHEMBL2103879	GANETESPIB	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AB1	heat shock protein 90 alpha family class B member 1	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Vascular endothelial growth factor receptor 3 inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Recruiting	https://clinicaltrials.gov/study/NCT04355858
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967,https://clinicaltrials.gov/study/NCT06027268
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Terminated	https://clinicaltrials.gov/study/NCT00832338
EFO_0000305	breast carcinoma	CHEMBL4297545	LUTETIUM OXODOTREOTIDE LU-177	Protein	Somatostatin receptor binding agent		SSTR4	somatostatin receptor 4	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04529044
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Epidermal growth factor receptor inhibitor		EGFR	epidermal growth factor receptor	2	Completed	https://clinicaltrials.gov/study/NCT00494481
MONDO_0007254	breast cancer	CHEMBL1751	DIGOXIN	Small molecule	Sodium/potassium-transporting ATPase inhibitor		ATP1A3	ATPase Na+/K+ transporting subunit alpha 3	2	Completed	https://clinicaltrials.gov/study/NCT01763931
MONDO_0007254	breast cancer	CHEMBL4297181	SAMOTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	2	Completed	https://clinicaltrials.gov/study/NCT04032080
MONDO_0007254	breast cancer	CHEMBL1230609	FORETINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT01138384,https://clinicaltrials.gov/study/NCT01147484
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Withdrawn	https://clinicaltrials.gov/study/NCT01229605,https://clinicaltrials.gov/study/NCT00678626,https://clinicaltrials.gov/study/NCT01825265,https://clinicaltrials.gov/study/NCT00964704,https://clinicaltrials.gov/study/NCT00006261,https://clinicaltrials.gov/study/NCT00434031,https://clinicaltrials.gov/study/NCT02067416
MONDO_0007254	breast cancer	CHEMBL941	IMATINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00087152,https://clinicaltrials.gov/study/NCT00338728,https://clinicaltrials.gov/study/NCT00193180
EFO_0005537	triple-negative breast cancer	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02595905
EFO_0000305	breast carcinoma	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist	Antagonist	ESR1	estrogen receptor 1	2	Terminated	https://clinicaltrials.gov/study/NCT00183963
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT00321633
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV1	NADH:ubiquinone oxidoreductase core subunit V1	2	Recruiting	https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT04559308,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBA1C	tubulin alpha 1c	2	Withdrawn	https://clinicaltrials.gov/study/NCT01227408
EFO_0006861	male breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
MONDO_0007254	breast cancer	CHEMBL1738889	ENOBOSARM	Small molecule	Androgen Receptor modulator		AR	androgen receptor	2	Completed	https://clinicaltrials.gov/study/NCT02463032
MONDO_0007254	breast cancer	CHEMBL1908360	EVEROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	2	Recruiting	https://clinicaltrials.gov/study/NCT05826964,https://clinicaltrials.gov/study/NCT05563220,https://clinicaltrials.gov/study/NCT05949541,https://clinicaltrials.gov/study/NCT04802759,https://clinicaltrials.gov/study/NCT05933395,https://clinicaltrials.gov/study/NCT04355858
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Completed	https://clinicaltrials.gov/study/NCT02282345
MONDO_0007254	breast cancer	CHEMBL1201748	CABAZITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Terminated	https://clinicaltrials.gov/study/NCT01934894
MONDO_0007254	breast cancer	CHEMBL1200778	DEXRAZOXANE HYDROCHLORIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	2	Terminated	https://clinicaltrials.gov/study/NCT00955890
MONDO_0007254	breast cancer	CHEMBL3813842	PAXALISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	2	Recruiting	https://clinicaltrials.gov/study/NCT03765983
EFO_0000186	invasive breast ductal carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02779855
MONDO_0007254	breast cancer	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC3	histone deacetylase 3	2	Completed	https://clinicaltrials.gov/study/NCT00098397
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA5	EPH receptor A5	2	Completed	https://clinicaltrials.gov/study/NCT00494481
EFO_1000984	inflammatory breast carcinoma	CHEMBL4297844	TRASTUZUMAB DERUXTECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	2	Recruiting	https://clinicaltrials.gov/study/NCT05795101
MONDO_0007254	breast cancer	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Unknown status	https://clinicaltrials.gov/study/NCT00398489,https://clinicaltrials.gov/study/NCT00077168,https://clinicaltrials.gov/study/NCT01266213,https://clinicaltrials.gov/study/NCT00687648,https://clinicaltrials.gov/study/NCT02072512
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB4	NADH:ubiquinone oxidoreductase subunit B4	2	Completed	https://clinicaltrials.gov/study/NCT01885013
MONDO_0007254	breast cancer	CHEMBL572881	MOTESANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Terminated	https://clinicaltrials.gov/study/NCT00356681
EFO_0000432	breast ductal carcinoma in situ	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02779855
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT00861705
EFO_1000984	inflammatory breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02623972
EFO_0000305	breast carcinoma	CHEMBL2103882	TIVANTINIB	Small molecule	Hepatocyte growth factor receptor inhibitor		MET	MET proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT01575522
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA12	NADH:ubiquinone oxidoreductase subunit A12	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	2	Recruiting	https://clinicaltrials.gov/study/NCT04305834
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT00119262,https://clinicaltrials.gov/study/NCT03018080,https://clinicaltrials.gov/study/NCT00513695
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist	Antagonist	ESR2	estrogen receptor 2	2	Suspended	https://clinicaltrials.gov/study/NCT00738777
MONDO_0007254	breast cancer	CHEMBL1614701	SELUMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 1 inhibitor		MAP2K1	mitogen-activated protein kinase kinase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999
MONDO_0007254	breast cancer	CHEMBL3186534	RIVOCERANIB	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Enrolling by invitation	https://clinicaltrials.gov/study/NCT03580395
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Suspended	https://clinicaltrials.gov/study/NCT04419181,https://clinicaltrials.gov/study/NCT02897050
MONDO_0007254	breast cancer	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05675579,https://clinicaltrials.gov/study/NCT05286437,https://clinicaltrials.gov/study/NCT04468061,https://clinicaltrials.gov/study/NCT05491083,https://clinicaltrials.gov/study/NCT03989089,https://clinicaltrials.gov/study/NCT03025035,https://clinicaltrials.gov/study/NCT04990921,https://clinicaltrials.gov/study/NCT04849364,https://clinicaltrials.gov/study/NCT04454528,https://clinicaltrials.gov/study/NCT04789096,https://clinicaltrials.gov/study/NCT06245889,https://clinicaltrials.gov/study/NCT05645380,https://clinicaltrials.gov/study/NCT05174832,https://clinicaltrials.gov/study/NCT03546686,https://clinicaltrials.gov/study/NCT03804944,https://clinicaltrials.gov/study/NCT05033756,https://clinicaltrials.gov/study/NCT05203445,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT05852691,https://clinicaltrials.gov/study/NCT05020860,https://clinicaltrials.gov/study/NCT05163223,https://clinicaltrials.gov/study/NCT04230109,https://clinicaltrials.gov/study/NCT04443348,https://clinicaltrials.gov/study/NCT05681728
EFO_0005537	triple-negative breast cancer	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		PSEN1	presenilin 1	2	Terminated	https://clinicaltrials.gov/study/NCT01151449
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA6	NADH:ubiquinone oxidoreductase subunit A6	2	Completed	https://clinicaltrials.gov/study/NCT01885013
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS7	NADH:ubiquinone oxidoreductase core subunit S7	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
MONDO_0007254	breast cancer	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT03555877,https://clinicaltrials.gov/study/NCT03477396,https://clinicaltrials.gov/study/NCT03248427,https://clinicaltrials.gov/study/NCT03078751,https://clinicaltrials.gov/study/NCT03613220,https://clinicaltrials.gov/study/NCT03839823
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Enrolling by invitation	https://clinicaltrials.gov/study/NCT03580395
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB6	NADH:ubiquinone oxidoreductase subunit B6	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0000305	breast carcinoma	CHEMBL3187723	BINIMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 1 inhibitor		MAP2K1	mitogen-activated protein kinase kinase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT03971409,https://clinicaltrials.gov/study/NCT05554354
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA7	NADH:ubiquinone oxidoreductase subunit A7	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL34259	METHOTREXATE	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	2	Unknown status	https://clinicaltrials.gov/study/NCT00687648,https://clinicaltrials.gov/study/NCT00033683,https://clinicaltrials.gov/study/NCT00002498,https://clinicaltrials.gov/study/NCT00012311
EFO_0005537	triple-negative breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT03154749,https://clinicaltrials.gov/study/NCT02413320
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB7	NADH:ubiquinone oxidoreductase subunit B7	2	Completed	https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT02488564
MONDO_0007254	breast cancer	CHEMBL1642	IMATINIB MESYLATE	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT00323063
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT01269346,https://clinicaltrials.gov/study/NCT02263495,https://clinicaltrials.gov/study/NCT01705691,https://clinicaltrials.gov/study/NCT01669252,https://clinicaltrials.gov/study/NCT01401959,https://clinicaltrials.gov/study/NCT01827787,https://clinicaltrials.gov/study/NCT01941407,https://clinicaltrials.gov/study/NCT02481050,https://clinicaltrials.gov/study/NCT00246090,https://clinicaltrials.gov/study/NCT05206656,https://clinicaltrials.gov/study/NCT01427933,https://clinicaltrials.gov/study/NCT01439282,https://clinicaltrials.gov/study/NCT00965523,https://clinicaltrials.gov/study/NCT00879086,https://clinicaltrials.gov/study/NCT03051659,https://clinicaltrials.gov/study/NCT01593020,https://clinicaltrials.gov/study/NCT01527487,https://clinicaltrials.gov/study/NCT04464174,https://clinicaltrials.gov/study/NCT03222856,https://clinicaltrials.gov/study/NCT01908101,https://clinicaltrials.gov/study/NCT01268150
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02876302,https://clinicaltrials.gov/study/NCT01730833
MONDO_0007254	breast cancer	CHEMBL3833344	GANCOTAMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 binding agent		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Terminated	https://clinicaltrials.gov/study/NCT02213744
MONDO_0007254	breast cancer	CHEMBL1567	SUNITINIB MALATE	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Terminated	https://clinicaltrials.gov/study/NCT00824538
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04143906,https://clinicaltrials.gov/study/NCT05263882,https://clinicaltrials.gov/study/NCT04517292
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Unknown status	https://clinicaltrials.gov/study/NCT02144194,https://clinicaltrials.gov/study/NCT01352494,https://clinicaltrials.gov/study/NCT03147963,https://clinicaltrials.gov/study/NCT00721747,https://clinicaltrials.gov/study/NCT01351597,https://clinicaltrials.gov/study/NCT00669773,https://clinicaltrials.gov/study/NCT03876587,https://clinicaltrials.gov/study/NCT01939054,https://clinicaltrials.gov/study/NCT00801411,https://clinicaltrials.gov/study/NCT01270373,https://clinicaltrials.gov/study/NCT02947061,https://clinicaltrials.gov/study/NCT00006120,https://clinicaltrials.gov/study/NCT01907529,https://clinicaltrials.gov/study/NCT00026078,https://clinicaltrials.gov/study/NCT00957125,https://clinicaltrials.gov/study/NCT00994968,https://clinicaltrials.gov/study/NCT02685657,https://clinicaltrials.gov/study/NCT00250874,https://clinicaltrials.gov/study/NCT00003066,https://clinicaltrials.gov/study/NCT00012311,https://clinicaltrials.gov/study/NCT00398489,https://clinicaltrials.gov/study/NCT00033683,https://clinicaltrials.gov/study/NCT01526499
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA7	NADH:ubiquinone oxidoreductase subunit A7	2	Completed	https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT01266486
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Withdrawn	https://clinicaltrials.gov/study/NCT05233696,https://clinicaltrials.gov/study/NCT05177796
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND1	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT05319873,https://clinicaltrials.gov/study/NCT04266249
MONDO_0007254	breast cancer	CHEMBL4650316	GIREDESTRANT	Small molecule	Estrogen receptor alpha degrader	Antagonist	ESR1	estrogen receptor 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04576455
MONDO_0007254	breast cancer	CHEMBL289228	TIPIFARNIB	Small molecule	Protein farnesyltransferase inhibitor		FNTB	farnesyltransferase, CAAX box, subunit beta	2	Withdrawn	https://clinicaltrials.gov/study/NCT00054470
MONDO_0007254	breast cancer	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Terminated	https://clinicaltrials.gov/study/NCT00216073,https://clinicaltrials.gov/study/NCT00169104,https://clinicaltrials.gov/study/NCT00130507,https://clinicaltrials.gov/study/NCT01290718,https://clinicaltrials.gov/study/NCT04066790,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT03329378,https://clinicaltrials.gov/study/NCT00088985,https://clinicaltrials.gov/study/NCT02000596,https://clinicaltrials.gov/study/NCT01928615,https://clinicaltrials.gov/study/NCT01185509,https://clinicaltrials.gov/study/NCT01912963,https://clinicaltrials.gov/study/NCT00138125,https://clinicaltrials.gov/study/NCT00674414,https://clinicaltrials.gov/study/NCT00118053,https://clinicaltrials.gov/study/NCT02213744,https://clinicaltrials.gov/study/NCT01363986,https://clinicaltrials.gov/study/NCT00810017,https://clinicaltrials.gov/study/NCT01873833,https://clinicaltrials.gov/study/NCT00453635,https://clinicaltrials.gov/study/NCT00133796,https://clinicaltrials.gov/study/NCT00079326,https://clinicaltrials.gov/study/NCT02598310,https://clinicaltrials.gov/study/NCT00427427,https://clinicaltrials.gov/study/NCT03894007,https://clinicaltrials.gov/study/NCT00824733,https://clinicaltrials.gov/study/NCT01690325,https://clinicaltrials.gov/study/NCT00817362
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Tyrosine-protein kinase ITK/TSK inhibitor		ITK	IL2 inducible T cell kinase	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
MONDO_0007254	breast cancer	CHEMBL1429	DESMOPRESSIN	Protein	Vasopressin receptor agonist		AVPR2	arginine vasopressin receptor 2	2	Completed	https://clinicaltrials.gov/study/NCT01606072
MONDO_0007254	breast cancer	CHEMBL2177390	IPATASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT2	AKT serine/threonine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT04464174,https://clinicaltrials.gov/study/NCT03853707,https://clinicaltrials.gov/study/NCT02301988
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC6	histone deacetylase 6	2	Completed	https://clinicaltrials.gov/study/NCT00676663,https://clinicaltrials.gov/study/NCT02708680,https://clinicaltrials.gov/study/NCT03291886,https://clinicaltrials.gov/study/NCT00828854
EFO_0000305	breast carcinoma	CHEMBL118	CELECOXIB	Small molecule	Cyclooxygenase-2 inhibitor		PTGS2	prostaglandin-endoperoxide synthase 2	2	Withdrawn	https://clinicaltrials.gov/study/NCT03185871
EFO_0000305	breast carcinoma	CHEMBL2396661	ALPELISIB	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT04762979
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV1	NADH:ubiquinone oxidoreductase core subunit V1	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0006861	male breast carcinoma	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT00017394
EFO_1000984	inflammatory breast carcinoma	CHEMBL2108738	NIVOLUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Terminated	https://clinicaltrials.gov/study/NCT02892734
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE1C	phosphodiesterase 1C	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT06176339,https://clinicaltrials.gov/study/NCT06186700
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Epidermal growth factor receptor inhibitor		ERBB4	erb-b2 receptor tyrosine kinase 4	2	Completed	https://clinicaltrials.gov/study/NCT00494481
EFO_0006861	male breast carcinoma	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Serine/threonine-protein kinase B-raf inhibitor		BRAF	B-Raf proto-oncogene, serine/threonine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00096434
MONDO_0007254	breast cancer	CHEMBL941	IMATINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT00193180,https://clinicaltrials.gov/study/NCT00087152,https://clinicaltrials.gov/study/NCT00338728
MONDO_0007254	breast cancer	CHEMBL1567	SUNITINIB MALATE	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT00482755
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB1	NADH:ubiquinone oxidoreductase subunit B1	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06105684,https://clinicaltrials.gov/study/NCT03638648,https://clinicaltrials.gov/study/NCT06247995,https://clinicaltrials.gov/study/NCT06229067,https://clinicaltrials.gov/study/NCT04246502,https://clinicaltrials.gov/study/NCT06374459,https://clinicaltrials.gov/study/NCT04922008,https://clinicaltrials.gov/study/NCT05469750,https://clinicaltrials.gov/study/NCT06291064,https://clinicaltrials.gov/study/NCT03684863,https://clinicaltrials.gov/study/NCT06134375
MONDO_0007254	breast cancer	CHEMBL1200694	SEVOFLURANE	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRA5	gamma-aminobutyric acid type A receptor subunit alpha5	2	Completed	https://clinicaltrials.gov/study/NCT02839668
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB8	NADH:ubiquinone oxidoreductase subunit B8	2	Unknown status	https://clinicaltrials.gov/study/NCT02506777,https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT02506790
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Withdrawn	https://clinicaltrials.gov/study/NCT05233696,https://clinicaltrials.gov/study/NCT05177796
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Withdrawn	https://clinicaltrials.gov/study/NCT02725541
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAB1	NADH:ubiquinone oxidoreductase subunit AB1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS6	NADH:ubiquinone oxidoreductase subunit S6	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0005537	triple-negative breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Suspended	https://clinicaltrials.gov/study/NCT04095689
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE9A	phosphodiesterase 9A	2	Recruiting	https://clinicaltrials.gov/study/NCT06087237
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT00321633
EFO_0005537	triple-negative breast cancer	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02595905
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	2	Recruiting	https://clinicaltrials.gov/study/NCT04266249
EFO_0006861	male breast carcinoma	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RA	interleukin 2 receptor subunit alpha	2	Completed	https://clinicaltrials.gov/study/NCT00003199,https://clinicaltrials.gov/study/NCT00006228
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04517292,https://clinicaltrials.gov/study/NCT06308939,https://clinicaltrials.gov/study/NCT05263882,https://clinicaltrials.gov/study/NCT06202313,https://clinicaltrials.gov/study/NCT04502680,https://clinicaltrials.gov/study/NCT04913571
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4L2	NDUFA4 mitochondrial complex associated like 2	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0005537	triple-negative breast cancer	CHEMBL4475463	AMCENESTRANT	Small molecule	Estrogen receptor alpha degrader	Antagonist	ESR1	estrogen receptor 1	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Recruiting	https://clinicaltrials.gov/study/NCT05546255,https://clinicaltrials.gov/study/NCT06102824,https://clinicaltrials.gov/study/NCT05530057,https://clinicaltrials.gov/study/NCT05458674,https://clinicaltrials.gov/study/NCT05810870,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT04624711,https://clinicaltrials.gov/study/NCT04681911
MONDO_0007254	breast cancer	CHEMBL298734	LONAFARNIB	Small molecule	Protein farnesyltransferase inhibitor		FNTA	farnesyltransferase, CAAX box, subunit alpha	2	Terminated	https://clinicaltrials.gov/study/NCT00773474
MONDO_0007254	breast cancer	CHEMBL1614701	SELUMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 2 inhibitor		MAP2K2	mitogen-activated protein kinase kinase 2	2	Terminated	https://clinicaltrials.gov/study/NCT00780676
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA2	NADH:ubiquinone oxidoreductase subunit A2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
MONDO_0007254	breast cancer	CHEMBL409	BICALUTAMIDE	Small molecule	Androgen Receptor antagonist		AR	androgen receptor	2	Completed	https://clinicaltrials.gov/study/NCT00468715,https://clinicaltrials.gov/study/NCT02697032
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Completed	https://clinicaltrials.gov/study/NCT00662025,https://clinicaltrials.gov/study/NCT00270413,https://clinicaltrials.gov/study/NCT00482755
EFO_0000432	breast ductal carcinoma in situ	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02779855
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Recruiting	https://clinicaltrials.gov/study/NCT05546255,https://clinicaltrials.gov/study/NCT05530057,https://clinicaltrials.gov/study/NCT04624711
EFO_0000305	breast carcinoma	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist	Antagonist	ESR1	estrogen receptor 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02860000,https://clinicaltrials.gov/study/NCT03179904,https://clinicaltrials.gov/study/NCT03939897,https://clinicaltrials.gov/study/NCT02632045
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00270413,https://clinicaltrials.gov/study/NCT00662025,https://clinicaltrials.gov/study/NCT00482755
MONDO_0007254	breast cancer	CHEMBL20684	ABT-751	Small molecule	Tubulin beta inhibitor		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT00063102
EFO_0000432	breast ductal carcinoma in situ	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator	Antagonist	ESR1	estrogen receptor 1	2	Recruiting	https://clinicaltrials.gov/study/NCT04666961,https://clinicaltrials.gov/study/NCT06075953,https://clinicaltrials.gov/study/NCT02993159
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Recruiting	https://clinicaltrials.gov/study/NCT04138719,https://clinicaltrials.gov/study/NCT05192798,https://clinicaltrials.gov/study/NCT05834582,https://clinicaltrials.gov/study/NCT03606967,https://clinicaltrials.gov/study/NCT05227664,https://clinicaltrials.gov/study/NCT01042379
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV2	NADH:ubiquinone oxidoreductase core subunit V2	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL1908360	EVEROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	2	Terminated	https://clinicaltrials.gov/study/NCT01272141
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04172259,https://clinicaltrials.gov/study/NCT00295893,https://clinicaltrials.gov/study/NCT02624973,https://clinicaltrials.gov/study/NCT00496795,https://clinicaltrials.gov/study/NCT01779206,https://clinicaltrials.gov/study/NCT02547987,https://clinicaltrials.gov/study/NCT02568839,https://clinicaltrials.gov/study/NCT03609047,https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT02339532,https://clinicaltrials.gov/study/NCT03161353
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB10	NADH:ubiquinone oxidoreductase subunit B10	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Completed	https://clinicaltrials.gov/study/NCT00191373
EFO_0005537	triple-negative breast cancer	CHEMBL1079175	MK-2206	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT1	AKT serine/threonine kinase 1	2	Terminated	https://clinicaltrials.gov/study/NCT01319539
MONDO_0007254	breast cancer	CHEMBL998	LORATADINE	Small molecule	Histamine H1 receptor antagonist		HRH1	histamine receptor H1	2	Completed	https://clinicaltrials.gov/study/NCT01712009
MONDO_0007254	breast cancer	CHEMBL3989868	TUCATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT03054363,https://clinicaltrials.gov/study/NCT02614794
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC5	histone deacetylase 5	2	Completed	https://clinicaltrials.gov/study/NCT00676663,https://clinicaltrials.gov/study/NCT02708680,https://clinicaltrials.gov/study/NCT03291886,https://clinicaltrials.gov/study/NCT00828854
MONDO_0007254	breast cancer	CHEMBL4297190	SURUFATINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT05186545
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT00059852,https://clinicaltrials.gov/study/NCT00003540,https://clinicaltrials.gov/study/NCT00662129,https://clinicaltrials.gov/study/NCT00005991,https://clinicaltrials.gov/study/NCT00002998,https://clinicaltrials.gov/study/NCT00006007
MONDO_0007254	breast cancer	CHEMBL2103879	GANETESPIB	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AB1	heat shock protein 90 alpha family class B member 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01560416
MONDO_0007254	breast cancer	CHEMBL271227	ABIRATERONE ACETATE	Small molecule	Cytochrome P450 17A1 inhibitor		CYP17A1	cytochrome P450 family 17 subfamily A member 1	2	Completed	https://clinicaltrials.gov/study/NCT01842321,https://clinicaltrials.gov/study/NCT01381874
MONDO_0007254	breast cancer	CHEMBL679	EPINEPHRINE	Small molecule	Adrenergic receptor agonist		ADRB2	adrenoceptor beta 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04603911
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT01196052,https://clinicaltrials.gov/study/NCT02924883,https://clinicaltrials.gov/study/NCT02073487,https://clinicaltrials.gov/study/NCT01904903,https://clinicaltrials.gov/study/NCT03530696,https://clinicaltrials.gov/study/NCT01835236,https://clinicaltrials.gov/study/NCT00943670,https://clinicaltrials.gov/study/NCT00509769,https://clinicaltrials.gov/study/NCT00679211,https://clinicaltrials.gov/study/NCT00679341
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4	2	Terminated	https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT02472353
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Terminated	https://clinicaltrials.gov/study/NCT01690325,https://clinicaltrials.gov/study/NCT00104624,https://clinicaltrials.gov/study/NCT03894007,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT00028483,https://clinicaltrials.gov/study/NCT00118053,https://clinicaltrials.gov/study/NCT00206453,https://clinicaltrials.gov/study/NCT00453635,https://clinicaltrials.gov/study/NCT00193024,https://clinicaltrials.gov/study/NCT00225056,https://clinicaltrials.gov/study/NCT00845910,https://clinicaltrials.gov/study/NCT00576901,https://clinicaltrials.gov/study/NCT00665457,https://clinicaltrials.gov/study/NCT00636441,https://clinicaltrials.gov/study/NCT01985841,https://clinicaltrials.gov/study/NCT00343512,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT00479856,https://clinicaltrials.gov/study/NCT00852332,https://clinicaltrials.gov/study/NCT00080626,https://clinicaltrials.gov/study/NCT00025493,https://clinicaltrials.gov/study/NCT03329378,https://clinicaltrials.gov/study/NCT00524459
MONDO_0007254	breast cancer	CHEMBL2177390	IPATASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT2	AKT serine/threonine kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT04802759,https://clinicaltrials.gov/study/NCT04920708,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT05332561
EFO_0000305	breast carcinoma	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	2	Terminated	https://clinicaltrials.gov/study/NCT02907918,https://clinicaltrials.gov/study/NCT02774681
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA13	NADH:ubiquinone oxidoreductase subunit A13	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT03698383
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT00861705
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase B-raf inhibitor		BRAF	B-Raf proto-oncogene, serine/threonine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00101400,https://clinicaltrials.gov/study/NCT01320111,https://clinicaltrials.gov/study/NCT00493636,https://clinicaltrials.gov/study/NCT00548899,https://clinicaltrials.gov/study/NCT00634634
EFO_0000305	breast carcinoma	CHEMBL135	ESTRADIOL	Small molecule	Estrogen receptor alpha agonist	Antagonist	ESR1	estrogen receptor 1	2	Terminated	https://clinicaltrials.gov/study/NCT00661531
MONDO_0007254	breast cancer	CHEMBL393220	ATORVASTATIN CALCIUM	Small molecule	HMG-CoA reductase inhibitor		HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase	2	Unknown status	https://clinicaltrials.gov/study/NCT00914017
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA5	NADH:ubiquinone oxidoreductase subunit A5	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0000305	breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Withdrawn	https://clinicaltrials.gov/study/NCT04351230
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Recruiting	https://clinicaltrials.gov/study/NCT05402722,https://clinicaltrials.gov/study/NCT05570253
MONDO_0007254	breast cancer	CHEMBL2108029	ERTUMAXOMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 cross-linking agent		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Terminated	https://clinicaltrials.gov/study/NCT00452140,https://clinicaltrials.gov/study/NCT00351858,https://clinicaltrials.gov/study/NCT00522457
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA8	NADH:ubiquinone oxidoreductase subunit A8	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0005537	triple-negative breast cancer	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04755868
EFO_0005537	triple-negative breast cancer	CHEMBL3545132	MIRVETUXIMAB SORAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBA4A	tubulin alpha 4a	2	Completed	https://clinicaltrials.gov/study/NCT03106077
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC10	histone deacetylase 10	2	Completed	https://clinicaltrials.gov/study/NCT00777049
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Unknown status	https://clinicaltrials.gov/study/NCT03412955,https://clinicaltrials.gov/study/NCT02175446
MONDO_0007254	breast cancer	CHEMBL235668	TIPIRACIL	Small molecule	Thymidine phosphorylase inhibitor		TYMP	thymidine phosphorylase	2	Withdrawn	https://clinicaltrials.gov/study/NCT04149444
MONDO_0007254	breast cancer	CHEMBL286738	IROSUSTAT	Small molecule	Steryl-sulfatase inhibitor		STS	steroid sulfatase	2	Completed	https://clinicaltrials.gov/study/NCT01785992
MONDO_0007254	breast cancer	CHEMBL289228	TIPIFARNIB	Small molecule	Protein farnesyltransferase inhibitor		FNTB	farnesyltransferase, CAAX box, subunit beta	2	Completed	https://clinicaltrials.gov/study/NCT00077363,https://clinicaltrials.gov/study/NCT00050141,https://clinicaltrials.gov/study/NCT00049114,https://clinicaltrials.gov/study/NCT00052728,https://clinicaltrials.gov/study/NCT00082810
MONDO_0007254	breast cancer	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT03990896,https://clinicaltrials.gov/study/NCT06193525,https://clinicaltrials.gov/study/NCT04756765,https://clinicaltrials.gov/study/NCT05288127,https://clinicaltrials.gov/study/NCT04892693,https://clinicaltrials.gov/study/NCT04039230,https://clinicaltrials.gov/study/NCT04849364
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02339532,https://clinicaltrials.gov/study/NCT00295893,https://clinicaltrials.gov/study/NCT02547987,https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT03609047,https://clinicaltrials.gov/study/NCT00496795,https://clinicaltrials.gov/study/NCT04172259,https://clinicaltrials.gov/study/NCT01779206,https://clinicaltrials.gov/study/NCT02568839,https://clinicaltrials.gov/study/NCT02624973,https://clinicaltrials.gov/study/NCT03161353
MONDO_0007254	breast cancer	CHEMBL841	LOPERAMIDE	Small molecule	Mu opioid receptor agonist		OPRM1	opioid receptor mu 1	2	Completed	https://clinicaltrials.gov/study/NCT04366713,https://clinicaltrials.gov/study/NCT02400476,https://clinicaltrials.gov/study/NCT02441946
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB1	NADH:ubiquinone oxidoreductase subunit B1	2	Completed	https://clinicaltrials.gov/study/NCT01885013
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist	Antagonist	ESR2	estrogen receptor 2	2	Terminated	https://clinicaltrials.gov/study/NCT02540330
EFO_0000305	breast carcinoma	CHEMBL1201827	PANITUMUMAB	Antibody	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Withdrawn	https://clinicaltrials.gov/study/NCT05177796
EFO_0000304	breast adenocarcinoma	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Completed	https://clinicaltrials.gov/study/NCT02282345
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04001829,https://clinicaltrials.gov/study/NCT02568839
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Recruiting	https://clinicaltrials.gov/study/NCT04138719,https://clinicaltrials.gov/study/NCT03606967,https://clinicaltrials.gov/study/NCT05227664,https://clinicaltrials.gov/study/NCT05192798,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT05834582
EFO_0005537	triple-negative breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Recruiting	https://clinicaltrials.gov/study/NCT05670925
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB5	NADH:ubiquinone oxidoreductase subunit B5	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0006861	male breast carcinoma	CHEMBL225072	PEMETREXED	Small molecule	GAR transformylase inhibitor		GART	phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase	2	Completed	https://clinicaltrials.gov/study/NCT00106002
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Completed	https://clinicaltrials.gov/study/NCT03530696
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA8	NADH:ubiquinone oxidoreductase subunit A8	2	Unknown status	https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT02506777,https://clinicaltrials.gov/study/NCT03192293
MONDO_0007254	breast cancer	CHEMBL52885	ENMD-981693	Small molecule	SRC inhibitor		HCK	HCK proto-oncogene, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00306631
MONDO_0007254	breast cancer	CHEMBL25	ASPIRIN	Small molecule	Cyclooxygenase inhibitor		PTGS2	prostaglandin-endoperoxide synthase 2	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04188119,https://clinicaltrials.gov/study/NCT03491410
MONDO_0007254	breast cancer	CHEMBL3186534	RIVOCERANIB	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Unknown status	https://clinicaltrials.gov/study/NCT03086785,https://clinicaltrials.gov/study/NCT02768415,https://clinicaltrials.gov/study/NCT03735082,https://clinicaltrials.gov/study/NCT03348098,https://clinicaltrials.gov/study/NCT03457467
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS8	NADH:ubiquinone oxidoreductase core subunit S8	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0005537	triple-negative breast cancer	CHEMBL3639788	TELAGLENASTAT	Small molecule	Glutaminase kidney isoform, mitochondrial inhibitor		GLS	glutaminase	2	Completed	https://clinicaltrials.gov/study/NCT03057600
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB6	NADH:ubiquinone oxidoreductase subunit B6	2	Terminated	https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT02472353
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT05206656,https://clinicaltrials.gov/study/NCT01705691,https://clinicaltrials.gov/study/NCT01669252,https://clinicaltrials.gov/study/NCT04464174,https://clinicaltrials.gov/study/NCT01427933,https://clinicaltrials.gov/study/NCT01527487,https://clinicaltrials.gov/study/NCT01439282,https://clinicaltrials.gov/study/NCT03051659,https://clinicaltrials.gov/study/NCT00246090,https://clinicaltrials.gov/study/NCT01941407,https://clinicaltrials.gov/study/NCT00879086,https://clinicaltrials.gov/study/NCT01827787,https://clinicaltrials.gov/study/NCT03222856,https://clinicaltrials.gov/study/NCT02263495,https://clinicaltrials.gov/study/NCT00965523,https://clinicaltrials.gov/study/NCT01268150,https://clinicaltrials.gov/study/NCT02481050,https://clinicaltrials.gov/study/NCT01908101,https://clinicaltrials.gov/study/NCT01593020,https://clinicaltrials.gov/study/NCT01269346,https://clinicaltrials.gov/study/NCT01401959
MONDO_0007254	breast cancer	CHEMBL1743028	GLEMBATUMUMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT01997333,https://clinicaltrials.gov/study/NCT01156753
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02876302,https://clinicaltrials.gov/study/NCT01730833
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Unknown status	https://clinicaltrials.gov/study/NCT01428414,https://clinicaltrials.gov/study/NCT00533936,https://clinicaltrials.gov/study/NCT02694224,https://clinicaltrials.gov/study/NCT03429972,https://clinicaltrials.gov/study/NCT00499525,https://clinicaltrials.gov/study/NCT02041338,https://clinicaltrials.gov/study/NCT00006120,https://clinicaltrials.gov/study/NCT00499603,https://clinicaltrials.gov/study/NCT03348098,https://clinicaltrials.gov/study/NCT01830244,https://clinicaltrials.gov/study/NCT03735082,https://clinicaltrials.gov/study/NCT01647672,https://clinicaltrials.gov/study/NCT01625429,https://clinicaltrials.gov/study/NCT01276769,https://clinicaltrials.gov/study/NCT02230319,https://clinicaltrials.gov/study/NCT00404404,https://clinicaltrials.gov/study/NCT00154882,https://clinicaltrials.gov/study/NCT02423603,https://clinicaltrials.gov/study/NCT00777673,https://clinicaltrials.gov/study/NCT01309607,https://clinicaltrials.gov/study/NCT02059876,https://clinicaltrials.gov/study/NCT01321775
MONDO_0007254	breast cancer	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator	Antagonist	ESR1	estrogen receptor 1	2	Completed	https://clinicaltrials.gov/study/NCT00052728,https://clinicaltrials.gov/study/NCT00007904,https://clinicaltrials.gov/study/NCT00499083,https://clinicaltrials.gov/study/NCT00003035,https://clinicaltrials.gov/study/NCT02866955,https://clinicaltrials.gov/study/NCT01831076,https://clinicaltrials.gov/study/NCT01124695,https://clinicaltrials.gov/study/NCT00080743,https://clinicaltrials.gov/study/NCT00003050,https://clinicaltrials.gov/study/NCT00194779,https://clinicaltrials.gov/study/NCT02806544,https://clinicaltrials.gov/study/NCT02291913,https://clinicaltrials.gov/study/NCT00003992,https://clinicaltrials.gov/study/NCT00287534,https://clinicaltrials.gov/study/NCT02988986,https://clinicaltrials.gov/study/NCT00295100,https://clinicaltrials.gov/study/NCT00003099,https://clinicaltrials.gov/study/NCT02384239,https://clinicaltrials.gov/study/NCT01220076,https://clinicaltrials.gov/study/NCT01614210,https://clinicaltrials.gov/study/NCT00003953,https://clinicaltrials.gov/study/NCT00002679,https://clinicaltrials.gov/study/NCT00002680,https://clinicaltrials.gov/study/NCT02404844,https://clinicaltrials.gov/study/NCT03045653,https://clinicaltrials.gov/study/NCT00005908,https://clinicaltrials.gov/study/NCT00728949,https://clinicaltrials.gov/study/NCT00365599,https://clinicaltrials.gov/study/NCT00253539
MONDO_0007254	breast cancer	CHEMBL1567	SUNITINIB MALATE	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	2	Completed	https://clinicaltrials.gov/study/NCT00482755
EFO_0006861	male breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00095888
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FGR	FGR proto-oncogene, Src family tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT00780676,https://clinicaltrials.gov/study/NCT05198843,https://clinicaltrials.gov/study/NCT00817531
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		YES1	YES proto-oncogene 1, Src family tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT00780676,https://clinicaltrials.gov/study/NCT00817531,https://clinicaltrials.gov/study/NCT05198843
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Unknown status	https://clinicaltrials.gov/study/NCT03412955
MONDO_0007254	breast cancer	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03901469,https://clinicaltrials.gov/study/NCT03964532
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT02263495,https://clinicaltrials.gov/study/NCT01269346,https://clinicaltrials.gov/study/NCT01908101,https://clinicaltrials.gov/study/NCT03051659,https://clinicaltrials.gov/study/NCT01593020,https://clinicaltrials.gov/study/NCT02481050,https://clinicaltrials.gov/study/NCT04464174,https://clinicaltrials.gov/study/NCT01401959,https://clinicaltrials.gov/study/NCT01439282,https://clinicaltrials.gov/study/NCT01527487,https://clinicaltrials.gov/study/NCT00965523,https://clinicaltrials.gov/study/NCT05206656,https://clinicaltrials.gov/study/NCT00879086,https://clinicaltrials.gov/study/NCT03222856,https://clinicaltrials.gov/study/NCT00246090,https://clinicaltrials.gov/study/NCT01669252,https://clinicaltrials.gov/study/NCT01427933,https://clinicaltrials.gov/study/NCT01268150,https://clinicaltrials.gov/study/NCT01705691,https://clinicaltrials.gov/study/NCT01827787,https://clinicaltrials.gov/study/NCT01941407
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Recruiting	https://clinicaltrials.gov/study/NCT04893109,https://clinicaltrials.gov/study/NCT04917900,https://clinicaltrials.gov/study/NCT04090398,https://clinicaltrials.gov/study/NCT04243616,https://clinicaltrials.gov/study/NCT03907800,https://clinicaltrials.gov/study/NCT04872985,https://clinicaltrials.gov/study/NCT05353361,https://clinicaltrials.gov/study/NCT04771871,https://clinicaltrials.gov/study/NCT05749016,https://clinicaltrials.gov/study/NCT04425018,https://clinicaltrials.gov/study/NCT05681728,https://clinicaltrials.gov/study/NCT05020860,https://clinicaltrials.gov/study/NCT05728268,https://clinicaltrials.gov/study/NCT06245889,https://clinicaltrials.gov/study/NCT03571633,https://clinicaltrials.gov/study/NCT01817452,https://clinicaltrials.gov/study/NCT05749575,https://clinicaltrials.gov/study/NCT04159142,https://clinicaltrials.gov/study/NCT05582538,https://clinicaltrials.gov/study/NCT05189067,https://clinicaltrials.gov/study/NCT04443348,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT04537286,https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT04329065,https://clinicaltrials.gov/study/NCT04676997,https://clinicaltrials.gov/study/NCT04780347,https://clinicaltrials.gov/study/NCT04576143,https://clinicaltrials.gov/study/NCT05918328,https://clinicaltrials.gov/study/NCT04355858,https://clinicaltrials.gov/study/NCT05889390,https://clinicaltrials.gov/study/NCT05633914,https://clinicaltrials.gov/study/NCT05761470,https://clinicaltrials.gov/study/NCT03412643,https://clinicaltrials.gov/study/NCT05174832,https://clinicaltrials.gov/study/NCT05383196,https://clinicaltrials.gov/study/NCT04877821,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT05629429,https://clinicaltrials.gov/study/NCT05068141,https://clinicaltrials.gov/study/NCT03150576,https://clinicaltrials.gov/study/NCT04722718,https://clinicaltrials.gov/study/NCT05900206,https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT03048942,https://clinicaltrials.gov/study/NCT05447702,https://clinicaltrials.gov/study/NCT05346107,https://clinicaltrials.gov/study/NCT05852691,https://clinicaltrials.gov/study/NCT05325632,https://clinicaltrials.gov/study/NCT05659056
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Recruiting	https://clinicaltrials.gov/study/NCT03879577,https://clinicaltrials.gov/study/NCT06107673,https://clinicaltrials.gov/study/NCT03497702,https://clinicaltrials.gov/study/NCT04872985,https://clinicaltrials.gov/study/NCT05483439,https://clinicaltrials.gov/study/NCT05638594,https://clinicaltrials.gov/study/NCT05918328,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT04717531,https://clinicaltrials.gov/study/NCT03367676,https://clinicaltrials.gov/study/NCT05088057,https://clinicaltrials.gov/study/NCT05475678,https://clinicaltrials.gov/study/NCT05645380,https://clinicaltrials.gov/study/NCT05189067,https://clinicaltrials.gov/study/NCT04576143,https://clinicaltrials.gov/study/NCT05900206,https://clinicaltrials.gov/study/NCT04947189,https://clinicaltrials.gov/study/NCT05426486
MONDO_0007254	breast cancer	CHEMBL4297736	PRALUZATAMAB RAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBA1B	tubulin alpha 1b	2	Completed	https://clinicaltrials.gov/study/NCT04596150
MONDO_0007254	breast cancer	CHEMBL522892	DOVITINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Terminated	https://clinicaltrials.gov/study/NCT01528345
MONDO_0007254	breast cancer	CHEMBL2103879	GANETESPIB	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AA1	heat shock protein 90 alpha family class A member 1	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBB3	tubulin beta 3 class III	2	Withdrawn	https://clinicaltrials.gov/study/NCT01227408
MONDO_0007254	breast cancer	CHEMBL225072	PEMETREXED	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	2	Terminated	https://clinicaltrials.gov/study/NCT02624700
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02568839,https://clinicaltrials.gov/study/NCT04001829
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	Bcr/Abl fusion protein		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	2	Withdrawn	https://clinicaltrials.gov/study/NCT01410708
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Tyrosine-protein kinase BRK inhibitor		PTK6	protein tyrosine kinase 6	2	Completed	https://clinicaltrials.gov/study/NCT00494481
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB9	NADH:ubiquinone oxidoreductase subunit B9	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Recruiting	https://clinicaltrials.gov/study/NCT03515798,https://clinicaltrials.gov/study/NCT05383196
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA10	NADH:ubiquinone oxidoreductase subunit A10	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA7	NADH:ubiquinone oxidoreductase subunit A7	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1042	CHOLECALCIFEROL	Small molecule	Vitamin D receptor agonist		VDR	vitamin D receptor	2	Completed	https://clinicaltrials.gov/study/NCT01948128,https://clinicaltrials.gov/study/NCT00867217,https://clinicaltrials.gov/study/NCT02186015,https://clinicaltrials.gov/study/NCT00859651
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT03853707,https://clinicaltrials.gov/study/NCT02413320,https://clinicaltrials.gov/study/NCT02689427,https://clinicaltrials.gov/study/NCT03057600,https://clinicaltrials.gov/study/NCT00733408,https://clinicaltrials.gov/study/NCT01881230,https://clinicaltrials.gov/study/NCT01818063
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967,https://clinicaltrials.gov/study/NCT06027268
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT01352494,https://clinicaltrials.gov/study/NCT02544243,https://clinicaltrials.gov/study/NCT00027989,https://clinicaltrials.gov/study/NCT03423849,https://clinicaltrials.gov/study/NCT02341911
MONDO_0007254	breast cancer	CHEMBL1879463	DACTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	2	Withdrawn	https://clinicaltrials.gov/study/NCT01288092
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA3	NADH:ubiquinone oxidoreductase subunit A3	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0005537	triple-negative breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		SRC	SRC proto-oncogene, non-receptor tyrosine kinase	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06355037
EFO_0000305	breast carcinoma	CHEMBL2108658	TREMELIMUMAB	Antibody	Cytotoxic T-lymphocyte protein 4 inhibitor		CTLA4	cytotoxic T-lymphocyte associated protein 4	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FGR	FGR proto-oncogene, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00410813,https://clinicaltrials.gov/study/NCT00767520,https://clinicaltrials.gov/study/NCT00696072,https://clinicaltrials.gov/study/NCT00754325,https://clinicaltrials.gov/study/NCT00546104
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FYN	FYN proto-oncogene, Src family tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT00780676,https://clinicaltrials.gov/study/NCT00817531,https://clinicaltrials.gov/study/NCT05198843
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT02924883,https://clinicaltrials.gov/study/NCT03530696,https://clinicaltrials.gov/study/NCT00679211,https://clinicaltrials.gov/study/NCT00509769,https://clinicaltrials.gov/study/NCT01904903,https://clinicaltrials.gov/study/NCT02073487,https://clinicaltrials.gov/study/NCT00943670,https://clinicaltrials.gov/study/NCT01196052,https://clinicaltrials.gov/study/NCT01835236,https://clinicaltrials.gov/study/NCT00679341
EFO_0005537	triple-negative breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT02413320,https://clinicaltrials.gov/study/NCT03154749
MONDO_0007254	breast cancer	CHEMBL1743028	GLEMBATUMUMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT01156753,https://clinicaltrials.gov/study/NCT01997333
MONDO_0007254	breast cancer	CHEMBL4303201	CATEQUENTINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT05206656
MONDO_0007254	breast cancer	CHEMBL223360	LINIFANIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Completed	https://clinicaltrials.gov/study/NCT00645177
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT05601440,https://clinicaltrials.gov/study/NCT05181462,https://clinicaltrials.gov/study/NCT06026657,https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT06102824,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT04739670
MONDO_0007254	breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Recruiting	https://clinicaltrials.gov/study/NCT04355858
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03567720,https://clinicaltrials.gov/study/NCT01815242,https://clinicaltrials.gov/study/NCT04262804,https://clinicaltrials.gov/study/NCT02252887,https://clinicaltrials.gov/study/NCT04297267
MONDO_0007254	breast cancer	CHEMBL185	FLUOROURACIL	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	2	Suspended	https://clinicaltrials.gov/study/NCT02897050
MONDO_0007254	breast cancer	CHEMBL94657	PATUPILONE	Small molecule	Tubulin stabiliser		TUBB2B	tubulin beta 2B class IIb	2	Completed	https://clinicaltrials.gov/study/NCT00450866
MONDO_0007254	breast cancer	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT03923179,https://clinicaltrials.gov/study/NCT04452370
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF4	NADH:ubiquinone oxidoreductase complex assembly factor 4	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC10	histone deacetylase 10	2	Withdrawn	https://clinicaltrials.gov/study/NCT02115594
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01730833,https://clinicaltrials.gov/study/NCT00295893,https://clinicaltrials.gov/study/NCT05498896,https://clinicaltrials.gov/study/NCT02779855,https://clinicaltrials.gov/study/NCT04398914,https://clinicaltrials.gov/study/NCT01796197,https://clinicaltrials.gov/study/NCT03125928,https://clinicaltrials.gov/study/NCT03609047,https://clinicaltrials.gov/study/NCT04083963,https://clinicaltrials.gov/study/NCT00616967,https://clinicaltrials.gov/study/NCT02187991,https://clinicaltrials.gov/study/NCT02788981,https://clinicaltrials.gov/study/NCT04603183,https://clinicaltrials.gov/study/NCT04734262,https://clinicaltrials.gov/study/NCT03950570,https://clinicaltrials.gov/study/NCT04215146,https://clinicaltrials.gov/study/NCT02883062,https://clinicaltrials.gov/study/NCT04172259,https://clinicaltrials.gov/study/NCT04251169,https://clinicaltrials.gov/study/NCT03747120,https://clinicaltrials.gov/study/NCT01853748,https://clinicaltrials.gov/study/NCT00609791,https://clinicaltrials.gov/study/NCT01779206,https://clinicaltrials.gov/study/NCT04418154,https://clinicaltrials.gov/study/NCT02546232,https://clinicaltrials.gov/study/NCT04538742,https://clinicaltrials.gov/study/NCT01815242,https://clinicaltrials.gov/study/NCT03567720,https://clinicaltrials.gov/study/NCT03616886,https://clinicaltrials.gov/study/NCT03387085,https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT02734290,https://clinicaltrials.gov/study/NCT04192331,https://clinicaltrials.gov/study/NCT01057069,https://clinicaltrials.gov/study/NCT01898117,https://clinicaltrials.gov/study/NCT03568422,https://clinicaltrials.gov/study/NCT00003042,https://clinicaltrials.gov/study/NCT02752685
EFO_0005537	triple-negative breast cancer	CHEMBL118	CELECOXIB	Small molecule	Cyclooxygenase-2 inhibitor		PTGS2	prostaglandin-endoperoxide synthase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT05756166
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Recruiting	https://clinicaltrials.gov/study/NCT04266249
EFO_0005537	triple-negative breast cancer	CHEMBL3187723	BINIMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 2 inhibitor		MAP2K2	mitogen-activated protein kinase kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT03106415
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC1	NADH:ubiquinone oxidoreductase subunit C1	2	Terminated	https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT01477060
MONDO_0007254	breast cancer	CHEMBL4650989	TALETRECTINIB	Small molecule	Proto-oncogene tyrosine-protein kinase ROS inhibitor		ROS1	ROS proto-oncogene 1, receptor tyrosine kinase	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06214793
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Completed	https://clinicaltrials.gov/study/NCT00321633
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB11	NADH:ubiquinone oxidoreductase subunit B11	2	Completed	https://clinicaltrials.gov/study/NCT01885013
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT01941407,https://clinicaltrials.gov/study/NCT01593020,https://clinicaltrials.gov/study/NCT01527487,https://clinicaltrials.gov/study/NCT01705691,https://clinicaltrials.gov/study/NCT00246090,https://clinicaltrials.gov/study/NCT05206656,https://clinicaltrials.gov/study/NCT02263495,https://clinicaltrials.gov/study/NCT00879086,https://clinicaltrials.gov/study/NCT03222856,https://clinicaltrials.gov/study/NCT04464174,https://clinicaltrials.gov/study/NCT02481050,https://clinicaltrials.gov/study/NCT01908101,https://clinicaltrials.gov/study/NCT01669252,https://clinicaltrials.gov/study/NCT01827787,https://clinicaltrials.gov/study/NCT01439282,https://clinicaltrials.gov/study/NCT03051659,https://clinicaltrials.gov/study/NCT01427933,https://clinicaltrials.gov/study/NCT01269346,https://clinicaltrials.gov/study/NCT01401959,https://clinicaltrials.gov/study/NCT00965523,https://clinicaltrials.gov/study/NCT01268150
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02764541,https://clinicaltrials.gov/study/NCT03573648,https://clinicaltrials.gov/study/NCT03633331,https://clinicaltrials.gov/study/NCT02738866,https://clinicaltrials.gov/study/NCT03147287,https://clinicaltrials.gov/study/NCT02624973,https://clinicaltrials.gov/study/NCT05384119,https://clinicaltrials.gov/study/NCT02668666,https://clinicaltrials.gov/study/NCT02605486,https://clinicaltrials.gov/study/NCT03284957,https://clinicaltrials.gov/study/NCT04224272,https://clinicaltrials.gov/study/NCT03609047
EFO_0006318	breast ductal adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Terminated	https://clinicaltrials.gov/study/NCT01891357
MONDO_0007254	breast cancer	CHEMBL997	IBANDRONIC ACID	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	2	Unknown status	https://clinicaltrials.gov/study/NCT00381368
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS8	NADH:ubiquinone oxidoreductase core subunit S8	2	Completed	https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT01310231
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV3	NADH:ubiquinone oxidoreductase subunit V3	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	2	Completed	https://clinicaltrials.gov/study/NCT00509587
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA9	NADH:ubiquinone oxidoreductase subunit A9	2	Completed	https://clinicaltrials.gov/study/NCT01885013
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS7	NADH:ubiquinone oxidoreductase core subunit S7	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1200694	SEVOFLURANE	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRD	gamma-aminobutyric acid type A receptor subunit delta	2	Completed	https://clinicaltrials.gov/study/NCT02839668
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB5	NADH:ubiquinone oxidoreductase subunit B5	2	Recruiting	https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT04559308
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT03423849,https://clinicaltrials.gov/study/NCT02544243,https://clinicaltrials.gov/study/NCT01352494,https://clinicaltrials.gov/study/NCT00027989,https://clinicaltrials.gov/study/NCT02341911
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF1	NADH:ubiquinone oxidoreductase complex assembly factor 1	2	Terminated	https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT04899349
EFO_1000984	inflammatory breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02623972
MONDO_0007254	breast cancer	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN8A	sodium voltage-gated channel alpha subunit 8	2	Completed	https://clinicaltrials.gov/study/NCT02839668,https://clinicaltrials.gov/study/NCT01204242
EFO_0005537	triple-negative breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT03154749,https://clinicaltrials.gov/study/NCT02413320
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB11	NADH:ubiquinone oxidoreductase subunit B11	2	Terminated	https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT01477060,https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT02360059
EFO_0005537	triple-negative breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT03154749,https://clinicaltrials.gov/study/NCT02413320
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Tyrosine-protein kinase LCK inhibitor		LCK	LCK proto-oncogene, Src family tyrosine kinase	2	Withdrawn	https://clinicaltrials.gov/study/NCT00615524
MONDO_0044915	salivary duct carcinoma	CHEMBL1201247	GOSERELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT05513365
MONDO_0007254	breast cancer	CHEMBL1614701	SELUMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 1 inhibitor		MAP2K1	mitogen-activated protein kinase kinase 1	2	Unknown status	https://clinicaltrials.gov/study/NCT02685657
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT00404066,https://clinicaltrials.gov/study/NCT00066443,https://clinicaltrials.gov/study/NCT00027885,https://clinicaltrials.gov/study/NCT04664972,https://clinicaltrials.gov/study/NCT00148668,https://clinicaltrials.gov/study/NCT00041067,https://clinicaltrials.gov/study/NCT00003953,https://clinicaltrials.gov/study/NCT00645866,https://clinicaltrials.gov/study/NCT00155259,https://clinicaltrials.gov/study/NCT00258375,https://clinicaltrials.gov/study/NCT01540110,https://clinicaltrials.gov/study/NCT00499122,https://clinicaltrials.gov/study/NCT00464646,https://clinicaltrials.gov/study/NCT00841828,https://clinicaltrials.gov/study/NCT00006682,https://clinicaltrials.gov/study/NCT01367028,https://clinicaltrials.gov/study/NCT02041351,https://clinicaltrials.gov/study/NCT00193050,https://clinicaltrials.gov/study/NCT01038804,https://clinicaltrials.gov/study/NCT00559754,https://clinicaltrials.gov/study/NCT00364611,https://clinicaltrials.gov/study/NCT00432172,https://clinicaltrials.gov/study/NCT00604435,https://clinicaltrials.gov/study/NCT00148070,https://clinicaltrials.gov/study/NCT00206518,https://clinicaltrials.gov/study/NCT00005800,https://clinicaltrials.gov/study/NCT02137083,https://clinicaltrials.gov/study/NCT00004888,https://clinicaltrials.gov/study/NCT00600249,https://clinicaltrials.gov/study/NCT00206505,https://clinicaltrials.gov/study/NCT00005963,https://clinicaltrials.gov/study/NCT00191243,https://clinicaltrials.gov/study/NCT02005549,https://clinicaltrials.gov/study/NCT00129376,https://clinicaltrials.gov/study/NCT00206466,https://clinicaltrials.gov/study/NCT00941330,https://clinicaltrials.gov/study/NCT00820872,https://clinicaltrials.gov/study/NCT03140553,https://clinicaltrials.gov/study/NCT00379015,https://clinicaltrials.gov/study/NCT00490646,https://clinicaltrials.gov/study/NCT00319618,https://clinicaltrials.gov/study/NCT00712881,https://clinicaltrials.gov/study/NCT00198237,https://clinicaltrials.gov/study/NCT00004175,https://clinicaltrials.gov/study/NCT01527487,https://clinicaltrials.gov/study/NCT00193180,https://clinicaltrials.gov/study/NCT00004906,https://clinicaltrials.gov/study/NCT01485926,https://clinicaltrials.gov/study/NCT00179309,https://clinicaltrials.gov/study/NCT01792050,https://clinicaltrials.gov/study/NCT00209092,https://clinicaltrials.gov/study/NCT00527449,https://clinicaltrials.gov/study/NCT00079118,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00525759,https://clinicaltrials.gov/study/NCT00203502,https://clinicaltrials.gov/study/NCT00524810,https://clinicaltrials.gov/study/NCT02838225,https://clinicaltrials.gov/study/NCT01150513,https://clinicaltrials.gov/study/NCT00015938,https://clinicaltrials.gov/study/NCT03735966,https://clinicaltrials.gov/study/NCT02132949,https://clinicaltrials.gov/study/NCT00475670,https://clinicaltrials.gov/study/NCT00494481,https://clinicaltrials.gov/study/NCT00247481,https://clinicaltrials.gov/study/NCT00193037,https://clinicaltrials.gov/study/NCT00214864,https://clinicaltrials.gov/study/NCT00217672,https://clinicaltrials.gov/study/NCT00769470,https://clinicaltrials.gov/study/NCT00428922,https://clinicaltrials.gov/study/NCT01396655,https://clinicaltrials.gov/study/NCT00212082,https://clinicaltrials.gov/study/NCT00976989,https://clinicaltrials.gov/study/NCT00545688,https://clinicaltrials.gov/study/NCT00005908,https://clinicaltrials.gov/study/NCT03742986,https://clinicaltrials.gov/study/NCT00248703,https://clinicaltrials.gov/study/NCT00193115,https://clinicaltrials.gov/study/NCT00365365,https://clinicaltrials.gov/study/NCT01959490,https://clinicaltrials.gov/study/NCT00193089,https://clinicaltrials.gov/study/NCT00039520,https://clinicaltrials.gov/study/NCT00054275,https://clinicaltrials.gov/study/NCT00274456,https://clinicaltrials.gov/study/NCT00201708,https://clinicaltrials.gov/study/NCT00365417,https://clinicaltrials.gov/study/NCT00107510,https://clinicaltrials.gov/study/NCT00820547,https://clinicaltrials.gov/study/NCT00055861,https://clinicaltrials.gov/study/NCT01208480,https://clinicaltrials.gov/study/NCT02834403,https://clinicaltrials.gov/study/NCT00695994,https://clinicaltrials.gov/study/NCT00212095,https://clinicaltrials.gov/study/NCT00003565,https://clinicaltrials.gov/study/NCT02365805,https://clinicaltrials.gov/study/NCT00028873,https://clinicaltrials.gov/study/NCT01671319,https://clinicaltrials.gov/study/NCT00044993,https://clinicaltrials.gov/study/NCT02229084,https://clinicaltrials.gov/study/NCT00077857,https://clinicaltrials.gov/study/NCT01658462,https://clinicaltrials.gov/study/NCT00068341,https://clinicaltrials.gov/study/NCT02748213,https://clinicaltrials.gov/study/NCT00679341,https://clinicaltrials.gov/study/NCT00006104,https://clinicaltrials.gov/study/NCT00773695,https://clinicaltrials.gov/study/NCT00232479,https://clinicaltrials.gov/study/NCT02846428,https://clinicaltrials.gov/study/NCT00149214,https://clinicaltrials.gov/study/NCT00146042,https://clinicaltrials.gov/study/NCT01025349,https://clinicaltrials.gov/study/NCT01446016,https://clinicaltrials.gov/study/NCT00493649,https://clinicaltrials.gov/study/NCT00123929,https://clinicaltrials.gov/study/NCT00203372,https://clinicaltrials.gov/study/NCT02909751,https://clinicaltrials.gov/study/NCT00754351,https://clinicaltrials.gov/study/NCT00015886,https://clinicaltrials.gov/study/NCT03887130,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT01142778,https://clinicaltrials.gov/study/NCT00003352,https://clinicaltrials.gov/study/NCT00088998
MONDO_0007254	breast cancer	CHEMBL3545262	SACITUZUMAB GOVITECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	2	Recruiting	https://clinicaltrials.gov/study/NCT04039230,https://clinicaltrials.gov/study/NCT05332561,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT06328387,https://clinicaltrials.gov/study/NCT06102824,https://clinicaltrials.gov/study/NCT04468061,https://clinicaltrials.gov/study/NCT05675579,https://clinicaltrials.gov/study/NCT04230109,https://clinicaltrials.gov/study/NCT06100874
MONDO_0007254	breast cancer	CHEMBL1879463	DACTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	2	Withdrawn	https://clinicaltrials.gov/study/NCT01288092
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS8	NADH:ubiquinone oxidoreductase core subunit S8	2	Completed	https://clinicaltrials.gov/study/NCT01885013
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Unknown status	https://clinicaltrials.gov/study/NCT03144947
EFO_0000305	breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD4	DNA polymerase delta 4, accessory subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Terminated	https://clinicaltrials.gov/study/NCT00079326,https://clinicaltrials.gov/study/NCT00790894,https://clinicaltrials.gov/study/NCT00765765
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02530489,https://clinicaltrials.gov/study/NCT02876107,https://clinicaltrials.gov/study/NCT02315196,https://clinicaltrials.gov/study/NCT04216472,https://clinicaltrials.gov/study/NCT01750073,https://clinicaltrials.gov/study/NCT02883062,https://clinicaltrials.gov/study/NCT02593175,https://clinicaltrials.gov/study/NCT04129996,https://clinicaltrials.gov/study/NCT04395989,https://clinicaltrials.gov/study/NCT04770272,https://clinicaltrials.gov/study/NCT04958785
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB8	NADH:ubiquinone oxidoreductase subunit B8	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL723	CARVEDILOL	Small molecule	Adrenergic receptor beta antagonist		ADRB2	adrenoceptor beta 2	2	Recruiting	https://clinicaltrials.gov/study/NCT03879629
EFO_0006861	male breast carcinoma	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00096434
EFO_0005537	triple-negative breast cancer	CHEMBL4297892	ANVATABART OPADOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Terminated	https://clinicaltrials.gov/study/NCT00722072,https://clinicaltrials.gov/study/NCT00622466,https://clinicaltrials.gov/study/NCT00573755
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Unknown status	https://clinicaltrials.gov/study/NCT02175446,https://clinicaltrials.gov/study/NCT03412955
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Unknown status	https://clinicaltrials.gov/study/NCT03412955
MONDO_0007254	breast cancer	CHEMBL554	LAPATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Withdrawn	https://clinicaltrials.gov/study/NCT01985893,https://clinicaltrials.gov/study/NCT01005641,https://clinicaltrials.gov/study/NCT00343759,https://clinicaltrials.gov/study/NCT00455039
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA11	NADH:ubiquinone oxidoreductase subunit A11	2	Completed	https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT01266486
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT00191243,https://clinicaltrials.gov/study/NCT00201760,https://clinicaltrials.gov/study/NCT00193206,https://clinicaltrials.gov/study/NCT00191854,https://clinicaltrials.gov/study/NCT01201265,https://clinicaltrials.gov/study/NCT00503906,https://clinicaltrials.gov/study/NCT00320541,https://clinicaltrials.gov/study/NCT00191347,https://clinicaltrials.gov/study/NCT00191269,https://clinicaltrials.gov/study/NCT00193050,https://clinicaltrials.gov/study/NCT00618826,https://clinicaltrials.gov/study/NCT00059852,https://clinicaltrials.gov/study/NCT01045304,https://clinicaltrials.gov/study/NCT04464174,https://clinicaltrials.gov/study/NCT00191815,https://clinicaltrials.gov/study/NCT00813956,https://clinicaltrials.gov/study/NCT00191451,https://clinicaltrials.gov/study/NCT00540358,https://clinicaltrials.gov/study/NCT00662129,https://clinicaltrials.gov/study/NCT00193076,https://clinicaltrials.gov/study/NCT00191373,https://clinicaltrials.gov/study/NCT00695994,https://clinicaltrials.gov/study/NCT01550848,https://clinicaltrials.gov/study/NCT00378313,https://clinicaltrials.gov/study/NCT00754351,https://clinicaltrials.gov/study/NCT02435680,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00846027,https://clinicaltrials.gov/study/NCT00623233,https://clinicaltrials.gov/study/NCT00063570,https://clinicaltrials.gov/study/NCT00193063,https://clinicaltrials.gov/study/NCT00532857,https://clinicaltrials.gov/study/NCT00601159,https://clinicaltrials.gov/study/NCT00192101,https://clinicaltrials.gov/study/NCT00334802,https://clinicaltrials.gov/study/NCT00192062,https://clinicaltrials.gov/study/NCT00532623,https://clinicaltrials.gov/study/NCT00450762,https://clinicaltrials.gov/study/NCT03025880,https://clinicaltrials.gov/study/NCT00212069,https://clinicaltrials.gov/study/NCT00003540,https://clinicaltrials.gov/study/NCT00002998,https://clinicaltrials.gov/study/NCT00128856,https://clinicaltrials.gov/study/NCT00403130,https://clinicaltrials.gov/study/NCT00325234,https://clinicaltrials.gov/study/NCT00110084,https://clinicaltrials.gov/study/NCT00894504,https://clinicaltrials.gov/study/NCT00244933,https://clinicaltrials.gov/study/NCT00493636,https://clinicaltrials.gov/study/NCT00006007,https://clinicaltrials.gov/study/NCT00480597,https://clinicaltrials.gov/study/NCT00005991,https://clinicaltrials.gov/study/NCT00191789,https://clinicaltrials.gov/study/NCT02263495,https://clinicaltrials.gov/study/NCT00316199
MONDO_0007254	breast cancer	CHEMBL1535	HYDROXYCHLOROQUINE	Small molecule	Toll-like receptor 7 antagonist		TLR7	toll like receptor 7	2	Recruiting	https://clinicaltrials.gov/study/NCT04523857,https://clinicaltrials.gov/study/NCT06328387
MONDO_0007254	breast cancer	CHEMBL4297892	ANVATABART OPADOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBA3C	tubulin alpha 3c	2	Recruiting	https://clinicaltrials.gov/study/NCT05018702,https://clinicaltrials.gov/study/NCT05426486,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT05018676,https://clinicaltrials.gov/study/NCT04829604
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT01908101
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02568839,https://clinicaltrials.gov/study/NCT04001829
MONDO_0007254	breast cancer	CHEMBL4297522	PEMIGATINIB	Small molecule	Fibroblast growth factor receptor 1 inhibitor		FGFR1	fibroblast growth factor receptor 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05560334
EFO_1000984	inflammatory breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02623972
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		LYN	LYN proto-oncogene, Src family tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT00817531,https://clinicaltrials.gov/study/NCT00780676,https://clinicaltrials.gov/study/NCT05198843
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Suspended	https://clinicaltrials.gov/study/NCT04419181,https://clinicaltrials.gov/study/NCT04675827
EFO_0006861	male breast carcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC1	histone deacetylase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01349959
EFO_0005537	triple-negative breast cancer	CHEMBL3707227	ATEZOLIZUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	2	Completed	https://clinicaltrials.gov/study/NCT03853707
MONDO_0007254	breast cancer	CHEMBL4594456	CADONILIMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06202313
MONDO_0007254	breast cancer	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Unknown status	https://clinicaltrials.gov/study/NCT00499525
EFO_1000984	inflammatory breast carcinoma	CHEMBL535	SUNITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Completed	https://clinicaltrials.gov/study/NCT00513695
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Recruiting	https://clinicaltrials.gov/study/NCT05823623,https://clinicaltrials.gov/study/NCT05296577
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE6A	phosphodiesterase 6A	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT06186700,https://clinicaltrials.gov/study/NCT06176339
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Terminated	https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT00104624,https://clinicaltrials.gov/study/NCT00845910,https://clinicaltrials.gov/study/NCT00118053,https://clinicaltrials.gov/study/NCT03329378,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT00453635,https://clinicaltrials.gov/study/NCT00193024,https://clinicaltrials.gov/study/NCT00852332,https://clinicaltrials.gov/study/NCT00028483,https://clinicaltrials.gov/study/NCT00524459,https://clinicaltrials.gov/study/NCT00025493,https://clinicaltrials.gov/study/NCT00636441,https://clinicaltrials.gov/study/NCT00343512,https://clinicaltrials.gov/study/NCT00665457,https://clinicaltrials.gov/study/NCT00225056,https://clinicaltrials.gov/study/NCT00206453,https://clinicaltrials.gov/study/NCT00080626,https://clinicaltrials.gov/study/NCT01985841,https://clinicaltrials.gov/study/NCT01690325,https://clinicaltrials.gov/study/NCT03894007,https://clinicaltrials.gov/study/NCT00479856,https://clinicaltrials.gov/study/NCT00576901
MONDO_0007254	breast cancer	CHEMBL1201199	LEUPROLIDE	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	2	Completed	https://clinicaltrials.gov/study/NCT01989780,https://clinicaltrials.gov/study/NCT02344550,https://clinicaltrials.gov/study/NCT00903162
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Terminated	https://clinicaltrials.gov/study/NCT00832338
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV3	NADH:ubiquinone oxidoreductase subunit V3	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Terminated	https://clinicaltrials.gov/study/NCT00832338
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Epidermal growth factor receptor inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBA4A	tubulin alpha 4a	2	Completed	https://clinicaltrials.gov/study/NCT00284180
MONDO_0007254	breast cancer	CHEMBL575448	BMS-754807	Small molecule	Insulin receptor inhibitor		INSR	insulin receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01225172
MONDO_0007254	breast cancer	CHEMBL1282	IMIQUIMOD	Small molecule	Toll-like receptor 7 agonist		TLR7	toll like receptor 7	2	Completed	https://clinicaltrials.gov/study/NCT00899574
MONDO_0007254	breast cancer	CHEMBL4650387	CDX-301	Protein	Tyrosine-protein kinase receptor FLT3 agonist		FLT3	fms related receptor tyrosine kinase 3	2	Recruiting	https://clinicaltrials.gov/study/NCT03804944
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC5	histone deacetylase 5	2	Completed	https://clinicaltrials.gov/study/NCT00777049
EFO_0000305	breast carcinoma	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	2	Recruiting	https://clinicaltrials.gov/study/NCT05319873
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC7	histone deacetylase 7	2	Withdrawn	https://clinicaltrials.gov/study/NCT02115594
MONDO_0007254	breast cancer	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04819243
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Recruiting	https://clinicaltrials.gov/study/NCT01817452,https://clinicaltrials.gov/study/NCT04355858,https://clinicaltrials.gov/study/NCT05174832,https://clinicaltrials.gov/study/NCT04329065,https://clinicaltrials.gov/study/NCT04872985,https://clinicaltrials.gov/study/NCT03150576,https://clinicaltrials.gov/study/NCT05353361,https://clinicaltrials.gov/study/NCT05659056,https://clinicaltrials.gov/study/NCT05629429,https://clinicaltrials.gov/study/NCT05068141,https://clinicaltrials.gov/study/NCT04681911,https://clinicaltrials.gov/study/NCT04537286,https://clinicaltrials.gov/study/NCT04443348,https://clinicaltrials.gov/study/NCT03412643,https://clinicaltrials.gov/study/NCT05900206,https://clinicaltrials.gov/study/NCT04745975,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04771871,https://clinicaltrials.gov/study/NCT03907800,https://clinicaltrials.gov/study/NCT04576143,https://clinicaltrials.gov/study/NCT05189067,https://clinicaltrials.gov/study/NCT05383196,https://clinicaltrials.gov/study/NCT05749575,https://clinicaltrials.gov/study/NCT04676997,https://clinicaltrials.gov/study/NCT05325632,https://clinicaltrials.gov/study/NCT04243616,https://clinicaltrials.gov/study/NCT04877821,https://clinicaltrials.gov/study/NCT05633914,https://clinicaltrials.gov/study/NCT04159142,https://clinicaltrials.gov/study/NCT05681728,https://clinicaltrials.gov/study/NCT05889390,https://clinicaltrials.gov/study/NCT04090398,https://clinicaltrials.gov/study/NCT05582538,https://clinicaltrials.gov/study/NCT05447702,https://clinicaltrials.gov/study/NCT04893109,https://clinicaltrials.gov/study/NCT03048942,https://clinicaltrials.gov/study/NCT04425018,https://clinicaltrials.gov/study/NCT03571633,https://clinicaltrials.gov/study/NCT04917900,https://clinicaltrials.gov/study/NCT05346107,https://clinicaltrials.gov/study/NCT05761470,https://clinicaltrials.gov/study/NCT05020860,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT06245889,https://clinicaltrials.gov/study/NCT05749016,https://clinicaltrials.gov/study/NCT04722718,https://clinicaltrials.gov/study/NCT05852691,https://clinicaltrials.gov/study/NCT05728268,https://clinicaltrials.gov/study/NCT04780347,https://clinicaltrials.gov/study/NCT05918328
EFO_0000305	breast carcinoma	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	2	Recruiting	https://clinicaltrials.gov/study/NCT05319873
EFO_1000984	inflammatory breast carcinoma	CHEMBL1567	SUNITINIB MALATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT00513695
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND3	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3	2	Completed	https://clinicaltrials.gov/study/NCT01885013
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT05041101
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Withdrawn	https://clinicaltrials.gov/study/NCT00005614
MONDO_0007254	breast cancer	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB7	NADH:ubiquinone oxidoreductase subunit B7	2	Completed	https://clinicaltrials.gov/study/NCT04170465
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Terminated	https://clinicaltrials.gov/study/NCT03358004,https://clinicaltrials.gov/study/NCT00088985,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT00194792,https://clinicaltrials.gov/study/NCT00049660
MONDO_0007254	breast cancer	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Terminated	https://clinicaltrials.gov/study/NCT03329378,https://clinicaltrials.gov/study/NCT03894007,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT01912963,https://clinicaltrials.gov/study/NCT02000596
EFO_0005537	triple-negative breast cancer	CHEMBL4298009	IERAMILIMAB	Antibody	Lymphocyte activation gene 3 protein inhibitor		LAG3	lymphocyte activating 3	2	Completed	https://clinicaltrials.gov/study/NCT03499899
EFO_0006861	male breast carcinoma	CHEMBL535	SUNITINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Completed	https://clinicaltrials.gov/study/NCT00513695
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND6	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04248998
MONDO_0007254	breast cancer	CHEMBL3545210	SR16234	Small molecule	Estrogen receptor alpha antagonist	Antagonist	ESR1	estrogen receptor 1	2	Completed	https://clinicaltrials.gov/study/NCT00166543
MONDO_0007254	breast cancer	CHEMBL413	SIROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	2	Completed	https://clinicaltrials.gov/study/NCT00411788
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02876302,https://clinicaltrials.gov/study/NCT01730833
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND1	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1	2	Completed	https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT01310231
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Unknown status	https://clinicaltrials.gov/study/NCT01372579
EFO_0005537	triple-negative breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC8	histone deacetylase 8	2	Terminated	https://clinicaltrials.gov/study/NCT01234532
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Terminated	https://clinicaltrials.gov/study/NCT00088985,https://clinicaltrials.gov/study/NCT00169104,https://clinicaltrials.gov/study/NCT02213744,https://clinicaltrials.gov/study/NCT00453635,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT00176488,https://clinicaltrials.gov/study/NCT02585388,https://clinicaltrials.gov/study/NCT00049660,https://clinicaltrials.gov/study/NCT01185509,https://clinicaltrials.gov/study/NCT00194792,https://clinicaltrials.gov/study/NCT01161368,https://clinicaltrials.gov/study/NCT00754702,https://clinicaltrials.gov/study/NCT00694200,https://clinicaltrials.gov/study/NCT03358004,https://clinicaltrials.gov/study/NCT00130507
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF4	NADH:ubiquinone oxidoreductase complex assembly factor 4	2	Recruiting	https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04559308
EFO_0000304	breast adenocarcinoma	CHEMBL3707227	ATEZOLIZUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02530489
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB5	NADH:ubiquinone oxidoreductase subunit B5	2	Terminated	https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT04899349,https://clinicaltrials.gov/study/NCT02472353,https://clinicaltrials.gov/study/NCT02360059,https://clinicaltrials.gov/study/NCT01477060
MONDO_0007254	breast cancer	CHEMBL1770916	NIROGACESTAT	Small molecule	Gamma-secretase inhibitor		PSEN2	presenilin 2	2	Withdrawn	https://clinicaltrials.gov/study/NCT02338531
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04517292,https://clinicaltrials.gov/study/NCT04143906,https://clinicaltrials.gov/study/NCT05263882
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist	Antagonist	ESR2	estrogen receptor 2	2	Withdrawn	https://clinicaltrials.gov/study/NCT03377101,https://clinicaltrials.gov/study/NCT04901299,https://clinicaltrials.gov/study/NCT05191004,https://clinicaltrials.gov/study/NCT02115594
MONDO_0007254	breast cancer	CHEMBL3644587	2X-121	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03562832
EFO_0000305	breast carcinoma	CHEMBL1079742	ERLOTINIB HYDROCHLORIDE	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Completed	https://clinicaltrials.gov/study/NCT00054132
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS7	NADH:ubiquinone oxidoreductase core subunit S7	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT04559308
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT00191373
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND1	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Terminated	https://clinicaltrials.gov/study/NCT00095888,https://clinicaltrials.gov/study/NCT00470249,https://clinicaltrials.gov/study/NCT00679029,https://clinicaltrials.gov/study/NCT00323063
MONDO_0007254	breast cancer	CHEMBL1201247	GOSERELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	2	Completed	https://clinicaltrials.gov/study/NCT03628066,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00532272,https://clinicaltrials.gov/study/NCT01989780,https://clinicaltrials.gov/study/NCT00432172,https://clinicaltrials.gov/study/NCT00196846,https://clinicaltrials.gov/study/NCT00303524,https://clinicaltrials.gov/study/NCT00010010,https://clinicaltrials.gov/study/NCT00322348,https://clinicaltrials.gov/study/NCT00235937,https://clinicaltrials.gov/study/NCT00186121,https://clinicaltrials.gov/study/NCT03007979
EFO_0005537	triple-negative breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		BLK	BLK proto-oncogene, Src family tyrosine kinase	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06355037
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA3	NADH:ubiquinone oxidoreductase subunit A3	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Terminated	https://clinicaltrials.gov/study/NCT00832338
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS1	NADH:ubiquinone oxidoreductase core subunit S1	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0005537	triple-negative breast cancer	CHEMBL2109406	PATRITUMAB	Antibody	Receptor tyrosine-protein kinase erbB-3 inhibitor		ERBB3	erb-b2 receptor tyrosine kinase 3	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL1200694	SEVOFLURANE	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRA6	gamma-aminobutyric acid type A receptor subunit alpha6	2	Completed	https://clinicaltrials.gov/study/NCT02839668
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT01352494,https://clinicaltrials.gov/study/NCT02544243,https://clinicaltrials.gov/study/NCT03423849,https://clinicaltrials.gov/study/NCT00027989,https://clinicaltrials.gov/study/NCT02341911
EFO_0000305	breast carcinoma	CHEMBL180022	NERATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03101748
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Recruiting	https://clinicaltrials.gov/study/NCT04624711,https://clinicaltrials.gov/study/NCT05530057,https://clinicaltrials.gov/study/NCT05546255
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Recruiting	https://clinicaltrials.gov/study/NCT03515798,https://clinicaltrials.gov/study/NCT05383196
MONDO_0007254	breast cancer	CHEMBL1082407	ENZALUTAMIDE	Small molecule	Androgen Receptor antagonist		AR	androgen receptor	2	Completed	https://clinicaltrials.gov/study/NCT02953860,https://clinicaltrials.gov/study/NCT02091960,https://clinicaltrials.gov/study/NCT01889238
MONDO_0007254	breast cancer	CHEMBL4297715	CAMRELIZUMAB	Antibody	Programmed cell death protein 1 antagonist		PDCD1	programmed cell death 1	2	Completed	https://clinicaltrials.gov/study/NCT04805736,https://clinicaltrials.gov/study/NCT03394287
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND1	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1	2	Unknown status	https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT02506777
MONDO_0007254	breast cancer	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1173055	RUCAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Completed	https://clinicaltrials.gov/study/NCT00664781
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04502680,https://clinicaltrials.gov/study/NCT06308939,https://clinicaltrials.gov/study/NCT04913571,https://clinicaltrials.gov/study/NCT05263882,https://clinicaltrials.gov/study/NCT04517292,https://clinicaltrials.gov/study/NCT06202313
MONDO_0007254	breast cancer	CHEMBL4297736	PRALUZATAMAB RAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT04596150
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE4C	phosphodiesterase 4C	2	Recruiting	https://clinicaltrials.gov/study/NCT06087237
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB1	NADH:ubiquinone oxidoreductase subunit B1	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0005537	triple-negative breast cancer	CHEMBL1082407	ENZALUTAMIDE	Small molecule	Androgen Receptor antagonist		AR	androgen receptor	2	Completed	https://clinicaltrials.gov/study/NCT02689427
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R2	phosphoinositide-3-kinase regulatory subunit 2	2	Recruiting	https://clinicaltrials.gov/study/NCT03698383
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04517292,https://clinicaltrials.gov/study/NCT04143906,https://clinicaltrials.gov/study/NCT05263882
MONDO_0007254	breast cancer	CHEMBL3545262	SACITUZUMAB GOVITECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06236269,https://clinicaltrials.gov/study/NCT06238921,https://clinicaltrials.gov/study/NCT06081244,https://clinicaltrials.gov/study/NCT06263543
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Recruiting	https://clinicaltrials.gov/study/NCT04266249
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Unknown status	https://clinicaltrials.gov/study/NCT03144947
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		LCK	LCK proto-oncogene, Src family tyrosine kinase	2	Withdrawn	https://clinicaltrials.gov/study/NCT01410708
EFO_0006861	male breast carcinoma	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05501704
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Completed	https://clinicaltrials.gov/study/NCT01835236,https://clinicaltrials.gov/study/NCT01196052,https://clinicaltrials.gov/study/NCT00943670,https://clinicaltrials.gov/study/NCT00679211,https://clinicaltrials.gov/study/NCT03530696,https://clinicaltrials.gov/study/NCT02073487,https://clinicaltrials.gov/study/NCT00509769,https://clinicaltrials.gov/study/NCT00679341,https://clinicaltrials.gov/study/NCT02924883,https://clinicaltrials.gov/study/NCT01904903
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Unknown status	https://clinicaltrials.gov/study/NCT00499525,https://clinicaltrials.gov/study/NCT00954135
MONDO_0007254	breast cancer	CHEMBL1908360	EVEROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	2	Terminated	https://clinicaltrials.gov/study/NCT02236572,https://clinicaltrials.gov/study/NCT00674414,https://clinicaltrials.gov/study/NCT02269670,https://clinicaltrials.gov/study/NCT01627067,https://clinicaltrials.gov/study/NCT00934895,https://clinicaltrials.gov/study/NCT00827567
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Fibroblast growth factor receptor 3 inhibitor		FGFR3	fibroblast growth factor receptor 3	2	Completed	https://clinicaltrials.gov/study/NCT01466972,https://clinicaltrials.gov/study/NCT00509587
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB2	NADH:ubiquinone oxidoreductase subunit B2	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03219476,https://clinicaltrials.gov/study/NCT04059484,https://clinicaltrials.gov/study/NCT02206984,https://clinicaltrials.gov/study/NCT03822468,https://clinicaltrials.gov/study/NCT04272801,https://clinicaltrials.gov/study/NCT05549505,https://clinicaltrials.gov/study/NCT03671330,https://clinicaltrials.gov/study/NCT02188745
EFO_0005537	triple-negative breast cancer	CHEMBL27	PROPRANOLOL	Small molecule	Beta-1 adrenergic receptor antagonist		ADRB1	adrenoceptor beta 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT05741164
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Vascular endothelial growth factor receptor 1 inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Completed	https://clinicaltrials.gov/study/NCT00662025,https://clinicaltrials.gov/study/NCT00482755,https://clinicaltrials.gov/study/NCT00270413
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Unknown status	https://clinicaltrials.gov/study/NCT03144947
MONDO_0007254	breast cancer	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC7	histone deacetylase 7	2	Completed	https://clinicaltrials.gov/study/NCT00098397
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Unknown status	https://clinicaltrials.gov/study/NCT02790580
MONDO_0007254	breast cancer	CHEMBL1614701	SELUMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 2 inhibitor		MAP2K2	mitogen-activated protein kinase kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT01160718
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04216472,https://clinicaltrials.gov/study/NCT01463072,https://clinicaltrials.gov/study/NCT02436993,https://clinicaltrials.gov/study/NCT02187991,https://clinicaltrials.gov/study/NCT04001829,https://clinicaltrials.gov/study/NCT02603679,https://clinicaltrials.gov/study/NCT03179904,https://clinicaltrials.gov/study/NCT02530489,https://clinicaltrials.gov/study/NCT03101748
MONDO_0007254	breast cancer	CHEMBL2220486	LUCITANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Terminated	https://clinicaltrials.gov/study/NCT02202746
MONDO_0007254	breast cancer	CHEMBL1289601	LENVATINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Unknown status	https://clinicaltrials.gov/study/NCT03168074
EFO_0000305	breast carcinoma	CHEMBL3707324	UTOMILUMAB	Antibody	Tumor necrosis factor receptor superfamily member 9 agonist		TNFRSF9	TNF receptor superfamily member 9	2	Recruiting	https://clinicaltrials.gov/study/NCT03971409
MONDO_0007254	breast cancer	CHEMBL941	IMATINIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00338728,https://clinicaltrials.gov/study/NCT00087152,https://clinicaltrials.gov/study/NCT00193180
EFO_0000305	breast carcinoma	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist	Antagonist	ESR1	estrogen receptor 1	2	Recruiting	https://clinicaltrials.gov/study/NCT04762979,https://clinicaltrials.gov/study/NCT05319873,https://clinicaltrials.gov/study/NCT05554354,https://clinicaltrials.gov/study/NCT02476786,https://clinicaltrials.gov/study/NCT02778685
MONDO_0007254	breast cancer	CHEMBL1642	IMATINIB MESYLATE	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	2	Terminated	https://clinicaltrials.gov/study/NCT00323063
EFO_0006861	male breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor		RRM1	ribonucleotide reductase catalytic subunit M1	2	Terminated	https://clinicaltrials.gov/study/NCT00095888
EFO_0006861	male breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	2	Terminated	https://clinicaltrials.gov/study/NCT00095888
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04498793,https://clinicaltrials.gov/study/NCT03959397,https://clinicaltrials.gov/study/NCT04290793,https://clinicaltrials.gov/study/NCT05444998,https://clinicaltrials.gov/study/NCT04301375,https://clinicaltrials.gov/study/NCT04907344,https://clinicaltrials.gov/study/NCT04499118,https://clinicaltrials.gov/study/NCT04194684,https://clinicaltrials.gov/study/NCT04659499,https://clinicaltrials.gov/study/NCT04639271,https://clinicaltrials.gov/study/NCT04900311,https://clinicaltrials.gov/study/NCT04946227,https://clinicaltrials.gov/study/NCT05872412
MONDO_0007254	breast cancer	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	2	Withdrawn	https://clinicaltrials.gov/study/NCT04038489,https://clinicaltrials.gov/study/NCT00434031,https://clinicaltrials.gov/study/NCT03554109,https://clinicaltrials.gov/study/NCT00006261,https://clinicaltrials.gov/study/NCT02053597,https://clinicaltrials.gov/study/NCT02215876,https://clinicaltrials.gov/study/NCT02850419,https://clinicaltrials.gov/study/NCT01227408,https://clinicaltrials.gov/study/NCT02067416
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06078384
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Withdrawn	https://clinicaltrials.gov/study/NCT04351230
EFO_0006861	male breast carcinoma	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	2	Completed	https://clinicaltrials.gov/study/NCT00096434
MONDO_0007254	breast cancer	CHEMBL4297844	TRASTUZUMAB DERUXTECAN	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 binding agent		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Recruiting	https://clinicaltrials.gov/study/NCT06102824,https://clinicaltrials.gov/study/NCT05795101,https://clinicaltrials.gov/study/NCT05900206,https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT05744375,https://clinicaltrials.gov/study/NCT05710666,https://clinicaltrials.gov/study/NCT06328387
MONDO_0007254	breast cancer	CHEMBL1237044	TRAMADOL	Small molecule	Mu opioid receptor agonist		OPRM1	opioid receptor mu 1	2	Completed	https://clinicaltrials.gov/study/NCT02839668
EFO_1000984	inflammatory breast carcinoma	CHEMBL535	SUNITINIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	2	Completed	https://clinicaltrials.gov/study/NCT00513695
EFO_0006861	male breast carcinoma	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Completed	https://clinicaltrials.gov/study/NCT00017394
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF3	NADH:ubiquinone oxidoreductase complex assembly factor 3	2	Completed	https://clinicaltrials.gov/study/NCT01885013
EFO_1000984	inflammatory breast carcinoma	CHEMBL289228	TIPIFARNIB	Small molecule	Protein farnesyltransferase inhibitor		FNTA	farnesyltransferase, CAAX box, subunit alpha	2	Completed	https://clinicaltrials.gov/study/NCT00049114
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Terminated	https://clinicaltrials.gov/study/NCT00754702,https://clinicaltrials.gov/study/NCT00088985,https://clinicaltrials.gov/study/NCT02213744,https://clinicaltrials.gov/study/NCT01185509,https://clinicaltrials.gov/study/NCT00453635,https://clinicaltrials.gov/study/NCT00694200,https://clinicaltrials.gov/study/NCT03358004,https://clinicaltrials.gov/study/NCT00169104,https://clinicaltrials.gov/study/NCT00130507,https://clinicaltrials.gov/study/NCT02585388,https://clinicaltrials.gov/study/NCT00176488,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT00049660,https://clinicaltrials.gov/study/NCT00194792,https://clinicaltrials.gov/study/NCT01161368,https://clinicaltrials.gov/study/NCT02229149
MONDO_0007254	breast cancer	CHEMBL679	EPINEPHRINE	Small molecule	Adrenergic receptor agonist		ADRA2C	adrenoceptor alpha 2C	2	Completed	https://clinicaltrials.gov/study/NCT02525718
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF2	NADH:ubiquinone oxidoreductase complex assembly factor 2	2	Completed	https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT02028221
MONDO_0007254	breast cancer	CHEMBL489	AFIMOXIFENE	Small molecule	Estrogen receptor modulator	Antagonist	ESR2	estrogen receptor 2	2	Completed	https://clinicaltrials.gov/study/NCT03931928
EFO_1000984	inflammatory breast carcinoma	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	2	Completed	https://clinicaltrials.gov/study/NCT00513695,https://clinicaltrials.gov/study/NCT00049114
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Unknown status	https://clinicaltrials.gov/study/NCT00027989
EFO_0006861	male breast carcinoma	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		PSEN1	presenilin 1	2	Terminated	https://clinicaltrials.gov/study/NCT01151449
EFO_0000305	breast carcinoma	CHEMBL1201247	GOSERELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	2	Completed	https://clinicaltrials.gov/study/NCT03007979
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Completed	https://clinicaltrials.gov/study/NCT00006007,https://clinicaltrials.gov/study/NCT00002998,https://clinicaltrials.gov/study/NCT00005991,https://clinicaltrials.gov/study/NCT00059852,https://clinicaltrials.gov/study/NCT00662129,https://clinicaltrials.gov/study/NCT00003540
MONDO_0007254	breast cancer	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Terminated	https://clinicaltrials.gov/study/NCT00549822,https://clinicaltrials.gov/study/NCT01225172,https://clinicaltrials.gov/study/NCT00573755,https://clinicaltrials.gov/study/NCT00880009,https://clinicaltrials.gov/study/NCT00796107,https://clinicaltrials.gov/study/NCT00498901,https://clinicaltrials.gov/study/NCT00684216,https://clinicaltrials.gov/study/NCT04191382,https://clinicaltrials.gov/study/NCT02585388,https://clinicaltrials.gov/study/NCT00611715,https://clinicaltrials.gov/study/NCT00499681,https://clinicaltrials.gov/study/NCT02269670,https://clinicaltrials.gov/study/NCT00461773,https://clinicaltrials.gov/study/NCT01205685,https://clinicaltrials.gov/study/NCT01430585,https://clinicaltrials.gov/study/NCT00101062,https://clinicaltrials.gov/study/NCT01919229,https://clinicaltrials.gov/study/NCT03874325,https://clinicaltrials.gov/study/NCT03709082,https://clinicaltrials.gov/study/NCT01368263,https://clinicaltrials.gov/study/NCT05085002
MONDO_0007254	breast cancer	CHEMBL225072	PEMETREXED	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	2	Completed	https://clinicaltrials.gov/study/NCT00063570,https://clinicaltrials.gov/study/NCT00102219,https://clinicaltrials.gov/study/NCT00006007,https://clinicaltrials.gov/study/NCT00149214,https://clinicaltrials.gov/study/NCT00191347,https://clinicaltrials.gov/study/NCT00065533,https://clinicaltrials.gov/study/NCT00325234
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB5	NADH:ubiquinone oxidoreductase subunit B5	2	Unknown status	https://clinicaltrials.gov/study/NCT02506777,https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT03192293
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Unknown status	https://clinicaltrials.gov/study/NCT02681562
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB10	NADH:ubiquinone oxidoreductase subunit B10	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL941	IMATINIB	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	2	Completed	https://clinicaltrials.gov/study/NCT00193180,https://clinicaltrials.gov/study/NCT00338728,https://clinicaltrials.gov/study/NCT00087152
MONDO_0007254	breast cancer	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 1 inhibitor		HDAC1	histone deacetylase 1	2	Terminated	https://clinicaltrials.gov/study/NCT04190056,https://clinicaltrials.gov/study/NCT01194427
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Completed	https://clinicaltrials.gov/study/NCT00005635,https://clinicaltrials.gov/study/NCT00096343,https://clinicaltrials.gov/study/NCT01959490,https://clinicaltrials.gov/study/NCT00003050,https://clinicaltrials.gov/study/NCT00919880,https://clinicaltrials.gov/study/NCT00002937,https://clinicaltrials.gov/study/NCT00768859,https://clinicaltrials.gov/study/NCT03982485,https://clinicaltrials.gov/study/NCT01740336,https://clinicaltrials.gov/study/NCT01705691,https://clinicaltrials.gov/study/NCT01204125,https://clinicaltrials.gov/study/NCT03644186,https://clinicaltrials.gov/study/NCT03248427,https://clinicaltrials.gov/study/NCT01792050,https://clinicaltrials.gov/study/NCT00475670,https://clinicaltrials.gov/study/NCT02263495,https://clinicaltrials.gov/study/NCT00251472,https://clinicaltrials.gov/study/NCT00635050,https://clinicaltrials.gov/study/NCT01656538,https://clinicaltrials.gov/study/NCT00542451,https://clinicaltrials.gov/study/NCT01008150,https://clinicaltrials.gov/study/NCT03193853,https://clinicaltrials.gov/study/NCT01688609,https://clinicaltrials.gov/study/NCT01256762,https://clinicaltrials.gov/study/NCT01816594,https://clinicaltrials.gov/study/NCT00334802,https://clinicaltrials.gov/study/NCT00093145,https://clinicaltrials.gov/study/NCT00003392,https://clinicaltrials.gov/study/NCT03301350,https://clinicaltrials.gov/study/NCT04224922,https://clinicaltrials.gov/study/NCT00072319,https://clinicaltrials.gov/study/NCT00110084,https://clinicaltrials.gov/study/NCT00856492,https://clinicaltrials.gov/study/NCT00499083,https://clinicaltrials.gov/study/NCT00773695,https://clinicaltrials.gov/study/NCT00503906,https://clinicaltrials.gov/study/NCT01722968,https://clinicaltrials.gov/study/NCT01036087,https://clinicaltrials.gov/study/NCT00618657,https://clinicaltrials.gov/study/NCT00479674,https://clinicaltrials.gov/study/NCT04408118,https://clinicaltrials.gov/study/NCT02229084,https://clinicaltrials.gov/study/NCT00002679,https://clinicaltrials.gov/study/NCT00194779,https://clinicaltrials.gov/study/NCT00148681,https://clinicaltrials.gov/study/NCT01506609,https://clinicaltrials.gov/study/NCT00316199,https://clinicaltrials.gov/study/NCT00256243,https://clinicaltrials.gov/study/NCT02938442,https://clinicaltrials.gov/study/NCT01203267,https://clinicaltrials.gov/study/NCT00028873,https://clinicaltrials.gov/study/NCT01023204,https://clinicaltrials.gov/study/NCT00723125,https://clinicaltrials.gov/study/NCT00005649,https://clinicaltrials.gov/study/NCT00503750,https://clinicaltrials.gov/study/NCT00003539,https://clinicaltrials.gov/study/NCT02132949,https://clinicaltrials.gov/study/NCT00019812,https://clinicaltrials.gov/study/NCT01827163,https://clinicaltrials.gov/study/NCT00096291,https://clinicaltrials.gov/study/NCT00629499,https://clinicaltrials.gov/study/NCT01106898,https://clinicaltrials.gov/study/NCT00645177,https://clinicaltrials.gov/study/NCT00006256,https://clinicaltrials.gov/study/NCT00006110,https://clinicaltrials.gov/study/NCT00403130,https://clinicaltrials.gov/study/NCT00467012,https://clinicaltrials.gov/study/NCT01421472,https://clinicaltrials.gov/study/NCT01320111,https://clinicaltrials.gov/study/NCT02474186,https://clinicaltrials.gov/study/NCT02280252,https://clinicaltrials.gov/study/NCT00482391,https://clinicaltrials.gov/study/NCT01973660,https://clinicaltrials.gov/study/NCT00846027,https://clinicaltrials.gov/study/NCT03072992,https://clinicaltrials.gov/study/NCT02370238,https://clinicaltrials.gov/study/NCT05112536,https://clinicaltrials.gov/study/NCT00254592,https://clinicaltrials.gov/study/NCT00511459,https://clinicaltrials.gov/study/NCT00378313,https://clinicaltrials.gov/study/NCT03887130,https://clinicaltrials.gov/study/NCT01572727,https://clinicaltrials.gov/study/NCT02909751,https://clinicaltrials.gov/study/NCT00096668,https://clinicaltrials.gov/study/NCT00274456,https://clinicaltrials.gov/study/NCT00733408,https://clinicaltrials.gov/study/NCT01446016,https://clinicaltrials.gov/study/NCT01423695,https://clinicaltrials.gov/study/NCT03853707,https://clinicaltrials.gov/study/NCT01276041,https://clinicaltrials.gov/study/NCT00662129,https://clinicaltrials.gov/study/NCT02365805,https://clinicaltrials.gov/study/NCT01204437,https://clinicaltrials.gov/study/NCT00618826,https://clinicaltrials.gov/study/NCT00392392,https://clinicaltrials.gov/study/NCT00795899,https://clinicaltrials.gov/study/NCT01190982,https://clinicaltrials.gov/study/NCT00320541,https://clinicaltrials.gov/study/NCT01982448,https://clinicaltrials.gov/study/NCT00004092,https://clinicaltrials.gov/study/NCT02687490,https://clinicaltrials.gov/study/NCT00001384,https://clinicaltrials.gov/study/NCT00370552,https://clinicaltrials.gov/study/NCT03326102,https://clinicaltrials.gov/study/NCT01818063,https://clinicaltrials.gov/study/NCT01835236,https://clinicaltrials.gov/study/NCT01307891,https://clinicaltrials.gov/study/NCT01432223,https://clinicaltrials.gov/study/NCT00407888,https://clinicaltrials.gov/study/NCT01672671,https://clinicaltrials.gov/study/NCT00394082,https://clinicaltrials.gov/study/NCT02783222,https://clinicaltrials.gov/study/NCT00001498,https://clinicaltrials.gov/study/NCT00394251,https://clinicaltrials.gov/study/NCT01593020,https://clinicaltrials.gov/study/NCT02301988,https://clinicaltrials.gov/study/NCT00532857,https://clinicaltrials.gov/study/NCT00915018,https://clinicaltrials.gov/study/NCT01779479,https://clinicaltrials.gov/study/NCT00971945,https://clinicaltrials.gov/study/NCT00193206,https://clinicaltrials.gov/study/NCT00052351,https://clinicaltrials.gov/study/NCT01617668,https://clinicaltrials.gov/study/NCT02954055,https://clinicaltrials.gov/study/NCT00146562,https://clinicaltrials.gov/study/NCT00003992,https://clinicaltrials.gov/study/NCT03121352,https://clinicaltrials.gov/study/NCT00136539,https://clinicaltrials.gov/study/NCT00007904,https://clinicaltrials.gov/study/NCT01989780,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00559845,https://clinicaltrials.gov/study/NCT02073487,https://clinicaltrials.gov/study/NCT01186991,https://clinicaltrials.gov/study/NCT00004013,https://clinicaltrials.gov/study/NCT00003035,https://clinicaltrials.gov/study/NCT02789657,https://clinicaltrials.gov/study/NCT01855828,https://clinicaltrials.gov/study/NCT00455533,https://clinicaltrials.gov/study/NCT00128856,https://clinicaltrials.gov/study/NCT02628613,https://clinicaltrials.gov/study/NCT00546156,https://clinicaltrials.gov/study/NCT02698891,https://clinicaltrials.gov/study/NCT00675259,https://clinicaltrials.gov/study/NCT01969032,https://clinicaltrials.gov/study/NCT03742986,https://clinicaltrials.gov/study/NCT02685059,https://clinicaltrials.gov/study/NCT00003612,https://clinicaltrials.gov/study/NCT00915603,https://clinicaltrials.gov/study/NCT02225652,https://clinicaltrials.gov/study/NCT00002826,https://clinicaltrials.gov/study/NCT00654836,https://clinicaltrials.gov/study/NCT01565499,https://clinicaltrials.gov/study/NCT00191854,https://clinicaltrials.gov/study/NCT01847001,https://clinicaltrials.gov/study/NCT03289819,https://clinicaltrials.gov/study/NCT00930930,https://clinicaltrials.gov/study/NCT00944047,https://clinicaltrials.gov/study/NCT01594177,https://clinicaltrials.gov/study/NCT00580333,https://clinicaltrials.gov/study/NCT00436566
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Withdrawn	https://clinicaltrials.gov/study/NCT03032614
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA3	NADH:ubiquinone oxidoreductase subunit A3	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL52885	ENMD-981693	Small molecule	SRC inhibitor		LCK	LCK proto-oncogene, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00306631
MONDO_0007254	breast cancer	CHEMBL1079742	ERLOTINIB HYDROCHLORIDE	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Completed	https://clinicaltrials.gov/study/NCT00059852,https://clinicaltrials.gov/study/NCT00030537,https://clinicaltrials.gov/study/NCT00733408,https://clinicaltrials.gov/study/NCT00054275,https://clinicaltrials.gov/study/NCT00109265,https://clinicaltrials.gov/study/NCT00633750
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBB4B	tubulin beta 4B class IVb	2	Withdrawn	https://clinicaltrials.gov/study/NCT01227408
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF1	NADH:ubiquinone oxidoreductase complex assembly factor 1	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Terminated	https://clinicaltrials.gov/study/NCT01498588
MONDO_0007254	breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04733417
MONDO_0007254	breast cancer	CHEMBL3187723	BINIMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 2 inhibitor		MAP2K2	mitogen-activated protein kinase kinase 2	2	Completed	https://clinicaltrials.gov/study/NCT04494958
MONDO_0007254	breast cancer	CHEMBL679	EPINEPHRINE	Small molecule	Adrenergic receptor agonist		ADRA2B	adrenoceptor alpha 2B	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04603911
MONDO_0007254	breast cancer	CHEMBL2408045	SAPITINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02299999
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Suspended	https://clinicaltrials.gov/study/NCT02897050,https://clinicaltrials.gov/study/NCT04419181
MONDO_0007254	breast cancer	CHEMBL94657	PATUPILONE	Small molecule	Tubulin stabiliser		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT00450866
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD1	DNA polymerase delta 1, catalytic subunit	2	Completed	https://clinicaltrials.gov/study/NCT00020176,https://clinicaltrials.gov/study/NCT01105650,https://clinicaltrials.gov/study/NCT00429572
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Terminated	https://clinicaltrials.gov/study/NCT03367689
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Unknown status	https://clinicaltrials.gov/study/NCT02423603,https://clinicaltrials.gov/study/NCT03348098,https://clinicaltrials.gov/study/NCT01276769,https://clinicaltrials.gov/study/NCT01647672,https://clinicaltrials.gov/study/NCT01625429,https://clinicaltrials.gov/study/NCT01321775,https://clinicaltrials.gov/study/NCT00499525,https://clinicaltrials.gov/study/NCT02041338,https://clinicaltrials.gov/study/NCT01830244,https://clinicaltrials.gov/study/NCT00533936,https://clinicaltrials.gov/study/NCT00777673,https://clinicaltrials.gov/study/NCT01309607,https://clinicaltrials.gov/study/NCT03735082,https://clinicaltrials.gov/study/NCT00006120,https://clinicaltrials.gov/study/NCT00404404,https://clinicaltrials.gov/study/NCT00154882,https://clinicaltrials.gov/study/NCT03429972,https://clinicaltrials.gov/study/NCT02230319,https://clinicaltrials.gov/study/NCT02059876,https://clinicaltrials.gov/study/NCT00499603,https://clinicaltrials.gov/study/NCT02694224,https://clinicaltrials.gov/study/NCT01428414
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4L2	NDUFA4 mitochondrial complex associated like 2	2	Completed	https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT01310231
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA11	NADH:ubiquinone oxidoreductase subunit A11	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0005537	triple-negative breast cancer	CHEMBL3545068	COPANLISIB HYDROCHLORIDE	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04345913
EFO_0000305	breast carcinoma	CHEMBL3218576	COPANLISIB	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03939897
EFO_0005537	triple-negative breast cancer	CHEMBL4297892	ANVATABART OPADOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBA3C	tubulin alpha 3c	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL723	CARVEDILOL	Small molecule	Adrenergic receptor alpha-1 antagonist		ADRA1B	adrenoceptor alpha 1B	2	Recruiting	https://clinicaltrials.gov/study/NCT03879629
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04538742,https://clinicaltrials.gov/study/NCT01057069,https://clinicaltrials.gov/study/NCT04734262,https://clinicaltrials.gov/study/NCT00609791,https://clinicaltrials.gov/study/NCT01796197,https://clinicaltrials.gov/study/NCT03747120,https://clinicaltrials.gov/study/NCT04398914,https://clinicaltrials.gov/study/NCT04083963,https://clinicaltrials.gov/study/NCT02546232,https://clinicaltrials.gov/study/NCT01730833,https://clinicaltrials.gov/study/NCT00616967,https://clinicaltrials.gov/study/NCT02734290,https://clinicaltrials.gov/study/NCT04215146,https://clinicaltrials.gov/study/NCT04603183,https://clinicaltrials.gov/study/NCT01815242,https://clinicaltrials.gov/study/NCT02299999,https://clinicaltrials.gov/study/NCT04251169,https://clinicaltrials.gov/study/NCT01779206,https://clinicaltrials.gov/study/NCT01898117,https://clinicaltrials.gov/study/NCT03387085,https://clinicaltrials.gov/study/NCT03125928,https://clinicaltrials.gov/study/NCT02779855,https://clinicaltrials.gov/study/NCT02883062,https://clinicaltrials.gov/study/NCT04418154,https://clinicaltrials.gov/study/NCT03609047,https://clinicaltrials.gov/study/NCT00003042,https://clinicaltrials.gov/study/NCT03567720,https://clinicaltrials.gov/study/NCT03616886,https://clinicaltrials.gov/study/NCT02752685,https://clinicaltrials.gov/study/NCT02788981,https://clinicaltrials.gov/study/NCT03950570,https://clinicaltrials.gov/study/NCT02187991,https://clinicaltrials.gov/study/NCT03568422,https://clinicaltrials.gov/study/NCT00295893,https://clinicaltrials.gov/study/NCT01853748,https://clinicaltrials.gov/study/NCT04192331,https://clinicaltrials.gov/study/NCT05498896,https://clinicaltrials.gov/study/NCT04172259
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA12	NADH:ubiquinone oxidoreductase subunit A12	2	Completed	https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT02488564
MONDO_0007254	breast cancer	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	2	Unknown status	https://clinicaltrials.gov/study/NCT00499525
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Recruiting	https://clinicaltrials.gov/study/NCT05296577,https://clinicaltrials.gov/study/NCT05823623
EFO_0005537	triple-negative breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV3	NADH:ubiquinone oxidoreductase subunit V3	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAB1	NADH:ubiquinone oxidoreductase subunit AB1	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06291064,https://clinicaltrials.gov/study/NCT04290793,https://clinicaltrials.gov/study/NCT04034823,https://clinicaltrials.gov/study/NCT06348134
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Recruiting	https://clinicaltrials.gov/study/NCT03515798,https://clinicaltrials.gov/study/NCT05383196
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS3	NADH:ubiquinone oxidoreductase core subunit S3	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL4279455	LAROTAXEL	Small molecule	Tubulin stabiliser		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT00387907,https://clinicaltrials.gov/study/NCT00087958
MONDO_0007254	breast cancer	CHEMBL3644587	2X-121	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03562832
MONDO_0007254	breast cancer	CHEMBL1201748	CABAZITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	2	Terminated	https://clinicaltrials.gov/study/NCT01934894
MONDO_0007254	breast cancer	CHEMBL628	PENTOXIFYLLINE	Small molecule	3',5'-cyclic phosphodiesterase inhibitor		PDE6B	phosphodiesterase 6B	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT06176339,https://clinicaltrials.gov/study/NCT06186700
EFO_0005537	triple-negative breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	2	Recruiting	https://clinicaltrials.gov/study/NCT03606967
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Completed	https://clinicaltrials.gov/study/NCT01105650,https://clinicaltrials.gov/study/NCT00020176,https://clinicaltrials.gov/study/NCT00429572
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA13	NADH:ubiquinone oxidoreductase subunit A13	2	Completed	https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT00930579
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA7	NADH:ubiquinone oxidoreductase subunit A7	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 6 inhibitor		HDAC6	histone deacetylase 6	2	Terminated	https://clinicaltrials.gov/study/NCT04190056,https://clinicaltrials.gov/study/NCT01194427
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL226267	ARZOXIFENE	Small molecule	Estrogen receptor modulator	Antagonist	ESR1	estrogen receptor 1	2	Completed	https://clinicaltrials.gov/study/NCT00253539
MONDO_0007254	breast cancer	CHEMBL1642	IMATINIB MESYLATE	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Terminated	https://clinicaltrials.gov/study/NCT00323063
MONDO_0007254	breast cancer	CHEMBL20684	ABT-751	Small molecule	Tubulin beta inhibitor		TUBB4B	tubulin beta 4B class IVb	2	Completed	https://clinicaltrials.gov/study/NCT00063102
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Withdrawn	https://clinicaltrials.gov/study/NCT03032614
MONDO_0007254	breast cancer	CHEMBL52885	ENMD-981693	Small molecule	SRC inhibitor		BLK	BLK proto-oncogene, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00306631
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS4	NADH:ubiquinone oxidoreductase subunit S4	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0005537	triple-negative breast cancer	CHEMBL1201827	PANITUMUMAB	Antibody	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02593175,https://clinicaltrials.gov/study/NCT02876107
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04001829,https://clinicaltrials.gov/study/NCT02568839
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	2	Completed	https://clinicaltrials.gov/study/NCT02614833
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Suspended	https://clinicaltrials.gov/study/NCT04675827,https://clinicaltrials.gov/study/NCT04419181
MONDO_0007254	breast cancer	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator	Antagonist	ESR1	estrogen receptor 1	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT06348134
EFO_0000432	breast ductal carcinoma in situ	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Terminated	https://clinicaltrials.gov/study/NCT00461344
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	2	Completed	https://clinicaltrials.gov/study/NCT01105650,https://clinicaltrials.gov/study/NCT00429572,https://clinicaltrials.gov/study/NCT00020176
MONDO_0007254	breast cancer	CHEMBL1535	HYDROXYCHLOROQUINE	Small molecule	Toll-like receptor 7 antagonist		TLR7	toll like receptor 7	2	Completed	https://clinicaltrials.gov/study/NCT03774472
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF3	NADH:ubiquinone oxidoreductase complex assembly factor 3	2	Recruiting	https://clinicaltrials.gov/study/NCT04559308,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04300790
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02957968,https://clinicaltrials.gov/study/NCT01730833,https://clinicaltrials.gov/study/NCT02530489
MONDO_0007254	breast cancer	CHEMBL2325741	CAPIVASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT3	AKT serine/threonine kinase 3	2	Completed	https://clinicaltrials.gov/study/NCT02077569
MONDO_0007254	breast cancer	CHEMBL328190	LASOFOXIFENE	Small molecule	Estrogen receptor modulator	Antagonist	ESR1	estrogen receptor 1	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL1743062	RAMUCIRUMAB	Antibody	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Completed	https://clinicaltrials.gov/study/NCT01427933,https://clinicaltrials.gov/study/NCT01234402
MONDO_0007254	breast cancer	CHEMBL1082407	ENZALUTAMIDE	Small molecule	Androgen Receptor antagonist		AR	androgen receptor	2	Terminated	https://clinicaltrials.gov/study/NCT04142060
MONDO_0007254	breast cancer	CHEMBL4297844	TRASTUZUMAB DERUXTECAN	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 binding agent		ERBB2	erb-b2 receptor tyrosine kinase 2	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT04538742,https://clinicaltrials.gov/study/NCT04539938,https://clinicaltrials.gov/study/NCT03248492
EFO_0006861	male breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Unknown status	https://clinicaltrials.gov/study/NCT01372579
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB1	NADH:ubiquinone oxidoreductase subunit B1	2	Completed	https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT02028221
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB8	NADH:ubiquinone oxidoreductase subunit B8	2	Completed	https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT00909506,https://clinicaltrials.gov/study/NCT00930579
EFO_0005537	triple-negative breast cancer	CHEMBL4297892	ANVATABART OPADOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA13	NADH:ubiquinone oxidoreductase subunit A13	2	Recruiting	https://clinicaltrials.gov/study/NCT04559308,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT04300790,https://clinicaltrials.gov/study/NCT01042379
EFO_0000305	breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	2	Terminated	https://clinicaltrials.gov/study/NCT01394211
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB3	NADH:ubiquinone oxidoreductase subunit B3	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4	NDUFA4 mitochondrial complex associated	2	Completed	https://clinicaltrials.gov/study/NCT01885013
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS2	NADH:ubiquinone oxidoreductase core subunit S2	2	Unknown status	https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT02506777
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Withdrawn	https://clinicaltrials.gov/study/NCT04351230
MONDO_0007254	breast cancer	CHEMBL517712	ATROPINE	Small molecule	Muscarinic acetylcholine receptor M3 antagonist		CHRM3	cholinergic receptor muscarinic 3	2	Completed	https://clinicaltrials.gov/study/NCT02839668
MONDO_0007254	breast cancer	CHEMBL521851	PICTILISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	2	Completed	https://clinicaltrials.gov/study/NCT01740336,https://clinicaltrials.gov/study/NCT01437566
MONDO_0007254	breast cancer	CHEMBL4298101	LADIRATUZUMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Recruiting	https://clinicaltrials.gov/study/NCT03424005,https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Unknown status	https://clinicaltrials.gov/study/NCT00003066,https://clinicaltrials.gov/study/NCT01526499,https://clinicaltrials.gov/study/NCT00033683,https://clinicaltrials.gov/study/NCT02144194,https://clinicaltrials.gov/study/NCT00250874,https://clinicaltrials.gov/study/NCT00957125,https://clinicaltrials.gov/study/NCT01270373,https://clinicaltrials.gov/study/NCT01907529,https://clinicaltrials.gov/study/NCT03147963,https://clinicaltrials.gov/study/NCT01939054,https://clinicaltrials.gov/study/NCT00994968,https://clinicaltrials.gov/study/NCT03876587,https://clinicaltrials.gov/study/NCT01352494,https://clinicaltrials.gov/study/NCT00026078,https://clinicaltrials.gov/study/NCT02685657,https://clinicaltrials.gov/study/NCT02947061,https://clinicaltrials.gov/study/NCT00398489,https://clinicaltrials.gov/study/NCT00801411,https://clinicaltrials.gov/study/NCT00669773,https://clinicaltrials.gov/study/NCT01351597,https://clinicaltrials.gov/study/NCT00006120,https://clinicaltrials.gov/study/NCT00721747,https://clinicaltrials.gov/study/NCT00012311
MONDO_0007254	breast cancer	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 2 inhibitor		HDAC2	histone deacetylase 2	2	Terminated	https://clinicaltrials.gov/study/NCT01194427,https://clinicaltrials.gov/study/NCT04190056
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Completed	https://clinicaltrials.gov/study/NCT01091428,https://clinicaltrials.gov/study/NCT00542451
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA1	NADH:ubiquinone oxidoreductase subunit A1	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF4	NADH:ubiquinone oxidoreductase complex assembly factor 4	2	Completed	https://clinicaltrials.gov/study/NCT01310231,https://clinicaltrials.gov/study/NCT04170465,https://clinicaltrials.gov/study/NCT05053841,https://clinicaltrials.gov/study/NCT01589367,https://clinicaltrials.gov/study/NCT04143282,https://clinicaltrials.gov/study/NCT00930579,https://clinicaltrials.gov/study/NCT02488564,https://clinicaltrials.gov/study/NCT02028221,https://clinicaltrials.gov/study/NCT01266486,https://clinicaltrials.gov/study/NCT00909506
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA12	NADH:ubiquinone oxidoreductase subunit A12	2	Unknown status	https://clinicaltrials.gov/study/NCT03192293,https://clinicaltrials.gov/study/NCT02506777,https://clinicaltrials.gov/study/NCT02506790
MONDO_0007254	breast cancer	CHEMBL4303669	ZOLEDRONIC ACID	Small molecule	Farnesyl diphosphate synthase inhibitor		FDPS	farnesyl diphosphate synthase	2	Unknown status	https://clinicaltrials.gov/study/NCT01654367
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Suspended	https://clinicaltrials.gov/study/NCT02897050,https://clinicaltrials.gov/study/NCT04419181
MONDO_0007254	breast cancer	CHEMBL521851	PICTILISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	2	Completed	https://clinicaltrials.gov/study/NCT01740336,https://clinicaltrials.gov/study/NCT01437566
EFO_0005537	triple-negative breast cancer	CHEMBL1743024	GANITUMAB	Antibody	Insulin-like growth factor I receptor antagonist		IGF1R	insulin like growth factor 1 receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0005537	triple-negative breast cancer	CHEMBL5095033	IBCASERTIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	2	Recruiting	https://clinicaltrials.gov/study/NCT05336721
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC11	histone deacetylase 11	2	Completed	https://clinicaltrials.gov/study/NCT00828854,https://clinicaltrials.gov/study/NCT02708680,https://clinicaltrials.gov/study/NCT00676663,https://clinicaltrials.gov/study/NCT03291886
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	2	Completed	https://clinicaltrials.gov/study/NCT00546104,https://clinicaltrials.gov/study/NCT00410813,https://clinicaltrials.gov/study/NCT00696072,https://clinicaltrials.gov/study/NCT00754325,https://clinicaltrials.gov/study/NCT00767520
MONDO_0007254	breast cancer	CHEMBL4297584	TENALISIB	Small molecule	PI3-kinase p110-gamma subunit inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	2	Completed	https://clinicaltrials.gov/study/NCT05021900
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF4	NADH:ubiquinone oxidoreductase complex assembly factor 4	2	Completed	https://clinicaltrials.gov/study/NCT01885013
MONDO_0007254	breast cancer	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 6 inhibitor		HDAC6	histone deacetylase 6	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT00616967
MONDO_0007254	breast cancer	CHEMBL180022	NERATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03812393,https://clinicaltrials.gov/study/NCT01494662,https://clinicaltrials.gov/study/NCT03377387
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB7	NADH:ubiquinone oxidoreductase subunit B7	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0007254	breast cancer	CHEMBL4594298	ENCEQUIDAR	Small molecule	P-glycoprotein 1 inhibitor		ABCB1	ATP binding cassette subfamily B member 1	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT02593175,https://clinicaltrials.gov/study/NCT01750073,https://clinicaltrials.gov/study/NCT04395989,https://clinicaltrials.gov/study/NCT02315196,https://clinicaltrials.gov/study/NCT02876107,https://clinicaltrials.gov/study/NCT02530489,https://clinicaltrials.gov/study/NCT04216472,https://clinicaltrials.gov/study/NCT04958785,https://clinicaltrials.gov/study/NCT04770272,https://clinicaltrials.gov/study/NCT04129996,https://clinicaltrials.gov/study/NCT02883062
MONDO_0007254	breast cancer	CHEMBL1201670	SARGRAMOSTIM	Protein	Granulocyte-macrophage colony-stimulating factor receptor agonist		CSF2RA	colony stimulating factor 2 receptor subunit alpha	2	Recruiting	https://clinicaltrials.gov/study/NCT05455658
EFO_0000305	breast carcinoma	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB8	NADH:ubiquinone oxidoreductase subunit B8	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
MONDO_0044915	salivary duct carcinoma	CHEMBL409	BICALUTAMIDE	Small molecule	Androgen Receptor antagonist		AR	androgen receptor	2	Recruiting	https://clinicaltrials.gov/study/NCT05513365
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		BLK	BLK proto-oncogene, Src family tyrosine kinase	2	Completed	https://clinicaltrials.gov/study/NCT00546104,https://clinicaltrials.gov/study/NCT00754325,https://clinicaltrials.gov/study/NCT00410813,https://clinicaltrials.gov/study/NCT00696072,https://clinicaltrials.gov/study/NCT00767520
MONDO_0007254	breast cancer	CHEMBL4297584	TENALISIB	Small molecule	PI3-kinase p110-delta subunit inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	2	Completed	https://clinicaltrials.gov/study/NCT05021900
MONDO_0007254	breast cancer	CHEMBL2110725	VINFLUNINE	Small molecule	Tubulin inhibitor		TUBA3E	tubulin alpha 3e	2	Completed	https://clinicaltrials.gov/study/NCT00284180
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Terminated	https://clinicaltrials.gov/study/NCT00832338
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT01463072,https://clinicaltrials.gov/study/NCT02436993,https://clinicaltrials.gov/study/NCT02603679,https://clinicaltrials.gov/study/NCT04001829,https://clinicaltrials.gov/study/NCT04216472,https://clinicaltrials.gov/study/NCT03101748,https://clinicaltrials.gov/study/NCT02530489,https://clinicaltrials.gov/study/NCT02187991,https://clinicaltrials.gov/study/NCT03179904
EFO_0006861	male breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	2	Terminated	https://clinicaltrials.gov/study/NCT00095888
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Withdrawn	https://clinicaltrials.gov/study/NCT02725541
MONDO_0007254	breast cancer	CHEMBL2109406	PATRITUMAB	Antibody	Receptor tyrosine-protein kinase erbB-3 inhibitor		ERBB3	erb-b2 receptor tyrosine kinase 3	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC9	histone deacetylase 9	2	Completed	https://clinicaltrials.gov/study/NCT02708680,https://clinicaltrials.gov/study/NCT00828854,https://clinicaltrials.gov/study/NCT00676663,https://clinicaltrials.gov/study/NCT03291886
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Withdrawn	https://clinicaltrials.gov/study/NCT04351230
EFO_0005537	triple-negative breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC5	histone deacetylase 5	2	Terminated	https://clinicaltrials.gov/study/NCT01234532
EFO_0005537	triple-negative breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Vascular endothelial growth factor receptor 3 inhibitor		FLT4	fms related receptor tyrosine kinase 4	2	Recruiting	https://clinicaltrials.gov/study/NCT05670925
EFO_0000305	breast carcinoma	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB4	NADH:ubiquinone oxidoreductase subunit B4	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0000305	breast carcinoma	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	2	Completed	https://clinicaltrials.gov/study/NCT02894398,https://clinicaltrials.gov/study/NCT02296801,https://clinicaltrials.gov/study/NCT04294225,https://clinicaltrials.gov/study/NCT03007979,https://clinicaltrials.gov/study/NCT04256941,https://clinicaltrials.gov/study/NCT00530868
EFO_0005537	triple-negative breast cancer	CHEMBL4298124	DOSTARLIMAB	Antibody	Programmed cell death protein 1 antagonist		PDCD1	programmed cell death 1	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
EFO_0006861	male breast carcinoma	CHEMBL941	IMATINIB	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	2	Completed	https://clinicaltrials.gov/study/NCT00045188
MONDO_0007254	breast cancer	CHEMBL655	MIDAZOLAM	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRA5	gamma-aminobutyric acid type A receptor subunit alpha5	2	Completed	https://clinicaltrials.gov/study/NCT03084536
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA1	NADH:ubiquinone oxidoreductase subunit A1	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04559308,https://clinicaltrials.gov/study/NCT03238495,https://clinicaltrials.gov/study/NCT04300790
MONDO_0007254	breast cancer	CHEMBL1751	DIGOXIN	Small molecule	Sodium/potassium-transporting ATPase inhibitor		ATP1A2	ATPase Na+/K+ transporting subunit alpha 2	2	Completed	https://clinicaltrials.gov/study/NCT01763931
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	2	Terminated	https://clinicaltrials.gov/study/NCT01985841,https://clinicaltrials.gov/study/NCT03329378,https://clinicaltrials.gov/study/NCT00453635,https://clinicaltrials.gov/study/NCT00104624,https://clinicaltrials.gov/study/NCT00028483,https://clinicaltrials.gov/study/NCT00343512,https://clinicaltrials.gov/study/NCT03894007,https://clinicaltrials.gov/study/NCT00845910,https://clinicaltrials.gov/study/NCT00524459,https://clinicaltrials.gov/study/NCT02229149,https://clinicaltrials.gov/study/NCT00665457,https://clinicaltrials.gov/study/NCT00479856,https://clinicaltrials.gov/study/NCT00852332,https://clinicaltrials.gov/study/NCT00080626,https://clinicaltrials.gov/study/NCT01690325,https://clinicaltrials.gov/study/NCT00025493,https://clinicaltrials.gov/study/NCT00476827,https://clinicaltrials.gov/study/NCT00636441,https://clinicaltrials.gov/study/NCT00118053,https://clinicaltrials.gov/study/NCT00193024,https://clinicaltrials.gov/study/NCT00576901,https://clinicaltrials.gov/study/NCT00225056,https://clinicaltrials.gov/study/NCT00206453
MONDO_0007254	breast cancer	CHEMBL4302409	LUTETIUM OXODOTREOTIDE	Protein	Somatostatin receptor binding agent		SSTR4	somatostatin receptor 4	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04529044
EFO_0005537	triple-negative breast cancer	CHEMBL4297892	ANVATABART OPADOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	2	Recruiting	https://clinicaltrials.gov/study/NCT01042379
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS5	NADH:ubiquinone oxidoreductase subunit S5	2	Unknown status	https://clinicaltrials.gov/study/NCT02506790,https://clinicaltrials.gov/study/NCT02506777,https://clinicaltrials.gov/study/NCT03192293
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHB2	EPH receptor B2	2	Completed	https://clinicaltrials.gov/study/NCT00494481
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	2	Completed	https://clinicaltrials.gov/study/NCT00540358,https://clinicaltrials.gov/study/NCT00334802,https://clinicaltrials.gov/study/NCT00601159,https://clinicaltrials.gov/study/NCT01045304,https://clinicaltrials.gov/study/NCT00191451,https://clinicaltrials.gov/study/NCT00813956,https://clinicaltrials.gov/study/NCT00005991,https://clinicaltrials.gov/study/NCT00003540,https://clinicaltrials.gov/study/NCT00894504,https://clinicaltrials.gov/study/NCT00201760,https://clinicaltrials.gov/study/NCT00191789,https://clinicaltrials.gov/study/NCT00006007,https://clinicaltrials.gov/study/NCT00503906,https://clinicaltrials.gov/study/NCT03025880,https://clinicaltrials.gov/study/NCT00244933,https://clinicaltrials.gov/study/NCT00618826,https://clinicaltrials.gov/study/NCT00191243,https://clinicaltrials.gov/study/NCT00192101,https://clinicaltrials.gov/study/NCT00192062,https://clinicaltrials.gov/study/NCT00193063,https://clinicaltrials.gov/study/NCT03839823,https://clinicaltrials.gov/study/NCT00378313,https://clinicaltrials.gov/study/NCT00002998,https://clinicaltrials.gov/study/NCT00063570,https://clinicaltrials.gov/study/NCT00191347,https://clinicaltrials.gov/study/NCT00191854,https://clinicaltrials.gov/study/NCT00316199,https://clinicaltrials.gov/study/NCT00128856,https://clinicaltrials.gov/study/NCT01201265,https://clinicaltrials.gov/study/NCT00191269,https://clinicaltrials.gov/study/NCT00193050,https://clinicaltrials.gov/study/NCT00662129,https://clinicaltrials.gov/study/NCT02263495,https://clinicaltrials.gov/study/NCT00403130,https://clinicaltrials.gov/study/NCT02435680,https://clinicaltrials.gov/study/NCT00191373,https://clinicaltrials.gov/study/NCT00059852,https://clinicaltrials.gov/study/NCT00191815,https://clinicaltrials.gov/study/NCT00623233,https://clinicaltrials.gov/study/NCT00450762,https://clinicaltrials.gov/study/NCT00532623,https://clinicaltrials.gov/study/NCT00325234,https://clinicaltrials.gov/study/NCT00480597,https://clinicaltrials.gov/study/NCT00846027,https://clinicaltrials.gov/study/NCT01550848,https://clinicaltrials.gov/study/NCT00320541,https://clinicaltrials.gov/study/NCT00493636,https://clinicaltrials.gov/study/NCT04464174,https://clinicaltrials.gov/study/NCT00532857,https://clinicaltrials.gov/study/NCT00212069,https://clinicaltrials.gov/study/NCT00193206,https://clinicaltrials.gov/study/NCT00193076,https://clinicaltrials.gov/study/NCT00695994,https://clinicaltrials.gov/study/NCT00110084,https://clinicaltrials.gov/study/NCT00754351
MONDO_0007254	breast cancer	CHEMBL4297892	ANVATABART OPADOTIN	Antibody drug conjugate	Tubulin inhibitor		TUBA3E	tubulin alpha 3e	2	Recruiting	https://clinicaltrials.gov/study/NCT05426486,https://clinicaltrials.gov/study/NCT05018702,https://clinicaltrials.gov/study/NCT01042379,https://clinicaltrials.gov/study/NCT04829604,https://clinicaltrials.gov/study/NCT05018676
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	2	Withdrawn	https://clinicaltrials.gov/study/NCT04351230
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1703	METFORMIN HYDROCHLORIDE	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB1	NADH:ubiquinone oxidoreductase subunit B1	2	Recruiting	https://clinicaltrials.gov/study/NCT05023967
EFO_0005537	triple-negative breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	2	Active, not recruiting	https://clinicaltrials.gov/study/NCT03639948
MONDO_0007254	breast cancer	CHEMBL4297736	PRALUZATAMAB RAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBA1C	tubulin alpha 1c	2	Completed	https://clinicaltrials.gov/study/NCT04596150
MONDO_0007254	breast cancer	CHEMBL4303201	CATEQUENTINIB	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	2	Not yet recruiting	https://clinicaltrials.gov/study/NCT04975451
MONDO_0007254	breast cancer	CHEMBL502835	NINTEDANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	2	Terminated	https://clinicaltrials.gov/study/NCT02389764
EFO_0000304	breast adenocarcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC9	histone deacetylase 9	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03725436,https://clinicaltrials.gov/study/NCT03554044
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
EFO_0005537	triple-negative breast cancer	CHEMBL1214827	ONALESPIB	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AA1	heat shock protein 90 alpha family class A member 1	1	Terminated	https://clinicaltrials.gov/study/NCT02474173
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Completed	https://clinicaltrials.gov/study/NCT03364348
EFO_0006861	male breast carcinoma	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 2 inhibitor		CDK2	cyclin dependent kinase 2	1	Terminated	https://clinicaltrials.gov/study/NCT00039455
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Completed	https://clinicaltrials.gov/study/NCT02120469
MONDO_0007254	breast cancer	CHEMBL1289494	TIVOZANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT00717340
MONDO_0007254	breast cancer	CHEMBL49642	INDIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Unknown status	https://clinicaltrials.gov/study/NCT01113970
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Recruiting	https://clinicaltrials.gov/study/NCT03994107,https://clinicaltrials.gov/study/NCT04205903,https://clinicaltrials.gov/study/NCT04152057,https://clinicaltrials.gov/study/NCT05307705
MONDO_0007254	breast cancer	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03616587,https://clinicaltrials.gov/study/NCT04556773
MONDO_0007254	breast cancer	CHEMBL3545366	VOXTALISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	1	Completed	https://clinicaltrials.gov/study/NCT01390818,https://clinicaltrials.gov/study/NCT01082068
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Completed	https://clinicaltrials.gov/study/NCT03112590,https://clinicaltrials.gov/study/NCT01320592,https://clinicaltrials.gov/study/NCT01918254,https://clinicaltrials.gov/study/NCT01031446,https://clinicaltrials.gov/study/NCT01306942,https://clinicaltrials.gov/study/NCT04261218,https://clinicaltrials.gov/study/NCT00445458,https://clinicaltrials.gov/study/NCT00006108,https://clinicaltrials.gov/study/NCT00301730,https://clinicaltrials.gov/study/NCT00050167,https://clinicaltrials.gov/study/NCT01133912,https://clinicaltrials.gov/study/NCT00900627,https://clinicaltrials.gov/study/NCT00951665,https://clinicaltrials.gov/study/NCT02599363,https://clinicaltrials.gov/study/NCT01172223,https://clinicaltrials.gov/study/NCT02041429,https://clinicaltrials.gov/study/NCT02001974,https://clinicaltrials.gov/study/NCT00368875,https://clinicaltrials.gov/study/NCT00426556,https://clinicaltrials.gov/study/NCT00803556,https://clinicaltrials.gov/study/NCT01973309,https://clinicaltrials.gov/study/NCT01862081,https://clinicaltrials.gov/study/NCT02379247,https://clinicaltrials.gov/study/NCT00691379,https://clinicaltrials.gov/study/NCT03166085,https://clinicaltrials.gov/study/NCT00637897,https://clinicaltrials.gov/study/NCT00724386,https://clinicaltrials.gov/study/NCT00054028,https://clinicaltrials.gov/study/NCT00574587,https://clinicaltrials.gov/study/NCT00983424,https://clinicaltrials.gov/study/NCT02015676,https://clinicaltrials.gov/study/NCT00068757,https://clinicaltrials.gov/study/NCT00004174,https://clinicaltrials.gov/study/NCT00003927,https://clinicaltrials.gov/study/NCT01423123,https://clinicaltrials.gov/study/NCT00807859,https://clinicaltrials.gov/study/NCT00748553,https://clinicaltrials.gov/study/NCT00002837,https://clinicaltrials.gov/study/NCT00960960,https://clinicaltrials.gov/study/NCT01625286,https://clinicaltrials.gov/study/NCT00031876,https://clinicaltrials.gov/study/NCT00001383,https://clinicaltrials.gov/study/NCT00820170,https://clinicaltrials.gov/study/NCT01070706,https://clinicaltrials.gov/study/NCT00887575,https://clinicaltrials.gov/study/NCT00009997,https://clinicaltrials.gov/study/NCT03411161,https://clinicaltrials.gov/study/NCT01484080,https://clinicaltrials.gov/study/NCT04132817,https://clinicaltrials.gov/study/NCT00107094,https://clinicaltrials.gov/study/NCT01493310,https://clinicaltrials.gov/study/NCT00788931,https://clinicaltrials.gov/study/NCT00322400,https://clinicaltrials.gov/study/NCT00003877,https://clinicaltrials.gov/study/NCT03800836,https://clinicaltrials.gov/study/NCT01042925,https://clinicaltrials.gov/study/NCT02073916,https://clinicaltrials.gov/study/NCT00442260,https://clinicaltrials.gov/study/NCT04247126,https://clinicaltrials.gov/study/NCT00680758,https://clinicaltrials.gov/study/NCT00717340,https://clinicaltrials.gov/study/NCT00707707,https://clinicaltrials.gov/study/NCT03505528,https://clinicaltrials.gov/study/NCT01254526,https://clinicaltrials.gov/study/NCT01003158,https://clinicaltrials.gov/study/NCT02628132,https://clinicaltrials.gov/study/NCT02060253
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC5	histone deacetylase 5	1	Terminated	https://clinicaltrials.gov/study/NCT00567879
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Withdrawn	https://clinicaltrials.gov/study/NCT03175666,https://clinicaltrials.gov/study/NCT04252768,https://clinicaltrials.gov/study/NCT03285607,https://clinicaltrials.gov/study/NCT00022230,https://clinicaltrials.gov/study/NCT02569489,https://clinicaltrials.gov/study/NCT04762901,https://clinicaltrials.gov/study/NCT04826016
MONDO_0007254	breast cancer	CHEMBL4297181	SAMOTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R5	phosphoinositide-3-kinase regulatory subunit 5	1	Completed	https://clinicaltrials.gov/study/NCT01655225
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Completed	https://clinicaltrials.gov/study/NCT00535119
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03725436,https://clinicaltrials.gov/study/NCT03554044
EFO_0000304	breast adenocarcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
EFO_0000305	breast carcinoma	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	1	Completed	https://clinicaltrials.gov/study/NCT02871791
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03554044,https://clinicaltrials.gov/study/NCT03725436
MONDO_0007254	breast cancer	CHEMBL3545132	MIRVETUXIMAB SORAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Withdrawn	https://clinicaltrials.gov/study/NCT03045393
MONDO_0007254	breast cancer	CHEMBL521851	PICTILISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R2	phosphoinositide-3-kinase regulatory subunit 2	1	Completed	https://clinicaltrials.gov/study/NCT00960960,https://clinicaltrials.gov/study/NCT00928330
EFO_0006861	male breast carcinoma	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Completed	https://clinicaltrials.gov/study/NCT00331552,https://clinicaltrials.gov/study/NCT00470301
MONDO_0007254	breast cancer	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03032107,https://clinicaltrials.gov/study/NCT02999477,https://clinicaltrials.gov/study/NCT03720431,https://clinicaltrials.gov/study/NCT03362060
MONDO_0007254	breast cancer	CHEMBL14762	SELICICLIB	Small molecule	Cyclin-dependent kinase 1 inhibitor		CDK1	cyclin dependent kinase 1	1	Withdrawn	https://clinicaltrials.gov/study/NCT01333423
EFO_0006861	male breast carcinoma	CHEMBL2103879	GANETESPIB	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AA1	heat shock protein 90 alpha family class A member 1	1	Completed	https://clinicaltrials.gov/study/NCT02060253
EFO_0006861	male breast carcinoma	CHEMBL289228	TIPIFARNIB	Small molecule	Protein farnesyltransferase inhibitor		FNTA	farnesyltransferase, CAAX box, subunit alpha	1	Completed	https://clinicaltrials.gov/study/NCT00470301
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAB1	NADH:ubiquinone oxidoreductase subunit AB1	1	Completed	https://clinicaltrials.gov/study/NCT02278965
EFO_0005537	triple-negative breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
MONDO_0007254	breast cancer	CHEMBL3581647	BIRABRESIB	Small molecule	Bromodomain and extra-terminal motif (BET) inhibitor		BRD4	bromodomain containing 4	1	Completed	https://clinicaltrials.gov/study/NCT02259114
MONDO_0007254	breast cancer	CHEMBL4279455	LAROTAXEL	Small molecule	Tubulin stabiliser		TUBB3	tubulin beta 3 class III	1	Completed	https://clinicaltrials.gov/study/NCT00327743
MONDO_0007254	breast cancer	CHEMBL4298024	BINTRAFUSP ALFA	Protein	Transforming growth factor beta binding agent		TGFB3	transforming growth factor beta 3	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03620201
MONDO_0007254	breast cancer	CHEMBL574737	UCN-01	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	1	Completed	https://clinicaltrials.gov/study/NCT00001444
EFO_0000305	breast carcinoma	CHEMBL2364628	RICOLINOSTAT	Small molecule	Histone deacetylase 6 inhibitor		HDAC6	histone deacetylase 6	1	Completed	https://clinicaltrials.gov/study/NCT02632071
EFO_0000304	breast adenocarcinoma	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC8	histone deacetylase 8	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
EFO_0000305	breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
EFO_0000305	breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE3	DNA polymerase epsilon 3, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT00100750
EFO_0006861	male breast carcinoma	CHEMBL2103840	DINACICLIB	Small molecule	Cyclin-dependent kinase 5 inhibitor		CDK5	cyclin dependent kinase 5	1	Completed	https://clinicaltrials.gov/study/NCT01624441
EFO_0006861	male breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Completed	https://clinicaltrials.gov/study/NCT01323530,https://clinicaltrials.gov/study/NCT01795586,https://clinicaltrials.gov/study/NCT02723877,https://clinicaltrials.gov/study/NCT01596751,https://clinicaltrials.gov/study/NCT01432886
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	1	Completed	https://clinicaltrials.gov/study/NCT03455270,https://clinicaltrials.gov/study/NCT02684032,https://clinicaltrials.gov/study/NCT04818632,https://clinicaltrials.gov/study/NCT02599714,https://clinicaltrials.gov/study/NCT01976169,https://clinicaltrials.gov/study/NCT02871791,https://clinicaltrials.gov/study/NCT04483505,https://clinicaltrials.gov/study/NCT03471663,https://clinicaltrials.gov/study/NCT03560531,https://clinicaltrials.gov/study/NCT02448771
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA2	DNA polymerase alpha 2, accessory subunit	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05989828
MONDO_0007254	breast cancer	CHEMBL1567	SUNITINIB MALATE	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Unknown status	https://clinicaltrials.gov/study/NCT00931450
MONDO_0007254	breast cancer	CHEMBL744	RILUZOLE	Small molecule	Sodium channel alpha subunit blocker		SCN4A	sodium voltage-gated channel alpha subunit 4	1	Withdrawn	https://clinicaltrials.gov/study/NCT00903214
EFO_0000305	breast carcinoma	CHEMBL288441	BOSUTINIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03854903
EFO_0000304	breast adenocarcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
EFO_1000100	Atypical Lobular Breast Hyperplasia	CHEMBL1023	BEXAROTENE	Small molecule	Retinoid X receptor agonist		RXRG	retinoid X receptor gamma	1	Completed	https://clinicaltrials.gov/study/NCT03323658
MONDO_0007254	breast cancer	CHEMBL2107862	RINTATOLIMOD	Oligonucleotide	Toll-like receptor 3 agonist		TLR3	toll like receptor 3	1	Completed	https://clinicaltrials.gov/study/NCT01355393,https://clinicaltrials.gov/study/NCT03599453
MONDO_0007254	breast cancer	CHEMBL3264610	SEVITERONEL	Small molecule	Androgen Receptor antagonist		AR	androgen receptor	1	Completed	https://clinicaltrials.gov/study/NCT02580448
EFO_0006861	male breast carcinoma	CHEMBL1276308	MIFEPRISTONE	Small molecule	Glucocorticoid receptor antagonist		NR3C1	nuclear receptor subfamily 3 group C member 1	1	Completed	https://clinicaltrials.gov/study/NCT01493310
MONDO_0007254	breast cancer	CHEMBL522892	DOVITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Terminated	https://clinicaltrials.gov/study/NCT01484041
MONDO_0007254	breast cancer	CHEMBL1200622	PARICALCITOL	Small molecule	Vitamin D receptor agonist		VDR	vitamin D receptor	1	Completed	https://clinicaltrials.gov/study/NCT00637897
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Terminated	https://clinicaltrials.gov/study/NCT00531271,https://clinicaltrials.gov/study/NCT00253318,https://clinicaltrials.gov/study/NCT01876251,https://clinicaltrials.gov/study/NCT00864175,https://clinicaltrials.gov/study/NCT00063934,https://clinicaltrials.gov/study/NCT00584012,https://clinicaltrials.gov/study/NCT02379585,https://clinicaltrials.gov/study/NCT02345772
MONDO_0007254	breast cancer	CHEMBL4297181	SAMOTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	1	Completed	https://clinicaltrials.gov/study/NCT01655225
MONDO_0007254	breast cancer	CHEMBL4298024	BINTRAFUSP ALFA	Protein	Transforming growth factor beta binding agent		TGFB2	transforming growth factor beta 2	1	Withdrawn	https://clinicaltrials.gov/study/NCT04756505
EFO_0000305	breast carcinoma	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03955640
EFO_0000305	breast carcinoma	CHEMBL1042	CHOLECALCIFEROL	Small molecule	Vitamin D receptor agonist		VDR	vitamin D receptor	1	Withdrawn	https://clinicaltrials.gov/study/NCT02856503
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	1	Unknown status	https://clinicaltrials.gov/study/NCT00931450
MONDO_0007254	breast cancer	CHEMBL393220	ATORVASTATIN CALCIUM	Small molecule	HMG-CoA reductase inhibitor		HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase	1	Completed	https://clinicaltrials.gov/study/NCT01980823
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FGR	FGR proto-oncogene, Src family tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT00903006
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Terminated	https://clinicaltrials.gov/study/NCT03579472
EFO_0005537	triple-negative breast cancer	CHEMBL3989514	IRINOTECAN HYDROCHLORIDE	Small molecule	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02419495
MONDO_0007254	breast cancer	CHEMBL1908360	EVEROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	1	Terminated	https://clinicaltrials.gov/study/NCT00253318,https://clinicaltrials.gov/study/NCT00473005,https://clinicaltrials.gov/study/NCT01939418
MONDO_0007254	breast cancer	CHEMBL705	ALITRETINOIN	Small molecule	Retinoid receptor agonist		RARA	retinoic acid receptor alpha	1	Completed	https://clinicaltrials.gov/study/NCT00001504
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA7	NADH:ubiquinone oxidoreductase subunit A7	1	Completed	https://clinicaltrials.gov/study/NCT02278965
MONDO_0007254	breast cancer	CHEMBL1023	BEXAROTENE	Small molecule	Retinoid X receptor agonist		RXRG	retinoid X receptor gamma	1	Completed	https://clinicaltrials.gov/study/NCT00055991
MONDO_0007254	breast cancer	CHEMBL1289494	TIVOZANIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Completed	https://clinicaltrials.gov/study/NCT00717340
MONDO_0007254	breast cancer	CHEMBL3545096	BGT-226	Small molecule	PI3-kinase class I inhibitor		PIK3R5	phosphoinositide-3-kinase regulatory subunit 5	1	Completed	https://clinicaltrials.gov/study/NCT00600275
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Terminated	https://clinicaltrials.gov/study/NCT02658084,https://clinicaltrials.gov/study/NCT04296942,https://clinicaltrials.gov/study/NCT04042051,https://clinicaltrials.gov/study/NCT03429101,https://clinicaltrials.gov/study/NCT04298918
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Unknown status	https://clinicaltrials.gov/study/NCT00764972
MONDO_0007254	breast cancer	CHEMBL3218576	COPANLISIB	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	1	Completed	https://clinicaltrials.gov/study/NCT02705859
MONDO_0007254	breast cancer	CHEMBL4279455	LAROTAXEL	Small molecule	Tubulin stabiliser		TUBB	tubulin beta class I	1	Completed	https://clinicaltrials.gov/study/NCT00327743
MONDO_0007254	breast cancer	CHEMBL2360464	PEMETREXED DISODIUM	Small molecule	GAR transformylase inhibitor		GART	phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase	1	Completed	https://clinicaltrials.gov/study/NCT00097383
EFO_1000984	inflammatory breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Unknown status	https://clinicaltrials.gov/study/NCT01880385
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM2	DNA primase subunit 2	1	Completed	https://clinicaltrials.gov/study/NCT01154426
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	PRIM2	DNA primase subunit 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03554044
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA1	NADH:ubiquinone oxidoreductase subunit A1	1	Completed	https://clinicaltrials.gov/study/NCT01650506,https://clinicaltrials.gov/study/NCT01980823
MONDO_0007254	breast cancer	CHEMBL3963485	ROGARATINIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR2	fibroblast growth factor receptor 2	1	Completed	https://clinicaltrials.gov/study/NCT04483505
MONDO_0007254	breast cancer	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 9 inhibitor		CDK9	cyclin dependent kinase 9	1	Completed	https://clinicaltrials.gov/study/NCT00020332,https://clinicaltrials.gov/study/NCT00003690
EFO_0006861	male breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Terminated	https://clinicaltrials.gov/study/NCT00063934
MONDO_0007254	breast cancer	CHEMBL3545132	MIRVETUXIMAB SORAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Withdrawn	https://clinicaltrials.gov/study/NCT03045393
MONDO_0007254	breast cancer	CHEMBL3545132	MIRVETUXIMAB SORAVTANSINE	Antibody drug conjugate	Folate receptor alpha binding agent		FOLR1	folate receptor alpha	1	Withdrawn	https://clinicaltrials.gov/study/NCT03045393
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Terminated	https://clinicaltrials.gov/study/NCT02474173,https://clinicaltrials.gov/study/NCT01238133
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02999477,https://clinicaltrials.gov/study/NCT03893955,https://clinicaltrials.gov/study/NCT04331067,https://clinicaltrials.gov/study/NCT02608216,https://clinicaltrials.gov/study/NCT03858322,https://clinicaltrials.gov/study/NCT03716180,https://clinicaltrials.gov/study/NCT02390427,https://clinicaltrials.gov/study/NCT04556773
MONDO_0007254	breast cancer	CHEMBL109480	TANESPIMYCIN	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AA1	heat shock protein 90 alpha family class A member 1	1	Completed	https://clinicaltrials.gov/study/NCT00004065,https://clinicaltrials.gov/study/NCT00773344
MONDO_0007254	breast cancer	CHEMBL1789844	IPILIMUMAB	Antibody	Cytotoxic T-lymphocyte protein 4 inhibitor		CTLA4	cytotoxic T-lymphocyte associated protein 4	1	Completed	https://clinicaltrials.gov/study/NCT04132817,https://clinicaltrials.gov/study/NCT01502592
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC1	histone deacetylase 1	1	Completed	https://clinicaltrials.gov/study/NCT00632489,https://clinicaltrials.gov/study/NCT01105312,https://clinicaltrials.gov/study/NCT00788931
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	1	Terminated	https://clinicaltrials.gov/study/NCT00616122,https://clinicaltrials.gov/study/NCT00905021,https://clinicaltrials.gov/study/NCT02074878
MONDO_0007254	breast cancer	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 9 inhibitor		CDK9	cyclin dependent kinase 9	1	Terminated	https://clinicaltrials.gov/study/NCT00039455
MONDO_0007254	breast cancer	CHEMBL572881	MOTESANIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	1	Withdrawn	https://clinicaltrials.gov/study/NCT01349088
EFO_1000984	inflammatory breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Unknown status	https://clinicaltrials.gov/study/NCT01880385
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Completed	https://clinicaltrials.gov/study/NCT03872791,https://clinicaltrials.gov/study/NCT02672475,https://clinicaltrials.gov/study/NCT04584112
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Completed	https://clinicaltrials.gov/study/NCT01816035
MONDO_0007254	breast cancer	CHEMBL1201568	PEGFILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	1	Withdrawn	https://clinicaltrials.gov/study/NCT04762901
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS8	NADH:ubiquinone oxidoreductase core subunit S8	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
EFO_0000305	breast carcinoma	CHEMBL544665	FINGOLIMOD HYDROCHLORIDE	Small molecule	Sphingosine 1-phosphate receptor agonist		S1PR4	sphingosine-1-phosphate receptor 4	1	Completed	https://clinicaltrials.gov/study/NCT03941743
EFO_0000305	breast carcinoma	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	1	Completed	https://clinicaltrials.gov/study/NCT02871791
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Recruiting	https://clinicaltrials.gov/study/NCT05092373
EFO_0000304	breast adenocarcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Completed	https://clinicaltrials.gov/study/NCT03364348
MONDO_0007254	breast cancer	CHEMBL1852688	INFIGRATINIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR2	fibroblast growth factor receptor 2	1	Terminated	https://clinicaltrials.gov/study/NCT04504331
MONDO_0007254	breast cancer	CHEMBL4297721	CDX-1140	Unknown	Tumor necrosis factor receptor superfamily member 5 agonist		CD40	CD40 molecule	1	Recruiting	https://clinicaltrials.gov/study/NCT05029999
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Terminated	https://clinicaltrials.gov/study/NCT00075673
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Completed	https://clinicaltrials.gov/study/NCT01281150,https://clinicaltrials.gov/study/NCT02060253,https://clinicaltrials.gov/study/NCT01288261,https://clinicaltrials.gov/study/NCT00470301,https://clinicaltrials.gov/study/NCT01493310,https://clinicaltrials.gov/study/NCT00368875,https://clinicaltrials.gov/study/NCT01276496
MONDO_0007254	breast cancer	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Terminated	https://clinicaltrials.gov/study/NCT01388647,https://clinicaltrials.gov/study/NCT02753595,https://clinicaltrials.gov/study/NCT03579472
MONDO_0007254	breast cancer	CHEMBL217092	SARACATINIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT01216176
MONDO_0007254	breast cancer	CHEMBL3360203	PILARALISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	1	Completed	https://clinicaltrials.gov/study/NCT01042925,https://clinicaltrials.gov/study/NCT01082068
MONDO_0007254	breast cancer	CHEMBL49642	INDIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Unknown status	https://clinicaltrials.gov/study/NCT01113970
MONDO_0007254	breast cancer	CHEMBL744	RILUZOLE	Small molecule	Sodium channel alpha subunit blocker		SCN8A	sodium voltage-gated channel alpha subunit 8	1	Withdrawn	https://clinicaltrials.gov/study/NCT00903214
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Terminated	https://clinicaltrials.gov/study/NCT02824575,https://clinicaltrials.gov/study/NCT02474173
MONDO_0007254	breast cancer	CHEMBL1567	SUNITINIB MALATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Terminated	https://clinicaltrials.gov/study/NCT00616122,https://clinicaltrials.gov/study/NCT00905021
MONDO_0007254	breast cancer	CHEMBL2109321	CAROTUXIMAB	Antibody	Endoglin inhibitor		ENG	endoglin	1	Completed	https://clinicaltrials.gov/study/NCT01326481
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05251766
MONDO_0007254	breast cancer	CHEMBL522892	DOVITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Completed	https://clinicaltrials.gov/study/NCT01421004
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Terminated	https://clinicaltrials.gov/study/NCT00634088
MONDO_0007254	breast cancer	CHEMBL2109229	OBLIMERSEN SODIUM	Oligonucleotide	Bcl-2 mRNA antisense inhibitor		BCL2	BCL2 apoptosis regulator	1	Completed	https://clinicaltrials.gov/study/NCT00003103
EFO_0000305	breast carcinoma	CHEMBL3408248	AZD-8186	Small molecule	PI3-kinase p110-delta subunit inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
EFO_0005537	triple-negative breast cancer	CHEMBL2336325	VISTUSERTIB	Small molecule	Serine/threonine-protein kinase mTOR inhibitor		MTOR	mechanistic target of rapamycin kinase	1	Unknown status	https://clinicaltrials.gov/study/NCT02583542
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
EFO_0006861	male breast carcinoma	CHEMBL1201550	DENILEUKIN DIFTITOX	Protein	Interleukin-2 receptor binding agent		IL2RA	interleukin 2 receptor subunit alpha	1	Completed	https://clinicaltrials.gov/study/NCT00425672
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Completed	https://clinicaltrials.gov/study/NCT00828074,https://clinicaltrials.gov/study/NCT00003902,https://clinicaltrials.gov/study/NCT00153907,https://clinicaltrials.gov/study/NCT00014430
MONDO_0007254	breast cancer	CHEMBL178	DAUNORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Unknown status	https://clinicaltrials.gov/study/NCT00004207
MONDO_0007254	breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Terminated	https://clinicaltrials.gov/study/NCT05103826
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	1	Completed	https://clinicaltrials.gov/study/NCT02154776,https://clinicaltrials.gov/study/NCT01626209,https://clinicaltrials.gov/study/NCT01248494,https://clinicaltrials.gov/study/NCT02058381,https://clinicaltrials.gov/study/NCT02088684,https://clinicaltrials.gov/study/NCT01339442
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Recruiting	https://clinicaltrials.gov/study/NCT05335473
EFO_0000305	breast carcinoma	CHEMBL554	LAPATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT01434303
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Terminated	https://clinicaltrials.gov/study/NCT02658084,https://clinicaltrials.gov/study/NCT03429101,https://clinicaltrials.gov/study/NCT04296942,https://clinicaltrials.gov/study/NCT04298918,https://clinicaltrials.gov/study/NCT04042051
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC9	histone deacetylase 9	1	Terminated	https://clinicaltrials.gov/study/NCT00567879
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLE	DNA polymerase epsilon, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT00100750,https://clinicaltrials.gov/study/NCT02479230
MONDO_0007254	breast cancer	CHEMBL2177390	IPATASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT1	AKT serine/threonine kinase 1	1	Recruiting	https://clinicaltrials.gov/study/NCT04253561
EFO_0000304	breast adenocarcinoma	CHEMBL4298024	BINTRAFUSP ALFA	Protein	Transforming growth factor beta binding agent		TGFB2	transforming growth factor beta 2	1	Withdrawn	https://clinicaltrials.gov/study/NCT04756505
MONDO_0007254	breast cancer	CHEMBL45	MELATONIN	Small molecule	Melatonin receptor agonist		MTNR1A	melatonin receptor 1A	1	Terminated	https://clinicaltrials.gov/study/NCT00506064
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FYN	FYN proto-oncogene, Src family tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT00924352,https://clinicaltrials.gov/study/NCT01306942,https://clinicaltrials.gov/study/NCT00452673,https://clinicaltrials.gov/study/NCT00820170
MONDO_0007254	breast cancer	CHEMBL2146883	COBIMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 2 inhibitor		MAP2K2	mitogen-activated protein kinase kinase 2	1	Terminated	https://clinicaltrials.gov/study/NCT03566485
MONDO_0007254	breast cancer	CHEMBL502835	NINTEDANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Completed	https://clinicaltrials.gov/study/NCT02619162
EFO_0000304	breast adenocarcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
EFO_0000304	breast adenocarcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC4	histone deacetylase 4	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02453620
EFO_0000305	breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Tyrosine-protein kinase LCK inhibitor		LCK	LCK proto-oncogene, Src family tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Unknown status	https://clinicaltrials.gov/study/NCT00764972
MONDO_0007254	breast cancer	CHEMBL1023	BEXAROTENE	Small molecule	Retinoid X receptor agonist		RXRA	retinoid X receptor alpha	1	Completed	https://clinicaltrials.gov/study/NCT00055991
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Withdrawn	https://clinicaltrials.gov/study/NCT00074139
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND5	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5	1	Completed	https://clinicaltrials.gov/study/NCT02278965
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02390427
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Completed	https://clinicaltrials.gov/study/NCT00003927,https://clinicaltrials.gov/study/NCT01306942,https://clinicaltrials.gov/study/NCT00960960,https://clinicaltrials.gov/study/NCT02041429,https://clinicaltrials.gov/study/NCT03800836,https://clinicaltrials.gov/study/NCT00820170,https://clinicaltrials.gov/study/NCT00951665,https://clinicaltrials.gov/study/NCT00691379,https://clinicaltrials.gov/study/NCT01493310,https://clinicaltrials.gov/study/NCT03411161,https://clinicaltrials.gov/study/NCT02073916,https://clinicaltrials.gov/study/NCT01172223,https://clinicaltrials.gov/study/NCT00301730,https://clinicaltrials.gov/study/NCT01423123,https://clinicaltrials.gov/study/NCT01973309,https://clinicaltrials.gov/study/NCT00322400,https://clinicaltrials.gov/study/NCT04261218,https://clinicaltrials.gov/study/NCT00003877,https://clinicaltrials.gov/study/NCT00807859,https://clinicaltrials.gov/study/NCT00803556,https://clinicaltrials.gov/study/NCT02060253,https://clinicaltrials.gov/study/NCT00724386,https://clinicaltrials.gov/study/NCT00900627,https://clinicaltrials.gov/study/NCT00050167,https://clinicaltrials.gov/study/NCT00002837,https://clinicaltrials.gov/study/NCT00707707,https://clinicaltrials.gov/study/NCT00368875,https://clinicaltrials.gov/study/NCT00717340,https://clinicaltrials.gov/study/NCT00068757,https://clinicaltrials.gov/study/NCT00426556,https://clinicaltrials.gov/study/NCT01625286,https://clinicaltrials.gov/study/NCT02628132,https://clinicaltrials.gov/study/NCT03505528,https://clinicaltrials.gov/study/NCT00637897,https://clinicaltrials.gov/study/NCT00680758,https://clinicaltrials.gov/study/NCT01862081,https://clinicaltrials.gov/study/NCT01133912,https://clinicaltrials.gov/study/NCT01254526,https://clinicaltrials.gov/study/NCT01070706,https://clinicaltrials.gov/study/NCT00107094,https://clinicaltrials.gov/study/NCT03166085,https://clinicaltrials.gov/study/NCT00004174,https://clinicaltrials.gov/study/NCT02015676,https://clinicaltrials.gov/study/NCT02001974,https://clinicaltrials.gov/study/NCT00788931,https://clinicaltrials.gov/study/NCT01003158,https://clinicaltrials.gov/study/NCT00887575,https://clinicaltrials.gov/study/NCT00006108,https://clinicaltrials.gov/study/NCT02599363,https://clinicaltrials.gov/study/NCT01484080,https://clinicaltrials.gov/study/NCT03112590,https://clinicaltrials.gov/study/NCT00574587,https://clinicaltrials.gov/study/NCT04132817,https://clinicaltrials.gov/study/NCT02379247,https://clinicaltrials.gov/study/NCT01042925,https://clinicaltrials.gov/study/NCT00009997,https://clinicaltrials.gov/study/NCT00445458,https://clinicaltrials.gov/study/NCT00983424,https://clinicaltrials.gov/study/NCT04247126,https://clinicaltrials.gov/study/NCT01320592,https://clinicaltrials.gov/study/NCT01031446,https://clinicaltrials.gov/study/NCT01918254,https://clinicaltrials.gov/study/NCT00031876,https://clinicaltrials.gov/study/NCT00001383,https://clinicaltrials.gov/study/NCT00442260,https://clinicaltrials.gov/study/NCT00054028,https://clinicaltrials.gov/study/NCT00748553
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Completed	https://clinicaltrials.gov/study/NCT03872791,https://clinicaltrials.gov/study/NCT04584112,https://clinicaltrials.gov/study/NCT02672475
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Terminated	https://clinicaltrials.gov/study/NCT03579472
MONDO_0007254	breast cancer	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	1	Unknown status	https://clinicaltrials.gov/study/NCT02422199
MONDO_0007254	breast cancer	CHEMBL1201649	ESTROGENS, CONJUGATED	Unknown	Estrogen receptor agonist		ESR2	estrogen receptor 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04821375
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Completed	https://clinicaltrials.gov/study/NCT01795586,https://clinicaltrials.gov/study/NCT01432886,https://clinicaltrials.gov/study/NCT02723877,https://clinicaltrials.gov/study/NCT01596751,https://clinicaltrials.gov/study/NCT01323530
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02390427
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Completed	https://clinicaltrials.gov/study/NCT02027376,https://clinicaltrials.gov/study/NCT00372424,https://clinicaltrials.gov/study/NCT00003103,https://clinicaltrials.gov/study/NCT00086957,https://clinicaltrials.gov/study/NCT00637897,https://clinicaltrials.gov/study/NCT01044485,https://clinicaltrials.gov/study/NCT00080665,https://clinicaltrials.gov/study/NCT00322400,https://clinicaltrials.gov/study/NCT04367090,https://clinicaltrials.gov/study/NCT00872625,https://clinicaltrials.gov/study/NCT00169000,https://clinicaltrials.gov/study/NCT01862081,https://clinicaltrials.gov/study/NCT00002901,https://clinicaltrials.gov/study/NCT00450892,https://clinicaltrials.gov/study/NCT00020332,https://clinicaltrials.gov/study/NCT01256567,https://clinicaltrials.gov/study/NCT02605915,https://clinicaltrials.gov/study/NCT00705315,https://clinicaltrials.gov/study/NCT02392845,https://clinicaltrials.gov/study/NCT00129896,https://clinicaltrials.gov/study/NCT00934856,https://clinicaltrials.gov/study/NCT00645333,https://clinicaltrials.gov/study/NCT00268918,https://clinicaltrials.gov/study/NCT05301530,https://clinicaltrials.gov/study/NCT00050167
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR1	estrogen receptor 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT01597388,https://clinicaltrials.gov/study/NCT06047184,https://clinicaltrials.gov/study/NCT03772353,https://clinicaltrials.gov/study/NCT03959891,https://clinicaltrials.gov/study/NCT04556773,https://clinicaltrials.gov/study/NCT03238196,https://clinicaltrials.gov/study/NCT02792465,https://clinicaltrials.gov/study/NCT05176080,https://clinicaltrials.gov/study/NCT03006172,https://clinicaltrials.gov/study/NCT03767335,https://clinicaltrials.gov/study/NCT01992952
MONDO_0007254	breast cancer	CHEMBL521851	PICTILISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	1	Completed	https://clinicaltrials.gov/study/NCT00928330,https://clinicaltrials.gov/study/NCT00960960
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Completed	https://clinicaltrials.gov/study/NCT02392845,https://clinicaltrials.gov/study/NCT00872625,https://clinicaltrials.gov/study/NCT00637897,https://clinicaltrials.gov/study/NCT04367090,https://clinicaltrials.gov/study/NCT00934856,https://clinicaltrials.gov/study/NCT01044485,https://clinicaltrials.gov/study/NCT00645333,https://clinicaltrials.gov/study/NCT00322400,https://clinicaltrials.gov/study/NCT00002901,https://clinicaltrials.gov/study/NCT00080665,https://clinicaltrials.gov/study/NCT00129896,https://clinicaltrials.gov/study/NCT00268918,https://clinicaltrials.gov/study/NCT05301530,https://clinicaltrials.gov/study/NCT00086957,https://clinicaltrials.gov/study/NCT00705315,https://clinicaltrials.gov/study/NCT00169000,https://clinicaltrials.gov/study/NCT01256567,https://clinicaltrials.gov/study/NCT01862081,https://clinicaltrials.gov/study/NCT00003103,https://clinicaltrials.gov/study/NCT00020332,https://clinicaltrials.gov/study/NCT02027376,https://clinicaltrials.gov/study/NCT00372424,https://clinicaltrials.gov/study/NCT02605915,https://clinicaltrials.gov/study/NCT00050167,https://clinicaltrials.gov/study/NCT00450892
MONDO_0007254	breast cancer	CHEMBL96172	EPOTHILONE D	Small molecule	Tubulin stabiliser		TUBB8	tubulin beta 8 class VIII	1	Completed	https://clinicaltrials.gov/study/NCT00337649
EFO_0000304	breast adenocarcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC6	histone deacetylase 6	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLE2	DNA polymerase epsilon 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT01154426
MONDO_0007254	breast cancer	CHEMBL2325741	CAPIVASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT2	AKT serine/threonine kinase 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04556773,https://clinicaltrials.gov/study/NCT01226316,https://clinicaltrials.gov/study/NCT03616587,https://clinicaltrials.gov/study/NCT01992952
MONDO_0007254	breast cancer	CHEMBL276711	SEMAXANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Completed	https://clinicaltrials.gov/study/NCT00005822
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Completed	https://clinicaltrials.gov/study/NCT01983501,https://clinicaltrials.gov/study/NCT00875979,https://clinicaltrials.gov/study/NCT02038010,https://clinicaltrials.gov/study/NCT00951665,https://clinicaltrials.gov/study/NCT02236000,https://clinicaltrials.gov/study/NCT01513083,https://clinicaltrials.gov/study/NCT00934856,https://clinicaltrials.gov/study/NCT02605915,https://clinicaltrials.gov/study/NCT02073916,https://clinicaltrials.gov/study/NCT02657343
MONDO_0007254	breast cancer	CHEMBL191413	REPARIXIN	Small molecule	Interleukin-8 receptor B modulator		CXCR2	C-X-C motif chemokine receptor 2	1	Completed	https://clinicaltrials.gov/study/NCT02001974
MONDO_0007254	breast cancer	CHEMBL1922094	APITOLISIB	Small molecule	Serine/threonine-protein kinase mTOR inhibitor		MTOR	mechanistic target of rapamycin kinase	1	Completed	https://clinicaltrials.gov/study/NCT01254526
MONDO_0007254	breast cancer	CHEMBL3218578	BGT-226	Small molecule	PI3-kinase class I inhibitor		PIK3R5	phosphoinositide-3-kinase regulatory subunit 5	1	Completed	https://clinicaltrials.gov/study/NCT00600275
EFO_0006318	breast ductal adenocarcinoma	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR2	estrogen receptor 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02983071
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Terminated	https://clinicaltrials.gov/study/NCT03579472
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00600496
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	1	Completed	https://clinicaltrials.gov/study/NCT02285179,https://clinicaltrials.gov/study/NCT01862081
MONDO_0007254	breast cancer	CHEMBL298734	LONAFARNIB	Small molecule	Protein farnesyltransferase inhibitor		FNTB	farnesyltransferase, CAAX box, subunit beta	1	Completed	https://clinicaltrials.gov/study/NCT00068757
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB10	NADH:ubiquinone oxidoreductase subunit B10	1	Completed	https://clinicaltrials.gov/study/NCT02278965
MONDO_0007254	breast cancer	CHEMBL2105737	SONIDEGIB	Small molecule	Smoothened homolog inhibitor		SMO	smoothened, frizzled class receptor	1	Completed	https://clinicaltrials.gov/study/NCT02027376
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	1	Terminated	https://clinicaltrials.gov/study/NCT02561832
MONDO_0007254	breast cancer	CHEMBL2109428	TRX-518	Antibody	Tumor necrosis factor receptor superfamily member 18 agonist		TNFRSF18	TNF receptor superfamily member 18	1	Terminated	https://clinicaltrials.gov/study/NCT03861403
MONDO_0007254	breast cancer	CHEMBL2325741	CAPIVASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT1	AKT serine/threonine kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT01625286
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Terminated	https://clinicaltrials.gov/study/NCT00584012,https://clinicaltrials.gov/study/NCT00063934,https://clinicaltrials.gov/study/NCT00864175,https://clinicaltrials.gov/study/NCT02345772,https://clinicaltrials.gov/study/NCT02379585,https://clinicaltrials.gov/study/NCT00253318,https://clinicaltrials.gov/study/NCT01876251,https://clinicaltrials.gov/study/NCT00531271
EFO_0000304	breast adenocarcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLA1	DNA polymerase alpha 1, catalytic subunit	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Terminated	https://clinicaltrials.gov/study/NCT02753595,https://clinicaltrials.gov/study/NCT03579472
EFO_0000305	breast carcinoma	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT01351909
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLE3	DNA polymerase epsilon 3, accessory subunit	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04750382
EFO_0005537	triple-negative breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
EFO_1000984	inflammatory breast carcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC11	histone deacetylase 11	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
EFO_0006861	male breast carcinoma	CHEMBL1201179	LAPATINIB DITOSYLATE	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT01245205,https://clinicaltrials.gov/study/NCT01783756
MONDO_0007254	breast cancer	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03616587,https://clinicaltrials.gov/study/NCT02608216
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC3	histone deacetylase 3	1	Completed	https://clinicaltrials.gov/study/NCT00632489,https://clinicaltrials.gov/study/NCT01105312,https://clinicaltrials.gov/study/NCT00788931
EFO_0005537	triple-negative breast cancer	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	1	Recruiting	https://clinicaltrials.gov/study/NCT05673200
MONDO_0007254	breast cancer	CHEMBL1289601	LENVATINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Unknown status	https://clinicaltrials.gov/study/NCT02562118
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC1	NADH:ubiquinone oxidoreductase subunit C1	1	Completed	https://clinicaltrials.gov/study/NCT02278965
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R5	phosphoinositide-3-kinase regulatory subunit 5	1	Terminated	https://clinicaltrials.gov/study/NCT01132664
MONDO_0007254	breast cancer	CHEMBL1201583	BEVACIZUMAB	Antibody	Vascular endothelial growth factor A inhibitor		VEGFA	vascular endothelial growth factor A	1	Completed	https://clinicaltrials.gov/study/NCT01508572,https://clinicaltrials.gov/study/NCT00960960,https://clinicaltrials.gov/study/NCT01254526,https://clinicaltrials.gov/study/NCT00705315,https://clinicaltrials.gov/study/NCT00691379,https://clinicaltrials.gov/study/NCT00368875,https://clinicaltrials.gov/study/NCT00095706,https://clinicaltrials.gov/study/NCT00468585
EFO_0006861	male breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Completed	https://clinicaltrials.gov/study/NCT01084057
EFO_0000304	breast adenocarcinoma	CHEMBL3545068	COPANLISIB HYDROCHLORIDE	Small molecule	PI3-kinase p110-delta subunit inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
EFO_0000305	breast carcinoma	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		NCSTN	nicastrin	1	Terminated	https://clinicaltrials.gov/study/NCT01071564
MONDO_0007254	breast cancer	CHEMBL3647420	PYROTINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03772353
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	1	Completed	https://clinicaltrials.gov/study/NCT02684032,https://clinicaltrials.gov/study/NCT03243331
EFO_0005537	triple-negative breast cancer	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	1	Suspended	https://clinicaltrials.gov/study/NCT05422794
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT04213898
MONDO_0004658	breast carcinoma in situ	CHEMBL118	CELECOXIB	Small molecule	Cyclooxygenase-2 inhibitor		PTGS2	prostaglandin-endoperoxide synthase 2	1	Completed	https://clinicaltrials.gov/study/NCT04081389
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	PRIM2	DNA primase subunit 2	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05989828
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLA1	DNA polymerase alpha 1, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT00100750,https://clinicaltrials.gov/study/NCT02479230
MONDO_0007254	breast cancer	CHEMBL160	CYCLOSPORINE	Protein	Cyclophilin A modulator		PPIA	peptidylprolyl isomerase A	1	Unknown status	https://clinicaltrials.gov/study/NCT00003920,https://clinicaltrials.gov/study/NCT00009763
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	1	Completed	https://clinicaltrials.gov/study/NCT01339442,https://clinicaltrials.gov/study/NCT01626209,https://clinicaltrials.gov/study/NCT01248494,https://clinicaltrials.gov/study/NCT02058381,https://clinicaltrials.gov/study/NCT02088684,https://clinicaltrials.gov/study/NCT02154776
MONDO_0007254	breast cancer	CHEMBL3581647	BIRABRESIB	Small molecule	Bromodomain and extra-terminal motif (BET) inhibitor		BRD2	bromodomain containing 2	1	Terminated	https://clinicaltrials.gov/study/NCT02698176
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Withdrawn	https://clinicaltrials.gov/study/NCT00074139
MONDO_0007254	breast cancer	CHEMBL3622820	ITACITINIB	Small molecule	Tyrosine-protein kinase JAK1 inhibitor		JAK1	Janus kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT02646748
MONDO_0007254	breast cancer	CHEMBL289228	TIPIFARNIB	Small molecule	Protein farnesyltransferase inhibitor		FNTA	farnesyltransferase, CAAX box, subunit alpha	1	Completed	https://clinicaltrials.gov/study/NCT00100750
EFO_0000304	breast adenocarcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLA2	DNA polymerase alpha 2, accessory subunit	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
EFO_0000305	breast carcinoma	CHEMBL2105717	CABOZANTINIB	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	1	Recruiting	https://clinicaltrials.gov/study/NCT05092373
MONDO_0007254	breast cancer	CHEMBL1214827	ONALESPIB	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AA1	heat shock protein 90 alpha family class A member 1	1	Completed	https://clinicaltrials.gov/study/NCT01246102
MONDO_0007254	breast cancer	CHEMBL2177390	IPATASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT3	AKT serine/threonine kinase 3	1	Recruiting	https://clinicaltrials.gov/study/NCT04253561
EFO_0000305	breast carcinoma	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	1	Completed	https://clinicaltrials.gov/study/NCT01344031
EFO_0005537	triple-negative breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	1	Terminated	https://clinicaltrials.gov/study/NCT02457910
EFO_0006861	male breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Terminated	https://clinicaltrials.gov/study/NCT00063934
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02390427,https://clinicaltrials.gov/study/NCT03032107
MONDO_0007254	breast cancer	CHEMBL3137309	VENETOCLAX	Small molecule	Apoptosis regulator Bcl-2 inhibitor		BCL2	BCL2 apoptosis regulator	1	Terminated	https://clinicaltrials.gov/study/NCT04298918,https://clinicaltrials.gov/study/NCT04274933
MONDO_0007254	breast cancer	CHEMBL2109399	T-DM1	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 binding agent		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04509596
MONDO_0007254	breast cancer	CHEMBL255863	NILOTINIB	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	1	Recruiting	https://clinicaltrials.gov/study/NCT04205903
MONDO_0007254	breast cancer	CHEMBL274654	ORANTINIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR3	fibroblast growth factor receptor 3	1	Unknown status	https://clinicaltrials.gov/study/NCT00024063
MONDO_0007254	breast cancer	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Completed	https://clinicaltrials.gov/study/NCT02605915,https://clinicaltrials.gov/study/NCT00316875,https://clinicaltrials.gov/study/NCT00290732,https://clinicaltrials.gov/study/NCT00442260,https://clinicaltrials.gov/study/NCT02562378,https://clinicaltrials.gov/study/NCT00129896,https://clinicaltrials.gov/study/NCT00009997,https://clinicaltrials.gov/study/NCT00003038,https://clinicaltrials.gov/study/NCT00005822,https://clinicaltrials.gov/study/NCT00574587,https://clinicaltrials.gov/study/NCT00003927,https://clinicaltrials.gov/study/NCT02015676,https://clinicaltrials.gov/study/NCT06098599,https://clinicaltrials.gov/study/NCT00028964,https://clinicaltrials.gov/study/NCT01172223,https://clinicaltrials.gov/study/NCT00002837,https://clinicaltrials.gov/study/NCT00004925,https://clinicaltrials.gov/study/NCT00006825,https://clinicaltrials.gov/study/NCT00278109,https://clinicaltrials.gov/study/NCT00530101,https://clinicaltrials.gov/study/NCT00093834,https://clinicaltrials.gov/study/NCT00976131
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Withdrawn	https://clinicaltrials.gov/study/NCT00074139
MONDO_0007254	breast cancer	CHEMBL521851	PICTILISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	1	Unknown status	https://clinicaltrials.gov/study/NCT02389842
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
EFO_0000305	breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLA1	DNA polymerase alpha 1, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT00100750
MONDO_0007254	breast cancer	CHEMBL1201670	SARGRAMOSTIM	Protein	Granulocyte-macrophage colony-stimulating factor receptor agonist		CSF2RA	colony stimulating factor 2 receptor subunit alpha	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02780401
EFO_0000305	breast carcinoma	CHEMBL34259	METHOTREXATE	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	1	Completed	https://clinicaltrials.gov/study/NCT03518242
EFO_0006861	male breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Terminated	https://clinicaltrials.gov/study/NCT00063934
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLE3	DNA polymerase epsilon 3, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01929941,https://clinicaltrials.gov/study/NCT01939418,https://clinicaltrials.gov/study/NCT01333137
EFO_0006861	male breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
EFO_0000305	breast carcinoma	CHEMBL288441	BOSUTINIB	Small molecule	Tyrosine-protein kinase SRC inhibitor		SRC	SRC proto-oncogene, non-receptor tyrosine kinase	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03854903
MONDO_0007254	breast cancer	CHEMBL705	ALITRETINOIN	Small molecule	Retinoid receptor agonist		RXRG	retinoid X receptor gamma	1	Completed	https://clinicaltrials.gov/study/NCT00001504
MONDO_0007254	breast cancer	CHEMBL598797	CUDC-101	Small molecule	Histone deacetylase inhibitor		HDAC7	histone deacetylase 7	1	Completed	https://clinicaltrials.gov/study/NCT01171924
MONDO_0007254	breast cancer	CHEMBL521851	PICTILISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	1	Unknown status	https://clinicaltrials.gov/study/NCT02389842
MONDO_0007254	breast cancer	CHEMBL3707227	ATEZOLIZUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	1	Terminated	https://clinicaltrials.gov/study/NCT03566485
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02419495
EFO_0000305	breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL2109531	MEDI-6469	Antibody	Tumor necrosis factor receptor superfamily member 4 agonist		TNFRSF4	TNF receptor superfamily member 4	1	Completed	https://clinicaltrials.gov/study/NCT01862900
MONDO_0007254	breast cancer	CHEMBL96172	EPOTHILONE D	Small molecule	Tubulin stabiliser		TUBB4A	tubulin beta 4A class IVa	1	Completed	https://clinicaltrials.gov/study/NCT00337649
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Recruiting	https://clinicaltrials.gov/study/NCT05335473
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	1	Completed	https://clinicaltrials.gov/study/NCT01154426,https://clinicaltrials.gov/study/NCT01251874,https://clinicaltrials.gov/study/NCT00535119
EFO_0006861	male breast carcinoma	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 6 inhibitor		HDAC6	histone deacetylase 6	1	Completed	https://clinicaltrials.gov/study/NCT00258349,https://clinicaltrials.gov/study/NCT01084057,https://clinicaltrials.gov/study/NCT00368875
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Terminated	https://clinicaltrials.gov/study/NCT02474173,https://clinicaltrials.gov/study/NCT01238133
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF1	NADH:ubiquinone oxidoreductase complex assembly factor 1	1	Completed	https://clinicaltrials.gov/study/NCT02278965
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor	Inhibitor	RRM1	ribonucleotide reductase catalytic subunit M1	1	Completed	https://clinicaltrials.gov/study/NCT00270907,https://clinicaltrials.gov/study/NCT01133912,https://clinicaltrials.gov/study/NCT00100750,https://clinicaltrials.gov/study/NCT02479230,https://clinicaltrials.gov/study/NCT01070706,https://clinicaltrials.gov/study/NCT02139358,https://clinicaltrials.gov/study/NCT04247126
EFO_0005537	triple-negative breast cancer	CHEMBL473417	VISMODEGIB	Small molecule	Smoothened homolog inhibitor		SMO	smoothened, frizzled class receptor	1	Terminated	https://clinicaltrials.gov/study/NCT01071564
MONDO_0007254	breast cancer	CHEMBL1200895	PHENELZINE SULFATE	Small molecule	Monoamine oxidase inhibitor		MAOA	monoamine oxidase A	1	Completed	https://clinicaltrials.gov/study/NCT03505528
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Completed	https://clinicaltrials.gov/study/NCT00924352,https://clinicaltrials.gov/study/NCT00637897,https://clinicaltrials.gov/study/NCT00568022,https://clinicaltrials.gov/study/NCT01084057,https://clinicaltrials.gov/study/NCT00825734,https://clinicaltrials.gov/study/NCT00322374
MONDO_0007254	breast cancer	CHEMBL217092	SARACATINIB	Small molecule	Tyrosine-protein kinase SRC inhibitor		SRC	SRC proto-oncogene, non-receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT01216176
EFO_0005537	triple-negative breast cancer	CHEMBL1789941	RUXOLITINIB	Small molecule	Tyrosine-protein kinase JAK2 inhibitor		JAK2	Janus kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT03012230
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Terminated	https://clinicaltrials.gov/study/NCT00450879,https://clinicaltrials.gov/study/NCT01407562
MONDO_0007254	breast cancer	CHEMBL1173055	RUCAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03542175
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Terminated	https://clinicaltrials.gov/study/NCT02824575,https://clinicaltrials.gov/study/NCT02474173
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1023	BEXAROTENE	Small molecule	Retinoid X receptor agonist		RXRB	retinoid X receptor beta	1	Completed	https://clinicaltrials.gov/study/NCT03323658
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
EFO_0000304	breast adenocarcinoma	CHEMBL4298024	BINTRAFUSP ALFA	Protein	Programmed cell death 1 ligand 1 binding agent		CD274	CD274 molecule	1	Withdrawn	https://clinicaltrials.gov/study/NCT04756505
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	1	Completed	https://clinicaltrials.gov/study/NCT01640665,https://clinicaltrials.gov/study/NCT00828074,https://clinicaltrials.gov/study/NCT00217399,https://clinicaltrials.gov/study/NCT00825734
MONDO_0007254	breast cancer	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		APH1B	aph-1 homolog B, gamma-secretase subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01208441
MONDO_0007254	breast cancer	CHEMBL522892	DOVITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Completed	https://clinicaltrials.gov/study/NCT01421004
EFO_0000305	breast carcinoma	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03554044
EFO_0005537	triple-negative breast cancer	CHEMBL1614701	SELUMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 1 inhibitor		MAP2K1	mitogen-activated protein kinase kinase 1	1	Unknown status	https://clinicaltrials.gov/study/NCT02583542
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Terminated	https://clinicaltrials.gov/study/NCT03579472
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Terminated	https://clinicaltrials.gov/study/NCT03579472
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Completed	https://clinicaltrials.gov/study/NCT02120469
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Completed	https://clinicaltrials.gov/study/NCT00003902,https://clinicaltrials.gov/study/NCT00014430,https://clinicaltrials.gov/study/NCT00828074,https://clinicaltrials.gov/study/NCT00153907
MONDO_0007254	breast cancer	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 2 inhibitor		HDAC2	histone deacetylase 2	1	Terminated	https://clinicaltrials.gov/study/NCT01249443
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Completed	https://clinicaltrials.gov/study/NCT00322374,https://clinicaltrials.gov/study/NCT00825734,https://clinicaltrials.gov/study/NCT01084057,https://clinicaltrials.gov/study/NCT00568022,https://clinicaltrials.gov/study/NCT00637897,https://clinicaltrials.gov/study/NCT00924352
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00049244
MONDO_0007254	breast cancer	CHEMBL1079175	MK-2206	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT2	AKT serine/threonine kinase 2	1	Terminated	https://clinicaltrials.gov/study/NCT00963547
MONDO_0007254	breast cancer	CHEMBL572881	MOTESANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Withdrawn	https://clinicaltrials.gov/study/NCT01349088
MONDO_0007254	breast cancer	CHEMBL2402737	IDASANUTLIN	Small molecule	Tumour suppressor p53/oncoprotein Mdm2 inhibitor		MDM2	MDM2 proto-oncogene	1	Terminated	https://clinicaltrials.gov/study/NCT03566485
MONDO_0003982	bilateral breast carcinoma	CHEMBL3989870	BERZOSERTIB	Small molecule	Serine-protein kinase ATR inhibitor		ATR	ATR serine/threonine kinase	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04052555
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
EFO_0006861	male breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Completed	https://clinicaltrials.gov/study/NCT01084057
EFO_0005537	triple-negative breast cancer	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02419495
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02390427,https://clinicaltrials.gov/study/NCT03032107
MONDO_0007254	breast cancer	CHEMBL3545366	VOXTALISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R2	phosphoinositide-3-kinase regulatory subunit 2	1	Completed	https://clinicaltrials.gov/study/NCT01390818,https://clinicaltrials.gov/study/NCT01082068
MONDO_0007254	breast cancer	CHEMBL554	LAPATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	1	Suspended	https://clinicaltrials.gov/study/NCT01589861
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB4	NADH:ubiquinone oxidoreductase subunit B4	1	Completed	https://clinicaltrials.gov/study/NCT01650506,https://clinicaltrials.gov/study/NCT01980823
MONDO_0007254	breast cancer	CHEMBL467399	BIIB021	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AA1	heat shock protein 90 alpha family class A member 1	1	Completed	https://clinicaltrials.gov/study/NCT00412412
EFO_0000305	breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Completed	https://clinicaltrials.gov/study/NCT04132817,https://clinicaltrials.gov/study/NCT04261218,https://clinicaltrials.gov/study/NCT00748553,https://clinicaltrials.gov/study/NCT00717340,https://clinicaltrials.gov/study/NCT00887575,https://clinicaltrials.gov/study/NCT00691379,https://clinicaltrials.gov/study/NCT00983424,https://clinicaltrials.gov/study/NCT03505528,https://clinicaltrials.gov/study/NCT00322400,https://clinicaltrials.gov/study/NCT02599363,https://clinicaltrials.gov/study/NCT00050167,https://clinicaltrials.gov/study/NCT00951665,https://clinicaltrials.gov/study/NCT00960960,https://clinicaltrials.gov/study/NCT01973309,https://clinicaltrials.gov/study/NCT00002837,https://clinicaltrials.gov/study/NCT00803556,https://clinicaltrials.gov/study/NCT01484080,https://clinicaltrials.gov/study/NCT00900627,https://clinicaltrials.gov/study/NCT00574587,https://clinicaltrials.gov/study/NCT00637897,https://clinicaltrials.gov/study/NCT01042925,https://clinicaltrials.gov/study/NCT02060253,https://clinicaltrials.gov/study/NCT00004174,https://clinicaltrials.gov/study/NCT00031876,https://clinicaltrials.gov/study/NCT03800836,https://clinicaltrials.gov/study/NCT00003927,https://clinicaltrials.gov/study/NCT01172223,https://clinicaltrials.gov/study/NCT01625286,https://clinicaltrials.gov/study/NCT02628132,https://clinicaltrials.gov/study/NCT01306942,https://clinicaltrials.gov/study/NCT00426556,https://clinicaltrials.gov/study/NCT00442260,https://clinicaltrials.gov/study/NCT01862081,https://clinicaltrials.gov/study/NCT00707707,https://clinicaltrials.gov/study/NCT00368875,https://clinicaltrials.gov/study/NCT01320592,https://clinicaltrials.gov/study/NCT03112590,https://clinicaltrials.gov/study/NCT03166085,https://clinicaltrials.gov/study/NCT03411161,https://clinicaltrials.gov/study/NCT02379247,https://clinicaltrials.gov/study/NCT00788931,https://clinicaltrials.gov/study/NCT00054028,https://clinicaltrials.gov/study/NCT01031446,https://clinicaltrials.gov/study/NCT00680758,https://clinicaltrials.gov/study/NCT00807859,https://clinicaltrials.gov/study/NCT02001974,https://clinicaltrials.gov/study/NCT00006108,https://clinicaltrials.gov/study/NCT01003158,https://clinicaltrials.gov/study/NCT01254526,https://clinicaltrials.gov/study/NCT01493310,https://clinicaltrials.gov/study/NCT01133912,https://clinicaltrials.gov/study/NCT01918254,https://clinicaltrials.gov/study/NCT00009997,https://clinicaltrials.gov/study/NCT01423123,https://clinicaltrials.gov/study/NCT00003877,https://clinicaltrials.gov/study/NCT00068757,https://clinicaltrials.gov/study/NCT00820170,https://clinicaltrials.gov/study/NCT04247126,https://clinicaltrials.gov/study/NCT02041429,https://clinicaltrials.gov/study/NCT00001383,https://clinicaltrials.gov/study/NCT00107094,https://clinicaltrials.gov/study/NCT00301730,https://clinicaltrials.gov/study/NCT00724386,https://clinicaltrials.gov/study/NCT02073916,https://clinicaltrials.gov/study/NCT01070706,https://clinicaltrials.gov/study/NCT02015676,https://clinicaltrials.gov/study/NCT00445458
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00600496
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	1	Recruiting	https://clinicaltrials.gov/study/NCT03742245
EFO_0005537	triple-negative breast cancer	CHEMBL3408248	AZD-8186	Small molecule	PI3-kinase p110-beta subunit inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
EFO_0000305	breast carcinoma	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	1	Completed	https://clinicaltrials.gov/study/NCT02871791
EFO_0005537	triple-negative breast cancer	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC2	histone deacetylase 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02393794
MONDO_0007254	breast cancer	CHEMBL1922094	APITOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	1	Completed	https://clinicaltrials.gov/study/NCT01254526
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD3	DNA polymerase delta 3, accessory subunit	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05989828
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Terminated	https://clinicaltrials.gov/study/NCT02753595,https://clinicaltrials.gov/study/NCT03579472,https://clinicaltrials.gov/study/NCT01388647
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		LYN	LYN proto-oncogene, Src family tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT00820170,https://clinicaltrials.gov/study/NCT00924352,https://clinicaltrials.gov/study/NCT01306942,https://clinicaltrials.gov/study/NCT00452673
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	1	Completed	https://clinicaltrials.gov/study/NCT00496665
MONDO_0007254	breast cancer	CHEMBL3545096	BGT-226	Small molecule	Serine/threonine-protein kinase mTOR inhibitor		MTOR	mechanistic target of rapamycin kinase	1	Completed	https://clinicaltrials.gov/study/NCT00600275
MONDO_0007254	breast cancer	CHEMBL3360203	PILARALISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	1	Completed	https://clinicaltrials.gov/study/NCT01042925,https://clinicaltrials.gov/study/NCT01082068
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Unknown status	https://clinicaltrials.gov/study/NCT00009763,https://clinicaltrials.gov/study/NCT03282825,https://clinicaltrials.gov/study/NCT02396108,https://clinicaltrials.gov/study/NCT01084863,https://clinicaltrials.gov/study/NCT00002627,https://clinicaltrials.gov/study/NCT00002628,https://clinicaltrials.gov/study/NCT00915369
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Terminated	https://clinicaltrials.gov/study/NCT00075673
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLA2	DNA polymerase alpha 2, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01333137,https://clinicaltrials.gov/study/NCT01939418,https://clinicaltrials.gov/study/NCT01929941
MONDO_0007254	breast cancer	CHEMBL1201247	GOSERELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	1	Completed	https://clinicaltrials.gov/study/NCT02333370,https://clinicaltrials.gov/study/NCT02586675
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Terminated	https://clinicaltrials.gov/study/NCT00634088
MONDO_0007254	breast cancer	CHEMBL1567	SUNITINIB MALATE	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT00905021,https://clinicaltrials.gov/study/NCT00616122
EFO_0000305	breast carcinoma	CHEMBL483158	ALISERTIB	Small molecule	Serine/threonine-protein kinase Aurora-A inhibitor		AURKA	aurora kinase A	1	Completed	https://clinicaltrials.gov/study/NCT02219789
EFO_0000305	breast carcinoma	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	1	Completed	https://clinicaltrials.gov/study/NCT02152943
MONDO_0007254	breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	1	Withdrawn	https://clinicaltrials.gov/study/NCT03846583,https://clinicaltrials.gov/study/NCT04316169
MONDO_0007254	breast cancer	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 1 inhibitor		HDAC1	histone deacetylase 1	1	Unknown status	https://clinicaltrials.gov/study/NCT00416130
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD1	DNA polymerase delta 1, catalytic subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01939418,https://clinicaltrials.gov/study/NCT01333137,https://clinicaltrials.gov/study/NCT01929941
MONDO_0007254	breast cancer	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	1	Withdrawn	https://clinicaltrials.gov/study/NCT04316169
MONDO_0007254	breast cancer	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Serine/threonine-protein kinase B-raf inhibitor		BRAF	B-Raf proto-oncogene, serine/threonine kinase	1	Completed	https://clinicaltrials.gov/study/NCT00828074,https://clinicaltrials.gov/study/NCT00217399
MONDO_0007254	breast cancer	CHEMBL348475	TARIQUIDAR	Small molecule	P-glycoprotein 1 inhibitor		ABCB1	ATP binding cassette subfamily B member 1	1	Completed	https://clinicaltrials.gov/study/NCT00001944
MONDO_0007254	breast cancer	CHEMBL2396661	ALPELISIB	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	1	Terminated	https://clinicaltrials.gov/study/NCT02734615
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Unknown status	https://clinicaltrials.gov/study/NCT02616848
MONDO_0007254	breast cancer	CHEMBL522892	DOVITINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Completed	https://clinicaltrials.gov/study/NCT01421004
MONDO_0007254	breast cancer	CHEMBL4297181	SAMOTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R2	phosphoinositide-3-kinase regulatory subunit 2	1	Completed	https://clinicaltrials.gov/study/NCT01655225
MONDO_0007254	breast cancer	CHEMBL45	MELATONIN	Small molecule	Melatonin receptor agonist		MTNR1B	melatonin receptor 1B	1	Terminated	https://clinicaltrials.gov/study/NCT00506064
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Platelet-derived growth factor receptor alpha inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Unknown status	https://clinicaltrials.gov/study/NCT00931450
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Recruiting	https://clinicaltrials.gov/study/NCT05092373
EFO_0000305	breast carcinoma	CHEMBL289228	TIPIFARNIB	Small molecule	Protein farnesyltransferase inhibitor		FNTB	farnesyltransferase, CAAX box, subunit beta	1	Completed	https://clinicaltrials.gov/study/NCT00100750
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV1	NADH:ubiquinone oxidoreductase core subunit V1	1	Completed	https://clinicaltrials.gov/study/NCT01980823,https://clinicaltrials.gov/study/NCT01650506
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD2	DNA polymerase delta 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02479230,https://clinicaltrials.gov/study/NCT00100750
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Fibroblast growth factor receptor 1 inhibitor		FGFR1	fibroblast growth factor receptor 1	1	Terminated	https://clinicaltrials.gov/study/NCT01407562,https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Unknown status	https://clinicaltrials.gov/study/NCT00002628,https://clinicaltrials.gov/study/NCT00915369,https://clinicaltrials.gov/study/NCT00002627,https://clinicaltrials.gov/study/NCT01084863,https://clinicaltrials.gov/study/NCT02396108,https://clinicaltrials.gov/study/NCT00009763,https://clinicaltrials.gov/study/NCT03282825
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Terminated	https://clinicaltrials.gov/study/NCT02753595,https://clinicaltrials.gov/study/NCT03579472
MONDO_0007254	breast cancer	CHEMBL2107856	IMETELSTAT	Oligonucleotide	Telomerase reverse transcriptase inhibitor		TERT	telomerase reverse transcriptase	1	Completed	https://clinicaltrials.gov/study/NCT00732056
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R2	phosphoinositide-3-kinase regulatory subunit 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02390427
EFO_1000984	inflammatory breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Unknown status	https://clinicaltrials.gov/study/NCT01880385
MONDO_0007254	breast cancer	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	1	Completed	https://clinicaltrials.gov/study/NCT01989546,https://clinicaltrials.gov/study/NCT04672460,https://clinicaltrials.gov/study/NCT04134884
MONDO_0007254	breast cancer	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 6 inhibitor		HDAC6	histone deacetylase 6	1	Recruiting	https://clinicaltrials.gov/study/NCT03742245
MONDO_0007254	breast cancer	CHEMBL1276308	MIFEPRISTONE	Small molecule	Glucocorticoid receptor antagonist		NR3C1	nuclear receptor subfamily 3 group C member 1	1	Completed	https://clinicaltrials.gov/study/NCT01493310
MONDO_0007254	breast cancer	CHEMBL941	IMATINIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT00080665
EFO_0000305	breast carcinoma	CHEMBL1079175	MK-2206	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT1	AKT serine/threonine kinase 1	1	Terminated	https://clinicaltrials.gov/study/NCT01281163
MONDO_0007254	breast cancer	CHEMBL180022	NERATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	1	Completed	https://clinicaltrials.gov/study/NCT00706030,https://clinicaltrials.gov/study/NCT01423123,https://clinicaltrials.gov/study/NCT00741260,https://clinicaltrials.gov/study/NCT02236000,https://clinicaltrials.gov/study/NCT01111825,https://clinicaltrials.gov/study/NCT00708903,https://clinicaltrials.gov/study/NCT00398567,https://clinicaltrials.gov/study/NCT00445458
EFO_0000305	breast carcinoma	CHEMBL288441	BOSUTINIB	Small molecule	Tyrosine-protein kinase Lyn inhibitor		LYN	LYN proto-oncogene, Src family tyrosine kinase	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03854903
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Completed	https://clinicaltrials.gov/study/NCT01498458
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT04213898
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS6	NADH:ubiquinone oxidoreductase subunit S6	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
EFO_0005537	triple-negative breast cancer	CHEMBL3187723	BINIMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 2 inhibitor		MAP2K2	mitogen-activated protein kinase kinase 2	1	Recruiting	https://clinicaltrials.gov/study/NCT05111561
MONDO_0007254	breast cancer	CHEMBL1173055	RUCAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03542175
EFO_0006861	male breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Fibroblast growth factor receptor 1 inhibitor		FGFR1	fibroblast growth factor receptor 1	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 1 inhibitor		HDAC1	histone deacetylase 1	1	Recruiting	https://clinicaltrials.gov/study/NCT03742245
MONDO_0007254	breast cancer	CHEMBL2219422	AFURESERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT2	AKT serine/threonine kinase 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04851613
MONDO_0007254	breast cancer	CHEMBL4297939	DATOPOTAMAB DERUXTECAN	Antibody drug conjugate	Tumor-associated calcium signal transducer 2 binding agent		TACSTD2	tumor associated calcium signal transducer 2	1	Recruiting	https://clinicaltrials.gov/study/NCT03401385
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Unknown status	https://clinicaltrials.gov/study/NCT00764972
MONDO_0007254	breast cancer	CHEMBL96172	EPOTHILONE D	Small molecule	Tubulin stabiliser		TUBB	tubulin beta class I	1	Completed	https://clinicaltrials.gov/study/NCT00337649
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Completed	https://clinicaltrials.gov/study/NCT01044485,https://clinicaltrials.gov/study/NCT00169000,https://clinicaltrials.gov/study/NCT01862081,https://clinicaltrials.gov/study/NCT02605915,https://clinicaltrials.gov/study/NCT00080665,https://clinicaltrials.gov/study/NCT00872625,https://clinicaltrials.gov/study/NCT00003103,https://clinicaltrials.gov/study/NCT05301530,https://clinicaltrials.gov/study/NCT00645333,https://clinicaltrials.gov/study/NCT00002901,https://clinicaltrials.gov/study/NCT00086957,https://clinicaltrials.gov/study/NCT02027376,https://clinicaltrials.gov/study/NCT02392845,https://clinicaltrials.gov/study/NCT00322400,https://clinicaltrials.gov/study/NCT00934856,https://clinicaltrials.gov/study/NCT04367090,https://clinicaltrials.gov/study/NCT00129896,https://clinicaltrials.gov/study/NCT00372424,https://clinicaltrials.gov/study/NCT00705315,https://clinicaltrials.gov/study/NCT00450892,https://clinicaltrials.gov/study/NCT00268918,https://clinicaltrials.gov/study/NCT00050167,https://clinicaltrials.gov/study/NCT00637897,https://clinicaltrials.gov/study/NCT01256567,https://clinicaltrials.gov/study/NCT00020332
MONDO_0007254	breast cancer	CHEMBL1879463	DACTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	1	Completed	https://clinicaltrials.gov/study/NCT01248494
MONDO_0007254	breast cancer	CHEMBL4650365	CAMIZESTRANT	Small molecule	Estrogen receptor alpha degrader		ESR1	estrogen receptor 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04541433,https://clinicaltrials.gov/study/NCT03616587
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT04213898
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA13	NADH:ubiquinone oxidoreductase subunit A13	1	Completed	https://clinicaltrials.gov/study/NCT02278965
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05900895
MONDO_0007254	breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Vascular endothelial growth factor receptor 3 inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Terminated	https://clinicaltrials.gov/study/NCT05103826
MONDO_0007254	breast cancer	CHEMBL274654	ORANTINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Unknown status	https://clinicaltrials.gov/study/NCT00024063
MONDO_0007254	breast cancer	CHEMBL601719	CRIZOTINIB	Small molecule	NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor)		ALK	ALK receptor tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT02074878
MONDO_0007254	breast cancer	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	1	Terminated	https://clinicaltrials.gov/study/NCT02936206,https://clinicaltrials.gov/study/NCT04504331,https://clinicaltrials.gov/study/NCT01194908
EFO_0000305	breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Recruiting	https://clinicaltrials.gov/study/NCT04253561,https://clinicaltrials.gov/study/NCT03994107,https://clinicaltrials.gov/study/NCT04170595,https://clinicaltrials.gov/study/NCT03321045,https://clinicaltrials.gov/study/NCT06162559,https://clinicaltrials.gov/study/NCT04152057,https://clinicaltrials.gov/study/NCT04487236,https://clinicaltrials.gov/study/NCT05378464,https://clinicaltrials.gov/study/NCT04120246
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Completed	https://clinicaltrials.gov/study/NCT00153907,https://clinicaltrials.gov/study/NCT00912275,https://clinicaltrials.gov/study/NCT00003902,https://clinicaltrials.gov/study/NCT00706030,https://clinicaltrials.gov/study/NCT00828074,https://clinicaltrials.gov/study/NCT00513058,https://clinicaltrials.gov/study/NCT00706069,https://clinicaltrials.gov/study/NCT00014430,https://clinicaltrials.gov/study/NCT00724386,https://clinicaltrials.gov/study/NCT00001944
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND6	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6	1	Completed	https://clinicaltrials.gov/study/NCT02278965
MONDO_0007254	breast cancer	CHEMBL252164	LUMINESPIB	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AA1	heat shock protein 90 alpha family class A member 1	1	Completed	https://clinicaltrials.gov/study/NCT01271920
EFO_0006861	male breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Fibroblast growth factor receptor 3 inhibitor		FGFR3	fibroblast growth factor receptor 3	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
MONDO_0007254	breast cancer	CHEMBL572881	MOTESANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Completed	https://clinicaltrials.gov/study/NCT00322400
MONDO_0007254	breast cancer	CHEMBL1201564	INTERFERON GAMMA-1B	Protein	Interferon gamma receptor agonist		IFNGR1	interferon gamma receptor 1	1	Completed	https://clinicaltrials.gov/study/NCT03112590
EFO_0000305	breast carcinoma	CHEMBL2103868	CABOZANTINIB S-MALATE	Small molecule	Hepatocyte growth factor receptor inhibitor		MET	MET proto-oncogene, receptor tyrosine kinase	1	Recruiting	https://clinicaltrials.gov/study/NCT05092373
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Completed	https://clinicaltrials.gov/study/NCT01816035
MONDO_0007254	breast cancer	CHEMBL572881	MOTESANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Completed	https://clinicaltrials.gov/study/NCT00322400
MONDO_0007254	breast cancer	CHEMBL1289601	LENVATINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Recruiting	https://clinicaltrials.gov/study/NCT04427293
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Terminated	https://clinicaltrials.gov/study/NCT02345772,https://clinicaltrials.gov/study/NCT02379585,https://clinicaltrials.gov/study/NCT00063934,https://clinicaltrials.gov/study/NCT00531271,https://clinicaltrials.gov/study/NCT01876251,https://clinicaltrials.gov/study/NCT00584012,https://clinicaltrials.gov/study/NCT00864175,https://clinicaltrials.gov/study/NCT00253318
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB5	NADH:ubiquinone oxidoreductase subunit B5	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Withdrawn	https://clinicaltrials.gov/study/NCT02070094
EFO_0000305	breast carcinoma	CHEMBL554	LAPATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	1	Terminated	https://clinicaltrials.gov/study/NCT01281163
MONDO_0007254	breast cancer	CHEMBL101253	VATALANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Terminated	https://clinicaltrials.gov/study/NCT00216047
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Completed	https://clinicaltrials.gov/study/NCT00825734,https://clinicaltrials.gov/study/NCT01084057,https://clinicaltrials.gov/study/NCT00568022,https://clinicaltrials.gov/study/NCT00322374,https://clinicaltrials.gov/study/NCT00924352,https://clinicaltrials.gov/study/NCT00637897
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02390427
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA12	NADH:ubiquinone oxidoreductase subunit A12	1	Completed	https://clinicaltrials.gov/study/NCT02278965
EFO_0006861	male breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Completed	https://clinicaltrials.gov/study/NCT01084057
EFO_0000305	breast carcinoma	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03554044
EFO_0005537	triple-negative breast cancer	CHEMBL1795071	RUXOLITINIB PHOSPHATE	Small molecule	Tyrosine-protein kinase JAK2 inhibitor		JAK2	Janus kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT03012230
MONDO_0007254	breast cancer	CHEMBL2408045	SAPITINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	1	Completed	https://clinicaltrials.gov/study/NCT01003158,https://clinicaltrials.gov/study/NCT00900627
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Completed	https://clinicaltrials.gov/study/NCT00050167,https://clinicaltrials.gov/study/NCT00934856,https://clinicaltrials.gov/study/NCT02027376,https://clinicaltrials.gov/study/NCT00002901,https://clinicaltrials.gov/study/NCT00705315,https://clinicaltrials.gov/study/NCT00372424,https://clinicaltrials.gov/study/NCT01044485,https://clinicaltrials.gov/study/NCT00020332,https://clinicaltrials.gov/study/NCT00268918,https://clinicaltrials.gov/study/NCT00129896,https://clinicaltrials.gov/study/NCT01862081,https://clinicaltrials.gov/study/NCT04367090,https://clinicaltrials.gov/study/NCT00872625,https://clinicaltrials.gov/study/NCT00080665,https://clinicaltrials.gov/study/NCT02605915,https://clinicaltrials.gov/study/NCT00645333,https://clinicaltrials.gov/study/NCT01256567,https://clinicaltrials.gov/study/NCT00169000,https://clinicaltrials.gov/study/NCT00450892,https://clinicaltrials.gov/study/NCT00086957,https://clinicaltrials.gov/study/NCT02392845,https://clinicaltrials.gov/study/NCT00322400,https://clinicaltrials.gov/study/NCT05301530,https://clinicaltrials.gov/study/NCT00003103,https://clinicaltrials.gov/study/NCT00637897
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Unknown status	https://clinicaltrials.gov/study/NCT00764972
MONDO_0007254	breast cancer	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	1	Completed	https://clinicaltrials.gov/study/NCT01857193,https://clinicaltrials.gov/study/NCT03308201,https://clinicaltrials.gov/study/NCT02732119,https://clinicaltrials.gov/study/NCT01597193,https://clinicaltrials.gov/study/NCT02820961,https://clinicaltrials.gov/study/NCT02623751,https://clinicaltrials.gov/study/NCT01870505,https://clinicaltrials.gov/study/NCT00933309,https://clinicaltrials.gov/study/NCT02833155,https://clinicaltrials.gov/study/NCT02871791,https://clinicaltrials.gov/study/NCT01202591,https://clinicaltrials.gov/study/NCT01594398
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC1	histone deacetylase 1	1	Terminated	https://clinicaltrials.gov/study/NCT00567879
MONDO_0007254	breast cancer	CHEMBL4297181	SAMOTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	1	Completed	https://clinicaltrials.gov/study/NCT01655225
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Terminated	https://clinicaltrials.gov/study/NCT00075673
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS3	NADH:ubiquinone oxidoreductase core subunit S3	1	Completed	https://clinicaltrials.gov/study/NCT01650506,https://clinicaltrials.gov/study/NCT01980823
MONDO_0007254	breast cancer	CHEMBL2108658	TREMELIMUMAB	Antibody	Cytotoxic T-lymphocyte protein 4 inhibitor		CTLA4	cytotoxic T-lymphocyte associated protein 4	1	Terminated	https://clinicaltrials.gov/study/NCT01334099
MONDO_0007254	breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02791334,https://clinicaltrials.gov/study/NCT03616587
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00600496
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD1	DNA polymerase delta 1, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT01154426
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	1	Withdrawn	https://clinicaltrials.gov/study/NCT03400254
EFO_0006861	male breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Terminated	https://clinicaltrials.gov/study/NCT00063934
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Completed	https://clinicaltrials.gov/study/NCT00014430,https://clinicaltrials.gov/study/NCT00828074,https://clinicaltrials.gov/study/NCT00153907,https://clinicaltrials.gov/study/NCT00003902
MONDO_0007254	breast cancer	CHEMBL1751	DIGOXIN	Small molecule	Sodium/potassium-transporting ATPase inhibitor		ATP1A4	ATPase Na+/K+ transporting subunit alpha 4	1	Completed	https://clinicaltrials.gov/study/NCT03928210
MONDO_0007254	breast cancer	CHEMBL180022	NERATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-4 inhibitor		ERBB4	erb-b2 receptor tyrosine kinase 4	1	Completed	https://clinicaltrials.gov/study/NCT00741260,https://clinicaltrials.gov/study/NCT01423123,https://clinicaltrials.gov/study/NCT00445458,https://clinicaltrials.gov/study/NCT00708903,https://clinicaltrials.gov/study/NCT00706030,https://clinicaltrials.gov/study/NCT00398567,https://clinicaltrials.gov/study/NCT01111825,https://clinicaltrials.gov/study/NCT02236000
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R5	phosphoinositide-3-kinase regulatory subunit 5	1	Completed	https://clinicaltrials.gov/study/NCT01862081,https://clinicaltrials.gov/study/NCT02285179
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Completed	https://clinicaltrials.gov/study/NCT00496665
MONDO_0007254	breast cancer	CHEMBL1201583	BEVACIZUMAB	Antibody	Vascular endothelial growth factor A inhibitor		VEGFA	vascular endothelial growth factor A	1	Withdrawn	https://clinicaltrials.gov/study/NCT03175666
EFO_0000305	breast carcinoma	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		PSENEN	presenilin enhancer, gamma-secretase subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01071564
MONDO_0007254	breast cancer	CHEMBL265502	SURAMIN	Small molecule	Acidic fibroblast growth factor inhibitor		FGF1	fibroblast growth factor 1	1	Completed	https://clinicaltrials.gov/study/NCT00003038,https://clinicaltrials.gov/study/NCT00054028
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC6	histone deacetylase 6	1	Completed	https://clinicaltrials.gov/study/NCT03473639,https://clinicaltrials.gov/study/NCT02820961,https://clinicaltrials.gov/study/NCT01594398,https://clinicaltrials.gov/study/NCT02833155
MONDO_0007254	breast cancer	CHEMBL1089	PHENELZINE	Small molecule	Monoamine oxidase inhibitor		MAOA	monoamine oxidase A	1	Completed	https://clinicaltrials.gov/study/NCT03505528
MONDO_0007254	breast cancer	CHEMBL1289601	LENVATINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Recruiting	https://clinicaltrials.gov/study/NCT04427293
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Terminated	https://clinicaltrials.gov/study/NCT01388647,https://clinicaltrials.gov/study/NCT02753595,https://clinicaltrials.gov/study/NCT03579472
MONDO_0007254	breast cancer	CHEMBL34259	METHOTREXATE	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	1	Recruiting	https://clinicaltrials.gov/study/NCT02897700
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Withdrawn	https://clinicaltrials.gov/study/NCT04762901,https://clinicaltrials.gov/study/NCT04826016,https://clinicaltrials.gov/study/NCT00022230,https://clinicaltrials.gov/study/NCT03175666,https://clinicaltrials.gov/study/NCT03285607,https://clinicaltrials.gov/study/NCT02569489,https://clinicaltrials.gov/study/NCT04252768
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04331067,https://clinicaltrials.gov/study/NCT03716180,https://clinicaltrials.gov/study/NCT03893955,https://clinicaltrials.gov/study/NCT03858322,https://clinicaltrials.gov/study/NCT02999477,https://clinicaltrials.gov/study/NCT04556773,https://clinicaltrials.gov/study/NCT02390427,https://clinicaltrials.gov/study/NCT02608216
EFO_0000304	breast adenocarcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Terminated	https://clinicaltrials.gov/study/NCT03579472
MONDO_0007254	breast cancer	CHEMBL1201670	SARGRAMOSTIM	Protein	Granulocyte-macrophage colony-stimulating factor receptor agonist		CSF2RA	colony stimulating factor 2 receptor subunit alpha	1	Withdrawn	https://clinicaltrials.gov/study/NCT00022230
MONDO_0007254	breast cancer	CHEMBL1201649	ESTROGENS, CONJUGATED	Unknown	Estrogen receptor agonist		ESR1	estrogen receptor 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04821375
EFO_0005537	triple-negative breast cancer	CHEMBL2364611	GALUNISERTIB	Small molecule	TGF-beta receptor type I inhibitor		TGFBR1	transforming growth factor beta receptor 1	1	Completed	https://clinicaltrials.gov/study/NCT02672475
MONDO_0007254	breast cancer	CHEMBL3545096	BGT-226	Small molecule	PI3-kinase class I inhibitor		PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	1	Completed	https://clinicaltrials.gov/study/NCT00600275
MONDO_0007254	breast cancer	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RB	interleukin 2 receptor subunit beta	1	Suspended	https://clinicaltrials.gov/study/NCT00673829
EFO_0000305	breast carcinoma	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT01922921,https://clinicaltrials.gov/study/NCT01434303,https://clinicaltrials.gov/study/NCT02152943
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA8	EPH receptor A8	1	Completed	https://clinicaltrials.gov/study/NCT00496665
EFO_1000984	inflammatory breast carcinoma	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	1	Completed	https://clinicaltrials.gov/study/NCT02227082
MONDO_0007254	breast cancer	CHEMBL3963485	ROGARATINIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR1	fibroblast growth factor receptor 1	1	Completed	https://clinicaltrials.gov/study/NCT04483505
EFO_0005537	triple-negative breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Suspended	https://clinicaltrials.gov/study/NCT05422794
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Tyrosine-protein kinase ITK/TSK inhibitor		ITK	IL2 inducible T cell kinase	1	Completed	https://clinicaltrials.gov/study/NCT01498458
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05251766
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FRK	fyn related Src family tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT00903006
MONDO_0007254	breast cancer	CHEMBL4298024	BINTRAFUSP ALFA	Protein	Transforming growth factor beta binding agent		TGFB1	transforming growth factor beta 1	1	Withdrawn	https://clinicaltrials.gov/study/NCT04756505
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Terminated	https://clinicaltrials.gov/study/NCT03579472
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05251766
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Unknown status	https://clinicaltrials.gov/study/NCT00764972
MONDO_0007254	breast cancer	CHEMBL3545366	VOXTALISIB	Small molecule	Serine/threonine-protein kinase mTOR inhibitor		MTOR	mechanistic target of rapamycin kinase	1	Completed	https://clinicaltrials.gov/study/NCT01082068,https://clinicaltrials.gov/study/NCT01390818
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Completed	https://clinicaltrials.gov/study/NCT01816035
EFO_0000305	breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Tyrosine-protein kinase ITK/TSK inhibitor		ITK	IL2 inducible T cell kinase	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
EFO_0005537	triple-negative breast cancer	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC9	histone deacetylase 9	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02393794
EFO_0005537	triple-negative breast cancer	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC5	histone deacetylase 5	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02393794
MONDO_0007254	breast cancer	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	1	Unknown status	https://clinicaltrials.gov/study/NCT00002627,https://clinicaltrials.gov/study/NCT00009763,https://clinicaltrials.gov/study/NCT00002628,https://clinicaltrials.gov/study/NCT00003920,https://clinicaltrials.gov/study/NCT00002616
MONDO_0007254	breast cancer	CHEMBL2146883	COBIMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 1 inhibitor		MAP2K1	mitogen-activated protein kinase kinase 1	1	Terminated	https://clinicaltrials.gov/study/NCT03566485
EFO_1000984	inflammatory breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Unknown status	https://clinicaltrials.gov/study/NCT01880385
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Terminated	https://clinicaltrials.gov/study/NCT02658084,https://clinicaltrials.gov/study/NCT03429101,https://clinicaltrials.gov/study/NCT04296942,https://clinicaltrials.gov/study/NCT04042051,https://clinicaltrials.gov/study/NCT04298918
MONDO_0007254	breast cancer	CHEMBL3545262	SACITUZUMAB GOVITECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	1	Terminated	https://clinicaltrials.gov/study/NCT04927884
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Withdrawn	https://clinicaltrials.gov/study/NCT01349088
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB3	NADH:ubiquinone oxidoreductase subunit B3	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
MONDO_0007254	breast cancer	CHEMBL1770916	NIROGACESTAT	Small molecule	Gamma-secretase inhibitor		APH1B	aph-1 homolog B, gamma-secretase subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01876251
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF4	NADH:ubiquinone oxidoreductase complex assembly factor 4	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLE2	DNA polymerase epsilon 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT00100750
MONDO_0007254	breast cancer	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT00828074,https://clinicaltrials.gov/study/NCT00217399
EFO_0000305	breast carcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC9	histone deacetylase 9	1	Completed	https://clinicaltrials.gov/study/NCT01434303
EFO_0005537	triple-negative breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	1	Terminated	https://clinicaltrials.gov/study/NCT01132664
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Completed	https://clinicaltrials.gov/study/NCT01640665,https://clinicaltrials.gov/study/NCT00825734,https://clinicaltrials.gov/study/NCT00217399,https://clinicaltrials.gov/study/NCT00828074
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBA3C	tubulin alpha 3c	1	Completed	https://clinicaltrials.gov/study/NCT00270907
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC8	histone deacetylase 8	1	Completed	https://clinicaltrials.gov/study/NCT01594398,https://clinicaltrials.gov/study/NCT02820961,https://clinicaltrials.gov/study/NCT02833155,https://clinicaltrials.gov/study/NCT03473639
MONDO_0007254	breast cancer	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	1	Recruiting	https://clinicaltrials.gov/study/NCT06139107,https://clinicaltrials.gov/study/NCT05337657,https://clinicaltrials.gov/study/NCT05307705,https://clinicaltrials.gov/study/NCT05464810
MONDO_0007254	breast cancer	CHEMBL1023	BEXAROTENE	Small molecule	Retinoid X receptor agonist		RXRB	retinoid X receptor beta	1	Completed	https://clinicaltrials.gov/study/NCT00055991
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Withdrawn	https://clinicaltrials.gov/study/NCT02396433
MONDO_0007254	breast cancer	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Completed	https://clinicaltrials.gov/study/NCT00217399,https://clinicaltrials.gov/study/NCT00828074
MONDO_0007254	breast cancer	CHEMBL3188267	CAPMATINIB	Small molecule	Hepatocyte growth factor receptor inhibitor		MET	MET proto-oncogene, receptor tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT03742349
EFO_0005537	triple-negative breast cancer	CHEMBL3408248	AZD-8186	Small molecule	PI3-kinase p110-delta subunit inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
EFO_0005537	triple-negative breast cancer	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC4	histone deacetylase 4	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02393794
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
EFO_0000305	breast carcinoma	CHEMBL2396661	ALPELISIB	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	1	Completed	https://clinicaltrials.gov/study/NCT03207529
EFO_0005537	triple-negative breast cancer	CHEMBL1023	BEXAROTENE	Small molecule	Retinoid X receptor agonist		RXRG	retinoid X receptor gamma	1	Recruiting	https://clinicaltrials.gov/study/NCT04664829
MONDO_0007254	breast cancer	CHEMBL1567	SUNITINIB MALATE	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	1	Unknown status	https://clinicaltrials.gov/study/NCT00931450
EFO_0005537	triple-negative breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
MONDO_0007254	breast cancer	CHEMBL3647420	PYROTINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	1	Completed	https://clinicaltrials.gov/study/NCT04367090,https://clinicaltrials.gov/study/NCT05252546,https://clinicaltrials.gov/study/NCT02361112,https://clinicaltrials.gov/study/NCT01937689
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC8	histone deacetylase 8	1	Terminated	https://clinicaltrials.gov/study/NCT00567879
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Completed	https://clinicaltrials.gov/study/NCT02120469
EFO_1000984	inflammatory breast carcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC7	histone deacetylase 7	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC2	NADH:ubiquinone oxidoreductase subunit C2	1	Completed	https://clinicaltrials.gov/study/NCT02278965
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02608216,https://clinicaltrials.gov/study/NCT04331067,https://clinicaltrials.gov/study/NCT03893955,https://clinicaltrials.gov/study/NCT04556773,https://clinicaltrials.gov/study/NCT02390427,https://clinicaltrials.gov/study/NCT03716180,https://clinicaltrials.gov/study/NCT03858322,https://clinicaltrials.gov/study/NCT02999477
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FRK	fyn related Src family tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT00820170,https://clinicaltrials.gov/study/NCT01306942,https://clinicaltrials.gov/study/NCT00924352,https://clinicaltrials.gov/study/NCT00452673
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05251766
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		LYN	LYN proto-oncogene, Src family tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT00903006
MONDO_0007254	breast cancer	CHEMBL1201568	PEGFILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	1	Terminated	https://clinicaltrials.gov/study/NCT00063934,https://clinicaltrials.gov/study/NCT00346229
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R5	phosphoinositide-3-kinase regulatory subunit 5	1	Completed	https://clinicaltrials.gov/study/NCT01626209,https://clinicaltrials.gov/study/NCT01248494,https://clinicaltrials.gov/study/NCT02154776,https://clinicaltrials.gov/study/NCT01339442,https://clinicaltrials.gov/study/NCT02058381,https://clinicaltrials.gov/study/NCT02088684
EFO_0006861	male breast carcinoma	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	1	Completed	https://clinicaltrials.gov/study/NCT01281150
EFO_0000305	breast carcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC10	histone deacetylase 10	1	Completed	https://clinicaltrials.gov/study/NCT01434303
EFO_0000304	breast adenocarcinoma	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Terminated	https://clinicaltrials.gov/study/NCT01697293
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	PRIM2	DNA primase subunit 2	1	Recruiting	https://clinicaltrials.gov/study/NCT04796220
MONDO_0007254	breast cancer	CHEMBL1879463	DACTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	1	Terminated	https://clinicaltrials.gov/study/NCT01495247
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Terminated	https://clinicaltrials.gov/study/NCT02474173,https://clinicaltrials.gov/study/NCT01407562,https://clinicaltrials.gov/study/NCT01512199,https://clinicaltrials.gov/study/NCT01495247,https://clinicaltrials.gov/study/NCT01980277,https://clinicaltrials.gov/study/NCT01090128,https://clinicaltrials.gov/study/NCT01249443,https://clinicaltrials.gov/study/NCT02358200,https://clinicaltrials.gov/study/NCT00140140,https://clinicaltrials.gov/study/NCT00041470,https://clinicaltrials.gov/study/NCT00003086,https://clinicaltrials.gov/study/NCT01929941,https://clinicaltrials.gov/study/NCT02297230,https://clinicaltrials.gov/study/NCT02379585
MONDO_0007254	breast cancer	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	1	Completed	https://clinicaltrials.gov/study/NCT00748553
EFO_1000984	inflammatory breast carcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC5	histone deacetylase 5	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS3	NADH:ubiquinone oxidoreductase core subunit S3	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
EFO_0005537	triple-negative breast cancer	CHEMBL574737	UCN-01	Small molecule	Protein kinase C (PKC) inhibitor		PRKCQ	protein kinase C theta	1	Completed	https://clinicaltrials.gov/study/NCT00031681
MONDO_0007254	breast cancer	CHEMBL1200475	DAUNORUBICIN CITRATE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Unknown status	https://clinicaltrials.gov/study/NCT00004207
MONDO_0007254	breast cancer	CHEMBL3545132	MIRVETUXIMAB SORAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Withdrawn	https://clinicaltrials.gov/study/NCT03045393
MONDO_0007254	breast cancer	CHEMBL574737	UCN-01	Small molecule	Protein kinase C (PKC) inhibitor		PRKCH	protein kinase C eta	1	Completed	https://clinicaltrials.gov/study/NCT00001444
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLE	DNA polymerase epsilon, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT01154426
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB9	NADH:ubiquinone oxidoreductase subunit B9	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD4	DNA polymerase delta 4, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT01154426
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Terminated	https://clinicaltrials.gov/study/NCT04296942,https://clinicaltrials.gov/study/NCT04298918,https://clinicaltrials.gov/study/NCT03429101,https://clinicaltrials.gov/study/NCT02658084,https://clinicaltrials.gov/study/NCT04042051
MONDO_0007254	breast cancer	CHEMBL3408248	AZD-8186	Small molecule	PI3-kinase p110-delta subunit inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	1	Completed	https://clinicaltrials.gov/study/NCT01884285
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB1	NADH:ubiquinone oxidoreductase subunit B1	1	Completed	https://clinicaltrials.gov/study/NCT02278965
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Terminated	https://clinicaltrials.gov/study/NCT01697293,https://clinicaltrials.gov/study/NCT02824575
MONDO_0007254	breast cancer	CHEMBL960	LEFLUNOMIDE	Small molecule	Dihydroorotate dehydrogenase inhibitor		DHODH	dihydroorotate dehydrogenase (quinone)	1	Recruiting	https://clinicaltrials.gov/study/NCT03709446
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD2	DNA polymerase delta 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT00100750
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR2	estrogen receptor 2	1	Terminated	https://clinicaltrials.gov/study/NCT02936206,https://clinicaltrials.gov/study/NCT00903006,https://clinicaltrials.gov/study/NCT02983604,https://clinicaltrials.gov/study/NCT02345772,https://clinicaltrials.gov/study/NCT02384746
EFO_0000305	breast carcinoma	CHEMBL1079175	MK-2206	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT1	AKT serine/threonine kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT01263145,https://clinicaltrials.gov/study/NCT01344031
EFO_0000305	breast carcinoma	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN2A	sodium voltage-gated channel alpha subunit 2	1	Completed	https://clinicaltrials.gov/study/NCT03502395
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD2	DNA polymerase delta 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT01154426
EFO_1000984	inflammatory breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Unknown status	https://clinicaltrials.gov/study/NCT01880385
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Terminated	https://clinicaltrials.gov/study/NCT03579472
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02390427
MONDO_0007254	breast cancer	CHEMBL271227	ABIRATERONE ACETATE	Small molecule	Cytochrome P450 17A1 inhibitor		CYP17A1	cytochrome P450 family 17 subfamily A member 1	1	Completed	https://clinicaltrials.gov/study/NCT00755885,https://clinicaltrials.gov/study/NCT01884285
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor	Inhibitor	RRM1	ribonucleotide reductase catalytic subunit M1	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05989828
MONDO_0007254	breast cancer	CHEMBL467399	BIIB021	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AB1	heat shock protein 90 alpha family class B member 1	1	Completed	https://clinicaltrials.gov/study/NCT00412412
EFO_0000305	breast carcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC7	histone deacetylase 7	1	Completed	https://clinicaltrials.gov/study/NCT01434303
EFO_0005537	triple-negative breast cancer	CHEMBL481	IRINOTECAN	Small molecule	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02419495
MONDO_0007254	breast cancer	CHEMBL1064	SIMVASTATIN	Small molecule	HMG-CoA reductase inhibitor		HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase	1	Recruiting	https://clinicaltrials.gov/study/NCT05464810
EFO_0005537	triple-negative breast cancer	CHEMBL574737	UCN-01	Small molecule	Protein kinase C (PKC) inhibitor		PRKCE	protein kinase C epsilon	1	Completed	https://clinicaltrials.gov/study/NCT00031681
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05251766
MONDO_0007254	breast cancer	CHEMBL4297939	DATOPOTAMAB DERUXTECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	1	Recruiting	https://clinicaltrials.gov/study/NCT03401385
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor	Inhibitor	RRM1	ribonucleotide reductase catalytic subunit M1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04750382
EFO_0000305	breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL1201182	TEMSIROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	1	Unknown status	https://clinicaltrials.gov/study/NCT00982631
MONDO_0007254	breast cancer	CHEMBL14762	SELICICLIB	Small molecule	Cyclin-dependent kinase 9 inhibitor		CDK9	cyclin dependent kinase 9	1	Withdrawn	https://clinicaltrials.gov/study/NCT01333423
MONDO_0007254	breast cancer	CHEMBL3545096	BGT-226	Small molecule	PI3-kinase class I inhibitor		PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	1	Completed	https://clinicaltrials.gov/study/NCT00600275
EFO_0005537	triple-negative breast cancer	CHEMBL3647420	PYROTINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Recruiting	https://clinicaltrials.gov/study/NCT03805399
MONDO_0007254	breast cancer	CHEMBL276711	SEMAXANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT00005822
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC5	histone deacetylase 5	1	Completed	https://clinicaltrials.gov/study/NCT00632489,https://clinicaltrials.gov/study/NCT01105312,https://clinicaltrials.gov/study/NCT00788931
EFO_0000304	breast adenocarcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLE2	DNA polymerase epsilon 2, accessory subunit	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Withdrawn	https://clinicaltrials.gov/study/NCT02396433
EFO_1000984	inflammatory breast carcinoma	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Unknown status	https://clinicaltrials.gov/study/NCT01880385
EFO_0006861	male breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Fibroblast growth factor receptor 1 inhibitor		FGFR1	fibroblast growth factor receptor 1	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL4650387	CDX-301	Protein	Tyrosine-protein kinase receptor FLT3 agonist		FLT3	fms related receptor tyrosine kinase 3	1	Completed	https://clinicaltrials.gov/study/NCT03329950
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF2	NADH:ubiquinone oxidoreductase complex assembly factor 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05251766,https://clinicaltrials.gov/study/NCT05019690,https://clinicaltrials.gov/study/NCT05274893
MONDO_0007254	breast cancer	CHEMBL3360203	PILARALISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	1	Completed	https://clinicaltrials.gov/study/NCT01082068,https://clinicaltrials.gov/study/NCT01042925
EFO_0000305	breast carcinoma	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR1	estrogen receptor 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03854903,https://clinicaltrials.gov/study/NCT03554044
EFO_0000305	breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	PRIM2	DNA primase subunit 2	1	Completed	https://clinicaltrials.gov/study/NCT00100750
MONDO_0007254	breast cancer	CHEMBL3184679	AZD-4547	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR3	fibroblast growth factor receptor 3	1	Completed	https://clinicaltrials.gov/study/NCT01791985,https://clinicaltrials.gov/study/NCT01202591
MONDO_0007254	breast cancer	CHEMBL2177390	IPATASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT2	AKT serine/threonine kinase 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03959891
MONDO_0007254	breast cancer	CHEMBL286738	IROSUSTAT	Small molecule	Steryl-sulfatase inhibitor		STS	steroid sulfatase	1	Completed	https://clinicaltrials.gov/study/NCT01840488
EFO_0005537	triple-negative breast cancer	CHEMBL3301587	DURVALUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	1	Completed	https://clinicaltrials.gov/study/NCT03544125
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Completed	https://clinicaltrials.gov/study/NCT02120469
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03641755
EFO_0006861	male breast carcinoma	CHEMBL1079175	MK-2206	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT3	AKT serine/threonine kinase 3	1	Completed	https://clinicaltrials.gov/study/NCT01245205
EFO_1000984	inflammatory breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Unknown status	https://clinicaltrials.gov/study/NCT01880385
MONDO_0007254	breast cancer	CHEMBL1201564	INTERFERON GAMMA-1B	Protein	Interferon gamma receptor agonist		IFNGR2	interferon gamma receptor 2	1	Completed	https://clinicaltrials.gov/study/NCT03112590
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03032107,https://clinicaltrials.gov/study/NCT02390427
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	1	Unknown status	https://clinicaltrials.gov/study/NCT02389842
MONDO_0007254	breast cancer	CHEMBL4297509	ELACESTRANT	Small molecule	Estrogen receptor alpha degrader		ESR1	estrogen receptor 1	1	Completed	https://clinicaltrials.gov/study/NCT02650817,https://clinicaltrials.gov/study/NCT02338349
MONDO_0007254	breast cancer	CHEMBL513	CARMUSTINE	Small molecule	Glutathione reductase inhibitor		GSR	glutathione-disulfide reductase	1	Recruiting	https://clinicaltrials.gov/study/NCT04150042
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Completed	https://clinicaltrials.gov/study/NCT00372424,https://clinicaltrials.gov/study/NCT01070706,https://clinicaltrials.gov/study/NCT00887575
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4L2	NDUFA4 mitochondrial complex associated like 2	1	Completed	https://clinicaltrials.gov/study/NCT02278965
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR2	estrogen receptor 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03685331
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC4	histone deacetylase 4	1	Completed	https://clinicaltrials.gov/study/NCT03473639,https://clinicaltrials.gov/study/NCT01594398,https://clinicaltrials.gov/study/NCT02820961,https://clinicaltrials.gov/study/NCT02833155
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	1	Withdrawn	https://clinicaltrials.gov/study/NCT03400254
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB7	NADH:ubiquinone oxidoreductase subunit B7	1	Completed	https://clinicaltrials.gov/study/NCT02278965
MONDO_0007254	breast cancer	CHEMBL574737	UCN-01	Small molecule	Protein kinase C (PKC) inhibitor		PRKCG	protein kinase C gamma	1	Completed	https://clinicaltrials.gov/study/NCT00001444
MONDO_0007254	breast cancer	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL3545096	BGT-226	Small molecule	PI3-kinase class I inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	1	Completed	https://clinicaltrials.gov/study/NCT00600275
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLA1	DNA polymerase alpha 1, catalytic subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01929941,https://clinicaltrials.gov/study/NCT01939418,https://clinicaltrials.gov/study/NCT01333137
MONDO_0007254	breast cancer	CHEMBL1201619	APROTININ	Unknown	Plasma kallikrein inhibitor		KLKB1	kallikrein B1	1	Terminated	https://clinicaltrials.gov/study/NCT00354900
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Terminated	https://clinicaltrials.gov/study/NCT02824575,https://clinicaltrials.gov/study/NCT01697293
EFO_0000304	breast adenocarcinoma	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC6	histone deacetylase 6	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
EFO_0006861	male breast carcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC10	histone deacetylase 10	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02608216,https://clinicaltrials.gov/study/NCT04556773,https://clinicaltrials.gov/study/NCT02390427,https://clinicaltrials.gov/study/NCT02999477,https://clinicaltrials.gov/study/NCT04331067,https://clinicaltrials.gov/study/NCT03858322,https://clinicaltrials.gov/study/NCT03893955,https://clinicaltrials.gov/study/NCT03716180
EFO_0000304	breast adenocarcinoma	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC5	histone deacetylase 5	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
MONDO_0007254	breast cancer	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT00217399,https://clinicaltrials.gov/study/NCT00828074
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		HCK	HCK proto-oncogene, Src family tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT00820170,https://clinicaltrials.gov/study/NCT01306942,https://clinicaltrials.gov/study/NCT00452673,https://clinicaltrials.gov/study/NCT00924352
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC7	histone deacetylase 7	1	Terminated	https://clinicaltrials.gov/study/NCT00754312,https://clinicaltrials.gov/study/NCT03361800,https://clinicaltrials.gov/study/NCT04296942
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD3	DNA polymerase delta 3, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01929941,https://clinicaltrials.gov/study/NCT01939418,https://clinicaltrials.gov/study/NCT01333137
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA8	NADH:ubiquinone oxidoreductase subunit A8	1	Completed	https://clinicaltrials.gov/study/NCT02278965
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor	Inhibitor	RRM1	ribonucleotide reductase catalytic subunit M1	1	Completed	https://clinicaltrials.gov/study/NCT01154426
MONDO_0007254	breast cancer	CHEMBL1922094	APITOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	1	Completed	https://clinicaltrials.gov/study/NCT01254526
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Suspended	https://clinicaltrials.gov/study/NCT05422794
EFO_0006861	male breast carcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC2	histone deacetylase 2	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV2	NADH:ubiquinone oxidoreductase core subunit V2	1	Completed	https://clinicaltrials.gov/study/NCT01980823,https://clinicaltrials.gov/study/NCT01650506
EFO_0005537	triple-negative breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Tyrosine-protein kinase SRC inhibitor		SRC	SRC proto-oncogene, non-receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT00496665
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Completed	https://clinicaltrials.gov/study/NCT00568022,https://clinicaltrials.gov/study/NCT00924352,https://clinicaltrials.gov/study/NCT00637897,https://clinicaltrials.gov/study/NCT01084057,https://clinicaltrials.gov/study/NCT00825734,https://clinicaltrials.gov/study/NCT00322374
MONDO_0007254	breast cancer	CHEMBL2109229	OBLIMERSEN SODIUM	Oligonucleotide	Bcl-2 mRNA antisense inhibitor		BCL2	BCL2 apoptosis regulator	1	Terminated	https://clinicaltrials.gov/study/NCT00063934
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Terminated	https://clinicaltrials.gov/study/NCT00864175,https://clinicaltrials.gov/study/NCT02345772,https://clinicaltrials.gov/study/NCT00531271,https://clinicaltrials.gov/study/NCT02379585,https://clinicaltrials.gov/study/NCT00584012,https://clinicaltrials.gov/study/NCT01876251,https://clinicaltrials.gov/study/NCT00253318,https://clinicaltrials.gov/study/NCT00063934
MONDO_0007254	breast cancer	CHEMBL3907479	FGFR INHIBITOR DEBIO 1347	Small molecule	Fibroblast growth factor receptor 2 inhibitor		FGFR2	fibroblast growth factor receptor 2	1	Completed	https://clinicaltrials.gov/study/NCT03344536
EFO_1000984	inflammatory breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Unknown status	https://clinicaltrials.gov/study/NCT01880385
EFO_1000984	inflammatory breast carcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC8	histone deacetylase 8	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
MONDO_0007254	breast cancer	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	1	Completed	https://clinicaltrials.gov/study/NCT00217399,https://clinicaltrials.gov/study/NCT00828074
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Terminated	https://clinicaltrials.gov/study/NCT02753595,https://clinicaltrials.gov/study/NCT03579472
EFO_1000984	inflammatory breast carcinoma	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT00004074
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Terminated	https://clinicaltrials.gov/study/NCT00634088
MONDO_0007254	breast cancer	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RA	interleukin 2 receptor subunit alpha	1	Withdrawn	https://clinicaltrials.gov/study/NCT00022230
MONDO_0007254	breast cancer	CHEMBL3186534	RIVOCERANIB	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05019690
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Withdrawn	https://clinicaltrials.gov/study/NCT00074139
MONDO_0007254	breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Terminated	https://clinicaltrials.gov/study/NCT05103826
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT00496665
MONDO_0007254	breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	1	Enrolling by invitation	https://clinicaltrials.gov/study/NCT05189717
EFO_0005537	triple-negative breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02419495
EFO_0000304	breast adenocarcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC9	histone deacetylase 9	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02453620
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor	Inhibitor	RRM1	ribonucleotide reductase catalytic subunit M1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03554044
EFO_0000305	breast carcinoma	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	1	Recruiting	https://clinicaltrials.gov/study/NCT05464810
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Withdrawn	https://clinicaltrials.gov/study/NCT00074139
MONDO_0007254	breast cancer	CHEMBL101253	VATALANIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	1	Completed	https://clinicaltrials.gov/study/NCT00268918
MONDO_0007254	breast cancer	CHEMBL3184679	AZD-4547	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR1	fibroblast growth factor receptor 1	1	Completed	https://clinicaltrials.gov/study/NCT01791985,https://clinicaltrials.gov/study/NCT01202591
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02419495
MONDO_0007254	breast cancer	CHEMBL3545154	POZIOTINIB	Small molecule	Epidermal growth factor receptor inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Terminated	https://clinicaltrials.gov/study/NCT03429101
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
MONDO_0007254	breast cancer	CHEMBL1173055	RUCAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03542175
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT00217399,https://clinicaltrials.gov/study/NCT00825734,https://clinicaltrials.gov/study/NCT01640665,https://clinicaltrials.gov/study/NCT00828074
EFO_0000305	breast carcinoma	CHEMBL4297721	CDX-1140	Unknown	Tumor necrosis factor receptor superfamily member 5 agonist		CD40	CD40 molecule	1	Recruiting	https://clinicaltrials.gov/study/NCT04616248
EFO_0000305	breast carcinoma	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		APH1B	aph-1 homolog B, gamma-secretase subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01071564
EFO_0000304	breast adenocarcinoma	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC11	histone deacetylase 11	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
MONDO_0007254	breast cancer	CHEMBL4073443	TOMIVOSERTIB	Small molecule	MAP kinase-interacting serine/threonine-protein kinase 1/2 inhibitor		MKNK1	MAPK interacting serine/threonine kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT04261218
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03685331
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Completed	https://clinicaltrials.gov/study/NCT01432886,https://clinicaltrials.gov/study/NCT01323530,https://clinicaltrials.gov/study/NCT02723877,https://clinicaltrials.gov/study/NCT01596751,https://clinicaltrials.gov/study/NCT01795586
MONDO_0007254	breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	1	Completed	https://clinicaltrials.gov/study/NCT01655225,https://clinicaltrials.gov/study/NCT04514159
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC9	histone deacetylase 9	1	Terminated	https://clinicaltrials.gov/study/NCT03361800,https://clinicaltrials.gov/study/NCT04296942,https://clinicaltrials.gov/study/NCT00754312
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		LCK	LCK proto-oncogene, Src family tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT01306942,https://clinicaltrials.gov/study/NCT00452673,https://clinicaltrials.gov/study/NCT00924352,https://clinicaltrials.gov/study/NCT00820170
MONDO_0007254	breast cancer	CHEMBL3647420	PYROTINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03772353
MONDO_0007254	breast cancer	CHEMBL1852688	INFIGRATINIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR3	fibroblast growth factor receptor 3	1	Terminated	https://clinicaltrials.gov/study/NCT04504331
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Terminated	https://clinicaltrials.gov/study/NCT00075673
EFO_0005537	triple-negative breast cancer	CHEMBL574737	UCN-01	Small molecule	Protein kinase C (PKC) inhibitor		PRKCH	protein kinase C eta	1	Completed	https://clinicaltrials.gov/study/NCT00031681
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD4	DNA polymerase delta 4, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT01154426
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02419495
MONDO_0007254	breast cancer	CHEMBL502835	NINTEDANIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR4	fibroblast growth factor receptor 4	1	Completed	https://clinicaltrials.gov/study/NCT02619162
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD4	DNA polymerase delta 4, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02479230,https://clinicaltrials.gov/study/NCT00100750
MONDO_0007254	breast cancer	CHEMBL3545366	VOXTALISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	1	Completed	https://clinicaltrials.gov/study/NCT01082068,https://clinicaltrials.gov/study/NCT01390818
MONDO_0007254	breast cancer	CHEMBL4279455	LAROTAXEL	Small molecule	Tubulin stabiliser		TUBB8	tubulin beta 8 class VIII	1	Completed	https://clinicaltrials.gov/study/NCT00327743
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor	Inhibitor	RRM1	ribonucleotide reductase catalytic subunit M1	1	Recruiting	https://clinicaltrials.gov/study/NCT04796220
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Completed	https://clinicaltrials.gov/study/NCT01498458
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	1	Recruiting	https://clinicaltrials.gov/study/NCT03742245
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Completed	https://clinicaltrials.gov/study/NCT00003902,https://clinicaltrials.gov/study/NCT00153907,https://clinicaltrials.gov/study/NCT00828074,https://clinicaltrials.gov/study/NCT00014430
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLE	DNA polymerase epsilon, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT00100750
MONDO_0007254	breast cancer	CHEMBL1908360	EVEROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	1	Completed	https://clinicaltrials.gov/study/NCT00574366,https://clinicaltrials.gov/study/NCT01031446,https://clinicaltrials.gov/study/NCT01857193,https://clinicaltrials.gov/study/NCT00458237,https://clinicaltrials.gov/study/NCT00426556,https://clinicaltrials.gov/study/NCT02871791,https://clinicaltrials.gov/study/NCT04818632,https://clinicaltrials.gov/study/NCT00680758,https://clinicaltrials.gov/study/NCT02732119
MONDO_0007254	breast cancer	CHEMBL2177390	IPATASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT1	AKT serine/threonine kinase 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03959891
MONDO_0007254	breast cancer	CHEMBL377559	RETASPIMYCIN HYDROCHLORIDE	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AB1	heat shock protein 90 alpha family class B member 1	1	Withdrawn	https://clinicaltrials.gov/study/NCT00627627
EFO_0000305	breast carcinoma	CHEMBL544665	FINGOLIMOD HYDROCHLORIDE	Small molecule	Sphingosine 1-phosphate receptor agonist		S1PR1	sphingosine-1-phosphate receptor 1	1	Completed	https://clinicaltrials.gov/study/NCT03941743
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLE	DNA polymerase epsilon, catalytic subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT04796220
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL513	CARMUSTINE	Small molecule	Glutathione reductase inhibitor		GSR	glutathione-disulfide reductase	1	Recruiting	https://clinicaltrials.gov/study/NCT04150042
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV1	NADH:ubiquinone oxidoreductase core subunit V1	1	Completed	https://clinicaltrials.gov/study/NCT02278965
EFO_0000305	breast carcinoma	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT01922921
MONDO_0007254	breast cancer	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		NCSTN	nicastrin	1	Terminated	https://clinicaltrials.gov/study/NCT01208441
EFO_0000305	breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor	Inhibitor	RRM1	ribonucleotide reductase catalytic subunit M1	1	Completed	https://clinicaltrials.gov/study/NCT00100750
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Suspended	https://clinicaltrials.gov/study/NCT05422794
MONDO_0007254	breast cancer	CHEMBL4594578	TEBOTELIMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	1	Terminated	https://clinicaltrials.gov/study/NCT04178460
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Unknown status	https://clinicaltrials.gov/study/NCT00764972
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Terminated	https://clinicaltrials.gov/study/NCT03579472
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02419495
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	PRIM1	DNA primase subunit 1	1	Recruiting	https://clinicaltrials.gov/study/NCT04796220
MONDO_0007254	breast cancer	CHEMBL101253	VATALANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Terminated	https://clinicaltrials.gov/study/NCT00216047
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA11	NADH:ubiquinone oxidoreductase subunit A11	1	Completed	https://clinicaltrials.gov/study/NCT01980823,https://clinicaltrials.gov/study/NCT01650506
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Terminated	https://clinicaltrials.gov/study/NCT01697293,https://clinicaltrials.gov/study/NCT02824575
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Tyrosine-protein kinase LCK inhibitor		LCK	LCK proto-oncogene, Src family tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT01498458
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC2	histone deacetylase 2	1	Completed	https://clinicaltrials.gov/study/NCT01594398,https://clinicaltrials.gov/study/NCT02833155,https://clinicaltrials.gov/study/NCT03473639,https://clinicaltrials.gov/study/NCT02820961
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLA2	DNA polymerase alpha 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT00100750,https://clinicaltrials.gov/study/NCT02479230
EFO_0000304	breast adenocarcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLE	DNA polymerase epsilon, catalytic subunit	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Terminated	https://clinicaltrials.gov/study/NCT00075673
EFO_0000305	breast carcinoma	CHEMBL3707227	ATEZOLIZUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	1	Recruiting	https://clinicaltrials.gov/study/NCT05092373
EFO_0000186	invasive breast ductal carcinoma	CHEMBL2396661	ALPELISIB	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT01791478
MONDO_0007254	breast cancer	CHEMBL3545132	MIRVETUXIMAB SORAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	1	Withdrawn	https://clinicaltrials.gov/study/NCT03045393
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT04856371
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD3	DNA polymerase delta 3, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT04247126,https://clinicaltrials.gov/study/NCT02139358,https://clinicaltrials.gov/study/NCT01133912,https://clinicaltrials.gov/study/NCT01070706,https://clinicaltrials.gov/study/NCT00270907,https://clinicaltrials.gov/study/NCT00100750,https://clinicaltrials.gov/study/NCT02479230
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB2	NADH:ubiquinone oxidoreductase subunit B2	1	Completed	https://clinicaltrials.gov/study/NCT02278965
EFO_0005537	triple-negative breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02419495
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC10	histone deacetylase 10	1	Terminated	https://clinicaltrials.gov/study/NCT03361800,https://clinicaltrials.gov/study/NCT04296942,https://clinicaltrials.gov/study/NCT00754312
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	1	Unknown status	https://clinicaltrials.gov/study/NCT02389842,https://clinicaltrials.gov/study/NCT02626507
EFO_0005537	triple-negative breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
EFO_0000304	breast adenocarcinoma	CHEMBL451887	CARFILZOMIB	Protein	26S proteosome inhibitor		PSMB5	proteasome 20S subunit beta 5	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLA1	DNA polymerase alpha 1, catalytic subunit	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05989828
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor		GPD2	glycerol-3-phosphate dehydrogenase 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
MONDO_0007254	breast cancer	CHEMBL2396661	ALPELISIB	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT01791478
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Withdrawn	https://clinicaltrials.gov/study/NCT00074139
MONDO_0007254	breast cancer	CHEMBL513	CARMUSTINE	Small molecule	Glutathione reductase inhibitor		GSR	glutathione-disulfide reductase	1	Withdrawn	https://clinicaltrials.gov/study/NCT00006123
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Terminated	https://clinicaltrials.gov/study/NCT02753595,https://clinicaltrials.gov/study/NCT01388647,https://clinicaltrials.gov/study/NCT03579472
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Completed	https://clinicaltrials.gov/study/NCT02120469
MONDO_0007254	breast cancer	CHEMBL4279455	LAROTAXEL	Small molecule	Tubulin stabiliser		TUBB4B	tubulin beta 4B class IVb	1	Completed	https://clinicaltrials.gov/study/NCT00327743
MONDO_0007254	breast cancer	CHEMBL49642	INDIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Unknown status	https://clinicaltrials.gov/study/NCT01113970
MONDO_0007254	breast cancer	CHEMBL1094636	NIRAPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	1	Terminated	https://clinicaltrials.gov/study/NCT04178460
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD4	DNA polymerase delta 4, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02139358,https://clinicaltrials.gov/study/NCT04247126,https://clinicaltrials.gov/study/NCT00270907,https://clinicaltrials.gov/study/NCT00100750,https://clinicaltrials.gov/study/NCT01070706,https://clinicaltrials.gov/study/NCT02479230,https://clinicaltrials.gov/study/NCT01133912
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLA1	DNA polymerase alpha 1, catalytic subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT04796220
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Completed	https://clinicaltrials.gov/study/NCT02632071,https://clinicaltrials.gov/study/NCT01263145
MONDO_0004658	breast carcinoma in situ	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Completed	https://clinicaltrials.gov/study/NCT04081389
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Completed	https://clinicaltrials.gov/study/NCT05301530,https://clinicaltrials.gov/study/NCT00129896,https://clinicaltrials.gov/study/NCT00450892,https://clinicaltrials.gov/study/NCT00086957,https://clinicaltrials.gov/study/NCT02027376,https://clinicaltrials.gov/study/NCT00372424,https://clinicaltrials.gov/study/NCT00268918,https://clinicaltrials.gov/study/NCT00322400,https://clinicaltrials.gov/study/NCT00872625,https://clinicaltrials.gov/study/NCT01256567,https://clinicaltrials.gov/study/NCT00705315,https://clinicaltrials.gov/study/NCT00003103,https://clinicaltrials.gov/study/NCT04367090,https://clinicaltrials.gov/study/NCT02605915,https://clinicaltrials.gov/study/NCT01862081,https://clinicaltrials.gov/study/NCT00080665,https://clinicaltrials.gov/study/NCT00169000,https://clinicaltrials.gov/study/NCT01044485,https://clinicaltrials.gov/study/NCT00050167,https://clinicaltrials.gov/study/NCT00645333,https://clinicaltrials.gov/study/NCT00934856,https://clinicaltrials.gov/study/NCT00002901,https://clinicaltrials.gov/study/NCT00020332,https://clinicaltrials.gov/study/NCT00637897,https://clinicaltrials.gov/study/NCT02392845
MONDO_0007254	breast cancer	CHEMBL49642	INDIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Unknown status	https://clinicaltrials.gov/study/NCT01113970
MONDO_0007254	breast cancer	CHEMBL1642	IMATINIB MESYLATE	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Completed	https://clinicaltrials.gov/study/NCT00080665
EFO_0005537	triple-negative breast cancer	CHEMBL4298024	BINTRAFUSP ALFA	Protein	Transforming growth factor beta binding agent		TGFB3	transforming growth factor beta 3	1	Terminated	https://clinicaltrials.gov/study/NCT03579472
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
MONDO_0007254	breast cancer	CHEMBL1214827	ONALESPIB	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AA1	heat shock protein 90 alpha family class A member 1	1	Terminated	https://clinicaltrials.gov/study/NCT02474173
MONDO_0007254	breast cancer	CHEMBL1282	IMIQUIMOD	Small molecule	Toll-like receptor 7 agonist		TLR7	toll like receptor 7	1	Terminated	https://clinicaltrials.gov/study/NCT03982004
EFO_0000304	breast adenocarcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
MONDO_0007254	breast cancer	CHEMBL3581647	BIRABRESIB	Small molecule	Bromodomain and extra-terminal motif (BET) inhibitor		BRDT	bromodomain testis associated	1	Terminated	https://clinicaltrials.gov/study/NCT02698176
MONDO_0007254	breast cancer	CHEMBL49642	INDIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Unknown status	https://clinicaltrials.gov/study/NCT01113970
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF3	NADH:ubiquinone oxidoreductase complex assembly factor 3	1	Completed	https://clinicaltrials.gov/study/NCT02278965
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLA1	DNA polymerase alpha 1, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT00100750
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00600496
MONDO_0007254	breast cancer	CHEMBL4297181	SAMOTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	1	Completed	https://clinicaltrials.gov/study/NCT01655225
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND5	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
EFO_0000305	breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
EFO_0000305	breast carcinoma	CHEMBL1908360	EVEROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	1	Completed	https://clinicaltrials.gov/study/NCT02152943,https://clinicaltrials.gov/study/NCT02871791
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	1	Unknown status	https://clinicaltrials.gov/study/NCT02626507
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
EFO_0006861	male breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Tyrosine-protein kinase LCK inhibitor		LCK	LCK proto-oncogene, Src family tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Terminated	https://clinicaltrials.gov/study/NCT00075673
MONDO_0007254	breast cancer	CHEMBL3301587	DURVALUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	1	Terminated	https://clinicaltrials.gov/study/NCT03199040
MONDO_0007254	breast cancer	CHEMBL4279455	LAROTAXEL	Small molecule	Tubulin stabiliser		TUBB1	tubulin beta 1 class VI	1	Completed	https://clinicaltrials.gov/study/NCT00327743
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLE2	DNA polymerase epsilon 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT01154426
EFO_1000984	inflammatory breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Unknown status	https://clinicaltrials.gov/study/NCT01880385
EFO_0000304	breast adenocarcinoma	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC1	histone deacetylase 1	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
MONDO_0007254	breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	1	Recruiting	https://clinicaltrials.gov/study/NCT06139107,https://clinicaltrials.gov/study/NCT05307705
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Terminated	https://clinicaltrials.gov/study/NCT01254136,https://clinicaltrials.gov/study/NCT00041470,https://clinicaltrials.gov/study/NCT02658084,https://clinicaltrials.gov/study/NCT01238029,https://clinicaltrials.gov/study/NCT00140140,https://clinicaltrials.gov/study/NCT00075673
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03554044,https://clinicaltrials.gov/study/NCT03725436
MONDO_0007254	breast cancer	CHEMBL598797	CUDC-101	Small molecule	Histone deacetylase inhibitor		HDAC3	histone deacetylase 3	1	Completed	https://clinicaltrials.gov/study/NCT01171924
EFO_0005537	triple-negative breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
EFO_1000984	inflammatory breast carcinoma	CHEMBL185	FLUOROURACIL	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	1	Unknown status	https://clinicaltrials.gov/study/NCT01880385
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor	Inhibitor	RRM1	ribonucleotide reductase catalytic subunit M1	1	Terminated	https://clinicaltrials.gov/study/NCT01333137,https://clinicaltrials.gov/study/NCT01939418,https://clinicaltrials.gov/study/NCT01929941
MONDO_0007254	breast cancer	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	1	Completed	https://clinicaltrials.gov/study/NCT00020332,https://clinicaltrials.gov/study/NCT00003690
MONDO_0007254	breast cancer	CHEMBL3545154	POZIOTINIB	Small molecule	Epidermal growth factor receptor inhibitor		ERBB3	erb-b2 receptor tyrosine kinase 3	1	Terminated	https://clinicaltrials.gov/study/NCT03429101
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC10	histone deacetylase 10	1	Completed	https://clinicaltrials.gov/study/NCT00632489,https://clinicaltrials.gov/study/NCT01105312,https://clinicaltrials.gov/study/NCT00788931
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	PRIM1	DNA primase subunit 1	1	Completed	https://clinicaltrials.gov/study/NCT00100750,https://clinicaltrials.gov/study/NCT02479230
MONDO_0007254	breast cancer	CHEMBL3360203	PILARALISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	1	Completed	https://clinicaltrials.gov/study/NCT01082068,https://clinicaltrials.gov/study/NCT01042925
MONDO_0007254	breast cancer	CHEMBL274654	ORANTINIB	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	1	Unknown status	https://clinicaltrials.gov/study/NCT00024063
MONDO_0007254	breast cancer	CHEMBL135	ESTRADIOL	Small molecule	Estrogen receptor alpha agonist		ESR1	estrogen receptor 1	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05900895
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Withdrawn	https://clinicaltrials.gov/study/NCT00074139
MONDO_0007254	breast cancer	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 1 inhibitor		CDK1	cyclin dependent kinase 1	1	Terminated	https://clinicaltrials.gov/study/NCT00039455
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT04213898
MONDO_0007254	breast cancer	CHEMBL941	IMATINIB	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	1	Completed	https://clinicaltrials.gov/study/NCT00080665
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Completed	https://clinicaltrials.gov/study/NCT01070706,https://clinicaltrials.gov/study/NCT00887575,https://clinicaltrials.gov/study/NCT00372424
MONDO_0007254	breast cancer	CHEMBL1237023	DENOSUMAB	Antibody	Tumor necrosis factor ligand superfamily member 11 inhibitor		TNFSF11	TNF superfamily member 11	1	Unknown status	https://clinicaltrials.gov/study/NCT03239756,https://clinicaltrials.gov/study/NCT03487055
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD1	DNA polymerase delta 1, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT02479230,https://clinicaltrials.gov/study/NCT00100750
MONDO_0007254	breast cancer	CHEMBL3907479	FGFR INHIBITOR DEBIO 1347	Small molecule	Fibroblast growth factor receptor 3 inhibitor		FGFR3	fibroblast growth factor receptor 3	1	Completed	https://clinicaltrials.gov/study/NCT03344536
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R5	phosphoinositide-3-kinase regulatory subunit 5	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02390427
MONDO_0007254	breast cancer	CHEMBL3545132	MIRVETUXIMAB SORAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Withdrawn	https://clinicaltrials.gov/study/NCT03045393
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		SRMS	src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites	1	Completed	https://clinicaltrials.gov/study/NCT01306942,https://clinicaltrials.gov/study/NCT00924352,https://clinicaltrials.gov/study/NCT00452673,https://clinicaltrials.gov/study/NCT00820170
MONDO_0007254	breast cancer	CHEMBL1879463	DACTOLISIB	Small molecule	Serine/threonine-protein kinase mTOR inhibitor		MTOR	mechanistic target of rapamycin kinase	1	Completed	https://clinicaltrials.gov/study/NCT01248494
MONDO_0007254	breast cancer	CHEMBL3545096	BGT-226	Small molecule	PI3-kinase class I inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	1	Completed	https://clinicaltrials.gov/study/NCT00600275
MONDO_0007254	breast cancer	CHEMBL4594557	EFTILAGIMOD ALFA	Unknown	Lymphocyte activation gene 3 protein vaccine antigen		LAG3	lymphocyte activating 3	1	Completed	https://clinicaltrials.gov/study/NCT00349934
EFO_0000305	breast carcinoma	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN8A	sodium voltage-gated channel alpha subunit 8	1	Completed	https://clinicaltrials.gov/study/NCT03502395
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD1	DNA polymerase delta 1, catalytic subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT04796220
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Terminated	https://clinicaltrials.gov/study/NCT00634088
EFO_0000304	breast adenocarcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC1	histone deacetylase 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02453620
EFO_0000305	breast carcinoma	CHEMBL3644587	2X-121	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	1	Withdrawn	https://clinicaltrials.gov/study/NCT02396433
MONDO_0007254	breast cancer	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Tyrosine-protein kinase ITK/TSK inhibitor		ITK	IL2 inducible T cell kinase	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB1	NADH:ubiquinone oxidoreductase subunit B1	1	Completed	https://clinicaltrials.gov/study/NCT01650506,https://clinicaltrials.gov/study/NCT01980823
MONDO_0007254	breast cancer	CHEMBL1879463	DACTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	1	Completed	https://clinicaltrials.gov/study/NCT01248494
MONDO_0007254	breast cancer	CHEMBL655	MIDAZOLAM	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRA1	gamma-aminobutyric acid type A receptor subunit alpha1	1	Completed	https://clinicaltrials.gov/study/NCT01655225,https://clinicaltrials.gov/study/NCT03955939
EFO_0005537	triple-negative breast cancer	CHEMBL185	FLUOROURACIL	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02419495
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Completed	https://clinicaltrials.gov/study/NCT02120469
EFO_0000305	breast carcinoma	CHEMBL1789844	IPILIMUMAB	Antibody	Cytotoxic T-lymphocyte protein 4 inhibitor		CTLA4	cytotoxic T-lymphocyte associated protein 4	1	Completed	https://clinicaltrials.gov/study/NCT01502592
EFO_0005537	triple-negative breast cancer	CHEMBL4298050	TIRAGOLUMAB	Antibody	T-cell immunoreceptor with Ig and ITIM domains inhibitor		TIGIT	T cell immunoreceptor with Ig and ITIM domains	1	Completed	https://clinicaltrials.gov/study/NCT04584112
MONDO_0007254	breast cancer	CHEMBL2325741	CAPIVASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT1	AKT serine/threonine kinase 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT01226316,https://clinicaltrials.gov/study/NCT01992952,https://clinicaltrials.gov/study/NCT04556773,https://clinicaltrials.gov/study/NCT03616587
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLE3	DNA polymerase epsilon 3, accessory subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT04796220
EFO_0006861	male breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Terminated	https://clinicaltrials.gov/study/NCT00063934
EFO_0000305	breast carcinoma	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR2	estrogen receptor 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03854903,https://clinicaltrials.gov/study/NCT03554044
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Recruiting	https://clinicaltrials.gov/study/NCT05918133,https://clinicaltrials.gov/study/NCT05673200,https://clinicaltrials.gov/study/NCT03805399
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC2	histone deacetylase 2	1	Terminated	https://clinicaltrials.gov/study/NCT04296942,https://clinicaltrials.gov/study/NCT00754312,https://clinicaltrials.gov/study/NCT03361800
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Withdrawn	https://clinicaltrials.gov/study/NCT00074139
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT01498458
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Fibroblast growth factor receptor 3 inhibitor		FGFR3	fibroblast growth factor receptor 3	1	Terminated	https://clinicaltrials.gov/study/NCT00450879,https://clinicaltrials.gov/study/NCT01407562
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	1	Completed	https://clinicaltrials.gov/study/NCT02236000,https://clinicaltrials.gov/study/NCT00951665,https://clinicaltrials.gov/study/NCT02073916,https://clinicaltrials.gov/study/NCT02657343,https://clinicaltrials.gov/study/NCT02038010,https://clinicaltrials.gov/study/NCT02605915,https://clinicaltrials.gov/study/NCT01983501,https://clinicaltrials.gov/study/NCT00934856,https://clinicaltrials.gov/study/NCT00875979,https://clinicaltrials.gov/study/NCT01513083
EFO_0000304	breast adenocarcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	PRIM2	DNA primase subunit 2	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
MONDO_0007254	breast cancer	CHEMBL2325741	CAPIVASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT3	AKT serine/threonine kinase 3	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03616587,https://clinicaltrials.gov/study/NCT01226316,https://clinicaltrials.gov/study/NCT01992952,https://clinicaltrials.gov/study/NCT04556773
MONDO_0007254	breast cancer	CHEMBL2402737	IDASANUTLIN	Small molecule	Tumour suppressor p53/oncoprotein Mdm2 inhibitor		TP53	tumor protein p53	1	Terminated	https://clinicaltrials.gov/study/NCT03566485
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05251766,https://clinicaltrials.gov/study/NCT05019690,https://clinicaltrials.gov/study/NCT05274893
EFO_0000304	breast adenocarcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC4	histone deacetylase 4	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLA1	DNA polymerase alpha 1, catalytic subunit	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03554044
MONDO_0007254	breast cancer	CHEMBL1489	AZACITIDINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	1	Completed	https://clinicaltrials.gov/study/NCT00748553
EFO_0006861	male breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC8	histone deacetylase 8	1	Terminated	https://clinicaltrials.gov/study/NCT04296942,https://clinicaltrials.gov/study/NCT03361800,https://clinicaltrials.gov/study/NCT00754312
MONDO_0007254	breast cancer	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04556773,https://clinicaltrials.gov/study/NCT00049244,https://clinicaltrials.gov/study/NCT04509596,https://clinicaltrials.gov/study/NCT05064085
MONDO_0007254	breast cancer	CHEMBL4297713	CABIRALIZUMAB	Antibody	Macrophage colony stimulating factor receptor antagonist		CSF1R	colony stimulating factor 1 receptor	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04331067
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Withdrawn	https://clinicaltrials.gov/study/NCT00074139
MONDO_0007254	breast cancer	CHEMBL574737	UCN-01	Small molecule	3-phosphoinositide dependent protein kinase-1 inhibitor		PDPK1	3-phosphoinositide dependent protein kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT00001444
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Completed	https://clinicaltrials.gov/study/NCT00535119
EFO_0006861	male breast carcinoma	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Terminated	https://clinicaltrials.gov/study/NCT00063934
MONDO_0007254	breast cancer	CHEMBL1094636	NIRAPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	1	Terminated	https://clinicaltrials.gov/study/NCT04178460
MONDO_0007254	breast cancer	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	1	Terminated	https://clinicaltrials.gov/study/NCT01208441,https://clinicaltrials.gov/study/NCT00516542,https://clinicaltrials.gov/study/NCT01199367
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Completed	https://clinicaltrials.gov/study/NCT01263145,https://clinicaltrials.gov/study/NCT02632071
MONDO_0007254	breast cancer	CHEMBL359744	DOXORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Withdrawn	https://clinicaltrials.gov/study/NCT00074139,https://clinicaltrials.gov/study/NCT00022230
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	1	Recruiting	https://clinicaltrials.gov/study/NCT03742245
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Platelet-derived growth factor receptor alpha inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Completed	https://clinicaltrials.gov/study/NCT00372424,https://clinicaltrials.gov/study/NCT00887575,https://clinicaltrials.gov/study/NCT01070706
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBB8	tubulin beta 8 class VIII	1	Completed	https://clinicaltrials.gov/study/NCT00270907
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Completed	https://clinicaltrials.gov/study/NCT02392845,https://clinicaltrials.gov/study/NCT00705315,https://clinicaltrials.gov/study/NCT00637897,https://clinicaltrials.gov/study/NCT00450892,https://clinicaltrials.gov/study/NCT01862081,https://clinicaltrials.gov/study/NCT00934856,https://clinicaltrials.gov/study/NCT00872625,https://clinicaltrials.gov/study/NCT01044485,https://clinicaltrials.gov/study/NCT00322400,https://clinicaltrials.gov/study/NCT00086957,https://clinicaltrials.gov/study/NCT00020332,https://clinicaltrials.gov/study/NCT02605915,https://clinicaltrials.gov/study/NCT00268918,https://clinicaltrials.gov/study/NCT00645333,https://clinicaltrials.gov/study/NCT04367090,https://clinicaltrials.gov/study/NCT02027376,https://clinicaltrials.gov/study/NCT00169000,https://clinicaltrials.gov/study/NCT00129896,https://clinicaltrials.gov/study/NCT00372424,https://clinicaltrials.gov/study/NCT00080665,https://clinicaltrials.gov/study/NCT00050167,https://clinicaltrials.gov/study/NCT00003103,https://clinicaltrials.gov/study/NCT05301530,https://clinicaltrials.gov/study/NCT00002901,https://clinicaltrials.gov/study/NCT01256567
MONDO_0007254	breast cancer	CHEMBL49642	INDIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Unknown status	https://clinicaltrials.gov/study/NCT01113970
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Withdrawn	https://clinicaltrials.gov/study/NCT01349088
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Unknown status	https://clinicaltrials.gov/study/NCT00931450
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBA4A	tubulin alpha 4a	1	Completed	https://clinicaltrials.gov/study/NCT00270907
MONDO_0007254	breast cancer	CHEMBL359744	DOXORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Terminated	https://clinicaltrials.gov/study/NCT01495884,https://clinicaltrials.gov/study/NCT00063934,https://clinicaltrials.gov/study/NCT00003086
MONDO_0007254	breast cancer	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2B	DNA topoisomerase II beta	1	Completed	https://clinicaltrials.gov/study/NCT00002509
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC4	histone deacetylase 4	1	Terminated	https://clinicaltrials.gov/study/NCT00567879
EFO_1000984	inflammatory breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Unknown status	https://clinicaltrials.gov/study/NCT01880385
MONDO_0007254	breast cancer	CHEMBL2219422	AFURESERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT3	AKT serine/threonine kinase 3	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04851613
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF3	NADH:ubiquinone oxidoreductase complex assembly factor 3	1	Completed	https://clinicaltrials.gov/study/NCT01980823,https://clinicaltrials.gov/study/NCT01650506
MONDO_0007254	breast cancer	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT00951665,https://clinicaltrials.gov/study/NCT02139358,https://clinicaltrials.gov/study/NCT05471648,https://clinicaltrials.gov/study/NCT00875979,https://clinicaltrials.gov/study/NCT00934856,https://clinicaltrials.gov/study/NCT01918254,https://clinicaltrials.gov/study/NCT03112590,https://clinicaltrials.gov/study/NCT02060253,https://clinicaltrials.gov/study/NCT03135171,https://clinicaltrials.gov/study/NCT02738970,https://clinicaltrials.gov/study/NCT02605915
MONDO_0004658	breast carcinoma in situ	CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist		IFNAR1	interferon alpha and beta receptor subunit 1	1	Completed	https://clinicaltrials.gov/study/NCT04081389
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Terminated	https://clinicaltrials.gov/study/NCT00634088
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND2	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2	1	Completed	https://clinicaltrials.gov/study/NCT01650506,https://clinicaltrials.gov/study/NCT01980823
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT00934856,https://clinicaltrials.gov/study/NCT02605915,https://clinicaltrials.gov/study/NCT00951665,https://clinicaltrials.gov/study/NCT02657343,https://clinicaltrials.gov/study/NCT01983501,https://clinicaltrials.gov/study/NCT01513083,https://clinicaltrials.gov/study/NCT02038010,https://clinicaltrials.gov/study/NCT02073916,https://clinicaltrials.gov/study/NCT00875979,https://clinicaltrials.gov/study/NCT02236000
MONDO_0007254	breast cancer	CHEMBL2109562	CAL	Antibody	Parathyroid hormone-related protein inhibitor		PTHLH	parathyroid hormone like hormone	1	Completed	https://clinicaltrials.gov/study/NCT00051779
MONDO_0007254	breast cancer	CHEMBL521851	PICTILISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	1	Completed	https://clinicaltrials.gov/study/NCT00960960,https://clinicaltrials.gov/study/NCT00928330
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLE3	DNA polymerase epsilon 3, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT00270907,https://clinicaltrials.gov/study/NCT02479230,https://clinicaltrials.gov/study/NCT04247126,https://clinicaltrials.gov/study/NCT01133912,https://clinicaltrials.gov/study/NCT02139358,https://clinicaltrials.gov/study/NCT01070706,https://clinicaltrials.gov/study/NCT00100750
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT04213898
EFO_0000305	breast carcinoma	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		PSEN2	presenilin 2	1	Terminated	https://clinicaltrials.gov/study/NCT01071564
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV2	NADH:ubiquinone oxidoreductase core subunit V2	1	Completed	https://clinicaltrials.gov/study/NCT02278965
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	PRIM2	DNA primase subunit 2	1	Completed	https://clinicaltrials.gov/study/NCT00270907,https://clinicaltrials.gov/study/NCT04247126,https://clinicaltrials.gov/study/NCT02139358,https://clinicaltrials.gov/study/NCT00100750,https://clinicaltrials.gov/study/NCT02479230,https://clinicaltrials.gov/study/NCT01133912,https://clinicaltrials.gov/study/NCT01070706
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Completed	https://clinicaltrials.gov/study/NCT02120469
MONDO_0007254	breast cancer	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	1	Withdrawn	https://clinicaltrials.gov/study/NCT01240928
MONDO_0007254	breast cancer	CHEMBL1908360	EVEROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	1	Unknown status	https://clinicaltrials.gov/study/NCT02616848,https://clinicaltrials.gov/study/NCT00930475
MONDO_0007254	breast cancer	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Completed	https://clinicaltrials.gov/study/NCT00828074,https://clinicaltrials.gov/study/NCT00217399
MONDO_0007254	breast cancer	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Terminated	https://clinicaltrials.gov/study/NCT00216047,https://clinicaltrials.gov/study/NCT00963547,https://clinicaltrials.gov/study/NCT00567879,https://clinicaltrials.gov/study/NCT02297230,https://clinicaltrials.gov/study/NCT00864175,https://clinicaltrials.gov/study/NCT02345772,https://clinicaltrials.gov/study/NCT02598427,https://clinicaltrials.gov/study/NCT01132664,https://clinicaltrials.gov/study/NCT01388647,https://clinicaltrials.gov/study/NCT02154529,https://clinicaltrials.gov/study/NCT00140140,https://clinicaltrials.gov/study/NCT01512199,https://clinicaltrials.gov/study/NCT01254136,https://clinicaltrials.gov/study/NCT00039455,https://clinicaltrials.gov/study/NCT00041470,https://clinicaltrials.gov/study/NCT00726180,https://clinicaltrials.gov/study/NCT02379585
MONDO_0007254	breast cancer	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 6 inhibitor		HDAC6	histone deacetylase 6	1	Unknown status	https://clinicaltrials.gov/study/NCT00416130
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB4	NADH:ubiquinone oxidoreductase subunit B4	1	Completed	https://clinicaltrials.gov/study/NCT02278965
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06177171
EFO_0005537	triple-negative breast cancer	CHEMBL4297190	SURUFATINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05746728
MONDO_0007254	breast cancer	CHEMBL575448	BMS-754807	Small molecule	Insulin-like growth factor I receptor inhibitor		IGF1R	insulin like growth factor 1 receptor	1	Completed	https://clinicaltrials.gov/study/NCT00788333
MONDO_0007254	breast cancer	CHEMBL101253	VATALANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT00268918
MONDO_0007254	breast cancer	CHEMBL1201247	GOSERELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	1	Withdrawn	https://clinicaltrials.gov/study/NCT01240928
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Completed	https://clinicaltrials.gov/study/NCT00875979,https://clinicaltrials.gov/study/NCT01983501,https://clinicaltrials.gov/study/NCT02657343,https://clinicaltrials.gov/study/NCT02073916,https://clinicaltrials.gov/study/NCT00951665,https://clinicaltrials.gov/study/NCT02038010,https://clinicaltrials.gov/study/NCT00934856,https://clinicaltrials.gov/study/NCT02236000,https://clinicaltrials.gov/study/NCT01513083,https://clinicaltrials.gov/study/NCT02605915
EFO_0005537	triple-negative breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R2	phosphoinositide-3-kinase regulatory subunit 2	1	Terminated	https://clinicaltrials.gov/study/NCT02457910
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLE3	DNA polymerase epsilon 3, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02479230,https://clinicaltrials.gov/study/NCT00100750
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
MONDO_0007254	breast cancer	CHEMBL1751	DIGOXIN	Small molecule	Sodium/potassium-transporting ATPase inhibitor		ATP1A2	ATPase Na+/K+ transporting subunit alpha 2	1	Completed	https://clinicaltrials.gov/study/NCT03928210
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Completed	https://clinicaltrials.gov/study/NCT00535119
MONDO_0007254	breast cancer	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RB	interleukin 2 receptor subunit beta	1	Unknown status	https://clinicaltrials.gov/study/NCT00002780,https://clinicaltrials.gov/study/NCT00002616
MONDO_0007254	breast cancer	CHEMBL1908373	ONAPRISTONE	Small molecule	Progesterone receptor antagonist		PGR	progesterone receptor	1	Withdrawn	https://clinicaltrials.gov/study/NCT04872608
MONDO_0007254	breast cancer	CHEMBL1079742	ERLOTINIB HYDROCHLORIDE	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	1	Completed	https://clinicaltrials.gov/study/NCT00033514
MONDO_0007254	breast cancer	CHEMBL574737	UCN-01	Small molecule	Protein kinase C (PKC) inhibitor		PRKCZ	protein kinase C zeta	1	Completed	https://clinicaltrials.gov/study/NCT00001444
EFO_0005537	triple-negative breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02419495
EFO_0006861	male breast carcinoma	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		APH1A	aph-1 homolog A, gamma-secretase subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01149356
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Completed	https://clinicaltrials.gov/study/NCT00535119
MONDO_0007254	breast cancer	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 6 inhibitor		HDAC6	histone deacetylase 6	1	Completed	https://clinicaltrials.gov/study/NCT01084057,https://clinicaltrials.gov/study/NCT00258349,https://clinicaltrials.gov/study/NCT00368875,https://clinicaltrials.gov/study/NCT00719875,https://clinicaltrials.gov/study/NCT00788112,https://clinicaltrials.gov/study/NCT00574587
EFO_0005537	triple-negative breast cancer	CHEMBL574737	UCN-01	Small molecule	3-phosphoinositide dependent protein kinase-1 inhibitor		PDPK1	3-phosphoinositide dependent protein kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT00031681
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Terminated	https://clinicaltrials.gov/study/NCT02474173,https://clinicaltrials.gov/study/NCT01238133
MONDO_0007254	breast cancer	CHEMBL4303201	CATEQUENTINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06331169
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR2	estrogen receptor 2	1	Withdrawn	https://clinicaltrials.gov/study/NCT04316169
MONDO_0004658	breast carcinoma in situ	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Completed	https://clinicaltrials.gov/study/NCT04081389
MONDO_0007254	breast cancer	CHEMBL502835	NINTEDANIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR2	fibroblast growth factor receptor 2	1	Completed	https://clinicaltrials.gov/study/NCT02619162
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Completed	https://clinicaltrials.gov/study/NCT03872791,https://clinicaltrials.gov/study/NCT04584112,https://clinicaltrials.gov/study/NCT02672475
MONDO_0007254	breast cancer	CHEMBL4298009	IERAMILIMAB	Antibody	Lymphocyte activation gene 3 protein inhibitor		LAG3	lymphocyte activating 3	1	Terminated	https://clinicaltrials.gov/study/NCT03742349
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00049244
EFO_0006861	male breast carcinoma	CHEMBL2107862	RINTATOLIMOD	Oligonucleotide	Toll-like receptor 3 agonist		TLR3	toll like receptor 3	1	Completed	https://clinicaltrials.gov/study/NCT01355393
EFO_0000305	breast carcinoma	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	1	Terminated	https://clinicaltrials.gov/study/NCT03128619
MONDO_0007254	breast cancer	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Completed	https://clinicaltrials.gov/study/NCT00217399,https://clinicaltrials.gov/study/NCT00828074
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03032107,https://clinicaltrials.gov/study/NCT02390427
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	1	Completed	https://clinicaltrials.gov/study/NCT02285179,https://clinicaltrials.gov/study/NCT01862081
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Terminated	https://clinicaltrials.gov/study/NCT00075673
EFO_0000186	invasive breast ductal carcinoma	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT01791478
EFO_0000304	breast adenocarcinoma	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC10	histone deacetylase 10	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
MONDO_0007254	breast cancer	CHEMBL377559	RETASPIMYCIN HYDROCHLORIDE	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AA1	heat shock protein 90 alpha family class A member 1	1	Withdrawn	https://clinicaltrials.gov/study/NCT00627627
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Recruiting	https://clinicaltrials.gov/study/NCT05307705,https://clinicaltrials.gov/study/NCT04152057,https://clinicaltrials.gov/study/NCT04205903,https://clinicaltrials.gov/study/NCT03994107
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Terminated	https://clinicaltrials.gov/study/NCT00041470,https://clinicaltrials.gov/study/NCT01238029,https://clinicaltrials.gov/study/NCT01254136,https://clinicaltrials.gov/study/NCT00140140,https://clinicaltrials.gov/study/NCT02658084,https://clinicaltrials.gov/study/NCT00075673
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND2	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
MONDO_0007254	breast cancer	CHEMBL4297844	TRASTUZUMAB DERUXTECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	1	Completed	https://clinicaltrials.gov/study/NCT03366428
MONDO_0007254	breast cancer	CHEMBL118	CELECOXIB	Small molecule	Cyclooxygenase-2 inhibitor		PTGS2	prostaglandin-endoperoxide synthase 2	1	Completed	https://clinicaltrials.gov/study/NCT00328432,https://clinicaltrials.gov/study/NCT03599453,https://clinicaltrials.gov/study/NCT01769625,https://clinicaltrials.gov/study/NCT01425476,https://clinicaltrials.gov/study/NCT00070057
EFO_0005537	triple-negative breast cancer	CHEMBL4297190	SURUFATINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05746728
MONDO_0007254	breast cancer	CHEMBL276711	SEMAXANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Completed	https://clinicaltrials.gov/study/NCT00005822
EFO_0000305	breast carcinoma	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR2	estrogen receptor 2	1	Completed	https://clinicaltrials.gov/study/NCT02219789,https://clinicaltrials.gov/study/NCT01344031
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		SRMS	src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites	1	Terminated	https://clinicaltrials.gov/study/NCT00903006
EFO_0000305	breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD1	DNA polymerase delta 1, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT00100750
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA8	NADH:ubiquinone oxidoreductase subunit A8	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
MONDO_0007254	breast cancer	CHEMBL1743079	TEPROTUMUMAB	Antibody	Insulin-like growth factor I receptor antagonist		IGF1R	insulin like growth factor 1 receptor	1	Completed	https://clinicaltrials.gov/study/NCT00882674
MONDO_0007254	breast cancer	CHEMBL185	FLUOROURACIL	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	1	Terminated	https://clinicaltrials.gov/study/NCT00003086
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	1	Unknown status	https://clinicaltrials.gov/study/NCT02626507
MONDO_0007254	breast cancer	CHEMBL109480	TANESPIMYCIN	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AB1	heat shock protein 90 alpha family class B member 1	1	Completed	https://clinicaltrials.gov/study/NCT00004065,https://clinicaltrials.gov/study/NCT00773344
EFO_0006861	male breast carcinoma	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	1	Terminated	https://clinicaltrials.gov/study/NCT01149356
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD3	DNA polymerase delta 3, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02479230,https://clinicaltrials.gov/study/NCT00100750
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Unknown status	https://clinicaltrials.gov/study/NCT02616848
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Terminated	https://clinicaltrials.gov/study/NCT01238133,https://clinicaltrials.gov/study/NCT02474173
EFO_0006861	male breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
EFO_0006861	male breast carcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC7	histone deacetylase 7	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND1	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1	1	Completed	https://clinicaltrials.gov/study/NCT02278965
MONDO_0007254	breast cancer	CHEMBL4297844	TRASTUZUMAB DERUXTECAN	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 binding agent		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Recruiting	https://clinicaltrials.gov/study/NCT05633979
MONDO_0007254	breast cancer	CHEMBL1200501	GOSERELIN ACETATE	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	1	Unknown status	https://clinicaltrials.gov/study/NCT02626507
MONDO_0007254	breast cancer	CHEMBL3	NICOTINE	Small molecule	Neuronal acetylcholine receptor; alpha4/beta2 agonist		CHRNA4	cholinergic receptor nicotinic alpha 4 subunit	1	Completed	https://clinicaltrials.gov/study/NCT03346161
MONDO_0007254	breast cancer	CHEMBL46740	BAZEDOXIFENE	Small molecule	Estrogen receptor modulator		ESR2	estrogen receptor 2	1	Completed	https://clinicaltrials.gov/study/NCT02448771
MONDO_0007254	breast cancer	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	1	Suspended	https://clinicaltrials.gov/study/NCT01618357
EFO_0000304	breast adenocarcinoma	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04481113
EFO_0000304	breast adenocarcinoma	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC7	histone deacetylase 7	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC2	NADH:ubiquinone oxidoreductase subunit C2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
EFO_0006861	male breast carcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC8	histone deacetylase 8	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Terminated	https://clinicaltrials.gov/study/NCT01697293,https://clinicaltrials.gov/study/NCT02824575
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05251766
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Recruiting	https://clinicaltrials.gov/study/NCT03805399,https://clinicaltrials.gov/study/NCT05673200,https://clinicaltrials.gov/study/NCT05918133
EFO_0000305	breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R2	phosphoinositide-3-kinase regulatory subunit 2	1	Withdrawn	https://clinicaltrials.gov/study/NCT03400254
MONDO_0007254	breast cancer	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	1	Recruiting	https://clinicaltrials.gov/study/NCT04487236
EFO_0005537	triple-negative breast cancer	CHEMBL1976040	ADAVOSERTIB	Small molecule	Serine/threonine-protein kinase WEE1 inhibitor		WEE1	WEE1 G2 checkpoint kinase	1	Completed	https://clinicaltrials.gov/study/NCT02482311
MONDO_0007254	breast cancer	CHEMBL101253	VATALANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Terminated	https://clinicaltrials.gov/study/NCT00216047
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA12	NADH:ubiquinone oxidoreductase subunit A12	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
MONDO_0007254	breast cancer	CHEMBL1535	HYDROXYCHLOROQUINE	Small molecule	Toll-like receptor 9 antagonist		TLR9	toll like receptor 9	1	Terminated	https://clinicaltrials.gov/study/NCT02414776
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Recruiting	https://clinicaltrials.gov/study/NCT05092373
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD4	DNA polymerase delta 4, accessory subunit	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03554044
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Completed	https://clinicaltrials.gov/study/NCT01816035
MONDO_0007254	breast cancer	CHEMBL705	ALITRETINOIN	Small molecule	Retinoid receptor agonist		RARB	retinoic acid receptor beta	1	Completed	https://clinicaltrials.gov/study/NCT00001504
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLE2	DNA polymerase epsilon 2, accessory subunit	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04750382
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00049244
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4L	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLE2	DNA polymerase epsilon 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT02479230,https://clinicaltrials.gov/study/NCT00100750
MONDO_0007254	breast cancer	CHEMBL3989514	IRINOTECAN HYDROCHLORIDE	Small molecule	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	1	Completed	https://clinicaltrials.gov/study/NCT00083148
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Completed	https://clinicaltrials.gov/study/NCT04584112,https://clinicaltrials.gov/study/NCT03872791,https://clinicaltrials.gov/study/NCT02672475
MONDO_0007254	breast cancer	CHEMBL4297181	SAMOTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	1	Completed	https://clinicaltrials.gov/study/NCT01655225
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLE	DNA polymerase epsilon, catalytic subunit	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04750382
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03032107,https://clinicaltrials.gov/study/NCT02390427
EFO_0005537	triple-negative breast cancer	CHEMBL1082407	ENZALUTAMIDE	Small molecule	Androgen Receptor antagonist		AR	androgen receptor	1	Terminated	https://clinicaltrials.gov/study/NCT02457910
MONDO_0007254	breast cancer	CHEMBL1184904	RETASPIMYCIN	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AA1	heat shock protein 90 alpha family class A member 1	1	Withdrawn	https://clinicaltrials.gov/study/NCT00627627
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4L2	NDUFA4 mitochondrial complex associated like 2	1	Completed	https://clinicaltrials.gov/study/NCT01980823,https://clinicaltrials.gov/study/NCT01650506
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Withdrawn	https://clinicaltrials.gov/study/NCT04252768,https://clinicaltrials.gov/study/NCT02569489,https://clinicaltrials.gov/study/NCT00022230,https://clinicaltrials.gov/study/NCT04762901,https://clinicaltrials.gov/study/NCT03175666,https://clinicaltrials.gov/study/NCT04826016,https://clinicaltrials.gov/study/NCT03285607
EFO_0000304	breast adenocarcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
EFO_0006318	breast ductal adenocarcinoma	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	1	Completed	https://clinicaltrials.gov/study/NCT03455270
MONDO_0007254	breast cancer	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	1	Unknown status	https://clinicaltrials.gov/study/NCT00931450,https://clinicaltrials.gov/study/NCT03125746
EFO_1000984	inflammatory breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Unknown status	https://clinicaltrials.gov/study/NCT01880385
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBB6	tubulin beta 6 class V	1	Completed	https://clinicaltrials.gov/study/NCT00270907
MONDO_0007254	breast cancer	CHEMBL3581693	BRILANESTRANT	Small molecule	Estrogen receptor alpha antagonist		ESR1	estrogen receptor 1	1	Terminated	https://clinicaltrials.gov/study/NCT01823835
EFO_0000305	breast carcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC3	histone deacetylase 3	1	Completed	https://clinicaltrials.gov/study/NCT01434303
EFO_0005537	triple-negative breast cancer	CHEMBL4298024	BINTRAFUSP ALFA	Protein	Transforming growth factor beta binding agent		TGFB1	transforming growth factor beta 1	1	Terminated	https://clinicaltrials.gov/study/NCT03579472
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF4	NADH:ubiquinone oxidoreductase complex assembly factor 4	1	Completed	https://clinicaltrials.gov/study/NCT01980823,https://clinicaltrials.gov/study/NCT01650506
MONDO_0007254	breast cancer	CHEMBL1201670	SARGRAMOSTIM	Protein	Granulocyte-macrophage colony-stimulating factor receptor agonist		CSF2RA	colony stimulating factor 2 receptor subunit alpha	1	Unknown status	https://clinicaltrials.gov/study/NCT00002780
MONDO_0007254	breast cancer	CHEMBL483321	CP-724714	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT00055926
MONDO_0007254	breast cancer	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	1	Completed	https://clinicaltrials.gov/study/NCT00568022,https://clinicaltrials.gov/study/NCT00083148,https://clinicaltrials.gov/study/NCT03958721,https://clinicaltrials.gov/study/NCT01300962,https://clinicaltrials.gov/study/NCT02361112,https://clinicaltrials.gov/study/NCT00632489,https://clinicaltrials.gov/study/NCT05052437,https://clinicaltrials.gov/study/NCT00618124,https://clinicaltrials.gov/study/NCT00327743,https://clinicaltrials.gov/study/NCT00031876,https://clinicaltrials.gov/study/NCT00807859,https://clinicaltrials.gov/study/NCT02650752,https://clinicaltrials.gov/study/NCT02754011,https://clinicaltrials.gov/study/NCT00050167,https://clinicaltrials.gov/study/NCT03473639,https://clinicaltrials.gov/study/NCT01326481,https://clinicaltrials.gov/study/NCT00706069,https://clinicaltrials.gov/study/NCT01498458,https://clinicaltrials.gov/study/NCT01640665,https://clinicaltrials.gov/study/NCT00008034,https://clinicaltrials.gov/study/NCT00153907,https://clinicaltrials.gov/study/NCT00169000,https://clinicaltrials.gov/study/NCT01323530,https://clinicaltrials.gov/study/NCT00468585,https://clinicaltrials.gov/study/NCT00452673,https://clinicaltrials.gov/study/NCT00741260,https://clinicaltrials.gov/study/NCT00003902,https://clinicaltrials.gov/study/NCT02025192,https://clinicaltrials.gov/study/NCT00006108,https://clinicaltrials.gov/study/NCT01471847
EFO_0005537	triple-negative breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	1	Completed	https://clinicaltrials.gov/study/NCT03544125
EFO_1000984	inflammatory breast carcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC1	histone deacetylase 1	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
MONDO_0007254	breast cancer	CHEMBL1214827	ONALESPIB	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AB1	heat shock protein 90 alpha family class B member 1	1	Terminated	https://clinicaltrials.gov/study/NCT02474173
MONDO_0007254	breast cancer	CHEMBL1082407	ENZALUTAMIDE	Small molecule	Androgen Receptor antagonist		AR	androgen receptor	1	Completed	https://clinicaltrials.gov/study/NCT01597193
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC1	histone deacetylase 1	1	Terminated	https://clinicaltrials.gov/study/NCT00754312,https://clinicaltrials.gov/study/NCT04296942,https://clinicaltrials.gov/study/NCT03361800
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLA2	DNA polymerase alpha 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT01154426
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05251766
EFO_0000304	breast adenocarcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC5	histone deacetylase 5	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
EFO_0000305	breast carcinoma	CHEMBL3644587	2X-121	Small molecule	Tankyrase 1/2 inhibitor		TNKS	tankyrase	1	Withdrawn	https://clinicaltrials.gov/study/NCT02396433
MONDO_0007254	breast cancer	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	1	Unknown status	https://clinicaltrials.gov/study/NCT03282825
MONDO_0007254	breast cancer	CHEMBL185	FLUOROURACIL	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	1	Withdrawn	https://clinicaltrials.gov/study/NCT03175666
MONDO_0007254	breast cancer	CHEMBL1879463	DACTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R2	phosphoinositide-3-kinase regulatory subunit 2	1	Completed	https://clinicaltrials.gov/study/NCT01248494
MONDO_0007254	breast cancer	CHEMBL101253	VATALANIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT00268918
MONDO_0007254	breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT05176080
EFO_0000305	breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLA2	DNA polymerase alpha 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT00100750
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Withdrawn	https://clinicaltrials.gov/study/NCT00074139
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAB1	NADH:ubiquinone oxidoreductase subunit AB1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Withdrawn	https://clinicaltrials.gov/study/NCT02396433
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Terminated	https://clinicaltrials.gov/study/NCT00140140,https://clinicaltrials.gov/study/NCT00075673,https://clinicaltrials.gov/study/NCT00041470,https://clinicaltrials.gov/study/NCT01238029,https://clinicaltrials.gov/study/NCT02658084,https://clinicaltrials.gov/study/NCT01254136
EFO_0000305	breast carcinoma	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN4A	sodium voltage-gated channel alpha subunit 4	1	Completed	https://clinicaltrials.gov/study/NCT03502395
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHB2	EPH receptor B2	1	Completed	https://clinicaltrials.gov/study/NCT00496665
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Terminated	https://clinicaltrials.gov/study/NCT00450879,https://clinicaltrials.gov/study/NCT01407562
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05251766
EFO_0000305	breast carcinoma	CHEMBL314854	FINGOLIMOD	Small molecule	Sphingosine 1-phosphate receptor agonist		S1PR5	sphingosine-1-phosphate receptor 5	1	Completed	https://clinicaltrials.gov/study/NCT03941743
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Epidermal growth factor receptor inhibitor		EGFR	epidermal growth factor receptor	1	Completed	https://clinicaltrials.gov/study/NCT00496665
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03685331
MONDO_0007254	breast cancer	CHEMBL5315324	KW-2450 FREE BASE	Small molecule	Insulin-like growth factor I receptor inhibitor		IGF1R	insulin like growth factor 1 receptor	1	Terminated	https://clinicaltrials.gov/study/NCT01199367
EFO_0006861	male breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Terminated	https://clinicaltrials.gov/study/NCT00063934
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Terminated	https://clinicaltrials.gov/study/NCT02824575,https://clinicaltrials.gov/study/NCT02474173
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1023	BEXAROTENE	Small molecule	Retinoid X receptor agonist		RXRA	retinoid X receptor alpha	1	Completed	https://clinicaltrials.gov/study/NCT03323658
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Completed	https://clinicaltrials.gov/study/NCT02120469
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Withdrawn	https://clinicaltrials.gov/study/NCT01349088
EFO_0006861	male breast carcinoma	CHEMBL1079175	MK-2206	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT2	AKT serine/threonine kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT01245205
EFO_0005537	triple-negative breast cancer	CHEMBL574737	UCN-01	Small molecule	Protein kinase C (PKC) inhibitor		PRKCD	protein kinase C delta	1	Completed	https://clinicaltrials.gov/study/NCT00031681
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		SRC	SRC proto-oncogene, non-receptor tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT00903006
MONDO_0007254	breast cancer	CHEMBL2364652	VANTICTUMAB	Antibody	Frizzled-1 antagonist		FZD1	frizzled class receptor 1	1	Completed	https://clinicaltrials.gov/study/NCT01973309
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Tyrosine-protein kinase TIE-2 inhibitor		TEK	TEK receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT00496665
EFO_0006861	male breast carcinoma	CHEMBL2103840	DINACICLIB	Small molecule	Cyclin-dependent kinase 1 inhibitor		CDK1	cyclin dependent kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT01624441
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Completed	https://clinicaltrials.gov/study/NCT00724386,https://clinicaltrials.gov/study/NCT00003902,https://clinicaltrials.gov/study/NCT00706069,https://clinicaltrials.gov/study/NCT00014430,https://clinicaltrials.gov/study/NCT00513058,https://clinicaltrials.gov/study/NCT00912275,https://clinicaltrials.gov/study/NCT00001944,https://clinicaltrials.gov/study/NCT00706030,https://clinicaltrials.gov/study/NCT00828074,https://clinicaltrials.gov/study/NCT00153907
EFO_0000305	breast carcinoma	CHEMBL4297844	TRASTUZUMAB DERUXTECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04294628
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Completed	https://clinicaltrials.gov/study/NCT01816035
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD4	DNA polymerase delta 4, accessory subunit	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04750382
EFO_0006861	male breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Completed	https://clinicaltrials.gov/study/NCT01084057
EFO_0006861	male breast carcinoma	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	1	Completed	https://clinicaltrials.gov/study/NCT01281150
MONDO_0007254	breast cancer	CHEMBL521851	PICTILISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	1	Unknown status	https://clinicaltrials.gov/study/NCT02389842
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Terminated	https://clinicaltrials.gov/study/NCT00634088
MONDO_0007254	breast cancer	CHEMBL226267	ARZOXIFENE	Small molecule	Estrogen receptor modulator		ESR2	estrogen receptor 2	1	Completed	https://clinicaltrials.gov/study/NCT00005886
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS5	NADH:ubiquinone oxidoreductase subunit S5	1	Completed	https://clinicaltrials.gov/study/NCT01980823,https://clinicaltrials.gov/study/NCT01650506
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Withdrawn	https://clinicaltrials.gov/study/NCT04826016
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05251766
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	1	Unknown status	https://clinicaltrials.gov/study/NCT02626507,https://clinicaltrials.gov/study/NCT02389842
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Unknown status	https://clinicaltrials.gov/study/NCT00764972
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	Ephrin type-A receptor 2 inhibitor		EPHA2	EPH receptor A2	1	Completed	https://clinicaltrials.gov/study/NCT01306942,https://clinicaltrials.gov/study/NCT00924352,https://clinicaltrials.gov/study/NCT00820170,https://clinicaltrials.gov/study/NCT00452673
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA5	NADH:ubiquinone oxidoreductase subunit A5	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Recruiting	https://clinicaltrials.gov/study/NCT05335473
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA9	NADH:ubiquinone oxidoreductase subunit A9	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
EFO_0000304	breast adenocarcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC8	histone deacetylase 8	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02453620
MONDO_0007254	breast cancer	CHEMBL4650336	EMVODODSTAT	Small molecule	Dihydroorotate dehydrogenase inhibitor		DHODH	dihydroorotate dehydrogenase (quinone)	1	Completed	https://clinicaltrials.gov/study/NCT00508586
EFO_0005537	triple-negative breast cancer	CHEMBL3237547	CEDAZURIDINE	Small molecule	Cytidine deaminase inhibitor		CDA	cytidine deaminase	1	Recruiting	https://clinicaltrials.gov/study/NCT05673200
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA10	NADH:ubiquinone oxidoreductase subunit A10	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
MONDO_0007254	breast cancer	CHEMBL1535	HYDROXYCHLOROQUINE	Small molecule	Toll-like receptor 7 antagonist		TLR7	toll like receptor 7	1	Withdrawn	https://clinicaltrials.gov/study/NCT04316169,https://clinicaltrials.gov/study/NCT03400254
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Completed	https://clinicaltrials.gov/study/NCT00828074,https://clinicaltrials.gov/study/NCT01640665,https://clinicaltrials.gov/study/NCT00217399,https://clinicaltrials.gov/study/NCT00825734
EFO_0000304	breast adenocarcinoma	CHEMBL3545068	COPANLISIB HYDROCHLORIDE	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
MONDO_0007254	breast cancer	CHEMBL1908360	EVEROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	1	Recruiting	https://clinicaltrials.gov/study/NCT05293964
MONDO_0007254	breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	1	Enrolling by invitation	https://clinicaltrials.gov/study/NCT05189717
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Withdrawn	https://clinicaltrials.gov/study/NCT00074139
MONDO_0007254	breast cancer	CHEMBL3833373	AVELUMAB	Antibody	Programmed cell death 1 ligand 1 other		CD274	CD274 molecule	1	Withdrawn	https://clinicaltrials.gov/study/NCT03175666
MONDO_0004658	breast carcinoma in situ	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Completed	https://clinicaltrials.gov/study/NCT04081389
MONDO_0007254	breast cancer	CHEMBL4279455	LAROTAXEL	Small molecule	Tubulin stabiliser		TUBB2A	tubulin beta 2A class IIa	1	Completed	https://clinicaltrials.gov/study/NCT00327743
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03685331
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Recruiting	https://clinicaltrials.gov/study/NCT05335473
MONDO_0007254	breast cancer	CHEMBL185	FLUOROURACIL	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	1	Recruiting	https://clinicaltrials.gov/study/NCT02897700
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Vascular endothelial growth factor receptor 1 inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Terminated	https://clinicaltrials.gov/study/NCT02074878,https://clinicaltrials.gov/study/NCT00905021,https://clinicaltrials.gov/study/NCT00616122
MONDO_0007254	breast cancer	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	1	Terminated	https://clinicaltrials.gov/study/NCT02983604,https://clinicaltrials.gov/study/NCT02990845,https://clinicaltrials.gov/study/NCT00905021
MONDO_0007254	breast cancer	CHEMBL1879463	DACTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R5	phosphoinositide-3-kinase regulatory subunit 5	1	Terminated	https://clinicaltrials.gov/study/NCT01495247
MONDO_0007254	breast cancer	CHEMBL521851	PICTILISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	1	Unknown status	https://clinicaltrials.gov/study/NCT02389842
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Vascular endothelial growth factor receptor 1 inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Unknown status	https://clinicaltrials.gov/study/NCT00931450
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC6	histone deacetylase 6	1	Terminated	https://clinicaltrials.gov/study/NCT00567879
MONDO_0007254	breast cancer	CHEMBL34259	METHOTREXATE	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	1	Completed	https://clinicaltrials.gov/study/NCT00496665
MONDO_0007254	breast cancer	CHEMBL96172	EPOTHILONE D	Small molecule	Tubulin stabiliser		TUBB2B	tubulin beta 2B class IIb	1	Completed	https://clinicaltrials.gov/study/NCT00337649
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Terminated	https://clinicaltrials.gov/study/NCT01697293,https://clinicaltrials.gov/study/NCT02824575
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Terminated	https://clinicaltrials.gov/study/NCT03579472,https://clinicaltrials.gov/study/NCT02753595
MONDO_0007254	breast cancer	CHEMBL2396661	ALPELISIB	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	1	Recruiting	https://clinicaltrials.gov/study/NCT05143229,https://clinicaltrials.gov/study/NCT05508906
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Unknown status	https://clinicaltrials.gov/study/NCT00764972
MONDO_0007254	breast cancer	CHEMBL4594578	TEBOTELIMAB	Antibody	Lymphocyte activation gene 3 protein inhibitor		LAG3	lymphocyte activating 3	1	Terminated	https://clinicaltrials.gov/study/NCT04178460
EFO_0000304	breast adenocarcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLA1	DNA polymerase alpha 1, catalytic subunit	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
MONDO_0004658	breast carcinoma in situ	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Completed	https://clinicaltrials.gov/study/NCT04081389
EFO_0005537	triple-negative breast cancer	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Completed	https://clinicaltrials.gov/study/NCT04584112
MONDO_0007254	breast cancer	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	1	Completed	https://clinicaltrials.gov/study/NCT01989546,https://clinicaltrials.gov/study/NCT04672460,https://clinicaltrials.gov/study/NCT04134884
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	1	Terminated	https://clinicaltrials.gov/study/NCT01132664
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Suspended	https://clinicaltrials.gov/study/NCT05422794
MONDO_0007254	breast cancer	CHEMBL1567	SUNITINIB MALATE	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	1	Unknown status	https://clinicaltrials.gov/study/NCT00931450
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Completed	https://clinicaltrials.gov/study/NCT01432886,https://clinicaltrials.gov/study/NCT01323530
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA3	EPH receptor A3	1	Completed	https://clinicaltrials.gov/study/NCT00496665
MONDO_0004658	breast carcinoma in situ	CHEMBL359744	DOXORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Completed	https://clinicaltrials.gov/study/NCT04081389
EFO_0000304	breast adenocarcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Completed	https://clinicaltrials.gov/study/NCT00169000,https://clinicaltrials.gov/study/NCT00050167,https://clinicaltrials.gov/study/NCT01256567,https://clinicaltrials.gov/study/NCT04367090,https://clinicaltrials.gov/study/NCT00003103,https://clinicaltrials.gov/study/NCT00705315,https://clinicaltrials.gov/study/NCT00645333,https://clinicaltrials.gov/study/NCT00002901,https://clinicaltrials.gov/study/NCT00020332,https://clinicaltrials.gov/study/NCT02605915,https://clinicaltrials.gov/study/NCT00086957,https://clinicaltrials.gov/study/NCT00450892,https://clinicaltrials.gov/study/NCT00872625,https://clinicaltrials.gov/study/NCT00372424,https://clinicaltrials.gov/study/NCT00322400,https://clinicaltrials.gov/study/NCT01044485,https://clinicaltrials.gov/study/NCT05301530,https://clinicaltrials.gov/study/NCT02392845,https://clinicaltrials.gov/study/NCT00637897,https://clinicaltrials.gov/study/NCT00934856,https://clinicaltrials.gov/study/NCT00268918,https://clinicaltrials.gov/study/NCT02027376,https://clinicaltrials.gov/study/NCT00080665,https://clinicaltrials.gov/study/NCT01862081,https://clinicaltrials.gov/study/NCT00129896
MONDO_0007254	breast cancer	CHEMBL160	CYCLOSPORINE	Protein	Cyclophilin A modulator		PPIA	peptidylprolyl isomerase A	1	Completed	https://clinicaltrials.gov/study/NCT00983424
MONDO_0007254	breast cancer	CHEMBL522892	DOVITINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT01421004
EFO_0005537	triple-negative breast cancer	CHEMBL1789941	RUXOLITINIB	Small molecule	Tyrosine-protein kinase JAK1 inhibitor		JAK1	Janus kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT03012230
MONDO_0007254	breast cancer	CHEMBL522892	DOVITINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Completed	https://clinicaltrials.gov/study/NCT01421004
EFO_0005537	triple-negative breast cancer	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	1	Recruiting	https://clinicaltrials.gov/study/NCT04664829,https://clinicaltrials.gov/study/NCT03805399
EFO_0000304	breast adenocarcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC11	histone deacetylase 11	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02453620
EFO_0000304	breast adenocarcinoma	CHEMBL4298024	BINTRAFUSP ALFA	Protein	Transforming growth factor beta binding agent		TGFB1	transforming growth factor beta 1	1	Withdrawn	https://clinicaltrials.gov/study/NCT04756505
EFO_0000305	breast carcinoma	CHEMBL1079175	MK-2206	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT3	AKT serine/threonine kinase 3	1	Completed	https://clinicaltrials.gov/study/NCT01344031,https://clinicaltrials.gov/study/NCT01263145
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS4	NADH:ubiquinone oxidoreductase subunit S4	1	Completed	https://clinicaltrials.gov/study/NCT01980823,https://clinicaltrials.gov/study/NCT01650506
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Completed	https://clinicaltrials.gov/study/NCT01795586,https://clinicaltrials.gov/study/NCT02723877,https://clinicaltrials.gov/study/NCT01432886,https://clinicaltrials.gov/study/NCT01596751,https://clinicaltrials.gov/study/NCT01323530
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Unknown status	https://clinicaltrials.gov/study/NCT00764972
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Terminated	https://clinicaltrials.gov/study/NCT00616122,https://clinicaltrials.gov/study/NCT02074878,https://clinicaltrials.gov/study/NCT00905021
MONDO_0007254	breast cancer	CHEMBL3545366	VOXTALISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	1	Completed	https://clinicaltrials.gov/study/NCT01082068,https://clinicaltrials.gov/study/NCT01390818
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBB	tubulin beta class I	1	Completed	https://clinicaltrials.gov/study/NCT00270907
MONDO_0007254	breast cancer	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	1	Recruiting	https://clinicaltrials.gov/study/NCT05035745
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLA1	DNA polymerase alpha 1, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT01154426
MONDO_0007254	breast cancer	CHEMBL359744	DOXORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Completed	https://clinicaltrials.gov/study/NCT00028964,https://clinicaltrials.gov/study/NCT00129896,https://clinicaltrials.gov/study/NCT00004925,https://clinicaltrials.gov/study/NCT00002837,https://clinicaltrials.gov/study/NCT00316875,https://clinicaltrials.gov/study/NCT00003038,https://clinicaltrials.gov/study/NCT00009997,https://clinicaltrials.gov/study/NCT00093834,https://clinicaltrials.gov/study/NCT00005822,https://clinicaltrials.gov/study/NCT02015676,https://clinicaltrials.gov/study/NCT00006825,https://clinicaltrials.gov/study/NCT00442260,https://clinicaltrials.gov/study/NCT00003927,https://clinicaltrials.gov/study/NCT06098599
MONDO_0007254	breast cancer	CHEMBL1094636	NIRAPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	1	Recruiting	https://clinicaltrials.gov/study/NCT03945721
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB4	NADH:ubiquinone oxidoreductase subunit B4	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
EFO_0006861	male breast carcinoma	CHEMBL1079175	MK-2206	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT1	AKT serine/threonine kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT01245205
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Withdrawn	https://clinicaltrials.gov/study/NCT00074139
EFO_0006861	male breast carcinoma	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Terminated	https://clinicaltrials.gov/study/NCT00039455
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Terminated	https://clinicaltrials.gov/study/NCT04296942,https://clinicaltrials.gov/study/NCT04298918,https://clinicaltrials.gov/study/NCT02658084,https://clinicaltrials.gov/study/NCT04042051,https://clinicaltrials.gov/study/NCT03429101
MONDO_0007254	breast cancer	CHEMBL4297844	TRASTUZUMAB DERUXTECAN	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 binding agent		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04556773
EFO_0000305	breast carcinoma	CHEMBL473417	VISMODEGIB	Small molecule	Smoothened homolog inhibitor		SMO	smoothened, frizzled class receptor	1	Terminated	https://clinicaltrials.gov/study/NCT01071564
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor	Inhibitor	RRM1	ribonucleotide reductase catalytic subunit M1	1	Completed	https://clinicaltrials.gov/study/NCT00100750
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
MONDO_0007254	breast cancer	CHEMBL572881	MOTESANIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT00322400
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03032107,https://clinicaltrials.gov/study/NCT02390427
MONDO_0007254	breast cancer	CHEMBL49642	INDIBULIN	Small molecule	Tubulin inhibitor		TUBA1A	tubulin alpha 1a	1	Unknown status	https://clinicaltrials.gov/study/NCT01113970
MONDO_0007254	breast cancer	CHEMBL2177390	IPATASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT1	AKT serine/threonine kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT03800836
MONDO_0007254	breast cancer	CHEMBL3989868	TUCATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Recruiting	https://clinicaltrials.gov/study/NCT06162559
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Terminated	https://clinicaltrials.gov/study/NCT02753595,https://clinicaltrials.gov/study/NCT03579472
MONDO_0007254	breast cancer	CHEMBL1289601	LENVATINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Unknown status	https://clinicaltrials.gov/study/NCT02562118
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	1	Completed	https://clinicaltrials.gov/study/NCT01251874,https://clinicaltrials.gov/study/NCT00535119,https://clinicaltrials.gov/study/NCT01154426
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB8	NADH:ubiquinone oxidoreductase subunit B8	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
MONDO_0007254	breast cancer	CHEMBL2109512	MCS-110	Antibody	Macrophage colony-stimulating factor 1 inhibitor		CSF1	colony stimulating factor 1	1	Withdrawn	https://clinicaltrials.gov/study/NCT03285607
EFO_0006861	male breast carcinoma	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	1	Terminated	https://clinicaltrials.gov/study/NCT00039455
MONDO_0007254	breast cancer	CHEMBL1879463	DACTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R2	phosphoinositide-3-kinase regulatory subunit 2	1	Terminated	https://clinicaltrials.gov/study/NCT01495247
MONDO_0007254	breast cancer	CHEMBL3545132	MIRVETUXIMAB SORAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Withdrawn	https://clinicaltrials.gov/study/NCT03045393
EFO_0005537	triple-negative breast cancer	CHEMBL3545185	SELINEXOR	Small molecule	Exportin-1 inhibitor		XPO1	exportin 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02419495
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02419495
EFO_0005537	triple-negative breast cancer	CHEMBL574737	UCN-01	Small molecule	Protein kinase C (PKC) inhibitor		PRKCZ	protein kinase C zeta	1	Completed	https://clinicaltrials.gov/study/NCT00031681
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Unknown status	https://clinicaltrials.gov/study/NCT00764972
EFO_0000305	breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Recruiting	https://clinicaltrials.gov/study/NCT05673200,https://clinicaltrials.gov/study/NCT03805399,https://clinicaltrials.gov/study/NCT05918133
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Epidermal growth factor receptor inhibitor		ERBB4	erb-b2 receptor tyrosine kinase 4	1	Completed	https://clinicaltrials.gov/study/NCT00496665
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Unknown status	https://clinicaltrials.gov/study/NCT00931450
MONDO_0007254	breast cancer	CHEMBL4303201	CATEQUENTINIB	Small molecule	Vascular endothelial growth factor receptor 3 inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06331169
EFO_0000304	breast adenocarcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
MONDO_0007254	breast cancer	CHEMBL3833373	AVELUMAB	Antibody	Programmed cell death 1 ligand 1 other		CD274	CD274 molecule	1	Recruiting	https://clinicaltrials.gov/study/NCT04360941
MONDO_0007254	breast cancer	CHEMBL3360203	PILARALISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R2	phosphoinositide-3-kinase regulatory subunit 2	1	Completed	https://clinicaltrials.gov/study/NCT01082068,https://clinicaltrials.gov/study/NCT01042925
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Terminated	https://clinicaltrials.gov/study/NCT01929941,https://clinicaltrials.gov/study/NCT02358200,https://clinicaltrials.gov/study/NCT01495247,https://clinicaltrials.gov/study/NCT01249443,https://clinicaltrials.gov/study/NCT02474173,https://clinicaltrials.gov/study/NCT00041470,https://clinicaltrials.gov/study/NCT00140140,https://clinicaltrials.gov/study/NCT00003086,https://clinicaltrials.gov/study/NCT01980277,https://clinicaltrials.gov/study/NCT02297230,https://clinicaltrials.gov/study/NCT01407562,https://clinicaltrials.gov/study/NCT02379585,https://clinicaltrials.gov/study/NCT01512199,https://clinicaltrials.gov/study/NCT01090128
MONDO_0007254	breast cancer	CHEMBL1614701	SELUMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 2 inhibitor		MAP2K2	mitogen-activated protein kinase kinase 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00600496
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Terminated	https://clinicaltrials.gov/study/NCT00075673
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Completed	https://clinicaltrials.gov/study/NCT02120469
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA7	NADH:ubiquinone oxidoreductase subunit A7	1	Completed	https://clinicaltrials.gov/study/NCT01650506,https://clinicaltrials.gov/study/NCT01980823
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV3	NADH:ubiquinone oxidoreductase subunit V3	1	Completed	https://clinicaltrials.gov/study/NCT02278965
MONDO_0007254	breast cancer	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	1	Recruiting	https://clinicaltrials.gov/study/NCT04427293,https://clinicaltrials.gov/study/NCT02977468,https://clinicaltrials.gov/study/NCT03272334,https://clinicaltrials.gov/study/NCT04265872
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB11	NADH:ubiquinone oxidoreductase subunit B11	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Recruiting	https://clinicaltrials.gov/study/NCT05092373
MONDO_0007254	breast cancer	CHEMBL1879463	DACTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R5	phosphoinositide-3-kinase regulatory subunit 5	1	Completed	https://clinicaltrials.gov/study/NCT01248494
EFO_0000305	breast carcinoma	CHEMBL1214827	ONALESPIB	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AA1	heat shock protein 90 alpha family class A member 1	1	Terminated	https://clinicaltrials.gov/study/NCT02474173
EFO_0000305	breast carcinoma	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT01351909
EFO_1000984	inflammatory breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Unknown status	https://clinicaltrials.gov/study/NCT01880385
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Unknown status	https://clinicaltrials.gov/study/NCT00002627,https://clinicaltrials.gov/study/NCT00009763,https://clinicaltrials.gov/study/NCT00002628,https://clinicaltrials.gov/study/NCT00915369,https://clinicaltrials.gov/study/NCT01084863,https://clinicaltrials.gov/study/NCT03282825,https://clinicaltrials.gov/study/NCT02396108
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Completed	https://clinicaltrials.gov/study/NCT00003902,https://clinicaltrials.gov/study/NCT00014430,https://clinicaltrials.gov/study/NCT00153907,https://clinicaltrials.gov/study/NCT00828074
MONDO_0007254	breast cancer	CHEMBL3545432	IXAZOMIB CITRATE	Small molecule	26S proteosome inhibitor		PSMB5	proteasome 20S subunit beta 5	1	Terminated	https://clinicaltrials.gov/study/NCT02384746
MONDO_0007254	breast cancer	CHEMBL1908373	ONAPRISTONE	Small molecule	Progesterone receptor antagonist		PGR	progesterone receptor	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT05618613
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Completed	https://clinicaltrials.gov/study/NCT00828074,https://clinicaltrials.gov/study/NCT00217399,https://clinicaltrials.gov/study/NCT01640665,https://clinicaltrials.gov/study/NCT00825734
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Terminated	https://clinicaltrials.gov/study/NCT01238029,https://clinicaltrials.gov/study/NCT01254136,https://clinicaltrials.gov/study/NCT02658084,https://clinicaltrials.gov/study/NCT00075673,https://clinicaltrials.gov/study/NCT00041470,https://clinicaltrials.gov/study/NCT00140140
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA5	NADH:ubiquinone oxidoreductase subunit A5	1	Completed	https://clinicaltrials.gov/study/NCT01650506,https://clinicaltrials.gov/study/NCT01980823
MONDO_0007254	breast cancer	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 3 inhibitor		HDAC3	histone deacetylase 3	1	Unknown status	https://clinicaltrials.gov/study/NCT00416130
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Completed	https://clinicaltrials.gov/study/NCT00322400,https://clinicaltrials.gov/study/NCT01862081,https://clinicaltrials.gov/study/NCT01044485,https://clinicaltrials.gov/study/NCT00169000,https://clinicaltrials.gov/study/NCT00086957,https://clinicaltrials.gov/study/NCT02392845,https://clinicaltrials.gov/study/NCT05301530,https://clinicaltrials.gov/study/NCT02605915,https://clinicaltrials.gov/study/NCT00080665,https://clinicaltrials.gov/study/NCT00129896,https://clinicaltrials.gov/study/NCT00268918,https://clinicaltrials.gov/study/NCT00050167,https://clinicaltrials.gov/study/NCT02027376,https://clinicaltrials.gov/study/NCT00020332,https://clinicaltrials.gov/study/NCT00003103,https://clinicaltrials.gov/study/NCT00450892,https://clinicaltrials.gov/study/NCT00872625,https://clinicaltrials.gov/study/NCT00002901,https://clinicaltrials.gov/study/NCT00645333,https://clinicaltrials.gov/study/NCT01256567,https://clinicaltrials.gov/study/NCT00372424,https://clinicaltrials.gov/study/NCT04367090,https://clinicaltrials.gov/study/NCT00705315,https://clinicaltrials.gov/study/NCT00637897,https://clinicaltrials.gov/study/NCT00934856
MONDO_0007254	breast cancer	CHEMBL1567	SUNITINIB MALATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Terminated	https://clinicaltrials.gov/study/NCT00616122,https://clinicaltrials.gov/study/NCT00905021
MONDO_0007254	breast cancer	CHEMBL3647420	PYROTINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	1	Unknown status	https://clinicaltrials.gov/study/NCT02500199,https://clinicaltrials.gov/study/NCT02422199
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT01498458
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA10	NADH:ubiquinone oxidoreductase subunit A10	1	Completed	https://clinicaltrials.gov/study/NCT02278965
EFO_0000305	breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
EFO_0000432	breast ductal carcinoma in situ	CHEMBL3349607	PASIREOTIDE	Protein	Somatostatin receptor 1 agonist		SSTR1	somatostatin receptor 1	1	Terminated	https://clinicaltrials.gov/study/NCT01372618
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03032107,https://clinicaltrials.gov/study/NCT02390427
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA13	NADH:ubiquinone oxidoreductase subunit A13	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
EFO_0006861	male breast carcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC6	histone deacetylase 6	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	PRIM2	DNA primase subunit 2	1	Completed	https://clinicaltrials.gov/study/NCT01154426
MONDO_0007254	breast cancer	CHEMBL1567	SUNITINIB MALATE	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	1	Terminated	https://clinicaltrials.gov/study/NCT00616122,https://clinicaltrials.gov/study/NCT00905021
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Recruiting	https://clinicaltrials.gov/study/NCT05335473
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLE2	DNA polymerase epsilon 2, accessory subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT04796220
MONDO_0007254	breast cancer	CHEMBL744	RILUZOLE	Small molecule	Sodium channel alpha subunit blocker		SCN7A	sodium voltage-gated channel alpha subunit 7	1	Withdrawn	https://clinicaltrials.gov/study/NCT00903214
MONDO_0007254	breast cancer	CHEMBL3581647	BIRABRESIB	Small molecule	Bromodomain and extra-terminal motif (BET) inhibitor		BRD4	bromodomain containing 4	1	Terminated	https://clinicaltrials.gov/study/NCT02698176
MONDO_0007254	breast cancer	CHEMBL3360203	PILARALISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	1	Completed	https://clinicaltrials.gov/study/NCT01042925,https://clinicaltrials.gov/study/NCT01082068
EFO_0000304	breast adenocarcinoma	CHEMBL1094636	NIRAPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04481113
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	1	Withdrawn	https://clinicaltrials.gov/study/NCT04872608
MONDO_0007254	breast cancer	CHEMBL1770916	NIROGACESTAT	Small molecule	Gamma-secretase inhibitor		PSENEN	presenilin enhancer, gamma-secretase subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01876251
EFO_0000304	breast adenocarcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC2	histone deacetylase 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02453620
MONDO_0007254	breast cancer	CHEMBL601719	CRIZOTINIB	Small molecule	Hepatocyte growth factor receptor inhibitor		MET	MET proto-oncogene, receptor tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT02074878
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Terminated	https://clinicaltrials.gov/study/NCT02658084,https://clinicaltrials.gov/study/NCT00140140,https://clinicaltrials.gov/study/NCT01238029,https://clinicaltrials.gov/study/NCT00075673,https://clinicaltrials.gov/study/NCT01254136,https://clinicaltrials.gov/study/NCT00041470
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Suspended	https://clinicaltrials.gov/study/NCT05422794
EFO_1000984	inflammatory breast carcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC9	histone deacetylase 9	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Completed	https://clinicaltrials.gov/study/NCT04584112,https://clinicaltrials.gov/study/NCT03872791,https://clinicaltrials.gov/study/NCT02672475
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	Bcr/Abl fusion protein		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT01306942,https://clinicaltrials.gov/study/NCT00820170,https://clinicaltrials.gov/study/NCT00924352,https://clinicaltrials.gov/study/NCT00452673
MONDO_0007254	breast cancer	CHEMBL522892	DOVITINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT01484041
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Platelet-derived growth factor receptor alpha inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Terminated	https://clinicaltrials.gov/study/NCT02074878,https://clinicaltrials.gov/study/NCT00905021,https://clinicaltrials.gov/study/NCT00616122
MONDO_0007254	breast cancer	CHEMBL3545132	MIRVETUXIMAB SORAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBA1B	tubulin alpha 1b	1	Withdrawn	https://clinicaltrials.gov/study/NCT03045393
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS4	NADH:ubiquinone oxidoreductase subunit S4	1	Completed	https://clinicaltrials.gov/study/NCT02278965
MONDO_0007254	breast cancer	CHEMBL3545366	VOXTALISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	1	Completed	https://clinicaltrials.gov/study/NCT01082068,https://clinicaltrials.gov/study/NCT01390818
EFO_0000304	breast adenocarcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC10	histone deacetylase 10	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02453620
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4L	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L	1	Completed	https://clinicaltrials.gov/study/NCT01980823,https://clinicaltrials.gov/study/NCT01650506
EFO_0000305	breast carcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC2	histone deacetylase 2	1	Completed	https://clinicaltrials.gov/study/NCT01434303
EFO_0005537	triple-negative breast cancer	CHEMBL1607	TOPOTECAN HYDROCHLORIDE	Small molecule	DNA topoisomerase I, mitochondrial inhibitor		TOP1MT	DNA topoisomerase I mitochondrial	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02419495
MONDO_0007254	breast cancer	CHEMBL1201740	NILOTINIB HYDROCHLORIDE MONOHYDRATE	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	1	Recruiting	https://clinicaltrials.gov/study/NCT04205903
MONDO_0007254	breast cancer	CHEMBL4298024	BINTRAFUSP ALFA	Protein	Transforming growth factor beta binding agent		TGFB2	transforming growth factor beta 2	1	Terminated	https://clinicaltrials.gov/study/NCT03579472,https://clinicaltrials.gov/study/NCT04296942
EFO_0000304	breast adenocarcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLA2	DNA polymerase alpha 2, accessory subunit	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05900895
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	1	Completed	https://clinicaltrials.gov/study/NCT02058381,https://clinicaltrials.gov/study/NCT02088684,https://clinicaltrials.gov/study/NCT01339442,https://clinicaltrials.gov/study/NCT01626209,https://clinicaltrials.gov/study/NCT02154776,https://clinicaltrials.gov/study/NCT01248494
MONDO_0007254	breast cancer	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04961632
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF1	NADH:ubiquinone oxidoreductase complex assembly factor 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Completed	https://clinicaltrials.gov/study/NCT01432886,https://clinicaltrials.gov/study/NCT01323530
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Completed	https://clinicaltrials.gov/study/NCT01983501,https://clinicaltrials.gov/study/NCT02236000,https://clinicaltrials.gov/study/NCT00934856,https://clinicaltrials.gov/study/NCT02657343,https://clinicaltrials.gov/study/NCT00951665,https://clinicaltrials.gov/study/NCT02605915,https://clinicaltrials.gov/study/NCT02073916,https://clinicaltrials.gov/study/NCT01513083,https://clinicaltrials.gov/study/NCT00875979,https://clinicaltrials.gov/study/NCT02038010
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD4	DNA polymerase delta 4, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT00100750
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
MONDO_0007254	breast cancer	CHEMBL1200895	PHENELZINE SULFATE	Small molecule	Monoamine oxidase inhibitor		MAOB	monoamine oxidase B	1	Completed	https://clinicaltrials.gov/study/NCT03505528
MONDO_0007254	breast cancer	CHEMBL1201577	CETUXIMAB	Antibody	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	1	Unknown status	https://clinicaltrials.gov/study/NCT00367250
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Completed	https://clinicaltrials.gov/study/NCT03364348
EFO_0006861	male breast carcinoma	CHEMBL3264610	SEVITERONEL	Small molecule	Androgen Receptor antagonist		AR	androgen receptor	1	Completed	https://clinicaltrials.gov/study/NCT02580448
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R2	phosphoinositide-3-kinase regulatory subunit 2	1	Completed	https://clinicaltrials.gov/study/NCT03243331,https://clinicaltrials.gov/study/NCT02684032
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD3	DNA polymerase delta 3, accessory subunit	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04750382
EFO_0006861	male breast carcinoma	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 3 inhibitor		HDAC3	histone deacetylase 3	1	Completed	https://clinicaltrials.gov/study/NCT00258349,https://clinicaltrials.gov/study/NCT00368875,https://clinicaltrials.gov/study/NCT01084057
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB7	NADH:ubiquinone oxidoreductase subunit B7	1	Completed	https://clinicaltrials.gov/study/NCT01650506,https://clinicaltrials.gov/study/NCT01980823
MONDO_0007254	breast cancer	CHEMBL1487	ATORVASTATIN	Small molecule	HMG-CoA reductase inhibitor		HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase	1	Completed	https://clinicaltrials.gov/study/NCT01980823
MONDO_0007254	breast cancer	CHEMBL1743062	RAMUCIRUMAB	Antibody	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	1	Completed	https://clinicaltrials.gov/study/NCT01256567
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Terminated	https://clinicaltrials.gov/study/NCT00531271,https://clinicaltrials.gov/study/NCT02379585,https://clinicaltrials.gov/study/NCT00063934,https://clinicaltrials.gov/study/NCT00864175,https://clinicaltrials.gov/study/NCT01876251,https://clinicaltrials.gov/study/NCT00584012,https://clinicaltrials.gov/study/NCT02345772,https://clinicaltrials.gov/study/NCT00253318
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	PRIM1	DNA primase subunit 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03554044
MONDO_0007254	breast cancer	CHEMBL3545307	MERESTINIB	Small molecule	Hepatocyte growth factor receptor inhibitor		MET	MET proto-oncogene, receptor tyrosine kinase	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02791334
MONDO_0007254	breast cancer	CHEMBL4297509	ELACESTRANT	Small molecule	Estrogen receptor alpha degrader		ESR1	estrogen receptor 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT05618613
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Terminated	https://clinicaltrials.gov/study/NCT01254136,https://clinicaltrials.gov/study/NCT02658084,https://clinicaltrials.gov/study/NCT00041470,https://clinicaltrials.gov/study/NCT00075673,https://clinicaltrials.gov/study/NCT01238029,https://clinicaltrials.gov/study/NCT00140140
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB8	NADH:ubiquinone oxidoreductase subunit B8	1	Completed	https://clinicaltrials.gov/study/NCT02278965
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB6	NADH:ubiquinone oxidoreductase subunit B6	1	Completed	https://clinicaltrials.gov/study/NCT02278965
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	Ephrin type-A receptor 2 inhibitor		EPHA2	EPH receptor A2	1	Terminated	https://clinicaltrials.gov/study/NCT00903006
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Terminated	https://clinicaltrials.gov/study/NCT02658084,https://clinicaltrials.gov/study/NCT04042051,https://clinicaltrials.gov/study/NCT03429101,https://clinicaltrials.gov/study/NCT04298918,https://clinicaltrials.gov/study/NCT04296942
MONDO_0007254	breast cancer	CHEMBL2364652	VANTICTUMAB	Antibody	Frizzled-8 antagonist		FZD8	frizzled class receptor 8	1	Completed	https://clinicaltrials.gov/study/NCT01973309
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03641755
EFO_0000305	breast carcinoma	CHEMBL2105717	CABOZANTINIB	Small molecule	Hepatocyte growth factor receptor inhibitor		MET	MET proto-oncogene, receptor tyrosine kinase	1	Recruiting	https://clinicaltrials.gov/study/NCT05092373
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	PRIM2	DNA primase subunit 2	1	Completed	https://clinicaltrials.gov/study/NCT02479230,https://clinicaltrials.gov/study/NCT00100750
EFO_0005537	triple-negative breast cancer	CHEMBL3187723	BINIMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 1 inhibitor		MAP2K1	mitogen-activated protein kinase kinase 1	1	Recruiting	https://clinicaltrials.gov/study/NCT05111561
MONDO_0007254	breast cancer	CHEMBL1289494	TIVOZANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Completed	https://clinicaltrials.gov/study/NCT00717340
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF2	NADH:ubiquinone oxidoreductase complex assembly factor 2	1	Completed	https://clinicaltrials.gov/study/NCT01650506,https://clinicaltrials.gov/study/NCT01980823
MONDO_0007254	breast cancer	CHEMBL2109583	F16IL2	Antibody	Tenascin other		TNC	tenascin C	1	Terminated	https://clinicaltrials.gov/study/NCT01131364
MONDO_0007254	breast cancer	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	1	Completed	https://clinicaltrials.gov/study/NCT00526617,https://clinicaltrials.gov/study/NCT01477489
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03554044,https://clinicaltrials.gov/study/NCT03725436
MONDO_0007254	breast cancer	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 6 inhibitor		HDAC6	histone deacetylase 6	1	Terminated	https://clinicaltrials.gov/study/NCT01249443
MONDO_0007254	breast cancer	CHEMBL4297843	TORIPALIMAB	Antibody	Programmed cell death protein 1 antagonist		PDCD1	programmed cell death 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03251313
MONDO_0007254	breast cancer	CHEMBL2325741	CAPIVASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT3	AKT serine/threonine kinase 3	1	Completed	https://clinicaltrials.gov/study/NCT01625286
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02419495
MONDO_0007254	breast cancer	CHEMBL135	ESTRADIOL	Small molecule	Estrogen receptor alpha agonist		ESR1	estrogen receptor 1	1	Completed	https://clinicaltrials.gov/study/NCT01916122
MONDO_0007254	breast cancer	CHEMBL3963485	ROGARATINIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR3	fibroblast growth factor receptor 3	1	Completed	https://clinicaltrials.gov/study/NCT04483505
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Terminated	https://clinicaltrials.gov/study/NCT03579472,https://clinicaltrials.gov/study/NCT01388647,https://clinicaltrials.gov/study/NCT02753595
MONDO_0007254	breast cancer	CHEMBL554	LAPATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	1	Unknown status	https://clinicaltrials.gov/study/NCT02422199
MONDO_0007254	breast cancer	CHEMBL744	RILUZOLE	Small molecule	Sodium channel alpha subunit blocker		SCN3A	sodium voltage-gated channel alpha subunit 3	1	Withdrawn	https://clinicaltrials.gov/study/NCT00903214
EFO_0006861	male breast carcinoma	CHEMBL1201179	LAPATINIB DITOSYLATE	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	1	Completed	https://clinicaltrials.gov/study/NCT01245205,https://clinicaltrials.gov/study/NCT01783756
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4	NDUFA4 mitochondrial complex associated	1	Completed	https://clinicaltrials.gov/study/NCT02278965
EFO_0005537	triple-negative breast cancer	CHEMBL4298024	BINTRAFUSP ALFA	Protein	Transforming growth factor beta binding agent		TGFB2	transforming growth factor beta 2	1	Terminated	https://clinicaltrials.gov/study/NCT03579472
MONDO_0007254	breast cancer	CHEMBL49642	INDIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Unknown status	https://clinicaltrials.gov/study/NCT01113970
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Terminated	https://clinicaltrials.gov/study/NCT02074878,https://clinicaltrials.gov/study/NCT00905021,https://clinicaltrials.gov/study/NCT00616122
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC11	histone deacetylase 11	1	Completed	https://clinicaltrials.gov/study/NCT01105312,https://clinicaltrials.gov/study/NCT00632489,https://clinicaltrials.gov/study/NCT00788931
MONDO_0007254	breast cancer	CHEMBL4297615	PARSACLISIB	Small molecule	PI3-kinase p110-delta subunit inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	1	Withdrawn	https://clinicaltrials.gov/study/NCT04142554
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Withdrawn	https://clinicaltrials.gov/study/NCT02396433
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Completed	https://clinicaltrials.gov/study/NCT00924352,https://clinicaltrials.gov/study/NCT00568022,https://clinicaltrials.gov/study/NCT01084057,https://clinicaltrials.gov/study/NCT00825734,https://clinicaltrials.gov/study/NCT00322374,https://clinicaltrials.gov/study/NCT00637897
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
MONDO_0007254	breast cancer	CHEMBL2336325	VISTUSERTIB	Small molecule	Serine/threonine-protein kinase mTOR inhibitor		MTOR	mechanistic target of rapamycin kinase	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT01597388
MONDO_0007254	breast cancer	CHEMBL276711	SEMAXANIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT00005822
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05019690,https://clinicaltrials.gov/study/NCT05274893,https://clinicaltrials.gov/study/NCT05251766
MONDO_0007254	breast cancer	CHEMBL4475463	AMCENESTRANT	Small molecule	Estrogen receptor alpha degrader		ESR1	estrogen receptor 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03816839
EFO_0000304	breast adenocarcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC8	histone deacetylase 8	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
MONDO_0007254	breast cancer	CHEMBL598797	CUDC-101	Small molecule	Histone deacetylase inhibitor		HDAC11	histone deacetylase 11	1	Completed	https://clinicaltrials.gov/study/NCT01171924
EFO_0005537	triple-negative breast cancer	CHEMBL1214827	ONALESPIB	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AB1	heat shock protein 90 alpha family class B member 1	1	Terminated	https://clinicaltrials.gov/study/NCT02474173
EFO_0005537	triple-negative breast cancer	CHEMBL1908360	EVEROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	1	Recruiting	https://clinicaltrials.gov/study/NCT03805399
EFO_0006861	male breast carcinoma	CHEMBL359744	DOXORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Terminated	https://clinicaltrials.gov/study/NCT00063934
MONDO_0007254	breast cancer	CHEMBL481	IRINOTECAN	Small molecule	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	1	Completed	https://clinicaltrials.gov/study/NCT00083148
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00600496
MONDO_0007254	breast cancer	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Serine/threonine-protein kinase RAF inhibitor		RAF1	Raf-1 proto-oncogene, serine/threonine kinase	1	Completed	https://clinicaltrials.gov/study/NCT00217399,https://clinicaltrials.gov/study/NCT00828074
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00049244
EFO_0000305	breast carcinoma	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT01351909
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Completed	https://clinicaltrials.gov/study/NCT01263145,https://clinicaltrials.gov/study/NCT02632071
EFO_0000305	breast carcinoma	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	1	Withdrawn	https://clinicaltrials.gov/study/NCT04418219
EFO_0000305	breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Fibroblast growth factor receptor 1 inhibitor		FGFR1	fibroblast growth factor receptor 1	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
EFO_0005537	triple-negative breast cancer	CHEMBL574737	UCN-01	Small molecule	Protein kinase C (PKC) inhibitor		PRKD3	protein kinase D3	1	Completed	https://clinicaltrials.gov/study/NCT00031681
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Unknown status	https://clinicaltrials.gov/study/NCT00764972
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	1	Completed	https://clinicaltrials.gov/study/NCT03243331,https://clinicaltrials.gov/study/NCT02684032
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05251766
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Recruiting	https://clinicaltrials.gov/study/NCT04205903,https://clinicaltrials.gov/study/NCT04152057,https://clinicaltrials.gov/study/NCT03994107,https://clinicaltrials.gov/study/NCT05307705
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00049244
EFO_0000305	breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Tyrosine-protein kinase LCK inhibitor		LCK	LCK proto-oncogene, Src family tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL705	ALITRETINOIN	Small molecule	Retinoid receptor agonist		RXRA	retinoid X receptor alpha	1	Completed	https://clinicaltrials.gov/study/NCT00001504
MONDO_0007254	breast cancer	CHEMBL3581647	BIRABRESIB	Small molecule	Bromodomain and extra-terminal motif (BET) inhibitor		BRD3	bromodomain containing 3	1	Terminated	https://clinicaltrials.gov/study/NCT02698176
MONDO_0007254	breast cancer	CHEMBL598797	CUDC-101	Small molecule	Histone deacetylase inhibitor		HDAC2	histone deacetylase 2	1	Completed	https://clinicaltrials.gov/study/NCT01171924
MONDO_0007254	breast cancer	CHEMBL4650316	GIREDESTRANT	Small molecule	Estrogen receptor alpha degrader		ESR1	estrogen receptor 1	1	Completed	https://clinicaltrials.gov/study/NCT03916744
MONDO_0007254	breast cancer	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	1	Terminated	https://clinicaltrials.gov/study/NCT00346229,https://clinicaltrials.gov/study/NCT00063934,https://clinicaltrials.gov/study/NCT00140140,https://clinicaltrials.gov/study/NCT00003086,https://clinicaltrials.gov/study/NCT00041470
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Completed	https://clinicaltrials.gov/study/NCT04367090,https://clinicaltrials.gov/study/NCT02027376,https://clinicaltrials.gov/study/NCT02392845,https://clinicaltrials.gov/study/NCT00322400,https://clinicaltrials.gov/study/NCT02605915,https://clinicaltrials.gov/study/NCT00637897,https://clinicaltrials.gov/study/NCT00080665,https://clinicaltrials.gov/study/NCT01862081,https://clinicaltrials.gov/study/NCT00129896,https://clinicaltrials.gov/study/NCT05301530,https://clinicaltrials.gov/study/NCT00705315,https://clinicaltrials.gov/study/NCT00020332,https://clinicaltrials.gov/study/NCT00050167,https://clinicaltrials.gov/study/NCT00450892,https://clinicaltrials.gov/study/NCT00934856,https://clinicaltrials.gov/study/NCT01044485,https://clinicaltrials.gov/study/NCT00002901,https://clinicaltrials.gov/study/NCT00169000,https://clinicaltrials.gov/study/NCT01256567,https://clinicaltrials.gov/study/NCT00086957,https://clinicaltrials.gov/study/NCT00003103,https://clinicaltrials.gov/study/NCT00372424,https://clinicaltrials.gov/study/NCT00268918,https://clinicaltrials.gov/study/NCT00872625,https://clinicaltrials.gov/study/NCT00645333
EFO_0000305	breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Fibroblast growth factor receptor 3 inhibitor		FGFR3	fibroblast growth factor receptor 3	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
EFO_0000304	breast adenocarcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	PRIM2	DNA primase subunit 2	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
MONDO_0007254	breast cancer	CHEMBL3545414	RIVOCERANIB MESYLATE	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05019690
MONDO_0007254	breast cancer	CHEMBL2107832	PIMASERTIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 2 inhibitor		MAP2K2	mitogen-activated protein kinase kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT01390818
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Terminated	https://clinicaltrials.gov/study/NCT02379585,https://clinicaltrials.gov/study/NCT00253318,https://clinicaltrials.gov/study/NCT01876251,https://clinicaltrials.gov/study/NCT00584012,https://clinicaltrials.gov/study/NCT00063934,https://clinicaltrials.gov/study/NCT00864175,https://clinicaltrials.gov/study/NCT00531271,https://clinicaltrials.gov/study/NCT02345772
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Terminated	https://clinicaltrials.gov/study/NCT03579472
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Terminated	https://clinicaltrials.gov/study/NCT03579472
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Completed	https://clinicaltrials.gov/study/NCT03364348
MONDO_0007254	breast cancer	CHEMBL1567	SUNITINIB MALATE	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	1	Terminated	https://clinicaltrials.gov/study/NCT00905021,https://clinicaltrials.gov/study/NCT00616122
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	1	Completed	https://clinicaltrials.gov/study/NCT02285179,https://clinicaltrials.gov/study/NCT01862081
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB11	NADH:ubiquinone oxidoreductase subunit B11	1	Completed	https://clinicaltrials.gov/study/NCT02278965
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05900895
MONDO_0007254	breast cancer	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	1	Recruiting	https://clinicaltrials.gov/study/NCT05307705
MONDO_0007254	breast cancer	CHEMBL574737	UCN-01	Small molecule	Protein kinase C (PKC) inhibitor		PRKCE	protein kinase C epsilon	1	Completed	https://clinicaltrials.gov/study/NCT00001444
EFO_0000304	breast adenocarcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC7	histone deacetylase 7	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02453620
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Completed	https://clinicaltrials.gov/study/NCT01432886,https://clinicaltrials.gov/study/NCT01323530
EFO_0000305	breast carcinoma	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN11A	sodium voltage-gated channel alpha subunit 11	1	Completed	https://clinicaltrials.gov/study/NCT03502395
EFO_1000984	inflammatory breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Unknown status	https://clinicaltrials.gov/study/NCT01880385
MONDO_0007254	breast cancer	CHEMBL1789941	RUXOLITINIB	Small molecule	Tyrosine-protein kinase JAK1 inhibitor		JAK1	Janus kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT02041429
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Unknown status	https://clinicaltrials.gov/study/NCT02616848
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02419495
MONDO_0004658	breast carcinoma in situ	CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist		IFNAR2	interferon alpha and beta receptor subunit 2	1	Completed	https://clinicaltrials.gov/study/NCT04081389
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA12	NADH:ubiquinone oxidoreductase subunit A12	1	Completed	https://clinicaltrials.gov/study/NCT01650506,https://clinicaltrials.gov/study/NCT01980823
MONDO_0007254	breast cancer	CHEMBL1567	SUNITINIB MALATE	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Unknown status	https://clinicaltrials.gov/study/NCT00931450
MONDO_0007254	breast cancer	CHEMBL3833373	AVELUMAB	Antibody	Programmed cell death 1 ligand 1 other		CD274	CD274 molecule	1	Terminated	https://clinicaltrials.gov/study/NCT03861403
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	1	Recruiting	https://clinicaltrials.gov/study/NCT04360941,https://clinicaltrials.gov/study/NCT04669587,https://clinicaltrials.gov/study/NCT04072952,https://clinicaltrials.gov/study/NCT05266105,https://clinicaltrials.gov/study/NCT05216432,https://clinicaltrials.gov/study/NCT05293964
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Completed	https://clinicaltrials.gov/study/NCT02599363,https://clinicaltrials.gov/study/NCT00009997,https://clinicaltrials.gov/study/NCT01484080,https://clinicaltrials.gov/study/NCT03112590,https://clinicaltrials.gov/study/NCT00707707,https://clinicaltrials.gov/study/NCT01625286,https://clinicaltrials.gov/study/NCT04247126,https://clinicaltrials.gov/study/NCT00807859,https://clinicaltrials.gov/study/NCT00050167,https://clinicaltrials.gov/study/NCT02073916,https://clinicaltrials.gov/study/NCT01070706,https://clinicaltrials.gov/study/NCT01306942,https://clinicaltrials.gov/study/NCT00724386,https://clinicaltrials.gov/study/NCT00960960,https://clinicaltrials.gov/study/NCT02041429,https://clinicaltrials.gov/study/NCT00031876,https://clinicaltrials.gov/study/NCT00574587,https://clinicaltrials.gov/study/NCT02015676,https://clinicaltrials.gov/study/NCT00788931,https://clinicaltrials.gov/study/NCT01918254,https://clinicaltrials.gov/study/NCT02001974,https://clinicaltrials.gov/study/NCT00691379,https://clinicaltrials.gov/study/NCT03411161,https://clinicaltrials.gov/study/NCT00680758,https://clinicaltrials.gov/study/NCT01973309,https://clinicaltrials.gov/study/NCT00803556,https://clinicaltrials.gov/study/NCT00301730,https://clinicaltrials.gov/study/NCT01254526,https://clinicaltrials.gov/study/NCT04132817,https://clinicaltrials.gov/study/NCT01320592,https://clinicaltrials.gov/study/NCT01423123,https://clinicaltrials.gov/study/NCT02628132,https://clinicaltrials.gov/study/NCT00004174,https://clinicaltrials.gov/study/NCT03505528,https://clinicaltrials.gov/study/NCT01172223,https://clinicaltrials.gov/study/NCT00637897,https://clinicaltrials.gov/study/NCT02379247,https://clinicaltrials.gov/study/NCT00368875,https://clinicaltrials.gov/study/NCT00001383,https://clinicaltrials.gov/study/NCT00003877,https://clinicaltrials.gov/study/NCT00107094,https://clinicaltrials.gov/study/NCT01042925,https://clinicaltrials.gov/study/NCT04261218,https://clinicaltrials.gov/study/NCT00748553,https://clinicaltrials.gov/study/NCT00322400,https://clinicaltrials.gov/study/NCT00951665,https://clinicaltrials.gov/study/NCT00820170,https://clinicaltrials.gov/study/NCT00006108,https://clinicaltrials.gov/study/NCT01493310,https://clinicaltrials.gov/study/NCT01862081,https://clinicaltrials.gov/study/NCT02060253,https://clinicaltrials.gov/study/NCT01031446,https://clinicaltrials.gov/study/NCT00887575,https://clinicaltrials.gov/study/NCT03166085,https://clinicaltrials.gov/study/NCT00442260,https://clinicaltrials.gov/study/NCT03800836,https://clinicaltrials.gov/study/NCT01133912,https://clinicaltrials.gov/study/NCT00445458,https://clinicaltrials.gov/study/NCT00900627,https://clinicaltrials.gov/study/NCT00068757,https://clinicaltrials.gov/study/NCT00983424,https://clinicaltrials.gov/study/NCT00002837,https://clinicaltrials.gov/study/NCT00717340,https://clinicaltrials.gov/study/NCT00054028,https://clinicaltrials.gov/study/NCT01003158,https://clinicaltrials.gov/study/NCT00003927,https://clinicaltrials.gov/study/NCT00426556
MONDO_0007254	breast cancer	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04961632
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Withdrawn	https://clinicaltrials.gov/study/NCT00074139
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Tyrosine-protein kinase ITK/TSK inhibitor		ITK	IL2 inducible T cell kinase	1	Terminated	https://clinicaltrials.gov/study/NCT01407562,https://clinicaltrials.gov/study/NCT00450879
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Completed	https://clinicaltrials.gov/study/NCT02120469
EFO_0000305	breast carcinoma	CHEMBL1079175	MK-2206	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT2	AKT serine/threonine kinase 2	1	Terminated	https://clinicaltrials.gov/study/NCT01281163
MONDO_0007254	breast cancer	CHEMBL3218576	COPANLISIB	Small molecule	PI3-kinase p110-delta subunit inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	1	Completed	https://clinicaltrials.gov/study/NCT02705859
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT04213898
EFO_0005537	triple-negative breast cancer	CHEMBL4297190	SURUFATINIB	Small molecule	Fibroblast growth factor receptor 1 inhibitor		FGFR1	fibroblast growth factor receptor 1	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05746728
MONDO_0007254	breast cancer	CHEMBL1879463	DACTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	1	Terminated	https://clinicaltrials.gov/study/NCT01495247
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		SRC	SRC proto-oncogene, non-receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT00452673,https://clinicaltrials.gov/study/NCT01306942,https://clinicaltrials.gov/study/NCT00820170,https://clinicaltrials.gov/study/NCT00924352
MONDO_0007254	breast cancer	CHEMBL1770916	NIROGACESTAT	Small molecule	Gamma-secretase inhibitor		APH1A	aph-1 homolog A, gamma-secretase subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01876251
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Completed	https://clinicaltrials.gov/study/NCT00001944,https://clinicaltrials.gov/study/NCT00724386,https://clinicaltrials.gov/study/NCT00513058,https://clinicaltrials.gov/study/NCT00153907,https://clinicaltrials.gov/study/NCT00014430,https://clinicaltrials.gov/study/NCT00706069,https://clinicaltrials.gov/study/NCT00003902,https://clinicaltrials.gov/study/NCT00912275,https://clinicaltrials.gov/study/NCT00706030,https://clinicaltrials.gov/study/NCT00828074
MONDO_0007254	breast cancer	CHEMBL939	GEFITINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	1	Completed	https://clinicaltrials.gov/study/NCT00086957
MONDO_0007254	breast cancer	CHEMBL3545096	BGT-226	Small molecule	PI3-kinase class I inhibitor		PIK3R2	phosphoinositide-3-kinase regulatory subunit 2	1	Completed	https://clinicaltrials.gov/study/NCT00600275
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04556773,https://clinicaltrials.gov/study/NCT03716180,https://clinicaltrials.gov/study/NCT03858322,https://clinicaltrials.gov/study/NCT02999477,https://clinicaltrials.gov/study/NCT03893955,https://clinicaltrials.gov/study/NCT02608216,https://clinicaltrials.gov/study/NCT04331067,https://clinicaltrials.gov/study/NCT02390427
MONDO_0007254	breast cancer	CHEMBL2035187	PACRITINIB	Small molecule	Tyrosine-protein kinase JAK2 inhibitor		JAK2	Janus kinase 2	1	Recruiting	https://clinicaltrials.gov/study/NCT04520269
EFO_0006861	male breast carcinoma	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT02060253
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Completed	https://clinicaltrials.gov/study/NCT01281150,https://clinicaltrials.gov/study/NCT00470301,https://clinicaltrials.gov/study/NCT01288261,https://clinicaltrials.gov/study/NCT01493310,https://clinicaltrials.gov/study/NCT01276496,https://clinicaltrials.gov/study/NCT02060253,https://clinicaltrials.gov/study/NCT00368875
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB10	NADH:ubiquinone oxidoreductase subunit B10	1	Completed	https://clinicaltrials.gov/study/NCT01980823,https://clinicaltrials.gov/study/NCT01650506
EFO_0006861	male breast carcinoma	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		PSENEN	presenilin enhancer, gamma-secretase subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01149356
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	1	Terminated	https://clinicaltrials.gov/study/NCT01823835
EFO_1000984	inflammatory breast carcinoma	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	1	Completed	https://clinicaltrials.gov/study/NCT02227082
MONDO_0007254	breast cancer	CHEMBL1743019	FIGITUMUMAB	Antibody	Insulin-like growth factor I receptor antagonist		IGF1R	insulin like growth factor 1 receptor	1	Withdrawn	https://clinicaltrials.gov/study/NCT00635245
EFO_0000304	breast adenocarcinoma	CHEMBL1094636	NIRAPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04481113
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Terminated	https://clinicaltrials.gov/study/NCT00531271,https://clinicaltrials.gov/study/NCT00864175,https://clinicaltrials.gov/study/NCT02345772,https://clinicaltrials.gov/study/NCT01876251,https://clinicaltrials.gov/study/NCT00253318,https://clinicaltrials.gov/study/NCT00063934,https://clinicaltrials.gov/study/NCT00584012,https://clinicaltrials.gov/study/NCT02379585
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS1	NADH:ubiquinone oxidoreductase core subunit S1	1	Completed	https://clinicaltrials.gov/study/NCT01650506,https://clinicaltrials.gov/study/NCT01980823
EFO_0000432	breast ductal carcinoma in situ	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	1	Recruiting	https://clinicaltrials.gov/study/NCT02872025
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Recruiting	https://clinicaltrials.gov/study/NCT05092373
MONDO_0007254	breast cancer	CHEMBL3218578	BGT-226	Small molecule	PI3-kinase class I inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	1	Completed	https://clinicaltrials.gov/study/NCT00600275
EFO_0006861	male breast carcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC5	histone deacetylase 5	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
MONDO_0007254	breast cancer	CHEMBL1237022	TOCILIZUMAB	Antibody	Interleukin-6 receptor alpha subunit inhibitor		IL6R	interleukin 6 receptor	1	Completed	https://clinicaltrials.gov/study/NCT03135171
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R2	phosphoinositide-3-kinase regulatory subunit 2	1	Completed	https://clinicaltrials.gov/study/NCT01862081,https://clinicaltrials.gov/study/NCT02285179
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA2	NADH:ubiquinone oxidoreductase subunit A2	1	Completed	https://clinicaltrials.gov/study/NCT02278965
MONDO_0007254	breast cancer	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL180022	NERATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT02236000,https://clinicaltrials.gov/study/NCT00708903,https://clinicaltrials.gov/study/NCT00741260,https://clinicaltrials.gov/study/NCT01423123,https://clinicaltrials.gov/study/NCT00706030,https://clinicaltrials.gov/study/NCT00445458,https://clinicaltrials.gov/study/NCT00398567,https://clinicaltrials.gov/study/NCT01111825
EFO_0000305	breast carcinoma	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03554044
EFO_0000305	breast carcinoma	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		PSEN1	presenilin 1	1	Terminated	https://clinicaltrials.gov/study/NCT01071564
MONDO_0007254	breast cancer	CHEMBL1201182	TEMSIROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	1	Completed	https://clinicaltrials.gov/study/NCT01111825,https://clinicaltrials.gov/study/NCT00998036
MONDO_0007254	breast cancer	CHEMBL4303201	CATEQUENTINIB	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06331169
EFO_0006861	male breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Completed	https://clinicaltrials.gov/study/NCT01084057
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR2	estrogen receptor 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT01992952,https://clinicaltrials.gov/study/NCT06047184,https://clinicaltrials.gov/study/NCT03767335,https://clinicaltrials.gov/study/NCT03959891,https://clinicaltrials.gov/study/NCT03772353,https://clinicaltrials.gov/study/NCT01597388,https://clinicaltrials.gov/study/NCT04556773,https://clinicaltrials.gov/study/NCT02792465,https://clinicaltrials.gov/study/NCT03006172,https://clinicaltrials.gov/study/NCT03238196,https://clinicaltrials.gov/study/NCT05176080
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	Serine/threonine-protein kinase mTOR inhibitor		MTOR	mechanistic target of rapamycin kinase	1	Withdrawn	https://clinicaltrials.gov/study/NCT03400254
EFO_0006861	male breast carcinoma	CHEMBL554	LAPATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	1	Completed	https://clinicaltrials.gov/study/NCT01245205,https://clinicaltrials.gov/study/NCT01783756
MONDO_0007254	breast cancer	CHEMBL14762	SELICICLIB	Small molecule	Cyclin-dependent kinase 5 inhibitor		CDK5	cyclin dependent kinase 5	1	Withdrawn	https://clinicaltrials.gov/study/NCT01333423
MONDO_0007254	breast cancer	CHEMBL1289601	LENVATINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Recruiting	https://clinicaltrials.gov/study/NCT04427293
MONDO_0007254	breast cancer	CHEMBL572881	MOTESANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Withdrawn	https://clinicaltrials.gov/study/NCT01349088
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF1	NADH:ubiquinone oxidoreductase complex assembly factor 1	1	Completed	https://clinicaltrials.gov/study/NCT01650506,https://clinicaltrials.gov/study/NCT01980823
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND5	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5	1	Completed	https://clinicaltrials.gov/study/NCT01980823,https://clinicaltrials.gov/study/NCT01650506
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Terminated	https://clinicaltrials.gov/study/NCT02824575,https://clinicaltrials.gov/study/NCT02474173
MONDO_0007254	breast cancer	CHEMBL3218578	BGT-226	Small molecule	Serine/threonine-protein kinase mTOR inhibitor		MTOR	mechanistic target of rapamycin kinase	1	Completed	https://clinicaltrials.gov/study/NCT00600275
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLA2	DNA polymerase alpha 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT00270907,https://clinicaltrials.gov/study/NCT00100750,https://clinicaltrials.gov/study/NCT01133912,https://clinicaltrials.gov/study/NCT01070706,https://clinicaltrials.gov/study/NCT02139358,https://clinicaltrials.gov/study/NCT02479230,https://clinicaltrials.gov/study/NCT04247126
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC9	histone deacetylase 9	1	Completed	https://clinicaltrials.gov/study/NCT01105312,https://clinicaltrials.gov/study/NCT00632489,https://clinicaltrials.gov/study/NCT00788931
EFO_0000305	breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL1567	SUNITINIB MALATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Unknown status	https://clinicaltrials.gov/study/NCT00931450
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
MONDO_0007254	breast cancer	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 3 inhibitor		HDAC3	histone deacetylase 3	1	Recruiting	https://clinicaltrials.gov/study/NCT03742245
EFO_0005537	triple-negative breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
MONDO_0007254	breast cancer	CHEMBL225072	PEMETREXED	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	1	Completed	https://clinicaltrials.gov/study/NCT00097383,https://clinicaltrials.gov/study/NCT00190671,https://clinicaltrials.gov/study/NCT01655225
MONDO_0007254	breast cancer	CHEMBL1201179	LAPATINIB DITOSYLATE	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	1	Completed	https://clinicaltrials.gov/study/NCT00379509,https://clinicaltrials.gov/study/NCT00424164,https://clinicaltrials.gov/study/NCT01172223,https://clinicaltrials.gov/study/NCT00316875,https://clinicaltrials.gov/study/NCT00544804,https://clinicaltrials.gov/study/NCT00753207,https://clinicaltrials.gov/study/NCT00085020
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Unknown status	https://clinicaltrials.gov/study/NCT02616848
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHB1	EPH receptor B1	1	Completed	https://clinicaltrials.gov/study/NCT00496665
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Terminated	https://clinicaltrials.gov/study/NCT03429101,https://clinicaltrials.gov/study/NCT04298918,https://clinicaltrials.gov/study/NCT04042051,https://clinicaltrials.gov/study/NCT04296942,https://clinicaltrials.gov/study/NCT02658084
MONDO_0007254	breast cancer	CHEMBL655	MIDAZOLAM	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRG1	gamma-aminobutyric acid type A receptor subunit gamma1	1	Completed	https://clinicaltrials.gov/study/NCT03955939,https://clinicaltrials.gov/study/NCT01655225
EFO_0000304	breast adenocarcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC11	histone deacetylase 11	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
MONDO_0007254	breast cancer	CHEMBL3545414	RIVOCERANIB MESYLATE	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	1	Completed	https://clinicaltrials.gov/study/NCT03945604
MONDO_0007254	breast cancer	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Tyrosine-protein kinase LCK inhibitor		LCK	LCK proto-oncogene, Src family tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Withdrawn	https://clinicaltrials.gov/study/NCT02070094
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Withdrawn	https://clinicaltrials.gov/study/NCT02070094
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND3	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
MONDO_0007254	breast cancer	CHEMBL225072	PEMETREXED	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	1	Completed	https://clinicaltrials.gov/study/NCT00190671,https://clinicaltrials.gov/study/NCT01655225,https://clinicaltrials.gov/study/NCT00097383
MONDO_0007254	breast cancer	CHEMBL3813873	PEXIDARTINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT01596751
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Completed	https://clinicaltrials.gov/study/NCT00003902,https://clinicaltrials.gov/study/NCT00014430,https://clinicaltrials.gov/study/NCT00828074,https://clinicaltrials.gov/study/NCT00153907
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	1	Terminated	https://clinicaltrials.gov/study/NCT01132664
MONDO_0007254	breast cancer	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	1	Completed	https://clinicaltrials.gov/study/NCT00020332,https://clinicaltrials.gov/study/NCT00003690
EFO_0000305	breast carcinoma	CHEMBL544665	FINGOLIMOD HYDROCHLORIDE	Small molecule	Sphingosine 1-phosphate receptor agonist		S1PR5	sphingosine-1-phosphate receptor 5	1	Completed	https://clinicaltrials.gov/study/NCT03941743
EFO_0005537	triple-negative breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
EFO_0006861	male breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Terminated	https://clinicaltrials.gov/study/NCT00063934
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Completed	https://clinicaltrials.gov/study/NCT00887575,https://clinicaltrials.gov/study/NCT00301730,https://clinicaltrials.gov/study/NCT03800836,https://clinicaltrials.gov/study/NCT02041429,https://clinicaltrials.gov/study/NCT00724386,https://clinicaltrials.gov/study/NCT01172223,https://clinicaltrials.gov/study/NCT01973309,https://clinicaltrials.gov/study/NCT01918254,https://clinicaltrials.gov/study/NCT00002837,https://clinicaltrials.gov/study/NCT00960960,https://clinicaltrials.gov/study/NCT00004174,https://clinicaltrials.gov/study/NCT02073916,https://clinicaltrials.gov/study/NCT00691379,https://clinicaltrials.gov/study/NCT01862081,https://clinicaltrials.gov/study/NCT00951665,https://clinicaltrials.gov/study/NCT00426556,https://clinicaltrials.gov/study/NCT02628132,https://clinicaltrials.gov/study/NCT01003158,https://clinicaltrials.gov/study/NCT02379247,https://clinicaltrials.gov/study/NCT00003927,https://clinicaltrials.gov/study/NCT00803556,https://clinicaltrials.gov/study/NCT00368875,https://clinicaltrials.gov/study/NCT00442260,https://clinicaltrials.gov/study/NCT00900627,https://clinicaltrials.gov/study/NCT00574587,https://clinicaltrials.gov/study/NCT00068757,https://clinicaltrials.gov/study/NCT00050167,https://clinicaltrials.gov/study/NCT01320592,https://clinicaltrials.gov/study/NCT00983424,https://clinicaltrials.gov/study/NCT00788931,https://clinicaltrials.gov/study/NCT01625286,https://clinicaltrials.gov/study/NCT01306942,https://clinicaltrials.gov/study/NCT00637897,https://clinicaltrials.gov/study/NCT00717340,https://clinicaltrials.gov/study/NCT00003877,https://clinicaltrials.gov/study/NCT00001383,https://clinicaltrials.gov/study/NCT01484080,https://clinicaltrials.gov/study/NCT00807859,https://clinicaltrials.gov/study/NCT00820170,https://clinicaltrials.gov/study/NCT00107094,https://clinicaltrials.gov/study/NCT02060253,https://clinicaltrials.gov/study/NCT01031446,https://clinicaltrials.gov/study/NCT00322400,https://clinicaltrials.gov/study/NCT00006108,https://clinicaltrials.gov/study/NCT00031876,https://clinicaltrials.gov/study/NCT01254526,https://clinicaltrials.gov/study/NCT01423123,https://clinicaltrials.gov/study/NCT01493310,https://clinicaltrials.gov/study/NCT03505528,https://clinicaltrials.gov/study/NCT00680758,https://clinicaltrials.gov/study/NCT03166085,https://clinicaltrials.gov/study/NCT03112590,https://clinicaltrials.gov/study/NCT02001974,https://clinicaltrials.gov/study/NCT00445458,https://clinicaltrials.gov/study/NCT04261218,https://clinicaltrials.gov/study/NCT00748553,https://clinicaltrials.gov/study/NCT00054028,https://clinicaltrials.gov/study/NCT04247126,https://clinicaltrials.gov/study/NCT00009997,https://clinicaltrials.gov/study/NCT00707707,https://clinicaltrials.gov/study/NCT01133912,https://clinicaltrials.gov/study/NCT04132817,https://clinicaltrials.gov/study/NCT01070706,https://clinicaltrials.gov/study/NCT02599363,https://clinicaltrials.gov/study/NCT03411161,https://clinicaltrials.gov/study/NCT01042925,https://clinicaltrials.gov/study/NCT02015676
MONDO_0007254	breast cancer	CHEMBL1535	HYDROXYCHLOROQUINE	Small molecule	Toll-like receptor 9 antagonist		TLR9	toll like receptor 9	1	Withdrawn	https://clinicaltrials.gov/study/NCT04316169,https://clinicaltrials.gov/study/NCT03400254
MONDO_0007254	breast cancer	CHEMBL4298024	BINTRAFUSP ALFA	Protein	Transforming growth factor beta binding agent		TGFB3	transforming growth factor beta 3	1	Withdrawn	https://clinicaltrials.gov/study/NCT04756505
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLE2	DNA polymerase epsilon 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT00100750,https://clinicaltrials.gov/study/NCT00270907,https://clinicaltrials.gov/study/NCT02479230,https://clinicaltrials.gov/study/NCT01133912,https://clinicaltrials.gov/study/NCT02139358,https://clinicaltrials.gov/study/NCT04247126,https://clinicaltrials.gov/study/NCT01070706
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	1	Completed	https://clinicaltrials.gov/study/NCT00707707,https://clinicaltrials.gov/study/NCT01237067
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03641755
MONDO_0007254	breast cancer	CHEMBL1751	DIGOXIN	Small molecule	Sodium/potassium-transporting ATPase inhibitor		ATP1A3	ATPase Na+/K+ transporting subunit alpha 3	1	Completed	https://clinicaltrials.gov/study/NCT03928210
MONDO_0007254	breast cancer	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 1 inhibitor		HDAC1	histone deacetylase 1	1	Terminated	https://clinicaltrials.gov/study/NCT01249443
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Completed	https://clinicaltrials.gov/study/NCT01263145,https://clinicaltrials.gov/study/NCT02632071
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Completed	https://clinicaltrials.gov/study/NCT01432886,https://clinicaltrials.gov/study/NCT01323530
EFO_0000305	breast carcinoma	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03955640
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC1	histone deacetylase 1	1	Completed	https://clinicaltrials.gov/study/NCT02833155,https://clinicaltrials.gov/study/NCT03473639,https://clinicaltrials.gov/study/NCT01594398,https://clinicaltrials.gov/study/NCT02820961
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Completed	https://clinicaltrials.gov/study/NCT04584112,https://clinicaltrials.gov/study/NCT02672475,https://clinicaltrials.gov/study/NCT03872791
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Recruiting	https://clinicaltrials.gov/study/NCT05335473
MONDO_0007254	breast cancer	CHEMBL383824	ALVESPIMYCIN	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AA1	heat shock protein 90 alpha family class A member 1	1	Completed	https://clinicaltrials.gov/study/NCT00803556
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Withdrawn	https://clinicaltrials.gov/study/NCT04826016
MONDO_0007254	breast cancer	CHEMBL252164	LUMINESPIB	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AB1	heat shock protein 90 alpha family class B member 1	1	Withdrawn	https://clinicaltrials.gov/study/NCT01361945
EFO_1000984	inflammatory breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Unknown status	https://clinicaltrials.gov/study/NCT01880385
MONDO_0007254	breast cancer	CHEMBL598797	CUDC-101	Small molecule	Histone deacetylase inhibitor		HDAC8	histone deacetylase 8	1	Completed	https://clinicaltrials.gov/study/NCT01171924
MONDO_0007254	breast cancer	CHEMBL118	CELECOXIB	Small molecule	Cyclooxygenase-2 inhibitor		PTGS2	prostaglandin-endoperoxide synthase 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT01881048
MONDO_0007254	breast cancer	CHEMBL4279455	LAROTAXEL	Small molecule	Tubulin stabiliser		TUBB4A	tubulin beta 4A class IVa	1	Completed	https://clinicaltrials.gov/study/NCT00327743
MONDO_0007254	breast cancer	CHEMBL4297844	TRASTUZUMAB DERUXTECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04556773
MONDO_0007254	breast cancer	CHEMBL4297844	TRASTUZUMAB DERUXTECAN	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 binding agent		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06331169
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Completed	https://clinicaltrials.gov/study/NCT00014430,https://clinicaltrials.gov/study/NCT00706030,https://clinicaltrials.gov/study/NCT00003902,https://clinicaltrials.gov/study/NCT00828074,https://clinicaltrials.gov/study/NCT00153907,https://clinicaltrials.gov/study/NCT00724386,https://clinicaltrials.gov/study/NCT00912275,https://clinicaltrials.gov/study/NCT00513058,https://clinicaltrials.gov/study/NCT00001944,https://clinicaltrials.gov/study/NCT00706069
MONDO_0007254	breast cancer	CHEMBL744	RILUZOLE	Small molecule	Sodium channel alpha subunit blocker		SCN2A	sodium voltage-gated channel alpha subunit 2	1	Withdrawn	https://clinicaltrials.gov/study/NCT00903214
EFO_0000305	breast carcinoma	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	1	Terminated	https://clinicaltrials.gov/study/NCT03128619
MONDO_0007254	breast cancer	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	1	Unknown status	https://clinicaltrials.gov/study/NCT03282825
MONDO_0007254	breast cancer	CHEMBL1922094	APITOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	1	Completed	https://clinicaltrials.gov/study/NCT01254526
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Unknown status	https://clinicaltrials.gov/study/NCT02396108,https://clinicaltrials.gov/study/NCT03282825,https://clinicaltrials.gov/study/NCT01084863,https://clinicaltrials.gov/study/NCT00002627,https://clinicaltrials.gov/study/NCT00009763,https://clinicaltrials.gov/study/NCT00915369,https://clinicaltrials.gov/study/NCT00002628
EFO_0000304	breast adenocarcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
EFO_0006861	male breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Terminated	https://clinicaltrials.gov/study/NCT00063934
MONDO_0007254	breast cancer	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	1	Terminated	https://clinicaltrials.gov/study/NCT00634088,https://clinicaltrials.gov/study/NCT01238029,https://clinicaltrials.gov/study/NCT01132664,https://clinicaltrials.gov/study/NCT00473005,https://clinicaltrials.gov/study/NCT04274933,https://clinicaltrials.gov/study/NCT02297230
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Completed	https://clinicaltrials.gov/study/NCT01862081,https://clinicaltrials.gov/study/NCT00268918,https://clinicaltrials.gov/study/NCT02605915,https://clinicaltrials.gov/study/NCT01256567,https://clinicaltrials.gov/study/NCT00002901,https://clinicaltrials.gov/study/NCT00169000,https://clinicaltrials.gov/study/NCT04367090,https://clinicaltrials.gov/study/NCT00322400,https://clinicaltrials.gov/study/NCT00003103,https://clinicaltrials.gov/study/NCT02027376,https://clinicaltrials.gov/study/NCT00872625,https://clinicaltrials.gov/study/NCT00050167,https://clinicaltrials.gov/study/NCT00129896,https://clinicaltrials.gov/study/NCT00372424,https://clinicaltrials.gov/study/NCT02392845,https://clinicaltrials.gov/study/NCT01044485,https://clinicaltrials.gov/study/NCT00020332,https://clinicaltrials.gov/study/NCT00705315,https://clinicaltrials.gov/study/NCT00934856,https://clinicaltrials.gov/study/NCT00086957,https://clinicaltrials.gov/study/NCT00450892,https://clinicaltrials.gov/study/NCT05301530,https://clinicaltrials.gov/study/NCT00080665,https://clinicaltrials.gov/study/NCT00637897,https://clinicaltrials.gov/study/NCT00645333
MONDO_0007254	breast cancer	CHEMBL1879463	DACTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	1	Terminated	https://clinicaltrials.gov/study/NCT01495247
MONDO_0007254	breast cancer	CHEMBL274654	ORANTINIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR1	fibroblast growth factor receptor 1	1	Unknown status	https://clinicaltrials.gov/study/NCT00024063
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05251766
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLE3	DNA polymerase epsilon 3, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT01154426
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Completed	https://clinicaltrials.gov/study/NCT00217399,https://clinicaltrials.gov/study/NCT00828074,https://clinicaltrials.gov/study/NCT01640665,https://clinicaltrials.gov/study/NCT00825734
MONDO_0007254	breast cancer	CHEMBL2103840	DINACICLIB	Small molecule	Cyclin-dependent kinase 1 inhibitor		CDK1	cyclin dependent kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT01676753
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHB3	EPH receptor B3	1	Completed	https://clinicaltrials.gov/study/NCT00496665
MONDO_0007254	breast cancer	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 2 inhibitor		HDAC2	histone deacetylase 2	1	Completed	https://clinicaltrials.gov/study/NCT00574587,https://clinicaltrials.gov/study/NCT01084057,https://clinicaltrials.gov/study/NCT00788112,https://clinicaltrials.gov/study/NCT00719875,https://clinicaltrials.gov/study/NCT00258349,https://clinicaltrials.gov/study/NCT00368875
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06177171
MONDO_0007254	breast cancer	CHEMBL522892	DOVITINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Terminated	https://clinicaltrials.gov/study/NCT01484041
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBA1B	tubulin alpha 1b	1	Completed	https://clinicaltrials.gov/study/NCT00270907
EFO_0000304	breast adenocarcinoma	CHEMBL462018	TRICIRIBINE PHOSPHATE	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT3	AKT serine/threonine kinase 3	1	Terminated	https://clinicaltrials.gov/study/NCT01697293
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Completed	https://clinicaltrials.gov/study/NCT02672475,https://clinicaltrials.gov/study/NCT04584112,https://clinicaltrials.gov/study/NCT03872791
EFO_0005537	triple-negative breast cancer	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		PSEN2	presenilin 2	1	Terminated	https://clinicaltrials.gov/study/NCT01238133,https://clinicaltrials.gov/study/NCT01071564
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB3	NADH:ubiquinone oxidoreductase subunit B3	1	Completed	https://clinicaltrials.gov/study/NCT02278965
MONDO_0007254	breast cancer	CHEMBL1201568	PEGFILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	1	Completed	https://clinicaltrials.gov/study/NCT00645333,https://clinicaltrials.gov/study/NCT03376503
MONDO_0007254	breast cancer	CHEMBL655	MIDAZOLAM	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRG2	gamma-aminobutyric acid type A receptor subunit gamma2	1	Completed	https://clinicaltrials.gov/study/NCT03955939,https://clinicaltrials.gov/study/NCT01655225
MONDO_0007254	breast cancer	CHEMBL3647420	PYROTINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Recruiting	https://clinicaltrials.gov/study/NCT04152057
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Completed	https://clinicaltrials.gov/study/NCT01070706,https://clinicaltrials.gov/study/NCT00887575,https://clinicaltrials.gov/study/NCT00372424
MONDO_0007254	breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT05176080
EFO_0005537	triple-negative breast cancer	CHEMBL4650276	SHR3680	Small molecule	Androgen Receptor antagonist		AR	androgen receptor	1	Recruiting	https://clinicaltrials.gov/study/NCT03805399
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	1	Completed	https://clinicaltrials.gov/study/NCT02154776,https://clinicaltrials.gov/study/NCT01248494,https://clinicaltrials.gov/study/NCT02088684,https://clinicaltrials.gov/study/NCT01339442,https://clinicaltrials.gov/study/NCT01626209,https://clinicaltrials.gov/study/NCT02058381
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	1	Completed	https://clinicaltrials.gov/study/NCT01498458
EFO_0000305	breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Fibroblast growth factor receptor 1 inhibitor		FGFR1	fibroblast growth factor receptor 1	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL521851	PICTILISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R5	phosphoinositide-3-kinase regulatory subunit 5	1	Completed	https://clinicaltrials.gov/study/NCT00960960,https://clinicaltrials.gov/study/NCT00928330
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD4	DNA polymerase delta 4, accessory subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT04796220
EFO_0005537	triple-negative breast cancer	CHEMBL1789844	IPILIMUMAB	Antibody	Cytotoxic T-lymphocyte protein 4 inhibitor		CTLA4	cytotoxic T-lymphocyte associated protein 4	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02419495
EFO_0005537	triple-negative breast cancer	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC10	histone deacetylase 10	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02393794
EFO_0006861	male breast carcinoma	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT02060253,https://clinicaltrials.gov/study/NCT00004074,https://clinicaltrials.gov/study/NCT00258349,https://clinicaltrials.gov/study/NCT00331552
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS1	NADH:ubiquinone oxidoreductase core subunit S1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
EFO_0005537	triple-negative breast cancer	CHEMBL574737	UCN-01	Small molecule	Protein kinase C (PKC) inhibitor		PRKCI	protein kinase C iota	1	Completed	https://clinicaltrials.gov/study/NCT00031681
EFO_0006861	male breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RB	interleukin 2 receptor subunit beta	1	Completed	https://clinicaltrials.gov/study/NCT00301730,https://clinicaltrials.gov/study/NCT00027807,https://clinicaltrials.gov/study/NCT00019916
MONDO_0007254	breast cancer	CHEMBL521851	PICTILISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	1	Unknown status	https://clinicaltrials.gov/study/NCT02389842
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Recruiting	https://clinicaltrials.gov/study/NCT03805399,https://clinicaltrials.gov/study/NCT05673200,https://clinicaltrials.gov/study/NCT05918133
MONDO_0007254	breast cancer	CHEMBL1496	ROSUVASTATIN	Small molecule	HMG-CoA reductase inhibitor		HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase	1	Withdrawn	https://clinicaltrials.gov/study/NCT02483871
MONDO_0007254	breast cancer	CHEMBL3218578	BGT-226	Small molecule	PI3-kinase class I inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	1	Completed	https://clinicaltrials.gov/study/NCT00600275
MONDO_0007254	breast cancer	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		PSEN1	presenilin 1	1	Terminated	https://clinicaltrials.gov/study/NCT01208441
MONDO_0007254	breast cancer	CHEMBL574737	UCN-01	Small molecule	Protein kinase C (PKC) inhibitor		PRKCA	protein kinase C alpha	1	Completed	https://clinicaltrials.gov/study/NCT00001444
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
MONDO_0007254	breast cancer	CHEMBL1642	IMATINIB MESYLATE	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT00080665
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	1	Completed	https://clinicaltrials.gov/study/NCT03243331,https://clinicaltrials.gov/study/NCT02684032
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Completed	https://clinicaltrials.gov/study/NCT01263145,https://clinicaltrials.gov/study/NCT02632071
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Recruiting	https://clinicaltrials.gov/study/NCT05092373
EFO_0000304	breast adenocarcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC2	histone deacetylase 2	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
MONDO_0007254	breast cancer	CHEMBL101253	VATALANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Completed	https://clinicaltrials.gov/study/NCT00268918
MONDO_0007254	breast cancer	CHEMBL4297615	PARSACLISIB	Small molecule	PI3-kinase p110-delta subunit inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	1	Completed	https://clinicaltrials.gov/study/NCT02646748
MONDO_0007254	breast cancer	CHEMBL2103879	GANETESPIB	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AA1	heat shock protein 90 alpha family class A member 1	1	Completed	https://clinicaltrials.gov/study/NCT02060253
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Recruiting	https://clinicaltrials.gov/study/NCT05307705,https://clinicaltrials.gov/study/NCT04152057,https://clinicaltrials.gov/study/NCT03994107,https://clinicaltrials.gov/study/NCT04205903
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Withdrawn	https://clinicaltrials.gov/study/NCT02070094
MONDO_0007254	breast cancer	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	1	Completed	https://clinicaltrials.gov/study/NCT02599363,https://clinicaltrials.gov/study/NCT01857193,https://clinicaltrials.gov/study/NCT02732119,https://clinicaltrials.gov/study/NCT02154776,https://clinicaltrials.gov/study/NCT02754011,https://clinicaltrials.gov/study/NCT02657343,https://clinicaltrials.gov/study/NCT02088684,https://clinicaltrials.gov/study/NCT02333370,https://clinicaltrials.gov/study/NCT02586675
MONDO_0007254	breast cancer	CHEMBL1042	CHOLECALCIFEROL	Small molecule	Vitamin D receptor agonist		VDR	vitamin D receptor	1	Withdrawn	https://clinicaltrials.gov/study/NCT02856503
MONDO_0007254	breast cancer	CHEMBL598797	CUDC-101	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	1	Completed	https://clinicaltrials.gov/study/NCT01171924
MONDO_0007254	breast cancer	CHEMBL522892	DOVITINIB	Small molecule	Fibroblast growth factor receptor 3 inhibitor		FGFR3	fibroblast growth factor receptor 3	1	Completed	https://clinicaltrials.gov/study/NCT01421004
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT04213898
MONDO_0007254	breast cancer	CHEMBL4297556	MM-111	Unknown	ErbB-2/ErbB-3 heterodimer inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT00911898
MONDO_0007254	breast cancer	CHEMBL14762	SELICICLIB	Small molecule	Cyclin-dependent kinase 7 inhibitor		CDK7	cyclin dependent kinase 7	1	Withdrawn	https://clinicaltrials.gov/study/NCT01333423
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	1	Withdrawn	https://clinicaltrials.gov/study/NCT02070094
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	1	Terminated	https://clinicaltrials.gov/study/NCT01823835
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBB4B	tubulin beta 4B class IVb	1	Completed	https://clinicaltrials.gov/study/NCT00270907
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC4	histone deacetylase 4	1	Completed	https://clinicaltrials.gov/study/NCT00788931,https://clinicaltrials.gov/study/NCT01105312,https://clinicaltrials.gov/study/NCT00632489
EFO_0000305	breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD4	DNA polymerase delta 4, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT00100750
EFO_0000305	breast carcinoma	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	1	Completed	https://clinicaltrials.gov/study/NCT02227082
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Completed	https://clinicaltrials.gov/study/NCT02632071,https://clinicaltrials.gov/study/NCT01263145
EFO_0000304	breast adenocarcinoma	CHEMBL2108738	NIVOLUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
EFO_0000304	breast adenocarcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC3	histone deacetylase 3	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
EFO_0000304	breast adenocarcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Completed	https://clinicaltrials.gov/study/NCT01513083,https://clinicaltrials.gov/study/NCT02038010,https://clinicaltrials.gov/study/NCT00875979,https://clinicaltrials.gov/study/NCT02073916,https://clinicaltrials.gov/study/NCT02236000,https://clinicaltrials.gov/study/NCT01983501,https://clinicaltrials.gov/study/NCT02605915,https://clinicaltrials.gov/study/NCT00934856,https://clinicaltrials.gov/study/NCT00951665,https://clinicaltrials.gov/study/NCT02657343
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Terminated	https://clinicaltrials.gov/study/NCT01876251,https://clinicaltrials.gov/study/NCT02345772,https://clinicaltrials.gov/study/NCT00253318,https://clinicaltrials.gov/study/NCT00584012,https://clinicaltrials.gov/study/NCT00063934,https://clinicaltrials.gov/study/NCT00531271,https://clinicaltrials.gov/study/NCT00864175,https://clinicaltrials.gov/study/NCT02379585
EFO_0006861	male breast carcinoma	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 7 inhibitor		CDK7	cyclin dependent kinase 7	1	Terminated	https://clinicaltrials.gov/study/NCT00039455
MONDO_0007254	breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	1	Withdrawn	https://clinicaltrials.gov/study/NCT04316169,https://clinicaltrials.gov/study/NCT03846583
MONDO_0007254	breast cancer	CHEMBL3813873	PEXIDARTINIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	1	Completed	https://clinicaltrials.gov/study/NCT01596751
MONDO_0007254	breast cancer	CHEMBL384467	DEXAMETHASONE	Small molecule	Glucocorticoid receptor agonist		NR3C1	nuclear receptor subfamily 3 group C member 1	1	Terminated	https://clinicaltrials.gov/study/NCT00253318
EFO_0006861	male breast carcinoma	CHEMBL3264610	SEVITERONEL	Small molecule	Cytochrome P450 17A1 inhibitor		CYP17A1	cytochrome P450 family 17 subfamily A member 1	1	Completed	https://clinicaltrials.gov/study/NCT02580448
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Terminated	https://clinicaltrials.gov/study/NCT00903006
EFO_1000984	inflammatory breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Unknown status	https://clinicaltrials.gov/study/NCT01880385
EFO_0000305	breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD2	DNA polymerase delta 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT00100750
EFO_0000305	breast carcinoma	CHEMBL288441	BOSUTINIB	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03854903
MONDO_0007254	breast cancer	CHEMBL1094636	NIRAPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	1	Withdrawn	https://clinicaltrials.gov/study/NCT04655183,https://clinicaltrials.gov/study/NCT04762901
MONDO_0007254	breast cancer	CHEMBL1642	IMATINIB MESYLATE	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT00080665
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
MONDO_0007254	breast cancer	CHEMBL1201199	LEUPROLIDE	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	1	Terminated	https://clinicaltrials.gov/study/NCT02990845,https://clinicaltrials.gov/study/NCT01823835
MONDO_0007254	breast cancer	CHEMBL598797	CUDC-101	Small molecule	Histone deacetylase inhibitor		HDAC10	histone deacetylase 10	1	Completed	https://clinicaltrials.gov/study/NCT01171924
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Withdrawn	https://clinicaltrials.gov/study/NCT04252768,https://clinicaltrials.gov/study/NCT04826016,https://clinicaltrials.gov/study/NCT03175666,https://clinicaltrials.gov/study/NCT02569489,https://clinicaltrials.gov/study/NCT04762901,https://clinicaltrials.gov/study/NCT00022230,https://clinicaltrials.gov/study/NCT03285607
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA6	NADH:ubiquinone oxidoreductase subunit A6	1	Completed	https://clinicaltrials.gov/study/NCT02278965
MONDO_0007254	breast cancer	CHEMBL3545366	VOXTALISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	1	Completed	https://clinicaltrials.gov/study/NCT01390818,https://clinicaltrials.gov/study/NCT01082068
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00600496
MONDO_0007254	breast cancer	CHEMBL3586404	ONATASERTIB	Small molecule	Serine/threonine-protein kinase mTOR inhibitor		MTOR	mechanistic target of rapamycin kinase	1	Completed	https://clinicaltrials.gov/study/NCT01177397
MONDO_0007254	breast cancer	CHEMBL1201619	APROTININ	Unknown	Plasminogen inhibitor		PLG	plasminogen	1	Terminated	https://clinicaltrials.gov/study/NCT00354900
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Withdrawn	https://clinicaltrials.gov/study/NCT04826016
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Terminated	https://clinicaltrials.gov/study/NCT03579472
EFO_0000305	breast carcinoma	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN10A	sodium voltage-gated channel alpha subunit 10	1	Completed	https://clinicaltrials.gov/study/NCT03502395
EFO_0005537	triple-negative breast cancer	CHEMBL574737	UCN-01	Small molecule	Protein kinase C (PKC) inhibitor		PRKCA	protein kinase C alpha	1	Completed	https://clinicaltrials.gov/study/NCT00031681
EFO_0000305	breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Withdrawn	https://clinicaltrials.gov/study/NCT04252768,https://clinicaltrials.gov/study/NCT04826016,https://clinicaltrials.gov/study/NCT03285607,https://clinicaltrials.gov/study/NCT04762901,https://clinicaltrials.gov/study/NCT00022230,https://clinicaltrials.gov/study/NCT02569489,https://clinicaltrials.gov/study/NCT03175666
EFO_0006861	male breast carcinoma	CHEMBL1201550	DENILEUKIN DIFTITOX	Protein	Interleukin-2 receptor binding agent		IL2RB	interleukin 2 receptor subunit beta	1	Completed	https://clinicaltrials.gov/study/NCT00425672
EFO_0006861	male breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL2108658	TREMELIMUMAB	Antibody	Cytotoxic T-lymphocyte protein 4 inhibitor		CTLA4	cytotoxic T-lymphocyte associated protein 4	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03132467
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Withdrawn	https://clinicaltrials.gov/study/NCT04826016
MONDO_0007254	breast cancer	CHEMBL3545154	POZIOTINIB	Small molecule	Epidermal growth factor receptor inhibitor		EGFR	epidermal growth factor receptor	1	Terminated	https://clinicaltrials.gov/study/NCT03429101
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB11	NADH:ubiquinone oxidoreductase subunit B11	1	Completed	https://clinicaltrials.gov/study/NCT01980823,https://clinicaltrials.gov/study/NCT01650506
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	1	Terminated	https://clinicaltrials.gov/study/NCT01407562,https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00049244
MONDO_0007254	breast cancer	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Fibroblast growth factor receptor 3 inhibitor		FGFR3	fibroblast growth factor receptor 3	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Terminated	https://clinicaltrials.gov/study/NCT01238133,https://clinicaltrials.gov/study/NCT02474173
MONDO_0007254	breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Vascular endothelial growth factor receptor 3 inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT05176080
MONDO_0007254	breast cancer	CHEMBL522892	DOVITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Terminated	https://clinicaltrials.gov/study/NCT01484041
MONDO_0007254	breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT05103826
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	Serine/threonine-protein kinase mTOR inhibitor		MTOR	mechanistic target of rapamycin kinase	1	Unknown status	https://clinicaltrials.gov/study/NCT02626507
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R5	phosphoinositide-3-kinase regulatory subunit 5	1	Withdrawn	https://clinicaltrials.gov/study/NCT03400254
MONDO_0007254	breast cancer	CHEMBL744	RILUZOLE	Small molecule	Sodium channel alpha subunit blocker		SCN5A	sodium voltage-gated channel alpha subunit 5	1	Withdrawn	https://clinicaltrials.gov/study/NCT00903214
EFO_0000304	breast adenocarcinoma	CHEMBL1738757	REBASTINIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
MONDO_0007254	breast cancer	CHEMBL3545096	BGT-226	Small molecule	PI3-kinase class I inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	1	Completed	https://clinicaltrials.gov/study/NCT00600275
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	1	Unknown status	https://clinicaltrials.gov/study/NCT02626507
MONDO_0007254	breast cancer	CHEMBL3707227	ATEZOLIZUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03289962
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Recruiting	https://clinicaltrials.gov/study/NCT04205903,https://clinicaltrials.gov/study/NCT05307705,https://clinicaltrials.gov/study/NCT03994107,https://clinicaltrials.gov/study/NCT04152057
EFO_0000304	breast adenocarcinoma	CHEMBL462018	TRICIRIBINE PHOSPHATE	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT2	AKT serine/threonine kinase 2	1	Terminated	https://clinicaltrials.gov/study/NCT01697293
EFO_0000304	breast adenocarcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD3	DNA polymerase delta 3, accessory subunit	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLA2	DNA polymerase alpha 2, accessory subunit	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03554044
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Recruiting	https://clinicaltrials.gov/study/NCT05092373
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBB3	tubulin beta 3 class III	1	Completed	https://clinicaltrials.gov/study/NCT00270907
EFO_0005537	triple-negative breast cancer	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	1	Withdrawn	https://clinicaltrials.gov/study/NCT05093387
MONDO_0007254	breast cancer	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 7 inhibitor		CDK7	cyclin dependent kinase 7	1	Terminated	https://clinicaltrials.gov/study/NCT00039455
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS2	NADH:ubiquinone oxidoreductase core subunit S2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02499146,https://clinicaltrials.gov/study/NCT03616587,https://clinicaltrials.gov/study/NCT03238196,https://clinicaltrials.gov/study/NCT03959891,https://clinicaltrials.gov/study/NCT03006172,https://clinicaltrials.gov/study/NCT03332797
MONDO_0007254	breast cancer	CHEMBL1567	SUNITINIB MALATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Unknown status	https://clinicaltrials.gov/study/NCT00931450
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT00452673,https://clinicaltrials.gov/study/NCT00924352,https://clinicaltrials.gov/study/NCT01306942,https://clinicaltrials.gov/study/NCT00820170
MONDO_0007254	breast cancer	CHEMBL481	IRINOTECAN	Small molecule	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT04728035
MONDO_0007254	breast cancer	CHEMBL572881	MOTESANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Withdrawn	https://clinicaltrials.gov/study/NCT01349088
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Completed	https://clinicaltrials.gov/study/NCT00748553,https://clinicaltrials.gov/study/NCT00803556,https://clinicaltrials.gov/study/NCT00724386,https://clinicaltrials.gov/study/NCT00574587,https://clinicaltrials.gov/study/NCT01031446,https://clinicaltrials.gov/study/NCT00068757,https://clinicaltrials.gov/study/NCT00887575,https://clinicaltrials.gov/study/NCT00426556,https://clinicaltrials.gov/study/NCT02599363,https://clinicaltrials.gov/study/NCT04261218,https://clinicaltrials.gov/study/NCT00445458,https://clinicaltrials.gov/study/NCT01862081,https://clinicaltrials.gov/study/NCT00001383,https://clinicaltrials.gov/study/NCT00006108,https://clinicaltrials.gov/study/NCT01306942,https://clinicaltrials.gov/study/NCT00788931,https://clinicaltrials.gov/study/NCT00368875,https://clinicaltrials.gov/study/NCT01003158,https://clinicaltrials.gov/study/NCT03166085,https://clinicaltrials.gov/study/NCT01320592,https://clinicaltrials.gov/study/NCT03411161,https://clinicaltrials.gov/study/NCT03112590,https://clinicaltrials.gov/study/NCT00322400,https://clinicaltrials.gov/study/NCT01070706,https://clinicaltrials.gov/study/NCT00900627,https://clinicaltrials.gov/study/NCT00951665,https://clinicaltrials.gov/study/NCT00107094,https://clinicaltrials.gov/study/NCT02628132,https://clinicaltrials.gov/study/NCT00003877,https://clinicaltrials.gov/study/NCT00691379,https://clinicaltrials.gov/study/NCT00009997,https://clinicaltrials.gov/study/NCT01423123,https://clinicaltrials.gov/study/NCT01133912,https://clinicaltrials.gov/study/NCT01042925,https://clinicaltrials.gov/study/NCT03800836,https://clinicaltrials.gov/study/NCT00807859,https://clinicaltrials.gov/study/NCT00004174,https://clinicaltrials.gov/study/NCT00983424,https://clinicaltrials.gov/study/NCT00820170,https://clinicaltrials.gov/study/NCT00031876,https://clinicaltrials.gov/study/NCT00717340,https://clinicaltrials.gov/study/NCT01918254,https://clinicaltrials.gov/study/NCT01254526,https://clinicaltrials.gov/study/NCT00003927,https://clinicaltrials.gov/study/NCT00050167,https://clinicaltrials.gov/study/NCT01493310,https://clinicaltrials.gov/study/NCT01484080,https://clinicaltrials.gov/study/NCT02073916,https://clinicaltrials.gov/study/NCT02060253,https://clinicaltrials.gov/study/NCT01625286,https://clinicaltrials.gov/study/NCT00442260,https://clinicaltrials.gov/study/NCT04132817,https://clinicaltrials.gov/study/NCT02041429,https://clinicaltrials.gov/study/NCT00960960,https://clinicaltrials.gov/study/NCT00680758,https://clinicaltrials.gov/study/NCT02001974,https://clinicaltrials.gov/study/NCT01973309,https://clinicaltrials.gov/study/NCT02379247,https://clinicaltrials.gov/study/NCT00054028,https://clinicaltrials.gov/study/NCT00707707,https://clinicaltrials.gov/study/NCT00637897,https://clinicaltrials.gov/study/NCT00002837,https://clinicaltrials.gov/study/NCT01172223,https://clinicaltrials.gov/study/NCT02015676,https://clinicaltrials.gov/study/NCT04247126,https://clinicaltrials.gov/study/NCT00301730,https://clinicaltrials.gov/study/NCT03505528
EFO_0005537	triple-negative breast cancer	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	1	Completed	https://clinicaltrials.gov/study/NCT04584112
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC1	NADH:ubiquinone oxidoreductase subunit C1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
EFO_0000305	breast carcinoma	CHEMBL4298024	BINTRAFUSP ALFA	Protein	Transforming growth factor beta binding agent		TGFB2	transforming growth factor beta 2	1	Completed	https://clinicaltrials.gov/study/NCT03524170
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
EFO_0000305	breast carcinoma	CHEMBL1201179	LAPATINIB DITOSYLATE	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	1	Completed	https://clinicaltrials.gov/study/NCT01434303
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02419495
MONDO_0007254	breast cancer	CHEMBL1079175	MK-2206	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT1	AKT serine/threonine kinase 1	1	Terminated	https://clinicaltrials.gov/study/NCT00963547
MONDO_0007254	breast cancer	CHEMBL2408045	SAPITINIB	Small molecule	Receptor tyrosine-protein kinase erbB-3 inhibitor		ERBB3	erb-b2 receptor tyrosine kinase 3	1	Completed	https://clinicaltrials.gov/study/NCT01003158,https://clinicaltrials.gov/study/NCT00900627
MONDO_0007254	breast cancer	CHEMBL655	MIDAZOLAM	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRG3	gamma-aminobutyric acid type A receptor subunit gamma3	1	Completed	https://clinicaltrials.gov/study/NCT01655225,https://clinicaltrials.gov/study/NCT03955939
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC3	histone deacetylase 3	1	Completed	https://clinicaltrials.gov/study/NCT02820961,https://clinicaltrials.gov/study/NCT01594398,https://clinicaltrials.gov/study/NCT02833155,https://clinicaltrials.gov/study/NCT03473639
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Completed	https://clinicaltrials.gov/study/NCT00001944,https://clinicaltrials.gov/study/NCT00513058,https://clinicaltrials.gov/study/NCT00724386,https://clinicaltrials.gov/study/NCT00014430,https://clinicaltrials.gov/study/NCT00153907,https://clinicaltrials.gov/study/NCT00706030,https://clinicaltrials.gov/study/NCT00706069,https://clinicaltrials.gov/study/NCT00828074,https://clinicaltrials.gov/study/NCT00003902,https://clinicaltrials.gov/study/NCT00912275
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLA1	DNA polymerase alpha 1, catalytic subunit	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04750382
MONDO_0007254	breast cancer	CHEMBL121	ROSIGLITAZONE	Small molecule	Peroxisome proliferator-activated receptor gamma agonist		PPARG	peroxisome proliferator activated receptor gamma	1	Completed	https://clinicaltrials.gov/study/NCT00933309
MONDO_0007254	breast cancer	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RB	interleukin 2 receptor subunit beta	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05989828
MONDO_0007254	breast cancer	CHEMBL522892	DOVITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Completed	https://clinicaltrials.gov/study/NCT01421004
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT04856371
MONDO_0007254	breast cancer	CHEMBL3581693	BRILANESTRANT	Small molecule	Estrogen receptor alpha antagonist		ESR1	estrogen receptor 1	1	Completed	https://clinicaltrials.gov/study/NCT02621957
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	1	Completed	https://clinicaltrials.gov/study/NCT01976169,https://clinicaltrials.gov/study/NCT03471663,https://clinicaltrials.gov/study/NCT02871791,https://clinicaltrials.gov/study/NCT02448771,https://clinicaltrials.gov/study/NCT04483505,https://clinicaltrials.gov/study/NCT03455270,https://clinicaltrials.gov/study/NCT04818632,https://clinicaltrials.gov/study/NCT03560531,https://clinicaltrials.gov/study/NCT02599714,https://clinicaltrials.gov/study/NCT02684032
MONDO_0007254	breast cancer	CHEMBL1922094	APITOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	1	Completed	https://clinicaltrials.gov/study/NCT01254526
MONDO_0007254	breast cancer	CHEMBL4279455	LAROTAXEL	Small molecule	Tubulin stabiliser		TUBB2B	tubulin beta 2B class IIb	1	Completed	https://clinicaltrials.gov/study/NCT00327743
EFO_0000186	invasive breast ductal carcinoma	CHEMBL1536	ERGOCALCIFEROL	Small molecule	Vitamin D receptor agonist		VDR	vitamin D receptor	1	Terminated	https://clinicaltrials.gov/study/NCT01816555
EFO_0000304	breast adenocarcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	PRIM1	DNA primase subunit 1	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD1	DNA polymerase delta 1, catalytic subunit	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03554044
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02419495
MONDO_0007254	breast cancer	CHEMBL598797	CUDC-101	Small molecule	Histone deacetylase inhibitor		HDAC6	histone deacetylase 6	1	Completed	https://clinicaltrials.gov/study/NCT01171924
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR1	estrogen receptor 1	1	Recruiting	https://clinicaltrials.gov/study/NCT05216432,https://clinicaltrials.gov/study/NCT05870579,https://clinicaltrials.gov/study/NCT05504213,https://clinicaltrials.gov/study/NCT05307705
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03032107,https://clinicaltrials.gov/study/NCT02390427
MONDO_0007254	breast cancer	CHEMBL3707227	ATEZOLIZUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	1	Completed	https://clinicaltrials.gov/study/NCT03800836,https://clinicaltrials.gov/study/NCT02605915
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Withdrawn	https://clinicaltrials.gov/study/NCT01349088
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase RAF inhibitor		RAF1	Raf-1 proto-oncogene, serine/threonine kinase	1	Unknown status	https://clinicaltrials.gov/study/NCT00764972
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Completed	https://clinicaltrials.gov/study/NCT00153907,https://clinicaltrials.gov/study/NCT00003902,https://clinicaltrials.gov/study/NCT00014430,https://clinicaltrials.gov/study/NCT00828074
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05251766
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLA1	DNA polymerase alpha 1, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT01154426
EFO_0000305	breast carcinoma	CHEMBL1738757	REBASTINIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Terminated	https://clinicaltrials.gov/study/NCT02474173,https://clinicaltrials.gov/study/NCT01238133
EFO_0006861	male breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Completed	https://clinicaltrials.gov/study/NCT01084057
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD2	DNA polymerase delta 2, accessory subunit	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04750382
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB2	NADH:ubiquinone oxidoreductase subunit B2	1	Completed	https://clinicaltrials.gov/study/NCT01650506,https://clinicaltrials.gov/study/NCT01980823
EFO_0006861	male breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Terminated	https://clinicaltrials.gov/study/NCT00063934
MONDO_0007254	breast cancer	CHEMBL383824	ALVESPIMYCIN	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AB1	heat shock protein 90 alpha family class B member 1	1	Completed	https://clinicaltrials.gov/study/NCT00803556
EFO_0000304	breast adenocarcinoma	CHEMBL359744	DOXORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Terminated	https://clinicaltrials.gov/study/NCT01697293
MONDO_0007254	breast cancer	CHEMBL2108707	GLEMBATUMUMAB	Antibody	Transmembrane glycoprotein NMB binding agent		GPNMB	glycoprotein nmb	1	Completed	https://clinicaltrials.gov/study/NCT00704158
MONDO_0007254	breast cancer	CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist		IFNAR1	interferon alpha and beta receptor subunit 1	1	Completed	https://clinicaltrials.gov/study/NCT03599453
MONDO_0007254	breast cancer	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	1	Terminated	https://clinicaltrials.gov/study/NCT04504331,https://clinicaltrials.gov/study/NCT01194908,https://clinicaltrials.gov/study/NCT02936206
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC7	histone deacetylase 7	1	Terminated	https://clinicaltrials.gov/study/NCT00567879
MONDO_0007254	breast cancer	CHEMBL655	MIDAZOLAM	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRA2	gamma-aminobutyric acid type A receptor subunit alpha2	1	Completed	https://clinicaltrials.gov/study/NCT01655225,https://clinicaltrials.gov/study/NCT03955939
EFO_0000305	breast carcinoma	CHEMBL1064	SIMVASTATIN	Small molecule	HMG-CoA reductase inhibitor		HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase	1	Recruiting	https://clinicaltrials.gov/study/NCT05464810
MONDO_0007254	breast cancer	CHEMBL3833344	GANCOTAMAB	Antibody	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Unknown status	https://clinicaltrials.gov/study/NCT01304797
MONDO_0007254	breast cancer	CHEMBL1201334	TRIPTORELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	1	Recruiting	https://clinicaltrials.gov/study/NCT04616729
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA3	NADH:ubiquinone oxidoreductase subunit A3	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Terminated	https://clinicaltrials.gov/study/NCT02753595,https://clinicaltrials.gov/study/NCT03579472,https://clinicaltrials.gov/study/NCT01388647
MONDO_0007254	breast cancer	CHEMBL3545132	MIRVETUXIMAB SORAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBA1A	tubulin alpha 1a	1	Withdrawn	https://clinicaltrials.gov/study/NCT03045393
MONDO_0007254	breast cancer	CHEMBL575448	BMS-754807	Small molecule	Insulin receptor inhibitor		INSR	insulin receptor	1	Completed	https://clinicaltrials.gov/study/NCT00788333
MONDO_0007254	breast cancer	CHEMBL3544983	TESEVATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Terminated	https://clinicaltrials.gov/study/NCT02154529
EFO_0000304	breast adenocarcinoma	CHEMBL3218576	COPANLISIB	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
EFO_0000304	breast adenocarcinoma	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC9	histone deacetylase 9	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
MONDO_0007254	breast cancer	CHEMBL1770916	NIROGACESTAT	Small molecule	Gamma-secretase inhibitor		PSEN2	presenilin 2	1	Terminated	https://clinicaltrials.gov/study/NCT01876251
MONDO_0007254	breast cancer	CHEMBL521851	PICTILISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	1	Completed	https://clinicaltrials.gov/study/NCT00960960,https://clinicaltrials.gov/study/NCT00928330
MONDO_0007254	breast cancer	CHEMBL572881	MOTESANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Withdrawn	https://clinicaltrials.gov/study/NCT01349088
EFO_0006861	male breast carcinoma	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		PSEN1	presenilin 1	1	Terminated	https://clinicaltrials.gov/study/NCT01149356
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
MONDO_0007254	breast cancer	CHEMBL598797	CUDC-101	Small molecule	Histone deacetylase inhibitor		HDAC5	histone deacetylase 5	1	Completed	https://clinicaltrials.gov/study/NCT01171924
EFO_0005537	triple-negative breast cancer	CHEMBL4297190	SURUFATINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05746728
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Completed	https://clinicaltrials.gov/study/NCT00924352,https://clinicaltrials.gov/study/NCT00825734,https://clinicaltrials.gov/study/NCT01084057,https://clinicaltrials.gov/study/NCT00568022,https://clinicaltrials.gov/study/NCT00322374,https://clinicaltrials.gov/study/NCT00637897
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05274893,https://clinicaltrials.gov/study/NCT05251766,https://clinicaltrials.gov/study/NCT05019690
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Epidermal growth factor receptor inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT00496665
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Terminated	https://clinicaltrials.gov/study/NCT02753595,https://clinicaltrials.gov/study/NCT03579472
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Withdrawn	https://clinicaltrials.gov/study/NCT04826016
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Withdrawn	https://clinicaltrials.gov/study/NCT01349088
MONDO_0007254	breast cancer	CHEMBL3581647	BIRABRESIB	Small molecule	Bromodomain and extra-terminal motif (BET) inhibitor		BRD3	bromodomain containing 3	1	Completed	https://clinicaltrials.gov/study/NCT02259114
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Terminated	https://clinicaltrials.gov/study/NCT02345772,https://clinicaltrials.gov/study/NCT01876251,https://clinicaltrials.gov/study/NCT02379585,https://clinicaltrials.gov/study/NCT00063934,https://clinicaltrials.gov/study/NCT00864175,https://clinicaltrials.gov/study/NCT00584012,https://clinicaltrials.gov/study/NCT00253318,https://clinicaltrials.gov/study/NCT00531271
MONDO_0007254	breast cancer	CHEMBL96172	EPOTHILONE D	Small molecule	Tubulin stabiliser		TUBB3	tubulin beta 3 class III	1	Completed	https://clinicaltrials.gov/study/NCT00337649
MONDO_0007254	breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT05176080
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT00372424,https://clinicaltrials.gov/study/NCT00887575,https://clinicaltrials.gov/study/NCT01070706
EFO_0000304	breast adenocarcinoma	CHEMBL462018	TRICIRIBINE PHOSPHATE	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT1	AKT serine/threonine kinase 1	1	Terminated	https://clinicaltrials.gov/study/NCT01697293
EFO_0000304	breast adenocarcinoma	CHEMBL3989922	NIRAPARIB TOSYLATE MONOHYDRATE	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04481113
EFO_0005537	triple-negative breast cancer	CHEMBL3989514	IRINOTECAN HYDROCHLORIDE	Small molecule	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	1	Completed	https://clinicaltrials.gov/study/NCT00031681
EFO_0005537	triple-negative breast cancer	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	1	Recruiting	https://clinicaltrials.gov/study/NCT05673200
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00600496
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Unknown status	https://clinicaltrials.gov/study/NCT00009763,https://clinicaltrials.gov/study/NCT01084863,https://clinicaltrials.gov/study/NCT00002628,https://clinicaltrials.gov/study/NCT02396108,https://clinicaltrials.gov/study/NCT00915369,https://clinicaltrials.gov/study/NCT00002627,https://clinicaltrials.gov/study/NCT03282825
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT03364348
MONDO_0007254	breast cancer	CHEMBL49642	INDIBULIN	Small molecule	Tubulin inhibitor		TUBA1B	tubulin alpha 1b	1	Unknown status	https://clinicaltrials.gov/study/NCT01113970
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03893955,https://clinicaltrials.gov/study/NCT02390427,https://clinicaltrials.gov/study/NCT02999477,https://clinicaltrials.gov/study/NCT04331067,https://clinicaltrials.gov/study/NCT03716180,https://clinicaltrials.gov/study/NCT03858322,https://clinicaltrials.gov/study/NCT02608216,https://clinicaltrials.gov/study/NCT04556773
MONDO_0007254	breast cancer	CHEMBL185	FLUOROURACIL	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	1	Completed	https://clinicaltrials.gov/study/NCT00872625
EFO_0000304	breast adenocarcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD1	DNA polymerase delta 1, catalytic subunit	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
MONDO_0007254	breast cancer	CHEMBL1042	CHOLECALCIFEROL	Small molecule	Vitamin D receptor agonist		VDR	vitamin D receptor	1	Completed	https://clinicaltrials.gov/study/NCT01425476,https://clinicaltrials.gov/study/NCT00976339,https://clinicaltrials.gov/study/NCT01769625
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS6	NADH:ubiquinone oxidoreductase subunit S6	1	Completed	https://clinicaltrials.gov/study/NCT01650506,https://clinicaltrials.gov/study/NCT01980823
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT01407562,https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	1	Completed	https://clinicaltrials.gov/study/NCT00372424,https://clinicaltrials.gov/study/NCT01070706,https://clinicaltrials.gov/study/NCT00887575
EFO_0000305	breast carcinoma	CHEMBL314854	FINGOLIMOD	Small molecule	Sphingosine 1-phosphate receptor agonist		S1PR4	sphingosine-1-phosphate receptor 4	1	Completed	https://clinicaltrials.gov/study/NCT03941743
MONDO_0007254	breast cancer	CHEMBL325041	BORTEZOMIB	Small molecule	26S proteosome inhibitor		PSMB5	proteasome 20S subunit beta 5	1	Recruiting	https://clinicaltrials.gov/study/NCT04265872
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Terminated	https://clinicaltrials.gov/study/NCT00140140,https://clinicaltrials.gov/study/NCT02379585,https://clinicaltrials.gov/study/NCT01090128,https://clinicaltrials.gov/study/NCT02297230,https://clinicaltrials.gov/study/NCT00003086,https://clinicaltrials.gov/study/NCT01512199,https://clinicaltrials.gov/study/NCT01495247,https://clinicaltrials.gov/study/NCT00041470,https://clinicaltrials.gov/study/NCT01249443,https://clinicaltrials.gov/study/NCT02358200,https://clinicaltrials.gov/study/NCT01407562,https://clinicaltrials.gov/study/NCT01980277,https://clinicaltrials.gov/study/NCT01929941,https://clinicaltrials.gov/study/NCT02474173
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Tyrosine-protein kinase LCK inhibitor		LCK	LCK proto-oncogene, Src family tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT01407562,https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL252164	LUMINESPIB	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AA1	heat shock protein 90 alpha family class A member 1	1	Withdrawn	https://clinicaltrials.gov/study/NCT01361945
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Terminated	https://clinicaltrials.gov/study/NCT03579472,https://clinicaltrials.gov/study/NCT02753595
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Terminated	https://clinicaltrials.gov/study/NCT03429101,https://clinicaltrials.gov/study/NCT02658084,https://clinicaltrials.gov/study/NCT04042051,https://clinicaltrials.gov/study/NCT04296942,https://clinicaltrials.gov/study/NCT04298918
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Completed	https://clinicaltrials.gov/study/NCT00934856,https://clinicaltrials.gov/study/NCT00322400,https://clinicaltrials.gov/study/NCT02392845,https://clinicaltrials.gov/study/NCT02027376,https://clinicaltrials.gov/study/NCT00086957,https://clinicaltrials.gov/study/NCT00705315,https://clinicaltrials.gov/study/NCT00002901,https://clinicaltrials.gov/study/NCT00003103,https://clinicaltrials.gov/study/NCT00450892,https://clinicaltrials.gov/study/NCT00372424,https://clinicaltrials.gov/study/NCT05301530,https://clinicaltrials.gov/study/NCT00020332,https://clinicaltrials.gov/study/NCT00169000,https://clinicaltrials.gov/study/NCT00129896,https://clinicaltrials.gov/study/NCT00645333,https://clinicaltrials.gov/study/NCT00637897,https://clinicaltrials.gov/study/NCT01862081,https://clinicaltrials.gov/study/NCT00872625,https://clinicaltrials.gov/study/NCT04367090,https://clinicaltrials.gov/study/NCT01044485,https://clinicaltrials.gov/study/NCT02605915,https://clinicaltrials.gov/study/NCT01256567,https://clinicaltrials.gov/study/NCT00050167,https://clinicaltrials.gov/study/NCT00080665,https://clinicaltrials.gov/study/NCT00268918
MONDO_0007254	breast cancer	CHEMBL2103840	DINACICLIB	Small molecule	Cyclin-dependent kinase 9 inhibitor		CDK9	cyclin dependent kinase 9	1	Completed	https://clinicaltrials.gov/study/NCT01676753
MONDO_0007254	breast cancer	CHEMBL101253	VATALANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Terminated	https://clinicaltrials.gov/study/NCT00216047
EFO_0000305	breast carcinoma	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	1	Completed	https://clinicaltrials.gov/study/NCT02227082
EFO_0000305	breast carcinoma	CHEMBL554	LAPATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	1	Completed	https://clinicaltrials.gov/study/NCT01434303
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Withdrawn	https://clinicaltrials.gov/study/NCT02070094
MONDO_0007254	breast cancer	CHEMBL2109399	T-DM1	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 binding agent		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT01976169
MONDO_0007254	breast cancer	CHEMBL3360203	PILARALISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	1	Completed	https://clinicaltrials.gov/study/NCT01082068,https://clinicaltrials.gov/study/NCT01042925
MONDO_0007254	breast cancer	CHEMBL574737	UCN-01	Small molecule	Protein kinase C (PKC) inhibitor		PRKD1	protein kinase D1	1	Completed	https://clinicaltrials.gov/study/NCT00001444
EFO_0009780	HER2 negative breast carcinoma	CHEMBL513	CARMUSTINE	Small molecule	Glutathione reductase inhibitor		GSR	glutathione-disulfide reductase	1	Recruiting	https://clinicaltrials.gov/study/NCT04150042
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Completed	https://clinicaltrials.gov/study/NCT01983501,https://clinicaltrials.gov/study/NCT02605915,https://clinicaltrials.gov/study/NCT01513083,https://clinicaltrials.gov/study/NCT02236000,https://clinicaltrials.gov/study/NCT02038010,https://clinicaltrials.gov/study/NCT02657343,https://clinicaltrials.gov/study/NCT00951665,https://clinicaltrials.gov/study/NCT02073916,https://clinicaltrials.gov/study/NCT00875979,https://clinicaltrials.gov/study/NCT00934856
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Unknown status	https://clinicaltrials.gov/study/NCT00931450
MONDO_0007254	breast cancer	CHEMBL574737	UCN-01	Small molecule	Cyclin-dependent kinase 2 inhibitor		CDK2	cyclin dependent kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT00001444
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Withdrawn	https://clinicaltrials.gov/study/NCT01349088
MONDO_0007254	breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	1	Recruiting	https://clinicaltrials.gov/study/NCT06139107,https://clinicaltrials.gov/study/NCT05307705
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLA2	DNA polymerase alpha 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT00100750
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Vascular endothelial growth factor receptor 1 inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT00887575,https://clinicaltrials.gov/study/NCT00372424,https://clinicaltrials.gov/study/NCT01070706
EFO_0000304	breast adenocarcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLE3	DNA polymerase epsilon 3, accessory subunit	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00600496
EFO_0005537	triple-negative breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	1	Terminated	https://clinicaltrials.gov/study/NCT02457910
EFO_0000305	breast carcinoma	CHEMBL314854	FINGOLIMOD	Small molecule	Sphingosine 1-phosphate receptor agonist		S1PR3	sphingosine-1-phosphate receptor 3	1	Completed	https://clinicaltrials.gov/study/NCT03941743
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	PRIM1	DNA primase subunit 1	1	Completed	https://clinicaltrials.gov/study/NCT00100750
MONDO_0007254	breast cancer	CHEMBL1879463	DACTOLISIB	Small molecule	Serine/threonine-protein kinase mTOR inhibitor		MTOR	mechanistic target of rapamycin kinase	1	Terminated	https://clinicaltrials.gov/study/NCT01495247
MONDO_0007254	breast cancer	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	1	Completed	https://clinicaltrials.gov/study/NCT00526617,https://clinicaltrials.gov/study/NCT01477489
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Completed	https://clinicaltrials.gov/study/NCT02060253,https://clinicaltrials.gov/study/NCT01493310,https://clinicaltrials.gov/study/NCT01276496,https://clinicaltrials.gov/study/NCT01288261,https://clinicaltrials.gov/study/NCT00470301,https://clinicaltrials.gov/study/NCT00368875,https://clinicaltrials.gov/study/NCT01281150
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC2	histone deacetylase 2	1	Completed	https://clinicaltrials.gov/study/NCT00788931,https://clinicaltrials.gov/study/NCT00632489,https://clinicaltrials.gov/study/NCT01105312
EFO_0006861	male breast carcinoma	CHEMBL1200501	GOSERELIN ACETATE	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	1	Terminated	https://clinicaltrials.gov/study/NCT01149356
MONDO_0007254	breast cancer	CHEMBL744	RILUZOLE	Small molecule	Sodium channel alpha subunit blocker		SCN11A	sodium voltage-gated channel alpha subunit 11	1	Withdrawn	https://clinicaltrials.gov/study/NCT00903214
EFO_0006861	male breast carcinoma	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		APH1B	aph-1 homolog B, gamma-secretase subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01149356
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Completed	https://clinicaltrials.gov/study/NCT00535119
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	PRIM1	DNA primase subunit 1	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05989828
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	1	Completed	https://clinicaltrials.gov/study/NCT01339442,https://clinicaltrials.gov/study/NCT02058381,https://clinicaltrials.gov/study/NCT02154776,https://clinicaltrials.gov/study/NCT01626209,https://clinicaltrials.gov/study/NCT01248494,https://clinicaltrials.gov/study/NCT02088684
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Recruiting	https://clinicaltrials.gov/study/NCT03994107,https://clinicaltrials.gov/study/NCT04152057,https://clinicaltrials.gov/study/NCT05307705,https://clinicaltrials.gov/study/NCT04205903
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	1	Unknown status	https://clinicaltrials.gov/study/NCT02389842
MONDO_0007254	breast cancer	CHEMBL522892	DOVITINIB	Small molecule	Fibroblast growth factor receptor 3 inhibitor		FGFR3	fibroblast growth factor receptor 3	1	Terminated	https://clinicaltrials.gov/study/NCT01484041
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00600496
MONDO_0007254	breast cancer	CHEMBL4297556	MM-111	Unknown	ErbB-2/ErbB-3 heterodimer inhibitor		ERBB3	erb-b2 receptor tyrosine kinase 3	1	Completed	https://clinicaltrials.gov/study/NCT00911898
MONDO_0007254	breast cancer	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RA	interleukin 2 receptor subunit alpha	1	Unknown status	https://clinicaltrials.gov/study/NCT00002780,https://clinicaltrials.gov/study/NCT00002616
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB9	NADH:ubiquinone oxidoreductase subunit B9	1	Completed	https://clinicaltrials.gov/study/NCT01980823,https://clinicaltrials.gov/study/NCT01650506
EFO_0005537	triple-negative breast cancer	CHEMBL481	IRINOTECAN	Small molecule	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	1	Completed	https://clinicaltrials.gov/study/NCT00031681
EFO_0005537	triple-negative breast cancer	CHEMBL574737	UCN-01	Small molecule	Protein kinase C (PKC) inhibitor		PRKCB	protein kinase C beta	1	Completed	https://clinicaltrials.gov/study/NCT00031681
EFO_0005537	triple-negative breast cancer	CHEMBL1023	BEXAROTENE	Small molecule	Retinoid X receptor agonist		RXRA	retinoid X receptor alpha	1	Recruiting	https://clinicaltrials.gov/study/NCT04664829
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	1	Terminated	https://clinicaltrials.gov/study/NCT00616122,https://clinicaltrials.gov/study/NCT02074878,https://clinicaltrials.gov/study/NCT00905021
MONDO_0007254	breast cancer	CHEMBL572881	MOTESANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT00322400
MONDO_0007254	breast cancer	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	1	Terminated	https://clinicaltrials.gov/study/NCT04691375,https://clinicaltrials.gov/study/NCT03237572,https://clinicaltrials.gov/study/NCT04682431,https://clinicaltrials.gov/study/NCT02990845,https://clinicaltrials.gov/study/NCT03982004
MONDO_0007254	breast cancer	CHEMBL3545366	VOXTALISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R5	phosphoinositide-3-kinase regulatory subunit 5	1	Completed	https://clinicaltrials.gov/study/NCT01082068,https://clinicaltrials.gov/study/NCT01390818
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Completed	https://clinicaltrials.gov/study/NCT00934856,https://clinicaltrials.gov/study/NCT00951665,https://clinicaltrials.gov/study/NCT02038010,https://clinicaltrials.gov/study/NCT02657343,https://clinicaltrials.gov/study/NCT02236000,https://clinicaltrials.gov/study/NCT01983501,https://clinicaltrials.gov/study/NCT00875979,https://clinicaltrials.gov/study/NCT02605915,https://clinicaltrials.gov/study/NCT02073916,https://clinicaltrials.gov/study/NCT01513083
MONDO_0007254	breast cancer	CHEMBL4802129	BALIXAFORTIDE	Protein	C-X-C chemokine receptor type 4 antagonist		CXCR4	C-X-C motif chemokine receptor 4	1	Withdrawn	https://clinicaltrials.gov/study/NCT04826016
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
MONDO_0007254	breast cancer	CHEMBL502835	NINTEDANIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR1	fibroblast growth factor receptor 1	1	Completed	https://clinicaltrials.gov/study/NCT02619162
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA8	NADH:ubiquinone oxidoreductase subunit A8	1	Completed	https://clinicaltrials.gov/study/NCT01650506,https://clinicaltrials.gov/study/NCT01980823
EFO_0006861	male breast carcinoma	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 1 inhibitor		CDK1	cyclin dependent kinase 1	1	Terminated	https://clinicaltrials.gov/study/NCT00039455
MONDO_0007254	breast cancer	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 2 inhibitor		CDK2	cyclin dependent kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT00003690,https://clinicaltrials.gov/study/NCT00020332
MONDO_0007254	breast cancer	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 2 inhibitor		HDAC2	histone deacetylase 2	1	Unknown status	https://clinicaltrials.gov/study/NCT00416130
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Completed	https://clinicaltrials.gov/study/NCT02632071,https://clinicaltrials.gov/study/NCT01263145
MONDO_0007254	breast cancer	CHEMBL1922094	APITOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R5	phosphoinositide-3-kinase regulatory subunit 5	1	Completed	https://clinicaltrials.gov/study/NCT01254526
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Unknown status	https://clinicaltrials.gov/study/NCT00764972
EFO_0006861	male breast carcinoma	CHEMBL429876	CILENGITIDE	Protein	Integrin alpha-V/beta-5 antagonist		ITGAV	integrin subunit alpha V	1	Completed	https://clinicaltrials.gov/study/NCT01276496
MONDO_0007254	breast cancer	CHEMBL1201834	CANAKINUMAB	Antibody	Interleukin-1 beta inhibitor		IL1B	interleukin 1 beta	1	Terminated	https://clinicaltrials.gov/study/NCT03742349
MONDO_0007254	breast cancer	CHEMBL1496	ROSUVASTATIN	Small molecule	HMG-CoA reductase inhibitor		HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase	1	Terminated	https://clinicaltrials.gov/study/NCT01051401
EFO_0006318	breast ductal adenocarcinoma	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	1	Completed	https://clinicaltrials.gov/study/NCT03455270
MONDO_0007254	breast cancer	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	1	Completed	https://clinicaltrials.gov/study/NCT00526617,https://clinicaltrials.gov/study/NCT01477489
EFO_0006861	male breast carcinoma	CHEMBL1743001	CIXUTUMUMAB	Antibody	Insulin-like growth factor I receptor antagonist		IGF1R	insulin like growth factor 1 receptor	1	Completed	https://clinicaltrials.gov/study/NCT00699491
MONDO_0007254	breast cancer	CHEMBL1743006	DALOTUZUMAB	Antibody	Insulin-like growth factor I receptor antagonist		IGF1R	insulin like growth factor 1 receptor	1	Terminated	https://clinicaltrials.gov/study/NCT00903006
MONDO_0007254	breast cancer	CHEMBL1789941	RUXOLITINIB	Small molecule	Tyrosine-protein kinase JAK2 inhibitor		JAK2	Janus kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT02041429
MONDO_0007254	breast cancer	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	1	Completed	https://clinicaltrials.gov/study/NCT01367626,https://clinicaltrials.gov/study/NCT02154776,https://clinicaltrials.gov/study/NCT01367652,https://clinicaltrials.gov/study/NCT02684032,https://clinicaltrials.gov/study/NCT03308201,https://clinicaltrials.gov/study/NCT01655225,https://clinicaltrials.gov/study/NCT01870505,https://clinicaltrials.gov/study/NCT00290745,https://clinicaltrials.gov/study/NCT00960960,https://clinicaltrials.gov/study/NCT01105312,https://clinicaltrials.gov/study/NCT01791985,https://clinicaltrials.gov/study/NCT01248494,https://clinicaltrials.gov/study/NCT01082068,https://clinicaltrials.gov/study/NCT02538484,https://clinicaltrials.gov/study/NCT02619162,https://clinicaltrials.gov/study/NCT02333370
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC4	histone deacetylase 4	1	Terminated	https://clinicaltrials.gov/study/NCT03361800,https://clinicaltrials.gov/study/NCT04296942,https://clinicaltrials.gov/study/NCT00754312
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLE3	DNA polymerase epsilon 3, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT01154426
MONDO_0007254	breast cancer	CHEMBL1743062	RAMUCIRUMAB	Antibody	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02791334
MONDO_0007254	breast cancer	CHEMBL4802152	SENAPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	1	Completed	https://clinicaltrials.gov/study/NCT03507543
MONDO_0007254	breast cancer	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Withdrawn	https://clinicaltrials.gov/study/NCT02336984
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLE	DNA polymerase epsilon, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT04247126,https://clinicaltrials.gov/study/NCT02479230,https://clinicaltrials.gov/study/NCT02139358,https://clinicaltrials.gov/study/NCT00270907,https://clinicaltrials.gov/study/NCT01133912,https://clinicaltrials.gov/study/NCT00100750,https://clinicaltrials.gov/study/NCT01070706
MONDO_0007254	breast cancer	CHEMBL191413	REPARIXIN	Small molecule	Interleukin-8 receptor A modulator		CXCR1	C-X-C motif chemokine receptor 1	1	Completed	https://clinicaltrials.gov/study/NCT02001974
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03725436,https://clinicaltrials.gov/study/NCT03554044
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Withdrawn	https://clinicaltrials.gov/study/NCT00074139
EFO_0000305	breast carcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC8	histone deacetylase 8	1	Completed	https://clinicaltrials.gov/study/NCT01434303
EFO_0000304	breast adenocarcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02419495
MONDO_0007254	breast cancer	CHEMBL1567	SUNITINIB MALATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Terminated	https://clinicaltrials.gov/study/NCT00905021,https://clinicaltrials.gov/study/NCT00616122
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Withdrawn	https://clinicaltrials.gov/study/NCT01349088
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	PRIM2	DNA primase subunit 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04750382
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT00828074,https://clinicaltrials.gov/study/NCT01640665,https://clinicaltrials.gov/study/NCT00825734,https://clinicaltrials.gov/study/NCT00217399
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS8	NADH:ubiquinone oxidoreductase core subunit S8	1	Completed	https://clinicaltrials.gov/study/NCT02278965
EFO_0000305	breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLE	DNA polymerase epsilon, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT00100750
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC2	histone deacetylase 2	1	Terminated	https://clinicaltrials.gov/study/NCT00567879
EFO_0000305	breast carcinoma	CHEMBL2103868	CABOZANTINIB S-MALATE	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	1	Recruiting	https://clinicaltrials.gov/study/NCT05092373
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Completed	https://clinicaltrials.gov/study/NCT00368875,https://clinicaltrials.gov/study/NCT00470301,https://clinicaltrials.gov/study/NCT02060253,https://clinicaltrials.gov/study/NCT01288261,https://clinicaltrials.gov/study/NCT01493310,https://clinicaltrials.gov/study/NCT01281150,https://clinicaltrials.gov/study/NCT01276496
EFO_0000305	breast carcinoma	CHEMBL3644587	2X-121	Small molecule	Tankyrase 1/2 inhibitor		TNKS2	tankyrase 2	1	Withdrawn	https://clinicaltrials.gov/study/NCT02396433
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Recruiting	https://clinicaltrials.gov/study/NCT04120246
MONDO_0007254	breast cancer	CHEMBL1201247	GOSERELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	1	Recruiting	https://clinicaltrials.gov/study/NCT05870579
MONDO_0007254	breast cancer	CHEMBL553	ERLOTINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00600496
EFO_0000305	breast carcinoma	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03554044
EFO_0005537	triple-negative breast cancer	CHEMBL574737	UCN-01	Small molecule	Protein kinase C (PKC) inhibitor		PRKCG	protein kinase C gamma	1	Completed	https://clinicaltrials.gov/study/NCT00031681
EFO_0000305	breast carcinoma	CHEMBL1201179	LAPATINIB DITOSYLATE	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	1	Terminated	https://clinicaltrials.gov/study/NCT01281163
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Recruiting	https://clinicaltrials.gov/study/NCT05092373
EFO_0000305	breast carcinoma	CHEMBL544665	FINGOLIMOD HYDROCHLORIDE	Small molecule	Sphingosine 1-phosphate receptor agonist		S1PR3	sphingosine-1-phosphate receptor 3	1	Completed	https://clinicaltrials.gov/study/NCT03941743
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBB1	tubulin beta 1 class VI	1	Completed	https://clinicaltrials.gov/study/NCT00270907
EFO_0005537	triple-negative breast cancer	CHEMBL1908360	EVEROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	1	Completed	https://clinicaltrials.gov/study/NCT02120469
MONDO_0007254	breast cancer	CHEMBL3647420	PYROTINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT04367090,https://clinicaltrials.gov/study/NCT02361112,https://clinicaltrials.gov/study/NCT05252546,https://clinicaltrials.gov/study/NCT01937689
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00049244
MONDO_0007254	breast cancer	CHEMBL1201670	SARGRAMOSTIM	Protein	Granulocyte-macrophage colony-stimulating factor receptor agonist		CSF2RA	colony stimulating factor 2 receptor subunit alpha	1	Completed	https://clinicaltrials.gov/study/NCT00003002,https://clinicaltrials.gov/study/NCT01355393,https://clinicaltrials.gov/study/NCT00027807,https://clinicaltrials.gov/study/NCT00003184,https://clinicaltrials.gov/study/NCT00088413,https://clinicaltrials.gov/study/NCT00791037,https://clinicaltrials.gov/study/NCT00005023,https://clinicaltrials.gov/study/NCT00079157
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	1	Withdrawn	https://clinicaltrials.gov/study/NCT03400254
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Completed	https://clinicaltrials.gov/study/NCT00322374,https://clinicaltrials.gov/study/NCT00568022,https://clinicaltrials.gov/study/NCT00825734,https://clinicaltrials.gov/study/NCT01084057,https://clinicaltrials.gov/study/NCT00637897,https://clinicaltrials.gov/study/NCT00924352
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FYN	FYN proto-oncogene, Src family tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT00903006
EFO_0005537	triple-negative breast cancer	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC6	histone deacetylase 6	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02393794
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Completed	https://clinicaltrials.gov/study/NCT03364348
MONDO_0007254	breast cancer	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	1	Completed	https://clinicaltrials.gov/study/NCT02154776,https://clinicaltrials.gov/study/NCT02088684,https://clinicaltrials.gov/study/NCT02586675,https://clinicaltrials.gov/study/NCT02732119,https://clinicaltrials.gov/study/NCT01857193,https://clinicaltrials.gov/study/NCT02599363,https://clinicaltrials.gov/study/NCT02657343,https://clinicaltrials.gov/study/NCT02333370,https://clinicaltrials.gov/study/NCT02754011
EFO_0005537	triple-negative breast cancer	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		APH1A	aph-1 homolog A, gamma-secretase subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01071564,https://clinicaltrials.gov/study/NCT01238133
MONDO_0007254	breast cancer	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RA	interleukin 2 receptor subunit alpha	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05989828
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	1	Completed	https://clinicaltrials.gov/study/NCT02684032,https://clinicaltrials.gov/study/NCT03243331
EFO_0005537	triple-negative breast cancer	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	1	Completed	https://clinicaltrials.gov/study/NCT03012230
MONDO_0007254	breast cancer	CHEMBL3545262	SACITUZUMAB GOVITECAN	Antibody drug conjugate	Tumor-associated calcium signal transducer 2 binding agent		TACSTD2	tumor associated calcium signal transducer 2	1	Recruiting	https://clinicaltrials.gov/study/NCT05143229
MONDO_0007254	breast cancer	CHEMBL101253	VATALANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Completed	https://clinicaltrials.gov/study/NCT00268918
MONDO_0007254	breast cancer	CHEMBL44657	ETOPOSIDE	Small molecule	DNA topoisomerase II inhibitor		TOP2A	DNA topoisomerase II alpha	1	Completed	https://clinicaltrials.gov/study/NCT00002509
MONDO_0007254	breast cancer	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02390427,https://clinicaltrials.gov/study/NCT00393783,https://clinicaltrials.gov/study/NCT03767335,https://clinicaltrials.gov/study/NCT03716180,https://clinicaltrials.gov/study/NCT04509596,https://clinicaltrials.gov/study/NCT03006172
MONDO_0007254	breast cancer	CHEMBL1201670	SARGRAMOSTIM	Protein	Granulocyte-macrophage colony-stimulating factor receptor agonist		CSF2RA	colony stimulating factor 2 receptor subunit alpha	1	Terminated	https://clinicaltrials.gov/study/NCT03982004
MONDO_0007254	breast cancer	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	1	Completed	https://clinicaltrials.gov/study/NCT04079517,https://clinicaltrials.gov/study/NCT00424164,https://clinicaltrials.gov/study/NCT00009997,https://clinicaltrials.gov/study/NCT00005822,https://clinicaltrials.gov/study/NCT02586675,https://clinicaltrials.gov/study/NCT02285179,https://clinicaltrials.gov/study/NCT02333370,https://clinicaltrials.gov/study/NCT00290745,https://clinicaltrials.gov/study/NCT00005886,https://clinicaltrials.gov/study/NCT01192308
EFO_0000304	breast adenocarcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC6	histone deacetylase 6	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02453620
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Tyrosine-protein kinase BRK inhibitor		PTK6	protein tyrosine kinase 6	1	Completed	https://clinicaltrials.gov/study/NCT00496665
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Terminated	https://clinicaltrials.gov/study/NCT02474173,https://clinicaltrials.gov/study/NCT01238133
MONDO_0007254	breast cancer	CHEMBL255863	NILOTINIB	Small molecule	Tyrosine-protein kinase ABL inhibitor		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	1	Recruiting	https://clinicaltrials.gov/study/NCT04205903
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00600496
EFO_1000984	inflammatory breast carcinoma	CHEMBL1201583	BEVACIZUMAB	Antibody	Vascular endothelial growth factor A inhibitor		VEGFA	vascular endothelial growth factor A	1	Unknown status	https://clinicaltrials.gov/study/NCT01880385
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		LCK	LCK proto-oncogene, Src family tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT00903006
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA10	NADH:ubiquinone oxidoreductase subunit A10	1	Completed	https://clinicaltrials.gov/study/NCT01980823,https://clinicaltrials.gov/study/NCT01650506
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R2	phosphoinositide-3-kinase regulatory subunit 2	1	Completed	https://clinicaltrials.gov/study/NCT02088684,https://clinicaltrials.gov/study/NCT01248494,https://clinicaltrials.gov/study/NCT01626209,https://clinicaltrials.gov/study/NCT02058381,https://clinicaltrials.gov/study/NCT02154776,https://clinicaltrials.gov/study/NCT01339442
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA11	NADH:ubiquinone oxidoreductase subunit A11	1	Completed	https://clinicaltrials.gov/study/NCT02278965
MONDO_0007254	breast cancer	CHEMBL1879463	DACTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	1	Completed	https://clinicaltrials.gov/study/NCT01248494
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Completed	https://clinicaltrials.gov/study/NCT00003902,https://clinicaltrials.gov/study/NCT00153907,https://clinicaltrials.gov/study/NCT00014430,https://clinicaltrials.gov/study/NCT00828074
MONDO_0007254	breast cancer	CHEMBL554	LAPATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Terminated	https://clinicaltrials.gov/study/NCT01199367,https://clinicaltrials.gov/study/NCT00963547,https://clinicaltrials.gov/study/NCT01238029,https://clinicaltrials.gov/study/NCT00634088,https://clinicaltrials.gov/study/NCT02131506,https://clinicaltrials.gov/study/NCT01495884,https://clinicaltrials.gov/study/NCT01658358
MONDO_0007254	breast cancer	CHEMBL1094636	NIRAPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	1	Withdrawn	https://clinicaltrials.gov/study/NCT04762901,https://clinicaltrials.gov/study/NCT04655183
MONDO_0007254	breast cancer	CHEMBL3545132	MIRVETUXIMAB SORAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBA3E	tubulin alpha 3e	1	Withdrawn	https://clinicaltrials.gov/study/NCT03045393
MONDO_0007254	breast cancer	CHEMBL2109637	HUHMFG1	Antibody	Mucin-1 other		MUC1	mucin 1, cell surface associated	1	Unknown status	https://clinicaltrials.gov/study/NCT00066547
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Completed	https://clinicaltrials.gov/study/NCT02120469
EFO_0005537	triple-negative breast cancer	CHEMBL225072	PEMETREXED	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02419495
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC5	histone deacetylase 5	1	Completed	https://clinicaltrials.gov/study/NCT02833155,https://clinicaltrials.gov/study/NCT03473639,https://clinicaltrials.gov/study/NCT02820961,https://clinicaltrials.gov/study/NCT01594398
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND3	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3	1	Completed	https://clinicaltrials.gov/study/NCT02278965
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Withdrawn	https://clinicaltrials.gov/study/NCT04826016
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05274893,https://clinicaltrials.gov/study/NCT05019690,https://clinicaltrials.gov/study/NCT05251766
MONDO_0007254	breast cancer	CHEMBL4650387	CDX-301	Protein	Tyrosine-protein kinase receptor FLT3 agonist		FLT3	fms related receptor tyrosine kinase 3	1	Recruiting	https://clinicaltrials.gov/study/NCT05029999
EFO_0000432	breast ductal carcinoma in situ	CHEMBL3349607	PASIREOTIDE	Protein	Somatostatin receptor 5 agonist		SSTR5	somatostatin receptor 5	1	Terminated	https://clinicaltrials.gov/study/NCT01372618
MONDO_0007254	breast cancer	CHEMBL1184904	RETASPIMYCIN	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AB1	heat shock protein 90 alpha family class B member 1	1	Withdrawn	https://clinicaltrials.gov/study/NCT00627627
MONDO_0007254	breast cancer	CHEMBL3545225	INCB-047986	Small molecule	Tyrosine-protein kinase JAK1 inhibitor		JAK1	Janus kinase 1	1	Terminated	https://clinicaltrials.gov/study/NCT01929941
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Completed	https://clinicaltrials.gov/study/NCT00828074,https://clinicaltrials.gov/study/NCT00153907,https://clinicaltrials.gov/study/NCT00003902,https://clinicaltrials.gov/study/NCT00014430
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00600496
EFO_0005537	triple-negative breast cancer	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06324240
EFO_0000305	breast carcinoma	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN1A	sodium voltage-gated channel alpha subunit 1	1	Completed	https://clinicaltrials.gov/study/NCT03502395
MONDO_0007254	breast cancer	CHEMBL1186894	AMRUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Completed	https://clinicaltrials.gov/study/NCT01033032
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Completed	https://clinicaltrials.gov/study/NCT01306942,https://clinicaltrials.gov/study/NCT00924352,https://clinicaltrials.gov/study/NCT00452673,https://clinicaltrials.gov/study/NCT00820170
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Completed	https://clinicaltrials.gov/study/NCT01432886,https://clinicaltrials.gov/study/NCT01323530
EFO_0006861	male breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Fibroblast growth factor receptor 3 inhibitor		FGFR3	fibroblast growth factor receptor 3	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL2177390	IPATASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT2	AKT serine/threonine kinase 2	1	Recruiting	https://clinicaltrials.gov/study/NCT04253561
MONDO_0007254	breast cancer	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	1	Recruiting	https://clinicaltrials.gov/study/NCT04433494
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02390427,https://clinicaltrials.gov/study/NCT03032107
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Withdrawn	https://clinicaltrials.gov/study/NCT02070094
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB10	NADH:ubiquinone oxidoreductase subunit B10	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
EFO_0000305	breast carcinoma	CHEMBL288441	BOSUTINIB	Small molecule	Tyrosine-protein kinase HCK inhibitor		HCK	HCK proto-oncogene, Src family tyrosine kinase	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03854903
MONDO_0007254	breast cancer	CHEMBL5283463	KW-2450	Small molecule	Insulin-like growth factor I receptor inhibitor		IGF1R	insulin like growth factor 1 receptor	1	Terminated	https://clinicaltrials.gov/study/NCT01199367
MONDO_0007254	breast cancer	CHEMBL96172	EPOTHILONE D	Small molecule	Tubulin stabiliser		TUBB6	tubulin beta 6 class V	1	Completed	https://clinicaltrials.gov/study/NCT00337649
EFO_0005537	triple-negative breast cancer	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC7	histone deacetylase 7	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02393794
EFO_0006861	male breast carcinoma	CHEMBL2103840	DINACICLIB	Small molecule	Cyclin-dependent kinase 2 inhibitor		CDK2	cyclin dependent kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT01624441
EFO_0006861	male breast carcinoma	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	1	Terminated	https://clinicaltrials.gov/study/NCT00039455
MONDO_0007254	breast cancer	CHEMBL1879463	DACTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	1	Completed	https://clinicaltrials.gov/study/NCT01248494
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03716180,https://clinicaltrials.gov/study/NCT02390427,https://clinicaltrials.gov/study/NCT04331067,https://clinicaltrials.gov/study/NCT03858322,https://clinicaltrials.gov/study/NCT02608216,https://clinicaltrials.gov/study/NCT02999477,https://clinicaltrials.gov/study/NCT04556773,https://clinicaltrials.gov/study/NCT03893955
MONDO_0007254	breast cancer	CHEMBL1201558	INTERFERON ALFA-2B	Protein	Interferon alpha/beta receptor agonist		IFNAR2	interferon alpha and beta receptor subunit 2	1	Completed	https://clinicaltrials.gov/study/NCT03599453
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Terminated	https://clinicaltrials.gov/study/NCT00905021,https://clinicaltrials.gov/study/NCT02074878,https://clinicaltrials.gov/study/NCT00616122
MONDO_0007254	breast cancer	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 3A inhibitor		DNMT3A	DNA methyltransferase 3 alpha	1	Terminated	https://clinicaltrials.gov/study/NCT01194908
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		HCK	HCK proto-oncogene, Src family tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT00903006
EFO_0000304	breast adenocarcinoma	CHEMBL4298024	BINTRAFUSP ALFA	Protein	Transforming growth factor beta binding agent		TGFB3	transforming growth factor beta 3	1	Withdrawn	https://clinicaltrials.gov/study/NCT04756505
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Terminated	https://clinicaltrials.gov/study/NCT03579472
EFO_0000304	breast adenocarcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC1	histone deacetylase 1	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
MONDO_0007254	breast cancer	CHEMBL1751	DIGOXIN	Small molecule	Sodium/potassium-transporting ATPase inhibitor		ATP1A1	ATPase Na+/K+ transporting subunit alpha 1	1	Completed	https://clinicaltrials.gov/study/NCT03928210
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC3	histone deacetylase 3	1	Terminated	https://clinicaltrials.gov/study/NCT00567879
MONDO_0007254	breast cancer	CHEMBL1144	PRAVASTATIN	Small molecule	HMG-CoA reductase inhibitor		HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase	1	Completed	https://clinicaltrials.gov/study/NCT02621957
EFO_0000305	breast carcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC1	histone deacetylase 1	1	Completed	https://clinicaltrials.gov/study/NCT01434303
MONDO_0004658	breast carcinoma in situ	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Completed	https://clinicaltrials.gov/study/NCT04081389
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Completed	https://clinicaltrials.gov/study/NCT00535119
MONDO_0007254	breast cancer	CHEMBL2107832	PIMASERTIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 1 inhibitor		MAP2K1	mitogen-activated protein kinase kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT01390818
MONDO_0007254	breast cancer	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		PSENEN	presenilin enhancer, gamma-secretase subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01208441
MONDO_0007254	breast cancer	CHEMBL572881	MOTESANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Completed	https://clinicaltrials.gov/study/NCT00322400
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Completed	https://clinicaltrials.gov/study/NCT01498458
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB2	NADH:ubiquinone oxidoreductase subunit B2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
EFO_0000304	breast adenocarcinoma	CHEMBL888	GEMCITABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor	Inhibitor	RRM1	ribonucleotide reductase catalytic subunit M1	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
EFO_0006861	male breast carcinoma	CHEMBL359744	DOXORUBICIN HYDROCHLORIDE	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Completed	https://clinicaltrials.gov/study/NCT00331552
MONDO_0007254	breast cancer	CHEMBL1399	ANASTROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	1	Completed	https://clinicaltrials.gov/study/NCT01597193,https://clinicaltrials.gov/study/NCT01216176,https://clinicaltrials.gov/study/NCT00588003,https://clinicaltrials.gov/study/NCT01791985,https://clinicaltrials.gov/study/NCT00217399
EFO_0005537	triple-negative breast cancer	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC8	histone deacetylase 8	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02393794
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT03364348
MONDO_0007254	breast cancer	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	1	Terminated	https://clinicaltrials.gov/study/NCT02734615
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC11	histone deacetylase 11	1	Terminated	https://clinicaltrials.gov/study/NCT00754312,https://clinicaltrials.gov/study/NCT04296942,https://clinicaltrials.gov/study/NCT03361800
EFO_0000432	breast ductal carcinoma in situ	CHEMBL3349607	PASIREOTIDE	Protein	Somatostatin receptor 2 agonist		SSTR2	somatostatin receptor 2	1	Terminated	https://clinicaltrials.gov/study/NCT01372618
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Recruiting	https://clinicaltrials.gov/study/NCT05673200,https://clinicaltrials.gov/study/NCT05918133,https://clinicaltrials.gov/study/NCT03805399
EFO_0000305	breast carcinoma	CHEMBL544665	FINGOLIMOD HYDROCHLORIDE	Small molecule	Sphingosine 1-phosphate receptor agonist		S1PR2	sphingosine-1-phosphate receptor 2	1	Completed	https://clinicaltrials.gov/study/NCT03941743
MONDO_0007254	breast cancer	CHEMBL1201247	GOSERELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	1	Unknown status	https://clinicaltrials.gov/study/NCT02626507
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R2	phosphoinositide-3-kinase regulatory subunit 2	1	Unknown status	https://clinicaltrials.gov/study/NCT02626507
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR2	estrogen receptor 2	1	Completed	https://clinicaltrials.gov/study/NCT00328120,https://clinicaltrials.gov/study/NCT01655225,https://clinicaltrials.gov/study/NCT01202591,https://clinicaltrials.gov/study/NCT01597193,https://clinicaltrials.gov/study/NCT01339442,https://clinicaltrials.gov/study/NCT06074757,https://clinicaltrials.gov/study/NCT02088684,https://clinicaltrials.gov/study/NCT02260661,https://clinicaltrials.gov/study/NCT04483505,https://clinicaltrials.gov/study/NCT02333370,https://clinicaltrials.gov/study/NCT02599714,https://clinicaltrials.gov/study/NCT03344536,https://clinicaltrials.gov/study/NCT02657343,https://clinicaltrials.gov/study/NCT04247126,https://clinicaltrials.gov/study/NCT03308201,https://clinicaltrials.gov/study/NCT01219699,https://clinicaltrials.gov/study/NCT02684032
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Withdrawn	https://clinicaltrials.gov/study/NCT04826016
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Completed	https://clinicaltrials.gov/study/NCT00050167,https://clinicaltrials.gov/study/NCT02015676,https://clinicaltrials.gov/study/NCT00368875,https://clinicaltrials.gov/study/NCT00006108,https://clinicaltrials.gov/study/NCT00983424,https://clinicaltrials.gov/study/NCT01031446,https://clinicaltrials.gov/study/NCT04132817,https://clinicaltrials.gov/study/NCT00001383,https://clinicaltrials.gov/study/NCT00031876,https://clinicaltrials.gov/study/NCT00807859,https://clinicaltrials.gov/study/NCT00637897,https://clinicaltrials.gov/study/NCT00003877,https://clinicaltrials.gov/study/NCT00445458,https://clinicaltrials.gov/study/NCT01862081,https://clinicaltrials.gov/study/NCT02060253,https://clinicaltrials.gov/study/NCT01973309,https://clinicaltrials.gov/study/NCT00724386,https://clinicaltrials.gov/study/NCT00322400,https://clinicaltrials.gov/study/NCT00054028,https://clinicaltrials.gov/study/NCT01625286,https://clinicaltrials.gov/study/NCT00426556,https://clinicaltrials.gov/study/NCT00003927,https://clinicaltrials.gov/study/NCT03411161,https://clinicaltrials.gov/study/NCT00717340,https://clinicaltrials.gov/study/NCT01254526,https://clinicaltrials.gov/study/NCT01133912,https://clinicaltrials.gov/study/NCT00301730,https://clinicaltrials.gov/study/NCT00691379,https://clinicaltrials.gov/study/NCT02599363,https://clinicaltrials.gov/study/NCT00803556,https://clinicaltrials.gov/study/NCT01306942,https://clinicaltrials.gov/study/NCT02628132,https://clinicaltrials.gov/study/NCT00680758,https://clinicaltrials.gov/study/NCT01423123,https://clinicaltrials.gov/study/NCT00960960,https://clinicaltrials.gov/study/NCT01172223,https://clinicaltrials.gov/study/NCT01070706,https://clinicaltrials.gov/study/NCT01003158,https://clinicaltrials.gov/study/NCT01918254,https://clinicaltrials.gov/study/NCT03800836,https://clinicaltrials.gov/study/NCT02379247,https://clinicaltrials.gov/study/NCT01484080,https://clinicaltrials.gov/study/NCT00009997,https://clinicaltrials.gov/study/NCT01320592,https://clinicaltrials.gov/study/NCT04247126,https://clinicaltrials.gov/study/NCT00900627,https://clinicaltrials.gov/study/NCT03112590,https://clinicaltrials.gov/study/NCT00004174,https://clinicaltrials.gov/study/NCT00951665,https://clinicaltrials.gov/study/NCT03505528,https://clinicaltrials.gov/study/NCT00107094,https://clinicaltrials.gov/study/NCT03166085,https://clinicaltrials.gov/study/NCT04261218,https://clinicaltrials.gov/study/NCT02073916,https://clinicaltrials.gov/study/NCT01493310,https://clinicaltrials.gov/study/NCT00002837,https://clinicaltrials.gov/study/NCT00887575,https://clinicaltrials.gov/study/NCT02001974,https://clinicaltrials.gov/study/NCT00068757,https://clinicaltrials.gov/study/NCT00820170,https://clinicaltrials.gov/study/NCT01042925,https://clinicaltrials.gov/study/NCT02041429,https://clinicaltrials.gov/study/NCT00707707,https://clinicaltrials.gov/study/NCT00442260,https://clinicaltrials.gov/study/NCT00748553,https://clinicaltrials.gov/study/NCT00788931,https://clinicaltrials.gov/study/NCT00574587
MONDO_0007254	breast cancer	CHEMBL572881	MOTESANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Completed	https://clinicaltrials.gov/study/NCT00322400
EFO_0006861	male breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Terminated	https://clinicaltrials.gov/study/NCT00063934
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA1	EPH receptor A1	1	Completed	https://clinicaltrials.gov/study/NCT00496665
MONDO_0007254	breast cancer	CHEMBL101253	VATALANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Terminated	https://clinicaltrials.gov/study/NCT00216047
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA6	NADH:ubiquinone oxidoreductase subunit A6	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Terminated	https://clinicaltrials.gov/study/NCT02824575,https://clinicaltrials.gov/study/NCT01697293
MONDO_0007254	breast cancer	CHEMBL1908360	EVEROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT05501769,https://clinicaltrials.gov/study/NCT03616587
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	1	Completed	https://clinicaltrials.gov/study/NCT01237067,https://clinicaltrials.gov/study/NCT00707707
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Terminated	https://clinicaltrials.gov/study/NCT00140140,https://clinicaltrials.gov/study/NCT00041470,https://clinicaltrials.gov/study/NCT00075673,https://clinicaltrials.gov/study/NCT01238029,https://clinicaltrials.gov/study/NCT01254136,https://clinicaltrials.gov/study/NCT02658084
MONDO_0007254	breast cancer	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02390427,https://clinicaltrials.gov/study/NCT03716180,https://clinicaltrials.gov/study/NCT05738993,https://clinicaltrials.gov/study/NCT03006172
EFO_0006861	male breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
EFO_0006861	male breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Tyrosine-protein kinase LCK inhibitor		LCK	LCK proto-oncogene, Src family tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Withdrawn	https://clinicaltrials.gov/study/NCT00074139
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02419495
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Recruiting	https://clinicaltrials.gov/study/NCT05673200,https://clinicaltrials.gov/study/NCT03805399,https://clinicaltrials.gov/study/NCT05918133
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03685331
MONDO_0007254	breast cancer	CHEMBL3545366	VOXTALISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	1	Completed	https://clinicaltrials.gov/study/NCT01082068,https://clinicaltrials.gov/study/NCT01390818
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLE3	DNA polymerase epsilon 3, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT00100750
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4	1	Completed	https://clinicaltrials.gov/study/NCT02278965
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	1	Terminated	https://clinicaltrials.gov/study/NCT00903006
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHB4	EPH receptor B4	1	Completed	https://clinicaltrials.gov/study/NCT00496665
MONDO_0007254	breast cancer	CHEMBL502835	NINTEDANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Completed	https://clinicaltrials.gov/study/NCT02619162
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND2	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2	1	Completed	https://clinicaltrials.gov/study/NCT02278965
EFO_0000305	breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Recruiting	https://clinicaltrials.gov/study/NCT03805399,https://clinicaltrials.gov/study/NCT05673200,https://clinicaltrials.gov/study/NCT05918133
EFO_0000304	breast adenocarcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLE3	DNA polymerase epsilon 3, accessory subunit	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
EFO_0005537	triple-negative breast cancer	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		NCSTN	nicastrin	1	Terminated	https://clinicaltrials.gov/study/NCT01238133,https://clinicaltrials.gov/study/NCT01071564
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	1	Completed	https://clinicaltrials.gov/study/NCT03243331,https://clinicaltrials.gov/study/NCT02684032
EFO_0006861	male breast carcinoma	CHEMBL2103879	GANETESPIB	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AB1	heat shock protein 90 alpha family class B member 1	1	Completed	https://clinicaltrials.gov/study/NCT02060253
EFO_0000432	breast ductal carcinoma in situ	CHEMBL3349607	PASIREOTIDE	Protein	Somatostatin receptor 3 agonist		SSTR3	somatostatin receptor 3	1	Terminated	https://clinicaltrials.gov/study/NCT01372618
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR1	estrogen receptor 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03685331
MONDO_0007254	breast cancer	CHEMBL1094636	NIRAPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	1	Recruiting	https://clinicaltrials.gov/study/NCT03945721
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Recruiting	https://clinicaltrials.gov/study/NCT04205903,https://clinicaltrials.gov/study/NCT04152057,https://clinicaltrials.gov/study/NCT03994107,https://clinicaltrials.gov/study/NCT05307705
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase RAF inhibitor		RAF1	Raf-1 proto-oncogene, serine/threonine kinase	1	Completed	https://clinicaltrials.gov/study/NCT01640665,https://clinicaltrials.gov/study/NCT00828074,https://clinicaltrials.gov/study/NCT00825734,https://clinicaltrials.gov/study/NCT00217399
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase B-raf inhibitor		BRAF	B-Raf proto-oncogene, serine/threonine kinase	1	Completed	https://clinicaltrials.gov/study/NCT00828074,https://clinicaltrials.gov/study/NCT00217399,https://clinicaltrials.gov/study/NCT01640665,https://clinicaltrials.gov/study/NCT00825734
MONDO_0007254	breast cancer	CHEMBL1743006	DALOTUZUMAB	Antibody	Insulin-like growth factor I receptor antagonist		IGF1R	insulin like growth factor 1 receptor	1	Completed	https://clinicaltrials.gov/study/NCT01220570,https://clinicaltrials.gov/study/NCT00759785
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Epidermal growth factor receptor inhibitor		ERBB3	erb-b2 receptor tyrosine kinase 3	1	Completed	https://clinicaltrials.gov/study/NCT00496665
MONDO_0007254	breast cancer	CHEMBL3264610	SEVITERONEL	Small molecule	Cytochrome P450 17A1 inhibitor		CYP17A1	cytochrome P450 family 17 subfamily A member 1	1	Completed	https://clinicaltrials.gov/study/NCT02580448
EFO_0000305	breast carcinoma	CHEMBL4298024	BINTRAFUSP ALFA	Protein	Programmed cell death 1 ligand 1 binding agent		CD274	CD274 molecule	1	Completed	https://clinicaltrials.gov/study/NCT03524170
EFO_0006861	male breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
EFO_0006861	male breast carcinoma	CHEMBL1201568	PEGFILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	1	Terminated	https://clinicaltrials.gov/study/NCT00063934
EFO_0006861	male breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Completed	https://clinicaltrials.gov/study/NCT01084057
EFO_1000984	inflammatory breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Unknown status	https://clinicaltrials.gov/study/NCT01880385
MONDO_0007254	breast cancer	CHEMBL1201199	LEUPROLIDE	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03332797
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD4	DNA polymerase delta 4, accessory subunit	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05989828
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Terminated	https://clinicaltrials.gov/study/NCT00450879,https://clinicaltrials.gov/study/NCT01407562
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA6	NADH:ubiquinone oxidoreductase subunit A6	1	Completed	https://clinicaltrials.gov/study/NCT01980823,https://clinicaltrials.gov/study/NCT01650506
MONDO_0007254	breast cancer	CHEMBL554	LAPATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT00424164,https://clinicaltrials.gov/study/NCT02073916,https://clinicaltrials.gov/study/NCT01300962,https://clinicaltrials.gov/study/NCT01044485,https://clinicaltrials.gov/study/NCT02650752,https://clinicaltrials.gov/study/NCT00952692,https://clinicaltrials.gov/study/NCT00753207,https://clinicaltrials.gov/study/NCT01471847,https://clinicaltrials.gov/study/NCT00085020,https://clinicaltrials.gov/study/NCT00632489,https://clinicaltrials.gov/study/NCT00450892,https://clinicaltrials.gov/study/NCT00912275,https://clinicaltrials.gov/study/NCT01172223,https://clinicaltrials.gov/study/NCT01133912,https://clinicaltrials.gov/study/NCT00513058,https://clinicaltrials.gov/study/NCT00544804,https://clinicaltrials.gov/study/NCT00807859,https://clinicaltrials.gov/study/NCT00316875,https://clinicaltrials.gov/study/NCT00379509
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Completed	https://clinicaltrials.gov/study/NCT02120469
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Completed	https://clinicaltrials.gov/study/NCT00934856,https://clinicaltrials.gov/study/NCT02073916,https://clinicaltrials.gov/study/NCT00951665,https://clinicaltrials.gov/study/NCT02605915,https://clinicaltrials.gov/study/NCT02038010,https://clinicaltrials.gov/study/NCT02657343,https://clinicaltrials.gov/study/NCT01513083,https://clinicaltrials.gov/study/NCT02236000,https://clinicaltrials.gov/study/NCT00875979,https://clinicaltrials.gov/study/NCT01983501
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Terminated	https://clinicaltrials.gov/study/NCT01238133,https://clinicaltrials.gov/study/NCT02474173
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Terminated	https://clinicaltrials.gov/study/NCT00075673,https://clinicaltrials.gov/study/NCT00041470,https://clinicaltrials.gov/study/NCT00140140,https://clinicaltrials.gov/study/NCT02658084,https://clinicaltrials.gov/study/NCT01238029,https://clinicaltrials.gov/study/NCT01254136
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Completed	https://clinicaltrials.gov/study/NCT00637897,https://clinicaltrials.gov/study/NCT01044485,https://clinicaltrials.gov/study/NCT00080665,https://clinicaltrials.gov/study/NCT02027376,https://clinicaltrials.gov/study/NCT00645333,https://clinicaltrials.gov/study/NCT00002901,https://clinicaltrials.gov/study/NCT05301530,https://clinicaltrials.gov/study/NCT00872625,https://clinicaltrials.gov/study/NCT00003103,https://clinicaltrials.gov/study/NCT00129896,https://clinicaltrials.gov/study/NCT02605915,https://clinicaltrials.gov/study/NCT04367090,https://clinicaltrials.gov/study/NCT00934856,https://clinicaltrials.gov/study/NCT00020332,https://clinicaltrials.gov/study/NCT02392845,https://clinicaltrials.gov/study/NCT00050167,https://clinicaltrials.gov/study/NCT00086957,https://clinicaltrials.gov/study/NCT00322400,https://clinicaltrials.gov/study/NCT00268918,https://clinicaltrials.gov/study/NCT01862081,https://clinicaltrials.gov/study/NCT00705315,https://clinicaltrials.gov/study/NCT01256567,https://clinicaltrials.gov/study/NCT00450892,https://clinicaltrials.gov/study/NCT00372424,https://clinicaltrials.gov/study/NCT00169000
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT04213898
EFO_0005537	triple-negative breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	1	Completed	https://clinicaltrials.gov/study/NCT03544125
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Completed	https://clinicaltrials.gov/study/NCT01795586,https://clinicaltrials.gov/study/NCT01323530,https://clinicaltrials.gov/study/NCT02723877,https://clinicaltrials.gov/study/NCT01432886,https://clinicaltrials.gov/study/NCT01596751
EFO_0005537	triple-negative breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Completed	https://clinicaltrials.gov/study/NCT01513083,https://clinicaltrials.gov/study/NCT02657343,https://clinicaltrials.gov/study/NCT02236000,https://clinicaltrials.gov/study/NCT00951665,https://clinicaltrials.gov/study/NCT01983501,https://clinicaltrials.gov/study/NCT00934856,https://clinicaltrials.gov/study/NCT02073916,https://clinicaltrials.gov/study/NCT00875979,https://clinicaltrials.gov/study/NCT02038010,https://clinicaltrials.gov/study/NCT02605915
EFO_1000100	Atypical Lobular Breast Hyperplasia	CHEMBL1023	BEXAROTENE	Small molecule	Retinoid X receptor agonist		RXRA	retinoid X receptor alpha	1	Completed	https://clinicaltrials.gov/study/NCT03323658
EFO_0006861	male breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Terminated	https://clinicaltrials.gov/study/NCT00063934
EFO_0000305	breast carcinoma	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03955640
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Completed	https://clinicaltrials.gov/study/NCT01070706,https://clinicaltrials.gov/study/NCT00372424,https://clinicaltrials.gov/study/NCT00887575
EFO_0000305	breast carcinoma	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03554044
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD1	DNA polymerase delta 1, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT04247126,https://clinicaltrials.gov/study/NCT02139358,https://clinicaltrials.gov/study/NCT01070706,https://clinicaltrials.gov/study/NCT00100750,https://clinicaltrials.gov/study/NCT01133912,https://clinicaltrials.gov/study/NCT02479230,https://clinicaltrials.gov/study/NCT00270907
EFO_0005537	triple-negative breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
EFO_0006861	male breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Terminated	https://clinicaltrials.gov/study/NCT00063934
MONDO_0007254	breast cancer	CHEMBL1852688	INFIGRATINIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR4	fibroblast growth factor receptor 4	1	Terminated	https://clinicaltrials.gov/study/NCT04504331
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02499146,https://clinicaltrials.gov/study/NCT03616587,https://clinicaltrials.gov/study/NCT03332797,https://clinicaltrials.gov/study/NCT03959891,https://clinicaltrials.gov/study/NCT03238196,https://clinicaltrials.gov/study/NCT03006172
EFO_0000305	breast carcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC11	histone deacetylase 11	1	Completed	https://clinicaltrials.gov/study/NCT01434303
EFO_0000304	breast adenocarcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD1	DNA polymerase delta 1, catalytic subunit	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
MONDO_0007254	breast cancer	CHEMBL3545132	MIRVETUXIMAB SORAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Withdrawn	https://clinicaltrials.gov/study/NCT03045393
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND6	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
MONDO_0007254	breast cancer	CHEMBL252164	LUMINESPIB	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AB1	heat shock protein 90 alpha family class B member 1	1	Completed	https://clinicaltrials.gov/study/NCT01271920
MONDO_0007254	breast cancer	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 1 inhibitor		HDAC1	histone deacetylase 1	1	Completed	https://clinicaltrials.gov/study/NCT00574587,https://clinicaltrials.gov/study/NCT00719875,https://clinicaltrials.gov/study/NCT00258349,https://clinicaltrials.gov/study/NCT00368875,https://clinicaltrials.gov/study/NCT01084057,https://clinicaltrials.gov/study/NCT00788112
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	1	Unknown status	https://clinicaltrials.gov/study/NCT02626507
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLA2	DNA polymerase alpha 2, accessory subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT04796220
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS5	NADH:ubiquinone oxidoreductase subunit S5	1	Completed	https://clinicaltrials.gov/study/NCT02278965
EFO_0000305	breast carcinoma	CHEMBL4298024	BINTRAFUSP ALFA	Protein	Transforming growth factor beta binding agent		TGFB3	transforming growth factor beta 3	1	Completed	https://clinicaltrials.gov/study/NCT03524170
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB7	NADH:ubiquinone oxidoreductase subunit B7	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Completed	https://clinicaltrials.gov/study/NCT00445458,https://clinicaltrials.gov/study/NCT02599363,https://clinicaltrials.gov/study/NCT01918254,https://clinicaltrials.gov/study/NCT03411161,https://clinicaltrials.gov/study/NCT01031446,https://clinicaltrials.gov/study/NCT04247126,https://clinicaltrials.gov/study/NCT02041429,https://clinicaltrials.gov/study/NCT03800836,https://clinicaltrials.gov/study/NCT01070706,https://clinicaltrials.gov/study/NCT00031876,https://clinicaltrials.gov/study/NCT01003158,https://clinicaltrials.gov/study/NCT00807859,https://clinicaltrials.gov/study/NCT02060253,https://clinicaltrials.gov/study/NCT00983424,https://clinicaltrials.gov/study/NCT01625286,https://clinicaltrials.gov/study/NCT01493310,https://clinicaltrials.gov/study/NCT02073916,https://clinicaltrials.gov/study/NCT00001383,https://clinicaltrials.gov/study/NCT00301730,https://clinicaltrials.gov/study/NCT00951665,https://clinicaltrials.gov/study/NCT00054028,https://clinicaltrials.gov/study/NCT01042925,https://clinicaltrials.gov/study/NCT00368875,https://clinicaltrials.gov/study/NCT00960960,https://clinicaltrials.gov/study/NCT02379247,https://clinicaltrials.gov/study/NCT00002837,https://clinicaltrials.gov/study/NCT02628132,https://clinicaltrials.gov/study/NCT00680758,https://clinicaltrials.gov/study/NCT00003877,https://clinicaltrials.gov/study/NCT00068757,https://clinicaltrials.gov/study/NCT01484080,https://clinicaltrials.gov/study/NCT00820170,https://clinicaltrials.gov/study/NCT01306942,https://clinicaltrials.gov/study/NCT00748553,https://clinicaltrials.gov/study/NCT00009997,https://clinicaltrials.gov/study/NCT00707707,https://clinicaltrials.gov/study/NCT00574587,https://clinicaltrials.gov/study/NCT00717340,https://clinicaltrials.gov/study/NCT00322400,https://clinicaltrials.gov/study/NCT01172223,https://clinicaltrials.gov/study/NCT00006108,https://clinicaltrials.gov/study/NCT00426556,https://clinicaltrials.gov/study/NCT01973309,https://clinicaltrials.gov/study/NCT03505528,https://clinicaltrials.gov/study/NCT00724386,https://clinicaltrials.gov/study/NCT00887575,https://clinicaltrials.gov/study/NCT04132817,https://clinicaltrials.gov/study/NCT00803556,https://clinicaltrials.gov/study/NCT00442260,https://clinicaltrials.gov/study/NCT00050167,https://clinicaltrials.gov/study/NCT01133912,https://clinicaltrials.gov/study/NCT00637897,https://clinicaltrials.gov/study/NCT02015676,https://clinicaltrials.gov/study/NCT01254526,https://clinicaltrials.gov/study/NCT00691379,https://clinicaltrials.gov/study/NCT01862081,https://clinicaltrials.gov/study/NCT03166085,https://clinicaltrials.gov/study/NCT00004174,https://clinicaltrials.gov/study/NCT02001974,https://clinicaltrials.gov/study/NCT00107094,https://clinicaltrials.gov/study/NCT00788931,https://clinicaltrials.gov/study/NCT01423123,https://clinicaltrials.gov/study/NCT01320592,https://clinicaltrials.gov/study/NCT00900627,https://clinicaltrials.gov/study/NCT03112590,https://clinicaltrials.gov/study/NCT00003927,https://clinicaltrials.gov/study/NCT04261218
MONDO_0007254	breast cancer	CHEMBL2108738	NIVOLUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	1	Completed	https://clinicaltrials.gov/study/NCT04132817
EFO_0000304	breast adenocarcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC10	histone deacetylase 10	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
EFO_0005537	triple-negative breast cancer	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC1	histone deacetylase 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02393794
EFO_0005537	triple-negative breast cancer	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		PSENEN	presenilin enhancer, gamma-secretase subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01071564,https://clinicaltrials.gov/study/NCT01238133
MONDO_0007254	breast cancer	CHEMBL4297831	SPARTALIZUMAB	Antibody	Programmed cell death protein 1 antagonist		PDCD1	programmed cell death 1	1	Terminated	https://clinicaltrials.gov/study/NCT03742349
EFO_0000305	breast carcinoma	CHEMBL3218576	COPANLISIB	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	1	Terminated	https://clinicaltrials.gov/study/NCT03128619
MONDO_0007254	breast cancer	CHEMBL101253	VATALANIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	1	Terminated	https://clinicaltrials.gov/study/NCT00216047
MONDO_0007254	breast cancer	CHEMBL2360464	PEMETREXED DISODIUM	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	1	Completed	https://clinicaltrials.gov/study/NCT00097383
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBB4A	tubulin beta 4A class IVa	1	Completed	https://clinicaltrials.gov/study/NCT00270907
MONDO_0007254	breast cancer	CHEMBL3833384	EFLAPEGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	1	Completed	https://clinicaltrials.gov/study/NCT03135951
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Unknown status	https://clinicaltrials.gov/study/NCT00002628,https://clinicaltrials.gov/study/NCT02396108,https://clinicaltrials.gov/study/NCT01084863,https://clinicaltrials.gov/study/NCT00002627,https://clinicaltrials.gov/study/NCT00915369,https://clinicaltrials.gov/study/NCT03282825,https://clinicaltrials.gov/study/NCT00009763
MONDO_0007254	breast cancer	CHEMBL3545097	SAPANISERTIB	Small molecule	Serine/threonine-protein kinase mTOR inhibitor		MTOR	mechanistic target of rapamycin kinase	1	Completed	https://clinicaltrials.gov/study/NCT02719691
EFO_0005537	triple-negative breast cancer	CHEMBL1082407	ENZALUTAMIDE	Small molecule	Androgen Receptor antagonist		AR	androgen receptor	1	Completed	https://clinicaltrials.gov/study/NCT03207529
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB8	NADH:ubiquinone oxidoreductase subunit B8	1	Completed	https://clinicaltrials.gov/study/NCT01650506,https://clinicaltrials.gov/study/NCT01980823
EFO_0005537	triple-negative breast cancer	CHEMBL1789844	IPILIMUMAB	Antibody	Cytotoxic T-lymphocyte protein 4 inhibitor		CTLA4	cytotoxic T-lymphocyte associated protein 4	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06324240
MONDO_0007254	breast cancer	CHEMBL4298024	BINTRAFUSP ALFA	Protein	Transforming growth factor beta binding agent		TGFB1	transforming growth factor beta 1	1	Terminated	https://clinicaltrials.gov/study/NCT03579472,https://clinicaltrials.gov/study/NCT04296942
EFO_0006861	male breast carcinoma	CHEMBL289228	TIPIFARNIB	Small molecule	Protein farnesyltransferase inhibitor		FNTB	farnesyltransferase, CAAX box, subunit beta	1	Completed	https://clinicaltrials.gov/study/NCT00470301
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAB1	NADH:ubiquinone oxidoreductase subunit AB1	1	Completed	https://clinicaltrials.gov/study/NCT01980823,https://clinicaltrials.gov/study/NCT01650506
EFO_0000304	breast adenocarcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
MONDO_0007254	breast cancer	CHEMBL2177390	IPATASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT2	AKT serine/threonine kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT03800836
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
MONDO_0007254	breast cancer	CHEMBL4297181	SAMOTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	1	Completed	https://clinicaltrials.gov/study/NCT01655225
MONDO_0007254	breast cancer	CHEMBL289228	TIPIFARNIB	Small molecule	Protein farnesyltransferase inhibitor		FNTB	farnesyltransferase, CAAX box, subunit beta	1	Completed	https://clinicaltrials.gov/study/NCT00100750
MONDO_0007254	breast cancer	CHEMBL3989868	TUCATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Withdrawn	https://clinicaltrials.gov/study/NCT03846583,https://clinicaltrials.gov/study/NCT04896320
EFO_0006861	male breast carcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC4	histone deacetylase 4	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
EFO_0000304	breast adenocarcinoma	CHEMBL2108738	NIVOLUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02453620
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Terminated	https://clinicaltrials.gov/study/NCT02753595,https://clinicaltrials.gov/study/NCT03579472
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02419495
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF3	NADH:ubiquinone oxidoreductase complex assembly factor 3	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
MONDO_0007254	breast cancer	CHEMBL1922094	APITOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R2	phosphoinositide-3-kinase regulatory subunit 2	1	Completed	https://clinicaltrials.gov/study/NCT01254526
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor		GPD2	glycerol-3-phosphate dehydrogenase 2	1	Completed	https://clinicaltrials.gov/study/NCT01650506,https://clinicaltrials.gov/study/NCT01980823
MONDO_0007254	breast cancer	CHEMBL1567	SUNITINIB MALATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Unknown status	https://clinicaltrials.gov/study/NCT00931450
EFO_0000304	breast adenocarcinoma	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC3	histone deacetylase 3	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03554044,https://clinicaltrials.gov/study/NCT03725436
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Completed	https://clinicaltrials.gov/study/NCT02632071,https://clinicaltrials.gov/study/NCT01263145
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Terminated	https://clinicaltrials.gov/study/NCT03579472
EFO_0000304	breast adenocarcinoma	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04481113
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Unknown status	https://clinicaltrials.gov/study/NCT00009763,https://clinicaltrials.gov/study/NCT03282825,https://clinicaltrials.gov/study/NCT02396108,https://clinicaltrials.gov/study/NCT01084863,https://clinicaltrials.gov/study/NCT00002628,https://clinicaltrials.gov/study/NCT00915369,https://clinicaltrials.gov/study/NCT00002627
EFO_0000305	breast carcinoma	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN3A	sodium voltage-gated channel alpha subunit 3	1	Completed	https://clinicaltrials.gov/study/NCT03502395
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Completed	https://clinicaltrials.gov/study/NCT02392845,https://clinicaltrials.gov/study/NCT00002901,https://clinicaltrials.gov/study/NCT00129896,https://clinicaltrials.gov/study/NCT00705315,https://clinicaltrials.gov/study/NCT00450892,https://clinicaltrials.gov/study/NCT00637897,https://clinicaltrials.gov/study/NCT00645333,https://clinicaltrials.gov/study/NCT00322400,https://clinicaltrials.gov/study/NCT00080665,https://clinicaltrials.gov/study/NCT00003103,https://clinicaltrials.gov/study/NCT00020332,https://clinicaltrials.gov/study/NCT00268918,https://clinicaltrials.gov/study/NCT02605915,https://clinicaltrials.gov/study/NCT02027376,https://clinicaltrials.gov/study/NCT00934856,https://clinicaltrials.gov/study/NCT04367090,https://clinicaltrials.gov/study/NCT00169000,https://clinicaltrials.gov/study/NCT00050167,https://clinicaltrials.gov/study/NCT01256567,https://clinicaltrials.gov/study/NCT00872625,https://clinicaltrials.gov/study/NCT00372424,https://clinicaltrials.gov/study/NCT05301530,https://clinicaltrials.gov/study/NCT01862081,https://clinicaltrials.gov/study/NCT00086957,https://clinicaltrials.gov/study/NCT01044485
MONDO_0007254	breast cancer	CHEMBL4279455	LAROTAXEL	Small molecule	Tubulin stabiliser		TUBB6	tubulin beta 6 class V	1	Completed	https://clinicaltrials.gov/study/NCT00327743
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA7	EPH receptor A7	1	Completed	https://clinicaltrials.gov/study/NCT00496665
EFO_0000304	breast adenocarcinoma	CHEMBL1201576	RITUXIMAB	Antibody	B-lymphocyte antigen CD20 binding agent		MS4A1	membrane spanning 4-domains A1	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
MONDO_0007254	breast cancer	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	1	Suspended	https://clinicaltrials.gov/study/NCT01618357
MONDO_0007254	breast cancer	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 7 inhibitor		CDK7	cyclin dependent kinase 7	1	Completed	https://clinicaltrials.gov/study/NCT00020332,https://clinicaltrials.gov/study/NCT00003690
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLE	DNA polymerase epsilon, catalytic subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01929941,https://clinicaltrials.gov/study/NCT01333137,https://clinicaltrials.gov/study/NCT01939418
MONDO_0007254	breast cancer	CHEMBL3218578	BGT-226	Small molecule	PI3-kinase class I inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	1	Completed	https://clinicaltrials.gov/study/NCT00600275
MONDO_0007254	breast cancer	CHEMBL521851	PICTILISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	1	Completed	https://clinicaltrials.gov/study/NCT00960960,https://clinicaltrials.gov/study/NCT00928330
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Terminated	https://clinicaltrials.gov/study/NCT01512199,https://clinicaltrials.gov/study/NCT02358200,https://clinicaltrials.gov/study/NCT01929941,https://clinicaltrials.gov/study/NCT02297230,https://clinicaltrials.gov/study/NCT01249443,https://clinicaltrials.gov/study/NCT01495247,https://clinicaltrials.gov/study/NCT00003086,https://clinicaltrials.gov/study/NCT01980277,https://clinicaltrials.gov/study/NCT02474173,https://clinicaltrials.gov/study/NCT01407562,https://clinicaltrials.gov/study/NCT00041470,https://clinicaltrials.gov/study/NCT01090128,https://clinicaltrials.gov/study/NCT02379585,https://clinicaltrials.gov/study/NCT00140140
MONDO_0007254	breast cancer	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		APH1A	aph-1 homolog A, gamma-secretase subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01208441
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
MONDO_0007254	breast cancer	CHEMBL2108585	CONTUSUGENE LADENOVEC	Gene	Cellular tumor antigen p53 exogenous gene		TP53	tumor protein p53	1	Completed	https://clinicaltrials.gov/study/NCT00004038
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Withdrawn	https://clinicaltrials.gov/study/NCT02396433
MONDO_0007254	breast cancer	CHEMBL655	MIDAZOLAM	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRA3	gamma-aminobutyric acid type A receptor subunit alpha3	1	Completed	https://clinicaltrials.gov/study/NCT01655225,https://clinicaltrials.gov/study/NCT03955939
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Withdrawn	https://clinicaltrials.gov/study/NCT02070094
MONDO_0007254	breast cancer	CHEMBL2219422	AFURESERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT1	AKT serine/threonine kinase 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04851613
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00600496
MONDO_0007254	breast cancer	CHEMBL574737	UCN-01	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	1	Completed	https://clinicaltrials.gov/study/NCT00001444
EFO_0005537	triple-negative breast cancer	CHEMBL84	TOPOTECAN	Small molecule	DNA topoisomerase I, mitochondrial inhibitor		TOP1MT	DNA topoisomerase I mitochondrial	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02419495
MONDO_0007254	breast cancer	CHEMBL1503	OMEPRAZOLE	Small molecule	Potassium-transporting ATPase inhibitor		ATP4A	ATPase H+/K+ transporting subunit alpha	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02950259
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03858322,https://clinicaltrials.gov/study/NCT03716180,https://clinicaltrials.gov/study/NCT03893955,https://clinicaltrials.gov/study/NCT04556773,https://clinicaltrials.gov/study/NCT02608216,https://clinicaltrials.gov/study/NCT04331067,https://clinicaltrials.gov/study/NCT02999477,https://clinicaltrials.gov/study/NCT02390427
MONDO_0007254	breast cancer	CHEMBL554	LAPATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Suspended	https://clinicaltrials.gov/study/NCT01589861
MONDO_0007254	breast cancer	CHEMBL574737	UCN-01	Small molecule	Serine/threonine-protein kinase Chk1 inhibitor		CHEK1	checkpoint kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT00001444
EFO_0005537	triple-negative breast cancer	CHEMBL2396661	ALPELISIB	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	1	Completed	https://clinicaltrials.gov/study/NCT03207529
EFO_0000305	breast carcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC4	histone deacetylase 4	1	Completed	https://clinicaltrials.gov/study/NCT01434303
MONDO_0007254	breast cancer	CHEMBL841	LOPERAMIDE	Small molecule	Mu opioid receptor agonist		OPRM1	opioid receptor mu 1	1	Completed	https://clinicaltrials.gov/study/NCT05252546
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	1	Unknown status	https://clinicaltrials.gov/study/NCT02626507
MONDO_0007254	breast cancer	CHEMBL1614701	SELUMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 1 inhibitor		MAP2K1	mitogen-activated protein kinase kinase 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00600496
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Completed	https://clinicaltrials.gov/study/NCT00014430,https://clinicaltrials.gov/study/NCT00513058,https://clinicaltrials.gov/study/NCT00706069,https://clinicaltrials.gov/study/NCT00724386,https://clinicaltrials.gov/study/NCT00003902,https://clinicaltrials.gov/study/NCT00153907,https://clinicaltrials.gov/study/NCT00912275,https://clinicaltrials.gov/study/NCT00828074,https://clinicaltrials.gov/study/NCT00001944,https://clinicaltrials.gov/study/NCT00706030
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	1	Completed	https://clinicaltrials.gov/study/NCT02285179,https://clinicaltrials.gov/study/NCT01862081
MONDO_0007254	breast cancer	CHEMBL4297843	TORIPALIMAB	Antibody	Programmed cell death protein 1 antagonist		PDCD1	programmed cell death 1	1	Completed	https://clinicaltrials.gov/study/NCT02838823
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Terminated	https://clinicaltrials.gov/study/NCT02074878,https://clinicaltrials.gov/study/NCT00616122,https://clinicaltrials.gov/study/NCT00905021
EFO_0006861	male breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Terminated	https://clinicaltrials.gov/study/NCT00063934
MONDO_0007254	breast cancer	CHEMBL554	LAPATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	1	Terminated	https://clinicaltrials.gov/study/NCT01495884,https://clinicaltrials.gov/study/NCT01238029,https://clinicaltrials.gov/study/NCT00963547,https://clinicaltrials.gov/study/NCT02131506,https://clinicaltrials.gov/study/NCT00634088,https://clinicaltrials.gov/study/NCT01199367,https://clinicaltrials.gov/study/NCT01658358
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Terminated	https://clinicaltrials.gov/study/NCT02345772,https://clinicaltrials.gov/study/NCT00864175,https://clinicaltrials.gov/study/NCT02379585,https://clinicaltrials.gov/study/NCT00063934,https://clinicaltrials.gov/study/NCT01876251,https://clinicaltrials.gov/study/NCT00531271,https://clinicaltrials.gov/study/NCT00584012,https://clinicaltrials.gov/study/NCT00253318
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Completed	https://clinicaltrials.gov/study/NCT02060253,https://clinicaltrials.gov/study/NCT01276496,https://clinicaltrials.gov/study/NCT01281150,https://clinicaltrials.gov/study/NCT00470301,https://clinicaltrials.gov/study/NCT00368875,https://clinicaltrials.gov/study/NCT01288261,https://clinicaltrials.gov/study/NCT01493310
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT04213898
EFO_0005537	triple-negative breast cancer	CHEMBL4650483	ERFONRILIMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	1	Completed	https://clinicaltrials.gov/study/NCT03872791
EFO_0006861	male breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Tyrosine-protein kinase ITK/TSK inhibitor		ITK	IL2 inducible T cell kinase	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		BLK	BLK proto-oncogene, Src family tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT00903006
EFO_0006861	male breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Completed	https://clinicaltrials.gov/study/NCT01084057
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Completed	https://clinicaltrials.gov/study/NCT00372424,https://clinicaltrials.gov/study/NCT05301530,https://clinicaltrials.gov/study/NCT00872625,https://clinicaltrials.gov/study/NCT00637897,https://clinicaltrials.gov/study/NCT01256567,https://clinicaltrials.gov/study/NCT00322400,https://clinicaltrials.gov/study/NCT04367090,https://clinicaltrials.gov/study/NCT00050167,https://clinicaltrials.gov/study/NCT02392845,https://clinicaltrials.gov/study/NCT00934856,https://clinicaltrials.gov/study/NCT02027376,https://clinicaltrials.gov/study/NCT00086957,https://clinicaltrials.gov/study/NCT00450892,https://clinicaltrials.gov/study/NCT00080665,https://clinicaltrials.gov/study/NCT00705315,https://clinicaltrials.gov/study/NCT00169000,https://clinicaltrials.gov/study/NCT00002901,https://clinicaltrials.gov/study/NCT00020332,https://clinicaltrials.gov/study/NCT01862081,https://clinicaltrials.gov/study/NCT00645333,https://clinicaltrials.gov/study/NCT02605915,https://clinicaltrials.gov/study/NCT00129896,https://clinicaltrials.gov/study/NCT00003103,https://clinicaltrials.gov/study/NCT01044485,https://clinicaltrials.gov/study/NCT00268918
MONDO_0007254	breast cancer	CHEMBL1201182	TEMSIROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00600496
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02999477,https://clinicaltrials.gov/study/NCT02608216,https://clinicaltrials.gov/study/NCT03893955,https://clinicaltrials.gov/study/NCT03858322,https://clinicaltrials.gov/study/NCT02390427,https://clinicaltrials.gov/study/NCT03716180,https://clinicaltrials.gov/study/NCT04556773,https://clinicaltrials.gov/study/NCT04331067
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Completed	https://clinicaltrials.gov/study/NCT02120469
MONDO_0007254	breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Vascular endothelial growth factor receptor 1 inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Terminated	https://clinicaltrials.gov/study/NCT05103826
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4	1	Completed	https://clinicaltrials.gov/study/NCT01980823,https://clinicaltrials.gov/study/NCT01650506
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA2	NADH:ubiquinone oxidoreductase subunit A2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
EFO_0006861	male breast carcinoma	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		PSEN2	presenilin 2	1	Terminated	https://clinicaltrials.gov/study/NCT01149356
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLE2	DNA polymerase epsilon 2, accessory subunit	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05989828
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB1	NADH:ubiquinone oxidoreductase subunit B1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
MONDO_0007254	breast cancer	CHEMBL2103839	RIDAFOROLIMUS	Small molecule	Serine/threonine-protein kinase mTOR inhibitor		MTOR	mechanistic target of rapamycin kinase	1	Completed	https://clinicaltrials.gov/study/NCT01220570
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Terminated	https://clinicaltrials.gov/study/NCT01407562,https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL1743024	GANITUMAB	Antibody	Insulin-like growth factor I receptor antagonist		IGF1R	insulin like growth factor 1 receptor	1	Withdrawn	https://clinicaltrials.gov/study/NCT01479179
MONDO_0007254	breast cancer	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 3 inhibitor		HDAC3	histone deacetylase 3	1	Terminated	https://clinicaltrials.gov/study/NCT01249443
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV2	NADH:ubiquinone oxidoreductase core subunit V2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
MONDO_0007254	breast cancer	CHEMBL2364649	MARGETUXIMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT04398108
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	1	Terminated	https://clinicaltrials.gov/study/NCT01132664
MONDO_0007254	breast cancer	CHEMBL2103840	DINACICLIB	Small molecule	Cyclin-dependent kinase 2 inhibitor		CDK2	cyclin dependent kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT01676753
MONDO_0007254	breast cancer	CHEMBL2108738	NIVOLUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04061863,https://clinicaltrials.gov/study/NCT04331067
EFO_0006861	male breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Recruiting	https://clinicaltrials.gov/study/NCT05918133,https://clinicaltrials.gov/study/NCT03805399,https://clinicaltrials.gov/study/NCT05673200
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Completed	https://clinicaltrials.gov/study/NCT02120469
MONDO_0007254	breast cancer	CHEMBL3218578	BGT-226	Small molecule	PI3-kinase class I inhibitor		PIK3R2	phosphoinositide-3-kinase regulatory subunit 2	1	Completed	https://clinicaltrials.gov/study/NCT00600275
MONDO_0007254	breast cancer	CHEMBL3408248	AZD-8186	Small molecule	PI3-kinase p110-beta subunit inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	1	Completed	https://clinicaltrials.gov/study/NCT01884285
MONDO_0007254	breast cancer	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	1	Recruiting	https://clinicaltrials.gov/study/NCT05996107,https://clinicaltrials.gov/study/NCT05870579,https://clinicaltrials.gov/study/NCT05508906
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	1	Withdrawn	https://clinicaltrials.gov/study/NCT03400254
MONDO_0007254	breast cancer	CHEMBL502835	NINTEDANIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR3	fibroblast growth factor receptor 3	1	Completed	https://clinicaltrials.gov/study/NCT02619162
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Terminated	https://clinicaltrials.gov/study/NCT02824575,https://clinicaltrials.gov/study/NCT02474173
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		YES1	YES proto-oncogene 1, Src family tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT00903006
MONDO_0007254	breast cancer	CHEMBL4303201	CATEQUENTINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06331169
EFO_0000304	breast adenocarcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00049244
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Unknown status	https://clinicaltrials.gov/study/NCT02616848
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLE	DNA polymerase epsilon, catalytic subunit	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05989828
MONDO_0007254	breast cancer	CHEMBL3301587	DURVALUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04556773,https://clinicaltrials.gov/study/NCT02826434,https://clinicaltrials.gov/study/NCT03132467
MONDO_0007254	breast cancer	CHEMBL521851	PICTILISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	1	Completed	https://clinicaltrials.gov/study/NCT00928330,https://clinicaltrials.gov/study/NCT00960960
EFO_0006861	male breast carcinoma	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	1	Terminated	https://clinicaltrials.gov/study/NCT00063934
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Completed	https://clinicaltrials.gov/study/NCT03364348
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Completed	https://clinicaltrials.gov/study/NCT03364348
EFO_0000305	breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Tyrosine-protein kinase ITK/TSK inhibitor		ITK	IL2 inducible T cell kinase	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Terminated	https://clinicaltrials.gov/study/NCT05103826
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV3	NADH:ubiquinone oxidoreductase subunit V3	1	Completed	https://clinicaltrials.gov/study/NCT01980823,https://clinicaltrials.gov/study/NCT01650506
EFO_0005537	triple-negative breast cancer	CHEMBL1201670	SARGRAMOSTIM	Protein	Granulocyte-macrophage colony-stimulating factor receptor agonist		CSF2RA	colony stimulating factor 2 receptor subunit alpha	1	Completed	https://clinicaltrials.gov/study/NCT04584112
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR2	estrogen receptor 2	1	Unknown status	https://clinicaltrials.gov/study/NCT02626507
MONDO_0007254	breast cancer	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	1	Recruiting	https://clinicaltrials.gov/study/NCT05035745
MONDO_0007254	breast cancer	CHEMBL3545376	ERDAFITINIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR4	fibroblast growth factor receptor 4	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03238196
EFO_0006861	male breast carcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC1	histone deacetylase 1	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA9	NADH:ubiquinone oxidoreductase subunit A9	1	Completed	https://clinicaltrials.gov/study/NCT01650506,https://clinicaltrials.gov/study/NCT01980823
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	PRIM2	DNA primase subunit 2	1	Terminated	https://clinicaltrials.gov/study/NCT01333137,https://clinicaltrials.gov/study/NCT01929941,https://clinicaltrials.gov/study/NCT01939418
MONDO_0004658	breast carcinoma in situ	CHEMBL2107862	RINTATOLIMOD	Oligonucleotide	Toll-like receptor 3 agonist		TLR3	toll like receptor 3	1	Completed	https://clinicaltrials.gov/study/NCT04081389
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	1	Terminated	https://clinicaltrials.gov/study/NCT01132664
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV3	NADH:ubiquinone oxidoreductase subunit V3	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Terminated	https://clinicaltrials.gov/study/NCT01090128,https://clinicaltrials.gov/study/NCT02379585,https://clinicaltrials.gov/study/NCT01929941,https://clinicaltrials.gov/study/NCT01512199,https://clinicaltrials.gov/study/NCT02297230,https://clinicaltrials.gov/study/NCT02358200,https://clinicaltrials.gov/study/NCT01407562,https://clinicaltrials.gov/study/NCT00003086,https://clinicaltrials.gov/study/NCT02474173,https://clinicaltrials.gov/study/NCT00140140,https://clinicaltrials.gov/study/NCT00041470,https://clinicaltrials.gov/study/NCT01495247,https://clinicaltrials.gov/study/NCT01980277,https://clinicaltrials.gov/study/NCT01249443
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Suspended	https://clinicaltrials.gov/study/NCT05422794
EFO_0006861	male breast carcinoma	CHEMBL1201583	BEVACIZUMAB	Antibody	Vascular endothelial growth factor A inhibitor		VEGFA	vascular endothelial growth factor A	1	Completed	https://clinicaltrials.gov/study/NCT00368875
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Withdrawn	https://clinicaltrials.gov/study/NCT02396433
EFO_0005537	triple-negative breast cancer	CHEMBL1614701	SELUMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase 2 inhibitor		MAP2K2	mitogen-activated protein kinase kinase 2	1	Unknown status	https://clinicaltrials.gov/study/NCT02583542
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	1	Withdrawn	https://clinicaltrials.gov/study/NCT04872608
MONDO_0007254	breast cancer	CHEMBL274654	ORANTINIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR4	fibroblast growth factor receptor 4	1	Unknown status	https://clinicaltrials.gov/study/NCT00024063
MONDO_0007254	breast cancer	CHEMBL4297844	TRASTUZUMAB DERUXTECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	1	Recruiting	https://clinicaltrials.gov/study/NCT05633979
EFO_0006861	male breast carcinoma	CHEMBL1276308	MIFEPRISTONE	Small molecule	Progesterone receptor antagonist		PGR	progesterone receptor	1	Completed	https://clinicaltrials.gov/study/NCT01493310
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Terminated	https://clinicaltrials.gov/study/NCT01512199,https://clinicaltrials.gov/study/NCT01980277,https://clinicaltrials.gov/study/NCT00003086,https://clinicaltrials.gov/study/NCT02379585,https://clinicaltrials.gov/study/NCT01495247,https://clinicaltrials.gov/study/NCT00041470,https://clinicaltrials.gov/study/NCT02474173,https://clinicaltrials.gov/study/NCT02358200,https://clinicaltrials.gov/study/NCT01407562,https://clinicaltrials.gov/study/NCT00140140,https://clinicaltrials.gov/study/NCT01249443,https://clinicaltrials.gov/study/NCT01929941,https://clinicaltrials.gov/study/NCT02297230,https://clinicaltrials.gov/study/NCT01090128
MONDO_0007254	breast cancer	CHEMBL3813873	PEXIDARTINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Completed	https://clinicaltrials.gov/study/NCT01596751
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD1	DNA polymerase delta 1, catalytic subunit	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04750382
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4L	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L	1	Completed	https://clinicaltrials.gov/study/NCT02278965
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05251766
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB5	NADH:ubiquinone oxidoreductase subunit B5	1	Completed	https://clinicaltrials.gov/study/NCT02278965
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA10	EPH receptor A10	1	Completed	https://clinicaltrials.gov/study/NCT00496665
MONDO_0007254	breast cancer	CHEMBL502835	NINTEDANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT02619162
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	PRIM1	DNA primase subunit 1	1	Completed	https://clinicaltrials.gov/study/NCT01133912,https://clinicaltrials.gov/study/NCT00270907,https://clinicaltrials.gov/study/NCT04247126,https://clinicaltrials.gov/study/NCT00100750,https://clinicaltrials.gov/study/NCT02139358,https://clinicaltrials.gov/study/NCT02479230,https://clinicaltrials.gov/study/NCT01070706
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	1	Completed	https://clinicaltrials.gov/study/NCT02285179,https://clinicaltrials.gov/study/NCT01862081
MONDO_0007254	breast cancer	CHEMBL1086218	VALSPODAR	Protein	P-glycoprotein 1 inhibitor		ABCB1	ATP binding cassette subfamily B member 1	1	Completed	https://clinicaltrials.gov/study/NCT00001302,https://clinicaltrials.gov/study/NCT00001383
EFO_1000984	inflammatory breast carcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC10	histone deacetylase 10	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
MONDO_0007254	breast cancer	CHEMBL4297181	SAMOTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	1	Completed	https://clinicaltrials.gov/study/NCT01655225
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	PRIM1	DNA primase subunit 1	1	Completed	https://clinicaltrials.gov/study/NCT01154426
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Withdrawn	https://clinicaltrials.gov/study/NCT02396433
MONDO_0007254	breast cancer	CHEMBL1094636	NIRAPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	1	Completed	https://clinicaltrials.gov/study/NCT05261269,https://clinicaltrials.gov/study/NCT02657889
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Terminated	https://clinicaltrials.gov/study/NCT02824575,https://clinicaltrials.gov/study/NCT01697293
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC11	histone deacetylase 11	1	Completed	https://clinicaltrials.gov/study/NCT02820961,https://clinicaltrials.gov/study/NCT03473639,https://clinicaltrials.gov/study/NCT01594398,https://clinicaltrials.gov/study/NCT02833155
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC8	histone deacetylase 8	1	Completed	https://clinicaltrials.gov/study/NCT00632489,https://clinicaltrials.gov/study/NCT01105312,https://clinicaltrials.gov/study/NCT00788931
MONDO_0007254	breast cancer	CHEMBL598797	CUDC-101	Small molecule	Histone deacetylase inhibitor		HDAC9	histone deacetylase 9	1	Completed	https://clinicaltrials.gov/study/NCT01171924
EFO_0000305	breast carcinoma	CHEMBL3218576	COPANLISIB	Small molecule	PI3-kinase p110-delta subunit inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	1	Terminated	https://clinicaltrials.gov/study/NCT03128619
MONDO_0007254	breast cancer	CHEMBL1922094	APITOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	1	Completed	https://clinicaltrials.gov/study/NCT01254526
EFO_0005537	triple-negative breast cancer	CHEMBL4297715	CAMRELIZUMAB	Antibody	Programmed cell death protein 1 antagonist		PDCD1	programmed cell death 1	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT04213898
EFO_0000305	breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Fibroblast growth factor receptor 3 inhibitor		FGFR3	fibroblast growth factor receptor 3	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00600496
MONDO_0007254	breast cancer	CHEMBL1879463	DACTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	1	Terminated	https://clinicaltrials.gov/study/NCT01495247
MONDO_0007254	breast cancer	CHEMBL3184679	AZD-4547	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR4	fibroblast growth factor receptor 4	1	Completed	https://clinicaltrials.gov/study/NCT01791985,https://clinicaltrials.gov/study/NCT01202591
MONDO_0007254	breast cancer	CHEMBL3301587	DURVALUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	1	Completed	https://clinicaltrials.gov/study/NCT02628132,https://clinicaltrials.gov/study/NCT02649686
MONDO_0007254	breast cancer	CHEMBL4650365	CAMIZESTRANT	Small molecule	Estrogen receptor alpha degrader		ESR1	estrogen receptor 1	1	Completed	https://clinicaltrials.gov/study/NCT05364255,https://clinicaltrials.gov/study/NCT04818632
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Unknown status	https://clinicaltrials.gov/study/NCT00764972
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03725436,https://clinicaltrials.gov/study/NCT03554044
EFO_0000304	breast adenocarcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
MONDO_0007254	breast cancer	CHEMBL1289494	TIVOZANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Completed	https://clinicaltrials.gov/study/NCT00717340
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Completed	https://clinicaltrials.gov/study/NCT01432886,https://clinicaltrials.gov/study/NCT02723877,https://clinicaltrials.gov/study/NCT01323530,https://clinicaltrials.gov/study/NCT01795586,https://clinicaltrials.gov/study/NCT01596751
MONDO_0004658	breast carcinoma in situ	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Completed	https://clinicaltrials.gov/study/NCT04081389
MONDO_0007254	breast cancer	CHEMBL3581647	BIRABRESIB	Small molecule	Bromodomain and extra-terminal motif (BET) inhibitor		BRDT	bromodomain testis associated	1	Completed	https://clinicaltrials.gov/study/NCT02259114
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD2	DNA polymerase delta 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT00270907,https://clinicaltrials.gov/study/NCT04247126,https://clinicaltrials.gov/study/NCT01070706,https://clinicaltrials.gov/study/NCT02479230,https://clinicaltrials.gov/study/NCT01133912,https://clinicaltrials.gov/study/NCT02139358,https://clinicaltrials.gov/study/NCT00100750
EFO_0000305	breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	PRIM1	DNA primase subunit 1	1	Completed	https://clinicaltrials.gov/study/NCT00100750
EFO_0000304	breast adenocarcinoma	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC4	histone deacetylase 4	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
EFO_0005537	triple-negative breast cancer	CHEMBL574737	UCN-01	Small molecule	Protein kinase C (PKC) inhibitor		PRKD1	protein kinase D1	1	Completed	https://clinicaltrials.gov/study/NCT00031681
MONDO_0007254	breast cancer	CHEMBL2103840	DINACICLIB	Small molecule	Cyclin-dependent kinase 5 inhibitor		CDK5	cyclin dependent kinase 5	1	Completed	https://clinicaltrials.gov/study/NCT01676753
MONDO_0007254	breast cancer	CHEMBL4298013	ELGEMTUMAB	Antibody	Receptor tyrosine-protein kinase erbB-3 inhibitor		ERBB3	erb-b2 receptor tyrosine kinase 3	1	Completed	https://clinicaltrials.gov/study/NCT02167854
EFO_0005537	triple-negative breast cancer	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC11	histone deacetylase 11	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02393794
MONDO_0007254	breast cancer	CHEMBL3545111	HEMAY-022	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT03308201,https://clinicaltrials.gov/study/NCT02476539
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Completed	https://clinicaltrials.gov/study/NCT00003902,https://clinicaltrials.gov/study/NCT00724386,https://clinicaltrials.gov/study/NCT00828074,https://clinicaltrials.gov/study/NCT00001944,https://clinicaltrials.gov/study/NCT00513058,https://clinicaltrials.gov/study/NCT00706069,https://clinicaltrials.gov/study/NCT00706030,https://clinicaltrials.gov/study/NCT00912275,https://clinicaltrials.gov/study/NCT00014430,https://clinicaltrials.gov/study/NCT00153907
MONDO_0007254	breast cancer	CHEMBL3581647	BIRABRESIB	Small molecule	Bromodomain and extra-terminal motif (BET) inhibitor		BRD2	bromodomain containing 2	1	Completed	https://clinicaltrials.gov/study/NCT02259114
MONDO_0007254	breast cancer	CHEMBL4594517	GILORALIMAB	Antibody	Tumor necrosis factor receptor superfamily member 5 agonist		CD40	CD40 molecule	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03893955
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05251766
EFO_0000305	breast carcinoma	CHEMBL1201179	LAPATINIB DITOSYLATE	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Terminated	https://clinicaltrials.gov/study/NCT01281163
EFO_1000984	inflammatory breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Unknown status	https://clinicaltrials.gov/study/NCT01880385
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLA2	DNA polymerase alpha 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT01154426
EFO_0005537	triple-negative breast cancer	CHEMBL225072	PEMETREXED	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02419495
MONDO_0007254	breast cancer	CHEMBL1200485	SORAFENIB TOSYLATE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Completed	https://clinicaltrials.gov/study/NCT00828074,https://clinicaltrials.gov/study/NCT00217399
MONDO_0007254	breast cancer	CHEMBL1201129	DECITABINE	Small molecule	DNA (cytosine-5)-methyltransferase 1 inhibitor		DNMT1	DNA methyltransferase 1	1	Terminated	https://clinicaltrials.gov/study/NCT01194908
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Unknown status	https://clinicaltrials.gov/study/NCT02616848
MONDO_0007254	breast cancer	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	1	Terminated	https://clinicaltrials.gov/study/NCT02358200
MONDO_0007254	breast cancer	CHEMBL3647420	PYROTINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Unknown status	https://clinicaltrials.gov/study/NCT02422199,https://clinicaltrials.gov/study/NCT02500199
MONDO_0007254	breast cancer	CHEMBL49642	INDIBULIN	Small molecule	Tubulin inhibitor		TUBA3C	tubulin alpha 3c	1	Unknown status	https://clinicaltrials.gov/study/NCT01113970
EFO_0006861	male breast carcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC9	histone deacetylase 9	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
MONDO_0007254	breast cancer	CHEMBL1201740	NILOTINIB HYDROCHLORIDE MONOHYDRATE	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	1	Recruiting	https://clinicaltrials.gov/study/NCT04205903
MONDO_0007254	breast cancer	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	1	Recruiting	https://clinicaltrials.gov/study/NCT05870579,https://clinicaltrials.gov/study/NCT05508906,https://clinicaltrials.gov/study/NCT05996107
MONDO_0007254	breast cancer	CHEMBL1201570	ANAKINRA	Protein	Interleukin-1 receptor antagonist		IL1R1	interleukin 1 receptor type 1	1	Completed	https://clinicaltrials.gov/study/NCT01802970
MONDO_0007254	breast cancer	CHEMBL14762	SELICICLIB	Small molecule	Cyclin-dependent kinase 2 inhibitor		CDK2	cyclin dependent kinase 2	1	Withdrawn	https://clinicaltrials.gov/study/NCT01333423
MONDO_0007254	breast cancer	CHEMBL1214827	ONALESPIB	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AB1	heat shock protein 90 alpha family class B member 1	1	Completed	https://clinicaltrials.gov/study/NCT01246102
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		FGR	FGR proto-oncogene, Src family tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT00820170,https://clinicaltrials.gov/study/NCT00452673,https://clinicaltrials.gov/study/NCT00924352,https://clinicaltrials.gov/study/NCT01306942
MONDO_0007254	breast cancer	CHEMBL1643	RIBAVIRIN	Small molecule	Inosine-5'-monophosphate dehydrogenase 1 inhibitor		IMPDH1	inosine monophosphate dehydrogenase 1	1	Terminated	https://clinicaltrials.gov/study/NCT01056757
MONDO_0007254	breast cancer	CHEMBL572881	MOTESANIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Withdrawn	https://clinicaltrials.gov/study/NCT01349088
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC1	NADH:ubiquinone oxidoreductase subunit C1	1	Completed	https://clinicaltrials.gov/study/NCT01650506,https://clinicaltrials.gov/study/NCT01980823
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00600496
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR1	estrogen receptor 1	1	Unknown status	https://clinicaltrials.gov/study/NCT02626507
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA6	EPH receptor A6	1	Completed	https://clinicaltrials.gov/study/NCT00496665
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02419495
EFO_0005537	triple-negative breast cancer	CHEMBL3989870	BERZOSERTIB	Small molecule	Serine-protein kinase ATR inhibitor		ATR	ATR serine/threonine kinase	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04052555
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	1	Completed	https://clinicaltrials.gov/study/NCT00535119,https://clinicaltrials.gov/study/NCT01154426,https://clinicaltrials.gov/study/NCT01251874
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Terminated	https://clinicaltrials.gov/study/NCT01388647,https://clinicaltrials.gov/study/NCT03579472,https://clinicaltrials.gov/study/NCT02753595
MONDO_0007254	breast cancer	CHEMBL2177390	IPATASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT3	AKT serine/threonine kinase 3	1	Completed	https://clinicaltrials.gov/study/NCT03800836
MONDO_0007254	breast cancer	CHEMBL744	RILUZOLE	Small molecule	Sodium channel alpha subunit blocker		SCN1A	sodium voltage-gated channel alpha subunit 1	1	Withdrawn	https://clinicaltrials.gov/study/NCT00903214
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Completed	https://clinicaltrials.gov/study/NCT00535119
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Terminated	https://clinicaltrials.gov/study/NCT00634088
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Withdrawn	https://clinicaltrials.gov/study/NCT04252768,https://clinicaltrials.gov/study/NCT03285607,https://clinicaltrials.gov/study/NCT04826016,https://clinicaltrials.gov/study/NCT02569489,https://clinicaltrials.gov/study/NCT04762901,https://clinicaltrials.gov/study/NCT03175666,https://clinicaltrials.gov/study/NCT00022230
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Completed	https://clinicaltrials.gov/study/NCT00368875,https://clinicaltrials.gov/study/NCT01281150,https://clinicaltrials.gov/study/NCT02060253,https://clinicaltrials.gov/study/NCT01288261,https://clinicaltrials.gov/study/NCT01493310,https://clinicaltrials.gov/study/NCT01276496,https://clinicaltrials.gov/study/NCT00470301
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Terminated	https://clinicaltrials.gov/study/NCT02753595,https://clinicaltrials.gov/study/NCT03579472
MONDO_0007254	breast cancer	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Withdrawn	https://clinicaltrials.gov/study/NCT01333423,https://clinicaltrials.gov/study/NCT03285607,https://clinicaltrials.gov/study/NCT04762901,https://clinicaltrials.gov/study/NCT00022230,https://clinicaltrials.gov/study/NCT00074139
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLE3	DNA polymerase epsilon 3, accessory subunit	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05989828
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	1	Completed	https://clinicaltrials.gov/study/NCT01306942,https://clinicaltrials.gov/study/NCT00924352,https://clinicaltrials.gov/study/NCT00820170,https://clinicaltrials.gov/study/NCT00452673
MONDO_0007254	breast cancer	CHEMBL96172	EPOTHILONE D	Small molecule	Tubulin stabiliser		TUBB2A	tubulin beta 2A class IIa	1	Completed	https://clinicaltrials.gov/study/NCT00337649
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS7	NADH:ubiquinone oxidoreductase core subunit S7	1	Completed	https://clinicaltrials.gov/study/NCT01980823,https://clinicaltrials.gov/study/NCT01650506
EFO_0000305	breast carcinoma	CHEMBL3408248	AZD-8186	Small molecule	PI3-kinase p110-beta subunit inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Completed	https://clinicaltrials.gov/study/NCT02120469
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Completed	https://clinicaltrials.gov/study/NCT01323530,https://clinicaltrials.gov/study/NCT01432886
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	1	Completed	https://clinicaltrials.gov/study/NCT02154776,https://clinicaltrials.gov/study/NCT02088684,https://clinicaltrials.gov/study/NCT01339442,https://clinicaltrials.gov/study/NCT01626209,https://clinicaltrials.gov/study/NCT01248494,https://clinicaltrials.gov/study/NCT02058381
MONDO_0007254	breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	1	Terminated	https://clinicaltrials.gov/study/NCT05103826
MONDO_0007254	breast cancer	CHEMBL522892	DOVITINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Terminated	https://clinicaltrials.gov/study/NCT01484041
MONDO_0007254	breast cancer	CHEMBL1079175	MK-2206	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT3	AKT serine/threonine kinase 3	1	Terminated	https://clinicaltrials.gov/study/NCT00963547
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA9	NADH:ubiquinone oxidoreductase subunit A9	1	Completed	https://clinicaltrials.gov/study/NCT02278965
MONDO_0007254	breast cancer	CHEMBL1852688	INFIGRATINIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR1	fibroblast growth factor receptor 1	1	Terminated	https://clinicaltrials.gov/study/NCT04504331
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00600496
MONDO_0007254	breast cancer	CHEMBL572881	MOTESANIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	1	Completed	https://clinicaltrials.gov/study/NCT00322400
EFO_1000984	inflammatory breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Unknown status	https://clinicaltrials.gov/study/NCT01880385
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB9	NADH:ubiquinone oxidoreductase subunit B9	1	Completed	https://clinicaltrials.gov/study/NCT02278965
MONDO_0007254	breast cancer	CHEMBL4297723	CEMIPLIMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT05064085
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Terminated	https://clinicaltrials.gov/study/NCT02379585,https://clinicaltrials.gov/study/NCT02345772,https://clinicaltrials.gov/study/NCT00864175,https://clinicaltrials.gov/study/NCT00253318,https://clinicaltrials.gov/study/NCT00063934,https://clinicaltrials.gov/study/NCT00584012,https://clinicaltrials.gov/study/NCT00531271,https://clinicaltrials.gov/study/NCT01876251
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Recruiting	https://clinicaltrials.gov/study/NCT05335473
EFO_0006861	male breast carcinoma	CHEMBL429876	CILENGITIDE	Protein	Integrin alpha-V/beta-3 antagonist		ITGB3	integrin subunit beta 3	1	Completed	https://clinicaltrials.gov/study/NCT01276496
MONDO_0007254	breast cancer	CHEMBL49642	INDIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Unknown status	https://clinicaltrials.gov/study/NCT01113970
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL481	IRINOTECAN	Small molecule	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	1	Recruiting	https://clinicaltrials.gov/study/NCT05694715
MONDO_0007254	breast cancer	CHEMBL574737	UCN-01	Small molecule	Protein kinase C (PKC) inhibitor		PRKD3	protein kinase D3	1	Completed	https://clinicaltrials.gov/study/NCT00001444
MONDO_0007254	breast cancer	CHEMBL2364652	VANTICTUMAB	Antibody	Frizzled-5 antagonist		FZD5	frizzled class receptor 5	1	Completed	https://clinicaltrials.gov/study/NCT01973309
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Completed	https://clinicaltrials.gov/study/NCT00535119
MONDO_0007254	breast cancer	CHEMBL3545132	MIRVETUXIMAB SORAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Withdrawn	https://clinicaltrials.gov/study/NCT03045393
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Completed	https://clinicaltrials.gov/study/NCT01816035
EFO_0000304	breast adenocarcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD4	DNA polymerase delta 4, accessory subunit	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	1	Completed	https://clinicaltrials.gov/study/NCT03364348
EFO_0005537	triple-negative breast cancer	CHEMBL2108738	NIVOLUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02419495,https://clinicaltrials.gov/study/NCT02393794
MONDO_0004658	breast carcinoma in situ	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Completed	https://clinicaltrials.gov/study/NCT04081389
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Unknown status	https://clinicaltrials.gov/study/NCT02616848
MONDO_0007254	breast cancer	CHEMBL2396661	ALPELISIB	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	1	Completed	https://clinicaltrials.gov/study/NCT01219699,https://clinicaltrials.gov/study/NCT02167854,https://clinicaltrials.gov/study/NCT02038010,https://clinicaltrials.gov/study/NCT02379247,https://clinicaltrials.gov/study/NCT01870505,https://clinicaltrials.gov/study/NCT02058381,https://clinicaltrials.gov/study/NCT02088684,https://clinicaltrials.gov/study/NCT01300962
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00600496
MONDO_0007254	breast cancer	CHEMBL4298024	BINTRAFUSP ALFA	Protein	Programmed cell death 1 ligand 1 binding agent		CD274	CD274 molecule	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03620201
MONDO_0007254	breast cancer	CHEMBL1289601	LENVATINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Unknown status	https://clinicaltrials.gov/study/NCT02562118
MONDO_0007254	breast cancer	CHEMBL1770916	NIROGACESTAT	Small molecule	Gamma-secretase inhibitor		PSEN1	presenilin 1	1	Terminated	https://clinicaltrials.gov/study/NCT01876251
MONDO_0007254	breast cancer	CHEMBL4650316	GIREDESTRANT	Small molecule	Estrogen receptor alpha degrader		ESR1	estrogen receptor 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03332797
MONDO_0007254	breast cancer	CHEMBL4297844	TRASTUZUMAB DERUXTECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06331169
MONDO_0007254	breast cancer	CHEMBL4298024	BINTRAFUSP ALFA	Protein	Transforming growth factor beta binding agent		TGFB2	transforming growth factor beta 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03620201
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	Serine/threonine-protein kinase mTOR inhibitor		MTOR	mechanistic target of rapamycin kinase	1	Completed	https://clinicaltrials.gov/study/NCT03243331,https://clinicaltrials.gov/study/NCT02684032
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05274893,https://clinicaltrials.gov/study/NCT05019690,https://clinicaltrials.gov/study/NCT05251766
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Withdrawn	https://clinicaltrials.gov/study/NCT04826016,https://clinicaltrials.gov/study/NCT02569489,https://clinicaltrials.gov/study/NCT04252768,https://clinicaltrials.gov/study/NCT00022230,https://clinicaltrials.gov/study/NCT03285607,https://clinicaltrials.gov/study/NCT04762901,https://clinicaltrials.gov/study/NCT03175666
MONDO_0007254	breast cancer	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 1 inhibitor		CDK1	cyclin dependent kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT00020332,https://clinicaltrials.gov/study/NCT00003690
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Terminated	https://clinicaltrials.gov/study/NCT01697293,https://clinicaltrials.gov/study/NCT02824575
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD1	DNA polymerase delta 1, catalytic subunit	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05989828
EFO_0000304	breast adenocarcinoma	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
EFO_0000305	breast carcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC5	histone deacetylase 5	1	Completed	https://clinicaltrials.gov/study/NCT01434303
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Suspended	https://clinicaltrials.gov/study/NCT05422794
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	1	Unknown status	https://clinicaltrials.gov/study/NCT02389842
EFO_0000304	breast adenocarcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD2	DNA polymerase delta 2, accessory subunit	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV1	NADH:ubiquinone oxidoreductase core subunit V1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
EFO_0005537	triple-negative breast cancer	CHEMBL4650483	ERFONRILIMAB	Antibody	Cytotoxic T-lymphocyte protein 4 inhibitor		CTLA4	cytotoxic T-lymphocyte associated protein 4	1	Completed	https://clinicaltrials.gov/study/NCT03872791
MONDO_0007254	breast cancer	CHEMBL3545096	BGT-226	Small molecule	PI3-kinase class I inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	1	Completed	https://clinicaltrials.gov/study/NCT00600275
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Unknown status	https://clinicaltrials.gov/study/NCT00915369,https://clinicaltrials.gov/study/NCT01084863,https://clinicaltrials.gov/study/NCT00002628,https://clinicaltrials.gov/study/NCT02396108,https://clinicaltrials.gov/study/NCT00009763,https://clinicaltrials.gov/study/NCT00002627,https://clinicaltrials.gov/study/NCT03282825
MONDO_0007254	breast cancer	CHEMBL6	INDOMETHACIN	Small molecule	Cyclooxygenase inhibitor		PTGS1	prostaglandin-endoperoxide synthase 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02950259
EFO_0005537	triple-negative breast cancer	CHEMBL2141296	IXAZOMIB	Small molecule	26S proteasome inhibitor		PSMB5	proteasome 20S subunit beta 5	1	Terminated	https://clinicaltrials.gov/study/NCT02993094
EFO_0000305	breast carcinoma	CHEMBL3644587	2X-121	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	1	Withdrawn	https://clinicaltrials.gov/study/NCT02396433
EFO_0006861	male breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Terminated	https://clinicaltrials.gov/study/NCT00063934
EFO_0005537	triple-negative breast cancer	CHEMBL3647420	PYROTINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	1	Recruiting	https://clinicaltrials.gov/study/NCT03805399
MONDO_0007254	breast cancer	CHEMBL1879463	DACTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	1	Terminated	https://clinicaltrials.gov/study/NCT01495247
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Withdrawn	https://clinicaltrials.gov/study/NCT04826016
MONDO_0007254	breast cancer	CHEMBL2109637	HUHMFG1	Antibody	Mucin-1 other		MUC1	mucin 1, cell surface associated	1	Completed	https://clinicaltrials.gov/study/NCT00096057
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00600496
MONDO_0007254	breast cancer	CHEMBL1201179	LAPATINIB DITOSYLATE	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT00424164,https://clinicaltrials.gov/study/NCT00753207,https://clinicaltrials.gov/study/NCT00085020,https://clinicaltrials.gov/study/NCT00379509,https://clinicaltrials.gov/study/NCT00316875,https://clinicaltrials.gov/study/NCT01172223,https://clinicaltrials.gov/study/NCT00544804
MONDO_0007254	breast cancer	CHEMBL4297181	SAMOTOLISIB	Small molecule	Serine/threonine-protein kinase mTOR inhibitor		MTOR	mechanistic target of rapamycin kinase	1	Completed	https://clinicaltrials.gov/study/NCT01655225
MONDO_0007254	breast cancer	CHEMBL4650286	M4344	Small molecule	Serine-protein kinase ATR inhibitor		ATR	ATR serine/threonine kinase	1	Withdrawn	https://clinicaltrials.gov/study/NCT04655183
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD4	DNA polymerase delta 4, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01939418,https://clinicaltrials.gov/study/NCT01333137,https://clinicaltrials.gov/study/NCT01929941
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHB6	EPH receptor B6	1	Completed	https://clinicaltrials.gov/study/NCT00496665
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05251766,https://clinicaltrials.gov/study/NCT05019690,https://clinicaltrials.gov/study/NCT05274893
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBA3E	tubulin alpha 3e	1	Completed	https://clinicaltrials.gov/study/NCT00270907
EFO_0000304	breast adenocarcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC5	histone deacetylase 5	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02453620
MONDO_0007254	breast cancer	CHEMBL503	LOVASTATIN	Small molecule	HMG-CoA reductase inhibitor		HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase	1	Terminated	https://clinicaltrials.gov/study/NCT00584012
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	1	Completed	https://clinicaltrials.gov/study/NCT01816035
EFO_0005537	triple-negative breast cancer	CHEMBL574737	UCN-01	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	1	Completed	https://clinicaltrials.gov/study/NCT00031681
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD3	DNA polymerase delta 3, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT00100750
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Unknown status	https://clinicaltrials.gov/study/NCT00931450
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD3	DNA polymerase delta 3, accessory subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT04796220
MONDO_0007254	breast cancer	CHEMBL574737	UCN-01	Small molecule	Protein kinase C (PKC) inhibitor		PRKCI	protein kinase C iota	1	Completed	https://clinicaltrials.gov/study/NCT00001444
EFO_0000304	breast adenocarcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC7	histone deacetylase 7	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
MONDO_0007254	breast cancer	CHEMBL274654	ORANTINIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR2	fibroblast growth factor receptor 2	1	Unknown status	https://clinicaltrials.gov/study/NCT00024063
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBB2A	tubulin beta 2A class IIa	1	Completed	https://clinicaltrials.gov/study/NCT00270907
EFO_0000304	breast adenocarcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC3	histone deacetylase 3	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02453620
MONDO_0007254	breast cancer	CHEMBL4297715	CAMRELIZUMAB	Antibody	Programmed cell death protein 1 antagonist		PDCD1	programmed cell death 1	1	Completed	https://clinicaltrials.gov/study/NCT02742935,https://clinicaltrials.gov/study/NCT03945604
MONDO_0007254	breast cancer	CHEMBL1879463	DACTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	1	Completed	https://clinicaltrials.gov/study/NCT01248494
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT02074878,https://clinicaltrials.gov/study/NCT00905021,https://clinicaltrials.gov/study/NCT00616122
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	PRIM1	DNA primase subunit 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04750382
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
MONDO_0007254	breast cancer	CHEMBL4650215	INAVOLISIB	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
MONDO_0007254	breast cancer	CHEMBL483158	ALISERTIB	Small molecule	Serine/threonine-protein kinase Aurora-A inhibitor		AURKA	aurora kinase A	1	Completed	https://clinicaltrials.gov/study/NCT02719691
MONDO_0007254	breast cancer	CHEMBL554	LAPATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Unknown status	https://clinicaltrials.gov/study/NCT02422199
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Fibroblast growth factor receptor 1 inhibitor		FGFR1	fibroblast growth factor receptor 1	1	Completed	https://clinicaltrials.gov/study/NCT01498458
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	1	Terminated	https://clinicaltrials.gov/study/NCT02561832
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05251766
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03554044,https://clinicaltrials.gov/study/NCT03725436
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05251766
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA2	EPH receptor A2	1	Completed	https://clinicaltrials.gov/study/NCT00496665
MONDO_0007254	breast cancer	CHEMBL34259	METHOTREXATE	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	1	Terminated	https://clinicaltrials.gov/study/NCT00616122
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R5	phosphoinositide-3-kinase regulatory subunit 5	1	Completed	https://clinicaltrials.gov/study/NCT03243331,https://clinicaltrials.gov/study/NCT02684032
MONDO_0007254	breast cancer	CHEMBL49642	INDIBULIN	Small molecule	Tubulin inhibitor		TUBA3E	tubulin alpha 3e	1	Unknown status	https://clinicaltrials.gov/study/NCT01113970
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	1	Withdrawn	https://clinicaltrials.gov/study/NCT03400254
EFO_0000304	breast adenocarcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Completed	https://clinicaltrials.gov/study/NCT02120469
MONDO_0007254	breast cancer	CHEMBL1282	IMIQUIMOD	Small molecule	Toll-like receptor 7 agonist		TLR7	toll like receptor 7	1	Completed	https://clinicaltrials.gov/study/NCT01421017
EFO_0005537	triple-negative breast cancer	CHEMBL574737	UCN-01	Small molecule	Cyclin-dependent kinase 2 inhibitor		CDK2	cyclin dependent kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT00031681
MONDO_0007254	breast cancer	CHEMBL4297844	TRASTUZUMAB DERUXTECAN	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 binding agent		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT03366428
MONDO_0007254	breast cancer	CHEMBL4475463	AMCENESTRANT	Small molecule	Estrogen receptor alpha degrader		ESR1	estrogen receptor 1	1	Completed	https://clinicaltrials.gov/study/NCT04940026
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Withdrawn	https://clinicaltrials.gov/study/NCT04826016
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC5	histone deacetylase 5	1	Terminated	https://clinicaltrials.gov/study/NCT00754312,https://clinicaltrials.gov/study/NCT04296942,https://clinicaltrials.gov/study/NCT03361800
EFO_0000304	breast adenocarcinoma	CHEMBL1743007	DARATUMUMAB	Antibody	Lymphocyte differentiation antigen CD38 inhibitor		CD38	CD38 molecule	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
EFO_0000305	breast carcinoma	CHEMBL1079175	MK-2206	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT2	AKT serine/threonine kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT01344031,https://clinicaltrials.gov/study/NCT01263145
MONDO_0007254	breast cancer	CHEMBL572881	MOTESANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Withdrawn	https://clinicaltrials.gov/study/NCT01349088
MONDO_0007254	breast cancer	CHEMBL3545132	MIRVETUXIMAB SORAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBA4A	tubulin alpha 4a	1	Withdrawn	https://clinicaltrials.gov/study/NCT03045393
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Completed	https://clinicaltrials.gov/study/NCT01084057,https://clinicaltrials.gov/study/NCT00637897,https://clinicaltrials.gov/study/NCT00568022,https://clinicaltrials.gov/study/NCT00924352,https://clinicaltrials.gov/study/NCT00322374,https://clinicaltrials.gov/study/NCT00825734
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC10	histone deacetylase 10	1	Completed	https://clinicaltrials.gov/study/NCT01594398,https://clinicaltrials.gov/study/NCT03473639,https://clinicaltrials.gov/study/NCT02833155,https://clinicaltrials.gov/study/NCT02820961
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR1	estrogen receptor 1	1	Completed	https://clinicaltrials.gov/study/NCT01219699,https://clinicaltrials.gov/study/NCT01655225,https://clinicaltrials.gov/study/NCT03308201,https://clinicaltrials.gov/study/NCT02260661,https://clinicaltrials.gov/study/NCT02333370,https://clinicaltrials.gov/study/NCT01202591,https://clinicaltrials.gov/study/NCT02088684,https://clinicaltrials.gov/study/NCT02684032,https://clinicaltrials.gov/study/NCT03344536,https://clinicaltrials.gov/study/NCT02657343,https://clinicaltrials.gov/study/NCT01597193,https://clinicaltrials.gov/study/NCT02599714,https://clinicaltrials.gov/study/NCT04247126,https://clinicaltrials.gov/study/NCT04483505,https://clinicaltrials.gov/study/NCT00328120,https://clinicaltrials.gov/study/NCT01339442,https://clinicaltrials.gov/study/NCT06074757
MONDO_0007254	breast cancer	CHEMBL4802129	BALIXAFORTIDE	Protein	C-X-C chemokine receptor type 4 antagonist		CXCR4	C-X-C motif chemokine receptor 4	1	Completed	https://clinicaltrials.gov/study/NCT01837095
MONDO_0007254	breast cancer	CHEMBL96172	EPOTHILONE D	Small molecule	Tubulin stabiliser		TUBB1	tubulin beta 1 class VI	1	Completed	https://clinicaltrials.gov/study/NCT00337649
MONDO_0007254	breast cancer	CHEMBL553	ERLOTINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	1	Completed	https://clinicaltrials.gov/study/NCT00033514,https://clinicaltrials.gov/study/NCT01650506,https://clinicaltrials.gov/study/NCT00834678,https://clinicaltrials.gov/study/NCT00574366,https://clinicaltrials.gov/study/NCT00998036,https://clinicaltrials.gov/study/NCT01594398
MONDO_0007254	breast cancer	CHEMBL655	MIDAZOLAM	Small molecule	GABA-A receptor; anion channel positive allosteric modulator		GABRA5	gamma-aminobutyric acid type A receptor subunit alpha5	1	Completed	https://clinicaltrials.gov/study/NCT01655225,https://clinicaltrials.gov/study/NCT03955939
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Completed	https://clinicaltrials.gov/study/NCT02632071,https://clinicaltrials.gov/study/NCT01263145
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Withdrawn	https://clinicaltrials.gov/study/NCT03285607,https://clinicaltrials.gov/study/NCT04762901,https://clinicaltrials.gov/study/NCT00022230,https://clinicaltrials.gov/study/NCT04826016,https://clinicaltrials.gov/study/NCT02569489,https://clinicaltrials.gov/study/NCT04252768,https://clinicaltrials.gov/study/NCT03175666
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Completed	https://clinicaltrials.gov/study/NCT00724386,https://clinicaltrials.gov/study/NCT00003902,https://clinicaltrials.gov/study/NCT00153907,https://clinicaltrials.gov/study/NCT00706069,https://clinicaltrials.gov/study/NCT00706030,https://clinicaltrials.gov/study/NCT00001944,https://clinicaltrials.gov/study/NCT00014430,https://clinicaltrials.gov/study/NCT00912275,https://clinicaltrials.gov/study/NCT00513058,https://clinicaltrials.gov/study/NCT00828074
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02419495
MONDO_0007254	breast cancer	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	1	Withdrawn	https://clinicaltrials.gov/study/NCT01349088,https://clinicaltrials.gov/study/NCT03175666
MONDO_0007254	breast cancer	CHEMBL2107881	REGRAMOSTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	1	Completed	https://clinicaltrials.gov/study/NCT00841399
MONDO_0007254	breast cancer	CHEMBL49642	INDIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Unknown status	https://clinicaltrials.gov/study/NCT01113970
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD2	DNA polymerase delta 2, accessory subunit	1	Recruiting	https://clinicaltrials.gov/study/NCT04796220
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD2	DNA polymerase delta 2, accessory subunit	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03554044
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Recruiting	https://clinicaltrials.gov/study/NCT05335473
MONDO_0007254	breast cancer	CHEMBL744	RILUZOLE	Small molecule	Sodium channel alpha subunit blocker		SCN9A	sodium voltage-gated channel alpha subunit 9	1	Withdrawn	https://clinicaltrials.gov/study/NCT00903214
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Unknown status	https://clinicaltrials.gov/study/NCT02396108,https://clinicaltrials.gov/study/NCT03282825,https://clinicaltrials.gov/study/NCT00915369,https://clinicaltrials.gov/study/NCT01084863,https://clinicaltrials.gov/study/NCT00009763,https://clinicaltrials.gov/study/NCT00002627,https://clinicaltrials.gov/study/NCT00002628
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
EFO_0005537	triple-negative breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
EFO_0006861	male breast carcinoma	CHEMBL1201670	SARGRAMOSTIM	Protein	Granulocyte-macrophage colony-stimulating factor receptor agonist		CSF2RA	colony stimulating factor 2 receptor subunit alpha	1	Completed	https://clinicaltrials.gov/study/NCT00791037,https://clinicaltrials.gov/study/NCT01355393
EFO_1000984	inflammatory breast carcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC2	histone deacetylase 2	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
EFO_0005537	triple-negative breast cancer	CHEMBL4298024	BINTRAFUSP ALFA	Protein	Programmed cell death 1 ligand 1 binding agent		CD274	CD274 molecule	1	Terminated	https://clinicaltrials.gov/study/NCT03579472
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC6	histone deacetylase 6	1	Terminated	https://clinicaltrials.gov/study/NCT04296942,https://clinicaltrials.gov/study/NCT00754312,https://clinicaltrials.gov/study/NCT03361800
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05019690,https://clinicaltrials.gov/study/NCT05251766,https://clinicaltrials.gov/study/NCT05274893
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Serine/threonine-protein kinase B-raf inhibitor		BRAF	B-Raf proto-oncogene, serine/threonine kinase	1	Unknown status	https://clinicaltrials.gov/study/NCT00764972
MONDO_0007254	breast cancer	CHEMBL1567	SUNITINIB MALATE	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Unknown status	https://clinicaltrials.gov/study/NCT00931450
MONDO_0007254	breast cancer	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Completed	https://clinicaltrials.gov/study/NCT01596751,https://clinicaltrials.gov/study/NCT01323530,https://clinicaltrials.gov/study/NCT02723877,https://clinicaltrials.gov/study/NCT01432886,https://clinicaltrials.gov/study/NCT01795586
MONDO_0007254	breast cancer	CHEMBL522892	DOVITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT01421004
MONDO_0007254	breast cancer	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RA	interleukin 2 receptor subunit alpha	1	Completed	https://clinicaltrials.gov/study/NCT00027807,https://clinicaltrials.gov/study/NCT00019916,https://clinicaltrials.gov/study/NCT00301730
MONDO_0007254	breast cancer	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	1	Withdrawn	https://clinicaltrials.gov/study/NCT00022230
MONDO_0007254	breast cancer	CHEMBL1922094	APITOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	1	Completed	https://clinicaltrials.gov/study/NCT01254526
MONDO_0007254	breast cancer	CHEMBL3218578	BGT-226	Small molecule	PI3-kinase class I inhibitor		PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	1	Completed	https://clinicaltrials.gov/study/NCT00600275
MONDO_0007254	breast cancer	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 3 inhibitor		HDAC3	histone deacetylase 3	1	Completed	https://clinicaltrials.gov/study/NCT00574587,https://clinicaltrials.gov/study/NCT00258349,https://clinicaltrials.gov/study/NCT00788112,https://clinicaltrials.gov/study/NCT00368875,https://clinicaltrials.gov/study/NCT00719875,https://clinicaltrials.gov/study/NCT01084057
EFO_0005537	triple-negative breast cancer	CHEMBL574737	UCN-01	Small molecule	Serine/threonine-protein kinase Chk1 inhibitor		CHEK1	checkpoint kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT00031681
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
MONDO_0007254	breast cancer	CHEMBL1200374	EXEMESTANE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	1	Recruiting	https://clinicaltrials.gov/study/NCT05307705
EFO_0005537	triple-negative breast cancer	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	1	Recruiting	https://clinicaltrials.gov/study/NCT05673200
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Withdrawn	https://clinicaltrials.gov/study/NCT02070094
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Completed	https://clinicaltrials.gov/study/NCT01323530,https://clinicaltrials.gov/study/NCT01432886
MONDO_0007254	breast cancer	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Recruiting	https://clinicaltrials.gov/study/NCT03994107,https://clinicaltrials.gov/study/NCT02897700
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00049244
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Completed	https://clinicaltrials.gov/study/NCT00924352,https://clinicaltrials.gov/study/NCT00322374,https://clinicaltrials.gov/study/NCT00637897,https://clinicaltrials.gov/study/NCT00825734,https://clinicaltrials.gov/study/NCT00568022,https://clinicaltrials.gov/study/NCT01084057
MONDO_0007254	breast cancer	CHEMBL5283463	KW-2450	Small molecule	Insulin receptor inhibitor		INSR	insulin receptor	1	Terminated	https://clinicaltrials.gov/study/NCT01199367
MONDO_0007254	breast cancer	CHEMBL49642	INDIBULIN	Small molecule	Tubulin inhibitor		TUBA1C	tubulin alpha 1c	1	Unknown status	https://clinicaltrials.gov/study/NCT01113970
MONDO_0007254	breast cancer	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 2 inhibitor		HDAC2	histone deacetylase 2	1	Recruiting	https://clinicaltrials.gov/study/NCT03742245
MONDO_0007254	breast cancer	CHEMBL4802152	SENAPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	1	Completed	https://clinicaltrials.gov/study/NCT03507543
MONDO_0007254	breast cancer	CHEMBL1289494	TIVOZANIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT00717340
MONDO_0007254	breast cancer	CHEMBL2364652	VANTICTUMAB	Antibody	Frizzled-7 antagonist		FZD7	frizzled class receptor 7	1	Completed	https://clinicaltrials.gov/study/NCT01973309
EFO_0000305	breast carcinoma	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR1	estrogen receptor 1	1	Completed	https://clinicaltrials.gov/study/NCT01344031,https://clinicaltrials.gov/study/NCT02219789
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Completed	https://clinicaltrials.gov/study/NCT01281150,https://clinicaltrials.gov/study/NCT02060253,https://clinicaltrials.gov/study/NCT01276496,https://clinicaltrials.gov/study/NCT01288261,https://clinicaltrials.gov/study/NCT00368875,https://clinicaltrials.gov/study/NCT00470301,https://clinicaltrials.gov/study/NCT01493310
EFO_0005537	triple-negative breast cancer	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		PSEN1	presenilin 1	1	Terminated	https://clinicaltrials.gov/study/NCT01238133,https://clinicaltrials.gov/study/NCT01071564
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Completed	https://clinicaltrials.gov/study/NCT01795586,https://clinicaltrials.gov/study/NCT02723877,https://clinicaltrials.gov/study/NCT01323530,https://clinicaltrials.gov/study/NCT01432886,https://clinicaltrials.gov/study/NCT01596751
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02390427
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Terminated	https://clinicaltrials.gov/study/NCT03579472
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Terminated	https://clinicaltrials.gov/study/NCT02379585,https://clinicaltrials.gov/study/NCT01249443,https://clinicaltrials.gov/study/NCT00041470,https://clinicaltrials.gov/study/NCT02474173,https://clinicaltrials.gov/study/NCT02297230,https://clinicaltrials.gov/study/NCT00003086,https://clinicaltrials.gov/study/NCT01407562,https://clinicaltrials.gov/study/NCT01495247,https://clinicaltrials.gov/study/NCT01090128,https://clinicaltrials.gov/study/NCT00140140,https://clinicaltrials.gov/study/NCT01929941,https://clinicaltrials.gov/study/NCT01980277,https://clinicaltrials.gov/study/NCT02358200,https://clinicaltrials.gov/study/NCT01512199
MONDO_0007254	breast cancer	CHEMBL1642	IMATINIB MESYLATE	Small molecule	Bcr/Abl fusion protein		BCR	BCR activator of RhoGEF and GTPase	1	Completed	https://clinicaltrials.gov/study/NCT00080665
EFO_0005537	triple-negative breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
EFO_0005537	triple-negative breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
EFO_0005537	triple-negative breast cancer	CHEMBL3301587	DURVALUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	1	Terminated	https://clinicaltrials.gov/study/NCT03199040
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	1	Completed	https://clinicaltrials.gov/study/NCT03243331,https://clinicaltrials.gov/study/NCT02684032
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4	NDUFA4 mitochondrial complex associated	1	Completed	https://clinicaltrials.gov/study/NCT01980823,https://clinicaltrials.gov/study/NCT01650506
EFO_0000304	breast adenocarcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor	Inhibitor	RRM1	ribonucleotide reductase catalytic subunit M1	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLE3	DNA polymerase epsilon 3, accessory subunit	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03554044
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL3707324	UTOMILUMAB	Antibody	Tumor necrosis factor receptor superfamily member 9 agonist		TNFRSF9	TNF receptor superfamily member 9	1	Completed	https://clinicaltrials.gov/study/NCT03364348
EFO_1000984	inflammatory breast carcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC6	histone deacetylase 6	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
MONDO_0007254	breast cancer	CHEMBL3218576	COPANLISIB	Small molecule	PI3-kinase p110-delta subunit inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	1	Terminated	https://clinicaltrials.gov/study/NCT04042051
EFO_0000305	breast carcinoma	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN7A	sodium voltage-gated channel alpha subunit 7	1	Completed	https://clinicaltrials.gov/study/NCT03502395
MONDO_0007254	breast cancer	CHEMBL101253	VATALANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Completed	https://clinicaltrials.gov/study/NCT00268918
MONDO_0007254	breast cancer	CHEMBL3360203	PILARALISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R5	phosphoinositide-3-kinase regulatory subunit 5	1	Completed	https://clinicaltrials.gov/study/NCT01082068,https://clinicaltrials.gov/study/NCT01042925
EFO_0005537	triple-negative breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	1	Completed	https://clinicaltrials.gov/study/NCT03544125
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Terminated	https://clinicaltrials.gov/study/NCT01876251,https://clinicaltrials.gov/study/NCT00864175,https://clinicaltrials.gov/study/NCT00531271,https://clinicaltrials.gov/study/NCT02379585,https://clinicaltrials.gov/study/NCT00253318,https://clinicaltrials.gov/study/NCT00584012,https://clinicaltrials.gov/study/NCT00063934,https://clinicaltrials.gov/study/NCT02345772
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS1	NADH:ubiquinone oxidoreductase core subunit S1	1	Completed	https://clinicaltrials.gov/study/NCT02278965
MONDO_0007254	breast cancer	CHEMBL101253	VATALANIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT00216047
MONDO_0007254	breast cancer	CHEMBL2364652	VANTICTUMAB	Antibody	Frizzled-2 antagonist		FZD2	frizzled class receptor 2	1	Completed	https://clinicaltrials.gov/study/NCT01973309
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4	NDUFA4 mitochondrial complex associated	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Terminated	https://clinicaltrials.gov/study/NCT00584012,https://clinicaltrials.gov/study/NCT00864175,https://clinicaltrials.gov/study/NCT02345772,https://clinicaltrials.gov/study/NCT01876251,https://clinicaltrials.gov/study/NCT00253318,https://clinicaltrials.gov/study/NCT00531271,https://clinicaltrials.gov/study/NCT00063934,https://clinicaltrials.gov/study/NCT02379585
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	1	Completed	https://clinicaltrials.gov/study/NCT02285179,https://clinicaltrials.gov/study/NCT01862081
EFO_0006861	male breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Terminated	https://clinicaltrials.gov/study/NCT02598427,https://clinicaltrials.gov/study/NCT02345772,https://clinicaltrials.gov/study/NCT02379585
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS4	NADH:ubiquinone oxidoreductase subunit S4	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Terminated	https://clinicaltrials.gov/study/NCT01876251,https://clinicaltrials.gov/study/NCT00584012,https://clinicaltrials.gov/study/NCT00531271,https://clinicaltrials.gov/study/NCT02345772,https://clinicaltrials.gov/study/NCT00063934,https://clinicaltrials.gov/study/NCT02379585,https://clinicaltrials.gov/study/NCT00864175,https://clinicaltrials.gov/study/NCT00253318
MONDO_0007254	breast cancer	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RB	interleukin 2 receptor subunit beta	1	Withdrawn	https://clinicaltrials.gov/study/NCT00022230
MONDO_0007254	breast cancer	CHEMBL941	IMATINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT00080665
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD3	DNA polymerase delta 3, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT01154426
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS2	NADH:ubiquinone oxidoreductase core subunit S2	1	Completed	https://clinicaltrials.gov/study/NCT01650506,https://clinicaltrials.gov/study/NCT01980823
MONDO_0007254	breast cancer	CHEMBL1879463	DACTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	1	Completed	https://clinicaltrials.gov/study/NCT01248494
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC10	histone deacetylase 10	1	Terminated	https://clinicaltrials.gov/study/NCT00567879
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC9	histone deacetylase 9	1	Completed	https://clinicaltrials.gov/study/NCT03473639,https://clinicaltrials.gov/study/NCT02833155,https://clinicaltrials.gov/study/NCT02820961,https://clinicaltrials.gov/study/NCT01594398
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02419495
EFO_1000294	HER2 Positive Breast Carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Completed	https://clinicaltrials.gov/study/NCT03364348
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Completed	https://clinicaltrials.gov/study/NCT00372424,https://clinicaltrials.gov/study/NCT02392845,https://clinicaltrials.gov/study/NCT01044485,https://clinicaltrials.gov/study/NCT01256567,https://clinicaltrials.gov/study/NCT00322400,https://clinicaltrials.gov/study/NCT00872625,https://clinicaltrials.gov/study/NCT00705315,https://clinicaltrials.gov/study/NCT02605915,https://clinicaltrials.gov/study/NCT00637897,https://clinicaltrials.gov/study/NCT00086957,https://clinicaltrials.gov/study/NCT00050167,https://clinicaltrials.gov/study/NCT00450892,https://clinicaltrials.gov/study/NCT00268918,https://clinicaltrials.gov/study/NCT02027376,https://clinicaltrials.gov/study/NCT00003103,https://clinicaltrials.gov/study/NCT00002901,https://clinicaltrials.gov/study/NCT00080665,https://clinicaltrials.gov/study/NCT00645333,https://clinicaltrials.gov/study/NCT04367090,https://clinicaltrials.gov/study/NCT05301530,https://clinicaltrials.gov/study/NCT00934856,https://clinicaltrials.gov/study/NCT00020332,https://clinicaltrials.gov/study/NCT01862081,https://clinicaltrials.gov/study/NCT00169000,https://clinicaltrials.gov/study/NCT00129896
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA5	NADH:ubiquinone oxidoreductase subunit A5	1	Completed	https://clinicaltrials.gov/study/NCT02278965
MONDO_0007254	breast cancer	CHEMBL1094636	NIRAPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05519670
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Unknown status	https://clinicaltrials.gov/study/NCT02616848
MONDO_0007254	breast cancer	CHEMBL3989868	TUCATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT01921335,https://clinicaltrials.gov/study/NCT02025192,https://clinicaltrials.gov/study/NCT01983501
EFO_0000305	breast carcinoma	CHEMBL1201179	LAPATINIB DITOSYLATE	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT01434303
MONDO_0007254	breast cancer	CHEMBL518924	MAVORIXAFOR	Small molecule	C-X-C chemokine receptor type 4 antagonist		CXCR4	C-X-C motif chemokine receptor 4	1	Enrolling by invitation	https://clinicaltrials.gov/study/NCT05103917
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	1	Unknown status	https://clinicaltrials.gov/study/NCT02389842
MONDO_0007254	breast cancer	CHEMBL3218578	BGT-226	Small molecule	PI3-kinase class I inhibitor		PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	1	Completed	https://clinicaltrials.gov/study/NCT00600275
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02419495
MONDO_0007254	breast cancer	CHEMBL4297884	PEPINEMAB	Antibody	Semaphorin-4D inhibitor		SEMA4D	semaphorin 4D	1	Recruiting	https://clinicaltrials.gov/study/NCT05378464
MONDO_0007254	breast cancer	CHEMBL601719	CRIZOTINIB	Small molecule	NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor)		NPM1	nucleophosmin 1	1	Terminated	https://clinicaltrials.gov/study/NCT02074878
MONDO_0007254	breast cancer	CHEMBL3907479	FGFR INHIBITOR DEBIO 1347	Small molecule	Fibroblast growth factor receptor 1 inhibitor		FGFR1	fibroblast growth factor receptor 1	1	Completed	https://clinicaltrials.gov/study/NCT03344536
EFO_0005537	triple-negative breast cancer	CHEMBL3707227	ATEZOLIZUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	1	Recruiting	https://clinicaltrials.gov/study/NCT05581004
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA1	NADH:ubiquinone oxidoreductase subunit A1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC7	histone deacetylase 7	1	Completed	https://clinicaltrials.gov/study/NCT00788931,https://clinicaltrials.gov/study/NCT01105312,https://clinicaltrials.gov/study/NCT00632489
EFO_0000305	breast carcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
MONDO_0007254	breast cancer	CHEMBL598797	CUDC-101	Small molecule	Histone deacetylase inhibitor		HDAC4	histone deacetylase 4	1	Completed	https://clinicaltrials.gov/study/NCT01171924
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	PRIM2	DNA primase subunit 2	1	Completed	https://clinicaltrials.gov/study/NCT00100750
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Terminated	https://clinicaltrials.gov/study/NCT03579472,https://clinicaltrials.gov/study/NCT02753595,https://clinicaltrials.gov/study/NCT01388647
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Terminated	https://clinicaltrials.gov/study/NCT02345772,https://clinicaltrials.gov/study/NCT00063934,https://clinicaltrials.gov/study/NCT02379585,https://clinicaltrials.gov/study/NCT00864175,https://clinicaltrials.gov/study/NCT00531271,https://clinicaltrials.gov/study/NCT01876251,https://clinicaltrials.gov/study/NCT00253318,https://clinicaltrials.gov/study/NCT00584012
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA2	NADH:ubiquinone oxidoreductase subunit A2	1	Completed	https://clinicaltrials.gov/study/NCT01980823,https://clinicaltrials.gov/study/NCT01650506
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Withdrawn	https://clinicaltrials.gov/study/NCT01349088
MONDO_0007254	breast cancer	CHEMBL2177390	IPATASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT3	AKT serine/threonine kinase 3	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03959891
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC6	histone deacetylase 6	1	Completed	https://clinicaltrials.gov/study/NCT01105312,https://clinicaltrials.gov/study/NCT00632489,https://clinicaltrials.gov/study/NCT00788931
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLE2	DNA polymerase epsilon 2, accessory subunit	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03554044
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Completed	https://clinicaltrials.gov/study/NCT03872791,https://clinicaltrials.gov/study/NCT02672475,https://clinicaltrials.gov/study/NCT04584112
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Unknown status	https://clinicaltrials.gov/study/NCT00931450
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF2	NADH:ubiquinone oxidoreductase complex assembly factor 2	1	Completed	https://clinicaltrials.gov/study/NCT02278965
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Withdrawn	https://clinicaltrials.gov/study/NCT02396433
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR2	estrogen receptor 2	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05792410,https://clinicaltrials.gov/study/NCT04856371,https://clinicaltrials.gov/study/NCT04355520
EFO_0000304	breast adenocarcinoma	CHEMBL408513	BELINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC2	histone deacetylase 2	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
MONDO_0007254	breast cancer	CHEMBL4298024	BINTRAFUSP ALFA	Protein	Transforming growth factor beta binding agent		TGFB1	transforming growth factor beta 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03620201
MONDO_0007254	breast cancer	CHEMBL6	INDOMETHACIN	Small molecule	Cyclooxygenase inhibitor		PTGS2	prostaglandin-endoperoxide synthase 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02950259
EFO_0000305	breast carcinoma	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03854903
MONDO_0007254	breast cancer	CHEMBL2325741	CAPIVASERTIB	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT2	AKT serine/threonine kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT01625286
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Suspended	https://clinicaltrials.gov/study/NCT05422794
EFO_0006861	male breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Terminated	https://clinicaltrials.gov/study/NCT00063934
MONDO_0007254	breast cancer	CHEMBL298734	LONAFARNIB	Small molecule	Protein farnesyltransferase inhibitor		FNTA	farnesyltransferase, CAAX box, subunit alpha	1	Completed	https://clinicaltrials.gov/study/NCT00068757
MONDO_0007254	breast cancer	CHEMBL521851	PICTILISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	1	Completed	https://clinicaltrials.gov/study/NCT00928330,https://clinicaltrials.gov/study/NCT00960960
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Recruiting	https://clinicaltrials.gov/study/NCT05335473
EFO_1000984	inflammatory breast carcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC3	histone deacetylase 3	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC2	NADH:ubiquinone oxidoreductase subunit C2	1	Completed	https://clinicaltrials.gov/study/NCT01650506,https://clinicaltrials.gov/study/NCT01980823
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB6	NADH:ubiquinone oxidoreductase subunit B6	1	Completed	https://clinicaltrials.gov/study/NCT01650506,https://clinicaltrials.gov/study/NCT01980823
MONDO_0007254	breast cancer	CHEMBL521851	PICTILISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R2	phosphoinositide-3-kinase regulatory subunit 2	1	Unknown status	https://clinicaltrials.gov/study/NCT02389842
EFO_0000305	breast carcinoma	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN5A	sodium voltage-gated channel alpha subunit 5	1	Completed	https://clinicaltrials.gov/study/NCT03502395
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Completed	https://clinicaltrials.gov/study/NCT01432886,https://clinicaltrials.gov/study/NCT01323530
EFO_0006861	male breast carcinoma	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 1 inhibitor		HDAC1	histone deacetylase 1	1	Completed	https://clinicaltrials.gov/study/NCT00258349,https://clinicaltrials.gov/study/NCT01084057,https://clinicaltrials.gov/study/NCT00368875
EFO_0005537	triple-negative breast cancer	CHEMBL1795071	RUXOLITINIB PHOSPHATE	Small molecule	Tyrosine-protein kinase JAK1 inhibitor		JAK1	Janus kinase 1	1	Completed	https://clinicaltrials.gov/study/NCT03012230
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R5	phosphoinositide-3-kinase regulatory subunit 5	1	Unknown status	https://clinicaltrials.gov/study/NCT02389842
MONDO_0007254	breast cancer	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor	Inhibitor	RRM1	ribonucleotide reductase catalytic subunit M1	1	Completed	https://clinicaltrials.gov/study/NCT02479230,https://clinicaltrials.gov/study/NCT00100750
EFO_0006861	male breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Terminated	https://clinicaltrials.gov/study/NCT00063934
EFO_0006861	male breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
EFO_0000304	breast adenocarcinoma	CHEMBL3989922	NIRAPARIB TOSYLATE MONOHYDRATE	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04481113
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Unknown status	https://clinicaltrials.gov/study/NCT00764972
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Terminated	https://clinicaltrials.gov/study/NCT02474173,https://clinicaltrials.gov/study/NCT02824575
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Terminated	https://clinicaltrials.gov/study/NCT02824575,https://clinicaltrials.gov/study/NCT02474173
MONDO_0007254	breast cancer	CHEMBL1908360	EVEROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	1	Enrolling by invitation	https://clinicaltrials.gov/study/NCT05189717
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Withdrawn	https://clinicaltrials.gov/study/NCT00074139
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	1	Unknown status	https://clinicaltrials.gov/study/NCT02389842
MONDO_0007254	breast cancer	CHEMBL3545185	SELINEXOR	Small molecule	Exportin-1 inhibitor		XPO1	exportin 1	1	Recruiting	https://clinicaltrials.gov/study/NCT05035745
MONDO_0007254	breast cancer	CHEMBL744	RILUZOLE	Small molecule	Sodium channel alpha subunit blocker		SCN10A	sodium voltage-gated channel alpha subunit 10	1	Withdrawn	https://clinicaltrials.gov/study/NCT00903214
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	1	Unknown status	https://clinicaltrials.gov/study/NCT00764972
EFO_0005537	triple-negative breast cancer	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02419495
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR1	estrogen receptor 1	1	Withdrawn	https://clinicaltrials.gov/study/NCT04316169
MONDO_0007254	breast cancer	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA3	NADH:ubiquinone oxidoreductase subunit A3	1	Completed	https://clinicaltrials.gov/study/NCT01650506,https://clinicaltrials.gov/study/NCT01980823
EFO_0000305	breast carcinoma	CHEMBL289228	TIPIFARNIB	Small molecule	Protein farnesyltransferase inhibitor		FNTA	farnesyltransferase, CAAX box, subunit alpha	1	Completed	https://clinicaltrials.gov/study/NCT00100750
EFO_0006861	male breast carcinoma	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Completed	https://clinicaltrials.gov/study/NCT01084057
MONDO_0007254	breast cancer	CHEMBL3545376	ERDAFITINIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR2	fibroblast growth factor receptor 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03238196
MONDO_0007254	breast cancer	CHEMBL3545132	MIRVETUXIMAB SORAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Withdrawn	https://clinicaltrials.gov/study/NCT03045393
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA13	NADH:ubiquinone oxidoreductase subunit A13	1	Completed	https://clinicaltrials.gov/study/NCT01650506,https://clinicaltrials.gov/study/NCT01980823
EFO_0000304	breast adenocarcinoma	CHEMBL1743048	OBINUTUZUMAB	Antibody	B-lymphocyte antigen CD20 binding agent		MS4A1	membrane spanning 4-domains A1	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
MONDO_0007254	breast cancer	CHEMBL3647420	PYROTINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	1	Recruiting	https://clinicaltrials.gov/study/NCT04152057
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1094636	NIRAPARIB	Small molecule	Poly [ADP-ribose] polymerase 2 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	1	Recruiting	https://clinicaltrials.gov/study/NCT05694715
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Completed	https://clinicaltrials.gov/study/NCT01498458
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
MONDO_0007254	breast cancer	CHEMBL1201438	ALDESLEUKIN	Protein	Interleukin-2 receptor agonist		IL2RA	interleukin 2 receptor subunit alpha	1	Suspended	https://clinicaltrials.gov/study/NCT00673829
EFO_0005537	triple-negative breast cancer	CHEMBL225072	PEMETREXED	Small molecule	GAR transformylase inhibitor		GART	phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02419495
MONDO_0007254	breast cancer	CHEMBL4298119	OLINVACIMAB	Antibody	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03720431
MONDO_0007254	breast cancer	CHEMBL574737	UCN-01	Small molecule	Protein kinase C (PKC) inhibitor		PRKCB	protein kinase C beta	1	Completed	https://clinicaltrials.gov/study/NCT00001444
EFO_0000305	breast carcinoma	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC6	histone deacetylase 6	1	Completed	https://clinicaltrials.gov/study/NCT01434303
EFO_0000304	breast adenocarcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	PRIM1	DNA primase subunit 1	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
EFO_0000305	breast carcinoma	CHEMBL4297844	TRASTUZUMAB DERUXTECAN	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 binding agent		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04294628
EFO_1000984	inflammatory breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
EFO_0005537	triple-negative breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
EFO_0006861	male breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
EFO_0006861	male breast carcinoma	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		NCSTN	nicastrin	1	Terminated	https://clinicaltrials.gov/study/NCT01149356
MONDO_0007254	breast cancer	CHEMBL1094636	NIRAPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05519670
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD3	DNA polymerase delta 3, accessory subunit	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03554044
MONDO_0007254	breast cancer	CHEMBL4298024	BINTRAFUSP ALFA	Protein	Programmed cell death 1 ligand 1 binding agent		CD274	CD274 molecule	1	Terminated	https://clinicaltrials.gov/study/NCT04296942,https://clinicaltrials.gov/study/NCT03579472
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB5	NADH:ubiquinone oxidoreductase subunit B5	1	Completed	https://clinicaltrials.gov/study/NCT01980823,https://clinicaltrials.gov/study/NCT01650506
MONDO_0007254	breast cancer	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	1	Completed	https://clinicaltrials.gov/study/NCT03599453,https://clinicaltrials.gov/study/NCT01676753,https://clinicaltrials.gov/study/NCT02129556,https://clinicaltrials.gov/study/NCT03329950,https://clinicaltrials.gov/study/NCT02646748,https://clinicaltrials.gov/study/NCT02657889
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	1	Terminated	https://clinicaltrials.gov/study/NCT01132664
MONDO_0007254	breast cancer	CHEMBL101253	VATALANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Completed	https://clinicaltrials.gov/study/NCT00268918
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R2	phosphoinositide-3-kinase regulatory subunit 2	1	Unknown status	https://clinicaltrials.gov/study/NCT02389842
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Terminated	https://clinicaltrials.gov/study/NCT03579472,https://clinicaltrials.gov/study/NCT02753595,https://clinicaltrials.gov/study/NCT01388647
EFO_0006861	male breast carcinoma	CHEMBL98	VORINOSTAT	Small molecule	Histone deacetylase 2 inhibitor		HDAC2	histone deacetylase 2	1	Completed	https://clinicaltrials.gov/study/NCT00258349,https://clinicaltrials.gov/study/NCT00368875,https://clinicaltrials.gov/study/NCT01084057
MONDO_0007254	breast cancer	CHEMBL1089	PHENELZINE	Small molecule	Monoamine oxidase inhibitor		MAOB	monoamine oxidase B	1	Completed	https://clinicaltrials.gov/study/NCT03505528
MONDO_0007254	breast cancer	CHEMBL3544983	TESEVATINIB	Small molecule	Ephrin type-B receptor 4 inhibitor		EPHB4	EPH receptor B4	1	Terminated	https://clinicaltrials.gov/study/NCT02154529
MONDO_0007254	breast cancer	CHEMBL413376	SURAMIN HEXASODIUM	Small molecule	Acidic fibroblast growth factor inhibitor		FGF1	fibroblast growth factor 1	1	Completed	https://clinicaltrials.gov/study/NCT00003038,https://clinicaltrials.gov/study/NCT00054028
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Macrophage colony stimulating factor receptor inhibitor		CSF1R	colony stimulating factor 1 receptor	1	Unknown status	https://clinicaltrials.gov/study/NCT00931450
EFO_1000984	inflammatory breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Unknown status	https://clinicaltrials.gov/study/NCT01880385
EFO_0000304	breast adenocarcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03032107,https://clinicaltrials.gov/study/NCT02390427
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Terminated	https://clinicaltrials.gov/study/NCT02658084,https://clinicaltrials.gov/study/NCT04042051,https://clinicaltrials.gov/study/NCT04296942,https://clinicaltrials.gov/study/NCT03429101,https://clinicaltrials.gov/study/NCT04298918
MONDO_0007254	breast cancer	CHEMBL3545132	MIRVETUXIMAB SORAVTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBA3C	tubulin alpha 3c	1	Withdrawn	https://clinicaltrials.gov/study/NCT03045393
MONDO_0007254	breast cancer	CHEMBL3	NICOTINE	Small molecule	Neuronal acetylcholine receptor; alpha4/beta2 agonist		CHRNB2	cholinergic receptor nicotinic beta 2 subunit	1	Completed	https://clinicaltrials.gov/study/NCT03346161
MONDO_0007254	breast cancer	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	1	Terminated	https://clinicaltrials.gov/study/NCT02734615
MONDO_0007254	breast cancer	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	1	Suspended	https://clinicaltrials.gov/study/NCT01618357
MONDO_0007254	breast cancer	CHEMBL46740	BAZEDOXIFENE	Small molecule	Estrogen receptor modulator		ESR1	estrogen receptor 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04821375
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLE	DNA polymerase epsilon, catalytic subunit	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03554044
EFO_0000305	breast carcinoma	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		APH1A	aph-1 homolog A, gamma-secretase subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01071564
EFO_0000305	breast carcinoma	CHEMBL79	LIDOCAINE	Small molecule	Sodium channel alpha subunit blocker		SCN9A	sodium voltage-gated channel alpha subunit 9	1	Completed	https://clinicaltrials.gov/study/NCT03502395
MONDO_0007254	breast cancer	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	1	Terminated	https://clinicaltrials.gov/study/NCT00039455
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS5	NADH:ubiquinone oxidoreductase subunit S5	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
MONDO_0007254	breast cancer	CHEMBL1567	SUNITINIB MALATE	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Terminated	https://clinicaltrials.gov/study/NCT00616122,https://clinicaltrials.gov/study/NCT00905021
MONDO_0007254	breast cancer	CHEMBL3544983	TESEVATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	1	Terminated	https://clinicaltrials.gov/study/NCT02154529
MONDO_0007254	breast cancer	CHEMBL225072	PEMETREXED	Small molecule	GAR transformylase inhibitor		GART	phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase	1	Completed	https://clinicaltrials.gov/study/NCT00097383,https://clinicaltrials.gov/study/NCT01655225,https://clinicaltrials.gov/study/NCT00190671
MONDO_0007254	breast cancer	CHEMBL1879463	DACTOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	1	Terminated	https://clinicaltrials.gov/study/NCT01495247
MONDO_0007254	breast cancer	CHEMBL2108501	LABETUZUMAB	Antibody	Carcinoembryonic antigen-related cell adhesion molecule 5 other		CEACAM5	CEA cell adhesion molecule 5	1	Completed	https://clinicaltrials.gov/study/NCT00041652
MONDO_0007254	breast cancer	CHEMBL3545097	SAPANISERTIB	Small molecule	Serine/threonine-protein kinase mTOR inhibitor		MTOR	mechanistic target of rapamycin kinase	1	Withdrawn	https://clinicaltrials.gov/study/NCT02619669
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Completed	https://clinicaltrials.gov/study/NCT00080665,https://clinicaltrials.gov/study/NCT00268918,https://clinicaltrials.gov/study/NCT04367090,https://clinicaltrials.gov/study/NCT00086957,https://clinicaltrials.gov/study/NCT00002901,https://clinicaltrials.gov/study/NCT00169000,https://clinicaltrials.gov/study/NCT02392845,https://clinicaltrials.gov/study/NCT00129896,https://clinicaltrials.gov/study/NCT00705315,https://clinicaltrials.gov/study/NCT00637897,https://clinicaltrials.gov/study/NCT00020332,https://clinicaltrials.gov/study/NCT02605915,https://clinicaltrials.gov/study/NCT00934856,https://clinicaltrials.gov/study/NCT01044485,https://clinicaltrials.gov/study/NCT00645333,https://clinicaltrials.gov/study/NCT05301530,https://clinicaltrials.gov/study/NCT01862081,https://clinicaltrials.gov/study/NCT00450892,https://clinicaltrials.gov/study/NCT02027376,https://clinicaltrials.gov/study/NCT00050167,https://clinicaltrials.gov/study/NCT00322400,https://clinicaltrials.gov/study/NCT01256567,https://clinicaltrials.gov/study/NCT00372424,https://clinicaltrials.gov/study/NCT00003103,https://clinicaltrials.gov/study/NCT00872625
EFO_0000305	breast carcinoma	CHEMBL477772	PAZOPANIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL2109406	PATRITUMAB	Antibody	Receptor tyrosine-protein kinase erbB-3 inhibitor		ERBB3	erb-b2 receptor tyrosine kinase 3	1	Terminated	https://clinicaltrials.gov/study/NCT01512199
EFO_0005537	triple-negative breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	1	Terminated	https://clinicaltrials.gov/study/NCT02457910
EFO_0005537	triple-negative breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLA2	DNA polymerase alpha 2, accessory subunit	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04750382
MONDO_0007254	breast cancer	CHEMBL2408045	SAPITINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT00900627,https://clinicaltrials.gov/study/NCT01003158
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02419495
MONDO_0007254	breast cancer	CHEMBL3833344	GANCOTAMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 binding agent		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Unknown status	https://clinicaltrials.gov/study/NCT01304797
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBB2B	tubulin beta 2B class IIb	1	Completed	https://clinicaltrials.gov/study/NCT00270907
EFO_0006861	male breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Terminated	https://clinicaltrials.gov/study/NCT00063934
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Withdrawn	https://clinicaltrials.gov/study/NCT00074139
EFO_0000304	breast adenocarcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD4	DNA polymerase delta 4, accessory subunit	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
MONDO_0007254	breast cancer	CHEMBL3707404	LUMRETUZUMAB	Antibody	Receptor tyrosine-protein kinase erbB-3 inhibitor		ERBB3	erb-b2 receptor tyrosine kinase 3	1	Completed	https://clinicaltrials.gov/study/NCT01918254
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Completed	https://clinicaltrials.gov/study/NCT02605915,https://clinicaltrials.gov/study/NCT00372424,https://clinicaltrials.gov/study/NCT00934856,https://clinicaltrials.gov/study/NCT00020332,https://clinicaltrials.gov/study/NCT00645333,https://clinicaltrials.gov/study/NCT00080665,https://clinicaltrials.gov/study/NCT02392845,https://clinicaltrials.gov/study/NCT00872625,https://clinicaltrials.gov/study/NCT00268918,https://clinicaltrials.gov/study/NCT01256567,https://clinicaltrials.gov/study/NCT05301530,https://clinicaltrials.gov/study/NCT00169000,https://clinicaltrials.gov/study/NCT00129896,https://clinicaltrials.gov/study/NCT01862081,https://clinicaltrials.gov/study/NCT02027376,https://clinicaltrials.gov/study/NCT00705315,https://clinicaltrials.gov/study/NCT00003103,https://clinicaltrials.gov/study/NCT01044485,https://clinicaltrials.gov/study/NCT00086957,https://clinicaltrials.gov/study/NCT00002901,https://clinicaltrials.gov/study/NCT00050167,https://clinicaltrials.gov/study/NCT00637897,https://clinicaltrials.gov/study/NCT04367090,https://clinicaltrials.gov/study/NCT00322400,https://clinicaltrials.gov/study/NCT00450892
EFO_0000304	breast adenocarcinoma	CHEMBL3218576	COPANLISIB	Small molecule	PI3-kinase p110-delta subunit inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
MONDO_0007254	breast cancer	CHEMBL4594417	PRUXELUTAMIDE	Small molecule	Androgen Receptor antagonist		AR	androgen receptor	1	Completed	https://clinicaltrials.gov/study/NCT04103853
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD1	DNA polymerase delta 1, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT01154426
EFO_0005537	triple-negative breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	1	Terminated	https://clinicaltrials.gov/study/NCT02457910
MONDO_0007254	breast cancer	CHEMBL4298024	BINTRAFUSP ALFA	Protein	Programmed cell death 1 ligand 1 binding agent		CD274	CD274 molecule	1	Withdrawn	https://clinicaltrials.gov/study/NCT04756505
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Withdrawn	https://clinicaltrials.gov/study/NCT01349088
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1042	CHOLECALCIFEROL	Small molecule	Vitamin D receptor agonist		VDR	vitamin D receptor	1	Withdrawn	https://clinicaltrials.gov/study/NCT02856503
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB	tubulin beta class I	1	Terminated	https://clinicaltrials.gov/study/NCT02474173,https://clinicaltrials.gov/study/NCT01238133
EFO_0006861	male breast carcinoma	CHEMBL1201550	DENILEUKIN DIFTITOX	Protein	Elongation factor 2 inhibitor		EEF2	eukaryotic translation elongation factor 2	1	Completed	https://clinicaltrials.gov/study/NCT00425672
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Terminated	https://clinicaltrials.gov/study/NCT00041470,https://clinicaltrials.gov/study/NCT02658084,https://clinicaltrials.gov/study/NCT00075673,https://clinicaltrials.gov/study/NCT01254136,https://clinicaltrials.gov/study/NCT00140140,https://clinicaltrials.gov/study/NCT01238029
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND6	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6	1	Completed	https://clinicaltrials.gov/study/NCT01980823,https://clinicaltrials.gov/study/NCT01650506
MONDO_0007254	breast cancer	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT04856371
MONDO_0007254	breast cancer	CHEMBL1567	SUNITINIB MALATE	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Terminated	https://clinicaltrials.gov/study/NCT00905021,https://clinicaltrials.gov/study/NCT00616122
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLE	DNA polymerase epsilon, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT01154426
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Withdrawn	https://clinicaltrials.gov/study/NCT02070094
EFO_0000305	breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD3	DNA polymerase delta 3, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT00100750
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	PRIM1	DNA primase subunit 1	1	Terminated	https://clinicaltrials.gov/study/NCT01333137,https://clinicaltrials.gov/study/NCT01929941,https://clinicaltrials.gov/study/NCT01939418
MONDO_0007254	breast cancer	CHEMBL4298024	BINTRAFUSP ALFA	Protein	Transforming growth factor beta binding agent		TGFB3	transforming growth factor beta 3	1	Terminated	https://clinicaltrials.gov/study/NCT03579472,https://clinicaltrials.gov/study/NCT04296942
MONDO_0007254	breast cancer	CHEMBL3545154	POZIOTINIB	Small molecule	Epidermal growth factor receptor inhibitor		ERBB4	erb-b2 receptor tyrosine kinase 4	1	Terminated	https://clinicaltrials.gov/study/NCT03429101
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND1	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Terminated	https://clinicaltrials.gov/study/NCT01407562,https://clinicaltrials.gov/study/NCT00140140,https://clinicaltrials.gov/study/NCT00041470,https://clinicaltrials.gov/study/NCT01512199,https://clinicaltrials.gov/study/NCT02358200,https://clinicaltrials.gov/study/NCT02297230,https://clinicaltrials.gov/study/NCT00003086,https://clinicaltrials.gov/study/NCT01249443,https://clinicaltrials.gov/study/NCT01090128,https://clinicaltrials.gov/study/NCT02474173,https://clinicaltrials.gov/study/NCT01980277,https://clinicaltrials.gov/study/NCT01929941,https://clinicaltrials.gov/study/NCT02379585,https://clinicaltrials.gov/study/NCT01495247
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Terminated	https://clinicaltrials.gov/study/NCT01407562,https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL598797	CUDC-101	Small molecule	Histone deacetylase inhibitor		HDAC1	histone deacetylase 1	1	Completed	https://clinicaltrials.gov/study/NCT01171924
EFO_0006861	male breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Terminated	https://clinicaltrials.gov/study/NCT00063934
MONDO_0007254	breast cancer	CHEMBL3545262	SACITUZUMAB GOVITECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	1	Recruiting	https://clinicaltrials.gov/study/NCT05143229
MONDO_0007254	breast cancer	CHEMBL538943	VINORELBINE TARTRATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Terminated	https://clinicaltrials.gov/study/NCT00075673
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	1	Withdrawn	https://clinicaltrials.gov/study/NCT03400254
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Completed	https://clinicaltrials.gov/study/NCT04584112,https://clinicaltrials.gov/study/NCT02672475,https://clinicaltrials.gov/study/NCT03872791
EFO_0000305	breast carcinoma	CHEMBL314854	FINGOLIMOD	Small molecule	Sphingosine 1-phosphate receptor agonist		S1PR2	sphingosine-1-phosphate receptor 2	1	Completed	https://clinicaltrials.gov/study/NCT03941743
MONDO_0007254	breast cancer	CHEMBL3137320	TALAZOPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	1	Terminated	https://clinicaltrials.gov/study/NCT02358200
MONDO_0007254	breast cancer	CHEMBL2109363	BRE-3 90Y	Antibody	Lactadherin binding agent		MFGE8	milk fat globule EGF and factor V/VIII domain containing	1	Completed	https://clinicaltrials.gov/study/NCT00007891
MONDO_0007254	breast cancer	CHEMBL941	IMATINIB	Small molecule	Platelet-derived growth factor receptor beta inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Completed	https://clinicaltrials.gov/study/NCT00080665
EFO_0000305	breast carcinoma	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
MONDO_0007254	breast cancer	CHEMBL3186534	RIVOCERANIB	Small molecule	Vascular endothelial growth factor receptor 2 inhibitor		KDR	kinase insert domain receptor	1	Completed	https://clinicaltrials.gov/study/NCT03945604
EFO_0008509	lobular breast carcinoma	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	1	Completed	https://clinicaltrials.gov/study/NCT01077453
MONDO_0007254	breast cancer	CHEMBL15770	SULINDAC	Small molecule	Cyclooxygenase inhibitor		PTGS2	prostaglandin-endoperoxide synthase 2	1	Completed	https://clinicaltrials.gov/study/NCT00245024
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		BLK	BLK proto-oncogene, Src family tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT01306942,https://clinicaltrials.gov/study/NCT00452673,https://clinicaltrials.gov/study/NCT00820170,https://clinicaltrials.gov/study/NCT00924352
EFO_0000304	breast adenocarcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02390427
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Terminated	https://clinicaltrials.gov/study/NCT02379585,https://clinicaltrials.gov/study/NCT00063934,https://clinicaltrials.gov/study/NCT00864175,https://clinicaltrials.gov/study/NCT01876251,https://clinicaltrials.gov/study/NCT00253318,https://clinicaltrials.gov/study/NCT00584012,https://clinicaltrials.gov/study/NCT02345772,https://clinicaltrials.gov/study/NCT00531271
MONDO_0007254	breast cancer	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB	tubulin beta class I	1	Terminated	https://clinicaltrials.gov/study/NCT04298918,https://clinicaltrials.gov/study/NCT03429101,https://clinicaltrials.gov/study/NCT04296942,https://clinicaltrials.gov/study/NCT02658084,https://clinicaltrials.gov/study/NCT04042051
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Completed	https://clinicaltrials.gov/study/NCT00496665
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	Bcr/Abl fusion protein		ABL1	ABL proto-oncogene 1, non-receptor tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT00903006
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Terminated	https://clinicaltrials.gov/study/NCT00003086,https://clinicaltrials.gov/study/NCT02474173,https://clinicaltrials.gov/study/NCT00140140,https://clinicaltrials.gov/study/NCT01929941,https://clinicaltrials.gov/study/NCT01249443,https://clinicaltrials.gov/study/NCT01407562,https://clinicaltrials.gov/study/NCT02297230,https://clinicaltrials.gov/study/NCT02358200,https://clinicaltrials.gov/study/NCT01980277,https://clinicaltrials.gov/study/NCT02379585,https://clinicaltrials.gov/study/NCT01495247,https://clinicaltrials.gov/study/NCT00041470,https://clinicaltrials.gov/study/NCT01090128,https://clinicaltrials.gov/study/NCT01512199
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA5	EPH receptor A5	1	Completed	https://clinicaltrials.gov/study/NCT00496665
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Withdrawn	https://clinicaltrials.gov/study/NCT02396433
EFO_0000305	breast carcinoma	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	1	Completed	https://clinicaltrials.gov/study/NCT03518242
EFO_0000305	breast carcinoma	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03854903
MONDO_0007254	breast cancer	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Unknown status	https://clinicaltrials.gov/study/NCT00367250,https://clinicaltrials.gov/study/NCT01084863,https://clinicaltrials.gov/study/NCT01304797
MONDO_0007254	breast cancer	CHEMBL521851	PICTILISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R5	phosphoinositide-3-kinase regulatory subunit 5	1	Unknown status	https://clinicaltrials.gov/study/NCT02389842
MONDO_0007254	breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT05176080
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	SRC inhibitor		YES1	YES proto-oncogene 1, Src family tyrosine kinase	1	Completed	https://clinicaltrials.gov/study/NCT01306942,https://clinicaltrials.gov/study/NCT00452673,https://clinicaltrials.gov/study/NCT00924352,https://clinicaltrials.gov/study/NCT00820170
MONDO_0007254	breast cancer	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172,https://clinicaltrials.gov/study/NCT02499146,https://clinicaltrials.gov/study/NCT04895761,https://clinicaltrials.gov/study/NCT03962647,https://clinicaltrials.gov/study/NCT06047184,https://clinicaltrials.gov/study/NCT01791478,https://clinicaltrials.gov/study/NCT03772353
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBA1A	tubulin alpha 1a	1	Completed	https://clinicaltrials.gov/study/NCT00270907
MONDO_0007254	breast cancer	CHEMBL3218578	BGT-226	Small molecule	PI3-kinase class I inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	1	Completed	https://clinicaltrials.gov/study/NCT00600275
MONDO_0007254	breast cancer	CHEMBL4297858	BUDIGALIMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03893955
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	1	Unknown status	https://clinicaltrials.gov/study/NCT02626507
EFO_0000305	breast carcinoma	CHEMBL1214827	ONALESPIB	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AB1	heat shock protein 90 alpha family class B member 1	1	Terminated	https://clinicaltrials.gov/study/NCT02474173
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Completed	https://clinicaltrials.gov/study/NCT01816035
EFO_0005537	triple-negative breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
MONDO_0007254	breast cancer	CHEMBL2108628	PACLITAXEL POLIGLUMEX	Small molecule	Tubulin stabiliser		TUBA1C	tubulin alpha 1c	1	Completed	https://clinicaltrials.gov/study/NCT00270907
EFO_1000984	inflammatory breast carcinoma	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	1	Completed	https://clinicaltrials.gov/study/NCT02227082
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS3	NADH:ubiquinone oxidoreductase core subunit S3	1	Completed	https://clinicaltrials.gov/study/NCT02278965
MONDO_0007254	breast cancer	CHEMBL3545110	RIBOCICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03616587,https://clinicaltrials.gov/study/NCT02608216
MONDO_0004658	breast carcinoma in situ	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Completed	https://clinicaltrials.gov/study/NCT04081389
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND3	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3	1	Completed	https://clinicaltrials.gov/study/NCT01650506,https://clinicaltrials.gov/study/NCT01980823
EFO_0005537	triple-negative breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	1	Terminated	https://clinicaltrials.gov/study/NCT02457910
MONDO_0007254	breast cancer	CHEMBL574737	UCN-01	Small molecule	Protein kinase C (PKC) inhibitor		PRKCD	protein kinase C delta	1	Completed	https://clinicaltrials.gov/study/NCT00001444
EFO_0000304	breast adenocarcinoma	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
MONDO_0007254	breast cancer	CHEMBL3218576	COPANLISIB	Small molecule	PI3-kinase p110-alpha subunit inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	1	Terminated	https://clinicaltrials.gov/study/NCT04042051
EFO_0000305	breast carcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD1	DNA polymerase delta 1, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT00100750
MONDO_0007254	breast cancer	CHEMBL2103879	GANETESPIB	Small molecule	Heat shock protein HSP90 inhibitor		HSP90AB1	heat shock protein 90 alpha family class B member 1	1	Completed	https://clinicaltrials.gov/study/NCT02060253
EFO_0000305	breast carcinoma	CHEMBL554	LAPATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Terminated	https://clinicaltrials.gov/study/NCT01281163
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB8	tubulin beta 8 class VIII	1	Recruiting	https://clinicaltrials.gov/study/NCT05092373
EFO_0006861	male breast carcinoma	CHEMBL2103840	DINACICLIB	Small molecule	Cyclin-dependent kinase 9 inhibitor		CDK9	cyclin dependent kinase 9	1	Completed	https://clinicaltrials.gov/study/NCT01624441
EFO_0005537	triple-negative breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
MONDO_0007254	breast cancer	CHEMBL3184679	AZD-4547	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR2	fibroblast growth factor receptor 2	1	Completed	https://clinicaltrials.gov/study/NCT01791985,https://clinicaltrials.gov/study/NCT01202591
MONDO_0007254	breast cancer	CHEMBL3963485	ROGARATINIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR4	fibroblast growth factor receptor 4	1	Completed	https://clinicaltrials.gov/study/NCT04483505
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Terminated	https://clinicaltrials.gov/study/NCT00634088
MONDO_0007254	breast cancer	CHEMBL1201752	IXABEPILONE	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Terminated	https://clinicaltrials.gov/study/NCT00634088
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Withdrawn	https://clinicaltrials.gov/study/NCT02569489,https://clinicaltrials.gov/study/NCT04826016,https://clinicaltrials.gov/study/NCT04762901,https://clinicaltrials.gov/study/NCT04252768,https://clinicaltrials.gov/study/NCT03285607,https://clinicaltrials.gov/study/NCT00022230,https://clinicaltrials.gov/study/NCT03175666
MONDO_0007254	breast cancer	CHEMBL2007641	PERTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Recruiting	https://clinicaltrials.gov/study/NCT04253561,https://clinicaltrials.gov/study/NCT06162559
MONDO_0007254	breast cancer	CHEMBL15770	SULINDAC	Small molecule	Cyclooxygenase inhibitor		PTGS1	prostaglandin-endoperoxide synthase 1	1	Completed	https://clinicaltrials.gov/study/NCT00245024
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD3	DNA polymerase delta 3, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT01154426
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor		GPD2	glycerol-3-phosphate dehydrogenase 2	1	Completed	https://clinicaltrials.gov/study/NCT02278965
MONDO_0007254	breast cancer	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Withdrawn	https://clinicaltrials.gov/study/NCT03846583,https://clinicaltrials.gov/study/NCT00006123,https://clinicaltrials.gov/study/NCT02336984,https://clinicaltrials.gov/study/NCT02569489,https://clinicaltrials.gov/study/NCT01479179
EFO_0006861	male breast carcinoma	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 9 inhibitor		CDK9	cyclin dependent kinase 9	1	Terminated	https://clinicaltrials.gov/study/NCT00039455
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02419495
MONDO_0007254	breast cancer	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 2 inhibitor		CDK2	cyclin dependent kinase 2	1	Terminated	https://clinicaltrials.gov/study/NCT00039455
MONDO_0007254	breast cancer	CHEMBL1421	DASATINIB	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT00903006
MONDO_0007254	breast cancer	CHEMBL1567	SUNITINIB MALATE	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Terminated	https://clinicaltrials.gov/study/NCT00616122,https://clinicaltrials.gov/study/NCT00905021
MONDO_0007254	breast cancer	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Fibroblast growth factor receptor 1 inhibitor		FGFR1	fibroblast growth factor receptor 1	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL3545262	SACITUZUMAB GOVITECAN	Antibody drug conjugate	Tumor-associated calcium signal transducer 2 binding agent		TACSTD2	tumor associated calcium signal transducer 2	1	Terminated	https://clinicaltrials.gov/study/NCT04927884
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC11	histone deacetylase 11	1	Terminated	https://clinicaltrials.gov/study/NCT00567879
MONDO_0007254	breast cancer	CHEMBL522892	DOVITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Terminated	https://clinicaltrials.gov/study/NCT01484041
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT00600496
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL888	GEMCITABINE	Small molecule	Ribonucleoside-diphosphate reductase RR1 inhibitor	Inhibitor	RRM1	ribonucleotide reductase catalytic subunit M1	1	Completed	https://clinicaltrials.gov/study/NCT01154426
MONDO_0007254	breast cancer	CHEMBL1770916	NIROGACESTAT	Small molecule	Gamma-secretase inhibitor		NCSTN	nicastrin	1	Terminated	https://clinicaltrials.gov/study/NCT01876251
EFO_0006861	male breast carcinoma	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	1	Completed	https://clinicaltrials.gov/study/NCT01783756
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR1	estrogen receptor 1	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT04856371,https://clinicaltrials.gov/study/NCT04355520,https://clinicaltrials.gov/study/NCT05792410
MONDO_0007254	breast cancer	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		PSEN2	presenilin 2	1	Terminated	https://clinicaltrials.gov/study/NCT01208441
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB2A	tubulin beta 2A class IIa	1	Terminated	https://clinicaltrials.gov/study/NCT03579472
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB3	tubulin beta 3 class III	1	Terminated	https://clinicaltrials.gov/study/NCT03579472
MONDO_0007254	breast cancer	CHEMBL1336	SORAFENIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Unknown status	https://clinicaltrials.gov/study/NCT00764972
MONDO_0007254	breast cancer	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT00803556,https://clinicaltrials.gov/study/NCT04175171,https://clinicaltrials.gov/study/NCT00928330,https://clinicaltrials.gov/study/NCT02060253,https://clinicaltrials.gov/study/NCT00574587,https://clinicaltrials.gov/study/NCT01423123,https://clinicaltrials.gov/study/NCT00006108,https://clinicaltrials.gov/study/NCT01300962,https://clinicaltrials.gov/study/NCT00009997,https://clinicaltrials.gov/study/NCT00085020,https://clinicaltrials.gov/study/NCT00960960,https://clinicaltrials.gov/study/NCT02167854,https://clinicaltrials.gov/study/NCT00412412,https://clinicaltrials.gov/study/NCT02139358,https://clinicaltrials.gov/study/NCT00014430,https://clinicaltrials.gov/study/NCT00807859,https://clinicaltrials.gov/study/NCT04905667,https://clinicaltrials.gov/study/NCT00004074,https://clinicaltrials.gov/study/NCT02738970,https://clinicaltrials.gov/study/NCT01306942,https://clinicaltrials.gov/study/NCT01042925,https://clinicaltrials.gov/study/NCT00068757,https://clinicaltrials.gov/study/NCT03135171,https://clinicaltrials.gov/study/NCT00337649,https://clinicaltrials.gov/study/NCT01373710,https://clinicaltrials.gov/study/NCT01271920,https://clinicaltrials.gov/study/NCT00788931,https://clinicaltrials.gov/study/NCT02015676,https://clinicaltrials.gov/study/NCT01471847,https://clinicaltrials.gov/study/NCT00086957,https://clinicaltrials.gov/study/NCT02705859,https://clinicaltrials.gov/study/NCT00398567,https://clinicaltrials.gov/study/NCT01325207,https://clinicaltrials.gov/study/NCT00258349,https://clinicaltrials.gov/study/NCT02562378,https://clinicaltrials.gov/study/NCT00426556,https://clinicaltrials.gov/study/NCT00095706,https://clinicaltrials.gov/study/NCT00301730,https://clinicaltrials.gov/study/NCT00800436,https://clinicaltrials.gov/study/NCT01921335,https://clinicaltrials.gov/study/NCT05301530,https://clinicaltrials.gov/study/NCT00129896,https://clinicaltrials.gov/study/NCT00004925,https://clinicaltrials.gov/study/NCT02605915,https://clinicaltrials.gov/study/NCT00458237,https://clinicaltrials.gov/study/NCT00932373,https://clinicaltrials.gov/study/NCT03112590,https://clinicaltrials.gov/study/NCT02657343,https://clinicaltrials.gov/study/NCT04367090,https://clinicaltrials.gov/study/NCT00006825,https://clinicaltrials.gov/study/NCT00033514,https://clinicaltrials.gov/study/NCT00788333,https://clinicaltrials.gov/study/NCT00450892,https://clinicaltrials.gov/study/NCT00372424,https://clinicaltrials.gov/study/NCT02649686,https://clinicaltrials.gov/study/NCT02025192,https://clinicaltrials.gov/study/NCT02843126
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB4B	tubulin beta 4B class IVb	1	Terminated	https://clinicaltrials.gov/study/NCT02824575,https://clinicaltrials.gov/study/NCT02474173
MONDO_0007254	breast cancer	CHEMBL592445	GEDATOLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R5	phosphoinositide-3-kinase regulatory subunit 5	1	Unknown status	https://clinicaltrials.gov/study/NCT02626507
MONDO_0007254	breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	1	Completed	https://clinicaltrials.gov/study/NCT01655225,https://clinicaltrials.gov/study/NCT04514159
MONDO_0004658	breast carcinoma in situ	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Completed	https://clinicaltrials.gov/study/NCT04081389
EFO_0000305	breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Terminated	https://clinicaltrials.gov/study/NCT02474173,https://clinicaltrials.gov/study/NCT02824575
EFO_0000305	breast carcinoma	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03218826
EFO_0006861	male breast carcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC11	histone deacetylase 11	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
MONDO_0007254	breast cancer	CHEMBL1201583	BEVACIZUMAB	Antibody	Vascular endothelial growth factor A inhibitor		VEGFA	vascular endothelial growth factor A	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05792410
MONDO_0007254	breast cancer	CHEMBL502835	NINTEDANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Completed	https://clinicaltrials.gov/study/NCT02619162
EFO_0006861	male breast carcinoma	CHEMBL506871	VELIPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	1	Completed	https://clinicaltrials.gov/study/NCT01281150
MONDO_0007254	breast cancer	CHEMBL535	SUNITINIB	Small molecule	Tyrosine-protein kinase receptor RET inhibitor		RET	ret proto-oncogene	1	Completed	https://clinicaltrials.gov/study/NCT01070706,https://clinicaltrials.gov/study/NCT00887575,https://clinicaltrials.gov/study/NCT00372424
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND1	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1	1	Completed	https://clinicaltrials.gov/study/NCT01980823,https://clinicaltrials.gov/study/NCT01650506
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT01816035
MONDO_0007254	breast cancer	CHEMBL2336325	VISTUSERTIB	Small molecule	Serine/threonine-protein kinase mTOR inhibitor		MTOR	mechanistic target of rapamycin kinase	1	Completed	https://clinicaltrials.gov/study/NCT01884285,https://clinicaltrials.gov/study/NCT02599714
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Completed	https://clinicaltrials.gov/study/NCT01288261,https://clinicaltrials.gov/study/NCT00368875,https://clinicaltrials.gov/study/NCT02060253,https://clinicaltrials.gov/study/NCT01281150,https://clinicaltrials.gov/study/NCT00470301,https://clinicaltrials.gov/study/NCT01276496,https://clinicaltrials.gov/study/NCT01493310
EFO_0006861	male breast carcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC3	histone deacetylase 3	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
MONDO_0007254	breast cancer	CHEMBL574737	UCN-01	Small molecule	Protein kinase C (PKC) inhibitor		PRKCQ	protein kinase C theta	1	Completed	https://clinicaltrials.gov/study/NCT00001444
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS8	NADH:ubiquinone oxidoreductase core subunit S8	1	Completed	https://clinicaltrials.gov/study/NCT01650506,https://clinicaltrials.gov/study/NCT01980823
MONDO_0007254	breast cancer	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA11	NADH:ubiquinone oxidoreductase subunit A11	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Terminated	https://clinicaltrials.gov/study/NCT00063934,https://clinicaltrials.gov/study/NCT00864175,https://clinicaltrials.gov/study/NCT00584012,https://clinicaltrials.gov/study/NCT01876251,https://clinicaltrials.gov/study/NCT00253318,https://clinicaltrials.gov/study/NCT02379585,https://clinicaltrials.gov/study/NCT00531271,https://clinicaltrials.gov/study/NCT02345772
MONDO_0007254	breast cancer	CHEMBL1201567	FILGRASTIM	Protein	Granulocyte colony stimulating factor receptor agonist		CSF3R	colony stimulating factor 3 receptor	1	Completed	https://clinicaltrials.gov/study/NCT00724386,https://clinicaltrials.gov/study/NCT00004174,https://clinicaltrials.gov/study/NCT00002837,https://clinicaltrials.gov/study/NCT00003927,https://clinicaltrials.gov/study/NCT00007891,https://clinicaltrials.gov/study/NCT00002509,https://clinicaltrials.gov/study/NCT00020410,https://clinicaltrials.gov/study/NCT00004085,https://clinicaltrials.gov/study/NCT00003877
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	1	Completed	https://clinicaltrials.gov/study/NCT01237067,https://clinicaltrials.gov/study/NCT00707707
EFO_0000305	breast carcinoma	CHEMBL1743082	TRASTUZUMAB EMTANSINE	Antibody drug conjugate	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Completed	https://clinicaltrials.gov/study/NCT01816035
MONDO_0007254	breast cancer	CHEMBL502835	NINTEDANIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Completed	https://clinicaltrials.gov/study/NCT02619162
EFO_0006318	breast ductal adenocarcinoma	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR1	estrogen receptor 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02983071
MONDO_0007254	breast cancer	CHEMBL2035187	PACRITINIB	Small molecule	Tyrosine-protein kinase receptor FLT3 inhibitor		FLT3	fms related receptor tyrosine kinase 3	1	Recruiting	https://clinicaltrials.gov/study/NCT04520269
EFO_0005537	triple-negative breast cancer	CHEMBL4297840	TISLELIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05746728
EFO_0000305	breast carcinoma	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor		TUBB2B	tubulin beta 2B class IIb	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
MONDO_0007254	breast cancer	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	1	Withdrawn	https://clinicaltrials.gov/study/NCT04872608,https://clinicaltrials.gov/study/NCT04316169,https://clinicaltrials.gov/study/NCT02619669
EFO_0005537	triple-negative breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R5	phosphoinositide-3-kinase regulatory subunit 5	1	Terminated	https://clinicaltrials.gov/study/NCT02457910
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor	Inhibitor	POLD2	DNA polymerase delta 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT01154426
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB4A	tubulin beta 4A class IVa	1	Completed	https://clinicaltrials.gov/study/NCT02120469
EFO_0006861	male breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Tyrosine-protein kinase ITK/TSK inhibitor		ITK	IL2 inducible T cell kinase	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
EFO_0005537	triple-negative breast cancer	CHEMBL574737	UCN-01	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	1	Completed	https://clinicaltrials.gov/study/NCT00031681
MONDO_0007254	breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor		TUBB6	tubulin beta 6 class V	1	Completed	https://clinicaltrials.gov/study/NCT01323530,https://clinicaltrials.gov/study/NCT01432886
MONDO_0007254	breast cancer	CHEMBL53463	DOXORUBICIN	Small molecule	DNA topoisomerase II alpha inhibitor		TOP2A	DNA topoisomerase II alpha	1	Terminated	https://clinicaltrials.gov/study/NCT00346229,https://clinicaltrials.gov/study/NCT01090128,https://clinicaltrials.gov/study/NCT02379585,https://clinicaltrials.gov/study/NCT01131364,https://clinicaltrials.gov/study/NCT00063934,https://clinicaltrials.gov/study/NCT01495884,https://clinicaltrials.gov/study/NCT00003086
EFO_0000305	breast carcinoma	CHEMBL1082407	ENZALUTAMIDE	Small molecule	Androgen Receptor antagonist		AR	androgen receptor	1	Completed	https://clinicaltrials.gov/study/NCT03207529
EFO_0000305	breast carcinoma	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	1	Completed	https://clinicaltrials.gov/study/NCT02227082
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor		TUBB1	tubulin beta 1 class VI	1	Recruiting	https://clinicaltrials.gov/study/NCT03805399,https://clinicaltrials.gov/study/NCT05918133,https://clinicaltrials.gov/study/NCT05673200
EFO_0006861	male breast carcinoma	CHEMBL1201182	TEMSIROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	1	Completed	https://clinicaltrials.gov/study/NCT00699491
EFO_0006861	male breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
EFO_0006861	male breast carcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB2A	tubulin beta 2A class IIa	1	Completed	https://clinicaltrials.gov/study/NCT01288261,https://clinicaltrials.gov/study/NCT02060253,https://clinicaltrials.gov/study/NCT01493310,https://clinicaltrials.gov/study/NCT01276496,https://clinicaltrials.gov/study/NCT00470301,https://clinicaltrials.gov/study/NCT00368875,https://clinicaltrials.gov/study/NCT01281150
MONDO_0007254	breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Vascular endothelial growth factor receptor 1 inhibitor		FLT1	fms related receptor tyrosine kinase 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT05176080
MONDO_0007254	breast cancer	CHEMBL24828	VANDETANIB	Small molecule	Ephrin receptor inhibitor		EPHA4	EPH receptor A4	1	Completed	https://clinicaltrials.gov/study/NCT00496665
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA1	NADH:ubiquinone oxidoreductase subunit A1	1	Completed	https://clinicaltrials.gov/study/NCT02278965
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR2	estrogen receptor 2	1	Recruiting	https://clinicaltrials.gov/study/NCT05870579,https://clinicaltrials.gov/study/NCT05307705,https://clinicaltrials.gov/study/NCT05216432,https://clinicaltrials.gov/study/NCT05504213
MONDO_0007254	breast cancer	CHEMBL601719	CRIZOTINIB	Small molecule	EML4-ALK		EML4	EMAP like 4	1	Terminated	https://clinicaltrials.gov/study/NCT02074878
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB1	tubulin beta 1 class VI	1	Recruiting	https://clinicaltrials.gov/study/NCT05307705,https://clinicaltrials.gov/study/NCT03994107,https://clinicaltrials.gov/study/NCT04152057,https://clinicaltrials.gov/study/NCT04205903
EFO_0006861	male breast carcinoma	CHEMBL1201247	GOSERELIN	Protein	Gonadotropin-releasing hormone receptor agonist		GNRHR	gonadotropin releasing hormone receptor	1	Terminated	https://clinicaltrials.gov/study/NCT01149356
MONDO_0007254	breast cancer	CHEMBL274654	ORANTINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Unknown status	https://clinicaltrials.gov/study/NCT00024063
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor	Inhibitor	TUBB	tubulin beta class I	1	Unknown status	https://clinicaltrials.gov/study/NCT02616848
EFO_0005537	triple-negative breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	1	Terminated	https://clinicaltrials.gov/study/NCT02457910
MONDO_0007254	breast cancer	CHEMBL1276308	MIFEPRISTONE	Small molecule	Progesterone receptor antagonist		PGR	progesterone receptor	1	Completed	https://clinicaltrials.gov/study/NCT01493310
EFO_0006861	male breast carcinoma	CHEMBL2109229	OBLIMERSEN SODIUM	Oligonucleotide	Bcl-2 mRNA antisense inhibitor		BCL2	BCL2 apoptosis regulator	1	Terminated	https://clinicaltrials.gov/study/NCT00063934
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS2	NADH:ubiquinone oxidoreductase core subunit S2	1	Completed	https://clinicaltrials.gov/study/NCT02278965
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC3	histone deacetylase 3	1	Terminated	https://clinicaltrials.gov/study/NCT00754312,https://clinicaltrials.gov/study/NCT04296942,https://clinicaltrials.gov/study/NCT03361800
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB3	NADH:ubiquinone oxidoreductase subunit B3	1	Completed	https://clinicaltrials.gov/study/NCT01980823,https://clinicaltrials.gov/study/NCT01650506
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03685331
MONDO_0007254	breast cancer	CHEMBL705	ALITRETINOIN	Small molecule	Retinoid receptor agonist		RARG	retinoic acid receptor gamma	1	Completed	https://clinicaltrials.gov/study/NCT00001504
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR1	estrogen receptor 1	1	Terminated	https://clinicaltrials.gov/study/NCT02345772,https://clinicaltrials.gov/study/NCT00903006,https://clinicaltrials.gov/study/NCT02983604,https://clinicaltrials.gov/study/NCT02936206,https://clinicaltrials.gov/study/NCT02384746
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB6	tubulin beta 6 class V	1	Completed	https://clinicaltrials.gov/study/NCT01256567,https://clinicaltrials.gov/study/NCT02605915,https://clinicaltrials.gov/study/NCT00372424,https://clinicaltrials.gov/study/NCT00934856,https://clinicaltrials.gov/study/NCT01862081,https://clinicaltrials.gov/study/NCT02392845,https://clinicaltrials.gov/study/NCT00645333,https://clinicaltrials.gov/study/NCT00169000,https://clinicaltrials.gov/study/NCT00705315,https://clinicaltrials.gov/study/NCT05301530,https://clinicaltrials.gov/study/NCT00086957,https://clinicaltrials.gov/study/NCT00050167,https://clinicaltrials.gov/study/NCT00322400,https://clinicaltrials.gov/study/NCT02027376,https://clinicaltrials.gov/study/NCT00003103,https://clinicaltrials.gov/study/NCT00450892,https://clinicaltrials.gov/study/NCT01044485,https://clinicaltrials.gov/study/NCT00872625,https://clinicaltrials.gov/study/NCT00020332,https://clinicaltrials.gov/study/NCT00637897,https://clinicaltrials.gov/study/NCT00002901,https://clinicaltrials.gov/study/NCT00080665,https://clinicaltrials.gov/study/NCT00129896,https://clinicaltrials.gov/study/NCT04367090,https://clinicaltrials.gov/study/NCT00268918
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL1094636	NIRAPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	1	Recruiting	https://clinicaltrials.gov/study/NCT05694715
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB4A	tubulin beta 4A class IVa	1	Recruiting	https://clinicaltrials.gov/study/NCT04205903,https://clinicaltrials.gov/study/NCT03994107,https://clinicaltrials.gov/study/NCT04152057,https://clinicaltrials.gov/study/NCT05307705
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA7	NADH:ubiquinone oxidoreductase subunit A7	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
MONDO_0007254	breast cancer	CHEMBL46740	BAZEDOXIFENE	Small molecule	Estrogen receptor modulator		ESR1	estrogen receptor 1	1	Completed	https://clinicaltrials.gov/study/NCT02448771
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor	Inhibitor	TUBB8	tubulin beta 8 class VIII	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05251766
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB	tubulin beta class I	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05019690,https://clinicaltrials.gov/study/NCT05251766,https://clinicaltrials.gov/study/NCT05274893
MONDO_0007254	breast cancer	CHEMBL49642	INDIBULIN	Small molecule	Tubulin inhibitor	Inhibitor	TUBA4A	tubulin alpha 4a	1	Unknown status	https://clinicaltrials.gov/study/NCT01113970
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLA1	DNA polymerase alpha 1, catalytic subunit	1	Completed	https://clinicaltrials.gov/study/NCT01070706,https://clinicaltrials.gov/study/NCT00270907,https://clinicaltrials.gov/study/NCT02479230,https://clinicaltrials.gov/study/NCT00100750,https://clinicaltrials.gov/study/NCT04247126,https://clinicaltrials.gov/study/NCT02139358,https://clinicaltrials.gov/study/NCT01133912
EFO_0006861	male breast carcinoma	CHEMBL554	LAPATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT01245205,https://clinicaltrials.gov/study/NCT01783756
EFO_0005537	triple-negative breast cancer	CHEMBL4297422	RG-4733	Small molecule	Gamma-secretase inhibitor		APH1B	aph-1 homolog B, gamma-secretase subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01238133,https://clinicaltrials.gov/study/NCT01071564
MONDO_0007254	breast cancer	CHEMBL522892	DOVITINIB	Small molecule	Vascular endothelial growth factor receptor inhibitor		KDR	kinase insert domain receptor	1	Terminated	https://clinicaltrials.gov/study/NCT01484041
EFO_0005537	triple-negative breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor	Inhibitor	TUBB2A	tubulin beta 2A class IIa	1	Completed	https://clinicaltrials.gov/study/NCT02120469
EFO_0005537	triple-negative breast cancer	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC3	histone deacetylase 3	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02393794
EFO_0000305	breast carcinoma	CHEMBL314854	FINGOLIMOD	Small molecule	Sphingosine 1-phosphate receptor agonist		S1PR1	sphingosine-1-phosphate receptor 1	1	Completed	https://clinicaltrials.gov/study/NCT03941743
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF4	NADH:ubiquinone oxidoreductase complex assembly factor 4	1	Completed	https://clinicaltrials.gov/study/NCT02278965
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB6	tubulin beta 6 class V	1	Completed	https://clinicaltrials.gov/study/NCT00535119
EFO_0000305	breast carcinoma	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	1	Terminated	https://clinicaltrials.gov/study/NCT03128619
MONDO_0007254	breast cancer	CHEMBL1096882	FLUDARABINE PHOSPHATE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05989828
MONDO_0007254	breast cancer	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	1	Terminated	https://clinicaltrials.gov/study/NCT02561832
MONDO_0007254	breast cancer	CHEMBL1094636	NIRAPARIB	Small molecule	Poly [ADP-ribose] polymerase-1 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	1	Completed	https://clinicaltrials.gov/study/NCT02657889,https://clinicaltrials.gov/study/NCT05261269
MONDO_0004658	breast carcinoma in situ	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB	tubulin beta class I	1	Completed	https://clinicaltrials.gov/study/NCT04081389
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS7	NADH:ubiquinone oxidoreductase core subunit S7	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1023	BEXAROTENE	Small molecule	Retinoid X receptor agonist		RXRG	retinoid X receptor gamma	1	Completed	https://clinicaltrials.gov/study/NCT03323658
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R2	phosphoinositide-3-kinase regulatory subunit 2	1	Terminated	https://clinicaltrials.gov/study/NCT01132664
MONDO_0007254	breast cancer	CHEMBL3545132	MIRVETUXIMAB SORAVTANSINE	Antibody drug conjugate	Tubulin inhibitor	Inhibitor	TUBA1C	tubulin alpha 1c	1	Withdrawn	https://clinicaltrials.gov/study/NCT03045393
MONDO_0007254	breast cancer	CHEMBL3545376	ERDAFITINIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR1	fibroblast growth factor receptor 1	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03238196
MONDO_0007254	breast cancer	CHEMBL3545376	ERDAFITINIB	Small molecule	Fibroblast growth factor receptor inhibitor		FGFR3	fibroblast growth factor receptor 3	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03238196
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		PRIM1	DNA primase subunit 1	1	Completed	https://clinicaltrials.gov/study/NCT01154426
MONDO_0007254	breast cancer	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Stem cell growth factor receptor inhibitor		KIT	KIT proto-oncogene, receptor tyrosine kinase	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
EFO_0000305	breast carcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	1	Completed	https://clinicaltrials.gov/study/NCT00100750
EFO_0000304	breast adenocarcinoma	CHEMBL1637	GEMCITABINE HYDROCHLORIDE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE	DNA polymerase epsilon, catalytic subunit	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
MONDO_0007254	breast cancer	CHEMBL1278146	FAMITINIB	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT05176080
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4L2	NDUFA4 mitochondrial complex associated like 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLE2	DNA polymerase epsilon 2, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01929941,https://clinicaltrials.gov/study/NCT01939418,https://clinicaltrials.gov/study/NCT01333137
MONDO_0007254	breast cancer	CHEMBL2360464	PEMETREXED DISODIUM	Small molecule	Dihydrofolate reductase inhibitor		DHFR	dihydrofolate reductase	1	Completed	https://clinicaltrials.gov/study/NCT00097383
MONDO_0007254	breast cancer	CHEMBL598797	CUDC-101	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT01171924
MONDO_0007254	breast cancer	CHEMBL27759	ENTINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC7	histone deacetylase 7	1	Completed	https://clinicaltrials.gov/study/NCT03473639,https://clinicaltrials.gov/study/NCT02833155,https://clinicaltrials.gov/study/NCT01594398,https://clinicaltrials.gov/study/NCT02820961
MONDO_0007254	breast cancer	CHEMBL5315324	KW-2450 FREE BASE	Small molecule	Insulin receptor inhibitor		INSR	insulin receptor	1	Terminated	https://clinicaltrials.gov/study/NCT01199367
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB	tubulin beta class I	1	Completed	https://clinicaltrials.gov/study/NCT01306942,https://clinicaltrials.gov/study/NCT02628132,https://clinicaltrials.gov/study/NCT01172223,https://clinicaltrials.gov/study/NCT01423123,https://clinicaltrials.gov/study/NCT02015676,https://clinicaltrials.gov/study/NCT01003158,https://clinicaltrials.gov/study/NCT00707707,https://clinicaltrials.gov/study/NCT00803556,https://clinicaltrials.gov/study/NCT04247126,https://clinicaltrials.gov/study/NCT00680758,https://clinicaltrials.gov/study/NCT02599363,https://clinicaltrials.gov/study/NCT00031876,https://clinicaltrials.gov/study/NCT00983424,https://clinicaltrials.gov/study/NCT00368875,https://clinicaltrials.gov/study/NCT01973309,https://clinicaltrials.gov/study/NCT00960960,https://clinicaltrials.gov/study/NCT01493310,https://clinicaltrials.gov/study/NCT00691379,https://clinicaltrials.gov/study/NCT00807859,https://clinicaltrials.gov/study/NCT00301730,https://clinicaltrials.gov/study/NCT00445458,https://clinicaltrials.gov/study/NCT00748553,https://clinicaltrials.gov/study/NCT01042925,https://clinicaltrials.gov/study/NCT00003877,https://clinicaltrials.gov/study/NCT00050167,https://clinicaltrials.gov/study/NCT03166085,https://clinicaltrials.gov/study/NCT02001974,https://clinicaltrials.gov/study/NCT01070706,https://clinicaltrials.gov/study/NCT00001383,https://clinicaltrials.gov/study/NCT00322400,https://clinicaltrials.gov/study/NCT00107094,https://clinicaltrials.gov/study/NCT01484080,https://clinicaltrials.gov/study/NCT03112590,https://clinicaltrials.gov/study/NCT00717340,https://clinicaltrials.gov/study/NCT00724386,https://clinicaltrials.gov/study/NCT00003927,https://clinicaltrials.gov/study/NCT00426556,https://clinicaltrials.gov/study/NCT03505528,https://clinicaltrials.gov/study/NCT03800836,https://clinicaltrials.gov/study/NCT01031446,https://clinicaltrials.gov/study/NCT00068757,https://clinicaltrials.gov/study/NCT04261218,https://clinicaltrials.gov/study/NCT00820170,https://clinicaltrials.gov/study/NCT00900627,https://clinicaltrials.gov/study/NCT00951665,https://clinicaltrials.gov/study/NCT02060253,https://clinicaltrials.gov/study/NCT02379247,https://clinicaltrials.gov/study/NCT01254526,https://clinicaltrials.gov/study/NCT02041429,https://clinicaltrials.gov/study/NCT00004174,https://clinicaltrials.gov/study/NCT00637897,https://clinicaltrials.gov/study/NCT00788931,https://clinicaltrials.gov/study/NCT00054028,https://clinicaltrials.gov/study/NCT01625286,https://clinicaltrials.gov/study/NCT00887575,https://clinicaltrials.gov/study/NCT02073916,https://clinicaltrials.gov/study/NCT00006108,https://clinicaltrials.gov/study/NCT03411161,https://clinicaltrials.gov/study/NCT01918254,https://clinicaltrials.gov/study/NCT00442260,https://clinicaltrials.gov/study/NCT01862081,https://clinicaltrials.gov/study/NCT00002837,https://clinicaltrials.gov/study/NCT01133912,https://clinicaltrials.gov/study/NCT00574587,https://clinicaltrials.gov/study/NCT00009997,https://clinicaltrials.gov/study/NCT04132817,https://clinicaltrials.gov/study/NCT01320592
Orphanet_145	Hereditary breast and ovarian cancer syndrome	CHEMBL521686	OLAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT06177171
MONDO_0007254	breast cancer	CHEMBL226267	ARZOXIFENE	Small molecule	Estrogen receptor modulator		ESR1	estrogen receptor 1	1	Completed	https://clinicaltrials.gov/study/NCT00005886
MONDO_0007254	breast cancer	CHEMBL705	ALITRETINOIN	Small molecule	Retinoid receptor agonist		RXRB	retinoid X receptor beta	1	Completed	https://clinicaltrials.gov/study/NCT00001504
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB	tubulin beta class I	1	Terminated	https://clinicaltrials.gov/study/NCT02379585,https://clinicaltrials.gov/study/NCT00584012,https://clinicaltrials.gov/study/NCT00253318,https://clinicaltrials.gov/study/NCT00864175,https://clinicaltrials.gov/study/NCT02345772,https://clinicaltrials.gov/study/NCT00063934,https://clinicaltrials.gov/study/NCT00531271,https://clinicaltrials.gov/study/NCT01876251
MONDO_0007254	breast cancer	CHEMBL4073443	TOMIVOSERTIB	Small molecule	MAP kinase-interacting serine/threonine-protein kinase 1/2 inhibitor		MKNK2	MAPK interacting serine/threonine kinase 2	1	Completed	https://clinicaltrials.gov/study/NCT04261218
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor	Inhibitor	TUBB1	tubulin beta 1 class VI	1	Withdrawn	https://clinicaltrials.gov/study/NCT00074139
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS7	NADH:ubiquinone oxidoreductase core subunit S7	1	Completed	https://clinicaltrials.gov/study/NCT02278965
EFO_0000305	breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRB	platelet derived growth factor receptor beta	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
MONDO_0007254	breast cancer	CHEMBL554	LAPATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	1	Completed	https://clinicaltrials.gov/study/NCT01133912,https://clinicaltrials.gov/study/NCT02073916,https://clinicaltrials.gov/study/NCT00753207,https://clinicaltrials.gov/study/NCT00807859,https://clinicaltrials.gov/study/NCT00513058,https://clinicaltrials.gov/study/NCT00316875,https://clinicaltrials.gov/study/NCT01471847,https://clinicaltrials.gov/study/NCT00379509,https://clinicaltrials.gov/study/NCT00085020,https://clinicaltrials.gov/study/NCT01044485,https://clinicaltrials.gov/study/NCT00912275,https://clinicaltrials.gov/study/NCT00450892,https://clinicaltrials.gov/study/NCT02650752,https://clinicaltrials.gov/study/NCT01300962,https://clinicaltrials.gov/study/NCT00424164,https://clinicaltrials.gov/study/NCT00952692,https://clinicaltrials.gov/study/NCT00544804,https://clinicaltrials.gov/study/NCT01172223,https://clinicaltrials.gov/study/NCT00632489
EFO_1000984	inflammatory breast carcinoma	CHEMBL343448	ROMIDEPSIN	Protein	Histone deacetylase inhibitor		HDAC4	histone deacetylase 4	1	Terminated	https://clinicaltrials.gov/study/NCT01938833
EFO_0000305	breast carcinoma	CHEMBL1079175	MK-2206	Small molecule	Serine/threonine-protein kinase AKT inhibitor		AKT3	AKT serine/threonine kinase 3	1	Terminated	https://clinicaltrials.gov/study/NCT01281163
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB6	NADH:ubiquinone oxidoreductase subunit B6	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03006172
MONDO_0007254	breast cancer	CHEMBL1683590	ERIBULIN	Small molecule	Tubulin inhibitor	Inhibitor	TUBB1	tubulin beta 1 class VI	1	Completed	https://clinicaltrials.gov/study/NCT02723877,https://clinicaltrials.gov/study/NCT01323530,https://clinicaltrials.gov/study/NCT01432886,https://clinicaltrials.gov/study/NCT01596751,https://clinicaltrials.gov/study/NCT01795586
EFO_0000305	breast carcinoma	CHEMBL4298024	BINTRAFUSP ALFA	Protein	Transforming growth factor beta binding agent		TGFB1	transforming growth factor beta 1	1	Completed	https://clinicaltrials.gov/study/NCT03524170
MONDO_0007254	breast cancer	CHEMBL521851	PICTILISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	1	Unknown status	https://clinicaltrials.gov/study/NCT02389842
EFO_0006861	male breast carcinoma	CHEMBL429876	CILENGITIDE	Protein	Integrin alpha-V/beta-5 antagonist		ITGB5	integrin subunit beta 5	1	Completed	https://clinicaltrials.gov/study/NCT01276496
EFO_0005537	triple-negative breast cancer	CHEMBL3707227	ATEZOLIZUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	1	Completed	https://clinicaltrials.gov/study/NCT04584112
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA3	NADH:ubiquinone oxidoreductase subunit A3	1	Completed	https://clinicaltrials.gov/study/NCT02278965
EFO_0000304	breast adenocarcinoma	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD3	DNA polymerase delta 3, accessory subunit	1	Suspended	https://clinicaltrials.gov/study/NCT03432741
MONDO_0007254	breast cancer	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	1	Completed	https://clinicaltrials.gov/study/NCT00424164,https://clinicaltrials.gov/study/NCT02285179,https://clinicaltrials.gov/study/NCT00005822,https://clinicaltrials.gov/study/NCT02333370,https://clinicaltrials.gov/study/NCT00005886,https://clinicaltrials.gov/study/NCT00009997,https://clinicaltrials.gov/study/NCT02586675,https://clinicaltrials.gov/study/NCT04079517,https://clinicaltrials.gov/study/NCT01192308,https://clinicaltrials.gov/study/NCT00290745
EFO_0005537	triple-negative breast cancer	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02419495
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB8	tubulin beta 8 class VIII	1	Suspended	https://clinicaltrials.gov/study/NCT05422794
EFO_0005537	triple-negative breast cancer	CHEMBL1023	BEXAROTENE	Small molecule	Retinoid X receptor agonist		RXRB	retinoid X receptor beta	1	Recruiting	https://clinicaltrials.gov/study/NCT04664829
EFO_1000100	Atypical Lobular Breast Hyperplasia	CHEMBL1023	BEXAROTENE	Small molecule	Retinoid X receptor agonist		RXRB	retinoid X receptor beta	1	Completed	https://clinicaltrials.gov/study/NCT03323658
MONDO_0007254	breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT03616587,https://clinicaltrials.gov/study/NCT02791334
EFO_0000304	breast adenocarcinoma	CHEMBL1789844	IPILIMUMAB	Antibody	Cytotoxic T-lymphocyte protein 4 inhibitor		CTLA4	cytotoxic T-lymphocyte associated protein 4	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT02453620
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	1	Recruiting	https://clinicaltrials.gov/study/NCT04360941,https://clinicaltrials.gov/study/NCT05216432,https://clinicaltrials.gov/study/NCT04669587,https://clinicaltrials.gov/study/NCT05293964,https://clinicaltrials.gov/study/NCT05266105,https://clinicaltrials.gov/study/NCT04072952
MONDO_0004658	breast carcinoma in situ	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS6	NADH:ubiquinone oxidoreductase subunit S6	1	Completed	https://clinicaltrials.gov/study/NCT02278965
MONDO_0007254	breast cancer	CHEMBL1567	SUNITINIB MALATE	Small molecule	Platelet-derived growth factor receptor inhibitor		PDGFRA	platelet derived growth factor receptor alpha	1	Unknown status	https://clinicaltrials.gov/study/NCT00931450
MONDO_0007254	breast cancer	CHEMBL888	GEMCITABINE	Small molecule	DNA polymerase (alpha/delta/epsilon) inhibitor		POLD2	DNA polymerase delta 2, accessory subunit	1	Terminated	https://clinicaltrials.gov/study/NCT01929941,https://clinicaltrials.gov/study/NCT01333137,https://clinicaltrials.gov/study/NCT01939418
MONDO_0007254	breast cancer	CHEMBL96172	EPOTHILONE D	Small molecule	Tubulin stabiliser	Inhibitor	TUBB4B	tubulin beta 4B class IVb	1	Completed	https://clinicaltrials.gov/study/NCT00337649
MONDO_0007254	breast cancer	CHEMBL118	CELECOXIB	Small molecule	Cyclooxygenase-2 inhibitor		PTGS2	prostaglandin-endoperoxide synthase 2	1	Terminated	https://clinicaltrials.gov/study/NCT00075673
MONDO_0007254	breast cancer	CHEMBL2387080	TASELISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	1	Unknown status	https://clinicaltrials.gov/study/NCT02389842
EFO_0000304	breast adenocarcinoma	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB2B	tubulin beta 2B class IIb	1	Terminated	https://clinicaltrials.gov/study/NCT02824575,https://clinicaltrials.gov/study/NCT01697293
EFO_0006861	male breast carcinoma	CHEMBL1201733	PAZOPANIB HYDROCHLORIDE	Small molecule	Vascular endothelial growth factor receptor inhibitor		FLT4	fms related receptor tyrosine kinase 4	1	Terminated	https://clinicaltrials.gov/study/NCT00450879
EFO_0006861	male breast carcinoma	CHEMBL1908360	EVEROLIMUS	Small molecule	FK506-binding protein 1A inhibitor		FKBP1A	FKBP prolyl isomerase 1A	1	Completed	https://clinicaltrials.gov/study/NCT01783756
MONDO_0007254	breast cancer	CHEMBL46740	BAZEDOXIFENE	Small molecule	Estrogen receptor modulator		ESR2	estrogen receptor 2	1	Active, not recruiting	https://clinicaltrials.gov/study/NCT04821375
MONDO_0007254	breast cancer	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	1	Unknown status	https://clinicaltrials.gov/study/NCT02562118
EFO_0000304	breast adenocarcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor	Inhibitor	TUBB1	tubulin beta 1 class VI	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
EFO_0000304	breast adenocarcinoma	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor	Inhibitor	TUBB4B	tubulin beta 4B class IVb	1	Terminated	https://clinicaltrials.gov/study/NCT02824575
MONDO_0007254	breast cancer	CHEMBL2109512	MCS-110	Antibody	Macrophage colony-stimulating factor 1 inhibitor		CSF1	colony stimulating factor 1	1	Terminated	https://clinicaltrials.gov/study/NCT03742349
MONDO_0007254	breast cancer	CHEMBL4297721	CDX-1140	Unknown	Tumor necrosis factor receptor superfamily member 5 agonist		CD40	CD40 molecule	1	Completed	https://clinicaltrials.gov/study/NCT03329950
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor	Inhibitor	TUBB4A	tubulin beta 4A class IVa	1	Completed	https://clinicaltrials.gov/study/NCT00513058,https://clinicaltrials.gov/study/NCT00706069,https://clinicaltrials.gov/study/NCT00912275,https://clinicaltrials.gov/study/NCT00828074,https://clinicaltrials.gov/study/NCT00014430,https://clinicaltrials.gov/study/NCT00003902,https://clinicaltrials.gov/study/NCT00153907,https://clinicaltrials.gov/study/NCT00001944,https://clinicaltrials.gov/study/NCT00724386,https://clinicaltrials.gov/study/NCT00706030
MONDO_0007254	breast cancer	CHEMBL1535	HYDROXYCHLOROQUINE	Small molecule	Toll-like receptor 7 antagonist		TLR7	toll like receptor 7	1	Terminated	https://clinicaltrials.gov/study/NCT02414776
MONDO_0007254	breast cancer	CHEMBL428690	ALVOCIDIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	1	Terminated	https://clinicaltrials.gov/study/NCT00039455
EFO_0005537	triple-negative breast cancer	CHEMBL1683544	ERIBULIN MESYLATE	Small molecule	Tubulin inhibitor	Inhibitor	TUBB4A	tubulin beta 4A class IVa	1	Terminated	https://clinicaltrials.gov/study/NCT03579472
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB2A	tubulin beta 2A class IIa	1	Not yet recruiting	https://clinicaltrials.gov/study/NCT05251766
MONDO_0007254	breast cancer	CHEMBL477772	PAZOPANIB	Small molecule	Fibroblast growth factor receptor 3 inhibitor		FGFR3	fibroblast growth factor receptor 3	1	Completed	https://clinicaltrials.gov/study/NCT01498458
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB8	tubulin beta 8 class VIII	0.5	Unknown status	https://clinicaltrials.gov/study/NCT03647514,https://clinicaltrials.gov/study/NCT03647280
MONDO_0007254	breast cancer	CHEMBL11	IMIPRAMINE	Small molecule	Serotonin transporter inhibitor		SLC6A4	solute carrier family 6 member 4	0.5	Completed	https://clinicaltrials.gov/study/NCT03122444
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC4	histone deacetylase 4	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT00993642
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB1	NADH:ubiquinone oxidoreductase subunit B1	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV1	NADH:ubiquinone oxidoreductase core subunit V1	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF3	NADH:ubiquinone oxidoreductase complex assembly factor 3	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV2	NADH:ubiquinone oxidoreductase core subunit V2	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor	Inhibitor	TUBB3	tubulin beta 3 class III	0.5	Completed	https://clinicaltrials.gov/study/NCT00949247
MONDO_0007254	breast cancer	CHEMBL139	DICLOFENAC	Small molecule	Cyclooxygenase inhibitor		PTGS1	prostaglandin-endoperoxide synthase 1	0.5	Completed	https://clinicaltrials.gov/study/NCT01380353
EFO_0000305	breast carcinoma	CHEMBL1201583	BEVACIZUMAB	Antibody	Vascular endothelial growth factor A inhibitor		VEGFA	vascular endothelial growth factor A	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF1	NADH:ubiquinone oxidoreductase complex assembly factor 1	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB10	NADH:ubiquinone oxidoreductase subunit B10	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB1	tubulin beta 1 class VI	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT04249167
MONDO_0007254	breast cancer	CHEMBL1042	CHOLECALCIFEROL	Small molecule	Vitamin D receptor agonist		VDR	vitamin D receptor	0.5	Recruiting	https://clinicaltrials.gov/study/NCT05331807
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor	Inhibitor	TUBB1	tubulin beta 1 class VI	0.5	Completed	https://clinicaltrials.gov/study/NCT00949247
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB2	NADH:ubiquinone oxidoreductase subunit B2	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND5	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4	NDUFA4 mitochondrial complex associated	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB4A	tubulin beta 4A class IVa	0.5	Completed	https://clinicaltrials.gov/study/NCT00331630
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4L	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB3	tubulin beta 3 class III	0.5	Completed	https://clinicaltrials.gov/study/NCT00949247
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC1	NADH:ubiquinone oxidoreductase subunit C1	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL2103875	TRAMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor		MAP2K2	mitogen-activated protein kinase kinase 2	0.5	Completed	https://clinicaltrials.gov/study/NCT01467310
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	0.5	Completed	https://clinicaltrials.gov/study/NCT01513356
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor	Inhibitor	TUBB	tubulin beta class I	0.5	Completed	https://clinicaltrials.gov/study/NCT02802748
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC8	histone deacetylase 8	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT00993642
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF2	NADH:ubiquinone oxidoreductase complex assembly factor 2	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB4B	tubulin beta 4B class IVb	0.5	Completed	https://clinicaltrials.gov/study/NCT00949247
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND2	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor	Inhibitor	TUBB4A	tubulin beta 4A class IVa	0.5	Completed	https://clinicaltrials.gov/study/NCT00949247
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAB1	NADH:ubiquinone oxidoreductase subunit AB1	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS1	NADH:ubiquinone oxidoreductase core subunit S1	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA9	NADH:ubiquinone oxidoreductase subunit A9	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB3	tubulin beta 3 class III	0.5	Completed	https://clinicaltrials.gov/study/NCT00331630
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA5	NADH:ubiquinone oxidoreductase subunit A5	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL198877	AUS-131	Small molecule	Estrogen receptor beta agonist		ESR2	estrogen receptor 2	0.5	Completed	https://clinicaltrials.gov/study/NCT02352025
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB4A	tubulin beta 4A class IVa	0.5	Completed	https://clinicaltrials.gov/study/NCT00949247
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC10	histone deacetylase 10	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT00993642
MONDO_0007254	breast cancer	CHEMBL1201583	BEVACIZUMAB	Antibody	Vascular endothelial growth factor A inhibitor		VEGFA	vascular endothelial growth factor A	0.5	Completed	https://clinicaltrials.gov/study/NCT00949247,https://clinicaltrials.gov/study/NCT02802098
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB6	tubulin beta 6 class V	0.5	Unknown status	https://clinicaltrials.gov/study/NCT03647280,https://clinicaltrials.gov/study/NCT03647514
MONDO_0007254	breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 4 inhibitor		CDK4	cyclin dependent kinase 4	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT04088032
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB9	NADH:ubiquinone oxidoreductase subunit B9	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB2A	tubulin beta 2A class IIa	0.5	Completed	https://clinicaltrials.gov/study/NCT00949247
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB1	tubulin beta 1 class VI	0.5	Completed	https://clinicaltrials.gov/study/NCT00331630
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS7	NADH:ubiquinone oxidoreductase core subunit S7	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor	Inhibitor	TUBB8	tubulin beta 8 class VIII	0.5	Completed	https://clinicaltrials.gov/study/NCT00949247
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA6	NADH:ubiquinone oxidoreductase subunit A6	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL2103875	TRAMETINIB	Small molecule	Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor		MAP2K1	mitogen-activated protein kinase kinase 1	0.5	Completed	https://clinicaltrials.gov/study/NCT01467310
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA10	NADH:ubiquinone oxidoreductase subunit A10	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL1201180	DICLOFENAC EPOLAMINE	Small molecule	Cyclooxygenase inhibitor		PTGS2	prostaglandin-endoperoxide synthase 2	0.5	Completed	https://clinicaltrials.gov/study/NCT01380353
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF1	NADH:ubiquinone oxidoreductase complex assembly factor 1	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS3	NADH:ubiquinone oxidoreductase core subunit S3	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL3137343	PEMBROLIZUMAB	Antibody	Programmed cell death protein 1 inhibitor		PDCD1	programmed cell death 1	0.5	Completed	https://clinicaltrials.gov/study/NCT03197389,https://clinicaltrials.gov/study/NCT03514121
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR1	estrogen receptor 1	0.5	Unknown status	https://clinicaltrials.gov/study/NCT02913430
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB6	NADH:ubiquinone oxidoreductase subunit B6	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4	NDUFA4 mitochondrial complex associated	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC2	NADH:ubiquinone oxidoreductase subunit C2	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA9	NADH:ubiquinone oxidoreductase subunit A9	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA5	NADH:ubiquinone oxidoreductase subunit A5	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA13	NADH:ubiquinone oxidoreductase subunit A13	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND6	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB4	NADH:ubiquinone oxidoreductase subunit B4	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL1237023	DENOSUMAB	Antibody	Tumor necrosis factor ligand superfamily member 11 inhibitor		TNFSF11	TNF superfamily member 11	0.5	Completed	https://clinicaltrials.gov/study/NCT03629717,https://clinicaltrials.gov/study/NCT02900469
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB10	NADH:ubiquinone oxidoreductase subunit B10	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4	NDUFA4 mitochondrial complex associated	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor	Inhibitor	TUBB2A	tubulin beta 2A class IIa	0.5	Completed	https://clinicaltrials.gov/study/NCT02802748
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS8	NADH:ubiquinone oxidoreductase core subunit S8	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA12	NADH:ubiquinone oxidoreductase subunit A12	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R3	phosphoinositide-3-kinase regulatory subunit 3	0.5	Completed	https://clinicaltrials.gov/study/NCT01513356
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA2	NADH:ubiquinone oxidoreductase subunit A2	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA10	NADH:ubiquinone oxidoreductase subunit A10	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor	Inhibitor	TUBB6	tubulin beta 6 class V	0.5	Completed	https://clinicaltrials.gov/study/NCT00949247
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA12	NADH:ubiquinone oxidoreductase subunit A12	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB6	NADH:ubiquinone oxidoreductase subunit B6	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB6	tubulin beta 6 class V	0.5	Completed	https://clinicaltrials.gov/study/NCT00331630
MONDO_0007254	breast cancer	CHEMBL4594611	PATRITUMAB DERUXTECAN	Antibody drug conjugate	Receptor tyrosine-protein kinase erbB-3 binding agent		ERBB3	erb-b2 receptor tyrosine kinase 3	0.5	Active, not recruiting	https://clinicaltrials.gov/study/NCT04610528
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R2	phosphoinositide-3-kinase regulatory subunit 2	0.5	Completed	https://clinicaltrials.gov/study/NCT01513356
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF2	NADH:ubiquinone oxidoreductase complex assembly factor 2	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS1	NADH:ubiquinone oxidoreductase core subunit S1	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA1	NADH:ubiquinone oxidoreductase subunit A1	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor	Inhibitor	TUBB2B	tubulin beta 2B class IIb	0.5	Completed	https://clinicaltrials.gov/study/NCT00949247
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor	Inhibitor	TUBB4A	tubulin beta 4A class IVa	0.5	Completed	https://clinicaltrials.gov/study/NCT02802748
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA8	NADH:ubiquinone oxidoreductase subunit A8	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC9	histone deacetylase 9	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT00993642
MONDO_0007254	breast cancer	CHEMBL45	MELATONIN	Small molecule	Melatonin receptor agonist		MTNR1B	melatonin receptor 1B	0.5	Completed	https://clinicaltrials.gov/study/NCT01805089
MONDO_0007254	breast cancer	CHEMBL3707227	ATEZOLIZUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	0.5	Active, not recruiting	https://clinicaltrials.gov/study/NCT03802604
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS7	NADH:ubiquinone oxidoreductase core subunit S7	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS2	NADH:ubiquinone oxidoreductase core subunit S2	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC2	NADH:ubiquinone oxidoreductase subunit C2	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	0.5	Unknown status	https://clinicaltrials.gov/study/NCT02913430
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC6	histone deacetylase 6	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT00993642
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB5	NADH:ubiquinone oxidoreductase subunit B5	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB3	tubulin beta 3 class III	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT04249167
MONDO_0007254	breast cancer	CHEMBL1201087	CABERGOLINE	Small molecule	Dopamine D2 receptor agonist		DRD2	dopamine receptor D2	0.5	Completed	https://clinicaltrials.gov/study/NCT01730729
MONDO_0007254	breast cancer	CHEMBL1743028	GLEMBATUMUMAB VEDOTIN	Antibody drug conjugate	Transmembrane glycoprotein NMB binding agent		GPNMB	glycoprotein nmb	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT03473691
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB7	NADH:ubiquinone oxidoreductase subunit B7	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND3	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor	Inhibitor	TUBB4B	tubulin beta 4B class IVb	0.5	Completed	https://clinicaltrials.gov/study/NCT02802748
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA3	NADH:ubiquinone oxidoreductase subunit A3	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF1	NADH:ubiquinone oxidoreductase complex assembly factor 1	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAB1	NADH:ubiquinone oxidoreductase subunit AB1	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB9	NADH:ubiquinone oxidoreductase subunit B9	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS7	NADH:ubiquinone oxidoreductase core subunit S7	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB4A	tubulin beta 4A class IVa	0.5	Unknown status	https://clinicaltrials.gov/study/NCT03647514,https://clinicaltrials.gov/study/NCT03647280
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF2	NADH:ubiquinone oxidoreductase complex assembly factor 2	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB	tubulin beta class I	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT04249167
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	0.5	Completed	https://clinicaltrials.gov/study/NCT01513356
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF4	NADH:ubiquinone oxidoreductase complex assembly factor 4	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB6	tubulin beta 6 class V	0.5	Completed	https://clinicaltrials.gov/study/NCT00949247
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF4	NADH:ubiquinone oxidoreductase complex assembly factor 4	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB2A	tubulin beta 2A class IIa	0.5	Unknown status	https://clinicaltrials.gov/study/NCT03647280,https://clinicaltrials.gov/study/NCT03647514
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	0.5	Completed	https://clinicaltrials.gov/study/NCT00949247
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAB1	NADH:ubiquinone oxidoreductase subunit AB1	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL554	LAPATINIB	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	0.5	Completed	https://clinicaltrials.gov/study/NCT00331630
MONDO_0007254	breast cancer	CHEMBL1743028	GLEMBATUMUMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor	Inhibitor	TUBB2A	tubulin beta 2A class IIa	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT03473691
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4L	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB9	NADH:ubiquinone oxidoreductase subunit B9	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS2	NADH:ubiquinone oxidoreductase core subunit S2	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA11	NADH:ubiquinone oxidoreductase subunit A11	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	0.5	Completed	https://clinicaltrials.gov/study/NCT04130152,https://clinicaltrials.gov/study/NCT02802748
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS5	NADH:ubiquinone oxidoreductase subunit S5	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT04630210
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA7	NADH:ubiquinone oxidoreductase subunit A7	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL1201585	TRASTUZUMAB	Antibody	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	0.5	Terminated	https://clinicaltrials.gov/study/NCT04102618
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS4	NADH:ubiquinone oxidoreductase subunit S4	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB1	NADH:ubiquinone oxidoreductase subunit B1	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB3	tubulin beta 3 class III	0.5	Unknown status	https://clinicaltrials.gov/study/NCT03647280,https://clinicaltrials.gov/study/NCT03647514
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	0.5	Unknown status	https://clinicaltrials.gov/study/NCT02913430
MONDO_0007254	breast cancer	CHEMBL25	ASPIRIN	Small molecule	Cyclooxygenase inhibitor		PTGS2	prostaglandin-endoperoxide synthase 2	0.5	Completed	https://clinicaltrials.gov/study/NCT00727948,https://clinicaltrials.gov/study/NCT02062255
MONDO_0007254	breast cancer	CHEMBL1173055	RUCAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP2	poly(ADP-ribose) polymerase 2	0.5	Active, not recruiting	https://clinicaltrials.gov/study/NCT03911453
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC11	histone deacetylase 11	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT00993642
EFO_0005537	triple-negative breast cancer	CHEMBL3707227	ATEZOLIZUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT04249167
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB4B	tubulin beta 4B class IVb	0.5	Unknown status	https://clinicaltrials.gov/study/NCT03647280,https://clinicaltrials.gov/study/NCT03647514
MONDO_0007254	breast cancer	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	0.5	Unknown status	https://clinicaltrials.gov/study/NCT02913430
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA3	NADH:ubiquinone oxidoreductase subunit A3	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB1	NADH:ubiquinone oxidoreductase subunit B1	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL11	IMIPRAMINE	Small molecule	Norepinephrine transporter inhibitor		SLC6A2	solute carrier family 6 member 2	0.5	Completed	https://clinicaltrials.gov/study/NCT03122444
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor	Inhibitor	TUBB8	tubulin beta 8 class VIII	0.5	Completed	https://clinicaltrials.gov/study/NCT02802748
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND5	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC1	NADH:ubiquinone oxidoreductase subunit C1	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS3	NADH:ubiquinone oxidoreductase core subunit S3	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB3	NADH:ubiquinone oxidoreductase subunit B3	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL1908373	ONAPRISTONE	Small molecule	Progesterone receptor antagonist		PGR	progesterone receptor	0.5	Completed	https://clinicaltrials.gov/study/NCT04142892
MONDO_0007254	breast cancer	CHEMBL25	ASPIRIN	Small molecule	Cyclooxygenase inhibitor		PTGS1	prostaglandin-endoperoxide synthase 1	0.5	Completed	https://clinicaltrials.gov/study/NCT02062255,https://clinicaltrials.gov/study/NCT00727948
MONDO_0007254	breast cancer	CHEMBL1358	FULVESTRANT	Small molecule	Estrogen receptor antagonist		ESR2	estrogen receptor 2	0.5	Unknown status	https://clinicaltrials.gov/study/NCT02913430
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	Cyclin-dependent kinase 4/cyclin D1 inhibitor		CDK4	cyclin dependent kinase 4	0.5	Completed	https://clinicaltrials.gov/study/NCT04130152
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA13	NADH:ubiquinone oxidoreductase subunit A13	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor		GPD2	glycerol-3-phosphate dehydrogenase 2	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND3	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB4	NADH:ubiquinone oxidoreductase subunit B4	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL1743028	GLEMBATUMUMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor	Inhibitor	TUBB8	tubulin beta 8 class VIII	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT03473691
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS6	NADH:ubiquinone oxidoreductase subunit S6	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA1	NADH:ubiquinone oxidoreductase subunit A1	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB2B	tubulin beta 2B class IIb	0.5	Completed	https://clinicaltrials.gov/study/NCT00331630
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor	Inhibitor	TUBB2A	tubulin beta 2A class IIa	0.5	Completed	https://clinicaltrials.gov/study/NCT00949247
MONDO_0007254	breast cancer	CHEMBL3301587	DURVALUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	0.5	Completed	https://clinicaltrials.gov/study/NCT02802098
MONDO_0007254	breast cancer	CHEMBL521	IBUPROFEN	Small molecule	Cyclooxygenase inhibitor		PTGS2	prostaglandin-endoperoxide synthase 2	0.5	Completed	https://clinicaltrials.gov/study/NCT02463383
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3R5	phosphoinositide-3-kinase regulatory subunit 5	0.5	Completed	https://clinicaltrials.gov/study/NCT01513356
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS2	NADH:ubiquinone oxidoreductase core subunit S2	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL1201670	SARGRAMOSTIM	Protein	Granulocyte-macrophage colony-stimulating factor receptor agonist		CSF2RA	colony stimulating factor 2 receptor subunit alpha	0.5	Completed	https://clinicaltrials.gov/study/NCT00640861
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC5	histone deacetylase 5	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT00993642
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor	Inhibitor	TUBB	tubulin beta class I	0.5	Completed	https://clinicaltrials.gov/study/NCT00949247
MONDO_0007254	breast cancer	CHEMBL554	LAPATINIB	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	0.5	Completed	https://clinicaltrials.gov/study/NCT00331630
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB	tubulin beta class I	0.5	Unknown status	https://clinicaltrials.gov/study/NCT03647514,https://clinicaltrials.gov/study/NCT03647280
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV1	NADH:ubiquinone oxidoreductase core subunit V1	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL1536	ERGOCALCIFEROL	Small molecule	Vitamin D receptor agonist		VDR	vitamin D receptor	0.5	Completed	https://clinicaltrials.gov/study/NCT03629717
MONDO_0007254	breast cancer	CHEMBL3707227	ATEZOLIZUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT04630210
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB	tubulin beta class I	0.5	Completed	https://clinicaltrials.gov/study/NCT00331630
MONDO_0007254	breast cancer	CHEMBL1743028	GLEMBATUMUMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor	Inhibitor	TUBB3	tubulin beta 3 class III	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT03473691
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS6	NADH:ubiquinone oxidoreductase subunit S6	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF3	NADH:ubiquinone oxidoreductase complex assembly factor 3	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB11	NADH:ubiquinone oxidoreductase subunit B11	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND6	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB4B	tubulin beta 4B class IVb	0.5	Completed	https://clinicaltrials.gov/study/NCT00331630
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA8	NADH:ubiquinone oxidoreductase subunit A8	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS8	NADH:ubiquinone oxidoreductase core subunit S8	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC2	histone deacetylase 2	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT00993642
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB8	NADH:ubiquinone oxidoreductase subunit B8	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB5	NADH:ubiquinone oxidoreductase subunit B5	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL1201179	LAPATINIB DITOSYLATE	Small molecule	Epidermal growth factor receptor erbB1 inhibitor		EGFR	epidermal growth factor receptor	0.5	Completed	https://clinicaltrials.gov/study/NCT00331630
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS3	NADH:ubiquinone oxidoreductase core subunit S3	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL3301610	ABEMACICLIB	Small molecule	Cyclin-dependent kinase 6 inhibitor		CDK6	cyclin dependent kinase 6	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT04088032
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV2	NADH:ubiquinone oxidoreductase core subunit V2	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV3	NADH:ubiquinone oxidoreductase subunit V3	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV3	NADH:ubiquinone oxidoreductase subunit V3	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB2	NADH:ubiquinone oxidoreductase subunit B2	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB2A	tubulin beta 2A class IIa	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT04249167
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB11	NADH:ubiquinone oxidoreductase subunit B11	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CB	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	0.5	Completed	https://clinicaltrials.gov/study/NCT01513356
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB10	NADH:ubiquinone oxidoreductase subunit B10	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC1	histone deacetylase 1	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT00993642
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB2A	tubulin beta 2A class IIa	0.5	Completed	https://clinicaltrials.gov/study/NCT00331630
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB4A	tubulin beta 4A class IVa	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT04249167
MONDO_0007254	breast cancer	CHEMBL1201180	DICLOFENAC EPOLAMINE	Small molecule	Cyclooxygenase inhibitor		PTGS1	prostaglandin-endoperoxide synthase 1	0.5	Completed	https://clinicaltrials.gov/study/NCT01380353
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB11	NADH:ubiquinone oxidoreductase subunit B11	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1276308	MIFEPRISTONE	Small molecule	Glucocorticoid receptor antagonist		NR3C1	nuclear receptor subfamily 3 group C member 1	0.5	Terminated	https://clinicaltrials.gov/study/NCT01138553
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA1	NADH:ubiquinone oxidoreductase subunit A1	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC1	NADH:ubiquinone oxidoreductase subunit C1	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF3	NADH:ubiquinone oxidoreductase complex assembly factor 3	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV3	NADH:ubiquinone oxidoreductase subunit V3	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB7	NADH:ubiquinone oxidoreductase subunit B7	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL1173055	RUCAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP3	poly(ADP-ribose) polymerase family member 3	0.5	Active, not recruiting	https://clinicaltrials.gov/study/NCT03911453
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB8	NADH:ubiquinone oxidoreductase subunit B8	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB4B	tubulin beta 4B class IVb	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT04249167
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND3	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL1743028	GLEMBATUMUMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor	Inhibitor	TUBB4B	tubulin beta 4B class IVb	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT03473691
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB6	tubulin beta 6 class V	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT04249167
MONDO_0007254	breast cancer	CHEMBL3707227	ATEZOLIZUMAB	Antibody	Programmed cell death 1 ligand 1 inhibitor		CD274	CD274 molecule	0.5	Terminated	https://clinicaltrials.gov/study/NCT04102618
MONDO_0007254	breast cancer	CHEMBL1743028	GLEMBATUMUMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor	Inhibitor	TUBB1	tubulin beta 1 class VI	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT03473691
MONDO_0007254	breast cancer	CHEMBL139	DICLOFENAC	Small molecule	Cyclooxygenase inhibitor		PTGS2	prostaglandin-endoperoxide synthase 2	0.5	Completed	https://clinicaltrials.gov/study/NCT01380353
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor	Inhibitor	TUBB3	tubulin beta 3 class III	0.5	Completed	https://clinicaltrials.gov/study/NCT02802748
MONDO_0007254	breast cancer	CHEMBL1173055	RUCAPARIB	Small molecule	PARP 1, 2 and 3 inhibitor		PARP1	poly(ADP-ribose) polymerase 1	0.5	Active, not recruiting	https://clinicaltrials.gov/study/NCT03911453
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB5	NADH:ubiquinone oxidoreductase subunit B5	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL1743028	GLEMBATUMUMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor	Inhibitor	TUBB4A	tubulin beta 4A class IVa	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT03473691
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB7	NADH:ubiquinone oxidoreductase subunit B7	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	0.5	Unknown status	https://clinicaltrials.gov/study/NCT02913430
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB4	NADH:ubiquinone oxidoreductase subunit B4	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS5	NADH:ubiquinone oxidoreductase subunit S5	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND1	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL83	TAMOXIFEN	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	0.5	Recruiting	https://clinicaltrials.gov/study/NCT04174352
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV1	NADH:ubiquinone oxidoreductase core subunit V1	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB8	tubulin beta 8 class VIII	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT04249167
MONDO_0007254	breast cancer	CHEMBL4297185	DAROLUTAMIDE	Small molecule	Androgen Receptor antagonist		AR	androgen receptor	0.5	Completed	https://clinicaltrials.gov/study/NCT03004534
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA11	NADH:ubiquinone oxidoreductase subunit A11	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA7	NADH:ubiquinone oxidoreductase subunit A7	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND4L	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB8	tubulin beta 8 class VIII	0.5	Completed	https://clinicaltrials.gov/study/NCT00949247
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFV2	NADH:ubiquinone oxidoreductase core subunit V2	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL1773	CAPECITABINE	Small molecule	Thymidylate synthase inhibitor		TYMS	thymidylate synthetase	0.5	Unknown status	https://clinicaltrials.gov/study/NCT03647514
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor	Inhibitor	TUBB2B	tubulin beta 2B class IIb	0.5	Completed	https://clinicaltrials.gov/study/NCT02802748
MONDO_0007254	breast cancer	CHEMBL189963	PALBOCICLIB	Small molecule	CDK6/cyclin D1 inhibitor		CDK6	cyclin dependent kinase 6	0.5	Completed	https://clinicaltrials.gov/study/NCT04130152
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB3	NADH:ubiquinone oxidoreductase subunit B3	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND1	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA2	NADH:ubiquinone oxidoreductase subunit A2	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA11	NADH:ubiquinone oxidoreductase subunit A11	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB6	NADH:ubiquinone oxidoreductase subunit B6	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC3	histone deacetylase 3	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT00993642
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFAF4	NADH:ubiquinone oxidoreductase complex assembly factor 4	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA12	NADH:ubiquinone oxidoreductase subunit A12	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA2	NADH:ubiquinone oxidoreductase subunit A2	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
EFO_0000432	breast ductal carcinoma in situ	CHEMBL1276308	MIFEPRISTONE	Small molecule	Progesterone receptor antagonist		PGR	progesterone receptor	0.5	Terminated	https://clinicaltrials.gov/study/NCT01138553
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND1	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	0.5	Completed	https://clinicaltrials.gov/study/NCT01513356
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA5	NADH:ubiquinone oxidoreductase subunit A5	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4L2	NDUFA4 mitochondrial complex associated like 2	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB3	NADH:ubiquinone oxidoreductase subunit B3	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL92	DOCETAXEL ANHYDROUS	Small molecule	Tubulin inhibitor	Inhibitor	TUBB4B	tubulin beta 4B class IVb	0.5	Completed	https://clinicaltrials.gov/study/NCT00949247
MONDO_0007254	breast cancer	CHEMBL4594611	PATRITUMAB DERUXTECAN	Antibody drug conjugate	DNA topoisomerase I inhibitor		TOP1	DNA topoisomerase I	0.5	Active, not recruiting	https://clinicaltrials.gov/study/NCT04610528
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS4	NADH:ubiquinone oxidoreductase subunit S4	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor	Inhibitor	TUBB1	tubulin beta 1 class VI	0.5	Completed	https://clinicaltrials.gov/study/NCT02802748
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA6	NADH:ubiquinone oxidoreductase subunit A6	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
EFO_0005537	triple-negative breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB2B	tubulin beta 2B class IIb	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT04249167
MONDO_0007254	breast cancer	CHEMBL786	TAMOXIFEN CITRATE	Small molecule	Estrogen receptor alpha modulator		ESR1	estrogen receptor 1	0.5	Recruiting	https://clinicaltrials.gov/study/NCT04174352
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND5	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL553025	VINORELBINE	Small molecule	Tubulin inhibitor	Inhibitor	TUBB6	tubulin beta 6 class V	0.5	Completed	https://clinicaltrials.gov/study/NCT02802748
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND2	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS6	NADH:ubiquinone oxidoreductase subunit S6	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND2	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL1098	BUPIVACAINE	Small molecule	Sodium channel protein type IV alpha subunit blocker		SCN4A	sodium voltage-gated channel alpha subunit 4	0.5	Completed	https://clinicaltrials.gov/study/NCT04019834
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB8	NADH:ubiquinone oxidoreductase subunit B8	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL521	IBUPROFEN	Small molecule	Cyclooxygenase inhibitor		PTGS1	prostaglandin-endoperoxide synthase 1	0.5	Completed	https://clinicaltrials.gov/study/NCT02463383
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFB2	NADH:ubiquinone oxidoreductase subunit B2	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA10	NADH:ubiquinone oxidoreductase subunit A10	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4L2	NDUFA4 mitochondrial complex associated like 2	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL2017974	BUPARLISIB	Small molecule	PI3-kinase class I inhibitor		PIK3CA	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	0.5	Completed	https://clinicaltrials.gov/study/NCT01513356
MONDO_0007254	breast cancer	CHEMBL1042	CHOLECALCIFEROL	Small molecule	Vitamin D receptor agonist		VDR	vitamin D receptor	0.5	Terminated	https://clinicaltrials.gov/study/NCT02936999
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		MT-ND6	mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB	tubulin beta class I	0.5	Completed	https://clinicaltrials.gov/study/NCT00949247
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA9	NADH:ubiquinone oxidoreductase subunit A9	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA3	NADH:ubiquinone oxidoreductase subunit A3	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA6	NADH:ubiquinone oxidoreductase subunit A6	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL1743028	GLEMBATUMUMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor	Inhibitor	TUBB6	tubulin beta 6 class V	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT03473691
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB8	tubulin beta 8 class VIII	0.5	Completed	https://clinicaltrials.gov/study/NCT00331630
MONDO_0007254	breast cancer	CHEMBL1743028	GLEMBATUMUMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor	Inhibitor	TUBB2B	tubulin beta 2B class IIb	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT03473691
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA7	NADH:ubiquinone oxidoreductase subunit A7	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL45	MELATONIN	Small molecule	Melatonin receptor agonist		MTNR1A	melatonin receptor 1A	0.5	Completed	https://clinicaltrials.gov/study/NCT01805089
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS8	NADH:ubiquinone oxidoreductase core subunit S8	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL1536	ERGOCALCIFEROL	Small molecule	Vitamin D receptor agonist		VDR	vitamin D receptor	0.5	Recruiting	https://clinicaltrials.gov/study/NCT05331807
MONDO_0007254	breast cancer	CHEMBL1743028	GLEMBATUMUMAB VEDOTIN	Antibody drug conjugate	Tubulin inhibitor	Inhibitor	TUBB	tubulin beta class I	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT03473691
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS5	NADH:ubiquinone oxidoreductase subunit S5	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB1	tubulin beta 1 class VI	0.5	Unknown status	https://clinicaltrials.gov/study/NCT03647280,https://clinicaltrials.gov/study/NCT03647514
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA4L2	NDUFA4 mitochondrial complex associated like 2	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL483254	PANOBINOSTAT	Small molecule	Histone deacetylase inhibitor		HDAC7	histone deacetylase 7	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT00993642
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFC2	NADH:ubiquinone oxidoreductase subunit C2	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
MONDO_0007254	breast cancer	CHEMBL1201179	LAPATINIB DITOSYLATE	Small molecule	Receptor protein-tyrosine kinase erbB-2 inhibitor		ERBB2	erb-b2 receptor tyrosine kinase 2	0.5	Completed	https://clinicaltrials.gov/study/NCT00331630
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB1	tubulin beta 1 class VI	0.5	Completed	https://clinicaltrials.gov/study/NCT00949247
EFO_0000305	breast carcinoma	CHEMBL5314386	ME-344	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS1	NADH:ubiquinone oxidoreductase core subunit S1	0.5	Completed	https://clinicaltrials.gov/study/NCT02806817
EFO_0000305	breast carcinoma	CHEMBL4297509	ELACESTRANT	Small molecule	Estrogen receptor alpha degrader		ESR1	estrogen receptor 1	0.5	Completed	https://clinicaltrials.gov/study/NCT04797728
MONDO_0007254	breast cancer	CHEMBL1444	LETROZOLE	Small molecule	Cytochrome P450 19A1 inhibitor		CYP19A1	cytochrome P450 family 19 subfamily A member 1	0.5	Terminated	https://clinicaltrials.gov/study/NCT04102618,https://clinicaltrials.gov/study/NCT00651976
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor		GPD2	glycerol-3-phosphate dehydrogenase 2	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL428647	PACLITAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB2B	tubulin beta 2B class IIb	0.5	Unknown status	https://clinicaltrials.gov/study/NCT03647514,https://clinicaltrials.gov/study/NCT03647280
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA13	NADH:ubiquinone oxidoreductase subunit A13	0.5	Not yet recruiting	https://clinicaltrials.gov/study/NCT05680662
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFS4	NADH:ubiquinone oxidoreductase subunit S4	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002
MONDO_0007254	breast cancer	CHEMBL3545252	DOCETAXEL	Small molecule	Tubulin inhibitor	Inhibitor	TUBB2B	tubulin beta 2B class IIb	0.5	Completed	https://clinicaltrials.gov/study/NCT00949247
MONDO_0007254	breast cancer	CHEMBL1431	METFORMIN	Small molecule	Mitochondrial complex I (NADH dehydrogenase) inhibitor		NDUFA8	NADH:ubiquinone oxidoreductase subunit A8	0.5	Withdrawn	https://clinicaltrials.gov/study/NCT01302002